IN	O
an	O
individual	O
with	O
Baraitser	O
-	O
Winter	O
syndrome-2	O
(	O
BRWS2	O
;	O
614583	O
)	O
,	O
Riviere	O
et	O
al	O
.	O

(	O
2012	O
)	O
identified	O
a	O
heterozygous	O
C	O
-	O
to	O
-	O
T	O
transition	B-Variation
at	O
nucleotide	O
404	O
of	O
the	B-Gene
ACTG1	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
an	O
ala	O
-	O
to	O
-	O
val	O
substitution	B-Variation
at	O
codon	O
135	O
(	O
A135V	O
)	O
.	O

This	O
mutation	B-Variation
occurred	O
de	O
novo	O
in	O
the	O
patient	O
and	O
was	O
not	O
observed	O
in	O
192	O
other	O
exomes	O
sequenced	O
.	O

In	O
an	O
individual	O
with	O
Baraitser	O
-	O
Winter	O
syndrome-2	O
(	O
BRWS2	O
;	O
614583	O
)	O
,	O
Riviere	O
et	O
al	O
.	O

(	O
2012	O
)	O
identified	O
a	O
heterozygous	O
C	O
-	O
to	O
-	O
A	O
transversion	B-Variation
at	O
nucleotide	O
608	O
of	O
the	B-Gene
ACTG1	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
an	O
thr	O
-	O
to	O
-	O
lys	O
substitution	B-Variation
at	O
codon	O
203	O
(	O
T203	O
K	O
)	O
.	O

This	O
mutation	B-Variation
occurred	O
de	O
novo	O
in	O
the	O
patient	O
and	O
was	O
not	O
observed	O
in	O
203	O
other	O
exomes	O
sequenced	O
.	O

In	O
3	O
unrelated	O
individuals	O
with	O
Baraitser	O
-	O
Winter	O
syndrome-2	O
(	O
BRWS2	O
;	O
614583	O
)	O
,	O
Riviere	O
et	O
al	O
.	O

(	O
2012	O
)	O
identified	O
a	O
heterozygous	O
C	O
-	O
to	O
-	O
T	O
transition	B-Variation
at	O
nucleotide	O
464	O
of	O
the	B-Gene
ACTG1	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
ser	O
-	O
to	O
-	O
phe	O
substitution	B-Variation
at	O
codon	O
155	O
(	O
S155F	O
)	O
.	O

This	O
mutation	B-Variation
was	O
proven	O
to	O
have	O
occurred	O
de	O
novo	O
in	O
2	O
of	O
the	O
3	O
;	O
in	O
the	O
third	O
,	O
parental	O
DNA	O
was	O
not	O
available	O
.	O

One	O
of	O
these	O
3	O
patients	O
,	O
LP98	O
-	O
096	O
,	O
was	O
reported	O
by	O
Baraitser	O
and	O
Winter	O
(	O
1988	O
)	O
.	O

This	O
mutation	B-Variation
was	O
not	O
identified	O
in	O
224	O
control	O
exomes	O
.	O

Riviere	O
et	O
al	O
.	O

(	O
2012	O
)	O
studied	O
lymphoblastoid	O
cell	O
lines	O
from	O
individuals	O
carrying	O
the	O
S155F	O
mutation	B-Variation
and	O
demonstrated	O
that	O
these	O
had	O
increased	B-Positive_Rgulation
F	B-Protein
-	I-Protein
actin	I-Protein
content	O
and	O
multiple	O
,	O
anomalous	B-Variation
F	O
-	O
actin	O
-	O
rich	O
filopodia	O
-	O
like	O
protrusions	O
compared	O
to	O
control	O
cells	O
,	O
resulting	O
in	O
increased	B-Positive_Rgulation
cell	B-Cell_Physiological_Activity
perimeter	I-Cell_Physiological_Activity
.	O

Cell	O
lines	O
also	O
showed	O
increased	B-Positive_Rgulation
sensitivity	B-Cell_Physiological_Activity
to	O
treatment	O
with	O
latrunculin	O
A.	O
In	O
affected	O
members	O
of	O
an	O
Italian	O
family	O
with	O
autosomal	O
dominant	O
distal	O
myopathy-4	O
(	O
MPD4	O
;	O
614065	O
)	O
,	O
Duff	O
et	O
al	O
.	O

(	O
2011	O
)	O
identified	O
a	O
heterozygous	O
577G	O
-	O
A	O
transition	B-Variation
in	O
exon	O
2	O
of	O
the	B-Gene
FLNC	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
an	O
ala193-to	O
-	O
thr	O
(	O
A193	O
T	O
)	O
substitution	B-Variation
in	O
a	O
highly	O
conserved	O
residue	O
in	O
the	O
CH2	O
domain	O
in	O
the	O
actin	B-Interaction
-	I-Interaction
binding	I-Interaction
domain	O
.	O

The	O
mutation	B-Variation
was	O
not	O
found	O
in	O
204	O
control	O
chromosomes	O
.	O

The	O
mutant	B-Variation
protein	B-Protein
had	O
slightly	O
decreased	B-Negative_Regulation
thermal	B-Molecular_Physiological_Activity
stability	I-Molecular_Physiological_Activity
and	O
showed	O
increased	B-Positive_Regulation
actin	B-Interaction
-	I-Interaction
binding	I-Interaction
activity	B-Molecular_Physiological_Activity
compared	O
to	O
the	O
wildtype	O
protein	O
.	O

Nuclear	O
localization	O
was	O
unaltered	O
,	O
but	O
transfection	O
resulted	O
in	O
the	O
formation	B-Positive_Regulation
of	O
intracellular	O
protein	B-Protein
aggregates	B-Molecular_Physiological_Activity
.	O

Duff	O
et	O
al	O
.	O

(	O
2011	O
)	O
concluded	O
that	O
the	O
disease	O
mechanism	O
somehow	O
involves	O
increased	B-Positive_Regulation
affinity	B-Molecular_Physiological_Activity
for	O
actin	B-Protein
.	O

The	O
phenotype	O
was	O
characterized	O
by	O
adult	O
onset	O
of	O
distal	O
muscle	O
weakness	O
and	O
atrophy	O
affecting	O
the	O
upper	O
and	O
lower	O
limbs	O
,	O
with	O
nonspecific	O
findings	O
on	O
muscle	O
biopsy	O
.	O

In	O
2	O
infant	O
sibs	O
with	O
severe	O
autosomal	O
recessive	O
nemaline	O
myopathy-3	O
(	O
NEM3	O
;	O
161800	O
)	O
leading	O
to	O
death	O
at	O
5	O
and	O
19	O
days	O
of	O
age	O
,	O
Nowak	O
et	O
al	O
.	O

(	O
1999	O
)	O
identified	O
compound	O
heterozygosity	O
for	O
2	O
mutations	B-Variation
in	O
the	B-Gene
ACTA1	I-Gene
gene	I-Gene
:	I-Gene
a	O
T	O
-	O
to	O
-	O
C	O
transition	B-Variation
in	O
exon	O
3	O
,	O
resulting	B-Regulation
in	I-Regulation
a	O
leu94-to	O
-	O
pro	O
(	O
L94P	O
)	O
substitution	B-Variation
inherited	O
from	O
the	O
unaffected	O
father	O
,	O
and	O
an	O
A	O
-	O
to	O
-	O
G	O
transition	B-Variation
in	O
exon	O
5	O
,	O
resulting	B-Regulation
in	I-Regulation
a	O
glu259-to	O
-	O
val	O
(	O
E259V	O
;	O
102610.0005	O
)	O
substitution	B-Variation
inherited	O
from	O
the	O
unaffected	O
mother	O
.	O

In	O
an	O
infant	O
with	O
nemaline	O
myopathy-3	O
(	O
NEM3	O
;	O
161800	O
)	O
who	O
presented	O
with	O
an	O
atypical	O
phenotype	O
of	O
stiffness	O
and	O
hypertonicity	O
,	O
Jain	O
et	O
al	O
.	O

(	O
2012	O
)	O
identified	O
a	O
de	O
novo	O
heterozygous	O
984G	O
-	O
C	O
transversion	B-Variation
in	O
the	B-Gene
ACTA1	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
lys328-to	O
-	O
asn	O
(	O
K328N	O
)	O
substitution	B-Variation
(	O
K326N	O
in	O
the	O
mature	O
protein	B-Protein
)	I-Protein
.	O

Patient	O
biopsy	O
showed	O
nemaline	O
bodies	O
and	O
32	O
%	O
mutant	B-Variation
actin	B-Protein
.	O

In	O
vitro	O
motility	O
analysis	O
of	O
actin	B-Protein
thin	O
filaments	O
derived	O
from	O
the	O
patient	O
's	O
tissue	O
showed	O
increased	B-Positive_Regulation
sensitivity	B-Molecular_Physiological_Activity
to	O
calcium	O
,	O
indicating	O
an	O
activated	B-Positive_Regulation
state	O
.	O

Expression	O
of	O
the	O
mutant	B-Variation
in	O
mouse	O
muscle	O
cells	O
did	O
not	O
result	O
in	O
the	O
formation	O
of	O
rod	O
-	O
like	O
structures	O
,	O
suggesting	O
a	O
different	O
mechanism	O
of	O
nemaline	O
body	O
formation	O
.	O

Medical	O
treatment	O
was	O
ineffective	O
,	O
and	O
the	O
patient	O
died	O
at	O
age	O
9	O
months	O
in	O
an	O
asystolic	O
episode	O
.	O

The	O
report	O
expanded	O
the	O
phenotypic	O
spectrum	O
associated	O
with	O
ACTA1	B-Gene
mutations	B-Variation
to	O
include	O
stiffness	O
,	O
rigidity	O
,	O
and	O
hypertonicity	O
.	O

In	O
7	O
of	O
10	O
patients	O
with	O
Baraitser	O
-	O
Winter	O
syndrome-1	O
(	O
BRWS1	O
;	O
243310	O
)	O
,	O
Riviere	O
et	O
al	O
.	O

(	O
2012	O
)	O
identified	O
a	O
heterozygous	O
G	O
-	O
to	O
-	O
A	O
transition	B-Variation
at	O
nucleotide	O
587	O
of	O
the	B-Gene
ACTB	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
an	O
arg	O
-	O
to	O
-	O
his	O
substitution	B-Variation
at	O
codon	O
196	O
(	O
R196H	O
)	O
.	O

In	O
2	O
patients	O
from	O
whom	O
parental	O
DNA	O
was	O
available	O
the	O
mutation	B-Variation
was	O
determined	O
to	O
have	O
occurred	O
de	O
novo	O
.	O

This	O
mutation	B-Variation
was	O
not	O
identified	O
in	O
212	O
other	O
exomes	O
.	O

Lymphoblastoid	O
cell	O
lines	O
established	O
from	O
patients	O
carrying	O
this	O
mutation	B-Variation
had	O
greatly	O
increased	B-Positive_Regulation
F	B-Protein
-	I-Protein
actin	I-Protein
content	O
and	O
multiple	O
,	O
anomalous	B-Variation
F	O
-	O
actin	O
-	O
rich	O
,	O
filopodia	O
-	O
like	O
protrusions	O
compared	O
to	O
control	O
cells	O
,	O
resulting	O
in	O
an	O
increased	B-Positive_Regulation
cell	B-Cell_Physiological_Activity
perimeter	I-Cell_Physiological_Activity
.	O

In	O
a	O
patient	O
with	O
Baraitser	O
-	O
Winter	O
syndrome-1	O
(	O
BRWS1	O
;	O
243310	O
)	O
,	O
Riviere	O
et	O
al	O
.	O

(	O
2012	O
)	O
identified	O
a	O
de	O
novo	O
mutation	B-Variation
,	O
a	O
heterozygous	O
C	O
-	O
to	O
-	O
G	O
transversion	B-Variation
at	O
nucleotide	O
193	O
of	O
the	B-Gene
ACTB	I-Gene
gene	I-Gene
resulting	B-Regulation
in	I-Regulation
a	O
leu	O
-	O
to	O
-	O
val	O
substitution	B-Variation
at	O
codon	O
65	O
(	O
L65V	O
)	O
.	O

This	O
mutation	B-Variation
was	O
not	O
identified	O
in	O
244	O
other	O
exomes	O
.	O

In	O
albumin	B-Protein
Casebrook	O
,	O
an	O
electrophoretically	O
slow	O
albumin	B-Protein
variant	B-Variation
with	O
a	O
relative	O
molecular	B-Molecular_Physiological_Activity
mass	I-Molecular_Physiological_Activity
of	O
2.5	O
kD	O
higher	B-Positive_Regulation
than	O
normal	O
albumin	B-Protein
,	O
Peach	O
and	O
Brennan	O
(	O
1991	O
)	O
identified	O
substitution	B-Variation
of	O
asparagine	O
for	O
aspartic	O
acid-494	O
.	O

The	O
mutation	B-Variation
introduced	O
an	O
asn	O
-	O
glu	O
-	O
thr	O
N	O
-	O
linked	O
oligosaccharide	O
attachment	O
sequence	O
centered	O
on	O
asn494	O
,	O
which	O
explained	O
the	O
increase	B-Positive_Regulation
in	O
molecular	B-Molecular_Physiological_Activity
mass	I-Molecular_Physiological_Activity
.	O

The	O
mutant	B-Variation
albumin	B-Protein
was	O
associated	O
with	O
no	O
apparent	O
pathology	O
and	O
was	O
detected	O
in	O
2	O
unrelated	O
individuals	O
of	O
Anglo	O
-	O
Saxon	O
descent	O
.	O

In	O
2	O
sibs	O
with	O
renal	O
tubular	O
dysgenesis	O
(	O
267430	O
)	O
from	O
a	O
consanguineous	O
Turkish	O
family	O
,	O
Gribouval	O
et	O
al	O
.	O

(	O
2005)found	O
homozygosity	O
for	O
a	O
frameshift	B-Variation
mutation	B-Variation
in	O
exon	O
8	O
of	O
the	B-Gene
ACE	I-Gene
gene	I-Gene
.	O

Deletion	B-Variation
of	O
4	O
nucleotides	O
,	O
1319_1322del	O
TGGA	O
,	O
resulted	B-Regulation
in	I-Regulation
a	O
frameshift	B-Variation
at	O
leucine-440	O
and	O
a	O
premature	B-Molecular_Physiological_Activity
stop	I-Molecular_Physiological_Activity
at	O
codon	O
455	O
.	O

Factors	O
involved	O
in	O
the	O
pathogenesis	O
of	O
atherosclerosis	O
,	O
thrombosis	O
,	O
and	O
vasoconstriction	O
contribute	O
to	O
the	O
development	O
of	O
coronary	O
heart	O
disease	O
.	O

In	O
a	O
study	O
comparing	O
patients	O
after	O
myocardial	O
infarction	O
(	O
MI	O
)	O
with	O
controls	O
,	O
Cambien	O
et	O
al	O
.	O

(	O
1992	O
)	O
found	O
association	O
between	O
coronary	O
heart	O
disease	O
and	O
the	O
ACE	O
/	O
ID	O
polymorphism	O
.	O

They	O
determined	O
that	O
the	O
frequency	O
of	O
the	O
ACE	O
/	O
DD	O
genotype	O
in	O
the	O
'	O
general	O
population	O
'	O
is	O
approximately	O
0.27	O
.	O

The	B-Gene
ACE	I-Gene
polymorphism	I-Gene
was	O
unrelated	O
to	O
blood	O
pressure	O
and	O
hypertension	O
.	O

Cambien	O
et	O
al	O
.	O

(	O
1992	O
)	O
estimated	O
that	O
in	O
the	O
low	O
-	O
risk	O
group	O
,	O
i.e.	O
,	O
those	O
without	O
tobacco	O
usage	O
,	O
high	O
blood	O
pressure	O
,	O
diabetes	O
,	O
obesity	O
,	O
or	O
hypercholesterolemia	O
,	O
the	O
ACE	O
/	O
DD	O
genotype	O
may	O
account	O
for	O
35	O
%	O
of	O
cases	O
of	O
myocardial	O
infarction	O
.	O

The	O
results	O
of	O
these	O
studies	O
correlate	O
with	O
those	O
of	O
Pfeffer	O
et	O
al	O
.	O

(	O
1992	O
)	O
,	O
which	O
showed	O
that	O
administration	O
of	O
an	O
ACE	B-something
inhibitor	I-something
not	O
only	O
decreased	B-Negative_Regulation
the	O
risk	O
of	O
developing	O
heart	O
failure	O
but	O
also	O
reduced	B-Negative_Regulation
the	O
risk	O
for	O
recurrent	O
myocardial	O
infarction	O
.	O

Experimental	O
studies	O
had	O
shown	O
that	B-Gene
ACE	I-Gene
gene	I-Gene
expression	B-Molecular_Physiological_Activity
is	O
increased	B-Positive_Regulation
in	O
myocardial	O
tissue	O
after	O
coronary	O
artery	O
occlusion	O
The	O
beta-1-adrenergic	O
receptor	O
,	O
a	O
key	O
cell	O
surface	O
signaling	O
protein	B-Protein
expressed	O
in	O
the	O
heart	O
and	O
other	O
organs	O
,	O
mediates	O
the	O
actions	O
of	O
catecholamines	O
in	O
the	O
sympathetic	O
nervous	O
system	O
.	O

Mason	O
et	O
al	O
.	O

(	O
1999	O
)	O
identified	O
a	O
C	O
-	O
to	O
-	O
G	O
transversion	B-Variation
in	O
the	O
intracellular	O
cytoplasmic	O
tail	O
near	O
the	O
seventh	O
transmembrane	O
-	O
spanning	O
segment	O
of	O
the	O
human	O
ADRB1	B-Gene
gene	O
,	O
resulting	B-Regulation
in	I-Regulation
an	O
arg389-to	O
-	O
gly	O
substitution	B-Variation
(	O
R389	O
G	O
)	O
.	O

Allele	O
frequencies	O
for	O
gly389	O
and	O
arg389	O
residues	O
were	O
0.26	O
and	O
0.74	O
,	O
respectively	O
(	O
the	O
former	O
had	O
previously	O
been	O
considered	O
as	O
the	O
human	O
wildtype	O
ADRB1	B-Gene
allele	O
)	O
.	O

Using	O
site	O
-	O
directed	O
mutagenesis	O
to	O
mimic	O
the	O
2	O
variants	B-Variation
,	O
cultured	O
cells	O
were	O
permanently	O
transfected	O
to	O
express	O
the	O
gly389	O
and	O
arg389	O
receptors	O
.	O

In	O
functional	O
studies	O
with	O
matched	O
expression	B-Molecular_Physiological_Activity
,	O
the	O
arg389	O
receptors	O
had	O
slightly	O
higher	B-Positive_Regulation
basal	O
levels	O
of	O
adenylyl	B-Enzyme
cyclase	I-Enzyme
activities	B-Molecular_Physiological_Activity
.	O

However	O
,	O
maximal	O
isoproterenol	O
-	O
stimulated	O
levels	O
were	O
markedly	O
higher	B-Positive_Regulation
for	O
the	O
arg389	O
receptor	O
as	O
compared	O
with	O
the	O
gly389	O
receptor	O
.	O

Agonist	O
-	O
promoted	O
binding	B-Interaction
was	O
also	O
increased	B-Positive_Regulation
for	O
the	O
arg389	O
receptor	O
,	O
consistent	O
with	O
enhanced	B-Positive_Regulation
coupling	B-Interaction
to	O
stimulatory	O
G	O
protein	B-Protein
(	O
Gs	O
;	O
see	O
139320	O
)	O
and	O
increased	B-Positive_Regulation
adenylyl	B-Enzyme
cyclase	I-Enzyme
activation	B-Molecular_Physiological_Activity
.	O

These	O
and	O
other	O
studies	O
indicated	O
that	O
this	O
polymorphic	O
variation	B-Variation
of	O
the	O
human	O
ADRB1	B-Gene
gene	O
results	O
in	O
alterations	B-Regulation
of	O
receptor	O
-	O
Gs	O
interaction	B-Interaction
with	O
functional	O
consequences	O
on	O
signal	O
transduction	O
,	O
consistent	O
with	O
its	O
localization	O
in	O
a	O
putative	O
G	B-Protein
-	I-Protein
protein	I-Protein
binding	B-Interaction
domain	O
.	O

Mason	O
et	O
al	O
.	O

(	O
1999	O
)	O
suggested	O
that	O
the	O
genetic	O
variation	B-Variation
of	O
the	O
ADRB1	B-Gene
gene	O
may	O
be	O
the	O
basis	O
of	O
interindividual	O
differences	O
in	O
pathophysiologic	O
characteristics	O
or	O
in	O
the	O
response	O
to	O
therapeutic	O
beta	O
-	O
adrenergic	O
receptor	O
agonists	O
and	O
antagonists	O
in	O
cardiovascular	O
and	O
other	O
diseases	O
.	O


In	O
2	O
sibs	O
,	O
born	O
of	O
consanguineous	O
parents	O
,	O
with	O
immunodeficiency-43	O
(	O
IMD43	O
;	O
241600	O
)	O
originally	O
reported	O
byWaldmann	O
(	O
1969	O
)	O
,	O
Wani	O
et	O
al	O
.	O

(	O
2006	O
)	O
identified	O
a	O
homozygous	O
c.913G	O
-	O
C	O
transversion	B-Variation
in	O
exon	O
1	O
of	O
the	B-Gene
B2Mgene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
an	O
ala11-to	O
-	O
pro	O
(	O
A11P	O
)	O
substitution	B-Variation
at	O
the	O
midpoint	O
of	O
the	O
signal	O
sequence	O
.	O

Both	O
sibs	O
hadB2	B-Molecular_Physiological_Activity
M	I-Molecular_Physiological_Activity
serum	I-Molecular_Physiological_Activity
levels	I-Molecular_Physiological_Activity
that	O
were	O
less	B-Negative_Regulation
than	O
1.0	O
%	O
of	O
normal	O
as	O
well	O
as	O
soluble	B-Molecular_Physiological_Activity
HLA	I-Molecular_Physiological_Activity
levels	I-Molecular_Physiological_Activity
that	O
were	O
less	B-Negative_Regulation
than	O
0.2	O
%	O
of	O
normal	O
.	O

Transfection	O
studies	O
showed	O
that	O
the	O
mutant	B-Variation
B2	I-Variation
M	I-Variation
gene	I-Variation
resulted	O
in	O
reduced	B-Negative_Regulation
expression	B-Molecular_Physiological_Activity
of	O
theB2	B-Gene
M	I-Gene
,	O
MHC	B-Gene
class	I-Gene
I	I-Gene
,	O
and	O
FcRn	B-Protein
protein	I-Protein
In	O
2	O
Turkish	O
sibs	O
,	O
born	O
of	O
consanguineous	O
parents	O
,	O
with	O
immunodeficiency-43	O
(	O
IMD43	O
;	O
241600	O
)	O
,	O
Ardeniz	O
et	O
al	O
.	O

(	O
2015	O
)	O
identified	O
a	O
homozygous	O
G	O
-	O
to	O
-	O
T	O
transversion	B-Variation
in	O
intron	O
1	O
of	O
the	B-Gene
B2	I-Gene
M	I-Gene
gene	I-Gene
(	O
c.67	O
+	O
1G	O
-	O
T	O
)	O
,	O
predicted	O
to	O
result	B-Regulation
in	I-Regulation
a	O
frameshift	B-Variation
and	O
premature	B-Molecular_Physiological_Activity
termination	I-Molecular_Physiological_Activity
in	O
exon	O
2	O
.	O

Each	O
unaffected	O
parent	O
was	O
heterozygous	O
for	O
the	O
mutation	B-Variation
,	O
which	O
was	O
not	O
found	O
in	O
200	O
control	O
chromosomes	O
.	O

Patient	O
cells	O
showed	O
absence	B-Negative_Regulation
of	O
the	O
mutant	B-Variation
transcript	B-Molecular_Physiological_Activity
,	O
consistent	O
with	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	B-Molecular_Physiological_Activity
.	O

Patient	O
lymphocytes	O
showed	O
no	B-Negative_Regulation
detectableB2	O
M	O
surface	O
protein	B-Protein
expression	B-Molecular_Physiological_Activity
,	O
and	O
undetectable	B-Negative_Regulation
serum	B-Molecular_Physiological_Activity
levels	I-Molecular_Physiological_Activity
of	I-Molecular_Physiological_Activity
B2M.	I-Molecular_Physiological_Activity
This	O
variant	B-Variation
,	O
formerly	O
titled	O
MYOCLONUS	O
-	O
DYSTONIA	O
SYNDROME	O
,	O
has	O
been	O
reclassified	O
based	O
on	O
the	O
findings	O
of	O
Klein	O
et	O
al	O
.	O

(	O
2002	O
)	O
.	O

In	O
a	O
family	O
of	O
Welsh	O
-	O
Scottish	O
-	O
German	O
origin	O
in	O
which	O
8	O
members	O
had	O
alcohol	O
-	O
responsive	O
myoclonus	O
-	O
dystonia	O
(	O
see	O
159900	O
)	O
,	O
Klein	O
et	O
al	O
.	O

(	O
1999	O
)	O
identified	O
a	O
heterozygous	O
G	O
-	O
to	O
-	O
A	O
transition	O
at	B-Variation
the	O
first	O
base	O
of	O
codon	O
154	O
of	O
the	O
DRD2	B-Gene
gene	I-Gene
,	I-Gene
resulting	O
in	B-Regulation
a	I-Regulation
val154-to	O
-	O
ile	O
(	O
V154I	O
)	O
substitution	O
.	B-Variation

By	O
in	O
vitro	O
functional	O
expression	O
assay	O
,	O
Klein	O
et	O
al	O
.	O

(	O
2000)found	O
that	O
the	O
V154I	O
-	B-Variation
mutant	I-Variation
protein	I-Variation
was	B-Protein
similar	O
to	O
wildtype	O
and	O
did	O
not	O
show	B-Neg
impaired	O
activity	B-Negative_Regulation
.	B-Molecular_Physiological_Activity

In	O
the	O
same	O
family	O
,	O
Klein	O
et	O
al	O
.	O

(	O
2002)identified	O
a	O
5-bp	O
deletion	O
in	B-Variation
the	O
SGCE	B-Gene
gene	I-Gene
(	I-Gene
604149.0005	O
)	O
in	O
all	O
8	O
affected	O
members	O
.	O

The	O
mutation	O
resulted	B-Variation
in	B-Regulation
a	I-Regulation
frameshift	O
and	B-Variation
premature	O
stop	B-Molecular_Physiological_Activity
.	I-Molecular_Physiological_Activity

There	O
were	O
2	O
unaffected	O
carriers	O
of	O
both	O
mutations	O
.	B-Variation

The	O
contribution	O
of	O
each	O
mutation	O
to	B-Variation
the	O
clinical	O
phenotype	O
could	O
not	O
be	O
determined	O
,	O
but	O
the	O
phenotype	O
most	O
likely	O
resulted	O
from	B-Regulation
the	I-Regulation
SGCE	O
mutation	B-Gene
,	B-Variation
as	O
Klein	O
et	O
al	O
.	O

(	O
2000	O
)	O
showed	O
that	O
the	O
V154I	O
DRD2	O
mutant	B-Gene
protein	B-Variation
was	B-Protein
similar	O
to	O
wildtype	O
and	O
did	O
not	O
show	B-Neg
impaired	O
activity	B-Negative_Regulation
in	B-Molecular_Physiological_Activity
in	O
vitro	O
studies	O
.	O

McInerney	O
et	O
al	O
.	O

(	O
1996	O
)	O
characterized	O
a	O
human	O
ESR	O
mutant	B-Variation
,	O
val364	O
to	O
glu	O
,	O
which	O
has	O
a	O
single	O
amino	O
acid	O
substitution	B-Variation
in	O
its	O
hormone	B-Interaction
-	I-Interaction
binding	I-Interaction
domain	O
.	O

While	O
this	O
mutant	B-Variation
is	O
fully	O
active	O
or	O
even	O
superactive	O
at	O
saturating	O
levels	O
of	O
estradiol	O
it	O
also	O
acts	O
as	O
a	O
strong	O
dominant	O
-	O
negative	O
inhibitor	B-Negative_Regulation
of	O
the	O
wildtype	O
ESR	O
and	O
it	O
is	O
able	O
to	O
repress	B-Negative_Regulation
ESR	O
-	O
mediated	O
transcription	B-Molecular_Physiological_Activity
when	O
the	O
mutant	B-Variation
and	O
wildtype	O
ESR	O
are	O
present	O
together	O
in	O
cells	O
,	O
even	O
without	O
DNA	B-Interaction
binding	I-Interaction
.	O

It	O
is	O
probable	O
that	O
altered	B-Regulation
interactions	B-Interaction
with	O
proteins	B-Protein
important	O
in	O
ESR	O
-	O
mediated	O
transcription	B-Molecular_Physiological_Activity
play	O
a	O
key	O
role	O
in	O
the	O
repression	B-Negative_Regulation
of	O
transcription	B-Molecular_Physiological_Activity
by	O
val364	O
to	O
glu	O
.	O


Among	O
310	O
individuals	O
from	O
eastern	O
India	O
,	O
Chakravorty	O
et	O
al	O
.	O

(	O
2006	O
)	O
found	O
that	O
the	O
frequency	O
of	O
the	O
IL1B	B-Gene
-31TT	O
genotype	O
was	O
0.071	O
compared	O
to	O
0.37	O
as	O
reported	O
in	O
Caucasians	O
.	O

Among	O
the	O
Indian	O
population	O
,	O
they	O
observed	O
a	O
significantly	O
higher	O
frequency	O
of	O
the	O
IL1B	B-Gene
-511TT	O
genotype	O
(	O
OR	O
of	O
4.22	O
)	O
and	O
-31CC	O
genotype	O
(	O
OR	O
of	O
2.16	O
)	O
in	O
H.	O
pylori	O
-	O
infected	O
persons	O
with	O
duodenal	O
ulcer	O
compared	O
to	O
infected	O
persons	O
with	O
normal	O
mucosa	O
.	O

The	O
-511T/-31C	O
haplotype	O
was	O
present	O
at	O
a	O
higher	O
frequency	O
in	O
H.	O
pylori	O
-	O
infected	O
duodenal	O
ulcer	O
patients	O
than	O
in	O
infected	O
controls	O
(	O
OR	O
of	O
2.47	O
)	O
.	O

Carriers	O
of	O
the	O
-31CC	O
genotype	O
had	O
significantly	O
lower	B-Negative_Regulation
IL1B	B-Gene
mRNA	B-Molecular_Physiological_Activity
levels	I-Molecular_Physiological_Activity
in	O
gastric	O
mucosa	O
compared	O
to	O
other	O
genotypes	O
,	O
and	O
IL1B	B-Gene
promoter	O
assay	O
showed	O
that	O
the	O
-31	O
T	O
promoter	O
had	O
a	O
10-fold	O
increase	B-Positive_Regulation
in	O
activity	B-Molecular_Physiological_Activity
compared	O
to	O
-31C.	O
Chakravorty	O
et	O
al	O
.	O

(	O
2006	O
)	O
suggested	O
that	O
H.	O
pylori	O
-	O
infected	O
individuals	O
with	O
the	O
-31CC	O
genotype	O
secrete	B-Molecular_Physiological_Activity
less	B-Negative_Regulation
IL1B	B-Gene
and	O
are	O
susceptible	O
to	O
duodenal	O
ulcers	O
.	O


In	O
affected	O
members	O
of	O
a	O
Japanese	O
family	O
with	O
autosomal	O
dominant	O
thrombocythemia-2	O
(	O
THCYT2	O
;	O
601977	O
)	O
,	O
Ding	O
et	O
al	O
.	O

(	O
2004	O
)	O
identified	O
a	O
heterozygous	O
1073G	O
-	O
A	O
transition	B-Variation
in	O
exon	O
10	O
of	O
the	B-Gene
MPL	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
ser505-to	O
-	O
asn	O
(	O
S505N	O
)	O
substitution	B-Variation
.	O

Cellular	O
studies	O
showed	O
that	O
mutant	B-Variation
cells	O
had	O
increased	B-Positive_Regulation
cytokine	O
-	O
independent	O
survival	B-Molecular_Physiological_Activity
and	O
constitutively	O
phosphorylated	O
Mek1/2	O
(	O
see	O
,	O
e.g.	O
,	O
176872	O
)	O
,	O
suggesting	O
that	O
S505N	O
is	O
an	O
activating	B-Positive_Regulation
mutation	B-Variation
.	O


Pikman	O
et	O
al	O
.	O

(	O
2006	O
)	O
identified	O
a	O
somatic	O
1544G	O
-	O
T	O
transversion	B-Variation
in	O
the	B-Gene
MPL	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
trp515-to	O
-	O
leu	O
(	O
W515L	O
)	O
substitution	B-Variation
,	O
in	O
4	O
(	O
9	O
%	O
)	O
of	O
45	O
patients	O
with	O
myelofibrosis	O
with	O
myeloid	O
metaplasia	O
(	O
see	O
254450	O
)	O
.	O

Two	O
of	O
the	O
patients	O
also	O
had	O
leukocytosis	O
and	O
thrombocytosis	O
at	O
the	O
time	O
of	O
disease	O
presentation	O
.	O

Functional	O
expression	O
studies	O
showed	O
that	O
this	O
was	O
an	O
activating	B-Positive_Regulation
mutation	B-Variation
conferring	O
cytokine	O
-	O
independent	O
growth	B-Cell_Physiological_Activity
and	O
hypersensitivity	B-Positive_Regulation
to	O
TPHO	O
in	O
cell	O
culture	O
.	O

The	O
W515L	O
mutant	B-Variation
protein	B-Protein
resulted	B-Regulation
in	I-Regulation
constitutive	O
phosphorylation	B-Molecular_Physiological_Activity
of	O
downstream	O
signaling	B-Pathway
molecules	O
,	O
including	O
JAK2	B-Gene
(	O
147796	O
)	O
,	O
STAT3	B-Gene
(	O
102582	O
)	O
,	O
and	O
ERK	B-Gene
(	O
600997	O
)	O
.	O

Expression	B-Molecular_Physiological_Activity
of	O
W515L	O
in	O
murine	O
bone	O
marrow	O
resulted	O
in	O
a	O
fully	O
penetrant	O
myeloproliferative	O
disorder	O
with	O
thrombocytosis	O
and	O
extramedullary	O
hematopoiesis	O
.	O


In	O
2	O
GISTs	O
with	O
the	O
550del27	O
mutation	B-Variation
,	O
which	O
encompasses	O
the	O
noncoding	O
region	O
in	O
intron	O
10	O
and	O
the	O
coding	O
region	O
in	O
exon	O
11	O
of	O
the	B-Gene
KIT	I-Gene
gene	I-Gene
,	O
Chen	O
et	O
al	O
.	O

(	O
2005	O
)	O
elucidated	O
an	O
unusual	O
mechanism	O
of	O
aberrant	O
pre	O
-	O
mRNA	O
splicing	O
resulting	O
in	O
constitutive	O
activation	B-Positive_Regulation
of	O
the	O
oncoprotein	B-Protein
.	O

The	O
deletion	B-Variation
of	O
noncoding	O
and	O
coding	O
regions	O
encompassing	O
the	O
3-prime	O
authentic	O
splice	O
site	O
creates	O
a	O
novel	O
intraexonic	O
pre	O
-	O
mRNA	O
3-prime	O
splice	O
acceptor	O
site	O
,	O
leading	O
to	O
in	O
-	O
frame	O
loss	O
of	O
27	O
nucleotides	O
.	O

Three	O
-	O
dimensional	O
structural	O
analysis	O
revealed	O
that	O
loss	B-Negative_Regulation
of	O
the	O
9	O
amino	O
acids	O
in	O
this	O
critical	O
location	O
unleashes	O
the	O
protein	O
from	O
autoinhibition	O
,	O
causing	O
KIT	B-Gene
to	O
become	O
constitutively	O
activated	B-Positive_Regulation
and	O
resulting	O
in	O
the	O
GIST	O
phenotype	O
.	O


In	O
a	O
3-year	O
-	O
old	O
Japanese	O
girl	O
(	O
TRS1	O
)	O
with	O
radioulnar	O
synostosis	O
and	O
amegakaryocytic	O
thrombocytopenia-2	O
(	O
RUSAT2	O
;	O
616738	O
)	O
,	O
Niihori	O
et	O
al	O
.	O

(	O
2015)identified	O
heterozygosity	O
for	O
a	O
c.2266A	O
-	O
G	O
transition	B-Variation
(	O
c.2266A	O
-	O
G	O
,	O
NM_001105078	O
)	O
in	O
the	B-Gene
MECOM	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
thr756-to	O
-	O
ala	O
(	O
T756A	O
)	O
substitution	B-Variation
at	O
a	O
highly	O
conserved	O
residue	O
within	O
the	O
eighth	O
zinc	O
finger	O
motif	O
in	O
the	O
C	O
-	O
terminal	O
zinc	O
finger	O
domain	O
.	O

The	O
mutation	B-Variation
was	O
not	O
present	O
in	O
her	O
unaffected	O
parents	O
or	O
healthy	O
brother	O
,	O
in	O
382	O
ethnically	O
matched	O
controls	O
,	O
or	O
in	O
the	O
dbSNP	O
,	O
1000	O
Genomes	O
Project	O
,	O
Human	O
Genetic	O
Variation	B-Variation
,	O
or	O
ExAC	O
databases	O
.	O

Luciferase	B-Enzyme
assays	O
using	O
pAP1	O
(	O
165160)-luc	O
in	O
transfected	O
NIH3T3	O
and	O
HEK293	O
cells	O
demonstrated	O
enhanced	O
suppression	B-Negative_Regulation
of	O
relative	O
luciferase	B-Enzyme
activity	B-Molecular_Physiological_Activity
with	O
the	O
T756A	O
mutant	B-Variation
compared	O
to	O
wildtype	O
EVI1	O
,	O
whereas	O
luciferase	B-Enzyme
assays	O
using	O
a	O
p3TP	O
-	O
lux	O
vector	O
showed	O
an	O
attenuated	B-Negative_Regulation
response	B-Molecular_Physiological_Activity
with	O
the	O
mutant	B-Variation
.	I-Variation

Niihori	I-Variation
et	O
al	O
.	O

(	O
2015	O
)	O
suggested	O
that	O
the	O
T756A	O
mutant	B-Variation
might	O
represent	O
a	O
gain	B-Positive_Regulation
-	I-Positive_Regulation
of	I-Positive_Regulation
-	I-Positive_Regulation
function	I-Positive_Regulation
effect	O
for	O
AP1	O
and	O
partial	O
loss	B-Negative_Regulation
of	I-Negative_Regulation
function	I-Negative_Regulation
for	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
(	O
190180	O
)	O
signaling	B-Pathway
.	O

In	O
an	O
8.75-year	O
-	O
old	O
Japanese	O
girl	O
(	O
TRS2	O
)	O
with	O
radioulnar	O
synostosis	O
and	O
amegakaryocytic	O
thrombocytopenia-2	O
(	O
RUSAT2	O
;	O
616738	O
)	O
,	O
originally	O
described	O
bySugita	O
et	O
al	O
.	O

(	O
2007	O
)	O
,	O
Niihori	O
et	O
al	O
.	O

(	O
2015	O
)	O
identified	O
heterozygosity	O
for	O
a	O
c.2252A	O
-	O
G	O
transition	B-Variation
(	O
c.2252A	O
-	O
G	O
,	O
NM_001105078	O
)	O
in	O
the	B-Gene
MECOM	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
his751-to	O
-	O
arg	O
(	O
H751R	O
)	O
substitution	B-Variation
at	O
a	O
highly	O
conserved	O
residue	O
within	O
the	O
eighth	O
zinc	O
finger	O
motif	O
in	O
the	O
C	O
-	O
terminal	O
zinc	O
finger	O
domain	O
.	O

The	O
mutation	B-Variation
was	O
not	O
present	O
in	O
her	O
unaffected	O
parents	O
,	O
in	O
382	O
ethnically	O
matched	O
controls	O
,	O
or	O
in	O
the	O
dbSNP	O
,	O
1000	O
Genomes	O
Project	O
,	O
Human	O
Genetic	O
Variation	O
,	O
or	O
ExAC	O
databases	O
.	O

Chromatin	O
immunoprecipitation	O
-	O
qPCR	O
assays	O
showed	O
a	O
significant	O
reduction	B-Negative_Regulation
in	O
immunoprecipitated	O
DNA	O
with	O
the	O
H751R	O
mutant	B-Variation
compared	O
to	O
wildtype	O
EVI1	O
.	O

Luciferase	O
assays	O
using	O
pAP1	O
(	O
165160)-luc	O
in	O
transfected	O
NIH3T3	O
and	O
HEK293	O
cells	O
demonstrated	O
enhanced	O
suppression	B-Negative_Regulation
of	O
relative	O
luciferase	B-Enzyme
activity	B-Molecular_Physiological_Activity
with	O
the	O
H751R	O
mutant	B-Variation
compared	O
to	O
wildtype	O
EVI1	O
,	O
whereas	O
luciferase	B-Enzyme
assays	O
using	O
a	O
p3TP	O
-	O
lux	O
vector	O
showed	O
an	O
attenuated	B-Negative_Regulation
response	B-Molecular_Physiological_Activity
with	O
the	O
mutant	B-Variation
.	I-Variation

Niihori	I-Variation
et	O
al	O
.	O

(	O
2015	O
)	O
suggested	O
that	O
the	O
H751R	O
mutant	B-Variation
might	O
represent	O
a	O
gain	B-Positive_Regulation
-	I-Positive_Regulation
of	I-Positive_Regulation
-	I-Positive_Regulation
function	I-Positive_Regulation
effect	O
for	O
AP1	O
and	O
partial	O
loss	B-Negative_Regulation
of	I-Negative_Regulation
function	I-Negative_Regulation
for	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
(	O
190180	O
)	O
signaling	B-Pathway
.	O

In	O
an	O
8-year	O
-	O
old	O
Japanese	O
boy	O
(	O
TRS3	O
)	O
with	O
radioulnar	O
synostosis	O
and	O
amegakaryocytic	O
thrombocytopenia-2	O
(	O
RUSAT2	O
;	O
616738	O
)	O
,	O
originally	O
reported	O
by	O
Yoshida	O
et	O
al	O
.	O

(	O
2010	O
)	O
,	O
Niihori	O
et	O
al	O
.	O

(	O
2015	O
)	O
identified	O
heterozygosity	O
for	O
a	O
c.2248C	O
-	O
T	O
transition	B-Variation
(	O
c.2248C	O
-	O
T	O
,	O
NM_001105078	O
)	O
in	O
the	B-Gene
MECOM	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
an	O
arg750-to	O
-	O
trp	O
(	O
R750W	O
)	O
substitution	B-Variation
at	O
a	O
highly	O
conserved	O
residue	O
within	O
the	O
eighth	O
zinc	O
finger	O
motif	O
in	O
the	O
C	O
-	O
terminal	O
zinc	O
finger	O
domain	O
.	O

The	O
mutation	B-Variation
was	O
not	O
present	O
in	O
his	O
unaffected	O
mother	O
,	O
in	O
382	O
ethnically	O
matched	O
controls	O
,	O
or	O
in	O
the	O
dbSNP	O
,	O
1000	O
Genomes	O
Project	O
,	O
Human	O
Genetic	O
Variation	B-Variation
,	O
or	O
ExAC	O
databases	O
.	O

DNA	O
from	O
the	O
father	O
was	O
not	O
available	O
.	O

Chromatin	O
immunoprecipitation	O
-	O
qPCR	O
assays	O
showed	O
a	O
significant	O
reduction	B-Negative_Regulation
in	O
immunoprecipitated	O
DNA	O
with	O
the	O
R750W	O
mutant	B-Variation
compared	O
to	O
wildtype	O
EVI1	O
.	O

Luciferase	B-Enzyme
assays	O
using	O
pAP1	O
(	O
165160)-luc	O
in	O
transfected	O
NIH3T3	O
and	O
HEK293	O
cells	O
demonstrated	O
enhanced	O
suppression	B-Negative_Regulation
of	O
relative	O
luciferase	B-Enzyme
activity	B-Molecular_Physiological_Activity
with	O
the	O
R750W	O
mutant	B-Variation
compared	O
to	O
wildtype	O
EVI1	O
,	O
whereas	O
luciferase	B-Enzyme
assays	O
using	O
a	O
p3TP	O
-	O
lux	O
vector	O
showed	O
an	O
attenuated	B-Negative_Regulation
response	B-Molecular_Physiological_Activity
with	O
the	O
mutant	B-Variation
.	I-Variation

Niihori	I-Variation
et	O
al	O
.	O

(	O
2015	O
)	O
suggested	O
that	O
the	O
R750W	O
mutant	B-Variation
might	O
represent	O
a	O
gain	B-Positive_Regulation
-	I-Positive_Regulation
of	I-Positive_Regulation
-	I-Positive_Regulation
function	I-Positive_Regulation
effect	O
for	O
AP1	O
and	O
partial	O
loss	B-Negative_Regulation
of	I-Negative_Regulation
function	I-Negative_Regulation
for	O
TGF	B-Protein
-	I-Protein
beta	I-Protein
(	O
190180	O
)	O
signaling	B-Pathway
.	O

In	O
a	O
7-year	O
-	O
old	O
boy	O
with	O
SHORT	O
syndrome	O
(	O
269880	O
)	O
,	O
Thauvin	O
-	O
Robinet	O
et	O
al	O
.	O

(	O
2013	O
)	O
identified	O
heterozygosity	O
for	O
a	O
de	O
novo	O
3-bp	O
deletion	B-Variation
(	O
c.1615_1617delATT	O
)	O
at	O
chr5:67,591,018	O
(	O
GRCh37	O
)	O
in	O
the	B-Gene
PIK3R1	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
deletion	B-Variation
of	O
ile539	O
in	O
the	O
inter	O
-	O
Src	O
homology	O
2	O
(	O
iSH2	O
)	O
domain	O
.	O

The	O
mutation	B-Variation
was	O
not	O
present	O
in	O
his	O
unaffected	O
parents	O
and	O
was	O
not	O
found	O
in	O
approximately	O
6,500	O
exomes	O
in	O
the	O
NHLBI	O
Exome	O
Variant	O
Server	O
,	O
dbSNP137	O
,	O
or	O
the	O
1000	O
Genomes	O
Project	O
.	O

Functional	O
studies	O
on	O
patient	O
fibroblasts	O
revealed	O
a	O
70	O
to	O
90	O
%	O
reduction	B-Negative_Regulation
in	O
the	O
effect	B-Molecular_Physiological_Activity
of	O
insulin	B-Protein
on	O
AKT	B-Gene
(	O
see	O
164730	O
)	O
activation	B-Molecular_Physiological_Activity
,	O
glycogen	B-Molecular_Physiological_Activity
synthesis	I-Molecular_Physiological_Activity
,	O
and	O
glucose	B-Molecular_Physiological_Activity
uptake	I-Molecular_Physiological_Activity
,	O
indicating	O
severe	O
insulin	B-Molecular_Physiological_Activity
resistance	I-Molecular_Physiological_Activity
for	O
both	O
proximal	O
and	O
distal	O
PI3K	B-Gene
-	I-Gene
dependent	I-Gene
signaling	B-Pathway
.	O

In	O
a	O
7-year	O
-	O
old	O
boy	O
with	O
SHORT	O
syndrome	O
(	O
269880	O
)	O
,	O
Thauvin	O
-	O
Robinet	O
et	O
al	O
.	O

(	O
2013	O
)	O
identified	O
heterozygosity	O
for	O
a	O
de	O
novo	O
c.1465G	O
-	O
A	O
transition	B-Variation
at	O
chr5:67,590,403	O
(	O
GRCh37	O
)	O
in	O
the	B-Gene
PIK3R1	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
glu489-to	O
-	O
lys	O
(	O
E489	O
K	O
)	O
substitution	B-Variation
at	O
a	O
highly	O
conserved	O
residue	O
in	O
the	O
inter	O
-	O
Src	O
homology	O
2	O
(	O
iSH2	O
)	O
domain	O
.	O

The	O
mutation	B-Variation
was	O
not	O
present	O
in	O
his	O
unaffected	O
parents	O
and	O
was	O
not	O
found	O
in	O
approximately	O
6,500	O
exomes	O
in	O
the	O
NHLBI	O
Exome	O
Variant	O
Server	O
,	O
dbSNP137	O
,	O
or	O
the	O
1000	O
Genomes	O
Project	O
.	O

Functional	O
studies	O
on	O
patient	O
fibroblasts	O
revealed	O
a	O
70	O
to	O
90	O
%	O
reduction	B-Negative_Regulation
in	O
the	O
effect	O
of	O
insulin	O
on	O
AKT	B-Pathway
(	I-Pathway
see	I-Pathway
164730	I-Pathway
)	I-Pathway
activation	I-Pathway
,	O
glycogen	B-Molecular_Physiological_Activity
synthesis	I-Molecular_Physiological_Activity
,	O
and	O
glucose	B-Molecular_Physiological_Activity
uptake	I-Molecular_Physiological_Activity
,	O
indicating	O
severe	O
insulin	O
resistance	B-Negative_Regulation
for	O
both	O
proximal	O
and	O
distal	O
PI3K	B-Pathway
-	I-Pathway
dependent	I-Pathway
signaling	I-Pathway
.	O

In	O
a	O
2-year	O
-	O
old	O
girl	O
with	O
SHORT	O
syndrome	O
(	O
269880	O
)	O
,	O
Dyment	O
et	O
al	O
.	O

(	O
2013	O
)	O
identified	O
heterozygosity	O
for	O
a	O
de	O
novo	O
1-bp	O
insertion	B-Variation
(	O
c.1906_1907insC	O
)	O
in	O
exon	O
14	O
of	O
the	B-Gene
PIK3R1	I-Gene
gene	I-Gene
,	O
causing	B-Regulation
a	O
frameshift	B-Variation
predicted	O
to	O
generate	B-Regulation
a	O
premature	B-Molecular_Physiological_Activity
termination	I-Molecular_Physiological_Activity
codon	I-Molecular_Physiological_Activity
(	O
Asn636ThrfsTer18	O
)	O
.	O

The	O
mutation	B-Variation
was	O
not	O
found	O
in	O
her	O
unaffected	O
parents	O
.	O

Functional	O
analysis	O
of	O
patient	O
lymphoblastoid	O
cells	O
showed	O
decreased	B-Negative_Regulation
phosphorylation	B-Molecular_Physiological_Activity
of	O
the	O
downstream	O
S6	O
target	O
of	O
the	O
PI3K	B-Pathway
-	I-Pathway
AKT	I-Pathway
(	I-Pathway
see	I-Pathway
164730)-mTOR	I-Pathway
(	I-Pathway
601231	I-Pathway
)	I-Pathway
pathway	I-Pathway
.	O

In	O
a	O
patient	O
with	O
immunodeficiency-36	O
(	O
IMD36	O
;	O
616005	O
)	O
,	O
Deau	O
et	O
al	O
.	O

(	O
2014	O
)	O
identified	O
a	O
de	O
novo	O
heterozygous	O
G	O
-	O
to	O
-	O
T	O
transversion	B-Variation
in	O
intron	O
10	O
of	O
the	B-Gene
PIK3R1	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
an	O
in	O
-	O
frame	O
deletion	B-Variation
of	O
exon	O
10	O
and	O
removal	O
of	O
a	O
peptide	O
sequence	O
that	O
is	O
part	O
of	O
an	O
alpha	O
-	O
helix	O
involved	O
in	O
p110	O
binding	B-Interaction
.	O

The	O
mutation	B-Variation
,	O
which	O
was	O
found	O
by	O
whole	O
-	O
exome	O
sequencing	O
and	O
confirmed	O
by	O
Sanger	O
sequencing	O
,	O
was	O
not	O
found	O
in	O
the	O
Exome	O
Variant	O
Server	O
database	O
or	O
in	O
an	O
in	O
-	O
house	O
control	O
database	O
.	O

The	O
same	O
splice	O
site	O
mutation	B-Variation
,	O
resulting	B-Regulation
from	I-Regulation
a	O
different	O
nucleotide	O
change	O
(	O
171833.0008	O
)	O
,	O
was	O
found	O
in	O
3	O
additional	O
patients	O
with	O
a	O
similar	O
disorder	O
.	O

Both	O
mutations	B-Variation
resulted	O
in	O
a	O
loss	B-Negative_Regulation
of	O
p85-mediated	O
inhibition	B-Molecular_Physiological_Activity
and	O
caused	O
increased	B-Positive_Regulation
phosphorylation	B-Molecular_Physiological_Activity
of	O
downstream	O
signaling	B-Pathway
pathways	B-Pathway
,	O
consistent	O
with	O
a	O
gain	B-Positive_Regulation
of	O
function	B-Molecular_Physiological_Activity
.	O

Immunologic	O
studies	O
showed	O
a	O
defect	B-Negative_Regulation
in	O
both	O
B-	O
and	O
T	O
-	O
cell	O
differentiation	O
.	O

In	O
the	O
numbering	O
system	O
of	O
amino	O
acids	O
provided	O
by	O
the	O
corrected	O
sequence	O
data	O
for	O
human	O
RYR1	B-Gene
according	O
to	O
Phillips	O
et	O
al	O
.	O

(	O
1996	O
)	O
,	O
this	O
mutation	O
was	O
referred	O
to	O
as	O
G2434R	O
by	O
Richter	O
et	O
al	O
.	O

(	O
1997	O
)	O
.	O

Functional	O
studies	O
showed	O
that	O
the	O
G2434R	O
mutation	B-Variation
enhanced	B-Positive_Regulation
the	O
sensitivity	B-Molecular_Physiological_Activity
of	O
RYR1	B-Gene
to	O
activating	B-Positive_Regulation
concentrations	O
of	O
calcium	O
and	O
to	O
caffeine	O
.	O

In	O
parallel	O
,	O
the	O
sensitivity	B-Molecular_Physiological_Activity
to	O
inhibiting	B-Negative_Regulation
concentrations	O
of	O
calcium	O
and	O
calmodulin	O
was	O
reduced	B-Negative_Regulation
,	O
transferring	O
the	O
mutant	B-Variation
calcium-	O
release	O
channel	O
into	O
a	O
hyperexcitable	O
state	O
.	O


In	O
affected	O
members	O
of	O
3	O
European	O
families	O
with	O
familial	O
hemiplegic	O
migraine-3	O
(	O
609634	O
)	O
,	O
Dichgans	O
et	O
al	O
.	O

(	O
2005	O
)	O
identified	O
a	O
heterozygous	O
4465C	O
-	O
A	O
transversion	B-Variation
in	O
exon	O
23	O
of	O
the	B-Gene
SCN1A	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
gln1489-to	O
-	O
lys	O
(	O
Q1489	O
K	O
)	O
substitution	B-Variation
in	O
the	O
cytoplasmic	O
linker	O
between	O
domains	O
III	O
and	O
IV	O
,	O
which	O
is	O
critical	O
for	O
fast	O
inactivation	B-Molecular_Physiological_Activity
.	O

The	O
mutation	B-Variation
occurs	O
in	O
a	O
highly	O
conserved	O
residue	O
of	O
the	O
protein	B-Protein
and	O
was	O
not	O
identified	O
in	O
1400	O
control	O
chromosomes	O
.	O

Functional	O
expression	O
studies	O
showed	O
that	O
the	O
Q1489	O
K	O
substitution	B-Variation
resulted	O
in	O
a	O
2-	O
to	O
4-fold	O
faster	B-Positive_Regulation
recovery	B-Molecular_Physiological_Activity
from	O
fast	O
inactivation	B-Molecular_Physiological_Activity
.	O

The	O
mutation	B-Variation
was	O
predicted	O
to	O
allow	O
higher	B-Positive_Regulation
neuronal	O
firing	O
rates	O
and	O
enhanced	B-Positive_Regulation
excitability	B-Molecular_Physiological_Activity
.	O

Dichgans	O
et	O
al	O
.	O

(	O
2005	O
)	O
suggested	O
that	O
the	O
mutation	B-Variation
may	O
facilitate	B-Positive_Regulation
initiation	B-Molecular_Physiological_Activity
and	O
propagation	B-Cell_Physiological_Activity
of	O
cortical	O
spreading	O
depression	O
,	O
which	O
is	O
thought	O
to	O
be	O
related	O
to	O
migraine	O
aura	O

In	O
an	O
infant	O
with	O
adrenal	O
failure	O
and	O
complete	O
46,XY	O
sex	O
reversal	O
(	O
SRXY3	O
;	O
612965	O
)	O
,	O
Achermann	O
et	O
al	O
.	O

(	O
2002)reported	O
a	O
homozygous	O
G	O
-	O
to	O
-	O
A	O
transition	B-Variation
in	O
exon	O
4	O
of	O
the	B-Gene
NR5A1	I-Gene
gene	I-Gene
,	O
which	O
resulted	B-Regulation
in	I-Regulation
an	O
arg92-to	O
-	O
gln	O
(	O
R92Q	O
)	O
amino	B-Variation
acid	I-Variation
change	I-Variation
.	O

This	O
mutation	B-Variation
altered	B-Regulation
a	O
highly	O
conserved	O
residue	O
of	O
the	O
A	O
box	O
,	O
a	O
region	O
that	O
functions	O
as	O
a	O
secondary	O
DNA	O
binding	B-Interaction
domain	O
.	O

Three	O
relatives	O
of	O
the	O
infant	O
(	O
parents	O
and	O
a	O
sister	O
)	O
were	O
phenotypically	O
normal	O
despite	O
being	O
heterozygous	O
for	O
the	O
mutation	B-Variation
.	O

In	O
functional	O
assays	O
,	O
the	O
R92Q	B-Gene
mutant	B-Variation
exhibited	O
partial	O
loss	B-Negative_Regulation
of	O
DNA	B-Interaction
binding	I-Interaction
and	O
transcriptional	B-Molecular_Physiological_Activity
activity	I-Molecular_Physiological_Activity
when	O
compared	O
with	O
the	O
G35E	O
P	O
-	O
box	O
change	O
(	O
184757.0001	O
)	O
,	O
consistent	O
with	O
its	O
phenotypic	O
expression	B-Molecular_Physiological_Activity
only	O
when	O
transmitted	O
as	O
a	O
homozygous	O
trait	O
Correa	O
et	O
al	O
.	O

(	O
2004	O
)	O
reported	O
a	O
novel	O
8-bp	O
microdeletion	B-Variation
of	O
SF1	B-Gene
,	O
isolated	O
from	O
a	O
46,XY	O
patient	O
who	O
presented	O
with	O
gonadal	O
agenesis	O
but	O
normal	O
adrenal	O
function	O
(	O
SRXY3	O
;	O
612965	O
)	O
,	O
that	O
causes	O
premature	B-Molecular_Physiological_Activity
termination	I-Molecular_Physiological_Activity
upstream	O
of	O
sequences	O
encoding	O
the	O
activation	B-Positive_Regulation
function-2	B-Molecular_Physiological_Activity
domain	O
.	O

In	O
cell	O
transfection	O
experiments	O
,	O
the	O
mutated	B-Variation
protein	B-Protein
possessed	O
no	B-Negative_Regulation
intrinsic	O
transcriptional	B-Molecular_Physiological_Activity
activity	I-Molecular_Physiological_Activity
but	O
rather	O
inhibited	B-Negative_Regulation
the	O
function	B-Molecular_Physiological_Activity
of	O
the	O
wildtype	O
protein	B-Protein
in	O
most	O
cell	O
types	O
.	O

The	O
authors	O
stated	O
that	O
this	O
was	O
the	O
first	O
example	O
of	O
an	O
apparent	O
dominant	O
-	O
negative	O
effect	O
of	O
an	O
SF1	B-Gene
mutation	B-Variation
in	O
humans	O
.	O

The	O
authors	O
concluded	O
that	O
these	O
findings	O
,	O
which	O
defined	O
an	O
SF1	B-Gene
mutation	B-Variation
that	O
apparently	O
differentially	O
affects	B-Regulation
its	O
transcriptional	B-Molecular_Physiological_Activity
activity	I-Molecular_Physiological_Activity
in	O
vivo	O
in	O
the	O
adrenal	O
cortex	O
and	O
the	O
gonads	O
,	O
may	O
be	O
relevant	O
to	O
patients	O
who	O
present	O
with	O
46,XY	O
sex	O
reversal	O
but	O
normal	O
adrenal	O
functions	O
.	O

In	O
a	O
46,XY	O
patient	O
showing	O
gonadal	O
dysgenesis	O
with	O
normal	O
adrenal	O
function	O
(	O
SRXY3	O
;	O
612965	O
)	O
,	O
Mallet	O
et	O
al	O
.	O

(	O
2004	O
)	O
reported	O
a	O
heterozygous	O
SF1	B-Gene
gene	I-Gene
mutation	B-Variation
,	O
a	O
C	O
-	O
to	O
-	O
A	O
transversion	B-Variation
in	O
exon	O
2	O
that	O
replaced	B-Regulation
cys16	O
with	O
a	O
stop	B-Molecular_Physiological_Activity
codon	I-Molecular_Physiological_Activity
(	O
C16X	O
)	O
.	O

The	O
patient	O
showed	O
low	B-Negative_Regulation
basal	O
levels	O
of	O
anti	O
-	O
mullerian	O
hormone	O
(	O
600957	O
)	O
and	O
testosterone	O
(	O
T	O
)	O
,	O
weak	B-Negative_Regulation
T	O
response	B-Cell_Physiological_Activity
to	O
chorionic	O
gonadotropin	O
(	O
see	O
118860	O
)	O
,	O
and	O
hypoplastic	O
testes	O
with	O
abundant	O
seminiferous	O
tubules	O
but	O
rare	O
germ	O
cells	O
.	O

This	O
mutation	B-Variation
caused	B-Regulation
premature	B-Molecular_Physiological_Activity
termination	I-Molecular_Physiological_Activity
of	O
translation	B-Molecular_Physiological_Activity
and	O
should	O
abolish	B-Negative_Regulation
all	O
SF1	B-Gene
activity	B-Molecular_Physiological_Activity
;	I-Molecular_Physiological_Activity
therefore	O
,	O
haploinsufficiency	O
could	O
explain	O
the	O
deleterious	B-Negative_Regulation
effect	O
of	O
this	O
mutation	B-Variation
,	O
suggesting	O
that	O
testis	B-Cell_Physiological_Activity
development	I-Cell_Physiological_Activity
is	O
more	O
SF1	B-Gene
dose	O
-	O
dependent	O
than	O
adrenal	B-Cell_Physiological_Activity
development	I-Cell_Physiological_Activity
.	O

The	O
authors	O
concluded	O
that	O
heterozygous	O
mutation	B-Variation
can	O
impair	B-Negative_Regulation
adrenal	B-Cell_Physiological_Activity
development	I-Cell_Physiological_Activity
only	O
if	O
the	O
2	O
mechanisms	O
,	O
gene	B-Gene
dosage	O
and	O
dominant	O
-	O
negative	O
effects	O
,	O
occur	O
.	O

Lourenco	O
et	O
al	O
.	O

(	O
2009	O
)	O
reported	O
a	O
girl	O
of	O
Roma	O
origin	O
who	O
presented	O
at	O
12.5	O
years	O
with	O
short	O
stature	O
and	O
a	O
46,XX	O
karyotype	O
.	O

She	O
was	O
diagnosed	O
with	O
ovarian	O
failure	O
(	O
POF7	O
;	O
612964	O
)	O
.	O

Analysis	O
of	O
the	B-Gene
NR5A1	I-Gene
gene	I-Gene
revealed	O
a	O
heterozygous	O
in	O
-	O
frame	O
9-bp	O
deletion	B-Variation
(	O
691_699delCTGCAGCTG	O
)	O
that	O
results	O
in	O
the	O
loss	B-Negative_Regulation
of	O
3	O
amino	O
acids	O
(	O
leu231_leu233	O
)	O
in	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
ligand	B-Interaction
-	I-Interaction
binding	I-Interaction
domain	O
.	O

In	O
silico	O
analysis	O
predicted	O
a	O
change	O
in	O
hydrophobicity	O
of	O
helix	O
1	O
of	O
the	O
ligand	B-Interaction
-	I-Interaction
binding	I-Interaction
domain	O
.	O

Functional	O
studies	O
indicated	O
that	O
the	O
mutation	B-Variation
substantially	O
impaired	B-Molecular_Physiological_Activity
NR5A1	I-Molecular_Physiological_Activity
transactivational	I-Molecular_Physiological_Activity
activity	B-Molecular_Physiological_Activity
.	O

The	O
deletion	B-Variation
was	O
not	O
observed	O
in	O
800	O
control	O
alleles	O
,	O
including	O
samples	O
from	O
69	O
unaffected	O
subjects	O
of	O
Roma	O
origin	O
and	O
56	O
unaffected	O
subjects	O
from	O
an	O
Indian	O
Gujarati	O
population	O
.	O

This	O
TPMT	O
variant	O
is	O
referred	O
to	O
as	O
the	O
TPMT*2	O
allele	O
(	O
Tai	O
et	O
al	O
.	O

,	O
1996	O
)	O
.	O

n	O
an	O
8-year	O
-	O
old	O
girl	O
with	O
thiopurine	O
S	O
-	O
methyltransferase	O
deficiency	O
(	O
610460	O
)	O
originally	O
reported	O
by	O
Evans	O
et	O
al	O
.	O

(	O
1991	O
)	O
,	O
Krynetski	O
et	O
al	O
.	O

(	O
1995	O
)	O
identified	O
a	O
238G	O
-	O
C	O
transversion	B-Variation
in	O
the	B-Gene
TPMT	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
an	O
ala80-to	O
-	O
pro	O
(	O
A80P	O
)	O
substitution	B-Variation
.	O

The	O
patient	O
developed	O
severe	O
hematologic	O
toxicity	O
after	O
conventional	O
therapy	O
for	O
acute	O
lymphoblastic	O
leukemia	O
with	O
oral	O
mercaptopurine	O
.	O

Functional	O
expression	O
studies	O
in	O
a	O
yeast	O
heterologous	O
expression	O
system	O
showed	O
that	O
the	O
A80P	O
mutant	B-Variation
enzyme	I-Variation
had	O
a	O
100-fold	O
reduction	B-Negative_Regulation
in	B-Molecular_Physiological_Activity
TPMT	I-Molecular_Physiological_Activity
catalytic	I-Molecular_Physiological_Activity
activity	B-Molecular_Physiological_Activity
compared	O
to	O
the	O
wildtype	O
enzyme	O
,	O
despite	O
a	O
comparable	O
level	O
of	O
mRNA	O
expression	B-Molecular_Physiological_Activity
.	O

A	O
mutation	O
-	O
specific	O
PCR	O
amplification	O
method	O
was	O
developed	O
and	O
used	O
to	O
detect	O
the	O
same	O
mutation	B-Variation
in	O
genomic	O
DNA	O
of	O
the	O
proposita	O
and	O
her	O
mother	O
.	O

Krynetski	O
et	O
al	O
.	O

(	O
1995	O
)	O
concluded	O
that	O
the	O
patient	O
had	O
a	O
second	O
inactivating	O
mutation	B-Variation
.	O

This	O
TPMT	O
variant	O
is	O
referred	O
to	O
as	O
TPMT*3A	O
(	O
Tai	O
et	O
al	O
.	O

,	O
1997	O
)	O
.	O

See	O
also	O
TPMT*3B	O
(	O
A154	O
T	O
;	O
187680.0004	O
)	O
andTPMT*3C	O
(	O
Y240C	O
;	O
187680.0005	O
)	O
.	O


In	O
4	O
individuals	O
with	O
decreased	B-Negative_Regulation
TPMT	I-Negative_Regulation
activity	I-Negative_Regulation
(	O
610460	O
)	O
,	O
Szumlanski	O
et	O
al	O
.	O

(	O
1996	O
)	O
identified	O
homozygosity	O
for	O
2	O
mutations	B-Variation
in	O
the	B-Gene
TPMT	I-Gene
gene	I-Gene
:	I-Gene
a	O
460G	O
-	O
A	O
transition	B-Variation
in	O
exon	O
7	O
resulting	B-Regulation
in	I-Regulation
an	O
ala154-to	O
-	O
thr	O
(	O
A154	O
T	O
)	O
substitution	B-Variation
,	O
and	O
a	O
719A	O
-	O
G	O
transition	B-Variation
in	O
exon	O
10	O
resulting	B-Regulation
in	I-Regulation
a	O
tyr240-to	O
-	O
cys	O
(	O
Y240C	O
)	O
substitution	B-Variation
.	O

Three	O
liver	O
samples	O
from	O
individuals	O
with	O
intermediate	B-Molecular_Physiological_Activity
TPMT	I-Molecular_Physiological_Activity
activity	I-Molecular_Physiological_Activity
were	O
heterozygous	O
for	O
the	O
2	O
mutations	B-Variation
.	O

In	O
vitro	O
functional	O
expression	O
studies	O
showed	O
that	O
each	O
mutation	B-Variation
independently	O
,	O
as	O
well	O
as	O
both	O
together	O
,	O
resulted	B-Regulation
in	I-Regulation
decreased	B-Molecular_Physiological_Activity
expression	I-Molecular_Physiological_Activity
of	B-Gene
TPMT	I-Gene
enzymatic	I-Gene
activity	B-Molecular_Physiological_Activity
and	O
immunoreactive	O
protein	O
.	O

In	O
an	O
individual	O
with	O
thiopurine	O
S	O
-	O
methyltransferase	O
deficiency	O
(	O
610460	O
)	O
,	O
Otterness	O
et	O
al	O
.	O

(	O
1998	O
)	O
identified	O
compound	O
heterozygosity	O
for	O
2	O
mutations	B-Variation
in	O
the	B-Gene
TPMT	I-Gene
gene	I-Gene
:	I-Gene
TPMT*3A	I-Gene
(	O
187680.0002	O
)	O
and	O
a	O
new	O
variant	O
allele	O
,	O
TPMT*4A	O
,	O
caused	O
by	O
a	O
G	O
-	O
to	O
-	O
A	O
transition	B-Variation
that	O
disrupted	B-Negative_Regulation
the	O
acceptor	O
splice	O
junction	O
at	O
the	O
final	O
3-prime	O
nucleotide	O
of	O
intron	O
9	O
.	O

The	O
new	O
allele	O
was	O
found	O
to	O
cosegregate	O
with	O
reduced	B-Molecular_Physiological_Activity
TPMT	I-Molecular_Physiological_Activity
activity	I-Molecular_Physiological_Activity
within	O
an	O
extended	O
kindred	O
.	O

The	O
mutation	B-Variation
was	O
found	O
to	O
lead	O
to	O
generation	B-Positive_Regulation
of	O
at	O
least	O
2	O
aberrant	O
mRNA	O
species	O
.	O

The	O
first	O
resulted	O
from	O
use	O
of	O
a	O
novel	O
splice	O
site	O
located	O
1	O
nucleotide	O
3-prime	O
downstream	O
from	O
the	O
original	O
splice	O
junction	O
.	O

This	O
mRNA	O
species	O
contained	O
a	O
single	O
nucleotide	O
deletion	B-Variation
and	O
a	O
frameshift	B-Variation
in	O
exon	O
10	O
,	O
the	O
terminal	O
exon	O
of	O
the	O
gene	B-Gene
.	O

The	O
second	O
novel	O
mRNA	O
species	O
resulted	O
from	O
activation	B-Positive_Regulation
of	O
a	O
cryptic	O
splice	O
site	O
located	O
within	O
intron	O
9	O
,	O
leading	B-Regulation
to	I-Regulation
inclusion	O
of	O
330	O
nucleotides	O
of	O
intron	O
sequence	O
.	O

That	O
sequence	O
contained	O
a	O
premature	B-Molecular_Physiological_Activity
translation	I-Molecular_Physiological_Activity
termination	I-Molecular_Physiological_Activity
codon	O
.	O

TPMT*4	O
was	O
the	O
first	O
reported	O
allele	O
for	O
low	B-Molecular_Physiological_Activity
TPMT	I-Molecular_Physiological_Activity
activity	I-Molecular_Physiological_Activity
as	B-Regulation
a	I-Regulation
result	I-Regulation
of	I-Regulation
a	O
mutation	B-Variation
within	O
an	O
intron	O
In	O
2	O
unrelated	O
patients	O
with	O
infantile	O
hemangioma	O
(	O
602089	O
)	O
,	O
Jinnin	O
et	O
al	O
.	O

(	O
2008	O
)	O
identified	O
a	O
germline	O
T	O
-	O
to	O
-	O
C	O
transition	B-Variation
in	O
the	O
KDR	B-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
cys482-to	O
-	O
arg	O
(	O
C482R	O
)	O
substitution	B-Variation
in	O
the	O
extracellular	O
region	O
.	O

The	O
same	O
change	B-Variation
was	O
identified	O
in	O
8	O
of	O
105	O
additional	O
individuals	O
with	O
hemangioma	O
and	O
in	O
12	O
of	O
295	O
controls	O
.	O

Expression	B-Molecular_Physiological_Activity
of	O
FLT1	B-Gene
(	O
165070	O
)	O
in	O
hemangioma	O
endothelial	O
cells	O
was	O
markedly	O
reduced	B-Negative_Regulation
,	O
and	O
KDR	B-Gene
activity	B-Molecular_Physiological_Activity
was	O
increased	B-Positive_Regulation
,	O
compared	O
to	O
controls	O
.	O

In	O
normal	O
endothelial	O
cells	O
,	O
FLT1	B-Gene
transcription	B-Molecular_Physiological_Activity
is	O
dependent	B-Regulation
on	I-Regulation
NFAT	B-Gene
(	O
see	O
,	O
e.g.	O
,	O
NFATC2	O
;	O
600490	O
)	O
activation	B-Molecular_Physiological_Activity
.	O

Further	O
studies	O
indicated	O
that	O
low	B-Negative_Regulation
VEGFR1	B-Gene
expression	B-Molecular_Physiological_Activity
in	O
hemangioma	O
cells	O
was	O
caused	B-Regulation
by	I-Regulation
reduced	B-Negative_Regulation
activity	B-Molecular_Physiological_Activity
of	O
a	O
pathway	B-Pathway
involving	O
ITGB1	B-Gene
(	O
135630	O
)	O
,	O
TEM8	B-Gene
(	O
ANTXR1;606410	O
)	O
,	O
KDR	B-Gene
,	O
and	O
NFAT	B-Gene
.	O

The	O
KDR	B-Gene
mutation	B-Variation
was	O
predicted	O
to	O
result	O
in	O
loss	B-Negative_Regulation
of	O
function	B-Molecular_Physiological_Activity
and	O
disruption	B-Negative_Regulation
of	O
the	O
normal	O
association	B-Interaction
of	O
these	O
molecules	O
,	O
leading	O
to	O
an	O
increased	O
risk	B-Negative_Regulation
for	O
development	B-Cell_Physiological_Activity
of	I-Cell_Physiological_Activity
hemangioma	I-Cell_Physiological_Activity
.	O

Yang	O
et	O
al	O
.	O

(	O
2009	O
)	O
identified	O
the	O
R130C	O
substitution	B-Variation
in	O
a	O
patient	O
with	O
HSD10	B-Gene
deficiency	O
reported	O
by	O
Sutton	O
et	O
al	O
.	O

(	O
2003	O
)	O
.	O

The	O
patient	O
had	O
a	O
severe	O
phenotype	O
with	O
seizures	O
and	O
visual	O
loss	O
,	O
and	O
died	O
at	O
age	O
10	O
years	O
.	O

Yang	O
et	O
al	O
.	O

(	O
2009	O
)	O
stated	O
that	O
the	O
R130C	O
substitution	B-Variation
resulted	B-Regulation
from	I-Regulation
a	O
419C	O
-	O
T	O
transition	B-Variation
in	O
exon	O
4	O
of	O
the	B-Gene
HSD17B10	I-Gene
gene	I-Gene
.	O

Fibroblast	B-Molecular_Physiological_Activity
HSD17B10	I-Molecular_Physiological_Activity
protein	I-Molecular_Physiological_Activity
levels	I-Molecular_Physiological_Activity
were	O
about	O
50	O
%	O
of	O
normal	O
controls	O
,	O
but	O
enzyme	B-Molecular_Physiological_Activity
activity	I-Molecular_Physiological_Activity
was	O
less	B-Negative_Regulation
than	O
1.4	O
%	O
of	O
normal	O
values	O
.	O

In	O
vitro	O
functional	O
expression	O
assays	O
showed	O
that	O
the	O
mutant	B-Variation
protein	B-Protein
had	O
almost	O
no	B-Negative_Regulation
catalytic	B-Molecular_Physiological_Activity
activity	I-Molecular_Physiological_Activity
toward	O
allopregnanolone	O
or	O
2-methyl-3-hydroxybutyryl	O
CoA.	O
Yang	O
et	O
al	O
.	O

(	O
2009	O
)	O
postulated	O
that	O
the	O
neurologic	B-Cell_Physiological_Activity
phenotype	I-Cell_Physiological_Activity
was	O
due	O
to	O
an	O
imbalance	B-Negative_Regulation
in	O
neurosteroid	B-Pathway
metabolism	I-Pathway
.	I-Pathway

Yang	O
(	O
2014	O
)	O
corrected	O
the	O
nucleotide	O
transition	B-Variation
to	O
388C	O
-	O
T.	O
In	O
affected	O
members	O
of	O
the	O
family	O
described	O
by	O
Reyniers	O
et	O
al	O
.	O

(	O
1999	O
)	O
with	O
mild	O
mental	O
retardation	O
distinguished	O
particularly	O
by	O
the	O
presence	O
of	O
chorioathetosis	O
(	O
MRXS10	O
;	O
300220	O
)	O
,	O
Lenski	O
et	O
al	O
.	O

(	O
2007	O
)	O
detected	O
a	O
C	O
-	O
to	O
-	O
A	O
transversion	B-Variation
in	O
exon	O
5	O
of	O
the	B-Gene
HADH2	I-Gene
gene	I-Gene
,	O
574C	O
-	O
A	O
,	O
that	O
resulted	B-Regulation
in	I-Regulation
a	O
silent	O
amino	O
acid	O
substitution	B-Variation
(	O
arg192	O
to	O
arg	O
,	O
R192R	O
)	O
.	O

The	O
mutation	B-Variation
resulted	O
in	O
anomalous	O
splicing	O
with	O
loss	B-Negative_Regulation
of	O
exon	O
5	O
and	O
a	O
premature	B-Molecular_Physiological_Activity
stop	I-Molecular_Physiological_Activity
codon	I-Molecular_Physiological_Activity
in	O
exon	O
6	O
.	O

Western	O
blot	O
analysis	O
demonstrated	O
that	O
the	O
mutation	B-Variation
resulted	O
in	O
60	O
to	O
70	O
%	O
reduced	B-Negative_Regulation
HADH2	B-Protein
protein	I-Protein
in	O
the	O
proband	O
.	O

Lenski	O
et	O
al	O
.	O

(	O
2007	O
)	O
concluded	O
that	O
reduced	B-Negative_Regulation
expression	B-Molecular_Physiological_Activity
of	O
the	O
wildtype	O
fragment	O
,	O
which	O
resulted	O
in	O
decreased	B-Negative_Regulation
protein	B-Molecular_Physiological_Activity
expression	I-Molecular_Physiological_Activity
,	O
rather	O
than	O
the	O
increased	B-Positive_Regulation
amount	O
of	O
aberrant	O
splicing	B-Molecular_Physiological_Activity
fragments	O
of	O
the	O
HADH2	B-Gene
gene	I-Gene
,	O
was	O
pathogenic	O
In	O
a	O
patient	O
with	O
HSD10	O
deficiency	O
and	O
mild	O
mental	O
retardation	O
(	O
300438	O
)	O
reported	O
by	O
Olpin	O
et	O
al	O
.	O

(	O
2002	O
)	O
,	O
Yang	O
et	O
al	O
.	O

(	O
2009	O
)	O
identified	O
a	O
776G	O
-	O
C	O
transversion	B-Variation
in	O
exon	O
6	O
of	O
the	B-Gene
HSD17B10	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
glu249-to	O
-	O
gln	O
(	O
E249Q	O
)	O
substitution	B-Variation
.	I-Variation

HSD17B10	I-Variation
protein	I-Variation
levels	I-Pathway
in	O
patient	O
fibroblasts	O
were	O
about	O
50	O
%	O
of	O
normal	O
controls	O
.	O

The	O
mutation	B-Variation
appeared	O
to	O
affect	B-Regulation
HSD10	O
subunit	O
interactions	B-Interaction
,	O
resulting	B-Regulation
in	I-Regulation
an	O
allosteric	B-Variation
regulatory	O
enzyme	B-Enzyme
.	O

In	O
vitro	O
functional	O
expression	O
assays	O
showed	O
that	O
the	O
mutant	B-Variation
protein	I-Variation
was	O
unable	B-Negative_Regulation
to	O
catalyze	O
the	O
dehydrogenation	B-Molecular_Physiological_Activity
of	O
2-methyl-3-hydroxybutyryl	O
CoA	O
and	O
the	O
oxidation	B-Molecular_Physiological_Activity
of	O
allopregnanolone	O
at	O
low	O
substrate	O
concentrations	O
.	O

Yang	O
et	O
al	O
.	O

(	O
2009)postulated	O
that	O
the	O
neurologic	B-Cell_Physiological_Activity
phenotype	I-Cell_Physiological_Activity
was	O
due	O
to	O
an	O
imbalance	B-Negative_Regulation
in	O
neurosteroid	B-Pathway
metabolism	I-Pathway
.	I-Pathway

Yang	O
(	O
2014)corrected	O
the	O
nucleotide	O
transversion	B-Variation
to	O
745C	O
-	O
T.	O
In	O
a	O
boy	O
with	O
a	O
severe	O
form	O
of	O
HSD10	B-Gene
deficiency	O
(	O
300438	O
)	O
,	O
Rauschenberger	O
et	O
al	O
.	O

(	O
2010	O
)	O
identified	O
a	O
hemizygous	O
c.257A	O
-	O
G	O
transition	B-Variation
in	O
exon	O
3	O
of	O
the	B-Gene
HSD17B10	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
an	O
asp86-to	O
-	O
gly	O
(	O
D86	O
G	O
)	O
substitution	B-Variation
.	O

Patient	O
fibroblasts	O
showed	O
about	O
30	O
%	O
residual	O
enzymatic	B-Molecular_Physiological_Activity
activity	I-Molecular_Physiological_Activity
.	O

The	O
patient	O
had	O
absent	O
neurologic	B-Cell_Physiological_Activity
development	I-Cell_Physiological_Activity
and	O
died	O
of	O
progressive	O
hypertrophic	O
cardiomyopathy	O
at	O
age	O
7	O
months	O
.	O

Patient	O
cells	O
showed	O
punctate	O
and	O
fragmented	O
mitochondrial	O
organization	O
.	O

Transfection	O
of	O
D86G	O
-	O
mutated	O
HSD17B10	O
into	O
HSD17B10-null	O
cells	O
failed	O
to	O
rescue	O
apoptosis	O
.	O

The	O
findings	O
suggested	O
that	O
the	O
mutation	B-Variation
causes	O
a	O
defect	B-Negative_Regulation
in	O
mitochondrial	O
function	B-Molecular_Physiological_Activity
,	O
which	O
is	O
responsible	O
for	O
clinical	O
features	O
of	O
the	O
disorder	O
.	O

In	O
2	O
affected	O
brothers	O
and	O
an	O
affected	O
uncle	O
from	O
a	O
family	O
with	O
Abruzzo	O
-	O
Erickson	O
syndrome	O
(	O
ABERS	O
;	O
302905	O
)	O
,	O
originally	O
described	O
by	O
Abruzzo	O
and	O
Erickson	O
(	O
1977	O
)	O
,	O
Pauws	O
et	O
al	O
.	O

(	O
2013	O
)	O
identified	O
a	O
-5T	O
-	O
A	O
transversion	B-Variation
in	O
intron	O
3	O
(	O
c.593	O
-	O
5T	O
-	O
A	O
)	O
of	O
the	B-Gene
TBX22	I-Gene
gene	I-Gene
,	O
within	O
the	O
conserved	O
splice	O
acceptor	O
consensus	O
sequence	O
for	O
exon	O
4	O
.	O

The	O
mutation	B-Variation
was	O
present	O
in	O
heterozygosity	O
in	O
the	O
obligate	O
carrier	O
mother	O
and	O
was	O
not	O
found	O
in	O
the	O
dbSNP	O
database	O
or	O
in	O
539	O
control	O
chromosomes	O
.	O

In	O
vitro	O
mRNA	O
splicing	O
assay	O
showed	O
significant	O
reduction	B-Negative_Regulation
in	O
or	O
absence	B-Negative_Regulation
of	O
a	O
471-bp	O
fragment	O
generated	O
with	O
the	O
wildtype	O
construct	O
when	O
the	O
mutant	B-Variation
construct	O
was	O
used	O
.	O

In	O
addition	O
,	O
clonal	O
sequence	O
analysis	O
of	O
RT	O
-	O
PCR	O
products	O
showed	O
that	O
the	O
c.593	O
-	O
5T	O
-	O
A	O
mutation	B-Variation
results	O
in	O
a	O
significant	O
increase	B-Positive_Regulation
in	O
the	O
most	O
upstream	O
cryptic	O
splice	O
site	O
product	O
with	O
little	O
wildtype	O
product	O
detected	O
,	O
suggesting	O
that	O
the	O
mutation	B-Variation
weakens	B-Negative_Regulation
or	O
abolishes	B-Negative_Regulation
the	O
wildtype	O
acceptor	O
splice	O
site	O
of	O
exon	O
4	O
.	O

In	O
2	O
brothers	O
with	O
AHC	O
with	O
hypogonadotropic	O
hypogonadism	O
(	O
300200	O
)	O
,	O
Muscatelli	O
et	O
al	O
.	O

(	O
1994	O
)	O
identified	O
a	O
1034G	O
-	O
A	O
transition	B-Variation
in	O
the	O
NR0B1	B-Gene
gene	I-Gene
,	O
which	O
was	O
predicted	O
to	O
generate	B-Regulation
an	O
arg267-to	O
-	O
pro	O
(	O
R267P	O
)	O
substitution	B-Variation
,	O
and	O
resulted	O
in	O
suppression	B-Negative_Regulation
of	O
a	O
CfoI	O
site	O

found	O
that	O
2	O
mutations	B-Variation
in	O
the	B-Gene
DAX1	I-Gene
gene	I-Gene
,	O
R267P	O
and	O
deletion	B-Variation
of	O
V269	O
,	O
impair	B-Negative_Regulation
transcriptional	B-Molecular_Physiological_Activity
silencing	I-Molecular_Physiological_Activity
of	O
the	O
STAR	O
promoter	O
,	O
suggesting	O
that	O
loss	B-Negative_Regulation
of	O
the	O
functional	O
repression	B-Molecular_Physiological_Activity
plays	B-Regulation
a	I-Regulation
role	I-Regulation
in	O
the	O
pathogenesis	B-Molecular_Physiological_Activity
of	O
AHC	O
.	O

In	O
5	O
male	O
patients	O
with	O
AHC	O
(	O
300200	O
)	O
from	O
the	O
Greenlandic	O
family	O
originally	O
reported	O
by	O
Petersen	O
et	O
al	O
.	O

(	O
1982),Schwartz	O
et	O
al	O
.	O

(	O
1997	O
)	O
identified	O
a	O
1553A	O
-	O
T	O
transversion	B-Variation
in	O
the	B-Gene
NR0B1	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
an	O
asn440-to	O
-	O
ile	O
(	O
N440I	O
)	O
substitution	B-Variation
.	O

The	O
substitution	B-Variation
represented	O
change	O
from	O
a	O
polar	O
amino	O
acid	O
to	O
a	O
nonpolar	O
amino	O
acid	O
.	O

Both	O
patients	O
who	O
had	O
reached	O
the	O
age	O
of	O
puberty	O
exhibited	O
hypogonadotropic	O
hypogonadism	O
.	O

The	O
authors	O
noted	O
that	O
among	O
33	O
female	O
relatives	O
at	O
risk	O
for	O
the	O
mutation	B-Variation
,	O
they	O
identified	O
10	O
as	O
carriers	O
and	O
excluded	O
23	O
from	O
being	O
carriers	O
,	O
information	O
important	O
for	O
genetic	O
counseling	O

determined	O
that	O
the	O
N440I	O
mutation	B-Variation
results	O
in	O
impaired	B-Negative_Regulation
RNA	B-Interaction
-	I-Interaction
binding	I-Interaction
activity	B-Molecular_Physiological_Activity
of	O
the	B-Protein
DAX1protein	I-Protein
Nakae	O
et	O
al	O
.	O

(	O
1996	O
)	O
characterized	O
the	O
DAX1	O
gene	O
from	O
6	O
patients	O
,	O
including	O
2	O
sibs	O
,	O
with	O
AHC	O
(	O
300200	O
)	O
,	O
and	O
found	O
5	O
novel	O
mutations	B-Variation
including	O
3	O
nonsense	O
and	O
2	O
frameshift	B-Variation
mutations	B-Variation
.	O

The	O
nonsense	O
mutations	B-Variation
were	O
a	O
C	O
-	O
to	O
-	O
T	O
transition	B-Variation
(	O
gln395-to	O
-	O
ter	O
;	O
Q395X	O
)	O
,	O
a	O
C	O
-	O
to	O
-	O
G	O
transversion	B-Variation
(	O
tyr271-to	O
-	O
ter	O
;	O
Y271X	O
;	O
300473.0010	O
)	O
,	O
and	O
a	O
C	O
-	O
to	O
-	O
A	O
transversion	B-Variation
(	O
tyr91-to	O
-	O
ter	O
;	O
Y91X	O
;	O
300473.0011	O
)	O
.	O

The	O
Y91X	O
mutation	B-Variation
was	O
found	O
in	O
2	O
sibs	O
.	O

The	O
frameshift	B-Variation
mutations	B-Variation
were	O
a	O
2-bp	O
deletion	B-Variation
(	O
1610delAT	O
)	O
and	O
a	O
1-bp	O
(	O
G	O
)	O
insertion	B-Variation
resulting	B-Regulation
in	I-Regulation
a	O
premature	B-Molecular_Physiological_Activity
stop	I-Molecular_Physiological_Activity
at	O
codon	O
462	O
(	O
300473.0012	O
)	O
,	O
and	O
a	O
1-bp	O
deletion	B-Variation
(	O
1169delC	O
)	O
,	O
resulting	B-Regulation
in	I-Regulation
a	O
frameshift	B-Variation
which	O
caused	B-Regulation
a	O
premature	B-Molecular_Physiological_Activity
stop	I-Molecular_Physiological_Activity
codon	I-Molecular_Physiological_Activity
at	O
position	O
371	O
(	O
300473.0013	O
)	O
.	O

A	O
21-year	O
-	O
old	O
male	O
patient	O
in	O
whom	O
the	O
Q395X	O
mutation	B-Variation
was	O
identified	O
had	O
hypogonadotropic	O
hypogonadism	O
;	O
the	O
other	O
5	O
patients	O
were	O
prepubertal	O
.	O

All	O
mutated	B-Variation
NR0B1	B-Protein
proteins	I-Protein
had	O
truncated	O
C	O
-	O
terminal	O
domains	O
,	O
suggesting	O
that	O
these	O
5	O
mutations	B-Variation
cause	B-Regulation
AHC	O
and	O
that	O
the	O
C	O
terminus	O
of	O
theDAX1	B-Protein
protein	I-Protein
,	O
especially	O
the	O
terminal	O
11	O
amino	O
acids	O
,	O
is	O
necessary	O
for	O
normal	O
adrenal	B-Cell_Physiological_Activity
cortical	I-Cell_Physiological_Activity
embryogenesis	I-Cell_Physiological_Activity
.	O

Salvi	O
et	O
al	O
.	O

(	O
2002	O
)	O
reported	O
a	O
patient	O
who	O
was	O
diagnosed	O
with	O
adrenal	O
failure	O
(	O
300200	O
)	O
at	O
6	O
weeks	O
of	O
age	O
,	O
but	O
who	O
experienced	O
recovery	O
of	O
adrenal	O
function	O
of	O
several	O
months	O
'	O
duration	O
later	O
in	O
infancy	O
.	O

He	O
subsequently	O
failed	O
to	O
undergo	O
puberty	O
because	O
of	O
hypogonadotropic	O
hypogonadism	O
of	O
pituitary	O
origin	O
,	O
and	O
he	O
was	O
also	O
diagnosed	O
with	O
schizophrenia	O
in	O
early	O
adulthood	O
.	O

Molecular	O
genetic	O
analyses	O
revealed	O
a	O
complex	O
rearrangement	B-Variation
in	B-Gene
DAX1	I-Gene
,	O
including	O
a	O
2.2-kb	O
deletion	B-Variation
spanning	O
the	O
entire	O
second	O
exon	O
and	O
a	O
small	O
27-bp	O
insertion	B-Variation
.	O

The	O
deletion	B-Variation
extended	O
from	O
position	O
4561	O
through	O
position	O
6801	O
,	O
completely	O
eliminating	O
exon	O
2	O
of	O
the	O
gene	B-Gene
.	O

The	O
putative	O
protein	O
encoded	O
by	O
this	O
mutated	O
gene	B-Gene
is	O
429	O
amino	O
acids	O
long	O
.	O

The	O
initial	O
389	O
residues	O
probably	O
correspond	O
to	O
the	O
wildtype	B-Gene
DAX1	I-Gene
sequence	I-Gene
,	O
whereas	O
the	O
last	O
40	O
amino	O
acids	O
are	O
presumably	O
completely	O
unrelated	O
,	O
being	O
transcribed	O
from	O
the	O
intronic	O
sequence	O
adjacent	O
to	O
exon	O
1	O
.	O

In	O
vitro	O
functional	O
analyses	O
confirmed	O
the	O
absence	B-Negative_Regulation
of	O
repressor	B-Molecular_Physiological_Activity
activity	I-Molecular_Physiological_Activity
exerted	B-Regulation
by	I-Regulation
the	O
mutant	B-Variation
protein	I-Variation
In	O
the	O
proband	O
of	O
a	O
5-generation	O
Scottish	O
kindred	O
,	O
3	O
members	O
of	O
which	O
had	O
adrenal	O
hypoplasia	O
(	O
300200	O
)	O
,	O
Brown	O
et	O
al	O
.	O

(	O
2003	O
)	O
identified	O
a	O
C	O
-	O
to	O
-	O
A	O
transversion	B-Variation
in	O
the	O
second	O
exon	O
of	O
the	B-Gene
DAX1	I-Gene
gene	I-Gene
that	O
resulted	B-Regulation
in	I-Regulation
the	O
change	O
of	O
tyr399	O
to	O
a	O
premature	B-Molecular_Physiological_Activity
stop	I-Molecular_Physiological_Activity
codon	I-Molecular_Physiological_Activity
(	O
Y399X	O
)	O
,	O
which	O
truncates	O
the	B-Gene
DAX1	I-Gene
protein	I-Gene
by	O
71	O
amino	O
acids	O
.	O

Kindred	O
analysis	O
established	O
that	O
the	O
mutation	B-Variation
had	O
been	O
inherited	O
from	O
the	O
proband	O
's	O
mother	O
.	O

The	O
proband	O
,	O
his	O
deceased	O
brother	O
,	O
and	O
a	O
maternal	O
cousin	O
were	O
hemizygous	O
for	O
the	O
mutation	B-Variation
.	O

The	O
mutation	B-Variation
was	O
associated	O
with	O
loss	B-Negative_Regulation
of	O
Leydig	O
cell	B-Cell_Physiological_Activity
responsiveness	I-Cell_Physiological_Activity
to	O
human	O
chorionic	O
gonadotropin	O
(	O
see	O
118860	O
)	O
;	O
the	O
35-year	O
-	O
old	O
proband	O
exhibited	O
hypogonadotropic	O
hypogonadism	O
.	O

Immunohistochemical	O
analysis	O
of	O
testicular	O
tissue	O
obtained	O
from	O
the	O
proband	O
's	O
affected	O
sib	O
,	O
who	O
had	O
died	O
from	O
adrenal	O
failure	O
as	O
a	O
neonate	O
,	O
showed	O
normal	O
testicular	O
morphology	O
and	O
expression	B-Molecular_Physiological_Activity
of	B-Gene
DAX1	I-Gene
,	O
steroidogenic	O
factor-1	O
(	O
184757	O
)	O
,	O
and	O
anti	O
-	O
mullerian	O
hormone	O
(	O
600957	O
)	O
.	O

Transient	O
transfection	O
assays	O
demonstrated	O
that	O
the	O
mutation	B-Variation
resulted	O
in	O
a	O
severe	O
loss	B-Negative_Regulation
of	B-Gene
DAX1	I-Gene
repressor	I-Gene
activity	I-Molecular_Physiological_Activity
In	O
an	O
11-year	O
-	O
old	O
prepubertal	O
Dutch	O
boy	O
with	O
mild	O
AHC	O
involving	O
isolated	O
mineralocorticoid	O
deficiency	O
(	O
see300200	O
)	O
,	O
Verrijn	O
Stuart	O
et	O
al	O
.	O

(	O
2007	O
)	O
identified	O
a	O
G	O
-	O
to	O
-	O
C	O
transversion	B-Variation
in	O
the	B-Gene
NR0B1	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
trp105-to	O
-	O
cys	O
(	O
W105C	O
)	O
substitution	B-Variation
in	O
the	O
N	O
terminus	O
of	B-Gene
DAX1	I-Gene
.	O

In	O
vitro	O
studies	O
of	B-Molecular_Physiological_Activity
DAX1	I-Molecular_Physiological_Activity
expression	I-Molecular_Physiological_Activity
and	O
function	B-Molecular_Physiological_Activity
in	O
transfected	O
cells	O
demonstrated	O
mild	O
loss	B-Negative_Regulation
of	O
both	O
repression	B-Molecular_Physiological_Activity
and	O
activation	B-Molecular_Physiological_Activity
functions	I-Molecular_Physiological_Activity
;	I-Molecular_Physiological_Activity
structure	O
-	O
function	O
analysis	O
suggested	O
that	O
mutations	B-Variation
in	O
the	O
N	O
terminus	O
are	O
compensated	O
by	O
the	O
presence	O
of	O
repeat	O
LXXLL	O
motifs	O
that	O
mediate	B-Interaction
DAX1	I-Interaction
interactions	I-Interaction
with	O
other	O
proteins	O
.	O

The	O
mutation	B-Variation
,	O
which	O
was	O
not	O
found	O
in	O
100	O
Dutch	O
controls	O
,	O
was	O
present	O
in	O
the	O
proband	O
's	O
mother	O
;	O
it	O
was	O
also	O
present	O
in	O
3	O
asymptomatic	O
male	O
relatives	O
,	O
indicating	O
phenotypic	O
heterogeneity	O
.	O

Mantovani	O
et	O
al	O
.	O

(	O
2002	O
)	O
reported	O
AHC	O
(	O
300200	O
)	O
in	O
a	O
patient	O
who	O
presented	O
with	O
hypogonadotropic	O
hypogonadism	O
at	O
28	O
years	O
of	O
age	O
.	O

Although	O
the	O
patient	O
had	O
no	O
clinical	O
evidence	O
of	O
adrenal	O
dysfunction	O
,	O
compensated	O
primary	O
adrenal	O
failure	O
was	O
diagnosed	O
by	O
biochemical	O
testing	O
.	O

Semen	O
analysis	O
showed	O
azoospermia	O
,	O
and	O
the	O
patient	O
did	O
not	O
achieve	O
fertility	O
after	O
8	O
months	O
of	O
treatment	O
with	O
gonadotropins	O
.	O

A	O
novel	O
tyr380-to	O
-	O
asp	O
(	O
Y380D	O
)	O
missense	O
mutation	B-Variation
in	O
the	B-Gene
DAX1	I-Gene
gene	I-Gene
,	O
which	O
caused	O
partial	O
loss	B-Negative_Regulation
of	O
function	B-Molecular_Physiological_Activity
in	O
transient	O
gene	O
expression	O
assays	O
,	O
was	O
found	O
.	O

The	O
authors	O
concluded	O
that	O
partial	O
loss	B-Negative_Regulation
-	I-Negative_Regulation
of	I-Negative_Regulation
-	I-Negative_Regulation
function	I-Negative_Regulation
mutations	B-Variation
in	B-Gene
DAX1	I-Gene
can	I-Gene
present	O
with	O
HHG	O
and	O
covert	O
adrenal	O
failure	O
in	O
adulthood	O
In	O
affected	O
members	O
of	O
a	O
family	O
with	O
complete	O
androgen	O
insensitivity	O
(	O
300068	O
)	O
,	O
Trifiro	O
et	O
al	O
.	O

(	O
1991	O
)	O
found	O
an	O
adenine	O
-	O
to	O
-	O
thymine	O
transversion	B-Variation
in	O
exon	O
8	O
that	O
changed	B-Regulation
the	O
sense	B-Molecular_Physiological_Activity
of	O
codon	O
882	O
from	O
lysine	O
to	O
an	O
amber	O
(	O
UAG	O
)	O
translation	B-Molecular_Physiological_Activity
termination	I-Molecular_Physiological_Activity
signal	I-Molecular_Physiological_Activity
.	O

(	O
See	O
141900.0312	O
for	O
the	O
origin	O
of	O
the	O
designation	O
'	O
amber	O
.	O

'	O
See	O
219700.0030	O
for	O
an	O
example	O
of	O
the	O
ochre	O
(	O
UAA	O
)	O
type	O
of	O
translation	O
termination	O
signal	O
.	O

)	O
In	O
6	O
of	O
24	O
specimens	O
of	O
prostatic	O
tissue	O
derived	O
from	O
transurethral	O
resections	O
in	O
patients	O
with	O
metastatic	O
prostate	O
cancer	O
,	O
Gaddipati	O
et	O
al	O
.	O

(	O
1994	O
)	O
found	O
a	O
thr877-to	O
-	O
ala	O
mutation	B-Variation
in	O
the	O
hormone	B-Interaction
-	I-Interaction
binding	I-Interaction
domain	O
of	O
the	B-Gene
AR	I-Gene
gene	I-Gene
.	O

The	O
same	O
mutation	B-Variation
had	O
been	O
reported	O
previously	O
in	O
a	O
metastatic	O
prostatic	O
cancer	O
cell	O
line	O
where	O
it	O
conferred	B-Regulation
on	I-Regulation
the	O
androgen	O
receptor	O
an	O
altered	O
ligand	B-Interaction
-	I-Interaction
binding	I-Interaction
specificity	I-Interaction
that	O
was	O
stimulated	O
by	O
estrogens	O
,	O
progestagens	O
,	O
and	O
antiandrogens	O
.	O

Gaddipati	O
et	O
al	O
.	O

(	O
1994	O
)	O
suggested	O
that	O
the	O
codon	O
877	O
mutant	B-Gene
AR	I-Gene
with	I-Gene
altered	B-Regulation
ligand	O
binding	B-Interaction
may	O
provide	O
a	O
selective	O
growth	B-Cell_Physiological_Activity
advantage	B-Positive_Regulation
in	O
the	O
genesis	O
of	O
a	O
subset	O
of	O
advanced	O
prostate	O
cancer	O
.	O

The	O
stimulatory	O
effect	O
of	O
the	O
usual	O
therapeutic	O
agents	O
on	O
the	O
codon	O
877	O
mutant	B-Variation
AR	I-Variation
may	I-Variation
contribute	O
to	O
treatment	O
-	O
refractory	O
disease	O
.	O

Schaffler	O
et	O
al	O
.	O

(	O
2000	O
)	O
described	O
a	O
nonmosaic	O
XY	O
sex	O
-	O
reversed	O
female	O
with	O
pure	O
gonadal	O
dysgenesis	O
,	O
including	O
46,XY	O
karyotype	O
,	O
completely	O
female	O
external	O
genitalia	O
,	O
normal	O
mullerian	O
ducts	O
,	O
absence	O
of	O
wolffian	O
ducts	O
,	O
and	O
streak	O
gonads	O
(	O
SRXY1	O
;	O
400044	O
)	O
,	O
who	O
harbored	O
a	O
yolk	O
-	O
sac	O
tumor	O
and	O
was	O
referred	O
for	O
the	O
assessment	O
of	O
primary	O
amenorrhea	O
.	O

They	O
identified	O
a	O
novel	O
de	O
novo	O
mutation	B-Variation
,	O
a	O
G	O
-	O
to	O
-	O
A	O
transition	B-Variation
at	O
position	O
284	O
within	O
the	O
HMG	O
box	O
of	O
the	B-Gene
SRY	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
gly95-to	O
-	O
glu	O
substitution	B-Variation
.	O

This	O
mutation	B-Variation
was	O
not	O
detected	O
in	O
the	O
patient	O
's	O
father	O
or	O
in	O
her	O
male	O
sibs	O
.	O

The	O
authors	O
concluded	O
that	O
these	O
data	O
provide	O
further	O
evidence	O
to	O
support	O
the	O
functional	O
importance	O
of	O
the	O
putative	O
DNA	B-Interaction
-	I-Interaction
binding	I-Interaction
activity	B-Molecular_Physiological_Activity
of	O
the	O
SRY	O
HMG	O
box	O
In	O
a	O
boy	O
with	O
2-methylbutyryl	O
glycinuria	O
(	O
610006	O
)	O
,	O
whose	O
parents	O
were	O
from	O
Somalia	O
,	O
Madsen	O
et	O
al	O
.	O

(	O
2006)identified	O
a	O
homozygous	O
A	O
-	O
to	O
-	O
G	O
transition	B-Variation
in	O
intron	O
3	O
of	O
the	B-Gene
ACADSB	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
the	O
skipping	B-Variation
of	O
exon	O
3	O
as	O
confirmed	O
by	O
mRNA	O
analysis	O
.	O

The	O
resultant	O
mRNA	O
likely	O
leads	B-Regulation
to	I-Regulation
nonsense	O
-	O
mediated	O
decay	B-Molecular_Physiological_Activity
,	O
but	O
any	O
residual	O
protein	O
was	O
predicted	O
to	O
lack	B-Negative_Regulation
vital	O
enzyme	B-Molecular_Physiological_Activity
activity	I-Molecular_Physiological_Activity
.	I-Molecular_Physiological_Activity

Madsen	I-Molecular_Physiological_Activity
et	O
al	O
.	O

(	O
2006	O
)	O
also	O
identified	O
the	O
splice	O
site	O
mutation	B-Variation
in	O
2	O
affected	O
sibs	O
previously	O
reported	O
by	O
Gibson	O
et	O
al	O
.	O

(	O
2000	O
)	O
;	O
see	O
600301.0002	O
.	O

In	O
a	O
Swiss	O
phenotypic	O
female	O
with	O
46,XY	O
sex	O
reversal	O
(	O
SRXY8	O
;	O
614279	O
)	O
,	O
Fluck	O
et	O
al	O
.	O

(	O
2011	O
)	O
identified	O
a	O
complex	O
rearrangement	B-Variation
that	O
resulted	B-Regulation
in	I-Regulation
the	O
patient	O
having	O
a	O
single	O
AKR1C1	B-Gene
(	B-Gene
600449)/AKR1C2	I-Gene
hybrid	I-Gene
on	O
allele	O
1	O
,	O
and	O
paternal	O
AKR1C1	B-Gene
,	O
an	O
AKR1C1	B-Gene
/	I-Gene
AKR1C2	I-Gene
hybrid	I-Gene
,	O
and	O
maternal	B-Gene
AKR1C2	I-Gene
genes	I-Gene
on	O
allele	O
2	O
.	O

The	O
intact	O
maternal	B-Gene
AKR1C2	I-Gene
gene	I-Gene
on	O
allele	O
2	O
carried	O
a	O
666T	O
-	O
G	O
transversion	B-Variation
in	O
exon	O
9	O
,	O
resulting	B-Regulation
in	I-Regulation
a	O
his222-to	O
-	O
gln	O
(	O
H222Q	O
)	O
substitution	B-Variation
.	O

The	O
mutation	B-Variation
was	O
not	O
found	O
in	O
200	O
controls	O
,	O
and	O
functional	O
analysis	O
demonstrated	O
markedly	O
reduced	B-Negative_Regulation
activity	B-Molecular_Physiological_Activity
compared	O
to	O
wildtype	O
.	O

In	O
a	O
Dutch	O
woman	O
with	O
3-methylglutaconic	O
aciduria	O
type	O
I	O
(	O
MGCA1	O
;	O
250950	O
)	O
,	O
Wortmann	O
et	O
al	O
.	O

(	O
2010	O
)	O
identified	O
compound	O
heterozygosity	O
for	O
2	O
mutations	B-Variation
in	O
the	B-Gene
AUH	I-Gene
gene	I-Gene
:	I-Gene
a	O
559G	O
-	O
A	O
transition	B-Variation
,	O
resulting	B-Regulation
in	I-Regulation
a	O
gly187-to	O
-	O
ser	O
(	O
G187S	O
)	O
substitution	B-Variation
,	O
and	O
a	O
650G	O
-	O
A	O
transition	B-Variation
,	O
resulting	B-Regulation
in	I-Regulation
a	O
gly217-to	O
-	O
asp	O
(	O
G217D	O
)	O
substitution	B-Variation
.	O

Both	O
mutations	B-Variation
were	O
predicted	O
to	O
abolish	B-Negative_Regulation
enzymatic	B-Molecular_Physiological_Activity
activity	I-Molecular_Physiological_Activity
by	O
altering	B-Regulation
trimer	B-Molecular_Physiological_Activity
formation	I-Molecular_Physiological_Activity
and	O
catalytic	B-Molecular_Physiological_Activity
activity	I-Molecular_Physiological_Activity
,	O
and	O
enzyme	B-Molecular_Physiological_Activity
activity	I-Molecular_Physiological_Activity
was	O
virtually	O
undetectable	B-Negative_Regulation
in	O
fibroblasts	O
and	O
lymphocytes	O
.	O

The	O
patient	O
first	O
developed	O
progressive	O
visual	O
loss	O
with	O
optic	O
atrophy	O
at	O
age	O
35	O
,	O
and	O
developed	O
dysarthria	O
,	O
limb	O
ataxia	O
,	O
and	O
gait	O
ataxia	O
over	O
the	O
following	O
16	O
years	O
.	O

Brain	O
MRI	O
at	O
age	O
61	O
years	O
showed	O
extensive	O
confluent	O
white	O
matter	O
abnormalities	O
in	O
the	O
supratentorial	O
region	O
with	O
involvement	O
of	O
the	O
deep	O
and	O
subcortical	O
white	O
matter	O
,	O
but	O
sparing	O
of	O
the	O
cerebellum	O
and	O
corpus	O
callosum	O
.	O

In	O
a	O
man	O
,	O
born	O
of	O
consanguineous	O
British	O
parents	O
,	O
with	O
3-methylglutaconic	O
aciduria	O
type	O
I	O
(	O
MGCA1	O
;	O
250950),Wortmann	O
et	O
al	O
.	O

(	O
2010	O
)	O
identified	O
a	O
homozygous	O
991A	O
-	O
T	O
transversion	B-Variation
,	O
resulting	B-Regulation
in	I-Regulation
a	O
lys331-to	O
-	O
ter	O
(	O
K331X	O
)	O
substitution	B-Variation
,	O
resulting	B-Regulation
in	I-Regulation
the	O
production	B-Molecular_Physiological_Activity
of	O
an	O
aberrant	O
protein	O
lacking	O
the	O
8	O
terminal	O
residues	O
.	O

The	O
terminal	O
part	O
of	O
the	O
protein	O
is	O
necessary	O
for	O
the	O
active	O
-	O
site	O
pocket	O
,	O
for	O
subunit	O
interaction	B-Interaction
,	O
and	O
trimer	O
stabilization	O
.	O

The	O
patient	O
had	O
a	O
complete	O
deficiency	B-Negative_Regulation
of	O
enzyme	B-Molecular_Physiological_Activity
activity	I-Molecular_Physiological_Activity
.	O

He	O
presented	O
at	O
age	O
30	O
years	O
with	O
mild	O
cerebellar	O
ataxia	O
,	O
which	O
progressed	O
to	O
spastic	O
paraparesis	O
,	O
nystagmus	O
,	O
and	O
dementia	O
over	O
the	O
next	O
29	O
years	O
.	O

Brain	O
MRI	O
at	O
age	O
50	O
years	O
showed	O
extensive	O
confluent	O
white	O
matter	O
abnormalities	O
in	O
the	O
supratentorial	O
region	O
with	O
involvement	O
of	O
the	O
deep	O
and	O
subcortical	O
white	O
matter	O
,	O
but	O
sparing	O
of	O
the	O
cerebellum	O
and	O
corpus	O
callosum	O
.	O

In	O
a	O
53-year	O
-	O
old	O
woman	O
and	O
her	O
57-year	O
-	O
old	O
brother	O
with	O
growth	O
hormone	O
insensitivity	O
syndrome	O
(	O
262500	O
)	O
,	O
Milward	O
et	O
al	O
.	O

(	O
2004	O
)	O
identified	O
a	O
homozygous	O
22-bp	O
deletion	B-Variation
in	O
exon	O
10	O
of	O
the	B-Gene
GHR	I-Gene
gene	I-Gene
.	O

The	O
mutation	B-Variation
was	O
predicted	O
to	O
result	B-Regulation
in	I-Regulation
frameshift	B-Variation
introducing	O
novel	O
codons	O
from	O
positions	O
424	O
through	O
449	O
followed	O
by	O
premature	B-Molecular_Physiological_Activity
termination	I-Molecular_Physiological_Activity
at	O
codon	O
450	O
.	O

The	O
predicted	O
protein	B-Protein
would	O
lack	B-Negative_Regulation
a	O
large	O
portion	O
of	O
the	O
intracellular	O
domain	O
.	O

In	O
the	O
truncated	O
protein	B-Protein
,	O
the	O
membrane	O
proximal	O
region	O
containing	O
Box1	O
and	O
Box2	O
,	O
critical	O
for	O
activation	B-Molecular_Physiological_Activity
of	O
JAK2	B-Gene
(	O
147796	O
)	O
and	O
STAT3	B-Gene
(	O
102582	O
)	O
,	O
would	O
be	O
intact	O
,	O
but	O
the	O
protein	B-Protein
would	O
lack	B-Negative_Regulation
the	O
C	O
-	O
terminal	O
tyrosine	O
residues	O
essential	O
for	O
STAT5	B-Gene
(	O
601511	O
)	O
activation	B-Molecular_Physiological_Activity
.	O

No	O
STAT5	B-Gene
activity	B-Molecular_Physiological_Activity
was	O
detected	O
in	O
cells	O
expressing	O
the	O
truncated	O
protein	B-Protein
,	O
consistent	O
with	O
its	O
lack	B-Negative_Regulation
of	O
a	O
STAT5	B-Gene
binding	B-Interaction
site	O
.	O

The	O
authors	O
concluded	O
that	O
the	O
loss	B-Negative_Regulation
of	O
signaling	B-Pathway
through	O
the	O
STAT5	B-Gene
pathway	B-Pathway
results	B-Regulation
in	I-Regulation
growth	O
hormone	O
insensitivity	O
syndrome	O
.	O

In	O
a	O
7-year	O
-	O
old	O
Japanese	O
girl	O
with	O
Bartter	O
syndrome	O
type	O
1	O
(	O
601678	O
)	O
,	O
Nozu	O
et	O
al	O
.	O

(	O
2009	O
)	O
identified	O
compound	O
heterozygosity	O
for	O
mutations	B-Variation
in	O
the	B-Gene
SLC12A1	I-Gene
gene	I-Gene
:	I-Gene
a	O
724	O
+	O
4A	O
-	O
G	O
transition	B-Variation
in	O
intron	O
5	O
,	O
predicted	O
to	O
result	B-Regulation
in	I-Regulation
skipping	O
of	O
exon	O
5	O
with	O
creation	O
of	O
a	O
premature	B-Molecular_Physiological_Activity
stop	I-Molecular_Physiological_Activity
codon	O
in	O
exon	O
6	O
,	O
and	O
a	O
1-bp	O
deletion	B-Variation
in	O
exon	O
16	O
(	O
2095delG	O
;	O
600839.0005	O
)	O
,	O
predicted	O
to	O
cause	B-Regulation
an	O
immediate	O
stop	B-Molecular_Physiological_Activity
codon	I-Molecular_Physiological_Activity
and	O
premature	B-Molecular_Physiological_Activity
termination	I-Molecular_Physiological_Activity
of	O
the	O
protein	B-Protein
.	O

The	O
unaffected	O
parents	O
were	O
each	O
heterozygous	O
for	O
1	O
of	O
the	O
mutations	B-Variation
;	I-Variation
the	O
intronic	O
mutation	B-Variation
was	O
not	O
detected	O
in	O
100	O
controls	O
.	O

RT	O
-	O
PCR	O
analysis	O
of	O
mRNA	O
extracted	O
from	O
the	O
proband	O
's	O
urinary	O
sediment	O
confirmed	O
complete	O
absence	B-Negative_Regulation
of	O
exon	O
5	O
sequences	O
,	O
and	O
RT	O
-	O
PCR	O
results	O
using	O
mRNA	O
from	O
patient	O
leukocytes	O
showed	O
no	O
bands	O
,	O
indicating	O
that	O
the	O
leukocytes	O
did	O
not	B-Negative_Regulation
express	B-Molecular_Physiological_Activity
SLC12A1	B-Gene
mRNA	O
.	O

Nozu	O
et	O
al	O
.	O

(	O
2009	O
)	O
stated	O
that	O
this	O
was	O
the	O
first	O
study	O
to	O
use	O
noninvasive	O
methods	O
for	O
both	O
an	O
in	O
vivo	O
assay	O
and	O
an	O
in	O
vitro	O
functional	O
splicing	O
assay	O
of	O
inherited	O
kidney	O
disease	O
.	O

]	O
Geller	O
et	O
al	O
.	O

(	O
2000	O
)	O
screened	O
the	O
mineralocorticoid	O
receptor	O
in	O
75	O
patients	O
with	O
early	O
onset	O
of	O
severe	O
hypertension	O
(	O
605115	O
)	O
.	O

In	O
a	O
15-year	O
-	O
old	O
boy	O
with	O
severe	O
hypertension	O
,	O
a	O
C	O
-	O
to	O
-	O
T	O
substitution	B-Variation
,	O
changing	B-Regulation
codon	O
810	O
of	O
the	O
hormone	B-Interaction
-	I-Interaction
binding	I-Interaction
domain	O
from	O
a	O
serine	O
to	O
a	O
leucine	O
,	O
was	O
identified	O
.	O

The	O
ser810-to	O
-	O
leu	O
(	O
S810L	O
)	O
mutation	B-Variation
was	O
identified	O
in	O
heterozygous	O
state	O
in	O
11	O
family	O
members	O
of	O
this	O
proband	O
who	O
had	O
been	O
diagnosed	O
with	O
severe	O
hypertension	O
before	O
the	O
age	O
of	O
20	O
years	O
,	O
resulting	B-Regulation
in	I-Regulation
constitutive	O
MR	O
activity	B-Molecular_Physiological_Activity
and	O
altered	B-Regulation
receptor	B-Molecular_Physiological_Activity
specificity	I-Molecular_Physiological_Activity
,	O
with	O
progesterone	O
and	O
other	O
steroids	O
lacking	O
21-hydroxyl	O
groups	O
,	O
normally	O
MR	O
antagonists	O
,	O
becoming	O
potent	O
agonists	O
.	O

This	O
resulted	O
in	O
profound	O
exacerbation	B-Negative_Regulation
of	O
hypertension	O
during	O
5	O
pregnancies	O
in	O
2	O
affected	O
women	O
in	O
this	O
kindred	O
.	O

Structural	O
and	O
biochemical	O
studies	O
indicated	O
that	O
S810L	O
results	O
in	O
the	O
gain	B-Positive_Regulation
of	O
a	O
van	O
der	O
Waals	O
interaction	B-Interaction
between	O
helix	O
5	O
and	O
helix	O
3	O
that	O
substitutes	O
for	O
interaction	B-Interaction
of	O
the	O
steroid	O
21-hydroxyl	O
group	O
with	O
helix	O
3	O
in	O
the	O
wildtype	O
receptor	O
.	O

This	O
helix	O
5-helix	O
3	O
interaction	B-Interaction
is	O
highly	O
conserved	O
among	O
diverse	O
nuclear	O
hormone	O
receptors	O
,	O
suggesting	O
its	O
general	O
role	O
in	O
receptor	O
activation	B-Positive_Regulation
.	O

The	O
effect	O
of	O
the	O
S810L	O
mutation	B-Variation
was	O
to	O
invert	B-Regulation
the	O
mineralocorticoid	O
receptor	O
from	O
aldosterone	O
-	O
responsive	O
to	O
progesterone	O
-	O
responsive	O
,	O
with	O
development	O
of	O
hypertension	O
during	O
pregnancy	O
.	O

This	O
was	O
the	O
first	O
mendelian	O
form	O
of	O
preeclampsia	O
to	O
be	O
identified	O
.	O

Ordinarily	O
,	O
blood	O
pressure	O
goes	O
down	O
during	O
early	O
stages	O
of	O
pregnancy	O
.	O

In	O
4	O
sibs	O
with	O
Grebe	O
type	O
acromesomelic	O
dysplasia	O
(	O
200700	O
)	O
from	O
an	O
Omani	O
family	O
,	O
Al	O
-	O
Yahyaee	O
et	O
al	O
.	O

(	O
2003)identified	O
2	O
mutations	B-Variation
in	O
the	B-Gene
GDF5	I-Gene
gene	I-Gene
:	I-Gene
a	O
silent	O
1137A	O
-	O
G	O
transition	B-Variation
encoding	O
lysine	O
and	O
a	O
1-bp	O
deletion	B-Variation
,	O
1144delG	O
,	O
predicting	B-Regulation
a	O
frameshift	B-Variation
resulting	O
in	O
loss	B-Negative_Regulation
of	O
the	O
biologically	B-Molecular_Physiological_Activity
active	I-Molecular_Physiological_Activity
C	O
terminus	O
of	O
the	O
protein	B-Protein
.	O

The	O
affected	O
sibs	O
were	O
homozygous	O
for	O
the	O
1144delG	O
mutation	B-Variation
and	O
each	O
parent	O
was	O
heterozygous	O
.	O

The	O
affected	O
sibs	O
had	O
normal	O
axial	O
skeletons	O
,	O
severely	O
shortened	O
and	O
deformed	O
limbs	O
with	O
severity	O
increasing	O
in	O
a	O
proximodistal	O
gradient	O
,	O
and	O
subluxated	O
joints	O
.	O

The	O
humeri	O
and	O
femora	O
were	O
hypoplastic	O
with	O
distal	O
malformations	O
.	O

The	O
radii	O
/	O
ulnae	O
were	O
shortened	O
and	O
deformed	O
whereas	O
carpal	O
bones	O
were	O
invariably	O
rudimentary	O
or	O
absent	O
.	O

The	O
tibiae	O
appeared	O
rudimentary	O
;	O
fibulae	O
were	O
absent	O
in	O
2	O
children	O
,	O
and	O
some	O
tarsal	O
and	O
metatarsal	O
bones	O
were	O
absent	O
.	O

Only	O
distal	O
phalanges	O
were	O
present	O
.	O

The	O
father	O
and	O
mother	O
had	O
short	O
first	O
metacarpal	O
and	O
middle	O
phalanx	O
of	O
the	O
fifth	O
finger	O
and	O
hallux	O
valgus	O
,	O
respectively	O
.	O

In	O
affected	O
members	O
of	O
a	O
family	O
with	O
proximal	O
symphalangism	O
(	O
SYM1B	O
;	O
615298	O
)	O
,	O
Seemann	O
et	O
al	O
.	O

(	O
2005	O
)	O
identified	O
a	O
1632G	O
-	O
T	O
transversion	B-Variation
in	O
the	B-Gene
GDF5	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
an	O
arg438-to	O
-	O
leu	O
(	O
R438L	O
)	O
substitution	B-Variation
.	O

Functional	O
studies	O
in	O
limb	O
bud	O
micromass	O
culture	O
and	O
ATDC5	O
and	O
C2C12	O
cells	O
showed	O
increased	B-Positive_Regulation
biologic	B-Cell_Physiological_Activity
activity	I-Cell_Physiological_Activity
when	O
compared	O
to	O
wildtype	O
GDF5	O
;	O
biosensor	O
interaction	O
analysis	O
revealed	O
normal	O
binding	B-Interaction
to	O
BMPR1B	O
ectodomain	O
but	O
increased	B-Positive_Regulation
binding	B-Interaction
to	O
that	O
of	O
BMPR1A.	O
In	O
a	O
20-month	O
-	O
old	O
boy	O
with	O
mild	O
fibular	O
hypoplasia	O
and	O
complex	O
brachydactyly	O
(	O
228900	O
)	O
,	O
Douzgou	O
et	O
al	O
.	O

(	O
2008)identified	O
compound	O
heterozygosity	O
for	O
2	O
mutations	B-Variation
in	O
the	B-Gene
GDF5	I-Gene
gene	I-Gene
:	I-Gene
a	O
1133G	O
-	O
A	O
transition	B-Variation
resulting	B-Regulation
in	I-Regulation
an	O
arg378-to	O
-	O
gln	O
(	O
R378Q	O
)	O
substitution	B-Variation
inherited	O
from	O
the	O
father	O
,	O
and	O
a	O
1306C	O
-	O
A	O
transversion	B-Variation
resulting	B-Regulation
in	I-Regulation
a	O
pro436-to	O
-	O
thr	O
(	O
P436	O
T	O
;	O
601146.0019	O
)	O
substitution	B-Variation
inherited	O
from	O
the	O
mother	O
.	O

The	O
R378Q	O
substitution	B-Variation
is	O
located	O
at	O
the	O
end	O
of	O
the	O
prodomain	O
within	O
the	O
recognition	O
motif	O
at	O
the	O
processing	O
site	O
of	B-Gene
GDF5	I-Gene
where	I-Gene
the	O
precursor	O
protein	O
is	O
cleaved	O
and	O
was	O
predicted	O
to	O
result	O
in	O
at	O
least	O
partial	O
loss	B-Negative_Regulation
of	O
function	B-Molecular_Physiological_Activity
.	O

The	O
P436	O
T	O
substitution	B-Variation
is	O
located	O
within	O
the	O
mature	O
domain	O
of	B-Gene
GDF5	I-Gene
and	I-Gene
was	O
predicted	O
to	O
interfere	B-Negative_Regulation
with	O
binding	B-Interaction
to	O
BMPR1B	O
(	O
603248	O
)	O
.	O

The	O
patient	O
's	O
mother	O
was	O
unaffected	O
,	O
whereas	O
the	O
father	O
had	O
very	O
mild	O
radiographic	O
features	O
of	O
brachymesophalangy	O
of	O
the	O
hand	O
digits	O
In	O
14	O
affected	O
individuals	O
from	O
a	O
6-generation	O
family	O
with	O
type	O
A2	O
brachydactyly	O
(	O
BDA2	O
;	O
112600	O
)	O
,	O
Ploger	O
et	O
al	O
.	O

(	O
2008	O
)	O
identified	O
heterozygosity	O
for	O
a	O
1139G	O
-	O
A	O
transition	B-Variation
in	O
the	B-Gene
GDF5	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
an	O
arg380-to	O
-	O
gln	O
(	O
R380Q	O
)	O
substitution	B-Variation
at	O
the	O
P2	O
position	O
of	O
the	O
subtilisin	O
-	O
like	O
proprotein	O
convertase	O
processing	O
site	O
.	O

The	O
mutation	B-Variation
was	O
not	O
found	O
in	O
unaffected	O
family	O
members	O
.	O

Analysis	O
of	O
the	O
R380Q	O
mutant	B-Variation
in	O
chicken	O
micromass	O
cultures	O
demonstrated	O
secretion	O
of	O
the	O
mutant	B-Variation
but	O
showed	O
a	O
severe	O
reduction	B-Negative_Regulation
in	O
biologic	B-Molecular_Physiological_Activity
activity	I-Molecular_Physiological_Activity
.	O

Western	O
blot	O
analyses	O
showed	O
that	O
the	O
mutation	B-Variation
interferes	B-Negative_Regulation
with	B-Molecular_Physiological_Activity
GDF5	I-Molecular_Physiological_Activity
processing	I-Molecular_Physiological_Activity
,	O
and	O
studies	O
in	O
E.	O
coli	O
confirmed	O
that	O
unprocessed	O
proGDF5	B-Protein
is	O
virtually	O
inactive	B-Negative_Regulation
In	O
an	O
Indian	O
child	O
with	O
severe	O
hyperinsulinemic	O
hypoglycemia	O
(	O
609975	O
)	O
,	O
Clayton	O
et	O
al	O
.	O

(	O
2001	O
)	O
identified	O
a	O
homozygous	O
773C	O
-	O
T	O
transition	B-Variation
in	O
exon	O
7	O
of	O
the	B-Gene
HADH	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
pro258-to	O
-	O
leu	O
(	O
P258L	O
)	O
substitution	B-Variation
in	O
1	O
of	O
the	O
alpha	O
-	O
helices	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
.	O

The	O
mutation	B-Variation
was	O
predicted	O
to	O
prevent	B-Negative_Regulation
normal	O
protein	B-Molecular_Physiological_Activity
folding	I-Molecular_Physiological_Activity
.	O

In	O
vitro	O
functional	O
expression	O
studies	O
showed	O
that	O
the	O
mutant	B-Variation
enzyme	I-Variation
had	O
no	B-Negative_Regulation
catalytic	B-Molecular_Physiological_Activity
activity	I-Molecular_Physiological_Activity
.	O

The	O
parents	O
were	O
heterozygous	O
for	O
the	O
mutation	B-Variation
.	I-Variation

Clayton	I-Variation
et	O
al	O
.	O

(	O
2001	O
)	O
postulated	O
that	O
the	O
increased	B-Positive_Regulation
insulin	B-Cell_Physiological_Activity
secretion	I-Cell_Physiological_Activity
in	O
this	O
patient	O
was	O
related	O
to	O
impaired	B-Negative_Regulation
fatty	B-Molecular_Physiological_Activity
acid	I-Molecular_Physiological_Activity
oxidation	I-Molecular_Physiological_Activity
and	O
suggested	O
that	O
a	O
lipid	B-Pathway
signaling	I-Pathway
pathway	I-Pathway
may	O
be	O
involved	O
in	O
the	O
control	B-Regulation
of	O
insulin	B-Cell_Physiological_Activity
secretion	I-Cell_Physiological_Activity
by	O
pancreatic	O
beta	O
-	O
cells	O
In	O
an	O
inbred	O
Pakistani	O
family	O
previously	O
reported	O
by	O
Vidnes	O
and	O
Oyasaeter	O
(	O
1977	O
)	O
in	O
which	O
4	O
sibs	O
,	O
2	O
males	O
and	O
2	O
females	O
,	O
had	O
hyperinsulinemic	O
hypoglycemia	O
(	O
609975	O
)	O
,	O
Molven	O
et	O
al	O
.	O

(	O
2004	O
)	O
demonstrated	O
a	O
6-bp	O
deletion	B-Variation
that	O
removed	B-Negative_Regulation
the	O
acceptor	O
splice	O
site	O
adjacent	O
to	O
exon	O
5	O
of	O
the	B-Gene
HADH	I-Gene
gene	I-Gene
.	O

They	O
demonstrated	O
that	O
exon	O
5	O
is	O
skipped	O
during	O
the	O
mRNA	B-Molecular_Physiological_Activity
splicing	I-Molecular_Physiological_Activity
process	O
,	O
so	O
that	O
exon	O
4	O
is	O
coupled	O
directly	O
onto	O
exon	O
6	O
.	O

This	O
led	O
to	O
an	O
in	O
-	O
frame	O
deletion	B-Variation
of	O
90	O
nucleotides	O
in	O
the	O
mature	O
mRNA	O
,	O
resulting	O
in	O
a	O
protein	O
product	O
predicted	O
to	O
lack	B-Negative_Regulation
30	O
amino	O
acids	O
.	O

Both	O
parents	O
were	O
heterozygous	O
.	O

In	O
9	O
Turkish	O
probands	O
with	O
diazoxide	O
-	O
responsive	O
hyperinsulinemic	O
hypoglycemia	O
(	O
HHF4	O
;	O
609975	O
)	O
,	O
3	O
of	O
whom	O
were	O
previously	O
studied	O
by	O
Flanagan	O
et	O
al	O
.	O

(	O
2011	O
)	O
,	O
Flanagan	O
et	O
al	O
.	O

(	O
2013	O
)	O
identified	O
homozygosity	O
for	O
a	O
636	O
+	O
471G	O
-	O
T	O
transversion	B-Variation
deep	O
within	O
intron	O
5	O
of	O
the	B-Gene
HADH	I-Gene
gene	I-Gene
,	O
creating	O
a	O
cryptic	O
splice	O
donor	O
site	O
that	O
results	B-Regulation
in	I-Regulation
the	O
inclusion	O
of	O
an	O
out	O
-	O
of	O
-	O
frame	O
141-bp	O
pseudoexon	B-Molecular_Physiological_Activity
and	O
premature	B-Molecular_Physiological_Activity
termination	I-Molecular_Physiological_Activity
.	O

The	O
mutation	B-Variation
was	O
present	O
in	O
heterozygosity	O
in	O
tested	O
parents	O
.	O

All	O
9	O
mutation	B-Variation
-	I-Variation
positive	I-Variation
Turkish	O
patients	O
were	O
also	O
homozygous	O
for	O
an	O
HADH	O
SNP	O
,	O
636	O
+	O
385A	O
-	O
G	O
(	O
rs732941	O
)	O
,	O
and	O
5	O
of	O
the	O
patients	O
were	O
known	O
to	O
share	O
a	O
1.6-Mb	O
haplotype	O
at	O
chromosome	O
4q25	O
(	O
chr4:108,874,712	O
-	O
108,968,640	O
;	O
GRCh37	O
)	O
.	O

Flanagan	O
et	O
al	O
.	O

(	O
2013	O
)	O
stated	O
that	O
the	O
636	O
+	O
471G	O
-	O
T	O
Turkish	O
founder	O
mutation	B-Variation
was	O
the	O
most	O
common	O
HADH	B-Gene
mutation	B-Variation
in	O
their	O
cohort	O
and	O
accounted	O
for	O
9	O
(	O
32	O
%	O
)	O
of	O
28	O
individuals	O
with	O
HADH	B-Gene
mutations	B-Variation
In	O
affected	O
members	O
of	O
a	O
consanguineous	O
Saudi	O
Arabian	O
family	O
with	O
juvenile	O
ALS16	O
(	O
614373	O
)	O
,	O
Al	O
-	O
Saif	O
et	O
al	O
.	O

(	O
2011	O
)	O
identified	O
a	O
homozygous	O
304G	O
-	O
C	O
transversion	B-Variation
in	O
exon	O
2	O
of	O
the	B-Gene
SIGMAR1	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
glu102-to	O
-	O
gln	O
(	O
E102Q	O
)	O
substitution	B-Variation
in	O
a	O
highly	O
conserved	O
residue	O
in	O
the	O
predicted	O
transmembrane	O
domain	O
.	O

The	O
mutation	B-Variation
was	O
not	O
found	O
in	O
271	O
controls	O
.	O

In	O
vitro	O
functional	O
expression	O
assays	O
in	O
the	O
motor	O
neuron	O
-	O
like	O
cell	O
line	O
NSC34	O
showed	O
that	O
the	O
mutant	B-Variation
protein	O
was	O
shifted	O
to	O
lower	O
density	O
membranes	O
and	O
formed	O
detergent	O
-	O
resistant	O
complexes	O
.	O

Transfected	O
cells	O
also	O
showed	O
an	O
almost	O
2-fold	O
increase	B-Positive_Regulation
in	O
apoptosis	B-Cell_Physiological_Activity
in	O
response	O
to	O
stress	O
compared	O
to	O
controls	O
.	O

The	O
findings	O
indicated	O
that	O
the	O
mutation	B-Variation
decreases	B-Negative_Regulation
the	O
viability	B-Cell_Physiological_Activity
of	O
motor	O
neurons	O
.	O

The	O
patients	O
had	O
a	O
very	O
early	O
age	O
of	O
onset	O
,	O
at	O
1	O
to	O
2	O
years	O
,	O
of	O
lower	O
limb	O
spasticity	O
and	O
weakness	O
.	O

The	O
disorder	O
was	O
slowly	O
progressive	O
,	O
and	O
involved	O
the	O
upper	O
limbs	O
.	O

Two	O
patients	O
were	O
wheelchair	O
-	O
bound	O
by	O
age	O
20	O
years	O
.	O

None	O
of	O
the	O
patients	O
had	O
bulbar	O
or	O
respiratory	O
involvement	O
,	O
and	O
all	O
had	O
normal	O
cognition	O
.	O

Fukunaga	O
et	O
al	O
.	O

(	O
2015	O
)	O
found	O
that	O
transfection	O
of	O
the	O
E102Q	O
mutation	B-Variation
into	O
neuro2A	O
cells	O
resulted	B-Regulation
in	I-Regulation
dissociation	B-Interaction
of	O
the	O
mutant	B-Variation
protein	B-Protein
from	O
the	O
ER	O
membrane	O
and	O
subsequent	O
cytoplasmic	O
aggregation	O
.	O

This	O
was	O
associated	O
with	O
disruption	B-Negative_Regulation
of	O
mitochondrial	O
structure	O
,	O
mitochondrial	O
damage	B-Negative_Regulation
,	O
decreased	B-Negative_Regulation
ATP	O
production	B-Molecular_Physiological_Activity
,	O
and	O
autophagic	O
cell	B-Cell_Physiological_Activity
death	I-Cell_Physiological_Activity
.	O

Cells	O
overexpressing	O
E102Q	O
showed	O
aberrant	O
extranuclear	O
localization	O
of	O
TDP43	O
(	O
605078	O
)	O
,	O
a	O
hallmark	O
of	O
AL	O
In	O
3	O
members	O
of	O
a	O
consanguineous	O
Chinese	O
family	O
with	O
childhood	O
-	O
onset	O
autosomal	O
recessive	O
distal	O
spinal	O
muscular	O
atrophy-2	O
(	O
DSMA2	O
;	O
605726	O
)	O
,	O
Li	O
et	O
al	O
.	O

(	O
2015	O
)	O
identified	O
a	O
homozygous	O
G	O
-	O
to	O
-	O
T	O
transversion	B-Variation
(	O
c.151	O
+	O
1G	O
-	O
T	O
,	O
NM_005866.3	O
)	O
affecting	O
a	O
splice	O
site	O
in	O
the	B-Gene
SIGMAR1	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
an	O
in	O
-	O
frame	O
deletion	B-Variation
of	O
20	O
amino	O
acids	O
in	O
exon	O
1	O
(	O
c.92_151del	O
,	O
p.31_50del	O
)	O
in	O
the	O
putative	O
extracellular	O
loop	O
.	O

The	O
mutation	B-Variation
,	O
which	O
was	O
found	O
by	O
a	O
combination	O
of	O
homozygosity	O
mapping	O
and	O
whole	O
-	O
exome	O
sequencing	O
and	O
confirmed	O
by	O
Sanger	O
sequencing	O
,	O
segregated	O
with	O
the	O
disorder	O
in	O
the	O
family	O
and	O
was	O
not	O
found	O
in	O
500	O
Chinese	O
controls	O
.	O

In	O
vitro	O
functional	O
expression	O
assays	O
in	O
HEK293	O
cells	O
showed	O
that	O
the	O
mutation	B-Variation
resulted	O
in	O
lower	B-Negative_Regulation
levels	B-Molecular_Physiological_Activity
of	O
the	O
protein	B-Protein
due	O
to	O
increased	B-Positive_Regulation
proteasomal	O
degradation	B-Molecular_Physiological_Activity
through	O
the	O
ER	O
-	O
associated	O
degradation	B-Molecular_Physiological_Activity
(	O
ERAD	O
)	O
pathway	B-Pathway
.	O

The	O
mutant	B-Variation
cell	O
lines	O
showed	O
increased	B-Positive_Regulation
ER	B-Cell_Physiological_Activity
stress	I-Cell_Physiological_Activity
and	O
apoptosis	B-Cell_Physiological_Activity
compared	O
to	O
wildtype	O
.	O

Fukunaga	O
et	O
al	O
.	O

(	O
2015	O
)	O
found	O
that	O
transfection	O
of	O
the	O
E102Q	O
mutation	B-Variation
into	O
neuro2A	O
cells	O
resulted	B-Regulation
in	I-Regulation
dissociation	B-Interaction
of	O
the	O
mutant	B-Variation
protein	B-Protein
from	O
the	O
ER	O
membrane	O
and	O
subsequent	O
cytoplasmic	O
aggregation	B-Interaction
.	O

This	O
was	O
associated	O
with	O
disruption	B-Negative_Regulation
of	O
mitochondrial	O
structure	O
,	O
mitochondrial	O
damage	B-Negative_Regulation
,	O
decreased	B-Negative_Regulation
ATP	O
production	B-Molecular_Physiological_Activity
,	O
and	O
autophagic	O
cell	O
death	B-Cell_Physiological_Activity
.	O

Cells	O
overexpressing	O
E102Q	O
showed	O
aberrant	O
extranuclear	O
localization	B-Molecular_Physiological_Activity
of	O
TDP43	O
(	O
605078	O
)	O
,	O
a	O
hallmark	O
of	O
ALS	O
.	O

Biebermann	O
et	O
al	O
.	O

(	O
2001	O
)	O
reported	O
a	O
family	O
in	O
which	O
3	O
individuals	O
had	O
nonautoimmune	O
hyperthyroidism	O
(	O
609152	O
)	O
caused	O
by	O
a	O
mutation	B-Variation
in	O
the	B-Gene
TSHR	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
gly431-to	O
-	O
ser	O
(	O
G431S	O
)	O
substitution	B-Variation
in	O
in	O
transmembrane	O
domain-1	O
of	O
the	O
protein	B-Protein
.	O

The	O
mutation	B-Variation
was	O
found	O
in	O
the	O
investigated	O
patient	O
,	O
his	O
father	O
,	O
and	O
the	O
paternal	O
grandmother	O
.	O

As	O
observed	O
in	O
other	O
familial	O
cases	O
of	O
nonautoimmune	O
hyperthyroidism	O
,	O
the	O
age	O
of	O
onset	O
of	O
the	O
disease	O
was	O
variable	O
,	O
ranging	O
from	O
early	O
childhood	O
in	O
the	O
patient	O
and	O
his	O
father	O
to	O
adolescence	O
in	O
the	O
grandmother	O
.	O

Functional	O
characterization	O
of	O
this	O
mutation	B-Variation
showed	O
a	O
constitutive	O
activation	B-Positive_Regulation
of	O
the	O
Gs	B-Pathway
/	I-Pathway
adenylyl	I-Pathway
cyclase	I-Pathway
system	I-Pathway
.	O

The	O
authors	O
concluded	O
that	O
constitutively	O
activating	B-Positive_Regulation
mutations	B-Variation
can	O
be	O
found	O
in	O
the	O
entire	O
transmembrane	O
domain	O
region	O
of	O
the	O
TSHR	O
,	O
indicating	O
the	O
important	O
role	O
of	O
all	O
parts	O
of	O
the	O
transmembrane	O
domain	O
region	O
for	O
maintaining	O
the	O
inactive	O
receptor	O
conformation	O
.	O


In	O
2	O
Chinese	O
brothers	O
with	O
primary	O
erythermalgia	O
(	O
133020	O
)	O
,	O
Han	O
et	O
al	O
.	O

(	O
2006	O
)	O
identified	O
a	O
2572C	O
-	O
T	O
transition	B-Variation
in	O
exon	O
15	O
of	O
the	B-Gene
SCN9A	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
leu858-to	O
-	O
phe	O
(	O
L858F	O
)	O
substitution	B-Variation
in	O
the	O
linker	O
region	O
between	O
transmembrane	O
segments	O
4	O
and	O
5	O
in	O
domain	O
2	O
.	O

The	O
asymptomatic	O
father	O
was	O
found	O
to	O
be	O
a	O
somatic	O
mosaic	O
for	O
the	O
mutation	B-Variation
,	O
which	O
was	O
present	O
in	O
13	O
%	O
of	O
his	O
leukocytes	O
.	O

In	O
vitro	O
functional	O
expression	O
studies	O
showed	O
that	O
the	O
L858F	B-Variation
protein	I-Variation
caused	B-Regulation
a	O
hyperpolarizing	B-Variation
shift	I-Variation
in	O
channel	O
activation	B-Molecular_Physiological_Activity
,	O
a	O
depolarizing	B-Variation
shift	I-Variation
of	O
inactivation	B-Molecular_Physiological_Activity
,	O
and	O
an	O
18-fold	O
increase	B-Positive_Regulation
in	O
deactivation	B-Molecular_Physiological_Activity
time	O
compared	O
to	O
wildtype	O
.	O

In	O
addition	O
,	O
the	O
mean	O
ramp	O
current	O
amplitude	O
in	O
response	O
to	O
slow	O
depolarization	B-Molecular_Physiological_Activity
was	O
higher	B-Positive_Regulation
in	O
L858F	O
-	O
mutant	O
channels	O
.	O

The	O
mutation	B-Variation
was	O
not	O
identified	O
in	O
200	O
alleles	O
from	O
Chinese	O
controls	O
.	O


In	O
17	O
affected	O
members	O
of	O
a	O
large	O
family	O
with	O
primary	O
erythermalgia	O
(	O
133020	O
)	O
reported	O
by	O
Finley	O
et	O
al	O
.	O

(	O
1992	O
)	O
,	O
Dib	O
-	O
Hajj	O
et	O
al	O
.	O

(	O
2005	O
)	O
identified	O
a	O
heterozygous	O
4393T	O
-	O
G	O
transversion	B-Variation
in	O
exon	O
23	O
of	O
the	B-Gene
SCN9A	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
phe1449-to	O
-	O
val	O
(	O
F1449V	O
)	O
substitution	B-Variation
in	O
the	O
N	O
terminus	O
of	O
loop	O
3	O
,	O
which	O
joins	O
domains	O
III	O
and	O
IV	O
of	O
the	O
protein	B-Protein
.	O

The	O
mutation	B-Variation
was	O
not	O
identified	O
in	O
5	O
unaffected	O
family	O
members	O
or	O
in	O
100	O
control	O
chromosomes	O
.	O

In	O
vitro	O
functional	O
expression	O
studies	O
showed	O
that	O
the	O
F1449V	O
mutant	B-Variation
protein	B-Protein
produced	B-Regulation
a	O
hyperpolarizing	B-Variation
shift	I-Variation
in	O
channel	O
activation	B-Molecular_Physiological_Activity
and	O
a	O
depolarizing	B-Molecular_Physiological_Activity
shift	I-Molecular_Physiological_Activity
in	O
steady	O
-	O
state	O
activation	B-Molecular_Physiological_Activity
,	O
lowering	O
the	O
threshold	O
for	O
single	O
action	O
potentials	O
and	O
high	O
frequency	O
firing	O
in	O
dorsal	O
root	O
ganglion	O
neurons	O
.	O

The	O
findings	O
were	O
consistent	O
with	O
a	O
gain	B-Positive_Regulation
-	I-Positive_Regulation
of	I-Positive_Regulation
-	I-Positive_Regulation
function	I-Positive_Regulation
mutation	B-Variation
.	O


In	O
a	O
39-year	O
-	O
old	O
Dutch	O
Caucasian	O
man	O
with	O
small	O
fiber	O
neuropathy	O
(	O
SFNP	O
;	O
see	O
133020	O
)	O
,	O
Faber	O
et	O
al	O
.	O

(	O
2012	O
)	O
identified	O
a	O
heterozygous	O
2159T	O
-	O
A	O
transversion	B-Variation
in	O
the	B-Gene
SCN9A	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
an	O
ile720-to	O
-	O
lys	O
(	O
I720	O
K	O
)	O
substitution	B-Variation
in	O
the	O
cytoplasmic	O
linker-1	O
region	O
between	O
domains	O
I	O
and	O
II	O
.	O

The	O
mutation	B-Variation
was	O
not	O
found	O
in	O
200	O
control	O
chromosomes	O
.	O

The	O
patient	O
developed	O
stabbing	O
pain	O
in	O
the	O
whole	O
body	O
at	O
age	O
37	O
years	O
.	O

Two	O
months	O
later	O
,	O
he	O
also	O
had	O
burning	O
pain	O
in	O
the	O
feet	O
and	O
lower	O
legs	O
,	O
followed	O
by	O
pain	O
in	O
the	O
lower	O
arms	O
.	O

He	O
also	O
had	O
numbness	O
and	O
hyperhidrosis	O
in	O
the	O
feet	O
.	O

He	O
had	O
distally	O
impaired	O
warmth	O
sensation	O
and	O
decreased	O
intraepithelial	O
nerve	O
fiber	O
density	O
compared	O
to	O
controls	O
.	O

In	O
vitro	O
functional	O
expression	O
and	O
electrophysiologic	O
studies	O
in	O
HEK293	O
and	O
dorsal	O
root	O
ganglion	O
neurons	O
showed	O
that	O
the	O
mutant	B-Variation
I720	O
K	O
protein	B-Protein
resulted	O
in	O
impaired	B-Negative_Regulation
slow	O
inactivation	B-Molecular_Physiological_Activity
and	O
hyperexcitability	B-Positive_Regulation
of	O
dorsal	O
root	O
ganglion	O
cells	O
.	O

I720	O
K	O
caused	B-Regulation
a	O
depolarizing	B-Variation
shift	I-Variation
in	O
the	O
resting	O
membrane	O
potential	O
and	O
an	O
increase	B-Positive_Regulation
in	O
the	O
number	O
of	O
action	B-Molecular_Physiological_Activity
potentials	I-Molecular_Physiological_Activity
evoked	O
by	O
a	O
depolarizing	O
stimulus	O
compared	O
to	O
control	O
.	O

Activation	O
,	O
fast	O
-	O
inactivation	O
,	O
and	O
ramp	O
currents	O
were	O
similar	O
to	O
wildtype	O
.	O


In	O
1	O
of	O
47	O
patients	O
with	O
sporadic	O
tetralogy	O
of	O
Fallot	O
(	O
187500	O
)	O
,	O
Pizzuti	O
et	O
al	O
.	O

(	O
2003	O
)	O
identified	O
a	O
1968A	O
-	O
G	O
transition	B-Variation
in	O
the	B-Gene
ZFPM2	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
ser657-to	O
-	O
gly	O
(	O
S657	O
G	O
)	O
mutation	B-Variation
.	O

Although	O
the	O
mutant	B-Variation
protein	B-Protein
retained	O
the	O
ability	O
to	O
bind	B-Interaction
the	O
partner	O
protein	B-Protein
GATA4	O
(	O
600576	O
)	O
and	O
repress	B-Negative_Regulation
GATA4-mediated	O
gene	B-Molecular_Physiological_Activity
activation	I-Molecular_Physiological_Activity
,	O
it	O
was	O
subtly	O
impaired	B-Negative_Regulation
in	O
this	O
function	B-Molecular_Physiological_Activity
.	O

In	O
a	O
sporadic	O
Italian	O
patient	O
with	O
tetralogy	O
of	O
Fallot	O
(	O
187500	O
)	O
,	O
De	O
Luca	O
et	O
al	O
.	O

(	O
2011	O
)	O
identified	O
a	O
heterozygous	O
1632G	O
-	O
A	O
transition	B-Variation
in	O
exon	O
8	O
of	O
the	B-Gene
ZFPM2	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
met544-to	O
-	O
ile	O
(	O
M544I	O
)	O
substitution	B-Variation
at	O
an	O
evolutionarily	O
conserved	O
residue	O
.	O

Parental	O
DNA	O
was	O
unavailable	O
for	O
analysis	O
;	O
the	O
mutation	B-Variation
was	O
not	O
found	O
in	O
500	O
population	O
-	O
matched	O
controls	O
.	O

In	O
a	O
Moroccan	O
patient	O
with	O
46,XY	O
sex	O
reversal-9	O
(	O
SRXY9	O
;	O
616067	O
)	O
,	O
Bashamboo	O
et	O
al	O
.	O

(	O
2014	O
)	O
identified	O
heterozygosity	O
for	O
a	O
de	O
novo	O
substitution	B-Variation
in	O
the	B-Gene
ZFPM2	I-Gene
gene	I-Gene
(	O
R260Q	O
;	O
603693.0010	O
)	O
as	O
well	O
as	O
homozygosity	O
for	O
the	O
M544I	O
substitution	B-Variation
.	O

The	O
proband	O
's	O
unaffected	O
second	O
-	O
cousin	O
parents	O
were	O
each	O
heterozygous	O
for	O
the	O
M544I	O
mutation	B-Variation
but	O
did	O
not	O
carry	O
the	O
R260Q	O
variant	B-Variation
;	I-Variation
neither	O
mutation	B-Variation
was	O
found	O
in	O
400	O
normospermic	O
ancestry	O
-	O
matched	O
controls	O
.	O

Bashamboo	O
et	O
al	O
.	O

(	O
2014	O
)	O
noted	O
that	O
there	O
was	O
no	O
reported	O
history	O
of	O
cardiac	O
anomalies	O
in	O
the	O
Moroccan	O
family	O
,	O
and	O
that	O
the	O
Italian	O
patient	O
reported	O
by	O
De	O
Luca	O
et	O
al	O
.	O

(	O
2011	O
)	O
had	O
no	O
reported	O
gonadal	O
anomalies	O
.	O

In	O
functional	O
assays	O
in	O
HEK293	O
T	O
cells	O
,	O
the	O
M544I	O
mutant	B-Variation
demonstrated	O
transactivation	B-Molecular_Physiological_Activity
activity	I-Molecular_Physiological_Activity
on	O
the	O
AMH	O
(	O
600957	O
)	O
promoter	O
that	O
was	O
similar	O
to	O
wildtype	O
,	O
although	O
there	O
was	O
a	O
significant	O
reduction	B-Negative_Regulation
in	O
the	O
ability	O
to	O
repress	B-Negative_Regulation
GATA4	O
/	O
NR5A1	O
(	O
184757)-dependent	O
transactivation	B-Molecular_Physiological_Activity
of	O
AMH	O
with	O
M544I	O
compared	O
to	O
wildtype	O
.	O

In	O
addition	O
,	O
the	O
M544I	O
mutant	B-Variation
exhibited	O
significantly	O
increased	B-Positive_Regulation
activation	B-Molecular_Physiological_Activity
of	O
the	O
SOX9	O
(	O
608160	O
)	O
enhancer	O
TESCO	O
compared	O
to	O
wildtype	O
.	O

In	O
4	O
affected	O
sibs	O
,	O
born	O
of	O
consanguineous	O
Arab	O
Muslim	O
parents	O
,	O
with	O
bilateral	O
striatal	O
necrosis	O
and	O
progressive	O
polyneuropathy	O
due	O
to	O
thiamine	O
metabolism	O
dysfunction	O
(	O
THMD4	O
;	O
613710	O
)	O
,	O
Spiegel	O
et	O
al	O
.	O

(	O
2009)identified	O
a	O
homozygous	O
373G	O
-	O
A	O
transition	B-Variation
in	O
the	B-Gene
SLC25A19	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
gly125-to	O
-	O
ser	O
(	O
G125S	O
)	O
substitution	B-Variation
in	O
the	O
highly	O
conserved	O
first	O
residue	O
of	O
the	O
third	O
transmembrane	O
domain	O
.	O

Functional	O
complementation	O
studies	O
in	O
yeast	O
showed	O
decreased	B-Negative_Regulation
protein	O
function	B-Molecular_Physiological_Activity
compared	O
to	O
controls	O
.	O

The	O
phenotype	O
was	O
characterized	O
by	O
recurrent	O
encephalopathic	O
episodes	O
in	O
childhood	O
with	O
essentially	O
full	O
psychomotor	O
recovery	O
,	O
as	O
well	O
as	O
by	O
a	O
chronic	O
progressive	O
polyneuropathy	O
.	O

Cognition	O
was	O
intact	O
.	O

Spiegel	O
et	O
al	O
.	O

(	O
2009)noted	O
that	O
the	O
phenotype	O
was	O
much	O
less	O
severe	O
than	O
that	O
described	O
in	O
Amish	O
lethal	O
microcephaly	O
(	O
607196	O
)	O
,	O
and	O
suggested	O
that	O
the	O
G125S	O
mutation	B-Variation
was	O
less	O
deleterious	O
than	O
the	O
G177A	O
mutation	B-Variation
.	O

Anikster	O
et	O
al	O
.	O

(	O
2001	O
)	O
identified	O
an	O
acceptor	O
splice	O
site	O
mutation	B-Variation
in	O
the	B-Gene
OPA3	I-Gene
gene	I-Gene
,	O
IVS1	O
-	O
1G	O
-	O
C	O
,	O
as	O
the	O
cause	O
of	O
3-methylglutaconic	O
aciduria	O
type	O
III	O
(	O
258501	O
)	O
,	O
or	O
optic	O
atrophy	O
plus	O
syndrome	O
,	O
in	O
several	O
Iraqi	O
Jewish	O
patients	O
.	O

The	O
mutation	B-Variation
abolished	B-Negative_Regulation
mRNA	O
expression	B-Molecular_Physiological_Activity
in	O
the	O
patients	O
'	O
fibroblasts	O
.	O

The	O
mutation	B-Variation
was	O
also	O
detected	O
in	O
8	O
of	O
85	O
healthy	O
ethnically	O
matched	O
controls	O
,	O
yielding	O
a	O
carrier	O
frequency	O
of	O
1	O
in	O
10	O
and	O
indicating	O
a	O
founder	O
effect	O
.	O

By	O
in	O
vitro	O
functional	O
expression	O
studies	O
using	O
rat	O
channels	O
in	O
human	O
cells	O
,	O
Khosravani	O
et	O
al	O
.	O

(	O
2004	O
)	O
demonstrated	O
that	O
the	O
V831	O
M	O
variant	B-Variation
resulted	O
in	O
about	O
50	O
%	O
slowing	B-Negative
of	O
inactivation	B-Molecular_Physiological_Activity
and	O
a	O
shift	O
to	O
depolarization	O
of	O
inactivation	B-Molecular_Physiological_Activity
compared	O
to	O
wildtype	O
channels	O
,	O
which	O
would	O
result	O
in	O
increased	B-Positive_Regulation
channel	O
activity	B-Molecular_Physiological_Activity
.	O


In	O
2	O
unrelated	O
Chinese	O
Han	O
patients	O
with	O
childhood	O
absence	O
epilepsy	O
(	O
611942	O
)	O
,	O
Chen	O
et	O
al	O
.	O

(	O
2003	O
)	O
identified	O
a	O
heterozygous	O
2397G	O
-	O
A	O
transition	B-Variation
in	O
exon	O
10	O
of	O
the	B-Gene
CACNA1H	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
gly773-to	O
-	O
asp	O
(	O
G773D	O
)	O
substitution	B-Variation
in	O
the	O
linker	O
region	O
between	O
domains	O
I	O
and	O
II	O
.	O

In	O
these	O
same	O
2	O
patients	O
and	O
a	O
third	O
unrelated	O
patient	O
,	O
Vitko	O
et	O
al	O
.	O

(	O
2005	O
)	O
found	O
that	O
all	O
3	O
had	O
the	O
G773D	O
variant	B-Variation
on	O
the	O
same	O
allele	O
as	O
a	O
common	O
arg788-to	O
-	O
cys	O
(	O
R788C	O
)	O
polymorphism	O
.	O

In	O
vitro	O
functional	O
expression	O
studies	O
by	O
Vitko	O
et	O
al	O
.	O

(	O
2005	O
)	O
demonstrated	O
that	O
both	O
the	O
G773D	O
and	O
the	O
R788C	O
variants	B-Variation
independently	O
altered	B-Regulation
the	O
voltage	B-Molecular_Physiological_Activity
dependence	I-Molecular_Physiological_Activity
of	O
channel	O
activation	B-Molecular_Physiological_Activity
,	O
and	O
together	O
resulted	O
in	O
an	O
even	O
stronger	B-Positive_Regulation
propensity	B-Molecular_Physiological_Activity
for	O
enhanced	B-Positive_Regulation
neuronal	B-Molecular_Physiological_Activity
firing	I-Molecular_Physiological_Activity
.	O

Vitko	O
et	O
al	O
.	O

(	O
2005	O
)	O
noted	O
that	O
the	O
findings	O
supported	O
the	O
idea	O
that	O
variants	B-Variation
in	O
the	B-Gene
CACNA1H	I-Gene
gene	I-Gene
are	O
susceptibility	O
alleles	O
that	O
contribute	O
to	O
the	O
development	B-Cell_Physiological_Activity
of	O
polygenic	O
disorders	O
such	O
as	O
idiopathic	O
generalized	O
epilepsy	O
.	O


In	O
2	O
Finnish	O
brothers	O
with	O
3-methylglutaconic	O
aciduria	O
type	O
V	O
(	O
MGCA5	O
;	O
610198	O
)	O
,	O
Ojala	O
et	O
al	O
.	O

(	O
2012	O
)	O
identified	O
a	O
homozygous	O
1-bp	O
deletion	B-Variation
(	O
c.300delA	O
)	O
in	O
exon	O
6	O
of	O
the	B-Gene
DNAJC19	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
frameshift	B-Variation
and	O
premature	B-Molecular_Physiological_Activity
termination	I-Molecular_Physiological_Activity
(	O
Ala100fsTer11	O
)	O
.	O

The	O
unaffected	O
parents	O
were	O
heterozygous	O
for	O
the	O
mutation	B-Variation
,	O
which	O
was	O
not	O
found	O
in	O
a	O
cohort	O
of	O
22	O
children	O
with	O
cardiomyopathy	O
.	O

Western	O
blot	O
analysis	O
of	O
patient	O
cells	O
showed	O
no	O
detectable	B-Protein
DNAJC19	I-Protein
protein	I-Protein
.	O

The	O
brothers	O
had	O
noncompaction	O
cardiomyopathy	O
,	O
which	O
resulted	O
in	O
death	O
in	O
1	O
patient	O
at	O
age	O
13	O
months	O
.	O

In	O
a	O
patient	O
with	O
3-methylcrotonyl	O
-	O
CoA	O
carboxylase-1	O
deficiency	O
(	O
MCC1D	O
;	O
210200	O
)	O
,	O
Gallardo	O
et	O
al	O
.	O

(	O
2001)identified	O
a	O
974T	O
-	O
G	O
transversion	B-Variation
in	O
the	B-Gene
MCCA	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
met325-to	O
-	O
arg	O
(	O
M325R	O
)	O
missense	O
mutation	B-Variation
.	O

This	O
nonconservative	O
substitution	B-Variation
led	O
to	O
absence	B-Negative_Regulation
of	O
labeling	O
of	O
MCC	O
-	O
alpha	O
by	O
biotin	O
,	O
indicating	O
that	O
the	O
mutation	B-Variation
affects	B-Regulation
either	O
the	O
stability	B-Molecular_Physiological_Activity
or	O
the	O
biotinylation	B-Molecular_Physiological_Activity
of	O
the	O
protein	B-Protein
In	O
a	O
Turkish	O
patient	O
with	O
severe	O
manifestations	O
of	O
3-methylcrotonyl	O
-	O
CoA	O
carboxylase-1	O
deficiency	O
(	O
MCC1D;210200	O
)	O
,	O
Baumgartner	O
et	O
al	O
.	O

(	O
2001	O
)	O
identified	O
a	O
homozygous	O
1594G	O
-	O
C	O
transversion	B-Variation
in	O
exon	O
13	O
of	O
the	B-Gene
MCCA	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
an	O
asp532-to	O
-	O
his	O
(	O
D532H	O
)	O
substitution	B-Variation
.	O

The	O
nucleotide	O
change	B-Variation
affects	B-Regulation
splicing	B-Molecular_Physiological_Activity
,	O
resulting	O
in	O
a	O
truncated	B-Negative_Regulation
protein	O
lacking	B-Negative_Regulation
functionally	B-Molecular_Physiological_Activity
important	O
domains	O
In	O
a	O
patient	O
,	O
born	O
of	O
consanguineous	O
Turkish	O
parents	O
,	O
with	O
a	O
severe	O
form	O
of	O
MCC2	O
deficiency	O
(	O
MCC2D;210210	O
)	O
manifest	O
as	O
fatal	O
neonatal	O
necrotizing	O
encephalopathy	O
,	O
Baykal	O
et	O
al	O
.	O

(	O
2005	O
)	O
identified	O
a	O
homozygous	O
G	O
-	O
to	O
-	O
A	O
transition	B-Variation
in	O
intron	O
16	O
of	O
the	B-Gene
MCCC2	I-Gene
gene	I-Gene
resulting	B-Regulation
in	I-Regulation
the	O
skipping	B-Variation
of	O
exon	O
16	O
.	O

MCC	O
activity	B-Molecular_Physiological_Activity
was	O
undetectable	B-Negative_Regulation
in	O
patient	O
fibroblasts	O
.	O

In	O
a	O
patient	O
with	O
combined	O
17-alpha	O
-	O
hydroxylase/17,20-lyase	O
deficiency	O
(	O
202110	O
)	O
,	O
Kagimoto	O
et	O
al	O
.	O

(	O
1988)demonstrated	O
a	O
4-base	O
duplication	B-Variation
in	O
exon	O
8	O
of	O
the	B-Gene
CYP17A1	I-Gene
gene	I-Gene
.	O

The	O
resultant	O
protein	O
had	O
an	O
altered	B-Variation
C	O
-	O
terminal	O
amino	O
acid	O
sequence	O
which	O
resulted	O
in	O
loss	B-Negative_Regulation
of	O
both	O
enzymatic	B-Molecular_Physiological_Activity
activities	I-Molecular_Physiological_Activity
.	O

This	O
mutation	B-Variation
was	O
also	O
found	O
in	O
affected	O
members	O
of	O
2	O
presumably	O
unrelated	O
Canadian	O
Mennonite	O
families	O
(	O
Kagimoto	O
et	O
al	O
.	O

,	O
1989	O
)	O
.	O

Imai	O
et	O
al	O
.	O

(	O
1992	O
)	O
identified	O
the	O
CYP17A1	B-Gene
4-bp	O
duplication	B-Variation
in	O
affected	O
members	O
of	O
6	O
families	O
residing	O
in	O
the	O
Friesland	O
region	O
of	O
the	O
Netherlands	O
.	O

Since	O
the	O
Mennonite	O
sect	O
derives	O
its	O
name	O
from	O
Menno	O
Simons	O
,	O
the	O
founder	O
of	O
the	O
group	O
in	O
Friesland	O
in	O
the	O
16th	O
century	O
,	O
the	O
4-bp	O
duplication	B-Variation
presumably	O
appeared	O
within	O
the	O
population	O
before	O
the	O
migration	O
of	O
the	O
Mennonites	O
from	O
the	O
Netherlands	O
to	O
Canada	O
In	O
a	O
46,XY	O
American	O
subject	O
with	O
complete	O
17-alpha	O
-	O
hydroxylase/17,20-lyase	O
deficiency	O
(	O
202110	O
)	O
,	O
Costa	O
-	O
Santos	O
et	O
al	O
.	O

(	O
2004	O
)	O
identified	O
homozygosity	O
for	O
a	O
4-bp	O
deletion	B-Variation
,	O
TTTT	O
,	O
near	O
the	O
3-prime	O
end	O
of	O
intron	O
3	O
of	O
the	B-Gene
CYP17A1	I-Gene
gene	I-Gene
.	O

RNA	O
derived	O
from	O
the	O
TTTT	O
deletion	B-Variation
skipped	O
exon	O
4	O
entirely	O
,	O
deleting	B-Variation
29	O
amino	O
acids	O
in	O
-	O
frame	O
;	O
cells	O
expressing	O
the	O
mutant	B-Variation
gene	O
had	O
no	B-Negative_Regulation
17-hydroxylase	B-Enzyme
activity	B-Molecular_Physiological_Activity
.	O

The	O
diagnosis	O
in	O
the	O
patient	O
had	O
been	O
based	O
on	O
extremely	O
elevated	B-Positive_Regulation
11-deoxycorticosterone	O
and	O
corticosterone	O
values	O
,	O
and	O
failure	B-Negative_Regulation
of	O
pubertal	B-Cell_Physiological_Activity
progression	I-Cell_Physiological_Activity
In	O
a	O
Japanese	O
child	O
,	O
born	O
of	O
consanguineous	O
parents	O
,	O
with	O
combined	O
17-alpha	O
-	O
hydroxylase/17,20-lyase	O
deficiency	O
(	O
202110	O
)	O
,	O
Yanase	O
et	O
al	O
.	O

(	O
1990	O
)	O
identified	O
a	O
7-bp	O
duplication	B-Variation
(	O
GCGCACA	O
)	O
in	O
exon	O
2	O
of	O
the	B-Gene
CYP17A1	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
frameshift	B-Variation
and	O
premature	B-Molecular_Physiological_Activity
stop	I-Molecular_Physiological_Activity
codon	O
N	O
-	O
terminal	O
to	O
the	O
heme	B-Interaction
-	I-Interaction
binding	I-Interaction
sequence	O
.	O

The	O
patient	O
was	O
genotypically	O
male	O
(	O
46,XY	O
)	O
,	O
but	O
phenotypically	O
female	O
.	O

The	O
mutation	B-Variation
led	O
to	O
the	O
absence	B-Negative_Regulation
of	O
a	O
functional	B-Molecular_Physiological_Activity
protein	O
in	O
the	O
adrenal	O
cortex	O
and	O
testis	O
.	O

This	O
lack	B-Negative_Regulation
of	O
protein	O
led	O
to	O
an	O
absence	B-Negative_Regulation
of	O
sex	O
steroids	O
,	O
resulting	B-Regulation
in	I-Regulation
female	O
external	O
genitalia	O
,	O
and	O
excessive	B-Positive_Regulation
secretion	B-Molecular_Physiological_Activity
of	O
steroids	O
with	O
mineralocorticoid	O
activity	B-Molecular_Physiological_Activity
,	O
resulting	B-Regulation
in	I-Regulation
hypertension	O
In	O
2	O
unrelated	O
patients	O
from	O
Guam	O
with	O
combined	O
17-alpha	O
-	O
hydroxylase/17,20-lyase	O
deficiency	O
(	O
202110	O
)	O
,	O
Lin	O
et	O
al	O
.	O

(	O
1991	O
)	O
identified	O
a	O
homozygous	O
ser106-to	O
-	O
pro	O
(	O
S106P	O
)	O
substitution	B-Variation
in	O
the	B-Gene
CYP17A1	I-Gene
gene	I-Gene
.	O

Functional	O
expression	O
studies	O
showed	O
that	O
the	O
mutation	B-Variation
abolished	B-Negative_Regulation
both	O
17-alpha	B-Enzyme
-	I-Enzyme
hydroxylase	I-Enzyme
and	O
17,20-lyase	B-Enzyme
activity	B-Molecular_Physiological_Activity
.	I-Molecular_Physiological_Activity

Jones	I-Molecular_Physiological_Activity
et	O
al	O
.	O

(	O
1992	O
)	O
reported	O
clinical	O
details	O
of	O
the	O
patients	O
,	O
both	O
of	O
whom	O
were	O
phenotypic	O
females	O
with	O
46,XY	O
karyotype	O
and	O
who	O
had	O
hypertension	O
.	O

The	O
finding	O
of	O
the	O
identical	O
defect	O
in	O
2	O
presumably	O
unrelated	O
individuals	O
from	O
a	O
relatively	O
small	O
population	O
suggested	O
to	O
Jones	O
et	O
al	O
.	O

(	O
1992	O
)	O
that	O
the	O
gene	B-Gene
might	O
be	O
frequent	O
in	O
that	O
population	O
.	O

In	O
a	O
32-year	O
-	O
old	O
Japanese	O
female	O
with	O
combined	O
partial	O
17-alpha	O
-	O
hydroxylase/17,20-lyase	O
deficiency	O
(	O
202110	O
)	O
,	O
Oshiro	O
et	O
al	O
.	O

(	O
1995	O
)	O
identified	O
a	O
1-bp	O
deletion	B-Variation
of	O
a	O
G	O
in	O
amino	O
acid	O
438	O
in	O
the	B-Gene
CYP17A1	I-Gene
gene	I-Gene
.	O

The	O
deletion	B-Variation
altered	B-Regulation
the	O
reading	B-Molecular_Physiological_Activity
frame	I-Molecular_Physiological_Activity
and	O
resulted	B-Regulation
in	I-Regulation
a	O
premature	B-Molecular_Physiological_Activity
stop	I-Molecular_Physiological_Activity
codon	O
at	O
position	O
443	O
.	O

The	O
ligand	O
of	O
heme	O
iron	O
,	O
cystine-442	O
,	O
was	O
absent	B-Negative_Regulation
.	O

The	O
truncated	B-Negative_Regulation
protein	O
showed	O
normal	O
amino	O
acid	O
residues	O
1	O
-	O
437	O
and	O
abnormal	O
amino	O
acid	O
residues	O
438	O
-	O
442	O
.	O

The	O
mutation	B-Variation
caused	O
loss	B-Negative_Regulation
of	O
an	O
AvaII	O
restriction	O
site	O
which	O
was	O
used	O
to	O
demonstrate	O
that	O
the	O
mother	O
and	O
a	O
sister	O
were	O
heterozygous	O
for	O
the	O
mutation	B-Variation
.	I-Variation

Oshiro	I-Variation
et	O
al	O
.	O

(	O
1995)reported	O
that	O
16	O
CYP17	O
allelic	O
variants	B-Variation
had	O
been	O
reported	O
In	O
2	O
French	O
Canadian	O
sibs	O
who	O
were	O
genotypically	O
male	O
with	O
a	O
female	O
phenotype	O
resulting	O
from	O
combined	O
partial	O
17-alpha	O
-	O
hydroxylase/17,20-lyase	O
deficiency	O
(	O
202110	O
)	O
,	O
Laflamme	O
et	O
al	O
.	O

(	O
1996	O
)	O
identified	O
a	O
homozygous	O
C	O
-	O
to	O
-	O
T	O
transition	B-Variation
in	O
exon	O
1	O
of	O
the	B-Gene
CYP17A1	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
an	O
arg96-to	O
-	O
trp	O
(	O
R96W	O
)	O
substitution	B-Variation
.	O

Functional	O
expression	O
studies	O
showed	O
that	O
the	O
mutation	B-Variation
almost	O
completely	O
abolished	B-Negative_Regulation
the	O
activity	B-Molecular_Physiological_Activity
of	O
the	O
mutant	B-Variation
protein	O
.	O

Laflamme	O
et	O
al	O
.	O

(	O
1996	O
)	O
pointed	O
out	O
that	O
17-alpha	O
-	O
hydroxylase/17,20-lyase	O
deficiency	B-Negative_Regulation
impairs	B-Negative_Regulation
steroid	O
biosynthesis	B-Cell_Physiological_Activity
in	O
the	O
adrenals	O
and	O
gonads	O
;	O
in	O
contrast	O
to	O
congenital	O
adrenal	O
hyperplasia	O
(	O
201910	O
)	O
,	O
caused	O
by	O
21-alpha	O
-	O
hydroxylase	O
or	O
11-beta	O
-	O
hydroxylase	O
deficiency	B-Negative_Regulation
,	O
in	O
which	O
steroid	O
formation	B-Molecular_Physiological_Activity
is	O
impaired	B-Negative_Regulation
exclusively	O
in	O
the	O
adrenals	O
Yamaguchi	O
et	O
al	O
.	O

(	O
1997	O
)	O
sequenced	O
the	O
CYP17	O
gene	O
from	O
a	O
Japanese	O
patient	O
with	O
combined	O
complete	O
17-alpha	O
-	O
hydroxylase/17,20-lyase	O
deficiency	O
(	O
202110	O
)	O
previously	O
reported	O
by	O
Yazaki	O
et	O
al	O
.	O

(	O
1982	O
)	O
.	O

The	O
patient	O
was	O
homozygous	O
for	O
a	O
G	O
-	O
to	O
-	O
A	O
transition	B-Variation
at	O
position	O
+5	O
of	O
the	O
5-prime	O
splice	O
site	O
of	O
intron	O
7	O
.	O

In	O
vitro	O
expression	O
analysis	O
of	O
an	O
allelic	O
minigene	O
containing	O
exons	O
6	O
-	O
8	O
of	O
the	O
mutant	B-Variation
gene	B-Gene
showed	O
skipping	B-Variation
of	O
exon	O
7	O
.	O

This	O
exon	O
skipping	B-Variation
alters	B-Regulation
the	O
translational	B-Molecular_Physiological_Activity
reading	O
frame	O
of	O
exon	O
8	O
and	O
introduces	O
a	O
premature	B-Molecular_Physiological_Activity
stop	I-Molecular_Physiological_Activity
codon	O
at	O
amino	O
acid	O
position	O
410	O
,	O
proximal	O
to	O
the	O
heme	O
iron	B-Interaction
-	I-Interaction
binding	I-Interaction
site	O
essential	O
for	O
the	O
enzymatic	B-Molecular_Physiological_Activity
activity	I-Molecular_Physiological_Activity
ofCYP17	B-Gene
.	O

Restriction	O
enzyme	O
analysis	O
showed	O
that	O
the	O
patient	O
was	O
homozygous	O
and	O
the	O
parents	O
were	O
heterozygous	O
for	O
the	O
mutation	B-Variation
.	O

In	O
a	O
Japanese	O
patient	O
with	O
combined	O
complete	O
17-alpha	O
-	O
hydroxylase/17,20-lyase	O
deficiency	O
(	O
202110	O
)	O
,	O
Suzuki	O
et	O
al	O
.	O

(	O
1998	O
)	O
identified	O
compound	O
heterozygosity	O
for	O
mutations	B-Variation
in	O
the	B-Gene
CYP17A1	I-Gene
gene	I-Gene
:	I-Gene
a	O
G	O
-	O
to	O
-	O
A	O
transition	B-Variation
,	O
resulting	B-Regulation
in	I-Regulation
a	O
trp17-to	O
-	O
ter	O
(	O
W17X	O
)	O
substitution	B-Variation
,	O
and	O
a	O
G	O
-	O
to	O
-	O
T	O
transversion	B-Variation
at	O
the	O
fifth	O
nucleotide	O
from	O
the	O
splice	O
donor	O
site	O
in	O
intron	O
2	O
(	O
IVS2	O
+	O
5G	O
-	O
T	O
;	O
609300.0017	O
)	O
.	O

The	O
patient	O
presented	O
with	O
female	O
genitalia	O
,	O
a	O
46,XY	O
karyotype	O
,	O
absent	B-Negative_Regulation
pubertal	B-Cell_Physiological_Activity
development	I-Cell_Physiological_Activity
,	O
and	O
hypertension	O
.	O

RT	O
-	O
PCR	O
analysis	O
using	O
RNA	O
isolated	O
from	O
the	O
testes	O
of	O
the	O
patient	O
revealed	O
that	O
the	O
IVS2	O
+	O
5G	O
-	O
T	O
mutation	B-Variation
caused	O
abnormal	B-Regulation
splicing	B-Molecular_Physiological_Activity
;	I-Molecular_Physiological_Activity
exon	O
2	O
was	O
spliced	O
with	O
intron	O
2	O
.	O

Skipping	B-Variation
exon	O
2	O
alters	B-Regulation
the	O
translational	B-Molecular_Physiological_Activity
reading	O
frame	O
of	O
exon	O
3	O
and	O
introduces	O
a	O
premature	B-Molecular_Physiological_Activity
termination	I-Molecular_Physiological_Activity
codon	O
.	O

In	O
semiquantitative	O
analysis	O
,	O
the	O
majority	O
of	O
the	O
transcript	O
for	O
IVS2	O
+	O
5G	O
-	O
T	O
skipped	B-Variation
exon	O
2	O
.	O

In	O
a	O
20-year	O
-	O
old	O
female	O
Turkish	O
46,XX	O
patient	O
with	O
complete	O
17-alpha	O
-	O
hydroxylase/17,20-lyase	O
deficiency	O
(	O
202110	O
)	O
who	O
presented	O
with	O
primary	O
amenorrhea	O
,	O
sexual	O
infantilism	O
,	O
and	O
easy	O
fatigability	O
,	O
Mussig	O
et	O
al	O
.	O

(	O
2005	O
)	O
detected	O
homozygosity	O
for	O
a	O
C	O
-	O
to	O
-	O
A	O
transversion	B-Variation
in	O
exon	O
1	O
of	O
the	B-Gene
CYP17A1	I-Gene
gene	I-Gene
that	O
introduced	O
a	O
stop	B-Molecular_Physiological_Activity
codon	I-Molecular_Physiological_Activity
in	O
place	O
of	O
tyrosine	O
at	O
codon	O
27	O
(	O
Y27X	O
)	O
.	O

The	O
patient	O
's	O
steroid	O
metabolism	O
showed	O
increased	B-Positive_Regulation
levels	B-Molecular_Physiological_Activity
of	O
mineralocorticoid	O
precursors	O
and	O
low	B-Negative_Regulation
or	O
undetectable	B-Negative_Regulation
plasma	O
concentrations	O
of	O
17-alpha	O
-	O
hydroxycorticoids	O
,	O
androgens	O
,	O
and	O
estrogens	O
before	O
and	O
after	O
ACTH	O
stimulation	O
.	O

The	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
urinary	O
steroid	O
profile	O
was	O
dominated	O
by	O
metabolites	O
of	O
corticosterone	O
and	O
its	O
precursors	O
,	O
while	O
cortisol	O
and	O
C19-steroid	O
metabolites	B-Pathway
were	O
lacking	B-Negative_Regulation
.	O

ACTH	O
,	O
FSH	O
(	O
see	O
136530	O
)	O
,	O
and	O
LH	O
(	O
see	O
152780	O
)	O
levels	B-Molecular_Physiological_Activity
were	O
elevated	B-Positive_Regulation
In	O
a	O
27-year	O
old	O
46,XX	O
Brazilian	O
patient	O
with	O
combined	O
partial	O
17-alpha	O
-	O
hydroxylase/17,20-lyase	O
deficiency	O
(	O
202110	O
)	O
,	O
Costa	O
-	O
Santos	O
et	O
al	O
.	O

(	O
2004	O
)	O
identified	O
compound	O
heterozygosity	O
for	O
a	O
Y329D	O
substitution	B-Variation
in	O
exon	O
6	O
of	O
the	B-Gene
CYP17A1	I-Gene
gene	I-Gene
(	O
609300.0025	O
)	O
and	O
an	O
AG	O
-	O
to	O
-	O
CG	O
substitution	B-Variation
at	O
the	O
3-prime	O
end	O
of	O
intron	O
2	O
(	O
IVS2ASA	O
-	O
C-2	O
)	O
.	O

In	O
transfection	O
studies	O
,	O
cells	O
expressing	O
the	O
mutant	B-Variation
gene	O
had	O
no	B-Negative_Regulation
17-hydroxylase	B-Enzyme
activity	B-Molecular_Physiological_Activity
.	O

The	O
RT	O
-	O
PCR	O
product	O
derived	O
from	O
these	O
cells	O
showed	O
that	O
the	O
mRNA	O
derived	O
from	O
the	O
AG	O
-	O
to	O
-	O
CG	O
mutation	B-Variation
used	O
the	O
first	O
AG	O
in	O
exon	O
3	O
as	O
the	O
splice	O
acceptor	O
site	O
,	O
shifting	O
the	O
reading	O
frame	O
and	O
introducing	O
a	O
stop	B-Molecular_Physiological_Activity
codon	I-Molecular_Physiological_Activity
.	O

The	O
patient	O
had	O
experienced	O
spontaneous	O
sexual	O
development	O
and	O
irregular	O
menses	O
.	O

Costa	O
-	O
Santos	O
et	O
al	O
.	O

(	O
2004	O
)	O
attributed	O
the	O
development	O
of	O
secondary	O
sexual	O
characteristics	O
to	O
the	O
presence	O
of	O
the	O
Y329D	O
mutation	B-Variation
,	O
which	O
retains	O
about	O
5	O
%	O
of	O
wildtype	O
17-alpha	B-Enzyme
-	I-Enzyme
hydroxylase	I-Enzyme
activity	B-Molecular_Physiological_Activity
In	O
3	O
consanguineous	O
Sri	O
Lankan	O
families	O
with	O
3	O
M	O
syndrome	O
(	O
273750	O
)	O
,	O
Huber	O
et	O
al	O
.	O

(	O
2005	O
)	O
found	O
that	O
affected	O
individuals	O
had	O
an	O
4333C	O
-	O
T	O
transition	B-Variation
in	O
exon	O
23	O
of	O
the	B-Gene
CUL7	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
conversion	B-Variation
of	O
arg1445	O
to	O
a	O
stop	B-Molecular_Physiological_Activity
codon	I-Molecular_Physiological_Activity
in	O
the	O
cullin	O
domain	O
of	O
the	O
protein	O
(	O
R1445X	O
)	O
.	O

Additional	O
studies	O
indicated	O
that	O
the	O
mutation	B-Variation
renderedCUL7	O
deficient	O
in	O
recruiting	O
ROC1	O
(	O
603814	O
)	O
to	O
the	O
E3	O
ubiquitin	O
ligase	B-Enzyme
complex	O
of	O
which	O
it	O
is	O
a	O
part	O
.	O

A	O
founder	O
effect	O
appeared	O
clearly	O
to	O
be	O
involved	O
.	O

In	O
5	O
consanguineous	O
families	O
,	O
4	O
from	O
Tunisia	O
and	O
1	O
from	O
Algeria	O
,	O
with	O
3	O
M	O
syndrome	O
(	O
273750	O
)	O
,	O
Huber	O
et	O
al	O
.	O

(	O
2005)identified	O
an	O
identical	O
2-bp	O
deletion	B-Variation
in	O
exon	O
24	O
of	O
the	B-Gene
CUL7	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
val1484-to	O
-	O
gly	O
substitution	B-Variation
and	O
a	O
frameshift	B-Variation
leading	B-Regulation
to	I-Regulation
termination	B-Molecular_Physiological_Activity
68	O
codons	O
downstream	O
(	O
Val1484GlyfsTer68	O
)	O
.	O

The	O
presence	O
of	O
the	O
same	O
deletion	B-Variation
in	O
multiple	O
consanguineous	O
families	O
suggested	O
a	O
founder	O
effect	O
in	O
this	O
region	O
of	O
North	O
Africa	O
.	O

Huber	O
et	O
al	O
.	O

(	O
2005)reported	O
the	O
deletion	B-Variation
as	O
4449_4450delTG	O
,	O
but	O
Huber	O
et	O
al	O
.	O

(	O
2009	O
)	O
reported	O
it	O
as	O
4450_4451delTG	O
.	O

Also	O
see609577.0005	O
.	O

In	O
all	O
43	O
affected	O
Yakut	O
individuals	O
with	O
Yakut	O
short	O
stature	O
syndrome	O
(	O
see	O
273750	O
)	O
,	O
Maksimova	O
et	O
al	O
.	O

(	O
2007)identified	O
a	O
homozygous	O
1-bp	O
insertion	B-Variation
(	O
4582_4583insT	O
)	O
in	O
the	B-Gene
CUL7	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
frameshift	B-Variation
and	O
premature	B-Molecular_Physiological_Activity
termination	I-Molecular_Physiological_Activity
.	O

As	O
the	O
Yakuts	O
are	O
considered	O
a	O
population	O
isolate	O
,	O
the	O
mutation	B-Variation
is	O
likely	O
due	O
to	O
a	O
founder	O
effect	O
In	O
a	O
southern	O
Italian	O
man	O
with	O
sideroblastic	O
anemia-3	O
(	O
SIDBA3	O
;	O
616860	O
)	O
,	O
Camaschella	O
et	O
al	O
.	O

(	O
2007	O
)	O
identified	O
a	O
homozygous	O
294A	O
-	O
G	O
transition	B-Variation
in	O
the	O
third	O
nucleotide	O
of	O
the	O
last	O
codon	O
of	B-Gene
GLRX5	I-Gene
exon	I-Gene
1	O
.	O

The	O
mutation	B-Variation
does	O
not	O
change	O
the	O
encoded	O
glutamine	O
at	O
position	O
98	O
,	O
but	O
is	O
predicted	O
to	O
interfere	B-Regulation
with	O
the	O
correct	O
RNA	B-Molecular_Physiological_Activity
splicing	I-Molecular_Physiological_Activity
.	O

Patient	O
cells	O
showed	O
decreased	B-Molecular_Physiological_Activity
GLRX5	I-Molecular_Physiological_Activity
expression	I-Molecular_Physiological_Activity
compared	O
to	O
controls	O
,	O
consistent	O
with	O
a	O
splicing	B-Molecular_Physiological_Activity
defect	B-Negative_Regulation
.	O

Further	O
analysis	O
indicated	O
dysregulation	B-Regulation
of	O
iron	B-Interaction
-	I-Interaction
binding	I-Interaction
proteins	O
.	O

In	O
in	O
vitro	O
cellular	O
transfection	O
and	O
functional	O
expression	O
assays	O
,	O
Liu	O
et	O
al	O
.	O

(	O
2016	O
)	O
found	O
that	O
the	O
K101Q	O
mutation	B-Variation
likely	O
prevents	B-Negative_Regulation
the	O
binding	B-Interaction
of	O
Fe	B-Protein
-	I-Protein
S	I-Protein
to	O
the	B-Protein
GLRX5	I-Protein
protein	I-Protein
,	O
whereas	O
the	O
L148S	O
mutation	B-Variation
may	O
interfere	B-Regulation
with	O
Fe	B-Protein
-	I-Protein
S	I-Protein
transfer	B-Molecular_Physiological_Activity
from	B-Gene
GLRX5	I-Gene
to	I-Gene
acceptor	O
proteins	B-Protein
.	I-Protein

Liu	O
et	O
al	O
.	O

(	O
2016	O
)	O
found	O
that	O
the	B-Gene
GLRX5-null	I-Gene
and	O
K101Q	O
mutations	B-Variation
resulted	O
in	O
a	O
significant	O
decrease	B-Negative_Regulation
in	O
pyruvate	B-Enzyme
dehydrogenase	I-Enzyme
(	O
PDH	O
)	O
and	O
alpha	B-Enzyme
-	I-Enzyme
ketoglutarate	I-Enzyme
dehydrogenase	I-Enzyme
(	O
KGDH	O
)	O
activities	B-Molecular_Physiological_Activity
,	O
whereas	O
the	O
L148S	O
and	O
combined	O
K101Q	O
/	O
L148S	O
mutations	B-Variation
did	O
not	O
affect	O
these	O
enzyme	O
complexes	O
,	O
which	O
explained	O
the	O
lack	O
of	O
additional	O
features	O
in	O
the	O
Chinese	O
patient	O
reported	O
byLiu	O
et	O
al	O
.	O

(	O
2014	O
)	O
In	O
2	O
unrelated	O
girls	O
of	O
Lebanese	O
descent	O
with	O
childhood	O
-	O
onset	O
spasticity	O
with	O
hyperglycinemia	O
(	O
SPAHGC;616859	O
)	O
,	O
Baker	O
et	O
al	O
.	O

(	O
2014	O
)	O
identified	O
a	O
homozygous	O
3-bp	O
deletion	B-Variation
(	O
c.151_153delAAG	O
)	O
in	O
exon	O
1	O
of	O
the	B-Gene
GLRX5gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
the	O
deletion	B-Variation
of	O
conserved	O
residue	O
lys51	O
(	O
K51del	O
)	O
,	O
which	O
is	O
in	O
the	O
glutaredoxin	O
domain	O
.	O

The	O
mutation	B-Variation
,	O
which	O
was	O
found	O
by	O
homozygosity	O
mapping	O
and	O
sequencing	O
of	O
candidate	O
genes	B-Gene
involved	O
in	O
iron	O
-	O
sulfur	O
cluster	O
biogenesis	O
,	O
segregated	O
with	O
the	O
disorder	O
in	O
both	O
families	O
and	O
was	O
not	O
found	O
in	O
172	O
Lebanese	O
controls	O
.	O

Patient	O
cells	O
showed	O
normal	B-Protein
GLRX5	I-Protein
protein	I-Protein
levels	B-Molecular_Physiological_Activity
,	O
but	O
there	O
were	O
reduced	O
to	O
absent	B-Negative_Regulation
levels	B-Molecular_Physiological_Activity
of	O
lipoate	O
on	O
the	O
E2	O
subunits	O
of	O
the	O
pyruvate	O
dehydrogenase	O
(	O
PDH	O
)	O
and	O
alpha	O
-	O
ketoglutarate	O
dehydrogenase	O
(	O
alpha	O
-	O
KGDH	O
)	O
complexes	O
compared	O
to	O
controls	O
;	O
lipoate	O
levels	O
normalized	O
after	O
transfection	O
with	O
wildtype	O
GLRX5	O
.	O

A	O
Chinese	O
patient	O
with	O
a	O
similar	O
phenotype	O
was	O
subsequently	O
found	O
to	O
be	O
compound	O
heterozygous	O
for	O
the	O
K51del	O
mutation	B-Variation
and	O
an	O
8-bp	O
insertion	B-Variation
(	O
c.82_83insGCGTGCGG	O
;	O
609588.0005	O
)	O
,	O
resulting	B-Regulation
in	I-Regulation
a	O
frameshift	B-Variation
and	O
premature	B-Molecular_Physiological_Activity
termination	I-Molecular_Physiological_Activity
(	O
Gly28GlyfsTer25	O
)	O
.	O

Each	O
unaffected	O
parent	O
was	O
heterozygous	O
for	O
1	O
of	O
the	O
mutations	B-Variation
,	O
neither	O
of	O
which	O
was	O
found	O
in	O
188	O
control	O
Chinese	O
alleles	O
.	O

The	O
findings	O
suggested	O
that	B-Gene
GLRX5	I-Gene
likely	I-Gene
functions	B-Molecular_Physiological_Activity
in	O
the	O
pathway	B-Pathway
that	O
provides	O
an	O
iron	O
-	O
sulfur	O
cluster	O
to	O
lipoate	O
synthase	O
In	O
3	O
sibs	O
with	O
hypochromic	O
microcytic	O
anemia	O
and	O
iron	O
overload	O
(	O
615234	O
)	O
,	O
born	O
of	O
nonconsanguineous	O
Pakistani	O
parents	O
,	O
Grandchamp	O
et	O
al	O
.	O

(	O
2011	O
)	O
identified	O
heterozygosity	O
for	O
a	O
c.300C	O
-	O
A	O
transition	B-Variation
in	O
exon	O
3	O
of	O
the	B-Gene
STEAP3gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
cys100-to	O
-	O
ter	O
(	O
C100X	O
)	O
substitution	B-Variation
.	O

The	O
mutation	B-Variation
was	O
inherited	O
from	O
their	O
unaffected	O
father	O
and	O
was	O
not	O
found	O
in	O
their	O
unaffected	O
mother	O
or	O
200	O
control	O
chromosomes	O
.	O

Quantitative	O
RT	O
-	O
PCR	O
from	O
blood	O
mRNA	O
of	O
all	O
5	O
family	O
members	O
and	O
10	O
controls	O
showed	O
that	O
the	B-Gene
STEAP3	I-Gene
mRNA	I-Gene
level	B-Molecular_Physiological_Activity
was	O
considerably	O
lower	B-Negative_Regulation
in	O
the	O
3	O
patients	O
,	O
whereas	O
both	O
parents	O
had	O
a	O
level	B-Molecular_Physiological_Activity
of	B-Gene
STEAP3	I-Gene
mRNA	I-Gene
corresponding	O
to	O
the	O
low	B-Negative_Regulation
-	I-Negative_Regulation
normal	I-Negative_Regulation
range	O
found	O
in	O
controls	O
.	O

In	O
B	O
lymphocyte	O
-	O
cell	O
lines	O
treated	O
to	O
prevent	O
degradation	O
due	O
to	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	O
,	O
quantitative	O
sequencing	O
of	O
a	O
cDNA	O
fragment	O
encompassing	O
the	O
mutated	B-Variation
nucleotide	O
demonstrated	O
that	O
expression	B-Molecular_Physiological_Activity
of	O
the	O
normal	O
allele	O
relative	O
to	O
that	O
of	O
the	O
mutated	B-Variation
allele	O
was	O
significantly	O
higher	B-Positive_Regulation
in	O
the	O
father	O
than	O
in	O
the	O
3	O
sibs	O
.	O

Grandchamp	O
et	O
al	O
.	O

(	O
2011	O
)	O
suggested	O
that	O
the	O
father	O
was	O
heterozygous	O
with	O
1	O
null	O
allele	O
and	O
1	O
normal	O
,	O
highly	O
expressed	O
allele	O
,	O
whereas	O
the	O
mother	O
had	O
2	O
weakly	O
expressed	O
alleles	O
,	O
and	O
each	O
affected	O
offspring	O
had	O
inherited	O
the	O
mutated	B-Variation
allele	O
from	O
their	O
father	O
and	O
1	O
of	O
the	O
weakly	O
expressed	O
alleles	O
from	O
their	O
mother	O
.	O

This	O
was	O
supported	O
by	O
the	O
fact	O
that	O
expression	B-Molecular_Physiological_Activity
of	O
both	O
alleles	O
from	O
the	O
mother	O
produced	O
an	O
amount	O
of	O
mRNA	O
that	O
was	O
roughly	O
equivalent	O
to	O
the	O
expression	B-Molecular_Physiological_Activity
products	O
from	O
the	O
single	O
normal	O
allele	O
of	O
the	O
father	O
.	O

In	O
a	O
patient	O
with	O
3-hydroxyisobutyryl	O
-	O
CoA	O
hydrolase	O
deficiency	O
(	O
HIBCHD	O
;	O
250620	O
)	O
,	O
Loupatty	O
et	O
al	O
.	O

(	O
2007	O
)	O
found	O
compound	O
heterozygosity	O
for	O
2	O
mutations	B-Variation
in	O
the	B-Gene
HIBCH	I-Gene
gene	I-Gene
.	O

The	O
patient	O
presented	O
with	O
progressive	O
infantile	O
neurodegeneration	O
and	O
was	O
born	O
of	O
nonconsanguineous	O
parents	O
.	O

The	O
patient	O
had	O
no	O
structural	O
abnormalities	O
of	O
the	O
brain	O
or	O
heart	O
and	O
no	O
dysmorphic	O
facial	O
features	O
,	O
and	O
was	O
alive	O
at	O
time	O
of	O
report	O
.	O

The	O
2	O
mutations	B-Variation
were	O
a	O
365A	O
-	O
G	O
transition	B-Variation
resulting	B-Regulation
in	I-Regulation
a	O
tyr122-to	O
-	O
cys	O
substitution	B-Variation
(	O
Y122C	O
)	O
carried	O
on	O
the	O
maternal	O
allele	O
,	O
and	O
a	O
splice	O
acceptor	O
site	O
mutation	B-Variation
,	O
IVS2	O
-	O
3C	O
-	O
G	O
(	O
610690.0003	O
)	O
,	O
carried	O
on	O
the	O
paternal	O
allele	O
.	O

The	O
missense	O
mutation	B-Variation
predicted	O
the	O
substitution	B-Variation
of	O
the	O
bulky	O
amino	O
acid	O
residue	O
tyrosine	O
,	O
which	O
is	O
conserved	O
among	O
different	O
species	O
.	O

The	O
splice	O
site	O
transversion	B-Variation
disrupted	B-Negative_Regulation
the	O
consensus	O
sequence	O
for	O
a	O
splice	O
acceptor	O
site	O
,	O
given	O
that	O
a	O
pyrimidine	O
(	O
cytosine	O
or	O
thymine	O
)	O
is	O
preferred	O
over	O
guanine	O
at	O
this	O
position	O
in	O
the	O
consensus	O
sequence	O
.	O

The	O
significance	O
of	O
this	O
mutation	B-Variation
on	O
splicing	O
was	O
investigated	O
by	O
analysis	O
of	O
HIBCH	O
cDNA	O
.	O

Sequence	O
analysis	O
revealed	O
a	O
heterozygous	O
2-bp	O
insertion	B-Variation
resulting	B-Regulation
from	I-Regulation
retention	O
of	O
the	O
3-prime	O
end	O
of	O
intron	O
2	O
,	O
causing	B-Regulation
a	O
frameshift	B-Variation
(	O
Arg27fsTer50	O
)	O
.	O

The	O
intronic	O
DNA	O
sequence	O
adjacent	O
to	O
the	O
IVS2	O
-	O
3C	O
-	O
G	O
mutation	B-Variation
showed	O
strong	O
homology	O
to	O
the	O
consensus	O
sequence	O
of	O
a	O
splice	O
acceptor	O
site	O
,	O
with	O
identity	O
at	O
9	O
of	O
10	O
intronic	O
bases	O
.	O

Loupatty	O
et	O
al	O
.	O

(	O
2007)found	O
that	O
heterozygosity	O
for	O
the	O
2	O
mutations	B-Variation
resulted	O
in	O
complete	O
absence	B-Negative_Regulation
of	B-Molecular_Physiological_Activity
HIBCH	I-Molecular_Physiological_Activity
activity	I-Molecular_Physiological_Activity
in	O
the	O
patient	O
,	O
indicative	O
of	O
a	O
pathogenetic	O
effect	O
in	O
both	O
mutations	B-Variation
.	O

In	O
2	O
sibs	O
,	O
born	O
of	O
distantly	O
related	O
Pakistani	O
parents	O
,	O
with	O
3-hydroxyisobutyryl	O
-	O
CoA	O
hydrolase	O
deficiency	O
(	O
HIBCHD	O
;	O
250620	O
)	O
,	O
Ferdinandusse	O
et	O
al	O
.	O

(	O
2013	O
)	O
identified	O
a	O
homozygous	O
c.950G	O
-	O
A	O
transition	B-Variation
in	O
the	B-Gene
HIBCH	I-Gene
gene	I-Gene
(	O
c.950G	O
-	O
A	O
,	O
NM_014362.2	O
)	O
,	O
resulting	B-Regulation
in	I-Regulation
a	O
gly317-to	O
-	O
glu	O
(	O
G317E	O
)	O
substitution	B-Variation
at	O
a	O
highly	O
conserved	O
residue	O
.	O

The	O
mutation	B-Variation
,	O
which	O
was	O
found	O
by	O
direct	O
sequencing	O
of	O
the	B-Gene
HIBCH	I-Gene
gene	I-Gene
,	O
segregated	O
with	O
the	O
disorder	O
in	O
the	O
family	O
and	O
was	O
not	O
found	O
in	O
the	O
dbSNP	O
or	O
1000	O
Genomes	O
Project	O
databases	O
.	O

Fibroblast	O
activity	O
of	B-Gene
HIBCH	I-Gene
was	I-Gene
below	O
the	O
level	O
of	O
detection	O
in	O
both	O
patients	O
.	O

In	O
a	O
female	O
patient	O
with	O
3-hydroxyisobutyryl	O
-	O
CoA	O
hydrolase	O
deficiency	O
(	O
HIBCHD	O
;	O
250620	O
)	O
,	O
Peters	O
et	O
al	O
.	O

(	O
2015)identified	O
compound	O
heterozygous	O
mutations	B-Variation
in	O
the	B-Gene
HIBCH	I-Gene
gene	I-Gene
:	I-Gene
a	O
single	O
-	O
basepair	O
insertion	B-Variation
(	O
c.129dupA	O
)	O
,	O
and	O
a	O
c.1033G	O
-	O
A	O
transition	B-Variation
(	O
610690.0007	O
)	O
.	O

The	O
c.129dupA	O
frameshift	B-Variation
mutation	B-Variation
introduces	O
a	O
stop	O
codon	O
8	O
amino	O
acids	O
downstream	O
.	O

The	O
missense	O
c.1033G	O
-	O
A	O
mutation	B-Variation
predicts	O
a	O
gly345	O
to	O
ser	O
(	O
G345S	O
)	O
change	O
affecting	O
the	O
substrate	O
binding	B-Interaction
pocket	O
and	O
was	O
predicted	O
to	O
be	O
damaging	B-Negative_Regulation
,	O
with	O
a	O
Polyphen2	O
score	O
of	O
0.997	O
.	O

In	O
a	O
5-year	O
-	O
old	O
boy	O
,	O
born	O
of	O
consanguineous	O
Tunisian	O
parents	O
,	O
with	O
3-hydroxyisobutyryl	O
-	O
CoA	O
hydrolase	O
deficiency	O
(	O
HIBCHD	O
;	O
250620	O
)	O
,	O
Reuter	O
et	O
al	O
.	O

(	O
2014	O
)	O
identified	O
a	O
homozygous	O
1-bp	O
insertion	B-Variation
(	O
c.1128_1129insT	O
,	O
NM_014362.3	O
)	O
in	O
the	B-Gene
HIBCH	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
frameshift	B-Variation
and	O
premature	B-Molecular_Physiological_Activity
termination	I-Molecular_Physiological_Activity
(	O
Lys377Ter	O
)	O
.	O

The	O
mutation	B-Variation
,	O
which	O
was	O
found	O
by	O
whole	O
-	O
exome	O
sequencing	O
and	O
confirmed	O
by	O
Sanger	O
sequencing	O
,	O
segregated	O
with	O
the	O
disorder	O
in	O
the	O
family	O
and	O
was	O
not	O
found	O
in	O
the	O
dbSNP	O
,	O
1000	O
Genomes	O
Project	O
,	O
or	O
Exome	O
Variant	O
Server	O
databases	O
.	O

Patient	O
cells	O
showed	O
no	B-Negative_Regulation
detectable	B-Molecular_Physiological_Activity
HIBCH	I-Molecular_Physiological_Activity
enzymatic	I-Molecular_Physiological_Activity
activity	I-Molecular_Physiological_Activity
.	O

In	O
affected	O
members	O
of	O
4	O
unrelated	O
families	O
of	O
Asian	O
origin	O
with	O
3	O
M	O
syndrome-2	O
(	O
3M2	O
;	O
612921	O
)	O
,	O
Hanson	O
et	O
al	O
.	O

(	O
2009	O
)	O
identified	O
a	O
homozygous	O
1-bp	O
insertion	B-Variation
(	O
1273insA	O
)	O
in	O
exon	O
3	O
of	O
the	B-Gene
OBSL1	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
frameshift	B-Variation
and	O
premature	B-Molecular_Physiological_Activity
termination	I-Molecular_Physiological_Activity
.	O

The	O
mutation	B-Variation
occurred	O
near	O
the	O
N	O
terminus	O
and	O
affected	O
all	O
OBSL1isoforms	O
,	O
consistent	O
with	O
complete	O
loss	B-Negative_Regulation
of	O
protein	B-Protein
function	B-Molecular_Physiological_Activity
and	O
a	O
null	O
phenotype	O
.	O

Two	O
of	O
the	O
families	O
were	O
large	O
consanguineous	O
families	O
with	O
multiple	O
affected	O
individuals	O
.	O

Two	O
additional	O
probands	O
with	O
the	O
disorder	O
were	O
compound	O
heterozygous	O
for	O
the	O
1273insA	O
mutation	O
and	O
another	O
truncating	O
mutation	O
in	O
the	B-Gene
OBSL1gene	I-Gene
:	I-Gene
a	O
1149C	O
-	O
A	O
transversion	B-Variation
in	O
exon	O
3	O
,	O
resulting	B-Regulation
in	I-Regulation
a	O
cys383-to	O
-	O
ter	O
substitution	B-Variation
(	O
C383X	O
;	O
610991.0002	O
)	O
,	O
and	O
a	O
10-bp	O
deletion	B-Variation
in	O
exon	O
3	O
(	O
610991.0003	O
)	O
,	O
respectively	O
.	O

In	O
5	O
affected	O
brothers	O
,	O
born	O
of	O
consanguineous	O
Arab	O
parents	O
,	O
with	O
alopecia	O
,	O
neurologic	O
defects	O
,	O
and	O
endocrinopathy	O
syndrome	O
(	O
ANES	O
;	O
612079	O
)	O
,	O
Nousbeck	O
et	O
al	O
.	O

(	O
2008	O
)	O
identified	O
a	O
homozygous	O
1052T	O
-	O
C	O
transition	B-Variation
in	O
the	B-Gene
RBM28	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
leu351-to	O
-	O
pro	O
(	O
L351P	O
)	O
substitution	B-Variation
within	O
the	O
C	O
-	O
terminal	O
region	O
of	O
the	O
RRM3	O
domain	O
.	O

The	O
mutation	B-Variation
was	O
not	O
identified	O
in	O
1,200	O
control	O
chromosomes	O
and	O
was	O
predicted	O
to	O
alter	O
the	O
first	O
alpha	O
helix	O
of	O
the	O
RRM3	O
domain	O
.	O

Normal	O
levels	O
of	O
mutant	B-Variation
mRNA	O
were	O
detected	O
,	O
but	O
immunoblotting	O
showed	O
barely	B-Negative_Regulation
detectable	O
levels	B-Molecular_Physiological_Activity
of	B-Protein
RBM28	I-Protein
protein	I-Protein
in	O
patient	O
fibroblasts	O
and	O
skin	O
,	O
suggesting	O
protein	B-Protein
destabilization	B-Molecular_Physiological_Activity
and	O
degradation	B-Molecular_Physiological_Activity
.	O

Transmission	O
electron	O
microscopy	O
of	O
cultured	O
patient	O
fibroblasts	O
showed	O
dilated	O
cisterns	O
of	O
the	O
rough	O
endoplasmic	O
reticulum	O
and	O
decreased	B-Negative_Regulation
number	O
of	O
free	O
ribosomes	O
.	O

In	O
a	O
Saudi	O
Arabian	O
patient	O
with	O
3MC	O
syndrome-2	O
(	O
265050	O
)	O
,	O
Rooryck	O
et	O
al	O
.	O

(	O
2011	O
)	O
identified	O
homozygosity	O
for	O
a	O
3-bp	O
in	O
-	O
frame	O
deletion	B-Variation
(	O
648CTC	O
)	O
in	O
exon	O
8	O
of	O
the	B-Gene
COLEC11	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
the	O
deletion	B-Variation
of	O
a	O
highly	O
conserved	O
serine	O
residue	O
(	O
ser217del	O
)	O
in	O
the	O
carbohydrate	O
recognition	O
domain	O
.	O

The	O
mutated	B-Variation
alleles	O
segregated	O
with	O
the	O
disorder	O
in	O
the	O
family	O
,	O
and	O
the	O
mutation	B-Variation
was	O
not	O
found	O
in	O
192	O
Saudi	O
control	O
chromosomes	O
.	O

described	O
another	O
patient	O
who	O
was	O
a	O
compound	O
heterozygote	O
for	O
C29R	O
and	O
an	O
R886H	O
substitution	B-Variation
(	O
612779.0006	O
)	O
.	O

The	O
patient	O
had	O
been	O
hospitalized	O
for	O
upper	O
airway	O
infection	O
and	O
was	O
being	O
investigated	O
for	O
unexplained	O
hypokalemia	O
.	O

However	O
,	O
there	O
were	O
no	O
convulsions	O
or	O
other	O
neurologic	O
abnormalities	O
.	O

By	O
assaying	O
recombinant	O
C29R	O
mutant	B-Variation
enzyme	B-Enzyme
,	O
they	O
found	O
that	O
C29R	O
had	O
no	B-Negative_Regulation
detectable	B-Gene
DPYD	I-Gene
activity	B-Molecular_Physiological_Activity
;	I-Molecular_Physiological_Activity
however	O
,	O
R886H	O
showed	O
activity	B-Molecular_Physiological_Activity
about	O
40	O
%	O
of	O
normal	O
.	O

The	O
authors	O
concluded	O
that	O
the	O
C29R	O
mutation	B-Variation
alone	O
was	O
sufficient	O
to	O
explain	O
the	O
DPD	O
-	O
deficient	O
phenotype	O
and	O
that	O
the	O
R886H	O
mutation	B-Variation
was	O
probably	O
a	O
rare	O
polymorphism	O
.	O

In	O
a	O
child	O
with	O
DPD	O
deficiency	O
(	O
274270	O
)	O
,	O
born	O
of	O
consanguineous	O
parents	O
,	O
Vreken	O
et	O
al	O
.	O

(	O
1997	O
)	O
identified	O
a	O
homozygous	O
1-bp	O
deletion	B-Variation
(	O
1897delC	O
)	O
in	O
the	B-Gene
DPYD	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
frameshift	B-Variation
and	O
premature	B-Molecular_Physiological_Activity
truncation	I-Molecular_Physiological_Activity
.	O

At	O
the	O
age	O
of	O
9	O
months	O
the	O
patient	O
showed	O
febrile	O
convulsions	O
,	O
severe	O
neuromotor	O
retardation	O
,	O
and	O
spastic	O
tetraplegia	O
.	O

Cerebral	O
MRI	O
showed	O
ventriculomegaly	O
with	O
white	O
matter	O
hypodensity	O
.	O

At	O
the	O
age	O
of	O
6	O
years	O
,	O
thymine	O
-	O
uraciluria	O
was	O
noted	O
and	O
DPD	O
deficiency	O
was	O
demonstrated	O
in	O
fibroblasts	O
.	O

An	O
earlier	O
-	O
born	O
child	O
had	O
died	O
before	O
her	O
first	O
birthday	O
with	O
severe	O
neuromotor	O
retardation	O
and	O
febrile	O
convulsions	O
.	O

Surprisingly	O
,	O
the	O
father	O
of	O
the	O
patient	O
was	O
also	O
completely	O
DPD	O
deficient	O
,	O
although	O
he	O
had	O
no	O
history	O
of	O
convulsions	O
.	O

The	O
mother	O
of	O
the	O
patient	O
showed	O
intermediate	O
DPD	O
activity	B-Molecular_Physiological_Activity
consistent	O
with	O
obligate	O
carrier	O
status	O
.	O

The	O
patient	O
was	O
heterozygous	O
for	O
this	O
1-bp	O
deletion	B-Variation
,	O
whereas	O
the	O
father	O
was	O
thought	O
to	O
be	O
homozygous	O
.	O

The	O
nature	O
of	O
the	O
heterozygous	O
mutation	B-Variation
carried	O
by	O
the	O
mother	O
and	O
transmitted	O
to	O
the	O
son	O
was	O
not	O
determined	O
Vreken	O
et	O
al	O
.	O

(	O
1997	O
)	O
described	O
a	O
patient	O
who	O
was	O
a	O
compound	O
heterozygote	O
for	O
a	O
C29R	O
mutation	B-Variation
(	O
612779.0004	O
)	O
and	O
an	O
arg886-to	O
-	O
his	O
(	O
R886H	O
)	O
substitution	B-Variation
.	O

By	O
assaying	O
recombinant	O
C29R	O
mutant	B-Variation
enzyme	B-Enzyme
,	O
they	O
found	O
that	O
C29R	O
had	O
no	B-Negative_Regulation
detectable	B-Molecular_Physiological_Activity
DPYD	I-Molecular_Physiological_Activity
activity	I-Molecular_Physiological_Activity
;	I-Molecular_Physiological_Activity
however	O
,	O
R886H	O
showed	O
activity	B-Molecular_Physiological_Activity
about	O
40	O
%	O
of	O
normal	O
.	O

The	O
authors	O
concluded	O
that	O
the	O
C29R	O
mutation	B-Variation
alone	O
was	O
sufficient	O
to	O
explain	O
the	O
DPD	O
-	O
deficient	O
phenotype	O
and	O
that	O
the	O
R886H	O
mutation	B-Variation
was	O
probably	O
a	O
rare	O
polymorphism	O
In	O
a	O
10-month	O
-	O
old	O
Indian	O
boy	O
with	O
5-oxoprolinase	O
deficiency	O
(	O
260005	O
)	O
,	O
Almaghlouth	O
et	O
al	O
.	O

(	O
2012	O
)	O
identified	O
homozygosity	O
for	O
a	O
1-bp	O
insertion	B-Variation
(	O
2601insC	O
)	O
in	O
the	B-Gene
OPLAH	I-Gene
gene	I-Gene
,	O
predicted	O
to	O
cause	B-Regulation
a	O
frameshift	B-Variation
and	O
premature	B-Molecular_Physiological_Activity
termination	I-Molecular_Physiological_Activity
sequence	O
resulting	O
in	O
almost	O
complete	O
removal	O
of	O
the	O
oxoprolinase	O
domain	O
.	O

His	O
clinically	O
unaffected	O
sister	O
was	O
also	O
homozygous	O
for	O
the	O
mutation	B-Variation
,	O
and	O
was	O
subsequently	O
found	O
to	O
have	O
increased	B-Positive_Regulation
5-oxoproline	O
excretion	B-Molecular_Physiological_Activity
in	O
the	O
urine	O
.	O

Their	O
first	O
-	O
cousin	O
parents	O
were	O
heterozygous	O
for	O
the	O
mutation	B-Variation
,	O
which	O
the	O
authors	O
stated	O
was	O
not	O
listed	O
in	O
any	O
public	O
databases	O
including	O
the	O
1000	O
Genomes	O
Project	O
.	O

In	O
a	O
1-year	O
-	O
old	O
girl	O
,	O
born	O
of	O
nonconsanguineous	O
parents	O
of	O
Indian	O
origin	O
,	O
who	O
had	O
massive	O
excretion	O
of	O
5-oxoproline	O
in	O
urine	O
but	O
no	O
symptoms	O
related	O
to	O
glutathione	O
cycle	O
defects	O
,	O
Calpena	O
et	O
al	O
.	O

(	O
2013	O
)	O
identified	O
heterozygosity	O
for	O
a	O
969C	O
-	O
A	O
transversion	B-Variation
in	O
the	B-Gene
OPLAH	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
ser323-to	O
-	O
arg	O
(	O
S323R	O
)	O
substitution	B-Variation
at	O
a	O
highly	O
conserved	O
residue	O
in	O
the	O
first	O
domain	O
,	O
near	O
an	O
ATP	B-Interaction
-	I-Interaction
binding	I-Interaction
site	O
.	O

The	O
presence	O
of	O
a	O
large	O
deletion	B-Variation
or	O
duplication	B-Variation
was	O
excluded	O
by	O
gel	O
electrophoresis	O
.	O

The	O
patient	O
's	O
asymptomatic	O
mother	O
was	O
also	O
heterozygous	O
for	O
the	O
mutation	B-Variation
,	O
which	O
was	O
not	O
found	O
in	O
her	O
father	O
or	O
in	O
128	O
controls	O
.	O

In	O
a	O
male	O
pseudohermaphrodite	O
with	O
salt	O
-	O
wasting	O
classic	O
3-beta	O
-	O
HSD	O
deficiency	O
congenital	O
adrenal	O
hyperplasia	O
(	O
201810	O
)	O
,	O
Chang	O
et	O
al	O
.	O

(	O
1993	O
)	O
found	O
in	O
exon	O
4	O
of	O
the	B-Gene
HSD3B2	I-Gene
gene	I-Gene
a	O
missense	O
mutation	B-Variation
at	O
codon	O
248	O
,	O
GTC	O
(	O
val	O
)	O
was	O
converted	O
to	O
AAC	O
(	O
asn	O
)	O
,	O
followed	O
by	O
a	O
frameshift	B-Variation
mutation	B-Variation
at	O
codon	O
249	O
in	O
which	O
CGA	O
(	O
arg	O
)	O
was	O
changed	O
to	O
TA	O
,	O
resulting	B-Regulation
in	I-Regulation
the	O
stop	B-Molecular_Physiological_Activity
codon	I-Molecular_Physiological_Activity
TAG	O
(	O
613890.0004	O
)	O
.	O

The	O
patient	O
,	O
a	O
Mexican	O
Hispanic	O
,	O
was	O
thought	O
to	O
be	O
homozygous	O
for	O
this	O
unusual	O
mutation	B-Variation
,	O
the	O
genesis	O
of	O
which	O
was	O
not	O
understood	O

Alos	O
et	O
al	O
.	O

(	O
2000	O
)	O
described	O
2	O
French	O
Canadian	O
patients	O
from	O
2	O
unrelated	O
families	O
who	O
presented	O
with	O
severe	O
salt	O
-	O
wasting	O
HSD3B	B-Gene
deficiency	O
(	O
201810	O
)	O
in	O
infancy	O
.	O

Although	O
the	O
diagnosis	O
was	O
considered	O
clinically	O
,	O
plasma	O
steroid	O
profiles	O
were	O
confusing	O
.	O

Alos	O
et	O
al	O
.	O

(	O
2000	O
)	O
directly	O
sequenced	O
DNA	O
fragments	O
generated	O
by	O
PCR	O
amplification	O
of	O
the	O
4	O
exons	O
,	O
exon	O
-	O
intron	O
boundaries	O
,	O
and	O
the	O
5-prime	O
-	O
flanking	O
regions	O
of	O
the	B-Gene
HSD3B2	I-Gene
gene	I-Gene
.	O

Sequencing	O
of	O
exon	O
2	O
revealed	O
a	O
C	O
-	O
to	O
-	O
A	O
transversion	B-Variation
in	O
both	O
alleles	O
of	O
both	O
cases	O
,	O
resulting	B-Regulation
in	I-Regulation
an	O
ala10-to	O
-	O
glu	O
substitution	B-Variation
(	O
GCA	O
to	O
GAA	O
)	O
.	O

This	O
ala	O
is	O
highly	O
conserved	O
in	O
the	O
vertebrate	O
HSD3B	B-Gene
gene	O
family	O
and	O
is	O
located	O
in	O
the	O
putative	O
NAD	B-Interaction
-	I-Interaction
binding	I-Interaction
domain	O
of	O
the	O
enzyme	B-Enzyme
.	O

The	O
mutant	B-Variation
HSD3B2	I-Variation
enzyme	I-Variation
exhibited	O
no	B-Negative_Regulation
detectable	O
activity	B-Molecular_Physiological_Activity
in	O
intact	O
transfected	O
Ad293	O
cells	O
.	O

Both	O
homozygous	O
patients	O
shared	O
the	O
same	O
haplotype	O
,	O
spanning	O
approximately	O
3.3	O
cM	O
surrounding	O
the	B-Gene
HSD3B2	I-Gene
gene	I-Gene
,	O
consistent	O
with	O
a	O
founder	O
effect	O
for	O
this	O
missense	O
mutation	B-Variation
.	O

The	O
46,XY	O
patient	O
presented	O
with	O
ambiguous	O
genitalia	O
at	O
birth	O
and	O
underwent	O
normal	O
masculinization	O
at	O
puberty	O
,	O
but	O
was	O
azoospermic	O
at	O
18.5	O
years	O
of	O
age	O
.	O

The	O
46,XX	O
patient	O
presented	O
progressive	O
breast	O
development	O
,	O
menarche	O
,	O
and	O
evidence	O
of	O
progesterone	O
secretion	O
In	O
a	O
patient	O
with	O
salt	O
-	O
wasting	O
3-beta	O
-	O
HSD	O
(	O
201810	O
)	O
from	O
Eastern	O
European	O
Jewish	O
parents	O
with	O
no	O
family	O
history	O
of	O
consanguinity	O
,	O
Pang	O
et	O
al	O
.	O

(	O
2002	O
)	O
found	O
a	O
homozygous	O
single	O
-	O
nucleotide	O
substitution	B-Variation
at	O
nucleotide	O
7031	O
in	O
exon	O
4	O
of	O
the	B-Gene
HSD3B2	I-Gene
gene	I-Gene
,	O
which	O
resulted	B-Regulation
in	I-Regulation
a	O
pro	O
-	O
to	O
-	O
thr	O
amino	O
acid	O
substitution	B-Variation
at	O
codon	O
222	O
(	O
P222	O
T	O
)	O
.	O

In	O
cells	O
transfected	O
with	O
the	O
mutant	B-Variation
protein	B-Protein
,	O
no	B-Negative_Regulation
enzyme	B-Enzyme
activity	B-Molecular_Physiological_Activity
was	O
detected	O
In	O
4	O
unrelated	O
patients	O
with	O
3	O
M	O
syndrome-3	O
(	O
3M3	O
;	O
614205	O
)	O
,	O
Hanson	O
et	O
al	O
.	O

(	O
2011	O
)	O
identified	O
a	O
homozygous	O
1-bp	O
duplication	B-Variation
(	O
612dupG	O
)	O
in	O
the	B-Gene
CCDC8	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
frameshift	B-Variation
and	O
premature	B-Molecular_Physiological_Activity
termination	I-Molecular_Physiological_Activity
,	O
predicted	O
to	O
lead	O
to	O
a	O
loss	B-Negative_Regulation
of	O
function	O
.	O

The	O
mutation	B-Variation
was	O
not	O
identified	O
in	O
611	O
controls	O
,	O
and	O
haplotype	O
analysis	O
indicated	O
a	O
founder	O
effect	O
for	O
2	O
of	O
the	O
patients	O
.	O

In	O
a	O
Turkish	O
girl	O
,	O
born	O
of	O
consanguineous	O
parents	O
,	O
with	O
MEGDEL	O
(	O
614739	O
)	O
,	O
Wortmann	O
et	O
al	O
.	O

(	O
2012	O
)	O
identified	O
a	O
homozygous	O
4-bp	O
deletion	B-Variation
(	O
1167delTCAG	O
)	O
in	O
a	O
canonical	O
splice	O
site	O
of	O
the	B-Gene
SERAC1	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
the	O
skipping	B-Variation
of	O
exon	O
12	O
and	O
nonsense	O
-	O
mediated	O
mRNA	B-Molecular_Physiological_Activity
decay	I-Molecular_Physiological_Activity
.	O

The	O
mutation	B-Variation
was	O
not	O
found	O
in	O
369	O
controls	O
.	O

The	O
patient	O
,	O
who	O
was	O
originally	O
reported	O
as	O
patient	O
1	O
by	O
Wortmann	O
et	O
al	O
.	O

(	O
2006	O
)	O
,	O
had	O
recurrent	O
infections	O
,	O
failure	O
to	O
thrive	O
,	O
mental	O
retardation	O
,	O
spasticity	O
and	O
extrapyramidal	O
symptoms	O
,	O
deafness	O
,	O
hypoglycemia	O
,	O
increased	O
serum	O
lactate	O
,	O
abnormal	O
lesions	O
on	O
brain	O
imaging	O
,	O
and	O
oxidative	O
phosphorylation	O
defects	O
.	O

In	O
a	O
Dutch	O
girl	O
with	O
MEGDEL	O
(	O
614739	O
)	O
,	O
Wortmann	O
et	O
al	O
.	O

(	O
2012	O
)	O
identified	O
a	O
homozygous	O
2-bp	O
duplication	B-Variation
(	O
1627dupTC	O
)	O
in	O
the	B-Gene
SERAC1	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
frameshift	B-Variation
and	O
premature	B-Molecular_Physiological_Activity
termination	I-Molecular_Physiological_Activity
(	O
Val544LeufsTer43	O
)	O
.	O

The	O
patient	O
was	O
originally	O
reported	O
as	O
patient	O
2	O
by	O
Wortmann	O
et	O
al	O
.	O

(	O
2006	O
)	O
.	O

The	O
mutation	B-Variation
was	O
not	O
found	O
in	O
369	O
controls	O
.	O

In	O
a	O
patient	O
with	O
MEGDEL	O
(	O
614739	O
)	O
,	O
Tort	O
et	O
al	O
.	O

(	O
2013	O
)	O
identified	O
a	O
homozygous	O
c.202C	O
-	O
T	O
transition	B-Variation
in	O
theSERAC1	B-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
an	O
arg68-to	O
-	O
ter	O
(	O
R68X	O
)	O
substitution	B-Variation
.	O

Western	O
blot	O
of	O
patient	O
cells	O
showed	O
no	B-Negative_Regulation
detectable	B-Protein
SERAC1	I-Protein
protein	I-Protein
.	O

The	O
mutation	B-Variation
,	O
which	O
was	O
found	O
by	O
exome	O
sequencing	O
and	O
confirmed	O
by	O
Sanger	O
sequencing	O
,	O
segregated	O
with	O
the	O
disorder	O
in	O
the	O
family	O
.	O

In	O
a	O
patient	O
with	O
2-aminoadipic	O
2-oxoadipic	O
aciduria	O
(	O
204750	O
)	O
,	O
Danhauser	O
et	O
al	O
.	O

(	O
2012	O
)	O
identified	O
compound	O
heterozygosity	O
for	O
mutation	B-Variation
in	O
the	B-Gene
DHTKD1	I-Gene
gene	I-Gene
,	O
an	O
A	O
-	O
to	O
-	O
G	O
transition	B-Variation
affecting	O
the	O
initiating	O
methionine	O
codon	O
and	O
a	O
nonsense	O
mutation	B-Variation
(	O
614984.0002	O
)	O
.	O

The	O
1A	O
-	O
G	O
mutation	B-Variation
was	O
predicted	O
to	O
cause	B-Regulation
out	B-Molecular_Physiological_Activity
-	I-Molecular_Physiological_Activity
of	I-Molecular_Physiological_Activity
-	I-Molecular_Physiological_Activity
frame	I-Molecular_Physiological_Activity
usage	I-Molecular_Physiological_Activity
of	O
the	O
next	O
AUG	O
triplet	O
160	O
nucleotides	O
downstream	O
and	O
thus	O
result	B-Regulation
in	I-Regulation
a	O
nonfunctional	B-Molecular_Physiological_Activity
protein	B-Protein
.	O

This	O
mutation	B-Variation
was	O
also	O
identified	O
in	O
the	O
patient	O
's	O
mother	O
.	O

In	O
2	O
patients	O
with	O
2-aminoadipic	O
2-oxoadipic	O
aciduria	O
(	O
204750	O
)	O
,	O
Danhauser	O
et	O
al	O
.	O

(	O
2012	O
)	O
identified	O
a	O
heterozygous	O
G	O
-	O
to	O
-	O
A	O
transition	B-Variation
at	O
nucleotide	O
2185	O
of	O
the	B-Gene
DHTHD1	I-Gene
gene	I-Gene
resulting	B-Regulation
in	I-Regulation
a	O
gly	O
-	O
to	O
-	O
arg	O
substitution	B-Variation
at	O
codon	O
729	O
(	O
G729R	O
)	O
.	O

In	O
1	O
patient	O
the	O
G729R	O
mutation	B-Variation
was	O
found	O
in	O
compound	O
heterozygosity	O
with	O
a	O
mutation	B-Variation
involving	O
the	O
initiator	O
methionine	O
(	O
614984.0001	O
)	O
,	O
and	O
in	O
the	O
other	O
patient	O
a	O
premature	B-Molecular_Physiological_Activity
termination	I-Molecular_Physiological_Activity
mutation	B-Variation
was	O
found	O
(	O
R410X	O
;	O
614984.0003	O
)	O
.	O

In	O
the	O
first	O
patient	O
the	O
G729R	O
mutation	B-Variation
occurred	O
de	O
novo	O
and	O
in	O
the	O
second	O
it	O
was	O
maternally	O
transmitted	O
.	O

Gly729	O
is	O
evolutionarily	O
conserved	O
from	O
Homo	O
sapiens	O
to	O
C.	O
elegans	O
and	O
D.	O
melanogaster	O
.	O

This	O
mutation	B-Variation
(	O
rs117225135	O
)	O
was	O
found	O
in	O
the	O
NHLBI	O
Exome	O
Variant	O
Server	O
with	O
a	O
minor	O
allele	O
frequency	O
of	O
0.17	O
%	O
,	O
corresponding	O
to	O
19	O
heterozygous	O
but	O
no	O
homozygous	O
carriers	O
among	O
5,379	O
individuals	O
.	O

In	O
a	O
Hispanic	O
boy	O
with	O
2,4-dienoyl	O
-	O
CoA	O
reductase	O
deficiency	O
(	O
DECRD	O
;	O
616034	O
)	O
,	O
Houten	O
et	O
al	O
.	O

(	O
2014	O
)	O
identified	O
a	O
homozygous	O
c.1018C	O
-	O
T	O
transition	B-Variation
in	O
exon	O
10	O
of	O
the	B-Gene
NADK2	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
an	O
arg340-to	O
-	O
ter	O
(	O
R340X	O
)	O
substitution	B-Variation
.	O

The	O
mutation	B-Variation
,	O
which	O
was	O
found	O
by	O
exome	O
sequencing	O
and	O
confirmed	O
by	O
Sanger	O
sequencing	O
,	O
segregated	O
with	O
the	O
disorder	O
in	O
the	O
family	O
and	O
was	O
not	O
present	O
in	O
the	O
dbSNP	O
(	O
build	O
135	O
)	O
,	O
1000	O
Genomes	O
Project	O
,	O
or	O
Exome	O
Variant	O
Server	O
databases	O
.	O

Analysis	O
of	O
patient	O
cells	O
indicated	O
that	O
the	O
mutation	B-Variation
causes	B-Regulation
nonsense	O
-	O
mediated	O
mRNA	B-Molecular_Physiological_Activity
decay	I-Molecular_Physiological_Activity
,	O
consistent	O
with	O
a	O
severe	O
loss	B-Negative_Regulation
of	O
protein	B-Molecular_Physiological_Activity
level	I-Molecular_Physiological_Activity
and	O
function	B-Molecular_Physiological_Activity
.	O

Wildtype	B-Gene
NADK2	I-Gene
was	I-Gene
able	O
to	O
rescue	O
deficient	O
DECR	O
activity	B-Molecular_Physiological_Activity
in	O
patient	O
fibroblasts	O
.	O

In	O
2	O
sibs	O
with	O
a	O
mild	O
form	O
of	O
3-methylglutaconic	O
aciduria	O
with	O
cataracts	O
,	O
neurologic	O
involvement	O
,	O
and	O
neutropenia	O
(	O
MEGCANN	O
;	O
616271	O
)	O
and	O
no	O
neurologic	O
impairment	O
,	O
Wortmann	O
et	O
al	O
.	O

(	O
2015	O
)	O
identified	O
compound	O
heterozygous	O
mutations	B-Variation
in	O
the	B-Gene
CLPB	I-Gene
gene	I-Gene
:	I-Gene
a	O
c.1233G	O
-	O
A	O
transition	B-Variation
(	O
c.1233G	O
-	O
A	O
,	O
NM_030813.4	O
)	O
in	O
exon	O
11	O
,	O
resulting	B-Regulation
in	I-Regulation
a	O
met411-to	O
-	O
ile	O
(	O
M411I	O
)	O
substitution	B-Variation
at	O
a	O
highly	O
conserved	O
residue	O
in	O
the	O
AAA+	O
domain	O
,	O
and	O
a	O
c.1850A	O
-	O
G	O
transition	B-Variation
in	O
exon	O
16	O
,	O
resulting	B-Regulation
in	I-Regulation
a	O
tyr617-to	O
-	O
cys	O
(	O
Y617C	O
;	O
616254.0005	O
)	O
substitution	B-Variation
at	O
a	O
highly	O
conserved	O
residue	O
in	O
the	O
D2	O
domain	O
.	O

Expression	B-Molecular_Physiological_Activity
of	O
the	O
M411I	O
or	O
Y617C	O
alleles	O
could	O
not	O
rescue	O
morpholino	O
knockdown	O
of	O
the	O
clpb	O
ortholog	O
in	O
zebrafish	O
,	O
suggesting	O
that	O
these	O
variants	B-Variation
have	O
little	B-Negative_Regulation
or	O
no	B-Negative_Regulation
residual	O
activity	B-Molecular_Physiological_Activity
.	O

In	O
3	O
sibs	O
with	O
a	O
moderately	O
severe	O
form	O
of	O
3-methylglutaconic	O
aciduria	O
with	O
cataracts	O
,	O
neurologic	O
involvement	O
,	O
and	O
neutropenia	O
(	O
MEGCANN	O
;	O
616271	O
)	O
,	O
Wortmann	O
et	O
al	O
.	O

(	O
2015	O
)	O
identified	O
compound	O
heterozygous	O
mutations	B-Variation
in	O
the	B-Gene
CLPB	I-Gene
gene	I-Gene
:	I-Gene
a	O
c.1222A	O
-	O
G	O
transition	B-Variation
(	O
c.1222A	O
-	O
G	O
,	O
NM_030813.4	O
)	O
in	O
exon	O
11	O
,	O
resulting	B-Regulation
in	I-Regulation
an	O
arg408-to	O
-	O
gly	O
(	O
R408	O
G	O
)	O
substitution	B-Variation
at	O
a	O
conserved	O
residue	O
in	O
the	O
AAA+	O
domain	O
,	O
and	O
a	O
c.1249C	O
-	O
T	O
transition	B-Variation
in	O
exon	O
11	O
,	O
resulting	B-Regulation
in	I-Regulation
an	O
arg417-to	O
-	O
ter	O
(	O
R417X	O
;	O
616254.0007	O
)	O
substitution	B-Variation
.	O

The	O
R408	O
G	O
mutation	B-Variation
had	O
a	O
frequency	O
of	O
0.011	O
%	O
(	O
22	O
of	O
122,848	O
alleles	O
)	O
in	O
the	O
Exome	O
Aggregation	O
Consortium	O
database	O
,	O
and	O
the	O
R417X	O
mutation	B-Variation
was	O
found	O
in	O
4	O
of	O
122,848	O
alleles	O
in	O
this	O
database	O
;	O
all	O
controls	O
were	O
heterozygous	O
for	O
the	O
mutations	B-Variation
.	O

In	O
vitro	O
functional	O
expression	O
studies	O
indicated	O
that	O
the	O
R408	O
G	O
mutant	B-Variation
protein	B-Protein
had	O
decreased	B-Negative_Regulation
ATPase	B-Enzyme
activity	B-Molecular_Physiological_Activity
at	O
26	O
%	O
of	O
wildtype	O
.	O

Expression	B-Molecular_Physiological_Activity
of	O
the	O
R408	O
G	O
mutant	B-Variation
allele	O
was	O
unable	O
to	O
rescue	O
morpholino	O
knockdown	O
of	O
the	O
clpb	O
ortholog	O
in	O
zebrafish	O
,	O
suggesting	O
that	O
this	O
variant	B-Variation
has	O
decreased	B-Negative_Regulation
residual	O
activity	B-Molecular_Physiological_Activity
.	O

In	O
4	O
patients	O
,	O
including	O
a	O
pair	O
of	O
sibs	O
,	O
from	O
Greenland	O
,	O
with	O
3-	O
methylglutaconic	O
aciduria	O
with	O
cataracts	O
,	O
neurologic	O
involvement	O
,	O
and	O
neutropenia	O
(	O
MEGCANN	O
;	O
616271	O
)	O
,	O
Saunders	O
et	O
al	O
.	O

(	O
2015	O
)	O
identified	O
a	O
homozygous	O
c.803C	O
-	O
T	O
transition	B-Variation
(	O
rs200032855	O
)	O
in	O
the	B-Gene
CLPB	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
thr268-to	O
-	O
met	O
(	O
T268	O
M	O
)	O
substitution	B-Variation
at	O
a	O
highly	O
conserved	O
residue	O
in	O
1	O
of	O
the	O
ankyrin	O
domains	O
.	O

The	O
mutation	B-Variation
,	O
which	O
was	O
found	O
by	O
homozygosity	O
mapping	O
and	O
candidate	O
gene	O
sequencing	O
,	O
segregated	O
with	O
the	O
disorder	O
in	O
1	O
of	O
the	O
families	O
.	O

The	O
carrier	O
frequency	O
of	O
the	O
mutation	B-Variation
in	O
Greenlandic	O
controls	O
was	O
found	O
to	O
be	O
3.3	O
%	O
.	O

The	O
variant	B-Variation
was	O
not	O
found	O
in	O
2,180	O
control	O
samples	O
in	O
the	O
U.S.	O
or	O
in	O
the	O
Exome	O
Variant	O
Server	O
database	O
,	O
but	O
was	O
reported	O
with	O
a	O
carrier	O
frequency	O
of	O
1	O
out	O
of	O
662	O
in	O
the	O
ClinSeq	O
database	O
.	O

Immunoblot	O
analysis	O
of	O
patient	O
fibroblasts	O
showed	O
absence	B-Negative_Regulation
of	O
the	B-Protein
CLPB	I-Protein
protein	I-Protein
In	O
4	O
sibs	O
,	O
born	O
of	O
consanguineous	O
Cambodian	O
parents	O
,	O
with	O
3-methylglutaconic	O
aciduria	O
with	O
cataracts	O
,	O
neurologic	O
involvement	O
,	O
and	O
neutropenia	O
(	O
MEGCANN	O
;	O
616271	O
)	O
,	O
Capo	O
-	O
Chichi	O
et	O
al	O
.	O

(	O
2015	O
)	O
identified	O
a	O
homozygous	O
1-bp	O
deletion	B-Variation
(	O
c.1685delT	O
,	O
NM_030813.3	O
)	O
in	O
the	B-Gene
CLPB	I-Gene
gene	I-Gene
,	O
resulting	B-Regulation
in	I-Regulation
a	O
frameshift	B-Variation
and	O
premature	B-Molecular_Physiological_Activity
termination	I-Molecular_Physiological_Activity
(	O
Ile562ThrfsTer23	O
)	O
.	O

The	O
mutation	B-Variation
was	O
found	O
by	O
a	O
combination	O
of	O
homozygosity	O
mapping	O
and	O
exome	O
sequencing	O
and	O
was	O
confirmed	O
by	O
Sanger	O
sequencing	O
.	O

It	O
segregated	O
with	O
the	O
disorder	O
in	O
the	O
family	O
and	O
was	O
not	O
found	O
in	O
the	O
dbSNP	O
,	O
1000	O
Genomes	O
Project	O
,	O
or	O
Exome	O
Sequencing	O
Project	O
databases	O
,	O
or	O
in	O
657	O
in	O
-	O
house	O
control	O
exomes	O
.	O

The	O
patients	O
had	O
a	O
severe	O
phenotype	O
:	O
at	O
birth	O
they	O
did	O
not	O
move	O
or	O
breathe	O
spontaneously	O
and	O
showed	O
sustained	O
clonic	O
movements	O
induced	O
by	O
minimal	O
tactile	O
stimulation	O
;	O
all	O
were	O
ventilator	O
-	O
dependent	O
and	O
died	O
in	O
the	O
first	O
week	O
of	O
life	O
after	O
removal	O
of	O
respiratory	O
support	O
.	O

[	O
Autosomal	O
dominant	O
limb	O
-	O
girdle	O
muscular	O
dystrophy	O
associated	O
with	O
conduction	O
defects	O
(	O
LGMD1B	O
)	O
:	O
a	O
description	O
of	O
8	O
new	O
families	O
with	O
the	O
LMNA	O
gene	O
mutations	O
]	O
.	O

La	O
dystrophie	O
musculaire	O
des	O
ceintures	O
autosomique	O
dominante	O
associée	O
à	O
des	O
troubles	O
de	O
la	O
conduction	O
cardiaque	O
(	O
LGMD1B	O
)	O
.	O

Description	O
de	O
8	O
nouvelles	O
familles	O
avec	O
mutations	O
du	O
gène	O
LMNA	O
.	O

INTRODUCTION	O
:	O
Limb	B-Disease
girdle	I-Disease
muscular	I-Disease
dystrophy	I-Disease
type	I-Disease
1b	I-Disease
(	O
LGMD1B	O
)	O
,	O
due	B-Reg
to	I-Reg
LMNA	B-Gene
gene	O
mutations	B-Var
,	O
is	O
a	O
relatively	O
rare	O
form	O
of	O
LGMD	O
characterized	O
by	O
proximal	O
muscle	O
involvement	O
associated	O
with	O
heart	O
involvement	O
comprising	O
atrio	O
-	O
ventricular	O
conduction	O
blocks	O
and	O
dilated	O
cardiomyopathy	O
.	O

Its	O
clinical	O
and	O
genetic	O
diagnosis	O
is	O
crucial	O
for	O
cardiac	O
management	O
and	O
genetic	O
counselling	O
.	O

Seven	O
LMNA	O
mutations	O
have	O
been	O
previously	O
reported	O
to	O
be	O
responsible	O
for	O
LGMD1B.	O
PATIENTS	O
AND	O
METHODS	O
:	O
We	O
describe	O
the	O
neurological	O
and	O
cardiologic	O
features	O
of	O
14	O
patients	O
belonging	O
to	O
8	O
families	O
in	O
whom	O
we	O
identified	O
6	O
different	O
LMNA	O
mutations	O
,	O
4	O
of	O
them	O
having	O
never	O
been	O
reported	O
.	O

Results	O
.	O

Eleven	O
patients	O
had	O
an	O
LGMD1B	O
phenotype	O
with	O
scapulohumeral	O
and	O
pelvic	O
-	O
femoral	O
involvement	O
.	O

Thirteen	O
patients	O
had	O
cardiac	O
disease	O
associating	O
conduction	O
defects	O
(	O
12	O
patients	O
)	O
or	O
arrhythmias	O
(	O
9	O
patients	O
)	O
.	O

Seven	O
patients	O
needed	O
cardiac	O
device	O
(	O
pacemaker	O
or	O
implantable	O
cardiac	O
defibrillator	O
)	O
and	O
two	O
had	O
heart	O
transplantation	O
.	O

CONCLUSION	O
:	O
This	O
study	O
allowed	O
us	O
to	O
specify	O
the	O
clinical	O
characteristics	O
of	O
this	O
entity	O
and	O
to	O
outline	O
the	O
first	O
phenotype	O
/	O
genotype	O
relations	O
resulting	O
from	O
these	O
observations	O
.	O

Genetics	O
of	O
laminopathies	O
.	O

Laminopathies	O
are	O
now	O
recognized	O
as	O
a	O
group	O
of	O
disorders	O
due	O
to	O
mutations	O
of	O
the	O
LMNA	O
gene	O
,	O
which	O
encodes	O
A	O
-	O
type	O
lamins	O
.	O

Primarily	O
,	O
mutations	B-Var
in	O
LMNA	B-Gene
have	O
been	O
associated	B-Reg
to	I-Reg
the	O
autosomal	O
forms	O
of	O
Emery	B-Disease
-	I-Disease
Dreifuss	I-Disease
muscular	I-Disease
dystrophy	I-Disease
,	O
a	O
rare	O
slowly	O
progressive	O
humero	O
-	O
peroneal	O
muscular	O
dystrophy	O
accompanied	O
by	O
early	O
contractures	O
and	O
dilated	O
cardiomyopathy	O
with	O
conduction	O
defects	O
.	O

LMNA	O
mutations	O
have	O
been	O
reported	O
to	O
be	O
responsible	O
for	O
up	O
to	O
10	O
distinct	O
phenotypes	O
that	O
affect	O
specifically	O
either	O
the	O
skeletal	O
and/or	O
cardiac	O
muscle	O
,	O
the	O
adipose	O
tissue	O
,	O
the	O
peripheral	O
nervous	O
tissue	O
,	O
the	O
bone	O
tissue	O
or	O
more	O
recently	O
premature	O
ageing	O
.	O

So	O
far	O
more	O
than	O
180	O
different	O
LMNA	O
mutations	O
have	O
been	O
identified	O
in	O
903	O
individuals	O
.	O

The	O
first	O
studies	O
of	O
phenotype	O
/	O
genotype	O
relationships	O
revealed	O
no	O
dear	O
relation	O
between	O
the	O
phenotype	O
and	O
the	O
type	O
and/or	O
the	O
localization	O
of	O
the	O
mutation	O
,	O
except	O
perhaps	O
for	O
the	O
globular	O
tail	O
domain	O
of	O
lamins	O
A	O
/	O
C.	O
Studies	O
of	O
the	O
consequences	O
of	O
LMNA	O
mutations	O
in	O
the	O
skin	O
cultured	O
fibroblasts	O
from	O
the	O
patients	O
reveal	O
abnormal	O
nuclei	O
in	O
variable	O
proportions	O
,	O
with	O
dysmorphic	O
nuclei	O
exhibiting	O
abnormal	O
patterns	O
of	O
expression	O
of	O
B	O
-	O
type	O
lamins	O
and	O
emerin	O
.	O

Finally	O
,	O
the	O
development	O
of	O
KO	O
and	O
KI	O
LMNA	O
mice	O
,	O
will	O
certainly	O
give	O
further	O
insight	O
into	O
the	O
pathophysiological	O
mechanisms	O
associated	O
with	O
LMNA	O
mutations	O
.	O

For	O
example	O
,	O
Lmna(H222P	O
/	O
H222P	O
)	O
mice	O
harbour	O
phenotypes	O
reminiscent	O
of	O
Emery	O
-	O
Dreifuss	O
muscular	O
dystrophy	O
.	O

Mutations	B-Var
in	O
the	O
mouse	O
Lmna	B-Gene
gene	O
causing	B-Reg
progeria	B-Disease
,	O
muscular	B-Disease
dystrophy	I-Disease
and	O
cardiomyopathy	B-Disease
.	O

At	O
least	O
ten	O
different	O
diseases	O
have	O
been	O
linked	O
to	O
mutations	O
in	O
proteins	O
associated	O
with	O
the	O
nuclear	O
envelope	O
(	O
NE	O
)	O
.	O

Eight	O
of	O
these	O
diseases	O
are	O
associated	O
with	O
mutations	O
in	O
the	O
lamin	O
A	O
gene	O
(	O
LMNA	O
)	O
.	O

These	O
diseases	O
include	O
the	O
premature	O
ageing	O
or	O
progeric	O
diseases	O
Hutchinson	O
-	O
Gilford	O
progeria	O
and	O
atypical	O
Werner	O
's	O
syndrome	O
,	O
diseases	O
affecting	O
striated	O
and	O
cardiac	O
muscle	O
including	O
muscular	O
dystrophies	O
and	O
dilated	O
cardiomyopathies	O
,	O
lipodystrophies	O
affecting	O
white	O
fat	O
deposition	O
and	O
skeletal	O
development	O
and	O
a	O
peripheral	O
neuropathy	O
resulting	O
in	O
motor	O
neuron	O
demyelination	O
.	O

To	O
understand	O
how	O
these	O
diseases	O
arise	O
from	O
different	O
mutations	O
in	O
the	O
same	O
protein	O
,	O
we	O
established	O
mouse	O
lines	O
carrying	O
some	O
of	O
the	O
same	O
mutations	O
found	O
in	O
the	O
human	O
LMNA	O
gene	O
,	O
as	O
both	O
mouse	O
and	O
human	O
lamin	O
genes	O
show	O
a	O
very	O
high	O
degree	O
of	O
sequence	O
conservation	O
.	O

We	O
have	O
generated	O
mice	O
with	O
different	O
mutations	O
resulting	O
in	O
progeria	O
,	O
muscular	O
dystrophy	O
and	O
dilated	O
cardiomyopathy	O
.	O

Our	O
mouse	O
lines	O
are	O
providing	O
novel	O
insights	O
into	O
how	O
changes	O
to	O
the	O
nuclear	O
lamina	O
affect	O
the	O
mechanical	O
integrity	O
of	O
the	O
nucleus	O
and	O
in	O
turn	O
intracellular	O
signalling	O
,	O
such	O
as	O
the	O
NF	O
-	O
kappaB	O
pathway	O
,	O
as	O
well	O
as	O
cell	O
proliferation	O
and	O
survival	O
,	O
cellular	O
functions	O
that	O
,	O
when	O
disrupted	O
,	O
may	O
be	O
the	O
basis	O
for	O
the	O
origin	O
of	O
such	O
diseases	O
.	O

A	O
novel	O
mutation	B-Var
of	O
the	O
cathepsin	B-Gene
C	I-Gene
gene	O
in	O
a	O
thai	O
family	O
with	B-Reg
Papillon	B-Disease
-	I-Disease
Lefevre	I-Disease
syndrome	I-Disease
.	O

BACKGROUND	O
:	O
Papillon	O
-	O
Lefevre	O
syndrome	O
(	O
PLS	O
)	O
is	O
a	O
rare	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
palmar-	O
plantar	O
hyperkeratosis	O
and	O
rapid	O
periodontal	O
destruction	O
of	O
both	O
primary	O
and	O
permanent	O
dentitions	O
.	O

It	O
has	O
been	O
shown	O
that	O
the	O
disease	O
is	O
caused	O
by	O
cathepsin	O
C	O
gene	O
(	B-Gene
CTSC	I-Gene
)	I-Gene
mutation	B-Var
leading	O
to	O
the	O
deficiency	B-NegReg
of	O
cathepsin	B-Enzyme
C	I-Enzyme
enzymatic	I-Enzyme
activity	B-MPA
.	O

This	O
study	O
demonstrates	O
the	O
clinical	O
manifestations	O
and	O
CTSC	O
mutational	O
and	O
enzymatic	O
activity	O
analyses	O
in	O
a	O
5-year	O
-	O
old	O
Thai	O
male	O
PLS	O
patient	O
and	O
his	O
parents	O
.	O

METHODS	O
:	O
Peripheral	O
blood	O
samples	O
were	O
obtained	O
for	O
genomic	O
DNA	O
isolation	O
.	O

All	O
exons	O
of	O
the	O
CTSC	O
gene	O
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
using	O
specific	O
primers	O
.	O

Mutations	O
were	O
identified	O
by	O
DNA	O
sequencing	O
.	O

Verification	O
of	O
the	O
mutation	O
was	O
performed	O
by	O
digestion	O
of	O
PCR	O
products	O
by	O
restriction	O
endonucleases	O
.	O

The	O
cathepsin	O
C	O
enzymatic	O
activity	O
was	O
determined	O
using	O
the	O
synthetic	O
substrate	O
glycyl-	O
L	O
-	O
arginine-7-amino-4-methylcoumarin	O
.	O

RESULTS	O
:	O
The	O
patient	O
demonstrated	O
classical	O
characteristics	O
of	O
PLS	O
,	O
including	O
hyperkeratotic	O
skin	O
lesions	O
.	O

By	O
the	O
age	O
of	O
5	O
,	O
all	O
of	O
his	O
primary	O
teeth	O
were	O
extracted	O
due	O
to	O
severe	O
periodontal	O
infection	O
.	O

The	O
parents	O
had	O
no	O
physical	O
abnormalities	O
.	O

The	O
periodontal	O
examination	O
revealed	O
localized	O
mild	O
periodontal	O
destruction	O
.	O

Sequence	O
analysis	O
showed	O
a	O
nucleotide	O
change	O
at	O
position	O
90	O
from	O
C	O
>	O
A	O
(	B-Var
c.90C	I-Var
>	I-Var
A	I-Var
)	I-Var
which	O
resulted	B-Reg
in	I-Reg
a	O
change	O
from	O
cysteine	O
residue	O
to	O
a	O
premature	B-MPA
stop	I-MPA
codon	I-MPA
at	O
the	O
amino	O
acid	O
position	O
30	O
in	O
the	O
exon	O
1	O
.	O

The	O
HpyCH4V	O
digestion	O
revealed	O
that	O
the	O
patient	O
was	O
homozygous	O
,	O
whereas	O
both	O
the	O
father	O
and	O
mother	O
were	O
heterozygous	O
carriers	O
of	O
this	O
mutation	O
.	O

The	O
cathepsin	O
C	O
activity	O
was	O
reduced	O
in	O
the	O
patient	O
's	O
mother	O
,	O
and	O
the	O
activity	O
in	O
the	O
patient	O
was	O
almost	O
completely	O
lost	O
.	O

CONCLUSIONS	O
:	O
This	O
is	O
the	O
first	O
study	O
to	O
demonstrate	O
a	O
CTSC	B-Gene
gene	O
mutation	O
in	O
a	O
Thai	O
family	O
with	O
PLS	O
.	O

The	O
identified	O
mutation	B-Var
is	O
novel	O
and	O
potentially	O
leads	O
to	O
the	O
drastic	O
reduction	B-NegReg
of	O
the	O
cathepsin	B-Enzyme
C	I-Enzyme
enzymatic	I-Enzyme
activity	B-MPA
.	O

This	O
suggests	O
that	O
the	O
mutation	O
is	O
pathogenetic	O
,	O
causing	B-Reg
the	O
PLS	B-Disease
.	O

Mutational	O
analysis	O
in	O
more	O
members	O
of	O
the	O
family	O
is	O
warranted	O
to	O
identify	O
whether	O
the	O
mutation	O
is	O
inherited	O
from	O
a	O
common	O
ancestor	O
.	O

Mutations	O
of	O
COL10A1	O
in	O
Schmid	O
metaphyseal	O
chondrodysplasia	O
.	O

Schmid	B-Disease
metaphyseal	I-Disease
chondrodysplasia	I-Disease
(	O
SMCD	O
)	O
is	O
a	O
dominantly	O
inherited	O
cartilage	O
disorder	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
gene	O
for	O
the	O
hypertrophic	O
cartilage	O
extracellular	O
matrix	O
structural	O
protein	O
,	O
collagen	O
X	O
(	B-Gene
COL10A1	I-Gene
)	I-Gene
.	O

Thirty	O
heterozygous	O
mutations	O
have	O
been	O
described	O
,	O
about	O
equally	O
divided	O
into	O
two	O
mutation	O
types	O
,	O
missense	O
mutations	O
,	O
and	O
mutations	O
that	O
introduce	O
premature	O
termination	O
signals	O
.	O

The	O
COL10A1	O
mutations	O
are	O
clustered	O
(	O
33/36	O
)	O
in	O
the	O
3	O
'	O
region	O
of	O
exon	O
3	O
,	O
which	O
codes	O
for	O
the	O
C	O
-	O
terminal	O
NC1	O
trimerization	O
domain	O
.	O

The	O
effect	O
of	O
COL10A1	O
missense	O
mutations	O
have	O
been	O
examined	O
by	O
in	O
vitro	O
expression	O
and	O
assembly	O
assays	O
and	O
cell	O
transfection	O
studies	O
,	O
which	O
suggest	O
that	O
a	O
common	O
consequence	O
is	O
the	O
disruption	O
of	O
collagen	O
X	O
trimerization	O
and	O
secretion	O
,	O
with	O
consequent	O
intracellular	O
degradation	O
.	O

The	O
effect	O
of	O
COL10A1	B-Gene
nonsense	B-Var
mutations	I-Var
in	O
cartilage	O
tissue	O
has	O
been	O
examined	O
in	O
two	O
patients	O
,	O
demonstrating	O
that	O
the	O
mutant	B-Var
mRNA	B-MPA
is	O
completely	O
removed	B-NegReg
by	O
nonsense	B-MPA
mediated	I-MPA
mRNA	I-MPA
decay	B-NegReg
.	O

Thus	O
for	O
both	O
classes	O
of	O
mutations	O
,	O
functional	O
haploinsufficiency	O
is	O
the	O
most	O
probable	O
cause	O
of	O
the	O
clinical	O
phenotype	O
in	O
SMCD	O
.	O

Sjögren	B-Disease
-	I-Disease
Larsson	I-Disease
syndrome	I-Disease
:	I-Disease
diversity	O
of	B-Reg
mutations	B-Var
and	O
polymorphisms	O
in	O
the	O
fatty	O
aldehyde	O
dehydrogenase	O
gene	O
(	B-Gene
ALDH3A2	I-Gene
)	I-Gene
.	O

Sjögren	B-Disease
-	I-Disease
Larsson	I-Disease
syndrome	I-Disease
(	O
SLS	O
)	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
ichthyosis	O
,	O
mental	O
retardation	O
,	O
and	O
spastic	O
diplegia	O
or	O
tetraplegia	O
.	O

The	O
disease	O
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
ALDH3A2	B-Gene
gene	O
(	O
also	O
known	O
as	O
FALDH	B-Gene
and	O
ALDH10	B-Gene
)	I-Gene
on	O
chromosome	O
17p11.2	O
that	O
encodes	O
fatty	O
aldehyde	O
dehydrogenase	O
(	O
FALDH	O
)	O
,	O
an	O
enzyme	O
that	O
catalyzes	O
the	O
oxidation	O
of	O
long	O
-	O
chain	O
aldehydes	O
derived	O
from	O
lipid	O
metabolism	O
.	O

In	O
SLS	O
patients	O
,	O
72	O
mutations	O
have	O
been	O
identified	O
,	O
with	O
a	O
distribution	O
that	O
is	O
scattered	O
throughout	O
the	O
ALDH3A2	O
gene	O
.	O

Most	O
mutations	O
are	O
private	O
but	O
several	O
common	O
mutations	O
have	O
been	O
detected	O
,	O
which	O
probably	O
reflect	O
founder	O
effects	O
or	O
recurrent	O
mutational	O
events	O
.	O

Missense	O
mutations	B-Var
comprise	O
the	O
most	O
abundant	O
class	O
(	O
38	O
%	O
)	O
and	O
expression	O
studies	O
indicate	O
that	O
most	O
of	O
these	O
result	O
in	O
a	O
profound	O
reduction	B-NegReg
in	O
enzyme	B-Enzyme
activity	B-MPA
.	O

Deletions	O
account	O
for	O
about	O
25	O
%	O
of	O
the	O
mutations	O
and	O
range	O
from	O
single	O
nucleotides	O
to	O
entire	O
exons	O
.	O

Twelve	O
splice	O
-	O
site	O
mutations	B-Var
have	O
been	O
demonstrated	O
to	O
cause	B-Reg
aberrant	B-MPA
splicing	I-MPA
in	O
cultured	O
fibroblasts	O
.	O

To	O
date	O
,	O
more	O
than	O
a	O
dozen	O
intragenic	O
ALDH3A2	O
polymorphisms	O
consisting	O
of	O
SNPs	O
and	O
one	O
microsatellite	O
marker	O
have	O
been	O
characterized	O
,	O
although	O
none	O
of	O
them	O
alter	O
the	O
FALDH	O
protein	O
sequence	O
.	O

The	O
striking	O
mutational	O
diversity	O
in	O
SLS	O
offers	O
a	O
challenge	O
for	O
DNA	O
-	O
based	O
diagnosis	O
,	O
but	O
promises	O
to	O
provide	O
a	O
wealth	O
of	O
information	O
about	O
enzyme	O
structure	O
-	O
function	O
correlations	O
.	O

Genetic	O
screening	O
of	O
familial	O
Mediterranean	O
fever	O
mutations	O
in	O
the	O
Palestinian	O
population	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
spectrum	O
of	O
mutations	B-Var
and	O
genotypes	O
in	O
the	O
pyrin	B-Gene
gene	O
in	B-Reg
familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	O
)	O
patients	O
.	O

METHODS	O
:	O
Blood	O
samples	O
of	O
511	O
suspected	O
FMF	O
patients	O
,	O
received	O
from	O
the	O
Molecular	O
Genetics	O
Laboratory	O
,	O
Makassed	O
Islamic	O
Charitable	O
Hospital	O
,	O
Mount	O
Olives	O
,	O
Jerusalem	O
during	O
the	O
period	O
from	O
June	O
1999	O
to	O
August	O
2004	O
,	O
were	O
investigated	O
by	O
genotyping	O
24	O
different	O
MEFV	O
mutations	O
.	O

RESULTS	O
:	O
Our	O
work	O
revealed	O
the	O
presence	O
of	O
14	O
different	O
mutations	O
from	O
the	O
identified	O
24	O
mutations	O
in	O
the	O
gene	O
which	O
are	O
assembled	O
in	O
6	O
homozygous	O
,	O
9	O
heterozygous	O
and	O
16	O
compound	O
heterozygous	O
genotypes	O
.	O

The	O
homozygous	O
genotypes	O
represent	O
the	O
predominant	O
format	O
among	O
our	O
patients	O
representing	O
approximately	O
38	O
%	O
of	O
the	O
revealed	O
genotypes	O
.	O

Interestingly	O
,	O
in	O
94	O
(	O
31.4	O
%	O
)	O
of	O
the	O
tested	O
subjects	O
,	O
only	O
one	O
mutation	O
in	O
the	O
pyrin	O
gene	O
could	O
be	O
identified	O
while	O
the	O
other	O
mutant	O
allele	O
remains	O
unidentified	O
.	O

Moreover	O
,	O
the	O
genotype	O
of	O
3	O
(	O
1	O
%	O
)	O
patients	O
revealed	O
the	O
presence	O
of	O
triplet	O
mutations	O
in	O
the	O
pyrin	O
gene	O
.	O

CONCLUSION	O
:	O
The	O
results	O
of	O
our	O
study	O
clearly	O
suggest	O
that	O
the	O
origin	O
of	O
FMF	O
among	O
the	O
Palestinian	O
population	O
is	O
mostly	O
homozygous	O
.	O

The	O
identification	O
of	O
a	O
significant	O
number	O
of	O
patients	O
with	O
one	O
known	O
mutation	O
indicates	O
potentially	O
the	O
presence	O
of	O
new	O
mutations	O
in	O
the	O
gene	O
which	O
will	O
be	O
investigated	O
in	O
the	O
future	O
.	O

Novel	O
CLN3	B-Gene
mutation	B-Var
predicted	O
to	O
cause	O
complete	O
loss	B-NegReg
of	O
protein	B-Protein
function	B-MPA
does	O
not	O
modify	O
the	O
classical	O
JNCL	O
phenotype	O
.	O

Juvenile	B-Disease
Neuronal	I-Disease
Ceroid	I-Disease
Lipofuscinosis	I-Disease
(	O
JNCL	O
)	O
,	O
or	O
Batten	O
disease	O
,	O
is	O
a	O
childhood	O
neurodegenerative	O
disease	O
that	O
is	O
characterized	O
clinically	O
by	O
progressive	O
visual	O
loss	O
,	O
seizures	O
,	O
dementia	O
,	O
and	O
motor	O
incoordination	O
.	O

Children	O
affected	O
with	O
this	O
disease	O
tend	O
to	O
develop	O
normally	O
for	O
the	O
first	O
5	O
years	O
of	O
life	O
.	O

However	O
,	O
once	O
disease	O
onset	O
occurs	O
,	O
they	O
decline	O
rapidly	O
and	O
die	O
in	O
their	O
late	O
20s	O
to	O
early	O
30s	O
.	O

Though	O
this	O
represents	O
the	O
typical	O
disease	O
course	O
,	O
the	O
onset	O
and	O
severity	O
of	O
disease	O
symptoms	O
can	O
vary	O
.	O

This	O
variability	O
is	O
presumed	O
to	O
be	O
the	O
result	O
of	O
both	O
differences	O
in	O
the	O
causative	O
genetic	O
mutation	O
in	O
the	O
CLN3	O
gene	O
as	O
well	O
as	O
environmental	O
influences	O
.	O

Most	O
cases	O
of	O
JNCL	B-Disease
are	O
caused	B-Reg
by	I-Reg
a	O
1	O
kb	O
deletion	B-Var
in	O
the	O
CLN3	B-Gene
gene	O
,	O
resulting	B-Reg
in	I-Reg
a	O
frameshift	B-Var
mutation	I-Var
predicted	O
to	O
leave	O
the	O
first	O
153	O
amino	O
acids	O
of	O
the	O
CLN3	O
protein	O
intact	O
,	O
followed	O
by	O
the	O
addition	O
of	O
28	O
novel	O
amino	O
acids	O
.	O

Here	O
we	O
report	O
the	O
discovery	O
of	O
a	O
novel	O
mutation	O
identified	O
as	O
a	O
G	O
to	O
T	O
transversion	O
at	O
nucleotide	O
49	O
(	B-Var
G49	I-Var
T	I-Var
)	I-Var
in	O
exon	O
2	O
of	O
CLN3	B-Gene
,	O
introducing	B-Reg
a	O
premature	O
stop	O
codon	O
(	B-Var
E17X	I-Var
)	I-Var
near	O
the	O
N	O
-	O
terminus	O
.	O

This	O
mutation	O
represents	O
the	O
most	O
5	O
'	O
mutation	O
described	O
to	O
date	O
.	O

The	O
patient	O
examined	O
in	O
this	O
study	O
was	O
heterozygous	O
for	O
the	O
common	O
1	O
kb	O
deletion	O
and	O
E17X.	O
She	O
had	O
classical	O
disease	O
progression	O
,	O
suggesting	O
that	O
this	O
mutation	O
in	O
CLN3	O
mimics	O
the	O
more	O
prevalent	O
1	O
kb	O
deletion	O
and	O
that	O
progression	O
of	O
JNCL	O
is	O
predominantly	O
the	O
result	O
of	O
loss	O
of	O
CLN3	O
function	O
.	O

Identification	O
of	O
a	O
novel	O
founder	O
mutation	O
in	O
the	O
DYSF	O
gene	O
causing	O
clinical	O
variability	O
in	O
the	O
Spanish	O
population	O
.	O

BACKGROUND	O
:	O
Mutations	B-Var
in	O
the	O
dysferlin	O
(	B-Gene
DYSF	I-Gene
)	I-Gene
gene	O
cause	B-Reg
3	O
different	O
phenotypes	O
of	O
muscular	O
dystrophies	O
:	O
Miyoshi	B-Disease
myopathy	I-Disease
,	O
limb	B-Disease
-	I-Disease
girdle	I-Disease
muscular	I-Disease
dystrophy	I-Disease
type	I-Disease
2B	I-Disease
,	O
and	O
distal	B-Disease
anterior	I-Disease
compartment	I-Disease
myopathy	I-Disease
.	O

OBJECTIVE	O
:	O
To	O
present	O
the	O
results	O
of	O
clinical	O
and	O
molecular	O
analysis	O
of	O
8	O
patients	O
with	O
dysferlinopathy	O
from	O
5	O
unrelated	O
families	O
.	O

DESIGN	O
:	O
Clinical	O
assessment	O
was	O
performed	O
with	O
a	O
standardized	O
protocol	O
.	O

A	O
muscle	O
biopsy	O
specimen	O
was	O
obtained	O
and	O
studied	O
by	O
immunohistochemistry	O
.	O

Genetic	O
analysis	O
was	O
performed	O
using	O
single	O
-	O
stranded	O
conformation	O
polymorphism	O
and	O
direct	O
sequencing	O
of	O
genomic	O
DNA	O
.	O

RESULTS	O
:	O
All	O
the	O
patients	O
presented	O
the	O
R1905X	O
mutation	O
in	O
the	O
DYSF	O
gene	O
in	O
homozygosity	O
,	O
and	O
the	O
haplotype	O
analysis	O
at	O
the	O
DYSF	O
locus	O
revealed	O
that	O
it	O
was	O
a	O
novel	O
and	O
founder	O
mutation	O
.	O

A	O
C	B-Var
-	I-Var
to	I-Var
-	I-Var
T	I-Var
transition	I-Var
at	O
nucleotide	O
position	O
6086	O
changes	O
an	O
arginine	O
into	O
a	O
stop	O
codon	O
,	O
leading	B-Reg
to	I-Reg
premature	B-MPA
termination	I-MPA
of	I-MPA
translation	I-MPA
.	O

This	O
mutation	O
was	O
expressed	O
as	O
3	O
different	O
clinical	O
phenotypes	O
(	O
limb	O
-	O
girdle	O
muscular	O
dystrophy	O
type	O
2B	O
,	O
Miyoshi	O
distal	O
myopathy	O
,	O
and	O
distal	O
anterior	O
dysferlinopathy	O
)	O
,	O
but	O
only	O
1	O
phenotype	O
was	O
found	O
in	O
the	O
same	O
family	O
.	O

CONCLUSIONS	O
:	O
The	O
new	O
R1905X	O
DYSF	O
founder	O
mutation	O
produced	O
the	O
3	O
possible	O
dysferlinopathy	O
phenotypes	O
without	O
intrafamilial	O
heterogeneity	O
.	O

This	O
homogeneous	O
population	O
in	O
Sueca	O
,	O
Spain	O
,	O
should	O
be	O
helpful	O
in	O
studying	O
the	O
modifying	O
factors	O
responsible	O
for	O
the	O
phenotypic	O
variability	O
.	O

A	O
novel	O
frameshift	B-Var
mutation	O
(	O
+	O
G	O
)	O
at	O
codons	O
15/16	O
in	O
a	O
beta0	B-Gene
thalassaemia	I-Gene
gene	I-Gene
results	O
in	O
a	O
significant	O
reduction	B-NegReg
of	O
beta	B-MPA
globin	I-MPA
mRNA	I-MPA
values	O
.	O

AIMS	O
:	O
To	O
identify	O
a	O
novel	O
beta	O
globin	O
gene	O
mutation	O
found	O
in	O
a	O
Chinese	O
family	O
,	O
and	O
also	O
to	O
assess	O
its	O
functional	O
consequences	O
.	O

METHODS	O
:	O
Haematological	O
analysis	O
was	O
performed	O
on	O
all	O
family	O
members	O
.	O

The	O
23	O
common	O
mutations	O
of	O
beta	O
thalassaemia	O
found	O
in	O
Chinese	O
populations	O
were	O
detected	O
by	O
means	O
of	O
a	O
reverse	O
dot	O
blot	O
method	O
.	O

Direct	O
DNA	O
sequencing	O
of	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplified	O
complete	O
beta	O
globin	O
gene	O
was	O
carried	O
out	O
to	O
identify	O
the	O
novel	O
mutation	O
.	O

A	O
real	O
time	O
,	O
one	O
step	O
reverse	O
transcription	O
PCR	O
assay	O
was	O
used	O
to	O
measure	O
beta	O
globin	O
mRNA	O
in	O
the	O
reticulocytes	O
of	O
heterozygous	O
patients	O
.	O

RESULTS	O
:	O
A	O
novel	O
frameshift	O
mutation	O
-	O
an	O
insertion	B-Var
of	O
G	O
between	O
codons	O
15	O
and	O
16	O
in	O
a	O
homonucleotide	O
run	O
of	O
four	O
guanines	O
-	O
was	O
determined	O
,	O
which	O
generates	B-Reg
a	O
new	O
premature	B-MPA
chain	I-MPA
terminator	I-MPA
at	O
the	O
22nd	O
codon	O
.	O

Relative	O
quantitative	O
analysis	O
of	O
the	O
beta	O
globin	O
mRNA	O
in	O
heterozygous	O
subjects	O
demonstrated	O
a	O
39.83	O
%	O
reduction	O
compared	O
normal	O
controls	O
.	O

CONCLUSIONS	O
:	O
The	O
significantly	O
lower	B-NegReg
amounts	B-MPA
of	I-MPA
beta	I-MPA
globin	I-MPA
mRNA	I-MPA
found	O
in	O
mutation	B-Var
carriers	O
is	O
probably	O
caused	B-Reg
by	I-Reg
the	O
rapid	O
nonsense	O
mediated	O
degradation	B-MPA
of	O
the	O
mutant	O
mRNA	O
.	O

These	O
data	O
,	O
combined	O
with	O
haematological	O
analysis	O
,	O
suggest	O
that	O
this	O
novel	O
mutation	B-Var
of	O
CDs	O
15/16	O
(	O
+	O
G	O
)	O
results	B-Reg
in	I-Reg
a	O
beta(0	B-Disease
)	I-Disease
thalassaemia	I-Disease
phenotype	O
.	O

Increased	O
risk	O
of	O
idiopathic	O
chronic	O
pancreatitis	O
in	O
cystic	O
fibrosis	O
carriers	O
.	O

Cystic	B-Disease
fibrosis	I-Disease
(	O
CF	O
)	O
is	O
a	O
recessive	O
disease	O
caused	B-Reg
by	I-Reg
mutations	B-Var
of	O
the	O
CF	O
transmembrane	O
conductance	O
regulator	O
(	B-Gene
CFTR	I-Gene
)	I-Gene
gene	O
.	O

The	O
risk	O
of	O
idiopathic	O
chronic	O
pancreatitis	O
(	O
ICP	O
)	O
is	O
increased	O
in	O
individuals	O
who	O
have	O
CFTR	O
genotypes	O
containing	O
a	O
CF	O
-	O
causing	O
mutation	O
plus	O
a	O
second	O
pathogenic	O
allele	O
.	O

It	O
is	O
unknown	O
whether	O
the	O
risk	O
of	O
ICP	O
is	O
increased	O
in	O
CF	O
carriers	O
who	O
have	O
one	O
CF	O
-	O
causing	O
mutation	O
plus	O
one	O
normal	O
allele	O
.	O

In	O
this	O
study	O
,	O
52	O
sporadic	O
cases	O
of	O
ICP	O
were	O
ascertained	O
through	O
the	O
European	O
Registry	O
of	O
Hereditary	O
Pancreatitis	O
and	O
Familial	O
Pancreatic	O
Cancer	O
.	O

Individuals	O
with	O
pathogenic	O
cationic	O
trypsinogen	O
mutations	O
were	O
excluded	O
.	O

DNA	O
was	O
comprehensively	O
tested	O
for	O
CFTR	O
mutations	O
using	O
a	O
robotically	O
enhanced	O
,	O
multiplexed	O
,	O
and	O
highly	O
redundant	O
form	O
of	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
followed	O
by	O
DNA	O
sequencing	O
.	O

Fifteen	O
subjects	O
had	O
a	O
total	O
of	O
18	O
pathogenic	O
CFTR	O
alleles	O
.	O

Eight	O
subjects	O
had	O
common	O
CF	O
-	O
causing	O
mutations	O
.	O

This	O
group	O
included	O
seven	O
CF	O
carriers	O
in	O
whom	O
the	O
second	O
CFTR	O
allele	O
was	O
normal	O
(	O
4.3	O
times	O
the	O
expected	O
frequency	O
,	O
P=0.0002	O
)	O
.	O

Three	O
subjects	O
had	O
compound	O
heterozygotes	O
genotypes	O
containing	O
two	O
pathogenic	O
alleles	O
(	O
31	O
times	O
the	O
expected	O
frequency	O
,	O
P<0.0001	O
)	O
.	O

A	O
variant	O
allele	O
of	O
uncertain	O
significance	O
(	O
p	O
.	O
R75Q	O
)	O
was	O
detected	O
in	O
eight	O
of	O
the	O
52	O
ICP	O
subjects	O
and	O
at	O
a	O
similar	O
frequency	O
(	O
13/96	O
)	O
in	O
random	O
donors	O
.	O

ICP	O
differs	O
from	O
other	O
established	O
CFTR	O
-	O
related	O
conditions	O
in	O
that	O
ICP	O
risk	O
is	O
increased	O
in	O
CF	O
carriers	O
who	O
have	O
one	O
documented	O
normal	O
CFTR	O
allele	O
.	O

Having	O
two	O
CFTR	O
mutations	O
imparts	O
a	O
higher	O
relative	O
risk	O
,	O
while	O
having	O
only	O
one	O
mutation	O
imparts	O
a	O
higher	O
attributable	O
risk	O
.	O

Mutation	O
identification	O
in	O
a	O
canine	O
model	O
of	O
X	O
-	O
linked	O
ectodermal	O
dysplasia	O
.	O

X	B-Disease
-	I-Disease
linked	I-Disease
hypohidrotic	I-Disease
ectodermal	I-Disease
dysplasia	I-Disease
(	O
XHED	O
)	O
,	O
an	O
inherited	O
disease	O
recognized	O
in	O
humans	O
,	O
mice	O
,	O
and	O
cattle	O
,	O
is	O
characterized	O
by	O
hypotrichosis	O
,	O
a	O
reduced	O
number	O
or	O
absence	O
of	O
sweat	O
glands	O
,	O
and	O
missing	O
or	O
malformed	O
teeth	O
.	O

In	O
a	O
subset	O
of	O
affected	O
individuals	O
and	O
animals	O
,	O
mutations	B-Var
in	O
the	O
EDA	B-Gene
gene	O
(	O
formerly	O
EDI	O
)	O
,	O
coding	O
for	O
ectodysplasin	O
,	O
have	O
been	O
found	O
to	O
cause	B-Reg
this	O
phenotype	O
.	O

Ectodysplasin	O
is	O
a	O
homotrimeric	O
transmembrane	O
protein	O
with	O
an	O
extracellular	O
TNF	O
-	O
like	O
domain	O
,	O
which	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
the	O
morphogenesis	O
of	O
hair	O
follicles	O
and	O
tooth	O
buds	O
during	O
fetal	O
development	O
.	O

Some	O
human	O
XHED	B-Disease
patients	O
also	O
have	O
concurrent	O
immunodeficiency	O
,	O
due	B-Reg
to	I-Reg
mutations	B-Var
in	O
the	O
NF	O
-	O
kappaB	O
essential	O
modulator	O
protein	O
(	B-Gene
IKBKG	I-Gene
;	I-Gene
formerly	O
NEMO	O
)	O
,	O
which	O
is	O
also	O
encoded	O
on	O
the	O
X	O
chromosome	O
.	O

In	O
a	O
breeding	O
colony	O
of	O
dogs	O
with	O
XHED	O
,	O
immune	O
system	O
defects	O
had	O
been	O
suspected	O
because	O
of	O
frequent	O
pulmonary	O
infections	O
and	O
unexpected	O
deaths	O
resulting	O
from	O
pneumonia	O
.	O

To	O
determine	O
if	O
defects	O
in	O
EDA	O
or	O
IKBKG	O
cause	O
XHED	O
in	O
the	O
dogs	O
,	O
linkage	O
analysis	O
and	O
sequencing	O
experiments	O
were	O
performed	O
.	O

A	O
polymorphic	O
marker	O
near	O
the	O
canine	O
EDA	O
gene	O
showed	O
significant	O
linkage	O
to	O
XHED	O
.	O

The	O
canine	O
EDA	B-Gene
gene	O
was	O
sequenced	O
and	O
a	O
nucleotide	B-Var
substitution	I-Var
(	O
G	O
to	O
A	O
)	O
in	O
the	O
splice	O
acceptor	O
site	O
of	O
intron	O
8	O
was	O
detected	O
in	O
affected	O
dogs	O
.	O

In	O
the	O
presence	O
of	O
the	O
A	O
residue	O
,	O
a	O
cryptic	O
acceptor	O
site	O
within	O
exon	O
9	O
is	O
used	O
,	O
leading	B-Reg
to	I-Reg
a	O
frame	B-MPA
shift	I-MPA
and	O
use	O
of	O
a	O
premature	B-MPA
stop	I-MPA
codon	I-MPA
that	O
truncates	B-NegReg
the	O
translation	B-MPA
of	O
both	O
isoforms	O
,	O
EDA	O
-	O
A1	O
and	O
EDA	O
-	O
A2	O
,	O
resulting	O
in	O
the	O
absence	B-NegReg
of	O
the	O
TNF	B-MPA
-	I-MPA
like	I-MPA
homology	I-MPA
domain	I-MPA
,	O
the	O
receptor	O
-	O
binding	O
site	O
of	O
ectodysplasin	O
.	O

Effects	O
of	O
a	O
leukemia	O
-	O
associated	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
of	O
SHP-2	O
phosphatase	O
on	O
interleukin-3	O
signaling	O
.	O

Mutations	B-Var
in	O
SHP-2	B-Gene
phosphatase	B-Enzyme
that	O
cause	O
hyperactivation	B-PosReg
of	O
its	O
catalytic	B-MPA
activity	I-MPA
have	O
been	O
identified	O
in	O
human	O
leukemias	B-Disease
,	O
particularly	O
juvenile	B-Disease
myelomonocytic	I-Disease
leukemia	I-Disease
,	O
which	O
is	O
characterized	O
by	O
hypersensitivity	O
of	O
myeloid	O
progenitor	O
cells	O
to	O
granulocyte	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
and	O
interleukin	O
(	O
IL)-3	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
by	O
which	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
mutations	O
of	O
SHP-2	O
induce	O
hematopoietic	O
malignancies	O
are	O
not	O
fully	O
understood	O
.	O

Our	O
previous	O
studies	O
have	O
shown	O
that	O
SHP-2	O
plays	O
an	O
essential	O
role	O
in	O
IL-3	O
signal	O
transduction	O
in	O
both	O
catalytic	O
-	O
dependent	O
and	O
-independent	O
manners	O
and	O
that	O
overexpression	O
(	O
5	O
-	O
6-fold	O
)	O
of	O
wild	O
type	O
(	O
WT	O
)	O
SHP-2	O
attenuates	O
IL-3-mediated	O
hematopoietic	O
cell	O
function	O
through	O
accelerated	O
dephosphorylation	O
of	O
STAT5	O
.	O

These	O
results	O
raised	O
the	O
possibility	O
that	O
SHP-2-associated	O
leukemias	O
are	O
not	O
solely	O
attributed	O
to	O
the	O
increased	O
catalytic	O
activity	O
of	O
GOF	O
mutant	O
SHP-2	O
.	O

GOF	O
mutant	O
SHP-2	O
must	O
have	O
gained	O
additional	O
capacities	O
.	O

To	O
test	O
this	O
possibility	O
,	O
we	O
investigated	O
effects	O
of	O
a	O
GOF	O
mutation	O
of	O
SHP-2	O
(	O
SHP-2	O
E76	O
K	O
)	O
on	O
hematopoietic	O
cell	O
function	O
and	O
IL-3	O
signal	O
transduction	O
by	O
comparing	O
with	O
those	O
of	O
overexpressed	O
WT	O
SHP-2	O
.	O

Our	O
results	O
showed	O
that	O
SHP-2	B-Gene
E76	B-Var
K	I-Var
mutation	I-Var
caused	O
myeloproliferative	B-Disease
disease	I-Disease
in	O
mice	O
,	O
while	O
overexpression	O
of	O
WT	O
SHP-2	O
decreased	O
hematopoietic	O
potential	O
of	O
the	O
transduced	O
cells	O
in	O
recipient	O
animals	O
.	O

The	O
E76	B-Var
K	I-Var
mutation	O
in	O
the	O
N	O
-	O
terminal	O
Src	O
homology	O
2	O
domain	O
increased	B-PosReg
interactions	B-Interaction
of	O
mutant	B-Var
SHP-2	B-Gene
with	O
Grb2	B-Protein
,	O
Gab2	O
,	O
and	O
p85	O
,	O
leading	O
to	O
hyperactivation	B-PosReg
of	O
IL-3-induced	B-Pathway
Erk	I-Pathway
and	I-Pathway
phosphatidylinositol	I-Pathway
3-kinase	I-Pathway
(	I-Pathway
PI3	I-Pathway
K	I-Pathway
)	I-Pathway
pathways	I-Pathway
.	O

In	O
addition	O
,	O
despite	O
the	O
substantial	O
increase	B-PosReg
in	O
the	O
catalytic	B-MPA
activity	I-MPA
,	O
dephosphorylation	B-MPA
of	I-MPA
STAT5	I-MPA
by	O
SHP-2	B-Gene
E76	B-Var
K	I-Var
was	O
dampened	B-NegReg
.	O

Furthermore	O
,	O
catalytically	O
inactive	O
SHP-2	B-Gene
E76	B-Var
K	I-Var
with	O
an	O
additional	O
C459S	B-Var
mutation	O
retained	O
the	O
capability	O
to	O
increase	B-PosReg
the	O
interaction	B-Interaction
with	O
Gab2	B-Protein
and	O
to	O
enhance	B-PosReg
the	O
activation	O
of	O
the	O
PI3	B-Pathway
K	I-Pathway
pathway	I-Pathway
.	O

Taken	O
together	O
,	O
these	O
studies	O
suggest	O
that	O
in	O
addition	O
to	O
the	O
elevated	O
catalytic	O
activity	O
,	O
fundamental	O
changes	O
in	O
physical	O
and	O
functional	O
interactions	O
between	O
GOF	O
mutant	O
SHP-2	O
and	O
signaling	O
partners	O
also	O
play	O
an	O
important	O
role	O
in	O
SHP-2-related	O
leukemigenesis	O
.	O

Familial	O
Mediterranean	O
fever	O
(	O
FMF	O
)	O
in	O
Lebanon	O
and	O
Jordan	O
:	O
a	O
population	O
genetics	O
study	O
and	O
report	O
of	O
three	O
novel	O
mutations	O
.	O

Familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	O
)	O
is	O
an	O
autosomal	O
recessive	O
disease	O
mostly	O
frequent	O
in	O
Mediterranean	O
populations	O
.	O

Over	O
50	O
mutations	B-Var
have	O
been	O
identified	O
in	O
the	O
gene	O
responsible	B-Reg
for	I-Reg
the	O
disease	O
,	O
MEFV	B-Gene
.	O

The	O
present	O
study	O
reports	O
the	O
frequencies	O
of	O
MEFV	B-Gene
mutations	B-Var
in	B-Reg
558	O
Lebanese	O
and	O
55	O
Jordanian	O
FMF	B-Disease
patients	O
and	O
points	O
out	O
the	O
severity	O
of	O
the	O
M694V	O
frequently	O
observed	O
mutation	O
among	O
these	O
patients	O
.	O

Three	O
novel	O
mutations	O
,	O
T177I	O
,	O
S108R	O
and	O
E474	O
K	O
were	O
also	O
identified	O
in	O
the	O
Lebanese	O
group	O
.	O

An	O
excess	O
of	O
homozygotes	O
and	O
a	O
deficit	O
of	O
heterozygotes	O
were	O
observed	O
in	O
both	O
samples	O
when	O
compared	O
to	O
the	O
expected	O
number	O
of	O
observed	O
genotypes	O
under	O
the	O
Hardy	O
-	O
Weinberg	O
hypothesis	O
.	O

Homozygotes	O
for	O
M694V	O
and	O
M694I	O
were	O
still	O
in	O
excess	O
in	O
the	O
Lebanese	O
group	O
of	O
patients	O
,	O
even	O
after	O
consanguinous	O
homozygotes	O
were	O
removed	O
,	O
or	O
population	O
structure	O
was	O
considered	O
.	O

This	O
excess	O
is	O
therefore	O
neither	O
due	O
to	O
consanguinity	O
nor	O
to	O
subgroups	O
in	O
the	O
Lebanese	O
population	O
,	O
but	O
rather	O
to	O
more	O
remote	O
consanguinity	O
or	O
to	O
a	O
selection	O
bias	O
favoring	O
the	O
census	O
of	O
these	O
genotypes	O
.	O

The	O
fact	O
that	O
FMF	O
female	O
patients	O
were	O
less	O
censed	O
than	O
male	O
patients	O
may	O
be	O
due	O
to	O
the	O
greater	O
resistance	O
of	O
females	O
to	O
pain	O
and	O
to	O
the	O
possibility	O
of	O
confusing	O
abdominal	O
and	O
gynecological	O
pain	O
.	O

The	O
phenotypic	O
heterogeneity	O
of	O
the	O
FMF	O
could	O
then	O
originate	O
both	O
from	O
genetic	O
causes	O
like	O
allelic	O
heterogeneity	O
or	O
modulating	O
genes	O
,	O
and	O
cultural	O
background	O
facing	O
the	O
physiological	O
consequences	O
of	O
genotypes	O
at	O
risk	O
.	O

[	O
Mutational	O
and	O
clinical	O
features	O
of	O
Japanese	O
patients	O
with	O
dysferlinopathy	O
(	O
Miyoshi	O
myopathy	O
and	O
limb	O
girdle	O
muscular	O
dystrophy	O
type	O
2B	O
)	O
]	O
.	O

Mutations	B-Var
in	O
the	O
dysferlin	B-Gene
gene	O
cause	B-Reg
both	O
Miyoshi	B-Disease
myopathy	I-Disease
(	O
MM	O
)	O
and	O
limb	B-Disease
girdle	I-Disease
muscular	I-Disease
dystrophy	I-Disease
2B	I-Disease
(	O
LGMD2B	O
)	O
.	O

We	O
examined	O
patients	O
with	O
dysferlinopathy	O
in	O
Japan	O
,	O
and	O
identified	O
28	O
and	O
12	O
different	O
mutations	O
respectively	O
in	O
MM	O
and	O
LGMD2B	O
patients	O
.	O

The	O
mean	O
age	O
at	O
onset	O
of	O
the	O
patients	O
with	O
MM	O
was	O
22	O
+	O
/-	O
9	O
years	O
(	O
range	O
12	O
-	O
48	O
years	O
)	O
and	O
that	O
of	O
the	O
patients	O
with	O
LGMD2B	O
was	O
26	O
+	O
/-	O
10	O
years	O
(	O
range	O
11	O
-	O
43	O
years	O
)	O
.	O

On	O
the	O
average	O
,	O
the	O
first	O
use	O
of	O
a	O
cane	O
was	O
at	O
33	O
years	O
(	O
14	O
years	O
after	O
the	O
onset	O
)	O
for	O
MM	O
and	O
39	O
years	O
(	O
15	O
years	O
after	O
onset	O
)	O
for	O
LGMD	O
2B.	O
Patients	O
became	O
wheelchair	O
-	O
bound	O
at	O
41	O
years	O
(	O
21	O
years	O
after	O
onset	O
)	O
in	O
MM	O
and	O
45	O
years	O
(	O
21	O
years	O
after	O
onset	O
)	O
for	O
LGMD2B.	O
The	O
mean	O
maximum	O
serum	O
CK	O
level	O
at	O
any	O
age	O
of	O
the	O
patients	O
was	O
5,829	O
+	O
/-	O
4,273	O
IU	O
/	O
l	O
(	O
range	O
1,289	O
-	O
12,566	O
IU	O
/	O
l	O
)	O
for	O
MM	O
and	O
3,787	O
+	O
/-	O
2,493	O
IU	O
/	O
l	O
(	O
627	O
-	O
10,000	O
IU	O
/	O
l	O
)	O
for	O
LGMD2B	O
:	O
in	O
both	O
disorders	O
,	O
the	O
serum	O
CK	O
level	O
fell	O
in	O
proportion	O
to	O
the	O
duration	O
of	O
the	O
illness	O
.	O

We	O
have	O
identified	O
four	O
common	O
four	O
mutations	O
(	O
C1939	O
G	O
,	O
G3370	O
T	O
,	O
3746delG	O
,	O
and	O
4870delT	O
)	O
in	O
Japanese	O
patients	O
with	O
MM	O
,	O
accounting	O
for	O
48	O
percent	O
of	O
all	O
MM	O
mutations	O
in	O
this	O
population	O
.	O

Two	O
of	O
the	O
four	O
mutations	O
(	O
G3370	O
T	O
,	O
and	O
4870delT	O
)	O
accounted	O
for	O
52	O
percent	O
of	O
the	O
mutations	O
in	O
LGMD2B	O
patients	O
,	O
while	O
the	O
3746delG	O
mutation	O
was	O
not	O
found	O
in	O
patients	O
with	O
LGMD2B.	O
The	O
G3370	B-Var
T	I-Var
mutation	O
may	O
be	O
associated	B-Reg
with	I-Reg
a	O
milder	O
form	O
of	O
MM	B-Disease
and	O
LGMD2B.	B-Disease
By	O
contrast	O
,	O
the	O
G3510A	B-Var
mutation	O
appears	O
to	O
be	O
associated	B-Reg
with	I-Reg
a	O
severe	O
form	O
of	O
MM	B-Disease
.	O

[	O
Molecular	O
pathomechanism	O
of	O
distal	O
myopathy	O
with	O
rimmed	O
vacuoles	O
]	O
.	O

Distal	B-Disease
myopathy	I-Disease
with	I-Disease
rimmed	I-Disease
vacuoles	I-Disease
(	O
DMRV	O
)	O
and	O
hereditary	B-Disease
inclusion	I-Disease
body	I-Disease
myopathy	I-Disease
(	O
HIBM	O
)	O
are	O
genetically	O
identical	O
autosomal	O
recessive	O
muscle	O
disorders	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
GNE	B-Gene
gene	O
.	O

This	O
gene	O
encodes	O
a	O
bifunctional	O
protein	O
with	O
UDP	O
-	O
GlcNAc	O
2-epimerase	O
and	O
ManNAc	O
kinase	O
activities	O
that	O
catalyze	O
the	O
rate	O
limiting	O
step	O
and	O
the	O
succeeding	O
step	O
,	O
respectively	O
,	O
in	O
the	O
sialic	O
acid	O
biosynthetic	O
pathway	O
.	O

V572L	O
mutation	O
is	O
the	O
most	O
prevalent	O
among	O
Japanese	O
DMRV	O
patients	O
and	O
accounts	O
for	O
about	O
60	O
%	O
of	O
mutant	O
alleles	O
.	O

Clinical	O
spectrum	O
of	O
DMRV	O
/	O
HIBM	O
seems	O
to	O
be	O
wider	O
than	O
previously	O
thought	O
in	O
terms	O
of	O
both	O
the	O
severity	O
of	O
the	O
disease	O
and	O
the	O
range	O
of	O
affected	O
organs	O
.	O

There	O
are	O
rare	O
asymptomatic	O
homozygotes	O
with	O
missense	O
GNE	O
mutations	O
,	O
indicating	O
the	O
presence	O
of	O
mitigating	O
factors	O
.	O

Surprisingly	O
,	O
more	O
than	O
10	O
%	O
of	O
the	O
patients	O
had	O
a	O
variety	O
of	O
cardiac	O
abnormalities	O
,	O
suggesting	O
that	O
skeletal	O
muscle	O
may	O
not	O
be	O
the	O
only	O
organ	O
involved	O
.	O

Studies	O
on	O
recombinant	O
GNE	B-Gene
demonstrate	O
a	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
nature	O
of	O
the	O
missense	O
mutations	B-Var
identified	O
.	O

Patients	O
'	O
cells	O
show	O
decreased	B-NegReg
sialylation	B-MPA
status	I-MPA
which	O
can	O
be	O
recovered	O
by	O
adding	O
GNE	O
metabolites	O
,	O
such	O
as	O
ManNAc	O
and	O
NeuAc	O
.	O

This	O
indicates	O
the	O
possibility	O
of	O
developing	O
a	O
therapy	O
for	O
DMRV	O
/	O
HIBM	O
by	O
giving	O
these	O
metabolites	O
to	O
patients	O
although	O
we	O
have	O
to	O
await	O
the	O
model	O
mice	O
that	O
are	O
currently	O
being	O
produced	O
at	O
several	O
laboratories	O
.	O

X	B-Disease
linked	I-Disease
cone	I-Disease
-	I-Disease
rod	I-Disease
dystrophy	I-Disease
,	O
CORDX3	O
,	O
is	O
caused	B-Reg
by	I-Reg
a	O
mutation	B-Var
in	O
the	O
CACNA1F	B-Gene
gene	O
.	O

BACKGROUND	O
:	O
X	B-Disease
linked	I-Disease
cone	I-Disease
-	I-Disease
rod	I-Disease
dystrophy	I-Disease
(	O
CORDX	O
)	O
is	O
a	O
recessive	O
retinal	O
disease	O
characterised	O
by	O
progressive	O
dysfunction	O
of	O
photoreceptors	O
.	O

It	O
is	O
genetically	O
heterogeneous	O
,	O
showing	O
linkage	O
to	O
three	O
X	O
chromosomal	O
loci	O
.	O

CORDX1	B-Disease
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
RPGR	B-Gene
gene	O
(	O
Xp21.1	O
)	O
,	O
CORDX2	O
is	O
located	O
on	O
Xq27.2	O
-	O
28	O
,	O
and	O
we	O
recently	O
localised	O
CORDX3	O
to	O
Xp11.4-q13.1	O
.	O

We	O
aimed	O
to	O
identify	O
the	O
causative	O
gene	O
behind	O
the	O
CORDX3	O
phenotype	O
.	O

METHODS	O
:	O
All	O
48	O
exons	O
of	O
the	O
CACNA1F	O
gene	O
were	O
screened	O
for	O
mutations	O
by	O
DNA	O
sequencing	O
.	O

RNA	O
from	O
cultured	O
lymphoblasts	O
and	O
peripheral	O
blood	O
activated	O
T	O
lymphocytes	O
was	O
analysed	O
by	O
RT	O
-	O
PCR	O
and	O
sequencing	O
.	O

RESULTS	O
:	O
A	O
novel	O
CACNA1F	O
mutation	O
,	O
IVS28	O
-	O
1	O
GCGTC	O
>	O
TGG	O
,	O
in	O
the	O
splice	O
acceptor	O
site	O
of	O
intron	O
28	O
was	O
identified	O
.	O

Messenger	O
RNA	O
studies	O
indicated	O
that	O
the	O
identified	O
mutation	B-Var
leads	O
to	O
altered	B-Reg
splicing	B-MPA
of	O
the	O
CACNA1F	B-Gene
transcript	B-MPA
.	O

Aberrant	B-Var
splice	I-Var
variants	I-Var
are	O
predicted	O
to	O
result	B-Reg
in	I-Reg
premature	B-MPA
termination	I-MPA
and	O
deletions	B-Var
of	O
the	O
encoded	B-Protein
protein	I-Protein
,	O
Ca(v)1.4	O
alpha1	O
subunit	O
.	O

CONCLUSION	O
:	O
CACNA1F	B-Gene
mutations	B-Var
cause	B-Reg
the	O
retinal	B-Disease
disorder	I-Disease
,	O
incomplete	O
congenital	B-Disease
stationary	I-Disease
night	I-Disease
blindness	I-Disease
(	O
CSNB2	O
)	O
,	O
although	O
mutations	O
have	O
also	O
been	O
detected	O
in	O
patients	O
with	O
divergent	O
diagnoses	O
.	O

Our	O
results	O
indicate	O
that	O
yet	O
another	O
phenotype	O
,	O
CORDX3	B-Disease
,	O
is	O
caused	B-Reg
by	I-Reg
a	O
mutation	B-Var
in	O
CACNA1F.	B-Gene
Clinically	O
,	O
CORDX3	O
shares	O
some	O
features	O
with	O
CSNB2	O
but	O
is	O
distinguishable	O
from	O
CSNB2	O
in	O
that	O
it	O
is	O
progressive	O
,	O
can	O
begin	O
in	O
adulthood	O
,	O
has	O
no	O
nystagmus	O
or	O
hyperopic	O
refraction	O
,	O
has	O
only	O
low	O
grade	O
astigmatism	O
,	O
and	O
in	O
dark	O
adaptation	O
lacks	O
cone	O
threshold	O
and	O
has	O
small	O
or	O
no	O
elevation	O
of	O
rod	O
threshold	O
.	O

Considering	O
all	O
features	O
,	O
CORDX3	O
is	O
more	O
similar	O
to	O
other	O
X	O
chromosomal	O
cone	O
-	O
rod	O
dystrophies	O
than	O
to	O
CSNB2	O
.	O

Novel	O
JARID1C	O
/	O
SMCX	O
mutations	O
in	O
patients	O
with	O
X	O
-	O
linked	O
mental	O
retardation	O
.	O

X	B-Disease
-	I-Disease
linked	I-Disease
mental	I-Disease
retardation	I-Disease
(	O
XLMR	O
)	O
is	O
a	O
heterogeneous	O
disorder	O
that	O
affects	O
approximately	O
2	O
in	O
1000	O
males	O
.	O

JARID1C	O
/	O
SMCX	O
is	O
relatively	O
new	O
among	O
the	O
known	O
XLMR	O
genes	O
,	O
and	O
seven	O
different	O
mutations	O
have	O
been	O
identified	O
previously	O
in	O
this	O
gene	O
[	O
Jensen	O
LR	O
et	O
al	O
.	O

,	O
Am	O
.	O

J.	O
Hum	O
.	O

Genet	O
.	O

76:227	O
-	O
236	O
,	O
2005	O
]	O
.	O

Here	O
,	O
we	O
report	O
five	O
novel	O
JARID1C	B-Gene
mutations	O
in	B-Reg
five	O
XLMR	B-Disease
families	O
.	O

The	O
changes	O
comprise	O
one	O
nonsense	O
mutation	O
(	B-Var
p	I-Var
.	I-Var
Arg332X	I-Var
)	I-Var
and	O
four	O
missense	O
mutations	O
(	B-Var
p	I-Var
.	I-Var
Asp87Gly	I-Var
;	I-Var
p	B-Var
.	I-Var
Phe642Leu	I-Var
;	I-Var
p	B-Var
.	I-Var
Arg750Trp	I-Var
;	I-Var
p	B-Var
.	I-Var
Tyr751Cys	I-Var
)	I-Var
affecting	O
evolutionarily	O
conserved	O
amino	O
acids	O
.	O

The	O
degree	O
of	O
mental	O
retardation	O
in	O
the	O
affected	O
males	O
ranged	O
from	O
mild	O
to	O
severe	O
,	O
and	O
some	O
patients	O
suffered	O
from	O
additional	O
disorders	O
such	O
as	O
epilepsy	O
,	O
short	O
stature	O
,	O
or	O
behavioral	O
problems	O
.	O

This	O
study	O
brings	O
the	O
total	O
number	O
of	O
reported	O
JARID1C	O
mutations	O
to	O
twelve	O
.	O

In	O
contrast	O
to	O
other	O
XLMR	O
genes	O
in	O
which	O
mutations	O
were	O
found	O
only	O
in	O
single	O
or	O
very	O
few	O
families	O
,	O
JARID1C	O
appears	O
to	O
be	O
one	O
of	O
the	O
more	O
frequently	O
mutated	O
genes	O
in	O
this	O
disorder	O
.	O

Missense	B-Var
mutations	I-Var
in	O
SH2D1A	B-Gene
identified	O
in	O
patients	O
with	B-Reg
X	B-Disease
-	I-Disease
linked	I-Disease
lymphoproliferative	I-Disease
disease	I-Disease
differentially	O
affect	O
the	O
expression	O
and	O
function	O
of	O
SAP	O
.	O

X	B-Disease
-	I-Disease
linked	I-Disease
lymphoproliferative	I-Disease
disease	I-Disease
(	O
XLP	O
)	O
is	O
an	O
immunodeficiency	O
resulting	B-Reg
from	I-Reg
mutations	B-Var
in	O
SH2D1A	B-Gene
,	O
which	O
encodes	O
signalling	O
lymphocytic	O
activation	O
molecule	O
(	O
SLAM)-associated	O
protein	O
(	O
SAP	O
)	O
.	O

In	O
addition	O
to	O
SLAM	O
,	O
SAP	O
associates	O
with	O
several	O
other	O
cell	O
-	O
surface	O
receptors	O
including	O
2B4	O
(	O
CD244	O
)	O
,	O
Ly9	O
(	O
CD229	O
)	O
,	O
CD84	O
and	O
NTB	O
-	O
A.	O
SAP	O
contains	O
a	O
single	O
src	O
-	O
homology-2	O
domain	O
and	O
acts	O
as	O
an	O
intracellular	O
adaptor	O
protein	O
by	O
recruiting	O
the	O
protein	O
tyrosine	O
kinase	O
FynT	O
to	O
the	O
cytoplasmic	O
domains	O
of	O
some	O
of	O
these	O
receptors	O
,	O
which	O
results	O
in	O
the	O
initiation	O
of	O
specific	O
downstream	O
signal	O
transduction	O
pathways	O
.	O

XLP	O
is	O
likely	O
to	O
result	O
from	O
perturbed	O
signalling	O
through	O
one	O
or	O
more	O
of	O
these	O
SAP	O
-	O
associating	O
receptors	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
missense	O
(	O
Y54C	O
,	O
I84	O
T	O
and	O
F87S	O
)	O
and	O
insertion	O
(	O
fs82	O
--	O
>	O
X103	O
)	O
mutations	O
in	O
four	O
different	O
kindreds	O
affected	O
by	O
XLP	O
.	O

Each	O
mutation	B-Var
dramatically	O
reduced	B-NegReg
the	O
half	B-MPA
-	I-MPA
life	I-MPA
of	O
SAP	B-Protein
,	O
thus	O
diminishing	B-NegReg
its	O
expression	B-MPA
in	O
primary	O
lymphocytes	O
as	O
well	O
as	O
in	O
transfected	O
cell	O
lines	O
.	O

Interestingly	O
,	O
although	O
the	O
Y54C	B-Var
and	O
F87S	B-Var
mutations	O
compromised	B-NegReg
the	O
ability	B-MPA
of	O
SAP	B-Protein
to	O
associate	B-Interaction
with	O
different	O
receptors	O
,	O
the	O
I84	O
T	O
mutation	O
had	O
no	O
effect	O
on	O
the	O
ability	O
of	O
SAP	O
to	O
bind	O
SLAM	O
,	O
CD84	O
or	O
2B4	O
.	O

However	O
,	O
signalling	B-MPA
downstream	I-MPA
of	I-MPA
SLAM	I-MPA
was	O
reduced	B-NegReg
in	O
the	O
presence	O
of	O
SAP	B-Protein
bearing	O
the	O
I84	B-Var
T	I-Var
mutation	O
.	O

These	O
findings	O
indicate	O
that	O
,	O
irrespective	O
of	O
the	O
type	O
of	O
mutation	O
,	O
signalling	O
through	O
SAP	O
-	O
associating	O
receptors	O
in	O
XLP	O
can	O
be	O
impaired	O
by	O
reducing	O
the	O
expression	O
of	O
SAP	O
,	O
the	O
ability	O
of	O
SAP	O
to	O
bind	O
surface	O
receptors	O
and/or	O
its	O
ability	O
to	O
activate	O
signal	O
transduction	O
downstream	O
of	O
the	O
SLAM	O
-	O
SAP	O
complex	O
.	O

The	O
R110C	B-Var
mutation	O
in	O
Notch3	B-Gene
causes	B-Reg
variable	O
clinical	O
features	O
in	O
two	O
Turkish	O
families	O
with	O
CADASIL	B-Disease
syndrome	I-Disease
.	O

Mutations	B-Var
in	O
Notch3	B-Gene
gene	O
are	O
responsible	B-Reg
for	O
the	O
cerebral	B-Disease
autosomal	I-Disease
dominant	I-Disease
arteriopathy	I-Disease
with	I-Disease
subcortical	I-Disease
infarcts	I-Disease
and	I-Disease
leukoencephalopathy	I-Disease
(	O
CADASIL	O
)	O
.	O

It	O
is	O
a	O
late	O
onset	O
neurological	O
disorder	O
recognized	O
by	O
recurrent	O
strokes	O
and	O
dementia	O
.	O

We	O
describe	O
here	O
the	O
clinical	O
and	O
molecular	O
findings	O
of	O
three	O
unrelated	O
Turkish	O
families	O
with	O
CADASIL	O
syndrome	O
.	O

Two	O
of	O
the	O
families	O
were	O
identified	O
to	O
have	O
the	O
same	O
mutation	O
,	O
p	O
.	O
R110C	O
(	O
c	O
.	O

C328	O
T	O
)	O
,	O
located	O
in	O
exon	O
3	O
of	O
the	O
Notch3	O
gene	O
.	O

Interestingly	O
,	O
the	O
phenotypic	O
expression	O
of	O
the	O
disease	O
in	O
these	O
two	O
families	O
was	O
markedly	O
different	O
in	O
severity	O
and	O
age	O
of	O
onset	O
implicating	O
additional	O
genetic	O
and/or	O
non	O
-	O
genetic	O
modulating	O
factors	O
involved	O
in	O
the	O
pathogenesis	O
.	O

In	O
addition	O
,	O
we	O
identified	O
the	O
novel	O
p	O
.	O
C201R	O
(	O
c	O
.	O

T601C	O
)	O
mutation	O
in	O
exon	O
4	O
of	O
the	O
Notch3	O
gene	O
in	O
a	O
proband	O
of	O
the	O
third	O
family	O
with	O
two	O
consecutive	O
stroke	O
-	O
like	O
episodes	O
and	O
typical	O
MRI	O
findings	O
.	O

Mutations	B-Var
described	O
here	O
cause	B-Reg
an	O
odd	B-MPA
number	I-MPA
of	I-MPA
cysteines	I-MPA
in	I-MPA
the	I-MPA
N	I-MPA
-	I-MPA
terminal	I-MPA
of	I-MPA
the	I-MPA
EGF	I-MPA
domain	I-MPA
of	O
Notch3	B-Gene
protein	B-Protein
,	O
which	O
seems	O
to	O
have	O
an	O
important	O
functional	O
effect	B-Reg
in	O
the	O
pathophysiology	O
of	O
CADASIL	B-Disease
.	O

The	O
phenotypic	O
variability	O
in	O
families	O
carrying	O
the	O
same	O
molecular	O
defect	O
as	O
presented	O
here	O
makes	O
the	O
prediction	O
of	O
prognosis	O
inconceivable	O
.	O

Although	O
DNA	O
analysis	O
is	O
effective	O
and	O
valuable	O
in	O
diagnosing	O
approximately	O
90	O
%	O
of	O
the	O
CADASIL	O
patients	O
,	O
lack	O
of	O
genotype	O
-	O
phenotype	O
correlation	O
and	O
prognostic	O
parameters	O
makes	O
the	O
presymptomatic	O
genetic	O
counseling	O
very	O
difficult	O
.	O

Entries	O
in	O
the	O
Leiden	O
Duchenne	O
muscular	O
dystrophy	O
mutation	O
database	O
:	O
an	O
overview	O
of	O
mutation	O
types	O
and	O
paradoxical	O
cases	O
that	O
confirm	O
the	O
reading	O
-	O
frame	O
rule	O
.	O

The	O
severe	O
Duchenne	B-Disease
and	O
milder	O
Becker	B-Disease
muscular	I-Disease
dystrophy	I-Disease
are	O
both	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
DMD	B-Gene
gene	O
.	O

This	O
gene	O
codes	O
for	O
dystrophin	O
,	O
a	O
protein	O
important	O
for	O
maintaining	O
the	O
stability	O
of	O
muscle	O
-	O
fiber	O
membranes	O
.	O

In	O
1988	O
,	O
Monaco	O
and	O
colleagues	O
postulated	O
an	O
explanation	O
for	O
the	O
phenotypic	O
difference	O
between	O
Duchenne	O
and	O
Becker	O
patients	O
in	O
the	O
reading	O
-	O
frame	O
rule	O
:	O
In	O
Duchenne	B-Disease
patients	O
,	O
mutations	B-Var
induce	B-Reg
a	B-MPA
shift	I-MPA
in	I-MPA
the	I-MPA
reading	I-MPA
frame	I-MPA
leading	B-Reg
to	O
prematurely	B-MPA
truncated	I-MPA
,	O
dysfunctional	B-NegReg
dystrophins	B-Protein
.	O

In	O
Becker	B-Disease
patients	O
,	O
in	B-Var
-	I-Var
frame	I-Var
mutations	I-Var
allow	B-Reg
the	O
synthesis	B-MPA
of	I-MPA
internally	I-MPA
deleted	I-MPA
,	O
but	O
largely	B-PosReg
functional	I-PosReg
dystrophins	B-Protein
.	O

Currently	O
,	O
over	O
4700	O
mutations	O
have	O
been	O
reported	O
in	O
the	O
Leiden	O
DMD	O
mutation	O
database	O
,	O
of	O
which	O
91	O
%	O
are	O
in	O
agreement	O
with	O
this	O
rule	O
.	O

In	O
this	O
study	O
we	O
provide	O
an	O
update	O
of	O
the	O
mutational	O
variability	O
in	O
the	O
DMD	O
gene	O
,	O
particularly	O
focusing	O
on	O
genotype	O
-	O
phenotype	O
correlations	O
and	O
mutations	O
that	O
appear	O
to	O
be	O
exceptions	O
to	O
the	O
reading	O
-	O
frame	O
rule	O
.	O

Prevalence	O
of	O
disease	O
-	O
causing	O
mutations	O
in	O
families	O
with	O
autosomal	O
dominant	O
retinitis	O
pigmentosa	O
:	O
a	O
screen	O
of	O
known	O
genes	O
in	O
200	O
families	O
.	O

PURPOSE	O
:	O
To	O
survey	O
families	O
with	O
clinical	O
evidence	O
of	O
autosomal	B-Disease
dominant	I-Disease
retinitis	I-Disease
pigmentosa	I-Disease
(	O
adRP	O
)	O
for	O
mutations	O
in	O
genes	O
known	O
to	O
cause	O
adRP	O
.	O

METHODS	O
:	O
Two	O
hundred	O
adRP	O
families	O
,	O
drawn	O
from	O
a	O
cohort	O
of	O
more	O
than	O
400	O
potential	O
families	O
,	O
were	O
selected	O
by	O
analysis	O
of	O
pedigrees	O
.	O

Minimum	O
criteria	O
for	O
inclusion	O
in	O
the	O
adRP	O
cohort	O
included	O
either	O
evidence	O
of	O
at	O
least	O
three	O
generations	O
of	O
affected	O
individuals	O
or	O
two	O
generations	O
with	O
evidence	O
of	O
male	O
-	O
to	O
-	O
male	O
transmission	O
.	O

Probands	O
from	O
each	O
family	O
were	O
screened	O
for	O
mutations	B-Var
in	O
13	O
genes	O
known	O
to	O
cause	B-Reg
adRP	B-Disease
:	I-Disease
CA4	B-Gene
,	O
CRX	B-Gene
,	O
FSCN2	B-Gene
,	O
IMPDH1	B-Gene
,	O
NRL	B-Gene
,	O
PRPF3	B-Gene
(	O
RP18	O
)	O
,	O
PRPF8	B-Gene
(	O
RP13	O
)	O
,	O
PRPF31	B-Gene
(	O
RP11	O
)	O
,	O
RDS	B-Gene
,	O
RHO	B-Gene
,	O
ROM1	B-Gene
,	O
RP1	B-Gene
,	O
and	O
RP9	B-Gene
.	O

Families	O
without	O
mutations	O
in	O
autosomal	O
genes	O
and	O
in	O
which	O
an	O
X	O
-	O
linked	O
mode	O
of	O
inheritance	O
could	O
not	O
be	O
excluded	O
were	O
tested	O
for	O
mutations	O
in	O
ORF	O
15	O
of	O
X	O
-	O
linked	O
RPGR	O
.	O

Potentially	O
pathogenic	O
variants	O
were	O
evaluated	O
based	O
on	O
a	O
variety	O
of	O
genetic	O
and	O
computational	O
criteria	O
,	O
to	O
confirm	O
or	O
exclude	O
pathogenicity	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
82	O
distinct	O
,	O
rare	O
(	O
nonpolymorphic	O
)	O
variants	O
were	O
detected	O
among	O
the	O
genes	O
tested	O
.	O

Of	O
these	O
,	O
57	O
are	O
clearly	O
pathogenic	O
based	O
on	O
multiple	O
criteria	O
,	O
10	O
are	O
probably	O
pathogenic	O
,	O
and	O
15	O
are	O
probably	O
benign	O
.	O

In	O
the	O
cohort	O
of	O
200	O
families	O
,	O
94	O
(	O
47	O
%	O
)	O
have	O
one	O
of	O
the	O
clearly	O
pathogenic	O
variants	O
and	O
10	O
(	O
5	O
%	O
)	O
have	O
one	O
of	O
the	O
probably	O
pathogenic	O
variants	O
.	O

One	O
family	O
(	O
0.5	O
%	O
)	O
has	O
digenic	O
RDS	O
-	O
ROM1	O
mutations	O
.	O

Two	O
families	O
(	O
1	O
%	O
)	O
have	O
a	O
pathogenic	O
RPGR	O
mutation	O
,	O
indicating	O
that	O
families	O
with	O
apparent	O
autosomal	O
transmission	O
of	O
RP	O
may	O
actually	O
have	O
X	O
-	O
linked	O
genetic	O
disease	O
.	O

Thus	O
,	O
107	O
families	O
(	O
53.5	O
%	O
)	O
have	O
mutations	O
in	O
known	O
genes	O
,	O
leaving	O
93	O
whose	O
underlying	O
cause	O
is	O
still	O
unknown	O
.	O

CONCLUSIONS	O
:	O
Together	O
,	O
the	O
known	O
adRP	O
genes	O
account	O
for	O
retinal	O
disease	O
in	O
approximately	O
half	O
of	O
the	O
families	O
in	O
this	O
survey	O
,	O
mostly	O
Americans	O
of	O
European	O
origin	O
.	O

Among	O
the	O
adRP	O
genes	O
,	O
IMPDH1	O
,	O
PRPF8	O
,	O
PRPF31	O
,	O
RDS	O
,	O
RHO	O
,	O
and	O
RP1	O
each	O
accounts	O
for	O
more	O
than	O
2	O
%	O
of	O
the	O
total	O
;	O
CRX	O
,	O
PRPF3	O
,	O
and	O
RPGR	O
each	O
accounts	O
for	O
roughly	O
1	O
%	O
.	O

Disease	O
-	O
causing	O
mutations	O
were	O
not	O
found	O
in	O
CA4	O
,	O
FSCN2	O
,	O
NRL	O
,	O
or	O
RP9	O
.	O

Because	O
some	O
mutations	O
are	O
frequent	O
and	O
some	O
regions	O
are	O
more	O
likely	O
to	O
harbor	O
mutations	O
than	O
others	O
,	O
more	O
than	O
two	O
thirds	O
of	O
the	O
detected	O
mutations	O
can	O
be	O
found	O
by	O
screening	O
less	O
than	O
10	O
%	O
of	O
the	O
total	O
gene	O
sequences	O
.	O

Among	O
the	O
remaining	O
families	O
,	O
mutations	O
may	O
lie	O
in	O
regions	O
of	O
known	O
genes	O
that	O
were	O
not	O
tested	O
,	O
mutations	O
may	O
not	O
be	O
detectable	O
by	O
PCR	O
-	O
based	O
sequencing	O
,	O
or	O
other	O
loci	O
may	O
be	O
involved	O
.	O

Clinical	O
and	O
genetic	O
analysis	O
of	O
Korean	O
patients	O
with	O
Miyoshi	O
myopathy	O
:	O
identification	O
of	O
three	O
novel	O
mutations	O
in	O
the	O
DYSF	O
gene	O
.	O

Miyoshi	B-Disease
myopathy	I-Disease
(	O
MM	O
)	O
is	O
an	O
autosomal	O
recessive	O
distal	O
muscular	O
dystrophy	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
dysferlin	O
gene	O
(	B-Gene
DYSF	I-Gene
)	I-Gene
on	O
chromosome	O
2p13	O
.	O

Although	O
MM	O
patients	O
and	O
their	O
mutations	O
in	O
the	O
DYSF	O
gene	O
have	O
been	O
found	O
from	O
all	O
over	O
the	O
world	O
,	O
there	O
is	O
only	O
one	O
report	O
of	O
genetically	O
confirmed	O
case	O
of	O
MM	O
in	O
Korea	O
.	O

Recently	O
,	O
we	O
encountered	O
three	O
unrelated	O
Korean	O
patients	O
with	O
MM	O
and	O
two	O
of	O
them	O
have	O
previously	O
been	O
considered	O
as	O
having	O
a	O
type	O
of	O
inflammatory	O
myopathy	O
.	O

The	O
clinical	O
and	O
laboratory	O
evaluation	O
showed	O
typical	O
features	O
of	O
muscle	O
involvement	O
in	O
MM	O
in	O
all	O
patients	O
but	O
one	O
patient	O
initially	O
had	O
moderate	O
proximal	O
muscle	O
involvement	O
and	O
another	O
showed	O
incomplete	O
quadriparesis	O
with	O
rapid	O
progression	O
.	O

Direct	O
sequencing	O
analysis	O
of	O
the	O
DYSF	O
gene	O
revealed	O
that	O
each	O
patient	O
had	O
compound	O
heterozygous	O
mutations	O
(	O
Gln832X	O
and	O
Trp992Arg	O
,	O
Gln832X	O
and	O
Trp999Cys	O
,	O
and	O
Lys1103X	O
and	O
Ile1401HisfsX8	O
,	O
respectively	O
)	O
among	O
which	O
three	O
were	O
novel	O
.	O

Although	O
MM	O
has	O
been	O
thought	O
to	O
be	O
quite	O
rare	O
in	O
Korea	O
,	O
it	O
should	O
be	O
considered	O
in	O
a	O
differential	O
diagnosis	O
of	O
patients	O
exhibiting	O
distal	O
myopathy	O
.	O

UBE2A	B-Gene
,	O
which	O
encodes	O
a	O
ubiquitin	O
-	O
conjugating	O
enzyme	O
,	O
is	O
mutated	B-Var
in	B-Reg
a	O
novel	O
X	B-Disease
-	I-Disease
linked	I-Disease
mental	I-Disease
retardation	I-Disease
syndrome	I-Disease
.	O

We	O
report	O
a	O
mutation	B-Var
of	O
UBE2A	B-Gene
/	I-Gene
HR6A	I-Gene
,	O
which	O
encodes	O
a	O
ubiquitin	O
-	O
conjugating	O
enzyme	O
(	O
E2	O
)	O
,	O
a	O
member	O
of	O
the	O
ubiquitin	O
proteasome	O
pathway	O
,	O
as	O
the	O
cause	B-Reg
of	O
a	O
novel	O
X	B-Disease
-	I-Disease
linked	I-Disease
mental	I-Disease
retardation	I-Disease
(	I-Disease
XLMR	I-Disease
)	I-Disease
syndrome	I-Disease
that	O
affects	O
three	O
males	O
in	O
a	O
two	O
-	O
generation	O
family	O
.	O

A	O
single	O
-	O
nucleotide	O
substitution	O
,	O
c.382C-->T	B-Var
in	O
UBE2A	B-Gene
,	O
led	B-Reg
to	I-Reg
a	O
premature	O
UAG	O
stop	O
codon	O
(	B-Var
Q128X	I-Var
)	I-Var
.	O

As	O
a	O
consequence	O
,	O
the	O
predicted	O
polypeptide	O
lacks	O
the	O
25	O
C	O
-	O
terminal	O
amino	O
acid	O
residues	O
.	O

The	O
importance	O
of	O
this	O
terminal	O
sequence	O
for	O
UBE2	O
function	O
is	O
inferred	O
by	O
its	O
conservation	O
in	O
vertebrates	O
and	O
in	O
Drosophila	O
.	O

UBE2A	O
mutations	O
do	O
not	O
appear	O
to	O
significantly	O
contribute	O
to	O
XLMR	O
,	O
since	O
no	O
UBE2A	O
mutations	O
were	O
identified	O
in	O
15	O
families	O
with	O
nonsyndromic	O
and	O
4	O
families	O
with	O
syndromic	O
idiopathic	O
XLMR	O
previously	O
mapped	O
to	O
intervals	O
encompassing	O
this	O
gene	O
.	O

This	O
is	O
the	O
first	O
description	O
of	O
a	O
mutation	O
in	O
a	O
ubiquitin	O
-	O
conjugating	O
enzyme	O
gene	O
as	O
the	O
cause	O
of	O
a	O
human	O
disease	O
.	O

Twenty	O
-	O
one	O
novel	O
mutations	B-Var
in	O
the	O
GLB1	B-Gene
gene	O
identified	O
in	B-Reg
a	O
large	O
group	O
of	O
GM1-gangliosidosis	B-Disease
and	O
Morquio	B-Disease
B	I-Disease
patients	O
:	O
possible	O
common	O
origin	O
for	O
the	O
prevalent	O
p	O
.	O
R59H	O
mutation	O
among	O
gypsies	O
.	O

GM1-gangliosidosis	B-Disease
and	O
Morquio	B-Disease
B	I-Disease
disease	O
are	O
rare	O
lysosomal	O
storage	O
disorders	O
caused	B-Reg
by	I-Reg
beta	B-MPA
-	I-MPA
galactosidase	I-MPA
deficiency	B-NegReg
due	O
to	O
mutations	B-Var
in	O
the	O
GLB1	B-Gene
gene	O
.	O

Three	O
major	O
clinical	O
forms	O
of	O
GM1-gangliosidosis	O
have	O
been	O
established	O
on	O
the	O
basis	O
of	O
age	O
of	O
onset	O
and	O
severity	O
of	O
symptoms	O
:	O
infantile	O
,	O
late	O
infantile	O
/	O
juvenile	O
,	O
and	O
adult	O
.	O

We	O
performed	O
mutation	O
analysis	O
on	O
30	O
GM1-gangliosidosis	O
and	O
five	O
Morquio	O
B	O
patients	O
,	O
mainly	O
of	O
Spanish	O
origin	O
,	O
and	O
all	O
the	O
causative	O
mutations	O
were	O
identified	O
.	O

Thirty	O
different	O
mutations	O
were	O
found	O
,	O
21	O
of	O
which	O
were	O
novel	O
.	O

With	O
the	O
exception	O
of	O
two	O
adults	O
and	O
one	O
juvenile	O
patient	O
,	O
all	O
the	O
GM1-gangliosidosis	O
patients	O
were	O
affected	O
by	O
the	O
infantile	O
form	O
.	O

Clinical	O
findings	O
are	O
presented	O
for	O
all	O
patients	O
.	O

We	O
report	O
the	O
association	O
of	O
the	O
novel	O
mutations	O
p	O
.	O
T420	O
K	O
and	O
p	O
.	O
L264S	O
with	O
the	O
adult	O
form	O
and	O
the	O
juvenile	O
form	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
the	O
novel	O
mutation	O
p	B-Var
.	I-Var
Y83C	I-Var
was	O
associated	B-Reg
with	I-Reg
Morquio	B-Disease
B	I-Disease
disease	O
.	O

Among	O
the	O
30	O
GM1-gangliosidosis	O
patients	O
,	O
6	O
were	O
of	O
Gypsy	O
origin	O
(	O
Roma	O
)	O
.	O

Moreover	O
,	O
those	O
six	O
Gypsy	O
patients	O
shared	O
not	O
only	O
the	O
same	O
mutation	O
(	O
p	O
.	O
R59H	O
)	O
but	O
also	O
a	O
common	O
haplotype	O
.	O

This	O
observation	O
indicates	O
a	O
possible	O
founder	O
effect	O
in	O
this	O
group	O
and	O
suggests	O
that	O
screening	O
of	O
the	O
p	O
.	O
R59H	O
mutation	O
may	O
be	O
appropriate	O
in	O
GM1-gangliosidosis	O
patients	O
of	O
Gypsy	O
origin	O
.	O

This	O
is	O
the	O
first	O
exhaustive	O
mutational	O
analysis	O
performed	O
in	O
a	O
large	O
group	O
of	O
Iberian	O
GM1-gangliosidosis	O
and	O
Morquio	O
B	O
patients	O
.	O

Misregulation	O
of	O
alternative	O
splicing	O
causes	O
pathogenesis	O
in	O
myotonic	O
dystrophy	O
.	O

Myotonic	B-Disease
dystrophy	I-Disease
(	O
DM	O
)	O
,	O
the	O
most	O
common	O
form	O
of	O
adult	O
onset	O
muscular	O
dystrophy	O
,	O
affects	O
skeletal	O
muscle	O
,	O
heart	O
,	O
and	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

Mortality	O
results	O
primarily	O
from	O
muscle	O
wasting	O
and	O
cardiac	O
arrhythmias	O
.	O

There	O
are	O
two	O
forms	O
of	O
the	O
disease	O
:	O
DM1	O
and	O
DM2	O
.	O

DM1	O
,	O
which	O
constitutes	O
98	O
%	O
of	O
cases	O
,	O
is	O
caused	O
by	O
a	O
CTG	O
expansion	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
(	O
UTR	O
)	O
of	O
the	O
DMPK	O
gene	O
.	O

DM2	B-Disease
is	O
caused	B-Reg
by	I-Reg
a	O
CCTG	B-Var
expansion	I-Var
in	O
the	O
first	O
intron	O
of	O
the	O
ZNF9	B-Gene
gene	O
.	O

RNA	O
containing	O
CUG-	O
or	O
CCUG	O
-	O
expanded	O
repeats	O
are	O
transcribed	O
but	O
are	O
retained	O
in	O
the	O
nucleus	O
in	O
foci	O
.	O

Disease	O
pathogenesis	O
results	O
primarily	O
from	O
a	O
gain	B-PosReg
of	I-PosReg
function	I-PosReg
of	O
the	O
expanded	B-MPA
RNAs	I-MPA
,	O
which	O
alter	B-Reg
developmentally	B-MPA
regulated	I-MPA
alternative	I-MPA
splicing	I-MPA
as	O
well	O
as	O
pathways	B-Pathway
of	I-Pathway
muscle	I-Pathway
differentiation	I-Pathway
.	O

The	O
toxic	O
RNA	O
has	O
been	O
implicated	O
in	O
sequestration	O
of	O
splicing	O
regulators	O
and	O
transcription	O
factors	O
thereby	O
causing	O
specific	O
symptoms	O
of	O
the	O
disease	O
.	O

Here	O
we	O
review	O
the	O
proposed	O
mechanisms	O
for	O
the	O
toxic	O
effects	O
of	O
the	O
expanded	O
repeats	O
and	O
discuss	O
the	O
molecular	O
mechanisms	O
of	O
splicing	O
misregulation	O
and	O
disease	O
pathogenesis	O
.	O

Clinical	O
aspects	O
and	O
physiopathology	O
of	O
Brugada	O
syndrome	O
:	O
review	O
of	O
current	O
concepts	O
.	O

Brugada	B-Disease
syndrome	I-Disease
(	O
BS	O
)	O
is	O
an	O
inherited	O
cardiac	O
disorder	O
characterized	O
by	O
typical	O
electrocardiographic	O
patterns	O
of	O
ST	O
segment	O
elevation	O
in	O
the	O
precordial	O
leads	O
,	O
right	O
bundle	O
branch	O
block	O
,	O
fast	O
polymorphic	O
ventricular	O
tachycardia	O
in	O
patients	O
without	O
any	O
structural	O
heart	O
disease	O
,	O
and	O
a	O
high	O
risk	O
of	O
sudden	O
cardiac	O
death	O
.	O

The	O
incidence	O
of	O
BS	O
is	O
high	O
in	O
male	O
vs.	O
female	O
(	O
i.e.	O
,	O
8	O
-	O
10/1	O
:	O
male	O
/	O
female	O
)	O
.	O

The	O
disorder	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
SCN5A	O
gene	O
encoding	O
Nav1.5	O
,	O
the	O
cardiac	O
sodium	O
channel	O
,	O
which	O
is	O
the	O
only	O
gene	O
in	O
which	O
mutations	O
were	O
found	O
to	O
cause	O
the	O
disease	O
.	O

Mutations	B-Var
in	O
SCN5A	B-Gene
associated	O
with	O
the	O
BS	B-Disease
phenotype	O
usually	O
result	O
in	O
a	O
loss	B-NegReg
of	O
channel	B-CPA
function	I-CPA
by	O
a	O
reduction	B-NegReg
in	O
Na+	B-CPA
currents	I-CPA
.	O

We	O
review	O
the	O
clinical	O
aspects	O
,	O
risk	O
stratification	O
,	O
and	O
therapeutic	O
management	O
of	O
this	O
important	O
syndrome	O
.	O

[	O
McLeod	O
syndrome	O
:	O
Multisystem	O
involvement	O
associated	O
with	O
neuroacanthocytosis	O
linked	O
to	O
X	O
chromosome	O
.	O

report	O
of	O
two	O
related	O
cases	O
]	O
.	O

Síndrome	O
de	O
McLeod	O
:	O
compromiso	O
multisistémico	O
asociado	O
a	O
neuroacantocitosis	O
ligada	O
al	O
cromosoma	O
X	O
,	O
en	O
una	O
familia	O
chilena	O
.	O

Neurological	O
abnormalities	O
associated	O
with	O
spiculated	O
,	O
"	O
acanthocytic	O
"	O
red	O
cells	O
in	O
blood	O
have	O
been	O
described	O
as	O
neuroacanthocytosis	O
.	O

This	O
is	O
a	O
heterogeneous	O
group	O
of	O
conditions	O
that	O
can	O
be	O
clearly	O
subdivided	O
on	O
the	O
basis	O
of	O
recent	O
genetic	O
findings	O
.	O

The	O
McLeod	B-Disease
Syndrome	I-Disease
,	O
one	O
of	O
the	O
core	O
neuroacanthocytosis	B-Disease
syndromes	I-Disease
,	O
is	O
a	O
rare	O
X	O
-	O
linked	O
disorder	O
caused	B-Reg
by	I-Reg
mutations	B-Var
of	O
the	O
XK	B-Gene
gene	O
,	O
an	O
X	O
-	O
chromosomal	O
gene	O
of	O
unknown	O
function	O
characterized	O
by	O
haemopoietic	O
abnormalities	O
and	O
late	O
-	O
onset	O
neurological	O
and	O
muscular	O
defects	O
.	O

We	O
report	O
two	O
Chilean	O
brothers	O
with	O
the	O
McLeod	O
phenotype	O
who	O
showed	O
important	O
psychiatric	O
features	O
.	O

The	O
diagnosis	O
may	O
be	O
elusive	O
if	O
the	O
presence	O
of	O
acanthocytosis	O
is	O
not	O
properly	O
studied	O
.	O

We	O
describe	O
a	O
method	O
which	O
allowed	O
the	O
diagnosis	O
that	O
unmasked	O
acanthocytosis	O
.	O

Otherwise	O
the	O
condition	O
could	O
have	O
remained	O
undiagnosed	O
as	O
it	O
had	O
been	O
for	O
decades	O
in	O
this	O
family	O
.	O

This	O
syndrome	O
must	O
be	O
considered	O
when	O
assessing	O
a	O
familial	O
movement	O
disorder	O
,	O
specially	O
affecting	O
males	O
with	O
relevant	O
psychiatric	O
features	O
.	O

A	O
reliable	O
test	O
for	O
acanthocytosis	O
assessment	O
is	O
available	O
.	O

A	O
new	O
variant	O
database	O
for	O
mismatch	O
repair	O
genes	O
associated	O
with	O
Lynch	O
syndrome	O
.	O

Mutations	B-Var
in	O
some	O
mismatch	O
repair	O
(	B-Gene
MMR	I-Gene
)	I-Gene
genes	O
are	O
associated	B-Reg
with	I-Reg
Lynch	B-Disease
syndrome	I-Disease
(	O
LS	O
;	O
also	O
called	O
hereditary	O
nonpolyposis	O
colorectal	O
cancer	O
[	O
HNPCC	O
]	O
)	O
,	O
an	O
autosomal	O
dominant	O
cancer	O
susceptibility	O
syndrome	O
.	O

Colorectal	O
cancer	O
(	O
CRC	O
)	O
is	O
the	O
most	O
frequent	O
cancer	O
observed	O
in	O
LS	O
.	O

However	O
,	O
tumors	O
occur	O
at	O
a	O
variety	O
of	O
extracolonic	O
sites	O
and	O
individuals	O
may	O
have	O
multiple	O
primary	O
cancers	O
.	O

LS	O
is	O
the	O
most	O
common	O
hereditary	O
form	O
of	O
CRC	O
,	O
accounting	O
for	O
approximately	O
1	O
%	O
of	O
all	O
CRC	O
.	O

Since	O
the	O
first	O
account	O
of	O
mutations	B-Var
in	O
MSH2	B-Gene
causing	B-Reg
this	O
cancer	B-Disease
susceptibility	O
syndrome	O
in	O
1993	O
,	O
mutations	B-Var
in	O
three	O
additional	O
MMR	O
genes	O
,	O
MLH1	B-Gene
,	O
MSH6	B-Gene
,	O
and	O
PMS2	B-Gene
,	O
have	O
been	O
shown	O
to	O
cause	B-Reg
LS	B-Disease
.	O

More	O
than	O
1,500	O
different	O
variants	O
have	O
been	O
identified	O
in	O
these	O
four	O
genes	O
and	O
approximately	O
80	O
%	O
of	O
the	O
alterations	O
have	O
been	O
identified	O
in	O
MLH1	O
and	O
MSH2	O
.	O

There	O
have	O
been	O
a	O
few	O
previous	O
attempts	O
to	O
systematically	O
record	O
MMR	O
variants	O
associated	O
with	O
LS	O
patients	O
;	O
however	O
,	O
they	O
were	O
not	O
complete	O
nor	O
were	O
they	O
continuously	O
updated	O
.	O

Thus	O
,	O
it	O
was	O
our	O
goal	O
to	O
generate	O
and	O
maintain	O
a	O
comprehensive	O
catalogue	O
of	O
MMR	O
variants	O
from	O
genes	O
known	O
to	O
be	O
mutated	O
in	O
LS	O
(	O
http://www.med.mun.ca/MMRvariants	O
;	O
last	O
accessed	O
8	O
February	O
2007	O
)	O
.	O

Providing	O
such	O
a	O
resource	O
should	O
aid	O
investigators	O
in	O
understanding	O
the	O
significance	O
of	O
the	O
variants	O
.	O

Complete	O
androgen	O
insensitivity	O
without	O
Wolffian	O
duct	O
development	O
:	O
the	O
AR	O
-	O
A	O
form	O
of	O
the	O
androgen	O
receptor	O
is	O
not	O
sufficient	O
for	O
male	O
genital	O
development	O
.	O

BACKGROUND	O
:	O
The	O
androgen	O
receptor	O
(	O
AR	O
)	O
is	O
essential	O
for	O
the	O
differentiation	O
of	O
male	O
external	O
and	O
internal	O
genitalia	O
.	O

It	O
is	O
normally	O
present	O
in	O
two	O
forms	O
,	O
a	O
full	O
-	O
length	O
form	O
B	O
and	O
an	O
N	O
-	O
terminal	O
truncated	O
form	O
A	O
with	O
still	O
unknown	O
function	O
.	O

Mutations	B-Var
in	O
the	O
AR	B-Gene
gene	O
cause	B-Reg
androgen	B-Disease
insensitivity	I-Disease
syndrome	I-Disease
(	O
AIS	O
)	O
,	O
which	O
is	O
divided	O
into	O
subgroups	O
according	O
to	O
the	O
degree	O
of	O
undermasculinization	O
.	O

Patients	O
with	O
completely	O
female	O
external	O
genitalia	O
are	O
classified	O
as	O
complete	O
AIS	O
(	O
CAIS	O
)	O
.	O

However	O
,	O
a	O
recent	O
study	O
has	O
shown	O
that	O
some	O
CAIS	O
patients	O
have	O
signs	O
of	O
internal	O
male	O
genital	O
differentiation	O
due	O
to	O
missense	O
mutations	O
that	O
show	O
some	O
degree	O
of	O
residual	O
function	O
.	O

OBJECTIVE	O
:	O
We	O
aimed	O
to	O
study	O
the	O
expression	O
of	O
the	O
different	O
forms	O
of	O
the	O
AR	O
in	O
two	O
CAIS	O
patients	O
in	O
relation	O
to	O
the	O
development	O
of	O
male	O
internal	O
genital	O
structures	O
.	O

One	O
patient	O
had	O
a	O
mutation	O
(	O
L7fsX33	O
)	O
that	O
affects	O
only	O
the	O
full	O
-	O
length	O
AR	O
-	O
B	O
form	O
of	O
the	O
AR	O
,	O
whereas	O
the	O
other	O
had	O
a	O
nonsense	O
mutation	O
(	O
Q733X	O
)	O
affecting	O
both	O
isoforms	O
.	O

MEASUREMENTS	O
AND	O
RESULTS	O
:	O
We	O
thoroughly	O
analysed	O
internal	O
genitalia	O
at	O
surgery	O
and	O
by	O
histological	O
examination	O
.	O

No	O
signs	O
of	O
Wolffian	O
duct	O
(	O
WD	O
)	O
development	O
were	O
present	O
in	O
any	O
of	O
the	O
patients	O
.	O

Western	O
blotting	O
of	O
proteins	O
from	O
gonadal	O
and	O
genital	O
skin	O
fibroblasts	O
was	O
performed	O
with	O
AR	O
antibodies	O
directed	O
against	O
different	O
AR	O
epitopes	O
.	O

The	O
N	O
-	O
terminally	O
truncated	O
A	O
form	O
was	O
expressed	O
in	O
normal	O
amounts	O
in	O
the	O
patient	O
with	O
the	O
L7fsX33	O
mutation	O
while	O
no	O
AR	O
was	O
detected	O
in	O
the	O
other	O
patient	O
.	O

CONCLUSION	O
:	O
The	O
presence	O
of	O
the	O
AR	O
-	O
A	O
form	O
does	O
not	O
seem	O
to	O
be	O
sufficient	O
for	O
WD	O
maintenance	O
and	O
differentiation	O
.	O

Comprehensive	O
analysis	O
of	O
the	O
gene	O
encoding	O
filaggrin	O
uncovers	O
prevalent	O
and	O
rare	O
mutations	O
in	O
ichthyosis	O
vulgaris	O
and	O
atopic	O
eczema	O
.	O

We	O
recently	O
reported	O
two	O
common	O
filaggrin	O
(	B-Gene
FLG	I-Gene
)	I-Gene
null	O
mutations	B-Var
that	O
cause	B-Reg
ichthyosis	B-Disease
vulgaris	I-Disease
and	O
predispose	B-Disease
to	I-Disease
eczema	I-Disease
and	O
secondary	B-Disease
allergic	I-Disease
diseases	I-Disease
.	O

We	O
show	O
here	O
that	O
these	O
common	O
European	O
mutations	O
are	O
ancestral	O
variants	O
carried	O
on	O
conserved	O
haplotypes	O
.	O

To	O
facilitate	O
comprehensive	O
analysis	O
of	O
other	O
populations	O
,	O
we	O
report	O
a	O
strategy	O
for	O
full	O
sequencing	O
of	O
this	O
large	O
,	O
highly	O
repetitive	O
gene	O
,	O
and	O
we	O
describe	O
15	O
variants	O
,	O
including	O
seven	O
that	O
are	O
prevalent	O
.	O

All	O
the	O
variants	B-Var
are	O
either	O
nonsense	O
or	O
frameshift	O
mutations	O
that	O
,	O
in	O
representative	O
cases	O
,	O
resulted	O
in	O
loss	B-NegReg
of	O
filaggrin	B-MPA
production	I-MPA
in	O
the	O
epidermis	O
.	O

In	O
an	O
Irish	O
case	O
-	O
control	O
study	O
,	O
the	O
five	O
most	O
common	O
European	O
mutations	O
showed	O
a	O
strong	O
association	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
childhood	O
eczema	O
(	O
chi2	O
test	O
:	O
P	O
=	O
2.12	O
x	O
10(-51	O
)	O
;	O
Fisher	O
's	O
exact	O
test	O
:	O
heterozygote	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
7.44	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
c.i	O
.	O

)	O
=	O
4.9	O
-	O
11.3	O
)	O
,	O
and	O
homozygote	O
OR	O
=	O
151	O
(	O
95	O
%	O
c.i	O
.	O

=	O
20	O
-	O
1,136	O
)	O
)	O
.	O

We	O
found	O
three	O
additional	O
rare	O
null	O
mutations	O
in	O
this	O
case	O
series	O
,	O
suggesting	O
that	O
the	O
genetic	O
architecture	O
of	O
filaggrin	O
-	O
related	O
atopic	O
dermatitis	O
consists	O
of	O
both	O
prevalent	O
and	O
rare	O
risk	O
alleles	O
.	O

Genetic	O
modifiers	O
of	O
the	O
Drosophila	O
blue	O
cheese	O
gene	O
link	O
defects	O
in	O
lysosomal	O
transport	O
with	O
decreased	O
life	O
span	O
and	O
altered	O
ubiquitinated	O
-	O
protein	O
profiles	O
.	O

Defects	O
in	O
lysosomal	O
trafficking	O
pathways	O
lead	O
to	O
decreased	O
cell	O
viability	O
and	O
are	O
associated	O
with	O
progressive	O
disorders	O
in	O
humans	O
.	O

Previously	O
we	O
have	O
found	O
that	O
loss	O
-	O
of	O
-	O
function	O
(	O
LOF	O
)	O
mutations	B-Var
in	O
the	O
Drosophila	O
gene	O
blue	O
cheese	O
(	B-Gene
bchs	I-Gene
)	I-Gene
lead	O
to	O
reduced	B-NegReg
adult	B-CPA
life	I-CPA
span	I-CPA
,	O
increased	B-PosReg
neuronal	B-CPA
death	I-CPA
,	O
and	O
widespread	B-CPA
CNS	I-CPA
degeneration	B-NegReg
that	O
is	O
associated	O
with	O
the	O
formation	O
of	O
ubiquitinated	O
-	O
protein	O
aggregates	O
.	O

To	O
identify	O
potential	O
genes	O
that	O
participate	O
in	O
the	O
bchs	O
functional	O
pathway	O
,	O
we	O
conducted	O
a	O
genetic	O
modifier	O
screen	O
based	O
on	O
alterations	O
of	O
an	O
eye	O
phenotype	O
that	O
arises	O
from	O
high	O
-	O
level	O
overexpression	O
of	O
Bchs	O
.	O

We	O
found	O
that	O
mutations	O
in	O
select	O
autophagic	O
and	O
endocytic	O
trafficking	O
genes	O
,	O
defects	O
in	O
cytoskeletal	O
and	O
motor	O
proteins	O
,	O
as	O
well	O
as	O
mutations	O
in	O
the	O
SUMO	O
and	O
ubiquitin	O
signaling	O
pathways	O
behave	O
as	O
modifiers	O
of	O
the	O
Bchs	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
eye	O
phenotype	O
.	O

Individual	O
mutant	O
alleles	O
that	O
produced	O
viable	O
adults	O
were	O
further	O
examined	O
for	O
bchs	O
-	O
like	O
phenotypes	O
.	O

Mutations	B-Var
in	O
several	O
lysosomal	B-Gene
trafficking	I-Gene
genes	I-Gene
resulted	O
in	O
significantly	O
decreased	B-NegReg
adult	B-CPA
life	I-CPA
spans	I-CPA
and	O
several	O
mutants	O
showed	O
changes	B-Reg
in	O
ubiquitinated	B-MPA
protein	I-MPA
profiles	I-MPA
as	O
young	O
adults	O
.	O

This	O
work	O
represents	O
a	O
novel	O
approach	O
to	O
examine	O
the	O
role	O
that	O
lysosomal	O
transport	O
and	O
function	O
have	O
on	O
adult	O
viability	O
.	O

The	O
genes	O
characterized	O
in	O
this	O
study	O
have	O
direct	O
human	O
homologs	O
,	O
suggesting	O
that	O
similar	O
defects	O
in	O
lysosomal	O
transport	O
may	O
play	O
a	O
role	O
in	O
human	O
health	O
and	O
age	O
-	O
related	O
processes	O
.	O

Increased	O
chromosome	O
instability	O
and	O
accumulation	O
of	O
DNA	O
double	O
-	O
strand	O
breaks	O
in	O
Werner	O
syndrome	O
cells	O
.	O

Werner	B-Disease
syndrome	I-Disease
(	O
WS	O
)	O
is	O
a	O
premature	O
aging	O
syndrome	O
caused	B-Reg
by	I-Reg
mutations	B-Var
of	O
the	O
WRN	B-Gene
gene	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
a	O
strain	O
of	O
WS	O
fibroblast	O
cells	O
shows	O
abnormal	O
karyotypes	O
characterized	O
by	O
several	O
complex	O
translocations	O
and	O
50-fold	O
more	O
frequency	O
of	O
abnormal	O
metaphases	O
including	O
dicentric	O
chromosomes	O
without	O
fragments	O
than	O
normal	O
cells	O
when	O
examined	O
at	O
a	O
similar	O
culture	O
stage	O
.	O

Further	O
,	O
telomere	O
fluorescence	O
in	O
situ	O
hybridization	O
indicates	O
that	O
the	O
abnormal	O
signals	O
,	O
extra	O
telomere	O
signal	O
and	O
loss	O
of	O
telomere	O
signal	O
,	O
emerge	O
two-	O
to	O
three	O
-	O
fold	O
more	O
frequently	O
in	O
WS	O
cells	O
than	O
in	O
normal	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
chromosome	O
instability	O
including	O
dysfunction	O
of	O
telomere	O
maintenance	O
is	O
more	O
prominent	O
in	O
WS	O
cells	O
than	O
in	O
normal	O
cells	O
.	O

In	O
addition	O
,	O
the	O
accumulation	O
of	O
DNA	O
double	O
-	O
strand	O
breaks	O
(	O
DSBs	O
)	O
at	O
the	O
G(1	O
)	O
phase	O
,	O
including	O
those	O
at	O
telomeres	O
,	O
detected	O
by	O
phosphorylated	O
ATM	O
(	O
ataxia	O
telangiectasia	O
mutated	O
)	O
foci	O
is	O
accelerated	O
in	O
WS	O
cells	O
even	O
at	O
a	O
low	O
senescence	O
level	O
.	O

The	O
increased	O
accumulation	O
of	O
DSBs	O
in	O
WS	O
cells	O
is	O
reduced	O
in	O
the	O
presence	O
of	O
anti	O
-	O
oxidative	O
agents	O
,	O
suggesting	O
that	O
enhanced	O
oxidative	O
stress	O
in	O
WS	O
cells	O
is	O
involved	O
in	O
accelerated	O
accumulation	O
of	O
DSBs	O
.	O

These	O
results	O
indicate	O
that	O
WS	O
cells	O
are	O
prone	O
to	O
accumulate	B-PosReg
DSBs	B-MPA
spontaneously	O
due	O
to	O
a	O
defect	B-Var
of	O
WRN	B-Gene
,	O
which	O
leads	O
to	O
increased	B-PosReg
chromosome	B-MPA
instability	I-MPA
that	O
could	O
activate	B-PosReg
checkpoints	B-MPA
,	O
resulting	O
in	O
accelerated	B-PosReg
senescence	B-CPA
.	O

A	O
novel	O
mutation	B-Var
in	O
TRIM37	B-Gene
is	O
associated	B-Reg
with	I-Reg
mulibrey	B-Disease
nanism	I-Disease
in	O
a	O
Turkish	O
boy	O
.	O

Mulibrey	O
nanism	O
is	O
a	O
rare	O
autosomal	O
-	O
recessive	O
disorder	O
characterized	O
by	O
prenatal	O
onset	O
severe	O
growth	O
retardation	O
and	O
pericardial	O
constriction	O
associated	O
with	O
abnormalities	O
of	O
muscle	O
,	O
liver	O
,	O
brain	O
and	O
eye	O
.	O

More	O
than	O
80	O
%	O
of	O
previously	O
reported	O
patients	O
are	O
of	O
Finnish	O
origin	O
in	O
whom	O
a	O
founder	O
mutation	O
in	O
the	O
TRIM37	O
gene	O
have	O
been	O
described	O
.	O

We	O
report	O
on	O
a	O
7-year	O
-	O
old	O
Turkish	O
boy	O
who	O
presented	O
with	O
classical	O
phenotypic	O
features	O
of	O
mulibrey	O
nanism	O
.	O

Mutation	O
screening	O
of	O
the	O
TRIM37	O
gene	O
revealed	O
that	O
the	O
proband	O
had	O
a	O
homozygous	O
two	O
base	O
pair	O
deletion	O
,	O
c.1894_1895delGA	B-Var
,	O
resulting	B-Reg
in	I-Reg
a	O
frame	B-Var
-	I-Var
shift	I-Var
and	O
a	O
premature	B-MPA
termination	I-MPA
codon	O
.	O

Our	O
proband	O
is	O
one	O
of	O
the	O
rare	O
examples	O
of	O
mulibrey	O
nanism	O
outside	O
Finland	O
and	O
extends	O
the	O
mutation	O
spectrum	O
in	O
this	O
disorder	O
.	O

Phenotype	O
-	O
genotype	O
correlation	O
in	O
eight	O
Polish	O
patients	O
with	O
inherited	O
Factor	O
XIII	O
deficiency	O
:	O
identification	O
of	O
three	O
novel	O
mutations	O
.	O

Inherited	B-Disease
factor	I-Disease
XIII	I-Disease
(	O
FXIII	O
)	O
deficiency	O
is	O
known	O
as	O
one	O
of	O
the	O
most	O
rare	O
blood	O
coagulation	O
disorder	O
in	O
humans	O
.	O

In	O
the	O
present	O
study	O
,	O
phenotype	O
and	O
genotype	O
of	O
eight	O
FXIII	O
deficient	O
Polish	O
patients	O
from	O
five	O
unrelated	O
families	O
were	O
compared	O
.	O

The	O
patients	O
presented	O
with	O
a	O
severe	O
phenotype	O
demonstrated	O
by	O
a	O
high	O
incidence	O
of	O
intracerebral	O
haemorrhages	O
(	O
seven	O
of	O
eight	O
patients	O
)	O
,	O
haemarthrosis	O
(	O
six	O
patients	O
)	O
and	O
bleeding	O
due	O
to	O
trauma	O
(	O
five	O
patients	O
)	O
.	O

Introduction	O
of	O
regular	O
substitution	O
with	O
FXIII	O
concentrate	O
prevented	O
spontaneous	O
bleeding	O
in	O
seven	O
patients	O
.	O

In	O
all	O
patients	O
,	O
mutations	O
within	O
the	O
F13A	B-Gene
gene	O
have	O
been	O
identified	O
revealing	O
four	O
missense	O
mutations	O
(	B-Var
Arg77Cys	I-Var
,	O
Arg260Cys	B-Var
,	O
Ala378Pro	B-Var
,	O
Gly420Ser	B-Var
)	I-Var
,	O
one	O
nonsense	O
mutation	O
(	B-Var
Arg661X	I-Var
)	I-Var
,	O
one	O
splice	O
site	O
mutation	O
(	B-Var
IVS5	I-Var
-	I-Var
1	I-Var
G	I-Var
>	I-Var
A	I-Var
)	I-Var
and	O
one	O
small	O
deletion	O
(	B-Var
c.499	I-Var
-	I-Var
512del	I-Var
)	I-Var
.	O

One	O
homozygous	O
large	O
deletion	O
involving	O
exon	O
15	O
was	O
detected	O
by	O
failure	O
of	O
PCR	O
product	O
.	O

The	O
corresponding	O
mutations	B-Var
resulted	O
in	O
severely	O
reduced	B-NegReg
FXIII	B-MPA
activity	I-MPA
and	O
FXIII	B-MPA
A	I-MPA
-	I-MPA
subunit	I-MPA
antigen	I-MPA
concentration	I-MPA
,	O
while	O
FXIII	O
B	O
-	O
subunit	O
antigen	O
remained	O
normal	O
or	O
mildly	O
decreased	O
.	O

Structural	O
analysis	O
demonstrated	O
that	O
the	O
novel	O
Ala378Pro	B-Var
mutation	O
may	O
cause	O
a	O
disruption	B-NegReg
of	O
the	O
FXIII	B-MPA
catalytic	I-MPA
triad	I-MPA
leading	O
to	O
a	O
non	B-NegReg
-	I-NegReg
functional	I-NegReg
protein	B-Protein
which	O
presumably	O
undergoes	O
premature	B-MPA
degradation	I-MPA
.	O

In	O
conclusion	O
,	O
the	O
severe	O
phenotype	O
with	O
high	O
incidence	O
of	O
intracranial	O
bleeding	O
and	O
haemarthrosis	O
was	O
in	O
accordance	O
with	O
laboratory	O
findings	O
on	O
FXIII	O
and	O
with	O
severe	O
molecular	O
defects	O
of	O
the	O
F13A	O
gene	O
.	O

Effects	O
of	O
prolonged	O
dark	O
adaptation	O
in	O
patients	O
with	O
retinitis	O
pigmentosa	O
of	O
Bothnia	O
type	O
:	O
an	O
electrophysiological	O
study	O
.	O

Bothnia	B-Disease
dystrophy	I-Disease
(	O
BD	O
)	O
is	O
a	O
variant	O
of	O
recessive	O
retinitis	O
punctata	O
albescens	O
(	O
RPA	O
)	O
,	O
caused	B-Reg
by	I-Reg
the	O
missense	O
mutation	O
R233W	B-Var
in	O
cellular	O
retinaldehyde	O
-	O
binding	O
protein	O
(	B-Protein
CRALBP	I-Protein
)	I-Protein
,	O
which	O
is	O
localized	O
in	O
the	O
retinal	O
pigment	O
epithelium	O
(	O
RPE	O
)	O
and	O
Müller	O
cells	O
of	O
the	O
retina	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
,	O
by	O
examining	O
the	O
electrophysiological	O
responses	O
of	O
the	O
retina	O
,	O
to	O
evaluate	O
the	O
capacity	O
of	O
recovery	O
of	O
the	O
whole	O
retinal	O
area	O
and	O
different	O
cell	O
types	O
induced	O
by	O
extremely	O
prolonged	O
dark	O
adaptation	O
(	O
DA	O
)	O
in	O
BD	O
disease	O
and	O
to	O
gain	O
further	O
understanding	O
of	O
the	O
pathogenesis	O
of	O
BD	O
.	O

Six	O
young	O
patients	O
underwent	O
bilateral	O
full	O
-	O
field	O
ERGs	O
after	O
24	O
h	O
of	O
DA	O
in	O
one	O
eye	O
and	O
standard	O
DA	O
in	O
the	O
fellow	O
eye	O
.	O

The	O
results	O
were	O
also	O
compared	O
with	O
the	O
effect	O
of	O
prolonged	O
DA	O
(	O
10	O
h	O
)	O
,	O
previously	O
studied	O
in	O
the	O
same	O
patients	O
.	O

After	O
extremely	O
prolonged	O
DA	O
(	O
24	O
h	O
)	O
the	O
rod	O
b	O
-	O
wave	O
and	O
the	O
mixed	O
rod	O
-	O
cone	O
a	O
-	O
wave	O
responses	O
reached	O
normal	O
though	O
delayed	O
amplitudes	O
.	O

An	O
increase	O
,	O
up	O
to	O
normal	O
level	O
,	O
in	O
the	O
oscillatory	O
response	O
was	O
found	O
.	O

There	O
was	O
no	O
obvious	O
recovery	O
of	O
the	O
cone	O
response	O
.	O

We	O
conclude	O
that	O
in	O
young	O
BD	O
patients	O
during	O
extremely	O
prolonged	O
DA	O
there	O
is	O
a	O
significant	O
additional	O
capacity	O
of	O
recovery	O
of	O
rod	O
function	O
and	O
also	O
significant	O
gain	O
of	O
activity	O
in	O
the	O
inner	O
retinal	O
layer	O
.	O

A	O
continuous	O
but	O
slow	O
regeneration	O
of	O
rod	O
photopigment	O
seems	O
to	O
occur	O
at	O
least	O
up	O
to	O
24	O
h.	O
The	O
visual	O
process	O
in	O
the	O
RPE	O
is	O
retarded	O
and	O
CRALBP	O
acts	O
in	O
this	O
process	O
;	O
also	O
,	O
the	O
Müller	O
cells	O
of	O
the	O
retina	O
seem	O
to	O
be	O
involved	O
.	O

The	O
findings	O
also	O
support	O
an	O
extremely	O
slow	O
synthesis	O
of	O
photopigments	O
and	O
irreversibly	O
disturbed	O
cone	O
function	O
early	O
in	O
BD	O
.	O

A	O
case	O
of	O
lethal	O
hypophosphatasia	O
providing	O
new	O
insights	O
into	O
the	O
perinatal	O
benign	O
form	O
of	O
hypophosphatasia	O
and	O
expression	O
of	O
the	O
ALPL	O
gene	O
.	O

Hypophosphatasia	B-Disease
is	O
a	O
rare	O
inherited	O
bone	O
disease	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
alkaline	O
phosphatase	O
liver	O
-	O
type	O
gene	O
(	B-Gene
ALPL	I-Gene
)	I-Gene
gene	O
,	O
with	O
extensive	O
allelic	O
heterogeneity	O
leading	O
to	O
a	O
range	O
of	O
clinical	O
phenotypes	O
.	O

We	O
report	O
here	O
a	O
patient	O
who	O
died	O
from	O
severe	O
lethal	O
hypophosphatasia	O
,	O
who	O
was	O
compound	O
heterozygous	O
for	O
the	O
mutation	O
c.1133A	O
>	O
T	O
(	O
D361V	O
)	O
and	O
the	O
newly	O
detected	O
missense	O
mutation	O
c791A	O
>	O
G	O
,	O
and	O
whose	O
parents	O
were	O
both	O
healthy	O
.	O

Because	O
the	O
c.1133A	O
>	O
T	O
(	O
D361V	O
)	O
mutation	O
was	O
previously	O
reported	O
to	O
have	O
a	O
dominant	O
-	O
negative	O
effect	O
and	O
to	O
be	O
responsible	O
for	O
the	O
uncommon	O
perinatal	O
benign	O
form	O
of	O
the	O
disease	O
,	O
we	O
studied	O
the	O
expression	O
of	O
the	O
ALPL	O
gene	O
in	O
this	O
family	O
.	O

Analysis	O
at	O
the	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
level	O
,	O
both	O
quantitative	O
and	O
qualitative	O
,	O
showed	O
that	O
the	O
paternal	O
c.1133A	B-Var
>	I-Var
T	I-Var
(	O
D361V	O
)	O
mutation	O
was	O
associated	O
with	O
over	B-PosReg
-	I-PosReg
expression	I-PosReg
of	O
the	O
ALPL	B-Gene
gene	O
and	O
that	O
the	O
maternal	O
c.791A	B-Var
>	I-Var
G	I-Var
mutation	O
lead	B-Reg
to	I-Reg
complete	O
skipping	B-Var
of	I-Var
exon	I-Var
7	I-Var
.	O

The	O
results	O
provide	O
an	O
explanation	O
of	O
the	O
lethal	O
phenotype	O
in	O
the	O
patient	O
where	O
the	O
two	O
ALPL	O
alleles	O
are	O
non	O
-	O
functional	O
and	O
in	O
the	O
asymptomatic	O
father	O
where	O
over	O
-	O
expression	O
of	O
the	O
normal	O
allele	O
could	O
counteract	O
the	O
effect	O
of	O
the	O
c.1133A	O
>	O
T	O
(	O
D361V	O
)	O
mutation	O
by	O
providing	O
an	O
increased	O
level	O
of	O
normal	O
mRNA	O
.	O

This	O
may	O
also	O
explain	O
the	O
variable	O
expression	O
of	O
hypophosphatasia	O
observed	O
in	O
parents	O
of	O
patients	O
with	O
the	O
perinatal	O
benign	O
form	O
.	O

Choreoacanthocytosis	O
in	O
a	O
Mexican	O
family	O
.	O

BACKGROUND	O
:	O
Choreoacanthocytosis	B-Disease
(	O
CHAC	O
)	O
(	O
Online	O
Mendelian	O
Inheritance	O
in	O
Man	O
accession	O
No	O
.	O

200150	O
)	O
is	O
a	O
hereditary	O
neurodegenerative	O
syndrome	O
characterized	O
by	O
movement	O
disorders	O
,	O
cognitive	O
decline	O
,	O
myopathy	O
,	O
behavioral	O
changes	O
,	O
and	O
acanthocytosis	O
and	O
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
VPS13A	B-Gene
gene	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
the	O
cases	O
of	O
2	O
Mexican	O
women	O
with	O
clinical	O
and	O
molecular	O
characteristics	O
compatible	O
with	O
CHAC	O
.	O

DESIGN	O
:	O
Case	O
reports	O
.	O

Patients	O
Choreoacanthocytosis	O
was	O
identified	O
in	O
2	O
Mexican	O
mestizo	O
sisters	O
with	O
healthy	O
consanguineous	O
parents	O
.	O

Clinical	O
manifestations	O
began	O
at	O
different	O
ages	O
.	O

RESULTS	O
:	O
The	O
onset	O
of	O
signs	O
and	O
symptoms	O
of	O
CHAC	O
in	O
the	O
proband	O
was	O
at	O
age	O
32	O
years	O
and	O
was	O
characterized	O
by	O
balancing	O
problems	O
followed	O
by	O
chorea	O
,	O
compulsive	O
lip	O
and	O
tongue	O
biting	O
with	O
buccolingual	O
self	O
-	O
mutilation	O
,	O
dysarthria	O
,	O
dysphagia	O
,	O
and	O
weight	O
loss	O
.	O

The	O
first	O
clinical	O
manifestations	O
in	O
the	O
proband	O
's	O
sister	O
occurred	O
at	O
age	O
45	O
years	O
and	O
included	O
multiple	O
motor	O
and	O
verbal	O
tics	O
,	O
with	O
coprolalia	O
,	O
followed	O
by	O
lip	O
and	O
tongue	O
biting	O
,	O
self	O
-	O
mutilation	O
,	O
and	O
chorea	O
.	O

The	O
clinical	O
findings	O
in	O
both	O
sisters	O
were	O
remarkable	O
for	O
acanthocytosis	O
that	O
developed	O
late	O
,	O
when	O
neurologic	O
changes	O
were	O
already	O
evident	O
.	O

Mutation	O
screening	O
of	O
the	O
VPS13A	O
gene	O
revealed	O
homozygosity	O
for	O
the	O
frameshift	O
mutation	O
c.3556_3557dupAC	O
in	O
exon	O
33	O
.	O

Currently	O
,	O
the	O
proband	O
's	O
sister	O
,	O
in	O
whom	O
neurologic	O
defects	O
developed	O
13	O
years	O
after	O
onset	O
of	O
CHAC	O
in	O
the	O
proband	O
,	O
is	O
the	O
least	O
affected	O
.	O

CONCLUSIONS	O
:	O
The	O
same	O
mutation	O
of	O
the	O
VPS13A	O
gene	O
can	O
be	O
expressed	O
differently	O
in	O
the	O
same	O
family	O
.	O

This	O
observation	O
confirms	O
the	O
notion	O
that	O
there	O
is	O
considerable	O
heterogeneity	O
in	O
the	O
clinical	O
manifestation	O
of	O
CHAC	O
.	O

Isolation	O
and	O
characterization	O
of	O
a	O
novel	O
human	O
RGS	O
mutant	O
displaying	O
gain	O
-	O
of	O
-	O
function	O
activity	O
.	O

Regulator	O
of	O
G	O
protein	O
signaling	O
(	O
RGS	O
)	O
proteins	O
play	O
a	O
crucial	O
role	O
in	O
the	O
adaptation	O
of	O
cells	O
to	O
stimulation	B-PosReg
by	O
G	B-Protein
protein	I-Protein
-	I-Protein
coupled	I-Protein
receptors	I-Protein
via	O
heterotrimeric	B-Protein
G	I-Protein
proteins	I-Protein
.	O

Alterations	B-Var
in	O
RGS	B-Protein
function	O
have	O
been	O
implicated	B-Reg
in	O
a	O
wide	O
range	O
of	O
disease	B-Disease
states	O
,	O
leading	O
to	O
many	O
researchers	O
focusing	O
on	O
controlling	O
the	O
action	O
of	O
these	O
regulatory	O
proteins	O
.	O

Previous	O
studies	O
have	O
centered	O
on	O
reducing	O
or	O
inhibiting	O
the	O
action	O
of	O
RGS	O
proteins	O
,	O
utilizing	O
inactive	O
mutants	O
or	O
small	O
molecular	O
RGS	O
inhibitors	O
.	O

Here	O
we	O
describe	O
the	O
isolation	O
and	O
characterization	O
of	O
a	O
novel	O
human	O
RGS4	B-Var
mutant	I-Var
which	O
displays	O
enhanced	B-PosReg
or	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
activity	O
.	O

RGS4(S30C	O
)	O
demonstrates	O
GOF	O
activity	O
both	O
in	O
an	O
in	O
vivo	O
yeast	B-Pathway
-	I-Pathway
based	I-Pathway
signalling	I-Pathway
pathway	I-Pathway
and	O
in	O
vitro	O
against	O
the	O
Galpha(o1	B-Protein
)	I-Protein
subunit	I-Protein
contained	I-Protein
in	I-Protein
an	I-Protein
alpha(2A)-adrenoreceptor	I-Protein
-	I-Protein
Galpha(o1)(C351I	I-Protein
)	I-Protein
fusion	I-Protein
protein	I-Protein
.	O

Mutational	O
analysis	O
of	O
serine	O
30	O
identified	O
a	O
number	O
of	O
alternative	O
substitutions	O
that	O
result	O
in	O
GOF	O
activity	O
.	O

GOF	O
activity	O
was	O
retained	O
upon	O
transposition	O
of	O
the	O
serine	O
30-cysteine	O
mutation	O
to	O
the	O
equivalent	O
serine	O
residue	O
in	O
human	O
RGS16	O
.	O

As	O
with	O
previously	O
identified	O
GOF	O
mutants	O
,	O
RGS4(S30C	B-Var
/	I-Var
S30F	I-Var
/	I-Var
S30	I-Var
K	I-Var
)	I-Var
demonstrate	O
increased	B-PosReg
steady	O
state	O
protein	B-MPA
levels	I-MPA
,	O
however	O
these	O
mutants	O
also	O
demonstrate	O
enhanced	B-PosReg
GAP	B-MPA
activity	I-MPA
through	O
an	O
additional	O
mechanism	O
distinct	O
from	O
the	O
increased	O
protein	O
content	O
.	O

The	O
identification	O
of	O
human	O
RGS	O
mutants	O
with	O
GOF	O
activity	O
may	O
provide	O
novel	O
therapeutic	O
agents	O
for	O
the	O
treatment	O
of	O
signaling	O
-	O
based	O
diseases	O
and	O
the	O
ability	O
to	O
transpose	O
these	O
mutations	O
to	O
other	O
human	O
RGS	O
proteins	O
extends	O
their	O
application	O
to	O
multiple	O
pathways	O
.	O

[	O
Phenotype	O
-	O
genotype	O
study	O
in	O
154	O
French	O
NF2	O
mutation	O
carriers	O
]	O
.	O

Analyse	O
phénotypique	O
de	O
154	O
patients	O
porteurs	O
d'une	O
mutation	O
constitutionnelle	O
du	O
gène	O
NF2	O
.	O

INTRODUCTION	O
:	O
Germline	B-Var
mutations	I-Var
in	O
the	O
NF2	B-Gene
gene	O
are	O
responsible	B-Reg
for	O
80	O
p.cent	O
of	O
neurofibromatosis	B-Disease
type	I-Disease
2	I-Disease
typical	O
cases	O
.	O

Mutations	O
are	O
mainly	O
truncating	O
mutations	O
or	O
deletions	O
,	O
missense	O
mutations	O
having	O
been	O
reported	O
in	O
few	O
cases	O
.	O

An	O
important	O
phenotypic	O
variability	O
is	O
observed	O
among	O
gene	O
carriers	O
.	O

To	O
assess	O
whether	O
the	O
phenotypic	O
variability	O
of	O
neurofibromatosis	O
2	O
could	O
be	O
linked	O
to	O
genotype	O
,	O
clinical	O
data	O
of	O
154	O
patients	O
whose	O
NF2	O
germline	O
alteration	O
had	O
been	O
identified	O
in	O
our	O
laboratory	O
have	O
been	O
collected	O
.	O

METHODS	O
:	O
A	O
retrospective	O
questionnaire	O
was	O
sent	O
to	O
the	O
physicians	O
in	O
charge	O
of	O
these	O
patients	O
.	O

Statistical	O
analyses	O
regarding	O
genotypic	O
and	O
phenotypic	O
data	O
were	O
performed	O
by	O
comparisons	O
of	O
average	O
values	O
and	O
correlation	O
tests	O
.	O

RESULTS	O
:	O
In	O
French	O
patients	O
,	O
type	O
of	O
mutation	O
was	O
correlated	O
neither	O
with	O
patients	O
'	O
sex	O
,	O
nor	O
with	O
disease	O
occurrence	O
mode	O
(	O
de	O
novo	O
or	O
inherited	O
mutation	O
)	O
.	O

Disease	O
associated	O
with	O
missense	O
mutations	O
occurred	O
later	O
,	O
with	O
a	O
less	O
severe	O
symptomatology	O
.	O

Patients	O
with	O
nonsense	O
or	O
frameshift	O
mutations	O
were	O
more	O
frequently	O
affected	O
with	O
meningiomas	O
and	O
spinal	O
tumours	O
,	O
in	O
addition	O
to	O
VIII	O
nerve	O
schwannomas	O
,	O
an	O
observation	O
that	O
underlies	O
the	O
genetic	O
determination	O
of	O
the	O
number	O
and	O
type	O
of	O
NF2-related	O
tumours	O
.	O

CONCLUSION	O
:	O
Results	O
from	O
the	O
literature	O
as	O
well	O
as	O
from	O
our	O
study	O
tend	O
to	O
show	O
that	O
only	O
few	O
correlations	O
exist	O
between	O
genotype	O
and	O
phenotype	O
in	O
the	O
NF2	O
disease	O
.	O

It	O
also	O
recognizes	O
that	O
missense	O
mutations	O
have	O
a	O
lower	O
level	O
of	O
evolution	O
,	O
severity	O
and	O
mortality	O
risk	O
.	O

Nonsense	O
and	O
frameshift	O
mutations	O
seem	O
to	O
be	O
associated	O
with	O
a	O
higher	O
number	O
of	O
meningiomas	O
and	O
spinal	O
tumours	O
.	O

Therefore	O
,	O
NF2	O
gene	O
screening	O
keeps	O
its	O
indications	O
in	O
both	O
typical	O
and	O
moderate	O
forms	O
of	O
the	O
disease	O
.	O

Mutations	O
are	O
responsible	O
of	O
80	O
p.cent	O
of	O
typical	O
forms	O
;	O
in	O
moderate	O
forms	O
,	O
identification	O
of	O
a	O
missense	O
mutation	O
seems	O
linked	O
to	O
a	O
lower	O
disease	O
evolution	O
.	O

In	O
any	O
case	O
,	O
assessment	O
and	O
supervision	O
should	O
be	O
identical	O
.	O

Finally	O
,	O
in	O
a	O
small	O
number	O
of	O
cases	O
,	O
the	O
NF2	O
gene	O
appears	O
to	O
be	O
implicated	O
in	O
clinical	O
forms	O
different	O
from	O
those	O
defined	O
by	O
NIH	O
and	O
it	O
might	O
be	O
of	O
interest	O
to	O
enlarge	O
the	O
clinical	O
features	O
suggestive	O
of	O
the	O
disease	O
.	O

Do	O
we	O
know	O
all	O
there	O
is	O
to	O
know	O
about	O
Familial	O
Adenomatous	O
Polyposis	O
?	O
Familial	B-Disease
Adenomatous	I-Disease
Polyposis	I-Disease
(	O
FAP	O
)	O
and	O
Attenuated	B-Disease
FAP	I-Disease
(	O
AFAP	O
)	O
are	O
caused	B-Reg
by	I-Reg
a	O
germline	B-Var
mutation	I-Var
in	O
the	O
Adenomatous	O
polyposis	O
coli	O
(	B-Gene
APC	I-Gene
)	I-Gene
gene	O
.	O

Recently	O
,	O
a	O
new	O
pathway	O
characterized	O
by	O
a	O
biallelic	O
mutation	O
in	O
the	O
MYH	O
gene	O
,	O
with	O
a	O
recessive	O
model	O
of	O
inheritance	O
was	O
discovered	O
for	O
this	O
inherited	O
syndrome	O
.	O

This	O
report	O
describes	O
a	O
Tunisian	O
patient	O
with	O
an	O
attenuated	O
FAP	O
phenotype	O
,	O
presenting	O
seven	O
colon	O
polyps	O
and	O
an	O
adenocarcinoma	O
but	O
no	O
detectable	O
germline	O
mutations	O
in	O
the	O
FAP	O
target	O
genes	O
.	O

A	O
well	O
known	O
somatic	O
mutation	O
was	O
found	O
in	O
the	O
APC	O
mutation	O
cluster	O
region	O
(	O
MCR	O
)	O
.	O

This	O
case	O
shows	O
that	O
further	O
studies	O
are	O
needed	O
to	O
fully	O
understand	O
all	O
the	O
pathways	O
of	O
the	O
FAP	O
syndrome	O
.	O

Mutations	B-Var
in	O
NALP12	B-Gene
cause	B-Reg
hereditary	B-Disease
periodic	I-Disease
fever	I-Disease
syndromes	I-Disease
.	O

NALP	O
proteins	O
,	O
also	O
known	O
as	O
NLRPs	O
,	O
belong	O
to	O
the	O
CATERPILLER	O
protein	O
family	O
involved	O
,	O
like	O
Toll	O
-	O
like	O
receptors	O
,	O
in	O
the	O
recognition	O
of	O
microbial	O
molecules	O
and	O
the	O
subsequent	O
activation	O
of	O
inflammatory	O
and	O
immune	O
responses	O
.	O

Current	O
advances	O
in	O
the	O
function	O
of	O
NALPs	O
support	O
the	O
recently	O
proposed	O
model	O
of	O
a	O
disease	O
continuum	O
bridging	O
autoimmune	O
and	O
autoinflammatory	O
disorders	O
.	O

Among	O
these	O
diseases	O
,	O
hereditary	O
periodic	O
fevers	O
(	O
HPFs	O
)	O
are	O
Mendelian	O
disorders	O
associated	O
with	O
sequence	O
variations	O
in	O
very	O
few	O
genes	O
;	O
these	O
variations	O
are	O
mostly	O
missense	O
mutations	O
whose	O
deleterious	O
effect	O
,	O
which	O
is	O
particularly	O
difficult	O
to	O
assess	O
,	O
is	O
often	O
questionable	O
.	O

The	O
growing	O
number	O
of	O
identified	O
sporadic	O
cases	O
of	O
periodic	O
fever	O
syndrome	O
,	O
together	O
with	O
the	O
lack	O
of	O
discriminatory	O
clinical	O
criteria	O
,	O
has	O
greatly	O
hampered	O
the	O
identification	O
of	O
new	O
disease	O
-	O
causing	O
genes	O
,	O
a	O
step	O
that	O
is	O
,	O
however	O
,	O
essential	O
for	O
appropriate	O
management	O
of	O
these	O
disorders	O
.	O

Using	O
a	O
candidate	O
gene	O
approach	O
,	O
we	O
identified	O
nonambiguous	O
mutations	O
in	O
NALP12	O
(	O
i.e.	O
,	O
nonsense	O
and	O
splice	O
site	O
)	O
in	O
two	O
families	O
with	O
periodic	O
fever	O
syndromes	O
.	O

As	O
shown	O
by	O
means	O
of	O
functional	O
studies	O
,	O
these	O
two	O
NALP12	B-Gene
mutations	B-Var
have	O
a	O
deleterious	O
effect	B-Reg
on	O
NF	B-Pathway
-	I-Pathway
kappaB	I-Pathway
signaling	I-Pathway
.	O

Overall	O
,	O
these	O
data	O
identify	O
a	O
group	O
of	O
HPFs	O
defined	O
by	O
molecular	O
defects	O
in	O
NALP12	O
,	O
opening	O
up	O
new	O
ways	O
to	O
manage	O
these	O
disorders	O
.	O

The	O
identification	O
of	O
these	O
first	O
NALP12	B-Gene
mutations	B-Var
in	O
patients	O
with	B-Reg
autoinflammatory	B-CPA
disorder	I-CPA
also	O
clearly	O
demonstrates	O
the	O
crucial	O
role	O
of	O
NALP12	O
in	O
inflammatory	O
signaling	O
pathways	O
,	O
thereby	O
assigning	O
a	O
precise	O
function	O
to	O
this	O
particular	O
member	O
of	O
an	O
emerging	O
family	O
of	O
proteins	O
whose	O
putative	O
biological	O
properties	O
are	O
currently	O
inferred	O
essentially	O
through	O
in	O
vitro	O
means	O
.	O

ABCA4	O
gene	O
analysis	O
in	O
patients	O
with	O
autosomal	O
recessive	O
cone	O
and	O
cone	O
rod	O
dystrophies	O
.	O

The	O
ATP	O
-	O
binding	O
cassette	O
(	O
ABC	O
)	O
transporters	O
constitute	O
a	O
family	O
of	O
large	O
membrane	O
proteins	O
,	O
which	O
transport	O
a	O
variety	O
of	O
substrates	O
across	O
membranes	O
.	O

The	O
ABCA4	O
protein	O
is	O
expressed	O
in	O
photoreceptors	O
and	O
possibly	O
functions	O
as	O
a	O
transporter	O
for	O
N	O
-	O
retinylidene	O
-	O
phosphatidylethanolamine	O
(	O
N	O
-	O
retinylidene	O
-	O
PE	O
)	O
,	O
the	O
Schiff	O
base	O
adduct	O
of	O
all	O
-	O
trans	O
-	O
retinal	O
with	O
PE	O
.	O

Mutations	B-Var
in	O
the	O
ABCA4	B-Gene
gene	O
have	O
been	O
initially	O
associated	B-Reg
with	I-Reg
autosomal	O
recessive	O
Stargardt	B-Disease
disease	I-Disease
.	O

Subsequent	O
studies	O
have	O
shown	O
that	O
mutations	B-Var
in	O
ABCA4	B-Gene
can	O
also	O
cause	B-Reg
a	O
variety	O
of	O
other	O
retinal	B-Disease
dystrophies	I-Disease
including	O
cone	B-Disease
rod	I-Disease
dystrophy	I-Disease
and	O
retinitis	B-Disease
pigmentosa	I-Disease
.	O

To	O
determine	O
the	O
prevalence	O
and	O
mutation	O
spectrum	O
of	O
ABCA4	O
gene	O
mutations	O
in	O
non	O
-	O
Stargardt	O
phenotypes	O
,	O
we	O
have	O
screened	O
64	O
unrelated	O
patients	O
with	O
autosomal	O
recessive	O
cone	O
(	O
arCD	O
)	O
and	O
cone	O
rod	O
dystrophy	O
(	O
arCRD	O
)	O
applying	O
the	O
Asper	O
Ophthalmics	O
ABCR400	O
microarray	O
followed	O
by	O
DNA	O
sequencing	O
of	O
all	O
coding	O
exons	O
of	O
the	O
ABCA4	O
gene	O
in	O
subjects	O
with	O
single	O
heterozygous	O
mutations	O
.	O

Disease	O
-	O
associated	O
ABCA4	O
alleles	O
were	O
identified	O
in	O
20	O
of	O
64	O
patients	O
with	O
arCD	O
or	O
arCRD	O
.	O

In	O
four	O
of	O
64	O
patients	O
(	O
6	O
%	O
)	O
only	O
one	O
mutant	O
ABCA4	O
allele	O
was	O
detected	O
and	O
in	O
16	O
patients	O
(	O
25	O
%	O
)	O
,	O
mutations	O
on	O
both	O
ABCA4	O
alleles	O
were	O
identified	O
.	O

Based	O
on	O
these	O
data	O
we	O
estimate	O
a	O
prevalence	O
of	O
31	O
%	O
for	O
ABCA4	O
mutations	O
in	O
arCD	O
and	O
arCRD	O
,	O
supporting	O
the	O
concept	O
that	O
the	O
ABCA4	O
gene	O
is	O
a	O
major	O
locus	O
for	O
various	O
types	O
of	O
degenerative	O
retinal	O
diseases	O
with	O
abnormalities	O
in	O
cone	O
or	O
both	O
cone	O
and	O
rod	O
function	O
.	O

Premature	O
termination	O
codons	O
in	O
PRPF31	O
cause	O
retinitis	O
pigmentosa	O
via	O
haploinsufficiency	O
due	O
to	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	O
.	O

Dominant	B-Var
mutations	I-Var
in	O
the	O
gene	O
encoding	O
the	O
mRNA	O
splicing	O
factor	O
PRPF31	B-Gene
cause	B-Reg
retinitis	B-Disease
pigmentosa	I-Disease
,	O
a	O
hereditary	O
form	O
of	O
retinal	O
degeneration	O
.	O

Most	O
of	O
these	O
mutations	O
are	O
characterized	O
by	O
DNA	O
changes	O
that	O
lead	O
to	O
premature	O
termination	O
codons	O
.	O

We	O
investigated	O
6	O
different	O
PRPF31	O
mutations	O
,	O
represented	O
by	O
single	O
-	O
base	O
substitutions	O
or	O
microdeletions	O
,	O
in	O
cell	O
lines	O
derived	O
from	O
9	O
patients	O
with	O
dominant	O
retinitis	O
pigmentosa	O
.	O

Five	O
of	O
these	O
mutations	B-Var
lead	B-Reg
to	I-Reg
premature	B-MPA
termination	I-MPA
codons	I-MPA
,	O
and	O
1	O
leads	B-Reg
to	I-Reg
the	O
skipping	B-MPA
of	I-MPA
exon	I-MPA
2	I-MPA
.	O

Allele	O
-	O
specific	O
measurement	O
of	O
PRPF31	O
transcripts	O
revealed	O
a	O
strong	O
reduction	B-NegReg
in	O
the	O
expression	B-MPA
of	O
mutant	B-Var
alleles	O
.	O

As	O
a	O
consequence	O
,	O
total	O
PRPF31	B-Gene
protein	B-Protein
abundance	B-MPA
was	O
decreased	B-NegReg
,	O
and	O
no	O
truncated	O
proteins	O
were	O
detected	O
.	O

Subnuclear	O
localization	O
of	O
the	O
full	O
-	O
length	O
PRPF31	O
that	O
was	O
present	O
remained	O
unaffected	O
.	O

Blocking	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	O
significantly	O
restored	O
the	O
amount	O
of	O
mutant	O
PRPF31	O
mRNA	O
but	O
did	O
not	O
restore	O
the	O
synthesis	O
of	O
mutant	O
proteins	O
,	O
even	O
in	O
conjunction	O
with	O
inhibitors	O
of	O
protein	O
degradation	O
pathways	O
.	O

Our	O
results	O
indicate	O
that	O
most	O
PRPF31	B-Gene
mutations	B-Var
ultimately	O
result	O
in	O
null	B-NegReg
alleles	B-MPA
through	O
the	O
activation	B-PosReg
of	O
surveillance	B-MPA
mechanisms	I-MPA
that	O
inactivate	B-NegReg
mutant	B-Var
mRNA	I-Var
and	O
,	O
possibly	O
,	O
proteins	B-Protein
.	O

Furthermore	O
,	O
these	O
data	O
provide	O
compelling	O
evidence	O
that	O
the	O
pathogenic	O
effect	O
of	O
PRPF31	O
mutations	O
is	O
likely	O
due	O
to	O
haploinsufficiency	O
rather	O
than	O
to	O
gain	O
of	O
function	O
.	O

Xeroderma	O
pigmentosum	O
-	O
variant	O
patients	O
from	O
America	O
,	O
Europe	O
,	O
and	O
Asia	O
.	O

Xeroderma	B-Disease
pigmentosum	I-Disease
-	I-Disease
variant	I-Disease
(	O
XP	O
-	O
V	O
)	O
patients	O
have	O
sun	O
sensitivity	O
and	O
increased	O
skin	O
cancer	O
risk	O
.	O

Their	O
cells	O
have	O
normal	O
nucleotide	O
excision	O
repair	O
,	O
but	O
have	O
defects	O
in	O
the	O
POLH	O
gene	O
encoding	O
an	O
error	O
-	O
prone	O
polymerase	O
,	O
DNA	O
polymerase	O
eta	O
(	O
pol	O
eta	O
)	O
.	O

To	O
survey	O
the	O
molecular	O
basis	O
of	O
XP	O
-	O
V	O
worldwide	O
,	O
we	O
measured	O
pol	O
eta	O
protein	O
in	O
skin	O
fibroblasts	O
from	O
putative	O
XP	O
-	O
V	O
patients	O
(	O
aged	O
8	O
-	O
66	O
years	O
)	O
from	O
10	O
families	O
in	O
North	O
America	O
,	O
Turkey	O
,	O
Israel	O
,	O
Germany	O
,	O
and	O
Korea	O
.	O

Pol	O
eta	O
was	O
undetectable	O
in	O
cells	O
from	O
patients	O
in	O
eight	O
families	O
,	O
whereas	O
two	O
showed	O
faint	O
bands	O
.	O

DNA	O
sequencing	O
identified	O
10	O
different	O
POLH	O
mutations	O
.	O

There	O
were	O
two	O
splicing	O
,	O
one	O
nonsense	O
,	O
five	O
frameshift	O
(	O
3	O
deletion	O
and	O
2	O
insertion	O
)	O
,	O
and	O
two	O
missense	O
mutations	O
.	O

Nine	O
of	O
these	O
mutations	O
involved	O
the	O
catalytic	O
domain	O
.	O

Although	O
affected	O
siblings	O
had	O
similar	O
clinical	O
features	O
,	O
the	O
relation	O
between	O
the	O
clinical	O
features	O
and	O
the	O
mutations	O
was	O
not	O
clear	O
.	O

POLH	O
mRNA	O
levels	O
were	O
normal	O
or	O
reduced	O
by	O
50	O
%	O
in	O
three	O
cell	O
strains	O
with	O
undetectable	O
levels	O
of	O
pol	O
eta	O
protein	O
,	O
indicating	O
that	O
nonsense	O
-	O
mediated	O
message	O
decay	O
was	O
limited	O
.	O

We	O
found	O
a	O
wide	O
spectrum	O
of	O
mutations	B-Var
in	O
the	O
POLH	B-Gene
gene	O
among	B-Reg
XP	B-Disease
-	I-Disease
V	I-Disease
patients	O
in	O
different	O
countries	O
,	O
suggesting	O
that	O
many	O
of	O
these	O
mutations	O
arose	O
independently	O
.	O

Four	O
novel	O
FXI	B-Gene
gene	O
mutations	B-Var
in	B-Reg
three	O
factor	B-Disease
XI-	I-Disease
deficient	I-Disease
patients	O
.	O

Hereditary	O
factor	O
XI	O
deficiency	O
is	O
a	O
mild	O
bleeding	O
disorder	O
,	O
which	O
is	O
highly	O
prevalent	O
among	O
Ashkenazi	O
Jews	O
,	O
but	O
has	O
been	O
reported	O
in	O
all	O
populations	O
.	O

In	O
Ashkenazi	O
Jews	O
,	O
two	O
factor	O
XI	O
gene	O
mutations	O
Glu	O
117X	O
(	O
type	O
II	O
)	O
and	O
Phe283Leu	O
(	O
type	O
III	O
)	O
are	O
particularly	O
common	O
.	O

In	O
other	O
ethnic	O
groups	O
,	O
factor	B-Disease
XI	I-Disease
deficiency	I-Disease
is	O
a	O
rare	O
bleeding	O
disorder	O
and	O
is	O
related	B-Reg
to	I-Reg
a	O
variety	O
of	O
mutations	B-Var
throughout	O
the	O
factor	B-Gene
XI	I-Gene
gene	O
.	O

Three	O
cases	O
of	O
quantitative	O
factor	O
XI	O
deficiency	O
in	O
relation	O
with	O
four	O
novel	O
missense	O
mutations	O
are	O
reported	O
:	O
a	O
compound	O
heterozygosity	O
for	O
two	O
novel	O
mutations	O
(	B-Var
Ala	I-Var
181	I-Var
Val	I-Var
and	O
Ala	B-Var
412	I-Var
Thr	I-Var
)	I-Var
with	O
a	O
severe	O
factor	O
XI	O
deficiency	O
and	O
two	O
missense	O
mutations	O
(	B-Var
His	I-Var
388	I-Var
Pro	I-Var
and	O
Trp	B-Var
407	I-Var
Cys	I-Var
)	I-Var
in	B-Reg
heterozygous	O
patients	O
with	O
partial	O
factor	B-Disease
XI	I-Disease
deficiency	I-Disease
.	O

[	O
A	O
novel	O
mutation	B-Var
in	O
the	O
SEDL	B-Gene
gene	O
leading	B-Reg
to	I-Reg
X	B-Disease
-	I-Disease
linked	I-Disease
spondyloepiphyseal	I-Disease
dysplasia	I-Disease
tarda	I-Disease
in	O
a	O
large	O
Chinese	O
pedigree	O
]	O
.	O

OBJECTIVE	O
:	O
To	O
identify	O
the	O
genetic	O
defect	O
in	O
a	O
four	O
-	O
generation	O
pedigree	O
with	O
X	O
-	O
linked	O
recessive	O
spondyloepiphyseal	O
dysplasia	O
tarda	O
(	O
SEDT	O
)	O
from	O
Southwest	O
China	O
.	O

METHODS	O
:	O
Linkage	O
analysis	O
with	O
one	O
panel	O
of	O
fluorescently	O
labeled	O
microsatellite	O
markers	O
on	O
chromosome	O
X	O
and	O
mutation	O
screening	O
of	O
SEDL	O
gene	O
by	O
direct	O
sequencing	O
were	O
performed	O
.	O

RESULTS	O
:	O
Linkage	O
between	O
SEDT	O
and	O
Xp22.2-Xp23.1	O
was	O
established	O
with	O
maximum	O
LOD	O
score	O
of	O
3.82	O
(	O
theta	O
=	O
0	O
)	O
between	O
DXS987	O
and	O
DXS8051	O
.	O

Upon	O
sequence	O
analysis	O
,	O
a	O
point	O
mutation	O
within	O
exon	O
4	O
of	O
the	O
SEDL	B-Gene
gene	O
(	B-Var
c.239A	I-Var
to	I-Var
G	I-Var
)	I-Var
was	O
found	O
which	O
resulted	B-Reg
in	I-Reg
substitution	O
of	O
histidine	O
with	O
arginine	O
at	O
codon	O
80	O
(	B-Var
His80Arg	I-Var
)	I-Var
.	O

CONCLUSION	O
:	O
A	O
novel	O
missense	O
mutation	O
(	O
H80R	O
)	O
was	O
identified	O
for	O
SEDL	O
gene	O
in	O
the	O
large	O
Chinese	O
SEDT	O
pedigree	O
.	O

Conditional	O
RNA	O
interference	O
in	O
vivo	O
to	O
study	O
mutant	O
p53	O
oncogenic	O
gain	O
of	O
function	O
on	O
tumor	O
malignancy	O
.	O

Mutant	B-Var
p53	B-Gene
proteins	B-Protein
are	O
thought	O
to	O
have	O
acquired	O
a	O
"	B-PosReg
gain	I-PosReg
of	I-PosReg
function	I-PosReg
"	I-PosReg
(	O
GOF	O
)	O
activity	O
that	O
mainly	O
contributes	O
to	O
tumor	B-CPA
aggressiveness	I-CPA
.	O

Previously	O
we	O
reported	O
that	O
constitutive	O
downregulation	B-NegReg
of	O
mutant	B-Var
p53	B-Gene
by	O
RNA	B-MPA
interference	I-MPA
reduces	B-NegReg
the	O
tumorigenicity	B-CPA
of	I-CPA
cancer	I-CPA
cells	I-CPA
in	I-CPA
an	I-CPA
animal	I-CPA
model	I-CPA
;	I-CPA
however	O
,	O
effects	O
of	O
adaptation	O
to	O
long	O
-	O
term	O
mutant	O
p53	O
inhibition	O
could	O
not	O
be	O
excluded	O
.	O

To	O
address	O
this	O
point	O
,	O
mimicking	O
more	O
physiological	O
conditions	O
,	O
we	O
now	O
describe	O
the	O
establishment	O
of	O
a	O
lentiviral	O
-	O
based	O
system	O
for	O
conditional	O
interference	O
with	O
mutant	O
p53	O
expression	O
.	O

In	O
vivo	O
studies	O
assessed	O
the	O
efficacy	O
of	O
conditional	B-MPA
RNA	I-MPA
interference	I-MPA
in	O
inhibiting	B-NegReg
gain	O
of	O
function	O
activity	B-MPA
of	O
mutant	B-Var
p53	B-Gene
proteins	B-Protein
by	O
reducing	O
tumor	O
growth	O
ability	O
.	O

Moreover	O
by	O
using	O
this	O
system	O
,	O
microarray	O
data	O
were	O
validated	O
in	O
vitro	O
and	O
in	O
vivo	O
and	O
putative	O
mutant	O
p53	O
target	O
genes	O
that	O
may	O
contribute	O
to	O
its	O
gain	O
of	O
function	O
effects	O
in	O
cancer	O
were	O
identified	O
.	O

Results	O
are	O
confirmatory	O
that	O
depletion	B-MPA
of	O
mutant	B-Var
p53	B-Gene
protein	B-Protein
impacts	B-Reg
on	O
tumor	B-CPA
malignancy	I-CPA
and	O
validated	O
the	O
inducible	O
lentiviral	O
-	O
based	O
system	O
as	O
an	O
efficient	O
tool	O
to	O
study	O
the	O
gain	O
of	O
function	O
activity	O
of	O
human	O
tumor	O
derived	O
p53	O
mutants	O
.	O

MLPA	O
analysis	O
/	O
complete	O
sequencing	O
of	O
the	O
DMD	O
gene	O
in	O
a	O
group	O
of	O
Bulgarian	O
Duchenne	O
/	O
Becker	O
muscular	O
dystrophy	O
patients	O
.	O

Duchenne	B-Disease
/	I-Disease
Becker	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	O
/	O
BMD	O
)	O
,	O
the	O
most	O
common	O
X	O
-	O
linked	O
muscular	O
dystrophy	O
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
enormously	O
large	O
DMD	B-Gene
gene	O
,	O
encoding	O
the	O
protein	O
called	O
dystrophin	O
.	O

This	O
gene	O
was	O
screened	O
in	O
a	O
group	O
of	O
27	O
unrelated	O
Bulgarian	O
DMD	O
/	O
BMD	O
patients	O
by	O
MLPA	O
analysis	O
/	O
complete	O
sequencing	O
.	O

We	O
managed	O
to	O
clarify	O
the	O
disease	O
-	O
causing	O
mutation	O
in	O
96.3	O
%	O
of	O
the	O
analyzed	O
families	O
.	O

The	O
MLPA	O
analysis	O
revealed	O
17	O
deletions	O
(	O
including	O
a	O
deletion	O
of	O
the	O
very	O
last	O
exon	O
79	O
)	O
,	O
6	O
duplications	O
and	O
1	O
point	O
mutation	O
.	O

Two	O
additional	O
point	O
mutations	O
(	O
one	O
of	O
them	O
novel	O
)	O
were	O
detected	O
after	O
complete	O
sequencing	O
of	O
the	O
DMD	O
gene	O
.	O

Altogether	O
,	O
25	O
carriers	O
and	O
11	O
noncarriers	O
were	O
detected	O
in	O
our	O
families	O
.	O

The	O
MLPA	O
test	O
proved	O
to	O
be	O
a	O
powerful	O
tool	O
in	O
detecting	O
deletions	O
/	O
duplications	O
and	O
in	O
some	O
cases	O
point	O
mutations	O
/	O
polymorphisms	O
along	O
the	O
DMD	O
gene	O
.	O

Using	O
this	O
approach	O
in	O
combination	O
with	O
a	O
direct	O
gene	O
sequencing	O
a	O
number	O
of	O
Bulgarian	O
DMD	O
/	O
BMD	O
patients	O
are	O
genetically	O
clarified	O
and	O
prepared	O
for	O
gene	O
therapy	O
in	O
future	O
.	O

A	O
case	O
of	O
Bernard	B-Disease
-	I-Disease
Soulier	I-Disease
Syndrome	I-Disease
due	B-Reg
to	I-Reg
a	O
homozygous	O
four	O
bases	O
deletion	B-Var
(	O
TGAG	O
)	O
of	O
GPIbalpha	B-Gene
gene	I-Gene
:	I-Gene
lack	O
of	O
GPIbalpha	O
but	O
absence	O
of	O
bleeding	O
.	O

More	O
than	O
20	O
DNA	O
mutations	O
with	O
different	O
inheritance	O
pattern	O
have	O
been	O
described	O
in	O
patients	O
with	O
Bernard	O
-	O
Soulier	O
Syndrome	O
(	O
BSS	O
)	O
,	O
leading	O
to	O
abnormal	O
or	O
absent	O
synthesis	O
and/or	O
expression	O
of	O
GPIbalpha	O
.	O

Clinical	O
phenotype	O
shows	O
considerable	O
variation	O
between	O
individuals	O
,	O
such	O
as	O
bleeding	O
,	O
platelet	O
count	O
and	O
the	O
percentage	O
of	O
large	O
platelets	O
.	O

We	O
describe	O
in	O
a	O
BSS	O
patient	O
the	O
first	O
case	O
of	O
homozygous	O
four	O
bases	O
deletion	O
(	O
TGAG	O
)	O
in	O
the	O
gpIbalpha	O
gene	O
coding	O
sequence	O
,	O
leading	O
to	O
a	O
premature	O
stop	O
codon	O
.	O

In	O
the	O
propositus	O
,	O
blood	O
smears	O
revealed	O
giant	O
platelets	O
(	O
30	O
x	O
10(9	O
)	O
platelets	O
/	O
L	O
)	O
,	O
and	O
platelet	O
agglutination	O
to	O
ristocetin	O
was	O
absent	O
.	O

Propositus	O
'	O
parents	O
are	O
consanguineous	O
.	O

His	O
father	O
and	O
paternal	O
grandmother	O
showed	O
a	O
mild	O
thrombocytopenia	O
(	O
108	O
x	O
10(9)/L	O
and	O
120	O
x	O
10(9)/L	O
platelets	O
respectively	O
)	O
while	O
mothers	O
and	O
sister	O
's	O
referred	O
normal	O
platelet	O
counts	O
.	O

The	O
surface	O
expression	O
of	O
GPIbalpha	O
was	O
practically	O
undetectable	O
by	O
flow	O
-	O
cytometry	O
and	O
western	O
blot	O
in	O
the	O
patient	O
and	O
was	O
reduced	O
in	O
the	O
father	O
.	O

Proband	O
's	O
DNA	O
analysis	O
revealed	O
a	O
homozygous	O
four	O
-	O
base	O
-	O
pair	O
deletion	B-Var
(	O
TGAG	O
)	O
,	O
starting	O
from	O
the	O
last	O
base	O
of	O
the	O
codon	O
for	O
Ser39	O
,	O
leading	B-Reg
to	I-Reg
a	O
coding	O
frame	O
shift	O
with	O
a	O
new	O
termination	B-MPA
codon	I-MPA
after	O
11	O
novel	O
amino	O
acids	O
.	O

The	O
same	O
mutation	O
was	O
seen	O
in	O
heterozygosis	O
in	O
both	O
parents	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
GPIbalpha	O
TGAG	O
deletion	O
in	O
homozygous	O
state	O
even	O
if	O
the	O
defect	O
has	O
already	O
been	O
described	O
in	O
a	O
case	O
of	O
compound	O
heterozygosis	O
.	O

Surprisingly	O
,	O
the	O
propositus	O
does	O
not	O
report	O
any	O
spontaneous	O
bleeding	O
tendency	O
.	O

Common	O
mutations	B-Var
in	B-Reg
Cuban	O
cystic	B-Disease
fibrosis	I-Disease
patients	O
.	O

So	O
far	O
,	O
more	O
than	O
1500	O
mutations	O
have	O
been	O
reported	O
in	O
the	O
cystic	O
fibrosis	O
transmembrane	O
conductance	O
regulator	O
(	B-Gene
CFTR	I-Gene
)	I-Gene
gene	O
.	O

Mutational	O
spectrum	O
varies	O
in	O
accordance	O
with	O
geographic	O
and/or	O
ethnic	O
origin	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
analyzed	O
seven	O
common	B-Reg
CF	B-Disease
mutations	O
(	B-Var
p	I-Var
.	I-Var
F508del	I-Var
,	O
p	B-Var
.	I-Var
G542X	I-Var
,	O
p	B-Var
.	I-Var
R1162X	I-Var
,	O
p	B-Var
.	I-Var
N1303	I-Var
K	I-Var
,	O
p	B-Var
.	I-Var
R334W	I-Var
,	O
p	B-Var
.	I-Var
R553X	I-Var
and	O
c.3120	B-Var
+	I-Var
1G	I-Var
>	I-Var
A	I-Var
)	I-Var
taking	O
into	O
account	O
the	O
ethnic	O
origin	O
of	O
the	O
Cuban	O
population	O
which	O
is	O
mainly	O
influenced	O
by	O
Spanish	O
and	O
sub	O
-	O
Sahara	O
African	O
contribution	O
.	O

All	O
but	O
p	O
.	O
N1303	O
K	O
have	O
been	O
detected	O
in	O
our	O
patients	O
,	O
the	O
p	O
.	O
F508del	O
being	O
the	O
most	O
prevalent	O
(	O
37.9	O
%	O
)	O
.	O

Overall	O
,	O
six	O
mutations	O
showed	O
frequencies	O
above	O
1	O
%	O
accounting	O
for	O
55.5	O
%	O
of	O
the	O
Cuban	O
CF	O
alleles	O
.	O

Mutation	B-Var
in	O
BAG3	B-Gene
causes	B-Reg
severe	O
dominant	O
childhood	B-Disease
muscular	I-Disease
dystrophy	I-Disease
.	O

OBJECTIVE	O
:	O
Myofibrillar	O
myopathies	O
(	O
MFMs	O
)	O
are	O
morphologically	O
distinct	O
but	O
genetically	O
heterogeneous	O
muscular	O
dystrophies	O
in	O
which	O
disintegration	O
of	O
Z	O
disks	O
and	O
then	O
of	O
myofibrils	O
is	O
followed	O
by	O
ectopic	O
accumulation	O
of	O
multiple	O
proteins	O
.	O

Cardiomyopathy	O
,	O
neuropathy	O
,	O
and	O
dominant	O
inheritance	O
are	O
frequent	O
associated	O
features	O
.	O

Mutations	O
in	O
alphaB	O
-	O
crystallin	O
,	O
desmin	O
,	O
myotilin	O
,	O
Zasp	O
,	O
or	O
filamin	O
-	O
C	O
can	O
cause	O
MFMs	O
and	O
were	O
detected	O
in	O
32	O
of	O
85	O
patients	O
of	O
the	O
Mayo	O
MFM	O
cohort	O
.	O

Bag3	B-Protein
,	O
another	O
Z	O
-	O
disk	O
-	O
associated	O
protein	O
,	O
has	O
antiapoptotic	O
properties	O
,	O
and	O
its	O
targeted	O
deletion	B-Var
in	O
mice	O
causes	B-Reg
fulminant	B-Disease
myopathy	I-Disease
with	O
early	O
lethality	O
.	O

We	O
therefore	O
searched	O
for	O
mutations	O
in	O
BAG3	O
in	O
53	O
unrelated	O
MFM	O
patients	O
.	O

METHODS	O
:	O
We	O
searched	O
for	O
mutations	O
in	O
BAG3	O
by	O
direct	O
sequencing	O
.	O

We	O
analyzed	O
structural	O
changes	O
in	O
muscle	O
by	O
histochemistry	O
,	O
immunocytochemistry	O
,	O
and	O
electron	O
microscopy	O
,	O
examined	O
mobility	O
of	O
the	O
mutant	O
Bag3	O
by	O
nondenaturing	O
electrophoresis	O
,	O
and	O
searched	O
for	O
abnormal	O
aggregation	O
of	O
the	O
mutant	O
protein	O
in	O
COS-7	O
(	O
SV-40	O
transformed	O
monkey	O
kidney	O
fibroblast-7	O
)	O
cells	O
.	O

RESULTS	O
:	O
We	O
identified	O
a	O
heterozygous	O
p	O
.	O
Pro209Leu	O
mutation	O
in	O
three	O
patients	O
.	O

All	O
presented	O
in	O
childhood	O
,	O
had	O
progressive	O
limb	O
and	O
axial	O
muscle	O
weakness	O
,	O
and	O
experienced	O
development	O
of	O
cardiomyopathy	O
and	O
severe	O
respiratory	O
insufficiency	O
in	O
their	O
teens	O
;	O
two	O
had	O
rigid	O
spines	O
,	O
and	O
one	O
a	O
peripheral	O
neuropathy	O
.	O

Electron	O
microscopy	O
showed	O
disintegration	O
of	O
Z	O
disks	O
,	O
extensive	O
accumulation	O
of	O
granular	O
debris	O
and	O
larger	O
inclusions	O
,	O
and	O
apoptosis	O
of	O
8	O
%	O
of	O
the	O
nuclei	O
.	O

On	O
nondenaturing	O
electrophoresis	O
of	O
muscle	O
extracts	O
,	O
the	O
Bag3	O
complex	O
migrated	O
faster	O
in	O
patient	O
than	O
control	O
extracts	O
,	O
and	O
expression	O
of	O
FLAG	O
-	O
labeled	O
mutant	O
and	O
wild	O
-	O
type	O
Bag3	O
in	O
COS	O
cells	O
showed	O
abnormal	O
aggregation	O
of	O
the	O
mutant	O
protein	O
.	O

INTERPRETATION	O
:	O
We	O
conclude	O
mutation	O
in	O
Bag3	O
defines	O
a	O
novel	O
severe	O
autosomal	O
dominant	O
childhood	O
muscular	O
dystrophy	O
.	O

Network	O
analyses	O
of	O
differentially	O
expressed	O
proteins	O
in	O
amniotic	O
fluid	O
supernatant	O
associated	O
with	O
abnormal	O
human	O
karyotypes	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
functional	O
roles	O
of	O
differentially	O
expressed	O
proteins	O
in	O
the	O
amniotic	B-Disease
fluid	I-Disease
supernatant	I-Disease
(	O
AFS	O
)	O
with	O
abnormal	O
karyotypes	O
.	O

DESIGN	O
:	O
Basic	O
and	O
clinical	O
research	O
.	O

SETTING	O
:	O
University	O
hospital	O
.	O

PATIENT(S	O
)	O
:	O
Samples	O
of	O
AFS	O
from	O
34	O
fetuses	O
with	O
normal	O
-	O
karyotype	O
,	O
17	O
with	O
trisomy	O
18	O
,	O
and	O
19	O
with	O
trisomy	O
21	O
.	O

INTERVENTION(S	O
)	O
:	O
Two	O
-	O
dimensional	O
chromatography	O
followed	O
by	O
mass	O
spectrometry	O
to	O
identify	O
the	O
proteins	O
differentially	O
expressed	O
in	O
AFS	O
of	O
trisomy-18	O
or	O
trisomy-21	O
fetuses	O
.	O

MAIN	O
OUTCOME	O
MEASURE(S	O
)	O
:	O
Differentially	O
expressed	O
proteins	O
were	O
confirmed	O
with	O
Western	O
blot	O
analysis	O
and	O
ELISA	O
.	O

The	O
roles	O
of	O
biologic	O
networks	O
in	O
the	O
pathophysiology	O
of	O
aneuploidies	O
were	O
analyzed	O
using	O
MetaCore	O
mapping	O
tools	O
.	O

RESULT(S	O
)	O
:	O
Levels	B-MPA
of	O
apolipoprotein	B-Protein
A1	I-Protein
,	O
AP-3mu	B-Protein
,	O
and	O
antitrypsin	B-Protein
were	O
significantly	O
decreased	B-NegReg
in	O
trisomy-18	B-Var
AFS	O
,	O
whereas	O
placental	B-Protein
protein-14	I-Protein
was	O
increased	B-PosReg
.	O

On	O
the	O
other	O
hand	O
,	O
apolipoprotein	B-Protein
A1	I-Protein
was	O
decreased	B-NegReg
in	O
trisomy-21	B-Var
AFS	O
,	O
but	O
antitrypsin	B-Protein
,	O
prealbumin	B-Protein
,	O
and	O
transferrin	B-Protein
were	O
increased	B-PosReg
in	O
trisomy	B-Var
21	I-Var
.	O

Biologic	O
network	O
analyses	O
revealed	O
that	O
the	O
proteins	O
of	O
the	O
trisomy-18	O
AFS	O
network	O
were	O
involved	O
in	O
immune	O
processes	O
,	O
dysfunction	O
of	O
skin	O
pigmentation	O
,	O
and	O
platelet	O
disorders	O
,	O
whereas	O
those	O
of	O
trisomy	O
21	O
were	O
associated	O
with	O
dysfunctional	O
lipid	O
and	O
cholesterol	O
metabolism	O
,	O
processes	O
of	O
metal	O
ion	O
transport	O
,	O
adenosine	O
triphosphate	O
metabolism	O
,	O
and	O
energy	O
-	O
coupled	O
protein	O
transport	O
.	O

CONCLUSION(S	O
)	O
:	O
The	O
combined	O
use	O
of	O
quantitative	O
proteomics	O
and	O
functional	O
network	O
analyses	O
may	O
integrally	O
analyze	O
the	O
pathophysiology	O
of	O
abnormal	O
karyotypes	O
.	O

Canonical	O
WNT	O
signalling	O
determines	O
lineage	O
specificity	O
in	O
Wilms	O
tumour	O
.	O

Wilms	O
tumours	O
(	O
WTs	O
)	O
have	O
two	O
distinct	O
types	O
of	O
histology	O
with	O
or	O
without	O
ectopic	O
mesenchymal	O
elements	O
,	O
suggesting	O
that	O
WTs	O
arise	O
from	O
either	O
the	O
mesenchymal	O
or	O
epithelial	O
nephrogenic	O
lineages	O
.	O

Regardless	O
of	O
the	O
presence	O
or	O
absence	O
of	O
CTNNB1	O
mutations	O
,	O
nuclear	O
accumulation	O
of	O
beta	O
-	O
catenin	O
is	O
often	O
observed	O
in	O
WTs	O
with	O
ectopic	O
mesenchymal	O
elements	O
.	O

Here	O
,	O
we	O
addressed	O
the	O
relationship	O
between	O
the	O
WNT	O
-	O
signalling	O
pathway	O
and	O
lineage	O
in	O
WTs	O
by	O
examining	O
CTNNB1	O
and	O
WT1	O
mutations	O
,	O
nuclear	O
accumulation	O
of	O
beta	O
-	O
catenin	O
,	O
tumour	O
histology	O
and	O
gene	O
expression	O
profiles	O
.	O

In	O
addition	O
,	O
we	O
screened	O
for	O
mutations	B-Var
in	O
WTX	B-Gene
,	O
which	O
has	O
been	O
proposed	O
to	O
be	O
a	O
negative	B-NegReg
regulator	O
of	O
the	O
canonical	O
WNT	B-Pathway
-	I-Pathway
signalling	I-Pathway
pathway	I-Pathway
.	O

Unsupervised	O
clustering	O
analysis	O
identified	O
two	O
classes	O
of	O
tumours	O
:	O
mesenchymal	O
lineage	O
WNT	O
-	O
dependent	O
tumours	O
,	O
and	O
epithelial	O
lineage	O
WNT	O
-	O
independent	O
tumours	O
.	O

In	O
contrast	O
to	O
the	O
mesenchymal	O
lineage	O
specificity	O
of	O
CTNNB1	O
mutations	O
,	O
WTX	O
mutations	O
were	O
surprisingly	O
observed	O
in	O
both	O
lineages	O
.	O

WTX	B-Gene
-	I-Gene
mutant	I-Gene
WTs	O
with	O
ectopic	O
mesenchymal	O
elements	O
had	O
nuclear	O
accumulation	B-PosReg
of	O
beta	B-Protein
-	I-Protein
catenin	I-Protein
,	O
upregulation	B-PosReg
of	O
WNT	B-Gene
target	I-Gene
genes	I-Gene
and	O
an	O
association	B-Reg
with	I-Reg
CTNNB1	B-Gene
mutations	B-Var
in	O
exon	O
7	O
or	O
8	O
.	O

However	O
,	O
epithelial	O
lineage	O
WTs	O
with	O
WTX	O
mutations	O
had	O
no	O
indications	O
of	O
active	O
WNT	O
signalling	O
,	O
suggesting	O
that	O
the	O
involvement	O
of	O
WTX	O
in	O
the	O
WNT	O
-	O
signalling	O
pathway	O
may	O
be	O
lineage	O
dependent	O
,	O
and	O
that	O
WTX	O
may	O
have	O
an	O
alternative	O
function	O
to	O
its	O
role	O
in	O
the	O
canonical	O
WNT	O
-	O
signalling	O
pathway	O
.	O

Apparent	B-Disease
mineralocorticoid	I-Disease
excess	I-Disease
syndrome	I-Disease
in	O
a	O
Brazilian	O
boy	O
caused	B-Reg
by	I-Reg
the	O
homozygous	O
missense	O
mutation	O
p	B-Var
.	I-Var
R186C	I-Var
in	O
the	O
HSD11B2	B-Gene
gene	O
.	O

The	O
apparent	O
mineralocorticoid	O
excess	O
syndrome	O
(	O
AME	O
)	O
is	O
a	O
rare	O
autosomal	O
recessive	O
disorder	O
due	O
to	O
the	O
deficiency	O
of	O
11beta	O
-	O
hydroxysteroid	O
dehydrogenase	O
type	O
2	O
enzyme	O
(	O
11beta	O
-	O
HSD2	O
)	O
.	O

The	O
11beta	O
-	O
HSD2	O
enzyme	O
,	O
encoded	O
by	O
HSD11B2	O
gene	O
,	O
metabolizes	O
active	O
cortisol	O
in	O
cortisone	O
.	O

Mutations	B-Var
on	O
HSD11B2	B-Gene
gene	O
affect	B-Reg
the	O
enzyme	B-Enzyme
activity	B-MPA
by	O
leading	O
to	O
an	O
excess	B-PosReg
of	O
cortisol	B-MPA
,	O
which	O
causes	B-Reg
its	O
inappropriate	O
access	B-MPA
to	I-MPA
mineralocorticoid	I-MPA
receptor	I-MPA
.	O

Therefore	O
,	O
cortisol	O
will	O
bind	O
mineralocorticoid	O
receptor	O
.	O

The	O
human	O
HSD11B2	O
gene	O
maps	O
to	O
chromosome	O
16q22	O
and	O
consists	O
of	O
five	O
exons	O
encoding	O
a	O
protein	O
of	O
405	O
amino	O
acids	O
.	O

We	O
present	O
here	O
clinical	O
and	O
molecular	O
studies	O
on	O
a	O
Brazilian	O
boy	O
who	O
was	O
born	O
pre	O
-	O
term	O
after	O
an	O
oligodramnious	O
pregnancy	O
.	O

He	O
was	O
diagnosed	O
as	O
having	O
AME	O
at	O
the	O
age	O
of	O
26	O
months	O
.	O

His	O
parents	O
are	O
second	O
cousins	O
.	O

Molecular	O
characterization	O
of	O
the	O
HSD11B2	O
gene	O
revealed	O
the	O
homozygous	O
mutation	O
p	O
.	O
R186C.	O
The	O
patient	O
described	O
here	O
is	O
the	O
second	O
case	O
of	O
HDS11B2	B-Gene
gene	O
mutation	B-Var
reported	O
in	O
Brazilian	O
patients	O
with	B-Reg
AME	B-Disease
.	O

[	O
Primary	O
hiperoxaluria	O
:	O
a	O
new	O
mutation	O
in	O
gen	O
AGXT	B-Gene
(	B-Var
R197Q	I-Var
)	I-Var
cause	B-Reg
of	I-Reg
neonatal	B-Disease
convulsions	I-Disease
]	I-Disease
.	O

Hiperoxaluria	O
primaria	O
:	O
una	O
nueva	O
mutación	O
en	O
el	O
gen	O
AGXT	O
(	O
r197q	O
)	O
causante	O
de	O
convulsiones	O
neonatales	O
.	O

Primary	O
hyperoxaluria	O
is	O
a	O
congenital	O
innate	O
error	O
of	O
the	O
metabolism	O
of	O
the	O
amino	O
acids	O
,	O
that	O
is	O
transmitted	O
like	O
an	O
autosomal	O
recessive	O
character	O
.	O

Two	O
types	O
of	O
hyperoxaluria	O
exist	O
:	O
the	O
primary	O
type	O
I	O
,	O
that	O
corresponds	O
to	O
the	O
peroxisomal	O
enzymatic	O
deficit	O
of	O
the	O
alanine	O
glyoxylate	O
aminotransferase	O
in	O
the	O
liver	O
(	O
AGT	O
)	O
and	O
type	O
II	O
,	O
due	O
to	O
the	O
deficit	O
of	O
the	O
glyoxylate	O
reductase	O
/	O
hydroxypyruvate	O
reductase	O
deficiency	O
(	O
GRHPR	O
)	O
.	O

The	O
primary	O
type	O
I	O
(	O
AGT	O
)	O
is	O
the	O
most	O
frequenty	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
female	O
infant	O
of	O
one	O
month	O
of	O
age	O
,	O
that	O
on	O
her	O
first	O
day	O
post	O
birth	O
,	O
presented	O
myoclonic	O
convulsions	O
and	O
tonic	O
spasms	O
,	O
both	O
during	O
wakefullness	O
and	O
sleep	O
periods	O
,	O
that	O
became	O
more	O
frequent	O
and	O
did	O
not	O
respond	O
to	O
the	O
use	O
of	O
anticonvulsants	O
.	O

The	O
ictal	O
Electroencephalogram	O
presented	O
an	O
intermittent	O
activity	O
of	O
spikes	O
and	O
spike	O
-	O
waves	O
of	O
high	O
voltage	O
in	O
the	O
right	O
hemisphere	O
.	O

Eight	O
minutes	O
after	O
the	O
intravenous	O
administration	O
of	O
150	O
mg	O
of	O
pyridoxine	O
,	O
it	O
was	O
observed	O
a	O
diminution	O
of	O
the	O
epileptic	O
activity	O
,	O
as	O
well	O
as	O
the	O
clinical	O
manifestations	O
.	O

The	O
determination	O
of	O
organic	O
acids	O
in	O
urine	O
revealed	O
an	O
increase	O
in	O
the	O
concentration	O
levels	O
of	O
oxalic	O
acid	O
(	O
3064	O
mmol	O
/	O
mol	O
of	O
creatinine	O
)	O
.	O

The	O
molecular	O
genetic	O
study	O
of	O
the	O
AGXT	O
gene	O
,	O
showed	O
the	O
existence	O
of	O
a	O
R197Q	O
mutation	O
in	O
exón	O
5	O
of	O
the	O
patient	O
and	O
her	O
father	O
.	O

She	O
received	O
treatment	O
with	O
pyridoxine	O
at	O
a	O
dose	O
of	O
50	O
mg	O
/	O
day	O
.	O

When	O
she	O
reached	O
the	O
age	O
of	O
three	O
months	O
both	O
a	O
normal	O
electroencephalogram	O
and	O
biochemistry	O
were	O
obtained	O
.	O

Although	O
it	O
is	O
a	O
rare	O
cause	O
of	O
neonatal	O
convulsions	O
,	O
hyperoxaluria	O
,	O
due	O
to	O
new	O
mutations	O
is	O
an	O
underdiagnosed	O
disease	O
by	O
neonatologists	O
and	O
paediatricias	O
.	O

Identification	O
of	O
the	O
CLCN7	B-Gene
gene	O
mutations	B-Var
in	O
two	O
Chinese	O
families	O
with	B-Reg
autosomal	B-Disease
dominant	I-Disease
osteopetrosis	I-Disease
(	I-Disease
type	I-Disease
II	I-Disease
)	I-Disease
.	O

Here	O
we	O
report	O
the	O
identification	O
of	O
two	O
different	O
mutations	O
in	O
chloride	O
channel	O
7	O
gene	O
in	O
two	O
unrelated	O
patients	O
with	O
autosomal	O
dominant	O
osteopetrosis	O
type	O
II	O
.	O

We	O
determined	O
that	O
one	O
patient	O
(	O
a	O
32-year	O
-	O
old	O
woman	O
)	O
carried	O
a	O
heterozygous	O
gene	O
for	O
a	O
R767W	O
mutation	O
in	O
exon	O
24	O
,	O
and	O
another	O
patient	O
(	O
a	O
17-year	O
-	O
old	O
boy	O
)	O
carried	O
a	O
heterozygous	O
gene	O
for	O
a	O
novel	O
frameshift	O
mutation	O
(	O
Glu798FS	O
)	O
in	O
exon	O
25	O
.	O

Recent	O
studies	O
have	O
reported	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
the	O
chloride	O
channel	O
7	O
(	B-Gene
CLCN7	I-Gene
)	I-Gene
gene	O
as	O
a	O
cause	O
of	O
autosomal	B-Disease
dominant	I-Disease
osteopetrosis	I-Disease
type	I-Disease
II	I-Disease
(	I-Disease
ADO	I-Disease
-	I-Disease
II	I-Disease
)	I-Disease
.	O

The	O
identification	O
of	O
gene	O
mutations	O
in	O
Chinese	O
with	O
ADO	O
has	O
not	O
been	O
reported	O
previously	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
mutations	O
of	O
the	O
CLCN7	O
gene	O
in	O
two	O
unrelated	O
Chinese	O
families	O
with	O
ADO	O
-	O
II	O
.	O

Two	O
probands	O
with	O
ADO	O
-	O
II	O
were	O
diagnosed	O
based	O
on	O
their	O
bone	O
characteristics	O
on	O
X	O
-	O
rays	O
and	O
their	O
laboratory	O
results	O
.	O

All	O
25	O
exons	O
of	O
the	O
CLCN7	O
gene	O
,	O
including	O
the	O
exon	O
-	O
intron	O
boundaries	O
,	O
were	O
sequenced	O
.	O

We	O
found	O
in	O
family	O
1	O
that	O
the	O
proband	O
(	O
a	O
32-year	O
-	O
old	O
woman	O
)	O
was	O
heterozygous	O
for	O
a	O
CLCN7	O
mutation	O
.	O

The	O
nonsynonymous	O
mutation	O
consisted	O
of	O
a	O
heterozygous	O
C	O
/	O
T	O
transition	O
at	O
codon	O
2327	O
in	O
exon	O
24	O
,	O
which	O
resulted	O
in	O
an	O
arginine	O
(	O
CGG)-to	O
tryptophan	O
(	O
TGG	O
)	O
substitution	O
at	O
position	O
767	O
(	O
R767W	O
)	O
.	O

The	O
same	O
heterozygous	O
mutation	O
(	O
C	O
/	O
T	O
)	O
was	O
determined	O
in	O
her	O
father	O
and	O
son	O
,	O
who	O
were	O
asymptomatic	O
with	O
normal	O
skeleton	O
radiography	O
.	O

In	O
family	O
2	O
,	O
we	O
found	O
that	O
the	O
proband	O
(	O
a	O
17-year	O
-	O
old	O
boy	O
)	O
carried	O
a	O
novel	O
frameshift	O
mutation	O
(	O
Glu798FS	O
)	O
resulting	O
from	O
a	O
G	O
insertion	O
between	O
codon	O
60	O
and	O
codon	O
61	O
in	O
exon	O
25	O
.	O

The	O
heterozygous	O
-/G	O
insertion	O
is	O
predicted	O
to	O
elongate	O
the	O
peptide	O
of	O
CLCN7	O
by	O
120	O
amino	O
acids	O
after	O
position	O
797	O
amino	O
acids	O
.	O

Similarly	O
,	O
some	O
individuals	O
of	O
this	O
family	O
carried	O
the	O
same	O
heterozygous	O
mutation	O
,	O
but	O
they	O
are	O
all	O
asymptomatic	O
.	O

Furthermore	O
,	O
the	O
R767W	O
and	O
Glu798FS	O
mutations	O
were	O
not	O
found	O
in	O
100	O
unrelated	O
controls	O
.	O

Our	O
present	O
findings	O
suggest	O
that	O
the	O
novel	O
Glu798FS	B-Var
mutation	O
in	O
exon	O
25	O
and	O
R767W	B-Var
in	O
exon	O
24	O
in	O
the	O
CLCN7	B-Gene
gene	O
were	O
responsible	B-Reg
for	O
ADO	B-Disease
-	I-Disease
II	I-Disease
in	O
these	O
Chinese	O
patients	O
.	O

Identification	O
and	O
functional	O
analysis	O
of	O
novel	O
variants	O
of	O
the	O
human	O
melanocortin	O
1	O
receptor	O
found	O
in	O
melanoma	O
patients	O
.	O

The	O
melanocortin	O
1	O
receptor	O
,	O
a	O
Gs	O
protein	O
-	O
coupled	O
receptor	O
expressed	O
in	O
epidermal	O
melanocytes	O
,	O
is	O
a	O
major	O
determinant	O
of	O
skin	O
pigmentation	O
and	O
phototype	O
and	O
an	O
important	O
contributor	O
to	O
melanoma	O
risk	O
.	O

MC1R	O
activation	O
stimulates	O
synthesis	O
of	O
black	O
,	O
strongly	O
photoprotective	O
eumelanin	O
pigments	O
.	O

Several	O
MC1R	O
alleles	O
are	O
associated	O
with	O
red	O
hair	O
,	O
fair	O
skin	O
,	O
increased	O
sensitivity	O
to	O
ultraviolet	O
radiation	O
,	O
and	O
increased	O
skin	O
cancer	O
risk	O
.	O

The	O
MC1R	O
gene	O
is	O
highly	O
polymorphic	O
,	O
but	O
only	O
a	O
few	O
naturally	O
occurring	O
alleles	O
have	O
been	O
functionally	O
characterized	O
,	O
which	O
complicates	O
the	O
establishment	O
of	O
accurate	O
correlations	O
between	O
the	O
signaling	O
properties	O
of	O
mutant	O
alleles	O
and	O
defined	O
cutaneous	O
phenotypes	O
.	O

We	O
report	O
the	O
functional	O
characterization	O
of	O
six	O
MC1R	B-Gene
alleles	O
found	O
in	O
Spanish	O
melanoma	B-Disease
patients	O
.	O

Two	O
variants	O
(	O
c.152T	O
>	O
C	O
,	O
p	O
.	O
Val51Ala	O
and	O
c.865T	O
>	O
C	O
,	O
p	O
.	O
Cys289Arg	O
)	O
have	O
never	O
been	O
described	O
,	O
and	O
the	O
others	O
(	O
c.112G	O
>	O
A	O
,	O
p	O
.	O
Val38Met	O
;	O
c.122C	O
>	O
T	O
,	O
p	O
.	O
Ser41Phe	O
;	O
c.383T	O
>	O
C	O
,	O
p	O
.	O
Met128Thr	O
;	O
and	O
c.842A	O
>	O
G	O
,	O
p	O
.	O
Asn281Ser	O
)	O
have	O
not	O
been	O
analyzed	O
for	O
function	O
.	O

p	B-Var
.	I-Var
Asn281Ser	I-Var
corresponds	O
to	O
a	O
functionally	O
silent	B-NegReg
polymorphism	B-MPA
.	O

The	O
other	O
mutations	O
are	O
associated	O
with	O
varying	O
degrees	O
of	O
loss	O
of	O
function	O
(	O
LOF	O
)	O
,	O
from	O
moderate	O
decreases	B-NegReg
in	O
coupling	B-MPA
to	O
the	O
cAMP	B-Pathway
pathway	I-Pathway
(	B-Var
p	I-Var
.	I-Var
Val38Met	I-Var
and	O
p	B-Var
.	I-Var
Val51Ala	I-Var
)	I-Var
to	O
nearly	O
complete	O
absence	B-NegReg
of	O
functional	B-MPA
coupling	I-MPA
(	B-Var
p	I-Var
.	I-Var
Ser41Phe	I-Var
,	O
p	B-Var
.	I-Var
Met128Thr	I-Var
,	O
and	O
p	B-Var
.	I-Var
Cys289Arg	I-Var
)	I-Var
.	O

The	O
LOF	O
p	B-Var
.	I-Var
Met128Thr	I-Var
and	O
p	B-Var
.	I-Var
Cys289Arg	I-Var
mutants	O
are	O
trafficked	O
to	O
the	O
cell	O
surface	O
,	O
but	O
are	O
unable	B-NegReg
to	O
bind	B-Interaction
agonists	O
efficiently	O
.	O

Conversely	O
,	O
LOF	O
of	O
p	B-Var
.	I-Var
Val38Met	I-Var
,	O
p	B-Var
.	I-Var
Ser41Phe	I-Var
,	O
and	O
p	B-Var
.	I-Var
Val51Ala	I-Var
is	O
due	O
to	O
reduced	B-NegReg
cell	B-CPA
surface	I-CPA
expression	I-CPA
as	O
a	O
consequence	O
of	O
retention	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
.	O

Therefore	O
,	O
LOF	O
of	O
MC1R	O
alleles	O
is	O
frequently	O
associated	O
with	O
aberrant	O
forward	O
trafficking	O
and	O
accumulation	O
within	O
the	O
ER	O
or	O
with	O
inability	O
to	O
bind	O
properly	O
the	O
activatory	O
ligand	O
.	O

A	O
case	O
of	O
factor	B-Disease
XI	I-Disease
deficiency	I-Disease
caused	B-Reg
by	I-Reg
compound	O
heterozygous	O
F11	B-Gene
gene	O
mutation	B-Var
.	O

Inherited	O
factor	O
XI	O
(	O
FXI	O
)	O
deficiency	O
is	O
a	O
rare	O
autosomal	O
recessive	O
bleeding	O
disorder	O
in	O
most	O
populations	O
except	O
for	O
Ashkenazi	O
Jews	O
.	O

In	O
this	O
report	O
,	O
a	O
25-year	O
-	O
old	O
Chinese	O
female	O
FXI	O
deficiency	O
case	O
has	O
been	O
studied	O
.	O

Routine	O
clotting	O
tests	O
showed	O
significantly	O
prolonged	O
activated	O
partial	O
thromboplastin	O
time	O
(	O
69.5	O
s	O
,	O
control	O
35	O
+	O
/-	O
10	O
s	O
)	O
while	O
prothrombin	O
time	O
(	O
12.3	O
s	O
,	O
control	O
13	O
+	O
/-	O
3	O
s)was	O
normal	O
.	O

FXI	O
:	O
C	O
and	O
FXI	O
:	O
Ag	O
were	O
2.6	O
%	O
and	O
2.5	O
%	O
,	O
respectively	O
,	O
indicating	O
that	O
this	O
case	O
was	O
cross	O
-	O
reacting	O
material	O
negative	O
.	O

The	O
activities	O
of	O
other	O
coagulation	O
factors	O
and	O
liver	O
function	O
were	O
in	O
normal	O
range	O
.	O

The	O
DNA	O
sequence	O
results	O
of	O
the	O
15	O
exons	O
and	O
their	O
boundaries	O
of	O
F11	O
gene	O
revealed	O
a	O
novel	O
G3733C	O
missense	O
mutation	O
in	O
exon	O
2	O
,	O
and	O
a	O
recurrent	O
C16642	O
T	O
nonsense	O
mutation	O
in	O
exon	O
8	O
.	O

The	O
G3733C	B-Var
mutation	O
caused	B-Reg
G-1R	B-Var
substitution	I-Var
in	O
FXI	B-Protein
signal	I-Protein
peptide	I-Protein
,	O
which	O
might	O
impair	B-NegReg
the	O
protein	B-MPA
's	I-MPA
secretion	I-MPA
and	O
introduced	B-PosReg
a	O
new	O
BssSI	O
enzyme	B-Enzyme
digestion	B-MPA
site	O
.	O

The	O
C16642	B-Var
T	I-Var
mutation	O
led	B-Reg
a	O
premature	B-MPA
stop	I-MPA
codon	I-MPA
at	O
amino	O
acid	O
position	O
263(Q263Term	B-Var
)	I-Var
.	O

G-1R	B-Var
and	O
Q263Term	B-Var
compound	O
heterozygous	O
mutations	O
in	O
F11	B-Gene
gene	O
were	O
the	O
cause	B-Reg
of	O
FXI	B-Disease
deficiency	I-Disease
for	O
this	O
proband	O
.	O

G-1R	B-Var
mutation	O
was	O
a	O
novel	O
F11	B-Gene
gene	O
mutation	O
causing	B-Reg
inherited	O
FXI	B-Disease
deficiency	I-Disease
.	O

Accelerated	O
inactivation	O
of	O
the	O
L	O
-	O
type	O
calcium	O
current	O
due	O
to	O
a	O
mutation	O
in	O
CACNB2b	O
underlies	O
Brugada	O
syndrome	O
.	O

Recent	O
studies	O
have	O
demonstrated	O
an	O
association	B-Reg
between	O
mutations	B-Var
in	O
CACNA1c	B-Gene
or	O
CACNB2b	B-Gene
and	O
Brugada	B-Disease
syndrome	I-Disease
(	O
BrS	O
)	O
.	O

Previously	O
described	O
mutations	O
all	O
caused	O
a	O
loss	O
of	O
function	O
secondary	O
to	O
a	O
reduction	O
of	O
peak	O
calcium	O
current	O
(	O
I(Ca	O
)	O
)	O
.	O

We	O
describe	O
a	O
novel	O
CACNB2b	B-Gene
mutation	B-Var
associated	O
with	O
BrS	O
in	O
which	O
loss	O
of	O
function	O
is	O
caused	O
by	O
accelerated	O
inactivation	B-NegReg
of	O
I(Ca	B-MPA
)	I-MPA
.	O

The	O
proband	O
,	O
a	O
32	O
year	O
old	O
male	O
,	O
displayed	O
a	O
Type	O
I	O
ST	O
segment	O
elevation	O
in	O
two	O
right	O
precordial	O
ECG	O
leads	O
following	O
a	O
procainamide	O
challenge	O
.	O

EP	O
study	O
was	O
positive	O
with	O
induction	O
of	O
polymorphic	O
VT	O
/	O
VF	O
.	O

Interrogation	O
of	O
implanted	O
ICD	O
revealed	O
brief	O
episodes	O
of	O
very	O
rapid	O
ventricular	O
tachycardia	O
.	O

He	O
was	O
also	O
diagnosed	O
with	O
vasovagal	O
syncope	O
.	O

Genomic	O
DNA	O
was	O
isolated	O
from	O
lymphocytes	O
.	O

All	O
exons	O
and	O
intron	O
borders	O
of	O
15	O
ion	O
channel	O
genes	O
were	O
amplified	O
and	O
sequenced	O
.	O

The	O
only	O
mutation	O
uncovered	O
was	O
a	O
missense	O
mutation	O
(	O
T11I	O
)	O
in	O
CACNB2b	O
.	O

We	O
expressed	O
WT	O
or	O
T11I	O
CACNB2b	O
in	O
TSA201	O
cells	O
co	O
-	O
transfected	O
with	O
WT	O
CACNA1c	O
and	O
CACNA2d	O
.	O

Patch	O
clamp	O
analysis	O
showed	O
no	O
significant	O
difference	O
between	O
WT	O
and	O
T11I	O
in	O
peak	O
I(Ca	O
)	O
density	O
,	O
steady	O
-	O
state	O
inactivation	O
or	O
recovery	O
from	O
inactivation	O
.	O

However	O
,	O
both	O
fast	O
and	O
slow	O
decays	O
of	O
I(Ca	O
)	O
were	O
significantly	O
faster	O
in	O
mutant	O
channels	O
between	O
0	O
and	O
+	O
20	O
mV.	O
Action	O
potential	O
voltage	O
clamp	O
experiments	O
showed	O
that	O
total	O
charge	O
was	O
reduced	O
by	O
almost	O
half	O
compared	O
to	O
WT	O
.	O

We	O
report	O
the	O
first	O
BrS	O
mutation	O
in	O
CaCNB2b	O
resulting	O
in	O
accelerated	O
inactivation	O
of	O
L	O
-	O
type	O
calcium	O
channel	O
current	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
faster	O
current	O
decay	O
results	O
in	O
a	O
loss	O
-	O
of	O
-	O
function	O
responsible	O
for	O
the	O
Brugada	O
phenotype	O
Electrophysiological	O
studies	O
in	O
a	O
mouse	O
model	O
of	O
Schwartz	O
-	O
Jampel	O
syndrome	O
demonstrate	O
muscle	O
fiber	O
hyperactivity	O
of	O
peripheral	O
nerve	O
origin	O
.	O

Schwartz	B-Disease
-	I-Disease
Jampel	I-Disease
syndrome	I-Disease
(	O
SJS	O
)	O
is	O
an	O
autosomal	O
-	O
recessive	O
condition	O
characterized	O
by	O
muscle	O
stiffness	O
and	O
chondrodysplasia	O
.	O

It	O
is	O
due	O
to	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
hypomorphic	O
mutations	B-Var
in	O
the	O
HSPG2	B-Gene
gene	O
that	O
encodes	O
for	O
perlecan	O
,	O
a	O
proteoglycan	O
secreted	O
into	O
the	O
basement	O
membrane	O
.	O

The	O
origin	O
of	O
muscle	O
stiffness	O
in	O
SJS	O
is	O
debated	O
.	O

To	O
resolve	O
this	O
issue	O
,	O
we	O
performed	O
an	O
electrophysiological	O
investigation	O
of	O
an	O
SJS	O
mouse	O
model	O
with	O
a	O
missense	O
mutation	O
in	O
the	O
HSPG2	O
gene	O
.	O

Compound	O
muscle	O
action	O
potential	O
amplitudes	O
,	O
distal	O
motor	O
latencies	O
,	O
repetitive	O
nerve	O
stimulation	O
tests	O
,	O
and	O
sensory	O
nerve	O
conduction	O
velocities	O
of	O
SJS	O
mice	O
were	O
normal	O
.	O

On	O
electromyography	O
(	O
EMG	O
)	O
,	O
neuromyotonic	O
discharges	O
,	O
that	O
is	O
,	O
bursts	O
of	O
motor	O
unit	O
action	O
potentials	O
firing	O
at	O
high	O
rates	O
(	O
120	O
-	O
300	O
HZ	O
)	O
,	O
were	O
constantly	O
observed	O
in	O
SJS	O
mice	O
in	O
all	O
muscles	O
,	O
except	O
in	O
the	O
diaphragm	O
.	O

Neuromyotonic	O
discharges	O
were	O
not	O
influenced	O
by	O
general	O
anesthesia	O
and	O
disappeared	O
with	O
curare	O
administration	O
.	O

They	O
persisted	O
after	O
complete	O
motor	O
nerve	O
section	O
,	O
terminating	O
only	O
with	O
Wallerian	O
degeneration	O
.	O

These	O
results	O
demonstrate	O
that	O
perlecan	O
deficiency	O
in	O
SJS	O
provokes	O
a	O
neuromyotonic	O
syndrome	O
.	O

The	O
findings	O
further	O
suggest	O
a	O
distal	O
axonal	O
localization	O
of	O
the	O
generator	O
of	O
neuromyotonic	O
discharges	O
.	O

SJS	O
should	O
now	O
be	O
considered	O
as	O
an	O
inherited	O
disorder	O
with	O
peripheral	O
nerve	O
hyperexcitability	O
.	O

MEFV	B-Gene
mutation	B-Var
carriage	O
in	O
Israeli	O
Jewish	O
individuals	O
from	O
ethnicities	O
with	O
low	O
risk	O
for	B-Reg
familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
.	O

Familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	O
)	O
is	O
a	O
disease	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
MEditerranean	O
FeVer	O
gene	O
(	B-Gene
MEFV	I-Gene
)	I-Gene
,	O
and	O
in	O
Israel	O
it	O
most	O
commonly	O
affects	O
Jews	O
of	O
North	O
African	O
extraction	O
,	O
in	O
whom	O
the	O
mutation	O
carrier	O
rate	O
is	O
as	O
high	O
as	O
1	O
in	O
5	O
.	O

To	O
assess	O
the	O
protective	O
as	O
well	O
as	O
the	O
modulating	O
affect	O
of	O
MEFV	O
mutation	O
carriage	O
on	O
various	O
inflammatory	O
disease	O
states	O
,	O
we	O
sought	O
to	O
define	O
the	O
frequency	O
of	O
MEFV	O
mutations	O
in	O
Israeli	O
Jewish	O
individuals	O
of	O
various	O
ethnicities	O
,	O
including	O
those	O
with	O
low	O
frequency	O
of	O
FMF	O
,	O
which	O
were	O
not	O
in	O
the	O
focus	O
of	O
our	O
attention	O
hitherto	O
.	O

A	O
total	O
of	O
163	O
adults	O
of	O
Bucharian	O
,	O
Turkish	O
,	O
Georgian	O
,	O
Yemenite	O
and	O
Bulgarian	O
origin	O
comprised	O
the	O
study	O
group	O
.	O

The	O
prevalence	O
of	O
the	O
most	O
frequent	O
MEFV	O
mutations	O
in	O
the	O
Israeli	O
Jewish	O
population	O
,	O
namely	O
:	O
M694V	O
,	O
V726A	O
and	O
E148Q	O
,	O
was	O
assessed	O
.	O

The	O
association	O
of	O
mutation	O
carriage	O
with	O
a	O
personal	O
history	O
of	O
FMF	O
-	O
like	O
phenomena	O
,	O
as	O
well	O
as	O
various	O
inflammatory	O
and	O
non	O
-	O
inflammatory	O
diseases	O
,	O
was	O
evaluated	O
.	O

A	O
high	O
MEFV	O
mutation	O
frequency	O
was	O
found	O
among	O
Jews	O
of	O
Bucharian	O
,	O
Georgian	O
and	O
Bulgarian	O
origin	O
(	O
20	O
%	O
)	O
,	O
whereas	O
intermediate	O
and	O
low	O
rates	O
were	O
detected	O
in	O
Jews	O
of	O
Turkish	O
and	O
Yemenite	O
extraction	O
(	O
14	O
and	O
8	O
%	O
,	O
respectively	O
)	O
.	O

FMF	O
-	O
like	O
manifestations	O
and	O
related	O
diseases	O
were	O
observed	O
more	O
often	O
in	O
MEFV	O
mutation	O
carriers	O
than	O
in	O
their	O
counterparts	O
.	O

MEFV	O
mutation	O
frequency	O
,	O
directly	O
assessed	O
by	O
DNA	O
analysis	O
,	O
exceeds	O
the	O
rate	O
calculated	O
from	O
disease	O
prevalence	O
in	O
Israeli	O
Jewish	O
individuals	O
originated	O
from	O
ethnicities	O
with	O
a	O
low	O
prevalence	O
of	O
FMF	O
.	O

MEFV	O
mutation	O
carriage	O
in	O
this	O
subgroup	O
is	O
associated	O
with	O
various	O
inflammatory	O
disorders	O
.	O

In	O
vivo	O
laser	O
confocal	O
microscopy	O
findings	O
and	O
mutational	O
analysis	O
for	O
Schnyder	O
's	O
crystalline	O
corneal	O
dystrophy	O
.	O

OBJECTIVE	O
:	O
To	O
identify	O
any	O
mutation	O
of	O
the	O
UbiA	O
prenyltransferase	O
domain	O
-	O
containing	O
protein	O
1	O
(	O
UBIAD1	O
)	O
gene	O
in	O
Japanese	O
patients	O
with	O
Schnyder	B-Disease
's	I-Disease
crystalline	I-Disease
corneal	I-Disease
dystrophy	I-Disease
(	O
SCCD	O
)	O
and	O
to	O
investigate	O
in	O
vivo	O
microstructural	O
phenotype	O
and	O
genotype	O
correlations	O
using	O
laser	O
scanning	O
confocal	O
microscopy	O
(	O
Heidelberg	O
Retina	O
Tomograph	O
2	O
Rostock	O
Cornea	O
Module	O
;	O
Heidelberg	O
Engineering	O
GmbH	O
,	O
Dossenheim	O
,	O
Germany	O
)	O
.	O

DESIGN	O
:	O
Small	O
,	O
comparative	O
case	O
series	O
.	O

PARTICIPANTS	O
:	O
Three	O
patients	O
from	O
3	O
pedigrees	O
(	O
3	O
males	O
)	O
with	O
clinically	O
diagnosed	O
SCCD	O
and	O
their	O
relatives	O
(	O
2	O
males	O
,	O
1	O
female	O
)	O
participated	O
in	O
this	O
study	O
.	O

TESTING	O
:	O
All	O
participants	O
were	O
examined	O
genetically	O
and	O
by	O
slit	O
-	O
lamp	O
biomicroscopy	O
and	O
in	O
vivo	O
laser	O
confocal	O
microscopy	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O
Genomic	O
DNA	O
from	O
the	O
patients	O
and	O
100	O
unrelated	O
healthy	O
volunteers	O
(	O
200	O
chromosomes	O
)	O
was	O
isolated	O
from	O
blood	O
samples	O
and	O
used	O
for	O
mutation	O
screening	O
of	O
the	O
UBIAD1	O
gene	O
.	O

Selected	O
confocal	O
images	O
of	O
corneal	O
layers	O
were	O
evaluated	O
qualitatively	O
for	O
shape	O
and	O
degree	O
of	O
light	O
reflection	O
of	O
deposits	O
.	O

RESULTS	O
:	O
Novel	O
mutations	O
in	O
the	O
UBIAD1	O
gene	O
(	O
Y174C	O
,	O
K181R	O
,	O
and	O
N233H	O
)	O
were	O
identified	O
.	O

Additionally	O
,	O
cosegregation	O
of	O
the	O
mutation	O
(	B-Var
Y174C	I-Var
)	I-Var
and	O
SCCD	O
was	O
confirmed	O
in	O
1	O
pedigree	O
,	O
indicating	O
that	O
the	O
mutation	O
of	O
the	O
UBIAD1	B-Gene
gene	O
is	O
causative	B-Reg
for	O
SCCD	B-Disease
.	O

The	O
3	O
mutations	O
were	O
absent	O
in	O
all	O
200	O
control	O
chromosomes	O
.	O

In	O
vivo	O
laser	O
confocal	O
microscopy	O
demonstrated	O
subepithelial	O
highly	O
reflective	O
crystals	O
in	O
4	O
cases	O
;	O
the	O
shapes	O
of	O
the	O
crystals	O
were	O
needle	O
-	O
shaped	O
(	O
3	O
cases	O
)	O
or	O
rectangular	O
(	O
1	O
case	O
)	O
.	O

A	O
phenotype	O
and	O
genotype	O
correlation	O
was	O
demonstrated	O
in	O
1	O
pedigree	O
,	O
and	O
phenotypic	O
heterogeneity	O
(	O
SCCD	O
with	O
or	O
without	O
crystals	O
caused	O
by	O
a	O
same	O
mutation	O
of	O
Y174C	O
in	O
the	O
UBIAD1	O
gene	O
)	O
also	O
was	O
demonstrated	O
in	O
1	O
pedigree	O
.	O

CONCLUSIONS	O
:	O
Nonsynonymous	O
novel	O
mutations	O
in	O
the	O
UBIAD1	O
gene	O
were	O
detected	O
in	O
3	O
unrelated	O
Japanese	O
pedigrees	O
with	O
SCCD	O
,	O
confirming	O
the	O
genetic	O
heterogeneity	O
of	O
this	O
disorder	O
.	O

In	O
vivo	O
laser	O
confocal	O
microscopy	O
is	O
capable	O
of	O
identifying	O
characteristic	O
corneal	O
microstructural	O
changes	O
related	O
to	O
genetically	O
mapped	O
SCCD	O
with	O
high	O
resolution	O
,	O
and	O
phenotypic	O
heterogeneity	O
was	O
presented	O
.	O

Further	O
confocal	O
and	O
mutational	O
analysis	O
using	O
a	O
larger	O
number	O
of	O
patients	O
with	O
SCCD	O
is	O
required	O
to	O
elucidate	O
in	O
vivo	O
microstructural	O
phenotype	O
and	O
genotype	O
correlations	O
.	O

FINANCIAL	O
DISCLOSURE(S	O
)	O
:	O
The	O
author(s	O
)	O
have	O
no	O
proprietary	O
or	O
commercial	O
interest	O
in	O
any	O
materials	O
discussed	O
in	O
this	O
article	O
.	O

Neutral	B-Disease
lipid	I-Disease
storage	I-Disease
disease	I-Disease
:	I-Disease
genetic	O
disorders	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
adipose	B-Enzyme
triglyceride	I-Enzyme
lipase	I-Enzyme
/	I-Enzyme
PNPLA2	I-Enzyme
or	O
CGI-58	B-Gene
/	I-Gene
ABHD5	I-Gene
.	O

Neutral	O
lipid	O
storage	O
disease	O
(	O
NLSD	O
)	O
is	O
a	O
group	O
of	O
autosomal	O
recessive	O
disorders	O
characterized	O
by	O
the	O
excessive	O
accumulation	O
of	O
neutral	O
lipids	O
in	O
multiple	O
tissues	O
.	O

Recently	O
,	O
two	O
genes	O
,	O
adipose	O
triglyceride	O
lipase	O
(	O
ATGL	O
/	O
PNPLA2	O
)	O
and	O
comparative	O
gene	O
identification-58	O
(	O
CGI-58	O
/	O
ABHD5	O
)	O
,	O
have	O
been	O
shown	O
to	O
cause	O
NLSD	O
.	O

ATGL	O
specifically	O
hydrolyzes	O
the	O
first	O
fatty	O
acid	O
from	O
triacylglycerols	O
(	O
TG	O
)	O
and	O
CGI-58	O
/	O
ABHD5	O
stimulates	O
ATGL	O
activity	O
by	O
a	O
currently	O
unknown	O
mechanism	O
.	O

Mutations	B-Var
in	O
both	O
the	O
ATGL	B-Gene
and	O
the	O
CGI-58	B-Gene
genes	O
are	O
associated	B-Reg
with	I-Reg
systemic	B-MPA
TG	I-MPA
accumulation	I-MPA
,	O
yet	O
the	O
resulting	O
clinical	O
manifestations	O
are	O
not	O
identical	O
.	O

Patients	O
with	O
defective	O
ATGL	O
function	O
suffer	O
from	O
more	O
severe	O
myopathy	O
(	O
NLSDM	O
)	O
than	O
patients	O
with	O
defective	O
CGI-58	O
function	O
.	O

On	O
the	O
other	O
hand	O
,	O
CGI-58	B-Gene
mutations	B-Var
are	O
always	O
associated	B-Reg
with	I-Reg
ichthyosis	O
(	B-Disease
NLSDI	I-Disease
)	I-Disease
,	O
which	O
was	O
not	O
observed	O
in	O
patients	O
with	O
defective	O
ATGL	O
function	O
.	O

These	O
observations	O
indicate	O
an	O
ATGL	O
-	O
independent	O
function	O
of	O
CGI-58	O
.	O

This	O
review	O
summarizes	O
recent	O
findings	O
with	O
the	O
goal	O
of	O
relating	O
structural	O
variants	O
of	O
ATGL	O
and	O
CGI-58	O
to	O
functional	O
consequences	O
in	O
lipid	O
metabolism	O
.	O

A	O
heterozygous	B-Var
null	I-Var
mutation	I-Var
combined	O
with	O
the	O
G1258A	B-Var
polymorphism	O
of	O
SPINK5	B-Gene
causes	O
impaired	B-NegReg
LEKTI	B-MPA
function	I-MPA
and	O
abnormal	B-MPA
expression	I-MPA
of	I-MPA
skin	I-MPA
barrier	I-MPA
proteins	I-MPA
.	O

BACKGROUND	O
:	O
Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
the	O
Kazal	O
-	O
type	O
serine	O
protease	O
inhibitor	O
,	O
LEKTI	O
,	O
encoded	O
by	O
the	O
SPINK5	B-Gene
gene	O
cause	O
the	O
rare	O
autosomal	O
recessive	O
skin	O
disease	O
Netherton	B-Disease
syndrome	I-Disease
(	O
NS	O
)	O
.	O

G1258A	O
polymorphism	O
in	O
SPINK5	O
may	O
be	O
associated	O
with	O
atopic	O
dermatitis	O
,	O
which	O
shares	O
several	O
clinical	O
features	O
with	O
NS	O
.	O

OBJECTIVES	O
:	O
To	O
determine	O
if	O
the	O
phenotype	O
of	O
NS	O
can	O
be	O
caused	O
by	O
a	O
single	O
null	O
mutation	O
in	O
SPINK5	O
combined	O
with	O
the	O
homozygous	O
G1258A	O
polymorphism	O
.	O

METHODS	O
:	O
We	O
screened	O
mutations	O
in	O
the	O
gene	O
SPINK5	O
by	O
direct	O
DNA	O
sequencing	O
and	O
position	O
cloning	O
and	O
examined	O
the	O
expressions	O
of	O
the	O
SPINK5-encoded	O
protein	O
LEKTI	O
and	O
other	O
relevant	O
proteins	O
by	O
immunostaining	O
and	O
immunoblot	O
.	O

RESULTS	O
:	O
We	O
describe	O
here	O
a	O
patient	O
who	O
was	O
clinically	O
diagnosed	O
with	O
NS	O
and	O
carried	O
a	O
single	O
null	O
mutation	O
in	O
SPINK5	O
combined	O
with	O
the	O
homozygous	O
G1258A	O
polymorphism	O
.	O

SPINK5	O
mRNA	O
was	O
present	O
at	O
normal	O
levels	O
and	O
LEKTI	O
was	O
expressed	O
in	O
the	O
epidermis	O
.	O

Nonetheless	O
,	O
the	O
putative	O
downstream	O
LEKTI	O
substrates	O
stratum	O
corneum	O
trypsin	O
-	O
like	O
enzyme	O
(	O
SCTE	O
)	O
,	O
desmoglein	O
1	O
and	O
protein	O
markers	O
of	O
keratinocyte	O
differentiation	O
were	O
expressed	O
abnormally	O
,	O
similar	O
to	O
that	O
seen	O
in	O
NS	O
if	O
two	O
null	O
mutant	O
alleles	O
are	O
present	O
.	O

CONCLUSION	O
:	O
This	O
finding	O
indicates	O
that	O
haploinsufficiency	O
of	O
SPINK5	O
can	O
cause	O
the	O
NS	O
phenotype	O
in	O
the	O
presence	O
of	O
one	O
null	O
mutation	O
with	O
homozygous	O
G1258A	O
polymorphisms	O
in	O
SPINK5	O
,	O
and	O
this	O
could	O
impair	O
the	O
function	O
of	O
LEKTI	O
and	O
therefore	O
acts	O
as	O
a	O
true	O
mutation	O
.	O

MEFV	B-Gene
mutations	B-Var
in	O
patients	O
with	B-Reg
Familial	B-Disease
Mediterranean	I-Disease
Fever	I-Disease
from	O
the	O
Aegean	O
region	O
of	O
Turkey	O
.	O

Familial	B-Disease
Mediterranean	I-Disease
Fever	I-Disease
(	O
FMF	O
)	O
which	O
is	O
frequently	O
present	O
in	O
Mediterranean	O
populations	O
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
MEFV	B-Gene
gene	O
.	O

According	O
to	O
recent	O
data	O
,	O
MEFV	O
mutations	O
are	O
not	O
the	O
only	O
cause	O
of	O
FMF	O
,	O
but	O
these	O
are	O
major	O
genetic	O
determinants	O
which	O
cause	O
FMF	O
.	O

It	O
has	O
also	O
been	O
suggested	O
that	O
there	O
may	O
be	O
a	O
number	O
of	O
other	O
genes	O
causing	O
FMF	O
.	O

The	O
MEFV	O
gene	O
is	O
located	O
at	O
16p13.3	O
and	O
encodes	O
a	O
protein	O
,	O
pyrin	O
/	O
marenostrin	O
.	O

More	O
than	O
70	O
disease	O
associated	O
mutations	O
and	O
totally	O
186	O
mutations	O
and	O
polymorphisms	O
have	O
been	O
defined	O
in	O
affected	O
individuals	O
.	O

We	O
have	O
retrospectively	O
evaluated	O
the	O
molecular	O
test	O
results	O
of	O
1,201	O
patients	O
identified	O
as	O
having	O
FMF	O
clinical	O
symptoms	O
referred	O
to	O
the	O
Molecular	O
Genetics	O
Laboratory	O
of	O
the	O
Department	O
of	O
Medical	O
Genetics	O
,	O
Faculty	O
of	O
Medicine	O
,	O
Ege	O
University	O
,	O
Izmir	O
/	O
Turkey	O
over	O
the	O
last	O
4	O
years	O
.	O

Patients	O
were	O
tested	O
for	O
12	O
common	O
mutations	O
in	O
the	O
MEFV	O
gene	O
using	O
a	O
strip	O
assay	O
method	O
(	O
Innogenetics	O
,	O
Belgium	O
)	O
.	O

Out	O
of	O
the	O
1,201	O
patients	O
tested	O
(	O
2,402	O
chromosomes	O
)	O
in	O
the	O
Aegean	O
region	O
in	O
Turkey	O
,	O
654	O
(	O
54.45	O
%	O
)	O
did	O
not	O
carry	O
any	O
mutations	O
,	O
among	O
the	O
547	O
(	O
45.55	O
%	O
)	O
patients	O
with	O
mutations	O
246	O
patients	O
were	O
either	O
homozygous	O
(	O
101	O
)	O
or	O
compound	O
heterozygous	O
(	O
145	O
)	O
,	O
296	O
carried	O
only	O
one	O
detected	O
mutation	O
,	O
and	O
five	O
patients	O
had	O
three	O
mutations	O
.	O

Allelic	O
frequencies	O
for	O
the	O
four	O
most	O
common	O
mutations	O
in	O
the	O
mutation	O
positive	O
groups	O
were	O
47.60	O
%	O
(	O
M694V	O
)	O
,	O
16.75	O
%	O
(	O
E148Q	O
)	O
,	O
12.95	O
%	O
(	O
V726A	O
)	O
,	O
11.94	O
%	O
(	O
M680I	O
G	O
/	O
C).The	O
remaining	O
alleles	O
(	O
10.76	O
%	O
)	O
showed	O
rare	O
mutations	O
which	O
were	O
R761H	O
,	O
P369S	O
,	O
A744S	O
,	O
K695R	O
,	O
F479L	O
,	O
M694I.	O
When	O
the	O
frequencies	O
of	O
mutations	O
detected	O
in	O
our	O
group	O
were	O
compared	O
to	O
the	O
frequencies	O
reported	O
in	O
the	O
other	O
regions	O
of	O
Turkey	O
,	O
an	O
increase	O
in	O
V726A	O
mutation	O
frequency	O
was	O
observed	O
.	O

No	O
patient	O
showed	O
a	O
I692del	O
mutation	O
which	O
is	O
sometimes	O
evident	O
in	O
other	O
Mediterranean	O
populations	O
.	O

Factor	B-Protein
VIII	I-Protein
mutations	B-Var
in	B-Reg
42	O
Moldovan	O
haemophilia	B-Disease
A	I-Disease
families	O
,	O
including	O
12	O
that	O
are	O
novel	O
.	O

Haemophilia	B-Disease
A	I-Disease
(	O
HA	O
)	O
is	O
a	O
bleeding	O
disorder	O
caused	B-Reg
by	I-Reg
mutations	B-Var
within	O
the	O
X	O
-	O
linked	O
F8	B-Gene
gene	O
.	O

A	O
series	O
of	O
42	O
unrelated	O
Moldovan	O
patients	O
with	O
HA	O
had	O
their	O
disease	O
-	O
causative	O
mutation	O
determined	O
to	O
provide	O
clinically	O
valuable	O
genotyping	O
information	O
for	O
a	O
historically	O
underserved	O
population	O
and	O
to	O
utilize	O
factor	O
VIII	O
(	O
FVIII	O
)	O
structural	O
information	O
to	O
analyse	O
the	O
effects	O
of	O
haemophilic	O
missense	O
substitutions	O
.	O

DNA	O
samples	O
were	O
analysed	O
to	O
detect	O
intron	O
22	O
and	O
intron	O
1	O
inversions	O
followed	O
by	O
heteroduplex	O
analysis	O
of	O
PCR	O
-	O
amplified	O
fragments	O
containing	O
all	O
exonic	O
sequences	O
.	O

Missense	O
sites	O
identified	O
by	O
DNA	O
sequencing	O
were	O
visualized	O
in	O
the	O
recently	O
described	O
crystal	O
structures	O
of	O
human	O
FVIII	O
.	O

Of	O
the	O
26	O
different	O
point	O
mutations	O
,	O
12	O
were	O
novel	O
.	O

Gel	O
electrophoresis	O
identified	O
samples	O
with	O
a	O
second	O
major	O
DNA	O
band	O
that	O
migrated	O
abnormally	O
;	O
these	O
amplified	O
products	O
were	O
sequenced	O
.	O

Thirteen	O
intron	O
22	O
inversions	O
and	O
one	O
intron	O
1	O
inversion	O
were	O
found	O
.	O

Two	O
patients	O
had	O
large	O
,	O
partial	O
gene	O
deletions	O
and	O
there	O
were	O
six	O
frameshift	O
,	O
two	O
non	O
-	O
sense	O
,	O
two	O
splicing	O
and	O
16	O
missense	O
genotypes	O
.	O

Two	O
subjects	O
with	O
an	O
intron	O
22	O
inversion	O
and	O
one	O
with	O
a	O
large	O
,	O
partial	O
gene	O
deletion	O
developed	O
an	O
alloimmune	O
inhibitor	O
.	O

Their	O
localization	O
suggests	O
intra-	O
and	O
possibly	O
inter	O
-	O
molecular	O
interactions	O
that	O
are	O
important	O
for	O
the	O
structural	O
integrity	O
and/or	O
procoagulant	O
function	O
of	O
FVIII	O
.	O

Investigation	O
of	O
C5a	O
receptor	O
gene	O
450	O
C	O
/	O
T	O
polymorphism	O
in	O
Turkish	O
patients	O
with	O
familial	O
Mediterranean	O
fever	O
.	O

Familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	O
)	O
is	O
a	O
genetic	O
disorder	O
with	O
acute	O
inflammatory	O
serosal	O
attacks	O
due	B-Reg
to	I-Reg
MEFV	B-Gene
gene	O
mutations	B-Var
which	O
resides	O
in	O
chromosome	O
16	O
.	O

Lack	O
of	O
a	O
C5a	O
inhibitor	O
activity	O
in	O
the	O
peritoneum	O
has	O
previously	O
been	O
proposed	O
in	O
part	O
to	O
contribute	O
in	O
propagation	O
of	O
the	O
serosal	O
inflammation	O
in	O
FMF	O
attacks	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
C5a	O
receptor	O
(	O
C5aR	O
)	O
gene	O
polymorphism	O
in	O
patients	O
with	O
FMF	O
and	O
its	O
relation	O
to	O
the	O
main	O
features	O
of	O
the	O
disease	O
.	O

A	O
polymorphism	O
in	O
the	O
coding	O
region	O
of	O
C5aR	O
gene	O
leading	O
to	O
C	O
to	O
T	O
transition	O
at	O
nucleotide	O
position	O
450	O
has	O
been	O
investigated	O
in	O
85	O
non	O
-	O
related	O
Turkish	O
FMF	O
patients	O
and	O
160	O
non	O
-	O
related	O
healthy	O
controls	O
by	O
using	O
PCR	O
-	O
RFLP	O
.	O

The	O
frequencies	O
of	O
C5aR	O
gene	O
450	O
CT	O
genotype	O
and	O
T	O
allele	O
were	O
not	O
significantly	O
different	O
between	O
Turkish	O
FMF	O
patients	O
and	O
healthy	O
subjects	O
(	O
14.12	O
and	O
8.24	O
%	O
for	O
FMF	O
vs.	O
10	O
and	O
5	O
%	O
for	O
controls	O
,	O
respectively	O
)	O
.	O

C5aR	O
gene	O
450	O
CT	O
genotype	O
tended	O
to	O
associate	O
with	O
the	O
presence	O
Henoch	O
-	O
Schonlein	O
purpura	O
(	O
OR	O
:	O
1.25	O
,	O
95	O
%	O
CI	O
:	O
0.917	O
-	O
1.704	O
,	O
P	O
=	O
0.017	O
)	O
but	O
with	O
no	O
other	O
clinical	O
findings	O
of	O
the	O
disease	O
.	O

C5aR	O
polymorphism	O
might	O
be	O
searched	O
in	O
populations	O
having	O
high	O
prevalence	O
of	O
FMF	O
.	O

Expression	O
of	O
the	O
familial	O
Mediterranean	O
fever	O
gene	O
is	O
regulated	O
by	O
nonsense	O
-	O
mediated	O
decay	O
.	O

Mutations	B-Var
in	O
the	O
MEditerranean	O
FeVer	O
(	B-Gene
MEFV	I-Gene
)	I-Gene
gene	O
are	O
responsible	B-Reg
for	O
familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	O
)	O
,	O
a	O
recessively	O
inherited	O
auto	O
-	O
inflammatory	O
disease	O
.	O

Cases	O
of	O
dominant	O
inheritance	O
and	O
phenotype	O
-	O
genotype	O
heterogeneity	O
have	O
been	O
reported	O
;	O
however	O
,	O
the	O
underlying	O
molecular	O
mechanism	O
is	O
not	O
currently	O
understood	O
.	O

The	O
FMF	O
protein	O
named	O
pyrin	O
or	O
marenostrin	O
(	O
P	O
/	O
M	O
)	O
is	O
thought	O
to	O
be	O
involved	O
in	O
regulating	O
innate	O
immunity	O
but	O
its	O
function	O
remains	O
subject	O
to	O
controversy	O
.	O

Recent	O
studies	O
postulate	O
that	O
a	O
defect	O
in	O
MEFV	O
expression	O
regulation	O
may	O
play	O
a	O
role	O
in	O
FMF	O
physiopathology	O
.	O

Our	O
group	O
,	O
along	O
with	O
others	O
,	O
has	O
identified	O
several	O
alternatively	O
spliced	O
MEFV	O
transcripts	O
in	O
leukocytes	O
.	O

Since	O
alternative	O
splicing	O
and	O
nonsense	O
-	O
mediated	O
decay	O
(	O
NMD	O
)	O
pathways	O
are	O
usually	O
coupled	O
in	O
the	O
post	O
-	O
transcriptional	O
regulation	O
of	O
gene	O
expression	O
,	O
we	O
hypothesized	O
that	O
NMD	O
could	O
contribute	O
to	O
the	O
regulation	O
of	O
the	O
MEFV	O
gene	O
.	O

To	O
address	O
this	O
issue	O
,	O
we	O
examined	O
the	O
effect	O
of	O
indirect	O
and	O
direct	O
inhibition	O
of	O
NMD	O
on	O
expression	O
of	O
the	O
MEFV	O
transcripts	O
in	O
THP1	O
,	O
monocyte	O
and	O
neutrophil	O
cells	O
.	O

We	O
showed	O
that	O
MEFV	O
is	O
the	O
first	O
auto	O
-	O
inflammatory	O
gene	O
regulated	O
by	O
NMD	O
in	O
both	O
a	O
cell-	O
and	O
transcript	O
-	O
specific	O
manner	O
.	O

These	O
results	O
and	O
preliminary	O
western	O
-	O
blot	O
analyses	O
suggest	O
the	O
possible	O
translation	O
of	O
alternatively	O
spliced	O
MEFV	O
transcripts	O
into	O
several	O
P	O
/	O
M	O
variants	O
according	O
to	O
cell	O
type	O
and	O
inflammatory	O
state	O
.	O

Our	O
results	O
introduce	O
the	O
novel	O
hypothesis	O
that	O
variation	O
of	O
NMD	O
efficiency	O
could	O
play	O
an	O
important	O
role	O
in	O
FMF	O
physiopathology	O
as	O
a	O
potent	O
phenotypic	O
modifier	O
.	O

Novel	O
PORCN	B-Gene
mutations	B-Var
in	B-Reg
focal	B-Disease
dermal	I-Disease
hypoplasia	I-Disease
.	O

Focal	O
dermal	O
hypoplasia	O
(	O
FDH	O
)	O
,	O
Goltz	O
or	O
Goltz	O
-	O
Gorlin	O
syndrome	O
,	O
is	O
an	O
X	O
-	O
linked	O
dominant	O
multisystem	O
disorder	O
characterized	O
primarily	O
by	O
involvement	O
of	O
the	O
skin	O
,	O
skeletal	O
system	O
and	O
eyes	O
.	O

We	O
screened	O
for	O
mutations	B-Var
in	O
the	O
PORCN	B-Gene
gene	O
in	B-Reg
eight	O
patients	O
of	O
Belgian	O
and	O
Finnish	O
origin	O
with	O
firm	O
clinical	O
suspicion	O
of	O
FDH	B-Disease
.	O

First	O
,	O
we	O
performed	O
quantitative	O
PCR	O
(	O
qPCR	O
)	O
analysis	O
to	O
define	O
the	O
copy	O
number	O
at	O
this	O
locus	O
.	O

Next	O
,	O
we	O
sequenced	O
the	O
coding	O
regions	O
and	O
flanking	O
intronic	O
sequences	O
of	O
the	O
PORCN	O
gene	O
.	O

Three	O
de	O
novo	O
mutations	O
were	O
identified	O
in	O
our	O
patients	O
with	O
FDH	O
:	O
a	O
150-kb	O
deletion	O
removing	O
six	O
genes	O
including	O
PORCN	O
,	O
as	O
defined	O
by	O
qPCR	O
and	O
X	O
-	O
array	O
-	O
CGH	O
,	O
and	O
two	O
heterozygous	O
missense	O
mutations	O
;	O
c.992T	O
>	O
G	O
(	O
p	O
.	O
L331R	O
)	O
in	O
exon	O
11	O
and	O
c.1094G	O
>	O
A	O
(	O
p	O
.	O
R365Q	O
)	O
in	O
exon	O
13	O
of	O
the	O
gene	O
.	O

Both	O
point	O
mutations	O
changed	O
highly	O
conserved	O
amino	O
acids	O
and	O
were	O
not	O
found	O
in	O
300	O
control	O
X	O
chromosomes	O
.	O

The	O
three	O
patients	O
in	O
whom	O
mutations	O
were	O
identified	O
all	O
present	O
with	O
characteristic	O
dermal	O
findings	O
together	O
with	O
limb	O
manifestations	O
,	O
which	O
were	O
not	O
seen	O
in	O
our	O
mutation	O
-	O
negative	O
patients	O
.	O

The	O
clinical	O
characteristics	O
of	O
our	O
patients	O
with	O
PORCN	O
mutations	O
were	O
compared	O
with	O
the	O
previously	O
reported	O
mutation	O
-	O
positive	O
cases	O
.	O

In	O
this	O
report	O
,	O
we	O
summarize	O
the	O
literature	O
on	O
PORCN	O
mutations	O
and	O
associated	O
phenotypes	O
.	O

Elevated	O
expression	O
of	O
p53	B-Gene
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	O
R175H	B-Var
in	O
endometrial	O
cancer	O
cells	O
can	O
increase	O
the	O
invasive	O
phenotypes	O
by	O
activation	O
of	O
the	O
EGFR	B-Pathway
/	I-Pathway
PI3K	I-Pathway
/	I-Pathway
AKT	I-Pathway
pathway	I-Pathway
.	O

BACKGROUND	O
:	O
p53	O
is	O
the	O
most	O
commonly	O
mutated	O
tumor	O
suppressor	O
gene	O
in	O
human	O
cancers	O
.	O

In	O
addition	O
to	O
the	O
loss	O
of	O
tumor	O
suppression	O
function	O
and	O
exertion	O
of	O
dominant	O
-	O
negative	O
effects	O
over	O
the	O
remaining	O
wild	O
-	O
type	O
protein	O
,	O
several	O
p53	O
mutants	O
can	O
gain	O
novel	O
oncogenic	O
functions	O
(	O
gain	O
-	O
of	O
-	O
function	O
,	O
GOF	O
)	O
that	O
actively	O
regulate	O
cancer	O
development	O
and	O
progression	O
.	O

In	O
human	O
endometrial	O
cancer	O
,	O
p53	B-Gene
mutation	B-Var
is	O
more	O
often	O
associated	B-Reg
with	O
aggressive	B-Disease
nonendometrioid	I-Disease
cancer	I-Disease
.	O

However	O
,	O
it	O
was	O
unknown	O
if	O
p53	O
mutants	O
contributed	O
to	O
endometrial	O
cancer	O
progression	O
through	O
the	O
GOF	O
properties	O
.	O

METHODS	O
:	O
To	O
clarify	O
the	O
relationship	O
between	O
expression	O
of	O
p53	O
GOF	O
mutation	O
(	O
p53-R175H	O
)	O
and	O
invasive	O
potential	O
of	O
human	O
endometrial	O
cancer	O
KLE	O
cells	O
,	O
we	O
tested	B-Reg
the	O
consequences	O
of	O
up	B-PosReg
-	I-PosReg
regulation	I-PosReg
and	O
down	B-NegReg
-	I-NegReg
regulation	I-NegReg
of	O
p53-R175H	O
in	O
KLE	O
cells	O
by	O
inducing	B-Reg
p53-R175H	B-Protein
expression	I-Protein
vector	I-Protein
or	O
suppressing	B-NegReg
the	O
p53	B-Gene
gene	I-Gene
with	O
short	O
hairpin	O
RNA	O
.	O

RESULTS	O
:	O
We	O
found	O
that	O
forced	O
over	B-PosReg
-	I-PosReg
expression	I-PosReg
of	O
p53-R175H	B-Gene
significantly	O
promoted	B-PosReg
cell	B-CPA
migration	I-CPA
and	O
invasion	B-CPA
,	O
and	O
induced	O
activation	B-PosReg
of	O
the	O
epidermal	B-Pathway
growth	I-Pathway
factor	I-Pathway
receptor	I-Pathway
(	I-Pathway
EGFR)/phosphatidylinositol	I-Pathway
3-kinase	I-Pathway
(	I-Pathway
PI3K)/AKT	I-Pathway
pathway	I-Pathway
.	O

Conversely	O
,	O
suppression	B-NegReg
of	O
p53-R175H	B-Protein
with	O
short	B-Gene
hairpin	I-Gene
RNA	I-Gene
significantly	O
inhibited	B-NegReg
cell	B-CPA
migration	I-CPA
and	I-CPA
invasion	I-CPA
,	O
and	O
resulted	O
in	O
attenuation	B-NegReg
of	O
EGFR	B-Pathway
/	I-Pathway
PI3K	I-Pathway
/	I-Pathway
AKT	I-Pathway
pathway	I-Pathway
.	O

CONCLUSION	O
:	O
These	O
findings	O
show	O
for	O
the	O
first	O
time	O
that	O
elevated	B-PosReg
expression	B-MPA
of	O
p53-R175H	B-Gene
mutant	O
may	O
exert	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
activity	I-MPA
to	O
activate	B-PosReg
the	O
EGFR	B-Pathway
/	I-Pathway
PI3K	I-Pathway
/	I-Pathway
AKT	I-Pathway
pathway	I-Pathway
and	O
thus	O
may	O
contribute	B-Reg
to	O
the	O
invasive	O
phenotype	O
in	O
endometrial	B-Disease
cancer	I-Disease
.	O

Longitudinal	O
course	O
of	O
cognitive	O
,	O
adaptive	O
,	O
and	O
behavioral	O
characteristics	O
in	O
Costello	O
syndrome	O
.	O

Costello	B-Disease
syndrome	I-Disease
is	O
a	O
rare	O
rasopathy	O
caused	B-Reg
by	I-Reg
germline	O
mutations	B-Var
in	O
the	O
oncogene	O
HRAS	B-Gene
resulting	O
in	O
increased	B-PosReg
signal	B-MPA
transduction	I-MPA
through	O
the	O
Ras	B-Pathway
/	I-Pathway
mitogen	I-Pathway
-	I-Pathway
activated	I-Pathway
protein	I-Pathway
kinase	I-Pathway
pathway	I-Pathway
.	O

In	O
contrast	O
to	O
the	O
more	O
common	O
rasopathies	O
,	O
such	O
as	O
neurofibromatosis	O
type	O
1	O
and	O
Noonan	O
syndrome	O
,	O
limited	O
information	O
is	O
available	O
on	O
standardized	O
cognitive	O
testing	O
in	O
this	O
cohort	O
.	O

Past	O
research	O
indicated	O
a	O
mean	O
average	O
IQ	O
in	O
the	O
mild	O
mental	O
retardation	O
range	O
,	O
with	O
strengths	O
in	O
fluid	O
reasoning	O
(	O
FR	O
)	O
and	O
weakness	O
in	O
expressive	O
language	O
,	O
as	O
well	O
as	O
static	O
skills	O
over	O
time	O
.	O

Here	O
we	O
report	O
on	O
standardized	O
IQ	O
and	O
adaptive	O
functioning	O
in	O
18	O
individuals	O
with	O
Costello	O
syndrome	O
,	O
nine	O
males	O
and	O
nine	O
females	O
,	O
and	O
longitudinal	O
development	O
for	O
11	O
who	O
had	O
previous	O
testing	O
.	O

The	O
overall	O
IQ	O
,	O
ranging	O
from	O
severe	O
mental	O
retardation	O
to	O
the	O
average	O
range	O
,	O
with	O
a	O
mean	O
in	O
the	O
mildly	O
mentally	O
retarded	O
range	O
,	O
was	O
again	O
found	O
to	O
be	O
stable	O
,	O
but	O
an	O
interesting	O
pattern	O
in	O
the	O
development	O
of	O
nonverbal	O
FR	O
was	O
identified	O
.	O

Participants	O
showed	O
an	O
improvement	O
in	O
nonverbal	O
FR	O
,	O
followed	O
by	O
stable	O
skills	O
thereafter	O
,	O
suggesting	O
a	O
"	O
late	O
bloomer	O
"	O
effect	O
in	O
late	O
childhood	O
/	O
early	O
adolescence	O
.	O

Overall	O
adaptive	O
functioning	O
fell	O
into	O
the	O
range	O
of	O
Intellectual	O
Disability	O
for	O
70	O
%	O
of	O
subjects	O
,	O
with	O
Socialization	O
as	O
a	O
relative	O
strength	O
and	O
Daily	O
Living	O
Skills	O
an	O
area	O
of	O
relative	O
difficulty	O
.	O

Interestingly	O
,	O
females	O
were	O
found	O
to	O
be	O
higher	O
functioning	O
than	O
males	O
in	O
all	O
domains	O
,	O
including	O
Communication	O
,	O
Daily	O
Living	O
Skills	O
and	O
Socialization	O
.	O

Caregivers	O
reported	O
significantly	O
more	O
behavioral	O
concerns	O
in	O
males	O
,	O
including	O
internalizing	O
,	O
externalizing	O
,	O
and	O
other	O
maladaptive	O
behaviors	O
.	O

In	O
contrast	O
,	O
no	O
gender	O
differences	O
were	O
found	O
in	O
cognitive	O
or	O
visuomotor	O
functioning	O
.	O

Molecular	O
analysis	O
of	O
42	O
patients	O
with	B-Reg
congenital	B-Disease
dyserythropoietic	I-Disease
anemia	I-Disease
type	I-Disease
II	I-Disease
:	I-Disease
new	O
mutations	B-Var
in	O
the	O
SEC23B	B-Gene
gene	O
and	O
a	O
search	O
for	O
a	O
genotype	O
-	O
phenotype	O
relationship	O
.	O

BACKGROUND	O
:	O
The	O
most	O
frequent	O
form	O
of	O
congenital	O
dyserythropoietic	O
anemia	O
is	O
the	O
type	O
II	O
form	O
.	O

Recently	O
it	O
was	O
shown	O
that	O
the	O
vast	O
majority	O
of	O
patients	O
with	O
congenital	B-Disease
dyserythropoietic	I-Disease
anemia	I-Disease
type	I-Disease
II	I-Disease
carry	B-Reg
mutations	B-Var
in	O
the	O
SEC23B	B-Gene
gene	O
.	O

Here	O
we	O
established	O
the	O
molecular	O
basis	O
of	O
42	O
cases	O
of	O
congenital	O
dyserythropoietic	O
anemia	O
type	O
II	O
and	O
attempted	O
to	O
define	O
a	O
genotype	O
-	O
phenotype	O
relationship	O
.	O

DESIGN	O
AND	O
METHODS	O
:	O
SEC23B	O
gene	O
sequencing	O
analysis	O
was	O
performed	O
to	O
assess	O
the	O
diversity	O
and	O
incidence	O
of	O
each	O
mutation	O
in	O
42	O
patients	O
with	O
congenital	O
dyserythropoietic	O
anemia	O
type	O
II	O
(	O
25	O
described	O
exclusively	O
in	O
this	O
work	O
)	O
,	O
from	O
the	O
Italian	O
and	O
the	O
French	O
Registries	O
,	O
and	O
the	O
relationship	O
of	O
these	O
mutations	O
with	O
the	O
clinical	O
presentation	O
.	O

To	O
this	O
purpose	O
,	O
we	O
divided	O
the	O
patients	O
into	O
two	O
groups	O
:	O
(	O
i	O
)	O
patients	O
with	O
two	O
missense	O
mutations	O
and	O
(	O
ii	O
)	O
patients	O
with	O
one	O
nonsense	O
and	O
one	O
missense	O
mutation	O
.	O

RESULTS	O
:	O
We	O
found	O
22	O
mutations	O
of	O
uneven	O
frequency	O
,	O
including	O
seven	O
novel	O
mutations	O
.	O

Compound	O
heterozygosity	O
for	O
a	O
missense	O
and	O
a	O
nonsense	O
mutation	O
tended	O
to	O
produce	O
a	O
more	O
severe	O
clinical	O
presentation	O
,	O
a	O
lower	O
reticulocyte	O
count	O
,	O
a	O
higher	O
serum	O
ferritin	O
level	O
,	O
and	O
,	O
in	O
some	O
cases	O
,	O
more	O
pronounced	O
transfusion	O
needs	O
,	O
than	O
homozygosity	O
or	O
compound	O
heterozygosity	O
for	O
two	O
missense	O
mutations	O
.	O

Homozygosity	O
or	O
compound	O
heterozygosity	O
for	O
two	O
nonsense	O
mutations	O
was	O
never	O
found	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
allowed	O
us	O
to	O
determine	O
the	O
most	O
frequent	O
mutations	O
in	O
patients	O
with	O
congenital	O
dyserythropoietic	O
anemia	O
type	O
II	O
.	O

Correlations	O
between	O
the	O
mutations	O
and	O
various	O
biological	O
parameters	O
suggested	O
that	O
the	O
association	O
of	O
one	O
missense	O
mutation	O
and	O
one	O
nonsense	O
mutation	O
was	O
significantly	O
more	O
deleterious	O
that	O
the	O
association	O
of	O
two	O
missense	O
mutations	O
.	O

However	O
,	O
there	O
was	O
an	O
overlap	O
between	O
the	O
two	O
categories	O
.	O

Identification	O
and	O
characterization	O
of	O
novel	O
sequence	O
variations	O
in	O
MECP2	O
gene	O
in	O
Rett	O
syndrome	O
patients	O
.	O

Rett	B-Disease
syndrome	I-Disease
(	O
RS	O
)	O
is	O
a	O
neurodevelopmental	O
disorder	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
MECP2	B-Gene
gene	O
.	O

Exons	O
2	O
,	O
3	O
,	O
and	O
4	O
,	O
in	O
addition	O
to	O
intronic	O
and	O
3'UTR	O
adjacent	O
regions	O
,	O
were	O
sequenced	O
in	O
80	O
patients	O
with	O
RS	O
.	O

Twenty	O
-	O
nine	O
sequence	O
variations	O
were	O
detected	O
in	O
49	O
patients	O
,	O
34	O
(	O
69.4	O
%	O
)	O
patients	O
with	O
the	O
classic	O
form	O
of	O
RS	O
,	O
and	O
15	O
(	O
30.6	O
%	O
)	O
patients	O
with	O
atypical	O
forms	O
of	O
RS	O
.	O

Thirteen	O
of	O
the	O
29	O
detected	O
mutations	O
represent	O
novel	O
sequence	O
variations	O
.	O

Missense	O
mutation	O
T158	O
M	O
was	O
the	O
most	O
commonly	O
observed	O
mutation	O
,	O
detected	O
in	O
nine	O
patients	O
(	O
11.2	O
%	O
)	O
.	O

Six	O
hotspot	O
pathogenic	O
mutations	O
(	O
R133C	O
,	O
T158	O
M	O
,	O
R168X	O
,	O
R255X	O
,	O
R270X	O
,	O
and	O
R294X	O
)	O
were	O
responsible	O
for	O
the	O
phenotype	O
in	O
26/80	O
patients	O
(	O
32.5	O
%	O
)	O
.	O

Ribosomal	O
protein	O
genes	O
RPS10	B-Gene
and	O
RPS26	B-Gene
are	O
commonly	O
mutated	B-Var
in	B-Reg
Diamond	B-Disease
-	I-Disease
Blackfan	I-Disease
anemia	I-Disease
.	O

Diamond	O
-	O
Blackfan	O
anemia	O
(	O
DBA	O
)	O
,	O
an	O
inherited	O
bone	O
marrow	O
failure	O
syndrome	O
characterized	O
by	O
anemia	O
that	O
usually	O
presents	O
before	O
the	O
first	O
birthday	O
or	O
in	O
early	O
childhood	O
,	O
is	O
associated	O
with	O
birth	O
defects	O
and	O
an	O
increased	O
risk	O
of	O
cancer	O
.	O

Although	O
anemia	O
is	O
the	O
most	O
prominent	O
feature	O
of	O
DBA	O
,	O
the	O
disease	O
is	O
also	O
characterized	O
by	O
growth	O
retardation	O
and	O
congenital	O
malformations	O
,	O
in	O
particular	O
craniofacial	O
,	O
upper	O
limb	O
,	O
heart	O
,	O
and	O
urinary	O
system	O
defects	O
that	O
are	O
present	O
in	O
approximately	O
30%-50	O
%	O
of	O
patients	O
.	O

DBA	O
has	O
been	O
associated	O
with	O
mutations	O
in	O
seven	O
ribosomal	O
protein	O
(	O
RP	O
)	O
genes	O
,	O
RPS19	O
,	O
RPS24	O
,	O
RPS17	O
,	O
RPL35A	O
,	O
RPL5	O
,	O
RPL11	O
,	O
and	O
RPS7	O
,	O
in	O
about	O
43	O
%	O
of	O
patients	O
.	O

To	O
continue	O
our	O
large	O
-	O
scale	O
screen	O
of	O
RP	O
genes	O
in	O
a	O
DBA	O
population	O
,	O
we	O
sequenced	O
35	O
ribosomal	O
protein	O
genes	O
,	O
RPL15	O
,	O
RPL24	O
,	O
RPL29	O
,	O
RPL32	O
,	O
RPL34	O
,	O
RPL9	O
,	O
RPL37	O
,	O
RPS14	O
,	O
RPS23	O
,	O
RPL10A	O
,	O
RPS10	O
,	O
RPS12	O
,	O
RPS18	O
,	O
RPL30	O
,	O
RPS20	O
,	O
RPL12	O
,	O
RPL7A	O
,	O
RPS6	O
,	O
RPL27A	O
,	O
RPLP2	O
,	O
RPS25	O
,	O
RPS3	O
,	O
RPL41	O
,	O
RPL6	O
,	O
RPLP0	O
,	O
RPS26	O
,	O
RPL21	O
,	O
RPL36AL	O
,	O
RPS29	O
,	O
RPL4	O
,	O
RPLP1	O
,	O
RPL13	O
,	O
RPS15A	O
,	O
RPS2	O
,	O
and	O
RPL38	O
,	O
in	O
our	O
DBA	O
patient	O
cohort	O
of	O
117	O
probands	O
.	O

We	O
identified	O
three	O
distinct	O
mutations	O
of	O
RPS10	O
in	O
five	O
probands	O
and	O
nine	O
distinct	O
mutations	O
of	O
RPS26	O
in	O
12	O
probands	O
.	O

Pre	O
-	O
rRNA	O
analysis	O
in	O
lymphoblastoid	O
cells	O
from	O
patients	O
bearing	O
mutations	B-Var
in	O
RPS10	B-Gene
and	O
RPS26	B-Gene
showed	O
elevated	B-PosReg
levels	B-MPA
of	I-MPA
18S	I-MPA
-	I-MPA
E	I-MPA
pre	I-MPA
-	I-MPA
rRNA	I-MPA
.	O

This	O
accumulation	O
is	O
consistent	O
with	O
the	O
phenotype	O
observed	O
in	O
HeLa	O
cells	O
after	O
knockdown	O
of	O
RPS10	O
or	O
RPS26	O
expression	O
with	O
siRNAs	O
,	O
which	O
indicates	O
that	O
mutations	B-Var
in	O
the	O
RPS10	B-Gene
and	O
RPS26	B-Gene
genes	O
in	O
DBA	O
patients	O
affect	B-Reg
the	O
function	B-MPA
of	I-MPA
the	I-MPA
proteins	I-MPA
in	I-MPA
rRNA	I-MPA
processing	O
.	O

Clinical	O
and	O
molecular	O
aspects	O
of	O
aniridia	O
.	O

Aniridia	O
is	O
a	O
severe	O
,	O
congenital	O
ocular	O
malformation	O
inherited	O
in	O
an	O
autosomal	O
-	O
dominant	O
fashion	O
with	O
high	O
penetrance	O
and	O
variable	O
expression	O
.	O

Eye	O
morphogenesis	O
in	O
humans	O
involves	O
a	O
molecular	O
genetic	O
cascade	O
in	O
which	O
a	O
number	O
of	O
developmental	O
genes	O
interact	O
in	O
a	O
highly	O
organized	O
process	O
during	O
the	O
embryonic	O
period	O
to	O
produce	O
functional	O
ocular	O
structures	O
.	O

Among	O
these	O
genes	O
,	O
paired	O
box	O
gene	O
6	O
(	O
PAX6	O
)	O
has	O
an	O
essential	O
role	O
as	O
it	O
encodes	O
a	O
phylogenetically	O
conserved	O
transcription	O
factor	O
almost	O
universally	O
employed	O
for	O
eye	O
formation	O
in	O
animals	O
with	O
bilateral	O
symmetry	O
,	O
despite	O
widely	O
different	O
embryological	O
origins	O
.	O

To	O
direct	O
eye	O
development	O
,	O
PAX6	O
regulates	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
diverse	O
molecules	O
,	O
hormones	O
,	O
and	O
structural	O
proteins	O
.	O

In	O
humans	O
,	O
PAX6	B-Gene
is	O
located	O
in	O
chromosome	O
11p13	O
,	O
and	O
its	O
mutations	B-Var
lead	B-Reg
to	I-Reg
a	O
variety	O
of	O
hereditary	B-CPA
ocular	I-CPA
malformations	I-CPA
of	O
the	O
anterior	O
and	O
posterior	O
segment	O
,	O
among	O
which	O
aniridia	O
and	O
most	O
probably	O
foveal	O
hypoplasia	O
are	O
the	O
major	O
signs	O
.	O

Aniridia	B-Disease
occurs	O
due	B-Reg
to	I-Reg
decreased	B-NegReg
dosage	B-MPA
of	O
the	O
PAX6	B-Gene
gene	O
and	O
exists	O
in	O
both	O
sporadic	O
and	O
familial	O
forms	O
.	O

The	O
mutations	O
are	O
scattered	O
throughout	O
the	O
gene	O
and	O
the	O
vast	O
majority	O
of	O
those	O
reported	O
so	O
far	O
are	O
nonsense	B-Var
mutations	I-Var
,	O
frameshift	B-Var
mutations	I-Var
,	O
or	O
splicing	B-Var
errors	I-Var
that	O
are	O
predicted	O
to	O
cause	B-Reg
pre	B-MPA
-	I-MPA
mature	I-MPA
truncation	I-MPA
of	O
the	O
PAX6	B-Gene
protein	B-Protein
,	O
causing	B-Reg
haploinsufficiency	B-MPA
.	O

Here	O
we	O
review	O
the	O
data	O
regarding	O
the	O
mechanisms	O
and	O
the	O
mutations	O
that	O
relate	O
to	O
aniridia	B-Disease
.	O

GARS	O
axonopathy	O
:	O
not	O
every	O
neuron	O
's	O
cup	O
of	O
tRNA	O
.	O

Charcot	B-Disease
-	I-Disease
Marie	I-Disease
-	I-Disease
Tooth	I-Disease
disease	I-Disease
type	I-Disease
2D	I-Disease
,	O
a	O
hereditary	O
axonal	O
neuropathy	O
,	O
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
glycyl	O
-	O
tRNA	O
synthetase	O
(	B-Gene
GARS	I-Gene
)	I-Gene
.	O

The	O
mutations	O
are	O
distributed	O
throughout	O
the	O
protein	O
in	O
multiple	O
functional	O
domains	O
.	O

In	O
biochemical	O
and	O
cell	O
culture	O
experiments	O
,	O
some	O
mutant	O
forms	O
of	O
GARS	O
have	O
been	O
indistinguishable	O
from	O
wild	O
-	O
type	O
protein	O
,	O
suggesting	O
that	O
these	O
in	O
vitro	O
tests	O
might	O
not	O
adequately	O
assess	O
the	O
aberrant	O
activity	O
responsible	O
for	O
axonal	O
degeneration	O
.	O

Recently	O
,	O
mouse	O
and	O
fly	O
models	O
have	O
offered	O
new	O
insights	O
into	O
the	O
disease	O
mechanism	O
.	O

There	O
are	O
still	O
gaps	O
in	O
our	O
understanding	O
of	O
how	O
mutations	O
in	O
a	O
ubiquitously	O
expressed	O
component	O
of	O
the	O
translation	O
machinery	O
result	O
in	O
axonal	O
neuropathy	O
.	O

Here	O
,	O
we	O
review	O
recent	O
reports	O
,	O
weigh	O
the	O
evidence	O
for	O
and	O
against	O
possible	O
mechanisms	O
and	O
suggest	O
areas	O
of	O
focus	O
for	O
future	O
work	O
.	O

Genotype	O
-	O
phenotype	O
correlation	O
in	O
a	O
large	O
population	O
of	O
muscular	B-Disease
dystrophy	I-Disease
patients	O
with	B-Reg
LAMA2	B-Gene
mutations	B-Var
.	O

Merosin	B-Disease
deficient	I-Disease
congenital	I-Disease
muscular	I-Disease
dystrophy	I-Disease
1A	I-Disease
(	O
MDC1A	O
)	O
results	B-Reg
from	I-Reg
mutations	B-Var
in	O
the	O
LAMA2	B-Gene
gene	O
.	O

We	O
report	O
51	O
patients	O
with	O
MDC1A	O
and	O
examine	O
the	O
relationship	O
between	O
degree	O
of	O
merosin	O
expression	O
,	O
genotype	O
and	O
clinical	O
features	O
.	O

Thirty	O
-	O
three	O
patients	O
had	O
absence	O
of	O
merosin	O
and	O
13	O
showed	O
some	O
residual	O
merosin	O
.	O

Compared	O
to	O
the	O
residual	O
merosin	O
group	O
,	O
patients	O
with	O
absent	O
merosin	O
had	O
an	O
earlier	O
presentation	O
(	O
<	O
7days	O
)	O
(	O
P=0.0073	O
)	O
,	O
were	O
more	O
likely	O
to	O
lack	O
independent	O
ambulation	O
(	O
P=0.0215	O
)	O
,	O
or	O
require	O
enteral	O
feeding	O
(	O
P=0.0099	O
)	O
and	O
ventilatory	O
support	O
(	O
P=0.0354	O
)	O
.	O

We	O
identified	O
33	O
novel	O
LAMA2	O
mutations	O
;	O
these	O
were	O
distributed	O
throughout	O
the	O
gene	O
in	O
patients	O
with	O
absent	O
merosin	O
,	O
with	O
minor	O
clusters	O
in	O
exon	O
27	O
,	O
14	O
,	O
25	O
and	O
26	O
(	O
55	O
%	O
of	O
mutations	O
)	O
.	O

Patients	O
with	O
residual	O
merosin	O
often	O
carried	O
at	O
least	O
one	O
splice	O
site	O
mutation	O
and	O
less	O
frequently	O
frameshift	O
mutations	O
.	O

This	O
large	O
study	O
identified	O
novel	O
LAMA2	O
mutations	O
and	O
highlights	O
the	O
role	O
of	O
immunohistochemical	O
studies	O
for	O
merosin	O
status	O
in	O
predicting	O
clinical	O
severity	O
of	O
MDC1A.	O
Novel	O
and	O
recurrent	O
mutations	O
in	O
the	O
filaggrin	O
gene	O
in	O
Chinese	O
patients	O
with	O
ichthyosis	O
vulgaris	O
.	O

BACKGROUND	O
:	O
Ichthyosis	B-Disease
vulgaris	I-Disease
(	O
IV	O
)	O
is	O
a	O
common	O
inherited	O
skin	O
disorder	O
,	O
and	O
the	O
filament	O
aggregating	O
protein	O
(	O
filaggrin	O
)	O
is	O
a	O
key	O
protein	O
involved	O
in	O
skin	O
barrier	O
function	O
.	O

Mutations	B-Var
in	O
the	O
filaggrin	O
gene	O
(	B-Gene
FLG	I-Gene
)	I-Gene
have	O
recently	O
been	O
identified	O
as	O
the	O
cause	B-Reg
of	O
IV	B-Disease
.	O

However	O
,	O
there	O
have	O
been	O
no	O
reports	O
of	O
FLG	O
mutations	O
in	O
mainland	O
Chinese	O
families	O
with	O
IV	O
.	O

OBJECTIVES	O
:	O
To	O
identify	O
FLG	O
mutations	O
in	O
Chinese	O
patients	O
with	O
IV	O
.	O

METHODS	O
:	O
Eleven	O
unrelated	O
Chinese	O
families	O
with	O
IV	O
were	O
examined	O
for	O
FLG	O
mutations	O
with	O
denaturing	O
high	O
-	O
performance	O
liquid	O
chromatography	O
prescreening	O
and	O
sequencing	O
.	O

SNaPShot	O
was	O
employed	O
to	O
obtain	O
a	O
high	O
-	O
throughput	O
screening	O
for	O
the	O
identified	O
mutations	O
.	O

RESULTS	O
:	O
Three	O
mutations	O
-	O
one	O
novel	O
mutation	O
(	O
Q1256X	O
)	O
and	O
two	O
known	O
mutations	O
(	O
3321delA	O
and	O
E2422X	O
)	O
-	O
were	O
identified	O
in	O
these	O
families	O
.	O

The	O
novel	O
mutation	O
,	O
Q1256X	O
,	O
found	O
in	O
a	O
Chinese	O
family	O
with	O
IV	O
,	O
was	O
located	O
in	O
filaggrin	O
repeat	O
3	O
.	O

Mutation	O
3321delA	O
,	O
previously	O
found	O
in	O
Japanese	O
patients	O
,	O
was	O
present	O
in	O
eight	O
Chinese	O
families	O
with	O
IV	O
.	O

Mutation	O
E2422X	O
,	O
previously	O
found	O
in	O
a	O
Dutch	O
patient	O
of	O
Chinese	O
origin	O
,	O
was	O
present	O
in	O
two	O
Chinese	O
families	O
with	O
IV	O
.	O

Neither	O
of	O
the	O
null	O
mutations	O
,	O
Q1256X	O
and	O
E2422X	O
,	O
were	O
found	O
in	O
100	O
unrelated	O
control	O
cases	O
from	O
the	O
Chinese	O
population	O
;	O
however	O
,	O
the	O
mutation	O
ratio	O
for	O
3321delA	O
was	O
3	O
%	O
in	O
these	O
controls	O
.	O

CONCLUSIONS	O
:	O
Our	O
study	O
suggests	O
that	O
each	O
population	O
may	O
have	O
a	O
unique	O
and	O
prevalent	O
set	O
of	O
FLG	O
mutations	O
.	O

Genetic	O
analysis	O
of	O
haemophilia	O
A	O
in	O
Taiwan	O
.	O

Haemophilia	B-Disease
A	I-Disease
(	O
HA	O
)	O
is	O
an	O
X	O
-	O
linked	O
bleeding	O
disorder	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
factor	O
VIII	O
(	B-Gene
FVIII	I-Gene
)	I-Gene
gene	O
.	O

Identification	O
of	O
these	O
mutations	O
is	O
becoming	O
increasingly	O
important	O
in	O
a	O
variety	O
of	O
clinical	O
settings	O
.	O

The	O
purpose	O
of	O
this	O
report	O
is	O
to	O
describe	O
our	O
experience	O
of	O
FVIII	O
gene	O
mutation	O
analysis	O
in	O
the	O
largest	O
cohort	O
of	O
patients	O
in	O
Taiwan	O
including	O
the	O
discovery	O
of	O
21	O
novel	O
mutations	O
.	O

We	O
tested	O
115	O
HA	O
patients	O
from	O
91	O
unrelated	O
families	O
,	O
including	O
79	O
severe	O
,	O
15	O
moderate	O
and	O
21	O
mild	O
types	O
starting	O
with	O
an	O
assay	O
for	O
the	O
intron	O
22	O
inversion	O
by	O
long	O
range	O
-	O
PCR	O
followed	O
if	O
necessary	O
by	O
additional	O
genetic	O
studies	O
.	O

Intron	O
22	O
inversion	O
accounted	O
for	O
27.8	O
%	O
of	O
the	O
total	O
and	O
36.7	O
%	O
of	O
severe	O
HA	O
patients	O
respectively	O
while	O
intron	O
1	O
inversion	O
comprised	O
7.6	O
%	O
of	O
severe	O
patients	O
.	O

These	O
were	O
clearly	O
different	O
from	O
the	O
known	O
data	O
in	O
caucasian	O
populations	O
.	O

Of	O
75	O
patients	O
without	O
intron	O
22	O
or	O
1	O
inversion	O
,	O
70	O
from	O
62	O
unrelated	O
families	O
revealed	O
56	O
different	O
mutations	O
by	O
denaturing	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
DHPLC	O
)	O
,	O
of	O
which	O
21	O
were	O
novel	O
.	O

Also	O
,	O
the	O
only	O
female	O
patient	O
with	O
severe	O
HA	O
was	O
found	O
to	O
have	O
heterozygous	O
non	O
-	O
sense	O
mutation	O
(	O
c.6683G	O
>	O
A	O
)	O
of	O
exon	O
24	O
.	O

Seven	O
patients	O
,	O
including	O
five	O
without	O
amplified	O
PCR	O
product	O
and	O
two	O
without	O
encoded	O
DNA	O
defect	O
turned	O
out	O
to	O
have	O
exon(s	O
)	O
deletion	O
or	O
insertion	O
by	O
reverse	O
transcript	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

In	O
our	O
study	O
,	O
the	O
combination	O
of	O
various	O
molecular	O
techniques	O
including	O
LR	O
-	O
PCR	O
,	O
multiplex	O
PCR	O
,	O
DHPLC	O
and	O
RT	O
-	O
PCR	O
analysis	O
enabled	O
definitive	O
detection	O
of	O
the	O
causative	O
FVIII	O
gene	O
defects	O
in	O
112	O
of	O
113	O
(	O
99	O
%	O
)	O
HA	O
patients	O
.	O

Mutation	O
spectra	O
in	O
autosomal	O
dominant	O
and	O
recessive	O
retinitis	O
pigmentosa	O
in	O
northern	O
Sweden	O
.	O

Retinal	O
degenerations	O
represent	O
a	O
heterogeneous	O
group	O
of	O
disorders	O
affecting	O
the	O
function	O
of	O
the	O
retina	O
.	O

The	O
frequency	O
of	O
retinitis	O
pigmentosa	O
(	O
RP	O
)	O
is	O
1/3500	O
worldwide	O
,	O
however	O
,	O
in	O
northern	O
Sweden	O
it	O
is	O
1/2000	O
due	O
to	O
limited	O
migration	O
and	O
a	O
'	O
founder	O
'	O
effect	O
.	O

In	O
this	O
study	O
we	O
identified	O
genetic	O
mechanisms	O
underlying	O
autosomal	O
dominant	O
and	O
recessive	O
RP	O
present	O
in	O
northern	O
Sweden	O
.	O

Several	O
novel	O
mutations	O
unique	O
for	O
this	O
region	O
were	O
found	O
.	O

In	O
an	O
autosomal	O
recessive	O
form	O
of	O
RP	O
,	O
Bothnia	B-Disease
dystrophy	I-Disease
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
RLBP1	B-Gene
gene	O
,	O
bi	O
-	O
allelic	O
mutations	O
R234W	O
,	O
M226	O
K	O
and	O
compound	O
heterozygosity	O
,	O
M226K+R234W	O
was	O
detected	O
.	O

In	O
dominant	O
form	O
of	O
RP	O
mapped	O
to	O
19q13.42	O
a	O
59	O
kb	O
genomic	O
deletion	O
including	O
the	O
PRPF31	O
and	O
three	O
other	O
genes	O
was	O
found	O
.	O

These	O
data	O
provide	O
additional	O
information	O
on	O
the	O
molecular	O
mechanisms	O
of	O
RP	O
evolvement	O
and	O
in	O
the	O
future	O
might	O
be	O
useful	O
in	O
development	O
of	O
therapeutic	O
strategies	O
.	O

Identification	O
of	O
the	O
disease	O
-	O
causing	O
mutations	O
allowed	O
introducing	O
molecular	O
genetic	O
testing	O
of	O
the	O
patients	O
and	O
their	O
families	O
into	O
the	O
clinical	O
practice	O
.	O

Sequence	O
variants	B-Var
of	O
the	O
DFNB31	B-Gene
gene	O
among	B-Reg
Usher	B-Disease
syndrome	I-Disease
patients	O
of	O
diverse	O
origin	O
.	O

PURPOSE	O
:	O
It	O
has	O
been	O
demonstrated	O
that	O
mutations	B-Var
in	O
deafness	O
,	O
autosomal	O
recessive	O
31	O
(	B-Gene
DFNB31	I-Gene
)	I-Gene
,	O
the	O
gene	O
encoding	O
whirlin	O
,	O
is	O
responsible	B-Reg
for	O
nonsyndromic	B-Disease
hearing	I-Disease
loss	I-Disease
(	O
NSHL	O
;	O
DFNB31	O
)	O
and	O
Usher	B-Disease
syndrome	I-Disease
type	I-Disease
II	I-Disease
(	O
USH2D	O
)	O
.	O

We	O
screened	O
DFNB31	O
in	O
a	O
large	O
cohort	O
of	O
patients	O
with	O
different	O
clinical	O
subtypes	O
of	O
Usher	O
syndrome	O
(	O
USH	O
)	O
to	O
determine	O
the	O
prevalence	O
of	O
DFNB31	O
mutations	O
among	O
USH	O
patients	O
.	O

METHODS	O
:	O
DFNB31	O
was	O
screened	O
in	O
149	O
USH2	O
,	O
29	O
USH1	O
,	O
six	O
atypical	O
USH	O
,	O
and	O
11	O
unclassified	O
USH	O
patients	O
from	O
diverse	O
ethnic	O
backgrounds	O
.	O

Mutation	O
detection	O
was	O
performed	O
by	O
direct	O
sequencing	O
of	O
all	O
coding	O
exons	O
.	O

RESULTS	O
:	O
We	O
identified	O
38	O
different	O
variants	O
among	O
195	O
patients	O
.	O

Most	O
variants	O
were	O
clearly	O
polymorphic	O
,	O
but	O
at	O
least	O
two	O
out	O
of	O
the	O
15	O
nonsynonymous	O
variants	O
(	B-Var
p	I-Var
.	I-Var
R350W	I-Var
and	O
p	B-Var
.	I-Var
R882S	I-Var
)	I-Var
are	O
predicted	O
to	O
impair	B-NegReg
whirlin	B-Protein
structure	B-MPA
and	O
function	B-MPA
,	O
suggesting	O
eventual	O
pathogenicity	O
.	O

No	O
putatively	O
pathogenic	O
mutation	O
was	O
found	O
in	O
the	O
second	O
allele	O
of	O
patients	O
with	O
these	O
mutations	O
.	O

CONCLUSIONS	O
:	O
DFNB31	O
is	O
not	O
a	O
major	O
cause	O
of	O
USH	O
.	O

The	O
tyrosine	O
phosphatase	O
Shp2	O
in	O
development	O
and	O
cancer	O
.	O

Deregulation	O
of	O
signaling	O
pathways	O
,	O
through	O
mutation	O
or	O
other	O
molecular	O
changes	O
,	O
can	O
ultimately	O
result	O
in	O
disease	O
.	O

The	O
tyrosine	O
phosphatase	O
Shp2	O
has	O
emerged	O
as	O
a	O
major	O
regulator	O
of	O
receptor	O
tyrosine	O
kinase	O
(	O
RTK	O
)	O
and	O
cytokine	O
receptor	O
signaling	O
.	O

In	O
the	O
last	O
decade	O
,	O
germline	O
mutations	O
in	O
the	O
human	O
PTPN11	O
gene	O
,	O
encoding	O
Shp2	O
,	O
were	O
linked	O
to	O
Noonan	O
(	O
NS	O
)	O
and	O
LEOPARD	O
syndromes	O
,	O
two	O
multisymptomatic	O
developmental	O
disorders	O
that	O
are	O
characterized	O
by	O
short	O
stature	O
,	O
craniofacial	O
defects	O
,	O
cardiac	O
defects	O
,	O
and	O
mental	O
retardation	O
.	O

Somatic	O
Shp2	B-Gene
mutations	B-Var
are	O
also	O
associated	B-Reg
with	O
several	O
types	O
of	O
human	O
malignancies	O
,	O
such	O
as	O
the	O
most	O
common	O
juvenile	O
leukemia	O
,	O
juvenile	B-Disease
myelomonocytic	I-Disease
leukemia	I-Disease
(	O
JMML	O
)	O
.	O

Whereas	O
NS	B-Disease
and	O
JMML	B-Disease
are	O
caused	O
by	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
mutations	B-Var
of	O
Shp2	B-Gene
,	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LOF	O
)	O
mutations	B-Var
are	O
thought	O
to	O
be	O
associated	O
with	O
LEOPARD	B-Disease
syndrome	I-Disease
.	O

Animal	O
models	O
that	O
carry	O
conditional	O
LOF	O
and	O
GOF	O
mutations	O
have	O
allowed	O
a	O
better	O
understanding	O
of	O
the	O
mechanism	O
of	O
Shp2	O
function	O
in	O
disease	O
,	O
and	O
shed	O
light	O
on	O
the	O
role	O
of	O
Shp2	O
in	O
signaling	O
pathways	O
that	O
control	O
decisive	O
events	O
during	O
embryonic	O
development	O
or	O
during	O
cellular	O
transformation	O
/	O
tumorigenesis	O
.	O

Partial	O
depletion	O
of	O
CREB	O
-	O
binding	O
protein	O
reduces	O
life	O
expectancy	O
in	O
a	O
mouse	O
model	O
of	O
Huntington	O
disease	O
.	O

Previous	O
studies	O
have	O
reported	O
that	O
mutant	B-Var
huntingtin	B-Gene
(	O
htt	O
)	O
interferes	B-Reg
with	O
cyclic	B-Protein
AMP	I-Protein
response	I-Protein
element	I-Protein
binding	I-Protein
protein	I-Protein
binding	B-Interaction
protein	B-Protein
(	O
CBP)-mediated	O
transcription	B-MPA
,	O
possibly	O
by	O
inhibiting	B-NegReg
the	O
acetylation	B-MPA
of	O
histones	B-Protein
.	O

In	O
Drosophila	O
models	O
that	O
express	O
fragments	O
of	O
mutant	O
htt	O
,	O
histone	O
deacetylase	O
inhibitors	O
reverse	O
deficits	O
in	O
histone	O
acetylation	O
,	O
rescue	O
photoreceptor	O
degeneration	O
,	O
and	O
prolong	O
their	O
survival	O
.	O

These	O
compounds	O
also	O
improve	O
motor	O
deficits	O
in	O
a	O
transgenic	O
mouse	O
model	O
of	O
Huntington	O
disease	O
(	O
HD	O
)	O
.	O

To	O
determine	O
whether	O
endogenous	O
CBP	O
depletion	O
contributes	O
to	O
HD	O
pathogenesis	O
,	O
we	O
crossed	O
HD	O
-	O
N171	O
-	O
82Q	O
transgenic	O
mice	O
with	O
mice	O
harboring	O
a	O
disrupted	O
CBP	O
gene	O
and	O
produced	O
mice	O
with	O
partial	O
(	O
50	O
%	O
)	O
depletion	O
of	O
CBP	O
.	O

This	O
reduction	O
of	O
CBP	O
levels	O
decreased	O
the	O
life	O
expectancy	O
of	O
the	O
HD	O
-	O
N171	O
-	O
82Q	O
Line	O
6	O
mouse	O
model	O
.	O

The	O
loss	O
of	O
CBP	O
had	O
no	O
obvious	O
impact	O
on	O
the	O
severity	O
of	O
motor	O
impairment	O
,	O
degeneration	O
of	O
the	O
striatum	O
,	O
mutant	O
htt	O
inclusion	O
formation	O
,	O
or	O
global	O
levels	O
of	O
acetylated	O
histones	O
H3	O
or	O
H4	O
in	O
brain	O
.	O

In	O
cell	O
models	O
,	O
we	O
confirmed	O
that	O
mutant	O
htt	O
inclusions	O
recruit	O
human	O
CBP	O
but	O
found	O
no	O
evidence	O
for	O
interactions	O
between	O
soluble	O
forms	O
of	O
mutant	O
htt	O
and	O
CBP	O
.	O

Although	O
we	O
identified	O
no	O
neurological	O
explanation	O
for	O
the	O
decreased	O
life	O
expectancy	O
of	O
HD	O
-	O
N171	O
-	O
82Q	O
mice	O
with	O
partial	O
depletion	O
of	O
CBP	O
,	O
the	O
data	O
are	O
consistent	O
with	O
the	O
notion	O
that	O
CBP	O
function	O
mitigates	O
mutant	O
htt	O
toxicity	O
by	O
a	O
currently	O
unidentified	O
mechanism	O
.	O

Type	O
I	O
hyperprolinemia	O
:	O
genotype	O
/	O
phenotype	O
correlations	O
.	O

Type	B-Disease
I	I-Disease
hyperprolinemia	I-Disease
(	O
HPI	O
)	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
associated	O
with	O
cognitive	O
and	O
psychiatric	O
troubles	O
,	O
caused	O
by	O
alterations	O
of	O
the	O
Proline	O
Dehydrogenase	O
gene	O
(	O
PRODH	O
)	O
at	O
22q11	O
.	O

HPI	B-Disease
results	B-Reg
from	I-Reg
PRODH	B-Gene
deletion	B-Var
and/or	O
missense	B-Var
mutations	I-Var
reducing	B-NegReg
proline	B-Enzyme
oxidase	I-Enzyme
(	O
POX	O
)	O
activity	B-MPA
.	O

The	O
goals	O
of	O
this	O
study	O
were	O
first	O
to	O
measure	O
in	O
controls	O
the	O
frequency	O
of	O
PRODH	O
variations	O
described	O
in	O
HPI	O
patients	O
,	O
second	O
to	O
assess	O
the	O
functional	O
effect	O
of	O
PRODH	O
mutations	O
on	O
POX	O
activity	O
,	O
and	O
finally	O
to	O
establish	O
genotype	O
/	O
enzymatic	O
activity	O
correlations	O
in	O
a	O
new	O
series	O
of	O
HPI	O
patients	O
.	O

Eight	O
of	O
14	O
variants	O
occurred	O
at	O
polymorphic	O
frequency	O
in	O
114	O
controls	O
.	O

POX	O
activity	O
was	O
determined	O
for	O
six	O
novel	O
mutations	O
and	O
two	O
haplotypes	O
.	O

The	O
c.1331G	O
>	O
A	O
,	O
p	O
.	O
G444D	O
allele	O
has	O
a	O
drastic	O
effect	O
,	O
whereas	O
the	O
c.23C	B-Var
>	I-Var
T	I-Var
,	O
p	B-Var
.	I-Var
P8L	I-Var
allele	O
and	O
the	O
c.[56C	B-Var
>	I-Var
A	I-Var
;	I-Var
172G	I-Var
>	I-Var
A	I-Var
]	I-Var
,	O
p.[Q19P	B-Var
;	I-Var
A58	I-Var
T	I-Var
]	I-Var
haplotype	O
result	O
in	O
a	O
moderate	O
decrease	B-NegReg
in	O
activity	B-MPA
.	O

Among	O
the	O
19	O
HPI	O
patients	O
,	O
10	O
had	O
a	O
predicted	O
residual	O
activity	O
<	O
50	O
%	O
.	O

Eight	O
out	O
of	O
nine	O
subjects	O
with	O
a	O
predicted	O
residual	O
activity	O
>	O
or	O
=	O
50	O
%	O
bore	O
at	O
least	O
one	O
c.824C	O
>	O
A	O
,	O
p	O
.	O
T275N	O
allele	O
,	O
which	O
has	O
no	O
detrimental	O
effect	O
on	O
activity	O
but	O
whose	O
frequency	O
in	O
controls	O
is	O
only	O
3	O
%	O
.	O

Our	O
results	O
suggest	O
that	O
PRODH	B-Gene
mutations	B-Var
lead	O
to	O
a	O
decreased	B-NegReg
POX	B-Enzyme
activity	B-MPA
or	O
affect	B-Reg
other	B-MPA
biological	I-MPA
parameters	I-MPA
causing	B-Reg
hyperprolinemia	B-Disease
.	O

Dihydropyrimidine	B-Disease
dehydrogenase	I-Disease
deficiency	I-Disease
caused	B-Reg
by	I-Reg
a	O
novel	O
genomic	O
deletion	O
c.505_513del	B-Var
of	O
DPYD	B-Gene
.	O

Dihydropyrimidine	O
dehydrogenase	O
(	O
DPD	O
)	O
deficiency	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
of	O
the	O
pyrimidine	O
degradation	O
pathway	O
.	O

In	O
a	O
patient	O
presenting	O
with	O
convulsions	O
,	O
psychomotor	O
retardation	O
and	O
Reye	O
like	O
syndrome	O
,	O
strongly	O
elevated	O
levels	O
of	O
uracil	O
and	O
thymine	O
were	O
detected	O
in	O
urine	O
.	O

No	O
DPD	O
activity	O
could	O
be	O
detected	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Analysis	O
of	O
the	O
gene	O
encoding	O
DPD	O
(	O
DPYD	O
)	O
showed	O
that	O
the	O
patient	O
was	O
homozygous	O
for	O
a	O
novel	O
c.505_513del	O
(	O
p.169_171del	O
)	O
mutation	O
in	O
exon	O
6	O
of	O
DPYD	O
.	O

Analysis	O
of	O
mutations	B-Var
causing	B-Reg
biotinidase	B-Disease
deficiency	I-Disease
.	O

Biotinidase	O
deficiency	O
is	O
an	O
inherited	O
disorder	O
in	O
which	O
the	O
vitamin	O
,	O
biotin	O
,	O
is	O
not	O
recycled	O
.	O

Individuals	O
with	O
biotinidase	O
deficiency	O
can	O
develop	O
neurological	O
and	O
cutaneous	O
symptoms	O
if	O
they	O
are	O
not	O
treated	O
with	O
biotin	O
.	O

Biotinidase	O
deficiency	O
screening	O
has	O
been	O
incorporated	O
into	O
essentially	O
all	O
newborn	O
screening	O
programs	O
in	O
the	O
United	O
States	O
and	O
in	O
many	O
countries	O
.	O

We	O
now	O
report	O
140	O
known	O
mutations	B-Var
in	O
the	O
biotinidase	O
gene	O
(	B-Gene
BTD	I-Gene
)	I-Gene
that	O
cause	B-Reg
biotinidase	B-Disease
deficiency	I-Disease
.	O

All	O
types	O
of	O
mutations	B-Var
have	O
been	O
found	O
to	O
cause	B-Reg
biotinidase	B-Disease
deficiency	I-Disease
.	O

Variants	O
have	O
been	O
identified	O
throughout	O
the	O
coding	O
sequence	O
.	O

Essentially	O
all	O
the	O
variants	B-Var
result	O
in	O
enzymatic	B-Enzyme
activities	B-MPA
with	O
less	B-NegReg
than	O
10	O
%	O
of	O
mean	O
normal	O
enzyme	O
activity	O
(	O
profound	O
biotinidase	O
deficiency	O
)	O
with	O
the	O
exception	O
of	O
the	O
c.1330G	B-Var
>	I-Var
C	I-Var
(	O
p	O
.	O
D444H	O
)	O
mutation	O
,	O
which	O
results	O
in	O
an	O
enzyme	B-Enzyme
having	O
50	B-NegReg
%	I-NegReg
of	O
mean	O
normal	O
serum	B-MPA
activity	I-MPA
.	O

The	O
putative	O
three	O
-	O
dimensional	O
structure	O
of	O
biotinidase	O
has	O
been	O
predicted	O
by	O
homology	O
to	O
that	O
of	O
nitrilases	O
/	O
amidases	O
.	O

The	O
effect	O
of	O
the	O
various	O
missense	O
mutations	O
can	O
be	O
predicted	O
to	O
affect	O
various	O
important	O
sites	O
within	O
the	O
structure	O
of	O
the	O
enzyme	O
.	O

This	O
compilation	O
of	O
variants	O
causing	O
biotinidase	O
deficiency	O
will	O
be	O
useful	O
to	O
clinical	O
laboratories	O
that	O
are	O
performing	O
mutation	O
analysis	O
for	O
confirmational	O
testing	O
when	O
the	O
enzymatic	O
results	O
are	O
equivocal	O
for	O
children	O
identified	O
through	O
newborn	O
screening	O
.	O

N88S	B-Var
mutation	O
in	O
the	O
BSCL2	B-Gene
gene	O
in	B-Reg
a	O
Serbian	O
family	O
with	O
distal	B-Disease
hereditary	I-Disease
motor	I-Disease
neuropathy	I-Disease
type	I-Disease
V	I-Disease
or	O
Silver	B-Disease
syndrome	I-Disease
.	O

BACKGROUND	O
:	O
Distal	B-Disease
hereditary	I-Disease
motor	I-Disease
neuropathy	I-Disease
type	I-Disease
V	I-Disease
(	O
dHMN	O
-	O
V	O
)	O
and	O
Silver	B-Disease
syndrome	I-Disease
are	O
rare	O
phenotypically	O
overlapping	O
diseases	O
which	O
can	O
be	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
Berardinelli	O
-	O
Seip	O
Congenital	O
Lipodystrophy	O
2	O
(	B-Gene
BSCL2	I-Gene
)	I-Gene
gene	O
or	O
Seipin	B-Gene
.	O

AIM	O
:	O
To	O
report	O
the	O
first	O
Serbian	O
family	O
with	O
a	O
BSCL2	O
mutation	O
showing	O
variable	O
expression	O
within	O
the	O
family	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
A	O
55-year	O
-	O
old	O
woman	O
presented	O
with	O
weakness	O
of	O
both	O
hands	O
at	O
the	O
age	O
of	O
45	O
.	O

At	O
age	O
47	O
,	O
she	O
noticed	O
distal	O
muscle	O
weakness	O
and	O
atrophy	O
in	O
her	O
legs	O
.	O

Physical	O
examination	O
revealed	O
atrophy	O
and	O
weakness	O
of	O
small	O
hand	O
muscles	O
and	O
mild	O
atrophy	O
and	O
weakness	O
of	O
the	O
lower	O
limbs	O
.	O

There	O
was	O
generalized	O
hyperreflexia	O
with	O
the	O
exception	O
of	O
ankle	O
reflexes	O
which	O
were	O
diminished	O
.	O

Her	O
25year	O
-	O
old	O
son	O
had	O
only	O
stiffness	O
of	O
both	O
legs	O
at	O
the	O
age	O
of	O
22	O
.	O

Physical	O
examination	O
revealed	O
only	O
generalized	O
hyporeflexia	O
.	O

The	O
third	O
affected	O
member	O
in	O
this	O
family	O
was	O
her	O
55year	O
-	O
old	O
cousin	O
who	O
showed	O
a	O
more	O
prominent	O
involvement	O
of	O
leg	O
muscles	O
with	O
mild	O
asymmetrical	O
weakness	O
of	O
hand	O
muscles	O
and	O
no	O
pyramidal	O
tract	O
features	O
.	O

RESULTS	O
:	O
In	O
all	O
three	O
patients	O
sensory	O
nerve	O
conduction	O
velocities	O
(	O
NCV	O
)	O
were	O
normal	O
in	O
all	O
extremities	O
.	O

Compound	O
muscle	O
action	O
potential	O
(	O
CMAP	O
)	O
amplitudes	O
were	O
markedly	O
reduced	O
in	O
all	O
patients	O
.	O

Concentric	O
needle	O
EMG	O
showed	O
evidence	O
of	O
chronic	O
denervation	O
in	O
distal	O
muscles	O
.	O

DNA	O
sequencing	O
of	O
BSCL2	O
was	O
performed	O
and	O
a	O
heterozygous	O
N88S	O
missense	O
mutation	O
in	O
BSCL2	O
gene	O
was	O
detected	O
in	O
all	O
three	O
patients	O
.	O

CONCLUSION	O
:	O
This	O
report	O
is	O
further	O
confirmation	O
of	O
phenotypic	O
heterogenity	O
due	O
to	O
the	O
N88S	O
mutation	O
of	O
BSCL2	O
gene	O
in	O
the	O
same	O
family	O
.	O

DOK7	B-Gene
mutations	B-Var
presenting	B-Reg
as	I-Reg
a	O
proximal	B-Disease
myopathy	I-Disease
in	O
French	O
Canadians	O
.	O

DOK7	B-Gene
mutations	B-Var
cause	B-Reg
a	O
congenital	B-Disease
myasthenic	I-Disease
syndrome	I-Disease
(	O
OMIM	O
254300	O
)	O
characterized	O
by	O
a	O
"	O
limb	O
-	O
girdle	O
"	O
phenotype	O
.	O

We	O
identified	O
7	O
French	O
-	O
Canadian	O
patients	O
with	O
a	O
previously	O
undiagnosed	O
proximal	O
myopathy	O
.	O

A	O
genome	O
wide	O
scan	O
was	O
performed	O
.	O

Homozygosity	O
mapping	O
identified	O
a	O
locus	O
on	O
chromosome	O
4p16.2	O
containing	O
DOK7	O
.	O

Sequencing	O
of	O
DOK7	O
revealed	O
homozygous	O
1124_1127dupTGCC	O
mutations	O
in	O
all	O
individuals	O
.	O

SNP	O
genotyping	O
of	O
42	O
kb	O
surrounding	O
DOK7	O
in	O
our	O
cohort	O
and	O
in	O
9	O
patients	O
of	O
various	O
European	O
origins	O
demonstrated	O
a	O
shared	O
haplotype	O
suggesting	O
a	O
common	O
ancestral	O
European	O
mutation	O
.	O

In	O
our	O
cohort	O
,	O
fatigability	O
was	O
not	O
prominent	O
;	O
rather	O
patients	O
reported	O
prolonged	O
periods	O
of	O
increased	O
weakness	O
.	O

Abnormalities	O
on	O
repetitive	O
nerve	O
stimulation	O
and	O
single	O
fiber	O
EMG	O
were	O
not	O
invariably	O
present	O
.	O

There	O
was	O
considerable	O
intra	O
-	O
familial	O
phenotypic	O
variability	O
,	O
and	O
we	O
report	O
an	O
asymptomatic	O
individual	O
.	O

DOK7	O
mutations	O
should	O
be	O
considered	O
in	O
patients	O
with	O
early	O
-	O
onset	O
myopathy	O
,	O
even	O
in	O
the	O
absence	O
of	O
symptoms	O
suggesting	O
a	O
possible	O
myasthenia	O
.	O

Identification	O
of	O
known	O
and	O
novel	O
PTCH	B-Gene
mutations	B-Var
in	B-Reg
both	O
syndromic	O
and	O
non	O
-	O
syndromic	O
keratocystic	B-Disease
odontogenic	I-Disease
tumors	I-Disease
.	O

AIM	O
:	O
To	O
clarify	O
the	O
role	O
of	O
PTCH	O
in	O
patients	O
with	O
NBCCS	O
-	O
related	O
and	O
non	O
-	O
sydromic	O
keratocystic	O
odontogenic	O
tumors	O
.	O

METHODOLOGY	O
:	O
Mutation	O
analysis	O
was	O
undertaken	O
in	O
8	O
sporadic	O
and	O
4	O
NBCCS	O
-	O
associated	O
KCOTs	O
.	O

RESULTS	O
:	O
Four	O
novel	O
and	O
two	O
known	O
mutations	O
were	O
identified	O
in	O
2	O
sporadic	O
and	O
3	O
syndromic	O
cases	O
,	O
two	O
of	O
which	O
being	O
germline	O
mutations	O
(	O
c.2179delT	O
,	O
c.2824delC	O
)	O
and	O
4	O
somatic	O
mutations	O
(	O
c.3162dupG	O
,	O
c.1362	O
-	O
1374dup	O
,	O
c.1012	O
C	O
>	O
T	O
,	O
c.403C	O
>	O
T	O
)	O
.	O

CONCLUSION	O
:	O
Our	O
findings	O
suggest	O
that	O
defects	O
of	O
PTCH	O
are	O
associated	O
with	O
the	O
pathogenesis	O
of	O
syndromic	O
as	O
well	O
as	O
a	O
subset	O
of	O
non	O
-	O
syndromic	O
KCOTs	O
.	O

Mutant	B-Var
p53	B-Gene
facilitates	B-PosReg
somatic	B-CPA
cell	I-CPA
reprogramming	I-CPA
and	O
augments	B-NegReg
the	O
malignant	B-CPA
potential	I-CPA
of	I-CPA
reprogrammed	I-CPA
cells	I-CPA
.	O

p53	B-Gene
deficiency	B-Var
enhances	B-PosReg
the	O
efficiency	O
of	O
somatic	B-CPA
cell	I-CPA
reprogramming	I-CPA
to	O
a	O
pluripotent	O
state	O
.	O

As	O
p53	O
is	O
usually	O
mutated	O
in	O
human	O
tumors	O
and	O
many	O
mutated	B-Var
forms	O
of	O
p53	B-Gene
gain	B-PosReg
novel	O
activities	B-MPA
,	O
we	O
studied	O
the	O
influence	O
of	O
mutant	O
p53	O
(	O
mut	O
-	O
p53	O
)	O
on	O
somatic	O
cell	O
reprogramming	O
.	O

Our	O
data	O
indicate	O
a	O
novel	O
gain	B-PosReg
of	O
function	B-MPA
(	O
GOF	O
)	O
property	O
for	O
mut	B-Var
-	I-Var
p53	I-Var
,	O
which	O
markedly	O
enhanced	B-PosReg
the	O
efficiency	O
of	O
the	O
reprogramming	B-CPA
process	I-CPA
compared	O
with	O
p53	O
deficiency	O
.	O

Importantly	O
,	O
this	O
novel	O
activity	B-MPA
of	O
mut	B-Var
-	I-Var
p53	I-Var
induced	O
alterations	B-Reg
in	O
the	O
characteristics	B-CPA
of	I-CPA
the	I-CPA
reprogrammed	I-CPA
cells	I-CPA
.	O

Although	O
p53	O
knockout	O
(	O
KO	O
)	O
cells	O
reprogrammed	O
with	O
only	O
Oct4	O
and	O
Sox2	O
maintained	O
their	O
pluripotent	B-MPA
capacity	I-MPA
in	O
vivo	O
,	O
reprogrammed	O
cells	O
expressing	O
mutant	B-Var
p53	B-Gene
lost	B-NegReg
this	O
capability	O
and	O
gave	B-Reg
rise	I-Reg
to	O
malignant	B-CPA
tumors	I-CPA
.	O

This	O
novel	O
GOF	O
of	O
mut	O
-	O
p53	O
is	O
not	O
attributed	O
to	O
its	O
effect	O
on	O
proliferation	O
,	O
as	O
both	O
p53	O
KO	O
and	O
mut	O
-	O
p53	O
cells	O
displayed	O
similar	O
proliferation	O
rates	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
an	O
oncogenic	B-MPA
activity	I-MPA
of	O
Klf4	O
,	O
as	O
its	O
overexpression	B-PosReg
in	O
either	O
p53	O
KO	O
or	O
mut	B-Var
-	I-Var
p53	I-Var
cells	O
induced	B-PosReg
aggressive	B-CPA
tumors	I-CPA
.	O

Overall	O
,	O
our	O
data	O
show	O
that	O
reprogrammed	O
cells	O
with	O
the	O
capacity	O
to	O
differentiate	O
into	O
the	O
three	O
germ	O
layers	O
in	O
vitro	O
can	O
form	O
malignant	O
tumors	O
,	O
suggesting	O
that	O
in	O
genetically	O
unstable	O
cells	O
,	O
such	O
as	O
those	O
in	O
which	O
p53	B-Gene
is	O
mutated	B-Var
,	O
reprogramming	B-CPA
may	O
result	B-Reg
in	I-Reg
the	O
generation	O
of	O
cells	B-CPA
with	I-CPA
malignant	I-CPA
tumor	I-CPA
-	I-CPA
forming	I-CPA
potential	I-CPA
.	O

NOTCH3	B-Gene
mutations	B-Var
and	O
clinical	O
features	O
in	O
33	O
mainland	O
Chinese	O
families	O
with	B-Reg
CADASIL	B-Disease
.	O

BACKGROUND	O
:	O
Cerebral	B-Disease
autosomal	I-Disease
dominant	I-Disease
arteriopathy	I-Disease
with	I-Disease
subcortical	I-Disease
infarcts	I-Disease
and	I-Disease
leucoencephalopathy	I-Disease
(	O
CADASIL	O
)	O
is	O
an	O
inherited	O
small	O
-	O
vessel	O
disease	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
NOTCH3	B-Gene
.	O

Although	O
CADASIL	O
cases	O
have	O
been	O
identified	O
worldwide	O
,	O
the	O
data	O
from	O
mainland	O
China	O
are	O
still	O
limited	O
.	O

OBJECTIVE	O
:	O
To	O
identify	O
NOTCH3	O
mutations	O
and	O
analyse	O
the	O
clinical	O
and	O
MRI	O
findings	O
in	O
a	O
large	O
series	O
of	O
CADASIL	O
patients	O
from	O
mainland	O
China	O
.	O

METHODS	O
:	O
Direct	O
sequencing	O
of	O
NOTCH3	O
and/or	O
skin	O
or	O
sural	O
nerve	O
biopsies	O
were	O
performed	O
on	O
48	O
unrelated	O
suspected	O
CADASIL	O
cases	O
of	O
Chinese	O
descent	O
.	O

The	O
clinical	O
manifestations	O
and	O
MRI	O
features	O
were	O
retrospectively	O
collected	O
and	O
analysed	O
in	O
the	O
33	O
index	O
patients	O
with	O
confirmed	O
diagnosis	O
and	O
their	O
available	O
affected	O
family	O
members	O
.	O

RESULTS	O
:	O
20	O
different	O
NOTCH3	O
mutations	O
were	O
identified	O
in	O
33	O
families	O
,	O
including	O
seven	O
novel	O
mutations	O
.	O

The	O
highest	O
mutation	O
frequency	O
was	O
in	O
exons	O
4	O
(	O
55	O
%	O
)	O
and	O
3	O
(	O
30	O
%	O
)	O
.	O

Granular	O
osmiophilic	O
material	O
in	O
smooth	O
muscle	O
cells	O
was	O
found	O
in	O
30	O
cases	O
who	O
were	O
biopsied	O
.	O

Clinical	O
presentation	O
included	O
TIA	O
/	O
stroke	O
in	O
82	O
%	O
,	O
cognitive	O
decline	O
in	O
60	O
%	O
,	O
and	O
migraine	O
with	O
aura	O
in	O
only	O
5	O
%	O
of	O
57	O
symptomatic	O
cases	O
.	O

MRI	O
detected	O
multiple	O
lacunar	O
infarcts	O
and	O
leucoaraiosis	O
in	O
all	O
symptomatic	O
cases	O
,	O
brainstem	O
lesions	O
in	O
64	O
%	O
of	O
symptomatic	O
cases	O
and	O
white	O
-	O
matter	O
lesions	O
in	O
the	O
temporal	O
pole	O
in	O
46	O
%	O
of	O
affected	O
members	O
.	O

CONCLUSIONS	O
:	O
The	O
mutational	O
spectrum	O
and	O
primary	O
clinical	O
features	O
of	O
patients	O
with	O
CADASIL	O
from	O
mainland	O
China	O
are	O
similar	O
to	O
those	O
in	O
Caucasians	O
.	O

However	O
,	O
migraine	O
with	O
aura	O
and	O
abnormal	O
white	O
matter	O
in	O
the	O
temporal	O
pole	O
are	O
less	O
common	O
than	O
among	O
Caucasians	O
,	O
while	O
brainstem	O
involvement	O
is	O
more	O
common	O
than	O
among	O
Caucasians	O
.	O

Prevalence	O
,	O
mutation	O
spectrum	O
and	O
phenotypic	O
variability	O
in	O
Norwegian	O
patients	O
with	O
Limb	O
Girdle	O
Muscular	O
Dystrophy	O
2I.	O
Mutations	B-Var
in	O
the	O
FKRP	B-Gene
(	O
Fukutin	O
Related	O
Protein	O
)	O
gene	O
produce	B-Reg
a	O
range	O
of	O
phenotypes	O
including	O
Limb	B-Disease
Girdle	I-Disease
Muscular	I-Disease
Dystrophy	I-Disease
Type	I-Disease
2I	I-Disease
(	O
LGMD2I	O
)	O
.	O

In	O
order	O
to	O
investigate	O
the	O
prevalence	O
,	O
the	O
mutation	O
spectrum	O
and	O
possible	O
genotype	O
-	O
phenotype	O
correlation	O
,	O
we	O
studied	O
a	O
cohort	O
of	O
Norwegian	O
patients	O
with	O
LGMD2I	O
,	O
ascertained	O
in	O
a	O
4-year	O
period	O
.	O

In	O
this	O
retrospective	O
study	O
of	O
genetically	O
tested	O
patients	O
,	O
we	O
identified	O
88	O
patients	O
from	O
69	O
families	O
,	O
who	O
were	O
either	O
homozygous	O
or	O
compound	O
heterozygous	O
for	O
FKRP	O
mutations	O
.	O

This	O
gives	O
a	O
minimum	O
prevalence	O
of	O
1/54,000	O
and	O
a	O
corresponding	O
carrier	O
frequency	O
of	O
1/116	O
in	O
the	O
Norwegian	O
population	O
.	O

Seven	O
different	O
FKRP	O
mutations	O
,	O
including	O
three	O
novel	O
changes	O
,	O
were	O
detected	O
.	O

Seventy	O
-	O
six	O
patients	O
were	O
homozygous	O
for	O
the	O
common	O
c.826C	O
>	O
A	O
mutation	O
.	O

These	O
patients	O
had	O
later	O
disease	O
onset	O
than	O
patients	O
who	O
were	O
compound	O
heterozygous	O
-	O
14.0	O
vs.	O
6.1	O
years	O
.	O

We	O
detected	O
substantial	O
variability	O
in	O
disease	O
severity	O
among	O
homozygous	O
patients	O
.	O

The	O
combined	O
impact	O
of	O
CYP2C19	O
and	O
CYP2B6	O
pharmacogenetics	O
on	O
cyclophosphamide	O
bioactivation	O
.	O

AIMS	O
:	O
The	O
role	O
of	O
CYP	O
pharmacogenetics	O
in	O
the	O
bioactivation	O
of	O
cyclophosphamide	O
is	O
still	O
controversial	O
.	O

Recent	O
clinical	O
studies	O
have	O
suggested	O
a	O
role	O
for	O
either	O
CYP2C19	O
or	O
CYP2B6	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
clarify	O
the	O
role	O
of	O
these	O
pharmacogenes	O
.	O

METHODS	O
:	O
We	O
used	O
a	O
combined	O
in	O
vitro	O
-	O
in	O
vivo	O
approach	O
to	O
determine	O
the	O
role	O
of	O
these	O
pharmacogenes	O
in	O
the	O
bioactivation	O
of	O
the	O
prodrug	O
to	O
4-hydroxy	O
cyclophosphamide	O
(	O
4-OHCP	O
)	O
.	O

Cyclophosphamide	O
metabolism	O
was	O
determined	O
in	O
a	O
human	O
liver	O
biobank	O
(	O
n=	O
14	O
)	O
and	O
in	O
patients	O
receiving	O
the	O
drug	O
for	O
treatment	O
of	O
lupus	O
nephritis	O
(	O
n=	O
16	O
)	O
RESULTS	O
:	O
In	O
livers	O
of	O
known	O
CYP2C19	O
and	O
CYP2B6	O
genotype	O
and	O
protein	O
expression	O
we	O
observed	O
that	O
there	O
was	O
a	O
combined	B-Interaction
role	O
for	O
both	O
CYP2C19	B-Var
and	O
CYP2B6	B-Var
in	O
the	O
bioactivation	B-MPA
of	I-MPA
cyclophosphamide	I-MPA
in	O
vitro	O
.	O

The	O
presence	O
of	O
at	O
least	O
one	O
loss	O
of	O
function	O
(	O
LoF	O
)	O
allele	O
at	O
either	O
CYP2C19	B-Var
or	O
CYP2B6	B-Var
resulted	O
in	O
a	O
significant	O
decrease	B-NegReg
in	O
both	O
V(max	B-MPA
)	I-MPA
(	I-MPA
P=	I-MPA
0.028	I-MPA
)	I-MPA
and	I-MPA
CL(int	I-MPA
)	I-MPA
(	I-MPA
P=	I-MPA
0.0017	I-MPA
)	I-MPA
compared	O
with	O
livers	O
with	O
no	O
LoF	O
alleles	O
.	O

This	O
dual	O
genotype	O
relationship	O
was	O
also	O
observed	O
in	O
a	O
preliminary	O
clinical	O
study	O
,	O
with	O
patients	O
who	O
had	O
≥1	O
LoF	O
allele	O
at	O
either	O
CYP2C19	B-Var
or	O
CYP2B6	B-Var
also	O
displaying	O
significantly	O
(	O
P=	O
0.0316	O
)	O
lower	B-NegReg
bioactivation	B-MPA
of	I-MPA
cyclophosphamide	I-MPA
.	O

The	O
mean	O
4-OHCP	O
:	O
CP	O
bioactivation	O
ratio	O
was	O
0.0014	O
(	O
95	O
%	O
CI	O
0.0007	O
,	O
0.002	O
)	O
compared	O
with	O
0.0071	O
(	O
95	O
%	O
CI	O
0.0001	O
,	O
0.014	O
)	O
in	O
patients	O
with	O
no	O
LoF	O
alleles	O
at	O
either	O
of	O
these	O
genes	O
.	O

CONCLUSIONS	O
:	O
The	O
presence	O
of	O
≥1	O
LoF	O
allele(s	O
)	O
at	O
either	O
CYP2B6	B-Var
or	O
CYP2C19	B-Var
appeared	O
to	O
result	O
in	O
decreased	B-NegReg
bioactivation	B-MPA
of	I-MPA
cyclophosphamide	I-MPA
both	O
in	O
vitro	O
and	O
in	O
patients	O
.	O

Further	O
clinical	O
studies	O
to	O
confirm	O
this	O
relationship	O
are	O
warranted	O
.	O

Mutant	O
p53	O
R248Q	O
but	O
not	O
R248W	O
enhances	O
in	O
vitro	O
invasiveness	O
of	O
human	O
lung	O
cancer	O
NCI	O
-	O
H1299	O
cells	O
.	O

More	O
than	O
half	O
of	O
all	O
human	B-Disease
cancers	I-Disease
are	O
associated	B-Reg
with	O
mutations	B-Var
of	O
the	O
TP53	B-Gene
gene	O
.	O

In	O
regard	O
to	O
the	O
functional	O
interaction	O
with	O
the	O
remaining	O
wild	O
-	O
type	O
(	O
WT	O
)	O
p53	O
allele	O
,	O
p53	O
mutations	O
are	O
classified	O
into	O
two	O
types	O
,	O
recessive	O
and	O
dominant	B-Var
-	I-Var
negative	I-Var
(	I-Var
DN	I-Var
)	I-Var
mutations	I-Var
.	O

The	O
latter	O
mutant	O
protein	O
has	O
a	O
DN	B-MPA
activity	I-MPA
over	B-PosReg
the	I-PosReg
remaining	I-PosReg
WT	I-PosReg
allele	I-PosReg
.	O

We	O
previously	O
showed	O
that	O
the	O
DN	O
p53	O
mutant	O
was	O
useful	O
as	O
a	O
predictor	O
of	O
poor	O
outcome	O
or	O
a	O
risk	O
factor	O
for	O
metastatic	O
recurrence	O
in	O
patients	O
with	O
some	O
types	O
of	O
cancers	O
,	O
regardless	O
of	O
the	O
presence	O
or	O
absence	O
of	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
of	O
WT	O
p53	O
,	O
suggesting	O
that	O
the	O
DN	B-Var
p53	B-Gene
had	O
'	B-PosReg
gain	I-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	I-PosReg
GOF	I-PosReg
)	I-PosReg
'	I-PosReg
activity	I-PosReg
besides	O
the	O
transdominance	O
function	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
GOF	O
activity	O
of	O
two	O
DN	O
p53	O
mutants	O
which	O
had	O
a	O
point	O
mutation	O
at	O
codon	O
248	O
(	O
R248Q	O
and	O
R248W	O
)	O
,	O
one	O
of	O
the	O
hot	O
spots	O
,	O
by	O
transfecting	O
them	O
respectively	O
into	O
H1299	O
cells	O
which	O
originally	O
expressed	O
no	O
p53	O
protein	O
.	O

Growth	O
activity	O
of	O
the	O
transfectants	O
with	O
the	O
two	O
mutants	O
was	O
not	O
different	O
from	O
that	O
of	O
parent	O
or	O
Mock	O
transfectants	O
.	O

Meanwhile	O
,	O
in	O
vitro	B-CPA
invasions	I-CPA
of	I-CPA
Matrigel	I-CPA
and	I-CPA
type	I-CPA
I	I-CPA
collagen	I-CPA
gel	I-CPA
by	O
R248Q	B-Var
-	I-Var
transfectants	I-Var
were	O
significantly	O
higher	B-PosReg
than	O
those	O
by	O
R248W	O
-	O
transfectants	O
or	O
the	O
control	O
cells	O
.	O

However	O
,	O
there	O
were	O
no	O
differences	O
in	O
cell	O
motile	O
activities	O
,	O
expressions	O
of	O
extracellular	O
matrix	O
-	O
degradative	O
enzymes	O
such	O
as	O
matrix	O
metalloproteinases	O
,	O
urokinase	O
-	O
type	O
plasminogen	O
activator	O
and	O
heparanase	O
,	O
and	O
their	O
inhibitors	O
,	O
between	O
R248Q-	O
and	O
R248W	O
-	O
transfectants	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
p53	O
mutants	O
have	O
a	O
different	O
quality	O
in	O
GOF	O
activities	O
even	O
if	O
the	O
mutations	O
occurred	O
at	O
the	O
same	O
codon	O
.	O

And	O
detailed	O
information	O
of	O
the	O
status	O
of	O
p53	O
,	O
including	O
transdominancy	O
and	O
GOF	O
activity	O
,	O
is	O
expected	O
to	O
be	O
useful	O
for	O
diagnosis	O
and	O
therapeutic	O
strategy	O
fitting	O
the	O
individual	O
patients	O
.	O

Novel	O
and	O
recurrent	O
connexin	O
30.3	O
and	O
connexin	O
31	O
mutations	O
associated	O
with	O
erythrokeratoderma	O
variabilis	O
.	O

Erythrokeratoderma	B-Disease
variabilis	I-Disease
(	O
EKV	O
)	O
is	O
characterized	O
by	O
fixed	O
hyperkeratotic	O
plaques	O
and	O
transient	O
erythema	O
.	O

Mutations	B-Var
in	O
the	O
genes	O
GJB3	B-Gene
and	O
GJB4	B-Gene
,	O
which	O
encode	O
connexin	O
(	O
Cx)31	O
and	O
Cx30.3	O
,	O
are	O
associated	B-Reg
with	O
EKV	B-Disease
.	O

We	O
report	O
one	O
novel	O
mutation	O
in	O
Cx31	O
and	O
one	O
recurrent	O
mutation	O
in	O
Cx30.3	O
in	O
two	O
different	O
families	O
.	O

One	O
novel	O
rare	O
sequence	O
variant	O
of	O
unknown	O
clinical	O
significance	O
was	O
also	O
identified	O
.	O

This	O
finding	O
extends	O
the	O
spectrum	O
of	O
known	O
EKV	O
-	O
associated	O
mutations	O
.	O

Thyroid	O
pathology	O
in	O
PTEN	O
-	O
hamartoma	O
tumor	O
syndrome	O
:	O
characteristic	O
findings	O
of	O
a	O
distinct	O
entity	O
.	O

BACKGROUND	O
:	O
Phosphatase	O
and	O
tensin	O
homolog	O
deleted	O
on	O
chromosome	O
ten	O
(	B-Disease
PTEN)-hamartoma	I-Disease
tumor	I-Disease
syndrome	I-Disease
(	O
PHTS	O
)	O
is	O
a	O
complex	O
disorder	O
caused	O
by	O
germline	O
inactivating	B-NegReg
mutations	B-Var
of	O
the	O
PTEN	B-Gene
tumor	O
suppressor	O
gene	O
.	O

PHTS	O
includes	O
Cowden	O
syndrome	O
(	O
CS	O
)	O
,	O
Bannayan	O
-	O
Riley	O
-	O
Ruvalcaba	O
syndrome	O
(	O
BRRS	O
)	O
,	O
and	O
Proteus	O
-	O
like	O
syndromes	O
.	O

Affected	O
individuals	O
develop	O
both	O
benign	O
and	O
malignant	O
tumors	O
in	O
a	O
variety	O
of	O
tissues	O
,	O
including	O
the	O
thyroid	O
.	O

This	O
study	O
is	O
to	O
better	O
characterize	O
and	O
describe	O
the	O
thyroid	O
pathology	O
within	O
the	O
different	O
entities	O
of	O
this	O
syndrome	O
,	O
and	O
examine	O
whether	O
there	O
is	O
an	O
association	O
between	O
specific	O
thyroid	O
findings	O
and	O
different	O
PTEN	O
mutations	O
.	O

METHODS	O
:	O
Twenty	O
patients	O
with	O
known	O
PTEN	O
mutations	O
,	O
and/or	O
clinical	O
diagnosis	O
of	O
PHTS	O
,	O
and	O
thyroid	O
pathology	O
were	O
identified	O
:	O
14	O
with	O
CS	O
and	O
6	O
with	O
BRRS	O
.	O

RESULTS	O
:	O
Thyroid	O
pathology	O
findings	O
were	O
as	O
follows	O
:	O
multiple	O
adenomatous	O
nodules	O
in	O
a	O
background	O
of	O
lymphocytic	O
thyroiditis	O
(	O
LT	O
)	O
in	O
75	O
%	O
,	O
papillary	O
carcinoma	O
in	O
60	O
%	O
,	O
LT	O
alone	O
in	O
55	O
%	O
,	O
follicular	O
carcinoma	O
in	O
45	O
%	O
,	O
C	O
-	O
cell	O
hyperplasia	O
in	O
55	O
%	O
,	O
and	O
follicular	O
adenomas	O
in	O
25	O
%	O
.	O

Within	O
the	O
papillary	O
carcinoma	O
group	O
,	O
there	O
were	O
6	O
microcarcinomas	O
,	O
5	O
follicular	O
variants	O
,	O
and	O
1	O
classical	O
type	O
.	O

CONCLUSIONS	O
:	O
There	O
were	O
no	O
morphologic	O
differences	O
between	O
the	O
thyroid	O
findings	O
in	O
CS	O
and	O
BRRS	O
.	O

Also	O
,	O
there	O
was	O
no	O
correlation	O
between	O
specific	O
PTEN	O
germline	O
mutations	O
(	O
exons	O
5	O
,	O
6	O
,	O
and	O
8)	O
and	O
pathologic	O
findings	O
.	O

Distinctive	O
and	O
characteristic	O
findings	O
in	O
PHTS	O
include	O
multiple	O
unique	O
adenomatous	O
nodules	O
in	O
a	O
background	O
of	O
LT	O
,	O
and	O
C	O
-	O
cell	O
hyperplasia	O
;	O
it	O
is	O
vital	O
that	O
pathologists	O
recognize	O
the	O
classical	O
histologic	O
features	O
of	O
this	O
syndrome	O
to	O
alert	O
clinicians	O
to	O
the	O
possibility	O
of	O
this	O
syndrome	O
in	O
their	O
patients	O
.	O

Variable	O
phenotypes	O
are	O
associated	O
with	O
PMP22	O
missense	O
mutations	O
.	O

Charcot	B-Disease
-	I-Disease
Marie	I-Disease
-	I-Disease
Tooth	I-Disease
disease	I-Disease
(	O
CMT	O
)	O
is	O
the	O
commonest	O
hereditary	O
neuropathy	O
encompassing	O
a	O
large	O
group	O
of	O
clinically	O
and	O
genetically	O
heterogeneous	O
disorders	O
.	O

The	O
commonest	O
form	O
of	O
CMT	B-Disease
,	O
CMT1A	B-Disease
,	O
is	O
usually	O
caused	B-Reg
by	I-Reg
a	O
1.4	O
megabase	O
duplication	B-Var
of	O
chromosome	O
17	O
containing	O
the	O
PMP22	B-Gene
gene	O
.	O

Mutations	B-Var
of	O
PMP22	B-Gene
are	O
a	O
less	O
common	O
cause	B-Reg
of	O
CMT	B-Disease
.	O

We	O
describe	O
clinical	O
,	O
electrophysiological	O
and	O
molecular	O
findings	O
of	O
10	O
patients	O
carrying	O
PMP22	O
missense	O
mutations	O
.	O

The	O
phenotype	O
varied	O
from	O
mild	O
hereditary	O
neuropathy	O
with	O
liability	O
to	O
pressure	O
palsies	O
(	O
HNPP	O
)	O
to	O
severe	O
CMT1	O
.	O

We	O
identified	O
six	O
different	O
point	O
mutations	O
,	O
including	O
two	O
novel	O
mutations	O
.	O

Three	O
families	O
were	O
also	O
found	O
to	O
harbour	O
a	O
Thr118Met	O
mutation	O
.	O

Although	O
PMP22	O
point	O
mutations	O
are	O
not	O
common	O
,	O
our	O
findings	O
highlight	O
the	O
importance	O
of	O
sequencing	O
the	O
PMP22	O
gene	O
in	O
patients	O
with	O
variable	O
CMT	O
phenotypes	O
and	O
also	O
confirm	O
that	O
the	O
PMP22	B-Gene
Thr118Met	B-Var
mutation	O
is	O
associated	B-Reg
with	I-Reg
a	O
neuropathy	B-CPA
albeit	O
with	O
reduced	O
penetrance	O
.	O

Genotype	O
-	O
phenotype	O
analysis	O
of	O
the	O
branchio	O
-	O
oculo	O
-	O
facial	O
syndrome	O
.	O

Branchio	B-Disease
-	I-Disease
oculo	I-Disease
-	I-Disease
facial	I-Disease
syndrome	I-Disease
(	O
BOFS	O
;	O
OMIM#113620	O
)	O
is	O
a	O
rare	O
autosomal	O
dominant	O
craniofacial	O
disorder	O
with	O
variable	O
expression	O
.	O

Major	O
features	O
include	O
cutaneous	O
and	O
ocular	O
abnormalities	O
,	O
characteristic	O
facies	O
,	O
renal	O
,	O
ectodermal	O
,	O
and	O
temporal	O
bone	O
anomalies	O
.	O

Having	O
determined	O
that	O
mutations	B-Var
involving	O
TFAP2A	B-Gene
result	B-Reg
in	I-Reg
BOFS	B-Disease
,	O
we	O
studied	O
a	O
total	O
of	O
30	O
families	O
(	O
41	O
affected	O
individuals	O
)	O
;	O
26/30	O
(	O
87	O
%	O
)	O
fulfilled	O
our	O
cardinal	O
diagnostic	O
criteria	O
.	O

The	O
original	O
family	O
with	O
the	O
3.2	O
Mb	O
deletion	O
including	O
the	O
TFAP2A	O
gene	O
remains	O
the	O
only	O
BOFS	O
family	O
without	O
the	O
typical	O
CL	O
/	O
P	O
and	O
the	O
only	O
family	O
with	O
a	O
deletion	O
.	O

We	O
have	O
identified	O
a	O
hotspot	O
region	O
in	O
the	O
highly	O
conserved	O
exons	O
4	O
and	O
5	O
of	O
TFAP2A	O
that	O
harbors	O
missense	O
mutations	O
in	O
27/30	O
(	O
90	O
%	O
)	O
families	O
.	O

Several	O
of	O
these	O
mutations	O
are	O
recurrent	O
.	O

Mosaicism	O
was	O
detected	O
in	O
one	O
family	O
.	O

To	O
date	O
,	O
genetic	O
heterogeneity	O
has	O
not	O
been	O
observed	O
.	O

Although	O
the	O
cardinal	O
criteria	O
for	O
BOFS	O
have	O
been	O
based	O
on	O
the	O
presence	O
of	O
each	O
of	O
the	O
core	O
defects	O
,	O
an	O
affected	O
family	O
member	O
or	O
thymic	O
remnant	O
,	O
we	O
documented	O
TFAP2A	O
mutations	O
in	O
three	O
(	O
10	O
%	O
)	O
probands	O
in	O
our	O
series	O
without	O
a	O
classic	O
cervical	O
cutaneous	O
defect	O
or	O
ectopic	O
thymus	O
.	O

Temporal	O
bone	O
anomalies	O
were	O
identified	O
in	O
3/5	O
patients	O
investigated	O
.	O

The	O
occurrence	O
of	O
CL	O
/	O
P	O
,	O
premature	O
graying	O
,	O
coloboma	O
,	O
heterochromia	O
irides	O
,	O
and	O
ectopic	O
thymus	O
,	O
are	O
evidence	O
for	O
BOFS	O
as	O
a	O
neurocristopathy	O
.	O

Intrafamilial	O
clinical	O
variability	O
can	O
be	O
marked	O
.	O

Although	O
there	O
does	O
not	O
appear	O
to	O
be	O
mutation	O
-	O
specific	O
genotype	O
-	O
phenotype	O
correlations	O
at	O
this	O
time	O
,	O
more	O
patients	O
need	O
to	O
be	O
studied	O
.	O

Clinical	O
testing	O
for	O
TFAP2A	O
mutations	O
is	O
now	O
available	O
and	O
will	O
assist	O
geneticists	O
in	O
confirming	O
the	O
typical	O
cases	O
or	O
excluding	O
the	O
diagnosis	O
in	O
atypical	O
cases	O
.	O

Twenty	O
-	O
five	O
novel	O
mutations	O
including	O
duplications	O
in	O
the	O
ATP7A	O
gene	O
.	O

Twenty	O
-	O
five	O
novel	O
mutations	O
including	O
duplications	O
in	O
the	O
ATP7A	O
gene	O
.	O

Menkes	B-Disease
disease	I-Disease
(	O
MD	O
)	O
and	O
occipital	B-Disease
horn	I-Disease
syndrome	I-Disease
(	O
OHS	O
)	O
are	O
allelic	O
X	O
-	O
linked	O
recessive	O
copper	O
deficiency	O
disorders	O
resulting	B-Reg
from	I-Reg
ATP7A	B-Gene
gene	O
mutations	B-Var
.	O

MD	O
is	O
a	O
severe	O
condition	O
leading	O
to	O
progressive	O
neurological	O
degeneration	O
and	O
death	O
in	O
early	O
childhood	O
,	O
whereas	O
OHS	O
has	O
a	O
milder	O
phenotype	O
with	O
mainly	O
connective	O
tissue	O
abnormalities	O
.	O

Until	O
now	O
,	O
molecular	O
analyses	O
have	O
revealed	O
only	O
deletions	O
and	O
point	O
mutations	O
in	O
both	O
diseases	O
.	O

This	O
study	O
reports	O
new	O
molecular	O
data	O
in	O
a	O
series	O
of	O
40	O
patients	O
referred	O
for	O
either	O
MD	O
or	O
OHS	O
.	O

We	O
describe	O
23	O
point	O
mutations	O
(	O
9	O
missense	O
mutations	O
,	O
7	O
splice	O
site	O
variants	O
,	O
4	O
nonsense	O
mutations	O
,	O
and	O
3	O
small	O
insertions	O
or	O
deletions	O
)	O
and	O
7	O
intragenic	O
deletions	O
.	O

Of	O
these	O
,	O
18	O
point	O
mutations	O
and	O
3	O
deletions	O
are	O
novel	O
.	O

Furthermore	O
,	O
our	O
finding	O
of	O
four	O
whole	O
exon	O
duplications	O
enlarges	O
the	O
mutation	O
spectrum	O
in	O
the	O
ATP7A	O
gene	O
.	O

ATP7A	O
alterations	O
were	O
found	O
in	O
85	O
%	O
of	O
cases	O
.	O

Of	O
these	O
alterations	O
,	O
two	O
thirds	O
were	O
point	O
mutations	O
and	O
the	O
remaining	O
one	O
third	O
consisted	O
of	O
large	O
rearrangements	O
.	O

We	O
found	O
that	O
66.6	O
%	O
of	O
point	O
mutations	B-Var
resulted	O
in	O
impaired	B-NegReg
ATP7A	B-Gene
transcript	B-MPA
splicing	I-MPA
,	O
a	O
phenomenon	O
more	O
frequent	O
than	O
expected	O
.	O

This	O
finding	O
enabled	O
us	O
to	O
confirm	O
the	O
pathogenic	O
role	O
of	O
ATP7A	O
mutations	O
,	O
particularly	O
in	O
missense	O
and	O
splice	O
site	O
variants	O
.	O

Phenotypic	O
heterogeneity	O
in	O
a	O
large	O
Thai	O
slow	O
-	O
channel	O
congenital	O
myasthenic	O
syndrome	O
kinship	O
.	O

The	O
slow	B-Disease
-	I-Disease
channel	I-Disease
congenital	I-Disease
myasthenic	I-Disease
syndrome	I-Disease
(	O
SCCMS	O
)	O
is	O
an	O
autosomal	O
dominant	O
neuromuscular	O
disorder	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
different	O
subunits	O
of	O
the	O
acetylcholine	O
receptor	O
(	B-Gene
AChR	I-Gene
)	I-Gene
.	O

We	O
here	O
report	O
our	O
clinical	O
findings	O
in	O
three	O
generations	O
of	O
a	O
large	O
Thai	O
kinship	O
suffering	O
from	O
SCCMS	O
and	O
trace	O
the	O
disease	O
to	O
the	O
p	O
.	O
Gly153Ser	O
mutation	O
in	O
the	O
AChR	O
α	O
subunit	O
.	O

The	O
same	O
mutation	O
had	O
previously	O
been	O
reported	O
only	O
in	O
Caucasian	O
but	O
not	O
in	O
Asian	O
patients	O
.	O

The	O
clinical	O
features	O
include	O
ptosis	O
,	O
ophthalmoparesis	O
,	O
and	O
weakness	O
of	O
the	O
cervical	O
and	O
finger	O
extensor	O
muscles	O
as	O
well	O
as	O
marked	O
phenotypic	O
heterogeneity	O
.	O

[	O
Anaemia	O
caused	O
by	O
a	O
congenital	O
haemoglobin	O
defect	O
can	O
also	O
occur	O
in	O
native	O
Dutch	O
patients	O
]	O
.	O

Anemie	O
door	O
aangeboren	O
afwijkingen	O
van	O
het	O
hemoglobine	O
,	O
ook	O
bij	O
autochtone	O
Nederlanders	O
.	O

An	O
11-year	O
-	O
old	O
boy	O
of	O
Dutch	O
descent	O
had	O
suffered	O
from	O
tiredness	O
,	O
pallor	O
and	O
poor	O
appetite	O
for	O
many	O
years	O
.	O

There	O
was	O
no	O
indication	O
of	O
chronic	O
infection	O
.	O

Iron	O
supplements	O
did	O
not	O
produce	O
sufficient	O
improvement	O
in	O
the	O
symptoms	O
.	O

Following	O
analysis	O
using	O
fast	O
protein	O
liquid	O
chromatography	O
and	O
DNA	O
sequencing	O
analysis	O
,	O
it	O
appeared	O
that	O
this	O
was	O
a	O
case	O
of	O
β	B-Disease
-	I-Disease
thalassaemia	I-Disease
intermedia	I-Disease
,	O
caused	B-Reg
by	I-Reg
a	O
point	B-Var
mutation	I-Var
in	O
the	O
promotor	O
region	O
of	O
the	O
β	B-Gene
-	I-Gene
globulin	I-Gene
gene	O
.	O

The	O
boy	O
's	O
parents	O
both	O
proved	O
to	O
be	O
heterozygotes	O
for	O
this	O
point	O
mutation	O
.	O

A	O
second	O
patient	O
,	O
a	O
5-year	O
-	O
old	O
girl	O
of	O
Dutch	O
descent	O
,	O
suffered	O
from	O
an	O
icterus	O
following	O
a	O
respiratory	O
tract	O
infection	O
.	O

Splenomegaly	O
,	O
hyperbilirubinaemia	O
and	O
microcytic	O
anaemia	O
with	O
raised	O
reticulocyte	O
values	O
were	O
observed	O
.	O

Because	O
of	O
the	O
presence	O
of	O
spherocytes	O
,	O
hereditary	O
spherocytosis	O
was	O
initially	O
suspected	O
.	O

On	O
further	O
analysis	O
Heinz	O
bodies	O
were	O
also	O
seen	O
,	O
following	O
which	O
DNA	O
sequencing	O
analysis	O
showed	O
a	O
de	O
novo	O
Hb	O
Köln	O
mutation	O
.	O

Congenital	O
haemoglobin	O
defects	O
are	O
usually	O
associated	O
with	O
people	O
originating	O
from	O
Africa	O
,	O
the	O
Mediterranean	O
,	O
the	O
Middle	O
-	O
East	O
or	O
South	O
-	O
East	O
Asia	O
.	O

That	O
such	O
abnormalities	O
can	O
also	O
occur	O
in	O
children	O
of	O
Dutch	O
descent	O
is	O
demonstrated	O
by	O
these	O
two	O
cases	O
.	O

Mild	O
recessive	O
dystrophic	B-Disease
epidermolysis	I-Disease
bullosa	I-Disease
associated	B-Reg
with	I-Reg
two	O
compound	O
heterozygous	O
COL7A1	B-Gene
mutations	B-Var
.	O

Dystrophic	B-Disease
epidermolysis	I-Disease
bullosa	I-Disease
is	O
a	O
group	O
of	O
inherited	O
skin	O
blistering	O
disorders	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
COL7A1	B-Gene
gene	O
coding	O
for	O
type	O
VII	O
collagen	O
.	O

More	O
than	O
500	O
different	O
COL7A1	B-Gene
mutations	B-Var
have	O
been	O
detected	B-Reg
in	O
dystrophic	B-Disease
epidermolysis	I-Disease
bullosa	I-Disease
to	O
date	O
.	O

Clarification	O
of	O
genotype	O
-	O
phenotype	O
correlations	O
is	O
of	O
particular	O
importance	O
for	O
the	O
development	O
of	O
novel	O
therapeutic	O
approaches	O
.	O

Here	O
we	O
report	O
a	O
female	O
patient	O
with	O
mild	O
dystrophic	O
epidermolysis	O
bullosa	O
harbouring	O
two	O
compound	O
heterozygous	O
COL7A1	O
mutations	O
,	O
namely	O
the	O
intronic	O
splice	O
site	O
mutation	O
c.3832	O
-	O
2A	O
>	O
G	O
and	O
the	O
glycine	O
substitution	O
p	O
.	O
G1347W.	O
Our	O
data	O
extend	O
the	O
current	O
knowledge	O
on	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
dystrophic	O
epidermolysis	O
bullosa	O
.	O

[	O
Association	O
of	O
mutation	O
types	O
and	O
distribution	O
characteristics	O
of	O
dystrophin	O
gene	O
with	O
clinical	O
symptoms	O
in	O
Chinese	O
population	O
]	O
.	O

Duchenne	O
muscular	O
dystrophy	O
(	O
DMD	O
)	O
is	O
X	O
-	O
linked	O
disorder	O
caused	O
by	O
mutations	O
in	O
the	O
dystrophin	O
gene	O
.	O

To	O
investigate	O
mutation	O
types	O
and	O
distribution	O
characteristics	O
of	O
dystrophin	O
gene	O
in	O
Chinese	O
DMD	O
patients	O
,	O
we	O
used	O
Multiplex	O
Ligation	O
-	O
Dependent	O
Probe	O
Amplification	O
(	O
MLPA	O
)	O
to	O
analyze	O
the	O
dystrophin	O
gene	O
in	O
720	O
DMD	O
patients	O
,	O
their	O
mothers	O
,	O
and	O
20	O
normal	O
adult	O
males	O
.	O

Results	O
showed	O
that	O
detection	O
rate	O
was	O
64.9	O
%	O
(	O
467/720	O
)	O
in	O
all	O
the	O
patients	O
,	O
gene	O
deletion	O
rate	O
was	O
54.3	O
%	O
(	O
391/720	O
)	O
,	O
and	O
gene	O
duplication	O
rate	O
was	O
10.6	O
%	O
(	O
76/720	O
)	O
.	O

The	O
rate	O
of	O
deletion	O
mutant	O
occurred	O
in	O
Exon	O
45	O
-	O
54	O
was	O
71.9	O
%	O
(	O
281/391	O
)	O
in	O
all	O
gene	O
deletion	O
patients	O
;	O
meanwhile	O
,	O
the	O
rate	O
of	O
gene	O
duplication	O
occurred	O
in	O
Exon	O
1	O
-	O
40	O
was	O
82.9	O
%	O
(	O
63/76	O
)	O
in	O
all	O
gene	O
duplication	O
ones	O
.	O

In	O
all	O
the	O
patients	O
with	O
gene	O
deletion	O
and	O
duplication	O
,	O
the	O
rate	O
of	O
DMD	O
and	O
IMD	O
was	O
90.6	O
%	O
(	O
423/467	O
)	O
,	O
and	O
BMD	O
,	O
9.4	O
%	O
(	O
44/467	O
)	O
.	O

This	O
indicates	O
that	O
the	O
main	O
reason	B-Reg
of	O
duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
is	O
dystrophin	B-Gene
gene	I-Gene
deletion	B-Var
mutation	O
,	O
which	O
would	O
occur	O
in	O
any	O
gene	O
unevenly	O
with	O
hot	O
spots	O
of	O
mutation	O
.	O

The	O
location	O
and	O
fragment	O
length	O
of	O
gene	O
deletion	O
and	O
duplication	O
can	O
not	O
decide	O
the	O
severity	O
of	O
clinical	O
symptoms	O
directly	O
.	O

AXIN2-associated	O
autosomal	O
dominant	O
ectodermal	O
dysplasia	O
and	O
neoplastic	O
syndrome	O
.	O

We	O
describe	O
a	O
family	O
with	O
a	O
novel	O
,	O
inherited	O
AXIN2	O
mutation	O
(	O
c.1989G	O
>	O
A	O
)	O
segregating	O
in	O
an	O
autosomal	O
dominant	O
pattern	O
with	O
oligodontia	O
and	O
variable	O
other	O
findings	O
including	O
colonic	O
polyposis	O
,	O
gastric	O
polyps	O
,	O
a	O
mild	O
ectodermal	O
dysplasia	O
phenotype	O
with	O
sparse	O
hair	O
and	O
eyebrows	O
,	O
and	O
early	O
onset	O
colorectal	O
and	O
breast	O
cancers	O
.	O

This	O
novel	O
mutation	O
predicts	O
p	O
.	O
Trp663X	O
,	O
which	O
is	O
a	O
truncated	O
protein	O
that	O
is	O
missing	O
the	O
last	O
three	O
exons	O
,	O
including	O
the	O
DIX	O
(	O
Disheveled	O
and	O
AXIN	O
interacting	O
)	O
domain	O
.	O

This	O
nonsense	O
mutation	B-Var
is	O
predicted	O
to	O
destroy	B-NegReg
the	O
inhibitory	B-MPA
action	I-MPA
of	O
AXIN2	B-Gene
on	O
WNT	B-Pathway
signaling	I-Pathway
.	O

Previous	O
authors	O
have	O
described	O
an	O
unrelated	O
family	O
with	O
autosomal	O
dominant	O
oligodontia	O
and	O
a	O
variable	O
colorectal	O
phenotype	O
segregating	O
with	O
a	O
nonsense	O
mutation	O
of	O
AXIN2	O
,	O
as	O
well	O
as	O
a	O
frameshift	O
AXIN2	O
mutation	O
in	O
an	O
unrelated	O
individual	O
with	O
oligodontia	O
.	O

Our	O
report	O
provides	O
additional	O
evidence	O
supporting	O
an	O
autosomal	B-Var
dominant	I-Var
AXIN2-associated	B-Gene
ectodermal	B-Disease
dysplasia	I-Disease
and	O
neoplastic	B-Disease
syndrome	I-Disease
.	O

The	O
Down	O
syndrome	O
critical	O
region	O
regulates	O
retinogeniculate	O
refinement	O
.	O

Down	B-Disease
syndrome	I-Disease
(	O
DS	O
)	O
is	O
a	O
developmental	O
disorder	O
caused	B-Reg
by	I-Reg
a	O
third	O
chromosome	O
21	O
in	O
humans	O
(	B-Var
Trisomy	I-Var
21	I-Var
)	I-Var
,	O
leading	O
to	O
neurological	O
deficits	O
and	O
cognitive	O
impairment	O
.	O

Studies	O
in	O
mouse	O
models	O
of	O
DS	O
suggest	O
that	O
cognitive	O
deficits	O
in	O
the	O
adult	O
are	O
associated	O
with	O
deficits	O
in	O
synaptic	O
learning	O
and	O
memory	O
mechanisms	O
,	O
but	O
it	O
is	O
unclear	O
whether	O
alterations	O
in	O
the	O
early	O
wiring	O
and	O
refinement	O
of	O
neuronal	O
circuits	O
contribute	O
to	O
these	O
deficits	O
.	O

Here	O
,	O
we	O
show	O
that	O
early	O
developmental	O
refinement	O
of	O
visual	O
circuits	O
is	O
perturbed	O
in	O
mouse	O
models	O
of	O
Down	O
syndrome	O
.	O

Specifically	O
,	O
we	O
find	O
excessive	O
eye	O
-	O
specific	O
segregation	O
of	O
retinal	O
axons	O
in	O
the	O
dorsal	O
lateral	O
geniculate	O
nucleus	O
.	O

Indeed	O
,	O
the	O
degree	O
of	O
refinement	O
scales	O
with	O
defects	O
in	O
the	O
"	O
Down	O
syndrome	O
critical	O
region	O
"	O
(	O
DSCR	O
)	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

We	O
further	O
identify	O
Dscam	O
(	O
Down	O
syndrome	O
cell	O
adhesion	O
molecule	O
)	O
,	O
a	O
gene	O
within	O
the	O
DSCR	O
,	O
as	O
a	O
regulator	O
of	O
eye	O
-	O
specific	O
segregation	O
of	O
retinogeniculate	O
projections	O
.	O

Although	O
Dscam	O
is	O
not	O
the	O
sole	O
gene	O
in	O
the	O
DSCR	O
contributing	O
to	O
enhanced	O
refinement	O
in	O
trisomy	O
,	O
Dscam	O
dosage	O
clearly	O
regulates	O
cell	O
spacing	O
and	O
dendritic	O
fasciculation	O
in	O
a	O
specific	O
class	O
of	O
retinal	O
ganglion	O
cells	O
.	O

Thus	O
,	O
altered	O
developmental	O
refinement	O
of	O
visual	O
circuits	O
that	O
occurs	O
before	O
sensory	O
experience	O
is	O
likely	O
to	O
contribute	O
to	O
visual	O
impairment	O
in	O
individuals	O
with	O
Down	O
syndrome	O
.	O

Identification	O
and	O
functional	O
consequences	O
of	O
a	O
recurrent	O
NLRP12	B-Gene
missense	B-Var
mutation	I-Var
in	B-Reg
periodic	B-Disease
fever	I-Disease
syndromes	I-Disease
.	O

OBJECTIVE	O
:	O
To	O
gain	O
insight	O
into	O
the	O
molecular	O
bases	O
of	O
genetically	O
unexplained	O
periodic	O
fever	O
syndromes	O
(	O
PFS	O
)	O
by	O
screening	O
NLRP12	O
,	O
a	O
gene	O
in	O
which	O
only	O
a	O
nonsense	O
and	O
a	O
splice	O
site	O
mutation	O
have	O
so	O
far	O
been	O
identified	O
,	O
and	O
to	O
assess	O
the	O
functional	O
consequences	O
of	O
the	O
identified	O
missense	O
variation	O
.	O

METHODS	O
:	O
NLRP12	O
was	O
screened	O
for	O
mutations	O
by	O
direct	O
sequencing	O
.	O

Functional	O
assays	O
were	O
performed	O
in	O
HEK	O
293	O
T	O
cells	O
stably	O
expressing	O
the	O
proapoptotic	O
protein	O
ASC	O
and	O
procaspase	O
1	O
,	O
in	O
order	O
to	O
determine	O
the	O
effects	O
of	O
normal	O
and	O
mutated	O
NLRP12	O
proteins	O
on	O
speck	O
formation	O
,	O
caspase	O
1	O
signaling	O
,	O
and	O
NF	O
-	O
κB	O
activation	O
.	O

RESULTS	O
:	O
A	O
heterozygous	O
NLRP12	B-Gene
missense	O
mutation	O
involving	O
a	O
CpG	O
site	O
(	B-Var
c.1054C	I-Var
>	I-Var
T	I-Var
;	I-Var
p	O
.	O
Arg352Cys	O
)	O
was	O
identified	O
in	O
exon	O
3	O
,	O
which	O
encodes	B-Reg
the	O
nucleotide	B-Interaction
-	I-Interaction
binding	I-Interaction
site	O
(	O
NBS	O
)	O
of	O
the	O
protein	B-Protein
,	O
in	O
2	O
patients	O
from	O
different	O
countries	O
and	O
carrying	O
different	O
NLRP12	O
haplotypes	O
.	O

The	O
mutation	B-Var
,	O
which	O
does	O
not	O
alter	O
the	O
inhibitory	O
effect	O
of	O
NLRP12	O
on	O
NF	O
-	O
κB	O
activation	O
,	O
increases	B-PosReg
speck	B-MPA
formation	I-MPA
and	O
activates	B-PosReg
caspase	B-MPA
1	I-MPA
signaling	I-MPA
.	O

To	O
define	O
this	O
new	O
class	O
of	O
PFS	O
,	O
we	O
propose	O
the	O
term	O
NLRP12-associated	O
disorders	O
(	O
NLRP12AD	O
)	O
.	O

CONCLUSION	O
:	O
Given	O
the	O
rarity	O
of	O
known	O
NLRP12-associated	O
disorders	O
,	O
the	O
identification	O
of	O
this	O
NLRP12	O
molecular	O
defect	O
contributes	O
to	O
the	O
delineation	O
of	O
the	O
clinical	O
spectrum	O
associated	O
with	O
mutations	O
in	O
this	O
gene	O
and	O
highlights	O
the	O
importance	O
of	O
screening	O
NLRP12	O
in	O
patients	O
presenting	O
with	O
unexplained	O
PFS	O
.	O

This	O
study	O
also	O
demonstrates	O
,	O
by	O
means	O
of	O
functional	O
assays	O
,	O
the	O
deleterious	O
effect	O
of	O
this	O
recurrent	O
missense	O
mutation	O
;	O
the	O
gain	B-PosReg
of	I-PosReg
function	I-PosReg
for	O
speck	B-MPA
formation	I-MPA
and	O
caspase	B-MPA
1	I-MPA
signaling	I-MPA
associated	O
with	O
this	O
NBS	O
mutation	B-Var
is	O
consistent	O
with	O
the	O
inflammatory	O
phenotype	O
of	O
PFS	O
.	O

New	O
homozygous	O
SPINK5	O
mutation	O
,	O
p	O
.	O
Gln333X	O
,	O
in	O
a	O
Turkish	O
pedigree	O
with	O
Netherton	O
syndrome	O
.	O

Netherton	B-Disease
syndrome	I-Disease
(	O
NS	O
)	O
is	O
a	O
rare	O
autosomal	O
recessive	O
genodermatosis	O
caused	O
by	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
the	O
SPINK5	B-Gene
gene	O
.	O

The	O
clinical	O
features	O
include	O
congenital	O
ichthyosis	O
,	O
trichorrhexis	O
invaginata	O
and	O
atopy	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
a	O
new	O
homozygous	O
SPINK5	B-Gene
mutation	O
,	O
p	B-Var
.	I-Var
Gln333X	I-Var
,	O
responsible	B-Reg
for	O
NS	B-Disease
in	O
affected	O
members	O
of	O
two	O
closely	O
related	O
Turkish	O
families	O
,	O
and	O
provide	O
an	O
overview	O
of	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
this	O
condition	O
.	O

Severer	O
phenotype	O
in	O
Unverricht	B-Disease
-	I-Disease
Lundborg	I-Disease
disease	I-Disease
(	O
EPM1	O
)	O
patients	O
compound	O
heterozygous	O
for	B-Reg
the	O
dodecamer	O
repeat	O
expansion	O
and	O
the	O
c.202C	B-Var
>	I-Var
T	I-Var
mutation	O
in	O
the	O
CSTB	B-Gene
gene	O
.	O

BACKGROUND	O
/	O
AIMS	O
:	O
Unverricht	B-Disease
-	I-Disease
Lundborg	I-Disease
disease	I-Disease
(	O
EPM1	O
)	O
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
cystatin	O
B	O
(	B-Gene
CSTB	I-Gene
)	I-Gene
gene	O
.	O

Most	O
patients	O
are	O
homozygous	O
for	O
the	O
expanded	O
dodecamer	O
repeat	O
mutation	O
alleles	O
,	O
but	O
9	O
other	O
EPM1-associated	O
mutations	O
have	O
also	O
been	O
identified	O
.	O

We	O
describe	O
the	O
clinical	O
,	O
cognitive	O
and	O
imaging	O
characteristics	O
of	O
5	O
Finnish	O
EPM1	O
patients	O
who	O
are	O
compound	O
heterozygous	O
for	O
the	O
dodecamer	O
repeat	O
expansion	O
and	O
the	O
c.202C	O
>	O
T	O
mutations	O
.	O

METHODS	O
:	O
Five	O
compound	O
heterozygous	O
patients	O
and	O
21	O
patients	O
homozygous	O
for	O
the	O
expansion	O
mutation	O
,	O
participating	O
in	O
an	O
ongoing	O
nationwide	O
clinical	O
and	O
molecular	O
genetics	O
study	O
,	O
were	O
evaluated	O
using	O
the	O
Unified	O
Myoclonus	O
Rating	O
Scale	O
test	O
and	O
comprehensive	O
neuropsychological	O
testing	O
.	O

All	O
patients	O
underwent	O
MR	O
imaging	O
.	O

The	O
MR	O
data	O
were	O
also	O
compared	O
with	O
those	O
of	O
24	O
healthy	O
control	O
subjects	O
.	O

RESULTS	O
:	O
Age	O
at	O
onset	O
of	O
symptoms	O
was	O
significantly	O
lower	O
in	O
the	O
compound	O
heterozygotes	O
than	O
in	O
the	O
homozygous	O
EPM1	O
patients	O
.	O

They	O
also	O
had	O
severer	O
myoclonus	O
and	O
drug	O
-	O
resistant	O
tonic	O
-	O
clonic	O
seizures	O
.	O

Moreover	O
,	O
they	O
had	O
lower	O
cognitive	O
performance	O
.	O

In	O
MRI	O
a	O
voxel	O
-	O
based	O
morphometry	O
analysis	O
of	O
primary	O
and	O
premotor	O
cortex	O
,	O
supplementary	O
motor	O
cortex	O
and	O
thalami	O
revealed	O
gray	O
matter	O
volume	O
loss	O
when	O
compared	O
with	O
the	O
healthy	O
controls	O
,	O
similar	O
to	O
patients	O
homozygous	O
for	O
the	O
expansion	O
mutation	O
.	O

CONCLUSION	O
:	O
Patients	O
compound	O
heterozygous	O
for	O
the	O
dodecamer	O
repeat	O
expansion	O
and	O
the	O
c.202C	O
>	O
T	O
mutations	O
seem	O
to	O
have	O
a	O
severer	O
form	O
of	O
EPM1	O
than	O
patients	O
homozygous	O
for	O
the	O
expansion	O
mutation	O
.	O

These	O
findings	O
have	O
implications	O
for	O
counseling	O
of	O
EPM1	O
patients	O
with	O
different	O
genetic	O
defects	O
.	O

Acquisition	O
of	O
steady	O
-	O
state	O
operant	O
behavior	O
in	O
long	O
-	O
living	O
Ames	O
Dwarf	O
mice	O
.	O

Ames	O
dwarf	O
mice	O
have	O
a	O
Prop-1	B-Gene
mutation	B-Var
that	O
has	O
been	O
identified	O
with	O
increased	B-PosReg
levels	B-MPA
of	I-MPA
IGF	I-MPA
-	I-MPA
I	I-MPA
in	O
the	O
central	O
nervous	O
system	O
,	O
upregulation	B-PosReg
of	O
neuroprotective	B-CPA
systems	I-CPA
,	O
and	O
increased	O
lifespan	O
.	O

To	O
elucidate	O
the	O
behavioral	O
effects	O
of	O
the	O
Prop-1	O
mutation	O
,	O
8	O
Ames	O
dwarf	O
and	O
7	O
normal	O
mice	O
(	O
all	O
of	O
whom	O
were	O
8	O
months	O
of	O
age	O
or	O
younger	O
)	O
were	O
compared	O
on	O
a	O
differential	O
-	O
reinforcement	O
-	O
of	O
-	O
low	O
-	O
rate	O
-	O
of	O
-	O
responding	O
schedule	O
of	O
reinforcement	O
and	O
a	O
matching	O
-	O
to	O
-	O
sample	O
task	O
.	O

On	O
both	O
tasks	O
,	O
nosepokes	O
were	O
reinforced	O
with	O
access	O
to	O
a	O
saccharin	O
solution	O
.	O

Comparisons	O
were	O
based	O
on	O
several	O
measures	O
of	O
behavioral	O
efficiency	O
:	O
pause	O
durations	O
,	O
intertrial	O
intervals	O
,	O
and	O
numbers	O
of	O
responses	O
.	O

Ames	O
dwarf	O
mice	O
were	O
generally	O
less	O
efficient	O
than	O
normal	O
mice	O
.	O

One	O
possible	O
cause	O
of	O
this	O
outcome	O
is	O
that	O
relatively	O
young	O
Ames	O
dwarf	O
mice	O
show	O
less	O
cognitive	O
development	O
than	O
age	O
-	O
matched	O
normal	O
mice	O
.	O

[	B-Gene
GNE	I-Gene
gene	O
mutation	B-Var
analysis	O
in	O
5	O
patients	O
with	B-Reg
distal	B-Disease
myopathy	I-Disease
with	I-Disease
rimmed	I-Disease
vacuoles	I-Disease
]	I-Disease
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
GNE	O
gene	O
mutations	O
in	O
5	O
Chinese	O
patients	O
with	O
distal	O
myopathy	O
with	O
rimmed	O
vacuoles	O
(	O
DMRV	O
)	O
.	O

METHODS	O
:	O
Five	O
patients	O
with	O
typical	O
clinical	O
and	O
pathological	O
features	O
of	O
DMRV	O
were	O
studied	O
.	O

All	O
the	O
11	O
coding	O
exons	O
and	O
the	O
flanking	O
intron	O
sequences	O
of	O
GNE	O
gene	O
were	O
amplified	O
by	O
PCR	O
and	O
sequenced	O
.	O

Four	O
family	O
members	O
of	O
case	O
5	O
were	O
also	O
examined	O
for	O
GNE	O
gene	O
mutations	O
.	O

RESULTS	O
:	O
All	O
the	O
patients	O
were	O
identified	O
to	O
have	O
different	O
GNE	O
gene	O
mutations	O
:	O
Cases	O
1	O
-	O
4	O
had	O
complex	O
heterozygous	O
mutations	O
and	O
case	O
5	O
had	O
homozygous	O
mutation	O
.	O

Six	O
reported	O
mutations	O
had	O
been	O
identified	O
,	O
including	O
1	O
nonsense	O
mutation	O
(	O
p	O
.	O
R8X	O
)	O
and	O
5	O
missense	O
mutations	O
(	O
p	O
.	O
D176V	O
,	O
p	O
.	O
I298	O
T	O
,	O
p	O
.	O
A591	O
T	O
,	O
P.A631V	O
,	O
and	O
p	O
.	O
V696	O
M	O
)	O
.	O

A	O
novel	O
mutation	O
(	O
c.317T	O
>	O
C	O
,	O
p	O
.	O
I106	O
T	O
)	O
was	O
identified	O
in	O
case	O
2	O
.	O

CONCLUSION	O
:	O
This	O
is	O
the	O
first	O
report	O
of	O
p	B-Var
.	I-Var
R8X	I-Var
,	O
p	B-Var
.	I-Var
I298	I-Var
T	I-Var
,	O
p	B-Var
.	I-Var
A591	I-Var
T	I-Var
and	O
p	B-Var
.	I-Var
V696	I-Var
M	I-Var
mutations	O
in	O
GNE	B-Gene
gene	O
in	O
Chinese	O
population	O
,	O
and	O
a	O
novel	O
mutation	O
p	B-Var
.	I-Var
I106	I-Var
T	I-Var
was	O
identified	O
.	O

These	O
findings	O
further	O
expand	O
the	O
clinical	O
and	O
genetic	O
spectrum	O
of	B-Reg
DMRV	B-Disease
in	O
China	O
.	O

Congenital	O
variant	O
of	O
Rett	O
syndrome	O
due	O
to	O
an	O
intragenic	O
large	O
deletion	O
in	O
MECP2	O
.	O

Rett	B-Disease
syndrome	I-Disease
(	O
RTT	O
)	O
is	O
a	O
neurodevelopmental	O
disorder	O
that	O
is	O
one	O
of	O
the	O
most	O
common	O
causes	O
of	O
mental	O
retardation	O
in	O
females	O
.	O

RTT	O
diagnosis	O
is	O
based	O
on	O
distinct	O
clinical	O
criteria	O
.	O

We	O
describe	O
here	O
a	O
female	O
patient	O
with	O
severe	O
phenotype	O
of	O
congenital	O
variant	O
RTT	O
.	O

The	O
patient	O
originally	O
presented	O
with	O
severe	O
developmental	O
delay	O
prior	O
to	O
the	O
age	O
of	O
6	O
months	O
and	O
later	O
exhibited	O
characteristic	O
features	O
of	O
RTT	O
that	O
included	O
air	O
swallowing	O
,	O
bruxism	O
,	O
and	O
hand	O
stereotypies	O
.	O

Results	O
of	O
an	O
array	O
-	O
based	O
comparative	O
genomic	O
hybridization	O
analysis	O
indicated	O
there	O
was	O
a	O
very	O
small	O
microdeletion	O
in	O
Xq28	O
.	O

Multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
analysis	O
further	O
confirmed	O
there	O
were	O
heterozygous	O
deletions	O
of	O
intron	O
2	O
,	O
exon	O
3	O
,	O
intron	O
3	O
,	O
and	O
part	O
of	O
exon	O
4	O
in	O
MECP2	O
.	O

Findings	O
in	O
the	O
present	O
patient	O
confirm	O
the	O
view	O
that	O
large	O
MECP2	B-Gene
deletions	B-Var
are	O
an	O
important	O
cause	B-Reg
of	O
severe	O
congenital	O
variant	O
RTT	B-Disease
.	O

To	O
ensure	O
an	O
accurate	O
diagnosis	O
of	O
congenital	O
variant	O
RTT	O
,	O
a	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
analysis	O
of	O
MECP2	O
should	O
be	O
performed	O
in	O
patients	O
suspected	O
of	O
having	O
this	O
disorder	O
.	O

Gain	O
-	O
of	O
-	O
function	O
mutant	B-Var
p53	B-Gene
upregulates	B-PosReg
CXC	B-MPA
chemokines	I-MPA
and	O
enhances	B-PosReg
cell	B-CPA
migration	I-CPA
.	O

The	O
role	O
of	O
dominant	O
transforming	O
p53	O
in	O
carcinogenesis	O
is	O
poorly	O
understood	O
.	O

Our	O
previous	O
data	O
suggested	O
that	O
aberrant	B-Var
p53	B-Protein
proteins	I-Protein
can	O
enhance	B-PosReg
tumorigenesis	B-CPA
and	I-CPA
metastasis	I-CPA
.	O

Here	O
,	O
we	O
examined	O
potential	O
mechanisms	O
through	O
which	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
p53	O
proteins	O
can	O
induce	O
motility	O
.	O

Cells	O
expressing	O
GOF	O
p53	B-Var
-R175H	I-Var
,	O
-R273H	I-Var
and	I-Var
-D281	I-Var
G	I-Var
showed	O
enhanced	B-PosReg
migration	B-CPA
,	O
which	O
was	O
reversed	O
by	O
RNA	O
interference	O
(	O
RNAi	O
)	O
or	O
transactivation	O
-	O
deficient	O
mutants	O
.	O

In	O
cells	O
with	O
engineered	O
or	O
endogenous	O
p53	O
mutants	O
,	O
enhanced	O
migration	O
was	O
reduced	O
by	O
downregulation	O
of	O
nuclear	O
factor	O
-	O
kappaB2	O
,	O
a	O
GOF	O
p53	O
target	O
.	O

We	O
found	O
that	O
GOF	B-Var
p53	I-Var
proteins	O
upregulate	B-PosReg
CXC	B-MPA
-	I-MPA
chemokine	I-MPA
expression	I-MPA
,	O
the	O
inflammatory	O
mediators	O
that	O
contribute	O
to	O
multiple	O
aspects	O
of	O
tumorigenesis	O
.	O

Elevated	B-PosReg
expression	B-MPA
of	O
CXCL5	O
,	O
CXCL8	O
and	O
CXCL12	O
was	O
found	O
in	O
cells	O
expressing	O
oncogenic	B-Var
p53	I-Var
.	O

Transcription	B-MPA
was	O
elevated	B-PosReg
as	O
CXCL5	B-MPA
and	I-MPA
CXCL8	I-MPA
promoter	I-MPA
activity	I-MPA
was	O
higher	B-PosReg
in	O
cells	O
expressing	O
GOF	B-Var
p53	I-Var
,	O
whereas	O
wild	O
-	O
type	O
p53	O
repressed	O
promoter	O
activity	O
.	O

Chromatin	O
immunoprecipitation	O
assays	O
revealed	O
enhanced	O
presence	O
of	O
acetylated	O
histone	O
H3	O
on	O
the	O
CXCL5	O
promoter	O
in	O
H1299	O
/	O
R273H	O
cells	O
,	O
in	O
agreement	O
with	O
increased	O
transcriptional	O
activity	O
of	O
the	O
promoter	O
,	O
whereas	O
RNAi	O
-	O
mediated	O
repression	O
of	O
CXCL5	O
inhibited	O
cell	O
migration	O
.	O

Consistent	O
with	O
this	O
,	O
knockdown	O
of	O
the	O
endogenous	B-Var
mutant	I-Var
p53	B-Gene
in	O
lung	O
cancer	O
or	O
melanoma	O
cells	O
reduced	B-NegReg
CXCL5	B-MPA
expression	I-MPA
and	O
cell	B-CPA
migration	I-CPA
.	O

Furthermore	O
,	O
short	O
hairpin	O
RNA	O
knockdown	O
of	O
mutant	B-Var
p53	B-Gene
in	O
MDA	O
-	O
MB-231	O
cells	O
reduced	B-NegReg
expression	B-MPA
of	I-MPA
a	I-MPA
number	I-MPA
of	I-MPA
key	I-MPA
targets	I-MPA
,	O
including	O
several	O
chemokines	O
and	O
other	O
inflammatory	O
mediators	O
.	O

Finally	O
,	O
CXCL5	B-MPA
expression	I-MPA
was	O
also	O
elevated	B-PosReg
in	O
lung	B-Disease
tumor	I-Disease
samples	O
containing	O
GOF	B-Var
p53	I-Var
,	O
indicating	O
relevance	O
to	O
human	O
cancer	O
.	O

The	O
data	O
suggest	O
a	O
mechanistic	O
link	O
between	O
GOF	O
p53	O
proteins	O
and	O
chemokines	O
in	O
enhanced	O
cell	O
motility	O
.	O

A	O
new	O
frame	B-Var
-	I-Var
shifting	I-Var
mutation	O
of	O
UGT1A1	B-Gene
gene	O
causes	B-Reg
type	B-Disease
I	I-Disease
Crigler	I-Disease
-	I-Disease
Najjar	I-Disease
syndrome	I-Disease
.	O

We	O
present	O
a	O
case	O
of	O
severe	O
persisting	O
unconjugated	O
hyperbilirubinemia	O
in	O
a	O
Uigur	O
infant	O
boy	O
,	O
eventually	O
diagnosed	O
as	O
Crigler	O
-	O
Najjar	O
syndrome	O
type	O
I.	O
DNA	O
analysis	O
of	O
his	O
blood	O
of	O
the	O
UGT1A1	O
gene	O
sequence	O
demonstrated	O
that	O
he	O
was	O
homozygous	O
for	O
an	O
insertion	O
mutation	O
causing	O
a	O
change	O
of	O
the	O
coding	O
exons	O
with	O
a	O
frame	O
-	O
shift	O
,	O
resulting	O
in	O
the	O
substitution	O
of	O
27	O
abnormal	O
amino	O
acid	O
residues	O
in	O
his	O
hepatic	O
bilirubin	O
uridine	O
diphosphoglucuronyl	O
transferase	O
enzyme	O
.	O

Both	O
of	O
his	O
parents	O
were	O
heterozygous	O
for	O
the	O
same	O
mutation	O
.	O

A	O
novel	O
frame	O
-	O
shifting	O
mutation	O
of	O
the	O
UGT1A1	O
gene	O
was	O
found	O
,	O
confirming	O
the	O
diagnosis	O
of	O
Crigler	O
-	O
Najjar	O
syndrome	O
type	O
I	O
for	O
this	O
patient	O
.	O

X	O
inactivation	O
in	O
females	O
with	O
X	O
-	O
linked	O
Charcot	O
-	O
Marie	O
-	O
Tooth	O
disease	O
.	O

X	B-Disease
-	I-Disease
linked	I-Disease
Charcot	I-Disease
-	I-Disease
Marie	I-Disease
-	I-Disease
Tooth	I-Disease
disease	I-Disease
(	O
CMT1X	O
)	O
is	O
the	O
second	O
most	O
common	O
inherited	O
neuropathy	O
,	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
gap	O
junction	O
beta-1	O
(	B-Gene
GJB1	I-Gene
)	I-Gene
.	O

Males	O
have	O
a	O
uniformly	O
moderately	O
severe	O
phenotype	O
while	O
females	O
have	O
a	O
variable	O
phenotype	O
,	O
suggested	O
to	O
be	O
due	O
to	O
X	O
inactivation	O
.	O

We	O
aimed	O
to	O
assess	O
X	O
inactivation	O
pattern	O
in	O
females	O
with	O
CMT1X	O
and	O
correlate	O
this	O
with	O
phenotype	O
using	O
the	O
CMT	O
examination	O
score	O
to	O
determine	O
whether	O
the	O
X	O
inactivation	O
pattern	O
accounted	O
for	O
the	O
variable	O
phenotype	O
in	O
females	O
with	O
CMT1X.	O
We	O
determined	O
X	O
inactivation	O
pattern	O
in	O
67	O
females	O
with	O
CMT1X	O
and	O
24	O
controls	O
using	O
the	O
androgen	O
receptor	O
assay	O
.	O

We	O
were	O
able	O
to	O
determine	O
which	O
X	O
chromosome	O
carried	O
the	O
GJB1	O
mutation	O
in	O
30	O
females	O
.	O

There	O
was	O
no	O
difference	O
in	O
X	O
inactivation	O
pattern	O
between	O
patients	O
and	O
controls	O
.	O

In	O
addition	O
,	O
there	O
was	O
no	O
correlation	O
between	O
X	O
inactivation	O
pattern	O
in	O
blood	O
and	O
phenotype	O
.	O

A	O
possible	O
explanation	O
for	O
these	O
findings	O
is	O
that	O
the	O
X	O
inactivation	O
pattern	O
in	O
Schwann	O
cells	O
rather	O
than	O
in	O
blood	O
may	O
explain	O
the	O
variable	O
phenotype	O
in	O
females	O
with	O
CMT1X.	O
Autosomal	B-Disease
dominant	I-Disease
polycystic	I-Disease
kidney	I-Disease
disease	I-Disease
:	I-Disease
comprehensive	O
mutation	B-Var
analysis	O
of	O
PKD1	B-Gene
and	O
PKD2	B-Gene
in	B-Reg
700	O
unrelated	O
patients	O
.	O

Autosomal	B-Disease
dominant	I-Disease
polycystic	I-Disease
kidney	I-Disease
disease	I-Disease
(	O
ADPKD	O
)	O
,	O
the	O
most	O
common	O
inherited	O
kidney	O
disorder	O
,	O
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
PKD1	B-Gene
or	O
PKD2	B-Gene
.	O

The	O
molecular	O
diagnosis	O
of	O
ADPKD	O
is	O
complicated	O
by	O
extensive	O
allelic	O
heterogeneity	O
and	O
particularly	O
by	O
the	O
presence	O
of	O
six	O
highly	O
homologous	O
sequences	O
of	O
PKD1	O
exons	O
1	O
-	O
33	O
.	O

Here	O
,	O
we	O
screened	O
PKD1	O
and	O
PKD2	O
for	O
both	O
conventional	O
mutations	O
and	O
gross	O
genomic	O
rearrangements	O
in	O
up	O
to	O
700	O
unrelated	O
ADPKD	O
patients	O
--	O
the	O
largest	O
patient	O
cohort	O
to	O
date	O
--	O
by	O
means	O
of	O
direct	O
sequencing	O
,	O
followed	O
by	O
quantitative	O
fluorescent	O
multiplex	O
polymerase	O
chain	O
reaction	O
or	O
array	O
-	O
comparative	O
genomic	O
hybridization	O
.	O

This	O
resulted	O
in	O
the	O
identification	O
of	O
the	O
largest	O
number	O
of	O
new	O
pathogenic	O
mutations	O
(	O
n	O
=	O
351	O
)	O
in	O
a	O
single	O
publication	O
,	O
expanded	O
the	O
spectrum	O
of	O
known	O
ADPKD	O
pathogenic	O
mutations	O
by	O
41.8	O
%	O
for	O
PKD1	O
and	O
by	O
23.8	O
%	O
for	O
PKD2	O
,	O
and	O
provided	O
new	O
insights	O
into	O
several	O
issues	O
,	O
such	O
as	O
the	O
population	O
-	O
dependent	O
distribution	O
of	O
recurrent	O
mutations	O
compared	O
with	O
founder	O
mutations	O
and	O
the	O
relative	O
paucity	O
of	O
pathogenic	O
missense	O
mutations	O
in	O
the	O
PKD2	O
gene	O
.	O

Our	O
study	O
,	O
together	O
with	O
others	O
,	O
highlights	O
the	O
importance	O
of	O
developing	O
novel	O
approaches	O
for	O
both	O
mutation	O
detection	O
and	O
functional	O
validation	O
of	O
nondefinite	O
pathogenic	O
mutations	O
to	O
increase	O
the	O
diagnostic	O
value	O
of	O
molecular	O
testing	O
for	O
ADPKD	O
.	O

A	O
novel	O
classification	O
system	O
to	O
predict	O
the	O
pathogenic	O
effects	O
of	O
CHD7	B-Gene
missense	B-Var
variants	I-Var
in	B-Reg
CHARGE	B-Disease
syndrome	I-Disease
.	O

CHARGE	B-Disease
syndrome	I-Disease
is	O
characterized	O
by	O
the	O
variable	O
occurrence	O
of	O
multisensory	O
impairment	O
,	O
congenital	O
anomalies	O
,	O
and	O
developmental	O
delay	O
,	O
and	O
is	O
caused	B-Reg
by	I-Reg
heterozygous	B-Var
mutations	I-Var
in	O
the	O
CHD7	B-Gene
gene	O
.	O

Correct	O
interpretation	O
of	O
CHD7	O
variants	O
is	O
essential	O
for	O
genetic	O
counseling	O
.	O

This	O
is	O
particularly	O
difficult	O
for	O
missense	O
variants	O
because	O
most	O
variants	O
in	O
the	O
CHD7	O
gene	O
are	O
private	O
and	O
a	O
functional	O
assay	O
is	O
not	O
yet	O
available	O
.	O

We	O
have	O
therefore	O
developed	O
a	O
novel	O
classification	O
system	O
to	O
predict	O
the	O
pathogenic	O
effects	O
of	O
CHD7	O
missense	O
variants	O
that	O
can	O
be	O
used	O
in	O
a	O
diagnostic	O
setting	O
.	O

Our	O
classification	O
system	O
combines	O
the	O
results	O
from	O
two	O
computational	O
algorithms	O
(	O
PolyPhen-2	O
and	O
Align	O
-	O
GVGD	O
)	O
and	O
the	O
prediction	O
of	O
a	O
newly	O
developed	O
structural	O
model	O
of	O
the	O
chromo-	O
and	O
helicase	O
domains	O
of	O
CHD7	O
with	O
segregation	O
and	O
phenotypic	O
data	O
.	O

The	O
combination	O
of	O
different	O
variables	O
will	O
lead	O
to	O
a	O
more	O
confident	O
prediction	O
of	O
pathogenicity	O
than	O
was	O
previously	O
possible	O
.	O

We	O
have	O
used	O
our	O
system	O
to	O
classify	O
145	O
CHD7	O
missense	O
variants	O
.	O

Our	O
data	O
show	O
that	O
pathogenic	O
missense	O
mutations	O
are	O
mainly	O
present	O
in	O
the	O
middle	O
of	O
the	O
CHD7	O
gene	O
,	O
whereas	O
benign	O
variants	O
are	O
mainly	O
clustered	O
in	O
the	O
5	O
'	O
and	O
3	O
'	O
regions	O
.	O

Finally	O
,	O
we	O
show	O
that	O
CHD7	O
missense	O
mutations	O
are	O
,	O
in	O
general	O
,	O
associated	O
with	O
a	O
milder	O
phenotype	O
than	O
truncating	O
mutations	O
.	O

Novel	O
mutation	O
in	O
SLC9A6	O
gene	O
in	O
a	O
patient	O
with	O
Christianson	O
syndrome	O
and	O
retinitis	O
pigmentosum	O
.	O

Mutations	B-Var
in	O
the	O
SLC9A6	B-Gene
gene	O
cause	B-Reg
Christianson	B-Disease
syndrome	I-Disease
in	O
boys	O
.	O

This	O
X	O
-	O
linked	O
syndrome	O
is	O
characterized	O
by	O
profound	O
mental	O
retardation	O
with	O
autistic	O
behavior	O
,	O
microcephaly	O
,	O
epilepsy	O
,	O
ophthalmoplegia	O
,	O
and	O
ataxia	O
.	O

Progressive	O
cerebellar	O
atrophy	O
with	O
motor	O
regression	O
is	O
a	O
remarkable	O
feature	O
in	O
some	O
patients	O
.	O

We	O
report	O
on	O
a	O
22year	O
-	O
old	O
male	O
patient	O
with	O
Christianson	O
syndrome	O
carrying	O
the	O
novel	O
p	O
.	O
Gln306X	O
mutation	O
.	O

The	O
infantile	O
phenotype	O
suggested	O
pervasive	O
developmental	O
disorder	O
,	O
then	O
profound	O
mental	O
retardation	O
ensued	O
.	O

In	O
later	O
childhood	O
,	O
progressive	O
cerebellar	O
atrophy	O
was	O
diagnosed	O
on	O
serial	O
brain	O
MRIs	O
and	O
motor	O
regression	O
occurred	O
.	O

Furthermore	O
,	O
ophthalmological	O
evaluations	O
showed	O
a	O
retinitis	O
pigmentosum	O
previously	O
unreported	O
in	O
this	O
condition	O
.	O

We	O
conclude	O
that	O
the	O
natural	O
history	O
of	O
the	O
disease	O
in	O
this	O
patient	O
tends	O
to	O
confirm	O
the	O
degenerative	O
nature	O
of	O
Christianson	O
syndrome	O
,	O
and	O
that	O
retinal	O
degeneration	O
may	O
be	O
part	O
of	O
the	O
condition	O
.	O

Before	O
the	O
onset	O
of	O
degeneration	O
,	O
the	O
syndromic	O
association	O
of	O
severe	O
mental	O
retardation	O
,	O
autistic	O
behavior	O
,	O
external	O
ophthalmoplegia	O
,	O
and	O
facial	O
dysmorphism	O
in	O
male	O
patients	O
is	O
a	O
clue	O
to	O
the	O
diagnosis	O
.	O

Mutation	B-Var
analysis	O
in	O
two	O
Chinese	O
families	O
with	B-Reg
multiple	B-Disease
endocrine	I-Disease
neoplasia	I-Disease
type	I-Disease
1	I-Disease
.	O

OBJECTIVE	O
:	O
This	O
study	O
aimed	O
at	O
identifing	O
mutations	O
in	O
two	O
Chinese	O
genealogies	O
with	O
MEN1	B-Gene
.	O

SUBJECTS	O
AND	O
METHODS	O
:	O
Three	O
members	O
of	O
two	O
Chinese	O
families	O
with	O
MEN1	O
were	O
enrolled	O
in	O
this	O
study	O
,	O
and	O
all	O
of	O
the	O
coding	O
regions	O
and	O
adjacent	O
sequences	O
of	O
the	O
MEN1	O
gene	O
were	O
amplified	O
and	O
sequenced	O
.	O

RESULTS	O
:	O
A	O
recurrent	O
mutation	O
of	O
heterozygous	O
change	O
T	O
>	O
A	O
at	O
IVS	O
4	O
+	O
1	O
was	O
found	O
in	O
family	O
I	O
,	O
and	O
a	O
novel	O
insGAGGTGG	O
mutation	O
(	O
c.703	O
-	O
709dup7bp	O
)	O
resulted	O
in	O
a	O
frameshift	O
(	O
p	O
.	O
A237Gfsx13	O
)	O
in	O
family	O
II	O
.	O

CONCLUSION	O
:	O
We	O
are	O
able	O
to	O
add	O
a	O
new	O
mutation	O
of	O
MEN1	O
gene	O
in	O
Chinese	O
patients	O
with	O
MEN1	O
that	O
will	O
be	O
useful	O
for	O
the	O
diagnosis	O
and	O
treatment	O
of	O
the	O
disease	O
.	O

Two	O
novel	O
mutations	O
in	O
the	O
lactase	O
gene	O
in	O
a	O
Japanese	O
infant	O
with	O
congenital	O
lactase	O
deficiency	O
.	O

Intestinal	O
lactase	O
is	O
required	O
for	O
the	O
hydrolysis	O
of	O
lactose	O
that	O
is	O
the	O
most	O
essential	O
carbohydrate	O
in	O
milk	O
and	O
the	O
primary	O
diet	O
source	O
of	O
newborn	O
.	O

Congenital	B-Disease
lactase	I-Disease
deficiency	I-Disease
[	O
CLD	O
(	O
MIM	O
223000	O
)	O
]	O
is	O
a	O
severe	O
gastrointestinal	O
disorder	O
and	O
is	O
characterized	O
by	O
watery	O
diarrhea	O
due	O
to	O
an	O
extremely	O
low	O
or	O
the	O
lack	O
of	O
lactase	O
activity	O
in	O
the	O
intestinal	O
wall	O
from	O
birth	O
.	O

CLD	O
is	O
a	O
rare	O
disease	O
and	O
occurs	O
more	O
frequently	O
in	O
Finland	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
mutations	B-Var
in	O
the	O
coding	O
region	O
of	O
the	O
lactase	O
(	B-Gene
LCT	I-Gene
)	I-Gene
gene	O
underlie	B-Reg
CLD	B-Disease
in	O
patients	O
from	O
Finland	O
and	O
other	O
European	O
countries	O
.	O

Here	O
,	O
we	O
report	O
two	O
novel	O
mutations	O
in	O
the	O
LCT	O
gene	O
in	O
a	O
Japanese	O
female	O
infant	O
with	O
clinical	O
features	O
consistent	O
with	O
those	O
of	O
CLD	O
.	O

She	O
suffered	O
from	O
severe	O
watery	O
diarrhea	O
from	O
the	O
age	O
of	O
2	O
days	O
on	O
breast	O
milk	O
/	O
lactose	O
containing	O
cow	O
's	O
milk	O
formula	O
.	O

With	O
the	O
lactose	O
-	O
free	O
hydrolyzed	O
cow	O
's	O
milk	O
formula	O
,	O
diarrhea	O
was	O
stopped	O
,	O
and	O
she	O
has	O
now	O
developed	O
well	O
on	O
a	O
lactose	O
-	O
free	O
diet	O
.	O

She	O
shows	O
a	O
lactose	O
-	O
intolerance	O
pattern	O
on	O
the	O
lactose	O
challenge	O
test	O
.	O

Sequence	O
analysis	O
revealed	O
the	O
two	O
mutations	O
in	O
her	O
LCT	B-Gene
gene	O
:	O
c.4419C	B-Var
>	I-Var
G	I-Var
(	O
p	O
.	O
Y1473X	O
)	O
in	O
exon	O
10	O
transmitted	O
from	O
her	O
mother	O
and	O
c.5387delA	B-Var
(	O
p	O
.	O
D1796fs	O
)	O
in	O
exon	O
16	O
transmitted	O
from	O
her	O
father	O
.	O

Both	O
mutations	O
cause	B-Reg
premature	B-MPA
truncation	I-MPA
of	O
lactase	B-Protein
polypeptide	I-Protein
and	O
are	O
supposed	O
to	O
be	B-Reg
responsible	I-Reg
for	I-Reg
CLD	B-Disease
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
on	O
mutations	O
in	O
the	O
LCT	O
gene	O
in	O
Japan	O
.	O

We	O
suggest	O
that	O
an	O
increased	O
awareness	O
is	O
required	O
regarding	O
CLD	O
.	O

Analysis	O
of	O
gene	O
mutations	O
in	O
Chinese	O
patients	O
with	O
maple	O
syrup	O
urine	O
disease	O
.	O

OBJECTIVE	O
:	O
Maple	B-Disease
syrup	I-Disease
urine	I-Disease
disease	I-Disease
(	O
MSUD	O
)	O
is	O
predominantly	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
BCKDHA	B-Gene
,	O
BCKDHB	B-Gene
and	O
DBT	B-Gene
genes	O
,	O
which	O
encode	O
for	O
the	O
E1α	O
,	O
E1β	O
and	O
E2	O
subunits	O
of	O
the	O
branched	O
-	O
chain	O
α	O
-	O
keto	O
acid	O
dehydrogenase	O
complex	O
,	O
respectively	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
screen	O
DNA	O
samples	O
from	O
16	O
Chinese	O
MSUD	O
patients	O
and	O
assess	O
a	O
potential	O
correlation	O
between	O
genotype	O
and	O
phenotype	O
.	O

METHODS	O
:	O
BCKDHA	O
,	O
BCKDHB	O
and	O
DBT	O
genes	O
were	O
analyzed	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
direct	O
sequencing	O
.	O

Segments	O
bearing	O
novel	O
mutations	O
were	O
identified	O
by	O
PCR	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
PCR	O
-	O
RFLP	O
)	O
analysis	O
.	O

RESULTS	O
:	O
Within	O
the	O
variant	O
alleles	O
,	O
28	O
mutations	O
(	O
28/32	O
,	O
87.5	O
%	O
)	O
,	O
were	O
detected	O
in	O
15	O
patients	O
,	O
while	O
one	O
patient	O
displayed	O
no	O
mutations	O
.	O

Mutations	O
were	O
comprised	O
of	O
20	O
different	O
:	O
6	O
BCKDHA	O
gene	O
mutations	O
in	O
4	O
cases	O
,	O
10	O
BCKDHB	O
gene	O
mutations	O
in	O
8	O
cases	O
and	O
4	O
DBT	O
gene	O
mutations	O
in	O
3	O
cases	O
.	O

From	O
these	O
,	O
14	O
were	O
novel	O
,	O
which	O
included	O
3	O
mutations	O
in	O
the	O
BCKDHA	O
gene	O
,	O
7	O
in	O
the	O
BCKDHB	O
gene	O
and	O
4	O
in	O
the	O
DBT	O
gene	O
.	O

Only	O
two	O
patients	O
with	O
mutations	O
in	O
the	O
BCKDHB	O
and	O
DBT	O
genes	O
were	O
thiamine	O
-	O
responsive	O
and	O
presented	O
a	O
better	O
clinical	O
outcome	O
.	O

CONCLUSION	O
:	O
We	O
identified	O
20	O
different	O
mutations	O
within	O
the	O
BCKDHA	O
,	O
BCKDHB	O
and	O
DBT	O
genes	O
among	O
16	O
Chinese	O
MSUD	O
patients	O
,	O
including	O
14	O
novel	O
mutations	O
.	O

The	O
majority	O
were	O
non	O
-	O
responsive	O
to	O
thiamine	O
,	O
associating	O
with	O
a	O
worse	O
clinical	O
outcome	O
.	O

Our	O
data	O
provide	O
the	O
basis	O
for	O
further	O
genotype	O
-	O
phenotype	O
correlation	O
studies	O
in	O
these	O
patients	O
,	O
which	O
will	O
be	O
beneficial	O
for	O
early	O
diagnosis	O
and	O
in	O
directing	O
the	O
approach	O
to	O
clinical	O
intervention	O
.	O

Cell	O
models	O
for	O
McArdle	O
disease	O
and	O
aminoglycoside	O
-	O
induced	O
read	O
-	O
through	O
of	O
a	O
premature	O
termination	O
codon	O
.	O

McArdle	B-Disease
disease	I-Disease
results	B-Reg
from	I-Reg
mutations	O
in	O
the	O
gene	O
encoding	O
muscle	O
glycogen	O
phosphorylase	O
(	B-Gene
PYGM	I-Gene
)	I-Gene
protein	O
and	O
the	O
two	O
most	O
common	O
mutations	O
are	O
a	O
premature	O
termination	O
codon	O
(	B-Var
R50X	I-Var
)	I-Var
and	O
a	O
missense	O
mutation	O
(	B-Var
G205S	I-Var
)	I-Var
.	O

Myoblasts	O
from	O
patients	O
can	O
not	O
be	O
used	O
to	O
create	O
a	O
cell	O
model	O
of	O
McArdle	O
disease	O
because	O
even	O
normal	O
myoblasts	O
produce	O
little	O
or	O
no	O
PYGM	O
protein	O
in	O
cell	O
culture	O
.	O

We	O
therefore	O
created	O
cell	O
models	O
by	O
expressing	O
wild	O
-	O
type	O
or	O
mutant	O
(	O
R50X	O
or	O
G205S	O
)	O
PYGM	O
from	O
cDNA	O
integrated	O
into	O
the	O
genome	O
of	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O

These	O
cell	O
lines	O
enable	O
the	O
study	O
of	O
McArdle	O
mutations	O
in	O
the	O
absence	O
of	O
nonsense	O
-	O
mediated	O
decay	O
of	O
mRNA	O
transcripts	O
.	O

Although	O
all	O
cell	O
lines	O
produced	O
stable	O
mRNA	O
,	O
only	O
wild	O
-	O
type	O
produced	O
detectable	O
PYGM	O
protein	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
G205S	B-Var
mutation	O
affects	O
PYGM	B-Gene
by	O
causing	B-Reg
misfolding	B-MPA
and	O
accelerated	B-Reg
protein	B-Protein
turnover	B-MPA
.	O

Using	O
the	O
N	O
-	O
terminal	O
region	O
of	O
PYGM	O
containing	O
the	O
R50X	O
mutation	O
fused	O
to	O
green	O
fluorescent	O
protein	O
,	O
we	O
were	O
able	O
to	O
demonstrate	O
both	O
small	O
amounts	O
of	O
truncated	O
protein	O
production	O
and	O
read	O
-	O
through	O
of	O
the	O
R50X	O
premature	O
termination	O
codon	O
induced	O
by	O
the	O
aminoglycoside	O
,	O
G418	O
.	O

Origins	O
of	O
albino	O
and	O
hooded	O
rats	O
:	O
implications	O
from	O
molecular	O
genetic	O
analysis	O
across	O
modern	O
laboratory	O
rat	O
strains	O
.	O

Albino	O
and	O
hooded	O
(	O
or	O
piebald	O
)	O
rats	O
are	O
one	O
of	O
the	O
most	O
frequently	O
used	O
laboratory	O
animals	O
for	O
the	O
past	O
150	O
years	O
.	O

Despite	O
this	O
fact	O
,	O
the	O
origin	O
of	O
the	O
albino	O
mutation	O
as	O
well	O
as	O
the	O
genetic	O
basis	O
of	O
the	O
hooded	O
phenotype	O
remained	O
unclear	O
.	O

Recently	O
,	O
the	O
albino	B-CPA
mutation	O
has	O
been	O
identified	O
as	B-Reg
the	O
Arg299His	B-Var
missense	I-Var
mutation	I-Var
in	O
the	O
Tyrosinase	B-Gene
gene	I-Gene
and	O
the	O
hooded	O
(	O
H	O
)	O
locus	O
has	O
been	O
mapped	O
to	O
the	O
∼460-kb	O
region	O
in	O
which	O
only	O
the	O
Kit	O
gene	O
exists	O
.	O

Here	O
,	O
we	O
surveyed	O
172	O
laboratory	O
rat	O
strains	O
for	O
the	O
albino	O
mutation	O
and	O
the	O
hooded	O
(	O
h	O
)	O
mutation	O
that	O
we	O
identified	O
by	O
positional	O
cloning	O
approach	O
to	O
investigate	O
possible	O
genetic	O
roots	O
and	O
relationships	O
of	O
albino	O
and	O
hooded	O
rats	O
.	O

All	O
of	O
117	O
existing	O
laboratory	O
albino	O
rats	O
shared	O
the	O
same	O
albino	O
missense	O
mutation	O
,	O
indicating	O
they	O
had	O
only	O
one	O
single	O
ancestor	O
.	O

Genetic	O
fine	O
mapping	O
followed	O
by	O
de	O
novo	O
sequencing	O
of	O
BAC	O
inserts	O
covering	O
the	O
H	O
locus	O
revealed	O
that	O
an	O
endogenous	O
retrovirus	O
(	O
ERV	O
)	O
element	O
was	O
inserted	O
into	O
the	O
first	O
intron	O
of	O
the	O
Kit	O
gene	O
where	O
the	O
hooded	O
allele	O
maps	O
.	O

A	O
solitary	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
was	O
found	O
at	O
the	O
same	O
position	O
to	O
the	O
ERV	O
insertion	O
in	O
another	O
allele	O
of	O
the	O
H	O
locus	O
,	O
which	O
causes	O
the	O
so	O
called	O
Irish	O
(	O
h(i	O
)	O
)	O
phenotype	O
.	O

The	O
ERV	O
and	O
the	O
solitary	O
LTR	O
insertions	O
were	O
completely	O
associated	O
with	O
the	O
hooded	O
and	O
Irish	O
coat	O
patterns	O
,	O
respectively	O
,	O
across	O
all	O
colored	O
rat	O
strains	O
examined	O
.	O

Interestingly	O
,	O
all	O
117	O
albino	O
rat	O
strains	O
shared	O
the	O
ERV	O
insertion	O
without	O
any	O
exception	O
,	O
which	O
strongly	O
suggests	O
that	O
the	O
albino	O
mutation	O
had	O
originally	O
occurred	O
in	O
hooded	O
rats	O
.	O

Allele	O
specific	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
activity	B-MPA
of	O
p53	B-Gene
mutants	B-Var
in	O
lung	B-Disease
cancer	I-Disease
cells	O
.	O

p53	B-Gene
mutations	B-Var
are	O
mostly	O
single	O
amino	O
acid	O
changes	O
resulting	B-Reg
in	I-Reg
expression	B-MPA
of	O
a	O
stable	O
mutant	O
protein	O
with	O
"	B-PosReg
gain	I-PosReg
of	I-PosReg
function	I-PosReg
"	I-PosReg
(	O
GOF	O
)	O
activity	B-MPA
having	O
a	O
dominant	O
oncogenic	O
role	O
rather	O
than	O
simple	O
loss	O
of	O
function	O
of	O
wild	O
-	O
type	O
p53	O
.	O

Knock	O
-	O
down	O
of	O
mutant	O
p53	O
in	O
human	O
lung	O
cancer	O
cell	O
lines	O
with	O
different	O
endogenous	O
p53	B-Gene
mutants	B-Var
results	O
in	O
loss	B-NegReg
of	O
GOF	O
activity	B-MPA
as	O
shown	O
by	O
lowering	B-NegReg
of	O
cell	B-CPA
growth	I-CPA
rate	I-CPA
.	O

Two	O
lung	O
cancer	O
cell	O
lines	O
,	O
ABC1	O
and	O
H1437	O
,	O
carrying	O
endogenous	O
mutants	B-Var
p53-P278S	I-Var
and	I-Var
-R267P	I-Var
,	O
show	O
reduction	B-NegReg
in	O
growth	B-MPA
rate	I-MPA
on	O
knock	O
-	O
down	O
on	O
p53	O
levels	O
.	O

However	O
,	O
whereas	O
reduction	B-NegReg
of	O
the	O
p53	B-Var
level	O
induces	O
loss	B-NegReg
of	O
tumorigenicity	B-MPA
in	O
nude	O
mice	O
for	O
ABC1	O
cells	O
,	O
it	O
escalates	B-PosReg
tumorigenicity	B-MPA
for	O
H1437	O
cells	O
.	O

We	O
have	O
tested	O
their	O
transactivation	O
potential	O
on	O
p53	O
target	O
gene	O
promoters	O
by	O
performing	O
transient	O
transcriptional	O
assays	O
in	O
the	O
p53-null	O
H1299	O
lung	O
cancer	O
cell	O
line	O
.	O

Interestingly	O
,	O
while	O
the	O
mutant	O
p53	O
target	O
promoter	O
Axl	O
was	O
activated	O
by	O
both	O
the	O
mutants	O
,	O
the	O
p21	O
promoter	O
was	O
activated	O
by	O
p53-R267P	O
and	O
wild	O
-	O
type	O
p53	O
but	O
not	O
by	O
p53-P278S	O
;	O
showing	O
a	O
clear	O
difference	O
in	O
transcriptional	O
activity	O
between	O
the	O
two	O
mutants	O
.	O

Our	O
results	O
demonstrate	O
allele	O
specificity	O
between	O
GOF	O
p53	O
mutants	O
and	O
attempt	O
to	O
show	O
that	O
the	O
specificity	O
is	O
dependent	O
on	O
the	O
transactivation	O
property	O
of	O
GOF	O
p53	O
;	O
it	O
also	O
suggests	O
importance	O
of	O
p21	O
activation	O
in	O
tumor	O
suppression	O
by	O
p53	O
.	O

Identification	O
of	O
a	O
novel	O
arylsulfatase	B-Gene
B	I-Gene
gene	I-Gene
mutation	B-Var
in	B-Reg
three	O
unrelated	O
Iranian	O
mucopolysaccharidosis	B-Disease
type	I-Disease
-	I-Disease
VI	I-Disease
patients	O
with	O
different	O
phenotype	O
severity	O
.	O

BACKGROUND	O
:	O
Mucopolysaccharidosis	B-Disease
type	I-Disease
-	I-Disease
VI	I-Disease
(	O
MPS	O
-	O
VI	O
)	O
,	O
which	O
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
,	O
results	B-Reg
from	I-Reg
the	O
deficiency	B-NegReg
of	O
N	B-Enzyme
-	I-Enzyme
acetylgalactosamine	I-Enzyme
4-sulfatase	I-Enzyme
(	O
arylsulfatase	O
B	O
)	O
activity	B-MPA
and	O
the	O
lysosomal	B-MPA
accumulation	B-PosReg
of	O
dermatan	O
sulfate	O
.	O

In	O
this	O
study	O
,	O
ARSB	O
mutation	O
analysis	O
was	O
performed	O
on	O
three	O
unrelated	O
patients	O
who	O
were	O
originally	O
from	O
the	O
West	O
Azerbaijan	O
province	O
of	O
Iran	O
.	O

METHODS	O
:	O
After	O
PCR	O
and	O
direct	O
DNA	O
sequencing	O
,	O
DNA	O
extraction	O
was	O
performed	O
.	O

RESULTS	O
:	O
Sequencing	O
analysis	O
revealed	O
a	O
novel	O
homozygous	O
missense	O
mutation	O
in	O
the	O
ARSB	O
gene	O
at	O
c.1457A	O
<	O
G	O
[	O
p.	O
D486V	O
]	O
in	O
three	O
unrelated	O
Iranian	O
MPS	O
-	O
VI	O
patients	O
with	O
different	O
phenotype	O
severity	O
.	O

CONCLUSION	O
:	O
The	O
mutation	O
type	O
in	O
three	O
patients	O
was	O
the	O
same	O
;	O
probably	O
,	O
because	O
of	O
a	O
foundation	O
effect	O
on	O
their	O
population	O
.	O

C.428_451	O
dup(24bp	O
)	O
mutation	O
of	O
the	O
ARX	O
gene	O
detected	O
in	O
a	O
Turkish	O
family	O
.	O

ARX	B-Gene
mutations	B-Var
give	B-Reg
rise	I-Reg
to	I-Reg
both	O
syndromic	O
and	O
nonsyndromic	O
forms	O
of	O
mental	B-Disease
retardation	I-Disease
(	O
MR	O
)	O
.	O

We	O
investigated	O
the	O
most	O
common	O
ARX	O
mutations	O
,	O
c.428_451	O
dup(24bp	O
)	O
and	O
c.333ins	O
(	O
GCG)7	O
in	O
a	O
series	O
of	O
370	O
mentally	O
retarded	O
FMR1	O
(	O
CGG)n	O
expansion	O
mutation	O
negative	O
Turkish	O
patients	O
using	O
PCR	O
amplification	O
and	O
high	O
resolution	O
MetaPhor	O
agarose	O
gel	O
electrophoresis	O
.	O

Sequence	O
analysis	O
was	O
also	O
performed	O
for	O
confirmation	O
and	O
discrimination	O
of	O
the	O
mutations	O
.	O

One	O
patient	O
representing	O
non	O
-	O
syndromic	O
X	O
-	O
linked	O
MR	B-Disease
showed	B-Reg
an	O
abnormal	O
band	O
pattern	O
on	O
agarose	O
gel	O
and	O
sequence	O
analysis	O
of	O
exon	O
2	O
of	O
the	O
ARX	B-Gene
gene	O
revealed	O
that	O
the	O
patient	O
had	O
the	O
c.428_451	B-Var
dup(24bp	I-Var
)	I-Var
mutation	O
.	O

When	O
we	O
screened	O
the	O
family	O
members	O
,	O
we	O
found	O
that	O
his	O
sister	O
and	O
mother	O
were	O
also	O
carrier	O
for	O
the	O
same	O
mutation	O
.	O

The	O
proband	O
showed	O
mild	O
MR	O
and	O
subtle	O
clinical	O
findings	O
like	O
dysarthria	O
and	O
lack	O
of	O
fine	O
motor	O
functions	O
.	O

In	O
conclusion	O
,	O
the	O
patients	O
with	O
weak	O
fine	O
motor	O
skills	O
and	O
positive	O
family	O
history	O
for	O
X	O
-	O
linked	O
MR	O
should	O
be	O
screened	O
for	O
the	O
most	O
common	O
ARX	O
gene	O
mutations	O
.	O

Analysis	O
of	O
a	O
Chinese	O
pedigree	O
with	O
Zellweger	B-Disease
syndrome	I-Disease
reveals	B-Reg
a	O
novel	O
PEX1	B-Gene
mutation	B-Var
by	O
next	O
-	O
generation	O
sequencing	O
.	O

BACKGROUND	O
:	O
Autosomal	O
recessive	O
Zellweger	B-Disease
spectrum	I-Disease
disorder	I-Disease
(	O
ZSD	O
)	O
,	O
the	O
main	O
subgroup	O
of	O
the	O
peroxisome	O
biogenesis	O
disorders	O
(	O
PBDs	O
)	O
,	O
can	O
be	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
any	O
of	O
the	O
13	O
PEX	B-Gene
genes	O
.	O

Zellweger	O
syndrome	O
(	O
ZS	O
)	O
is	O
the	O
most	O
common	O
and	O
severe	O
phenotype	O
in	O
the	O
heterogeneous	O
ZSD	O
.	O

For	O
the	O
large	O
number	O
genes	O
involved	O
,	O
it	O
is	O
difficult	O
to	O
make	O
a	O
precise	O
genetic	O
diagnosis	O
by	O
traditional	O
methods	O
at	O
a	O
time	O
.	O

A	O
combination	O
of	O
enrichment	O
of	O
targeted	O
genes	O
and	O
next	O
-	O
generation	O
sequencing	O
(	O
NGS	O
)	O
would	O
result	O
in	O
both	O
high	O
efficiency	O
and	O
low	O
cost	O
for	O
targeted	O
sequencing	O
of	O
genes	O
of	O
interest	O
.	O

METHODS	O
:	O
To	O
identify	O
potential	O
mutations	O
in	O
a	O
Chinese	O
family	O
associated	O
with	O
Zellweger	O
syndrome	O
,	O
1930	O
kb	O
of	O
all	O
the	O
targeted	O
region	O
of	O
PEX	O
genes	O
were	O
captured	O
and	O
sequenced	O
using	O
NGS	O
.	O

We	O
also	O
performed	O
Sanger	O
sequencing	O
to	O
validate	O
the	O
NGS	O
results	O
.	O

RESULTS	O
:	O
Here	O
,	O
we	O
reported	O
a	O
Chinese	O
patient	O
diagnosed	O
as	O
a	O
severe	O
classic	O
type	O
of	O
PBD	O
based	O
on	O
a	O
clinical	O
investigation	O
.	O

We	O
then	O
performed	O
microarray	O
-	O
based	O
NGS	O
to	O
detect	O
the	O
variants	O
in	O
PEX	O
genes	O
of	O
the	O
whole	O
family	O
.	O

One	O
reported	O
heterozygosis	O
mutation	O
(	O
c.782_783delAA	O
)	O
was	O
identified	O
in	O
the	O
patient	O
's	O
father	O
and	O
one	O
novel	O
heterozygosis	O
missense	O
mutation	O
(	O
c.475G	O
>	O
C	O
)	O
was	O
found	O
in	O
the	O
patient	O
's	O
mother	O
,	O
the	O
patient	O
inherited	O
both	O
mutations	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
proved	O
that	O
the	O
application	O
of	O
target	O
sequence	O
capture	O
using	O
chip	O
and	O
high	O
-	O
throughput	O
NGS	O
is	O
a	O
valuable	O
tool	O
for	O
the	O
molecular	O
diagnosis	O
of	O
peroxisome	O
biogenesis	O
disorders	O
.	O

The	O
accuracy	O
,	O
high	O
-	O
throughput	O
and	O
speed	O
of	O
the	O
method	O
make	O
it	O
suitable	O
for	O
clinical	O
application	O
.	O

Gain	O
-	O
of	O
-	O
Function	O
Activity	O
of	O
Mutant	O
p53	O
in	O
Lung	O
Cancer	O
through	O
Up	O
-	O
Regulation	O
of	O
Receptor	O
Protein	O
Tyrosine	O
Kinase	O
Axl	O
.	O

p53	O
mutations	O
are	O
present	O
in	O
up	O
to	O
70	O
%	O
of	O
lung	O
cancer	O
.	O

Cancer	O
cells	O
with	O
p53	B-Gene
mutations	B-Var
,	O
in	O
general	O
,	O
grow	B-CPA
more	O
aggressively	B-PosReg
than	O
those	O
with	O
wild	O
-	O
type	O
p53	O
or	O
no	O
p53	O
.	O

Expression	O
of	O
tumor	O
-	O
derived	O
mutant	B-Var
p53	B-Gene
in	O
cells	O
leads	O
to	O
up	B-PosReg
-	I-PosReg
regulated	I-PosReg
expression	B-MPA
of	I-MPA
genes	I-MPA
that	O
may	O
affect	B-Reg
cell	B-CPA
growth	I-CPA
and	O
oncogenesis	B-CPA
.	O

In	O
our	O
study	O
of	O
this	O
aggressive	O
phenotype	O
,	O
we	O
have	O
investigated	O
the	O
receptor	O
protein	O
tyrosine	B-Enzyme
kinase	I-Enzyme
Axl	I-Enzyme
,	O
which	O
is	O
up	B-PosReg
-	I-PosReg
regulated	I-PosReg
by	O
p53	B-Gene
mutants	B-Var
at	O
both	O
RNA	O
and	O
protein	O
levels	O
in	O
H1299	O
lung	O
cancer	O
cells	O
expressing	O
mutants	O
p53-R175H	O
,	O
-R273H	O
,	O
and	O
-D281G.	O
Knockdown	O
of	O
endogenous	O
mutant	O
p53	O
levels	O
in	O
human	O
lung	O
cancer	O
cells	O
H1048	O
(	O
p53-R273C	O
)	O
and	O
H1437	O
(	O
p53-R267P	O
)	O
led	O
to	O
a	O
reduction	O
in	O
the	O
level	O
of	O
Axl	O
as	O
well	O
.	O

This	O
effect	O
on	O
Axl	O
expression	O
is	O
refractory	O
to	O
the	O
mutations	O
at	O
positions	O
22	O
and	O
23	O
of	O
p53	O
,	O
suggesting	O
that	O
p53	O
's	O
transactivation	O
domain	O
may	O
not	O
play	O
a	O
critical	O
role	O
in	O
the	O
up	O
-	O
regulation	O
of	O
Axl	O
gene	O
expression	O
.	O

Chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assays	O
carried	O
out	O
with	O
acetylated	O
histone	O
antibodies	O
demonstrated	O
induced	O
histone	B-Reg
acetylation	B-MPA
on	I-MPA
the	I-MPA
Axl	I-MPA
promoter	I-MPA
region	I-MPA
by	O
mutant	B-Var
p53	B-Gene
.	O

Direct	O
mutant	O
p53	O
nucleation	O
on	O
the	O
Axl	O
promoter	O
was	O
demonstrated	O
by	O
ChIP	O
assays	O
using	O
antibodies	O
against	O
p53	O
.	O

The	O
Axl	O
promoter	O
has	O
a	O
p53	O
/	O
p63	O
binding	O
site	O
,	O
which	O
however	O
is	O
not	O
required	O
for	O
mutant	O
p53-mediated	O
transactivation	O
.	O

Knockdown	O
of	O
Axl	O
by	O
Axl	O
-	O
specific	O
RNAi	O
caused	O
a	O
reduction	O
of	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
activities	O
,	O
reducing	O
the	O
cell	O
growth	O
rate	O
and	O
motility	O
rate	O
in	O
lung	O
cancer	O
cells	O
expressing	O
mutant	O
p53	O
.	O

This	O
indicates	O
that	O
for	O
lung	O
cancer	O
cell	O
lines	O
with	O
mutant	B-Var
p53	B-Gene
,	O
GOF	O
activities	B-MPA
are	O
mediated	B-Reg
in	O
part	O
through	O
Axl	B-Protein
.	O

Aspartylglucosaminuria	B-Disease
:	I-Disease
unusual	O
neonatal	O
presentation	O
in	O
Qatari	O
twins	O
with	B-Reg
a	O
novel	O
aspartylglucosaminidase	B-Gene
gene	I-Gene
mutation	B-Var
and	O
3	O
new	O
cases	O
in	O
a	O
Turkish	O
family	O
.	O

Aspartylglucosaminuria	O
is	O
a	O
rare	O
autosomal	O
recessive	O
lysosomal	O
storage	O
disorder	O
leading	O
early	O
to	O
a	O
progressive	O
intellectual	O
disability	O
.	O

Monozygous	O
Qatari	O
twins	O
presented	O
with	O
an	O
unusual	O
perinatal	O
manifestation	O
characterized	O
by	O
severe	O
muscular	O
hypotonia	O
,	O
scarce	O
spontaneous	O
movements	O
,	O
multiple	O
contractures	O
,	O
and	O
respiratory	O
insufficiency	O
.	O

Biochemical	O
investigations	O
suggested	B-Reg
aspartylglucosaminuria	B-Disease
,	O
and	O
a	O
novel	O
homozygous	O
mutation	O
c.439T	B-Var
>	I-Var
C	I-Var
(	O
p	O
.	O
S147P	O
)	O
was	O
found	O
in	O
the	O
aspartylglucosaminidase	B-Gene
gene	I-Gene
.	O

However	O
,	O
it	O
can	O
not	O
be	O
excluded	O
that	O
the	O
unusual	O
neonatal	O
presentation	O
is	O
due	O
to	O
an	O
additional	O
autosomal	O
recessive	O
disease	O
in	O
this	O
multiply	O
consanguineous	O
family	O
.	O

The	O
classical	O
aspartylglucosaminuria	O
phenotype	O
(	O
progressive	O
speech	O
delay	O
,	O
psychomotor	O
retardation	O
,	O
and	O
behavioral	O
abnormalities	O
)	O
was	O
observed	O
in	O
3	O
Turkish	O
siblings	O
.	O

Although	O
aspartylglucosaminuria	O
was	O
suspected	O
early	O
,	O
the	O
definite	O
diagnosis	O
was	O
not	O
confirmed	O
until	O
the	O
age	O
of	O
18	O
years	O
.	O

A	O
novel	O
homozygous	O
mutation	O
c.346C	O
>	O
T	O
(	O
p	O
.	O
R116W	O
)	O
was	O
found	O
.	O

These	O
5	O
cases	O
emphasize	O
that	O
aspartylglucosaminuria	O
is	O
panethnic	O
and	O
may	O
possibly	O
present	O
with	O
prenatal	O
manifestation	O
.	O

Screening	O
for	O
aspartylglucosaminuria	O
should	O
be	O
done	O
in	O
all	O
patients	O
with	O
unexplained	O
psychomotor	O
retardation	O
.	O

Mutations	O
of	O
the	O
thyroid	O
peroxidase	O
gene	O
in	O
Chinese	O
siblings	O
with	O
congenital	O
goitrous	O
hypothyroidism	O
.	O

OBJECTIVES	O
:	O
To	O
investigate	O
thyroid	O
peroxidase	O
gene	O
(	B-Gene
TPO	I-Gene
)	I-Gene
mutations	B-Var
in	B-Reg
a	O
Chinese	O
siblings	O
with	O
congenital	B-Disease
goitrous	I-Disease
hypothyroidism	I-Disease
(	O
CGH	O
)	O
.	O

SUBJECTS	O
AND	O
METHODS	O
:	O
The	O
proband	O
,	O
his	O
sister	O
,	O
and	O
their	O
parents	O
were	O
enrolled	O
.	O

All	O
subjects	O
underwent	O
clinical	O
examination	O
and	O
laboratory	O
tests	O
.	O

Mutation	O
screening	O
of	O
the	O
TPO	O
gene	O
was	O
performed	O
by	O
sequencing	O
fragments	O
amplified	O
from	O
extracted	O
genomic	O
DNA	O
.	O

RESULTS	O
:	O
The	O
siblings	O
were	O
diagnosed	O
as	O
CGH	O
with	O
neurodevelopmental	O
deficits	O
.	O

Two	O
compound	O
heterozygous	O
inactivating	O
mutations	O
were	O
found	O
in	O
the	O
two	O
patients	O
:	O
a	O
frameshift	O
mutation	O
between	O
positions	O
2268	O
and	O
2269	O
(	O
c.2268	O
-	O
2269	O
insT	O
)	O
and	O
a	O
missense	O
mutation	O
at	O
c.2089	O
G	O
>	O
A	O
(	O
p	O
.	O
G667S	O
)	O
of	O
the	O
TPO	O
gene	O
.	O

Their	O
parents	O
,	O
with	O
normal	O
thyroid	O
hormone	O
levels	O
,	O
were	O
heterozygous	O
for	O
mutations	O
c.2268	O
-	O
2269	O
insT	O
and	O
c.2089	O
G	O
>	O
A	O
,	O
respectively	O
.	O

The	O
polymorphisms	O
of	O
c.1207	O
G	O
>	O
T	O
,	O
c.1283	O
G	O
>	O
C	O
,	O
and	O
c.2088	O
C	O
>	O
T	O
were	O
detected	O
in	O
the	O
family	O
.	O

CONCLUSIONS	O
:	O
CGH	B-Disease
of	O
the	O
Chinese	O
siblings	O
was	O
due	B-Reg
to	I-Reg
the	O
TPO	B-Gene
gene	O
mutations	O
(	B-Var
c.2268	I-Var
-	I-Var
2269	I-Var
insT	I-Var
and	O
c.2089	B-Var
G	I-Var
>	I-Var
A	I-Var
)	I-Var
.	O

Nebulin	O
(	O
NEB	O
)	O
mutations	O
in	O
a	O
childhood	O
onset	O
distal	O
myopathy	O
with	O
rods	O
and	O
cores	O
uncovered	O
by	O
next	O
generation	O
sequencing	O
.	O

Recessive	O
nebulin	O
(	B-Gene
NEB	I-Gene
)	I-Gene
mutations	B-Var
are	O
a	O
common	O
cause	B-Reg
of	O
nemaline	B-Disease
myopathy	I-Disease
(	O
NM	O
)	O
,	O
typically	O
characterized	O
by	O
generalized	O
weakness	O
of	O
early	O
-	O
onset	O
and	O
nemaline	O
rods	O
on	O
muscle	O
biopsy	O
.	O

Exceptional	O
adult	O
cases	O
with	O
additional	O
cores	O
and	O
an	O
isolated	O
distal	O
weakness	O
have	O
been	O
reported	O
.	O

The	O
large	O
NEB	O
gene	O
with	O
183	O
exons	O
has	O
been	O
an	O
obstacle	O
for	O
the	O
genetic	O
work	O
-	O
up	O
.	O

Here	O
we	O
report	O
a	O
childhood	O
-	O
onset	O
case	O
with	O
distal	O
weakness	O
and	O
a	O
core	O
-	O
rod	O
myopathy	O
,	O
associated	O
with	O
recessive	O
NEB	O
mutations	O
identified	O
by	O
next	O
generation	O
sequencing	O
(	O
NGS	O
)	O
.	O

This	O
6-year	O
-	O
old	O
boy	O
presented	O
with	O
a	O
history	O
of	O
gross	O
-	O
motor	O
difficulties	O
following	O
a	O
normal	O
early	O
development	O
.	O

He	O
had	O
distal	O
leg	O
weakness	O
with	O
bilateral	O
foot	O
drop	O
,	O
as	O
well	O
as	O
axial	O
muscle	O
weakness	O
,	O
scoliosis	O
and	O
spinal	O
rigidity	O
;	O
additionally	O
he	O
required	O
nocturnal	O
respiratory	O
support	O
.	O

Muscle	O
magnetic	O
resonance	O
(	O
MR	O
)	O
imaging	O
showed	O
distal	O
involvement	O
in	O
the	O
medial	O
and	O
anterior	O
compartment	O
of	O
the	O
lower	O
leg	O
.	O

A	O
muscle	O
biopsy	O
featured	O
both	O
rods	O
and	O
cores	O
.	O

Initial	O
targeted	O
testing	O
identified	O
a	O
heterozygous	O
Nebulin	O
exon	O
55	O
deletion	O
.	O

Further	O
analysis	O
using	O
NGS	O
revealed	O
a	O
frameshifting	O
4	O
bp	O
duplication	O
,	O
c.24372_24375dup	O
(	O
P.Val8126fs	O
)	O
,	O
on	O
the	O
opposite	O
allele	O
.	O

This	O
case	O
illustrates	O
that	O
NEB	B-Gene
mutations	B-Var
can	O
cause	B-Reg
childhood	O
onset	O
distal	O
NM	B-Disease
,	O
with	O
additional	O
cores	O
on	O
muscle	O
biopsy	O
and	O
proves	O
the	O
diagnostic	O
utility	O
of	O
NGS	O
for	O
myopathies	O
,	O
particularly	O
when	O
large	O
genes	O
are	O
implicated	O
.	O

Gain	O
-	O
of	O
-	O
function	O
mutations	O
in	O
PDR1	O
,	O
a	O
regulator	O
of	O
antifungal	O
drug	O
resistance	O
in	O
Candida	O
glabrata	O
,	O
control	O
adherence	O
to	O
host	O
cells	O
.	O

Candida	O
glabrata	O
is	O
an	O
emerging	O
opportunistic	O
pathogen	O
that	O
is	O
known	O
to	O
develop	O
resistance	O
to	O
azole	O
drugs	O
due	O
to	O
increased	O
drug	O
efflux	O
.	O

The	O
mechanism	O
consists	O
of	O
CgPDR1-mediated	O
upregulation	O
of	O
ATP	O
-	O
binding	O
cassette	O
transporters	O
.	O

A	O
range	O
of	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
mutations	B-Var
in	O
CgPDR1	B-Gene
have	O
been	O
found	O
to	O
lead	B-PosReg
not	O
only	O
to	O
azole	B-MPA
resistance	I-MPA
but	O
also	O
to	O
enhanced	B-PosReg
virulence	B-MPA
.	O

This	O
implicates	B-Reg
CgPDR1	B-Gene
in	O
the	O
regulation	B-MPA
of	O
the	O
interaction	B-Interaction
of	O
C.	O
glabrata	O
with	O
the	O
host	O
.	O

To	O
identify	O
specific	O
CgPDR1-regulated	O
steps	O
of	O
the	O
host	O
-	O
pathogen	O
interaction	O
,	O
we	O
investigated	O
in	O
this	O
work	O
the	O
interaction	O
of	O
selected	O
CgPDR1	O
GOF	O
mutants	O
with	O
murine	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
and	O
human	O
acute	O
monocytic	O
leukemia	O
cell	O
line	O
(	O
THP-1)-derived	O
macrophages	O
,	O
as	O
well	O
as	O
different	O
epithelial	O
cell	O
lines	O
.	O

GOF	O
mutations	B-Var
in	O
CgPDR1	B-Gene
did	O
not	O
influence	O
survival	O
and	O
replication	O
within	O
macrophages	O
following	O
phagocytosis	O
but	O
led	O
to	O
decreased	B-NegReg
adherence	B-CPA
to	I-CPA
and	I-CPA
uptake	I-CPA
by	I-CPA
macrophages	I-CPA
.	O

This	O
may	O
allow	O
evasion	O
from	O
the	O
host	O
's	O
innate	O
cellular	O
immune	O
response	O
.	O

The	O
interaction	O
with	O
epithelial	O
cells	O
revealed	O
an	O
opposite	O
trend	O
,	O
suggesting	O
that	O
GOF	O
mutations	B-Var
in	O
CgPDR1	B-Gene
may	O
favor	B-PosReg
epithelial	B-CPA
colonization	I-CPA
of	O
the	O
host	O
by	O
C.	O
glabrata	O
through	O
increased	B-PosReg
adherence	B-CPA
to	O
epithelial	O
cell	O
layers	O
.	O

These	O
data	O
reveal	O
that	O
GOF	O
mutations	B-Var
in	O
CgPDR1	B-Gene
modulate	B-Reg
the	O
interaction	B-Interaction
with	O
host	O
cells	O
in	O
ways	O
that	O
may	O
contribute	O
to	O
increased	B-PosReg
virulence	B-MPA
.	O

EDM1	O
:	O
a	O
novel	O
point	B-Var
mutation	I-Var
in	O
cartilage	O
oligomeric	O
matrix	O
protein	O
gene	O
in	O
a	O
Chinese	O
family	O
with	B-Reg
multiple	B-Disease
epiphyseal	I-Disease
dysplasia	I-Disease
.	O

BACKGROUND	O
:	O
Multiple	B-Disease
epiphysis	I-Disease
dysplasia	I-Disease
(	O
MED	O
)	O
is	O
a	O
common	O
skeletal	O
dysplasia	O
with	O
a	O
significant	O
locus	O
heterogeneity	O
.	O

In	B-Reg
the	O
majority	O
of	O
clinically	O
defined	O
cases	O
,	O
mutations	B-Var
have	O
been	O
identified	O
in	O
the	O
gene	O
encoding	O
cartilage	O
algometric	O
matrix	O
protein	O
(	B-Gene
COMP	I-Gene
)	I-Gene
.	O

METHODS	O
:	O
Five	O
patients	O
were	O
included	O
in	O
the	O
study	O
.	O

Linkage	O
analysis	O
and	O
mutation	O
analysis	O
of	O
the	O
COMP	O
gene	O
were	O
conducted	O
in	O
the	O
patients	O
and	O
their	O
family	O
members	O
.	O

RESULTS	O
:	O
We	O
have	O
identified	O
a	O
novel	O
mutation	O
in	O
axon	O
14	O
of	O
COMP	O
gene	O
in	O
the	O
family	O
.	O

CONCLUSIONS	O
:	O
This	O
mutation	O
produced	O
a	O
severe	O
MED	O
phenotype	O
with	O
marked	O
short	O
stature	O
,	O
early	O
onset	O
osteoarthritis	O
,	O
and	O
remarkable	O
radiographic	O
changes	O
.	O

Our	O
results	O
extended	O
the	O
range	O
of	O
disease	O
-	O
causing	O
mutations	O
in	O
COMP	O
gene	O
and	O
contributed	O
more	O
information	O
about	O
relationship	O
between	O
mutations	O
and	O
phenotype	O
.	O

A	O
patient	O
with	O
limb	B-Disease
girdle	I-Disease
muscular	I-Disease
dystrophy	I-Disease
carries	B-Reg
a	O
TRIM32	B-Gene
deletion	B-Var
,	O
detected	O
by	O
a	O
novel	O
CGH	O
array	O
,	O
in	O
compound	O
heterozygosis	O
with	O
a	O
nonsense	O
mutation	O
.	O

Limb	B-Disease
girdle	I-Disease
muscular	I-Disease
dystrophy	I-Disease
2H	I-Disease
is	O
a	O
rare	O
autosomal	O
recessive	O
muscular	O
dystrophy	O
,	O
clinically	O
highly	O
variable	O
,	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
TRIM32	B-Gene
gene	O
.	O

Here	O
we	O
describe	O
a	O
35-years	O
-	O
old	O
who	O
experienced	O
progressive	O
muscle	O
weakness	O
.	O

The	O
muscle	O
biopsy	O
revealed	O
an	O
unspecific	O
pattern	O
of	O
atrophic	O
and	O
hypertrophic	O
fibers	O
;	O
the	O
immunohistochemistry	O
for	O
several	O
proteins	O
was	O
normal	O
.	O

Comparative	O
genomic	O
hybridization	O
(	O
CGH	O
)	O
analysis	O
showed	O
a	O
heterozygous	O
deletion	O
of	O
the	O
entire	O
TRIM32	O
gene	O
.	O

On	O
the	O
other	O
allele	O
we	O
identified	O
the	O
R316X	O
nonsense	O
mutation	O
.	O

The	O
genetic	O
diagnosis	O
of	O
LGMD2H	O
in	O
this	O
case	O
was	O
reached	O
by	O
using	O
a	O
novel	O
high	O
throughput	O
diagnostic	O
tool	O
.	O

Mutant	O
p53	O
prolongs	O
NF	O
-	O
κB	O
activation	O
and	O
promotes	O
chronic	O
inflammation	O
and	O
inflammation	O
-	O
associated	O
colorectal	O
cancer	O
.	O

The	O
tumor	O
suppressor	O
p53	O
is	O
frequently	O
mutated	O
in	O
human	O
cancer	O
.	O

Common	O
mutant	O
p53	O
(	O
mutp53	O
)	O
isoforms	O
can	O
actively	O
promote	O
cancer	O
through	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
mechanisms	O
.	O

We	O
report	O
that	O
mutp53	O
prolongs	O
TNF	O
-	O
α	O
-	O
induced	O
NF	O
-	O
κB	O
activation	O
in	O
cultured	O
cells	O
and	O
intestinal	O
organoid	O
cultures	O
.	O

Remarkably	O
,	O
when	O
exposed	O
to	O
dextran	O
sulfate	O
sodium	O
,	O
mice	O
harboring	O
a	O
germline	O
p53	O
mutation	O
develop	O
severe	O
chronic	O
inflammation	O
and	O
persistent	O
tissue	O
damage	O
,	O
and	O
are	O
highly	O
prone	O
to	O
inflammation	O
-	O
associated	O
colon	O
cancer	O
.	O

This	O
mutp53	O
GOF	O
is	O
manifested	O
by	O
rapid	O
onset	O
of	O
flat	O
dysplastic	O
lesions	O
that	O
progress	B-PosReg
to	O
invasive	B-Disease
carcinoma	I-Disease
with	O
mutp53	B-Var
accumulation	B-PosReg
and	O
augmented	O
NF	B-Protein
-	I-Protein
κB	I-Protein
activation	B-PosReg
,	O
faithfully	O
recapitulating	O
features	O
frequently	O
observed	O
in	O
human	O
colitis	B-Disease
-	I-Disease
associated	I-Disease
colorectal	I-Disease
cancer	I-Disease
(	O
CAC	O
)	O
.	O

These	O
findings	O
might	O
explain	O
the	O
early	O
appearance	O
of	O
p53	O
mutations	O
in	O
human	O
CAC	O
.	O

Epigenetic	O
and	O
genetic	O
alterations	O
of	O
the	O
imprinting	O
disorder	O
Beckwith	O
-	O
Wiedemann	O
syndrome	O
and	O
related	O
disorders	O
.	O

Genomic	O
imprinting	O
is	O
an	O
epigenetic	O
phenomenon	O
that	O
leads	O
to	O
parent	O
-	O
specific	O
differential	O
expression	O
of	O
a	O
subset	O
of	O
genes	O
.	O

Most	O
imprinted	O
genes	O
form	O
clusters	O
,	O
or	O
imprinting	O
domains	O
,	O
and	O
are	O
regulated	O
by	O
imprinting	O
control	O
regions	O
.	O

As	O
imprinted	O
genes	O
have	O
an	O
important	O
role	O
in	O
growth	O
and	O
development	O
,	O
aberrant	O
expression	O
of	O
imprinted	O
genes	O
due	O
to	O
genetic	O
or	O
epigenetic	O
abnormalities	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
human	O
disorders	O
,	O
or	O
imprinting	O
disorders	O
.	O

Beckwith	B-Disease
-	I-Disease
Wiedemann	I-Disease
syndrome	I-Disease
(	O
BWS	O
)	O
is	O
a	O
representative	O
imprinting	O
disorder	O
characterized	O
by	O
macrosomia	O
,	O
macroglossia	O
and	O
abdominal	O
wall	O
defects	O
,	O
and	O
exhibits	O
a	O
predisposition	O
to	O
tumorigenesis	O
.	O

The	O
relevant	O
imprinted	O
chromosomal	O
region	O
in	O
BWS	O
is	O
11p15.5	O
,	O
which	O
consists	O
of	O
two	O
imprinting	O
domains	O
,	O
IGF2	O
/	O
H19	O
and	O
CDKN1C	O
/	O
KCNQ1OT1	O
.	O

BWS	O
has	O
five	O
known	O
causative	O
epigenetic	O
and	O
genetic	O
alterations	O
:	O
loss	O
of	O
methylation	O
(	O
LOM	O
)	O
at	O
KvDMR1	O
,	O
gain	O
of	O
methylation	O
(	O
GOM	O
)	O
at	O
H19DMR	O
,	O
paternal	O
uniparental	O
disomy	O
,	O
CDKN1C	O
mutations	O
and	O
chromosomal	O
rearrangements	O
.	O

Opposite	O
methylation	O
defects	O
,	O
GOM	O
and	O
LOM	O
,	O
at	O
H19DMR	O
are	O
known	O
to	O
cause	O
clinically	O
opposite	O
disorders	O
:	O
BWS	O
and	O
Silver	O
-	O
Russell	O
syndrome	O
,	O
respectively	O
.	O

Interestingly	O
,	O
a	O
recent	O
study	O
discovered	O
that	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
or	O
gain	B-PosReg
of	I-PosReg
function	I-PosReg
of	O
CDKN1C	B-Gene
also	O
causes	O
clinically	O
opposite	O
disorders	O
,	O
BWS	B-Disease
and	O
IMAGe	B-Disease
(	I-Disease
intrauterine	I-Disease
growth	I-Disease
restriction	I-Disease
,	O
metaphyseal	I-Disease
dysplasia	I-Disease
,	O
adrenal	I-Disease
hypoplasia	I-Disease
congenita	I-Disease
,	O
and	I-Disease
genital	I-Disease
anomalies	I-Disease
)	I-Disease
syndrome	I-Disease
,	O
respectively	O
.	O

Furthermore	O
,	O
several	O
clinical	O
studies	O
have	O
suggested	O
a	O
relationship	O
between	O
assisted	O
reproductive	O
technology	O
(	O
ART	O
)	O
and	O
the	O
risk	O
of	O
imprinting	O
disorders	O
,	O
along	O
with	O
the	O
existence	O
of	O
trans	O
-	O
acting	O
factors	O
that	O
regulate	O
multiple	O
imprinted	O
differentially	O
methylated	O
regions	O
.	O

In	O
this	O
review	O
,	O
we	O
describe	O
the	O
latest	O
knowledge	O
surrounding	O
the	O
imprinting	O
mechanism	O
of	O
11p15.5	O
,	O
in	O
addition	O
to	O
epigenetic	O
and	O
genetic	O
etiologies	O
of	O
BWS	O
,	O
associated	O
childhood	O
tumors	O
,	O
the	O
effects	O
of	O
ART	O
and	O
multilocus	O
hypomethylation	O
disorders	O
.	O

Characterization	O
of	O
seizure	O
-	O
like	O
events	O
recorded	O
in	O
vivo	O
in	O
a	O
mouse	O
model	O
of	O
Rett	O
syndrome	O
.	O

Rett	B-Disease
syndrome	I-Disease
is	O
a	O
neurodevelopmental	O
disorder	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
X	O
-	O
linked	O
gene	O
encoding	O
methyl	O
-	O
CpG	O
-	O
binding	O
protein	O
2	O
(	B-Gene
MECP2	I-Gene
)	I-Gene
.	O

Spontaneous	O
recurrent	O
discharge	O
episodes	O
are	O
displayed	O
in	O
Rett	O
-	O
related	O
seizures	O
as	O
in	O
other	O
types	O
of	O
epilepsies	O
.	O

The	O
aim	O
of	O
this	O
paper	O
is	O
to	O
investigate	O
the	O
seizure	O
-	O
like	O
event	O
(	O
SLE	O
)	O
and	O
inter	O
-	O
SLE	O
states	O
in	O
a	O
female	O
MeCP2-deficient	O
mouse	O
model	O
of	O
Rett	O
syndrome	O
and	O
compare	O
them	O
to	O
those	O
found	O
in	O
other	O
spontaneous	O
recurrent	O
epilepsy	O
models	O
.	O

The	O
study	O
was	O
performed	O
on	O
a	O
small	O
population	O
of	O
female	O
MeCP2-deficient	O
mice	O
using	O
telemetric	O
local	O
field	O
potential	O
(	O
LFP	O
)	O
recordings	O
over	O
a	O
24	O
h	O
period	O
.	O

Durations	O
of	O
SLEs	O
and	O
inter	O
-	O
SLEs	O
were	O
extracted	O
using	O
a	O
rule	O
-	O
based	O
automated	O
SLE	O
detection	O
system	O
for	O
both	O
daytime	O
and	O
nighttime	O
,	O
as	O
well	O
as	O
high	O
and	O
low	O
power	O
levels	O
of	O
the	O
delta	O
frequency	O
range	O
(	O
0.5	O
-	O
4	O
Hz	O
)	O
of	O
the	O
recorded	O
LFPs	O
.	O

The	O
results	O
suggest	O
SLE	O
occurrences	O
are	O
not	O
influenced	O
by	O
circadian	O
rhythms	O
,	O
but	O
had	O
a	O
significantly	O
greater	O
association	O
with	O
delta	O
power	O
.	O

Investigating	O
inter	O
-	O
SLE	O
and	O
SLE	O
states	O
by	O
fitting	O
duration	O
histograms	O
to	O
the	O
gamma	O
distribution	O
showed	O
that	O
SLE	O
initiation	O
and	O
termination	O
were	O
associated	O
with	O
random	O
and	O
deterministic	O
mechanisms	O
,	O
respectively	O
.	O

These	O
findings	O
when	O
compared	O
to	O
reported	O
studies	O
on	O
epilepsy	O
suggest	O
that	O
Rett	O
-	O
related	O
seizures	O
share	O
many	O
similarities	O
with	O
absence	O
epilepsy	O
.	O

Familial	B-Disease
lipoprotein	I-Disease
lipase	I-Disease
deficiency	I-Disease
:	I-Disease
a	O
case	O
of	O
compound	O
heterozygosity	O
of	O
a	O
novel	O
duplication	O
(	O
R44Kfs*4	O
)	O
and	O
a	O
common	O
mutation	O
(	B-Var
N291S	I-Var
)	I-Var
in	B-Reg
the	O
lipoprotein	B-Gene
lipase	I-Gene
gene	I-Gene
.	O

Familial	B-Disease
lipoprotein	I-Disease
lipase	I-Disease
(	I-Disease
LPL	I-Disease
)	I-Disease
deficiency	I-Disease
(	O
FLLD	O
)	O
is	O
a	O
rare	O
autosomal	O
recessive	O
genetic	O
disorder	O
caused	B-Reg
by	I-Reg
homozygous	O
or	O
compound	O
heterozygous	O
mutations	B-Var
in	O
the	O
LPL	B-Gene
gene	O
.	O

FLLD	O
individuals	O
usually	O
express	O
an	O
impaired	O
or	O
non	O
-	O
functional	O
LPL	O
enzyme	O
with	O
low	O
or	O
absent	O
triglyceride	O
(	O
TG	O
)	O
hydrolysis	O
activity	O
causing	O
severe	O
hypertriglyceridaemia	O
.	O

Here	O
we	O
report	O
a	O
case	O
of	O
FLLD	O
in	O
a	O
29-year	O
-	O
old	O
man	O
,	O
who	O
initially	O
presented	O
with	O
eruptive	O
cutaneous	O
xanthomata	O
,	O
elevated	O
plasma	O
TG	O
concentration	O
but	O
no	O
other	O
co	O
-	O
morbidities	O
.	O

Subsequent	O
genetic	O
testing	O
of	O
the	O
patient	O
revealed	O
compound	O
heterozygosity	O
of	O
a	O
novel	O
duplication	O
(	B-Var
p	I-Var
.	I-Var
R44Kfs*4	I-Var
)	I-Var
leading	B-Reg
to	I-Reg
a	O
premature	B-MPA
stop	I-MPA
codon	O
in	O
exon	O
2	O
and	O
a	O
known	O
mutation	O
(	B-Var
N291S	I-Var
)	I-Var
in	O
exon	O
5	O
of	O
the	O
LPL	B-Gene
gene	O
.	O

Further	O
biochemical	O
analysis	O
of	O
the	O
patient	O
's	O
postheparin	O
plasma	O
confirmed	O
a	O
reduction	B-NegReg
of	O
total	O
lipase	B-Enzyme
activity	B-MPA
compared	O
with	O
his	O
heterozygous	O
father	O
carrying	O
the	O
common	O
N291S	B-Var
mutation	O
and	O
to	O
a	O
healthy	O
control	O
.	O

Also	O
the	O
patient	O
showed	O
increased	B-PosReg
(	O
1.85-fold	O
)	O
activity	B-MPA
of	O
hepatic	B-Enzyme
lipase	I-Enzyme
(	O
HL	O
)	O
,	O
indicating	O
a	O
functional	O
link	O
between	O
HL	O
and	O
LPL	O
.	O

In	O
summary	O
,	O
we	O
report	O
a	O
case	O
of	O
FLLD	B-Disease
caused	B-Reg
by	I-Reg
compound	O
heterozygosity	O
of	O
a	O
new	O
duplication	B-Var
and	O
a	O
common	O
mutation	B-Var
in	O
the	O
LPL	B-Gene
gene	O
,	O
resulting	O
in	O
residual	B-NegReg
LPL	B-Enzyme
activity	B-MPA
.	O

With	O
such	O
mutations	O
,	O
individuals	O
may	O
not	O
receive	O
a	O
diagnosis	O
before	O
classical	O
FLLD	O
symptoms	O
appear	O
later	O
in	O
adulthood	O
.	O

Nevertheless	O
,	O
early	O
diagnosis	O
and	O
lipid	O
-	O
lowering	O
treatment	O
may	O
favour	O
a	O
reduced	O
risk	O
of	O
premature	O
cardiovascular	O
disease	O
or	O
acute	O
pancreatitis	O
in	O
such	O
individuals	O
.	O

Microarray	O
analysis	O
of	O
unbalanced	O
translocation	O
in	O
Wolf	O
-	O
Hirschhorn	O
syndrome	O
.	O

Wolf	B-Disease
-	I-Disease
Hirschhorn	I-Disease
syndrome	I-Disease
(	O
WHS	O
)	O
is	O
caused	B-Reg
by	I-Reg
deletions	B-Var
involving	O
chromosome	O
region	O
4p16.3	B-Gene
,	O
which	O
is	O
characterized	O
by	O
growth	O
delay	O
,	O
mild	O
-	O
to	O
-	O
severe	O
mental	O
retardation	O
,	O
hypotonia	O
,	O
facial	O
dysmorphisms	O
and	O
shows	O
extensive	O
phenotypic	O
variability	O
include	O
feeding	O
difficulties	O
,	O
epilepsy	O
and	O
congenital	O
anomalies	O
.	O

Variation	O
in	O
the	O
size	O
of	O
the	O
deletion	O
involving	O
chromosome	O
region	O
4p16.3	O
may	O
explain	O
the	O
clinical	O
variation	O
.	O

However	O
,	O
previous	O
studies	O
indicate	O
that	O
duplication	O
for	O
another	O
chromosome	O
region	O
due	O
to	O
an	O
unbalanced	O
translocation	O
elucidate	O
approximately	O
40	O
-	O
45	O
%	O
WHS	O
patients	O
.	O

Therefore	O
,	O
we	O
used	O
whole	O
genomic	O
cytogenetics	O
array	O
to	O
analyze	O
the	O
entire	O
genome	O
at	O
a	O
significantly	O
higher	O
resolution	O
over	O
conventional	O
cytogenetics	O
to	O
characterize	O
the	O
exact	O
subtelomeric	O
aberration	O
region	O
of	O
one	O
patient	O
with	O
developmental	O
delay	O
and	O
several	O
facial	O
characteristics	O
reminiscent	O
Wolf	O
-	O
Hirschhorn	O
syndrome	O
.	O

Here	O
we	O
report	O
that	O
our	O
patient	O
had	O
3.7	O
Mb	O
deletion	O
at	O
the	O
4p16.2	O
and	O
6.8	O
Mb	O
duplication	O
at	O
8p23.1	O
resulted	O
from	O
the	O
unbalanced	O
translocations	O
der(4)t(4;8)(p16.2;p23.1	O
)	O
.	O

We	O
confirmed	O
that	O
our	O
patient	O
with	O
monosomy	O
4p16.2	O
which	O
is	O
consistent	O
with	O
Wolf	O
-	O
Hirschhorn	O
syndrome	O
and	O
trisomy	O
8p23.1	O
.	O

The	O
combination	O
of	O
the	O
4p	O
deletion	O
with	O
8p	O
partial	O
trisomy	O
explains	O
the	O
complex	O
phenotype	O
presented	O
by	O
our	O
patient	O
.	O

Novel	O
ALPL	O
genetic	O
alteration	O
associated	O
with	O
an	O
odontohypophosphatasia	O
phenotype	O
.	O

Hypophosphatasia	B-Disease
(	O
HPP	O
)	O
is	O
an	O
inherited	O
disorder	O
of	O
mineral	O
metabolism	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
ALPL	B-Gene
,	O
encoding	O
tissue	O
non	O
-	O
specific	O
alkaline	O
phosphatase	O
(	O
TNAP	O
)	O
.	O

Here	O
,	O
we	O
report	O
the	O
molecular	O
findings	O
from	O
monozygotic	O
twins	O
,	O
clinically	O
diagnosed	O
with	O
tooth	O
-	O
specific	O
odontohypophosphatasia	O
(	O
odonto	O
-	O
HPP	O
)	O
.	O

Sequencing	O
of	O
ALPL	O
identified	O
two	O
genetic	O
alterations	O
in	O
the	O
probands	O
,	O
including	O
a	O
heterozygous	O
missense	O
mutation	O
c.454C	B-Var
>	I-Var
T	I-Var
,	O
leading	B-Reg
to	I-Reg
change	O
of	O
arginine	O
152	O
to	O
cysteine	O
(	B-Var
p	I-Var
.	I-Var
R152C	I-Var
)	I-Var
,	O
and	O
a	O
novel	O
heterozygous	O
gene	O
deletion	O
c.1318_1320delAAC	B-Var
,	O
leading	B-Reg
to	I-Reg
the	O
loss	O
of	O
an	O
asparagine	O
residue	O
at	O
codon	O
440	O
(	B-Var
p	I-Var
.	I-Var
N440del	I-Var
)	I-Var
.	O

Clinical	O
identification	O
of	O
low	O
serum	O
TNAP	O
activity	O
,	O
dental	O
abnormalities	O
,	O
and	O
pedigree	O
data	O
strongly	O
suggests	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
between	O
p	O
.	O
N440del	O
and	O
odonto	O
-	O
HPP	O
in	O
this	O
family	O
.	O

Computational	O
analysis	O
of	O
the	O
p	B-Var
.	I-Var
N440del	I-Var
protein	O
structure	O
revealed	O
an	O
alteration	B-Reg
in	O
the	O
tertiary	B-MPA
structure	I-MPA
affecting	B-Reg
the	O
collagen	B-Interaction
-	I-Interaction
binding	I-Interaction
site	I-Interaction
(	O
loop	O
422	O
-	O
452	O
)	O
,	O
which	O
could	O
potentially	O
impair	B-NegReg
the	O
mineralization	B-MPA
process	I-MPA
.	O

Nevertheless	O
,	O
the	O
probands	O
(	O
compound	O
heterozygous	O
:	O
p.[N440del];[R152C	O
]	O
)	O
feature	O
early	O
-	O
onset	O
and	O
severe	O
odonto	O
-	O
HPP	O
phenotype	O
,	O
whereas	O
the	O
father	O
(	O
p.[N440del];[=	O
]	O
)	O
has	O
only	O
moderate	O
symptoms	O
,	O
suggesting	O
p	O
.	O
R152C	O
may	O
contribute	O
or	O
predispose	O
to	O
a	O
more	O
severe	O
dental	O
phenotype	O
in	O
combination	O
with	O
the	O
deletion	O
.	O

These	O
results	O
assist	O
in	O
defining	O
the	O
genotype	O
-	O
phenotype	O
associations	O
for	O
odonto	O
-	O
HPP	O
,	O
and	O
further	O
identify	O
the	O
collagen	O
-	O
binding	O
site	O
as	O
a	O
region	O
of	O
potential	O
structural	O
importance	O
for	O
TNAP	O
function	O
in	O
the	O
biomineralization	O
.	O

Analysis	O
of	O
STK11	O
gene	O
variant	O
in	O
five	O
Chinese	O
patients	O
with	O
Peutz	O
-	O
Jeghers	O
syndrome	O
.	O

BACKGROUND	O
:	O
Peutz	B-Disease
-	I-Disease
Jeghers	I-Disease
syndrome	I-Disease
(	O
PJS	O
)	O
is	O
a	O
rare	O
autosomal	O
dominant	O
inherited	O
disorder	O
characterized	O
by	O
gastrointestinal	O
hamartomatous	O
polyps	O
and	O
mucocutaneous	O
pigmentation	O
.	O

Germline	O
mutation	B-Var
of	O
a	O
serine	O
/	O
threonine	O
kinase	O
11(STK11	B-Gene
)	I-Gene
gene	O
has	O
been	O
identified	O
as	O
a	O
cause	B-Reg
of	O
PJS	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
molecular	O
basis	O
of	O
five	O
Chinese	O
PJS	O
patients	O
.	O

METHODS	O
:	O
Blood	O
samples	O
were	O
collected	O
from	O
five	O
unrelated	O
Chinese	O
PJS	O
patients	O
and	O
their	O
parents	O
.	O

The	O
entire	O
coding	O
region	O
of	O
the	O
STK11	O
gene	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
and	O
analyzed	O
by	O
direct	O
sequencing	O
.	O

RESULTS	O
:	O
Three	O
different	O
frameshift	O
mutations	O
(	O
c.519insTGTG	O
,	O
c.792_793insT	O
,	O
and	O
c.334_335insC	O
)	O
,	O
all	O
of	O
which	O
would	O
cause	O
truncation	O
of	O
the	O
gene	O
product	O
,	O
were	O
found	O
in	O
three	O
patients	O
.	O

One	O
missense	O
mutation	O
(	O
p	O
.	O
Ser307Thr	O
)	O
and	O
one	O
3bp	O
deletion	O
mutation	O
(	O
c.228	O
-	O
230del	O
CGT	O
)	O
were	O
identified	O
in	O
the	O
remaining	O
two	O
patients	O
.	O

All	O
of	O
the	O
five	O
investigated	O
patients	O
carried	O
de	O
novo	O
mutations	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
support	O
that	O
mutation	B-Var
of	O
the	O
LKB1	B-Gene
gene	O
is	O
a	O
cause	B-Reg
of	O
PJS	B-Disease
,	O
and	O
expand	O
the	O
spectrum	O
of	O
the	O
STK11	O
gene	O
mutations	O
.	O

Clinical	O
relevance	O
of	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutations	B-Var
of	O
p53	B-Gene
in	O
high	B-Disease
-	I-Disease
grade	I-Disease
serous	I-Disease
ovarian	I-Disease
carcinoma	I-Disease
.	O

PURPOSE	O
:	O
Inactivation	O
of	O
TP53	O
,	O
which	O
occurs	O
predominantly	O
by	O
missense	O
mutations	O
in	O
exons	O
4	O
-	O
9	O
,	O
is	O
a	O
major	O
genetic	O
alteration	O
in	O
a	O
subset	O
of	O
human	O
cancer	O
.	O

In	O
spite	O
of	O
growing	O
evidence	O
that	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
mutations	B-Var
of	O
p53	B-Gene
also	O
have	O
oncogenic	B-CPA
activity	I-CPA
,	O
little	O
is	O
known	O
about	O
the	O
clinical	O
relevance	O
of	O
these	O
mutations	O
.	O

METHODS	O
:	O
The	O
clinicopathological	O
features	O
of	O
high	O
-	O
grade	O
serous	O
ovarian	O
carcinoma	O
(	O
HGS	O
-	O
OvCa	O
)	O
patients	O
with	O
GOF	O
p53	O
mutations	O
were	O
evaluated	O
according	O
to	O
a	O
comprehensive	O
somatic	O
mutation	O
profile	O
comprised	O
of	O
whole	O
exome	O
sequencing	O
,	O
mRNA	O
expression	O
,	O
and	O
protein	O
expression	O
profiles	O
obtained	O
from	O
the	O
Cancer	O
Genome	O
Atlas	O
(	O
TCGA	O
)	O
.	O

RESULTS	O
:	O
Patients	O
with	O
a	O
mutant	O
p53	B-Protein
protein	I-Protein
(	O
mutp53	O
)	O
with	O
a	O
GOF	O
mutation	B-Var
showed	O
higher	B-PosReg
p53	B-MPA
mRNA	I-MPA
and	I-MPA
protein	I-MPA
expression	I-MPA
levels	I-MPA
than	O
patients	O
with	O
p53	O
mutation	O
with	O
no	O
evidence	O
of	O
GOF	O
(	O
NE	O
-	O
GOF	O
)	O
.	O

GOF	O
mutations	O
were	O
more	O
likely	O
to	O
occur	O
within	O
mutational	O
hotspots	O
,	O
and	O
at	O
CpG	O
sites	O
,	O
and	O
resulted	O
in	O
mutp53	O
with	O
higher	O
functional	O
severity	O
(	O
FS	O
)	O
scores	O
.	O

Clinically	O
,	O
patients	O
with	O
GOF	O
mutations	B-Var
showed	O
a	O
higher	B-PosReg
frequency	O
of	O
platinum	B-CPA
resistance	I-CPA
(	O
22/58	O
,	O
37.9	O
%	O
)	O
than	O
patients	O
with	O
NE	O
-	O
GOF	O
mutations	O
(	O
12/56	O
,	O
21.4	O
%	O
)	O
(	O
p=0.054	O
)	O
.	O

Furthermore	O
,	O
patients	O
with	O
GOF	O
mutations	B-Var
were	O
more	O
likely	O
to	O
develop	B-PosReg
distant	B-CPA
metastasis	I-CPA
(	O
36/55	O
,	O
65.5	O
%	O
)	O
than	O
local	O
recurrence	O
(	O
19/55	O
,	O
34.5	O
%	O
)	O
,	O
whereas	O
patients	O
with	O
NE	O
-	O
GOF	O
mutations	O
showed	O
a	O
higher	O
frequency	O
of	O
locoregional	O
recurrence	O
(	O
26/47	O
,	O
55.3	O
%	O
)	O
than	O
distant	O
metastasis	O
(	O
21/47	O
,	O
44.7	O
%	O
)	O
(	O
p=0.035	O
)	O
.	O

There	O
were	O
no	O
differences	O
in	O
overall	O
or	O
progression	O
-	O
free	O
survival	O
between	O
patients	O
with	O
GOF	O
or	O
NE	O
-	O
GOF	O
mutp53	O
.	O

CONCLUSION	O
:	O
This	O
study	O
demonstrates	O
that	O
patient	O
with	O
GOF	B-PosReg
mutp53	B-Var
is	O
characterized	O
by	O
a	O
greater	B-PosReg
likelihood	O
of	O
platinum	B-CPA
treatment	I-CPA
resistance	I-CPA
and	O
distant	B-CPA
metastatic	I-CPA
properties	I-CPA
in	O
HGS	B-Disease
-	I-Disease
OvCa	I-Disease
.	O

Recurrent	O
de	O
novo	O
c.316G	O
>	O
A	O
mutation	O
in	O
NIPA1	O
hotspot	O
.	O

Mutations	B-Var
in	O
the	O
NIPA1	B-Gene
cause	B-Reg
autosomal	O
dominant	O
form	O
of	O
hereditary	B-Disease
spastic	I-Disease
paraplegia	I-Disease
.	O

Allelic	O
heterogeneity	O
of	O
known	O
NIPA1	B-Gene
mutations	O
is	O
quite	O
limited	O
and	O
the	O
most	O
common	O
mutation	O
is	O
c.316G	B-Var
>	I-Var
A	I-Var
resulting	B-Reg
in	I-Reg
p	B-Protein
.	I-Protein
G106R	I-Protein
protein	O
change	B-MPA
.	O

Here	O
we	O
report	O
the	O
first	O
direct	O
evidence	O
of	O
de	O
novo	O
c.316G	O
>	O
A	O
mutation	O
in	O
the	O
same	O
hotspot	O
of	O
the	O
gene	O
in	O
two	O
unrelated	O
patients	O
who	O
had	O
otherwise	O
a	O
prototypical	O
NIPA1-associated	O
phenotype	O
with	O
a	O
severe	O
form	O
of	O
uncomplicated	O
spastic	O
paraplegia	O
.	O

De	O
novo	O
nature	O
of	O
these	O
mutations	O
was	O
confirmed	O
by	O
sequencing	O
both	O
sets	O
of	O
clinically	O
unaffected	O
parents	O
and	O
confirmation	O
of	O
paternity	O
.	O

We	O
also	O
discuss	O
likely	O
molecular	O
mechanisms	O
accounting	O
for	O
recurrent	O
mutations	O
in	O
this	O
segment	O
of	O
the	O
gene	O
.	O

Apparently	O
sporadic	O
patients	O
without	O
a	O
positive	O
family	O
history	O
of	O
hereditary	O
spastic	O
paraplegia	O
need	O
to	O
be	O
also	O
evaluated	O
for	O
possible	O
disease	O
-	O
causing	O
mutations	O
in	O
genes	O
that	O
are	O
inherited	O
in	O
an	O
autosomal	O
dominant	O
fashion	O
.	O

Spliced	O
MDM2	O
isoforms	O
promote	O
mutant	O
p53	O
accumulation	O
and	O
gain	O
-	O
of	O
-	O
function	O
in	O
tumorigenesis	O
.	O

The	O
tumour	O
suppressor	O
p53	O
is	O
frequently	O
mutated	O
in	O
tumours	O
.	O

Mutant	B-Var
p53	B-Protein
(	O
Mutp53	O
)	O
proteins	O
often	O
gain	B-PosReg
new	I-PosReg
activities	I-PosReg
in	O
promoting	B-CPA
tumorigenesis	I-CPA
,	O
defined	O
as	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
.	O

Mutp53	O
can	O
accumulate	O
to	O
high	O
levels	O
in	O
tumours	O
,	O
which	O
promotes	O
mutp53	B-Var
GOF	B-PosReg
in	O
tumorigenesis	B-CPA
.	O

The	O
mechanism	O
of	O
mutp53	O
accumulation	O
is	O
poorly	O
understood	O
.	O

Here	O
we	O
find	O
that	O
MDM2	O
isoforms	O
promote	O
mutp53	O
accumulation	O
in	O
tumours	O
.	O

MDM2	O
isoform	O
B	O
(	O
MDM2-B	O
)	O
,	O
the	O
MDM2	O
isoform	O
most	O
frequently	O
over	O
-	O
expressed	O
in	O
human	O
tumours	O
,	O
interacts	O
with	O
full	O
-	O
length	O
MDM2	O
to	O
inhibit	O
MDM2-mediated	O
mutp53	O
degradation	O
,	O
promoting	O
mutp53	O
accumulation	O
and	O
GOF	O
in	O
tumorigenesis	O
.	O

Furthermore	O
,	O
MDM2-B	O
overexpression	O
correlates	O
with	O
mutp53	O
accumulation	O
in	O
human	O
tumours	O
.	O

In	O
mutp53	O
knock	O
-	O
in	O
mice	O
,	O
a	O
MDM2	O
isoform	O
similar	O
to	O
human	O
MDM2-B	O
is	O
overexpressed	O
in	O
the	O
majority	O
of	O
tumours	O
,	O
which	O
promotes	O
mutp53	O
accumulation	O
and	O
tumorigenesis	O
.	O

Thus	O
,	O
overexpression	O
of	O
MDM2	O
isoforms	O
promotes	O
mutp53	O
accumulation	O
in	O
tumours	O
,	O
contributing	O
to	O
mutp53	B-Var
GOF	B-PosReg
in	O
tumorigenesis	B-CPA
.	O

This	O
may	O
be	O
an	O
important	O
mechanism	O
by	O
which	O
MDM2	O
isoforms	O
promote	O
tumorigenesis	O
.	O

Mutant	B-Var
p53	B-Gene
gain	B-PosReg
of	I-PosReg
function	I-PosReg
can	O
be	O
at	O
the	O
root	O
of	O
dedifferentiation	O
of	O
human	B-Disease
osteosarcoma	I-Disease
MG63	O
cells	O
into	O
3AB	O
-	O
OS	O
cancer	O
stem	O
cells	O
.	O

Osteosarcoma	O
is	O
a	O
highly	O
metastatic	O
tumor	O
affecting	O
adolescents	O
,	O
for	O
which	O
there	O
is	O
no	O
second	O
-	O
line	O
chemotherapy	O
.	O

As	O
suggested	O
for	O
most	O
tumors	O
,	O
its	O
capability	O
to	O
overgrow	O
is	O
probably	O
driven	O
by	O
cancer	O
stem	O
cells	O
(	O
CSCs	O
)	O
,	O
and	O
finding	O
new	O
targets	O
to	O
kill	O
CSCs	O
may	O
be	O
critical	O
for	O
improving	O
patient	O
survival	O
.	O

TP53	O
is	O
the	O
most	O
frequently	O
mutated	O
tumor	O
suppressor	O
gene	O
in	O
cancers	O
and	O
mutant	O
p53	O
protein	O
(	O
mutp53	O
)	O
can	O
acquire	O
gain	O
of	O
function	O
(	O
GOF	O
)	O
strongly	O
contributing	O
to	O
malignancy	O
.	O

Studies	O
thus	O
far	O
have	O
not	O
shown	O
p53-GOF	O
in	O
osteosarcoma	O
.	O

Here	O
,	O
we	O
investigated	O
TP53	O
gene	O
status	O
/	O
role	O
in	O
3AB	O
-	O
OS	O
cells	O
-	O
a	O
highly	O
aggressive	O
CSC	O
line	O
previously	O
selected	O
from	O
human	O
osteosarcoma	O
MG63	O
cells	O
-	O
to	O
evaluate	O
its	O
involvement	O
in	O
promoting	O
proliferation	O
,	O
invasiveness	O
,	O
resistance	O
to	O
apoptosis	O
and	O
stemness	O
.	O

By	O
RT	O
-	O
PCR	O
,	O
methylation	O
-	O
specific	O
PCR	O
,	O
fluorescent	O
in	O
situ	O
hybridization	O
,	O
DNA	O
sequence	O
,	O
western	O
blot	O
and	O
immunofluorescence	O
analyses	O
,	O
we	O
have	O
shown	O
that	O
-	O
in	O
comparison	O
with	O
parental	O
MG63	O
cells	O
where	O
TP53	O
gene	O
is	O
hypermethylated	O
,	O
rearranged	O
and	O
in	O
single	O
copy	O
-	O
in	O
3AB	O
-	O
OS	O
cells	O
,	O
TP53	O
is	O
unmethylated	O
,	O
rearranged	O
and	O
in	O
multiple	O
copies	O
,	O
and	O
mutp53	O
(	O
p53-R248W	O
/	O
P72R	O
)	O
is	O
post	O
-	O
translationally	O
modified	O
and	O
with	O
nuclear	O
localization	O
.	O

p53-R248W	O
/	O
P72R	O
-	O
knockdown	O
by	O
short	O
-	O
interfering	O
RNA	O
reduced	O
the	O
growth	O
and	O
replication	O
rate	O
of	O
3AB	O
-	O
OS	O
cells	O
,	O
markedly	O
increasing	O
cell	O
cycle	O
inhibitor	O
levels	O
and	O
sensitized	O
3AB	O
-	O
OS	O
cells	O
to	O
TRAIL	O
-	O
induced	O
apoptosis	O
by	O
DR5	O
up	O
-	O
regulation	O
;	O
moreover	O
,	O
it	O
strongly	O
decreased	O
the	O
levels	O
of	O
stemness	O
and	O
invasiveness	O
genes	O
.	O

We	O
have	O
also	O
found	O
that	O
the	O
ectopic	O
expression	O
of	O
p53-R248W	B-Var
/	I-Var
P72R	I-Var
in	O
MG63	O
cells	O
promoted	B-PosReg
cancer	B-CPA
stem	I-CPA
-	I-CPA
like	I-CPA
features	I-CPA
,	O
as	O
high	B-CPA
proliferation	I-CPA
rate	I-CPA
,	O
sphere	B-CPA
formation	I-CPA
,	O
clonogenic	B-CPA
growth	I-CPA
,	O
high	B-CPA
migration	I-CPA
and	O
invasive	B-CPA
ability	I-CPA
;	I-CPA
furthermore	O
,	O
it	O
strongly	O
increased	B-PosReg
the	O
levels	B-MPA
of	I-MPA
stemness	I-MPA
proteins	I-MPA
.	O

Overall	O
,	O
the	O
findings	O
suggest	O
the	O
involvement	B-Reg
of	O
p53-R248W	B-Var
/	I-Var
P72R	I-Var
at	O
the	O
origin	B-CPA
of	I-CPA
the	I-CPA
aberrant	I-CPA
characters	I-CPA
of	I-CPA
the	I-CPA
3AB	I-CPA
-	I-CPA
OS	I-CPA
cells	I-CPA
with	O
the	O
hypothesis	O
that	O
its	O
GOF	O
can	O
be	O
at	O
the	O
root	O
of	O
the	O
dedifferentiation	O
of	O
MG63	O
cells	O
into	O
CSCs	O
.	O

Late	O
adult	O
-	O
onset	O
of	O
X	O
-	O
linked	O
myopathy	O
with	O
excessive	O
autophagy	O
.	O

INTRODUCTION	O
:	O
X	B-Disease
-	I-Disease
linked	I-Disease
myopathy	I-Disease
with	I-Disease
excessive	I-Disease
autophagy	I-Disease
(	O
XMEA	O
)	O
is	O
characterized	O
by	O
autophagic	O
vacuoles	O
with	O
sarcolemmal	O
features	O
.	O

Mutations	B-Var
in	O
VMA21	B-Gene
result	O
in	O
insufficient	B-NegReg
lysosome	B-MPA
acidification	I-MPA
,	O
causing	B-Reg
progressive	B-CPA
proximal	I-CPA
weakness	I-CPA
with	O
onset	O
before	O
age	O
20	O
years	O
and	O
loss	O
of	O
ambulation	O
by	O
middle	O
age	O
.	O

METHODS	O
:	O
We	O
describe	O
a	O
patient	O
with	O
onset	O
of	O
slowly	O
progressive	O
proximal	O
weakness	O
of	O
the	O
lower	O
limbs	O
after	O
age	O
50	O
,	O
who	O
maintains	O
ambulation	O
with	O
the	O
assistance	O
of	O
a	O
cane	O
at	O
age	O
71	O
.	O

RESULTS	O
:	O
Muscle	O
biopsy	O
at	O
age	O
66	O
showed	O
complex	O
muscle	O
fiber	O
splitting	O
,	O
internalized	O
capillaries	O
,	O
and	O
vacuolar	O
changes	O
characteristic	O
of	O
autophagic	O
vacuolar	O
myopathy	O
.	O

Vacuoles	O
stained	O
positive	O
for	O
sarcolemmal	O
proteins	O
,	O
LAMP2	O
,	O
and	O
complement	O
C5b-9	O
.	O

Ultrastructural	O
evaluation	O
further	O
revealed	O
basal	O
lamina	O
reduplication	O
and	O
extensive	O
autophagosome	O
extrusion	O
.	O

Sanger	O
sequencing	O
identified	O
a	O
known	O
pathologic	O
splice	O
site	O
mutation	O
in	O
VMA21	O
(	O
c.164	O
-	O
7T	O
>	O
G	O
)	O
.	O

CONCLUSIONS	O
:	O
This	O
case	O
expands	O
the	O
clinical	O
phenotype	O
of	O
XMEA	O
and	O
suggests	O
VMA21	O
sequencing	O
be	O
considered	O
in	O
evaluating	O
men	O
with	O
LAMP2-positive	O
autophagic	O
vacuolar	O
myopathy	O
.	O

Unequal	O
prognostic	O
potentials	O
of	O
p53	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
in	O
human	O
cancers	O
associate	O
with	O
drug	O
-	O
metabolizing	O
activity	O
.	O

Mutation	O
of	O
p53	O
is	O
the	O
most	O
common	O
genetic	O
change	O
in	O
human	O
cancer	O
,	O
causing	O
complex	O
effects	O
including	O
not	O
only	O
loss	O
of	O
wild	O
-	O
type	O
function	O
but	O
also	O
gain	O
of	O
novel	O
oncogenic	O
functions	O
(	O
GOF	O
)	O
.	O

It	O
is	O
increasingly	O
likely	O
that	O
p53-hotspot	O
mutations	O
may	O
confer	O
different	O
types	O
and	O
magnitudes	O
of	O
GOF	O
,	O
but	O
the	O
evidences	O
are	O
mainly	O
supported	O
by	O
cellular	O
and	O
transgenic	O
animal	O
models	O
.	O

Here	O
we	O
combine	O
large	O
-	O
scale	O
cancer	O
genomic	O
data	O
to	O
characterize	O
the	O
prognostic	O
significance	O
of	O
different	O
p53	O
mutations	O
in	O
human	O
cancers	O
.	O

Unexpectedly	O
,	O
only	O
mutations	O
on	O
the	O
Arg248	O
and	O
Arg282	O
positions	O
displayed	O
significant	O
association	O
with	O
shorter	O
patient	O
survival	O
,	O
but	O
such	O
association	O
was	O
not	O
evident	O
for	O
other	O
hotspot	O
GOF	O
mutations	O
.	O

Gene	O
set	O
enrichment	O
analysis	O
on	O
these	O
mutations	B-Var
revealed	O
higher	B-PosReg
activity	B-MPA
of	O
drug	B-Enzyme
-	I-Enzyme
metabolizing	I-Enzyme
enzymes	I-Enzyme
,	O
including	O
the	O
CYP3A4	B-Enzyme
cytochrome	I-Enzyme
P450	I-Enzyme
.	O

Ectopic	B-MPA
expression	I-MPA
of	O
p53	B-Gene
mutant	B-Var
R282W	I-Var
in	O
H1299	O
and	O
SaOS2	O
cells	O
significantly	O
upregulated	B-PosReg
CYP3A4	B-MPA
mRNA	I-MPA
and	I-MPA
protein	I-MPA
levels	I-MPA
,	O
and	O
cancer	O
cell	O
lines	O
bearing	O
mortality	O
-	O
associated	O
p53	B-Gene
mutations	B-Var
display	O
higher	B-PosReg
CYP3A4	B-Enzyme
expression	B-MPA
and	O
resistance	B-CPA
to	O
several	O
CYP3A4-metabolized	O
chemotherapeutic	O
drugs	O
.	O

Our	O
results	O
suggest	O
that	O
p53	O
mutations	O
have	O
unequal	O
GOF	O
activities	O
in	O
human	O
cancers	O
,	O
and	O
future	O
evaluation	O
of	O
p53	O
as	O
a	O
cancer	O
biomarker	O
should	O
consider	O
which	O
mutation	O
is	O
present	O
in	O
the	O
tumor	O
,	O
rather	O
than	O
having	O
comparison	O
between	O
wild	O
-	O
type	O
and	O
mutant	O
genotypes	O
.	O

Disruption	O
of	O
the	O
temporally	O
regulated	O
cloaca	O
endodermal	O
β	O
-	O
catenin	O
signaling	O
causes	O
anorectal	O
malformations	O
.	O

The	O
cloaca	O
is	O
temporally	O
formed	O
and	O
eventually	O
divided	O
by	O
the	O
urorectal	O
septum	O
(	O
URS	O
)	O
during	O
urogenital	O
and	O
anorectal	O
organ	O
development	O
.	O

Although	O
congenital	O
malformations	O
,	O
such	O
as	O
anorectal	B-Disease
malformations	I-Disease
(	O
ARMs	O
)	O
,	O
are	O
frequently	O
observed	O
during	O
this	O
process	O
,	O
the	O
underlying	O
pathogenic	O
mechanisms	O
remain	O
unclear	O
.	O

β	O
-	O
Catenin	O
is	O
a	O
critical	O
component	O
of	O
canonical	O
Wnt	O
signaling	O
and	O
is	O
essential	O
for	O
the	O
regulation	O
of	O
cell	O
differentiation	O
and	O
morphogenesis	O
during	O
embryogenesis	O
.	O

The	O
expression	O
of	O
β	O
-	O
catenin	O
is	O
observed	O
in	O
endodermal	O
epithelia	O
,	O
including	O
URS	O
epithelia	O
.	O

We	O
modulated	O
the	O
β	O
-	O
catenin	O
gene	O
conditionally	O
in	O
endodermal	O
epithelia	O
by	O
utilizing	O
tamoxifen	O
-	O
inducible	O
Cre	O
driver	O
line	O
(	O
Shh(CreERT2	O
)	O
)	O
.	O

Both	O
β	B-Protein
-	I-Protein
catenin	I-Protein
loss-	B-NegReg
and	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
LOF	O
and	O
GOF	O
)	O
mutants	B-Var
displayed	O
abnormal	O
clefts	B-CPA
in	I-CPA
the	I-CPA
perineal	I-CPA
region	I-CPA
and	O
hypoplastic	B-CPA
elongation	I-CPA
of	I-CPA
the	I-CPA
URS	I-CPA
.	O

The	O
mutants	B-Var
also	O
displayed	O
reduced	B-NegReg
cell	B-CPA
proliferation	I-CPA
in	I-CPA
the	I-CPA
URS	I-CPA
mesenchyme	I-CPA
.	O

In	O
addition	O
,	O
the	O
β	B-Protein
-	I-Protein
catenin	I-Protein
GOF	O
mutants	B-Var
displayed	O
reduced	O
apoptosis	O
and	O
subsequently	O
increased	O
apoptosis	O
in	O
the	O
URS	O
epithelium	O
.	O

This	O
instability	O
possibly	O
resulted	O
in	O
reduced	B-NegReg
expression	B-MPA
levels	I-MPA
of	O
differentiation	O
markers	O
,	O
such	O
as	O
keratin	B-Protein
1	I-Protein
and	O
filaggrin	B-Protein
,	O
in	O
the	O
perineal	O
epithelia	O
.	O

The	O
expression	B-MPA
of	O
bone	B-Gene
morphogenetic	I-Gene
protein	I-Gene
(	I-Gene
Bmp	I-Gene
)	I-Gene
genes	I-Gene
,	O
such	O
as	O
Bmp4	B-Gene
and	O
Bmp7	B-Gene
,	O
was	O
also	O
ectopically	O
induced	B-PosReg
in	O
the	O
epithelia	O
of	O
the	O
URS	O
in	O
the	O
β	B-Protein
-	I-Protein
catenin	I-Protein
GOF	O
mutants	B-Var
.	O

The	O
expression	B-MPA
of	O
the	O
Msx2	B-Gene
gene	I-Gene
and	O
phosphorylated	O
-	O
Smad1/5/8	O
,	O
possible	O
readouts	B-MPA
of	I-MPA
Bmp	I-MPA
signaling	I-MPA
,	O
was	O
also	O
increased	B-PosReg
in	O
the	O
mutants	B-Var
.	O

Moreover	O
,	O
we	O
introduced	O
an	O
additional	O
mutation	O
for	O
a	O
Bmp	O
receptor	O
gene	O
:	O
BmprIA	O
.	O

The	O
Shh(CreERT2/+	O
)	O
;	O
β	O
-	O
catenin(flox(ex3)/+	O
)	O
;	O
BmprIA(flox/-	O
)	O
mutants	O
displayed	O
partial	O
restoration	O
of	O
URS	O
elongation	O
compared	O
with	O
the	O
β	O
-	O
catenin	O
GOF	O
mutants	O
.	O

These	O
results	O
indicate	O
that	O
some	O
ARM	B-Disease
phenotypes	O
in	O
the	O
β	B-Protein
-	I-Protein
catenin	I-Protein
GOF	B-PosReg
mutants	B-Var
were	O
caused	B-Reg
by	I-Reg
abnormal	O
Bmp	B-MPA
signaling	I-MPA
.	O

The	O
current	O
analysis	O
revealed	O
the	O
close	O
relation	O
of	O
endodermal	O
β	O
-	O
catenin	O
signaling	O
to	O
the	O
ARM	O
phenotypes	O
.	O

These	O
results	O
are	O
considered	O
to	O
shed	O
light	O
on	O
the	O
pathogenic	O
mechanisms	O
of	O
human	O
ARMs	O
.	O

Dysregulation	O
of	O
Wnt	O
inhibitory	O
factor	O
1	O
(	O
Wif1	O
)	O
expression	O
resulted	O
in	O
aberrant	O
Wnt	O
-	O
β	O
-	O
catenin	O
signaling	O
and	O
cell	O
death	O
of	O
the	O
cloaca	O
endoderm	O
,	O
and	O
anorectal	O
malformations	O
.	O

In	O
mammalian	O
urorectal	O
development	O
,	O
the	O
urorectal	O
septum	O
(	O
urs	O
)	O
descends	O
from	O
the	O
ventral	O
body	O
wall	O
to	O
the	O
cloaca	O
membrane	O
(	O
cm	O
)	O
to	O
partition	O
the	O
cloaca	O
into	O
urogenital	O
sinus	O
and	O
rectum	O
.	O

Defective	O
urs	O
growth	O
results	O
in	O
human	O
congenital	O
anorectal	O
malformations	O
(	O
ARMs	O
)	O
,	O
and	O
their	O
pathogenic	O
mechanisms	O
are	O
unclear	O
.	O

Recent	O
studies	O
only	O
focused	O
on	O
the	O
importance	O
of	O
urs	O
mesenchyme	O
proliferation	O
,	O
which	O
is	O
induced	O
by	O
endoderm	O
-	O
derived	O
Sonic	O
Hedgehog	O
(	O
Shh	O
)	O
.	O

Here	O
,	O
we	O
showed	O
that	O
the	O
programmed	O
cell	O
death	O
of	O
the	O
apical	O
urs	O
and	O
proximal	O
cm	O
endoderm	O
is	O
particularly	O
crucial	O
for	O
the	O
growth	O
of	O
urs	O
during	O
septation	O
.	O

The	O
apoptotic	O
endoderm	O
was	O
closely	O
associated	O
with	O
the	O
tempo	O
-	O
spatial	O
expression	O
of	O
Wnt	O
inhibitory	O
factor	O
1	O
(	O
Wif1	O
)	O
,	O
which	O
is	O
an	O
inhibitor	O
of	O
Wnt	O
-	O
β	O
-	O
catenin	O
signaling	O
.	O

In	O
Wif1(lacZ	O
/	O
lacZ	O
)	O
mutant	O
mice	O
and	O
cultured	O
urorectum	O
with	O
exogenous	O
Wif1	O
,	O
cloaca	O
septation	O
was	O
defective	O
with	O
undescended	O
urs	O
and	O
hypospadias	O
-	O
like	O
phenotypes	O
,	O
and	O
such	O
septation	O
defects	O
were	O
also	O
observed	O
in	O
Shh(-/-	O
)	O
mutants	O
and	O
in	O
endodermal	O
β	O
-	O
catenin	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
mutants	O
.	O

In	O
addition	O
,	O
Wif1	O
and	O
Shh	O
were	O
expressed	O
in	O
a	O
complementary	O
manner	O
in	O
the	O
cloaca	O
endoderm	O
,	O
and	O
Wif1	O
was	O
ectopically	O
expressed	O
in	O
the	O
urs	O
and	O
cm	O
associated	O
with	O
excessive	O
endodermal	O
apoptosis	O
and	O
septation	O
defects	O
in	O
Shh(-/-	O
)	O
mutants	O
.	O

Furthermore	O
,	O
apoptotic	B-CPA
cells	I-CPA
were	O
markedly	O
reduced	B-NegReg
in	O
the	O
endodermal	B-Protein
β	I-Protein
-	I-Protein
catenin	I-Protein
GOF	B-PosReg
mutant	B-Var
embryos	O
,	O
which	O
counteracted	O
the	O
inhibitory	O
effects	O
of	O
Wif1	O
.	O

Taken	O
altogether	O
,	O
these	O
data	O
suggest	O
that	O
regulated	O
expression	O
of	O
Wif1	O
is	O
critical	O
for	O
the	O
growth	O
of	O
the	O
urs	O
during	O
cloaca	O
septation	O
.	O

Hence	O
,	O
Wif1	O
governs	O
cell	O
apoptosis	O
of	O
urs	O
endoderm	O
by	O
repressing	O
β	O
-	O
catenin	O
signal	O
,	O
which	O
may	O
facilitate	O
the	O
protrusion	O
of	O
the	O
underlying	O
proliferating	O
mesenchymal	O
cells	O
towards	O
the	O
cm	O
for	O
cloaca	O
septation	O
.	O

Dysregulation	O
of	O
this	O
endodermal	O
Shh	O
-	O
Wif1-β	O
-	O
catenin	O
signaling	O
axis	O
contributes	O
to	O
ARM	O
pathogenesis	O
.	O

Novel	O
homozygous	O
PANK2	B-Gene
mutation	B-Var
causing	B-Reg
atypical	O
pantothenate	B-Disease
kinase	I-Disease
-	I-Disease
associated	I-Disease
neurodegeneration	I-Disease
(	O
PKAN	O
)	O
in	O
a	O
Cypriot	O
family	O
.	O

Pantothenate	B-Disease
kinase	I-Disease
-	I-Disease
associated	I-Disease
neurodegeneration	I-Disease
(	O
PKAN	O
)	O
is	O
the	O
commonest	O
,	O
recessively	O
inherited	O
form	O
of	O
neurodegeneration	O
with	O
brain	O
iron	O
accumulation	O
(	O
NBIA	O
)	O
resulting	B-Reg
from	I-Reg
mutations	B-Var
in	O
the	O
pantothenate	O
kinase	O
2	O
(	B-Gene
PANK2	I-Gene
)	I-Gene
gene	O
on	O
chromosome	O
20	O
.	O

PKAN	O
is	O
usually	O
rapidly	O
progressive	O
,	O
presenting	O
in	O
the	O
vast	O
majority	O
in	O
the	O
first	O
decade	O
of	O
life	O
(	O
classic	O
form	O
)	O
.	O

A	O
rarer	O
,	O
later	O
onset	O
and	O
slowly	O
progressive	O
(	O
atypical	O
)	O
PKAN	O
form	O
also	O
exists	O
.	O

We	O
present	O
two	O
siblings	O
of	O
Cypriot	O
descent	O
,	O
a	O
27-year	O
-	O
old	O
man	O
and	O
his	O
clinically	O
asymptomatic	O
younger	O
sister	O
,	O
both	O
of	O
whom	O
were	O
found	O
to	O
be	O
homozygous	O
for	O
a	O
novel	O
c.695A	O
>	O
G	O
(	O
p	O
.	O
Asp232Gly	O
)	O
missense	O
mutation	O
in	O
exon	O
2	O
of	O
the	O
PANK2	O
gene	O
.	O

The	O
index	O
patient	O
presented	O
with	O
a	O
5-year	O
history	O
of	O
slowly	O
progressive	O
gait	O
disturbance	O
,	O
dysarthria	O
,	O
mild	O
axial	O
rigidity	O
and	O
bradykinesia	O
.	O

His	O
brain	O
MRI	O
scan	O
revealed	O
the	O
characteristic	O
"	O
eye	O
-	O
of	O
-	O
the	O
-	O
tiger	O
"	O
sign	O
.	O

Atypical	O
genetically	O
confirmed	O
PKAN	O
cases	O
are	O
sparsely	O
reported	O
and	O
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
of	O
patients	O
presenting	O
with	O
a	O
progressive	O
extrapyramidal	O
syndrome	O
particularly	O
if	O
the	O
radiographic	O
findings	O
are	O
suggestive	O
of	O
iron	O
accumulation	O
.	O

Effective	O
treatment	O
strategies	O
for	O
PKAN	O
are	O
not	O
currently	O
available	O
and	O
symptomatic	O
therapy	O
is	O
often	O
unsatisfactory	O
.	O

However	O
,	O
early	O
diagnosis	O
including	O
the	O
presymptomatic	O
stage	O
is	O
important	O
for	O
genetic	O
counseling	O
and	O
will	O
be	O
crucial	O
for	O
testing	O
novel	O
therapeutics	O
in	O
the	O
future	O
.	O

A	O
novel	O
SUCLA2	B-Gene
mutation	B-Var
in	O
a	O
Portuguese	O
child	O
associated	O
with	B-Reg
"	O
mild	O
"	O
methylmalonic	B-Disease
aciduria	I-Disease
.	O

Succinyl	O
-	O
coenzyme	O
A	O
synthase	O
is	O
a	O
mitochondrial	O
matrix	O
enzyme	O
that	O
catalyzes	O
the	O
reversible	O
synthesis	O
of	O
succinate	O
and	O
adenosine	O
triphosphate	O
(	O
ATP	O
)	O
from	O
succinyl	O
-	O
coenzyme	O
A	O
and	O
adenosine	O
diphosphate	O
(	O
ADP	O
)	O
in	O
the	O
tricarboxylic	O
acid	O
cycle	O
.	O

This	O
enzyme	O
is	O
made	O
up	O
of	O
α	O
and	O
β	O
subunits	O
encoded	O
by	O
SUCLG1	O
and	O
SUCLA2	O
,	O
respectively	O
.	O

We	O
present	O
a	O
child	O
with	O
severe	O
muscular	O
hypotonia	O
,	O
dystonia	O
,	O
failure	O
to	O
thrive	O
,	O
sensorineural	O
deafness	O
,	O
and	O
dysmorphism	O
.	O

Metabolic	O
investigations	O
disclosed	O
hyperlactacidemia	O
,	O
moderate	O
urinary	O
excretion	O
of	O
methylmalonic	O
acid	O
,	O
and	O
elevated	O
levels	O
of	O
C4-dicarboxylic	O
carnitine	O
in	O
blood	O
.	O

We	O
identified	O
a	O
novel	O
homozygous	O
p	O
.	O
M329V	O
in	O
SUCLA2	B-Gene
.	O

In	O
cultured	O
cells	O
,	O
the	O
p	B-Var
.	I-Var
M329V	I-Var
resulted	O
in	O
a	O
reduced	B-NegReg
amount	B-MPA
of	O
the	O
SUCLA2	B-Gene
protein	B-Protein
,	O
impaired	B-NegReg
production	B-CPA
of	I-CPA
mitochondrial	I-CPA
ATP	I-CPA
,	O
and	O
enhanced	B-PosReg
production	B-CPA
of	I-CPA
reactive	I-CPA
oxygen	I-CPA
species	I-CPA
,	O
which	O
was	O
partially	O
reduced	O
by	O
using	O
5-aminoimidazole-4-carboxamide	O
ribonucleotide	O
in	O
the	O
culture	O
medium	O
.	O

Expanding	O
the	O
array	O
of	O
SUCLA2	O
mutations	O
,	O
we	O
suggested	O
that	O
reactive	O
oxygen	O
species	O
scavengers	O
are	O
likely	O
to	O
impact	O
on	O
disease	O
prognosis	O
.	O

Molecular	O
profiling	O
of	O
complete	O
congenital	O
stationary	O
night	O
blindness	O
:	O
a	O
pilot	O
study	O
on	O
an	O
Indian	O
cohort	O
.	O

PURPOSE	O
:	O
Congenital	B-Disease
stationary	I-Disease
night	I-Disease
blindness	I-Disease
(	O
CSNB	O
)	O
is	O
a	O
non	O
-	O
progressive	O
retinal	O
disorder	O
that	O
shows	O
genetic	O
and	O
clinical	O
heterogeneity	O
.	O

CSNB	O
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
,	O
autosomal	O
dominant	O
,	O
or	O
X	O
-	O
linked	O
recessive	O
trait	O
and	O
shows	O
a	O
good	O
genotype	O
-	O
phenotype	O
correlation	O
.	O

Clinically	O
,	O
CSNB	O
is	O
classified	O
as	O
the	O
Riggs	O
type	O
and	O
the	O
Schubert	O
-	O
Bornschein	O
type	O
.	O

The	O
latter	O
form	O
is	O
further	O
sub	O
-	O
classified	O
into	O
complete	O
and	O
incomplete	O
forms	O
based	O
on	O
specific	O
waveforms	O
on	O
the	O
electroretinogram	O
(	O
ERG	O
)	O
.	O

There	O
are	O
no	O
molecular	O
genetic	O
data	O
for	O
CSNB	O
in	O
the	O
Indian	O
population	O
.	O

Therefore	O
,	O
we	O
present	O
for	O
the	O
first	O
time	O
molecular	O
profiling	O
of	O
eight	O
families	O
with	O
complete	O
CSNB	O
(	O
cCSNB	O
)	O
.	O

METHODS	O
:	O
The	O
index	O
patients	O
and	O
their	O
other	O
affected	O
family	O
members	O
were	O
comprehensively	O
evaluated	O
for	O
the	O
phenotype	O
,	O
including	O
complete	O
ophthalmic	O
evaluation	O
,	O
ERG	O
,	O
fundus	O
autofluorescence	O
,	O
optical	O
coherence	O
tomography	O
,	O
and	O
color	O
vision	O
test	O
.	O

The	O
known	O
gene	O
defects	O
for	O
cCSNB	O
,	O
LRIT3	O
,	O
TRPM1	O
,	O
GRM6	O
,	O
GPR179	O
,	O
and	O
NYX	O
,	O
were	O
screened	O
by	O
PCR	O
direct	O
sequencing	O
.	O

Bioinformatic	O
analyses	O
were	O
performed	O
using	O
SIFT	O
and	O
PolyPhen	O
for	O
the	O
identified	O
missense	O
mutations	O
.	O

RESULTS	O
:	O
All	O
eight	O
affected	O
index	O
patients	O
and	O
affected	O
family	O
members	O
were	O
identified	O
as	O
having	B-Reg
cCSNB	B-Disease
based	O
on	O
their	O
ERG	O
waveforms	O
.	O

Mutations	B-Var
in	O
the	O
TRPM1	B-Gene
gene	O
were	O
identified	O
in	O
six	O
index	O
patients	O
.	O

The	O
two	O
remaining	O
index	O
patients	O
each	O
carried	O
a	O
GPR179	B-Gene
and	O
GRM6	B-Gene
mutation	B-Var
.	O

Seven	O
of	O
the	O
patients	O
revealed	O
homozygous	O
mutations	O
,	O
while	O
one	O
patient	O
showed	O
a	O
compound	O
heterozygous	O
mutation	O
.	O

Six	O
of	O
the	O
eight	O
mutations	O
identified	O
are	O
novel	O
.	O

CONCLUSIONS	O
:	O
This	O
is	O
the	O
first	O
report	O
on	O
molecular	O
profiling	O
of	O
candidate	O
genes	O
in	O
CSNB	O
in	O
an	O
Indian	O
cohort	O
.	O

As	O
shown	O
for	O
other	O
cohorts	O
,	O
TRPM1	B-Gene
seems	O
to	O
be	O
a	O
major	O
gene	O
defect	B-Var
in	O
patients	O
with	B-Reg
cCSNB	B-Disease
in	O
India	O
.	O

Significance	O
of	O
the	O
melanocortin	O
1	O
receptor	O
in	O
the	O
DNA	O
damage	O
response	O
of	O
human	O
melanocytes	O
to	O
ultraviolet	O
radiation	O
.	O

Activation	O
of	O
the	O
melanocortin	O
1	O
receptor	O
(	O
MC1R	O
)	O
by	O
α	O
-	O
melanocortin	O
(	O
α	O
-	O
MSH	O
)	O
stimulates	O
eumelanin	O
synthesis	O
and	O
enhances	O
repair	O
of	O
ultraviolet	O
radiation	O
(	O
UV)-induced	O
DNA	O
damage	O
.	O

We	O
report	O
on	O
the	O
DNA	O
damage	O
response	O
(	O
DDR	O
)	O
of	O
human	O
melanocytes	O
to	O
UV	O
and	O
its	O
enhancement	O
by	O
α	O
-	O
MSH	O
.	O

α	O
-	O
MSH	O
up	O
-	O
regulated	O
the	O
levels	O
of	O
XPC	O
,	O
the	O
enzyme	O
that	O
recognizes	O
DNA	O
damage	O
sites	O
,	O
enhanced	O
the	O
UV	O
-	O
induced	O
phosphorylation	O
of	O
the	O
DNA	O
damage	O
sensors	O
ataxia	O
telangiectasia	O
and	O
Rad3-related	O
(	O
ATR	O
)	O
and	O
ataxia	O
telangiectasia	O
mutated	O
(	O
ATM	O
)	O
and	O
their	O
respect	O
-	O
ive	O
substrates	O
checkpoint	O
kinases	O
1	O
and	O
2	O
,	O
and	O
increased	O
phosphorylated	O
H2AX	O
(	O
γH2AX	O
)	O
formation	O
.	O

These	O
effects	O
required	O
functional	O
MC1R	O
and	O
were	O
absent	O
in	O
melanocytes	O
expressing	O
loss	O
of	O
function	O
(	O
LOF	O
)	O
MC1R.	O
The	O
levels	O
of	O
wild	O
-	O
type	O
p53-induced	O
phosphatase	O
1	O
(	O
Wip1	O
)	O
,	O
which	O
dephosphorylates	O
γH2AX	O
,	O
correlated	O
inversely	O
with	O
γH2AX	O
.	O

We	O
propose	O
that	O
α	O
-	O
MSH	O
increases	O
UV	O
-	O
induced	O
γH2AX	O
to	O
facilitate	O
formation	O
of	O
DNA	O
repair	O
complexes	O
and	O
repair	O
of	O
DNA	O
photoproducts	O
,	O
and	O
LOF	B-Var
of	O
MC1R	B-Protein
compromises	B-NegReg
the	O
DDR	B-MPA
and	O
genomic	B-CPA
stability	I-CPA
of	I-CPA
melanocytes	I-CPA
.	O

UBQLN2	B-Gene
mutation	B-Var
causing	B-Reg
heterogeneous	B-Disease
X	I-Disease
-	I-Disease
linked	I-Disease
dominant	I-Disease
neurodegeneration	I-Disease
.	O

We	O
report	O
a	O
5-generation	O
family	O
with	O
phenotypically	O
diverse	O
neurodegenerative	O
disease	O
including	O
relentlessly	O
progressive	O
choreoathetoid	O
movements	O
,	O
dysarthria	O
,	O
dysphagia	O
,	O
spastic	O
paralysis	O
,	O
and	O
behavioral	O
dementia	O
in	O
descendants	O
of	O
a	O
67-year	O
-	O
old	O
woman	O
with	O
amyotrophic	O
lateral	O
sclerosis	O
.	O

Disease	O
onset	O
varied	O
with	O
gender	O
,	O
occurring	O
in	O
male	O
children	O
and	O
adult	O
women	O
.	O

Exome	O
sequence	O
analyses	O
revealed	O
a	O
novel	O
mutation	O
(	O
c.1490C	O
>	O
T	O
,	O
p	O
.	O
P497L	O
)	O
in	O
the	O
ubiquilin-2	O
gene	O
(	O
UBQLN2	O
)	O
with	O
X	O
-	O
linked	O
inheritance	O
in	O
all	O
studied	O
affected	O
individuals	O
.	O

As	O
ubiquilin-2-positive	O
inclusions	O
were	O
identified	O
in	O
brain	O
,	O
we	O
suggest	O
that	O
mutant	B-Var
peptide	O
predisposes	B-Reg
to	I-Reg
protein	B-Protein
misfolding	B-MPA
and	O
accumulation	B-PosReg
.	O

Our	O
findings	O
expand	O
the	O
spectrum	O
of	O
neurodegenerative	O
phenotypes	O
caused	O
by	O
UBQLN2	O
mutations	O
.	O

Splicing	B-Var
mutation	I-Var
in	O
MVK	B-Gene
is	O
a	O
cause	B-Reg
of	O
porokeratosis	B-Disease
of	I-Disease
Mibelli	I-Disease
.	O

Porokeratosis	O
is	O
a	O
chronic	O
skin	O
disorder	O
characterized	O
by	O
the	O
presence	O
of	O
patches	O
with	O
elevated	O
,	O
thick	O
,	O
keratotic	O
borders	O
,	O
with	O
histological	O
cornoid	O
lamella	O
.	O

Classic	O
porokeratosis	O
of	O
Mibelli	O
(	O
PM	O
)	O
frequently	O
appears	O
in	O
childhood	O
with	O
a	O
risk	O
of	O
malignant	O
transformation	O
.	O

Disseminated	O
superficial	O
actinic	O
porokeratosis	O
(	O
DSAP	O
)	O
is	O
the	O
most	O
common	O
subtype	O
of	O
porokeratosis	O
with	O
genetic	O
heterogeneities	O
,	O
and	O
mevalonate	O
kinase	O
gene	O
(	O
MVK	O
)	O
mutations	O
have	O
been	O
identified	O
in	O
minor	O
portion	O
of	O
DSAP	O
families	O
of	O
Chinese	O
origin	O
.	O

To	O
confirm	O
the	O
previous	O
findings	O
about	O
MVK	O
mutations	O
in	O
DSAP	O
patients	O
and	O
test	O
MVK	O
's	O
role(s	O
)	O
in	O
PM	O
development	O
,	O
we	O
performed	O
genomic	O
sequence	O
analysis	O
for	O
3	O
DSAP	O
families	O
and	O
1	O
PM	O
family	O
of	O
Chinese	O
origin	O
.	O

We	O
identified	O
a	O
splicing	O
mutation	O
of	O
MVK	O
gene	O
,	O
designated	O
as	O
c.1039	O
+	O
1G	O
>	O
A	O
,	O
in	O
the	O
PM	O
family	O
.	O

No	O
MVK	O
mutations	O
were	O
found	O
in	O
three	O
DSAP	O
families	O
.	O

Sequence	O
analysis	O
for	O
complementary	O
DNA	O
templates	O
from	O
PM	O
lesions	O
of	O
all	O
patients	O
revealed	O
a	O
mutation	O
at	O
splice	O
donor	O
site	O
of	O
intron	O
10	O
,	O
designated	O
as	O
c.1039	B-Var
+	I-Var
1G	I-Var
>	I-Var
A	I-Var
,	O
leading	B-Reg
to	I-Reg
the	O
splicing	B-MPA
defect	I-MPA
and	O
termination	B-MPA
codon	I-MPA
52	O
amino	O
acids	O
after	O
exon	O
10	O
.	O

Although	O
no	O
MVK	O
mutations	O
in	O
DSAP	O
patients	O
were	O
found	O
as	O
reported	O
previously	O
,	O
we	O
identified	O
MVK	O
simultaneously	O
responsible	O
for	O
PM	O
development	O
.	O

Assessing	O
the	O
functional	O
consequence	O
of	O
loss	O
of	O
function	O
variants	O
using	O
electronic	O
medical	O
record	O
and	O
large	O
-	O
scale	O
genomics	O
consortium	O
efforts	O
.	O

Estimates	O
from	O
large	O
scale	O
genome	O
sequencing	O
studies	O
indicate	O
that	O
each	O
human	O
carries	O
up	O
to	O
20	O
genetic	O
variants	O
that	O
are	O
predicted	O
to	O
results	O
in	O
loss	O
of	O
function	O
(	O
LOF	O
)	O
of	O
protein	O
-	O
coding	O
genes	O
.	O

While	O
some	O
are	O
known	O
disease	O
-	O
causing	O
variants	O
or	O
common	O
,	O
tolerated	O
,	O
LOFs	O
in	O
non	O
-	O
essential	O
genes	O
,	O
the	O
majority	O
remain	O
of	O
unknown	O
consequence	O
.	O

We	O
explore	O
the	O
possibility	O
of	O
using	O
imputed	O
GWAS	O
data	O
from	O
large	O
biorepositories	O
such	O
as	O
the	O
electronic	O
medical	O
record	O
and	O
genomics	O
(	O
eMERGE	O
)	O
consortium	O
to	O
determine	O
the	O
effects	O
of	O
rare	O
LOFs	O
.	O

Here	O
,	O
we	O
show	O
that	O
two	O
hypocholesterolemia	B-Disease
-	I-Disease
associated	I-Disease
LOF	B-NegReg
mutations	B-Var
in	O
the	O
PCSK9	B-Gene
gene	O
can	O
be	O
accurately	O
imputed	O
into	O
large	O
-	O
scale	O
GWAS	O
datasets	O
which	O
raises	O
the	O
possibility	O
of	O
assessing	O
LOFs	O
through	O
genomics	O
-	O
linked	O
medical	O
records	O
.	O

Whole	O
exome	O
sequencing	O
reveals	O
concomitant	O
mutations	B-Var
of	O
multiple	O
FA	B-Gene
genes	O
in	B-Reg
individual	O
Fanconi	B-Disease
anemia	I-Disease
patients	O
.	O

BACKGROUND	O
:	O
Fanconi	O
anemia	O
(	O
FA	O
)	O
is	O
a	O
rare	O
inherited	O
genetic	O
syndrome	O
with	O
highly	O
variable	O
clinical	O
manifestations	O
.	O

Fifteen	O
genetic	O
subtypes	O
of	O
FA	O
have	O
been	O
identified	O
.	O

Traditional	O
complementation	O
tests	O
for	O
grouping	O
studies	O
have	O
been	O
used	O
generally	O
in	O
FA	O
patients	O
and	O
in	O
stepwise	O
methods	O
to	O
identify	O
the	O
FA	O
type	O
,	O
which	O
can	O
result	O
in	O
incomplete	O
genetic	O
information	O
from	O
FA	O
patients	O
.	O

METHODS	O
:	O
We	O
diagnosed	O
five	O
pediatric	O
patients	O
with	O
FA	O
based	O
on	O
clinical	O
manifestations	O
,	O
and	O
we	O
performed	O
exome	O
sequencing	O
of	O
peripheral	O
blood	O
specimens	O
from	O
these	O
patients	O
and	O
their	O
family	O
members	O
.	O

The	O
related	O
sequencing	O
data	O
were	O
then	O
analyzed	O
by	O
bioinformatics	O
,	O
and	O
the	O
FANC	O
gene	O
mutations	O
identified	O
by	O
exome	O
sequencing	O
were	O
confirmed	O
by	O
PCR	O
re	O
-	O
sequencing	O
.	O

RESULTS	O
:	O
Homozygous	O
and	O
compound	O
heterozygous	O
mutations	O
of	O
FANC	O
genes	O
were	O
identified	O
in	O
all	O
of	O
the	O
patients	O
.	O

The	O
FA	O
subtypes	O
of	O
the	O
patients	O
included	O
FANCA	O
,	O
FANCM	O
and	O
FANCD2	O
.	O

Interestingly	O
,	O
four	O
FA	O
patients	O
harbored	O
multiple	O
mutations	O
in	O
at	O
least	O
two	O
FA	O
genes	O
,	O
and	O
some	O
of	O
these	O
mutations	O
have	O
not	O
been	O
previously	O
reported	O
.	O

These	O
patients	O
'	O
clinical	O
manifestations	O
were	O
vastly	O
different	O
from	O
each	O
other	O
,	O
as	O
were	O
their	O
treatment	O
responses	O
to	O
androstanazol	O
and	O
prednisone	O
.	O

This	O
finding	O
suggests	O
that	O
heterozygous	O
mutation(s	O
)	O
in	O
FA	O
genes	O
could	O
also	O
have	O
diverse	O
biological	O
and/or	O
pathophysiological	O
effects	O
on	O
FA	O
patients	O
or	O
FA	O
gene	O
carriers	O
.	O

Interestingly	O
,	O
we	O
were	O
not	O
able	O
to	O
identify	O
de	O
novo	O
mutations	O
in	O
the	O
genes	O
implicated	O
in	O
DNA	O
repair	O
pathways	O
when	O
the	O
sequencing	O
data	O
of	O
patients	O
were	O
compared	O
with	O
those	O
of	O
their	O
parents	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
indicate	O
that	O
Chinese	O
FA	O
patients	O
and	O
carriers	O
might	O
have	O
higher	O
and	O
more	O
complex	O
mutation	O
rates	O
in	O
FANC	O
genes	O
than	O
have	O
been	O
conventionally	O
recognized	O
.	O

Testing	O
of	O
the	O
fifteen	O
FANC	O
genes	O
in	O
FA	O
patients	O
and	O
their	O
family	O
members	O
should	O
be	O
a	O
regular	O
clinical	O
practice	O
to	O
determine	O
the	O
optimal	O
care	O
for	O
the	O
individual	O
patient	O
,	O
to	O
counsel	O
the	O
family	O
and	O
to	O
obtain	O
a	O
better	O
understanding	O
of	O
FA	O
pathophysiology	O
.	O

Mutations	B-Var
in	O
SMARCAD1	B-Gene
cause	B-Reg
autosomal	B-Disease
dominant	I-Disease
adermatoglyphia	I-Disease
and	O
perturb	B-Reg
the	O
expression	B-MPA
of	O
epidermal	O
differentiation	O
-	O
associated	O
genes	O
.	O

BACKGROUND	O
:	O
Autosomal	O
dominant	O
adermatoglyphia	O
(	O
ADG	O
)	O
is	O
characterized	O
by	O
lack	O
of	O
palmoplantar	O
epidermal	O
ridges	O
.	O

Recently	O
,	O
ADG	O
was	O
found	O
to	O
be	O
caused	O
in	O
one	O
family	O
by	O
a	O
mutation	O
in	O
SMARCAD1	O
,	O
a	O
member	O
of	O
the	O
SNF	O
subfamily	O
of	O
the	O
helicase	O
protein	O
superfamily	O
.	O

OBJECTIVES	O
:	O
To	O
investigate	O
the	O
genetic	O
basis	O
of	O
ADG	O
.	O

METHODS	O
:	O
We	O
used	O
direct	O
sequencing	O
and	O
global	O
gene	O
expression	O
analysis	O
.	O

RESULTS	O
:	O
We	O
identified	O
three	O
novel	O
heterozygous	O
mutations	O
in	O
SMARCAD1	O
(	O
c.378	O
+	O
2	O
T	O
>	O
C	O
,	O
c.378	O
+	O
5	O
G	O
>	O
C	O
and	O
c.378	O
+	O
1	O
G	O
>	O
A	O
)	O
in	O
a	O
total	O
of	O
six	O
patients	O
.	O

Surprisingly	O
,	O
all	O
four	O
ADG	O
-	O
causing	O
mutations	B-Var
identified	O
to	O
date	O
disrupt	B-NegReg
a	O
single	B-MPA
conserved	I-MPA
donor	I-MPA
splice	I-MPA
site	I-MPA
adjacent	O
to	O
the	O
3	O
'	O
end	O
of	O
a	O
noncoding	O
exon	O
and	O
are	O
predicted	O
to	O
result	O
in	O
haploinsufficiency	B-NegReg
for	O
a	O
skin	B-MPA
-	I-MPA
specific	I-MPA
isoform	I-MPA
of	O
SMARCAD1	B-Gene
.	O

These	O
data	O
indicate	O
a	O
pivotal	O
role	O
for	O
the	O
SMARCAD1-skin	O
specific	O
isoform	O
in	O
dermatoglyph	O
formation	O
.	O

In	O
order	O
to	O
better	O
understand	O
the	O
consequences	O
of	O
ADG	O
-	O
associated	O
mutations	O
,	O
we	O
ascertained	O
the	O
global	O
transcription	O
profiles	O
of	O
primary	O
keratinocytes	O
downregulated	O
for	O
SMARCAD1	O
and	O
of	O
patient	O
-	O
derived	O
keratinocytes	O
.	O

A	O
total	O
of	O
eight	O
genes	O
were	O
found	O
to	O
be	O
differentially	O
expressed	O
in	O
both	O
patient	O
-	O
derived	O
and	O
knocked	O
down	O
keratinocytes	O
.	O

Of	O
interest	O
,	O
these	O
differentially	O
expressed	O
genes	O
have	O
been	O
implicated	O
in	O
epidermal	O
ontogenesis	O
and	O
differentiation	O
,	O
and	O
in	O
psoriasis	O
,	O
which	O
is	O
characterized	O
by	O
abnormal	O
finger	O
ridge	O
patterns	O
.	O

CONCLUSIONS	O
:	O
The	O
present	O
data	O
suggest	O
that	O
ADG	O
is	O
genetically	O
homogeneous	O
and	O
result	O
from	O
perturbed	O
expression	O
of	O
epidermal	O
differentiation	O
-	O
associated	O
genes	O
.	O

PDGF	O
,	O
pericytes	O
and	O
the	O
pathogenesis	O
of	O
idiopathic	O
basal	O
ganglia	O
calcification	O
(	O
IBGC	O
)	O
.	O

Platelet	O
-	O
derived	O
growth	O
factors	O
(	O
PDGFs	O
)	O
are	O
important	O
mitogens	O
for	O
various	O
types	O
of	O
mesenchymal	O
cells	O
,	O
and	O
as	O
such	O
,	O
they	O
exert	O
critical	O
functions	O
during	O
organogenesis	O
in	O
mammalian	O
embryonic	O
and	O
early	O
postnatal	O
development	O
.	O

Increased	O
or	O
ectopic	B-Var
PDGF	B-Protein
activity	B-MPA
may	O
also	O
cause	B-Reg
or	O
contribute	B-Reg
to	O
diseases	O
such	O
as	O
cancer	B-Disease
and	O
tissue	B-Disease
fibrosis	I-Disease
.	O

Until	O
recently	O
,	O
no	O
loss	O
-	O
of	O
-	O
function	O
(	O
LOF	O
)	O
mutations	O
in	O
PDGF	O
or	O
PDGF	O
receptor	O
genes	O
were	O
reported	O
as	O
causally	O
linked	O
to	O
a	O
human	O
disease	O
.	O

This	O
changed	O
in	O
2013	O
when	O
reports	O
appeared	O
on	O
presumed	O
LOF	B-NegReg
mutations	B-Var
in	O
the	O
genes	O
encoding	O
PDGF	B-Gene
-	I-Gene
B	I-Gene
and	O
its	O
receptor	O
PDGF	O
receptor	O
-	O
beta	O
(	B-Gene
PDGF	I-Gene
-	I-Gene
Rβ	I-Gene
)	I-Gene
in	O
familial	B-Disease
idiopathic	I-Disease
basal	I-Disease
ganglia	I-Disease
calcification	I-Disease
(	O
IBGC	O
)	O
,	O
a	O
brain	O
disease	O
characterized	O
by	O
anatomically	O
localized	O
calcifications	O
in	O
or	O
near	O
the	O
blood	O
microvessels	O
.	O

Here	O
,	O
we	O
review	O
PDGF	O
-	O
B	O
and	O
PDGF	O
-	O
Rβ	O
biology	O
with	O
special	O
reference	O
to	O
their	O
functions	O
in	O
brain	O
-	O
blood	O
vessel	O
development	O
,	O
pericyte	O
recruitment	O
and	O
the	O
regulation	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O

We	O
also	O
discuss	O
various	O
scenarios	O
for	O
IBGC	O
pathogenesis	O
suggested	O
by	O
observations	O
in	O
patients	O
and	O
genetically	O
engineered	O
animal	O
models	O
of	O
the	O
disease	O
.	O

Mutant	B-Var
p53	B-Gene
gains	O
new	O
function	O
in	O
promoting	B-PosReg
inflammatory	B-MPA
signals	I-MPA
by	O
repression	B-NegReg
of	O
the	O
secreted	O
interleukin-1	O
receptor	O
antagonist	O
.	O

The	O
TP53	B-Gene
tumor	I-Gene
-	I-Gene
suppressor	I-Gene
gene	I-Gene
is	O
frequently	O
mutated	O
in	O
human	O
cancer	O
.	O

Missense	B-Var
mutations	I-Var
can	O
add	O
novel	O
functions	O
(	O
gain	O
-	O
of	O
-	O
function	O
,	O
GOF	O
)	O
that	O
promote	B-PosReg
tumor	B-CPA
malignancy	I-CPA
.	O

Here	O
we	O
report	O
that	O
mutant	B-Var
(	O
mut	O
)	O
p53	B-Gene
promotes	B-PosReg
tumor	B-CPA
malignancy	I-CPA
by	O
suppressing	B-NegReg
the	O
expression	B-MPA
of	O
a	O
natural	O
occurring	O
anti	O
-	O
inflammatory	O
cytokine	O
,	O
the	O
secreted	O
interleukin-1	O
receptor	O
antagonist	O
(	O
sIL-1Ra	O
,	O
IL1RN	O
)	O
.	O

We	O
show	O
that	O
mutp53	B-Var
but	O
not	O
wild	O
-	O
type	O
(	O
wt	O
)	O
p53	O
suppresses	B-NegReg
the	O
sIL-1Ra	B-MPA
production	I-MPA
in	O
conditioned	O
media	O
of	O
cancer	O
cells	O
.	O

Moreover	O
,	O
mutp53	O
,	O
but	O
not	O
wtp53	O
,	O
binds	O
physically	O
the	O
sIL-1Ra	O
promoter	O
and	O
the	O
protein	O
-	O
protein	O
interaction	O
with	O
the	O
transcriptional	O
co	O
-	O
repressor	O
MAFF	O
(	O
v	O
-	O
MAF	O
musculoaponeurotic	O
fibrosarcoma	O
oncogene	O
family	O
,	O
protein	O
F	O
)	O
is	O
required	O
for	O
mutp53-induced	O
sIL-1Ra	O
suppression	O
.	O

Remarkably	O
,	O
when	O
exposed	O
to	O
IL-1	O
beta	O
(	O
IL-1β	O
)	O
inflammatory	O
stimuli	O
,	O
mutp53	O
sustains	O
a	O
ready	O
-	O
to	O
-	O
be	O
-	O
activated	O
in	O
vitro	O
and	O
in	O
vivo	O
cancer	O
cells	O
'	O
response	O
through	O
the	O
sIL-1Ra	O
repression	O
.	O

Taken	O
together	O
,	O
these	O
results	O
identify	O
sIL-1Ra	O
as	O
a	O
novel	O
mutp53	O
target	O
gene	O
,	O
whose	O
suppression	O
might	O
be	O
required	O
to	O
generate	O
a	O
chronic	O
pro	O
-	O
inflammatory	O
tumor	O
microenvironment	O
through	O
which	O
mutp53	O
promotes	O
tumor	O
malignancy	O
.	O

Rare	O
variants	O
in	O
PPARG	O
with	O
decreased	O
activity	O
in	O
adipocyte	O
differentiation	O
are	O
associated	O
with	O
increased	O
risk	O
of	O
type	O
2	O
diabetes	O
.	O

Peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
gamma	O
(	O
PPARG	O
)	O
is	O
a	O
master	O
transcriptional	O
regulator	O
of	O
adipocyte	O
differentiation	O
and	O
a	O
canonical	O
target	O
of	O
antidiabetic	O
thiazolidinedione	O
medications	O
.	O

In	O
rare	O
families	O
,	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LOF	O
)	O
mutations	B-Var
in	O
PPARG	B-Gene
are	O
known	O
to	O
cosegregate	O
with	O
lipodystrophy	B-Disease
and	O
insulin	B-Disease
resistance	I-Disease
;	I-Disease
in	O
the	O
general	O
population	O
,	O
the	O
common	O
P12A	B-Var
variant	O
is	O
associated	O
with	O
a	O
decreased	B-NegReg
risk	O
of	O
type	B-Disease
2	I-Disease
diabetes	I-Disease
(	O
T2D	O
)	O
.	O

Whether	O
and	O
how	O
rare	O
variants	O
in	O
PPARG	O
and	O
defects	O
in	O
adipocyte	O
differentiation	O
influence	O
risk	O
of	O
T2D	O
in	O
the	O
general	O
population	O
remains	O
undetermined	O
.	O

By	O
sequencing	O
PPARG	O
in	O
19,752	O
T2D	O
cases	O
and	O
controls	O
drawn	O
from	O
multiple	O
studies	O
and	O
ethnic	O
groups	O
,	O
we	O
identified	O
49	O
previously	O
unidentified	O
,	O
nonsynonymous	O
PPARG	O
variants	O
(	O
MAF	O
<	O
0.5	O
%	O
)	O
.	O

Considered	O
in	O
aggregate	O
(	O
with	O
or	O
without	O
computational	O
prediction	O
of	O
functional	O
consequence	O
)	O
,	O
these	O
rare	O
variants	O
showed	O
no	O
association	O
with	O
T2D	O
(	O
OR	O
=	O
1.35	O
;	O
P	O
=	O
0.17	O
)	O
.	O

The	O
function	O
of	O
the	O
49	O
variants	O
was	O
experimentally	O
tested	O
in	O
a	O
novel	O
high	O
-	O
throughput	O
human	O
adipocyte	O
differentiation	O
assay	O
,	O
and	O
nine	O
were	O
found	O
to	O
have	O
reduced	O
activity	O
in	O
the	O
assay	O
.	O

Carrying	O
any	O
of	O
these	O
nine	O
LOF	O
variants	O
was	O
associated	O
with	O
a	O
substantial	O
increase	O
in	O
risk	O
of	O
T2D	O
(	O
OR	O
=	O
7.22	O
;	O
P	O
=	O
0.005	O
)	O
.	O

The	O
combination	O
of	O
large	O
-	O
scale	O
DNA	O
sequencing	O
and	O
functional	O
testing	O
in	O
the	O
laboratory	O
reveals	O
that	O
approximately	O
1	O
in	O
1,000	O
individuals	O
carries	O
a	O
variant	B-Var
in	O
PPARG	B-Gene
that	O
reduces	B-NegReg
function	B-CPA
in	I-CPA
a	I-CPA
human	I-CPA
adipocyte	I-CPA
differentiation	I-CPA
assay	I-CPA
and	O
is	O
associated	B-Reg
with	O
a	O
substantial	O
risk	O
of	O
T2D.	B-Disease
Genetics	O
and	O
pathophysiology	O
of	O
primary	O
dystonia	O
with	O
special	O
emphasis	O
on	O
DYT1	O
and	O
DYT5	O
.	O

DYT1	O
and	O
DYT5	O
are	O
early	O
-	O
onset	O
dominant	O
inherited	O
dystonias	O
.	O

DYT1	B-Disease
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
of	O
the	O
TOR1A	B-Gene
gene	O
,	O
located	O
on	O
9q34	O
,	O
which	O
causes	O
dysfunction	B-NegReg
of	O
the	O
D1	B-Pathway
direct	I-Pathway
pathway	I-Pathway
or	O
the	O
indirect	B-Pathway
pathway	I-Pathway
.	O

Dysfunction	O
of	O
the	O
former	O
causes	O
postural	B-Disease
-	I-Disease
type	I-Disease
and	I-Disease
segmental	I-Disease
dystonia	I-Disease
;	I-Disease
the	O
latter	O
causes	O
action	B-Disease
-	I-Disease
type	I-Disease
dystonia	I-Disease
.	O

In	O
families	O
with	O
action	O
-	O
type	O
dystonia	O
,	O
there	O
are	O
cases	O
with	O
focal	O
and	O
segmental	O
dystonia	O
.	O

Ages	O
of	O
onset	O
of	O
postural	O
-	O
type	O
dystonia	O
are	O
around	O
6	O
years	O
,	O
and	O
8	O
to	O
10	O
years	O
in	O
cases	O
of	O
action	O
-	O
type	O
dystonia	O
.	O

Focal	O
and	O
segmental	O
dystonia	O
develops	O
in	O
the	O
teens	O
.	O

Mental	O
and	O
psychological	O
functions	O
are	O
preserved	O
.	O

DYT5	B-Disease
is	O
caused	B-Reg
by	I-Reg
heterozygous	O
mutations	B-Var
of	O
the	O
GCH1	B-Gene
gene	O
,	O
located	O
on	O
14q22.1-q22.2	O
.	O

Again	O
,	O
mental	O
and	O
psychological	O
functions	O
are	O
preserved	O
.	O

Clinically	O
,	O
there	O
are	O
two	O
types	O
:	O
postural	O
and	O
action	O
.	O

Postural	O
-	O
type	O
dystonia	O
occurs	O
around	O
6	O
years	O
of	O
age	O
,	O
with	O
postural	O
dystonia	O
of	O
one	O
leg	O
,	O
and	O
all	O
extremities	O
and	O
trunk	O
muscles	O
are	O
involved	O
by	O
the	O
late	O
teens	O
.	O

Action	O
-	O
type	O
dystonia	O
shows	O
dystonic	O
movements	O
from	O
around	O
8	O
to	O
10	O
years	O
of	O
age	O
.	O

In	O
both	O
types	O
,	O
all	O
symptoms	O
show	O
diurnal	O
fluctuations	O
that	O
diminish	O
with	O
age	O
and	O
are	O
no	O
longer	O
apparent	O
in	O
the	O
late	O
teens	O
.	O

L	O
-	O
dopa	O
produces	O
dramatic	O
effects	O
,	O
which	O
continue	O
throughout	O
the	O
course	O
of	O
the	O
illness	O
.	O

In	O
both	O
postural	O
and	O
action	O
types	O
,	O
each	O
family	O
or	O
sporadic	O
case	O
has	O
a	O
particular	O
mutation	O
.	O

It	O
remains	O
unclear	O
why	O
specific	O
mutations	O
cause	O
certain	O
age-	O
and	O
gender	O
-	O
specific	O
symptoms	O
.	O

First	O
report	O
of	O
a	O
deletion	O
encompassing	O
an	O
entire	O
exon	O
in	O
the	O
homogentisate	O
1,2-dioxygenase	O
gene	O
causing	O
alkaptonuria	O
.	O

Alkaptonuria	B-Disease
is	O
often	O
diagnosed	O
clinically	O
with	O
episodes	O
of	O
dark	O
urine	O
,	O
biochemically	O
by	O
the	O
accumulation	O
of	O
peripheral	O
homogentisic	O
acid	O
and	O
molecularly	O
by	B-Reg
the	I-Reg
presence	I-Reg
of	I-Reg
mutations	B-Var
in	O
the	O
homogentisate	O
1,2-dioxygenase	O
gene	O
(	B-Gene
HGD	I-Gene
)	I-Gene
.	O

Alkaptonuria	B-Disease
is	O
invariably	O
associated	B-Reg
with	I-Reg
HGD	B-Gene
mutations	B-Var
,	O
which	O
consist	O
of	O
single	B-Var
nucleotide	I-Var
variants	I-Var
and	O
small	B-Var
insertions	I-Var
/	I-Var
deletions	I-Var
.	O

Surprisingly	O
,	O
the	O
presence	O
of	O
deletions	O
beyond	O
a	O
few	O
nucleotides	O
among	O
over	O
150	O
reported	O
deleterious	O
mutations	O
has	O
not	O
been	O
described	O
,	O
raising	O
the	O
suspicion	O
that	O
this	O
gene	O
might	O
be	O
protected	O
against	O
the	O
detrimental	O
mechanisms	O
of	O
gene	O
rearrangements	O
.	O

The	O
quest	O
for	O
an	O
HGD	O
mutation	O
in	O
a	O
proband	O
with	O
AKU	O
revealed	O
with	O
a	O
SNP	O
array	O
five	O
large	O
regions	O
of	O
homozygosity	O
(	O
5	O
-	O
16	O
Mb	O
)	O
,	O
one	O
of	O
which	O
includes	O
the	O
HGD	O
gene	O
.	O

A	O
homozygous	O
deletion	O
of	O
649	O
bp	O
deletion	O
that	O
encompasses	O
the	O
72	O
nucleotides	O
of	O
exon	O
2	O
and	O
surrounding	O
DNA	O
sequences	O
in	O
flanking	O
introns	O
of	O
the	O
HGD	O
gene	O
was	O
unveiled	O
in	O
a	O
proband	O
with	O
AKU	O
.	O

The	O
nature	O
of	O
this	O
deletion	O
suggests	O
that	O
this	O
in	O
-	O
frame	O
deletion	O
could	O
generate	O
a	O
protein	O
without	O
exon	O
2	O
.	O

Thus	O
,	O
we	O
modeled	O
the	O
tertiary	O
structure	O
of	O
the	O
mutant	O
protein	O
structure	O
to	O
determine	O
the	O
effect	O
of	O
exon	O
2	O
deletion	O
.	O

While	O
the	O
two	O
β	O
-	O
pleated	O
sheets	O
encoded	O
by	O
exon	O
2	O
were	O
missing	O
in	O
the	O
mutant	O
structure	O
,	O
other	O
β	O
-	O
pleated	O
sheets	O
are	O
largely	O
unaffected	O
by	O
the	O
deletion	O
.	O

However	O
,	O
nine	O
novel	O
α	O
-	O
helical	O
coils	O
substituted	O
the	O
eight	O
coils	O
present	O
in	O
the	O
native	O
HGD	O
crystal	O
structure	O
.	O

Thus	O
,	O
this	O
deletion	B-Var
results	B-Reg
in	I-Reg
a	O
deleterious	O
enzyme	B-Enzyme
,	O
which	O
is	O
consistent	O
with	O
the	O
proband	O
's	O
phenotype	O
.	O

Screening	O
for	O
mutations	O
in	O
the	O
HGD	O
gene	O
,	O
particularly	O
in	O
the	O
Middle	O
East	O
,	O
ought	O
to	O
include	O
this	O
exon	O
2	O
deletion	O
in	O
order	O
to	O
determine	O
its	O
frequency	O
and	O
uncover	O
its	O
origin	O
.	O

Identification	O
of	O
two	O
novel	O
mutations	O
in	O
patients	O
with	O
X	O
-	O
linked	O
primary	O
immunodeficiencies	O
.	O

Primary	B-Disease
immunodeficiency	I-Disease
diseases	I-Disease
(	O
PID	O
)	O
are	O
a	O
heterogeneous	O
group	O
of	O
inherited	O
disorders	O
with	O
defects	O
in	O
one	O
or	O
more	O
component	O
of	O
the	O
immune	O
system	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
gene	O
mutations	O
in	O
four	O
X	O
-	O
linked	O
PID	O
pedigrees	O
,	O
which	O
include	O
one	O
X-	O
linked	O
agammaglobulinemia	O
(	O
XLA	O
)	O
pedigree	O
,	O
one	O
X	O
-	O
linked	O
chronic	O
granulomatous	O
disease	O
(	O
XCGD	O
)	O
pedigree	O
,	O
and	O
two	O
X	O
-	O
linked	O
Hyper	O
IgM	O
syndrome	O
(	O
XHIGM	O
)	O
pedigrees	O
.	O

Sequence	O
analysis	O
of	O
the	O
BTK	B-Gene
gene	O
revealed	O
a	O
novel	O
mutation	O
(	B-Var
c.1802_1803delinsGCC	I-Var
,	O
p	O
.	O
Phe601CysfsX3	O
)	O
which	O
results	B-Reg
in	O
the	O
developmental	B-CPA
arrest	I-CPA
of	I-CPA
B	I-CPA
cells	I-CPA
in	O
the	O
bone	O
marrow	O
.	O

Sequence	O
analysis	O
of	O
the	O
CYBB	B-Gene
gene	O
revealed	O
a	O
recurrent	O
frameshift	O
mutation	O
(	B-Var
c.1313_1314delinsT	I-Var
)	I-Var
in	O
exon	O
10	O
,	O
which	O
generates	B-Reg
a	O
premature	B-MPA
stop	I-MPA
codon	O
(	O
p	O
.	O
Lys438IlefsX63	O
)	O
.	O

One	O
novel	O
frameshift	O
mutation	O
(	B-Var
c.114delG	I-Var
,	O
p	O
.	O
Ser39GlnfsX14	O
)	O
and	O
one	O
recurrent	O
missense	O
mutation	O
(	B-Var
c.499G	I-Var
>	I-Var
C	I-Var
,	O
p	O
.	O
Gly167Arg	O
)	O
were	O
found	O
in	O
the	O
CD40LG	B-Gene
gene	O
and	O
cause	O
defective	B-NegReg
T	B-CPA
cell	I-CPA
functioning	I-CPA
.	O

In	O
conclusion	O
,	O
our	O
study	O
identified	O
two	O
novel	O
mutations	O
on	O
the	O
BTK	O
and	O
CD40LG	O
genes	O
in	O
Chinese	O
patients	O
and	O
established	O
accurate	O
and	O
simple	O
genetic	O
diagnostic	O
methods	O
for	O
three	O
X	O
-	O
linked	O
PID	O
.	O

Novel	O
COL9A3	B-Gene
mutation	B-Var
in	O
a	O
family	O
diagnosed	O
with	B-Reg
multiple	B-Disease
epiphyseal	I-Disease
dysplasia	I-Disease
:	I-Disease
a	O
case	O
report	O
.	O

BACKGROUND	O
:	O
Multiple	O
epiphyseal	O
dysplasia	O
is	O
a	O
common	O
skeletal	O
dysplasia	O
characterized	O
by	O
mild	O
short	O
stature	O
,	O
early	O
-	O
onset	O
osteoarthritis	O
mainly	O
involving	O
the	O
hip	O
and	O
knee	O
joints	O
,	O
and	O
abnormally	O
small	O
and/or	O
irregular	O
epiphyses	O
.	O

Multiple	O
epiphyseal	O
dysplasia	O
is	O
clinically	O
and	O
genetically	O
heterogeneous	O
and	O
six	O
genes	O
are	O
associated	O
with	O
the	O
phenotype	O
of	O
multiple	O
epiphyseal	O
dysplasia	O
.	O

CASE	O
PRESENTATION	O
:	O
A	O
12-year	O
-	O
old	O
Korean	O
boy	O
presented	O
with	O
intermittent	O
knee	O
pain	O
.	O

His	O
height	O
was	O
144.6	O
cm	O
(	O
20th	O
percentile	O
)	O
and	O
family	O
history	O
was	O
notable	O
for	O
early	O
-	O
onset	O
osteoarthritis	O
in	O
his	O
father	O
.	O

The	O
proband	O
's	O
x	O
-	O
rays	O
revealed	O
epiphyseal	O
changes	O
characteristic	O
of	O
multiple	O
epiphyseal	O
dysplasia	O
associated	O
with	O
a	O
collagen	O
IX	O
defect	O
,	O
with	O
manifestations	O
primarily	O
restricted	O
to	O
the	O
knees	O
.	O

Mutational	O
analysis	O
identified	O
a	O
novel	O
c.104G	B-Var
>	I-Var
A	I-Var
substitution	O
in	O
exon	O
2	O
of	O
COL9A3	B-Gene
,	O
resulting	B-Reg
in	I-Reg
p	B-Var
.	I-Var
Gly35Asp	I-Var
in	O
the	O
proband	O
and	O
his	O
father	O
.	O

In	O
silico	O
analyses	O
predicted	O
the	O
p	O
.	O
Gly35Asp	O
amino	O
acid	O
change	O
to	O
be	O
detelerious	O
,	O
and	O
molecular	O
dynamics	O
simulation	O
demonstrated	O
a	O
major	O
structural	O
change	O
in	O
the	O
heterotrimeric	O
collagen	O
IX	O
.	O

CONCLUSION	O
:	O
So	O
far	O
,	O
three	O
COL9A3	O
mutations	O
,	O
have	O
been	O
reported	O
.	O

These	O
three	O
mutations	B-Var
are	O
located	O
at	O
the	O
splice	O
donor	O
or	O
acceptor	O
site	O
of	O
COL9A3	B-Gene
and	O
cause	B-Reg
skipping	B-MPA
of	I-MPA
exon	I-MPA
3	I-MPA
,	O
resulting	B-Reg
in	I-Reg
the	O
deletion	B-Var
of	O
12	O
aminoacids	O
in	O
the	O
COL3	O
domain	O
of	O
COL9A3	B-Gene
.	O

In	O
contrast	O
,	O
the	O
novel	O
missense	O
mutation	O
identified	O
in	O
this	O
two	O
-	O
generation	O
family	O
with	O
multiple	O
epiphyseal	O
dysplasia	O
is	O
a	O
missense	O
mutation	B-Var
affecting	B-Reg
the	O
Gly	B-MPA
residue	I-MPA
of	O
the	O
Pro	O
-	O
Pro	O
-	O
Gly	O
repeat	O
sequence	O
in	O
the	O
COL3	O
domain	O
of	O
collage	O
IX	O
,	O
with	O
accompanying	O
major	O
structural	B-MPA
change	O
of	O
the	O
collagen	B-Protein
peptide	O
.	O

Rett	O
-	O
like	O
onset	O
in	O
late	B-Disease
-	I-Disease
infantile	I-Disease
neuronal	I-Disease
ceroid	I-Disease
lipofuscinosis	I-Disease
(	O
CLN7	O
)	O
caused	B-Reg
by	I-Reg
compound	O
heterozygous	O
mutation	B-Var
in	O
the	O
MFSD8	B-Gene
gene	O
and	O
review	O
of	O
the	O
literature	O
data	O
on	O
clinical	O
onset	O
signs	O
.	O

BACKGROUND	O
:	O
We	O
present	O
clinical	O
and	O
molecular	O
findings	O
of	O
a	O
patient	O
with	O
ceroid	O
-	O
lipofuscinosis	O
CLN7	B-Disease
,	O
with	B-Reg
a	O
compound	O
heterozygous	O
mutation	B-Var
of	O
the	O
MFSD8	B-Gene
gene	O
,	O
with	O
Rett	O
syndrome	O
clinical	O
signs	O
onset	O
and	O
a	O
later	O
development	O
of	O
full	O
picture	O
of	O
vLINCL	O
.	O

CASE	O
PRESENTATION	O
:	O
A	O
7	O
years	O
-	O
old	O
female	O
patient	O
with	O
normal	O
development	O
until	O
the	O
age	O
12	O
months	O
,	O
developed	O
Rett	O
like	O
clinical	O
picture	O
(	O
psychomotor	O
regression	O
,	O
microcephaly	O
,	O
stereotypic	O
hands	O
movements	O
in	O
the	O
midline	O
,	O
hyperventilation	O
episodes	O
)	O
present	O
at	O
the	O
onset	O
of	O
her	O
condition	O
(	O
age	O
18	O
months	O
)	O
,	O
features	O
still	O
present	O
at	O
the	O
initial	O
evaluation	O
in	O
our	O
clinic	O
at	O
age	O
5	O
years	O
.	O

RESULTS	O
:	O
MECP2	O
(	O
methyl	O
CpG	O
binding	O
protein	O
2	O
)	O
gene	O
mutation	O
was	O
negative	O
.	O

At	O
age	O
6	O
years	O
she	O
was	O
readmitted	O
for	O
severe	O
ataxia	O
and	O
blindness	O
,	O
seizures	O
,	O
and	O
severe	O
developmental	O
regression	O
leading	O
to	O
NCL	O
(	O
neuronal	O
ceroid	O
lipofuscinosis	O
)	O
suspicion	O
.	O

EEG	O
showed	O
slow	O
background	O
with	O
IRDA	O
(	O
intermittent	O
rhythmic	O
delta	O
activity	O
)	O
.	O

A	O
conjunctive	O
biopsy	O
showed	O
abnormal	O
curvilinear	O
and	O
fingerprint	O
lysosomal	O
deposits	O
,	O
and	O
genetic	O
analysis	O
revealed	O
two	O
heterozygous	O
mutations	O
of	O
MFSD8	O
gene	O
(	O
c.881C	O
>	O
A	O
p	O
.	O
Thr294Lys	O
and	O
c.754	O
+	O
2	O
T	O
>	O
A	O
)	O
each	O
inherited	O
from	O
carrier	O
parents	O
and	O
a	O
heterozygous	O
variant	O
(	O
c.470A	O
>	O
C	O
p	O
.	O
Asp157Ala	O
)	O
of	O
CLN5	O
gene	O
.	O

CONCLUSION	O
:	O
NCL	O
should	O
be	O
suspected	O
and	O
MFSD8	O
genetic	O
testing	O
should	O
also	O
be	O
considered	O
in	O
patients	O
with	O
Rett	O
like	O
phenotype	O
at	O
onset	O
and	O
negative	O
MECP2	O
mutation	O
.	O

Such	O
cases	O
should	O
be	O
carefully	O
and	O
frequently	O
re	O
-	O
evaluated	O
in	O
order	O
to	O
avoid	O
delayed	O
diagnosis	O
and	O
offer	O
proper	O
genetic	O
advice	O
to	O
the	O
family	O
.	O

In	O
our	O
knowledge	O
,	O
this	O
might	O
be	O
the	O
first	O
case	O
of	O
CLN7	O
disease	O
with	O
Rett	O
like	O
onset	O
described	O
in	O
the	O
literature	O
,	O
which	O
developed	O
typical	O
vLINCL	O
clinical	O
phenotype	O
after	O
age	O
5.5	O
years	O
.	O

A	O
short	O
review	O
of	O
the	O
literature	O
showing	O
NCL	O
onset	O
modalities	O
is	O
presented	O
.	O

Novel	O
homozygous	B-Var
deletion	I-Var
of	O
segmental	O
KAL1	B-Gene
and	O
entire	O
STS	B-Gene
cause	B-Reg
Kallmann	B-Disease
syndrome	I-Disease
and	O
X	B-Disease
-	I-Disease
linked	I-Disease
ichthyosis	I-Disease
in	O
a	O
Chinese	O
family	O
.	O

Kallmann	O
syndrome	O
(	O
KS	O
)	O
is	O
a	O
genetically	O
heterogeneous	O
disease	O
characterised	O
by	O
hypogonadotrophic	O
hypogonadism	O
in	O
association	O
with	O
anosmia	O
or	O
hyposmia	O
.	O

This	O
condition	O
affects	O
1	O
in	O
10	O
000	O
men	O
and	O
1	O
in	O
50	O
000	O
women	O
.	O

Defects	O
in	O
seventeen	O
genes	O
including	O
KAL1	O
gene	O
contribute	O
to	O
the	O
molecular	O
basis	O
of	O
KS	O
.	O

We	O
report	O
the	O
clinical	O
characteristics	O
,	O
molecular	O
causes	O
and	O
treatment	O
outcome	O
of	O
two	O
Chinese	O
brothers	O
with	O
KS	O
and	O
X	O
-	O
linked	O
ichthyosis	O
.	O

The	O
phenotypes	O
of	O
the	O
patients	O
were	O
characterised	O
by	O
bilateral	O
cryptorchidism	O
,	O
unilateral	O
renal	O
agenesis	O
in	O
one	O
patient	O
but	O
normal	O
kidney	O
development	O
in	O
another	O
.	O

The	O
patients	O
had	O
low	O
serum	O
testosterone	O
,	O
follicle	O
-	O
stimulating	O
hormone	O
and	O
luteinising	O
hormone	O
levels	O
and	O
a	O
blunt	O
response	O
to	O
the	O
gonadotrophin	O
-	O
releasing	O
hormone	O
stimulation	O
test	O
.	O

After	O
human	O
chorionic	O
gonadotrophin	O
treatment	O
,	O
the	O
serum	O
testosterone	O
levels	O
were	O
normalized	O
,	O
and	O
the	O
pubic	O
hair	O
,	O
penis	O
length	O
and	O
testicular	O
volumes	O
were	O
greatly	O
improved	O
in	O
both	O
of	O
the	O
patients	O
.	O

The	O
two	O
affected	O
siblings	O
had	O
the	O
same	O
novel	O
deletion	O
at	O
Xp22.3	O
including	O
exons	O
9	O
-	O
14	O
of	O
KAL1	O
gene	O
and	O
entire	O
STS	O
gene	O
.	O

Our	O
study	O
broadens	O
the	O
mutation	B-Var
spectrum	O
in	O
the	O
KAL1	B-Gene
gene	O
associated	B-Reg
with	I-Reg
KS	B-Disease
and	O
facilitates	O
the	O
genetic	O
diagnosis	O
and	O
counselling	O
for	O
KS	O
.	O

[	O
Heterozygote	O
forms	O
of	O
familial	O
Mediterranean	O
fever	O
can	O
be	O
manifested	O
in	O
adults	O
as	O
myofacial	O
pain	O
syndrome	O
]	O
.	O

Heterozygote	O
Formen	O
des	O
familiären	O
Mittelmeerfiebers	O
können	O
beim	O
Erwachsenen	O
als	O
myofasziales	O
Schmerzsyndrom	O
imponieren	O
.	O

BACKGROUND	O
:	O
Familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	O
)	O
is	O
a	O
disease	O
characterized	O
by	O
recurrent	O
fever	O
,	O
serositis	O
,	O
arthritis	O
and	O
unspecific	O
myalgia	O
.	O

It	O
is	O
prevalent	O
among	O
Mediterranean	O
people	O
and	O
has	O
been	O
shown	O
to	O
be	O
associated	B-Reg
with	O
mutations	B-Var
in	O
the	O
Mediterranean	O
fever	O
(	B-Gene
MEFV	I-Gene
)	I-Gene
gene	O
which	O
,	O
encodes	O
pyrin	O
a	O
regulatory	O
protein	O
of	O
the	O
inflammasome	O
.	O

As	O
heterozygous	B-Var
mutations	I-Var
in	O
MEFV	B-Gene
can	O
be	O
associated	B-Reg
with	O
only	O
mild	O
inflammatory	O
symptoms	O
,	O
such	O
as	O
arthralgia	B-CPA
or	O
chronic	B-CPA
fibromyalgic	I-CPA
pain	I-CPA
,	O
FMF	O
may	O
be	O
underdiagnosed	O
in	O
the	O
current	O
diagnostic	O
work	O
-	O
up	O
of	O
musculoskeletal	O
diseases	O
.	O

METHODS	O
:	O
The	O
selection	O
of	O
patients	O
was	O
carried	O
out	O
according	O
to	O
the	O
following	O
criteria	O
:	O
myofacial	O
pain	O
syndrome	O
,	O
seronegative	O
oligoarthralgia	O
,	O
a	O
slight	O
inflammatory	O
constellation	O
and	O
ethnic	O
origin	O
from	O
the	O
Mediterranean	O
area	O
.	O

When	O
these	O
criteria	O
were	O
fulfilled	O
a	O
molecular	O
genetic	O
investigation	O
was	O
carried	O
out	O
RESULTS	O
:	O
This	O
article	O
presents	O
evidence	O
that	O
9	O
out	O
of	O
12	O
Mediterranean	O
patients	O
with	O
recurrent	O
myofascial	B-Disease
pain	I-Disease
syndrome	I-Disease
and	O
mild	B-CPA
inflammation	I-CPA
revealed	B-Reg
heterozygote	B-Var
mutations	I-Var
in	O
the	O
MEFV	B-Gene
gene	O
and	O
7	O
of	O
these	O
patients	O
benefitted	O
from	O
treatment	O
with	O
colchicine	O
.	O

DISCUSSION	O
:	O
As	O
colchicine	O
treatment	O
not	O
only	O
improved	O
the	O
myofascial	O
pain	O
but	O
also	O
prevented	O
FMF	O
-	O
associated	O
amyloidosis	O
and	O
nephropathy	O
,	O
differential	O
diagnosis	O
of	O
fibromyalgia	O
in	O
patients	O
of	O
Mediterranean	O
origin	O
should	O
include	O
FMF	O
and	O
a	O
genetic	O
screening	O
of	O
the	O
MEFV	O
locus	O
.	O

Loss	O
-	O
of	O
-	O
function	O
de	O
novo	O
mutations	O
play	O
an	O
important	O
role	O
in	O
severe	O
human	O
neural	O
tube	O
defects	O
.	O

BACKGROUND	O
:	O
Neural	B-Disease
tube	I-Disease
defects	I-Disease
(	O
NTDs	O
)	O
are	O
very	O
common	O
and	O
severe	O
birth	O
defects	O
that	O
are	O
caused	O
by	O
failure	O
of	O
neural	O
tube	O
closure	O
and	O
that	O
have	O
a	O
complex	O
aetiology	O
.	O

Anencephaly	O
and	O
spina	O
bifida	O
are	O
severe	O
NTDs	O
that	O
affect	O
reproductive	O
fitness	O
and	O
suggest	O
a	O
role	O
for	O
de	O
novo	O
mutations	O
(	O
DNMs	O
)	O
in	O
their	O
aetiology	O
.	O

METHODS	O
:	O
We	O
used	O
whole	O
-	O
exome	O
sequencing	O
in	O
43	O
sporadic	O
cases	O
affected	O
with	O
myelomeningocele	O
or	O
anencephaly	O
and	O
their	O
unaffected	O
parents	O
to	O
identify	O
DNMs	O
in	O
their	O
exomes	O
.	O

RESULTS	O
:	O
We	O
identified	O
42	O
coding	O
DNMs	O
in	O
25	O
cases	O
,	O
of	O
which	O
6	O
were	O
loss	O
of	O
function	O
(	O
LoF	O
)	O
showing	O
a	O
higher	O
rate	O
of	O
LoF	O
DNM	O
in	O
our	O
cohort	O
compared	O
with	O
control	O
cohorts	O
.	O

Notably	O
,	O
we	O
identified	O
two	O
protein	B-Protein
-	I-Protein
truncating	I-Protein
DNMs	B-Var
in	O
two	O
independent	O
cases	O
in	O
SHROOM3	B-Gene
,	O
previously	O
associated	O
with	O
NTDs	O
only	O
in	O
animal	O
models	O
.	O

We	O
have	O
demonstrated	O
a	O
significant	O
enrichment	O
of	O
LoF	B-NegReg
DNMs	B-Var
in	O
this	O
gene	O
in	O
NTDs	B-Disease
compared	O
with	O
the	O
gene	O
specific	O
DNM	O
rate	O
and	O
to	O
the	O
DNM	O
rate	O
estimated	O
from	O
control	O
cohorts	O
.	O

We	O
also	O
identified	O
one	O
nonsense	O
DNM	O
in	O
PAX3	O
and	O
two	O
potentially	O
causative	O
missense	O
DNMs	O
in	O
GRHL3	O
and	O
PTPRS	O
.	O

CONCLUSIONS	O
:	O
Our	O
study	O
demonstrates	O
an	O
important	O
role	O
of	O
LoF	B-NegReg
DNMs	B-Var
in	O
the	O
development	O
of	O
NTDs	B-Disease
and	O
strongly	O
implicates	O
SHROOM3	B-Gene
in	O
its	O
aetiology	O
.	O

In	O
silico	O
analyses	O
of	O
missense	O
mutations	O
in	O
coagulation	O
factor	O
VIII	O
:	O
identification	O
of	O
severity	O
determinants	O
of	O
haemophilia	O
A.	O
Factor	O
VIII	O
(	B-Gene
FVIII	I-Gene
)	I-Gene
mutations	B-Var
cause	B-Reg
haemophilia	B-Disease
A	I-Disease
(	O
HA	O
)	O
,	O
an	O
X	O
-	O
linked	O
recessive	O
coagulation	O
disorder	O
.	O

Over	O
1000	O
missense	O
mutations	O
in	O
FVIII	O
are	O
known	O
and	O
they	O
lead	O
to	O
variable	O
clinical	O
phenotypes	O
(	O
severe	O
,	O
moderate	O
and	O
mild	O
)	O
.	O

The	O
exact	O
molecular	O
basis	O
of	O
this	O
phenotypic	O
heterogeneity	O
by	O
FVIII	O
missense	O
mutations	O
is	O
elusive	O
to	O
date	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
identify	O
the	O
severity	O
determinants	O
that	O
cause	O
phenotypic	O
heterogeneity	O
of	O
HA	O
.	O

We	O
compiled	O
and	O
curated	O
a	O
data	O
set	O
of	O
766	O
missense	O
mutations	O
from	O
the	O
repertoire	O
of	O
missense	O
mutations	O
in	O
FVIII	O
.	O

We	O
analysed	O
these	O
mutations	O
by	O
computational	O
programs	O
(	O
e.g.	O
Swiss	O
-	O
PdbViewer	O
)	O
and	O
different	O
mutation	O
analysis	O
servers	O
(	O
e.g.	O
SIFT	O
,	O
PROVEAN	O
,	O
CUPSAT	O
,	O
PolyPhen2	O
,	O
MutPred	O
)	O
;	O
and	O
various	O
sequence-	O
and	O
structure	O
-	O
based	O
parameters	O
were	O
assessed	O
for	O
any	O
significant	O
distribution	O
bias	O
among	O
different	O
HA	O
phenotypes	O
.	O

Our	O
analyses	O
suggest	O
that	O
'	O
mutations	O
in	O
evolutionary	O
conserved	O
residues	O
'	O
,	O
'	O
mutations	O
in	O
buried	O
residues	O
'	O
,	O
mutation	B-Var
-	I-Var
induced	I-Var
'	O
steric	O
clash	O
'	O
and	O
'	B-MPA
surface	I-MPA
electrostatic	I-MPA
potential	I-MPA
alteration	I-MPA
'	I-MPA
act	O
as	O
risk	O
factors	B-Reg
towards	O
severe	O
HA	B-Disease
.	O

We	O
have	O
developed	O
a	O
grading	O
system	O
for	O
FVIII	O
mutations	O
combining	O
the	O
severity	O
determinants	O
,	O
and	O
the	O
grading	O
pattern	O
correlates	O
with	O
HA	O
phenotype	O
.	O

This	O
study	O
will	O
help	O
to	O
correctly	O
associate	O
the	O
HA	O
phenotype	O
with	O
a	O
mutation	O
and	O
aid	O
early	O
characterization	O
of	O
novel	O
variants	O
.	O

Analysis	O
of	O
loss	O
-	O
of	O
-	O
function	O
variants	O
and	O
20	O
risk	O
factor	O
phenotypes	O
in	O
8,554	O
individuals	O
identifies	O
loci	O
influencing	O
chronic	O
disease	O
.	O

A	O
typical	O
human	O
exome	O
harbors	O
dozens	O
of	O
loss	O
-	O
of	O
-	O
function	O
(	O
LOF	O
)	O
variants	O
,	O
which	O
can	O
lower	O
disease	O
risk	O
factor	O
levels	O
and	O
affect	O
drug	O
efficacy	O
.	O

We	O
hypothesized	O
that	O
LOF	O
variants	O
are	O
enriched	O
in	O
genes	O
influencing	O
risk	O
factor	O
levels	O
and	O
the	O
onset	O
of	O
common	O
chronic	O
diseases	O
,	O
such	O
as	O
cardiovascular	O
disease	O
and	O
diabetes	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
sequenced	O
the	O
exomes	O
of	O
8,554	O
individuals	O
and	O
analyzed	O
the	O
effects	O
of	O
predicted	O
LOF	O
variants	O
on	O
20	O
chronic	O
disease	O
risk	O
factor	O
phenotypes	O
.	O

Analysis	O
of	O
this	O
sample	O
as	O
discovery	O
and	O
replication	O
strata	O
of	O
equal	O
size	O
verified	O
two	O
relationships	O
in	O
well	O
-	O
studied	O
genes	O
(	O
PCSK9	O
and	O
APOC3	O
)	O
and	O
identified	O
eight	O
new	O
loci	O
.	O

Previously	O
unknown	O
relationships	O
included	O
elevated	B-PosReg
fasting	O
glucose	B-MPA
in	O
carriers	O
of	O
heterozygous	O
LOF	B-NegReg
variation	B-Var
in	O
TXNDC5	B-Gene
,	O
which	O
encodes	O
a	O
biomarker	O
for	O
type	O
1	O
diabetes	O
progression	O
,	O
and	O
apparent	O
recessive	B-NegReg
effects	I-NegReg
of	O
C1QTNF8	B-Gene
on	O
serum	B-MPA
magnesium	I-MPA
levels	I-MPA
.	O

These	O
data	O
demonstrate	O
the	O
utility	O
of	O
functional	O
-	O
variant	O
annotation	O
within	O
a	O
large	O
sample	O
of	O
deeply	O
phenotyped	O
individuals	O
for	O
gene	O
discovery	O
.	O

Mutant	O
p53	O
-	O
Heat	O
Shock	O
Response	O
Oncogenic	O
Cooperation	O
:	O
A	O
New	O
Mechanism	O
of	O
Cancer	O
Cell	O
Survival	O
.	O

The	O
main	O
tumor	O
suppressor	O
function	O
of	O
p53	O
as	O
a	O
"	O
guardian	O
of	O
the	O
genome	O
"	O
is	O
to	O
respond	O
to	O
cellular	O
stress	O
by	O
transcriptional	O
activation	O
of	O
apoptosis	O
,	O
growth	O
arrest	O
,	O
or	O
senescence	O
in	O
damaged	O
cells	O
.	O

Not	O
surprisingly	O
,	O
mutations	O
in	O
the	O
p53	O
gene	O
are	O
the	O
most	O
frequent	O
genetic	O
alteration	O
in	O
human	O
cancers	O
.	O

Importantly	O
,	O
mutant	B-Var
p53	B-Gene
(	O
mutp53	O
)	O
proteins	B-Protein
not	O
only	O
lose	B-NegReg
their	O
wild	O
-	O
type	O
tumor	B-CPA
suppressor	I-CPA
activity	I-CPA
but	O
also	O
can	O
actively	O
promote	B-PosReg
tumor	B-CPA
development	I-CPA
.	O

Two	O
main	O
mechanisms	O
accounting	O
for	O
mutp53	B-Var
proto	O
-	O
oncogenic	O
activity	O
are	O
inhibition	O
of	O
the	O
wild	O
-	O
type	O
p53	O
in	O
a	O
dominant	O
-	O
negative	O
fashion	O
and	O
gain	B-PosReg
of	O
additional	O
oncogenic	B-CPA
activities	I-CPA
known	O
as	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
.	O

Here	O
,	O
we	O
discuss	O
a	O
novel	O
mechanism	O
of	O
mutp53	B-Var
GOF	O
,	O
which	O
relies	O
on	O
its	O
oncogenic	O
cooperation	O
with	O
the	O
heat	O
shock	O
machinery	O
.	O

This	O
coordinated	O
adaptive	O
mechanism	O
renders	O
cancer	O
cells	O
more	B-PosReg
resistant	B-CPA
to	O
proteotoxic	O
stress	O
and	O
provides	O
both	O
,	O
a	O
strong	O
survival	B-CPA
advantage	I-CPA
to	O
cancer	O
cells	O
and	O
a	O
promising	O
means	O
for	O
therapeutic	O
intervention	O
.	O

X	B-Disease
-	I-Disease
linked	I-Disease
adrenal	I-Disease
hypoplasia	I-Disease
congenita	I-Disease
:	I-Disease
clinical	O
and	O
follow	O
-	O
up	O
findings	O
of	O
two	O
kindreds	O
,	O
one	O
with	B-Reg
a	O
novel	O
NR0B1	B-Gene
mutation	B-Var
.	O

X	B-Disease
-	I-Disease
linked	I-Disease
adrenal	I-Disease
hypoplasia	I-Disease
congenita	I-Disease
typically	O
manifests	O
as	O
primary	O
adrenal	B-Disease
insufficiency	I-Disease
in	O
the	O
newborn	O
age	O
and	O
hypogonadotropic	B-Disease
hypogonadism	I-Disease
in	O
males	O
,	O
being	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
NR0B1	B-Gene
gene	O
.	O

We	O
present	O
the	O
clinical	O
and	O
follow	O
-	O
up	O
findings	O
of	O
two	O
kindreds	O
with	O
NR0B1	O
mutations	O
.	O

The	O
proband	O
of	O
kindred	O
A	O
had	O
a	O
diagnosis	O
of	O
primary	O
adrenal	O
insufficiency	O
when	O
he	O
was	O
a	O
newborn	O
.	O

Family	O
history	O
was	O
relevant	O
for	O
a	O
maternal	O
uncle	O
death	O
at	O
the	O
newborn	O
age	O
.	O

Beyond	O
2	O
year	O
-	O
old	O
steroid	O
measurements	O
rendered	O
undetectable	O
and	O
delayed	O
bone	O
age	O
was	O
noticed	O
.	O

Molecular	O
analysis	O
of	O
NR0B1	B-Gene
gene	O
revealed	O
a	O
previously	O
unreported	O
mutation	O
(	B-Var
c.1084A	I-Var
>	I-Var
T	I-Var
)	I-Var
,	O
leading	B-Reg
to	I-Reg
a	O
premature	O
stop	O
codon	O
,	O
p	B-MPA
.	I-MPA
Lys362	I-MPA
*	I-MPA
,	O
in	O
exon	O
1	O
.	O

His	O
mother	O
and	O
sister	O
were	O
asymptomatic	O
carriers	O
.	O

At	O
14	O
year	O
-	O
old	O
he	O
had	O
3	O
mL	O
of	O
testicular	O
volume	O
and	O
biochemical	O
surveys	O
(	O
LH	O
<	O
0.1	O
UI	O
/	O
L	O
,	O
total	O
testosterone	O
<	O
10	O
ng	O
/	O
dL	O
)	O
concordant	O
with	O
hypogonadotrophic	O
hypogonadism	O
.	O

Kindred	O
B	O
had	O
two	O
males	O
diagnosed	O
with	O
adrenal	O
insufficiency	O
at	O
the	O
newborn	O
age	O
.	O

By	O
3	O
year	O
-	O
old	O
both	O
siblings	O
had	O
undetectable	O
androgen	O
levels	O
and	O
delayed	O
bone	O
age	O
.	O

NR0B1	O
molecular	O
analysis	O
identified	O
a	O
nonsense	O
mutation	O
in	O
both	O
cases	O
,	O
c.243C	O
>	O
G	O
;	O
p	O
.	O
Tyr81	O
*	O
,	O
in	O
exon	O
1	O
.	O

Their	O
mother	O
and	O
sister	O
were	O
asymptomatic	O
carriers	O
.	O

At	O
14	O
year	O
-	O
old	O
(	O
Tanner	O
stage	O
1	O
)	O
hypothalamic	O
-	O
pituitary	O
-	O
gonadal	O
axis	O
evaluation	O
in	O
both	O
males	O
(	O
LH	O
<	O
0.1UI	O
/	O
L	O
,	O
total	O
testosterone	O
<	O
10	O
ng	O
/	O
dL	O
)	O
confirmed	O
hypogonadotropic	O
hypogonadism	O
.	O

In	O
conclusion	O
,	O
biochemical	O
profiles	O
,	O
bone	O
age	O
and	O
an	O
X	O
-	O
linked	O
inheritance	O
led	O
to	O
suspicion	O
of	O
NR0B1	O
mutations	O
.	O

Two	O
nonsense	O
mutations	O
were	O
detected	O
in	O
both	O
kindreds	O
,	O
one	O
previously	O
unreported	O
(	O
c.1084A	O
>	O
T	O
;	O
p	O
.	O
Lys362	O
*	O
)	O
.	O

Mutation	O
identification	O
allowed	O
the	O
timely	O
institution	O
of	O
testosterone	O
in	O
patients	O
at	O
puberty	O
and	O
an	O
appropriate	O
genetic	O
counselling	O
for	O
relatives	O
.	O

Phenotypic	O
Variability	O
and	O
Newly	O
Identified	O
Mutations	B-Var
of	O
the	O
IVD	B-Gene
Gene	O
in	O
Japanese	O
Patients	O
with	B-Reg
Isovaleric	B-Disease
Acidemia	I-Disease
.	O

Isovaleric	O
acidemia	O
(	O
IVA	O
)	O
is	O
an	O
autosomal	O
recessive	O
inborn	O
error	O
affecting	O
leucine	O
metabolism	O
.	O

It	O
is	O
caused	O
by	O
a	O
deficiency	O
in	O
isovaleryl	O
-	O
CoA	O
dehydrogenase	O
(	O
IVD	O
)	O
,	O
a	O
mitochondrial	O
matrix	O
enzyme	O
that	O
catalyzes	O
the	O
oxidation	O
of	O
isovaleryl	O
-	O
CoA	O
to	O
3-methylcrotonyl	O
-	O
CoA.	O
IVD	O
is	O
a	O
FAD	O
-	O
containing	O
enzyme	O
,	O
consisting	O
of	O
four	O
identical	O
subunits	O
.	O

Clinical	O
features	O
of	O
IVA	O
include	O
poor	O
feeding	O
,	O
vomiting	O
,	O
lethargy	O
,	O
developmental	O
delay	O
,	O
metabolic	O
acidosis	O
,	O
and	O
a	O
characteristic	O
"	O
sweaty	O
foot	O
"	O
odor	O
.	O

IVA	O
is	O
one	O
of	O
the	O
target	O
disorders	O
for	O
newborn	O
screening	O
by	O
tandem	O
mass	O
spectrometry	O
(	O
MS	O
/	O
MS	O
)	O
.	O

The	O
human	O
IVD	O
gene	O
is	O
located	O
on	O
chromosome	O
15q	O
.	O

To	O
date	O
,	O
over	O
50	O
disease	O
-	O
causing	O
mutations	O
have	O
been	O
reported	O
worldwide	O
.	O

In	O
this	O
study	O
,	O
we	O
searched	O
for	O
IVD	O
mutations	O
in	O
five	O
Japanese	O
patients	O
with	O
IVA	O
(	O
neonatal	O
type	O
,	O
two	O
patients	O
;	O
chronic	O
intermittent	O
type	O
,	O
two	O
patients	O
;	O
and	O
mild	O
biochemical	O
type	O
,	O
one	O
patient	O
)	O
.	O

The	O
diagnosis	O
of	O
IVA	O
was	O
confirmed	O
by	O
urinary	O
organic	O
acid	O
analysis	O
using	O
gas	O
chromatography	O
and	O
mass	O
spectrometry	O
.	O

All	O
coding	O
exons	O
and	O
the	O
flanking	O
introns	O
in	O
the	O
IVD	O
gene	O
were	O
amplified	O
by	O
PCR	O
and	O
were	O
directly	O
sequenced	O
.	O

We	O
thus	O
identified	O
six	O
hitherto	O
unknown	O
mutations	O
(	O
p	O
.	O
G94D	O
,	O
p	O
.	O
E116	O
K	O
,	O
p	O
.	O
M167	O
T	O
,	O
p	O
.	O
L243P	O
,	O
p	O
.	O
L246P	O
,	O
and	O
c.696	O
+	O
1G	O
>	O
T	O
)	O
and	O
four	O
previously	O
reported	O
(	O
p	O
.	O
R53P	O
,	O
p	O
.	O
R395C	O
,	O
p	O
.	O
Y403C	O
,	O
and	O
p	O
.	O
E411	O
K	O
)	O
pathogenic	O
mutations	O
.	O

All	O
patients	O
were	O
compound	O
heterozygotes	O
,	O
and	O
each	O
mutation	O
was	O
identified	O
in	O
a	O
single	O
patient	O
.	O

Pathogenicity	O
of	O
newly	O
identified	O
mutations	O
was	O
validated	O
using	O
computational	O
programs	O
.	O

Among	O
them	O
,	O
the	O
p	B-Var
.	I-Var
M167	I-Var
T	I-Var
is	O
believed	O
to	O
influence	B-Reg
FAD	B-Interaction
binding	I-Interaction
,	O
as	O
the	O
position	O
167	O
is	O
present	O
in	O
one	O
of	O
the	O
FAD	O
-	O
binding	O
sites	O
.	O

Our	O
results	O
have	O
illustrated	O
the	O
heterogeneous	O
mutation	O
spectrum	O
and	O
clinical	O
presentation	O
of	O
IVA	O
in	O
the	O
Japanese	O
patients	O
.	O

Molecular	O
and	O
clinical	O
features	O
of	O
inherited	O
neuropathies	O
due	O
to	O
PMP22	O
duplication	O
.	O

PMP22	O
is	O
a	O
transmembrane	O
glycoprotein	O
component	O
of	O
myelin	O
,	O
important	O
for	O
myelin	O
functioning	O
.	O

Mutation	B-Var
of	O
PMP22	B-Gene
gene	O
which	O
encodes	O
for	O
the	O
production	O
of	O
PMP22	O
glycoprotein	O
is	O
associated	B-Reg
with	I-Reg
a	O
variety	O
of	O
inherited	O
neuropathies	B-Disease
.	O

This	O
literature	O
review	O
sought	O
to	O
review	O
the	O
molecular	O
mechanism	O
and	O
clinical	O
features	O
of	O
inherited	O
neuropathies	O
caused	O
by	O
PMP22	O
duplication	O
.	O

PMP22	O
duplication	O
causes	O
CMT1A	O
which	O
accounts	O
for	O
more	O
than	O
half	O
of	O
all	O
CMT	O
cases	O
and	O
about	O
70	O
%	O
of	O
CMT1	O
cases	O
.	O

It	O
manifests	O
with	O
muscle	O
weakness	O
,	O
depressed	O
reflexes	O
,	O
impaired	O
distal	O
sensation	O
,	O
hand	O
and	O
foot	O
deformities	O
,	O
slowing	O
of	O
NCV	O
and	O
onion	O
bulbs	O
.	O

With	O
no	O
specific	O
treatment	O
available	O
,	O
it	O
is	O
managed	O
conservatively	O
.	O

Future	O
treatment	O
may	O
be	O
based	O
on	O
the	O
molecular	O
genetics	O
of	O
the	O
disease	O
.	O

A	O
novel	O
gene	O
insertion	B-Var
combined	O
with	O
a	O
missense	O
mutation	O
causing	B-Reg
factor	B-Disease
VII	I-Disease
deficiency	I-Disease
in	O
two	O
unrelated	O
Chinese	O
families	O
.	O

Hereditary	O
coagulation	O
factor	O
VII	O
(	O
FVII	O
)	O
deficiency	O
is	O
a	O
rare	O
bleeding	O
disorder	O
characterized	O
by	O
reduced	O
FVII	O
activity	O
(	O
FVII	O
:	O
C	O
)	O
and	O
inconsistent	O
FVII	O
antigen	O
(	O
FVII	O
:	O
Ag	O
)	O
.	O

In	O
our	O
study	O
,	O
two	O
pregnant	O
probands	O
were	O
diagnosed	O
with	O
FVII	O
deficiency	O
,	O
based	O
on	O
the	O
tests	O
that	O
FVII	O
:	O
C	O
were	O
both	O
3	O
%	O
and	O
FVII	O
:	O
Ag	O
were	O
less	O
than	O
7.5	O
%	O
.	O

Gene	O
sequencing	O
revealed	O
the	O
same	O
compound	O
mutations	O
,	O
a	O
recurrent	O
missense	O
mutation	O
p	O
.	O
Arg277Cys	O
and	O
a	O
novel	O
insertion	O
mutation	O
g.11520	O
-	O
11521insT.	O
What	O
is	O
more	O
,	O
haplotype	O
analysis	O
of	O
SNPs	O
excluded	O
the	O
possibility	O
of	O
consanguinity	O
between	O
the	O
two	O
families	O
.	O

According	O
to	O
the	O
model	O
,	O
we	O
speculated	O
that	O
although	O
the	O
insertion	B-Var
mutation	O
was	O
close	O
to	O
the	O
carboxy	O
-	O
terminal	O
,	O
it	O
induced	B-PosReg
the	O
protein	B-MPA
extension	I-MPA
and	O
affected	B-Reg
the	B-MPA
3	I-MPA
'	I-MPA
untranslated	I-MPA
region	I-MPA
of	O
F7	B-Gene
gene	O
,	O
which	O
is	O
significant	O
to	O
posttranscriptional	O
regulation	O
.	O

Hypothetically	O
,	O
the	O
stability	O
or	O
translational	O
efficiency	O
of	O
mRNA	O
may	O
be	O
influenced	O
,	O
resulting	O
in	O
reducing	O
FVII	O
:	O
C.	O
Hereditary	O
spastic	O
paraplegia	O
SPG4	O
:	O
what	O
is	O
known	O
and	O
not	O
known	O
about	O
the	O
disease	O
.	O

Mutations	O
in	O
more	O
than	O
70	O
distinct	O
loci	O
and	O
more	O
than	O
50	O
mutated	O
gene	O
products	O
have	O
been	O
identified	O
in	O
patients	O
with	O
hereditary	B-Disease
spastic	I-Disease
paraplegias	I-Disease
,	O
a	O
diverse	O
group	O
of	O
neurological	O
disorders	O
characterized	O
predominantly	O
,	O
but	O
not	O
exclusively	O
,	O
by	O
progressive	O
lower	O
limb	O
spasticity	O
and	O
weakness	O
resulting	O
from	O
distal	O
degeneration	O
of	O
corticospinal	O
tract	O
axons	O
.	O

Mutations	B-Var
in	O
the	O
SPAST	B-Gene
(	O
previously	O
known	O
as	O
SPG4	B-Gene
)	I-Gene
gene	O
that	O
encodes	O
the	O
microtubule	O
-	O
severing	O
protein	O
called	O
spastin	O
,	O
are	O
the	O
most	O
common	O
cause	B-Reg
of	O
the	O
disease	B-Disease
.	O

The	O
aetiology	O
of	O
the	O
disease	O
is	O
poorly	O
understood	O
,	O
but	O
partial	O
loss	B-NegReg
of	O
microtubule	B-CPA
-	I-CPA
severing	I-CPA
activity	I-CPA
resulting	O
from	O
inactivating	B-Var
mutations	I-Var
in	O
one	O
SPAST	B-Gene
allele	O
is	O
the	O
most	O
postulated	O
explanation	O
.	O

Microtubule	O
severing	O
is	O
important	O
for	O
regulating	O
various	O
aspects	O
of	O
the	O
microtubule	O
array	O
,	O
including	O
microtubule	O
number	O
,	O
length	O
,	O
and	O
mobility	O
.	O

In	O
addition	O
,	O
higher	O
numbers	O
of	O
dynamic	O
plus	O
-	O
ends	O
of	O
microtubules	O
,	O
resulting	O
from	O
microtubule	O
-	O
severing	O
events	O
,	O
may	O
play	O
a	O
role	O
in	O
endosomal	O
tubulation	O
and	O
fission	O
.	O

Even	O
so	O
,	O
there	O
is	O
growing	O
evidence	O
that	O
decreased	O
severing	O
of	O
microtubules	O
does	O
not	O
fully	O
explain	O
HSP	O
-	O
SPG4	O
.	O

The	O
presence	O
of	O
two	O
translation	O
initiation	O
codons	O
in	O
SPAST	O
allows	O
synthesis	O
of	O
two	O
spastin	O
isoforms	O
:	O
a	O
full	O
-	O
length	O
isoform	O
called	O
M1	O
and	O
a	O
slightly	O
shorter	O
isoform	O
called	O
M87	O
.	O

M87	O
is	O
more	O
abundant	O
in	O
both	O
neuronal	O
and	O
non	O
-	O
neuronal	O
tissues	O
.	O

Studies	O
on	O
rodents	O
suggest	O
that	O
M1	O
is	O
only	O
readily	O
detected	O
in	O
adult	O
spinal	O
cord	O
,	O
which	O
is	O
where	O
nerve	O
degeneration	O
mainly	O
occurs	O
in	O
humans	O
with	O
HSP	O
-	O
SPG4	O
.	O

M1	O
,	O
due	O
to	O
its	O
hydrophobic	O
N	O
-	O
terminal	O
domain	O
not	O
shared	O
by	O
M87	O
,	O
may	O
insert	O
into	O
endoplasmic	O
reticulum	O
membrane	O
,	O
and	O
together	O
with	O
reticulons	O
,	O
atlastin	O
and	O
REEP1	O
,	O
may	O
play	O
a	O
role	O
in	O
the	O
morphogenesis	O
of	O
this	O
organelle	O
.	O

Some	B-Var
mutated	I-Var
spastins	B-Protein
may	O
act	O
in	O
dominant	O
-	O
negative	O
fashion	O
to	O
lower	B-NegReg
microtubule	B-CPA
-	I-CPA
severing	I-CPA
activity	I-CPA
,	O
but	O
others	B-Var
have	O
detrimental	B-NegReg
effects	I-NegReg
on	O
neurons	B-CPA
without	O
further	O
lowering	O
microtubule	O
severing	O
.	O

The	O
observed	O
adverse	B-NegReg
effects	I-NegReg
on	O
microtubule	B-CPA
dynamics	I-CPA
,	O
axonal	B-CPA
transport	I-CPA
,	O
endoplasmic	B-CPA
reticulum	I-CPA
,	O
and	O
endosomal	B-CPA
trafficking	I-CPA
are	O
likely	O
caused	O
not	O
only	O
by	O
diminished	B-NegReg
severing	B-CPA
of	I-CPA
microtubules	I-CPA
,	O
but	O
also	O
by	O
neurotoxicity	B-CPA
of	B-Reg
mutant	B-Var
spastin	B-Protein
proteins	I-Protein
,	O
chiefly	O
M1	B-Protein
.	O

Some	O
large	O
deletions	O
in	O
SPAST	O
might	O
also	O
affect	O
the	O
function	O
of	O
adjacent	O
genes	O
,	O
further	O
complicating	O
the	O
aetiology	O
of	O
the	O
disease	O
.	O

Identification	O
and	O
functional	O
characterization	O
of	O
natural	O
human	O
melanocortin	O
1	O
receptor	O
mutant	O
alleles	O
in	O
Pakistani	O
population	O
.	O

Melanocortin	O
1	O
receptor	O
(	O
MC1R	O
)	O
,	O
a	O
Gs	O
protein	O
-	O
coupled	O
receptor	O
of	O
the	O
melanocyte	O
's	O
plasma	O
membrane	O
,	O
is	O
a	O
major	O
determinant	O
of	O
skin	O
pigmentation	O
and	O
phototype	O
.	O

Upon	O
activation	O
by	O
α	O
-	O
melanocyte	O
stimulating	O
hormone	O
,	O
MC1R	O
triggers	O
the	O
cAMP	O
cascade	O
to	O
stimulate	O
eumelanogenesis	O
.	O

We	O
used	O
whole	O
-	O
exome	O
sequencing	O
to	O
identify	O
causative	O
alleles	O
in	O
Pakistani	O
families	O
with	O
skin	O
and	O
hair	O
hypopigmentation	O
.	O

Six	O
MC1R	O
mutations	O
segregated	O
with	O
the	O
phenotype	O
in	O
seven	O
families	O
,	O
including	O
a	O
p	O
.	O
Val174del	O
in	O
-	O
frame	O
deletion	O
and	O
a	O
p	O
.	O
Tyr298	O
*	O
nonsense	O
mutation	O
,	O
that	O
were	O
analyzed	O
for	O
function	O
in	O
heterologous	O
HEK293	O
cells	O
.	O

p	B-Var
.	I-Var
Tyr298	I-Var
*	I-Var
MC1R	B-Gene
showed	O
no	B-NegReg
agonist	B-MPA
-	I-MPA
induced	I-MPA
signaling	I-MPA
to	O
the	O
cAMP	B-Pathway
or	O
ERK	B-Pathway
pathways	I-Pathway
,	O
nor	B-NegReg
detectable	O
agonist	B-Interaction
binding	I-Interaction
.	O

Conversely	O
,	O
signaling	O
was	O
comparable	O
for	O
p	B-Var
.	I-Var
Val174del	I-Var
and	O
wild	O
-	O
type	O
in	O
HEK	O
cells	O
overexpressing	O
the	O
proteins	O
,	O
but	O
binding	O
analysis	O
suggested	O
impaired	B-NegReg
cell	B-MPA
surface	I-MPA
expression	I-MPA
.	O

Flow	O
cytometry	O
and	O
confocal	O
imaging	O
studies	O
revealed	O
reduced	B-NegReg
plasma	B-MPA
membrane	I-MPA
expression	I-MPA
of	O
p	B-Var
.	I-Var
Val174del	I-Var
and	O
p	B-Var
.	I-Var
Tyr298	I-Var
*	I-Var
.	O

Therefore	O
,	O
p	B-Var
.	I-Var
Tyr298	I-Var
*	I-Var
was	O
a	O
total	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LOF	O
)	O
allele	O
,	O
while	O
p	B-Var
.	I-Var
Val174del	I-Var
displayed	O
a	O
partial	B-NegReg
LOF	I-NegReg
attribute	O
.	O

Clinical	O
phenotype	O
in	O
genetically	O
confirmed	O
von	O
Willebrand	O
disease	O
type	O
2N	O
patients	O
reflects	O
a	O
haemophilia	O
A	O
phenotype	O
.	O

INTRODUCTION	O
:	O
Von	B-Disease
Willebrand	I-Disease
disease	I-Disease
(	I-Disease
VWD	I-Disease
)	I-Disease
type	I-Disease
2N	I-Disease
is	O
characterized	O
by	O
a	O
defective	B-NegReg
binding	B-Interaction
of	O
factor	B-Protein
VIII	I-Protein
(	O
FVIII	O
)	O
to	O
von	B-Protein
Willebrand	I-Protein
factor	I-Protein
(	O
VWF	O
)	O
resulting	O
in	O
diminished	B-NegReg
plasma	B-CPA
FVIII	I-CPA
levels	I-CPA
and	O
a	O
clinical	O
phenotype	O
mimicking	O
mild	O
haemophilia	O
A.	O
Several	O
mutations	B-Var
in	O
the	O
FVIII	O
binding	O
site	O
of	O
VWF	B-Gene
have	O
been	O
reported	O
.	O

AIM	O
:	O
This	O
study	O
aims	O
to	O
examine	O
the	O
effect	O
of	O
genotype	O
on	O
clinical	O
phenotype	O
in	O
a	O
cohort	O
of	O
VWD	O
2N	O
patients	O
.	O

METHODS	O
:	O
Patients	O
with	O
at	O
least	O
one	O
genetically	O
confirmed	O
2N	O
mutation	O
were	O
selected	O
retrospectively	O
from	O
a	O
cohort	O
of	O
patients	O
with	O
suspected	O
VWD	O
.	O

Clinical	O
and	O
laboratory	O
phenotypes	O
including	O
bleeding	O
scores	O
(	O
BS	O
)	O
were	O
obtained	O
and	O
analysed	O
.	O

RESULTS	O
:	O
Forty	O
-	O
two	O
VWD	O
2N	O
patients	O
with	O
a	O
mean	O
age	O
of	O
44	O
years	O
were	O
included	O
.	O

Eleven	O
patients	O
were	O
homozygous	O
or	O
compound	O
heterozygous	O
(	O
genetically	O
confirmed	O
group	O
)	O
and	O
31	O
patients	O
were	O
heterozygously	O
affected	O
(	O
carriers	O
group	O
)	O
.	O

Statistically	O
significant	O
differences	O
between	O
genetically	O
confirmed	O
VWD	O
2N	O
patients	O
and	O
carriers	O
were	O
found	O
in	O
FVIII	O
activity	O
,	O
VWF	O
antigen	O
levels	O
,	O
VWF	O
-	O
FVIII	O
binding	O
capacity	O
,	O
FVIII	O
/	O
VWF	O
antigen	O
ratio	O
(	O
all	O
P<0.001	O
)	O
,	O
VWF	O
-	O
ristocetin	O
activity	O
(	O
p=0.001	O
)	O
and	O
VWF	O
collagen	O
binding	O
(	O
P	O
=	O
0.002	O
)	O
.	O

Median	O
BS	O
was	O
6	O
in	O
genetically	O
confirmed	O
VWD	O
2N	O
patients	O
compared	O
with	O
3	O
in	O
carriers	O
(	O
P	O
=	O
0.047	O
)	O
.	O

Haemarthrosis	O
,	O
muscle	O
haematomas	O
and	O
postpartum	O
haemorrhage	O
were	O
only	O
reported	O
in	O
genetically	O
confirmed	O
2N	O
patients	O
.	O

CONCLUSION	O
:	O
Phenotypic	O
analysis	O
showed	O
that	O
all	O
laboratory	O
parameters	O
are	O
lower	O
in	O
genetically	O
confirmed	O
VWD	O
2N	O
patients	O
compared	O
with	O
heterozygous	O
2N	O
carriers	O
.	O

The	O
clinical	O
phenotype	O
in	O
genetically	O
confirmed	O
VWD	O
2N	O
patients	O
is	O
comparable	O
to	O
mild	O
haemophilia	O
A	O
patients	O
and	O
more	O
severe	O
than	O
heterozygous	O
2N	O
carriers	O
.	O

A	O
novel	O
SLC12A3	B-Gene
gene	O
homozygous	O
mutation	B-Var
of	B-Reg
Gitelman	B-Disease
syndrome	I-Disease
in	O
an	O
Asian	O
pedigree	O
and	O
literature	O
review	O
.	O

OBJECTIVES	O
:	O
Gitelman	B-Disease
syndrome	I-Disease
(	O
GS	O
)	O
is	O
an	O
autosomal	O
recessive	O
disease	O
characterized	O
by	O
hypokalemic	O
metabolic	O
alkalosis	O
in	O
combination	O
with	O
significant	O
hypomagnesemia	O
and	O
hypocalciuria	O
which	O
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
SLC12A3	B-Gene
gene	O
.	O

In	O
this	O
study	O
,	O
we	O
reported	O
a	O
case	O
of	O
GS	O
pedigree	O
and	O
reviewed	O
pertinent	O
literature	O
so	O
as	O
to	O
explore	O
the	O
relationship	O
between	O
clinical	O
characteristics	O
and	O
genotype	O
meanwhile	O
provide	O
recommendations	O
for	O
the	O
diagnosis	O
and	O
treatment	O
of	O
GS	O
.	O

DESIGN	O
AND	O
METHODS	O
:	O
This	O
is	O
a	O
pedigree	O
-	O
based	O
genetic	O
study	O
of	O
GS	O
and	O
11	O
members	O
from	O
one	O
family	O
were	O
included	O
.	O

We	O
summarized	O
their	O
clinical	O
features	O
,	O
analyzed	O
laboratory	O
parameters	O
related	O
to	O
GS	O
and	O
SLC12A3	O
gene	O
.	O

RESULTS	O
:	O
The	O
proband	O
experienced	O
intermittent	O
severe	O
symptoms	O
of	O
weakness	O
accompanied	O
by	O
significant	O
hypokalemia	O
,	O
hypomagnesemia	O
and	O
hypocalciuria	O
in	O
laboratory	O
test	O
with	O
poor	O
treatments	O
.	O

His	O
mother	O
had	O
more	O
slight	O
symptoms	O
of	O
weakness	O
than	O
him	O
with	O
mild	O
hypokalemia	O
and	O
hypocalciuria	O
.	O

Mild	O
hypomagnesemia	O
was	O
also	O
observed	O
in	O
his	O
sister	O
with	O
occasional	O
weakness	O
.	O

All	O
other	O
pedigree	O
members	O
had	O
normal	O
laboratory	O
test	O
with	O
no	O
GS	O
-	O
related	O
symptoms	O
.	O

A	O
homozygous	O
mutation	O
of	O
SLC12A3	O
gene	O
(	O
c.488C	O
>	O
T	O
)	O
was	O
detected	O
by	O
genetic	O
testing	O
in	O
three	O
members	O
,	O
and	O
six	O
were	O
carriers	O
of	O
this	O
mutation	O
.	O

CONCLUSIONS	O
:	O
Genotype	O
and	O
phenotype	O
vary	O
significantly	O
among	O
GS	O
patients	O
.	O

Male	O
patients	O
tend	O
to	O
experience	O
more	O
severe	O
symptoms	O
and	O
poor	O
treatment	O
effect	O
.	O

Further	O
large	O
-	O
scale	O
population	O
,	O
animal	O
,	O
and	O
molecular	O
biology	O
experiments	O
are	O
required	O
to	O
investigate	O
the	O
complexity	O
of	O
GS	O
and	O
to	O
find	O
a	O
better	O
treatment	O
regimen	O
for	O
this	O
disease	O
.	O

Gain	O
-	O
of	O
-	O
function	O
p53	O
mutants	O
co	O
-	O
opt	O
chromatin	O
pathways	O
to	O
drive	O
cancer	O
growth	O
.	O

TP53	O
(	O
which	O
encodes	O
p53	O
protein	O
)	O
is	O
the	O
most	O
frequently	O
mutated	O
gene	O
among	O
all	O
human	O
cancers	O
.	O

Prevalent	O
p53	B-Gene
missense	B-Var
mutations	I-Var
abrogate	B-NegReg
its	O
tumour	B-CPA
suppressive	I-CPA
function	I-CPA
and	O
lead	O
to	O
a	O
'	B-PosReg
gain	I-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
'	I-PosReg
(	O
GOF	O
)	O
that	O
promotes	B-PosReg
cancer	B-Disease
.	O

Here	O
we	O
show	O
that	O
p53	B-Gene
GOF	B-PosReg
mutants	B-Var
bind	O
to	O
and	O
upregulate	B-PosReg
chromatin	B-Gene
regulatory	I-Gene
genes	I-Gene
,	O
including	O
the	O
methyltransferases	B-Enzyme
MLL1	I-Enzyme
(	O
also	O
known	O
as	O
KMT2A	O
)	O
,	O
MLL2	B-Enzyme
(	O
also	O
known	O
as	O
KMT2D	O
)	O
,	O
and	O
acetyltransferase	B-Enzyme
MOZ	I-Enzyme
(	O
also	O
known	O
as	O
KAT6A	O
or	O
MYST3	O
)	O
,	O
resulting	O
in	O
genome	O
-	O
wide	O
increases	B-PosReg
of	O
histone	B-MPA
methylation	I-MPA
and	O
acetylation	B-MPA
.	O

Analysis	O
of	O
The	O
Cancer	O
Genome	O
Atlas	O
shows	O
specific	O
upregulation	B-PosReg
of	O
MLL1	B-Enzyme
,	O
MLL2	B-Enzyme
,	O
and	O
MOZ	B-Enzyme
in	O
p53	B-Gene
GOF	B-Var
patient	O
-	O
derived	O
tumours	O
,	O
but	O
not	O
in	O
wild	O
-	O
type	O
p53	O
or	O
p53	O
null	O
tumours	O
.	O

Cancer	O
cell	O
proliferation	O
is	O
markedly	O
lowered	O
by	O
genetic	O
knockdown	O
of	O
MLL1	O
or	O
by	O
pharmacological	O
inhibition	O
of	O
the	O
MLL1	O
methyltransferase	O
complex	O
.	O

Our	O
study	O
reveals	O
a	O
novel	O
chromatin	O
mechanism	O
underlying	O
the	O
progression	O
of	O
tumours	O
with	O
GOF	O
p53	O
,	O
and	O
suggests	O
new	O
possibilities	O
for	O
designing	O
combinatorial	O
chromatin	O
-	O
based	O
therapies	O
for	O
treating	O
individual	O
cancers	O
driven	O
by	O
prevalent	O
GOF	O
p53	O
mutations	O
.	O

Darier	O
disease	O
in	O
israel	O
:	O
combined	O
evaluation	O
of	O
genetic	O
and	O
neuropsychiatric	O
aspects	O
.	O

BACKGROUND	O
:	O
Darier	B-Disease
disease	I-Disease
(	O
DD	O
)	O
is	O
a	O
rare	O
genodermatose	O
caused	B-Reg
by	I-Reg
heterozygous	O
mutations	B-Var
in	O
the	O
ATP2A2	B-Gene
gene	O
and	O
has	O
been	O
associated	O
with	O
neuropsychiatric	O
manifestations	O
.	O

OBJECTIVES	O
:	O
To	O
investigate	O
the	O
genetic	O
basis	O
of	O
Israeli	O
patients	O
with	O
DD	O
,	O
and	O
its	O
association	O
with	O
neuropsychiatric	O
phenotype	O
.	O

METHODS	O
:	O
A	O
cohort	O
of	O
32	O
families	O
comprising	O
74	O
affected	O
individuals	O
and	O
13	O
unaffected	O
family	O
members	O
recruited	O
from	O
the	O
Haemek	O
Dermatology	O
Department	O
and	O
other	O
dermatology	O
clinics	O
in	O
Israel	O
were	O
evaluated	O
by	O
detailed	O
questionnaires	O
,	O
physical	O
examination	O
,	O
and	O
genetic	O
analysis	O
.	O

Main	O
outcome	O
measures	O
were	O
genetic	O
mutations	O
,	O
psychiatric	O
profile	O
,	O
and	O
their	O
association	O
.	O

RESULTS	O
:	O
23	O
mutations	O
in	O
ATP2A2	O
gene	O
were	O
scattered	O
over	O
the	O
entire	O
gene	O
,	O
14	O
of	O
them	O
novel	O
.	O

Two	O
families	O
shared	O
the	O
same	O
mutation	O
.	O

Twenty	O
-	O
one	O
patients	O
(	O
28.3	O
%	O
)	O
had	O
a	O
history	O
of	O
psychiatric	O
disorder	O
,	O
most	O
of	O
them	O
mood	O
disorders	O
;	O
another	O
7	O
(	O
9.4	O
%	O
)	O
patients	O
were	O
highly	O
suspected	O
of	O
having	O
a	O
psychiatric	O
disorder	O
;	O
21	O
(	O
27.6	O
%	O
)	O
reported	O
suicidal	O
thoughts	O
;	O
and	O
5	O
(	O
6.6	O
%	O
)	O
had	O
attempted	O
suicide	O
.	O

Psychiatric	O
phenotype	O
demonstrated	O
inter-	O
and	O
intra	O
-	O
familial	O
variability	O
,	O
and	O
was	O
not	O
associated	O
with	O
disease	O
severity	O
,	O
family	O
history	O
of	O
psychiatric	O
disease	O
,	O
or	O
mutation	O
location	O
.	O

CONCLUSIONS	O
:	O
The	O
cohort	O
demonstrated	O
genetic	O
heterogeneity	O
with	O
no	O
mutation	O
cluster	O
along	O
the	O
gene	O
,	O
and	O
high	O
prevalence	O
of	O
psychiatric	O
disorders	O
.	O

Although	O
no	O
clear	O
genotype	O
-	O
phenotype	O
correlation	O
was	O
found	O
,	O
the	O
results	O
point	O
to	O
a	O
major	O
effect	O
of	O
genetic	O
background	O
on	O
psychiatric	O
phenotype	O
,	O
together	O
with	O
other	O
modifiers	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

DNA	O
damage	O
-	O
induced	O
ephrin	O
-	O
B2	O
reverse	O
signaling	O
promotes	O
chemoresistance	O
and	O
drives	O
EMT	O
in	O
colorectal	O
carcinoma	O
harboring	O
mutant	O
p53	O
.	O

Mutation	O
in	O
the	O
TP53	O
gene	O
positively	O
correlates	O
with	O
increased	O
incidence	O
of	O
chemoresistance	O
in	O
different	O
cancers	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
mechanism	O
of	O
chemoresistance	O
and	O
epithelial	O
-	O
to	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
in	O
colorectal	O
cancer	O
involving	O
the	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
mutant	O
p53	O
/	O
ephrin	O
-	O
B2	O
signaling	O
axis	O
.	O

Bioinformatic	O
analysis	O
of	O
the	O
NCI-60	O
data	O
set	O
and	O
subsequent	O
hub	O
prediction	O
identified	O
EFNB2	O
as	O
a	O
possible	O
GOF	O
mutant	O
p53	O
target	O
gene	O
,	O
responsible	O
for	O
chemoresistance	O
.	O

We	O
show	O
that	O
the	O
mutant	B-Var
p53-NF	B-Gene
-	I-Gene
Y	I-Gene
complex	O
transcriptionally	O
upregulates	B-PosReg
EFNB2	B-Gene
expression	B-MPA
in	O
response	B-MPA
to	I-MPA
DNA	I-MPA
damage	I-MPA
.	O

Moreover	O
,	O
the	O
acetylated	O
form	O
of	O
mutant	B-Var
p53	B-Gene
protein	B-Protein
is	O
recruited	B-PosReg
on	O
the	O
EFNB2	O
promoter	O
and	O
positively	O
regulates	B-Reg
its	O
expression	B-MPA
in	O
conjunction	O
with	O
coactivator	O
p300	O
.	O

In	O
vitro	O
cell	O
line	O
and	O
in	O
vivo	O
nude	O
mice	O
data	O
show	O
that	O
EFNB2	O
silencing	O
restores	O
chemosensitivity	O
in	O
mutant	O
p53-harboring	O
tumors	O
.	O

In	O
addition	O
,	O
we	O
observed	O
high	O
expression	O
of	O
EFNB2	O
in	O
patients	O
having	O
neoadjuvant	O
non	O
-	O
responder	O
colorectal	O
carcinoma	O
compared	O
with	O
those	O
having	O
responder	O
version	O
of	O
the	O
disease	O
.	O

In	O
the	O
course	O
of	O
deciphering	O
the	O
drug	O
resistance	O
mechanism	O
,	O
we	O
also	O
show	O
that	O
ephrin	O
-	O
B2	O
reverse	O
signaling	O
induces	B-PosReg
ABCG2	B-Gene
expression	B-MPA
after	O
drug	O
treatment	O
that	O
involves	O
JNK	B-MPA
-	I-MPA
c	I-MPA
-	I-MPA
Jun	I-MPA
signaling	I-MPA
in	O
mutant	B-Var
p53	B-Gene
cells	O
.	O

Moreover	O
,	O
5-fluorouracil	O
-	O
induced	O
ephrin	O
-	O
B2	O
reverse	O
signaling	O
promotes	O
tumorigenesis	O
through	O
the	O
Src	O
-	O
ERK	O
pathway	O
,	O
and	O
drives	O
EMT	O
via	O
the	O
Src	O
-	O
FAK	O
pathway	O
.	O

We	O
thus	O
conclude	O
that	O
targeting	O
ephrin	O
-	O
B2	O
might	O
enhance	O
the	O
therapeutic	O
potential	O
of	O
DNA	O
-	O
damaging	O
chemotherapeutic	O
agents	O
in	O
mutant	O
p53-bearing	O
human	O
tumors	O
.	O

Cell	O
Death	O
and	O
Differentiation	O
advance	O
online	O
publication	O
,	O
23	O
October	O
2015	O
;	O
doi:10.1038	O
/	O
cdd.2015.133	O
.	O

A	O
recurrent	B-Var
germline	I-Var
mutation	I-Var
in	O
the	O
PIGA	B-Gene
gene	O
causes	B-Reg
Simpson	B-Disease
-	I-Disease
Golabi	I-Disease
-	I-Disease
Behmel	I-Disease
syndrome	I-Disease
type	I-Disease
2	I-Disease
.	O

Hypomorphic	O
germline	O
mutations	O
in	O
the	O
PIGA	O
(	O
phosphatidylinositol	O
glycan	O
class	O
A	O
)	O
gene	O
recently	O
were	O
recognized	O
as	O
the	O
cause	O
of	O
a	O
clinically	O
heterogeneous	O
spectrum	O
of	O
X	O
-	O
linked	O
disorders	O
including	O
(	O
i	O
)	O
early	O
onset	O
epileptic	O
encephalopathy	O
with	O
severe	O
muscular	O
hypotonia	O
,	O
dysmorphism	O
,	O
multiple	O
congenital	O
anomalies	O
,	O
and	O
early	O
death	O
(	O
"	O
MCAHS2	O
"	O
)	O
,	O
(	O
ii	O
)	O
neurodegenerative	O
encephalopathy	O
with	O
systemic	O
iron	O
overload	O
(	O
ferro	O
-	O
cerebro	O
-	O
cutaneous	O
syndrome	O
,	O
"	O
FCCS	O
"	O
)	O
,	O
and	O
(	O
iii	O
)	O
intellectual	O
disability	O
and	O
seizures	O
without	O
dysmorphism	O
.	O

Previous	O
studies	O
showed	O
that	O
the	O
recurrent	O
PIGA	O
germline	O
mutation	O
c.1234C	O
>	O
T	O
(	O
p	O
.	O
Arg412	O
*	O
)	O
leads	O
to	O
a	O
clinical	O
phenotype	O
at	O
the	O
most	O
severe	O
end	O
of	O
the	O
spectrum	O
associated	O
with	O
early	O
infantile	O
lethality	O
.	O

We	O
identified	O
three	O
additional	O
individuals	O
from	O
two	O
unrelated	O
families	O
with	O
the	O
same	O
PIGA	O
mutation	O
.	O

Major	O
clinical	O
findings	O
include	O
early	O
onset	O
intractable	O
epileptic	O
encephalopathy	O
with	O
a	O
burst	O
-	O
suppression	O
pattern	O
on	O
EEG	O
,	O
generalized	O
muscular	O
hypotonia	O
,	O
structural	O
brain	O
abnormalities	O
,	O
macrocephaly	O
and	O
increased	O
birth	O
weight	O
,	O
joint	O
contractures	O
,	O
coarse	O
facial	O
features	O
,	O
widely	O
spaced	O
eyes	O
,	O
a	O
short	O
nose	O
with	O
anteverted	O
nares	O
,	O
gingival	O
overgrowth	O
,	O
a	O
wide	O
mouth	O
,	O
short	O
limbs	O
with	O
short	O
distal	O
phalanges	O
,	O
and	O
a	O
small	O
penis	O
.	O

Based	O
on	O
the	O
phenotypic	O
overlap	O
with	O
Simpson	O
-	O
Golabi	O
-	O
Behmel	O
syndrome	O
type	O
2	O
(	O
SGBS2	O
)	O
,	O
we	O
hypothesized	O
that	O
both	O
disorders	O
might	O
have	O
the	O
same	O
underlying	O
cause	O
.	O

We	O
were	O
able	O
to	O
confirm	O
the	O
same	O
c.1234C	O
>	O
T	O
(	O
p	O
.	O
Arg412	O
*	O
)	O
mutation	O
in	O
the	O
DNA	O
sample	O
from	O
an	O
affected	O
fetus	O
of	O
the	O
original	O
family	O
affected	O
with	O
SGBS2	O
.	O

We	O
conclude	O
that	O
the	O
recurrent	O
PIGA	B-Gene
germline	O
mutation	O
c.1234C	B-Var
>	I-Var
T	I-Var
leads	B-Reg
to	I-Reg
a	O
recognizable	B-CPA
clinical	I-CPA
phenotype	I-CPA
with	O
a	O
poor	O
prognosis	O
and	O
is	O
the	O
cause	B-Reg
of	O
SGBS2	B-Disease
.	O

©	O
2015	O
Wiley	O
Periodicals	O
,	O
Inc.	O
Incontinentia	O
pigmenti	O
(	O
Bloch	O
-	O
Sulzberger	O
syndrome	O
)	O
.	O

Incontinentia	B-Disease
pigmenti	I-Disease
(	O
IP	O
;	O
Bloch	O
-	O
Sulzberger	O
syndrome	O
;	O
OMIM	O
#	O
308300	O
)	O
is	O
an	O
X	O
-	O
linked	O
dominant	O
neurocutaneous	O
disorder	O
with	O
presumed	O
male	O
lethality	O
.	O

It	O
is	O
usually	O
diagnosed	O
in	O
female	O
newborns	O
based	O
on	O
skin	O
features	O
(	O
erythematous	O
,	O
vesicular	O
,	O
or	O
bullous	O
eruption	O
in	O
linear	O
streaks	O
)	O
.	O

The	O
skin	O
lesions	O
evolve	O
into	O
a	O
verrucous	O
stage	O
,	O
followed	O
by	O
atrophy	O
and	O
scarring	O
,	O
leaving	O
linear	O
areas	O
of	O
hypopigmentation	O
and	O
hyperpigmented	O
macules	O
in	O
bizarre	O
patterns	O
following	O
Blaschko	O
's	O
lines	O
.	O

Systemic	O
and	O
neurologic	O
complications	O
include	O
focal	O
seizures	O
and	O
hemorrhagic	O
cerebral	O
infarction	O
in	O
infants	O
,	O
and	O
retinal	O
vasculopathy	O
leading	O
to	O
blindness	O
.	O

Hypodontia	O
,	O
conical	O
or	O
pegged	O
teeth	O
,	O
and	O
linear	O
areas	O
of	O
alopecia	O
persist	O
into	O
adulthood	O
.	O

IP	B-Disease
is	O
caused	B-Reg
by	I-Reg
mutation	B-Var
of	O
the	O
IKBKG	B-Gene
/	I-Gene
NEMO	I-Gene
gene	O
on	O
Xq28	O
.	O

Deletion	O
of	O
exons	O
4	O
to	O
10	O
(	O
NEMOΔ4	O
-	O
10	O
)	O
accounts	O
for	O
about	O
80	O
%	O
of	O
cases	O
(	O
familial	O
and	O
sporadic	O
)	O
.	O

NEMO	B-Gene
mutation	B-Var
leads	O
to	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
of	O
NF	B-MPA
-	I-MPA
κB	I-MPA
,	O
a	O
critical	O
protein	O
that	O
modulates	O
cellular	O
proliferation	O
,	O
apoptosis	O
,	O
and	O
response	O
to	O
proinflammatory	O
factors	O
,	O
leading	B-Reg
to	I-Reg
the	O
characteristic	O
features	O
of	O
IP	B-Disease
.	O

In	O
female	O
carriers	O
,	O
selective	O
loss	O
of	O
cells	O
expressing	O
the	O
mutant	O
X	O
-	O
chromosome	O
results	O
in	O
completely	O
skewed	O
X	O
-	O
inactivation	O
in	O
the	O
majority	O
of	O
cases	O
.	O

Study	O
of	O
mouse	O
models	O
in	O
which	O
various	O
components	O
of	O
the	O
NF	O
-	O
κB	O
pathway	O
(	O
including	O
NEMO	O
)	O
have	O
been	O
knocked	O
out	O
has	O
contributed	O
significantly	O
to	O
our	O
understanding	O
of	O
disease	O
pathogenesis	O
.	O

Lipoid	O
proteinosis	O
.	O

Lipoid	B-Disease
proteinosis	I-Disease
is	O
a	O
rare	O
autosomal	O
recessive	O
disorder	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
ECM1	B-Gene
,	O
encoding	O
extracellular	O
matrix	O
protein	O
1	O
,	O
a	O
glycoprotein	O
expressed	O
in	O
many	O
organs	O
and	O
which	O
has	O
important	O
protein	O
-	O
protein	O
interactions	O
in	O
tissue	O
homeostasis	O
.	O

Although	O
the	O
disease	O
usually	O
presents	O
clinically	O
with	O
warty	O
infiltration	O
of	O
the	O
skin	O
and	O
mucous	O
membranes	O
and	O
a	O
hoarse	O
voice	O
,	O
neuropsychological	O
and	O
neuropsychiatric	O
abnormalities	O
are	O
often	O
prominent	O
features	O
.	O

There	O
may	O
be	O
bean-	O
or	O
comma	O
-	O
shaped	O
intracranial	O
calcifications	O
,	O
often	O
selectively	O
affecting	O
the	O
amygdala	O
.	O

Patients	O
with	O
lipoid	O
proteinosis	O
therefore	O
have	O
been	O
used	O
as	O
models	O
for	O
demonstrating	O
physiologic	O
and	O
pathologic	O
abnormalities	O
of	O
the	O
amygdala	O
with	O
respect	O
to	O
fear	O
processing	O
,	O
affect	O
and	O
cognition	O
,	O
anxiety	O
and	O
memory	O
.	O

Clinically	O
,	O
patients	O
may	O
also	O
have	O
epilepsy	O
,	O
especially	O
involving	O
the	O
temporal	O
lobes	O
.	O

Less	O
common	O
or	O
rare	O
disease	O
associations	O
are	O
headache	O
(	O
including	O
migraine	O
)	O
,	O
ataxia	O
,	O
dizziness	O
,	O
schizophrenia	O
,	O
generalized	O
dystonia	O
,	O
transient	O
brachiofacial	O
paralysis	O
,	O
and	O
intracerebral	O
hemorrhage	O
.	O

Beyond	O
the	O
foci	O
of	O
calcification	O
,	O
the	O
cause	O
of	O
the	O
neurologic	O
abnormalities	O
in	O
lipoid	O
proteinosis	O
is	O
unknown	O
,	O
although	O
the	O
ECM1	O
protein	O
can	O
normally	O
bind	O
to	O
various	O
extracellular	O
matrix	O
proteins	O
and	O
glycosaminoglycans	O
as	O
well	O
as	O
certain	O
enzymes	O
,	O
including	O
matrix	O
metalloproteinase	O
9	O
.	O

Loss	O
of	O
key	O
protein	O
-	O
protein	O
interactions	O
may	O
underscore	O
some	O
of	O
the	O
disease	O
pathophysiology	O
.	O

There	O
is	O
currently	O
no	O
effective	O
treatment	O
for	O
lipoid	O
proteinosis	O
and	O
clinical	O
care	O
is	O
largely	O
supportive	O
.	O

Paternal	O
uniparental	O
disomy	O
11p15.5	O
in	O
the	O
pancreatic	O
nodule	O
of	O
an	O
infant	O
with	O
Costello	O
syndrome	O
:	O
Shared	O
mechanism	O
for	O
hyperinsulinemic	O
hypoglycemia	O
in	O
neonates	O
with	O
Costello	O
and	O
Beckwith	O
-	O
Wiedemann	O
syndrome	O
and	O
somatic	O
loss	O
of	O
heterozygosity	O
in	O
Costello	O
syndrome	O
driving	O
clonal	O
expansion	O
.	O

Costello	B-Disease
syndrome	I-Disease
(	O
CS	O
)	O
entails	O
a	O
cancer	O
predisposition	O
and	O
is	O
caused	O
by	O
activating	B-PosReg
HRAS	B-Gene
mutations	B-Var
,	O
typically	O
arising	O
de	O
novo	O
in	O
the	O
paternal	O
germline	O
.	O

Hypoglycemia	O
is	O
common	O
in	O
CS	O
neonates	O
.	O

A	O
previously	O
reported	O
individual	O
with	O
the	O
rare	O
HRAS	O
p	O
.	O
Gln22Lys	O
had	O
hyperinsulinemic	O
hypoglycemia	O
.	O

Autopsy	O
showed	O
a	O
discrete	O
pancreatic	O
nodule	O
.	O

The	O
morphologic	O
and	O
immunohistochemistry	O
findings	O
,	O
including	O
loss	O
of	O
p57(Kip2	O
)	O
protein	O
,	O
were	O
identical	O
to	O
a	O
focal	O
lesion	O
of	O
congenital	O
hyperinsulinism	O
,	O
however	O
,	O
no	O
KCNJ11	O
or	O
ABCC8	O
mutation	O
was	O
identified	O
and	O
germline	O
derived	O
DNA	O
showed	O
no	O
alternation	O
of	O
the	O
maternal	O
or	O
paternal	O
11p15	O
alleles	O
.	O

Here	O
we	O
report	O
paternal	O
uniparental	O
disomy	O
(	O
pUPD	O
)	O
within	O
the	O
lesion	O
,	O
similar	O
to	O
the	O
pUPD11p15.5	O
in	O
Beckwith	O
-	O
Wiedemann	O
syndrome	O
(	O
BWS	O
)	O
.	O

The	O
similar	O
extent	O
of	O
the	O
pUPD	O
suggests	O
a	O
similar	O
mechanism	O
driving	O
hyperinsulinemia	O
in	O
both	O
conditions	O
.	O

After	O
coincidental	O
somatic	O
LOH	O
and	O
pUPD	O
,	O
the	O
growth	O
promoting	O
effects	O
of	O
the	O
paternally	O
derived	O
HRAS	O
mutation	O
,	O
in	O
combination	O
with	O
the	O
increased	O
function	O
of	O
the	O
adjacent	O
paternally	O
expressed	O
IGF2	O
,	O
may	O
together	O
result	O
in	O
clonal	O
expansion	O
.	O

Although	O
this	O
somatic	O
LOH	O
within	O
pancreatic	O
tissue	O
resulted	O
in	O
hyperinsulinism	O
,	O
similar	O
LOH	O
in	O
mesenchymal	O
cells	O
may	O
drive	O
embryonal	O
rhabdomyosarcoma	O
(	O
ERMS	O
)	O
.	O

Interestingly	O
,	O
biallelic	O
IGF2	O
expression	O
has	O
been	O
linked	O
to	O
rhabdomyosarcoma	O
tumorigenesis	O
and	O
pUPD11	O
occurred	O
in	O
all	O
8	O
ERMS	O
samples	O
from	O
CS	O
individuals	O
.	O

Somatic	O
KRAS	O
and	O
HRAS	O
mutations	O
occur	O
with	O
comparable	O
frequency	O
in	O
isolated	O
malignancies	O
.	O

Yet	O
,	O
the	O
malignancy	O
risk	O
in	O
CS	O
is	O
notably	O
higher	O
than	O
in	O
Noonan	O
syndrome	O
with	O
a	O
KRAS	O
mutation	O
.	O

It	O
is	O
conceivable	O
that	O
HRAS	O
co	O
-	O
localization	O
with	O
IGF2	O
and	O
the	O
combined	O
effect	O
of	O
pUPD	O
11p15.5	O
on	O
both	O
genes	O
contributes	O
to	O
the	O
oncogenic	O
potential	O
.	O

©	O
2015	O
Wiley	O
Periodicals	O
,	O
Inc.	O
Urine	O
-	O
sample	O
-	O
derived	O
human	O
induced	O
pluripotent	O
stem	O
cells	O
as	O
a	O
model	O
to	O
study	O
PCSK9-mediated	O
autosomal	O
dominant	O
hypercholesterolemia	O
.	O

Proprotein	O
convertase	O
subtilisin	O
kexin	O
type	O
9	O
(	O
PCSK9	O
)	O
is	O
a	O
critical	O
modulator	O
of	O
cholesterol	O
homeostasis	O
.	O

Whereas	O
PCSK9	B-Gene
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
mutations	B-Var
are	O
associated	O
with	O
autosomal	B-Disease
dominant	I-Disease
hypercholesterolemia	I-Disease
(	O
ADH	O
)	O
and	O
premature	B-Disease
atherosclerosis	I-Disease
,	O
PCSK9	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LOF	O
)	O
mutations	B-Var
have	B-PosReg
a	O
cardio	B-CPA
-	I-CPA
protective	I-CPA
effect	I-CPA
and	O
in	O
some	O
cases	O
can	O
lead	O
to	O
familial	B-Disease
hypobetalipoproteinemia	I-Disease
(	O
FHBL	O
)	O
.	O

However	O
,	O
limitations	O
of	O
the	O
currently	O
available	O
cellular	O
models	O
preclude	O
deciphering	O
the	O
consequences	O
of	O
PCSK9	O
mutation	O
further	O
.	O

We	O
aimed	O
to	O
validate	O
urine	O
-	O
sample	O
-	O
derived	O
human	O
induced	O
pluripotent	O
stem	O
cells	O
(	O
UhiPSCs	O
)	O
as	O
an	O
appropriate	O
tool	O
to	O
model	O
PCSK9-mediated	O
ADH	O
and	O
FHBL	O
.	O

To	O
achieve	O
our	O
goal	O
,	O
urine	O
-	O
sample	O
-	O
derived	O
somatic	O
cells	O
were	O
reprogrammed	O
into	O
hiPSCs	O
by	O
using	O
episomal	O
vectors	O
.	O

UhiPSC	O
were	O
efficiently	O
differentiated	O
into	O
hepatocyte	O
-	O
like	O
cells	O
(	O
HLCs	O
)	O
.	O

Compared	O
to	O
control	O
cells	O
,	O
cells	O
originally	O
derived	O
from	O
an	O
individual	O
with	O
ADH	O
(	O
HLC	O
-	O
S127R	O
)	O
secreted	O
less	O
PCSK9	O
in	O
the	O
media	O
(	O
-38.5	O
%	O
;	O
P=0.038	O
)	O
and	O
had	O
a	O
71	O
%	O
decrease	O
(	O
P<0.001	O
)	O
of	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
uptake	O
,	O
whereas	O
cells	O
originally	O
derived	O
from	O
an	O
individual	O
with	O
FHBL	O
(	O
HLC	O
-	O
R104C	O
/	O
V114A	O
)	O
displayed	O
a	O
strong	O
decrease	O
in	O
PCSK9	O
secretion	O
(	O
-89.7	O
%	O
;	O
P<0.001	O
)	O
and	O
had	O
a	O
106	O
%	O
increase	O
(	O
P=0.0104	O
)	O
of	O
LDL	O
uptake	O
.	O

Pravastatin	O
treatment	O
significantly	O
enhanced	O
LDL	O
receptor	O
(	O
LDLR	O
)	O
and	O
PCSK9	O
mRNA	O
gene	O
expression	O
,	O
as	O
well	O
as	O
PCSK9	O
secretion	O
and	O
LDL	O
uptake	O
in	O
both	O
control	O
and	O
S127R	O
HLCs	O
.	O

Pravastatin	O
treatment	O
of	O
multiple	O
clones	O
led	O
to	O
an	O
average	O
increase	O
of	O
LDL	O
uptake	O
of	O
2.19±0.77-fold	O
in	O
HLC	O
-	O
S127R	O
compared	O
to	O
1.38±0.49	O
fold	O
in	O
control	O
HLCs	O
(	O
P<0.01	O
)	O
,	O
in	O
line	O
with	O
the	O
good	O
response	O
to	O
statin	O
treatment	O
of	O
individuals	O
carrying	O
the	O
S127R	O
mutation	O
(	O
mean	O
LDL	O
cholesterol	O
reduction=60.4	O
%	O
,	O
n=5	O
)	O
.	O

In	O
conclusion	O
,	O
urine	O
samples	O
provide	O
an	O
attractive	O
and	O
convenient	O
source	O
of	O
somatic	O
cells	O
for	O
reprogramming	O
and	O
hepatocyte	O
differentiation	O
,	O
but	O
also	O
a	O
powerful	O
tool	O
to	O
further	O
decipher	O
PCSK9	O
mutations	O
and	O
function	O
.	O

Progranulin	O
deficiency	O
induces	O
overactivation	O
of	O
WNT5A	O
expression	O
via	O
TNF	O
-	O
α	O
/	O
NF	O
-	O
κB	O
pathway	O
in	O
peripheral	O
cells	O
from	O
frontotemporal	O
dementia	O
-	O
linked	O
granulin	O
mutation	O
carriers	O
.	O

BACKGROUND	O
:	O
Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
progranulin	O
gene	O
(	B-Gene
GRN	I-Gene
)	I-Gene
mutations	B-Var
have	O
been	O
identified	O
as	O
the	O
major	O
cause	O
of	O
frontotemporal	B-Disease
lobar	I-Disease
degeneration	I-Disease
with	O
transactive	O
response	O
(	O
TAR	O
)	O
DNA	O
-	O
binding	O
protein	O
43	O
(	O
TDP-43	O
)	O
pathology	O
(	O
frontotemporal	O
lobar	O
degeneration	O
[	O
FTLD]-TDP	O
)	O
;	O
however	O
,	O
little	O
is	O
known	O
about	O
the	O
association	O
between	O
progranulin	O
(	O
PGRN	O
)	O
deficiency	O
and	O
neuronal	O
loss	O
in	O
individuals	O
with	O
FTLD	O
-	O
TDP	O
.	O

Previously	O
we	O
reported	O
enhanced	O
proliferative	O
activity	O
associated	O
with	O
the	O
activation	O
of	O
WNT5A	O
/	O
CDK6	O
/	O
pRb	O
signalling	O
in	O
PGRN	O
-	O
deficient	O
cells	O
.	O

The	O
objective	O
of	O
this	O
work	O
was	O
to	O
elucidate	O
the	O
association	O
between	O
PGRN	O
deficiency	O
,	O
WNT5A	O
signalling	O
and	O
cell	O
proliferation	O
in	O
immortalized	O
lymphoblasts	O
from	O
carriers	O
of	O
the	O
c.709	O
-	O
1	O
G	O
>	O
A	O
GRN	O
mutation	O
(	O
asymptomatic	O
and	O
FTLD	O
-	O
TDP	O
)	O
.	O

METHODS	O
:	O
We	O
assessed	O
cell	O
proliferation	O
in	O
carriers	O
of	O
the	O
c.709	O
-	O
1	O
G	O
>	O
A	O
GRN	O
gene	O
mutation	O
and	O
controls	O
without	O
GRN	O
mutation	O
and	O
without	O
sign	O
of	O
neurologic	O
degeneration	O
by	O
cell	O
counting	O
or	O
using	O
an	O
MTT	O
assay	O
.	O

We	O
used	O
a	O
luciferase	O
assay	O
to	O
measure	O
the	O
nuclear	O
factor	O
-	O
κ	O
(	O
NF	O
-	O
κ	O
)	O
activity	O
.	O

We	O
evaluated	O
messenger	O
RNA	O
levels	O
using	O
quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
and	O
protein	O
levels	O
by	O
immunoblotting	O
.	O

Co	O
-	O
immunoprecipitation	O
was	O
used	O
to	O
analyze	O
the	O
interaction	O
between	O
PGRN	O
and	O
its	O
receptors	O
.	O

RESULTS	O
:	O
We	O
enrolled	O
19	O
carriers	O
of	O
the	O
GRN	O
gene	O
mutation	O
and	O
10	O
controls	O
in	O
this	O
study	O
.	O

The	O
PGRN	B-Gene
-	I-Gene
deficient	I-Gene
cells	O
showed	O
increased	B-PosReg
expression	B-MPA
of	O
WNT5A	B-Gene
due	O
to	O
NF	B-Pathway
-	I-Pathway
κB	I-Pathway
signalling	I-Pathway
overactivation	B-PosReg
.	O

We	O
observed	O
a	O
competition	O
between	O
PGRN	O
and	O
tumour	O
necrosis	O
factor	O
-	O
α	O
(	O
TNF	O
-	O
α	O
)	O
for	O
binding	O
both	O
TNF	O
receptors	O
(	O
TNFR	O
)	O
I	O
and	O
II	O
.	O

Blocking	O
NF	O
-	O
κB	O
signalling	O
using	O
wedelolactone	O
or	O
specific	O
antibodies	O
against	O
TNFRs	O
inhibited	O
WNT5A	O
overexpression	O
and	O
proliferation	O
of	O
PGRN	O
-	O
deficient	O
cells	O
.	O

Conversely	O
,	O
the	O
activation	O
of	O
NF	O
-	O
κB	O
signalling	O
by	O
TNF	O
-	O
α	O
increased	O
WNT5A	O
-	O
dependent	O
proliferation	O
of	O
control	O
cells	O
.	O

LIMITATIONS	O
:	O
All	O
cell	O
lines	O
were	O
derived	O
from	O
individuals	O
harboring	O
the	O
same	O
splicing	O
GRN	O
mutation	O
.	O

Nevertheless	O
,	O
most	O
of	O
the	O
known	O
GRN	B-Gene
mutations	B-Var
lead	B-Reg
to	I-Reg
haploinsufficiency	B-Var
of	O
the	O
protein	B-Protein
.	O

CONCLUSION	O
:	O
Our	O
results	O
revealed	O
an	O
important	O
role	O
of	O
NF	O
-	O
κB	O
signalling	O
in	O
PGRN	O
-	O
associated	O
FTLD	O
-	O
TDP	O
and	O
confirm	O
that	O
PGRN	O
can	O
bind	O
to	O
TNF	O
-	O
a	O
receptors	O
regulating	O
the	O
expression	O
of	O
WNT5A	O
,	O
suggesting	O
novel	O
targets	O
for	O
treatment	O
of	O
FTLD	O
-	O
TDP	O
linked	O
to	O
GRN	O
mutations	O
.	O

Recurrent	O
MLK4	B-Gene
Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
Function	I-NegReg
Mutations	B-Var
Suppress	B-NegReg
JNK	B-Pathway
Signaling	I-Pathway
to	O
Promote	B-PosReg
Colon	B-Disease
Tumorigenesis	I-Disease
.	O

MLK4	O
is	O
a	O
member	O
of	O
the	O
mixed	O
-	O
lineage	O
family	O
of	O
kinases	O
that	O
regulate	O
the	O
JNK	O
,	O
p38	O
,	O
and	O
ERK	O
kinase	O
signaling	O
pathways	O
.	O

MLK4	O
mutations	O
have	O
been	O
identified	O
in	O
various	O
human	O
cancers	O
,	O
including	O
frequently	O
in	O
colorectal	O
cancer	O
,	O
where	O
their	O
function	O
and	O
pathobiological	O
importance	O
have	O
been	O
uncertain	O
.	O

In	O
this	O
study	O
,	O
we	O
assessed	O
the	O
functional	O
consequences	O
of	O
MLK4	O
mutations	O
in	O
colon	O
tumorigenesis	O
.	O

Biochemical	O
data	O
indicated	O
that	O
a	O
majority	O
of	O
MLK4	B-Gene
mutations	B-Var
are	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LOF	O
)	O
mutations	O
that	O
can	O
exert	O
dominant	O
-	O
negative	O
effects	O
.	O

In	O
seeking	O
to	O
understand	O
the	O
abrogated	O
activity	O
of	O
these	O
mutants	O
,	O
we	O
elucidated	O
a	O
new	O
MLK4	O
catalytic	O
domain	O
structure	O
.	O

To	O
determine	O
whether	O
MLK4	O
is	O
required	O
to	O
maintain	O
tumorigenic	O
phenotypes	O
,	O
we	O
reconstituted	O
its	O
signaling	O
axis	O
in	O
colon	O
cancer	O
cells	O
harboring	O
MLK4-inactivating	O
mutations	O
.	O

We	O
found	O
that	O
restoring	O
MLK4	O
activity	O
reduced	O
cell	O
viability	O
,	O
proliferation	O
,	O
and	O
colony	O
formation	O
in	O
vitro	O
and	O
delayed	O
tumor	O
growth	O
in	O
vivo	O
.	O

Mechanistic	O
investigations	O
established	O
that	O
restoring	O
the	O
function	O
of	O
MLK4	O
selectively	O
induced	O
the	O
JNK	O
pathway	O
and	O
its	O
downstream	O
targets	O
,	O
cJUN	O
,	O
ATF3	O
,	O
and	O
the	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitors	O
CDKN1A	O
and	O
CDKN2B.	O
Our	O
work	O
indicates	O
that	O
MLK4	B-Gene
is	O
a	O
novel	O
tumor	O
-	O
suppressing	O
kinase	O
harboring	O
frequent	O
LOF	B-NegReg
mutations	B-Var
that	O
lead	O
to	O
diminished	B-NegReg
signaling	B-MPA
in	O
the	O
JNK	B-Pathway
pathway	I-Pathway
and	O
enhanced	B-PosReg
proliferation	B-CPA
in	O
colon	O
cancer	O
.	O

Cancer	O
Res	O
;	O
76(3	O
)	O
;	O
1	O
-	O
12	O
.	O

©	O
2015	O
AACR	O
.	O

ADIPOR1	B-Gene
is	O
Mutated	B-Var
in	B-Reg
Syndromic	O
Retinitis	B-Disease
Pigmentosa	I-Disease
.	O

Retinitis	O
pigmentosa	O
(	O
RP	O
)	O
is	O
a	O
genetically	O
heterogeneous	O
retinal	O
disorder	O
.	O

Despite	O
the	O
numerous	O
genes	O
associated	O
with	O
RP	O
already	O
identified	O
,	O
the	O
genetic	O
basis	O
remains	O
unknown	O
in	O
a	O
substantial	O
number	O
of	O
patients	O
and	O
families	O
.	O

In	O
this	O
study	O
,	O
we	O
performed	O
whole	O
exome	O
sequencing	O
to	O
investigate	O
the	O
molecular	O
basis	O
of	O
a	O
syndromic	O
RP	O
case	O
which	O
can	O
not	O
be	O
solved	O
by	O
mutations	O
in	O
known	O
disease	O
-	O
causing	O
genes	O
.	O

After	O
applying	O
a	O
series	O
of	O
variant	O
filtering	O
strategies	O
,	O
we	O
identified	O
an	O
apparently	O
homozygous	O
frameshift	O
mutation	O
,	O
c.31delC	O
(	O
p	O
.	O
Q11Rfs*24	O
)	O
in	O
the	O
ADIPOR1	O
gene	O
.	O

The	O
reported	O
phenotypes	O
of	O
Adipor1-null	O
mice	O
contain	O
retinal	O
dystrophy	O
,	O
obesity	O
and	O
behavioral	O
abnormalities	O
,	O
which	O
highly	O
mimic	O
those	O
in	O
the	O
syndromic	O
RP	O
patient	O
.	O

We	O
further	O
confirmed	O
ADIPOR1	O
retina	O
expression	O
by	O
immunohistochemistry	O
.	O

Our	O
results	O
established	O
ADIPOR1	O
as	O
a	O
novel	O
disease	O
-	O
causing	O
gene	O
for	O
syndromic	O
RP	O
and	O
highlight	O
the	O
importance	O
of	O
fatty	O
acid	O
transport	O
in	O
the	O
retina	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Dysferlinopathy	O
in	O
Iran	O
:	O
Clinical	O
and	O
genetic	O
report	O
.	O

BACKGROUND	O
:	O
Dysferlinopathy	B-Disease
is	O
caused	B-Reg
by	I-Reg
a	O
very	O
wide	O
range	O
of	O
autosomal	O
recessively	O
inherited	O
mutations	B-Var
of	O
the	O
Dysferlin	B-Gene
gene	I-Gene
.	O

It	O
causes	B-Reg
a	O
spectrum	O
of	O
muscle	O
diseases	O
including	O
limb	B-Disease
-	I-Disease
girdle	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
LGMD	O
)	O
2B	O
and	O
Miyoshi	B-Disease
myopathy	I-Disease
(	O
MM	O
)	O
.	O

We	O
describe	O
the	O
clinical	O
course	O
and	O
mutational	O
analyses	O
of	O
15	O
Iranian	O
patients	O
with	O
dysferlinopathy	O
from	O
9	O
different	O
families	O
.	O

METHODS	O
:	O
Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
and	O
55	O
exons	O
and	O
flanking	O
intronic	O
boundaries	O
of	O
the	O
dysferlin	O
gene	O
(	O
DYSF	O
;	O
NM_003494.2	O
)	O
were	O
screened	O
for	O
mutations	O
and	O
analyzed	O
.	O

RESULTS	O
:	O
From	O
15	O
studied	O
patients	O
in	O
9	O
families	O
,	O
5	O
patients	O
were	O
male	O
.	O

Seven	O
families	O
had	O
consanguineous	O
marriage	O
.	O

Median	O
age	O
of	O
onset	O
was	O
16.8	O
;	O
and	O
the	O
median	O
age	O
of	O
diagnosis	O
was	O
26.6	O
.	O

The	O
onset	O
was	O
clearly	O
distal	O
in	O
7	O
patients	O
,	O
and	O
proximal	O
in	O
6	O
patients	O
.	O

Three	O
patients	O
had	O
partial	O
biceps	O
atrophy	O
and	O
13	O
showed	O
prominent	O
calf	O
muscle	O
wasting	O
.	O

Foot	O
plantar	O
flexors	O
,	O
deep	O
finger	O
flexors	O
and	O
hip	O
adductors	O
were	O
predominantly	O
involved	O
.	O

Genetic	O
testing	O
showed	O
homozygous	O
mutation	O
of	O
dysferlin	O
gene	O
in	O
9	O
probands	O
,	O
5	O
of	O
which	O
were	O
not	O
previously	O
reported	O
.	O

CONCLUSION	O
:	O
This	O
work	O
,	O
in	O
fact	O
,	O
may	O
help	O
shed	O
some	O
light	O
on	O
the	O
pattern	O
of	O
this	O
morbidity	O
in	O
Iran	O
,	O
an	O
effort	O
that	O
may	O
have	O
not	O
been	O
attempted	O
so	O
far	O
.	O

Limb	O
-	O
girdle	O
muscular	O
dystrophy	O
type	O
2A	O
in	O
Brazilian	O
children	O
.	O

Calpainopathy	O
is	O
an	O
autosomal	B-Disease
recessive	I-Disease
limb	I-Disease
girdle	I-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
LGMD2A	O
)	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
CAPN3	B-Gene
gene	O
.	O

Objective	O
To	O
present	O
clinical	O
and	O
histological	O
findings	O
in	O
six	O
children	O
with	O
a	O
molecular	O
diagnosis	O
of	O
LGMD2A	O
and	O
additionally	O
the	O
MRI	O
findings	O
in	O
two	O
of	O
them	O
.	O

Method	O
We	O
retrospectively	O
assessed	O
medical	O
records	O
of	O
6	O
patients	O
with	O
mutation	O
on	O
CAPN3	O
gene	O
.	O

Results	O
All	O
patients	O
were	O
female	O
(	O
three	O
to	O
12	O
years	O
)	O
.	O

The	O
mean	O
of	O
age	O
of	O
disease	O
onset	O
was	O
9	O
years	O
.	O

All	O
of	O
them	O
showed	O
progressive	O
weakness	O
with	O
predominance	O
in	O
lower	O
limbs	O
.	O

Other	O
findings	O
were	O
scapular	O
winging	O
,	O
joint	O
contractures	O
and	O
calf	O
hypertrophy	O
.	O

One	O
female	O
had	O
a	O
more	O
severe	O
phenotype	O
than	O
her	O
dizygotic	O
twin	O
sister	O
that	O
was	O
confirmed	O
by	O
muscle	O
MRI	O
.	O

Muscle	O
biopsies	O
showed	O
a	O
dystrophic	O
pattern	O
in	O
all	O
patients	O
.	O

Conclusion	O
In	O
this	O
cohort	O
of	O
children	O
with	O
LGMD2A	O
,	O
the	O
clinical	O
aspects	O
were	O
similar	O
to	O
adults	O
with	O
the	O
same	O
disorder	O
.	O

Frequency	O
of	O
mutations	O
in	O
Mediterranean	O
fever	O
gene	O
,	O
with	O
gender	O
and	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
a	O
Turkish	O
population	O
.	O

Familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	O
)	O
is	O
the	O
most	O
common	O
hereditary	O
inflammatory	O
periodic	O
disease	O
,	O
characterized	O
by	O
recurrent	O
episodes	O
of	O
fever	O
,	O
abdominal	O
pain	O
,	O
synovitis	O
and	O
pleurisy	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
frequency	O
and	O
distribution	O
of	O
Mediterranean	O
fever	O
(	B-Gene
MEFV	I-Gene
)	I-Gene
gene	O
mutations	B-Var
and	O
to	O
investigate	O
the	O
clinical	O
characteristics	O
and	O
genotype	O
-	O
phenotype	O
correlation	O
in	B-Reg
patients	O
with	O
FMF	B-Disease
in	O
Aydin	O
,	O
a	O
province	O
in	O
western	O
Anatolia	O
,	O
Turkey	O
.	O

Therefore	O
,	O
we	O
retrospectively	O
analysed	O
MEFV	O
gene	O
mutations	O
in	O
383	O
patients	O
with	O
suspected	O
FMF	O
and	O
the	O
clinical	O
features	O
of	O
327	O
among	O
them	O
.	O

The	O
MEFV	O
gene	O
mutations	O
were	O
investigated	O
using	O
the	O
reverse	O
dot	O
-	O
blot	O
hybridization	O
technique	O
.	O

We	O
detected	O
26	O
different	O
genotypes	O
and	O
11	O
different	O
mutations	O
.	O

The	O
most	O
common	O
mutations	O
in	O
our	O
cohort	O
were	O
p	O
.	O
M694V	O
(	O
41.15	O
%	O
)	O
,	O
p	O
.	O
E148Q	O
(	O
20.35	O
%	O
)	O
,	O
p	O
.	O
M680I(G	O
/	O
C	O
)	O
(	O
12.39	O
%	O
)	O
and	O
p	O
.	O
R761H	O
(	O
9.73	O
%	O
)	O
.	O

Abdominal	O
pain	O
(	O
86.2	O
%	O
)	O
,	O
fever	O
(	O
80.7	O
%	O
)	O
,	O
arthralgia	O
(	O
57.2	O
%	O
)	O
,	O
vomiting	O
(	O
36.1	O
%	O
)	O
,	O
arthritis	O
(	O
34.6	O
%	O
)	O
,	O
fatigue	O
(	O
31.5	O
%	O
)	O
,	O
anorexia	O
(	O
22.9	O
%	O
)	O
and	O
chest	O
pain	O
(	O
19.0	O
%	O
)	O
were	O
the	O
most	O
prevalent	O
clinical	O
features	O
in	O
our	O
patients	O
.	O

This	O
is	O
the	O
first	O
study	O
from	O
Aydin	O
in	O
which	O
the	O
distribution	O
of	O
MEFV	B-Gene
gene	O
mutations	B-Var
and	O
clinical	O
features	O
were	O
evaluated	O
in	B-Reg
patients	O
with	O
FMF	B-Disease
.	O

We	O
found	O
that	O
the	O
most	O
common	O
mutation	O
was	O
p	O
.	O
M694V	O
in	O
our	O
region	O
,	O
while	O
the	O
frequency	O
of	O
the	O
p	O
.	O
R761H	O
mutation	O
was	O
higher	O
compared	O
to	O
other	O
regions	O
of	O
Turkey	O
with	O
respect	O
to	O
extracted	O
data	O
from	O
previous	O
similar	O
studies	O
.	O

Presented	O
results	O
supported	O
the	O
clinical	O
findings	O
in	O
the	O
literature	O
that	O
the	O
homozygous	O
p	O
.	O
M694V	O
and	O
compound	O
heterozygous	O
genotype	O
were	O
associated	O
with	O
more	O
severe	O
courses	O
in	O
FMF	O
patients	O
.	O

Delayed	O
hemoglobin	O
switching	O
and	O
perinatal	O
neocytolysis	O
in	O
mice	O
with	O
gain	O
-	O
of	O
-	O
function	O
erythropoietin	O
receptor	O
.	O

Mutations	B-Var
of	O
the	O
truncated	O
cytoplasmic	O
domain	O
of	O
human	O
erythropoietin	O
receptor	O
(	B-Gene
EPOR	I-Gene
)	I-Gene
result	B-Reg
in	I-Reg
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
of	O
erythropoietin	B-Pathway
(	I-Pathway
EPO	I-Pathway
)	I-Pathway
signaling	I-Pathway
and	O
a	O
dominantly	B-Disease
inherited	I-Disease
polycythemia	I-Disease
,	O
primary	B-Disease
familial	I-Disease
and	I-Disease
congenital	I-Disease
polycythemia	I-Disease
(	O
PFCP	O
)	O
.	O

We	O
interrogated	O
the	O
unexplained	O
transient	O
absence	O
of	O
perinatal	O
polycythemia	O
observed	O
in	O
PFCP	O
patients	O
using	O
an	O
animal	O
model	O
of	O
PFCP	O
to	O
examine	O
its	O
erythropoiesis	O
during	O
embryonic	O
,	O
perinatal	O
,	O
and	O
early	O
postnatal	O
periods	O
.	O

In	O
this	O
model	O
,	O
we	O
replaced	O
the	O
murine	O
EpoR	O
gene	O
(	O
mEpoR	O
)	O
with	O
the	O
wild	O
-	O
type	O
human	O
EPOR	O
(	O
wtHEPOR	O
)	O
or	O
mutant	O
human	O
EPOR	O
gene	O
(	O
mtHEPOR	O
)	O
and	O
previously	O
reported	O
that	O
the	O
gain	O
-	O
of	O
-	O
function	O
mtHEPOR	O
mice	O
become	O
polycythemic	O
at	O
3~6	O
weeks	O
of	O
age	O
,	O
but	O
not	O
at	O
birth	O
,	O
similar	O
to	O
the	O
phenotype	O
of	O
PFCP	O
patients	O
.	O

In	O
contrast	O
,	O
wtHEPOR	O
mice	O
had	O
sustained	O
anemia	O
.	O

We	O
report	O
that	O
the	O
mtHEPOR	O
fetuses	O
are	O
polycythemic	O
,	O
but	O
their	O
polycythemia	O
is	O
abrogated	O
in	O
the	O
perinatal	O
period	O
and	O
reappears	O
again	O
at	O
3	O
weeks	O
after	O
birth	O
.	O

mtHEPOR	O
fetuses	O
have	O
a	O
delayed	O
switch	O
from	O
primitive	O
to	O
definitive	O
erythropoiesis	O
,	O
augmented	O
erythropoietin	O
signaling	O
,	O
and	O
prolonged	O
Stat5	O
phosphorylation	O
while	O
the	O
wtHEPOR	O
fetuses	O
are	O
anemic	O
.	O

Our	O
study	O
demonstrates	O
the	O
in	O
vivo	O
effect	O
of	O
excessive	O
EPO	O
/	O
EPOR	O
signaling	O
on	O
developmental	O
erythropoiesis	O
switch	O
and	O
describes	O
that	O
fetal	O
polycythemia	O
in	O
this	O
PFCP	O
model	O
is	O
followed	O
by	O
transient	O
correction	O
of	O
polycythemia	O
in	O
perinatal	O
life	O
associated	O
with	O
low	O
Epo	O
levels	O
and	O
increased	O
exposure	O
of	O
erythrocytes	O
'	O
phosphatidylserine	O
.	O

We	O
suggest	O
that	O
neocytolysis	O
contributes	O
to	O
the	O
observed	O
perinatal	O
correction	O
of	O
polycythemia	O
in	O
mtHEPOR	O
newborns	O
as	O
embryos	O
leaving	O
the	O
hypoxic	O
uterus	O
are	O
exposed	O
to	O
normoxia	O
at	O
birth	O
.	O

KEY	O
MESSAGE	O
:	O
Human	O
gain	O
-	O
of	O
-	O
function	O
EPOR	B-Gene
(	O
mtHEPOR	O
)	O
causes	B-Reg
fetal	B-Disease
polycythemia	I-Disease
in	O
knock	B-Var
-	I-Var
in	I-Var
mice	O
.	O

Wild	O
-	O
type	O
human	O
EPOR	O
causes	O
fetal	O
anemia	O
in	O
knock	O
-	O
in	O
mouse	O
model	O
.	O

mtHEPOR	O
mice	O
have	O
delayed	O
switch	O
from	O
primitive	O
to	O
definitive	O
erythropoiesis	O
.	O

Polycythemia	O
of	O
mtHEPOR	O
mice	O
is	O
transiently	O
corrected	O
in	O
perinatal	O
life	O
.	O

mtHEPOR	O
newborns	O
have	O
low	O
Epo	O
and	O
increased	O
exposure	O
of	O
erythrocytes	O
'	O
phosphatidylserine	O
.	O

Renal	O
Cell	O
Carcinoma	O
Programmed	O
Death	O
-	O
ligand	O
1	O
,	O
a	O
New	O
Direct	O
Target	O
of	O
Hypoxia	O
-	O
inducible	O
Factor-2	O
Alpha	O
,	O
is	O
Regulated	O
by	O
von	O
Hippel	O
-	O
Lindau	O
Gene	O
Mutation	O
Status	O
.	O

BACKGROUND	O
:	O
Clear	O
cell	O
renal	O
cell	O
carcinomas	O
(	O
ccRCC	O
)	O
frequently	O
display	O
a	O
loss	O
of	O
function	O
of	O
the	O
von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	O
)	O
gene	O
.	O

OBJECTIVE	O
:	O
To	O
elucidate	O
the	O
putative	O
relationship	O
between	O
VHL	O
mutation	O
status	O
and	O
immune	O
checkpoint	O
ligand	O
programmed	O
death	O
-	O
ligand	O
1	O
(	O
PD	O
-	O
L1	O
)	O
expression	O
.	O

DESIGN	O
,	O
SETTING	O
,	O
AND	O
PARTICIPANTS	O
:	O
A	O
series	O
of	O
32	O
renal	O
tumors	O
composed	O
of	O
11	O
VHL	O
tumor	O
-	O
associated	O
and	O
21	O
sporadic	O
RCCs	O
were	O
used	O
to	O
evaluate	O
PD	O
-	O
L1	O
expression	O
levels	O
after	O
sequencing	O
of	O
the	O
three	O
exons	O
and	O
exon	O
-	O
intron	O
junctions	O
of	O
the	O
VHL	O
gene	O
.	O

The	O
786-O	O
,	O
A498	O
,	O
and	O
RCC4	O
cell	O
lines	O
were	O
used	O
to	O
investigate	O
the	O
mechanisms	O
of	O
PD	O
-	O
L1	O
regulation	O
.	O

OUTCOME	O
MEASUREMENTS	O
AND	O
STATISTICAL	O
ANALYSIS	O
:	O
Fisher	O
's	O
exact	O
test	O
was	O
used	O
for	O
VHL	O
mutation	O
and	O
Kruskal	O
-	O
Wallis	O
test	O
for	O
PD	O
-	O
L1	O
expression	O
.	O

If	O
no	O
covariate	O
accounted	O
for	O
the	O
association	O
of	O
VHL	O
and	O
PD	O
-	O
L1	O
,	O
then	O
a	O
Kruskal	O
-	O
Wallis	O
test	O
was	O
used	O
;	O
otherwise	O
Cochran	O
-	O
Mantel	O
-	O
Haenzsel	O
test	O
was	O
used	O
.	O

We	O
also	O
used	O
the	O
Fligner	O
-	O
Policello	O
test	O
to	O
compare	O
two	O
medians	O
when	O
the	O
distributions	O
had	O
different	O
dispersions	O
.	O

RESULTS	O
AND	O
LIMITATIONS	O
:	O
We	O
demonstrated	O
that	O
tumors	O
from	O
ccRCC	O
patients	O
with	O
VHL	B-Gene
biallelic	O
inactivation	B-Var
(	O
ie	O
,	O
loss	O
of	O
function	O
)	O
display	O
a	O
significant	O
increase	B-PosReg
in	O
PD	B-Protein
-	I-Protein
L1	I-Protein
expression	B-MPA
compared	O
with	O
ccRCC	O
tumors	O
carrying	O
one	O
VHL	O
wild	O
-	O
type	O
allele	O
.	O

Using	O
the	O
inducible	O
VHL	O
786-O	O
-	O
derived	O
cell	O
lines	O
with	O
varying	O
hypoxia	O
-	O
inducible	O
factor-2	O
alpha	O
(	O
HIF-2α	O
)	O
stabilization	O
levels	O
,	O
we	O
showed	O
that	O
PD	B-Protein
-	I-Protein
L1	I-Protein
expression	B-MPA
levels	I-MPA
positively	O
correlate	B-Reg
with	O
VHL	B-Gene
mutation	B-Var
and	O
HIF-2α	O
expression	O
.	O

Targeting	O
HIF-2α	O
decreased	O
PD	O
-	O
L1	O
,	O
while	O
HIF-2α	O
overexpression	O
increased	O
PD	O
-	O
L1	O
mRNA	O
and	O
protein	O
levels	O
in	O
ccRCC	O
cells	O
.	O

Interestingly	O
,	O
chromatin	O
immunoprecipitation	O
and	O
luciferase	O
assays	O
revealed	O
a	O
direct	O
binding	O
of	O
HIF-2α	O
to	O
a	O
transcriptionally	O
active	O
hypoxia	O
-	O
response	O
element	O
in	O
the	O
human	O
PD	O
-	O
L1	O
proximal	O
promoter	O
in	O
786-O	O
cells	O
.	O

CONCLUSIONS	O
:	O
Our	O
work	O
provides	O
the	O
first	O
evidence	O
that	O
VHL	B-Gene
mutations	B-Var
positively	O
correlate	B-Reg
with	O
PD	B-Protein
-	I-Protein
L1	I-Protein
expression	B-MPA
in	O
ccRCC	O
and	O
may	O
influence	B-Reg
the	O
response	B-MPA
to	I-MPA
ccRCC	I-MPA
anti	I-MPA
-	I-MPA
PD	I-MPA
-	I-MPA
L1	I-MPA
/	I-MPA
PD-1	I-MPA
immunotherapy	I-MPA
.	O

PATIENT	O
SUMMARY	O
:	O
We	O
investigated	O
the	O
relationship	O
between	O
von	O
Hippel	O
-	O
Lindau	O
mutations	O
and	O
programmed	O
death	O
-	O
ligand	O
1	O
expression	O
.	O

We	O
demonstrated	O
that	O
von	B-Gene
Hippel	I-Gene
-	I-Gene
Lindau	I-Gene
mutation	B-Var
status	O
significantly	O
correlated	B-Reg
with	O
programmed	B-MPA
death	I-MPA
-	I-MPA
ligand	I-MPA
1	I-MPA
expression	I-MPA
in	O
clear	O
cell	O
renal	O
cell	O
carcinomas	O
.	O

Huntington	O
's	O
Disease	O
:	O
Relationship	O
Between	O
Phenotype	O
and	O
Genotype	O
.	O

Huntington	B-Disease
's	I-Disease
disease	I-Disease
(	O
HD	O
)	O
is	O
an	O
autosomal	O
dominant	O
inherited	O
neurodegenerative	O
disease	O
with	O
the	O
typical	O
manifestations	O
of	O
involuntary	O
movements	O
,	O
psychiatric	O
and	O
behavior	O
disorders	O
,	O
and	O
cognitive	O
impairment	O
.	O

It	O
is	O
caused	B-Reg
by	I-Reg
the	O
dynamic	B-Var
mutation	I-Var
in	I-Var
CAG	I-Var
triplet	I-Var
repeat	I-Var
number	I-Var
in	I-Var
exon	I-Var
1	I-Var
of	O
huntingtin	O
(	B-Gene
HTT	I-Gene
)	I-Gene
gene	O
.	O

The	O
symptoms	O
of	O
HD	O
especially	O
the	O
age	O
at	O
onset	O
are	O
related	O
to	O
the	O
genetic	O
characteristics	O
,	O
both	O
the	O
CAG	O
triplet	O
repeat	O
and	O
the	O
modified	O
factors	O
.	O

Here	O
,	O
we	O
reviewed	O
the	O
recent	O
advancement	O
on	O
the	O
genotype	O
-	O
phenotype	O
relationship	O
of	O
HD	O
,	O
mainly	O
focus	O
on	O
the	O
characteristics	O
of	O
different	O
expanded	O
CAG	O
repeat	O
number	O
,	O
genetic	O
modifiers	O
,	O
and	O
CCG	O
repeat	O
number	O
in	O
the	O
3	O
'	O
end	O
of	O
CAG	O
triplet	O
repeat	O
and	O
their	O
effects	O
on	O
the	O
phenotype	O
.	O

We	O
also	O
reviewed	O
the	O
special	O
forms	O
of	O
HD	O
(	O
juvenile	O
HD	O
,	O
atypical	O
onset	O
HD	O
,	O
and	O
homozygous	O
HD	O
)	O
and	O
their	O
phenotype	O
-	O
genotype	O
correlations	O
.	O

The	O
review	O
will	O
aid	O
clinicians	O
to	O
predict	O
the	O
onset	O
age	O
and	O
disease	O
course	O
of	O
HD	O
,	O
give	O
the	O
genetic	O
counseling	O
,	O
and	O
accelerate	O
research	O
into	O
the	O
HD	O
mechanism	O
.	O

Polyamine	B-Enzyme
oxidase	I-Enzyme
5	I-Enzyme
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
Arabidopsis	O
thaliana	O
trigger	B-Reg
metabolic	B-MPA
and	I-MPA
transcriptional	I-MPA
reprogramming	I-MPA
and	O
promote	B-PosReg
salt	B-MPA
stress	I-MPA
tolerance	I-MPA
.	O

The	O
family	O
of	O
polyamine	O
oxidases	O
(	O
PAO	O
)	O
in	O
Arabidopsis	O
(	O
AtPAO1	O
-	O
5	O
)	O
mediates	O
polyamine	O
(	O
PA	O
)	O
back	O
-	O
conversion	O
,	O
which	O
reverses	O
the	O
PA	O
biosynthetic	O
pathway	O
from	O
spermine	O
and	O
its	O
structural	O
isomer	O
thermospermine	O
(	O
tSpm	O
)	O
into	O
spermidine	O
and	O
then	O
putrescine	O
.	O

Here	O
,	O
we	O
have	O
studied	O
the	O
involvement	O
of	O
PA	O
back	O
-	O
conversion	O
in	O
Arabidopsis	O
salinity	O
tolerance	O
.	O

AtPAO5	O
is	O
the	O
Arabidopsis	O
PAO	O
gene	O
member	O
most	O
transcriptionally	O
induced	O
by	O
salt	O
stress	O
.	O

Two	O
independent	O
loss	O
-	O
of	O
-	O
function	O
mutants	B-Var
(	O
atpao5	O
-	O
2	O
and	O
atpao5	O
-	O
3	O
)	O
were	O
found	O
to	O
exhibit	O
constitutively	O
higher	B-PosReg
tSpm	B-MPA
levels	I-MPA
,	O
with	O
associated	O
increased	O
salt	O
tolerance	O
.	O

Using	O
global	O
transcriptional	O
and	O
metabolomic	O
analyses	O
,	O
the	O
underlying	O
mechanisms	O
were	O
studied	O
.	O

Stimulation	B-PosReg
of	O
abscisic	B-MPA
acid	I-MPA
and	I-MPA
jasmonate	I-MPA
(	I-MPA
JA	I-MPA
)	I-MPA
biosynthesis	I-MPA
and	O
accumulation	B-MPA
of	I-MPA
important	I-MPA
compatible	I-MPA
solutes	I-MPA
,	O
such	O
as	O
sugars	O
,	O
polyols	O
and	O
proline	O
,	O
as	O
well	O
as	O
TCA	B-MPA
cycle	I-MPA
intermediates	I-MPA
were	O
observed	O
in	O
atpao5	O
mutants	B-Var
under	O
salt	O
stress	O
.	O

Expression	O
analyses	O
indicate	O
that	O
tSpm	O
modulates	O
the	O
transcript	O
levels	O
of	O
several	O
target	O
genes	O
,	O
including	O
many	O
involved	O
in	O
the	O
biosynthesis	O
and	O
signalling	O
of	O
JA	O
,	O
some	O
of	O
which	O
are	O
already	O
known	O
to	O
promote	O
salinity	O
tolerance	O
.	O

Transcriptional	O
modulation	O
by	O
tSpm	O
is	O
isomer	O
-	O
dependent	O
,	O
thus	O
demonstrating	O
the	O
specificity	O
of	O
this	O
response	O
.	O

Overall	O
,	O
we	O
conclude	O
that	O
tSpm	O
triggers	O
metabolic	O
and	O
transcriptional	O
reprogramming	O
that	O
promotes	O
salt	O
stress	O
tolerance	O
in	O
Arabidopsis	O
.	O

Recessive	B-Disease
dystrophic	I-Disease
epidermolysis	I-Disease
bullosa	I-Disease
caused	B-Reg
by	I-Reg
a	O
de	B-CPA
novo	I-CPA
interstitial	I-CPA
deletion	B-NegReg
spanning	O
COL7A1	B-Gene
and	O
a	O
hemizygous	O
splicing	B-Var
mutation	I-Var
in	I-Var
trans	I-Var
.	O

BACKGROUND	O
:	O
Recessive	B-Disease
dystrophic	I-Disease
epidermolysis	I-Disease
bullosa	I-Disease
(	O
RDEB	O
)	O
is	O
a	O
rare	O
heritable	O
blistering	O
skin	O
condition	O
caused	O
by	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
the	O
COL7A1	B-Gene
gene	O
.	O

Incongruent	O
gene	O
transmission	O
is	O
occasionally	O
reported	O
in	O
recessive	O
diseases	O
,	O
and	O
its	O
underlying	O
mechanism	O
is	O
often	O
uniparental	O
disomy	O
(	O
UPD	O
)	O
.	O

AIM	O
:	O
To	O
understand	O
the	O
genetic	O
basis	O
of	O
incongruent	O
gene	O
transmission	O
in	O
a	O
Chinese	O
family	O
with	O
RDEB	O
,	O
in	O
which	O
a	O
discrepancy	O
of	O
COL7A1	O
genotyping	O
was	O
encountered	O
during	O
our	O
mutation	O
analysis	O
.	O

METHODS	O
:	O
We	O
used	O
a	O
pCAS2	O
minigene	O
-	O
based	O
in	O
vitro	O
splicing	O
assay	O
to	O
confirm	O
the	O
pathogenicity	O
of	O
the	O
splicing	O
variant	O
we	O
identified	O
in	O
the	O
proband	O
.	O

Next	O
,	O
a	O
combination	O
of	O
genetic	O
tools	O
,	O
including	O
whole	O
-	O
genome	O
SNP	O
array	O
analysis	O
and	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
copy	O
number	O
analysis	O
,	O
was	O
used	O
to	O
unravel	O
the	O
cause	O
of	O
the	O
discrepancy	O
in	O
the	O
COL7A1	O
genotyping	O
.	O

RESULTS	O
:	O
Sanger	O
sequencing	O
identified	O
a	O
novel	O
,	O
single	O
-	O
peak	O
mutation	O
,	O
c.4980	O
+	O
5G	O
>	O
C	O
,	O
in	O
COL7A1	O
in	O
the	O
proband	O
,	O
which	O
was	O
heterozygous	O
in	O
his	O
father	O
and	O
wild	O
type	O
in	O
his	O
mother	O
.	O

In	O
vitro	O
splicing	O
assay	O
showed	O
that	O
c.4980	O
+	O
5G	O
>	O
C	O
was	O
pathogenic	O
and	O
led	O
to	O
skipping	O
of	O
COL7A1	O
exon	O
53	O
.	O

SNP	O
array	O
analysis	O
and	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
of	O
the	O
proband	O
's	O
DNA	O
revealed	O
a	O
maternally	O
derived	O
,	O
de	O
novo	O
,	O
interstitial	O
deletion	O
on	O
chromosome	O
3p21.31	O
,	O
which	O
removed	O
COL7A1	O
and	O
15	O
flanking	O
genes	O
,	O
excluding	O
the	O
possibility	O
of	O
UPD	O
.	O

CONCLUSION	O
:	O
Our	O
findings	O
favour	O
an	O
exceptionally	O
rare	O
event	O
,	O
namely	O
a	O
de	O
novo	O
COL7A1	O
microdeletion	O
in	O
concurrence	O
with	O
an	O
inherited	O
mutation	O
in	O
trans	O
.	O

This	O
study	O
should	O
aid	O
molecular	O
diagnosis	O
and	O
genetic	O
counselling	O
of	O
RDEB	O
and	O
possibly	O
other	O
recessive	O
diseases	O
in	O
which	O
genotyping	O
discrepancy	O
is	O
encountered	O
.	O

A	O
novel	O
frameshift	O
mutation	O
leading	O
to	O
inherited	O
type	O
I	O
antithrombin	O
deficiency	O
.	O

Inherited	B-Disease
antithrombin	I-Disease
(	I-Disease
AT	I-Disease
)	I-Disease
deficiency	I-Disease
is	O
an	O
autosomal	O
dominant	O
thrombotic	O
disorder	O
.	O

We	O
encountered	O
a	O
case	O
of	O
inherited	O
type	O
I	O
AT	B-Disease
deficiency	I-Disease
and	O
identified	B-Reg
the	O
mutation	O
responsible	O
;	O
a	O
novel	O
5406delA	B-Var
mutation	I-Var
in	O
the	O
SERPINC1	B-Gene
gene	O
appeared	O
to	O
have	O
caused	B-Reg
a	O
frameshift	B-MPA
with	I-MPA
premature	I-MPA
termination	I-MPA
at	I-MPA
amino	I-MPA
acid	I-MPA
+283	I-MPA
.	O

The	O
recombinant	O
AT	O
protein	O
including	O
5406delA	O
was	O
not	O
detected	O
in	O
cell	O
lysates	O
or	O
culture	O
supernatants	O
.	O

These	O
results	O
will	O
contribute	O
to	O
the	O
creation	O
of	O
an	O
accurate	O
database	O
and	O
define	O
the	O
molecular	O
basis	O
for	O
AT	O
deficiency	O
.	O

Increase	O
in	O
NRAS	O
mutant	O
allele	O
percentage	O
during	O
metastatic	O
melanoma	O
progression	O
.	O

One	O
-	O
fifth	O
of	O
cutaneous	B-Disease
melanomas	I-Disease
have	O
dominant	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutations	B-Var
of	O
the	O
NRAS	B-Gene
oncogene	O
.	O

We	O
report	O
the	O
first	O
two	O
cases	O
of	O
increasing	O
NRAS	O
mutant	O
allele	O
frequency	O
in	O
melanoma	O
metastases	O
and	O
show	O
that	O
the	O
chromosomal	O
mechanism	O
of	O
this	O
homozygosity	O
is	O
an	O
increased	O
polysomy	O
of	O
chromosome	O
1	O
.	O

We	O
observed	O
an	O
increase	O
in	O
NRAS	O
mutant	O
allele	O
percentage	O
(	O
NRAS	O
-	O
MA%	O
)	O
in	O
the	O
metastatic	O
melanoma	O
progression	O
from	O
2	O
patients	O
with	O
melanomas	O
harbouring	O
a	O
NRAS	O
mutation	O
(	O
p	O
.	O
Q61	O
K	O
in	O
case	O
1	O
and	O
p	O
.	O
Q61R	O
in	O
case	O
2	O
)	O
.	O

In	O
case	O
1	O
,	O
we	O
observed	O
a	O
NRAS	O
-	O
MA%	O
increase	O
from	O
18	O
%	O
within	O
the	O
first	O
metastatic	O
node	O
to	O
81	O
%	O
,	O
92	O
%	O
and	O
85	O
%	O
respectively	O
in	O
the	O
three	O
subsequent	O
metastases	O
:	O
lymph	O
node	O
,	O
brain	O
and	O
subcutaneous	O
metastases	O
biopsied	O
1	O
,	O
6	O
and	O
17	O
months	O
,	O
respectively	O
,	O
after	O
the	O
initial	O
lymph	O
node	O
biopsy	O
.	O

In	O
case	O
2	O
,	O
we	O
observed	O
an	O
increase	O
in	O
NRAS	O
-	O
MA%	O
from	O
40	O
%	O
within	O
the	O
primary	O
melanoma	O
to	O
63	O
%	O
within	O
the	O
metastatic	O
lymph	O
node	O
.	O

FISH	O
analysis	O
showed	O
the	O
same	O
results	O
in	O
both	O
cases	O
:	O
a	O
frequent	O
polysomy	O
of	O
chromosome	O
1	O
in	O
metastasis	O
samples	O
with	O
NRAS	O
mutant	O
allele	O
percentage	O
>	O
60	O
%	O
,	O
while	O
most	O
cells	O
were	O
disomic	O
in	O
the	O
samples	O
with	O
well	O
-	O
balanced	O
heterozygous	O
mutations	O
.	O

The	O
percentage	O
of	O
NRAS	O
mutant	O
allele	O
may	O
increase	O
during	O
metastatic	O
progression	O
and	O
may	O
be	O
associated	O
with	O
chromosomal	O
instability	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
evaluate	O
the	O
prognostic	O
impact	O
of	O
the	O
NRAS	O
homozygous	O
status	O
and/or	O
polyploidy	O
in	O
metastatic	O
cutaneous	O
melanomas	O
.	O

A	O
Comprehensive	O
Analysis	O
of	O
Choroideremia	O
:	O
From	O
Genetic	O
Characterization	O
to	O
Clinical	O
Practice	O
.	O

Choroideremia	B-Disease
(	O
CHM	O
)	O
is	O
a	O
rare	O
X	O
-	O
linked	O
disease	O
leading	O
to	O
progressive	O
retinal	O
degeneration	O
resulting	O
in	O
blindness	O
.	O

The	O
disorder	O
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
CHM	B-Gene
gene	O
encoding	O
REP-1	O
protein	O
,	O
an	O
essential	O
component	O
of	O
the	O
Rab	O
geranylgeranyltransferase	O
(	O
GGTase	O
)	O
complex	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
evaluated	O
a	O
multi	O
-	O
technique	O
analysis	O
algorithm	O
to	O
describe	O
the	O
mutational	O
spectrum	O
identified	O
in	O
a	O
large	O
cohort	O
of	O
cases	O
and	O
further	O
correlate	O
CHM	O
variants	O
with	O
phenotypic	O
characteristics	O
and	O
biochemical	O
defects	O
of	O
choroideremia	O
patients	O
.	O

Molecular	O
genetic	O
testing	O
led	O
to	O
the	O
characterization	O
of	O
36	O
out	O
of	O
45	O
unrelated	O
CHM	O
families	O
(	O
80	O
%	O
)	O
,	O
allowing	O
the	O
clinical	O
reclassification	O
of	O
four	O
CHM	O
families	O
.	O

Haplotype	O
reconstruction	O
showed	O
independent	O
origins	O
for	O
the	O
recurrent	O
p	O
.	O
Arg293	O
*	O
and	O
p	O
.	O
Lys178Argfs*5	O
mutations	O
,	O
suggesting	O
the	O
presence	O
of	O
hotspots	O
in	O
CHM	O
,	O
as	O
well	O
as	O
the	O
identification	O
of	O
two	O
different	O
unrelated	O
events	O
involving	O
exon	O
9	O
deletion	O
.	O

No	O
certain	O
genotype	O
-	O
phenotype	O
correlation	O
could	O
be	O
established	O
.	O

Furthermore	O
,	O
all	O
the	O
patients	O
´	O
fibroblasts	O
analyzed	O
presented	O
significantly	O
increased	O
levels	O
of	O
unprenylated	O
Rabs	O
proteins	O
compared	O
to	O
control	O
cells	O
;	O
however	O
,	O
this	O
was	O
not	O
related	O
to	O
the	O
genotype	O
.	O

This	O
research	O
demonstrates	O
the	O
major	O
potential	O
of	O
the	O
algorithm	O
proposed	O
for	O
diagnosis	O
.	O

Our	O
data	O
enhance	O
the	O
importance	O
of	O
establish	O
a	O
differential	O
diagnosis	O
with	O
other	O
retinal	O
dystrophies	O
,	O
supporting	O
the	O
idea	O
of	O
an	O
underestimated	O
prevalence	O
of	O
choroideremia	O
.	O

Moreover	O
,	O
they	O
suggested	O
that	O
the	O
severity	O
of	O
the	O
disorder	O
can	O
not	O
be	O
exclusively	O
explained	O
by	O
the	O
genotype	O
.	O

Four	O
novel	O
ATP2C1	B-Gene
mutations	B-Var
in	O
Chinese	O
patients	O
with	B-Reg
Hailey	B-Disease
-	I-Disease
Hailey	I-Disease
disease	I-Disease
.	O

Hailey	O
-	O
Hailey	O
disease	O
(	O
HHD	O
)	O
is	O
a	O
kind	O
of	O
autosomal	O
dominant	O
dermatosis	O
.	O

The	O
ATP2C1	O
gene	O
has	O
been	O
identified	O
as	O
the	O
pathogenic	O
gene	O
of	O
HHD	O
since	O
2000	O
.	O

In	O
this	O
study	O
,	O
direct	O
DNA	O
sequencing	O
was	O
used	O
to	O
identify	O
ATP2C1	O
gene	O
mutations	O
in	O
four	O
Chinese	O
families	O
and	O
two	O
sporadic	O
cases	O
with	O
HHD	O
.	O

The	O
entire	O
coding	O
and	O
flanking	O
intronic	O
sequences	O
of	O
ATP2C1	O
were	O
screened	O
for	O
mutations	O
and	O
five	O
heterozygous	O
mutations	O
of	O
the	O
ATP2C1	O
gene	O
were	O
detected	O
in	O
the	O
four	O
pedigrees	O
and	O
two	O
sporadic	O
cases	O
with	O
HHD	O
.	O

Four	O
of	O
them	O
were	O
novel	O
,	O
including	O
three	O
frame	O
-	O
shift	O
mutations	O
(	O
c.1330delC	O
,	O
c.888_889insT	O
,	O
c.478_479insA	O
)	O
and	O
one	O
nonsense	O
mutation	O
(	O
c.1720C	O
>	O
T	O
)	O
.	O

These	O
data	O
added	O
new	O
variants	O
to	O
the	O
database	O
of	O
ATP2C1	B-Gene
mutations	B-Var
associated	B-Reg
with	I-Reg
HHD	B-Disease
.	O

Glycogen	O
storage	O
disease	O
type	O
III	O
:	O
diagnosis	O
,	O
genotype	O
,	O
management	O
,	O
clinical	O
course	O
and	O
outcome	O
.	O

Glycogen	B-Disease
storage	I-Disease
disease	I-Disease
type	I-Disease
III	I-Disease
(	O
GSDIII	O
)	O
is	O
a	O
rare	O
disorder	O
of	O
glycogenolysis	O
due	B-Reg
to	I-Reg
AGL	B-Gene
gene	O
mutations	B-Var
,	O
causing	O
glycogen	O
debranching	O
enzyme	O
deficiency	O
and	O
storage	O
of	O
limited	O
dextrin	O
.	O

Patients	O
with	O
GSDIIIa	O
show	O
involvement	O
of	O
liver	O
and	O
cardiac	O
/	O
skeletal	O
muscle	O
,	O
whereas	O
GSDIIIb	O
patients	O
display	O
only	O
liver	O
symptoms	O
and	O
signs	O
.	O

The	O
International	O
Study	O
on	O
Glycogen	O
Storage	O
Disease	O
(	O
ISGSDIII	O
)	O
is	O
a	O
descriptive	O
retrospective	O
,	O
international	O
,	O
multi	O
-	O
centre	O
cohort	O
study	O
of	O
diagnosis	O
,	O
genotype	O
,	O
management	O
,	O
clinical	O
course	O
and	O
outcome	O
of	O
175	O
patients	O
from	O
147	O
families	O
(	O
86	O
%	O
GSDIIIa	O
;	O
14	O
%	O
GSDIIIb	O
)	O
,	O
with	O
follow	O
-	O
up	O
into	O
adulthood	O
in	O
91	O
patients	O
.	O

In	O
total	O
58	O
AGL	O
mutations	O
(	O
non	O
-	O
missense	O
mutations	O
were	O
overrepresented	O
and	O
21	O
novel	O
mutations	O
were	O
observed	O
)	O
were	O
identified	O
in	O
76	O
families	O
.	O

GSDIII	O
patients	O
first	O
presented	O
before	O
the	O
age	O
of	O
1.5	O
years	O
,	O
hepatomegaly	O
was	O
the	O
most	O
common	O
presenting	O
clinical	O
sign	O
.	O

Dietary	O
management	O
was	O
very	O
diverse	O
and	O
included	O
frequent	O
meals	O
,	O
uncooked	O
cornstarch	O
and	O
continuous	O
gastric	O
drip	O
feeding	O
.	O

Chronic	O
complications	O
involved	O
the	O
liver	O
(	O
hepatic	O
cirrhosis	O
,	O
adenoma(s	O
)	O
,	O
and/or	O
hepatocellular	O
carcinoma	O
in	O
11	O
%	O
)	O
,	O
heart	O
(	O
cardiac	O
involvement	O
and	O
cardiomyopathy	O
,	O
in	O
58	O
%	O
and	O
15	O
%	O
,	O
respectively	O
,	O
generally	O
presenting	O
in	O
early	O
childhood	O
)	O
,	O
and	O
muscle	O
(	O
pain	O
in	O
34	O
%	O
)	O
.	O

Type	O
2	O
diabetes	O
mellitus	O
was	O
diagnosed	O
in	O
eight	O
out	O
of	O
91	O
adult	O
patients	O
(	O
9	O
%	O
)	O
.	O

In	O
adult	O
patients	O
no	O
significant	O
correlation	O
was	O
detected	O
between	O
(	O
non-	O
)	O
missense	O
AGL	O
genotypes	O
and	O
hepatic	O
,	O
cardiac	O
or	O
muscular	O
complications	O
.	O

This	O
study	O
demonstrates	O
heterogeneity	O
in	O
a	O
large	O
cohort	O
of	O
ageing	O
GSDIII	O
patients	O
.	O

An	O
international	O
GSD	O
patient	O
registry	O
is	O
warranted	O
to	O
prospectively	O
define	O
the	O
clinical	O
course	O
,	O
heterogeneity	O
and	O
the	O
effect	O
of	O
different	O
dietary	O
interventions	O
in	O
patients	O
with	O
GSDIII	O
.	O

Transcriptome	O
profiling	O
identifies	O
genes	O
and	O
pathways	O
deregulated	O
upon	O
floxuridine	O
treatment	O
in	O
colorectal	O
cancer	O
cells	O
harboring	O
GOF	O
mutant	O
p53	O
.	O

Mutation	O
in	O
TP53	O
is	O
a	O
common	O
genetic	O
alteration	O
in	O
human	O
cancers	O
.	O

Certain	O
tumor	O
associated	O
p53	B-Gene
missense	B-Var
mutants	I-Var
acquire	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
properties	O
and	O
confer	O
oncogenic	O
phenotypes	O
including	O
enhanced	B-PosReg
chemoresistance	B-CPA
.	O

The	O
colorectal	O
cancers	O
(	O
CRC	O
)	O
harboring	O
mutant	O
p53	O
are	O
generally	O
aggressive	O
in	O
nature	O
and	O
difficult	O
to	O
treat	O
.	O

To	O
identify	O
a	O
potential	O
gene	O
expression	O
signature	O
of	O
GOF	O
mutant	O
p53-driven	O
acquired	O
chemoresistance	O
in	O
CRC	O
,	O
we	O
performed	O
transcriptome	O
profiling	O
of	O
floxuridine	O
(	O
FUdR	O
)	O
treated	O
SW480	O
cells	O
expressing	O
mutant	O
p53(R273H	O
)	O
(	O
GEO	O
#	O
:	O
GSE77533	O
)	O
.	O

We	O
obtained	O
several	O
genes	O
differentially	O
regulated	O
between	O
FUdR	O
treated	O
and	O
untreated	O
cells	O
.	O

Further	O
,	O
functional	O
characterization	O
and	O
pathway	O
analysis	O
revealed	O
significant	O
enrichment	O
of	O
crucial	O
biological	O
processes	O
and	O
pathways	O
upon	O
FUdR	O
treatment	O
in	O
SW480	O
cells	O
.	O

Our	O
data	O
suggest	O
that	O
in	O
response	O
to	O
chemotherapeutics	O
treatment	O
,	O
cancer	O
cells	O
with	O
GOF	B-PosReg
mutant	B-Var
p53	B-Gene
can	O
modulate	B-Reg
key	B-Pathway
cellular	I-Pathway
pathways	I-Pathway
to	O
withstand	B-CPA
the	I-CPA
cytotoxic	I-CPA
effect	I-CPA
of	I-CPA
the	I-CPA
drugs	I-CPA
.	O

The	O
genes	O
and	O
pathways	O
identified	O
in	O
the	O
present	O
study	O
can	O
be	O
further	O
validated	O
and	O
targeted	O
for	O
better	O
chemotherapy	O
response	O
in	O
colorectal	O
cancer	O
patients	O
harboring	O
mutant	O
p53	O
.	O

Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
Function	I-PosReg
Mutations	B-Var
in	O
RARB	B-Gene
Cause	B-Reg
Intellectual	B-MPA
Disability	I-MPA
with	O
Progressive	B-MPA
Motor	I-MPA
Impairment	I-MPA
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
signaling	O
plays	O
a	O
key	O
role	O
in	O
the	O
development	O
and	O
function	O
of	O
several	O
systems	O
in	O
mammals	O
.	O

We	O
previously	O
discovered	O
that	O
the	O
de	O
novo	O
mutations	O
c.1159C	B-Var
>	I-Var
T	I-Var
(	O
p	O
.	O
Arg387Cys	O
)	O
and	O
c.1159C	B-Var
>	I-Var
A	I-Var
(	O
p	O
.	O
Arg387Ser	O
)	O
in	O
the	O
RA	O
Receptor	O
Beta	O
(	B-Gene
RARB	I-Gene
)	I-Gene
gene	O
cause	B-Reg
microphthalmia	B-Disease
and	O
diaphragmatic	B-Disease
hernia	I-Disease
.	O

However	O
,	O
the	O
natural	O
history	O
of	O
affected	O
subjects	O
beyond	O
the	O
prenatal	O
or	O
neonatal	O
period	O
was	O
unknown	O
.	O

Here	O
,	O
we	O
describe	O
nine	O
additional	O
subjects	O
with	O
microphthalmia	O
who	O
have	O
de	O
novo	O
mutations	O
in	O
RARB	O
,	O
including	O
the	O
previously	O
described	O
p	O
.	O
Arg387Cys	O
as	O
well	O
as	O
the	O
novel	O
c.887G	O
>	O
C	O
(	O
p	O
.	O
Gly296Ala	O
)	O
and	O
c.638T	O
>	O
C	O
(	O
p	O
.	O
Leu213Pro	O
)	O
.	O

Moreover	O
,	O
we	O
review	O
the	O
information	O
on	O
four	O
previously	O
reported	O
cases	O
.	O

All	O
subjects	O
who	O
survived	O
the	O
neonatal	O
period	O
(	O
n	O
=	O
10	O
)	O
displayed	O
severe	O
global	O
developmental	O
delay	O
with	O
progressive	O
motor	O
impairment	O
due	O
to	O
spasticity	O
and/or	O
dystonia	O
(	O
with	O
or	O
without	O
chorea	O
)	O
.	O

The	O
majority	O
of	O
subjects	O
also	O
showed	O
Chiari	O
type	O
I	O
malformation	O
and	O
severe	O
feeding	O
difficulties	O
.	O

We	O
previously	O
found	O
that	O
p	O
.	O
Arg387Cys	O
and	O
p	O
.	O
Arg387Ser	O
induce	O
a	O
gain	O
-	O
of	O
-	O
function	O
.	O

We	O
show	O
here	O
that	O
the	O
p	B-Var
.	I-Var
Gly296Ala	I-Var
and	O
p	B-Var
.	I-Var
Leu213Pro	I-Var
RARB	B-Gene
mutations	O
further	O
promote	B-PosReg
the	O
RA	B-MPA
ligand	I-MPA
-	I-MPA
induced	I-MPA
transcriptional	I-MPA
activity	I-MPA
by	O
twofold	O
to	O
threefold	O
over	O
the	O
wild	O
-	O
type	O
receptor	O
,	O
also	O
indicating	O
a	O
gain	O
-	O
of	O
-	O
function	O
mechanism	O
.	O

These	O
observations	O
suggest	O
that	O
precise	O
regulation	O
of	O
RA	O
signaling	O
is	O
required	O
for	O
brain	O
development	O
and/or	O
function	O
in	O
humans	O
.	O

Long	O
-	O
term	O
vemurafenib	O
treatment	O
drives	B-Reg
inhibitor	B-MPA
resistance	I-MPA
through	O
a	O
spontaneous	O
KRAS	B-Gene
G12D	B-Var
mutation	O
in	O
a	O
BRAF	O
V600E	O
papillary	O
thyroid	O
carcinoma	O
model	O
.	O

The	O
BRAF	O
V600E	O
mutation	O
is	O
commonly	O
observed	O
in	O
papillary	O
thyroid	O
cancer	O
(	O
PTC	O
)	O
and	O
predominantly	O
activates	O
the	O
MAPK	O
pathway	O
.	O

Presence	O
of	O
BRAF	O
V600E	O
predicts	O
increasing	O
risk	O
of	O
recurrence	O
and	O
higher	O
mortality	O
rate	O
,	O
and	O
treatment	O
options	O
for	O
such	O
patients	O
are	O
limited	O
.	O

Vemurafenib	O
,	O
a	O
BRAF	O
V600E	O
inhibitor	O
,	O
is	O
initially	O
effective	O
,	O
but	O
cells	O
inevitably	O
develop	O
alternative	O
mechanisms	O
of	O
pathway	O
activation	O
.	O

Mechanisms	O
of	O
primary	O
resistance	O
have	O
been	O
described	O
in	O
short	O
-	O
term	O
cultures	O
of	O
PTC	O
cells	O
;	O
however	O
,	O
mechanisms	O
of	O
acquired	O
resistance	O
have	O
not	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
possible	O
adaptive	O
mechanisms	O
of	O
BRAF	O
V600E	O
inhibitor	O
resistance	O
in	O
KTC1	O
thyroid	O
cancer	O
cells	O
following	O
long	O
-	O
term	O
vemurafenib	O
exposure	O
.	O

We	O
found	O
that	O
a	O
subpopulation	O
of	O
KTC1	O
cells	O
acquired	O
resistance	O
to	O
vemurafenib	O
following	O
5	O
months	O
of	O
treatment	O
with	O
the	O
inhibitor	O
.	O

Resistance	O
coincided	O
with	O
the	O
spontaneous	O
acquisition	O
of	O
a	O
KRAS	O
G12D	O
activating	O
mutation	O
.	O

Increases	O
in	O
activated	O
AKT	O
,	O
ERK1/2	O
,	O
and	O
EGFR	O
were	O
observed	O
in	O
these	O
cells	O
.	O

In	O
addition	O
,	O
the	O
resistant	O
cells	O
were	O
less	O
sensitive	O
to	O
combinations	O
of	O
vemurafenib	O
and	O
MEK1	O
inhibitor	O
or	O
AKT	O
inhibitor	O
.	O

These	O
results	O
support	O
the	O
KRAS	B-Gene
G12D	B-Var
mutation	O
as	O
a	O
genetic	O
mechanism	O
of	O
spontaneously	O
acquired	B-Reg
secondary	B-MPA
BRAF	I-MPA
inhibitor	I-MPA
resistance	I-MPA
in	O
BRAF	O
V600E	O
thyroid	O
cancer	O
cells	O
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
the	O
APX1	B-Gene
gene	O
result	O
in	O
enhanced	B-PosReg
selenium	B-MPA
tolerance	I-MPA
in	O
Arabidopsis	O
thaliana	O
.	O

It	O
is	O
generally	O
recognized	O
that	O
excess	O
selenium	O
(	O
Se	O
)	O
has	O
a	O
negative	O
effect	O
on	O
the	O
growth	O
and	O
development	O
of	O
plants	O
.	O

Numerous	O
studies	O
have	O
identified	O
key	O
genes	O
involved	O
in	O
selenium	O
tolerance	O
in	O
plants	O
;	O
however	O
,	O
our	O
understanding	O
of	O
its	O
molecular	O
mechanisms	O
is	O
far	O
from	O
complete	O
.	O

In	O
this	O
study	O
,	O
we	O
isolated	O
an	O
Arabidopsis	O
selenium	O
-	O
resistant	O
mutant	B-Var
from	O
the	O
mutant	O
XVE	O
pool	O
lines	O
because	O
of	O
its	O
increased	B-PosReg
root	B-MPA
growth	I-MPA
and	O
fresh	B-MPA
weight	I-MPA
in	O
Se	O
stress	O
,	O
and	O
cloned	O
the	O
gene	O
,	O
which	O
encodes	O
the	O
cytosolic	O
ascorbate	O
peroxidase	O
(	O
APX1	O
)	O
.	O

Two	O
other	O
APX1	O
gene	O
knockout	O
allelic	O
lines	O
were	O
also	O
selenium	O
resistant	O
,	O
and	O
the	O
APX1-complementary	O
COM1	O
restored	O
the	O
growth	O
state	O
of	O
wild	O
type	O
under	O
Se	O
stress	O
.	O

In	O
addition	O
,	O
these	O
APX1	O
allelic	O
lines	O
accumulated	O
more	O
Se	O
than	O
did	O
wild	O
-	O
type	O
plants	O
when	O
subjected	O
to	O
Se	O
stress	O
.	O

Further	O
analysis	O
revealed	O
that	O
the	O
APX1-mediated	O
Se	O
tolerance	O
was	O
associated	O
,	O
at	O
least	O
in	O
part	O
,	O
with	O
the	O
enhanced	O
activities	O
of	O
antioxidant	O
enzymes	O
catalase	O
,	O
glutathione	O
peroxidase	O
and	O
glutathione	O
reductase	O
.	O

Moreover	O
,	O
enhanced	B-PosReg
Se	B-MPA
resistance	I-MPA
of	O
the	O
mutants	B-Var
was	O
associated	B-Reg
with	O
glutathione	B-MPA
(	O
GSH	O
)	O
,	O
which	O
had	O
the	O
higher	O
expression	O
level	O
of	O
GSH1	O
gene	O
involved	O
in	O
GSH	O
synthesis	O
and	O
consequently	O
increased	O
GSH	O
content	O
.	O

Our	O
results	O
provide	O
genetic	O
evidence	O
indicating	O
that	O
loss	O
-	O
of	O
-	O
function	O
of	O
APX1	O
results	O
in	O
tolerance	O
to	O
Se	O
stress	O
.	O

Coexistence	O
of	O
Mosaic	O
Uniparental	O
Isodisomy	O
and	O
a	O
KCNJ11	O
Mutation	O
Presenting	O
as	O
Diffuse	O
Congenital	O
Hyperinsulinism	O
and	O
Hemihypertrophy	O
.	O

BACKGROUND	O
:	O
Isolated	O
hyperinsulinaemic	B-Disease
hypoglycaemia	I-Disease
(	O
HH	O
)	O
commonly	O
results	B-Reg
from	I-Reg
recessively	B-Var
inherited	I-Var
mutations	I-Var
in	O
the	O
ABCC8	B-Gene
and	O
KCNJ11	B-Gene
genes	O
that	O
are	O
located	O
on	O
chromosome	O
11p15.1	O
.	O

More	O
rarely	O
,	O
HH	O
can	O
feature	O
in	O
patients	O
with	O
Beckwith	O
-	O
Wiedemann	O
syndrome	O
(	O
BWS	O
)	O
,	O
a	O
congenital	O
overgrowth	O
disorder	O
,	O
resulting	O
from	O
defects	O
at	O
a	O
differentially	O
methylated	O
region	O
telomeric	O
to	O
the	O
K	O
-	O
ATP	O
channel	O
genes	O
at	O
chromosome	O
11p15.5	O
.	O

SUBJECT	O
:	O
We	O
undertook	O
genetic	O
testing	O
in	O
a	O
patient	O
with	O
diazoxide	O
-	O
unresponsive	O
HH	O
diagnosed	O
at	O
birth	O
.	O

Physical	O
examination	O
later	O
revealed	O
hemihypertrophy	O
of	O
the	O
right	O
arm	O
,	O
a	O
feature	O
of	O
BWS	O
.	O

RESULTS	O
:	O
We	O
identified	O
a	O
novel	O
mosaic	O
,	O
paternally	O
-	O
inherited	O
KCNJ11	O
mutation(s	O
)	O
in	O
the	O
patient	O
.	O

Further	O
analysis	O
confirmed	O
uniparental	O
disomy	O
(	O
UPD	O
)	O
of	O
chromosome	O
11	O
,	O
which	O
extended	O
across	O
the	O
KCNJ11	O
gene	O
at	O
11p15.1	O
and	O
the	O
BWS	O
locus	O
at	O
11p15.5	O
.	O

CONCLUSION	O
:	O
These	O
results	O
highlight	O
the	O
importance	O
of	O
considering	O
UPD	O
as	O
a	O
mechanism	O
of	O
disease	O
in	O
patients	O
with	O
HH	O
and	O
a	O
paternally	O
inherited	O
K	O
-	O
ATP	O
channel	O
mutation	O
,	O
especially	O
when	O
additional	O
syndromic	O
features	O
are	O
present	O
.	O

Loss	O
of	O
T	O
-	O
cell	O
quiescence	O
by	O
targeting	O
Slfn2	O
prevents	O
the	O
development	O
and	O
progression	O
of	O
T	O
-	O
ALL	O
.	O

T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T	O
-	O
ALL	O
)	O
is	O
an	O
aggressive	O
malignancy	O
of	O
thymocytes	O
.	O

Despite	O
significant	O
improvement	O
in	O
the	O
treatment	O
of	O
T	O
-	O
ALL	O
,	O
approximately	O
20	O
%	O
of	O
children	O
and	O
most	O
adults	O
undergo	O
relapse	O
.	O

Previous	O
findings	O
demonstrated	O
that	O
loss	B-NegReg
of	O
T	B-CPA
-	I-CPA
cell	I-CPA
quiescence	I-CPA
due	O
to	O
a	O
mutation	B-Var
in	O
the	O
Slfn2	B-Gene
gene	O
(	O
elektra	O
)	O
leads	B-Reg
to	I-Reg
acquisition	O
of	O
an	O
aberrant	B-CPA
developmental	I-CPA
program	I-CPA
by	O
which	O
T	O
-	O
cells	O
lose	B-NegReg
their	O
renewal	B-CPA
capabilities	I-CPA
and	O
undergo	B-CPA
apoptosis	I-CPA
.	O

Here	O
we	O
show	O
that	O
the	O
elektra	O
mutation	O
in	O
Slfn2	O
completely	O
prevents	O
a	O
severe	O
lymphoproliferative	O
disease	O
caused	O
by	O
overexpression	O
of	O
BCL2	O
in	O
combination	O
with	O
Fas	O
deficiency	O
in	O
mice	O
.	O

Moreover	O
,	O
Slfn2	O
impaired	O
-	O
function	O
protects	O
mice	O
from	O
experimental	O
disease	O
similar	O
to	O
human	O
T	O
-	O
ALL	O
by	O
severely	O
impairing	O
the	O
proliferation	O
potential	O
and	O
survival	O
of	O
leukemic	O
T	O
-	O
cells	O
,	O
partially	O
by	O
activation	O
of	O
the	O
p53	O
tumor	O
suppressor	O
protein	O
.	O

Our	O
study	O
suggest	O
that	O
in	O
certain	O
malignancies	O
,	O
such	O
as	O
T	O
-	O
ALL	O
,	O
a	O
novel	O
therapeutic	O
strategy	O
may	O
be	O
applied	O
by	O
imposing	O
aberrant	O
development	O
of	O
leukemic	O
cells	O
.	O

Furthermore	O
,	O
as	O
the	O
elektra	O
mutation	B-Var
in	O
Slfn2	B-Gene
seems	O
to	O
impair	B-Reg
only	O
T	B-CPA
-	I-CPA
cells	I-CPA
and	O
monocytes	B-CPA
,	O
targeting	O
Slfn2	O
is	O
expected	O
to	O
be	O
harmless	O
to	O
other	O
cell	O
types	O
,	O
and	O
thereby	O
could	O
be	O
a	O
promising	O
target	O
for	O
treating	O
malignancies	O
.	O

Together	O
our	O
results	O
demonstrate	O
the	O
potential	O
of	O
targeting	O
Slfn2	O
and	O
its	O
human	O
paralog	O
for	O
T	O
-	O
ALL	O
treatment	O
.	O

Mutational	B-Var
Spectrum	O
of	O
the	O
MEFV	B-Gene
Gene	O
in	O
AA	O
Amyloidosis	O
Associated	B-Reg
With	I-Reg
Familial	B-Disease
Mediterranean	I-Disease
Fever	I-Disease
.	O

INTRODUCTION	O
:	O
Familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
(	O
FMF	O
)	O
is	O
a	O
recessively	O
inherited	O
disease	O
which	O
is	O
characterized	O
by	O
recurrent	O
episodic	O
fever	O
,	O
abdominal	O
pain	O
,	O
and	O
polyserositis	O
.	O

It	O
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
MEFV	B-Gene
gene	O
,	O
encoding	O
the	O
pyrin	O
protein	O
.	O

The	O
most	O
important	O
complication	O
of	O
FMF	O
is	O
secondary	O
(	O
AA	O
)	O
amyloidosis	O
that	O
leads	O
to	O
kidney	O
failure	O
.	O

This	O
study	O
aimed	O
to	O
identify	O
the	O
frequency	O
and	O
distribution	O
of	O
MEFV	O
mutations	O
in	O
Turkish	O
patients	O
with	O
FMF	O
-	O
associated	O
AA	O
amyloidosis	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
A	O
total	O
of	O
57	O
patients	O
with	O
FMF	O
-	O
associated	O
AA	O
amyloidosis	O
and	O
60	O
healthy	O
controls	O
were	O
included	O
in	O
this	O
study	O
.	O

We	O
analyzed	O
the	O
MEFV	O
gene	O
for	O
E148Q	O
,	O
M694V	O
,	O
M680I	O
,	O
and	O
V726A	O
mutations	O
and	O
R202Q	O
variant	O
by	O
polymerase	O
chain	O
reaction	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
methods	O
.	O

Results	O
.	O

The	O
male	O
-	O
female	O
ratio	O
was	O
0.72	O
.	O

The	O
mean	O
age	O
of	O
the	O
patients	O
was	O
29.8	O
±	O
12.8	O
years	O
.	O

Among	O
the	O
patients	O
,	O
the	O
rate	O
of	O
the	O
MEFV	O
mutations	O
was	O
found	O
to	O
be	O
77.2	O
%	O
.	O

The	O
most	O
frequently	O
observed	O
genotype	O
was	O
homozygous	O
M694V	O
mutation	O
,	O
which	O
was	O
present	O
in	O
17	O
patients	O
(	O
29.8	O
%	O
,	O
P	O
<	O
.001	O
)	O
,	O
followed	O
by	O
compound	O
heterozygous	O
M680I	O
/	O
M694V	O
(	O
14.3	O
%	O
,	O
P	O
=	O
.01	O
)	O
.	O

The	O
R202Q	O
allele	O
frequencies	O
were	O
significantly	O
different	O
between	O
patients	O
and	O
control	O
group	O
(	O
P	O
=	O
.02	O
;	O
odds	O
ratio	O
,	O
0.53	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0.30	O
to	O
0.94	O
)	O
.	O

CONCLUSIONS	O
:	O
In	O
this	O
study	O
,	O
mutation	O
analysis	O
of	O
MEFV	O
gene	O
confirmed	O
that	O
the	O
most	O
frequent	O
mutation	O
was	O
homozygous	O
M694V	O
genotype	O
.	O

R202Q	O
may	O
be	O
important	O
in	O
patients	O
with	O
FMF	O
-	O
associated	O
AA	O
amyloidosis	O
.	O

Thus	O
,	O
it	O
is	O
suggested	O
that	O
investigation	O
of	O
R202Q	O
should	O
be	O
considered	O
as	O
a	O
genetic	O
test	O
for	O
Turkish	O
FMF	O
patients	O
.	O

Oncogenic	O
Mutant	O
p53	O
Gain	O
of	O
Function	O
Nourishes	O
the	O
Vicious	O
Cycle	O
of	O
Tumor	O
Development	O
and	O
Cancer	O
Stem	O
-	O
Cell	O
Formation	O
.	O

More	O
than	O
half	O
of	O
human	O
tumors	O
harbor	O
an	O
inactivated	O
p53	O
tumor	O
-	O
suppressor	O
gene	O
.	O

It	O
is	O
well	O
accepted	O
that	O
mutant	B-Var
p53	B-Gene
shows	O
an	O
oncogenic	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
activity	O
that	O
facilitates	B-PosReg
the	O
transformed	B-MPA
phenotype	I-MPA
of	I-MPA
cancer	I-MPA
cells	I-MPA
.	O

In	O
addition	O
,	O
a	O
growing	O
body	O
of	O
evidence	O
supports	O
the	O
notion	O
that	O
cancer	O
stem	O
cells	O
comprise	O
a	O
seminal	O
constituent	O
in	O
the	O
initiation	O
and	O
progression	O
of	O
cancer	O
development	O
.	O

Here	O
,	O
we	O
elaborate	O
on	O
the	O
mutant	B-Var
p53	B-Gene
oncogenic	O
GOF	B-PosReg
leading	O
toward	O
the	B-MPA
acquisition	I-MPA
of	I-MPA
a	I-MPA
transformed	I-MPA
phenotype	I-MPA
,	O
as	O
well	O
as	O
placing	O
mutant	O
p53	O
as	O
a	O
major	O
component	O
in	O
the	O
establishment	O
of	O
cancer	O
stem	O
cell	O
entity	O
.	O

Therefore	O
,	O
therapy	O
targeted	O
toward	O
cancer	O
stem	O
cells	O
harboring	O
mutant	O
p53	O
is	O
expected	O
to	O
pave	O
the	O
way	O
to	O
eradicate	O
tumor	O
growth	O
and	O
recurrence	O
.	O

N	O
-	O
glycan	O
containing	O
a	O
core	O
α1,3-fucose	O
residue	O
is	O
required	O
for	O
basipetal	O
auxin	O
transport	O
and	O
gravitropic	O
response	O
in	O
rice	O
(	O
Oryza	O
sativa	O
)	O
.	O

In	O
plants	O
,	O
α1,3-fucosyltransferase	O
(	O
FucT	O
)	O
catalyzes	O
the	O
transfer	O
of	O
fucose	O
from	O
GDP	O
-	O
fucose	O
to	O
asparagine	O
-	O
linked	O
GlcNAc	O
of	O
the	O
N	O
-	O
glycan	O
core	O
in	O
the	O
medial	O
Golgi	O
.	O

To	O
explore	O
the	O
physiological	O
significance	O
of	O
this	O
processing	O
,	O
we	O
isolated	O
two	O
Oryza	O
sativa	O
(	O
rice	O
)	O
mutants	O
(	O
fuct-1	O
and	O
fuct-2	O
)	O
with	O
loss	O
of	O
FucT	O
function	O
.	O

Biochemical	O
analyses	O
of	O
the	O
N	O
-	O
glycan	O
structure	O
confirmed	O
that	O
α1,3-fucose	O
is	O
missing	B-Var
from	O
the	O
N	O
-	O
glycans	O
of	O
allelic	O
fuct-1	B-Gene
and	O
fuct-2	B-Gene
.	O

Compared	O
with	O
the	O
wild	O
-	O
type	O
cv	O
Kitaake	O
,	O
fuct-1	O
displayed	O
a	O
larger	B-PosReg
tiller	B-MPA
angle	I-MPA
,	O
shorter	B-NegReg
internode	B-MPA
and	O
panicle	B-MPA
lengths	O
,	O
and	O
decreased	B-NegReg
grain	B-MPA
filling	I-MPA
as	O
well	O
as	O
an	O
increase	B-PosReg
in	O
chalky	B-MPA
grains	I-MPA
with	I-MPA
abnormal	I-MPA
shape	I-MPA
.	O

The	O
mutant	O
allele	O
fuct-2	O
gave	O
rise	O
to	O
similar	O
developmental	O
abnormalities	O
,	O
although	O
they	O
were	O
milder	O
than	O
those	O
of	O
fuct-1	O
.	O

Restoration	O
of	O
a	O
normal	O
tiller	O
angle	O
in	O
fuct-1	O
by	O
complementation	O
demonstrated	O
that	O
the	O
phenotype	O
is	O
caused	O
by	O
the	O
loss	O
of	O
FucT	O
function	O
.	O

Both	O
fuct-1	O
and	O
fuct-2	O
plants	O
exhibited	O
reduced	O
gravitropic	O
responses	O
.	O

Expression	O
of	O
the	O
genes	O
involved	O
in	O
tiller	O
and	O
leaf	O
angle	O
control	O
was	O
also	O
affected	O
in	O
the	O
mutants	O
.	O

We	O
demonstrate	O
that	O
reduced	O
basipetal	O
auxin	O
transport	O
and	O
low	O
auxin	O
accumulation	O
at	O
the	O
base	O
of	O
the	O
shoot	O
in	O
fuct-1	O
account	O
for	O
both	O
the	O
reduced	O
gravitropic	O
response	O
and	O
the	O
increased	O
tiller	O
angle	O
.	O

Hajdu	O
-	O
Cheney	O
Syndrome	O
,	O
a	O
Disease	O
Associated	O
with	O
NOTCH2	O
Mutations	O
.	O

Notch	O
plays	O
an	O
important	O
function	O
in	O
skeletal	O
homeostasis	O
,	O
osteoblastogenesis	O
,	O
and	O
osteoclastogenesis	O
.	O

Hajdu	B-Disease
-	I-Disease
Cheney	I-Disease
syndrome	I-Disease
(	O
HCS	O
)	O
is	O
a	O
rare	O
disease	O
associated	O
with	O
mutations	B-Var
in	O
NOTCH2	B-Gene
leading	B-Reg
to	I-Reg
the	O
translation	B-MPA
of	I-MPA
a	I-MPA
truncated	I-MPA
NOTCH2	B-Gene
stable	O
protein	B-Protein
.	O

As	O
a	O
consequence	O
,	O
a	O
gain	O
-	O
of	O
-	O
NOTCH2	O
function	O
is	O
manifested	O
.	O

HCS	O
is	O
inherited	O
as	O
an	O
autosomal	O
dominant	O
disease	O
although	O
sporadic	O
cases	O
exist	O
.	O

HCS	O
is	O
characterized	O
by	O
craniofacial	O
developmental	O
defects	O
,	O
including	O
platybasia	O
and	O
wormian	O
bones	O
,	O
osteoporosis	O
with	O
fractures	O
,	O
and	O
acro	O
-	O
osteolysis	O
.	O

Subjects	O
may	O
suffer	O
severe	O
neurological	O
complications	O
,	O
and	O
HCS	O
presents	O
with	O
cardiovascular	O
defects	O
and	O
polycystic	O
kidneys	O
.	O

An	O
experimental	O
mouse	O
model	O
harboring	O
a	O
HCSNotch2	O
mutation	O
exhibits	O
osteopenia	O
secondary	O
to	O
enhanced	O
bone	O
resorption	O
suggesting	O
this	O
as	O
a	O
possible	O
mechanism	O
for	O
the	O
skeletal	O
disease	O
.	O

If	O
the	O
same	O
mechanisms	O
were	O
operational	O
in	O
humans	O
,	O
anti	O
-	O
resorptive	O
therapy	O
could	O
correct	O
the	O
bone	O
loss	O
,	O
but	O
not	O
necessarily	O
the	O
acro	O
-	O
osteolysis	O
.	O

In	O
conclusion	O
,	O
HCS	O
is	O
a	O
devastating	O
disease	O
associated	O
with	O
a	O
gain	O
-	O
of	O
-	O
NOTCH2	O
function	O
resulting	O
in	O
diverse	O
clinical	O
manifestations	O
.	O

Phenotypes	O
and	O
Genotypes	O
in	O
Five	O
Children	O
with	O
Congenital	O
Insensitivity	O
to	O
Pain	O
with	O
Anhidrosis	O
.	O

BACKGROUND	O
:	O
Congenital	B-Disease
insensitivity	I-Disease
to	I-Disease
pain	I-Disease
with	I-Disease
anhidrosis	I-Disease
is	O
an	O
extremely	O
rare	O
hereditary	O
disorder	O
linked	B-Reg
to	I-Reg
variants	B-Var
in	O
NTRK1	B-Gene
.	O

Our	O
goal	O
was	O
to	O
characterize	O
the	O
clinical	O
features	O
and	O
the	O
genetic	O
basis	O
of	O
the	O
disorder	O
in	O
Chinese	O
patients	O
.	O

METHODS	O
:	O
Patients	O
were	O
enrolled	O
via	O
social	O
networking	O
.	O

Clinical	O
features	O
were	O
investigated	O
by	O
interview	O
,	O
chart	O
review	O
,	O
and	O
physical	O
examination	O
.	O

DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
to	O
genotype	O
NTRK1	O
in	O
patients	O
and	O
their	O
parents	O
.	O

Variants	O
identified	O
were	O
checked	O
against	O
a	O
control	O
cohort	O
by	O
high	O
-	O
throughput	O
sequencing	O
,	O
and	O
the	O
effects	O
of	O
these	O
variants	O
were	O
assessed	O
in	O
silico	O
.	O

RESULTS	O
:	O
Clinical	O
features	O
in	O
five	O
patients	O
were	O
cataloged	O
,	O
and	O
six	O
loss	O
-	O
of	O
-	O
function	O
NTRK1	O
variants	O
were	O
identified	O
,	O
including	O
a	O
frameshift	O
variant	O
c.963delG	O
,	O
a	O
nonsense	O
variant	O
c.1804C	O
>	O
T	O
,	O
an	O
intron	O
variant	O
c.851	O
-	O
33T	O
>	O
A	O
,	O
and	O
three	O
missense	O
variants	O
c.1802T	O
>	O
G	O
,	O
c.2074C	O
>	O
T	O
,	O
and	O
c.2311C	O
>	O
T.	O
CONCLUSIONS	O
:	O
The	O
results	O
expand	O
the	O
spectrum	O
of	O
clinical	O
and	O
genetic	O
features	O
of	O
congenital	O
insensitivity	O
to	O
pain	O
with	O
anhidrosis	O
and	O
will	O
help	O
facilitate	O
analysis	O
of	O
genotype	O
-	O
phenotype	O
association	O
in	O
the	O
future	O
.	O

The	O
impact	O
of	O
intermittent	O
versus	O
continuous	O
exposure	O
to	O
EGFR	O
tyrosine	O
kinase	O
inhibitor	O
on	O
selection	O
of	O
EGFR	O
T790M	O
-	O
mutant	O
drug	O
-	O
resistant	O
clones	O
in	O
a	O
lung	O
cancer	O
cell	O
line	O
carrying	O
activating	O
EGFR	O
mutation	O
.	O

Drug	O
-	O
resistant	O
cell	O
lines	O
are	O
essential	O
tools	O
for	O
investigating	O
the	O
mechanisms	O
of	O
resistance	O
to	O
molecular	O
-	O
targeted	O
anti	O
-	O
cancer	O
drugs	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
how	O
to	O
establish	O
clinically	O
relevant	O
drug	O
-	O
resistant	O
cell	O
lines	O
.	O

Our	O
study	O
examined	O
the	O
impact	O
of	O
a	O
drug	O
-	O
free	O
period	O
on	O
the	O
establishment	O
of	O
a	O
cell	O
line	O
with	O
clinically	O
relevant	O
resistance	O
to	O
molecular	O
-	O
targeted	O
drugs	O
.	O

We	O
used	O
PC9	O
cells	O
,	O
a	O
lung	O
cancer	O
cell	O
line	O
carrying	O
EGFR	O
mutation	O
,	O
because	O
this	O
is	O
a	O
validated	O
target	O
for	O
EGFR	O
tyrosine	O
kinase	O
inhibitors	O
(	O
TKI	O
)	O
.	O

PC9	O
cells	O
were	O
intermittently	O
or	O
continuously	O
exposed	O
to	O
increasing	O
concentrations	O
of	O
gefitinib	O
(	O
0.01	O
μM	O
to	O
1.0	O
μM	O
)	O
and	O
the	O
emergence	O
of	O
the	O
most	O
common	O
acquired	O
resistance	O
mutation	O
in	O
EGFR	O
,	O
T790	O
M	O
,	O
was	O
determined	O
.	O

T790	O
M	O
was	O
detected	O
at	O
a	O
25-fold	O
lower	O
drug	O
concentration	O
in	O
cells	O
continuously	O
exposed	O
to	O
gefitinib	O
(	O
PC9	O
/	O
GRc	O
)	O
than	O
in	O
cells	O
intermittently	O
exposed	O
to	O
gefitinib	O
(	O
PC9	O
/	O
GRi	O
)	O
(	O
0.04	O
μM	O
vs	O
1.0	O
μM	O
,	O
respectively	O
)	O
.	O

The	O
mutation	B-Var
frequencies	O
at	O
those	O
drug	O
concentrations	O
were	O
19.8	O
%	O
and	O
8.0	O
%	O
in	O
PC9	O
/	O
GRc	O
and	O
PC9	O
/	O
GRi	O
cells	O
,	O
respectively	O
.	O

After	O
drug	O
-	O
free	O
culture	O
for	O
8	O
weeks	O
,	O
resistance	B-MPA
to	I-MPA
gefitinib	I-MPA
decreased	B-NegReg
in	O
the	O
PC9	O
/	O
GRi	O
cells	O
but	O
not	O
in	O
the	O
PC9	O
/	O
GRc	O
cells	O
.	O

In	O
the	O
PC9	O
/	O
GRc	O
cells	O
,	O
the	O
frequency	O
of	O
the	O
T790	O
M	O
mutation	O
was	O
consistently	O
about	O
20	O
%	O
from	O
0.04	O
μM	O
to	O
1.0	O
μM	O
of	O
gefitinib	O
.	O

In	O
the	O
PC9	O
/	O
GRc	O
cells	O
,	O
the	O
T790	O
M	O
mutation	O
was	O
detected	O
in	O
all	O
single	O
-	O
cell	O
clones	O
,	O
at	O
frequencies	O
ranging	O
from	O
7.0	O
%	O
to	O
37.0	O
%	O
,	O
with	O
a	O
median	O
of	O
19.5	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
17.3%-20.9	O
%	O
)	O
.	O

In	O
conclusion	O
,	O
compared	O
with	O
intermittent	O
drug	O
exposure	O
,	O
continuous	O
exposure	O
might	O
select	O
better	O
minor	O
drug	O
-	O
resistant	O
clones	O
when	O
creating	O
cell	O
lines	O
resistant	O
to	O
molecular	O
-	O
targeted	O
drugs	O
.	O

Loss	B-NegReg
of	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
RP1	B-Gene
are	O
responsible	O
for	O
retinitis	B-Disease
pigmentosa	I-Disease
in	O
consanguineous	O
familial	O
cases	O
.	O

PURPOSE	O
:	O
This	O
study	O
was	O
undertaken	O
to	O
identify	O
causal	O
mutations	O
responsible	O
for	O
autosomal	O
recessive	O
retinitis	O
pigmentosa	O
(	O
arRP	O
)	O
in	O
consanguineous	O
families	O
.	O

METHODS	O
:	O
Large	O
consanguineous	O
families	O
were	O
ascertained	O
from	O
the	O
Punjab	O
province	O
of	O
Pakistan	O
.	O

An	O
ophthalmic	O
examination	O
consisting	O
of	O
a	O
fundus	O
evaluation	O
and	O
electroretinography	O
(	O
ERG	O
)	O
was	O
completed	O
,	O
and	O
small	O
aliquots	O
of	O
blood	O
were	O
collected	O
from	O
all	O
participating	O
individuals	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
white	O
blood	O
cells	O
,	O
and	O
a	O
genome	O
-	O
wide	O
linkage	O
or	O
a	O
locus	O
-	O
specific	O
exclusion	O
analysis	O
was	O
completed	O
with	O
polymorphic	O
short	O
tandem	O
repeats	O
(	O
STRs	O
)	O
.	O

Two	O
-	O
point	O
logarithm	O
of	O
odds	O
(	O
LOD	O
)	O
scores	O
were	O
calculated	O
,	O
and	O
all	O
coding	O
exons	O
and	O
exon	O
-	O
intron	O
boundaries	O
of	O
RP1	O
were	O
sequenced	O
to	O
identify	O
the	O
causal	O
mutation	O
.	O

RESULTS	O
:	O
The	O
ophthalmic	O
examination	O
showed	O
that	O
affected	O
individuals	O
in	O
all	O
families	O
manifest	O
cardinal	O
symptoms	O
of	O
RP	O
.	O

Genome	O
-	O
wide	O
scans	O
localized	O
the	O
disease	O
phenotype	O
to	O
chromosome	O
8q	O
,	O
a	O
region	O
harboring	O
RP1	O
,	O
a	O
gene	O
previously	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
RP	O
.	O

Sanger	O
sequencing	O
identified	O
a	O
homozygous	O
single	O
base	O
deletion	O
in	O
exon	O
4	O
:	O
c.3697delT	O
(	O
p	O
.	O
S1233Pfs22	O
*	O
)	O
,	O
a	O
single	O
base	O
substitution	O
in	O
intron	O
3	O
:	O
c.787	O
+	O
1G	O
>	O
A	O
(	O
p	O
.	O
I263Nfs8	O
*	O
)	O
,	O
a	O
2	O
bp	O
duplication	O
in	O
exon	O
2	O
:	O
c.551_552dupTA	O
(	O
p	O
.	O
Q185Yfs4	O
*	O
)	O
and	O
an	O
11,117	O
bp	O
deletion	O
that	O
removes	O
all	O
three	O
coding	O
exons	O
of	O
RP1	O
.	O

These	O
variations	O
segregated	O
with	O
the	O
disease	O
phenotype	O
within	O
the	O
respective	O
families	O
and	O
were	O
not	O
present	O
in	O
ethnically	O
matched	O
control	O
samples	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
strongly	O
suggest	O
that	O
these	O
mutations	O
in	O
RP1	O
are	O
responsible	O
for	O
the	O
retinal	O
phenotype	O
in	O
affected	O
individuals	O
of	O
all	O
four	O
consanguineous	O
families	O
.	O

Ectrodactyly	B-Disease
and	I-Disease
Lethal	I-Disease
Pulmonary	I-Disease
Acinar	I-Disease
Dysplasia	I-Disease
Associated	B-Reg
with	O
Homozygous	O
FGFR2	B-Gene
Mutations	B-Var
Identified	O
by	O
Exome	O
Sequencing	O
.	O

Ectrodactyly	O
/	O
split	O
hand	O
-	O
foot	O
malformation	O
is	O
genetically	O
heterogeneous	O
with	O
more	O
than	O
100	O
syndromic	O
associations	O
.	O

Acinar	O
dysplasia	O
is	O
a	O
rare	O
congenital	O
lung	O
lesion	O
of	O
unknown	O
etiology	O
,	O
which	O
is	O
frequently	O
lethal	O
postnatally	O
.	O

To	O
date	O
,	O
there	O
have	O
been	O
no	O
reports	O
of	O
combinations	O
of	O
these	O
two	O
phenotypes	O
.	O

Here	O
,	O
we	O
present	O
an	O
infant	O
from	O
a	O
consanguineous	O
union	O
with	O
both	O
ectrodactyly	O
and	O
autopsy	O
confirmed	O
acinar	O
dysplasia	O
.	O

SNP	O
array	O
and	O
whole	O
-	O
exome	O
sequencing	O
analyses	O
of	O
the	O
affected	O
infant	O
identified	O
a	O
novel	O
homozygous	O
Fibroblast	O
Growth	O
Factor	O
Receptor	O
2	O
(	O
FGFR2	O
)	O
missense	O
mutation	O
(	O
p	O
.	O
R255Q	O
)	O
in	O
the	O
IgIII	O
domain	O
(	O
D3	O
)	O
.	O

Expression	O
studies	O
of	O
Fgfr2	O
in	O
development	O
show	O
localization	O
to	O
the	O
affected	O
limbs	O
and	O
organs	O
.	O

Molecular	O
modeling	O
and	O
genetic	O
and	O
functional	O
assays	O
support	O
that	O
this	O
mutation	O
is	O
at	O
least	O
a	O
partial	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	B-Var
,	O
and	O
contributes	O
to	O
ectrodactyly	B-Disease
and	I-Disease
acinar	I-Disease
dysplasia	I-Disease
only	O
in	O
homozygosity	O
,	O
unlike	O
previously	O
reported	O
heterozygous	O
activating	O
FGFR2	B-Gene
mutations	B-Var
that	O
cause	B-Reg
Crouzon	B-Disease
,	O
Apert	B-Disease
,	O
and	O
Pfeiffer	B-Disease
syndromes	I-Disease
.	O

This	O
is	O
the	O
first	O
report	O
of	O
mutations	O
in	O
a	O
human	O
disease	O
with	O
ectrodactyly	O
with	O
pulmonary	O
acinar	O
dysplasia	O
and	O
,	O
as	O
such	O
,	O
homozygous	O
loss	O
-	O
of	O
-	O
function	O
FGFR2	O
mutations	O
represent	O
a	O
unique	O
syndrome	O
.	O

TBR1	O
regulates	O
autism	O
risk	O
genes	O
in	O
the	O
developing	O
neocortex	O
.	O

Exome	O
sequencing	O
studies	O
have	O
identified	O
multiple	O
genes	O
harboring	O
de	O
novo	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LoF	O
)	O
variants	B-Var
in	O
individuals	O
with	O
autism	B-Disease
spectrum	I-Disease
disorders	I-Disease
(	O
ASD	O
)	O
,	O
including	O
TBR1	B-Gene
,	O
a	O
master	O
regulator	O
of	O
cortical	O
development	O
.	O

We	O
performed	O
ChIP	O
-	O
seq	O
for	O
TBR1	O
during	O
mouse	O
cortical	O
neurogenesis	O
and	O
show	O
that	O
TBR1-bound	O
regions	O
are	O
enriched	O
adjacent	O
to	O
ASD	O
genes	O
.	O

ASD	O
genes	O
were	O
also	O
enriched	O
among	O
genes	O
that	O
are	O
differentially	O
expressed	O
in	O
Tbr1	O
knockouts	O
,	O
which	O
together	O
with	O
the	O
ChIP	O
-	O
seq	O
data	O
,	O
suggests	O
direct	O
transcriptional	O
regulation	O
.	O

Of	O
the	O
nine	O
ASD	O
genes	O
examined	O
,	O
seven	O
were	O
misexpressed	O
in	O
the	O
cortices	O
of	O
Tbr1	O
knockout	O
mice	O
,	O
including	O
six	O
with	O
increased	O
expression	O
in	O
the	O
deep	O
cortical	O
layers	O
.	O

ASD	O
genes	O
with	O
adjacent	O
cortical	O
TBR1	O
ChIP	O
-	O
seq	O
peaks	O
also	O
showed	O
unusually	O
low	O
levels	O
of	O
LoF	O
mutations	O
in	O
a	O
reference	O
human	O
population	O
and	O
among	O
Icelanders	O
.	O

We	O
then	O
leveraged	O
TBR1	O
binding	O
to	O
identify	O
an	O
appealing	O
subset	O
of	O
candidate	O
ASD	O
genes	O
.	O

Our	O
findings	O
highlight	O
a	O
TBR1-regulated	O
network	O
of	O
ASD	O
genes	O
in	O
the	O
developing	O
neocortex	O
that	O
are	O
relatively	O
intolerant	O
to	O
LoF	O
mutations	O
,	O
indicating	O
that	O
these	O
genes	O
may	O
play	O
critical	O
roles	O
in	O
normal	O
cortical	O
development	O
.	O

A	O
rare	O
DNA	O
contact	O
mutation	B-Var
in	O
cancer	O
confers	B-PosReg
p53	B-Gene
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
and	O
tumor	B-CPA
cell	I-CPA
survival	I-CPA
via	O
TNFAIP8	B-Gene
induction	O
.	O

The	O
p53	O
tumor	O
suppressor	O
gene	O
encodes	O
a	O
sequence	O
-	O
specific	O
transcription	O
factor	O
.	O

Mutations	B-Var
in	O
the	O
coding	O
sequence	O
of	O
p53	B-Gene
occur	O
frequently	O
in	O
human	O
cancer	O
and	O
often	O
result	B-Reg
in	I-Reg
single	O
amino	O
acid	O
substitutions	B-Var
(	O
missense	O
mutations	O
)	O
in	O
the	O
DNA	O
binding	B-Interaction
domain	O
(	O
DBD	O
)	O
,	O
blocking	B-NegReg
normal	O
tumor	B-CPA
suppressive	I-CPA
functions	I-CPA
.	O

In	O
addition	O
to	O
the	O
loss	O
of	O
canonical	O
functions	O
,	O
some	O
missense	B-Var
mutations	I-Var
in	O
p53	B-Gene
confer	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
activities	B-CPA
to	I-CPA
tumor	I-CPA
cells	I-CPA
.	O

While	O
many	O
missense	O
mutations	O
in	O
p53	O
cluster	O
at	O
six	O
"	O
hotspot	O
"	O
amino	O
acids	O
,	O
the	O
majority	O
of	O
mutations	O
in	O
human	O
cancer	O
occur	O
elsewhere	O
in	O
the	O
DBD	O
and	O
at	O
a	O
much	O
lower	O
frequency	O
.	O

We	O
report	O
here	O
that	O
mutations	B-Var
at	I-Var
K120	I-Var
,	O
a	O
non	O
-	O
hotspot	O
DNA	O
contact	O
residue	O
,	O
confer	B-PosReg
p53	B-Gene
with	O
the	O
previously	O
unrecognized	O
ability	B-MPA
to	O
bind	B-Interaction
and	O
activate	B-PosReg
the	O
transcription	B-MPA
of	O
the	O
pro	O
-	O
survival	O
TNFAIP8	B-Gene
gene	O
.	O

Mutant	O
K120	O
p53	O
binds	O
the	O
TNFAIP8	O
locus	O
at	O
a	O
cryptic	O
p53	O
response	O
element	O
that	O
is	O
not	O
occupied	O
by	O
wild	O
-	O
type	O
p53	O
.	O

Furthermore	O
,	O
induction	O
of	O
TNFAIP8	O
is	O
critical	O
for	O
the	O
evasion	O
of	O
apoptosis	O
by	O
tumor	O
cells	O
expressing	O
the	O
K120R	O
variant	O
of	O
p53	O
.	O

These	O
findings	O
identify	O
induction	O
of	O
pro	O
-	O
survival	O
targets	O
as	O
a	O
mechanism	O
of	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
activity	B-MPA
for	O
mutant	B-Var
p53	B-Gene
and	O
will	O
likely	O
broaden	O
our	O
understanding	O
of	O
this	O
phenomenon	O
beyond	O
the	O
limited	O
number	O
of	O
GOF	O
activities	O
currently	O
reported	O
for	O
hotspot	O
mutants	O
.	O

X	B-Disease
-	I-Disease
linked	I-Disease
Congenital	I-Disease
Adrenal	I-Disease
Hypoplasia	I-Disease
with	B-Reg
a	O
Novel	O
NR0B1	B-Gene
/	I-Gene
DAX	I-Gene
Gene	O
Mutation	B-Var
.	O

BACKGROUND	O
:	O
The	O
etiology	O
of	O
primary	O
adrenal	O
insufficiency	O
has	O
implications	O
for	O
further	O
management	O
of	O
the	O
condition	O
.	O

CASE	O
CHARACTERISTICS	O
:	O
A	O
5-year	O
-	O
old	O
boy	O
presented	O
in	O
adrenal	O
crisis	O
with	O
glucocorticoid	O
and	O
mineralocorticoid	O
deficiency	O
.	O

OBSERVATION	O
:	O
Investigations	O
confirmed	O
primary	O
adrenal	B-CPA
insufficiency	B-NegReg
and	O
ruled	O
out	O
the	O
common	O
etiologies	O
.	O

Genetic	O
testing	O
identified	O
a	O
novel	O
NR0B1	B-Gene
/	I-Gene
DAX	I-Gene
gene	O
mutation	B-Var
.	O

MESSAGE	O
:	O
A	O
genetic	O
diagnosis	O
in	O
children	O
with	O
primary	O
adrenal	O
insufficiency	O
is	O
useful	O
to	O
provide	O
genetic	O
counselling	O
.	O

Severe	O
Early	B-Disease
-	I-Disease
Onset	I-Disease
Combined	I-Disease
Immunodeficiency	I-Disease
due	O
to	O
Heterozygous	O
Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
Function	I-PosReg
Mutations	B-Var
in	O
STAT1	B-Gene
.	O

PURPOSE	O
:	O
Loss	O
and	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
mutations	O
in	O
human	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
1	O
(	O
STAT1	O
)	O
lead	O
to	O
distinct	O
phenotypes	O
.	O

Although	O
recurrent	O
infections	O
are	O
common	O
to	O
both	O
types	O
of	O
STAT1	O
mutations	O
,	O
GOF	B-PosReg
mutations	B-Var
are	O
distinguished	O
by	O
chronic	B-Disease
mucocutaneous	I-Disease
candidiasis	I-Disease
and	O
autoimmunity	B-Disease
.	O

However	O
,	O
the	O
clinical	O
spectra	O
of	O
STAT1	O
GOF	O
mutations	O
continue	O
to	O
expand	O
.	O

We	O
here	O
describe	O
two	O
patients	O
with	O
STAT1	B-Gene
GOF	B-PosReg
mutations	B-Var
presenting	O
early	O
in	O
life	O
with	O
combined	B-Disease
immunodeficiency	I-Disease
(	O
CID	O
)	O
.	O

METHODS	O
:	O
Clinical	O
data	O
and	O
laboratory	O
findings	O
including	O
immunophenotyping	O
,	O
level	O
of	O
interferon	O
(	O
IFN)-γ	O
/	O
IL-17(+	O
)	O
T	O
cells	O
,	O
interferon	O
-	O
induced	O
STAT1	O
phosphorylation	O
,	O
and	O
JAK	O
inhibitor	O
assays	O
were	O
evaluated	O
.	O

Sequencing	O
of	O
STAT1	O
gene	O
was	O
performed	O
by	O
Sanger	O
sequencer	O
.	O

RESULTS	O
:	O
Patient	O
1	O
(	O
P1	O
)	O
had	O
persistent	O
oral	O
candidiasis	O
and	O
cytomegalovirus	O
(	O
CMV	O
)	O
infection	O
since	O
2	O
months	O
of	O
age	O
and	O
later	O
developed	O
cavitary	O
lung	O
lesions	O
due	O
to	O
Mycobacterium	O
tuberculosis	O
.	O

Patient	O
2	O
(	O
P2	O
)	O
presented	O
with	O
oral	O
candidiasis	O
and	O
recurrent	O
pneumonia	O
at	O
4	O
months	O
of	O
age	O
and	O
subsequently	O
developed	O
CMV	O
pneumonitis	O
.	O

Both	O
patients	O
suffered	O
heterozygous	O
missense	B-Var
mutations	I-Var
in	O
STAT1	B-Gene
,	O
leading	B-Reg
to	I-Reg
deleterious	O
amino	O
acid	O
substitutions	B-Var
in	O
the	O
DNA	O
binding	O
domain	O
(	O
P1	O
:	O
c.1154C	B-Var
>	I-Var
T	I-Var
;	I-Var
p	B-Var
.	I-Var
T385	I-Var
M	I-Var
;	I-Var
P2	O
.	O

c.971	B-Var
G	I-Var
>	I-Var
T	I-Var
;	I-Var
p	B-Var
.	I-Var
C324F	I-Var
)	I-Var
.	O

Circulating	O
CD4(+	O
)	O
T	O
cells	O
of	O
both	O
patients	O
exhibited	O
increased	B-PosReg
interferon	B-MPA
-	I-MPA
γ	I-MPA
and	O
decreased	B-NegReg
IL-17	B-MPA
expression	I-MPA
as	O
compared	O
to	O
controls	O
.	O

They	O
also	O
exhibited	O
increased	B-PosReg
IFN	B-MPA
-	I-MPA
β	I-MPA
and	O
-γ	B-MPA
-	I-MPA
induced	I-MPA
STAT1	I-MPA
phosphorylation	I-MPA
that	O
was	O
reversed	O
upon	O
treatment	O
with	O
the	O
JAK	O
kinase	O
inhibitor	O
ruxolitinib	O
.	O

CONCLUSION	O
:	O
STAT1	O
GOF	O
mutations	O
may	O
present	O
early	O
in	O
life	O
with	O
CID	O
,	O
consistent	O
with	O
the	O
clinical	O
heterogeneity	O
of	O
the	O
disease	O
.	O

JAK	O
kinase	O
inhibitors	O
may	O
potentially	O
be	O
useful	O
in	O
some	O
patients	O
as	O
adjunct	O
therapy	O
pending	O
definitive	O
treatment	O
with	O
bone	O
marrow	O
transplantation	O
.	O

Directed	O
evolution	O
of	O
a	O
sphingomyelin	O
flippase	O
reveals	O
mechanism	O
of	O
substrate	O
backbone	O
discrimination	O
by	O
a	O
P4-ATPase	O
.	O

Phospholipid	O
flippases	O
in	O
the	O
type	O
IV	O
P	O
-	O
type	O
ATPase	O
(	O
P4-ATPases	O
)	O
family	O
establish	O
membrane	O
asymmetry	O
and	O
play	O
critical	O
roles	O
in	O
vesicular	O
transport	O
,	O
cell	O
polarity	O
,	O
signal	O
transduction	O
,	O
and	O
neurologic	O
development	O
.	O

All	O
characterized	O
P4-ATPases	O
flip	O
glycerophospholipids	O
across	O
the	O
bilayer	O
to	O
the	O
cytosolic	O
leaflet	O
of	O
the	O
membrane	O
,	O
but	O
how	O
these	O
enzymes	O
distinguish	O
glycerophospholipids	O
from	O
sphingolipids	O
is	O
not	O
known	O
.	O

We	O
used	O
a	O
directed	O
evolution	O
approach	O
to	O
examine	O
the	O
molecular	O
mechanisms	O
through	O
which	O
P4-ATPases	O
discriminate	O
substrate	O
backbone	O
.	O

A	O
mutagenesis	O
screen	O
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
has	O
identified	O
several	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutations	B-Var
in	O
the	O
P4-ATPase	B-Enzyme
Dnf1	O
that	O
facilitate	B-PosReg
the	O
transport	B-MPA
of	O
a	O
novel	O
lipid	O
substrate	O
,	O
sphingomyelin	O
.	O

We	O
found	O
that	O
a	O
highly	O
conserved	O
asparagine	O
(	O
N220	O
)	O
in	O
the	O
first	O
transmembrane	O
segment	O
is	O
a	O
key	O
enforcer	O
of	O
glycerophospholipid	O
selection	O
,	O
and	O
specific	O
substitutions	O
at	O
this	O
site	O
allow	O
transport	O
of	O
sphingomyelin	O
.	O

Loss	B-NegReg
of	I-NegReg
function	I-NegReg
mutation	B-Var
in	O
LOX	B-Gene
causes	O
thoracic	B-Disease
aortic	I-Disease
aneurysm	I-Disease
and	I-Disease
dissection	I-Disease
in	O
humans	O
.	O

Thoracic	O
aortic	O
aneurysms	O
and	O
dissections	O
(	O
TAAD	O
)	O
represent	O
a	O
substantial	O
cause	O
of	O
morbidity	O
and	O
mortality	O
worldwide	O
.	O

Many	O
individuals	O
presenting	O
with	O
an	O
inherited	O
form	O
of	O
TAAD	O
do	O
not	O
have	O
causal	O
mutations	O
in	O
the	O
set	O
of	O
genes	O
known	O
to	O
underlie	O
disease	O
.	O

Using	O
whole	O
-	O
genome	O
sequencing	O
in	O
two	O
first	O
cousins	O
with	O
TAAD	O
,	O
we	O
identified	O
a	O
missense	O
mutation	O
in	O
the	O
lysyl	O
oxidase	O
(	B-Gene
LOX	I-Gene
)	I-Gene
gene	O
(	B-Var
c.893	I-Var
T	I-Var
>	I-Var
G	I-Var
encoding	O
p	B-Var
.	I-Var
Met298Arg	I-Var
)	I-Var
that	O
cosegregated	O
with	O
disease	O
in	O
the	O
family	O
.	O

Using	O
clustered	O
regularly	O
interspaced	O
short	O
palindromic	O
repeats	O
(	O
CRISPR)/clustered	O
regularly	O
interspaced	O
short	O
palindromic	O
repeats	O
-	O
associated	O
protein-9	O
nuclease	O
(	O
Cas9	O
)	O
genome	O
engineering	O
tools	O
,	O
we	O
introduced	O
the	O
human	O
mutation	O
into	O
the	O
homologous	O
position	O
in	O
the	O
mouse	O
genome	O
,	O
creating	O
mice	O
that	O
were	O
heterozygous	O
and	O
homozygous	O
for	O
the	O
human	O
allele	O
.	O

Mutant	O
mice	O
that	O
were	O
heterozygous	O
for	O
the	O
human	O
allele	O
displayed	O
disorganized	O
ultrastructural	O
properties	O
of	O
the	O
aortic	O
wall	O
characterized	O
by	O
fragmented	O
elastic	O
lamellae	O
,	O
whereas	O
mice	O
homozygous	O
for	O
the	O
human	O
allele	O
died	O
shortly	O
after	O
parturition	O
from	O
ascending	O
aortic	O
aneurysm	O
and	O
spontaneous	O
hemorrhage	O
.	O

These	O
data	O
suggest	O
that	O
a	O
missense	B-Var
mutation	I-Var
in	O
LOX	B-Gene
is	O
associated	B-Reg
with	O
aortic	B-Disease
disease	I-Disease
in	O
humans	O
,	O
likely	O
through	O
insufficient	B-NegReg
cross	B-Interaction
-	I-Interaction
linking	I-Interaction
of	O
elastin	B-Protein
and	O
collagen	B-MPA
in	O
the	O
aortic	O
wall	O
.	O

Mutation	B-Var
carriers	O
may	O
be	O
predisposed	B-Reg
to	O
vascular	B-Disease
diseases	I-Disease
because	O
of	O
weakened	B-NegReg
vessel	B-CPA
walls	I-CPA
under	O
stress	O
conditions	O
.	O

LOX	O
sequencing	O
for	O
clinical	O
TAAD	O
may	O
identify	O
additional	O
mutation	O
carriers	O
in	O
the	O
future	O
.	O

Additional	O
studies	O
using	O
our	O
mouse	O
model	O
of	O
LOX	O
-	O
associated	O
TAAD	O
have	O
the	O
potential	O
to	O
clarify	O
the	O
mechanism	O
of	O
disease	O
and	O
identify	O
novel	O
therapeutics	O
specific	O
to	O
this	O
genetic	O
cause	O
.	O

Fanconi	O
-	O
Bickel	O
syndrome	O
in	O
two	O
Palestinian	O
children	O
:	O
marked	O
phenotypic	O
variability	O
with	O
identical	O
mutation	O
.	O

BACKGROUND	O
:	O
Fanconi	B-Disease
-	I-Disease
Bickel	I-Disease
syndrome	I-Disease
(	O
FBS	O
,	O
OMIM	O
227810	O
)	O
is	O
a	O
rare	O
autosomal	O
recessive	O
disease	O
caused	B-Reg
by	I-Reg
a	O
deficiency	B-Var
of	O
glucose	O
transporter	O
2	O
(	B-Gene
GLUT2	I-Gene
)	I-Gene
,	O
a	O
member	O
of	O
the	O
facilitative	O
glucose	O
transporter	O
family	O
(	O
Santer	O
et	O
al	O
.	O

J	O
Inherit	O
Metab	O
Dis	O
21:191	O
-	O
194	O
,	O
1998	O
)	O
.	O

The	O
typical	O
clinical	O
picture	O
is	O
characterized	O
by	O
hepatorenal	O
glycogen	O
accumulation	O
resulting	O
in	O
hepato-	O
and	O
nephromegaly	O
,	O
impaired	O
utilization	O
of	O
glucose	O
and	O
galactose	O
,	O
proximal	O
renal	O
tubular	O
dysfunction	O
,	O
rickets	O
and	O
severe	O
short	O
stature	O
.	O

CASE	O
PRESENTATION	O
:	O
We	O
report	O
2	O
Palestinian	O
patients	O
from	O
2	O
families	O
who	O
were	O
homozygous	O
for	O
the	O
mutation	O
p	O
.	O
R301X	O
(	O
C	O
>	O
T	O
)	O
in	O
exon	O
7of	O
GLUT2	O
gene	O
.	O

Patient	O
1	O
showed	O
clinical	O
and	O
laboratory	O
improvement	O
with	O
age	O
characterized	O
by	O
normal	O
growth	O
and	O
resolution	O
of	O
rickets	O
.	O

Patient	O
2	O
had	O
severe	O
phenotype	O
characterized	O
by	O
progressive	O
weight	O
loss	O
,	O
persistent	O
metabolic	O
acidosis	O
,	O
marked	O
polyuria	O
and	O
clinical	O
and	O
laboratory	O
findings	O
of	O
rickets	O
progressing	O
to	O
death	O
at	O
age	O
10	O
months	O
.	O

CONCLUSION	O
:	O
This	O
report	O
further	O
expands	O
the	O
clinical	O
spectrum	O
of	O
FBS	O
even	O
with	O
identical	O
mutations	O
.	O

Other	O
yet	O
unknown	O
genetic	O
,	O
environmental	O
or	O
stochastic	O
factors	O
may	O
be	O
responsible	O
for	O
phenotypic	O
variability	O
.	O

De	O
Novo	O
Mutations	B-Var
in	O
SON	B-Gene
Disrupt	O
RNA	O
Splicing	O
of	O
Genes	O
Essential	O
for	O
Brain	O
Development	O
and	O
Metabolism	O
,	O
Causing	B-Reg
an	O
Intellectual	B-Disease
-	I-Disease
Disability	I-Disease
Syndrome	I-Disease
.	O

The	O
overall	O
understanding	O
of	O
the	O
molecular	O
etiologies	O
of	O
intellectual	O
disability	O
(	O
ID	O
)	O
and	O
developmental	O
delay	O
(	O
DD	O
)	O
is	O
increasing	O
as	O
next	O
-	O
generation	O
sequencing	O
technologies	O
identify	O
genetic	O
variants	O
in	O
individuals	O
with	O
such	O
disorders	O
.	O

However	O
,	O
detailed	O
analyses	O
conclusively	O
confirming	O
these	O
variants	O
,	O
as	O
well	O
as	O
the	O
underlying	O
molecular	O
mechanisms	O
explaining	O
the	O
diseases	O
,	O
are	O
often	O
lacking	O
.	O

Here	O
,	O
we	O
report	O
on	O
an	O
ID	B-Disease
syndrome	I-Disease
caused	O
by	O
de	O
novo	O
heterozygous	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LoF	O
)	O
mutations	B-Var
in	O
SON	B-Gene
.	O

The	O
syndrome	O
is	O
characterized	O
by	O
ID	O
and/or	O
DD	O
,	O
malformations	O
of	O
the	O
cerebral	O
cortex	O
,	O
epilepsy	O
,	O
vision	O
problems	O
,	O
musculoskeletal	O
abnormalities	O
,	O
and	O
congenital	O
malformations	O
.	O

Knockdown	O
of	O
son	O
in	O
zebrafish	O
resulted	O
in	O
severe	O
malformation	O
of	O
the	O
spine	O
,	O
brain	O
,	O
and	O
eyes	O
.	O

Importantly	O
,	O
analyses	O
of	O
RNA	O
from	O
affected	O
individuals	O
revealed	O
that	O
genes	O
critical	O
for	O
neuronal	B-CPA
migration	I-CPA
and	O
cortex	B-CPA
organization	I-CPA
(	O
TUBG1	O
,	O
FLNA	O
,	O
PNKP	O
,	O
WDR62	O
,	O
PSMD3	O
,	O
and	O
HDAC6	O
)	O
and	O
metabolism	B-CPA
(	O
PCK2	O
,	O
PFKL	O
,	O
IDH2	O
,	O
ACY1	O
,	O
and	O
ADA	O
)	O
are	O
significantly	O
downregulated	B-NegReg
because	O
of	O
the	O
accumulation	B-PosReg
of	O
mis	O
-	O
spliced	O
transcripts	O
resulting	O
from	O
erroneous	B-Var
SON	I-Var
-	I-Var
mediated	I-Var
RNA	I-Var
splicing	I-Var
.	O

Our	O
data	O
highlight	O
SON	O
as	O
a	O
master	O
regulator	O
governing	O
neurodevelopment	O
and	O
demonstrate	O
the	O
importance	O
of	O
SON	O
-	O
mediated	O
RNA	O
splicing	O
in	O
human	O
development	O
.	O

Gli2	O
gene	O
-	O
environment	O
interactions	O
contribute	O
to	O
the	O
etiological	O
complexity	O
of	O
holoprosencephaly	O
:	O
evidence	O
from	O
a	O
mouse	O
model	O
.	O

Holoprosencephaly	B-Disease
(	O
HPE	O
)	O
is	O
a	O
common	O
and	O
severe	O
human	O
developmental	O
abnormality	O
marked	O
by	O
malformations	O
of	O
the	O
forebrain	O
and	O
face	O
.	O

Although	O
several	O
genetic	O
mutations	O
have	O
been	O
linked	O
to	O
HPE	O
,	O
phenotypic	O
outcomes	O
range	O
dramatically	O
,	O
and	O
most	O
cases	O
can	O
not	O
be	O
attributed	O
to	O
a	O
specific	O
cause	O
.	O

Gene	O
-	O
environment	O
interaction	O
has	O
been	O
invoked	O
as	O
a	O
premise	O
to	O
explain	O
the	O
etiological	O
complexity	O
of	O
HPE	O
,	O
but	O
identification	O
of	O
interacting	O
factors	O
has	O
been	O
extremely	O
limited	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
mutations	B-Var
in	O
Gli2	B-Gene
,	O
which	O
encodes	O
a	O
Hedgehog	O
pathway	O
transcription	O
factor	O
,	O
can	O
cause	B-Reg
or	O
predispose	O
to	O
HPE	B-Disease
depending	O
upon	O
gene	O
dosage	O
.	O

On	O
the	O
C57BL/6J	O
background	O
,	O
homozygous	B-Var
GLI2	B-Gene
loss	B-NegReg
of	I-NegReg
function	I-NegReg
results	O
in	O
the	O
characteristic	O
brain	O
and	O
facial	O
features	O
seen	O
in	O
severe	O
human	O
HPE	B-Disease
,	O
including	O
midfacial	O
hypoplasia	O
,	O
hypotelorism	O
and	O
medial	O
forebrain	O
deficiency	O
with	O
loss	O
of	O
ventral	O
neurospecification	O
.	O

Although	O
normally	O
indistinguishable	O
from	O
wild	O
-	O
type	O
littermates	O
,	O
we	O
demonstrate	O
that	O
mice	O
with	O
single	O
-	O
allele	O
Gli2	O
mutations	O
exhibit	O
increased	O
penetrance	O
and	O
severity	O
of	O
HPE	O
in	O
response	O
to	O
low	O
-	O
dose	O
teratogen	O
exposure	O
.	O

This	O
genetic	O
predisposition	O
is	O
associated	O
with	O
a	O
Gli2	O
dosage	O
-	O
dependent	O
attenuation	O
of	O
Hedgehog	O
ligand	O
responsiveness	O
at	O
the	O
cellular	O
level	O
.	O

In	O
addition	O
to	O
revealing	O
a	O
causative	O
role	O
for	O
GLI2	O
in	O
HPE	O
genesis	O
,	O
these	O
studies	O
demonstrate	O
a	O
mechanism	O
by	O
which	O
normally	O
silent	O
genetic	O
and	O
environmental	O
factors	O
can	O
interact	O
to	O
produce	O
severe	O
outcomes	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
provide	O
a	O
framework	O
for	O
the	O
understanding	O
of	O
the	O
extreme	O
phenotypic	O
variability	O
observed	O
in	O
humans	O
carrying	O
GLI2	O
mutations	O
and	O
a	O
paradigm	O
for	O
reducing	O
the	O
incidence	O
of	O
this	O
morbid	O
birth	O
defect	O
.	O

Identification	O
of	O
15	O
novel	O
partial	O
SHOX	O
deletions	O
and	O
13	O
partial	O
duplications	O
,	O
and	O
a	O
review	O
of	O
the	O
literature	O
reveals	O
intron	O
3	O
to	O
be	O
a	O
hotspot	O
region	O
.	O

Short	O
stature	O
homeobox	O
gene	O
(	O
SHOX	O
)	O
is	O
located	O
in	O
the	O
pseudoautosomal	O
region	O
1	O
of	O
the	O
sex	O
chromosomes	O
.	O

It	O
encodes	O
a	O
transcription	O
factor	O
implicated	O
in	O
the	O
skeletal	O
growth	O
.	O

Point	B-Var
mutations	I-Var
,	O
deletions	B-Var
or	O
duplications	B-Var
of	O
SHOX	B-Gene
or	O
its	O
transcriptional	O
regulatory	O
elements	O
are	O
associated	B-Reg
with	O
two	O
skeletal	O
dysplasias	O
,	O
Léri	B-Disease
-	I-Disease
Weill	I-Disease
dyschondrosteosis	I-Disease
(	O
LWD	O
)	O
and	O
Langer	B-Disease
mesomelic	I-Disease
dysplasia	I-Disease
(	O
LMD	O
)	O
,	O
as	O
well	O
as	O
in	O
a	O
small	O
proportion	O
of	O
idiopathic	B-Disease
short	I-Disease
stature	I-Disease
(	O
ISS	O
)	O
individuals	O
.	O

We	O
have	O
identified	O
a	O
total	O
of	O
15	O
partial	O
SHOX	O
deletions	O
and	O
13	O
partial	O
SHOX	O
duplications	O
in	O
LWD	O
,	O
LMD	O
and	O
ISS	O
patients	O
referred	O
for	O
routine	O
SHOX	O
diagnostics	O
during	O
a	O
10	O
year	O
period	O
(	O
2004	O
-	O
2014	O
)	O
.	O

Subsequently	O
,	O
we	O
characterized	O
these	O
alterations	O
using	O
MLPA	O
(	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
assay	O
)	O
,	O
fine	O
-	O
tiling	O
array	O
CGH	O
(	O
comparative	O
genomic	O
hybridation	O
)	O
and	O
breakpoint	O
PCR	O
.	O

Nearly	O
half	O
of	O
the	O
alterations	O
have	O
a	O
distal	O
or	O
proximal	O
breakpoint	O
in	O
intron	O
3	O
.	O

Evaluation	O
of	O
our	O
data	O
and	O
that	O
in	O
the	O
literature	O
reveals	O
that	O
although	O
partial	O
deletions	O
and	O
duplications	O
only	O
account	O
for	O
a	O
small	O
fraction	O
of	O
SHOX	O
alterations	O
,	O
intron	O
3	O
appears	O
to	O
be	O
a	O
breakpoint	O
hotspot	O
,	O
with	O
alterations	O
arising	O
by	O
non	O
-	O
allelic	O
homologous	O
recombination	O
,	O
non	O
-	O
homologous	O
end	O
joining	O
or	O
other	O
complex	O
mechanisms	O
.	O

VHL	O
Germline	O
Mutations	O
in	O
Argentinian	O
Patients	O
with	O
Clinical	O
Diagnoses	O
or	O
Single	O
Typical	O
Manifestations	O
of	O
Type	O
1	O
von	O
Hippel	O
-	O
Lindau	O
Disease	O
.	O

AIMS	O
:	O
von	B-Disease
Hippel	I-Disease
-	I-Disease
Lindau	I-Disease
(	O
VHL	O
)	O
disease	O
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
VHL	B-Gene
tumor	O
suppressor	O
gene	O
.	O

As	O
tumors	O
that	O
develop	O
in	O
the	O
context	O
of	O
VHL	O
also	O
occur	O
in	O
a	O
sporadic	O
context	O
,	O
the	O
frequency	O
of	O
this	O
syndrome	O
may	O
be	O
underestimated	O
.	O

Our	O
aim	O
was	O
to	O
identify	O
VHL	O
gene	O
mutations	O
in	O
Argentinian	O
patients	O
who	O
fulfilled	O
the	O
clinical	O
criteria	O
for	O
type	O
1	O
VHL	O
disease	O
and	O
in	O
patients	O
with	O
VHL	O
-	O
associated	O
manifestations	O
that	O
did	O
not	O
meet	O
these	O
criteria	O
.	O

METHODS	O
:	O
We	O
performed	O
a	O
retrospective	O
cohort	O
study	O
,	O
including	O
patients	O
who	O
met	O
current	O
diagnostic	O
criteria	O
for	O
type	O
1	O
VHL	O
(	O
Group	O
1	O
,	O
n	O
=	O
19	O
)	O
and	O
patients	O
with	O
VHL	O
-	O
associated	O
manifestations	O
that	O
did	O
not	O
meet	O
these	O
criteria	O
(	O
Group	O
2	O
,	O
n	O
=	O
21	O
)	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
leukocytes	O
.	O

Mutation	O
analysis	O
involved	O
DNA	O
sequencing	O
,	O
while	O
large	O
deletions	O
were	O
determined	O
by	O
universal	O
primer	O
quantitative	O
fluorescent	O
multiplex	O
polymerase	O
chain	O
reaction	O
(	O
UPQFM	O
-	O
PCR	O
)	O
and	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
(	O
MLPA	O
)	O
analysis	O
.	O

RESULTS	O
:	O
VHL	O
mutations	O
were	O
detected	O
in	O
16/19	O
(	O
84.2	O
%	O
)	O
patients	O
in	O
Group	O
1	O
and	O
included	O
:	O
gross	O
deletions	O
(	O
4/16	O
)	O
;	O
nonsense	O
mutations	O
(	O
6/16	O
)	O
;	O
frameshift	O
mutations	O
(	O
4/16	O
)	O
;	O
missense	O
mutations	O
(	O
1/16	O
)	O
;	O
and	O
splicing	O
mutations	O
(	O
1/16	O
)	O
.	O

Three	O
of	O
these	O
mutations	O
were	O
novel	O
.	O

No	O
alterations	O
were	O
found	O
in	O
3	O
of	O
19	O
VHL	O
patients	O
.	O

In	O
Group	O
2	O
,	O
one	O
nonsense	O
VHL	O
mutation	O
was	O
detected	O
in	O
a	O
young	O
patient	O
with	O
a	O
solitary	O
central	O
nervous	O
system	O
hemangioblastoma	O
without	O
familial	O
history	O
.	O

A	O
study	O
of	O
30	O
first	O
-	O
degree	O
relatives	O
revealed	O
four	O
carriers	O
with	O
VHL	O
mutations	O
.	O

CONCLUSIONS	O
:	O
We	O
found	O
three	O
novel	O
mutations	O
in	O
the	O
VHL	O
gene	O
in	O
our	O
population	O
.	O

Our	O
results	O
emphasize	O
the	O
importance	O
of	O
a	O
complete	O
genetic	O
study	O
of	O
VHL	O
to	O
confirm	O
type	O
1	O
VHL	O
disease	O
,	O
not	O
only	O
in	O
patients	O
with	O
clinical	O
diagnostic	O
criteria	O
but	O
also	O
in	O
those	O
presenting	O
a	O
single	O
typical	O
manifestation	O
.	O

Dysferlin	O
Gene	O
Mutation	O
Spectrum	O
in	O
a	O
Large	O
Cohort	O
of	O
Chinese	O
Patients	O
with	O
Dysferlinopathy	O
.	O

BACKGROUND	O
:	O
Dysferlinopathy	B-Disease
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
dysferlin	O
(	B-Gene
DYSF	I-Gene
)	I-Gene
gene	O
.	O

Here	O
,	O
we	O
described	O
the	O
genetic	O
features	O
of	O
a	O
large	O
cohort	O
of	O
Chinese	O
patients	O
with	O
this	O
disease	O
.	O

METHODS	O
:	O
Eighty	O
-	O
nine	O
index	O
patients	O
were	O
included	O
in	O
the	O
study	O
.	O

DYSF	O
gene	O
analysis	O
was	O
performed	O
by	O
Sanger	O
sequencing	O
in	O
41	O
patients	O
and	O
targeted	O
next	O
generation	O
sequencing	O
(	O
NGS	O
)	O
in	O
48	O
patients	O
.	O

Multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
(	O
MLPA	O
)	O
was	O
performed	O
to	O
detect	O
exon	O
duplication	O
/	O
deletion	O
in	O
patients	O
with	O
only	O
one	O
pathogenic	O
mutation	O
.	O

RESULTS	O
:	O
Among	O
the	O
89	O
index	O
patients	O
,	O
79	O
patients	O
were	O
demonstrated	O
to	O
carry	O
two	O
disease	O
-	O
causing	O
(	O
73	O
cases	O
)	O
or	O
possibly	O
disease	O
-	O
causing	O
mutations	O
(	O
6	O
cases	O
)	O
,	O
including	O
26	O
patients	O
with	O
homozygous	O
mutations	O
.	O

We	O
identified	O
105	O
different	O
mutations	O
,	O
including	O
59	O
novel	O
ones	O
.	O

Notably	O
,	O
in	O
13	O
patients	O
in	O
whom	O
only	O
one	O
pathogenic	O
mutation	O
was	O
initially	O
found	O
by	O
Sanger	O
sequencing	O
or	O
NGS	O
,	O
3	O
were	O
further	O
identified	O
to	O
carry	O
exon	O
deletions	O
by	O
MLPA	O
.	O

The	O
mutations	O
identified	O
in	O
this	O
study	O
appeared	O
to	O
cluster	O
in	O
the	O
N	O
-	O
terminal	O
region	O
.	O

Mutation	O
types	O
included	O
missense	O
mutations	O
(	O
30.06	O
%	O
)	O
,	O
nonsense	O
mutations	O
(	O
17.18	O
%	O
)	O
,	O
frameshift	O
mutations	O
(	O
30.67	O
%	O
)	O
,	O
in	O
-	O
frame	O
deletions	O
(	O
2.45	O
%	O
)	O
,	O
intronic	O
mutations	O
(	O
17.79	O
%	O
)	O
,	O
and	O
exonic	O
rearrangement	O
(	O
1.84	O
%	O
)	O
.	O

No	O
genotype	O
-	O
phenotype	O
correlation	O
was	O
identified	O
.	O

CONCLUSIONS	O
:	O
DYSF	O
mutations	O
in	O
Chinese	O
patients	O
clustered	O
in	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
gene	O
.	O

Exonic	O
rearrangements	O
were	O
found	O
in	O
23	O
%	O
of	O
patients	O
with	O
only	O
one	O
pathogenic	O
mutation	O
identified	O
by	O
Sanger	O
sequencing	O
or	O
NGS	O
.	O

The	O
novel	O
mutations	O
found	O
in	O
this	O
study	O
greatly	O
expanded	O
the	O
mutational	O
spectrum	O
of	O
dysferlinopathy	O
.	O

Whole	O
-	O
exome	O
sequencing	O
identifies	O
multiple	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
of	O
NF	O
-	O
κB	O
pathway	O
regulators	O
in	O
nasopharyngeal	O
carcinoma	O
.	O

Nasopharyngeal	O
carcinoma	O
(	O
NPC	O
)	O
is	O
an	O
epithelial	O
malignancy	O
with	O
a	O
unique	O
geographical	O
distribution	O
.	O

The	O
genomic	O
abnormalities	O
leading	O
to	O
NPC	O
pathogenesis	O
remain	O
unclear	O
.	O

In	O
total	O
,	O
135	O
NPC	O
tumors	O
were	O
examined	O
to	O
characterize	O
the	O
mutational	O
landscape	O
using	O
whole	O
-	O
exome	O
sequencing	O
and	O
targeted	O
resequencing	O
.	O

An	O
APOBEC	O
cytidine	O
deaminase	O
mutagenesis	O
signature	O
was	O
revealed	O
in	O
the	O
somatic	O
mutations	O
.	O

Noticeably	O
,	O
multiple	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
were	O
identified	O
in	O
several	O
NF	O
-	O
κB	O
signaling	O
negative	O
regulators	O
NFKBIA	O
,	O
CYLD	O
,	O
and	O
TNFAIP3	O
Functional	O
studies	O
confirmed	O
that	O
inhibition	O
of	O
NFKBIA	O
had	O
a	O
significant	O
impact	O
on	O
NF	O
-	O
κB	O
activity	O
and	O
NPC	O
cell	O
growth	O
.	O

The	O
identified	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
NFKBIA	B-Gene
leading	O
to	O
protein	B-MPA
truncation	I-MPA
contributed	O
to	O
the	O
altered	B-Reg
NF	B-Pathway
-	I-Pathway
κB	I-Pathway
activity	B-MPA
,	O
which	O
is	O
critical	O
for	O
NPC	O
tumorigenesis	O
.	O

In	O
addition	O
,	O
somatic	O
mutations	O
were	O
found	O
in	O
several	O
cancer	O
-	O
relevant	O
pathways	O
,	O
including	O
cell	O
cycle	O
-	O
phase	O
transition	O
,	O
cell	O
death	O
,	O
EBV	O
infection	O
,	O
and	O
viral	O
carcinogenesis	O
.	O

These	O
data	O
provide	O
an	O
enhanced	O
road	O
map	O
for	O
understanding	O
the	O
molecular	O
basis	O
underlying	O
NPC	O
.	O

ACOX2	O
deficiency	O
:	O
A	O
disorder	O
of	O
bile	O
acid	O
synthesis	O
with	O
transaminase	O
elevation	O
,	O
liver	O
fibrosis	O
,	O
ataxia	O
,	O
and	O
cognitive	O
impairment	O
.	O

Acyl	O
CoA	O
Oxidase	O
2	O
(	O
ACOX2	O
)	O
encodes	O
branched	O
-	O
chain	O
acyl	O
-	O
CoA	O
oxidase	O
,	O
a	O
peroxisomal	O
enzyme	O
believed	O
to	O
be	O
involved	O
in	O
the	O
metabolism	O
of	O
branched	O
-	O
chain	O
fatty	O
acids	O
and	O
bile	O
acid	O
intermediates	O
.	O

Deficiency	O
of	O
this	O
enzyme	O
has	O
not	O
been	O
described	O
previously	O
.	O

We	O
report	O
an	O
8-y	O
-	O
old	O
male	O
with	O
intermittently	O
elevated	O
transaminase	O
levels	O
,	O
liver	O
fibrosis	O
,	O
mild	O
ataxia	O
,	O
and	O
cognitive	O
impairment	O
.	O

Exome	O
sequencing	O
revealed	O
a	O
previously	O
unidentified	O
homozygous	O
premature	O
termination	O
mutation	O
(	B-Var
p	I-Var
.	I-Var
Y69	I-Var
*	I-Var
)	I-Var
in	O
ACOX2	B-Gene
Immunohistochemistry	O
confirmed	O
the	O
absence	B-NegReg
of	O
ACOX2	B-Gene
expression	B-MPA
in	O
the	O
patient	O
's	O
liver	O
,	O
and	O
biochemical	O
analysis	O
showed	O
marked	O
elevation	B-PosReg
of	O
intermediate	B-MPA
bile	I-MPA
acids	I-MPA
upstream	O
of	O
ACOX2	O
.	O

These	O
findings	O
define	O
a	O
potentially	O
treatable	O
inborn	O
error	O
of	O
bile	O
acid	O
biosynthesis	O
caused	O
by	O
ACOX2	O
deficiency	O
.	O

Prevalence	O
and	O
phenotypic	O
characterization	O
of	O
MC4R	O
variants	O
in	O
a	O
large	O
pediatric	O
cohort	O
.	O

OBJECTIVE	O
:	O
We	O
aimed	O
to	O
determine	O
the	O
prevalence	O
of	O
melanocortin-4	O
receptor	O
(	O
MC4R	O
)	O
variants	O
in	O
a	O
large	O
German	O
cohort	O
of	O
children	O
with	O
obesity	O
in	O
a	O
pediatric	O
outpatient	O
clinic	O
and	O
to	O
ascertain	O
whether	O
there	O
is	O
a	O
specific	O
phenotype	O
associated	O
with	O
loss	O
-	O
of	O
-	O
function	O
variants	O
as	O
previously	O
reported	O
.	O

STUDY	O
DESIGN	O
:	O
Eight	O
hundred	O
and	O
ninety	O
-	O
nine	O
patients	O
from	O
our	O
pediatric	O
obesity	O
clinic	O
were	O
screened	O
for	O
MC4R	O
variants	O
by	O
DNA	O
sequencing	O
after	O
PCR	O
amplification	O
.	O

Retrospective	O
statistical	O
analysis	O
of	O
anthropometric	O
and	O
metabolic	O
characteristics	O
was	O
performed	O
,	O
comparing	O
patients	O
with	O
and	O
without	O
MC4R	O
variants	O
across	O
the	O
entire	O
cohort	O
(	O
n=586	O
)	O
as	O
well	O
as	O
in	O
case	O
-	O
control	O
analysis	O
using	O
patients	O
with	O
common	O
sequence	O
MC4R	O
individually	O
matched	O
for	O
age	O
,	O
sex	O
and	O
body	O
mass	O
index	O
standard	O
deviation	O
score	O
(	O
SDS	O
)	O
(	O
n=11	O
case	O
-	O
control	O
pairs	O
)	O
.	O

RESULTS	O
:	O
We	O
identified	O
heterozygous	O
variants	O
within	O
the	O
coding	O
region	O
of	O
the	O
MC4R	B-Gene
gene	O
in	O
n=22	O
(	O
2.45	O
%	O
)	O
patients	O
.	O

Fourteen	O
(	O
1.56	O
%	O
)	O
had	O
a	O
variant	B-Var
that	O
impaired	B-NegReg
receptor	B-CPA
function	I-CPA
.	O

One	O
new	O
frameshift	O
(	O
p	O
.	O
F152Sfs	O
)	O
,	O
an	O
yet	O
unpublished	O
nonsense	O
mutation	O
(	O
p	O
.	O
Q156X	O
)	O
and	O
one	O
nonsynonymous	O
variation	O
(	O
p	O
.	O
V65E	O
)	O
described	O
in	O
the	O
Mouse	O
Genome	O
Database	O
were	O
detected	O
.	O

Across	O
the	O
whole	O
cohort	O
,	O
at	O
all	O
ages	O
,	O
mean	O
height	O
SDS	O
in	O
subjects	O
with	O
impaired	O
receptor	O
function	O
was	O
higher	O
than	O
in	O
patients	O
with	O
common	O
sequence	O
MC4R.	O
In	O
matched	O
individuals	O
,	O
this	O
trend	O
persisted	O
(	O
8	O
of	O
the	O
11	O
pairs	O
)	O
within	O
the	O
case	O
-	O
control	O
setting	O
.	O

No	O
differences	O
were	O
found	O
regarding	O
metabolic	O
characteristics	O
.	O

CONCLUSIONS	O
:	O
The	O
observed	O
prevalence	O
of	O
mutations	O
causing	O
impaired	O
receptor	O
function	O
in	O
this	O
large	O
cohort	O
is	O
comparable	O
to	O
other	O
pediatric	O
cohorts	O
.	O

MC4R	O
deficiency	O
tends	O
to	O
lead	O
to	O
a	O
taller	O
stature	O
,	O
confirming	O
previous	O
clinical	O
reports	O
.	O

The	O
association	O
of	O
MC4R	O
mutations	O
with	O
a	O
distinct	O
phenotype	O
concerning	O
metabolic	O
characteristics	O
remains	O
questionable	O
.	O

The	O
anti	B-MPA
-	I-MPA
adipogenic	I-MPA
effect	I-MPA
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
is	O
absent	B-NegReg
with	O
PCSK9	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
variants	B-Var
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
effect	O
of	O
(	O
1	O
)	O
an	O
oral	O
fat	O
load	O
and	O
(	O
2	O
)	O
pro	O
-	O
protein	O
convertase	O
subtilisin	O
/	O
kexin	O
type	O
(	O
PCSK	O
)	O
9	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LOF	O
)	O
variant	B-Var
status	O
on	O
the	O
ability	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
to	O
inhibit	B-NegReg
human	B-MPA
adipogenesis	I-MPA
.	O

METHODS	O
:	O
PBMC	O
from	O
subjects	O
with	O
one	O
or	O
more	O
PCSK9	O
LOF	O
variants	O
versus	O
non	O
-	O
variant	O
controls	O
were	O
compared	O
in	O
the	O
fasting	O
state	O
and	O
after	O
an	O
oral	O
fat	O
load	O
.	O

RESULTS	O
:	O
Fasting	O
triglyceride	O
(	O
TG	O
)	O
levels	O
were	O
lower	O
in	O
the	O
LOF	O
variant	O
versus	O
non	O
-	O
variant	O
group	O
but	O
rose	O
to	O
the	O
same	O
level	O
after	O
the	O
oral	O
fat	O
load	O
.	O

Conditioned	O
medium	O
from	O
PBMC	O
was	O
obtained	O
in	O
fasting	O
(	O
PBMC	O
-	O
CM	O
-	O
F	O
)	O
and	O
4-h	O
postprandial	O
(	O
PBMC	O
-	O
CM	O
-	O
PP	O
)	O
states	O
.	O

PBMC	O
-	O
CM	O
-	O
PP	O
from	O
non	O
-	O
variant	O
controls	O
inhibited	O
adipogenesis	O
of	O
human	O
preadipocytes	O
more	O
than	O
did	O
PBMC	O
-	O
CM	O
-	O
F.	O
In	O
contrast	O
,	O
PBMC	O
-	O
CM	O
-	O
F	O
or	O
-PP	O
from	O
PCSK9	B-Gene
LOF	B-NegReg
variant	B-Var
subjects	O
had	O
no	O
effect	O
on	O
adipogenesis	B-MPA
.	O

After	O
the	O
oral	O
fat	O
load	O
,	O
PBMC	O
from	O
PCSK9	B-Gene
LOF	B-NegReg
variant	B-Var
subjects	O
showed	O
significant	O
increases	B-PosReg
in	O
mRNA	B-MPA
levels	I-MPA
of	I-MPA
interleukin-1β	I-MPA
,	O
tumor	B-MPA
necrosis	I-MPA
factor	I-MPA
-	I-MPA
α	I-MPA
,	O
sterol	B-MPA
regulatory	I-MPA
element	I-MPA
binding	I-MPA
protein-1c	I-MPA
,	O
CD36	B-MPA
,	O
and	O
monocyte	O
chemoattractant	O
protein-1	O
(	O
MCP-1	O
)	O
,	O
only	O
MCP-1	O
mRNA	O
levels	O
increased	O
in	O
PBMC	O
from	O
non	O
-	O
variant	O
controls	O
.	O

CONCLUSIONS	O
:	O
The	O
absence	B-NegReg
of	O
anti	B-MPA
-	I-MPA
adipogenic	I-MPA
action	I-MPA
of	O
PBMC	O
from	O
PCSK9	B-Gene
LOF	O
variant	B-Var
subjects	O
points	O
to	O
a	O
novel	B-PosReg
role	I-PosReg
for	O
PCSK9	O
in	O
PBMC	O
-	O
adipose	O
cell	O
interactions	B-Interaction
.	O

Novel	O
MBTPS2	B-Gene
missense	B-Var
mutation	I-Var
causes	B-Reg
a	O
keratosis	B-Disease
follicularis	I-Disease
spinulosa	I-Disease
decalvans	I-Disease
phenotype	O
:	O
mutation	O
update	O
and	O
review	O
of	O
the	O
literature	O
.	O

Keratosis	B-Disease
follicularis	I-Disease
spinulosa	I-Disease
decalvans	I-Disease
(	O
KFSD	O
)	O
is	O
an	O
X	O
-	O
linked	O
condition	O
characterized	O
by	O
keratotic	O
follicular	O
papules	O
and	O
progressive	O
alopecia	O
,	O
which	O
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
MBTPS2	B-Gene
gene	O
.	O

We	O
carried	O
out	O
a	O
genetic	O
study	O
on	O
a	O
child	O
who	O
was	O
suspected	O
clinically	O
to	O
have	O
KFSD	O
.	O

Sanger	O
sequencing	O
was	O
performed	O
to	O
detect	O
mutations	O
in	O
the	O
entire	O
coding	O
region	O
of	O
MBTPS2	O
.	O

A	O
novel	O
missense	O
mutation	O
(	B-Var
c.599C	I-Var
>	I-Var
T	I-Var
)	I-Var
was	O
identified	O
in	O
the	O
patient	O
,	O
confirming	B-Reg
a	O
diagnosis	O
of	O
KFSD	B-Disease
.	O

We	O
reviewed	O
related	O
cases	O
with	O
MBTPS2	O
mutations	O
for	O
evidence	O
of	O
genotype	O
-	O
phenotype	O
correlations	O
.	O

Atopic	O
Dermatitis	O
Susceptibility	O
Variants	O
in	O
Filaggrin	O
Hitchhike	O
Hornerin	O
Selective	O
Sweep	O
.	O

Human	O
skin	O
has	O
evolved	O
rapidly	O
,	O
leaving	O
evolutionary	O
signatures	O
in	O
the	O
genome	O
.	O

The	O
filaggrin	O
(	B-Gene
FLG	I-Gene
)	I-Gene
gene	O
is	O
widely	O
studied	O
for	O
its	O
skin	O
-	O
barrier	O
function	O
in	O
humans	O
.	O

The	O
extensive	B-Var
genetic	I-Var
variation	I-Var
in	O
this	O
gene	O
,	O
especially	O
common	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LoF	O
)	O
mutations	B-Var
,	O
has	O
been	O
established	O
as	O
primary	O
risk	O
factors	O
for	O
atopic	B-Disease
dermatitis	I-Disease
.	O

To	O
investigate	O
the	O
evolution	O
of	O
this	O
gene	O
,	O
we	O
analyzed	O
2,504	O
human	O
genomes	O
and	O
genotyped	O
the	O
copy	O
number	O
variation	O
of	O
filaggrin	O
repeats	O
within	O
FLG	O
in	O
126	O
individuals	O
from	O
diverse	O
ancestral	O
backgrounds	O
.	O

We	O
were	O
unable	O
to	O
replicate	O
a	O
recent	O
study	O
claiming	O
that	O
LoF	O
of	O
FLG	O
is	O
adaptive	O
in	O
northern	O
latitudes	O
with	O
lower	O
ultraviolet	O
light	O
exposure	O
.	O

Instead	O
,	O
we	O
present	O
multiple	O
lines	O
of	O
evidence	O
suggesting	O
that	O
FLG	O
genetic	O
variation	O
,	O
including	O
LoF	O
variants	O
,	O
have	O
little	O
or	O
no	O
effect	O
on	O
fitness	O
in	O
modern	O
humans	O
.	O

Haplotype	O
-	O
level	O
scrutinization	O
of	O
the	O
locus	O
revealed	O
signatures	O
of	O
a	O
recent	O
selective	O
sweep	O
in	O
Asia	O
,	O
which	O
increased	O
the	O
allele	O
frequency	O
of	O
a	O
haplotype	O
group	O
(	O
Huxian	O
haplogroup	O
)	O
in	O
Asian	O
populations	O
.	O

Functionally	O
,	O
we	O
found	O
that	O
the	O
Huxian	O
haplogroup	O
carries	O
dozens	O
of	O
functional	O
variants	O
in	O
FLG	O
and	O
hornerin	O
(	O
HRNR	O
)	O
genes	O
,	O
including	O
those	O
that	O
are	O
associated	O
with	O
atopic	O
dermatitis	O
susceptibility	O
,	O
HRNR	O
expression	O
levels	O
and	O
microbiome	O
diversity	O
on	O
the	O
skin	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
target	O
of	O
the	O
adaptive	O
sweep	O
is	O
HRNR	O
gene	O
function	O
,	O
and	O
the	O
functional	O
FLG	O
variants	O
that	O
involve	O
susceptibility	O
to	O
atopic	O
dermatitis	O
,	O
seem	O
to	O
hitchhike	O
the	O
selective	O
sweep	O
on	O
HRNR	O
.	O

Our	O
study	O
presents	O
a	O
novel	O
case	O
of	O
a	O
locus	O
that	O
harbors	O
clinically	O
relevant	O
common	O
genetic	O
variation	O
with	O
complex	O
evolutionary	O
trajectories	O
.	O

Temperature	O
-	O
dependent	O
autoimmunity	O
mediated	O
by	O
chs1	O
requires	O
its	O
neighboring	O
TNL	O
gene	O
SOC3	O
.	O

Toll	O
/	O
interleukin	O
receptor	O
(	O
TIR)-nucleotide	O
binding	O
site	O
(	O
NB)-type	O
(	O
TN	O
)	O
proteins	O
are	O
encoded	O
by	O
a	O
family	O
of	O
21	O
genes	O
in	O
the	O
Arabidopsis	O
genome	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
a	O
mutation	O
in	O
the	O
TN	O
gene	O
CHS1	O
activates	O
the	O
activation	O
of	O
defense	O
responses	O
at	O
low	O
temperatures	O
.	O

However	O
,	O
the	O
underlying	O
molecular	O
mechanism	O
remains	O
unknown	O
.	O

To	O
genetically	O
dissect	O
chs1-mediated	O
signaling	O
,	O
we	O
isolated	O
genetic	O
suppressors	O
of	O
chs1	O
-	O
2	O
(	O
soc	O
)	O
.	O

Several	O
independent	O
soc	O
mutants	O
carried	O
mutations	O
in	O
the	O
same	O
TIR	O
-	O
NB	O
-	O
leucine	O
-	O
rich	O
repeat	O
(	O
LRR	O
)	O
(	O
TNL)-encoding	O
gene	O
SOC3	O
,	O
which	O
is	O
adjacent	O
to	O
CHS1	O
on	O
chromosome	O
1	O
.	O

Expression	B-MPA
of	O
SOC3	B-Gene
was	O
upregulated	B-PosReg
in	O
the	O
chs1	B-Gene
-	I-Gene
2	I-Gene
mutant	B-Var
.	O

Mutations	O
in	O
six	O
soc3	O
alleles	O
and	O
downregulation	O
of	O
SOC3	O
by	O
an	O
artificial	O
microRNA	O
construct	O
fully	O
rescued	O
the	O
chilling	O
sensitivity	O
and	O
defense	O
defects	O
of	O
chs1	O
-	O
2	O
.	O

Biochemical	O
studies	O
showed	O
that	O
CHS1	O
interacted	O
with	O
the	O
NB	O
and	O
LRR	O
domains	O
of	O
SOC3	O
;	O
however	O
,	O
mutated	O
chs1	O
interacted	O
with	O
the	O
TIR	O
,	O
NB	O
and	O
LRR	O
domains	O
of	O
SOC3	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

This	O
study	O
reveals	O
that	O
the	O
TN	O
protein	O
CHS1	O
interacts	O
with	O
the	O
TNL	O
protein	O
SOC3	O
to	O
modulate	O
temperature	O
-	O
dependent	O
autoimmunity	O
.	O

INPPL1	B-Gene
gene	O
mutations	B-Var
in	B-Reg
opsismodysplasia	B-Disease
.	O

The	O
INPPL1	O
(	O
inositol	O
polyphosphate	O
phosphatase	O
-	O
like	O
1	O
)	O
gene	O
encodes	O
the	O
inositol	O
phosphatase	O
,	O
SHIP2	O
(	O
for	O
src	O
homology	O
2	O
domain	O
-	O
containing	O
inositol	O
phosphatase	O
2	O
)	O
.	O

SHIP2	O
functions	O
to	O
dephosphorylate	O
,	O
and	O
negatively	O
regulate	O
,	O
the	O
lipid	O
second	O
messenger	O
phosphatidylinositol	O
(	O
3,4,5)P3	O
.	O

SHIP2	O
has	O
been	O
well	O
studied	O
in	O
the	O
area	O
of	O
insulin	O
resistance	O
and	O
obesity	O
but	O
has	O
roles	O
in	O
cancer	O
and	O
other	O
disorders	O
.	O

Recently	O
,	O
it	O
was	O
reported	O
that	O
mutations	B-Var
in	O
INPPL1	B-Gene
cause	B-Reg
opsismodysplasia	B-Disease
,	O
a	O
rare	O
,	O
autosomal	O
recessive	O
severe	O
skeletal	O
dysplasia	O
.	O

This	O
review	O
focuses	O
on	O
the	O
mutations	O
associated	O
with	O
opsismodysplasia	O
and	O
explores	O
the	O
role	O
of	O
INPPL1/	O
SHIP2	O
in	O
skeletal	O
development	O
.	O

Genetic	O
screening	O
of	O
the	O
FLCN	O
gene	O
identify	O
six	O
novel	O
variants	O
and	O
a	O
Danish	O
founder	O
mutation	O
.	O

Pathogenic	O
germline	O
mutations	B-Var
in	O
the	O
folliculin	O
(	B-Gene
FLCN	I-Gene
)	I-Gene
tumor	O
suppressor	O
gene	O
predispose	O
to	B-Reg
Birt	B-Disease
-	I-Disease
Hogg	I-Disease
-	I-Disease
Dubé	I-Disease
(	O
BHD	O
)	O
syndrome	O
,	O
a	O
rare	O
disease	O
characterized	O
by	O
the	O
development	O
of	O
cutaneous	O
hamartomas	O
(	O
fibrofolliculomas	O
)	O
,	O
multiple	O
lung	O
cysts	O
,	O
spontaneous	O
pneumothoraces	O
and	O
renal	O
cell	O
cancer	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
the	O
identification	O
of	O
13	O
variants	O
and	O
three	O
polymorphisms	O
in	O
the	O
FLCN	O
gene	O
in	O
143	O
Danish	O
patients	O
or	O
families	O
with	O
suspected	O
BHD	O
syndrome	O
.	O

Functional	O
mini	O
-	O
gene	O
splicing	O
analysis	O
revealed	O
that	O
two	O
intronic	O
variants	O
(	O
c.1062	O
+	O
2T	O
>	O
G	O
and	O
c.1177	O
-	O
5_1177	O
-	O
3del	O
)	O
introduced	O
splicing	O
aberrations	O
.	O

Eleven	O
families	O
exhibited	O
the	O
c.1062	O
+	O
2T	O
>	O
G	O
mutation	O
.	O

Combined	O
single	O
nucleotide	O
polymorphism	O
array	O
-	O
haplotype	O
analysis	O
showed	O
that	O
these	O
families	O
share	O
a	O
3-Mb	O
genomic	O
fragment	O
containing	O
the	O
FLCN	O
gene	O
,	O
revealing	O
that	O
the	O
c.1062	O
+	O
2T	O
>	O
G	O
mutation	O
is	O
a	O
Danish	O
founder	O
mutation	O
.	O

On	O
the	O
basis	O
of	O
in	O
silico	O
prediction	O
and	O
functional	O
splicing	O
assays	O
,	O
we	O
classify	O
the	O
16	O
identified	O
variants	O
in	O
the	O
FLCN	O
gene	O
as	O
follows	O
:	O
nine	O
as	O
pathogenic	O
,	O
one	O
as	O
likely	O
pathogenic	O
,	O
three	O
as	O
likely	O
benign	O
and	O
three	O
as	O
polymorphisms	O
.	O

In	O
conclusion	O
,	O
the	O
study	O
describes	O
the	O
FLCN	O
mutation	O
spectrum	O
in	O
Danish	O
BHD	O
patients	O
,	O
and	O
contributes	O
to	O
a	O
better	O
understanding	O
of	O
BHD	O
syndrome	O
and	O
management	O
of	O
BHD	O
patients	O
.	O

Structural	O
brain	O
abnormalities	O
in	O
a	O
single	O
gene	O
disorder	O
associated	O
with	O
epilepsy	O
,	O
language	O
impairment	O
and	O
intellectual	O
disability	O
.	O

Childhood	O
speech	O
and	O
language	O
deficits	O
are	O
highly	O
prevalent	O
and	O
are	O
a	O
common	O
feature	O
of	O
neurodevelopmental	O
disorders	O
.	O

However	O
,	O
it	O
is	O
difficult	O
to	O
investigate	O
the	O
underlying	O
causal	O
pathways	O
because	O
many	O
diagnostic	O
groups	O
have	O
a	O
heterogeneous	O
aetiology	O
.	O

Studying	O
disorders	O
with	O
a	O
shared	O
genetic	O
cause	O
and	O
shared	O
cognitive	O
deficits	O
can	O
provide	O
crucial	O
insight	O
into	O
the	O
cellular	O
mechanisms	O
and	O
neural	O
systems	O
that	O
give	O
rise	O
to	O
those	O
impairments	O
.	O

The	O
current	O
study	O
investigated	O
structural	O
brain	O
differences	O
of	O
individuals	O
with	O
mutations	B-Var
in	O
ZDHHC9	B-Gene
,	O
which	O
is	O
associated	B-Reg
with	I-Reg
a	O
specific	O
neurodevelopmental	O
phenotype	O
including	O
prominent	O
speech	B-Disease
and	I-Disease
language	I-Disease
impairments	I-Disease
and	O
intellectual	B-Disease
disability	I-Disease
.	O

We	O
used	O
multiple	O
structural	O
neuroimaging	O
methods	O
to	O
characterise	O
neuroanatomy	O
in	O
this	O
group	O
,	O
and	O
observed	O
bilateral	O
reductions	O
in	O
cortical	O
thickness	O
in	O
areas	O
surrounding	O
the	O
temporo	O
-	O
parietal	O
junction	O
,	O
parietal	O
lobule	O
,	O
and	O
inferior	O
frontal	O
lobe	O
,	O
and	O
decreased	O
microstructural	O
integrity	O
of	O
cortical	O
,	O
subcortical	O
-	O
cortical	O
,	O
and	O
interhemispheric	O
white	O
matter	O
projections	O
.	O

These	O
findings	O
are	O
compared	O
to	O
reports	O
for	O
other	O
genetic	O
groups	O
and	O
genetically	O
heterogeneous	O
disorders	O
with	O
a	O
similar	O
presentation	O
.	O

Overlap	O
in	O
the	O
neuroanatomical	O
phenotype	O
suggests	O
a	O
common	O
pathway	O
that	O
particularly	O
affects	O
the	O
development	O
of	O
temporo	O
-	O
parietal	O
and	O
inferior	O
frontal	O
areas	O
,	O
and	O
their	O
connections	O
.	O

Pharmacological	O
Chaperoning	O
:	O
A	O
Potential	O
Treatment	O
for	O
PMM2-CDG	O
.	O

The	O
congenital	B-Disease
disorder	I-Disease
of	I-Disease
glycosylation	I-Disease
(	I-Disease
CDG	I-Disease
)	I-Disease
due	I-Disease
to	I-Disease
phosphomannomutase	I-Disease
2	I-Disease
deficiency	I-Disease
(	O
PMM2-CDG	O
)	O
,	O
the	O
most	O
common	O
N	O
-	O
glycosylation	O
disorder	O
,	O
is	O
a	O
multisystem	O
disease	O
for	O
which	O
no	O
effective	O
treatment	O
is	O
available	O
.	O

The	O
recent	O
functional	O
characterization	O
of	O
disease	O
-	O
causing	O
mutations	O
described	O
in	O
patients	O
with	O
PMM2-CDG	B-Disease
led	O
to	O
the	O
idea	O
of	O
a	O
therapeutic	O
strategy	O
involving	O
pharmacological	O
chaperones	O
(	O
PC	O
)	O
to	O
rescue	O
PMM2	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
.	O

The	O
present	O
work	O
describes	O
the	O
high	O
-	O
throughput	O
screening	O
,	O
by	O
differential	O
scanning	O
fluorimetry	O
,	O
of	O
10,000	O
low	O
-	O
molecular	O
-	O
weight	O
compounds	O
from	O
a	O
commercial	O
library	O
,	O
to	O
search	O
for	O
possible	O
PCs	O
for	O
the	O
enzyme	O
PMM2	O
.	O

This	O
exercise	O
identified	O
eight	O
compounds	O
that	O
increased	O
the	O
thermal	O
stability	O
of	O
PMM2	O
.	O

Of	O
these	O
,	O
four	O
compounds	O
functioned	O
as	O
potential	O
PCs	O
that	O
significantly	O
increased	O
the	O
stability	O
of	O
several	O
destabilizing	O
and	O
oligomerization	O
mutants	O
and	O
also	O
increased	O
PMM	O
activity	O
in	O
a	O
disease	O
model	O
of	O
cells	O
overexpressing	O
PMM2	O
mutations	O
.	O

Structural	O
analysis	O
revealed	O
one	O
of	O
these	O
compounds	O
to	O
provide	O
an	O
excellent	O
starting	O
point	O
for	O
chemical	O
optimization	O
since	O
it	O
passed	O
tests	O
based	O
on	O
a	O
number	O
of	O
pharmacochemical	O
quality	O
filters	O
.	O

The	O
present	O
results	O
provide	O
the	O
first	O
proof	O
-	O
of	O
-	O
concept	O
of	O
a	O
possible	O
treatment	O
for	O
PMM2-CDG	O
and	O
describe	O
a	O
promising	O
chemical	O
structure	O
as	O
a	O
starting	O
point	O
for	O
the	O
development	O
of	O
new	O
therapeutic	O
agents	O
for	O
this	O
severe	O
orphan	O
disease	O
.	O

Subtypes	O
of	O
SERPINC1	O
mutations	O
and	O
the	O
thrombotic	O
phenotype	O
of	O
inherited	O
antithrombin	O
deficient	O
individuals	O
in	O
Chinese	O
Han	O
population	O
.	O

Inherited	B-Disease
antithrombin	I-Disease
(	I-Disease
AT	I-Disease
)	I-Disease
deficiency	I-Disease
is	O
a	O
rare	O
autosomal	O
disease	O
that	O
could	O
increase	O
the	O
risk	O
of	O
venous	O
thromboembolism	O
(	O
VTE	O
)	O
and	O
usually	O
caused	B-Reg
by	I-Reg
mutations	B-Var
of	O
SERPINC1	B-Gene
.	O

Although	O
a	O
number	O
of	O
mutations	O
of	O
SERPINC1	O
have	O
been	O
reported	O
in	O
Chinese	O
Han	O
population	O
,	O
the	O
impact	O
of	O
different	O
subtypes	O
of	O
these	O
mutations	O
on	O
the	O
thrombotic	O
phenotype	O
is	O
still	O
unknown	O
.	O

Here	O
,	O
we	O
performed	O
a	O
retrospective	O
cohort	O
study	O
including	O
169	O
AT	O
patients	O
from	O
63	O
families	O
to	O
compare	O
the	O
clinical	O
features	O
between	O
null	O
mutation	O
carriers	O
and	O
missense	O
mutation	O
carriers	O
.	O

We	O
found	O
that	O
patients	O
carrying	O
null	O
mutations	O
have	O
a	O
higher	O
risk	O
of	O
VTE	O
(	O
HR	O
2.29	O
,	O
95	O
%	O
CI	O
1.16	O
-	O
4.69	O
,	O
P=0.02	O
adjusted	O
for	O
sex	O
and	O
VTE	O
family	O
history	O
)	O
and	O
earlier	O
median	O
onset	O
age	O
of	O
VTE	O
(	O
27	O
vs.	O
32years	O
,	O
P=0.045	O
)	O
as	O
well	O
as	O
lower	O
AT	O
activities	O
(	O
47.6±1.0	O
%	O
vs.	O
59.1±2.3	O
%	O
,	O
P<0.001	O
)	O
than	O
those	O
with	O
missense	O
mutations	O
.	O

We	O
also	O
observed	O
that	O
thrombus	O
location	O
sites	O
showed	O
no	O
difference	O
between	O
null	O
mutation	O
carriers	O
and	O
missense	O
mutation	O
carriers	O
,	O
gene	O
locations	O
of	O
the	O
mutations	O
did	O
not	O
relate	O
with	O
the	O
incidence	O
rate	O
of	O
VTE	O
.	O

This	O
study	O
demonstrated	O
that	O
different	O
types	O
of	O
SERPINC1	O
mutations	O
may	O
play	O
different	O
roles	O
in	O
the	O
development	O
of	O
VTE	O
and	O
should	O
be	O
considered	O
in	O
the	O
prevention	O
of	O
VTE	O
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
of	O
an	O
Arabidopsis	O
NADPH	B-Enzyme
pyrophosphohydrolase	I-Enzyme
,	O
AtNUDX19	O
,	O
impacts	B-Reg
on	O
the	O
pyridine	B-MPA
nucleotides	I-MPA
status	I-MPA
and	O
confers	B-PosReg
photooxidative	B-CPA
stress	I-CPA
tolerance	I-CPA
.	O

The	O
levels	O
and	O
redox	O
states	O
of	O
pyridine	O
nucleotides	O
,	O
such	O
as	O
NADP(H	O
)	O
,	O
regulate	O
the	O
cellular	O
redox	O
homeostasis	O
,	O
which	O
is	O
crucial	O
for	O
photooxidative	O
stress	O
response	O
in	O
plants	O
.	O

However	O
,	O
how	O
they	O
are	O
controlled	O
is	O
poorly	O
understood	O
.	O

An	O
Arabidopsis	O
Nudix	O
hydrolase	O
,	O
AtNUDX19	O
,	O
was	O
previously	O
identified	O
to	O
have	O
NADPH	O
hydrolytic	O
activity	O
in	O
vitro	O
,	O
suggesting	O
this	O
enzyme	O
to	O
be	O
a	O
regulator	O
of	O
the	O
NADPH	O
status	O
.	O

We	O
herein	O
examined	O
the	O
physiological	O
role	O
of	O
AtNUDX19	B-Gene
using	O
its	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutants	B-Var
.	O

NADPH	B-CPA
levels	I-CPA
were	O
increased	B-PosReg
in	O
nudx19	B-Gene
mutants	B-Var
under	O
both	O
normal	O
and	O
high	O
light	O
conditions	O
,	O
while	O
NADP(+	B-MPA
)	I-MPA
and	O
NAD(+	B-MPA
)	I-MPA
levels	I-MPA
were	O
decreased	B-PosReg
.	O

Despite	O
the	O
high	O
redox	O
states	O
of	O
NADP(H	O
)	O
,	O
nudx19	O
mutants	O
exhibited	O
high	O
tolerance	O
to	O
moderate	O
light-	O
or	O
methylviologen	O
-	O
induced	O
photooxidative	O
stresses	O
.	O

This	O
tolerance	O
might	O
be	O
partially	O
attributed	O
to	O
the	O
activation	O
of	O
either	O
or	O
both	O
photosynthesis	O
and	O
the	O
antioxidant	O
system	O
.	O

Furthermore	O
,	O
a	O
microarray	O
analysis	O
suggested	O
the	O
role	O
of	O
ANUDX19	O
in	O
regulation	O
of	O
the	O
salicylic	O
acid	O
(	O
SA	O
)	O
response	O
in	O
a	O
negative	O
manner	O
.	O

Indeed	O
,	O
nudx19	O
mutants	O
accumulated	O
SA	O
and	O
showed	O
high	O
sensitivity	O
to	O
the	O
hormone	O
.	O

Our	O
findings	O
demonstrate	O
that	O
ANUDX19	O
acts	O
as	O
an	O
NADPH	O
pyrophosphohydrolase	O
to	O
modulate	O
cellular	O
levels	O
and	O
redox	O
states	O
of	O
pyridine	O
nucleotides	O
and	O
fine	O
-	O
tunes	O
photooxidative	O
stress	O
response	O
through	O
the	O
regulation	O
of	O
photosynthesis	O
,	O
antioxidant	O
system	O
,	O
and	O
possibly	O
hormonal	O
signaling	O
.	O

Compound	O
heterozygous	O
LDLR	O
variant	O
in	O
severely	O
affected	O
familial	O
hypercholesterolemia	O
patient	O
.	O

Familial	B-Disease
hypercholesterolemia	I-Disease
(	O
FH	O
)	O
is	O
most	O
commonly	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
LDL	O
receptor	O
(	B-Gene
LDLR	I-Gene
)	I-Gene
,	O
which	O
is	O
responsible	O
for	O
hepatic	O
clearance	O
of	O
LDL	O
from	O
the	O
blood	O
circulation	O
.	O

We	O
described	O
a	O
severely	O
affected	O
FH	O
proband	O
and	O
their	O
first	O
-	O
degree	O
blood	O
relatives	O
;	O
the	O
proband	O
was	O
resistant	O
to	O
statin	O
therapy	O
and	O
was	O
managed	O
on	O
an	O
LDL	O
apheresis	O
program	O
.	O

In	O
order	O
to	O
find	O
the	O
causative	O
genetic	O
variant	O
in	O
this	O
family	O
,	O
direct	O
exon	O
sequencing	O
of	O
the	O
LDLR	O
,	O
APOB	O
and	O
PCSK9	O
genes	O
was	O
performed	O
.	O

We	O
identified	O
a	O
compound	O
heterozygous	O
mutation	O
in	O
the	O
proband	O
with	O
missense	O
p.(W577C	O
)	O
and	O
frameshift	O
p.(G676Afs33	O
)	O
variants	O
at	O
exons	O
12	O
and	O
14	O
of	O
the	O
LDLR	O
gene	O
respectively	O
.	O

DNA	O
sequencing	O
of	O
LDLR	O
gene	O
from	O
the	O
parents	O
demonstrated	O
that	O
the	O
missense	O
variant	O
was	O
inherited	O
from	O
the	O
mother	O
and	O
frameshift	O
variant	O
was	O
inherited	O
from	O
the	O
father	O
.	O

The	O
frameshift	B-Var
variant	I-Var
resulted	O
in	O
a	O
stop	B-MPA
signal	I-MPA
33	I-MPA
codons	I-MPA
downstream	I-MPA
of	O
the	O
deletion	B-NegReg
,	O
which	O
most	O
likely	O
led	O
to	O
a	O
truncated	B-Protein
protein	I-Protein
that	O
lacks	B-NegReg
important	B-MPA
functional	I-MPA
domains	I-MPA
,	O
including	O
the	O
trans	O
-	O
membrane	O
domain	O
and	O
the	O
cytoplasmic	O
tail	O
domain	O
.	O

The	O
missense	O
variant	O
is	O
also	O
predicted	O
to	O
be	O
likely	O
pathogenic	O
and	O
affect	O
EGF	O
-	O
precursor	O
homology	O
domain	O
of	O
the	O
LDLR	O
protein	O
.	O

The	O
segregation	O
pattern	O
of	O
the	O
variants	O
was	O
consistent	O
with	O
the	O
lipid	O
profile	O
,	O
suggesting	O
a	O
more	O
severe	O
FH	O
phenotype	O
when	O
the	O
variants	O
are	O
in	O
the	O
compound	O
heterozygous	O
state	O
.	O

The	O
finding	O
of	O
a	O
compound	O
heterozygous	O
mutation	O
causing	O
severe	O
FH	O
phenotype	O
is	O
important	O
for	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
and	O
also	O
enlarges	O
the	O
spectrum	O
of	O
FH	O
-	O
causative	O
LDLR	O
variants	O
in	O
the	O
Arab	O
population	O
,	O
including	O
the	O
Saudi	O
population	O
.	O

Activity	O
of	O
NaV1.2	O
promotes	O
neurodegeneration	O
in	O
an	O
animal	O
model	O
of	O
multiple	O
sclerosis	O
.	O

Counteracting	O
the	O
progressive	O
neurological	O
disability	O
caused	O
by	O
neuronal	O
and	O
axonal	O
loss	O
is	O
the	O
major	O
unmet	O
clinical	O
need	O
in	O
multiple	O
sclerosis	O
therapy	O
.	O

However	O
,	O
the	O
mechanisms	O
underlying	O
irreversible	O
neuroaxonal	O
degeneration	O
in	O
multiple	O
sclerosis	O
and	O
its	O
animal	O
model	O
experimental	O
autoimmune	O
encephalomyelitis	O
(	O
EAE	O
)	O
are	O
not	O
well	O
understood	O
.	O

A	O
long	O
-	O
standing	O
hypothesis	O
holds	O
that	O
the	O
distribution	O
of	O
voltage	O
-	O
gated	O
sodium	O
channels	O
along	O
demyelinated	O
axons	O
contributes	O
to	O
neurodegeneration	O
by	O
increasing	O
neuroaxonal	O
sodium	O
influx	O
and	O
energy	O
demand	O
during	O
CNS	O
inflammation	O
.	O

Here	O
,	O
we	O
tested	O
this	O
hypothesis	O
in	O
vivo	O
by	O
inserting	O
a	O
human	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	B-Var
in	O
the	O
mouse	O
NaV1.2-encoding	O
gene	O
Scn2a	B-Gene
that	O
is	O
known	O
to	O
increase	O
NaV1.2-mediated	O
persistent	O
sodium	O
currents	O
.	O

In	O
mutant	O
mice	O
,	O
CNS	B-CPA
inflammation	I-CPA
during	I-CPA
EAE	I-CPA
leads	O
to	O
elevated	B-PosReg
neuroaxonal	B-CPA
degeneration	I-CPA
and	O
increased	B-PosReg
disability	B-CPA
and	O
lethality	B-CPA
compared	O
with	O
wild	O
-	O
type	O
littermate	O
controls	O
.	O

Importantly	O
,	O
immune	O
cell	O
infiltrates	O
were	O
not	O
different	O
between	O
mutant	O
EAE	O
mice	O
and	O
wild	O
-	O
type	O
EAE	O
mice	O
.	O

Thus	O
,	O
this	O
study	O
shows	O
that	O
increased	O
neuronal	O
NaV1.2	O
activity	O
exacerbates	O
inflammation	O
-	O
induced	O
neurodegeneration	O
irrespective	O
of	O
immune	O
cell	O
alterations	O
and	O
identifies	O
NaV1.2	O
as	O
a	O
promising	O
neuroprotective	O
drug	O
target	O
in	O
multiple	O
sclerosis	O
.	O

Exome	O
sequencing	O
reveals	O
germline	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
EGFR	B-Gene
mutation	B-Var
in	O
an	O
adult	O
with	O
Lhermitte	B-Disease
-	I-Disease
Duclos	I-Disease
disease	I-Disease
.	O

Lhermitte	B-Disease
-	I-Disease
Duclos	I-Disease
disease	I-Disease
(	O
LDD	O
)	O
is	O
a	O
rare	O
cerebellar	O
disorder	O
believed	O
to	O
be	O
pathognomonic	O
for	O
Cowden	O
syndrome	O
.	O

Presently	O
,	O
the	O
only	O
known	O
etiology	B-Reg
is	O
germline	O
PTEN	B-Gene
mutation	B-Var
.	O

We	O
report	O
a	O
41-yr	O
-	O
old	O
white	O
female	O
diagnosed	O
with	O
LDD	O
and	O
wild	O
-	O
type	O
for	O
PTEN	O
.	O

Exome	O
sequencing	O
revealed	O
a	O
germline	O
heterozygous	O
EGFR	B-Gene
mutation	B-Var
that	O
breaks	B-NegReg
a	O
disulfide	B-MPA
bond	I-MPA
in	I-MPA
the	I-MPA
receptor	I-MPA
's	I-MPA
extracellular	I-MPA
domain	I-MPA
,	O
resulting	O
in	O
constitutive	B-MPA
activation	B-PosReg
.	O

Functional	O
studies	O
demonstrate	O
activation	B-PosReg
of	O
ERK	B-Pathway
/	I-Pathway
AKT	I-Pathway
signaling	I-Pathway
pathways	I-Pathway
,	O
mimicking	O
PTEN	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
downstream	O
effects	O
.	O

The	O
identification	O
of	O
EGFR	O
as	O
a	O
candidate	O
LDD	O
susceptibility	O
gene	O
contributes	O
to	O
advancement	O
of	O
molecular	O
diagnosis	O
and	O
targeted	O
therapy	O
for	O
this	O
rare	O
condition	O
with	O
limited	O
treatment	O
options	O
.	O

Variants	O
of	O
genes	O
encoding	O
collagens	O
and	O
matrix	O
metalloproteinase	O
system	O
increased	O
the	O
risk	O
of	O
aortic	O
dissection	O
.	O

Aortic	O
dissection	O
(	O
AD	O
)	O
is	O
a	O
devastating	O
,	O
heterogeneous	O
condition	O
of	O
aorta	O
.	O

The	O
homeostasis	O
between	O
collagens	O
and	O
matrix	O
metalloproteases	O
(	O
MMPs)/tissue	O
inhibitors	O
of	O
MMPs	O
(	O
TIMPs	O
)	O
system	O
in	O
the	O
extracellular	O
matrix	O
plays	O
an	O
important	O
role	O
for	O
structure	O
and	O
functions	O
of	O
aorta	O
.	O

However	O
,	O
our	O
knowledge	O
on	O
association	O
between	O
variants	O
of	O
genes	O
in	O
this	O
system	O
and	O
pathogenesis	O
of	O
AD	O
is	O
very	O
limited	O
.	O

We	O
analyzed	O
all	O
yet	O
known	O
coding	O
human	O
genes	O
of	O
collagens	O
(	O
45	O
genes	O
)	O
,	O
MMPs	O
/	O
TIMPs	O
(	O
27	O
genes	O
)	O
in	O
702	O
sporadic	O
AD	O
patients	O
and	O
in	O
163	O
matched	O
healthy	O
controls	O
,	O
by	O
using	O
massively	O
targeted	O
next	O
-	O
generation	O
and	O
Sanger	O
sequencing	O
.	O

To	O
define	O
the	O
pathogenesis	O
of	O
potential	O
disease	O
-	O
causing	O
candidate	O
genes	O
,	O
we	O
performed	O
transcriptome	O
sequencing	O
and	O
pedigree	O
co	O
-	O
segregation	O
analysis	O
in	O
some	O
genes	O
and	O
generated	O
Col5a2	O
knockout	O
rats	O
.	O

We	O
identified	O
257	O
pathogenic	O
or	O
likely	O
pathogenic	O
variants	O
which	O
involved	O
88.89	O
%	O
(	O
64/72	O
)	O
genes	O
in	O
collagens	O
-	O
MMPs	O
/	O
TIMPs	O
system	O
and	O
accounted	O
for	O
31.05	O
%	O
(	O
218/702	O
)	O
sporadic	O
AD	O
patients	O
.	O

In	O
them	O
,	O
84.86	O
%	O
patients	O
(	O
185/218	O
)	O
carried	O
one	O
variant	O
,	O
12.84	O
%	O
two	O
variants	O
and	O
2.30	O
%	O
more	O
than	O
two	O
variants	O
.	O

Importantly	O
,	O
we	O
identified	O
52	O
novel	O
probably	O
pathogenic	O
loss	O
-	O
of	O
-	O
function	O
(	O
LOF	O
)	O
variants	O
(	O
20	O
nonsense	O
,	O
16	O
frameshift	O
,	O
14	O
splice	O
sites	O
,	O
one	O
stop	O
-	O
loss	O
,	O
one	O
initiation	O
codon	O
)	O
in	O
11.06	O
%	O
(	O
50/452	O
)	O
AD	O
patients	O
,	O
which	O
were	O
absent	O
in	O
163	O
controls	O
(	O
P=2.5×10(-5	O
)	O
)	O
.	O

Transcriptome	O
sequencing	O
revealed	O
that	O
identified	O
variants	B-Var
induced	O
dyshomeostasis	B-Reg
in	O
expression	B-CPA
of	I-CPA
collagens	I-CPA
-	I-CPA
TIMPs	I-CPA
/	I-CPA
MMPs	I-CPA
systems	I-CPA
.	O

The	O
Col5a2	B-Gene
(	O
-/-	O
)	O
rats	O
manifested	O
growth	B-CPA
retardation	I-CPA
and	O
aortic	B-CPA
dysplasia	I-CPA
.	O

Our	O
study	O
provides	O
a	O
first	O
comprehensive	O
map	O
of	O
genetic	O
alterations	O
in	O
collagens	O
-	O
MMPs	O
/	O
TIMPs	O
system	O
in	O
sporadic	O
AD	O
patients	O
and	O
suggests	O
that	O
variants	O
of	O
these	O
genes	O
contribute	O
largely	O
to	O
AD	O
pathogenesis	O
.	O

Alanine	O
-	O
scanning	O
mutagenesis	O
of	O
human	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
1	O
to	O
estimate	O
loss-	O
or	O
gain	O
-	O
of	O
-	O
function	O
variants	O
.	O

BACKGROUND	O
:	O
Germline	B-Var
heterozygous	I-Var
mutations	I-Var
in	O
human	O
signal	B-Gene
transducer	I-Gene
and	O
activator	B-Gene
of	I-Gene
transcription	I-Gene
1	I-Gene
(	O
STAT1	O
)	O
can	O
cause	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
(	O
LOF	O
)	O
,	O
as	O
in	O
patients	O
with	O
Mendelian	O
susceptibility	O
to	O
mycobacterial	B-Disease
diseases	I-Disease
,	O
or	O
gain	B-PosReg
of	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
,	O
as	O
in	O
patients	O
with	O
chronic	B-Disease
mucocutaneous	I-Disease
candidiasis	I-Disease
.	O

LOF	O
and	O
GOF	O
mutations	B-Var
are	O
equally	O
rare	O
and	O
can	O
affect	B-Reg
the	O
same	O
domains	B-MPA
of	O
STAT1	B-Gene
,	O
especially	O
the	O
coiled	B-MPA
-	I-MPA
coil	I-MPA
domain	I-MPA
(	O
CCD	O
)	O
and	O
DNA	B-MPA
-	I-MPA
binding	I-MPA
domain	I-MPA
(	O
DBD	O
)	O
.	O

Moreover	O
,	O
6	O
%	O
of	O
patients	O
with	O
chronic	O
mucocutaneous	O
candidiasis	O
with	O
a	O
GOF	O
STAT1	O
mutation	O
have	O
mycobacterial	O
disease	O
,	O
obscuring	O
the	O
functional	O
significance	O
of	O
the	O
identified	O
STAT1	O
mutations	O
.	O

Current	O
computational	O
approaches	O
,	O
such	O
as	O
combined	O
annotation	O
-	O
dependent	O
depletion	O
,	O
do	O
not	O
distinguish	O
LOF	O
and	O
GOF	O
variants	O
.	O

OBJECTIVE	O
:	O
We	O
estimated	O
variations	O
in	O
the	O
CCD	O
/	O
DBD	O
of	O
STAT1	O
.	O

METHODS	O
:	O
We	O
mutagenized	O
342	O
individual	O
wild	O
-	O
type	O
amino	O
acids	O
in	O
the	O
CCD	O
/	O
DBD	O
(	O
45.6	O
%	O
of	O
full	O
-	O
length	O
STAT1	O
)	O
to	O
alanine	O
and	O
tested	O
the	O
mutants	O
for	O
STAT1	O
transcriptional	O
activity	O
.	O

RESULTS	O
:	O
Of	O
these	O
342	O
mutants	O
,	O
201	O
were	O
neutral	O
,	O
30	O
were	O
LOF	O
,	O
and	O
111	O
were	O
GOF	O
mutations	O
in	O
a	O
luciferase	O
assay	O
.	O

This	O
assay	O
system	O
correctly	O
estimated	O
all	O
previously	O
reported	O
LOF	O
mutations	O
(	O
100	O
%	O
)	O
and	O
slightly	O
fewer	O
GOF	O
mutations	O
(	O
78.1	O
%	O
)	O
in	O
the	O
CCD	O
/	O
DBD	O
of	O
STAT1	O
.	O

We	O
found	O
that	O
GOF	O
alanine	O
mutants	O
occurred	O
at	O
the	O
interface	O
of	O
the	O
antiparallel	O
STAT1	O
dimer	O
,	O
suggesting	O
that	O
they	O
destabilize	O
this	O
dimer	O
.	O

This	O
assay	O
also	O
precisely	O
predicted	O
the	O
effect	O
of	O
2	O
hypomorphic	O
and	O
dominant	O
negative	O
mutations	O
,	O
E157	O
K	O
and	O
G250E	O
,	O
in	O
the	O
CCD	O
of	O
STAT1	O
that	O
we	O
found	O
in	O
2	O
unrelated	O
patients	O
with	O
Mendelian	O
susceptibility	O
to	O
mycobacterial	O
diseases	O
.	O

CONCLUSION	O
:	O
The	O
systematic	O
alanine	O
-	O
scanning	O
assay	O
is	O
a	O
useful	O
tool	O
to	O
estimate	O
the	O
GOF	O
or	O
LOF	O
status	O
and	O
the	O
effect	O
of	O
heterozygous	O
missense	O
mutations	O
in	O
STAT1	O
identified	O
in	O
patients	O
with	O
severe	O
infectious	O
diseases	O
,	O
including	O
mycobacterial	O
and	O
fungal	O
diseases	O
.	O

GBA2	B-Gene
Mutations	B-Var
Cause	B-Reg
a	O
Marinesco	B-Disease
-	I-Disease
Sjögren	I-Disease
-	I-Disease
Like	I-Disease
Syndrome	I-Disease
:	I-Disease
Genetic	O
and	O
Biochemical	O
Studies	O
.	O

BACKGROUND	O
:	O
With	O
the	O
advent	O
new	O
sequencing	O
technologies	O
,	O
we	O
now	O
have	O
the	O
tools	O
to	O
understand	O
the	O
phenotypic	O
diversity	O
and	O
the	O
common	O
occurrence	O
of	O
phenocopies	O
.	O

We	O
used	O
these	O
techniques	O
to	O
investigate	O
two	O
Norwegian	O
families	O
with	O
an	O
autosomal	O
recessive	O
cerebellar	O
ataxia	O
with	O
cataracts	O
and	O
mental	O
retardation	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
chip	O
analysis	O
followed	O
by	O
Exome	O
sequencing	O
identified	O
a	O
2	O
bp	O
homozygous	O
deletion	O
in	O
GBA2	O
in	O
both	O
families	O
,	O
c.1528_1529del	B-Var
[	O
p	O
.	O
Met510Valfs*17	O
]	O
.	O

Furthermore	O
,	O
we	O
report	O
the	O
biochemical	O
characterization	O
of	O
GBA2	O
in	O
these	O
patients	O
.	O

Our	O
studies	O
show	O
that	O
a	O
reduced	B-NegReg
activity	B-MPA
of	O
GBA2	B-Gene
is	O
sufficient	O
to	O
elevate	B-PosReg
the	O
levels	B-MPA
of	O
glucosylceramide	B-MPA
to	O
similar	O
levels	O
as	O
seen	O
in	O
Gaucher	O
disease	O
.	O

Furthermore	O
,	O
leucocytes	O
seem	O
to	O
be	O
the	O
proper	O
enzyme	O
source	O
for	O
in	O
vitro	O
analysis	O
of	O
GBA2	O
activity	O
.	O

CONCLUSIONS	O
:	O
We	O
report	O
GBA2	B-Gene
mutations	B-Var
causing	B-Reg
a	O
Marinesco	B-Disease
-	I-Disease
Sjögren	I-Disease
-	I-Disease
like	I-Disease
syndrome	I-Disease
in	O
two	O
Norwegian	O
families	O
.	O

One	O
of	O
the	O
families	O
was	O
originally	O
diagnosed	O
with	O
Marinesco	O
-	O
Sjögren	O
syndrome	O
based	O
on	O
an	O
autosomal	O
recessive	O
cerebellar	O
ataxia	O
with	O
cataracts	O
and	O
mental	O
retardation	O
.	O

Our	O
findings	O
highlight	O
the	O
phenotypic	O
variability	O
associated	O
with	O
GBA2	O
mutations	O
,	O
and	O
suggest	O
that	O
patients	O
with	O
Marinesco	O
-	O
Sjögren	O
-	O
like	O
syndromes	O
should	O
be	O
tested	O
for	O
mutations	O
in	O
this	O
gene	O
.	O

Compound	O
Heterozygosity	O
for	O
Null	B-Var
Mutations	I-Var
and	O
a	O
Common	O
Hypomorphic	O
Risk	O
Haplotype	O
in	O
TBX6	B-Gene
Causes	B-Reg
Congenital	B-Disease
Scoliosis	I-Disease
.	O

Congenital	O
scoliosis	O
(	O
CS	O
)	O
occurs	O
as	O
a	O
result	O
of	O
vertebral	O
malformations	O
and	O
has	O
an	O
incidence	O
of	O
0.5	O
-	O
1/1,000	O
births	O
.	O

Recently	O
,	O
TBX6	O
on	O
chromosome	O
16p11.2	O
was	O
reported	O
as	O
a	O
disease	O
gene	O
for	O
CS	O
;	O
about	O
10	O
%	O
of	O
Chinese	O
CS	O
patients	O
were	O
compound	O
heterozygotes	O
for	O
rare	O
null	O
mutations	O
and	O
a	O
common	O
haplotype	O
defined	O
by	O
three	O
SNPs	O
in	O
TBX6	O
.	O

All	O
patients	O
had	O
hemivertebrae	O
.	O

We	O
recruited	O
94	O
Japanese	O
CS	O
patients	O
,	O
investigated	O
the	O
TBX6	O
locus	O
for	O
both	O
mutations	O
and	O
the	O
risk	O
haplotype	O
,	O
examined	O
transcriptional	O
activities	O
of	O
mutant	O
TBX6	O
in	O
vitro	O
,	O
and	O
evaluated	O
clinical	O
and	O
radiographic	O
features	O
.	O

We	O
identified	O
TBX6	O
null	O
mutations	O
in	O
nine	O
patients	O
,	O
including	O
a	O
missense	O
mutation	O
that	O
had	O
a	O
loss	O
of	O
function	O
in	O
vitro	O
.	O

All	O
had	O
the	O
risk	O
haplotype	O
in	O
the	O
opposite	O
allele	O
.	O

One	O
of	O
the	O
mutations	O
showed	O
dominant	O
negative	O
effect	O
.	O

Although	O
all	O
Chinese	O
patients	O
had	O
one	O
or	O
more	O
hemivertebrae	O
,	O
two	O
Japanese	O
patients	O
did	O
not	O
have	O
hemivertebra	O
.	O

The	O
compound	O
heterozygosity	O
of	O
null	O
mutations	O
and	O
the	O
common	O
risk	O
haplotype	O
in	O
TBX6	O
also	O
causes	O
CS	O
in	O
Japanese	O
patients	O
with	O
similar	O
incidence	O
.	O

Hemivertebra	O
was	O
not	O
a	O
specific	O
type	O
of	O
spinal	O
malformation	O
in	O
TBX6-associated	O
CS	O
(	O
TACS	O
)	O
.	O

A	O
heterozygous	O
TBX6	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	B-Var
has	O
been	O
reported	O
in	O
a	O
family	O
with	O
autosomal	B-Disease
-	I-Disease
dominant	I-Disease
spondylocostal	I-Disease
dysostosis	I-Disease
,	O
but	O
it	O
may	O
represent	O
a	O
spectrum	O
of	O
the	O
same	O
disease	O
with	O
TACS	O
.	O

Aspartylglucosaminuria	B-Disease
caused	B-Reg
by	I-Reg
a	O
novel	O
homozygous	O
mutation	B-Var
in	O
the	O
AGA	B-Gene
gene	O
was	O
identified	O
by	O
an	O
exome	O
-	O
first	O
approach	O
in	O
a	O
patient	O
from	O
Japan	O
.	O

BACKGROUND	O
:	O
Aspartylglucosaminuria	O
(	O
AGU	O
)	O
is	O
an	O
autosomal	O
recessive	O
lysosomal	O
storage	O
disorder	O
caused	O
by	O
a	O
deficiency	O
of	O
the	O
lysosomal	O
enzyme	O
,	O
aspartylglucosaminidase	O
(	O
AGA	O
)	O
.	O

This	O
disorder	O
is	O
rare	O
in	O
the	O
general	O
population	O
except	O
in	O
Finland	O
.	O

Since	O
the	O
most	O
characteristic	O
feature	O
of	O
this	O
disorder	O
is	O
a	O
progressive	O
developmental	O
regression	O
,	O
patients	O
often	O
show	O
no	O
specific	O
symptoms	O
in	O
the	O
initial	O
stages	O
,	O
and	O
thus	O
early	O
diagnosis	O
is	O
often	O
challenging	O
.	O

CASE	O
REPORT	O
:	O
We	O
encountered	O
a	O
16-year	O
-	O
old	O
boy	O
who	O
began	O
to	O
show	O
difficulties	O
in	O
his	O
speech	O
at	O
the	O
age	O
of	O
6years	O
.	O

Due	O
to	O
a	O
mild	O
regression	O
in	O
his	O
development	O
,	O
he	O
gradually	O
lost	O
common	O
daily	O
abilities	O
.	O

His	O
diagnosis	O
was	O
first	O
obtained	O
through	O
exome	O
sequencing	O
that	O
identified	O
a	O
novel	O
homozygous	O
mutation	O
in	O
the	O
AGA	O
gene	O
.	O

This	O
result	O
was	O
reasonable	O
because	O
of	O
parental	O
consanguinity	O
.	O

Reduced	O
enzymatic	O
activity	O
of	O
AGA	O
was	O
then	O
confirmed	O
.	O

His	O
urine	O
was	O
retrospectively	O
screened	O
by	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
(	O
MALDI	O
-	O
TOF	O
-	O
MS	O
)	O
and	O
a	O
specific	O
pattern	O
of	O
abnormal	O
metabolites	O
was	O
identified	O
.	O

CONCLUSIONS	O
:	O
Because	O
both	O
exome	O
sequencing	O
and	O
MALDI	O
-	O
TOF	O
-	O
MS	O
screening	O
are	O
adaptable	O
and	O
comprehensive	O
,	O
future	O
combinatory	O
use	O
of	O
these	O
methods	O
would	O
be	O
useful	O
for	O
diagnosis	O
of	O
rare	O
inborn	O
errors	O
of	O
metabolism	O
such	O
as	O
AGU	O
.	O

WT1	O
Haploinsufficiency	O
Supports	O
Milder	O
Renal	O
Manifestation	O
in	O
Two	O
Patients	O
with	O
Denys	O
-	O
Drash	O
Syndrome	O
.	O

Denys	B-Disease
-	I-Disease
Drash	I-Disease
syndrome	I-Disease
(	O
DDS	O
)	O
is	O
characterized	O
by	O
nephropathy	O
,	O
genital	O
abnormalities	O
,	O
and	O
predisposition	O
to	O
Wilms	O
'	O
tumor	O
.	O

DDS	O
patients	O
usually	O
present	B-Reg
heterozygous	O
de	O
novo	O
germline	O
WT1	B-Gene
mutations	B-Var
.	O

The	O
WT1	O
gene	O
comprises	O
10	O
exons	O
encoding	O
the	O
N	O
-	O
terminal	O
transactivation	O
and	O
the	O
C	O
-	O
terminal	O
DNA	O
-	O
binding	O
regions	O
.	O

Two	O
unrelated	O
patients	O
with	O
genital	O
ambiguity	O
and	O
Wilms	O
'	O
tumor	O
were	O
analyzed	O
by	O
sequencing	O
of	O
the	O
WT1	O
gene	O
,	O
and	O
3	O
mutations	O
in	O
exon	O
1	O
were	O
identified	O
of	O
which	O
2	O
are	O
novel	O
.	O

Patient	O
1	O
carried	O
a	O
c.555delC	B-Var
mutation	O
that	O
causes	B-Reg
a	O
frameshift	B-Var
and	O
a	O
premature	B-MPA
stop	I-MPA
codon	O
.	O

Patient	O
2	O
carried	O
both	O
c.421A	B-Var
>	I-Var
C	I-Var
and	O
c.424C	B-Var
>	I-Var
T	I-Var
aberrations	O
that	O
lead	B-Reg
to	I-Reg
the	O
missense	O
p	B-Var
.	I-Var
Lys141Gln	I-Var
and	O
the	O
nonsense	O
p	B-Var
.	I-Var
Lys142	I-Var
*	I-Var
mutation	O
,	O
respectively	O
.	O

As	O
both	O
patients	O
were	O
heterozygous	O
for	O
the	O
mutations	O
,	O
we	O
tested	O
their	O
parents	O
who	O
did	O
not	O
carry	O
any	O
mutation	O
.	O

Therefore	O
,	O
the	O
3	O
WT1	O
mutations	O
occurred	O
de	O
novo	O
in	O
both	O
patients	O
.	O

Heterozygous	O
mutations	B-Var
result	O
in	O
WT1	B-Gene
haploinsufficiency	O
as	O
they	O
impair	B-NegReg
protein	B-Protein
production	B-MPA
.	O

They	O
are	O
associated	O
with	O
a	O
milder	O
DDS	O
phenotype	O
as	O
observed	O
in	O
the	O
patients	O
studied	O
here	O
.	O

Delineating	O
the	O
phenotypic	O
spectrum	O
of	O
Bainbridge	B-Disease
-	I-Disease
Ropers	I-Disease
syndrome	I-Disease
:	I-Disease
12	O
new	O
patients	O
with	O
de	O
novo	O
,	O
heterozygous	O
,	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
ASXL3	B-Gene
and	O
review	O
of	O
published	O
literature	O
.	O

BACKGROUND	O
:	O
Bainbridge	B-Disease
-	I-Disease
Ropers	I-Disease
syndrome	I-Disease
(	O
BRPS	O
)	O
is	O
a	O
recently	O
described	O
developmental	O
disorder	O
caused	B-Reg
by	I-Reg
de	O
novo	O
truncating	B-Var
mutations	I-Var
in	O
the	O
additional	O
sex	O
combs	O
like	O
3	O
(	B-Gene
ASXL3	I-Gene
)	I-Gene
gene	O
.	O

To	O
date	O
,	O
there	O
have	O
been	O
fewer	O
than	O
10	O
reported	O
patients	O
.	O

OBJECTIVES	O
:	O
Here	O
,	O
we	O
delineate	O
the	O
BRPS	O
phenotype	O
further	O
by	O
describing	O
a	O
series	O
of	O
12	O
previously	O
unreported	O
patients	O
identified	O
by	O
the	O
Deciphering	O
Developmental	O
Disorders	O
study	O
.	O

METHODS	O
:	O
Trio	O
-	O
based	O
exome	O
sequencing	O
was	O
performed	O
on	O
all	O
12	O
patients	O
included	O
in	O
this	O
study	O
,	O
which	O
found	O
a	O
de	O
novo	O
truncating	O
mutation	O
in	O
ASXL3	O
.	O

Detailed	O
phenotypic	O
information	O
and	O
patient	O
images	O
were	O
collected	O
and	O
summarised	O
as	O
part	O
of	O
this	O
study	O
.	O

RESULTS	O
:	O
By	O
obtaining	O
genotype	O
:	O
phenotype	O
data	O
,	O
we	O
have	O
been	O
able	O
to	O
demonstrate	O
a	O
second	O
mutation	O
cluster	O
region	O
within	O
ASXL3	O
.	O

This	O
report	O
expands	O
the	O
phenotype	O
of	O
older	O
patients	O
with	O
BRPS	O
;	O
common	O
emerging	O
features	O
include	O
severe	O
intellectual	O
disability	O
(	O
11/12	O
)	O
,	O
poor/	O
absent	O
speech	O
(	O
12/12	O
)	O
,	O
autistic	O
traits	O
(	O
9/12	O
)	O
,	O
distinct	O
face	O
(	O
arched	O
eyebrows	O
,	O
prominent	O
forehead	O
,	O
high	O
-	O
arched	O
palate	O
,	O
hypertelorism	O
and	O
downslanting	O
palpebral	O
fissures	O
)	O
,	O
(	O
9/12	O
)	O
,	O
hypotonia	O
(	O
11/12	O
)	O
and	O
significant	O
feeding	O
difficulties	O
(	O
9/12	O
)	O
when	O
young	O
.	O

DISCUSSION	O
:	O
Similarities	O
in	O
the	O
patients	O
reported	O
previously	O
in	O
comparison	O
with	O
this	O
cohort	O
included	O
their	O
distinctive	O
craniofacial	O
features	O
,	O
feeding	O
problems	O
,	O
absent	O
/	O
limited	O
speech	O
and	O
intellectual	O
disability	O
.	O

Shared	O
behavioural	O
phenotypes	O
include	O
autistic	O
traits	O
,	O
hand	O
-	O
flapping	O
,	O
rocking	O
,	O
aggressive	O
behaviour	O
and	O
sleep	O
disturbance	O
.	O

CONCLUSIONS	O
:	O
This	O
series	O
expands	O
the	O
phenotypic	O
spectrum	O
of	O
this	O
severe	O
disorder	O
and	O
highlights	O
its	O
surprisingly	O
high	O
frequency	O
.	O

With	O
the	O
advent	O
of	O
advanced	O
genomic	O
screening	O
,	O
we	O
are	O
likely	O
to	O
identify	O
more	O
variants	O
in	O
this	O
gene	O
presenting	O
with	O
a	O
variable	O
phenotype	O
,	O
which	O
this	O
study	O
will	O
explore	O
.	O

Rhomboid	O
family	O
member	O
2	O
regulates	O
cytoskeletal	O
stress	O
-	O
associated	O
Keratin	O
16	O
.	O

Keratin	O
16	O
(	O
K16	O
)	O
is	O
a	O
cytoskeletal	O
scaffolding	O
protein	O
highly	O
expressed	O
at	O
pressure	O
-	O
bearing	O
sites	O
of	O
the	O
mammalian	O
footpad	O
.	O

It	O
can	O
be	O
induced	O
in	O
hyperproliferative	O
states	O
such	O
as	O
wound	O
healing	O
,	O
inflammation	O
and	O
cancer	O
.	O

Here	O
we	O
show	O
that	O
the	O
inactive	O
rhomboid	O
protease	O
RHBDF2	O
(	O
iRHOM2	O
)	O
regulates	O
thickening	O
of	O
the	O
footpad	O
epidermis	O
through	O
its	O
interaction	O
with	O
K16	O
.	O

K16	O
expression	O
is	O
absent	O
in	O
the	O
thinned	O
footpads	O
of	O
irhom2(-/-	O
)	O
mice	O
compared	O
with	O
irhom2(+/+)mice	O
,	O
due	O
to	O
reduced	O
keratinocyte	O
proliferation	O
.	O

Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutations	B-Var
in	O
iRHOM2	B-Gene
underlie	O
Tylosis	B-Disease
with	I-Disease
oesophageal	I-Disease
cancer	I-Disease
(	O
TOC	O
)	O
,	O
characterized	O
by	O
palmoplantar	O
thickening	O
,	O
upregulate	B-PosReg
K16	B-MPA
with	O
robust	O
downregulation	B-NegReg
of	O
its	O
type	B-MPA
II	I-MPA
keratin	I-MPA
binding	I-MPA
partner	I-MPA
,	O
K6	I-MPA
.	O

By	O
orchestrating	O
the	O
remodelling	O
and	O
turnover	O
of	O
K16	O
,	O
and	O
uncoupling	O
it	O
from	O
K6	O
,	O
iRHOM2	O
regulates	O
the	O
epithelial	O
response	O
to	O
physical	O
stress	O
.	O

These	O
findings	O
contribute	O
to	O
our	O
understanding	O
of	O
the	O
molecular	O
mechanisms	O
underlying	O
hyperproliferation	O
of	O
the	O
palmoplantar	O
epidermis	O
in	O
both	O
physiological	O
and	O
disease	O
states	O
,	O
and	O
how	O
this	O
'	O
stress	O
'	O
keratin	O
is	O
regulated	O
.	O

Ruxolitinib	O
reverses	O
dysregulated	O
T	O
helper	O
cell	O
responses	O
and	O
controls	O
autoimmunity	O
caused	O
by	O
a	O
novel	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
1	O
(	O
STAT1	O
)	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
.	O

BACKGROUND	O
:	O
Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
mutations	B-Var
in	O
the	O
human	B-Gene
signal	I-Gene
transducer	I-Gene
and	I-Gene
activator	I-Gene
of	I-Gene
transcription	I-Gene
1	I-Gene
(	O
STAT1	O
)	O
manifest	O
in	O
immunodeficiency	O
and	O
autoimmunity	O
with	O
impaired	B-NegReg
TH17	B-CPA
cell	I-CPA
differentiation	I-CPA
and	O
exaggerated	B-PosReg
responsiveness	B-Interaction
to	I-Interaction
type	I-Interaction
I	I-Interaction
and	I-Interaction
II	I-Interaction
interferons	I-Interaction
.	O

Allogeneic	O
bone	O
marrow	O
transplantation	O
has	O
been	O
attempted	O
in	O
severely	O
affected	O
patients	O
,	O
but	O
outcomes	O
have	O
been	O
poor	O
.	O

OBJECTIVE	O
:	O
We	O
sought	O
to	O
define	O
the	O
effect	O
of	O
increased	O
STAT1	O
activity	O
on	O
T	O
helper	O
cell	O
polarization	O
and	O
to	O
investigate	O
the	O
therapeutic	O
potential	O
of	O
ruxolitinib	O
in	O
treating	O
autoimmunity	O
secondary	O
to	O
STAT1	O
GOF	O
mutations	O
.	O

METHODS	O
:	O
We	O
used	O
in	O
vitro	O
polarization	O
assays	O
,	O
as	O
well	O
as	O
phenotypic	O
and	O
functional	O
analysis	O
of	O
STAT1-mutated	O
patient	O
cells	O
.	O

RESULTS	O
:	O
We	O
report	O
a	O
child	O
with	O
a	O
novel	O
mutation	B-Var
in	I-Var
the	I-Var
linker	I-Var
domain	I-Var
of	O
STAT1	B-Gene
who	O
had	O
life	O
-	O
threatening	O
autoimmune	O
cytopenias	O
and	O
chronic	O
mucocutaneous	O
candidiasis	O
.	O

Naive	O
lymphocytes	O
from	O
the	O
affected	O
patient	O
displayed	O
increased	B-PosReg
TH1	B-CPA
and	I-CPA
follicular	I-CPA
T	I-CPA
helper	I-CPA
cell	I-CPA
and	O
suppressed	B-NegReg
TH17	B-CPA
cell	I-CPA
responses	I-CPA
.	O

The	O
mutation	B-Var
augmented	B-PosReg
cytokine	B-MPA
-	I-MPA
induced	I-MPA
STAT1	I-MPA
phosphorylation	I-MPA
without	O
affecting	O
dephosphorylation	O
kinetics	O
.	O

Treatment	O
with	O
the	O
Janus	O
kinase	O
1/2	O
inhibitor	O
ruxolitinib	O
reduced	O
hyperresponsiveness	O
to	O
type	O
I	O
and	O
II	O
interferons	O
,	O
normalized	O
TH1	O
and	O
follicular	O
T	O
helper	O
cell	O
responses	O
,	O
improved	O
TH17	O
differentiation	O
,	O
cured	O
mucocutaneous	O
candidiasis	O
,	O
and	O
maintained	O
remission	O
of	O
immune	O
-	O
mediated	O
cytopenias	O
.	O

CONCLUSIONS	O
:	O
Autoimmunity	O
and	O
infection	O
caused	O
by	O
STAT1	B-Gene
GOF	B-PosReg
mutations	B-Var
are	O
the	O
result	O
of	O
dysregulated	O
T	B-CPA
helper	I-CPA
cell	I-CPA
responses	I-CPA
.	O

Janus	O
kinase	O
inhibitor	O
therapy	O
could	O
represent	O
an	O
effective	O
targeted	O
treatment	O
for	O
long	O
-	O
term	O
disease	O
control	O
in	O
severely	O
affected	O
patients	O
for	O
whom	O
hematopoietic	O
stem	O
cell	O
transplantation	O
is	O
not	O
available	O
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	B-Var
of	O
the	O
calcium	B-Protein
sensor	I-Protein
CBL1	I-Protein
increases	B-PosReg
aluminum	B-MPA
sensitivity	I-MPA
in	O
Arabidopsis	O
.	O

Despite	O
the	O
physiological	O
importance	O
of	O
aluminum	O
(	O
Al	O
)	O
phytotoxicity	O
for	O
plants	O
,	O
it	O
remained	O
unknown	O
if	O
,	O
and	O
how	O
,	O
calcineurin	O
B	O
-	O
like	O
calcium	O
sensors	O
(	O
CBLs	O
)	O
and	O
CBL	O
-	O
interacting	O
protein	O
kinases	O
(	O
CIPKs	O
)	O
are	O
involved	O
in	O
Al	O
resistance	O
.	O

We	O
performed	O
a	O
comparative	O
physiological	O
and	O
whole	O
transcriptome	O
investigation	O
of	O
an	O
Arabidopsis	O
CBL1	B-Gene
mutant	B-Var
(	O
cbl1	O
)	O
and	O
the	O
wild	O
-	O
type	O
(	O
WT	O
)	O
.	O

cbl1	O
plants	O
exudated	O
less	B-NegReg
Al	B-MPA
-	I-MPA
chelating	I-MPA
malate	I-MPA
,	O
accumulated	O
more	B-PosReg
Al	B-MPA
,	O
and	O
displayed	O
a	O
severe	B-CPA
root	I-CPA
growth	I-CPA
reduction	B-NegReg
in	O
response	O
to	O
Al	O
.	O

Genes	O
involved	O
in	O
metabolism	O
,	O
transport	O
,	O
cell	O
wall	O
modification	O
,	O
transcription	O
and	O
oxidative	O
stress	O
were	O
differentially	O
regulated	O
between	O
the	O
two	O
lines	O
,	O
under	O
both	O
control	O
and	O
Al	O
stress	O
treatments	O
.	O

Exposure	O
to	O
Al	O
resulted	O
in	O
up	O
-	O
regulation	O
of	O
a	O
large	O
set	O
of	O
genes	O
only	O
in	O
WT	O
and	O
not	O
cbl1	O
shoots	O
,	O
while	O
a	O
different	O
set	O
of	O
genes	O
were	O
down	O
-	O
regulated	O
in	O
cbl1	O
but	O
not	O
in	O
WT	O
roots	O
.	O

These	O
differences	O
allowed	O
us	O
,	O
for	O
the	O
first	O
time	O
,	O
to	O
define	O
a	O
calcium	O
-	O
regulated	O
/	O
dependent	O
transcriptomic	O
network	O
for	O
Al	O
stress	O
responses	O
.	O

Our	O
analyses	O
reveal	O
not	O
only	O
the	O
fundamental	O
role	O
of	O
CBL1	O
in	O
the	O
adjustment	O
of	O
central	O
transcriptomic	O
networks	O
involved	O
in	O
maintaining	O
adequate	O
physiological	O
homeostasis	O
processes	O
,	O
but	O
also	O
that	O
a	O
high	O
shoot	O
-	O
root	O
dynamics	O
is	O
required	O
for	O
the	O
proper	O
deployment	O
of	O
Al	O
resistance	O
responses	O
in	O
the	O
root	O
.	O

Clinical	O
and	O
molecular	O
consequences	O
of	O
disease	O
-	O
associated	O
de	O
novo	O
mutations	O
in	O
SATB2	O
.	O

PURPOSE	O
:	O
To	O
characterize	O
features	O
associated	O
with	O
de	O
novo	O
mutations	O
affecting	O
SATB2	O
function	O
in	O
individuals	O
ascertained	O
on	O
the	O
basis	O
of	O
intellectual	O
disability	O
.	O

METHODS	O
:	O
Twenty	O
previously	O
unreported	O
individuals	O
with	O
19	O
different	O
SATB2	O
mutations	O
(	O
11	O
loss	O
-	O
of	O
-	O
function	O
and	O
8	O
missense	O
variants	O
)	O
were	O
studied	O
.	O

Fibroblasts	O
were	O
used	O
to	O
measure	O
mutant	O
protein	O
production	O
.	O

Subcellular	O
localization	O
and	O
mobility	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
SATB2	O
were	O
assessed	O
using	O
fluorescently	O
tagged	O
protein	O
.	O

RESULTS	O
:	O
Recurrent	O
clinical	O
features	O
included	O
neurodevelopmental	O
impairment	O
(	O
19/19	O
)	O
,	O
absent	O
/	O
near	O
absent	O
speech	O
(	O
16/19	O
)	O
,	O
normal	O
somatic	O
growth	O
(	O
17/19	O
)	O
,	O
cleft	O
palate	O
(	O
9/19	O
)	O
,	O
drooling	O
(	O
12/19	O
)	O
,	O
and	O
dental	O
anomalies	O
(	O
8/19	O
)	O
.	O

Six	O
of	O
eight	O
missense	O
variants	O
clustered	O
in	O
the	O
first	O
CUT	O
domain	O
.	O

Sibling	O
recurrence	O
due	O
to	O
gonadal	O
mosaicism	O
was	O
seen	O
in	O
one	O
family	O
.	O

A	O
nonsense	B-Var
mutation	I-Var
in	I-Var
the	I-Var
last	I-Var
exon	I-Var
resulted	B-Reg
in	I-Reg
production	O
of	O
a	O
truncated	B-MPA
protein	B-Protein
retaining	O
all	O
three	O
DNA	O
-	O
binding	O
domains	O
.	O

SATB2	B-Gene
nuclear	O
mobility	O
was	O
mutation	O
-	O
dependent	O
;	O
p	B-Var
.	I-Var
Arg389Cys	I-Var
in	I-Var
CUT1	I-Var
increased	B-PosReg
mobility	B-MPA
and	O
both	O
p	B-Var
.	I-Var
Gly515Ser	I-Var
in	I-Var
CUT2	I-Var
and	O
p	B-Var
.	I-Var
Gln566Lys	I-Var
between	I-Var
CUT2	I-Var
and	I-Var
HOX	I-Var
reduced	B-NegReg
mobility	B-MPA
.	O

The	O
clinical	O
features	O
in	O
individuals	O
with	O
missense	O
variants	O
were	O
indistinguishable	O
from	O
those	O
with	O
loss	O
of	O
function	O
.	O

CONCLUSION	O
:	O
SATB2	B-Gene
haploinsufficiency	B-Var
is	O
a	O
common	O
cause	B-Reg
of	O
syndromic	B-Disease
intellectual	I-Disease
disability	I-Disease
.	O

When	O
mutant	B-Var
SATB2	B-Gene
protein	O
is	O
produced	O
,	O
the	O
protein	B-Protein
appears	O
functionally	B-MPA
inactive	B-NegReg
with	O
a	O
disrupted	O
pattern	O
of	O
chromatin	O
or	O
matrix	O
association	O
.	O

Genet	O
Med	O
advance	O
online	O
publication	O
02	O
February	O
2017	O
.	O

Complexity	O
of	O
mechanisms	O
among	O
human	O
proprotein	O
convertase	O
subtilisin	O
-	O
kexin	O
type	O
9	O
variants	O
.	O

PURPOSE	O
OF	O
REVIEW	O
:	O
There	O
are	O
many	O
reports	O
of	O
human	O
variants	B-Var
in	O
proprotein	O
convertase	O
subtilisin	O
-	O
kexin	O
type	O
9	O
(	B-Gene
PCSK9	I-Gene
)	I-Gene
that	O
are	O
either	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
or	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LOF	O
)	O
,	O
with	O
downstream	O
effects	B-Reg
on	O
LDL	B-Disease
cholesterol	I-Disease
and	O
cardiovascular	B-Disease
disease	I-Disease
(	O
CVD	O
)	O
risk	O
.	O

However	O
,	O
data	O
on	O
particular	O
mechanisms	O
have	O
only	O
been	O
minimally	O
curated	O
.	O

RECENT	O
FINDINGS	O
:	O
GOF	B-PosReg
variants	B-Var
are	O
individually	O
ultrarare	O
,	O
affect	B-Reg
all	O
domains	B-Protein
of	I-Protein
the	I-Protein
protein	I-Protein
,	O
act	O
to	O
reduce	B-NegReg
LDL	B-Protein
receptor	I-Protein
expression	B-MPA
through	O
several	O
mechanisms	O
,	O
are	O
a	O
minor	O
cause	B-Reg
of	O
familial	B-Disease
hypercholesterolemia	I-Disease
,	O
have	O
been	O
reported	O
mainly	O
within	O
families	O
,	O
have	O
variable	O
LDL	O
cholesterol	O
-	O
raising	O
effects	O
,	O
and	O
are	O
associated	O
with	O
increased	O
CVD	O
risk	O
mainly	O
through	O
observational	O
studies	O
in	O
families	O
and	O
small	O
cohorts	O
.	O

In	O
contrast	O
,	O
LOF	B-NegReg
variants	B-Var
can	O
be	O
either	O
ultrarare	O
mutations	O
or	O
relatively	O
more	O
common	O
polymorphisms	O
seen	O
in	O
populations	O
,	O
affect	B-Reg
all	O
domains	B-Protein
of	I-Protein
the	I-Protein
protein	I-Protein
,	O
act	O
to	O
increase	B-PosReg
LDL	B-Protein
receptor	I-Protein
expression	B-MPA
through	O
several	O
mechanisms	O
,	O
have	O
variable	O
LDL	B-MPA
cholesterol	I-MPA
-	I-MPA
lowering	I-MPA
effects	O
,	O
and	O
have	O
been	O
associated	O
with	O
decreased	B-NegReg
CVD	B-Disease
risk	O
mainly	O
through	O
Mendelian	O
randomization	O
studies	O
in	O
epidemiologic	O
populations	O
.	O

SUMMARY	O
:	O
There	O
is	O
considerable	O
complexity	O
underlying	O
the	O
clinical	O
concept	O
of	O
both	O
LOF	O
and	O
GOF	O
variants	O
of	O
PCSK9	O
.	O

But	O
despite	O
the	O
underlying	O
mechanistic	O
heterogeneity	O
,	O
altered	O
PCSK9	O
secretion	O
or	O
function	O
is	O
ultimately	O
correlated	O
with	O
plasma	O
LDL	O
cholesterol	O
level	O
,	O
which	O
is	O
also	O
the	O
driver	O
of	O
CVD	O
outcomes	O
.	O

Loss	B-Var
of	O
Ssq1	B-Gene
leads	B-Reg
to	O
mitochondrial	B-CPA
dysfunction	I-CPA
,	O
activation	B-CPA
of	I-CPA
autophagy	I-CPA
and	O
cell	B-CPA
cycle	I-CPA
arrest	I-CPA
due	O
to	O
iron	B-MPA
overload	B-PosReg
triggered	O
by	O
mitochondrial	B-MPA
iron	I-MPA
-	I-MPA
sulfur	I-MPA
cluster	I-MPA
assembly	I-MPA
defects	B-NegReg
in	O
Candida	O
albicans	O
.	O

Iron	O
-	O
sulfur	O
clusters	O
perform	O
essential	O
functions	O
in	O
enzymatic	O
catalysis	O
and	O
homeostatic	O
regulation	O
.	O

Here	O
we	O
for	O
the	O
first	O
time	O
identified	O
Ssq1	O
as	O
an	O
essential	O
component	O
for	O
iron	O
-	O
sulfur	O
cluster	O
assembly	O
in	O
Candida	O
albicans	O
.	O

Ssq1	O
played	O
an	O
important	O
role	O
in	O
cell	O
growth	O
.	O

Shutting	O
off	O
SSQ1	O
led	O
to	O
accumulation	O
of	O
intracellular	O
iron	O
,	O
especially	O
in	O
mitochondria	O
,	O
and	O
disorder	O
of	O
intracellular	O
iron	O
regulation	O
.	O

In	O
tetO	O
-	O
SSQ1	O
,	O
iron	O
overloading	O
triggered	O
the	O
oxidative	O
damage	O
of	O
mitochondrial	O
function	O
.	O

Surprisingly	O
,	O
disruption	O
of	O
SSQ1	O
activated	O
autophagic	O
pathway	O
.	O

The	O
mitochondrial	B-CPA
dysfunction	I-CPA
was	O
further	O
aggravated	B-NegReg
when	O
CCZ1	B-Gene
(	O
which	O
is	O
essential	O
for	O
autophagy	O
)	O
and	O
SSQ1	B-Gene
was	O
simultaneously	O
deleted	B-Var
,	O
suggesting	O
that	O
autophagy	O
played	O
a	O
critical	O
role	O
in	O
maintenance	O
of	O
mitochondrial	O
function	O
in	O
tetO	O
-	O
SSQ1	O
.	O

In	O
addition	O
,	O
double	O
deletion	B-Var
of	O
SSQ1	B-Gene
and	O
CCZ1	B-Gene
further	O
elevated	B-PosReg
cellular	B-MPA
iron	I-MPA
levels	I-MPA
in	O
comparison	O
with	O
tetO	O
-	O
SSQ1	O
,	O
indicating	O
that	O
autophagy	O
participated	O
in	O
maintenance	O
of	O
iron	O
homeostasis	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
loss	B-Var
of	O
SSQ1	B-Gene
led	O
to	O
increasing	B-PosReg
protein	B-Protein
expression	B-MPA
of	O
Rnr1	B-Gene
and	O
redistribution	B-MPA
of	O
Rnr2	B-Gene
from	O
the	O
nucleus	O
to	O
cytoplasm	O
,	O
and	O
further	O
resulted	B-Reg
in	O
cell	B-CPA
cycle	I-CPA
arrest	I-CPA
.	O

The	O
results	O
implied	O
that	O
cell	O
cycle	O
arrest	O
was	O
caused	O
by	O
activating	O
the	O
checkpoint	O
pathway	O
because	O
of	O
impairing	O
the	O
iron	O
-	O
sulfur	O
cluster	O
assembly	O
in	O
tetO	O
-	O
SSQ1	O
.	O

Shutting	O
off	O
SSQ1	O
led	O
to	O
a	O
significant	O
defect	O
in	O
filamentous	O
development	O
.	O

Interestingly	O
,	O
the	O
tetO	O
-	O
SSQ1ccz1Δ	O
/	O
Δ	O
growth	O
was	O
inhibited	O
on	O
hyphae	O
-	O
inducing	O
solid	O
media	O
.	O

Both	O
tetO	O
-	O
SSQ1	O
and	O
tetO	O
-	O
SSQ1ccz1Δ	O
/	O
Δ	O
exhibited	O
extremely	O
attenuated	O
virulence	O
,	O
indicating	O
that	O
Ssq1	O
might	O
provide	O
a	O
promising	O
target	O
for	O
antifungal	O
drugs	O
development	O
.	O

In	O
summary	O
,	O
our	O
findings	O
provide	O
new	O
insights	O
into	O
the	O
understanding	O
of	O
iron	O
-	O
sulfur	O
cluster	O
assembly	O
-	O
related	O
gene	O
in	O
C.	O
albicans	O
.	O

Towards	O
trans	O
-	O
diagnostic	O
mechanisms	O
in	O
psychiatry	O
:	O
neurobehavioral	O
profile	O
of	O
rats	O
with	O
a	O
loss	O
-	O
of	O
-	O
function	O
point	O
mutation	O
in	O
the	O
dopamine	O
transporter	O
gene	O
.	O

The	O
research	O
domain	O
criteria	O
(	O
RDoC	O
)	O
matrix	O
has	O
been	O
developed	O
to	O
reorient	O
psychiatric	O
research	O
towards	O
measurable	O
behavioral	O
dimensions	O
and	O
underlying	O
mechanisms	O
.	O

Here	O
,	O
we	O
used	O
a	O
new	O
genetic	O
rat	O
model	O
with	O
a	O
loss	O
-	O
of	O
-	O
function	O
point	O
mutation	O
in	O
the	O
dopamine	O
transporter	O
(	O
DAT	O
)	O
gene	O
(	O
Slc6a3_N157	O
K	O
)	O
to	O
systematically	O
study	O
the	O
RDoC	O
matrix	O
.	O

First	O
,	O
we	O
examined	O
the	O
impact	O
of	O
the	O
Slc6a3_N157	O
K	O
mutation	O
on	O
monoaminergic	O
signaling	O
.	O

We	O
then	O
performed	O
behavioral	O
tests	O
representing	O
each	O
of	O
the	O
five	O
RDoC	O
domains	O
:	O
negative	O
and	O
positive	O
valence	O
systems	O
,	O
cognitive	O
,	O
social	O
and	O
arousal	O
/	O
regulatory	O
systems	O
.	O

The	O
use	O
of	O
RDoC	O
may	O
be	O
particularly	O
helpful	O
for	O
drug	O
development	O
.	O

We	O
studied	O
the	O
effects	O
of	O
a	O
novel	O
pharmacological	O
approach	O
metabotropic	O
glutamate	O
receptor	O
mGluR2/3	O
antagonism	O
,	O
in	O
DAT	O
mutants	O
in	O
a	O
comparative	O
way	O
with	O
standard	O
medications	O
.	O

Loss	B-NegReg
of	O
DAT	B-Gene
functionality	O
in	O
mutant	B-Var
rats	O
not	O
only	O
elevated	B-PosReg
subcortical	B-MPA
extracellular	I-MPA
dopamine	I-MPA
concentration	I-MPA
but	O
also	O
altered	B-Reg
the	O
balance	B-MPA
of	I-MPA
monoaminergic	I-MPA
transmission	I-MPA
.	O

DAT	O
mutant	O
rats	O
showed	O
deficits	O
in	O
all	O
five	O
RDoC	O
domains	O
.	O

Thus	O
,	O
mutant	O
rats	O
failed	O
to	O
show	O
conditioned	O
fear	O
responses	O
,	O
were	O
anhedonic	O
,	O
were	O
unable	O
to	O
learn	O
stimulus	O
-	O
reward	O
associations	O
,	O
showed	O
impaired	O
cognition	O
and	O
social	O
behavior	O
,	O
and	O
were	O
hyperactive	O
.	O

Hyperactivity	O
in	O
mutant	O
rats	O
was	O
reduced	O
by	O
amphetamine	O
and	O
atomoxetine	O
,	O
which	O
are	O
well	O
-	O
established	O
medications	O
to	O
reduce	O
hyperactivity	O
in	O
humans	O
.	O

The	O
mGluR2/3	O
antagonist	O
LY341495	O
also	O
normalized	O
hyperactivity	O
in	O
DAT	O
mutant	O
rats	O
without	O
affecting	O
extracellular	O
dopamine	O
levels	O
.	O

We	O
systematically	O
characterized	O
an	O
altered	O
dopamine	O
system	O
within	O
the	O
context	O
of	O
the	O
RDoC	O
matrix	O
and	O
studied	O
mGluR2/3	O
antagonism	O
as	O
a	O
new	O
pharmacological	O
strategy	O
to	O
treat	O
mental	O
disorders	O
with	O
underlying	O
subcortical	O
dopaminergic	O
hyperactivity	O
.	O

Conformational	O
disruption	O
of	O
PI3Kδ	O
regulation	O
by	O
immunodeficiency	O
mutations	O
in	O
PIK3CD	O
and	O
PIK3R1	O
.	O

Activated	B-Disease
PI3	I-Disease
K	I-Disease
Delta	I-Disease
Syndrome	I-Disease
(	O
APDS	O
)	O
is	O
a	O
primary	O
immunodeficiency	O
disease	O
caused	B-Reg
by	O
activating	O
mutations	B-Var
in	O
either	O
the	O
leukocyte	O
-	O
restricted	O
p110δ	O
catalytic	O
(	B-Gene
PIK3CD	I-Gene
)	I-Gene
subunit	O
or	O
the	O
ubiquitously	O
expressed	O
p85α	O
regulatory	O
(	O
PIK3R1	O
)	O
subunit	O
of	O
class	O
IA	O
phosphoinositide	O
3-kinases	O
(	O
PI3Ks	O
)	O
.	O

There	O
are	O
two	O
classes	O
of	O
APDS	O
:	O
APDS1	O
that	O
arises	O
from	O
p110δ	O
mutations	O
that	O
are	O
analogous	O
to	O
oncogenic	O
mutations	O
found	O
in	O
the	O
broadly	O
expressed	O
p110α	O
subunit	O
and	O
APDS2	O
that	O
occurs	O
from	O
a	O
splice	O
mutation	O
resulting	O
in	O
p85α	O
with	O
a	O
central	O
deletion	O
(	O
Δ434	O
-	O
475	O
)	O
.	O

As	O
p85	O
regulatory	O
subunits	O
associate	O
with	O
and	O
inhibit	O
all	O
class	O
IA	O
catalytic	O
subunits	O
,	O
APDS2	O
mutations	O
are	O
expected	O
to	O
similarly	O
activate	O
p110α	O
,	O
β	O
,	O
and	O
δ	O
,	O
yet	O
APDS2	O
largely	O
phenocopies	O
APDS1	O
without	O
dramatic	O
effects	O
outside	O
the	O
immune	O
system	O
.	O

We	O
have	O
examined	O
the	O
molecular	O
mechanism	O
of	O
activation	O
of	O
both	O
classes	O
of	O
APDS	O
mutations	O
using	O
a	O
combination	O
of	O
biochemical	O
assays	O
and	O
hydrogen	O
-	O
deuterium	O
exchange	O
mass	O
spectrometry	O
.	O

Intriguingly	O
,	O
we	O
find	O
that	O
an	O
APDS2	B-Gene
mutation	B-Var
in	O
p85α	O
leads	O
to	O
substantial	O
basal	O
activation	B-PosReg
of	O
p110δ	B-MPA
(	I-MPA
>	I-MPA
300-fold	I-MPA
)	I-MPA
and	O
disrupts	B-NegReg
inhibitory	B-MPA
interactions	I-MPA
from	O
the	O
nSH2	O
,	O
iSH2	O
,	O
and	O
cSH2	O
domains	O
of	O
p85	O
,	O
whereas	O
p110α	O
is	O
only	O
minimally	O
basally	O
activated	O
(	O
∼2-fold	O
)	O
when	O
associated	O
with	O
mutated	O
p85α	O
.	O

APDS1	O
mutations	O
in	O
p110δ	O
(	O
N334	O
K	O
,	O
E525	O
K	O
,	O
E1021	O
K	O
)	O
mimic	O
the	O
activation	O
mechanisms	O
previously	O
discovered	O
for	O
oncogenic	O
mutations	O
in	O
p110α	O
.	O

All	O
APDS	O
mutations	O
were	O
potently	O
inhibited	O
by	O
the	O
Food	O
and	O
Drug	O
Administration	O
-	O
approved	O
p110δ	O
inhibitor	O
idelalisib	O
.	O

Our	O
results	O
define	O
the	O
molecular	O
basis	O
of	O
how	O
PIK3CD	O
and	O
PIK3R1	O
mutations	O
result	O
in	O
APDS	O
and	O
reveal	O
a	O
potential	O
path	O
to	O
treatment	O
for	O
all	O
APDS	O
patients	O
.	O

Identification	O
of	O
TAZ	B-Gene
mutations	B-Var
in	O
pediatric	O
patients	O
with	B-Reg
cardiomyopathy	B-Disease
by	O
targeted	O
next	O
-	O
generation	O
sequencing	O
in	O
a	O
Chinese	O
cohort	O
.	O

BACKGROUND	O
:	O
Barth	O
syndrome	O
(	O
BTHS	O
)	O
is	O
a	O
rare	O
X	O
-	O
linked	O
recessive	O
disease	O
characterized	O
by	O
cardiomyopathy	O
,	O
neutropenia	O
,	O
skeletal	O
myopathy	O
and	O
growth	O
delay	O
.	O

Early	O
diagnosis	O
and	O
appropriate	O
treatment	O
may	O
improve	O
the	O
prognosis	O
of	O
this	O
disease	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
determine	O
the	O
role	O
of	O
targeted	O
next	O
-	O
generation	O
sequencing	O
(	O
NGS	O
)	O
in	O
the	O
early	O
diagnosis	O
of	O
BTHS	O
in	O
children	O
with	O
cardiomyopathy	O
.	O

METHODS	O
:	O
During	O
the	O
period	O
between	O
2012	O
and	O
2015	O
,	O
a	O
gene	O
panel	O
-	O
based	O
NGS	O
approach	O
was	O
used	O
to	O
search	O
for	O
potentially	O
disease	O
-	O
causing	O
genetic	O
variants	O
in	O
all	O
patients	O
referred	O
to	O
our	O
institution	O
with	O
a	O
clinical	O
diagnosis	O
of	O
primary	O
cardiomyopathy	O
.	O

NGS	O
was	O
performed	O
using	O
the	O
Illumina	O
sequencing	O
system	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
180	O
Chinese	O
pediatric	O
patients	O
(	O
114	O
males	O
and	O
66	O
females	O
)	O
diagnosed	O
with	O
primary	O
cardiomyopathy	O
were	O
enrolled	O
in	O
this	O
study	O
.	O

TAZ	O
mutations	O
were	O
identified	O
in	O
four	O
of	O
the	O
male	O
index	O
patients	O
,	O
including	O
two	O
novel	O
mutations	O
(	O
c.527A	O
>	O
G	O
,	O
p	O
.	O
H176R	O
and	O
c.134_136delinsCC	O
,	O
p	O
.	O
H45PfsX38	O
)	O
.	O

All	O
four	O
probands	O
and	O
two	O
additional	O
affected	O
male	O
family	O
members	O
were	O
born	O
at	O
full	O
term	O
with	O
a	O
median	O
birth	O
weight	O
of	O
2350	O
g	O
(	O
range	O
,	O
2000	O
-	O
2850	O
g	O
)	O
.	O

The	O
median	O
age	O
at	O
diagnosis	O
of	O
cardiomyopathy	O
was	O
3.0	O
months	O
(	O
range	O
,	O
1.0	O
-	O
20.0	O
months	O
)	O
.	O

The	O
baseline	O
echocardiography	O
revealed	O
prominent	O
dilation	O
and	O
trabeculations	O
of	O
the	O
left	O
ventricle	O
with	O
impaired	O
systolic	O
function	O
in	O
the	O
six	O
patients	O
,	O
four	O
of	O
which	O
fulfilled	O
the	O
diagnostic	O
criteria	O
of	O
left	O
ventricular	O
noncompaction	O
.	O

Other	O
aspects	O
of	O
their	O
clinical	O
presentations	O
included	O
hypotonia	O
(	O
6/6	O
)	O
,	O
growth	O
delay	O
(	O
6/6	O
)	O
,	O
neutropenia	O
(	O
3/6	O
)	O
and	O
3-methylglutaconic	O
aciduria	O
(	O
4/5	O
)	O
.	O

Five	O
patients	O
died	O
at	O
a	O
median	O
age	O
of	O
7.5	O
months	O
(	O
range	O
,	O
7.0	O
-	O
12.0	O
months	O
)	O
.	O

The	O
cause	O
of	O
death	O
was	O
heart	O
failure	O
associated	O
with	O
infection	O
in	O
three	O
patients	O
and	O
cardiac	O
arrhythmia	O
in	O
two	O
patients	O
.	O

The	O
remaining	O
one	O
patient	O
survived	O
beyond	O
infancy	O
but	O
had	O
fallen	O
into	O
a	O
persistent	O
vegetative	O
state	O
after	O
suffering	O
from	O
cardiac	O
arrest	O
.	O

CONCLUSIONS	O
:	O
This	O
is	O
the	O
first	O
report	O
of	O
systematic	O
mutation	O
screening	O
of	O
TAZ	O
in	O
a	O
large	O
cohort	O
of	O
pediatric	O
patients	O
with	O
primary	O
cardiomyopathy	O
using	O
the	O
NGS	O
approach	O
.	O

TAZ	O
mutations	O
were	O
found	O
in	O
4/114	O
(	O
3.5	O
%	O
)	O
male	O
patients	O
with	O
primary	O
cardiomyopathy	O
.	O

Our	O
findings	O
indicate	O
that	O
the	O
inclusion	O
of	O
TAZ	O
gene	O
testing	O
in	O
cardiomyopathy	O
genetic	O
testing	O
panels	O
may	O
contribute	O
to	O
the	O
early	O
diagnosis	O
of	O
BTHS	O
.	O

Mutations	B-Var
in	O
DONSON	B-Gene
disrupt	B-NegReg
replication	B-MPA
fork	I-MPA
stability	I-MPA
and	O
cause	B-Reg
microcephalic	B-Disease
dwarfism	I-Disease
.	O

To	O
ensure	O
efficient	O
genome	O
duplication	O
,	O
cells	O
have	O
evolved	O
numerous	O
factors	O
that	O
promote	O
unperturbed	O
DNA	O
replication	O
and	O
protect	O
,	O
repair	O
and	O
restart	O
damaged	O
forks	O
.	O

Here	O
we	O
identify	O
downstream	O
neighbor	O
of	O
SON	O
(	O
DONSON	O
)	O
as	O
a	O
novel	O
fork	O
protection	O
factor	O
and	O
report	O
biallelic	O
DONSON	O
mutations	O
in	O
29	O
individuals	O
with	O
microcephalic	O
dwarfism	O
.	O

We	O
demonstrate	O
that	O
DONSON	O
is	O
a	O
replisome	O
component	O
that	O
stabilizes	O
forks	O
during	O
genome	O
replication	O
.	O

Loss	B-Var
of	O
DONSON	B-Gene
leads	B-Reg
to	I-Reg
severe	O
replication	B-MPA
-	I-MPA
associated	I-MPA
DNA	I-MPA
damage	I-MPA
arising	O
from	O
nucleolytic	O
cleavage	O
of	O
stalled	O
replication	O
forks	O
.	O

Furthermore	O
,	O
ATM-	B-MPA
and	I-MPA
Rad3-related	I-MPA
(	I-MPA
ATR)-dependent	I-MPA
signaling	I-MPA
in	O
response	O
to	O
replication	O
stress	O
is	O
impaired	B-NegReg
in	O
DONSON	B-Gene
-	I-Gene
deficient	I-Gene
cells	O
,	O
resulting	O
in	O
decreased	B-NegReg
checkpoint	B-MPA
activity	I-MPA
and	O
the	O
potentiation	B-PosReg
of	O
chromosomal	B-MPA
instability	I-MPA
.	O

Hypomorphic	B-Var
mutations	I-Var
in	O
DONSON	B-Gene
substantially	O
reduce	B-NegReg
DONSON	B-Gene
protein	B-Protein
levels	B-MPA
and	O
impair	B-NegReg
fork	B-MPA
stability	I-MPA
in	O
cells	O
from	O
patients	O
,	O
consistent	O
with	O
defective	O
DNA	O
replication	O
underlying	O
the	O
disease	O
phenotype	O
.	O

In	O
summary	O
,	O
we	O
have	O
identified	O
mutations	B-Var
in	O
DONSON	B-Gene
as	O
a	O
common	O
cause	B-Reg
of	O
microcephalic	B-Disease
dwarfism	I-Disease
and	O
established	O
DONSON	O
as	O
a	O
critical	O
replication	O
fork	O
protein	O
required	O
for	O
mammalian	O
DNA	O
replication	O
and	O
genome	O
stability	O
.	O

Phenotypic	O
spectrum	O
of	O
Charcot	B-Disease
-	I-Disease
Marie	I-Disease
-	I-Disease
Tooth	I-Disease
disease	O
due	B-Reg
to	I-Reg
LITAF	B-Gene
/	I-Gene
SIMPLE	I-Gene
mutations	B-Var
:	I-Var
a	O
study	O
of	O
18	O
patients	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
Charcot	B-Disease
-	I-Disease
Marie	I-Disease
-	I-Disease
Tooth	I-Disease
(	O
CMT	O
)	O
1C	O
due	B-Reg
to	I-Reg
mutations	B-Var
in	O
LITAF	B-Gene
/	I-Gene
SIMPLE	I-Gene
is	O
a	O
rare	O
subtype	O
amongst	O
the	O
autosomal	O
dominant	O
demyelinating	O
forms	O
of	O
CMT	O
.	O

Our	O
objective	O
was	O
to	O
report	O
the	O
clinical	O
and	O
electrophysiological	O
characteristics	O
of	O
18	O
CMT1C	O
patients	O
and	O
compare	O
them	O
to	O
20	O
patients	O
with	O
PMP22	O
mutations	O
:	O
10	O
CMT1A	O
patients	O
and	O
10	O
patients	O
with	O
hereditary	O
neuropathy	O
with	O
liability	O
to	O
pressure	O
palsies	O
(	O
HNPP	O
)	O
.	O

METHODS	O
:	O
Charcot	O
-	O
Marie	O
-	O
Tooth	O
1C	O
patients	O
were	O
followed	O
-	O
up	O
in	O
referral	O
centres	O
for	O
neuromuscular	O
diseases	O
or	O
were	O
identified	O
by	O
familial	O
survey	O
.	O

All	O
CMT1A	O
and	O
HNPP	O
patients	O
were	O
recruited	O
at	O
the	O
referral	O
centre	O
for	O
neuromuscular	O
diseases	O
of	O
Pitié	O
-	O
Salpêtrière	O
Hospital	O
.	O

RESULTS	O
:	O
Two	O
phenotypes	O
were	O
identified	O
amongst	O
18	O
CMT1C	O
patients	O
:	O
the	O
classical	O
CMT	O
form	O
(	O
'	O
CMT	O
-	O
like	O
'	O
,	O
11	O
cases	O
)	O
and	O
a	O
predominantly	O
sensory	O
form	O
(	O
'	O
sensory	O
form	O
'	O
,	O
seven	O
cases	O
)	O
.	O

The	O
mean	O
CMT	O
neuropathy	O
score	O
was	O
4.45	O
in	O
CMT1C	O
patients	O
.	O

Motor	O
nerve	O
conduction	O
velocities	O
in	O
the	O
upper	O
limbs	O
were	O
significantly	O
more	O
reduced	O
in	O
CMT1A	O
than	O
in	O
CMT1C	O
patients	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
motor	O
nerve	O
conduction	O
velocity	O
of	O
the	O
median	O
nerve	O
was	O
significantly	O
lower	O
in	O
CMT1C	O
compared	O
to	O
the	O
HNPP	O
group	O
.	O

Distal	O
motor	O
latency	O
was	O
significantly	O
more	O
prolonged	O
in	O
CMT1A	O
patients	O
compared	O
to	O
the	O
CMT1C	O
and	O
HNPP	O
groups	O
,	O
the	O
latter	O
two	O
groups	O
having	O
similar	O
distal	O
motor	O
latency	O
values	O
.	O

Molecular	O
analysis	O
revealed	O
five	O
new	O
LITAF	O
/	O
SIMPLE	O
mutations	O
(	O
Ala111Thr	O
,	O
Gly112Ala	O
,	O
Trp116Arg	O
,	O
Pro135Leu	O
,	O
Arg160Cys	O
)	O
.	O

CONCLUSIONS	O
:	O
Our	O
study	O
delineates	O
CMT1C	O
as	O
mostly	O
a	O
mild	O
form	O
of	O
neuropathy	O
,	O
and	O
gives	O
clinical	O
and	O
electrophysiological	O
clues	O
differentiating	O
CMT1C	O
from	O
CMT1A	O
and	O
HNPP	O
.	O

Delineating	O
phenotypes	O
in	O
CMT	O
subtypes	O
is	O
important	O
to	O
orient	O
molecular	O
diagnosis	O
and	O
to	O
help	O
to	O
interpret	O
complex	O
molecular	O
findings	O
.	O

N	O
-	O
cadherin	O
Regulation	O
of	O
Bone	O
Growth	O
and	O
Homeostasis	O
Is	O
Osteolineage	O
Stage	O
-	O
Specific	O
.	O

N	O
-	O
cadherin	O
inhibits	O
osteogenic	O
cell	O
differentiation	O
and	O
canonical	O
Wnt	O
/	O
β	O
-	O
catenin	O
signaling	O
in	O
vitro	O
.	O

However	O
,	O
in	O
vivo	O
both	O
conditional	O
Cdh2	O
ablation	O
and	O
overexpression	O
in	O
osteoblasts	O
lead	O
to	O
low	O
bone	O
mass	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
N	O
-	O
cadherin	O
has	O
different	O
effects	O
on	O
osteolineage	O
cells	O
depending	O
upon	O
their	O
differentiation	O
stage	O
.	O

Embryonic	O
conditional	O
osteolineage	O
Cdh2	B-Gene
deletion	B-Var
in	O
mice	O
results	O
in	O
defective	B-NegReg
growth	B-MPA
,	O
low	B-NegReg
bone	B-MPA
mass	I-MPA
,	O
and	O
reduced	B-NegReg
osteoprogenitor	B-MPA
number	I-MPA
.	O

These	O
abnormalities	O
are	O
prevented	O
by	O
delaying	O
Cdh2	O
ablation	O
until	O
1	O
month	O
of	O
age	O
,	O
thus	O
targeting	O
only	O
committed	O
and	O
mature	O
osteoblasts	O
,	O
suggesting	O
they	O
are	O
the	O
consequence	O
of	O
N	O
-	O
cadherin	O
deficiency	O
in	O
osteoprogenitors	O
.	O

Indeed	O
,	O
diaphyseal	O
trabecularization	O
actually	O
increases	O
when	O
Cdh2	O
is	O
ablated	O
postnatally	O
.	O

The	O
sclerostin	O
-	O
insensitive	O
Lrp5(A214V	O
)	O
mutant	O
,	O
associated	O
with	O
high	O
bone	O
mass	O
,	O
does	O
not	O
rescue	O
the	O
growth	O
defect	O
,	O
but	O
it	O
overrides	O
the	O
low	O
bone	O
mass	O
of	O
embryonically	O
Cdh2-deleted	O
mice	O
,	O
suggesting	O
N	O
-	O
cadherin	O
interacts	O
with	O
Wnt	O
signaling	O
to	O
control	O
bone	O
mass	O
.	O

Finally	O
,	O
bone	O
accrual	O
and	O
β	O
-	O
catenin	O
accumulation	O
after	O
administration	O
of	O
an	O
anti	O
-	O
Dkk1	O
antibody	O
are	O
enhanced	O
in	O
N	O
-	O
cadherin	O
-	O
deficient	O
mice	O
.	O

Thus	O
,	O
although	O
lack	O
of	O
N	O
-	O
cadherin	O
in	O
embryonic	O
and	O
perinatal	O
age	O
is	O
detrimental	O
to	O
bone	O
growth	O
and	O
bone	O
accrual	O
,	O
in	O
adult	O
mice	O
loss	O
of	O
N	O
-	O
cadherin	O
in	O
osteolineage	O
cells	O
favors	O
bone	O
formation	O
.	O

Hence	O
,	O
N	O
-	O
cadherin	O
inhibition	O
may	O
widen	O
the	O
therapeutic	O
window	O
of	O
osteoanabolic	O
agents	O
.	O

©	O
2017	O
American	O
Society	O
for	O
Bone	O
and	O
Mineral	O
Research	O
.	O

MAX	O
inactivation	O
is	O
an	O
early	O
event	O
in	O
GIST	O
development	O
that	O
regulates	O
p16	O
and	O
cell	O
proliferation	O
.	O

KIT	B-Gene
,	O
PDGFRA	B-Gene
,	O
NF1	B-Gene
and	O
SDH	B-Gene
mutations	B-Var
are	O
alternate	O
initiating	O
events	O
,	O
fostering	B-Reg
hyperplasia	O
in	O
gastrointestinal	B-MPA
stromal	I-MPA
tumours	I-MPA
(	O
GISTs	O
)	O
,	O
and	O
additional	O
genetic	O
alterations	O
are	O
required	O
for	O
progression	O
to	O
malignancy	O
.	O

The	O
most	O
frequent	O
secondary	O
alteration	O
,	O
demonstrated	O
in	O
∼70	O
%	O
of	O
GISTs	O
,	O
is	O
chromosome	O
14q	O
deletion	O
.	O

Here	O
we	O
report	O
hemizygous	O
or	O
homozygous	O
inactivating	O
mutations	O
of	O
the	O
chromosome	O
14q	O
MAX	O
gene	O
in	O
16	O
of	O
76	O
GISTs	O
(	O
21	O
%	O
)	O
.	O

We	O
find	O
MAX	O
mutations	O
in	O
17	O
%	O
and	O
50	O
%	O
of	O
sporadic	O
and	O
NF1-syndromic	O
GISTs	O
,	O
respectively	O
,	O
and	O
we	O
find	O
loss	O
of	O
MAX	O
protein	O
expression	O
in	O
48	O
%	O
and	O
90	O
%	O
of	O
sporadic	O
and	O
NF1-syndromic	O
GISTs	O
,	O
respectively	O
,	O
and	O
in	O
three	O
of	O
eight	O
micro	O
-	O
GISTs	O
,	O
which	O
are	O
early	O
GISTs	O
.	O

MAX	O
genomic	O
inactivation	O
is	O
associated	O
with	O
p16	O
silencing	O
in	O
the	O
absence	O
of	O
p16	O
coding	O
sequence	O
deletion	O
and	O
MAX	O
induction	O
restores	O
p16	O
expression	O
and	O
inhibits	O
GIST	O
proliferation	O
.	O

Hence	O
,	O
MAX	O
inactivation	O
is	O
a	O
common	O
event	O
in	O
GIST	O
progression	O
,	O
fostering	O
cell	O
cycle	O
activity	O
in	O
early	O
GISTs	O
.	O

ATR	B-Gene
Mutations	B-Var
Promote	B-PosReg
the	O
Growth	B-MPA
of	O
Melanoma	B-Disease
Tumors	I-Disease
by	O
Modulating	O
the	O
Immune	O
Microenvironment	O
.	O

Melanomas	O
accumulate	O
a	O
high	O
burden	O
of	O
mutations	B-Var
that	O
could	O
potentially	O
generate	B-Reg
neoantigens	B-MPA
,	O
yet	O
somehow	O
suppress	B-NegReg
the	O
immune	B-MPA
response	I-MPA
to	I-MPA
facilitate	I-MPA
continued	I-MPA
growth	I-MPA
.	O

In	O
this	O
study	O
,	O
we	O
identify	O
a	O
subset	O
of	O
human	O
melanomas	O
that	O
have	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
ATR	O
,	O
a	O
kinase	O
that	O
recognizes	O
and	O
repairs	O
UV	O
-	O
induced	O
DNA	O
damage	O
and	O
is	O
required	O
for	O
cellular	O
proliferation	O
.	O

ATR	B-Gene
mutant	B-Var
tumors	O
exhibit	O
both	O
the	O
accumulation	O
of	O
multiple	O
mutations	O
and	O
the	O
altered	O
expression	O
of	O
inflammatory	O
genes	O
,	O
resulting	O
in	O
decreased	B-NegReg
T	B-MPA
cell	I-MPA
recruitment	I-MPA
and	O
increased	B-PosReg
recruitment	B-MPA
of	I-MPA
macrophages	I-MPA
known	O
to	O
spur	O
tumor	O
invasion	O
.	O

Taken	O
together	O
,	O
these	O
studies	O
identify	O
a	O
mechanism	O
by	O
which	O
melanoma	O
cells	O
modulate	O
the	O
immune	O
microenvironment	O
to	O
promote	O
continued	O
growth	O
.	O

Regulation	O
of	O
endometrial	O
cell	O
proliferation	O
by	O
estrogen	O
-	O
induced	O
BDNF	O
signaling	O
pathway	O
.	O

Brain	O
-	O
derived	O
neurotrophic	O
factor	O
(	O
BDNF	O
)	O
is	O
a	O
member	O
of	O
the	O
neurotrophin	O
growth	O
factors	O
family	O
.	O

Recent	O
studies	O
indicated	O
that	O
the	O
level	O
of	O
BDNF	O
in	O
follicular	O
fluid	O
is	O
a	O
marker	O
for	O
oocyte	O
quality	O
and	O
infertility	O
.	O

Here	O
,	O
we	O
intend	O
to	O
further	O
investigate	O
the	O
function	O
of	O
BDNF	O
and	O
its	O
signaling	O
pathway	O
in	O
the	O
regulation	O
of	O
endometrial	O
cells	O
proliferation	O
.	O

We	O
found	O
that	O
BDNF	O
is	O
a	O
critical	O
growth	O
factor	O
in	O
endometrial	O
cells	O
.	O

Activation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
signaling	O
pathway	O
is	O
required	O
for	O
BNDF	O
-	O
regulated	O
endometrial	O
cell	O
proliferation	O
.	O

Furthermore	O
,	O
BDNF	O
is	O
an	O
effector	O
of	O
estrogen	O
in	O
endometrial	O
cells	O
.	O

Finally	O
,	O
we	O
investigated	O
the	O
different	O
role	O
of	O
Val66Met	O
,	O
a	O
single	O
-	O
nucleotide	O
polymorphism	O
of	O
the	O
BDNF	O
gene	O
,	O
in	O
regulating	O
endometrial	O
cells	O
proliferation	O
.	O

The	O
results	O
showed	O
that	O
BDNF(V66	B-Gene
M	I-Gene
)	I-Gene
polymorphism	B-Var
is	O
a	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
polymorphism	B-Var
in	O
the	O
regulation	B-MPA
of	I-MPA
endometrial	I-MPA
cells	I-MPA
growth	I-MPA
.	O

Given	O
the	O
correlation	O
between	O
endometriosis	O
and	O
infertility	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
role	O
of	O
BDNF	O
in	O
regulating	O
endometrial	O
cells	O
proliferation	O
and	O
to	O
develop	O
new	O
therapeutic	O
strategies	O
for	O
the	O
treatment	O
of	O
endometriosis	O
-	O
related	O
infertility	O
.	O

Impact	O
of	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutations	B-Var
in	O
the	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
-	O
related	O
protein	O
5	O
(	B-Gene
LRP5	I-Gene
)	I-Gene
on	O
glucose	B-MPA
and	I-MPA
lipid	I-MPA
homeostasis	I-MPA
.	O

LRP5	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
have	O
been	O
shown	O
to	O
cause	O
profound	B-MPA
osteoporosis	I-MPA
and	O
have	O
been	O
associated	O
with	O
impaired	B-MPA
insulin	I-MPA
sensitivity	I-MPA
and	O
dysregulated	B-MPA
lipid	I-MPA
metabolism	I-MPA
.	O

We	O
hypothesized	O
that	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
in	O
LRP5	O
would	O
also	O
affect	O
these	O
parameters	O
.	O

We	O
therefore	O
studied	O
individuals	O
with	O
LRP5	B-Gene
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutations	B-Var
exhibiting	O
high	O
bone	O
mass	O
(	O
HBM	O
)	O
phenotypes	O
and	O
found	O
that	O
while	O
there	O
was	O
no	O
detected	O
change	O
in	O
insulin	O
sensitivity	O
,	O
there	O
was	O
a	O
significant	O
reduction	B-NegReg
in	O
serum	B-MPA
LDL	I-MPA
.	O

INTRODUCTION	O
:	O
Wnt	O
signaling	O
through	O
LRP5	O
represents	O
a	O
newly	O
appreciated	O
metabolic	O
pathway	O
,	O
which	O
potentially	O
represents	O
a	O
target	O
for	O
drug	O
discovery	O
in	O
type	O
2	O
diabetes	O
and	O
hyperlipidemia	O
.	O

Studies	O
in	O
animal	O
models	O
suggest	O
a	O
physiologic	O
link	O
between	O
LRP5	O
and	O
glucose	O
and	O
lipid	O
homeostasis	O
;	O
however	O
,	O
whether	O
it	O
plays	O
a	O
similar	O
role	O
in	O
humans	O
is	O
unclear	O
.	O

As	O
current	O
literature	O
links	O
loss	O
-	O
of	O
-	O
function	O
LRP5	O
to	O
impaired	O
glucose	O
and	O
lipid	O
metabolism	O
,	O
we	O
hypothesized	O
that	O
individuals	O
with	O
an	O
HBM	O
-	O
causing	O
mutation	O
in	O
LRP5	O
would	O
exhibit	O
improved	O
glucose	O
and	O
lipid	O
homeostasis	O
.	O

Since	O
studies	O
in	O
animal	O
models	O
have	O
suggested	O
that	O
Wnt	O
signaling	O
augments	O
insulin	O
secretion	O
,	O
we	O
also	O
examined	O
the	O
effect	O
of	O
Wnt	O
signaling	O
on	O
glucose	O
-	O
stimulated	O
insulin	O
secretion	O
on	O
human	O
pancreatic	O
islets	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
matched	O
case	O
-	O
control	O
study	O
.	O

We	O
used	O
several	O
methods	O
to	O
assess	O
glucose	O
and	O
lipid	O
metabolism	O
in	O
11	O
individuals	O
with	O
HBM	O
-	O
causing	O
mutations	O
in	O
LRP5	O
.	O

Affected	O
study	O
participants	O
were	O
recruited	O
from	O
previously	O
identified	O
kindreds	O
with	O
HBM	O
-	O
causing	O
LRP5	O
mutations	O
and	O
included	O
9	O
males	O
and	O
2	O
females	O
.	O

Two	O
subjects	O
that	O
were	O
being	O
treated	O
with	O
insulin	O
for	O
type	O
2	O
diabetes	O
were	O
excluded	O
from	O
our	O
analysis	O
,	O
as	O
this	O
would	O
have	O
obscured	O
our	O
ability	O
to	O
determine	O
the	O
impact	O
of	O
gain	O
-	O
of	O
-	O
function	O
LRP5	O
mutations	O
on	O
glucose	O
metabolism	O
.	O

The	O
mean	O
age	O
of	O
the	O
evaluated	O
study	O
subjects	O
was	O
55	O
±	O
7	O
with	O
a	O
mean	O
BMI	O
of	O
27.2	O
±	O
2.0	O
.	O

Control	O
subjects	O
were	O
matched	O
and	O
recruited	O
from	O
the	O
general	O
community	O
at	O
an	O
equivalent	O
ratio	O
,	O
with	O
18	O
males	O
and	O
4	O
females	O
(	O
mean	O
age	O
56	O
±	O
4	O
;	O
mean	O
BMI	O
27.2	O
±	O
1.0	O
)	O
.	O

Study	O
testing	O
was	O
conducted	O
at	O
an	O
academic	O
medical	O
center	O
.	O

RESULTS	O
:	O
There	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
affected	O
and	O
matched	O
control	O
populations	O
for	O
HbA1c	O
(	O
p	O
=	O
0.06	O
)	O
,	O
eAG	O
(	O
p	O
=	O
0.06	O
)	O
,	O
insulin	O
(	O
p	O
=	O
0.82	O
)	O
,	O
HOMA	O
-	O
B	O
(	O
p	O
=	O
0.34	O
)	O
,	O
or	O
HOMA	O
-	O
IR	O
(	O
p	O
=	O
0.66	O
)	O
.	O

The	O
mean	O
Insulin	O
Sensitivity	O
Index	O
(	O
ISI	O
)	O
was	O
also	O
similar	O
between	O
control	O
and	O
affected	O
individuals	O
.	O

Total	O
cholesterol	O
(	O
p	O
=	O
0.43	O
)	O
,	O
triglycerides	O
(	O
TG	O
)	O
(	O
p	O
=	O
0.56	O
)	O
,	O
and	O
HDL	O
(	O
p	O
=	O
0.32	O
)	O
were	O
not	O
different	O
between	O
the	O
same	O
two	O
groups	O
.	O

In	O
a	O
small	O
subset	O
of	O
studied	O
subjects	O
,	O
intramyocellular	O
and	O
hepatic	O
lipid	O
content	O
were	O
similar	O
in	O
the	O
affected	O
individuals	O
and	O
controls	O
when	O
quantified	O
by	O
proton	O
magnetic	O
resonance	O
spectroscopy	O
(	O
MRS	O
)	O
.	O

However	O
,	O
the	O
mean	O
value	O
for	O
serum	O
LDL	O
was	O
significantly	O
lower	O
(	O
p	O
=	O
0.04	O
)	O
in	O
affected	O
individuals	O
.	O

In	O
primary	O
human	O
islets	O
,	O
there	O
were	O
no	O
differences	O
between	O
control	O
and	O
Wnt	O
treatment	O
groups	O
for	O
insulin	O
secretion	O
measured	O
as	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
for	O
first	O
phase	O
(	O
p	O
=	O
0.17	O
)	O
or	O
second	O
phase	O
(	O
p	O
=	O
0.33	O
)	O
insulin	O
secretion	O
.	O

CONCLUSIONS	O
:	O
Although	O
our	O
sample	O
size	O
was	O
small	O
,	O
our	O
data	O
do	O
not	O
support	O
the	O
hypothesis	O
that	O
HBM	O
-	O
causing	O
LRP5	O
mutations	O
,	O
associated	O
with	O
increased	O
Wnt	O
signaling	O
,	O
improve	O
glucose	O
metabolism	O
in	O
humans	O
.	O

However	O
,	O
it	O
does	O
appear	O
that	O
LRP5	B-Gene
variants	B-Var
may	O
affect	B-Reg
LDL	B-MPA
metabolism	I-MPA
,	O
a	O
major	O
risk	O
factor	O
for	O
coronary	O
artery	O
disease	O
.	O

The	O
molecular	O
mechanisms	O
underpinning	O
this	O
effect	O
warrant	O
further	O
study	O
.	O

A	O
Novel	O
Homozygous	O
Missense	O
Mutation	B-Var
in	O
HOXC13	B-Gene
Leads	B-Reg
to	I-Reg
Autosomal	O
Recessive	O
Pure	B-Disease
Hair	I-Disease
and	I-Disease
Nail	I-Disease
Ectodermal	I-Disease
Dysplasia	I-Disease
.	O

Pure	O
hair	O
and	O
nail	O
ectodermal	O
dysplasia	O
(	O
PHNED	O
)	O
is	O
a	O
rare	O
disorder	O
that	O
presents	O
with	O
hypotrichosis	O
and	O
nail	O
dystrophy	O
while	O
sparing	O
other	O
ectodermal	O
structures	O
such	O
as	O
teeth	O
and	O
sweat	O
glands	O
.	O

We	O
describe	O
a	O
homozygous	O
novel	O
missense	O
mutation	B-Var
in	O
the	O
HOXC13	B-Gene
gene	O
that	O
resulted	B-Reg
in	I-Reg
autosomal	O
recessive	O
PHNED	B-Disease
in	O
a	O
Hispanic	O
child	O
.	O

The	O
mutation	O
c.812A	O
>	O
G	O
(	O
p	O
.	O
Gln271Arg	O
)	O
is	O
located	O
within	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
the	O
HOXC13	O
gene	O
,	O
cosegregates	O
within	O
the	O
family	O
,	O
and	O
is	O
predicted	O
to	O
be	O
maximally	O
damaging	O
.	O

This	O
is	O
the	O
first	O
reported	O
case	O
of	O
a	O
missense	O
HOXC13	B-Gene
mutation	B-Var
resulting	B-Reg
in	I-Reg
PHNED	B-Disease
and	O
the	O
first	O
reported	O
case	O
of	O
PHNED	O
identified	O
in	O
a	O
North	O
American	O
family	O
.	O

Our	O
findings	O
illustrate	O
the	O
critical	O
role	O
of	O
HOXC13	O
in	O
human	O
hair	O
and	O
nail	O
development	O
.	O

The	O
Microtubule	O
-	O
Associated	O
Protein	O
MAP18	O
Affects	O
ROP2	O
GTPase	O
Activity	O
during	O
Root	O
Hair	O
Growth	O
.	O

Establishment	O
and	O
maintenance	O
of	O
the	O
polar	O
site	O
are	O
important	O
for	O
root	O
hair	O
tip	O
growth	O
.	O

We	O
previously	O
reported	O
that	O
Arabidopsis	O
(	O
Arabidopsis	O
thaliana	O
)	O
MICROTUBULE	O
-	O
ASSOCIATED	O
PROTEIN18	O
(	O
MAP18	O
)	O
functions	O
in	O
controlling	O
the	O
direction	O
of	O
pollen	O
tube	O
growth	O
and	O
root	O
hair	O
elongation	O
.	O

Additionally	O
,	O
the	O
Rop	O
GTPase	O
ROP2	O
was	O
reported	O
as	O
a	O
positive	O
regulator	O
of	O
both	O
root	O
hair	O
initiation	O
and	O
tip	O
growth	O
in	O
Arabidopsis	O
.	O

Both	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
of	O
ROP2	B-Gene
and	O
knockdown	B-Var
of	O
MAP18	B-Gene
lead	O
to	O
a	O
decrease	B-NegReg
in	O
root	B-MPA
hair	I-MPA
length	I-MPA
,	O
whereas	O
overexpression	O
of	O
either	O
MAP18	O
or	O
ROP2	O
causes	O
multiple	O
tips	O
or	O
a	O
branching	O
hair	O
phenotype	O
.	O

However	O
,	O
it	O
is	O
unclear	O
whether	O
MAP18	O
and	O
ROP2	O
coordinately	O
regulate	O
root	O
hair	O
growth	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
MAP18	O
and	O
ROP2	O
interact	O
genetically	O
and	O
functionally	O
.	O

MAP18	O
interacts	O
physically	O
with	O
ROP2	O
in	O
vitro	O
and	O
in	O
vivo	O
and	O
preferentially	O
binds	O
to	O
the	O
inactive	O
form	O
of	O
the	O
ROP2	O
protein	O
.	O

MAP18	O
promotes	O
ROP2	O
activity	O
during	O
root	O
hair	O
tip	O
growth	O
.	O

Further	O
investigation	O
revealed	O
that	O
MAP18	O
competes	O
with	O
RhoGTPase	O
GDP	O
DISSOCIATION	O
INHIBITOR1	O
/	O
SUPERCENTIPEDE1	O
for	O
binding	O
to	O
ROP2	O
,	O
in	O
turn	O
affecting	O
the	O
localization	O
of	O
active	O
ROP2	O
in	O
the	O
plasma	O
membrane	O
of	O
the	O
root	O
hair	O
tip	O
.	O

These	O
results	O
reveal	O
a	O
novel	O
function	O
of	O
MAP18	O
in	O
the	O
regulation	O
of	O
ROP2	O
activation	O
during	O
root	O
hair	O
growth	O
.	O

SERPINC1	B-Gene
gene	O
mutations	B-Var
in	B-Reg
antithrombin	B-Disease
deficiency	I-Disease
.	O

Existing	O
evidence	O
suggests	O
that	O
in	O
most	O
cases	O
antithrombin	B-Disease
deficiency	I-Disease
can	O
be	O
explained	B-Reg
by	I-Reg
mutations	B-Var
in	O
its	O
gene	O
,	O
SERPINC1	B-Gene
.	O

We	O
investigated	O
the	O
molecular	O
background	O
of	O
antithrombin	O
deficiency	O
in	O
a	O
single	O
centre	O
family	O
cohort	O
study	O
.	O

We	O
included	O
a	O
total	O
of	O
21	O
families	O
comprising	O
15	O
original	O
probands	O
and	O
sixty	O
-	O
six	O
relatives	O
,	O
6	O
of	O
who	O
were	O
surrogate	O
probands	O
for	O
the	O
genetic	O
analysis	O
.	O

Antithrombin	O
activity	O
and	O
antigen	O
levels	O
were	O
measured	O
.	O

The	O
heparin	O
-	O
antithrombin	O
binding	O
ratio	O
assay	O
was	O
used	O
to	O
distinguish	O
between	O
the	O
different	O
subtypes	O
of	O
type	O
II	O
antithrombin	O
deficiency	O
.	O

SERPINC1	O
mutations	O
were	O
detected	O
by	O
direct	O
sequencing	O
of	O
all	O
7	O
exons	O
and	O
regulatory	O
regions	O
,	O
and	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
.	O

Eighty	O
-	O
six	O
per	O
cent	O
of	O
the	O
families	O
had	O
a	O
detrimental	O
SERPINC1	O
gene	O
mutation	O
that	O
segregated	O
in	O
the	O
family	O
.	O

We	O
detected	O
13	O
different	O
SERPINC1	O
gene	O
mutations	O
of	O
which	O
5	O
were	O
novel	O
.	O

Among	O
all	O
these	O
mutations	O
,	O
44	O
%	O
was	O
associated	O
with	O
type	O
I	O
deficiency	O
,	O
whereas	O
the	O
remainder	O
was	O
associated	O
with	O
type	O
II	O
heparin	O
binding	O
site	O
(	O
11	O
%	O
)	O
,	O
type	O
II	O
pleiotropic	O
effect	O
(	O
33	O
%	O
)	O
,	O
type	O
II	O
reactive	O
site	O
(	O
6	O
%	O
)	O
or	O
had	O
the	O
antithrombin	O
Cambridge	O
II	O
mutation	O
(	O
6	O
%	O
)	O
.	O

The	O
current	O
study	O
reports	O
several	O
novel	O
SERPINC1	O
mutations	O
,	O
thereby	O
adding	O
to	O
our	O
knowledge	O
of	O
the	O
molecular	O
background	O
of	O
antithrombin	O
deficiency	O
.	O

Finally	O
,	O
our	O
results	O
point	O
out	O
the	O
importance	O
of	O
future	O
research	O
outside	O
the	O
conventional	O
SERPINC1	O
gene	O
approach	O
.	O

A	O
Ras	O
GTPase	O
associated	O
protein	O
is	O
involved	O
in	O
the	O
phototropic	O
and	O
circadian	O
photobiology	O
responses	O
in	O
fungi	O
.	O

Light	O
is	O
an	O
environmental	O
signal	O
perceived	O
by	O
most	O
eukaryotic	O
organisms	O
and	O
that	O
can	O
have	O
major	O
impacts	O
on	O
their	O
growth	O
and	O
development	O
.	O

The	O
MadC	O
protein	O
in	O
the	O
fungus	O
Phycomyces	O
blakesleeanus	O
(	O
Mucoromycotina	O
)	O
has	O
been	O
postulated	O
to	O
form	O
part	O
of	O
the	O
photosensory	O
input	O
for	O
phototropism	O
of	O
the	O
fruiting	O
body	O
sporangiophores	O
,	O
but	O
the	O
madC	O
gene	O
has	O
remained	O
unidentified	O
since	O
the	O
1960s	O
when	O
madC	O
mutants	O
were	O
first	O
isolated	O
.	O

In	O
this	O
study	O
the	O
madC	O
gene	O
was	O
identified	O
by	O
positional	O
cloning	O
.	O

All	O
madC	O
mutant	O
strains	O
contain	O
loss	O
-	O
of	O
-	O
function	O
point	O
mutations	O
within	O
a	O
gene	O
predicted	O
to	O
encode	O
a	O
GTPase	O
activating	O
protein	O
(	O
GAP	O
)	O
for	O
Ras	O
.	O

The	O
madC	O
gene	O
complements	O
the	O
Saccharomyces	O
cerevisiae	O
Ras	O
-	O
GAP	O
ira1	O
mutant	O
and	O
the	O
encoded	O
MadC	O
protein	O
interacts	O
with	O
P.	O
blakesleeanus	O
Ras	O
homologs	O
in	O
yeast	O
two	O
-	O
hybrid	O
assays	O
,	O
indicating	O
that	O
MadC	O
is	O
a	O
regulator	O
of	O
Ras	O
signaling	O
.	O

Deletion	B-Var
of	O
the	O
homolog	O
in	O
the	O
filamentous	O
ascomycete	O
Neurospora	O
crassa	O
affects	B-Reg
the	O
circadian	B-MPA
clock	I-MPA
output	I-MPA
,	O
yielding	B-Reg
a	O
pattern	O
of	O
asexual	B-MPA
conidiation	I-MPA
similar	O
to	O
a	O
ras-1	O
mutant	O
that	O
is	O
used	O
in	O
circadian	O
studies	O
in	O
N.	O
crassa	O
.	O

Thus	O
,	O
MadC	O
is	O
unlikely	O
to	O
be	O
a	O
photosensor	O
,	O
yet	O
is	O
a	O
fundamental	O
link	O
in	O
the	O
photoresponses	O
from	O
blue	O
light	O
perceived	O
by	O
the	O
conserved	O
White	O
Collar	O
complex	O
with	O
Ras	O
signaling	O
in	O
two	O
distantly	O
-	O
related	O
filamentous	O
fungal	O
species	O
.	O

Paradoxical	O
gain	O
-	O
of	O
-	O
function	O
mutant	O
of	O
the	O
G	O
-	O
protein	O
-	O
coupled	O
receptor	O
PROKR2	O
promotes	O
early	O
puberty	O
.	O

The	O
human	O
genome	O
encodes	O
~750	O
G	O
-	O
protein	O
-	O
coupled	O
receptors	O
(	O
GPCRs	O
)	O
,	O
including	O
prokineticin	O
receptor	O
2	O
(	O
PROKR2	O
)	O
involved	O
in	O
the	O
regulation	O
of	O
sexual	O
maturation	O
.	O

Previously	O
reported	O
pathogenic	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
of	O
GPCR	O
genes	O
invariably	O
encoded	O
aberrant	O
receptors	O
with	O
excessive	O
signal	O
transduction	O
activity	O
.	O

Although	O
in	O
vitro	O
assays	O
demonstrated	O
that	O
an	O
artificially	O
created	O
inactive	O
mutant	O
of	O
PROKR2	O
exerted	O
paradoxical	O
gain	O
-	O
of	O
-	O
function	O
effects	O
when	O
co	O
-	O
transfected	O
with	O
wild	O
-	O
type	O
proteins	O
,	O
such	O
a	O
phenomenon	O
has	O
not	O
been	O
observed	O
in	O
vivo	O
.	O

Here	O
,	O
we	O
report	O
a	O
heterozygous	O
frameshift	O
mutation	O
of	O
PROKR2	O
identified	O
in	O
a	O
3.5-year	O
-	O
old	O
girl	O
with	O
central	O
precocious	O
puberty	O
.	O

The	O
mutant	B-Var
mRNA	O
escaped	B-NegReg
nonsense	B-MPA
-	I-MPA
mediated	I-MPA
decay	I-MPA
and	O
generated	O
a	O
GPCR	O
lacking	B-NegReg
two	B-MPA
transmembrane	I-MPA
domains	I-MPA
and	O
the	O
carboxyl	O
-	O
terminal	O
tail	O
.	O

The	O
mutant	O
protein	O
had	O
no	O
in	O
vitro	O
signal	O
transduction	O
activity	O
;	O
however	O
,	O
cells	O
co	O
-	O
expressing	O
the	O
mutant	O
and	O
wild	O
-	O
type	O
PROKR2	O
exhibited	O
markedly	O
exaggerated	O
ligand	O
-	O
induced	O
Ca(2	O
+	O
)	O
responses	O
.	O

The	O
results	O
indicate	O
that	O
certain	O
inactive	O
PROKR2	B-Gene
mutants	B-Var
can	O
cause	O
early	O
puberty	O
by	O
enhancing	B-PosReg
the	O
functional	B-MPA
property	O
of	O
coexisting	O
wild	O
-	O
type	O
proteins	O
.	O

Considering	O
the	O
structural	O
similarity	O
among	O
GPCRs	O
,	O
this	O
paradoxical	O
gain	O
-	O
of	O
-	O
function	O
mechanism	O
may	O
underlie	O
various	O
human	O
disorders	O
.	O

The	O
Tension	O
-	O
sensitive	O
Ion	O
Transport	O
Activity	O
of	O
MSL8	O
is	O
Critical	O
for	O
its	O
Function	O
in	O
Pollen	O
Hydration	O
and	O
Germination	O
.	O

All	O
cells	O
respond	O
to	O
osmotic	O
challenges	O
,	O
including	O
those	O
imposed	O
during	O
normal	O
growth	O
and	O
development	O
.	O

Mechanosensitive	O
(	O
MS	O
)	O
ion	O
channels	O
provide	O
a	O
conserved	O
mechanism	O
for	O
regulating	O
osmotic	O
forces	O
by	O
conducting	O
ions	O
in	O
response	O
to	O
increased	O
membrane	O
tension	O
.	O

We	O
previously	O
demonstrated	O
that	O
the	O
MS	O
ion	O
channel	O
MscS	O
-	O
Like	O
8	O
(	O
MSL8	O
)	O
is	O
required	O
for	O
pollen	O
to	O
survive	O
multiple	O
osmotic	O
challenges	O
that	O
occur	O
during	O
the	O
normal	O
process	O
of	O
fertilization	O
,	O
and	O
that	O
it	O
can	O
inhibit	O
pollen	O
germination	O
.	O

However	O
,	O
it	O
remained	O
unclear	O
whether	O
these	O
physiological	O
functions	O
required	O
ion	O
flux	O
through	O
a	O
mechanically	O
gated	O
channel	O
provided	O
by	O
MSL8	O
.	O

We	O
introduced	O
two	O
point	O
mutations	B-Var
into	O
the	O
predicted	O
pore	O
-	O
lining	O
domain	O
of	O
MSL8	B-Gene
that	O
disrupted	B-NegReg
normal	B-MPA
channel	I-MPA
function	I-MPA
in	O
different	O
ways	O
.	O

The	O
Ile711Ser	B-Var
mutation	O
increased	B-PosReg
the	O
tension	B-MPA
threshold	I-MPA
of	O
the	O
MSL8	B-Gene
channel	O
while	O
leaving	B-Reg
conductance	B-MPA
unchanged	I-MPA
,	O
and	O
the	O
Phe720Leu	B-Var
mutation	I-Var
severely	O
disrupted	B-NegReg
the	O
MSL8	B-Gene
channel	B-Pathway
.	O

Both	O
of	O
these	O
mutations	B-Var
impaired	B-NegReg
the	O
ability	B-MPA
of	O
MSL8	O
to	O
preserve	O
pollen	O
viability	O
during	O
hydration	O
and	O
to	O
maintain	B-Reg
the	O
integrity	B-MPA
of	O
the	O
pollen	O
tube	O
when	O
expressed	O
at	O
endogenous	O
levels	O
.	O

When	O
overexpressed	O
in	O
an	O
msl8	O
-	O
4	O
null	O
background	O
,	O
MSL8I711S	O
could	O
partially	O
rescue	O
loss	O
-	O
of	O
-	O
function	O
phenotypes	O
,	O
while	O
MSL8F720L	O
could	O
not	O
.	O

When	O
overexpressed	O
in	O
the	O
wild	O
-	O
type	O
Ler	O
background	O
,	O
MSL8I711S	O
suppressed	O
pollen	O
germination	O
,	O
similar	O
to	O
wild	O
-	O
type	O
MSL8	O
.	O

In	O
contrast	O
,	O
MSL8F720L	O
failed	O
to	O
suppress	O
pollen	O
germination	O
and	O
increased	O
pollen	O
bursting	O
,	O
thereby	O
phenocopying	O
the	O
msl8	O
-	O
4	O
mutant	O
.	O

Thus	O
,	O
an	O
intact	O
MSL8	O
channel	O
is	O
required	O
for	O
normal	O
pollen	O
function	O
during	O
hydration	O
and	O
germination	O
.	O

These	O
data	O
establish	O
MSL8	O
as	O
the	O
first	O
plant	O
MS	O
channel	O
to	O
fulfill	O
previously	O
established	O
criteria	O
for	O
assignment	O
as	O
a	O
mechanotransducer	O
.	O

RACK1	O
cooperates	O
with	O
NRAS(Q61	O
K	O
)	O
to	O
promote	O
melanoma	O
in	O
vivo	O
.	O

Melanoma	O
is	O
the	O
deadliest	O
skin	O
cancer	O
.	O

RACK1	O
(	O
Receptor	O
for	O
activated	O
protein	O
kinase	O
C	O
)	O
protein	O
was	O
proposed	O
as	O
a	O
biological	O
marker	O
of	O
melanoma	O
in	O
human	O
and	O
domestic	O
animal	O
species	O
harboring	O
spontaneous	O
melanomas	O
.	O

As	O
a	O
scaffold	O
protein	O
,	O
RACK1	O
is	O
able	O
to	O
coordinate	O
the	O
interaction	O
of	O
key	O
signaling	O
molecules	O
implicated	O
in	O
both	O
physiological	O
cellular	O
functions	O
and	O
tumorigenesis	O
.	O

A	O
role	O
for	O
RACK1	O
in	O
rewiring	O
ERK	O
and	O
JNK	O
signaling	O
pathways	O
in	O
melanoma	O
cell	O
lines	O
had	O
been	O
proposed	O
.	O

Here	O
,	O
we	O
used	O
a	O
genetic	O
approach	O
to	O
test	O
this	O
hypothesis	O
in	O
vivo	O
in	O
the	O
mouse	O
.	O

We	O
show	O
that	O
Rack1	B-Gene
knock	B-Var
-	I-Var
down	I-Var
in	O
the	O
mouse	O
melanoma	O
cell	O
line	O
B16	O
reduces	B-NegReg
invasiveness	B-MPA
and	O
induces	B-Reg
cell	B-MPA
differentiation	I-MPA
.	O

We	O
have	O
developed	O
the	O
first	O
mouse	O
model	O
for	O
RACK1	O
gain	O
of	O
function	O
,	O
Tyr::Rack1-HA	O
transgenic	O
mice	O
,	O
targeting	O
RACK1	O
to	O
melanocytes	O
in	O
vivo	O
.	O

RACK1	O
overexpression	O
was	O
not	O
sufficient	O
to	O
initiate	O
melanomas	O
despite	O
activated	O
ERK	O
and	O
AKT	O
.	O

However	O
,	O
in	O
a	O
context	O
of	O
melanoma	O
predisposition	O
,	O
RACK1	O
overexpression	O
reduced	O
latency	O
and	O
increased	O
incidence	O
and	O
metastatic	O
rate	O
.	O

In	O
primary	O
melanoma	O
cells	O
from	O
Tyr::Rack1-HA	O
,	O
Tyr::NRas(Q61	O
K	O
)	O
mice	O
,	O
activated	O
JNK	O
(	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
)	O
and	O
activated	O
STAT3	O
(	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
)	O
acted	O
as	O
RACK1	O
oncogenic	O
partners	O
in	O
tumoral	O
progression	O
.	O

A	O
sequential	O
and	O
coordinated	O
activation	O
of	O
ERK	O
,	O
JNK	O
and	O
STAT3	O
with	O
RACK1	O
is	O
shown	O
to	O
accelerate	O
aggressive	O
melanoma	O
development	O
in	O
vivo	O
.	O

Identification	O
and	O
characterization	O
of	O
a	O
novel	O
DGAT1	O
missense	O
mutation	O
associated	O
with	O
congenital	O
diarrhea	O
.	O

Acyl	O
-	O
CoA	O
:	O
diacylglycerol	O
acyltransferase	O
(	O
DGAT)1	O
and	O
DGAT2	O
catalyze	O
triglyceride	O
(	O
TG	O
)	O
biosynthesis	O
in	O
humans	O
.	O

Biallelic	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
human	O
DGAT1	B-Gene
result	O
in	O
severe	O
congenital	B-Disease
diarrhea	I-Disease
and	O
protein	B-Disease
-	I-Disease
losing	I-Disease
enteropathy	I-Disease
.	O

Additionally	O
,	O
pharmacologic	O
inhibition	O
of	O
DGAT1	O
led	O
to	O
dose	O
-	O
related	O
diarrhea	O
in	O
human	O
clinical	O
trials	O
.	O

Here	O
we	O
identify	O
a	O
previously	O
unknown	O
DGAT1	O
mutation	O
in	O
identical	O
twins	O
of	O
South	O
Asian	O
descent	O
.	O

These	O
male	O
patients	O
developed	O
watery	O
diarrhea	O
shortly	O
after	O
birth	O
,	O
with	O
protein	O
-	O
losing	O
enteropathy	O
and	O
failure	O
to	O
thrive	O
.	O

Exome	O
sequencing	O
revealed	O
a	O
homozygous	O
recessive	O
mutation	O
in	O
DGAT1	O
,	O
c.314T	O
>	O
C	O
,	O
p	O
.	O
L105P.	O
We	O
show	O
here	O
that	O
the	O
p	B-Var
.	I-Var
L105P	I-Var
DGAT1	B-Gene
enzyme	O
produced	O
from	O
the	O
mutant	B-Var
allele	O
is	O
less	B-NegReg
abundant	O
,	O
resulting	O
in	O
partial	O
loss	B-NegReg
of	O
TG	B-MPA
synthesis	I-MPA
activity	I-MPA
and	O
decreased	B-NegReg
formation	B-MPA
of	I-MPA
lipid	I-MPA
droplets	I-MPA
in	O
patient	O
-	O
derived	O
primary	O
dermal	O
fibroblasts	O
.	O

Thus	O
,	O
in	O
contrast	O
with	O
complete	O
loss	O
-	O
of	O
-	O
function	O
alleles	O
of	O
DGAT1	O
,	O
the	O
p	B-Var
.	I-Var
L105P	I-Var
missense	I-Var
allele	O
partially	O
reduces	B-NegReg
TG	B-MPA
synthesis	I-MPA
activity	I-MPA
and	O
causes	B-Reg
a	O
less	B-MPA
severe	I-MPA
clinical	I-MPA
phenotype	I-MPA
.	O

Our	O
findings	O
add	O
to	O
the	O
growing	O
recognition	O
of	O
DGAT1	B-Gene
deficiency	B-Var
as	O
a	O
cause	B-Reg
of	O
congenital	B-Disease
diarrhea	I-Disease
with	O
protein	B-Disease
-	I-Disease
losing	I-Disease
enteropathy	I-Disease
and	O
indicate	O
that	O
DGAT1	B-Gene
mutations	B-Var
result	B-Reg
in	I-Reg
a	O
spectrum	B-Disease
of	I-Disease
diseases	I-Disease
.	O

Control	O
of	O
Kir	O
channel	O
gating	O
by	O
cytoplasmic	O
domain	O
interface	O
interactions	O
.	O

Inward	O
rectifier	O
potassium	O
(	O
Kir	O
)	O
channels	O
are	O
expressed	O
in	O
almost	O
all	O
mammalian	O
tissues	O
and	O
play	O
critical	O
roles	O
in	O
the	O
control	O
of	O
excitability	O
.	O

Pancreatic	O
ATP	O
-	O
sensitive	O
K	O
(	O
KATP	O
)	O
channels	O
are	O
key	O
regulators	O
of	O
insulin	O
secretion	O
and	O
comprise	O
Kir6.2	O
subunits	O
coupled	O
to	O
sulfonylurea	O
receptors	O
.	O

Because	O
these	O
channels	O
are	O
reversibly	O
inhibited	O
by	O
cytoplasmic	O
ATP	O
,	O
they	O
link	O
cellular	O
metabolism	O
with	O
membrane	O
excitability	O
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
the	O
pore	O
-	O
forming	O
Kir6.2	B-Gene
subunit	O
cause	O
congenital	B-Disease
hyperinsulinism	I-Disease
as	O
a	O
result	O
of	O
diminished	B-NegReg
channel	B-MPA
activity	I-MPA
.	O

Here	O
,	O
we	O
show	O
that	O
several	O
disease	O
mutations	B-Var
,	O
which	O
disrupt	B-NegReg
intersubunit	B-CPA
salt	I-CPA
bridges	I-CPA
at	O
the	O
interface	O
of	O
the	O
cytoplasmic	O
domains	O
(	O
CD	O
-	O
I	O
)	O
of	O
adjacent	O
subunits	O
,	O
induce	O
loss	B-NegReg
of	O
channel	B-MPA
activity	I-MPA
via	O
a	O
novel	O
channel	O
behavior	O
:	O
after	O
ATP	O
removal	O
,	O
channels	O
open	O
but	O
then	O
rapidly	O
inactivate	O
.	O

Re	O
-	O
exposure	O
to	O
inhibitory	O
ATP	O
causes	O
recovery	O
from	O
this	O
inactivation	O
.	O

Inactivation	O
can	O
be	O
abolished	O
by	O
application	O
of	O
phosphatidylinositol-4,5-bisphosphate	O
(	O
PIP2	O
)	O
to	O
the	O
cytoplasmic	O
face	O
of	O
the	O
membrane	O
,	O
an	O
effect	O
that	O
can	O
be	O
explained	O
by	O
a	O
simple	O
kinetic	O
model	O
in	O
which	O
PIP2	O
binding	O
competes	O
with	O
the	O
inactivation	O
process	O
.	O

Kir2.1	O
channels	O
contain	O
homologous	O
salt	O
bridges	O
,	O
and	O
we	O
find	O
that	O
mutations	O
that	O
disrupt	O
CD	O
-	O
I	O
interactions	O
in	O
Kir2.1	O
also	O
reduce	O
channel	O
activity	O
and	O
PIP2	O
sensitivity	O
.	O

Kir2.1	O
channels	O
also	O
contain	O
an	O
additional	O
CD	O
-	O
I	O
salt	O
bridge	O
that	O
is	O
not	O
present	O
in	O
Kir6.2	O
channels	O
.	O

Introduction	O
of	O
this	O
salt	O
bridge	O
into	O
Kir6.2	O
partially	O
rescues	O
inactivating	O
mutants	O
from	O
the	O
phenotype	O
.	O

These	O
results	O
indicate	O
that	O
the	O
stability	O
of	O
the	O
intersubunit	O
CD	O
-	O
I	O
is	O
a	O
major	O
determinant	O
of	O
the	O
inactivation	O
process	O
in	O
Kir6.2	O
and	O
may	O
control	O
gating	O
in	O
other	O
Kir	O
channels	O
.	O

Patient	O
-	O
specific	O
induced	O
pluripotent	O
stem	O
cells	O
to	O
evaluate	O
the	O
pathophysiology	O
of	O
TRNT1-associated	O
Retinitis	O
pigmentosa	O
.	O

Retinitis	B-Disease
pigmentosa	I-Disease
(	O
RP	O
)	O
is	O
a	O
heterogeneous	O
group	O
of	O
monogenic	O
disorders	O
characterized	O
by	O
progressive	O
death	O
of	O
the	O
light	O
-	O
sensing	O
photoreceptor	O
cells	O
of	O
the	O
outer	O
neural	O
retina	O
.	O

We	O
recently	O
identified	O
novel	O
hypomorphic	O
mutations	B-Var
in	O
the	O
tRNA	O
Nucleotidyl	O
Transferase	O
,	O
CCA	O
-	O
Adding	O
1	O
(	B-Gene
TRNT1	I-Gene
)	I-Gene
gene	O
that	O
cause	B-Reg
early	O
-	O
onset	O
RP	B-Disease
.	O

To	O
model	O
this	O
disease	O
in	O
vitro	O
,	O
we	O
generated	O
patient	O
-	O
specific	O
iPSCs	O
and	O
iPSC	O
-	O
derived	O
retinal	O
organoids	O
from	O
dermal	O
fibroblasts	O
of	O
patients	O
with	O
molecularly	O
confirmed	O
TRNT1-associated	O
RP	O
.	O

Pluripotency	O
was	O
confirmed	O
using	O
rt	O
-	O
PCR	O
,	O
immunocytochemistry	O
,	O
and	O
a	O
TaqMan	O
Scorecard	O
Assay	O
.	O

Mutations	B-Var
in	O
TRNT1	B-Gene
caused	O
reduced	B-NegReg
levels	B-MPA
of	I-MPA
full	I-MPA
-	I-MPA
length	I-MPA
TRNT1	B-Gene
protein	B-Protein
and	O
expression	B-MPA
of	I-MPA
a	I-MPA
truncated	I-MPA
smaller	I-MPA
protein	B-Protein
in	O
both	O
patient	O
-	O
specific	O
iPSCs	O
and	O
iPSC	O
-	O
derived	O
retinal	O
organoids	O
.	O

Patient	O
-	O
specific	O
iPSCs	O
and	O
iPSC	O
-	O
derived	O
retinal	O
organoids	O
exhibited	O
a	O
deficit	O
in	O
autophagy	O
,	O
as	O
evidenced	O
by	O
aberrant	O
accumulation	O
of	O
LC3-II	O
and	O
elevated	O
levels	O
of	O
oxidative	O
stress	O
.	O

Autologous	O
stem	O
cell	O
-	O
based	O
disease	O
modeling	O
will	O
provide	O
a	O
platform	O
for	O
testing	O
multiple	O
avenues	O
of	O
treatment	O
in	O
patients	O
suffering	O
from	O
TRNT1-associated	O
RP	O
.	O

Gain	B-Var
-	I-Var
of	I-Var
-	I-Var
function	I-Var
p53	B-Gene
activates	B-PosReg
multiple	O
signaling	B-Pathway
pathways	I-Pathway
to	O
induce	B-PosReg
oncogenicity	B-CPA
in	O
lung	B-Disease
cancer	I-Disease
cells	O
.	O

Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
mutants	B-Var
of	O
p53	B-Gene
upregulate	B-PosReg
genes	B-Gene
implicated	B-Reg
in	O
cell	B-CPA
proliferation	I-CPA
and	O
oncogenesis	B-CPA
.	O

Here	O
,	O
we	O
report	O
that	O
GOF	B-Var
p53	B-Gene
induces	O
tumorigenicity	O
through	O
simultaneous	O
activation	B-PosReg
of	O
key	B-Pathway
oncogenic	I-Pathway
pathways	I-Pathway
including	O
those	O
controlling	O
putative	O
tumor	O
-	O
initiating	O
cell	O
functions	O
.	O

We	O
determined	O
that	O
in	O
cells	O
expressing	O
p53-R273H	B-Gene
,	O
GOF	O
p53	O
simultaneously	O
upregulates	B-PosReg
genes	O
from	O
multiple	B-Pathway
signaling	I-Pathway
pathways	I-Pathway
by	O
recognizing	O
promoters	O
containing	O
distinct	O
transcription	O
factor	O
(	O
TF	O
)	O
binding	O
sites	O
.	O

Our	O
analytical	O
data	O
support	O
a	O
model	O
in	O
which	O
GOF	B-Var
p53	B-Gene
complexes	O
with	O
two	O
TFs	O
on	O
the	O
promoter	O
-	O
a	O
mediator	O
protein	O
,	O
Med17	O
,	O
and	O
a	O
histone	O
acetyl	O
transferase	O
,	O
activating	B-PosReg
histone	B-MPA
acetylation	I-MPA
-	I-MPA
and	I-MPA
enhances	B-PosReg
gene	B-MPA
expression	I-MPA
to	O
signal	O
cell	O
proliferation	O
and	O
oncogenesis	O
.	O

Thus	O
,	O
therapeutic	O
inhibition	O
of	O
one	O
GOF	O
p53-induced	O
pathway	O
would	O
be	O
insufficient	O
to	O
prevent	O
tumor	O
growth	O
as	O
the	O
oncoprotein	O
activates	O
a	O
multitude	O
of	O
parallel	O
pathways	O
.	O

This	O
discovery	O
suggests	O
enormous	O
selection	O
advantage	O
for	O
cancer	O
cells	O
with	O
GOF	O
p53	O
to	O
induce	O
oncogenic	O
growth	O
,	O
highlighting	O
the	O
problems	O
of	O
cancer	O
therapy	O
.	O

Hand	O
eczema	O
,	O
atopic	O
dermatitis	O
and	O
filaggrin	O
mutations	O
in	O
adult	O
Danes	O
:	O
a	O
registry	O
-	O
based	O
study	O
assessing	O
risk	O
of	O
disability	O
pension	O
.	O

BACKGROUND	O
:	O
Atopic	O
dermatitis	O
and	O
hand	O
eczema	O
often	O
impair	O
the	O
ability	O
of	O
people	O
to	O
work	O
.	O

Only	O
a	O
few	O
studies	O
have	O
investigated	O
whether	O
individuals	O
with	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
filaggrin	O
gene	O
(	B-Gene
FLG	I-Gene
)	I-Gene
mutations	B-Var
,	O
who	O
often	O
have	O
severe	O
and	O
early	O
onset	O
of	O
dermatitis	B-Disease
,	O
experience	O
occupational	O
consequences	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
personal	O
consequences	O
of	O
having	O
atopic	O
dermatitis	O
and/or	O
hand	O
eczema	O
and	O
FLG	O
mutations	O
.	O

METHOD	O
:	O
Adult	O
Danes	O
from	O
the	O
general	O
population	O
(	O
n	O
=	O
3247	O
)	O
and	O
patients	O
with	O
atopic	O
dermatitis	O
and/or	O
hand	O
eczema	O
(	O
n	O
=	O
496	O
)	O
were	O
genotyped	O
for	O
common	O
FLG	O
mutations	O
,	O
and	O
completed	O
a	O
questionnaire	O
about	O
skin	O
symptoms	O
and	O
hand	O
eczema	O
.	O

Socioeconomic	O
variables	O
,	O
including	O
disability	O
pension	O
,	O
and	O
information	O
on	O
work	O
in	O
risk	O
occupations	O
were	O
retrieved	O
from	O
national	O
registries	O
.	O

The	O
reasons	O
for	O
granting	O
disability	O
pension	O
were	O
unknown	O
.	O

RESULTS	O
:	O
Disability	O
pension	O
was	O
associated	O
with	O
hand	O
eczema	O
in	O
the	O
general	O
population	O
,	O
especially	O
among	O
individuals	O
with	O
a	O
history	O
of	O
atopic	O
dermatitis	O
.	O

Moreover	O
,	O
self	O
-	O
reported	O
hand	O
eczema	O
and	O
atopic	O
dermatitis	O
were	O
associated	O
with	O
particularly	O
high	O
risk	O
of	O
disability	O
pension	O
among	O
FLG	O
mutation	O
carriers	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
4.02	O
and	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
1.15	O
-	O
14.11	O
;	O
and	O
OR	O
6.01	O
and	O
95%CI	O
:	O
2.37	O
-	O
15.34	O
,	O
respectively	O
]	O
.	O

Furthermore	O
,	O
60	O
%	O
of	O
the	O
FLG	O
mutation	O
carriers	O
with	O
atopic	O
dermatitis	O
who	O
developed	O
hand	O
eczema	O
had	O
experienced	O
symptoms	O
before	O
adulthood	O
.	O

CONCLUSION	O
:	O
In	O
the	O
general	O
population	O
,	O
self	O
-	O
reported	O
hand	O
eczema	O
and	O
atopic	O
dermatitis	O
,	O
particularly	O
in	O
individuals	O
with	O
a	O
genetically	O
impaired	O
skin	O
barrier	O
,	O
were	O
associated	O
with	O
disability	O
pension	O
,	O
suggesting	O
that	O
FLG	B-Gene
mutations	B-Var
carriers	B-Reg
with	I-Reg
a	O
history	O
of	O
atopic	B-Disease
dermatitis	I-Disease
and	O
hand	B-Disease
eczema	I-Disease
could	O
benefit	O
from	O
early	O
attention	O
with	O
respect	O
to	O
choice	O
of	O
occupation	O
.	O

Hydrocephalus	B-Disease
due	O
to	O
multiple	O
ependymal	O
malformations	O
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
MPDZ	B-Gene
gene	O
.	O

Congenital	O
hydrocephalus	O
is	O
considered	O
as	O
either	O
acquired	O
due	O
to	O
haemorrhage	O
,	O
infection	O
or	O
neoplasia	O
or	O
as	O
of	O
developmental	O
nature	O
and	O
is	O
divided	O
into	O
two	O
subgroups	O
,	O
communicating	O
and	O
obstructive	O
.	O

Congenital	O
hydrocephalus	O
is	O
either	O
syndromic	O
or	O
non	O
-	O
syndromic	O
,	O
and	O
in	O
the	O
latter	O
no	O
cause	O
is	O
found	O
in	O
more	O
than	O
half	O
of	O
the	O
patients	O
.	O

In	O
patients	O
with	O
isolated	B-Disease
hydrocephalus	I-Disease
,	O
L1CAM	B-Gene
mutations	B-Var
represent	O
the	O
most	O
common	B-Reg
aetiology	O
.	O

More	O
recently	O
,	O
a	O
founder	O
mutation	O
has	O
also	O
been	O
reported	O
in	O
the	O
MPDZ	O
gene	O
in	O
foetuses	O
presenting	O
massive	O
hydrocephalus	O
,	O
but	O
the	O
neuropathology	O
remains	O
unknown	O
.	O

We	O
describe	O
here	O
three	O
novel	O
homozygous	O
null	O
mutations	O
in	O
the	O
MPDZ	O
gene	O
in	O
foetuses	O
whose	O
post	O
-	O
mortem	O
examination	O
has	O
revealed	O
a	O
homogeneous	O
phenotype	O
characterized	O
by	O
multiple	O
ependymal	O
malformations	O
along	O
the	O
aqueduct	O
of	O
Sylvius	O
,	O
the	O
third	O
and	O
fourth	O
ventricles	O
as	O
well	O
as	O
the	O
central	O
canal	O
of	O
the	O
medulla	O
,	O
consisting	O
in	O
multifocal	O
rosettes	O
with	O
immature	O
cell	O
accumulation	O
in	O
the	O
vicinity	O
of	O
ependymal	O
lining	O
early	O
detached	O
from	O
the	O
ventricular	O
zone	O
.	O

MPDZ	O
also	O
named	O
MUPP1	O
is	O
an	O
essential	O
component	O
of	O
tight	O
junctions	O
which	O
are	O
expressed	O
from	O
early	O
brain	O
development	O
in	O
the	O
choroid	O
plexuses	O
and	O
ependyma	O
.	O

Alterations	O
in	O
the	O
formation	O
of	O
tight	O
junctions	O
within	O
the	O
ependyma	O
very	O
likely	O
account	O
for	O
the	O
lesions	O
observed	O
and	O
highlight	O
for	O
the	O
first	O
time	O
that	O
primary	O
multifocal	O
ependymal	O
malformations	O
of	O
the	O
ventricular	O
system	O
is	O
genetically	O
determined	O
in	O
humans	O
.	O

Therefore	O
,	O
MPDZ	O
sequencing	O
should	O
be	O
performed	O
when	O
neuropathological	O
examination	O
reveals	O
multifocal	O
ependymal	O
rosette	O
formation	O
within	O
the	O
aqueduct	O
of	O
Sylvius	O
,	O
of	O
the	O
third	O
and	O
fourth	O
ventricles	O
and	O
of	O
the	O
central	O
canal	O
of	O
the	O
medulla	O
.	O

Short	O
hairpin	O
RNA	O
is	O
more	O
effective	O
than	O
long	O
hairpin	O
RNA	O
in	O
eliciting	O
pointed	O
loss	O
-	O
of	O
-	O
function	O
phenotypes	O
in	O
Drosophila	O
.	O

Pointed	O
(	O
Pnt	O
)	O
is	O
a	O
transcriptional	O
activator	O
that	O
functions	O
downstream	O
of	O
the	O
highly	O
conserved	O
Receptor	O
Tyrosine	O
Kinase	O
(	O
RTK	O
)	O
signaling	O
pathway	O
.	O

Pnt	O
is	O
an	O
ETS	O
family	O
transcription	O
factor	O
and	O
encodes	O
for	O
two	O
proteins	O
,	O
PntP1	O
and	O
PntP2	O
.	O

However	O
,	O
while	O
PntP1	O
is	O
constitutively	O
active	O
,	O
PntP2	O
is	O
only	O
active	O
after	O
being	O
phosphorylated	O
by	O
MAPK	O
in	O
the	O
RTK	O
pathway	O
.	O

As	O
mutations	B-Var
in	O
pnt	B-Gene
perturb	B-Reg
the	O
development	B-CPA
of	I-CPA
several	I-CPA
tissues	I-CPA
,	O
we	O
wanted	O
to	O
examine	O
the	O
effect	O
and	O
efficacy	O
of	O
using	O
RNAi	O
to	O
target	O
Pnt	O
.	O

We	O
have	O
expressed	O
pnt	O
RNAi	O
in	O
the	O
eyes	O
,	O
oocyte	O
,	O
and	O
heart	O
cells	O
using	O
three	O
different	O
RNAi	O
lines	O
:	O
Valium20	O
,	O
Valium10	O
,	O
and	O
VDRC	O
.	O

Valium20	O
is	O
distinct	O
since	O
it	O
generates	O
a	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
,	O
while	O
Valium10	O
and	O
VDRC	O
produce	O
long	O
hairpin	O
dsRNA	O
.	O

We	O
found	O
that	O
for	O
each	O
tissue	O
examined	O
Valium20	O
exhibited	O
the	O
strongest	O
phenotype	O
while	O
the	O
Valium10	O
and	O
VDRC	O
lines	O
produced	O
varying	O
levels	O
of	O
severity	O
and	O
that	O
the	O
long	O
hairpin	O
RNA	O
produced	O
by	O
the	O
Valium10	O
and	O
VDRC	O
lines	O
are	O
unable	O
to	O
effectively	O
knockdown	O
pnt	O
in	O
embryonic	O
tissues	O
.	O

New	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	B-Var
shows	O
CACNA1D	B-Gene
as	O
recurrently	O
mutated	O
gene	O
in	O
autism	B-Disease
spectrum	I-Disease
disorders	I-Disease
and	O
epilepsy	B-Disease
.	O

CACNA1D	O
encodes	O
the	O
pore	O
-	O
forming	O
α1-subunit	O
of	O
Cav1.3	O
,	O
an	O
L	O
-	O
type	O
voltage	O
-	O
gated	O
Ca2	O
+	O
-channel	O
.	O

Despite	O
the	O
recent	O
discovery	O
of	O
two	O
de	O
novo	O
missense	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
in	O
Cav1.3	O
in	O
two	O
individuals	O
with	O
autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
and	O
intellectual	O
disability	O
CACNA1D	O
has	O
not	O
been	O
considered	O
a	O
prominent	O
ASD	O
-	O
risk	O
gene	O
in	O
large	O
scale	O
genetic	O
analyses	O
,	O
since	O
such	O
studies	O
primarly	O
focus	O
on	O
likely	O
-	O
disruptive	O
genetic	O
variants	O
.	O

Here	O
we	O
report	O
the	O
discovery	O
and	O
characterization	O
of	O
a	O
third	O
de	O
novo	O
missense	O
mutation	O
in	O
CACNA1D	O
(	O
V401L	O
)	O
in	O
a	O
patient	O
with	O
ASD	O
and	O
epilepsy	O
.	O

For	O
the	O
functional	O
characterization	O
we	O
introduced	O
mutation	O
V401L	O
into	O
two	O
major	O
C	O
-	O
terminal	O
long	O
and	O
short	O
Cav1.3	O
splice	O
variants	O
,	O
expressed	O
wild	O
-	O
type	O
or	O
mutant	O
channel	O
complexes	O
in	O
tsA-201	O
cells	O
and	O
performed	O
whole	O
-	O
cell	O
patch	O
-	O
clamp	O
recordings	O
.	O

Mutation	O
V401L	B-Var
,	O
localized	O
within	O
the	O
channel	O
's	O
activation	O
gate	O
,	O
significantly	O
enhanced	B-PosReg
current	B-MPA
densities	I-MPA
,	O
shifted	O
voltage	O
dependence	O
of	O
activation	O
and	O
inactivation	O
to	O
more	O
negative	O
voltages	O
and	O
reduced	O
channel	O
inactivation	O
in	O
both	O
Cav1.3	O
splice	O
variants	O
.	O

Altogether	O
these	O
gating	O
changes	B-Var
are	O
expected	O
to	O
result	O
in	O
enhanced	B-PosReg
Ca2	B-MPA
+	I-MPA
-influx	I-MPA
through	I-MPA
the	I-MPA
channel	I-MPA
,	O
thus	O
representing	O
a	O
strong	O
gain	O
-	O
of	O
-	O
function	O
phenotype	O
.	O

Additionally	O
,	O
we	O
also	O
found	O
that	O
mutant	O
channels	O
retained	O
full	O
sensitivity	O
towards	O
the	O
clinically	O
available	O
Ca2	O
+	O
-channel	O
blocker	O
isradipine	O
.	O

Our	O
findings	O
strengthen	O
the	O
evidence	O
for	O
CACNA1D	O
as	O
a	O
novel	O
candidate	O
autism	O
risk	O
gene	O
and	O
encourage	O
experimental	O
therapy	O
with	O
available	O
channel	O
-	O
blockers	O
for	O
this	O
mutation	O
.	O

The	O
additional	O
presence	O
of	O
seizures	O
and	O
neurological	O
abnormalities	O
in	O
our	O
patient	O
define	O
a	O
novel	O
phenotype	O
partially	O
overlapping	O
with	O
symptoms	O
in	O
two	O
individuals	O
with	O
PASNA	O
(	O
congential	O
primary	O
aldosteronism	O
,	O
seizures	O
and	O
neurological	O
abnormalities	O
)	O
caused	O
by	O
similar	O
Cav1.3	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
.	O

ATM	O
Gene	O
Mutation	O
Detection	O
Techniques	O
and	O
Functional	O
Analysis	O
.	O

Ataxia	B-Disease
Telangiectasia	I-Disease
(	O
A	O
-	O
T	O
)	O
is	O
caused	O
by	O
biallelic	O
inactivation	B-NegReg
of	O
the	O
Ataxia	O
Telangiectasia	O
Mutated	O
(	B-Gene
ATM	I-Gene
)	I-Gene
gene	O
,	O
due	O
to	O
nonsense	B-Var
or	I-Var
missense	I-Var
mutations	I-Var
,	O
small	O
insertions	O
/	O
deletions	O
(	B-Var
indels	I-Var
)	I-Var
,	O
splicing	B-Var
alterations	I-Var
,	O
and	O
large	B-Var
genomic	I-Var
rearrangements	I-Var
.	O

After	O
establishing	O
A	O
-	O
T	O
clinical	O
diagnosis	O
,	O
a	O
molecular	O
confirmation	O
is	O
needed	O
,	O
based	O
on	O
the	O
detection	O
of	O
one	O
of	O
these	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
at	O
least	O
one	O
allele	O
.	O

In	O
most	O
cases	O
,	O
the	O
pathogenicity	O
of	O
the	O
detected	O
mutations	O
is	O
sufficient	O
to	O
make	O
a	O
definitive	O
diagnosis	O
.	O

More	O
rarely	O
,	O
mutations	O
of	O
unknown	O
consequences	O
are	O
identified	O
and	O
direct	O
biological	O
analyses	O
are	O
required	O
to	O
establish	O
their	O
pathogenic	O
characters	O
.	O

In	O
such	O
cases	O
,	O
complementary	O
analyses	O
of	O
ATM	O
expression	O
,	O
localization	O
,	O
and	O
activity	O
allow	O
fine	O
characterization	O
of	O
these	O
mutations	O
and	O
facilitate	O
A	O
-	O
T	O
diagnosis	O
.	O

Here	O
,	O
we	O
present	O
genetic	O
and	O
biochemical	O
protocols	O
currently	O
used	O
in	O
the	O
laboratory	O
that	O
have	O
proven	O
to	O
be	O
highly	O
accurate	O
,	O
reproducible	O
,	O
and	O
quantitative	O
.	O

We	O
also	O
provide	O
additional	O
discussion	O
on	O
the	O
critical	O
points	O
of	O
the	O
techniques	O
presented	O
here	O
.	O

Proteomic	O
analysis	O
of	O
filaggrin	O
deficiency	O
identifies	O
molecular	O
signatures	O
characteristic	O
of	O
atopic	O
eczema	O
.	O

BACKGROUND	O
:	O
Atopic	B-Disease
eczema	I-Disease
(	O
AE	O
)	O
is	O
characterized	O
by	O
skin	O
barrier	O
and	O
immune	O
dysfunction	O
.	O

Null	B-Var
mutations	I-Var
in	O
filaggrin	O
(	B-Gene
FLG	I-Gene
)	I-Gene
,	O
a	O
key	O
epidermal	O
barrier	O
protein	O
,	O
strongly	O
predispose	B-Reg
to	O
AE	B-Disease
;	I-Disease
however	O
,	O
the	O
precise	O
role	O
of	O
FLG	O
deficiency	O
in	O
AE	O
pathogenesis	O
remains	O
incompletely	O
understood	O
.	O

OBJECTIVES	O
:	O
We	O
sought	O
to	O
identify	O
global	O
proteomic	O
changes	O
downstream	O
of	O
FLG	O
deficiency	O
in	O
human	O
epidermal	O
living	O
skin	O
-	O
equivalent	O
(	O
LSE	O
)	O
models	O
and	O
validate	O
findings	O
in	O
skin	O
of	O
patients	O
with	O
AE	O
.	O

METHODS	O
:	O
Differentially	O
expressed	O
proteins	O
from	O
paired	O
control	O
(	O
nontargeting	O
control	O
short	O
hairpin	O
RNA	O
[	O
shNT	O
]	O
)	O
and	O
FLG	O
knockdown	O
(	O
FLG	O
knockdown	O
short	O
hairpin	O
RNA	O
[	O
shFLG	O
]	O
)	O
LSEs	O
were	O
identified	O
by	O
means	O
of	O
proteomic	O
analysis	O
(	O
liquid	O
chromatography	O
-	O
mass	O
spectrometry	O
)	O
and	O
Ingenuity	O
Pathway	O
Analysis	O
.	O

Expression	O
of	O
key	O
targets	O
was	O
validated	O
in	O
independent	O
LSE	O
samples	O
(	O
quantitative	O
RT	O
-	O
PCR	O
and	O
Western	O
blotting	O
)	O
and	O
in	O
normal	O
and	O
AE	O
skin	O
biopsy	O
specimens	O
(	O
immunofluorescence	O
)	O
.	O

RESULTS	O
:	O
Proteomic	O
analysis	O
identified	O
17	O
(	O
P	O
≤	O
.05	O
)	O
differentially	O
expressed	O
proteins	O
after	O
FLG	O
knockdown	O
,	O
including	O
kallikrein-7	O
(	O
KLK7	O
;	O
2.2-fold	O
)	O
,	O
cyclophilin	O
A	O
(	O
PPIA	O
;	O
0.9-fold	O
)	O
,	O
and	O
cofilin-1	O
(	O
CFL1	O
,	O
1.3-fold	O
)	O
.	O

Differential	O
protein	O
expression	O
was	O
confirmed	O
in	O
shNT	O
/	O
shFLG	O
LSEs	O
;	O
however	O
,	O
only	O
KLK7	O
was	O
transcriptionally	O
dysregulated	O
.	O

Molecular	B-Pathway
pathways	I-Pathway
overrepresented	B-PosReg
after	O
FLG	B-Gene
knockdown	B-Var
included	O
inflammation	O
,	O
protease	O
activity	O
,	O
cell	O
structure	O
,	O
and	O
stress	O
.	O

Furthermore	O
,	O
KLK7	O
(	O
1.8-fold	O
)	O
and	O
PPIA	O
(	O
0.65-fold	O
)	O
proteins	O
were	O
differentially	O
expressed	O
in	O
lesional	O
biopsy	O
specimens	O
from	O
patients	O
with	O
AE	O
relative	O
to	O
normal	O
skin	O
.	O

CONCLUSIONS	O
:	O
For	O
the	O
first	O
time	O
,	O
we	O
show	O
that	O
loss	B-Var
of	O
FLG	B-Gene
in	O
the	O
absence	O
of	O
inflammation	O
is	O
sufficient	O
to	O
alter	B-Reg
the	O
expression	B-MPA
level	I-MPA
of	I-MPA
proteins	I-MPA
relevant	O
to	O
the	O
pathogenesis	O
of	O
AE	O
.	O

These	O
include	O
proteins	O
regulating	O
inflammatory	O
,	O
proteolytic	O
,	O
and	O
cytoskeletal	O
functions	O
.	O

We	O
identify	O
PPIA	O
as	O
a	O
novel	O
protein	O
with	O
levels	O
that	O
are	O
decreased	O
in	O
clinically	O
active	O
AE	O
skin	O
and	O
show	O
that	O
the	O
characteristic	O
upregulation	O
of	O
KLK7	O
expression	O
in	O
patients	O
with	O
AE	O
occurs	O
downstream	O
of	O
FLG	O
loss	O
.	O

Importantly	O
,	O
we	O
highlight	O
disconnect	O
between	O
the	O
epidermal	O
proteome	O
and	O
transcriptome	O
,	O
emphasizing	O
the	O
utility	O
of	O
global	O
proteomic	O
studies	O
.	O

TREM2	O
deficiency	O
impairs	O
chemotaxis	O
and	O
microglial	O
responses	O
to	O
neuronal	O
injury	O
.	O

Sequence	O
variations	B-Var
in	O
the	O
triggering	O
receptor	O
expressed	O
on	O
myeloid	O
cells	O
2	O
(	B-Gene
TREM2	I-Gene
)	I-Gene
have	O
been	O
linked	B-Reg
to	I-Reg
an	O
increased	O
risk	O
for	O
neurodegenerative	O
disorders	O
such	O
as	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
and	O
frontotemporal	B-Disease
lobar	I-Disease
degeneration	I-Disease
.	O

In	O
the	O
brain	O
,	O
TREM2	O
is	O
predominantly	O
expressed	O
in	O
microglia	O
.	O

Several	O
disease	O
-	O
associated	O
TREM2	B-Gene
variants	B-Var
result	O
in	O
a	O
loss	O
of	O
function	O
by	O
reducing	B-NegReg
microglial	B-CPA
phagocytosis	I-CPA
,	O
impairing	B-NegReg
lipid	B-MPA
sensing	I-MPA
,	O
preventing	B-NegReg
binding	B-Interaction
of	O
lipoproteins	B-Protein
and	O
affecting	B-Reg
shielding	B-MPA
of	I-MPA
amyloid	I-MPA
plaques	I-MPA
.	O

We	O
here	O
investigate	O
the	O
consequences	O
of	O
TREM2	O
loss	O
of	O
function	O
on	O
the	O
microglia	O
transcriptome	O
.	O

Among	O
the	O
differentially	O
expressed	O
messenger	O
RNAs	O
in	O
wild	O
-	O
type	O
and	O
Trem2(-/-	O
)	O
microglia	O
,	O
gene	O
clusters	O
are	O
identified	O
which	O
represent	O
gene	O
functions	O
in	O
chemotaxis	O
,	O
migration	O
and	O
mobility	O
.	O

Functional	O
analyses	O
confirm	O
that	O
loss	B-Var
of	O
TREM2	B-Gene
impairs	B-NegReg
appropriate	O
microglial	B-CPA
responses	I-CPA
to	I-CPA
injury	I-CPA
and	I-CPA
signals	I-CPA
that	O
normally	O
evoke	O
chemotaxis	O
on	O
multiple	O
levels	O
.	O

In	O
an	O
ex	O
vivo	O
organotypic	O
brain	O
slice	O
assay	O
,	O
absence	O
of	O
TREM2	O
reduces	O
the	O
distance	O
migrated	O
by	O
microglia	O
.	O

Moreover	O
,	O
migration	O
towards	O
defined	O
chemo	O
-	O
attractants	O
is	O
reduced	O
upon	O
ablation	O
of	O
TREM2	O
and	O
can	O
be	O
rescued	O
by	O
TREM2	O
re	O
-	O
expression	O
.	O

In	O
vivo	O
,	O
microglia	O
lacking	O
TREM2	O
migrate	O
less	O
towards	O
injected	O
apoptotic	O
neurons	O
,	O
and	O
outgrowth	O
of	O
microglial	O
processes	O
towards	O
sites	O
of	O
laser	O
-	O
induced	O
focal	O
CNS	O
damage	O
in	O
the	O
somatosensory	O
cortex	O
is	O
slowed	O
.	O

The	O
apparent	O
lack	O
of	O
chemotactic	O
stimulation	O
upon	O
depletion	O
of	O
TREM2	O
is	O
consistent	O
with	O
a	O
stable	O
expression	O
profile	O
of	O
genes	O
characterizing	O
the	O
homoeostatic	O
signature	O
of	O
microglia	O
.	O

Novel	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
mutation	B-Var
in	O
KRIT1	B-Gene
/	I-Gene
CCM1	I-Gene
is	O
associated	B-Reg
with	I-Reg
distinctly	O
progressive	O
cerebral	B-Disease
and	I-Disease
spinal	I-Disease
cavernous	I-Disease
malformations	I-Disease
after	O
radiochemotherapy	O
for	O
intracranial	O
malignant	O
germ	O
cell	O
tumor	O
.	O

PURPOSE	O
:	O
Cerebrospinal	B-Disease
cavernous	I-Disease
malformations	I-Disease
(	O
CCMs	O
)	O
are	O
vascular	O
lesions	O
characterized	O
by	O
dilated	O
and	O
leaky	O
capillary	O
caverns	O
.	O

CCMs	O
can	O
cause	O
seizures	O
,	O
focal	O
neurological	O
deficits	O
or	O
acute	O
intracranial	O
hemorrhage	O
;	O
however	O
,	O
most	O
patients	O
are	O
asymptomatic	O
.	O

CCMs	O
occur	O
either	O
sporadically	O
or	O
as	O
a	O
familial	O
autosomal	O
-	O
dominant	O
disorder	O
.	O

We	O
present	O
a	O
clinical	O
and	O
molecular	O
study	O
of	O
a	O
patient	O
with	O
distinctive	O
cerebral	O
and	O
spinal	O
cavernous	O
malformations	O
following	O
radiochemotherapy	O
for	O
a	O
malignant	O
brain	O
tumor	O
.	O

METHODS	O
:	O
The	O
patient	O
had	O
multiple	O
magnet	O
resonance	O
imaging	O
(	O
MRI	O
)	O
examinations	O
of	O
his	O
brain	O
and	O
spine	O
following	O
radiochemotherapy	O
for	O
a	O
primary	O
intracranial	O
germ	O
cell	O
tumor	O
(	O
GCT	O
)	O
,	O
as	O
part	O
of	O
his	O
oncologic	O
follow	O
-	O
up	O
.	O

The	O
MRI	O
sequences	O
included	O
susceptibility	O
-	O
weighted	O
imaging	O
(	O
SWI	O
)	O
.	O

The	O
coding	O
exons	O
and	O
their	O
flanking	O
intronic	O
regions	O
of	O
KRIT1	O
/	O
CCM1	O
gene	O
were	O
analyzed	O
for	O
mutations	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
direct	O
sequencing	O
.	O

RESULTS	O
:	O
MRI	O
revealed	O
numerous	O
cerebral	O
and	O
spinal	O
microhemorrhages	O
and	O
pronounced	O
cavernous	O
malformations	O
that	O
progressed	O
with	O
subsequent	O
follow	O
-	O
up	O
imaging	O
.	O

Genetic	O
analysis	O
demonstrated	O
a	O
novel	O
heterozygous	O
KRIT1	B-Gene
/	I-Gene
CCM1	I-Gene
two	O
base	O
pair	O
deletion	O
(	B-Var
c.1535_1536delTG	I-Var
)	I-Var
in	O
exon	O
14	O
.	O

This	O
deletion	O
leads	B-Reg
to	I-Reg
a	O
frameshift	B-Var
with	O
a	O
premature	B-MPA
stop	I-MPA
codon	I-MPA
at	O
nucleotide	O
position	O
1553	O
and	O
a	O
highly	O
likely	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
of	O
the	O
KRIT1	B-Protein
protein	I-Protein
.	O

CONCLUSION	O
:	O
We	O
describe	O
a	O
patient	O
with	O
a	O
novel	O
heterozygous	O
germ	O
line	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
mutation	B-Var
in	O
KRIT1	B-Gene
,	O
which	O
is	O
associated	B-Reg
with	I-Reg
rapid	O
-	O
onset	O
and	O
highly	O
progressive	O
CCMs	B-Disease
after	O
radiochemotherapy	O
for	O
a	O
malignant	O
brain	O
tumor	O
.	O

Real	O
-	O
World	O
Data	O
on	O
Prognostic	O
Factors	O
for	O
Overall	O
Survival	O
in	O
EGFR	B-Gene
Mutation	B-Var
-	I-Var
Positive	I-Var
Advanced	O
Non	B-Disease
-	I-Disease
Small	I-Disease
Cell	I-Disease
Lung	I-Disease
Cancer	I-Disease
Patients	O
Treated	O
with	O
First	O
-	O
Line	O
Gefitinib	O
.	O

BACKGROUND	O
:	O
This	O
study	O
aimed	O
to	O
identify	O
independent	O
prognostic	O
factors	O
for	O
overall	O
survival	O
(	O
OS	O
)	O
of	O
patients	O
with	O
advanced	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
harboring	O
an	O
activating	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
mutation	O
and	O
receiving	O
gefitinib	O
as	O
first	O
-	O
line	O
treatment	O
in	O
real	O
-	O
world	O
practice	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
enrolled	O
226	O
patients	O
from	O
June	O
2011	O
to	O
May	O
2013	O
.	O

During	O
this	O
period	O
,	O
gefitinib	O
was	O
the	O
only	O
EGFR	O
-	O
tyrosine	O
kinase	O
inhibitor	O
reimbursed	O
by	O
the	O
Bureau	O
of	O
National	O
Health	O
Insurance	O
of	O
Taiwan	O
.	O

RESULTS	O
:	O
The	O
median	O
progression	O
-	O
free	O
survival	O
and	O
median	O
OS	O
were	O
11.9	O
months	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
9.7	O
-	O
14.2	O
)	O
and	O
26.9	O
months	O
(	O
21.2	O
-	O
32.5	O
)	O
,	O
respectively	O
.	O

The	O
Cox	O
proportional	O
hazards	O
regression	O
model	O
revealed	O
that	O
postoperative	O
recurrence	O
,	O
performance	O
status	O
(	O
Eastern	O
Cooperative	O
Oncology	O
Grade	O
[	O
ECOG	O
]	O
≥2	O
)	O
,	O
smoking	O
index	O
(	O
≥20	O
pack	O
-	O
years	O
)	O
,	O
liver	O
metastasis	O
at	O
initial	O
diagnosis	O
,	O
and	O
chronic	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
infection	O
were	O
independent	O
prognostic	O
factors	O
for	O
OS	O
(	O
hazard	O
ratio	O
[	O
95	O
%	O
CI	O
]	O
0.3	O
[	O
0.11	O
-	O
0.83	O
]	O
,	O
p	O
=	O
.02	O
;	O
2.69	O
[	O
1.60	O
-	O
4.51	O
]	O
,	O
p	O
<	O
.001	O
;	O
1.92	O
[	O
1.24	O
-	O
2.97	O
]	O
,	O
p	O
=	O
.003	O
;	O
2.26	O
[	O
1.34	O
-	O
3.82	O
]	O
,	O
p	O
=	O
.002	O
;	O
3.38	O
[	O
1.85	O
-	O
7.78	O
]	O
,	O
p	O
<	O
.001	O
,	O
respectively	O
)	O
.	O

However	O
,	O
brain	O
metastasis	O
(	O
BM	O
)	O
at	O
initial	O
diagnosis	O
or	O
intracranial	O
progression	O
during	O
gefitinib	O
treatment	O
had	O
no	O
impact	O
on	O
OS	O
(	O
1.266	O
[	O
0.83	O
-	O
1.93	O
]	O
,	O
p	O
=	O
.275	O
and	O
0.75	O
[	O
0.48	O
-	O
1.19	O
]	O
,	O
p	O
=	O
.211	O
,	O
respectively	O
)	O
.	O

CONCLUSION	O
:	O
HCV	O
infection	O
,	O
performance	O
status	O
(	O
ECOG	O
≥2	O
)	O
,	O
newly	O
diagnosed	O
advanced	O
NSCLC	O
without	O
prior	O
operation	O
,	O
and	O
liver	O
metastasis	O
predicted	O
poor	O
OS	O
in	O
EGFR	O
mutation	O
-	O
positive	O
advanced	O
NSCLC	O
patients	O
treated	O
with	O
first	O
-	O
line	O
gefitinib	O
;	O
however	O
,	O
neither	O
BM	O
at	O
initial	O
diagnosis	O
nor	O
intracranial	O
progression	O
during	O
gefitinib	O
treatment	O
had	O
an	O
impact	O
on	O
OS	O
.	O

The	O
Oncologist	O
2017;22:1	O
-	O
9	O
IMPLICATIONS	O
FOR	O
PRACTICE	O
:	O
The	O
finding	O
that	O
chronic	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
infection	O
might	O
predict	O
poor	O
overall	O
survival	O
(	O
OS	O
)	O
in	O
epidermal	O
growth	O
factor	O
receptor	O
mutation	O
-	O
positive	O
advanced	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
patients	O
treated	O
with	O
first	O
-	O
line	O
gefitinib	O
may	O
raise	O
awareness	O
of	O
benefit	O
from	O
anti	O
-	O
HCV	O
treatment	O
in	O
this	O
patient	O
population	O
.	O

Brain	O
metastasis	O
in	O
the	O
initial	O
diagnosis	O
or	O
intracranial	O
progression	O
during	O
gefitinib	O
treatment	O
is	O
not	O
a	O
prognostic	O
factor	O
for	O
OS	O
.	O

This	O
study	O
,	O
which	O
enrolled	O
a	O
real	O
-	O
world	O
population	O
of	O
NSCLC	O
patients	O
,	O
including	O
sicker	O
patients	O
who	O
were	O
not	O
eligible	O
for	O
a	O
clinical	O
trial	O
,	O
may	O
have	O
impact	O
on	O
guiding	O
usual	O
clinical	O
practice	O
.	O

Loss	B-Var
of	O
the	O
homologous	O
recombination	O
gene	O
rad51	B-Gene
leads	B-Reg
to	O
Fanconi	B-Disease
anemia	I-Disease
-	I-Disease
like	I-Disease
symptoms	I-Disease
in	O
zebrafish	O
.	O

RAD51	O
is	O
an	O
indispensable	O
homologous	O
recombination	O
protein	O
,	O
necessary	O
for	O
strand	O
invasion	O
and	O
crossing	O
over	O
.	O

It	O
has	O
recently	O
been	O
designated	O
as	O
a	O
Fanconi	B-Disease
anemia	I-Disease
(	O
FA	O
)	O
gene	O
,	O
following	O
the	O
discovery	O
of	O
two	O
patients	O
carrying	O
dominant	O
-	O
negative	O
mutations	O
.	O

FA	O
is	O
a	O
hereditary	O
DNA	O
-	O
repair	O
disorder	O
characterized	O
by	O
various	O
congenital	O
abnormalities	O
,	O
progressive	O
bone	O
marrow	O
failure	O
,	O
and	O
cancer	O
predisposition	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
a	O
viable	O
vertebrate	O
model	O
of	O
RAD51	O
loss	O
.	O

Zebrafish	O
rad51	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutants	B-Var
developed	O
key	O
features	O
of	O
FA	B-Disease
,	O
including	O
hypocellular	O
kidney	O
marrow	O
,	O
sensitivity	O
to	O
cross	O
-	O
linking	O
agents	O
,	O
and	O
decreased	O
size	O
.	O

We	O
show	O
that	O
some	O
of	O
these	O
symptoms	O
stem	O
from	O
both	O
decreased	O
proliferation	O
and	O
increased	O
apoptosis	O
of	O
embryonic	O
hematopoietic	O
stem	O
and	O
progenitor	O
cells	O
.	O

Comutation	O
of	O
p53	O
was	O
able	O
to	O
rescue	O
the	O
hematopoietic	O
defects	O
seen	O
in	O
the	O
single	O
mutants	O
,	O
but	O
led	O
to	O
tumor	O
development	O
.	O

We	O
further	O
demonstrate	O
that	O
prolonged	O
inflammatory	O
stress	O
can	O
exacerbate	O
the	O
hematological	O
impairment	O
,	O
leading	O
to	O
an	O
additional	O
decrease	O
in	O
kidney	O
marrow	O
cell	O
numbers	O
.	O

These	O
findings	O
strengthen	O
the	O
assignment	O
of	O
RAD51	O
as	O
a	O
Fanconi	O
gene	O
and	O
provide	O
more	O
evidence	O
for	O
the	O
notion	O
that	O
aberrant	O
p53	O
signaling	O
during	O
embryogenesis	O
leads	O
to	O
the	O
hematological	O
defects	O
seen	O
later	O
in	O
life	O
in	O
FA	O
.	O

Further	O
research	O
on	O
this	O
zebrafish	O
FA	O
model	O
will	O
lead	O
to	O
a	O
deeper	O
understanding	O
of	O
the	O
molecular	O
basis	O
of	O
bone	O
marrow	O
failure	O
in	O
FA	O
and	O
the	O
cellular	O
role	O
of	O
RAD51	O
.	O

Gene	O
Co	O
-	O
Expression	O
Network	O
Analysis	O
for	O
Identifying	O
Modules	O
and	O
Functionally	O
Enriched	O
Pathways	O
in	O
SCA2	O
.	O

Spinocerebellar	B-Disease
ataxia	I-Disease
type	I-Disease
2	I-Disease
(	O
SCA2	O
)	O
is	O
an	O
autosomal	O
dominant	O
neurodegenerative	O
disease	O
caused	B-Reg
by	I-Reg
CAG	B-Var
repeat	I-Var
expansion	I-Var
in	O
the	O
ATXN2	B-Gene
gene	O
.	O

The	O
repeat	O
resides	O
in	O
an	O
encoded	O
region	O
of	O
the	O
gene	O
resulting	O
in	O
polyglutamine	O
(	O
polyQ	O
)	O
expansion	O
which	O
has	O
been	O
assumed	O
to	O
result	O
in	O
gain	O
of	O
function	O
,	O
predominantly	O
,	O
for	O
the	O
ATXN2	O
protein	O
.	O

We	O
evaluated	O
temporal	O
cerebellar	O
expression	O
profiles	O
by	O
RNA	O
sequencing	O
of	O
ATXN2Q127	O
mice	O
vs	O
wildtype	O
littermates	O
.	O

ATXN2Q127	O
mice	O
are	O
characterized	O
by	O
a	O
progressive	O
motor	O
phenotype	O
onset	O
,	O
and	O
have	O
progressive	O
cerebellar	O
molecular	O
and	O
neurophysiological	O
(	O
Purkinje	O
cell	O
firing	O
frequency	O
)	O
phenotypes	O
.	O

Our	O
analysis	O
revealed	O
previously	O
uncharacterized	O
early	O
and	O
progressive	O
abnormal	O
patterning	O
of	O
cerebellar	O
gene	O
expression	O
.	O

Weighted	O
Gene	O
Coexpression	O
Network	O
Analysis	O
(	O
WGCNA	O
)	O
revealed	O
four	O
gene	O
modules	O
that	O
were	O
significantly	O
correlated	O
with	O
disease	O
status	O
,	O
composed	O
primarily	O
of	O
genes	O
associated	O
with	O
GTPase	O
signaling	O
,	O
calcium	O
signaling	O
,	O
and	O
cell	O
death	O
.	O

Of	O
these	O
genes	O
,	O
few	O
overlapped	O
with	O
differentially	O
expressed	O
cerebellar	O
genes	O
that	O
we	O
identified	O
in	O
Atxn2-/-	O
knockout	O
mice	O
vs	O
wildtype	O
littermates	O
,	O
suggesting	O
that	O
loss	O
-	O
of	O
-	O
function	O
is	O
not	O
a	O
significant	O
component	O
of	O
disease	O
pathology	O
.	O

We	O
conclude	O
that	O
SCA2	O
is	O
a	O
disease	O
characterized	O
by	O
gain	O
of	O
function	O
for	O
ATXN2	O
.	O

Exposure	O
to	O
phenols	O
,	O
parabens	O
and	O
UV	O
filters	O
:	O
Associations	O
with	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
filaggrin	O
gene	O
in	O
men	O
from	O
the	O
general	O
population	O
.	O

BACKGROUND	O
:	O
Filaggrin	O
is	O
an	O
epidermal	O
protein	O
that	O
is	O
important	O
for	O
normal	O
skin	O
barrier	O
functions	O
.	O

Up	O
to	O
10	O
%	O
of	O
Europeans	O
and	O
Asians	O
carry	O
filaggrin	O
gene	O
(	B-Gene
FLG	I-Gene
)	I-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
function	I-NegReg
mutations	B-Var
that	O
appear	O
to	O
facilitate	B-PosReg
trans	B-CPA
-	I-CPA
epidermal	I-CPA
penetration	I-CPA
of	O
certain	O
chemicals	O
.	O

We	O
previously	O
showed	O
that	O
mutation	O
carriers	O
have	O
higher	O
internal	O
exposure	O
to	O
certain	O
phthalates	O
,	O
compared	O
to	O
controls	O
,	O
and	O
hypothesized	O
that	O
they	O
could	O
have	O
increased	O
trans	O
-	O
epidermal	O
penetration	O
of	O
other	O
chemicals	O
.	O

OBJECTIVES	O
:	O
We	O
investigated	O
exposure	O
to	O
non	O
-	O
persistent	O
chemicals	O
in	O
young	O
Danish	O
men	O
with	O
and	O
without	O
FLG	O
mutations	O
.	O

METHODS	O
:	O
Concentrations	O
of	O
eight	O
simple	O
phenols	O
,	O
six	O
parabens	O
and	O
nine	O
UV	O
filters	O
were	O
analysed	O
in	O
urine	O
from	O
65	O
FLG	O
loss	O
-	O
of	O
-	O
function	O
mutation	O
carriers	O
and	O
130	O
non	O
-	O
carriers	O
(	O
controls	O
)	O
.	O

Regression	O
analyses	O
,	O
controlling	O
for	O
urinary	O
dilution	O
and	O
confounders	O
,	O
were	O
performed	O
to	O
estimate	O
associations	O
between	O
FLG	O
mutation	O
status	O
and	O
chemical	O
concentrations	O
in	O
urine	O
.	O

RESULTS	O
:	O
FLG	O
mutation	O
carriers	O
had	O
80	O
%	O
(	O
13	O
-	O
180	O
%	O
)	O
higher	O
urinary	O
concentrations	O
of	O
methyl	O
paraben	O
(	O
MeP	O
)	O
and	O
91	O
%	O
(	O
13	O
-	O
219	O
%	O
)	O
higher	O
concentrations	O
of	O
n	O
-	O
propyl	O
paraben	O
(	O
n	O
-	O
PrP	O
)	O
than	O
controls	O
.	O

For	O
13	O
compounds	O
,	O
levels	O
were	O
higher	O
in	O
FLG	O
mutation	O
carriers	O
,	O
although	O
differences	O
were	O
only	O
statistically	O
significant	O
for	O
MeP	O
and	O
n	O
-	O
PrP.	O
Combined	O
statistical	O
analysis	O
of	O
concentrations	O
of	O
all	O
the	O
18	O
compounds	O
that	O
were	O
detectable	O
in	O
>	O
10	O
%	O
of	O
subjects	O
,	O
suggested	O
that	O
concentrations	O
were	O
generally	O
higher	O
in	O
mutation	O
carriers	O
(	O
p=0.03	O
)	O
.	O

CONCLUSION	O
:	O
FLG	O
loss	O
-	O
of	O
-	O
function	O
mutation	O
carriers	O
have	O
a	O
higher	O
internal	O
exposure	O
to	O
some	O
non	O
-	O
persistent	O
chemicals	O
,	O
independently	O
of	O
atopic	O
dermatitis	O
.	O

This	O
may	O
be	O
due	O
to	O
increased	O
trans	O
-	O
epidermal	O
absorption	O
and/or	O
higher	O
exposure	O
,	O
and	O
mutation	O
carriers	O
may	O
constitute	O
a	O
group	O
susceptible	O
to	O
increased	O
absorption	O
of	O
chemicals	O
and	O
topical	O
medication	O
.	O

GRIN2B	O
gain	O
of	O
function	O
mutations	O
are	O
sensitive	O
to	O
radiprodil	O
,	O
a	O
negative	O
allosteric	O
modulator	O
of	O
GluN2B	O
-	O
containing	O
NMDA	O
receptors	O
.	O

De	O
novo	O
gain	B-PosReg
of	I-PosReg
function	I-PosReg
mutations	B-Var
in	O
GRIN2B	B-Gene
encoding	O
the	O
GluN2B	O
subunit	O
of	O
the	O
N	O
-	O
methyl	O
-	O
d	O
-	O
aspartate	O
(	O
NMDA	O
)	O
receptor	O
have	O
been	O
linked	O
with	O
epileptic	B-Disease
encephalopathies	I-Disease
,	O
including	O
infantile	B-Disease
spasms	I-Disease
.	O

We	O
investigated	O
the	O
effects	O
of	O
radiprodil	O
,	O
a	O
selective	O
GluN2B	O
negative	O
allosteric	O
modulator	O
and	O
other	O
non	O
-	O
selective	O
NMDA	O
receptor	O
inhibitors	O
on	O
glutamate	O
currents	O
mediated	O
by	O
NMDA	O
receptors	O
containing	O
mutated	O
GluN2B	O
subunits	O
.	O

The	O
experiments	O
were	O
performed	O
in	O
Xenopus	O
oocytes	O
co	O
-	O
injected	O
with	O
the	O
following	O
human	O
mRNAs	O
:	O
GRIN1	O
/	O
GRIN2B	O
,	O
GRIN1	O
/	O
GRIN2B	O
-	O
R540H	O
,	O
GRIN1	O
/	O
GRIN2B	O
-	O
N615I	O
and	O
GRIN1	O
/	O
GRIN2B	O
-	O
V618G.	O
Glutamate	O
displayed	O
slightly	O
increased	O
potency	O
in	O
the	O
R540H	O
variant	O
,	O
but	O
not	O
in	O
N615I	O
and	O
V618	O
G	O
variants	O
.	O

However	O
,	O
the	O
inhibition	O
by	O
Mg(2	O
+	O
)	O
was	O
completely	O
abolished	O
in	O
N615I	O
and	O
V618	O
G	O
variants	O
.	O

In	O
fact	O
,	O
Mg(2	O
+	O
)	O
enhanced	O
glutamate	O
responses	O
in	O
those	O
variants	O
.	O

The	O
potency	O
of	O
radiprodil	O
to	O
block	O
glutamate	O
-	O
evoked	O
currents	O
was	O
not	O
affected	O
in	O
any	O
of	O
the	O
variants	O
,	O
while	O
the	O
effects	O
by	O
non	O
-	O
selective	O
NMDA	O
inhibitors	O
were	O
greatly	O
reduced	O
in	O
some	O
of	O
the	O
variants	O
.	O

Additionally	O
,	O
in	O
the	O
Mg(2	O
+	O
)	O
insensitive	O
variants	O
,	O
radiprodil	O
blocked	O
glutamate	O
-	O
activated	O
currents	O
with	O
the	O
same	O
potency	O
as	O
in	O
the	O
absence	O
of	O
Mg(2	O
+	O
)	O
.	O

The	O
gain	O
of	O
function	O
observed	O
in	O
the	O
reported	O
GRIN2B	O
variants	O
could	O
be	O
a	O
key	O
pathophysiological	O
factor	O
leading	O
to	O
neuronal	O
hyper	O
-	O
excitability	O
in	O
epileptic	O
encephalopathies	O
.	O

The	O
GluN2B	O
-	O
selective	O
inhibitor	O
radiprodil	O
fully	O
retained	O
its	O
pharmacological	O
profile	O
under	O
these	O
conditions	O
,	O
while	O
other	O
non	O
-	O
selective	O
NMDA	O
receptor	O
antagonists	O
lost	O
their	O
potency	O
.	O

Consequently	O
,	O
our	O
data	O
suggest	O
that	O
radiprodil	O
may	O
be	O
a	O
valuable	O
therapeutic	O
option	O
for	O
treatment	O
of	O
pediatric	O
epileptic	O
encephalopathies	O
associated	O
with	O
GRIN2B	O
mutations	O
.	O

PAI-1	O
gain	O
-	O
of	O
-	O
function	O
genotype	O
,	O
factors	O
increasing	O
PAI-1	O
levels	O
,	O
and	O
airway	O
obstruction	O
:	O
The	O
GALA	O
II	O
Cohort	O
.	O

BACKGROUND	O
:	O
PAI-1	B-Gene
gain	O
-	O
of	O
-	O
function	O
variants	B-Var
promote	B-PosReg
airway	B-CPA
fibrosis	I-CPA
and	O
are	O
associated	B-Reg
with	I-Reg
asthma	B-Disease
and	O
with	O
worse	O
lung	O
function	O
in	O
subjects	O
with	O
asthma	O
.	O

OBJECTIVE	O
:	O
We	O
sought	O
to	O
determine	O
whether	O
the	O
association	O
of	O
a	O
gain	O
-	O
of	O
-	O
function	O
polymorphism	O
in	O
plasminogen	O
activator	O
inhibitor-1	O
(	O
PAI-1	O
)	O
with	O
airway	O
obstruction	O
is	O
modified	O
by	O
asthma	O
status	O
,	O
and	O
whether	O
any	O
genotype	O
effect	O
persists	O
after	O
accounting	O
for	O
common	O
exposures	O
that	O
increase	O
PAI-1	O
level	O
.	O

METHODS	O
:	O
We	O
studied	O
2070	O
Latino	O
children	O
(	O
8	O
-	O
21y	O
)	O
with	O
genotypic	O
and	O
pulmonary	O
function	O
data	O
from	O
the	O
GALA	O
II	O
cohort	O
.	O

We	O
estimated	O
the	O
relationship	O
of	O
the	O
PAI-1	O
risk	O
allele	O
with	O
FEV1	O
/	O
FVC	O
by	O
multivariate	O
linear	O
regression	O
,	O
stratified	O
by	O
asthma	O
status	O
.	O

We	O
examined	O
the	O
association	O
of	O
the	O
polymorphism	O
with	O
asthma	O
and	O
airway	O
obstruction	O
within	O
asthmatics	O
via	O
multivariate	O
logistic	O
regression	O
.	O

We	O
replicated	O
associations	O
in	O
the	O
SAPPHIRE	O
cohort	O
of	O
African	O
Americans	O
(	O
n=1056	O
)	O
.	O

Secondary	O
analysis	O
included	O
the	O
effect	O
of	O
the	O
at	O
-	O
risk	O
polymorphism	O
on	O
postbronchodilator	O
lung	O
function	O
.	O

RESULTS	O
:	O
There	O
was	O
an	O
interaction	O
between	O
asthma	O
status	O
and	O
the	O
PAI-1	O
polymorphism	O
on	O
FEV1	O
/FVC	O
(	O
P=.03	O
)	O
.	O

The	O
gain	O
-	O
of	O
-	O
function	O
variants	O
,	O
genotypes	O
(	O
AA	O
/	O
AG	O
)	O
,	O
were	O
associated	O
with	O
lower	O
FEV1	O
/FVC	O
in	O
subjects	O
with	O
asthma	O
(	O
β=-1.25	O
,	O
CI	O
:	O
-2.14,-0.35	O
,	O
P=.006	O
)	O
,	O
but	O
not	O
in	O
controls	O
.	O

Subjects	O
with	O
asthma	O
and	O
the	O
AA	O
/	O
AG	O
genotypes	O
had	O
a	O
5	O
%	O
decrease	O
in	O
FEV1	O
/FVC	O
(	O
P<.001	O
)	O
.	O

In	O
asthmatics	O
,	O
the	O
risk	O
genotype	O
(	O
AA	O
/	O
AG	O
)	O
was	O
associated	O
with	O
a	O
39	O
%	O
increase	O
in	O
risk	O
of	O
clinically	O
relevant	O
airway	O
obstruction	O
(	O
OR=1.39	O
,	O
CI	O
:	O
1.01	O
,	O
1.92	O
,	O
P=.04	O
)	O
.	O

These	O
associations	O
persisted	O
after	O
exclusion	O
of	O
factors	O
that	O
increase	O
PAI-1	O
including	O
tobacco	O
exposure	O
and	O
obesity	O
.	O

CONCLUSIONS	O
AND	O
CLINICAL	O
RELEVANCE	O
:	O
The	O
decrease	O
in	O
the	O
FEV1	O
/FVC	O
ratio	O
associated	O
with	O
the	O
risk	O
genotype	O
was	O
modified	O
by	O
asthma	O
status	O
.	O

The	O
genotype	O
increased	O
the	O
odds	O
of	O
airway	O
obstruction	O
by	O
75	O
%	O
within	O
asthmatics	O
only	O
.	O

As	O
exposures	O
known	O
to	O
increase	O
PAI-1	O
levels	O
did	O
not	O
mitigate	O
this	O
association	O
,	O
PAI-1	O
may	O
contribute	O
to	O
airway	O
obstruction	O
in	O
the	O
context	O
of	O
chronic	O
asthmatic	O
airway	O
inflammation	O
.	O

Severe	O
hypertriglyceridemia	B-Disease
due	O
to	O
two	O
novel	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
lipoprotein	B-Enzyme
lipase	I-Enzyme
gene	O
mutations	O
(	B-Var
C310R	I-Var
/	I-Var
E396V	I-Var
)	I-Var
in	O
a	O
Chinese	O
family	O
associated	B-Reg
with	I-Reg
recurrent	B-Disease
acute	I-Disease
pancreatitis	I-Disease
.	O

Lipoprotein	O
lipase	O
(	O
LPL	O
)	O
is	O
widely	O
expressed	O
in	O
skeletal	O
muscles	O
,	O
cardiac	O
muscles	O
as	O
well	O
as	O
adipose	O
tissue	O
and	O
involved	O
in	O
the	O
catabolism	O
of	O
triglyceride	O
.	O

Herein	O
we	O
have	O
systematically	O
characterized	O
two	O
novel	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
LPL	O
from	O
a	O
Chinese	O
family	O
in	O
which	O
afflicted	O
members	O
were	O
manifested	O
by	O
severe	O
hypertriglyceridemia	O
and	O
recurrent	O
pancreatitis	O
.	O

DNA	O
sequencing	O
revealed	O
that	O
the	O
proband	O
was	O
a	O
heterozygote	O
carrying	O
a	O
novel	O
c	O
.	O

T928C	O
(	O
p	O
.	O
C310R	O
)	O
mutation	O
in	O
exon	O
6	O
of	O
the	O
LPL	O
gene	O
.	O

Another	O
member	O
of	O
the	O
family	O
was	O
detected	O
to	O
be	O
a	O
compound	O
heterozygote	O
who	O
along	O
with	O
the	O
c	O
.	O

T928C	O
mutation	O
also	O
carried	O
a	O
novel	O
missense	O
mutation	O
c	O
.	O

A1187	O
T	O
(	O
p	O
.	O
E396V	O
)	O
in	O
exon	O
8	O
of	O
the	O
LPL	O
gene	O
.	O

Furthermore	O
,	O
COS-1	O
cells	O
were	O
transfected	O
with	O
lentiviruses	O
containing	O
the	O
mutant	O
LPL	O
genes	O
.	O

While	O
C310R	B-Var
markedly	O
reduced	B-NegReg
the	O
overall	O
LPL	B-MPA
protein	I-MPA
level	I-MPA
,	O
COS-1	O
cells	O
carrying	O
E396V	O
or	O
double	O
mutations	O
contained	O
similar	O
overall	O
LPL	O
protein	O
levels	O
to	O
the	O
wild	O
-	O
type	O
.	O

The	O
specific	O
activity	O
of	O
the	O
LPL	O
mutants	O
remained	O
at	O
comparable	O
magnitude	O
to	O
the	O
wild	O
-	O
type	O
.	O

However	O
,	O
few	O
LPL	O
were	O
detected	O
in	O
the	O
culture	O
medium	O
for	O
the	O
mutants	O
,	O
suggesting	O
that	O
both	O
mutations	B-Var
caused	B-Reg
aberrant	O
triglyceride	B-MPA
catabolism	I-MPA
.	O

More	O
specifically	O
,	O
E396V	B-Var
and	O
double	B-Var
mutations	I-Var
dampened	B-NegReg
the	O
transport	B-MPA
of	I-MPA
LPL	I-MPA
to	I-MPA
the	I-MPA
cell	I-MPA
surface	I-MPA
,	O
while	O
for	O
the	O
C310R	B-Var
mutation	O
,	O
reducing	B-NegReg
LPL	B-MPA
protein	I-MPA
level	I-MPA
might	O
be	O
involved	O
.	O

By	O
characterizing	O
these	O
two	O
novel	O
LPL	O
mutations	O
,	O
this	O
study	O
has	O
expanded	O
our	O
understanding	O
on	O
the	O
pathogenesis	O
of	O
familial	O
hypertriglyceridemia	O
(	O
FHTG	O
)	O
.	O

Truncating	O
mutations	O
in	O
SPAST	O
patients	O
are	O
associated	O
with	O
a	O
high	O
rate	O
of	O
psychiatric	O
comorbidities	O
in	O
hereditary	O
spastic	O
paraplegia	O
.	O

BACKGROUND	O
:	O
The	O
hereditary	B-Disease
spastic	I-Disease
paraplegias	I-Disease
(	O
HSPs	O
)	O
are	O
a	O
rare	O
and	O
heterogeneous	O
group	O
of	O
neurodegenerative	O
disorders	O
that	O
are	O
clinically	O
characterised	O
by	O
progressive	O
lower	O
limb	O
spasticity	O
.	O

They	O
are	O
classified	O
as	O
either	O
'	O
pure	O
'	O
or	O
'	O
complex	O
'	O
where	O
spastic	O
paraplegia	O
is	O
complicated	O
with	O
additional	O
neurological	O
features	O
.	O

Mutations	B-Var
in	O
the	O
spastin	O
gene	O
(	B-Gene
SPAST	I-Gene
)	I-Gene
are	O
the	O
most	O
common	O
cause	B-Reg
of	O
HSP	B-Disease
and	O
typically	O
present	O
with	O
a	O
pure	O
form	O
.	O

METHODS	O
:	O
We	O
assessed	O
in	O
detail	O
the	O
phenotypic	O
and	O
genetic	O
spectrum	O
of	O
SPAST	O
-	O
related	O
HSP	O
focused	O
on	O
118	O
patients	O
carrying	O
SPAST	O
mutations	O
.	O

RESULTS	O
:	O
This	O
study	O
,	O
one	O
of	O
the	O
largest	O
cohorts	O
of	O
genetically	O
confirmed	O
spastin	O
patients	O
to	O
date	O
,	O
contributes	O
with	O
the	O
discovery	O
of	O
a	O
significant	O
number	O
of	O
novel	O
SPAST	O
mutations	O
.	O

Our	O
data	O
reveal	O
a	O
high	O
rate	O
of	O
complex	O
cases	O
(	O
25	O
%	O
)	O
,	O
with	O
psychiatric	O
disorders	O
among	O
the	O
most	O
common	O
comorbidity	O
(	O
10	O
%	O
of	O
all	O
SPASTpatients	O
)	O
.	O

Further	O
,	O
we	O
identify	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
between	O
patients	O
carrying	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
SPAST	B-Gene
and	O
the	O
presence	O
of	O
psychiatric	B-Disease
disorders	I-Disease
.	O

WNT10A	B-Gene
mutation	B-Var
causes	B-Reg
ectodermal	B-Disease
dysplasia	I-Disease
by	O
impairing	B-NegReg
progenitor	B-CPA
cell	I-CPA
proliferation	I-CPA
and	O
KLF4-mediated	B-CPA
differentiation	I-CPA
.	O

Human	O
WNT10A	O
mutations	O
are	O
associated	O
with	O
developmental	O
tooth	O
abnormalities	O
and	O
adolescent	O
onset	O
of	O
a	O
broad	O
range	O
of	O
ectodermal	O
defects	O
.	O

Here	O
we	O
show	O
that	O
β	O
-	O
catenin	O
pathway	O
activity	O
and	O
adult	O
epithelial	O
progenitor	O
proliferation	O
are	O
reduced	O
in	O
the	O
absence	O
of	O
WNT10A	O
,	O
and	O
identify	O
Wnt	O
-	O
active	O
self	O
-	O
renewing	O
stem	O
cells	O
in	O
affected	O
tissues	O
including	O
hair	O
follicles	O
,	O
sebaceous	O
glands	O
,	O
taste	O
buds	O
,	O
nails	O
and	O
sweat	O
ducts	O
.	O

Human	O
and	O
mouse	O
WNT10A	O
mutant	O
palmoplantar	O
and	O
tongue	O
epithelia	O
also	O
display	O
specific	O
differentiation	O
defects	O
that	O
are	O
mimicked	O
by	O
loss	O
of	O
the	O
transcription	O
factor	O
KLF4	O
.	O

We	O
find	O
that	O
β	O
-	O
catenin	O
interacts	O
directly	O
with	O
region	O
-	O
specific	O
LEF	O
/	O
TCF	O
factors	O
,	O
and	O
with	O
KLF4	O
in	O
differentiating	O
,	O
but	O
not	O
proliferating	O
,	O
cells	O
to	O
promote	O
expression	O
of	O
specialized	O
keratins	O
required	O
for	O
normal	O
tissue	O
structure	O
and	O
integrity	O
.	O

Our	O
data	O
identify	O
WNT10A	O
as	O
a	O
critical	O
ligand	O
controlling	O
adult	O
epithelial	O
proliferation	O
and	O
region	O
-	O
specific	O
differentiation	O
,	O
and	O
suggest	O
downstream	O
β	O
-	O
catenin	O
pathway	O
activation	O
as	O
a	O
potential	O
approach	O
to	O
ameliorate	O
regenerative	O
defects	O
in	O
WNT10A	O
patients	O
.	O

R202Q	B-Var
/	I-Var
M694V	I-Var
as	O
novel	O
MEFV	B-Gene
gene	O
mutations	O
in	B-Reg
chronic	B-Disease
periodontitis	I-Disease
and	O
familial	B-Disease
Mediterranean	I-Disease
fever	I-Disease
.	O

BACKGROUND	O
AND	O
OBJECTIVE	O
:	O
Familial	O
Mediterranean	O
fever	O
(	O
FMF	O
)	O
and	O
chronic	O
periodontitis	O
are	O
inflammatory	O
diseases	O
leading	O
to	O
an	O
increase	O
in	O
the	O
number	O
of	O
inflammasomes	O
.	O

To	O
date	O
,	O
no	O
published	O
studies	O
have	O
reported	O
on	O
mutations	O
in	O
the	O
Mediterranean	O
fever	O
(	O
MEFV	O
)	O
gene	O
in	O
patients	O
with	O
chronic	O
periodontitis	O
,	O
although	O
the	O
roles	B-Reg
of	O
MEFV	B-Gene
gene	O
mutations	B-Var
in	O
FMF	B-Disease
and	O
FMF	B-Disease
-	I-Disease
associated	I-Disease
amyloidosis	I-Disease
(	O
FMF	O
-	O
A	O
)	O
are	O
well	O
known	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
frequencies	O
of	O
MEFV	O
gene	O
mutations	O
and	O
serum	O
amyloid	O
A	O
(	O
SAA	O
)	O
and	O
high	O
-	O
sensitivity	O
C	O
-	O
reactive	O
protein	O
(	O
hs	O
-	O
CRP	O
)	O
levels	O
in	O
patients	O
with	O
chronic	O
periodontitis	O
,	O
FMF	O
and	O
FMF	O
-	O
A.	O
MATERIAL	O
AND	O
METHODS	O
:	O
The	O
study	O
population	O
included	O
122	O
patients	O
with	O
FMF	O
and	O
128	O
subjects	O
who	O
were	O
systemically	O
healthy	O
.	O

Clinical	O
periodontal	O
parameters	O
,	O
including	O
the	O
plaque	O
index	O
,	O
gingival	O
index	O
,	O
probing	O
pocket	O
depth	O
,	O
clinical	O
attachment	O
level	O
and	O
percentage	O
of	O
bleeding	O
on	O
probing	O
were	O
recorded	O
.	O

Blood	O
samples	O
were	O
obtained	O
from	O
patients	O
with	O
FMF	O
and	O
systemically	O
healthy	O
controls	O
,	O
and	O
all	O
mutations	O
located	O
on	O
exons	O
2	O
and	O
10	O
of	O
the	O
MEFV	O
gene	O
were	O
analyzed	O
by	O
DNA	O
Sanger	O
Sequencing	O
,	O
which	O
is	O
the	O
gold	O
standard	O
.	O

SAA	O
and	O
high	O
-	O
sensitive	O
CRP	O
levels	O
were	O
also	O
assessed	O
.	O

RESULTS	O
:	O
Mean	O
gingival	O
index	O
,	O
percentage	O
of	O
bleeding	O
on	O
probing	O
,	O
probing	O
pocket	O
depth	O
and	O
clinical	O
attachment	O
level	O
,	O
and	O
the	O
levels	O
of	O
SAA	O
and	O
hs	O
-	O
CRP	O
were	O
higher	O
in	O
the	O
FMF	O
-	O
A	O
group	O
than	O
those	O
in	O
the	O
FMF	O
and	O
control	O
groups	O
.	O

The	O
two	O
most	O
relevant	O
mutations	O
in	O
patients	O
with	O
FMF	O
were	O
heterozygous	O
M694V	O
(	O
46.2	O
%	O
)	O
,	O
and	O
heterozygous	O
R202Q	O
(	O
32.7	O
%	O
)	O
.	O

The	O
frequencies	O
of	O
the	O
homozygous	O
M694V	O
and	O
R202Q	O
mutations	O
in	O
the	O
FMF	O
-	O
A	O
group	O
were	O
53.8	O
%	O
and	O
46.1	O
%	O
,	O
respectively	O
.	O

The	O
complex	O
R202Q	O
/	O
M694V	O
homozygous	O
state	O
led	O
to	O
an	O
increased	O
risk	O
of	O
chronic	O
periodontitis	O
(	O
odds	O
ratio	O
:	O
3.6	O
)	O
,	O
and	O
FMF	O
-	O
A	O
(	O
odds	O
ratio	O
:	O
7.6	O
)	O
.	O

CONCLUSION	O
:	O
This	O
is	O
the	O
first	O
study	O
to	O
report	O
the	O
R202Q	O
mutation	O
in	O
patients	O
with	O
periodontitis	O
.	O

Furthermore	O
,	O
the	O
MEFV	O
gene	O
-	O
mediated	O
inflammatory	O
pathway	O
increased	O
serum	O
acute	O
phase	O
reactants	O
,	O
and	O
the	O
changes	O
in	O
the	O
R202Q	B-Var
and	O
M694V	B-Var
could	O
play	B-Reg
a	I-Reg
role	I-Reg
in	O
inflammatory	B-Disease
-	I-Disease
genetic	I-Disease
diseases	I-Disease
,	O
such	O
as	O
FMF	O
,	O
FMF	O
-	O
associated	O
amyloidosis	O
and	O
chronic	O
periodontitis	O
.	O

Loss	B-Var
of	I-Var
function	I-Var
in	O
ROBO1	B-Gene
is	O
associated	B-Reg
with	O
tetralogy	B-Disease
of	I-Disease
Fallot	I-Disease
and	O
septal	B-Disease
defects	I-Disease
.	O

BACKGROUND	O
:	O
Congenital	O
heart	O
disease	O
(	O
CHD	O
)	O
is	O
a	O
common	O
birth	O
defect	O
affecting	O
approximately	O
1	O
%	O
of	O
newborns	O
.	O

Great	O
progress	O
has	O
been	O
made	O
in	O
elucidating	O
the	O
genetic	O
aetiology	O
of	O
CHD	O
with	O
advances	O
in	O
genomic	O
technology	O
,	O
which	O
we	O
leveraged	O
in	O
recovering	O
a	O
new	O
pathway	O
affecting	O
heart	O
development	O
in	O
humans	O
previously	O
known	O
to	O
affect	O
heart	O
development	O
in	O
an	O
animal	O
model	O
.	O

METHODS	O
:	O
Four	O
hundred	O
and	O
sixteen	O
individuals	O
from	O
Thailand	O
and	O
the	O
USA	O
diagnosed	O
with	O
CHD	O
and/or	O
congenital	O
diaphragmatic	O
hernia	O
were	O
evaluated	O
with	O
chromosomal	O
microarray	O
and	O
whole	O
exome	O
sequencing	O
.	O

The	O
DECIPHER	O
Consortium	O
and	O
medical	O
literature	O
were	O
searched	O
for	O
additional	O
patients	O
.	O

Murine	O
hearts	O
from	O
ENU	O
-	O
induced	O
mouse	O
mutants	O
and	O
transgenic	O
mice	O
were	O
evaluated	O
using	O
both	O
episcopic	O
confocal	O
histopathology	O
and	O
troponin	O
I	O
stained	O
sections	O
.	O

RESULTS	O
:	O
Loss	O
of	O
function	O
ROBO1	O
variants	O
were	O
identified	O
in	O
three	O
families	O
;	O
each	O
proband	O
had	O
a	O
ventricular	O
septal	O
defect	O
,	O
and	O
one	O
proband	O
had	O
tetralogy	O
of	O
Fallot	O
.	O

Additionally	O
,	O
a	O
microdeletion	O
in	O
an	O
individual	O
with	O
CHD	O
was	O
found	O
in	O
the	O
medical	O
literature	O
.	O

Mouse	O
models	O
showed	O
perturbation	O
of	O
the	O
Slit	O
-	O
Robo	O
signalling	O
pathway	O
,	O
causing	O
septation	O
and	O
outflow	O
tract	O
defects	O
and	O
craniofacial	O
anomalies	O
.	O

Two	O
probands	O
had	O
variable	O
facial	O
features	O
consistent	O
with	O
the	O
mouse	O
model	O
.	O

CONCLUSION	O
:	O
Our	O
findings	O
identify	O
Slit	O
-	O
Robo	O
as	O
a	O
significant	O
pathway	O
in	O
human	O
heart	O
development	O
and	O
CHD	O
.	O

Human	O
IκBα	O
Gain	O
of	O
Function	O
:	O
a	O
Severe	O
and	O
Syndromic	O
Immunodeficiency	O
.	O

Germline	O
heterozygous	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
mutations	B-Var
of	O
NFKBIA	B-Gene
,	O
encoding	O
IκBα	O
,	O
cause	O
an	O
autosomal	O
dominant	O
(	O
AD	O
)	O
form	O
of	O
anhidrotic	B-Disease
ectodermal	I-Disease
dysplasia	I-Disease
with	I-Disease
immunodeficiency	I-Disease
(	O
EDA	O
-	O
ID	O
)	O
.	O

Fourteen	O
unrelated	O
patients	O
have	O
been	O
reported	O
since	O
the	O
identification	O
of	O
the	O
first	O
case	O
in	O
2003	O
.	O

All	O
mutations	B-Var
enhanced	B-PosReg
the	O
inhibitory	B-MPA
activity	I-MPA
of	O
IκBα	B-Protein
,	O
by	O
preventing	B-NegReg
its	O
phosphorylation	B-MPA
on	I-MPA
serine	I-MPA
32	I-MPA
or	I-MPA
36	I-MPA
and	O
its	O
subsequent	O
degradation	B-MPA
.	O

The	O
mutation	O
certainly	O
or	O
probably	O
occurred	O
de	O
novo	O
in	O
13	O
patients	O
,	O
whereas	O
it	O
was	O
inherited	O
from	O
a	O
parent	O
with	O
somatic	O
mosaicism	O
in	O
one	O
patient	O
.	O

Eleven	O
mutations	O
,	O
belonging	O
to	O
two	O
groups	O
,	O
were	O
identified	O
:	O
(	O
i	O
)	O
missense	O
mutations	O
affecting	O
S32	O
,	O
S36	O
,	O
or	O
neighboring	O
residues	O
(	O
8	O
mutations	O
,	O
11	O
patients	O
)	O
and	O
(	O
ii	O
)	O
nonsense	O
mutations	O
upstream	O
from	O
S32	O
associated	O
with	O
the	O
reinitiation	O
of	O
translation	O
downstream	O
from	O
S36	O
(	O
3	O
mutations	O
,	O
3	O
patients	O
)	O
.	O

Thirteen	O
patients	O
had	O
developmental	O
features	O
of	O
EDA	O
,	O
the	O
severity	O
and	O
nature	O
of	O
which	O
differed	O
between	O
cases	O
.	O

All	O
patient	O
cells	O
tested	O
displayed	O
impaired	O
NF	O
-	O
κB	O
-	O
mediated	O
responses	O
to	O
the	O
stimulation	O
of	O
various	O
surface	O
receptors	O
involved	O
in	O
cell	O
-	O
intrinsic	O
(	O
fibroblasts	O
)	O
,	O
innate	O
(	O
monocytes	O
)	O
,	O
and	O
adaptive	O
(	O
B	O
and	O
T	O
cells	O
)	O
immunity	O
,	O
including	O
TLRs	O
,	O
IL-1Rs	O
,	O
TNFRs	O
,	O
TCR	O
,	O
and	O
BCR	O
.	O

All	O
patients	O
had	O
profound	O
B	O
-	O
cell	O
deficiency	O
.	O

Specific	O
immunological	O
features	O
,	O
found	O
in	O
some	O
,	O
but	O
not	O
all	O
patients	O
,	O
included	O
a	O
lack	O
of	O
peripheral	O
lymph	O
nodes	O
,	O
lymphocytosis	O
,	O
dysfunctional	O
α	O
/	O
β	O
T	O
cells	O
,	O
and	O
a	O
lack	O
of	O
circulating	O
γ	O
/	O
δ	O
T	O
cells	O
.	O

The	O
patients	O
had	O
various	O
pyogenic	O
,	O
mycobacterial	O
,	O
fungal	O
,	O
and	O
viral	O
severe	O
infections	O
.	O

Patients	O
with	O
a	O
missense	O
mutation	O
tended	O
to	O
display	O
more	O
severe	O
phenotypes	O
,	O
probably	O
due	O
to	O
higher	O
levels	O
of	O
GOF	O
proteins	O
.	O

In	O
the	O
absence	O
of	O
hematopoietic	O
stem	O
cell	O
transplantation	O
(	O
HSCT	O
)	O
,	O
this	O
condition	O
cause	O
death	O
before	O
the	O
age	O
of	O
1	O
year	O
(	O
one	O
child	O
)	O
.	O

Two	O
survivors	O
have	O
been	O
on	O
prophylaxis	O
(	O
at	O
9	O
and	O
22	O
years	O
)	O
.	O

Six	O
children	O
died	O
after	O
HSCT	O
.	O

Five	O
survived	O
,	O
four	O
of	O
whom	O
have	O
been	O
on	O
prophylaxis	O
(	O
3	O
to	O
21	O
years	O
post	O
HSCT	O
)	O
,	O
whereas	O
one	O
has	O
been	O
well	O
with	O
no	O
prophylaxis	O
.	O

Heterozygous	O
GOF	O
mutations	O
in	O
IκBα	O
underlie	O
a	O
severe	O
and	O
syndromic	O
immunodeficiency	O
,	O
the	O
interindividual	O
variability	O
of	O
which	O
might	O
partly	O
be	O
ascribed	O
to	O
the	O
dichotomy	O
of	O
missense	O
and	O
nonsense	O
mutations	O
,	O
and	O
the	O
hematopoietic	O
component	O
of	O
which	O
can	O
be	O
rescued	O
by	O
HSCT	O
.	O

ARX	B-Gene
polyalanine	B-Var
expansion	I-Var
mutations	I-Var
lead	B-Reg
to	I-Reg
migration	B-CPA
impediment	I-CPA
in	I-CPA
the	I-CPA
rostral	I-CPA
cortex	I-CPA
coupled	I-CPA
with	O
a	O
developmental	B-CPA
deficit	I-CPA
of	I-CPA
calbindin	I-CPA
-	I-CPA
positive	I-CPA
cortical	I-CPA
GABAergic	I-CPA
interneurons	I-CPA
.	O

The	O
Aristaless	O
-	O
related	O
homeobox	O
gene	O
(	O
ARX	O
)	O
is	O
indispensable	O
for	O
interneuron	O
development	O
.	O

Patients	O
with	O
ARX	O
polyalanine	O
expansion	O
mutations	O
of	O
the	O
first	O
two	O
tracts	O
(	O
namely	O
PA1	O
and	O
PA2	O
)	O
suffer	O
from	O
intellectual	O
disability	O
of	O
varying	O
severity	O
,	O
with	O
seizures	O
a	O
frequent	O
comorbidity	O
.	O

The	O
impact	O
of	O
PA1	O
and	O
PA2	O
mutations	O
on	O
the	O
brain	O
development	O
is	O
unknown	O
,	O
hindering	O
the	O
search	O
for	O
therapeutic	O
interventions	O
.	O

Here	O
,	O
we	O
characterized	O
the	O
disturbances	O
to	O
cortical	O
interneuron	O
development	O
in	O
mice	O
modeling	O
the	O
two	O
most	O
common	O
ARX	O
polyalanine	O
expansion	O
mutations	O
in	O
human	O
.	O

We	O
found	O
a	O
consistent	O
∼40	O
-	O
50	O
%	O
reduction	O
of	O
calbindin	O
-	O
positive	O
interneurons	O
,	O
but	O
not	O
Stt+	O
or	O
Cr+	O
interneurons	O
,	O
within	O
the	O
cortex	O
of	O
newborn	O
hemizygous	O
mice	O
(	O
p=0.024	O
)	O
for	O
both	O
mutant	O
strains	O
compared	O
to	O
wildtype	O
(	O
p=0.011	O
)	O
.	O

We	O
demonstrate	O
that	O
this	O
was	O
a	O
consequence	O
of	O
calbindin	O
precursor	O
cells	O
being	O
arrested	O
or	O
delayed	O
at	O
the	O
ventral	O
subpallium	O
en	O
route	O
of	O
tangential	O
migration	O
.	O

Ex	O
-	O
vivo	O
assay	O
validated	O
this	O
migration	O
deficit	O
in	O
PA1	O
cells	O
(	O
p=0.0002	O
)	O
suggesting	O
that	O
the	O
defect	O
is	O
contributed	O
by	O
intrinsic	O
loss	O
of	O
Arx	O
function	O
within	O
migrating	O
cells	O
.	O

Both	O
humans	O
and	O
mice	O
with	O
PA1	O
mutations	O
present	O
with	O
severe	O
clinical	O
features	O
,	O
including	O
intellectual	O
disability	O
and	O
infantile	O
spasms	O
.	O

Our	O
data	O
further	O
demonstrated	O
the	O
pathogenic	O
mechanism	O
was	O
robustly	O
shared	O
between	O
PA1	O
and	O
PA2	O
mutations	O
,	O
as	O
previously	O
reported	O
including	O
Arx	O
protein	O
reduction	O
and	O
overlapping	O
transcriptome	O
profiles	O
within	O
the	O
developing	O
mouse	O
brains	O
.	O

Data	O
from	O
our	O
study	O
demonstrated	O
that	O
cortical	B-CPA
calbindin	I-CPA
interneuron	I-CPA
development	B-CPA
and	O
migration	B-CPA
is	O
negatively	B-NegReg
affected	O
by	O
ARX	B-Gene
polyalanine	B-Var
expansion	I-Var
mutations	I-Var
.	O

Understanding	O
the	O
cellular	O
pathogenesis	O
contributing	O
to	O
disease	O
manifestation	O
is	O
necessary	O
to	O
screen	O
efficacy	O
of	O
potential	O
therapeutic	O
interventions	O
.	O

Linking	O
the	O
degree	O
of	O
virilization	O
in	O
females	O
with	O
congenital	O
adrenal	O
hyperplasia	O
to	O
genotype	O
.	O

Mutations	B-Var
of	O
CYP21A2	B-Gene
variably	O
decrease	B-NegReg
21-hydroxylase	B-Enzyme
activity	B-MPA
and	O
result	B-Reg
in	I-Reg
a	O
spectrum	O
of	O
disease	O
expressions	O
in	O
patients	O
with	O
congenital	B-Disease
adrenal	I-Disease
hyperplasia	I-Disease
(	O
CAH	O
)	O
.	O

We	O
examined	O
the	O
association	O
between	O
CYP21A2	O
mutations	O
and	O
virilization	O
(	O
Prader	O
score	O
)	O
in	O
females	O
with	O
CAH	O
.	O

The	O
study	O
population	O
included	O
187	O
CAH	B-Disease
females	O
with	B-Reg
fully	O
characterized	O
CYP21A2	B-Gene
mutations	B-Var
.	O

One	O
hundred	O
fifty	O
-	O
eight	O
patients	O
were	O
sorted	O
into	O
groups	O
by	O
expected	O
enzyme	O
activity	O
(	O
percent	O
of	O
normal	O
activity	O
)	O
of	O
the	O
less	O
severely	O
affected	O
allele	O
:	O
(	O
A	O
)	O
null	O
,	O
0	O
%	O
;	O
(	O
B	O
)	O
I2	O
G	O
,	O
1	O
%	O
;	O
(	O
C	O
)	O
I172N	O
,	O
2	O
%	O
;	O
and	O
(	O
D	O
)	O
V281L	O
,	O
>	O
2	O
%	O
.	O

We	O
observed	O
an	O
inverse	O
relationship	O
between	O
virilization	O
and	O
residual	O
enzyme	O
activity	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Subjects	O
in	O
group	O
A	O
or	O
B	O
had	O
a	O
significantly	O
higher	O
likelihood	O
(	O
unadjusted	O
odds	O
ratio	O
:	O
16	O
;	O
P	O
<	O
0.001	O
)	O
of	O
developing	O
severe	O
virilization	O
compared	O
with	O
those	O
in	O
group	O
C.	O
Surprisingly	O
,	O
24	O
%	O
of	O
group	O
D	O
patients	O
,	O
whose	O
mutation	O
is	O
usually	O
associated	O
with	O
nonclassical	O
(	O
NC	O
)	O
CAH	O
,	O
had	O
severe	O
virilization	O
.	O

Among	O
subjects	O
with	O
the	O
NC	O
P30L	O
mutation	O
,	O
66	O
%	O
expressed	O
unexpected	O
virilization	O
.	O

Virilization	O
,	O
usually	O
leading	O
to	O
extensive	O
reconstructive	O
surgery	O
,	O
is	O
highly	O
likely	O
in	O
patients	O
with	O
null	O
or	O
I2	O
G	O
mutations	O
;	O
however	O
,	O
NC	O
mutations	O
(	O
P30L	O
/	O
V281L	O
)	O
may	O
also	O
lead	O
to	O
unexpected	O
virilization	O
.	O

These	O
findings	O
have	O
implications	O
for	O
prenatal	O
counseling	O
and	O
highlight	O
the	O
need	O
for	O
additional	O
investigations	O
into	O
other	O
factors	O
that	O
influence	O
virilization	O
in	O
CAH	O
.	O

Inducible	O
activation	O
of	O
FGFR2	O
in	O
adult	O
mice	O
promotes	O
bone	O
formation	O
after	O
bone	O
marrow	O
ablation	O
.	O

Apert	B-Disease
syndrome	I-Disease
is	O
one	O
of	O
the	O
most	O
severe	O
craniosynostoses	O
,	O
resulting	O
from	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutations	B-Var
in	O
fibroblast	O
growth	O
factor	O
receptor	O
2	O
(	B-Gene
FGFR2	I-Gene
)	I-Gene
.	O

Previous	O
studies	O
have	O
shown	O
that	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
of	O
FGFR2	O
(	O
S252W	O
or	O
P253R	O
)	O
cause	O
skull	O
malformation	O
of	O
human	O
Apert	O
syndrome	O
by	O
affecting	O
both	O
chondrogenesis	O
and	O
osteogenesis	O
,	O
underscoring	O
the	O
key	O
role	O
of	O
FGFR2	O
in	O
bone	O
development	O
.	O

However	O
,	O
the	O
effects	O
of	O
FGFR2	O
on	O
bone	O
formation	O
at	O
the	O
adult	O
stage	O
have	O
not	O
been	O
fully	O
investigated	O
.	O

To	O
investigate	O
the	O
role	O
of	O
FGFR2	O
in	O
bone	O
formation	O
,	O
we	O
generated	O
mice	O
with	O
tamoxifen	O
-	O
inducible	O
expression	O
of	O
mutant	O
FGFR2	O
(	O
P253R	O
)	O
at	O
the	O
adult	O
stage	O
.	O

Mechanical	O
bone	O
marrow	O
ablation	O
(	O
BMX	O
)	O
was	O
performed	O
in	O
both	O
wild	O
-	O
type	O
and	O
Fgfr2	B-Gene
mutant	B-Var
(	O
MT	O
)	O
mice	O
.	O

Changes	O
in	O
newly	O
formed	O
trabecular	O
bone	O
were	O
assessed	O
by	O
micro	O
-	O
computed	O
tomography	O
and	O
bone	O
histomorphometry	O
.	O

We	O
found	O
that	O
MT	O
mice	O
exhibited	O
increased	B-PosReg
trabecular	B-CPA
bone	I-CPA
formation	I-CPA
and	O
decreased	B-NegReg
bone	B-CPA
resorption	I-CPA
after	O
BMX	O
accompanied	O
with	O
a	O
remarkable	O
increase	B-PosReg
in	O
bone	B-CPA
marrow	I-CPA
stromal	I-CPA
cell	I-CPA
recruitment	B-CPA
and	O
proliferation	B-CPA
,	O
osteoblast	B-CPA
proliferation	B-CPA
and	O
differentiation	B-CPA
,	O
and	O
enhanced	B-PosReg
Wnt/?-catenin	B-CPA
activity	I-CPA
.	O

Furthermore	O
,	O
pharmacologically	O
inhibiting	O
Wnt	O
/	O
β	O
-	O
catenin	O
signaling	O
can	O
partially	O
reverse	O
the	O
increased	O
trabecular	O
bone	O
formation	O
and	O
decreased	O
bone	O
resorption	O
in	O
MT	O
mice	O
after	O
BMX	O
.	O

Our	O
data	O
demonstrate	O
that	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	B-Var
in	O
FGFR2	B-Gene
exerts	B-MPA
a	I-MPA
Wnt	I-MPA
/	I-MPA
β	I-MPA
-	I-MPA
catenin	I-MPA
-	I-MPA
dependent	I-MPA
anabolic	I-MPA
effect	I-MPA
on	O
trabecular	O
bone	O
by	O
promoting	B-PosReg
bone	B-CPA
formation	I-CPA
and	O
inhibiting	B-NegReg
bone	B-CPA
resorption	I-CPA
at	I-CPA
the	I-CPA
adult	I-CPA
stage	I-CPA
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Early	B-Disease
-	I-Disease
onset	I-Disease
autoimmune	I-Disease
disease	I-Disease
due	O
to	O
a	O
heterozygous	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	B-Var
in	O
TNFAIP3	B-Gene
(	O
A20	O
)	O
.	O

The	O
moving	O
junction	O
protein	O
RON4	O
,	O
although	O
not	O
critical	O
,	O
facilitates	O
host	O
cell	O
invasion	O
and	O
stabilizes	O
MJ	O
members	O
.	O

Toxoplasma	O
gondii	O
is	O
an	O
obligate	O
intracellular	O
parasite	O
of	O
phylum	O
Apicomplexa	O
.	O

To	O
facilitate	O
high	O
-	O
efficiency	O
invasion	O
of	O
host	O
cells	O
,	O
T.	O
gondii	O
secretes	O
various	O
proteins	O
related	O
to	O
the	O
moving	O
junction	O
(	O
MJ	O
)	O
complex	O
from	O
rhoptries	O
and	O
micronemes	O
into	O
the	O
interface	O
between	O
the	O
parasite	O
and	O
host	O
.	O

AMA1	O
/	O
RON2/4/5/8	O
is	O
an	O
important	O
MJ	O
complex	O
,	O
but	O
its	O
mechanism	O
of	O
assembly	O
remains	O
unclear	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
the	O
CRISPR	O
-	O
Cas9	O
system	O
to	O
generate	O
a	O
derivative	O
of	O
T.	O
gondii	O
strain	O
RH	O
with	O
a	O
null	B-Var
mutation	I-Var
in	O
TgRON4	B-Gene
,	O
thought	O
to	O
be	O
an	O
essential	O
MJ	O
component	O
.	O

Deficiency	B-NegReg
of	O
TgRON4	B-Protein
moderately	O
decreased	B-NegReg
invasion	B-CPA
ability	I-CPA
relative	O
to	O
that	O
of	O
the	O
wild	O
-	O
type	O
parasite	O
.	O

In	O
addition	O
,	O
expression	B-MPA
of	I-MPA
the	I-MPA
endogenous	I-MPA
N	I-MPA
-	I-MPA
terminal	I-MPA
fragment	I-MPA
of	O
RON5	B-Protein
decreased	B-NegReg
in	O
the	O
mutant	B-Var
.	O

Together	O
,	O
the	O
results	O
improve	O
our	O
understanding	O
of	O
the	O
assembly	O
mechanism	O
of	O
the	O
MJ	O
complex	O
of	O
T.	O
gondii	O
and	O
raise	O
the	O
possibility	O
of	O
developing	O
new	O
therapeutic	O
drugs	O
that	O
target	O
this	O
complex	O
.	O

Natural	O
and	O
induced	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
SlMBP21	B-Gene
MADS	O
-	O
box	O
gene	O
led	O
to	O
jointless-2	B-CPA
phenotype	I-CPA
in	O
tomato	O
.	O

Abscission	O
is	O
the	O
mechanism	O
by	O
which	O
plants	O
disconnect	O
unfertilized	O
flowers	O
,	O
ripe	O
fruits	O
,	O
senescent	O
or	O
diseased	O
organs	O
from	O
the	O
plant	O
.	O

In	O
tomato	O
,	O
pedicel	O
abscission	O
is	O
an	O
important	O
agronomic	O
factor	O
that	O
controls	O
yield	O
and	O
post	O
-	O
harvest	O
fruit	O
quality	O
.	O

Two	O
non	O
-	O
allelic	O
mutations	O
,	O
jointless	O
(	O
j	O
)	O
and	O
jointless-2	O
(	O
j-2	O
)	O
,	O
controlling	O
pedicel	O
abscission	O
zone	O
formation	O
have	O
been	O
documented	O
but	O
only	O
j-2	O
has	O
been	O
extensively	O
used	O
in	O
breeding	O
.	O

J	O
was	O
shown	O
to	O
encode	O
a	O
MADS	O
-	O
box	O
protein	O
.	O

Using	O
a	O
combination	O
of	O
physical	O
mapping	O
and	O
gene	O
expression	O
analysis	O
we	O
identified	O
a	O
positional	O
candidate	O
,	O
Solyc12g038510	O
,	O
associated	O
with	O
j-2	O
phenotype	O
.	O

Targeted	O
knockout	O
of	O
Solyc12g038510	O
,	O
using	O
CRISPR	O
/	O
Cas9	O
system	O
,	O
validated	O
our	O
hypothesis	O
.	O

Solyc12g038510	O
encodes	O
the	O
MADS	O
-	O
box	O
protein	O
SlMBP21	O
.	O

Molecular	O
analysis	O
of	O
j-2	O
natural	O
variation	O
revealed	O
two	O
independent	O
loss	O
-	O
of	O
-	O
function	O
mutants	O
.	O

The	O
first	O
results	O
of	O
an	O
insertion	O
of	O
a	O
Rider	O
retrotransposable	O
element	O
.	O

The	O
second	O
results	O
of	O
a	O
stop	O
codon	O
mutation	O
that	O
leads	O
to	O
a	O
truncated	O
protein	O
form	O
.	O

To	O
bring	O
new	O
insights	O
into	O
the	O
role	O
of	O
J	O
and	O
J-2	O
in	O
abscission	O
zone	O
formation	O
,	O
we	O
phenotyped	O
the	O
single	O
and	O
the	O
double	O
mutants	O
and	O
the	O
engineered	O
alleles	O
.	O

We	O
showed	O
that	O
J	O
is	O
epistatic	O
to	O
J-2	O
and	O
that	O
the	O
branched	O
inflorescences	O
and	O
the	O
leafy	O
sepals	O
observed	O
in	O
accessions	O
harboring	O
j-2	O
alleles	O
are	O
likely	O
the	O
consequences	O
of	O
linkage	O
drags	O
.	O

Nephron	B-CPA
development	I-CPA
and	O
extrarenal	B-CPA
features	I-CPA
in	O
a	O
child	O
with	O
congenital	O
nephrotic	O
syndrome	O
caused	B-Reg
by	I-Reg
null	O
LAMB2	B-Gene
mutations	B-Var
.	O

BACKGROUND	O
:	O
Congenital	O
nephrotic	O
syndrome	O
(	O
CNS	O
)	O
is	O
a	O
rare	O
disorder	O
caused	O
by	O
various	O
structural	O
and	O
developmental	O
defects	O
of	O
glomeruli	O
.	O

It	O
occurs	O
typically	O
as	O
an	O
isolated	O
kidney	O
disorder	O
but	O
associates	O
sometimes	O
with	O
other	O
systemic	O
,	O
extrarenal	O
manifestations	O
.	O

CASE	O
PRESENTATIONS	O
:	O
An	O
infant	O
presented	O
with	O
severe	O
CNS	O
,	O
which	O
progressed	O
rapidly	O
to	O
renal	O
failure	O
at	O
age	O
of	O
3	O
months	O
and	O
death	O
at	O
27	O
months	O
.	O

The	O
clinical	O
phenotypes	O
and	O
genetic	O
causes	O
were	O
studied	O
,	O
including	O
the	O
renal	O
pathology	O
at	O
autopsy	O
.	O

Besides	O
the	O
CNS	O
,	O
the	O
affected	O
child	O
had	O
remarkable	O
right	O
-	O
side	O
predominant	O
eye	O
-	O
ball	O
hypoplasia	O
with	O
bilateral	O
anterior	O
chamber	O
dysgenesis	O
(	O
microcoria	O
)	O
.	O

Brain	O
MRI	O
revealed	O
grossly	O
normal	O
development	O
in	O
the	O
cerebrum	O
,	O
cerebellum	O
,	O
and	O
brain	O
stem	O
.	O

Auditory	O
brainstem	O
responses	O
were	O
bilaterally	O
blunted	O
,	O
suggesting	O
a	O
defective	O
auditory	O
system	O
.	O

At	O
autopsy	O
,	O
both	O
kidneys	O
were	O
mildly	O
atrophied	O
with	O
persistent	O
fetal	O
lobulation	O
.	O

Microscopic	O
examination	O
showed	O
a	O
diffuse	O
global	O
sclerosis	O
.	O

However	O
,	O
despite	O
of	O
the	O
smaller	O
size	O
of	O
glomeruli	O
,	O
the	O
nephron	O
number	O
remained	O
similar	O
to	O
that	O
of	O
the	O
age	O
-	O
matched	O
control	O
.	O

Whole	O
-	O
exome	O
sequencing	O
revealed	O
that	O
the	O
affected	O
child	O
was	O
compound	O
heterozygous	O
for	O
novel	O
truncating	O
LAMB2	O
mutations	O
:	O
a	O
4-bp	O
insertion	O
(	O
p	O
.	O
Gly1693Alafs*8	O
)	O
and	O
a	O
splicing	O
donor	O
-	O
site	O
substitution	O
(	O
c.1225	O
+	O
1	O
G	O
>	O
A	O
)	O
,	O
presumably	O
deleting	O
the	O
coiled	O
-	O
coil	O
domains	O
that	O
form	O
the	O
laminin	O
5	O
-	O
2	O
-	O
1	O
heterotrimer	O
complex	O
.	O

CONCLUSIONS	O
:	O
Our	O
case	O
represents	O
a	O
variation	O
of	O
Pierson	O
syndrome	O
that	O
accompanies	O
CNS	O
with	O
unilateral	O
ocular	O
hypoplasia	O
.	O

The	O
average	O
number	O
but	O
smaller	O
glomeruli	O
could	O
reflect	O
either	O
mal	O
-	O
development	O
or	O
glomerulosclerosis	O
.	O

Heterogeneous	O
clinical	O
expression	O
of	O
LAMB2	O
defects	O
may	O
associate	O
with	O
the	O
difference	O
in	O
fetal	O
β1	O
subtype	O
compensation	O
among	O
affected	O
tissues	O
.	O

Further	O
study	O
is	O
necessary	O
to	O
evaluate	O
incidence	O
and	O
features	O
of	O
auditory	O
defect	O
under	O
LAMB2	O
deficiency	O
.	O

Exome	O
sequencing	O
reveals	O
independent	O
SGCD	B-Gene
deletions	B-Var
causing	B-Reg
limb	B-Disease
girdle	I-Disease
muscular	I-Disease
dystrophy	I-Disease
in	O
Boston	O
terriers	O
.	O

BACKGROUND	O
:	O
Limb	O
-	O
girdle	O
muscular	O
dystrophies	O
(	O
LGMDs	O
)	O
are	O
a	O
heterogeneous	O
group	O
of	O
inherited	O
autosomal	O
myopathies	O
that	O
preferentially	O
affect	O
voluntary	O
muscles	O
of	O
the	O
shoulders	O
and	O
hips	O
.	O

LGMD	O
has	O
been	O
clinically	O
described	O
in	O
several	O
breeds	O
of	O
dogs	O
,	O
but	O
the	O
responsible	O
mutations	O
are	O
unknown	O
.	O

The	O
clinical	O
presentation	O
in	O
dogs	O
is	O
characterized	O
by	O
marked	O
muscle	O
weakness	O
and	O
atrophy	O
in	O
the	O
shoulder	O
and	O
hips	O
during	O
puppyhood	O
.	O

METHODS	O
:	O
Following	O
clinical	O
evaluation	O
,	O
the	O
identification	O
of	O
the	O
dystrophic	O
histological	O
phenotype	O
on	O
muscle	O
histology	O
,	O
and	O
demonstration	O
of	O
the	O
absence	O
of	O
sarcoglycan	O
-	O
sarcospan	O
complex	O
by	O
immunostaining	O
,	O
whole	O
exome	O
sequencing	O
was	O
performed	O
on	O
five	O
Boston	O
terriers	O
:	O
one	O
affected	O
dog	O
and	O
its	O
three	O
family	O
members	O
and	O
one	O
unrelated	O
affected	O
dog	O
.	O

RESULTS	O
:	O
Within	O
sarcoglycan	O
-	O
δ	O
(	B-Gene
SGCD	I-Gene
)	I-Gene
,	O
a	O
two	O
base	O
pair	O
deletion	O
segregating	O
with	O
LGMD	O
in	O
the	O
family	O
was	O
discovered	O
,	O
and	O
a	O
deletion	O
encompassing	O
exons	O
7	O
and	O
8	O
was	O
found	O
in	O
the	O
unrelated	O
dog	O
.	O

Both	O
mutations	B-Var
are	O
predicted	O
to	O
cause	O
an	O
absence	B-NegReg
of	O
SGCD	B-Gene
protein	B-Protein
,	O
confirmed	O
by	O
immunohistochemistry	O
.	O

The	O
mutations	O
are	O
private	O
to	O
each	O
family	O
.	O

CONCLUSIONS	O
:	O
Here	O
,	O
we	O
describe	O
the	O
first	O
cases	O
of	O
canine	O
LGMD	O
characterized	O
at	O
the	O
molecular	O
level	O
with	O
the	O
classification	O
of	O
LGMD2F.	O
Calcium	O
pumps	O
and	O
interacting	O
BON1	O
protein	O
modulate	O
calcium	O
signature	O
,	O
stomatal	O
closure	O
,	O
and	O
plant	O
immunity	O
.	O

Calcium	O
signaling	O
is	O
essential	O
for	O
environmental	O
responses	O
including	O
immune	O
responses	O
.	O

Here	O
we	O
provide	O
evidence	O
that	O
the	O
evolutionarily	O
conserved	O
protein	O
BONZAI1	O
(	O
BON1	O
)	O
functions	O
together	O
with	O
autoinhibited	O
calcium	O
ATPase	O
10	O
(	O
ACA10	O
)	O
and	O
ACA8	O
to	O
regulate	O
calcium	O
signals	O
in	O
Arabidopsis	O
.	O

BON1	O
is	O
a	O
plasma	O
membrane	O
localized	O
protein	O
that	O
negatively	O
regulates	O
the	O
expression	O
of	O
immune	O
receptor	O
genes	O
and	O
positively	O
regulates	O
stomatal	O
closure	O
.	O

We	O
found	O
that	O
BON1	O
interacts	O
with	O
the	O
autoinhibitory	O
domains	O
of	O
ACA10	O
and	O
ACA8	O
,	O
and	O
the	O
aca10	B-Gene
loss	B-NegReg
of	I-NegReg
function	I-NegReg
(	O
LOF	O
)	O
mutants	B-Var
have	O
an	O
autoimmune	O
phenotype	O
similar	O
to	O
that	O
of	O
the	O
bon1	B-Gene
LOF	B-NegReg
mutants	B-Var
.	O

Genetic	O
evidences	O
indicate	O
that	O
BON1	O
positively	O
regulates	O
the	O
activities	O
of	O
ACA10	O
and	O
ACA8	O
.	O

Consistent	O
with	O
this	O
idea	O
,	O
the	O
steady	B-MPA
level	I-MPA
of	I-MPA
calcium	I-MPA
concentration	I-MPA
is	O
increased	B-PosReg
in	O
both	O
aca10	B-Gene
and	O
bon1	B-Gene
mutants	B-Var
.	O

Most	O
strikingly	O
,	O
cytosolic	O
calcium	O
oscillation	O
imposed	O
by	O
external	O
calcium	O
treatment	O
was	O
altered	O
in	O
aca10	O
,	O
aca8	O
,	O
and	O
bon1	O
mutants	O
in	O
guard	O
cells	O
.	O

In	O
addition	O
,	O
calcium	B-CPA
and	I-CPA
pathogen	I-CPA
induced	I-CPA
stomatal	I-CPA
closure	I-CPA
was	O
compromised	B-NegReg
in	O
the	O
aca10	B-Gene
and	O
bon1	B-Gene
mutants	B-Var
.	O

Taken	O
together	O
,	O
this	O
study	O
indicates	O
that	O
ACA10/8	O
and	O
BON1	O
physically	O
interact	O
on	O
plasma	O
membrane	O
and	O
function	O
in	O
the	O
generation	O
of	O
cytosol	O
calcium	O
signatures	O
that	O
are	O
critical	O
for	O
stomatal	O
movement	O
and	O
impact	O
plant	O
immunity	O
.	O

Extracellular	O
inhibitors	O
can	O
attenuate	O
tumorigenic	O
Wnt	O
pathway	O
activity	O
in	O
adenomatous	O
polyposis	O
coli	O
mutants	O
:	O
Predictions	O
of	O
a	O
validated	O
mathematical	O
model	O
.	O

BACKGROUND	O
:	O
Despite	O
considerable	O
investigational	O
efforts	O
,	O
no	O
method	O
to	O
overcome	O
the	O
pathogenesis	O
caused	O
by	O
loss	O
of	O
function	O
(	O
LoF	O
)	O
mutations	O
in	O
tumor	O
suppressor	O
genes	O
has	O
been	O
successfully	O
translated	O
to	O
the	O
clinic	O
.	O

The	O
most	O
frequent	O
LoF	B-NegReg
mutation	B-Var
in	O
human	O
cancers	O
is	O
Adenomatous	B-Gene
polyposis	I-Gene
coli	I-Gene
(	O
APC	O
)	O
,	O
causing	O
aberrant	O
activation	B-PosReg
of	O
the	O
Wnt	B-Pathway
pathway	I-Pathway
.	O

In	O
nearly	O
all	O
colon	B-Disease
cancer	I-Disease
tumors	I-Disease
,	O
the	O
APC	B-Protein
protein	I-Protein
is	O
truncated	O
,	O
but	O
still	O
retains	B-NegReg
partial	I-NegReg
binding	B-Interaction
abilities	B-MPA
.	O

OBJECTIVE	O
&	O
METHODS	O
:	O
Here	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
extracellular	O
inhibitors	O
of	O
the	O
Wnt	O
pathway	O
,	O
although	O
acting	O
upstream	O
of	O
the	O
APC	O
mutation	O
,	O
can	O
restore	O
normal	O
levels	O
of	O
pathway	O
activity	O
in	O
colon	O
cancer	O
cells	O
.	O

To	O
this	O
end	O
,	O
we	O
developed	O
and	O
simulated	O
a	O
mathematical	O
model	O
for	O
the	O
Wnt	O
pathway	O
in	O
different	O
APC	O
mutants	O
,	O
with	O
or	O
without	O
the	O
effects	O
of	O
the	O
extracellular	O
inhibitors	O
,	O
Secreted	O
Frizzled	O
-	O
Related	O
Protein1	O
(	O
sFRP1	O
)	O
and	O
Dickhopf1	O
(	O
Dkk1	O
)	O
.	O

We	O
compared	O
our	O
model	O
predictions	O
to	O
experimental	O
data	O
in	O
the	O
literature	O
.	O

RESULTS	O
:	O
Our	O
model	O
accurately	O
predicts	O
T	O
-	O
cell	O
factor	O
(	O
TCF	O
)	O
activity	O
in	O
mutant	O
cells	O
that	O
vary	O
in	O
APC	O
mutation	O
.	O

Model	O
simulations	O
suggest	O
that	O
both	O
sFRP1	O
and	O
DKK1	O
can	O
reduce	O
TCF	O
activity	O
in	O
APC1638N/1572	O
T	O
and	O
Apcmin	O
/	O
min	O
mutants	O
,	O
but	O
restoration	O
of	O
normal	O
activity	O
levels	O
is	O
possible	O
only	O
in	O
the	O
former	O
.	O

When	O
applied	O
in	O
combination	O
,	O
synergism	O
between	O
the	O
two	O
inhibitors	O
can	O
reduce	O
their	O
effective	O
doses	O
to	O
one	O
-	O
fourth	O
of	O
the	O
doses	O
required	O
under	O
single	O
inhibitor	O
application	O
.	O

Overall	O
,	O
re	O
-	O
establishment	O
of	O
normal	O
Wnt	O
pathway	O
activity	O
is	O
predicted	O
for	O
every	O
APC	O
mutant	O
in	O
whom	O
TCF	O
activity	O
is	O
increased	O
by	O
up	O
to	O
11	O
fold	O
.	O

CONCLUSIONS	O
:	O
Our	O
work	O
suggests	O
that	O
extracellular	O
inhibitors	O
can	O
effectively	O
restore	O
normal	O
Wnt	O
pathway	O
activity	O
in	O
APC	O
-	O
truncated	O
cancer	O
cells	O
,	O
even	O
though	O
these	O
LoF	O
mutations	O
occur	O
downstream	O
of	O
the	O
inhibitory	O
action	O
.	O

The	O
insufficient	O
activity	O
of	O
the	O
truncated	O
APC	O
can	O
be	O
quantitatively	O
balanced	O
by	O
the	O
upstream	O
intervention	O
.	O

This	O
new	O
concept	O
of	O
upstream	O
intervention	O
to	O
control	O
the	O
effects	O
of	O
downstream	O
mutations	O
may	O
be	O
considered	O
also	O
for	O
other	O
partial	O
LoF	O
mutations	O
in	O
other	O
signaling	O
pathways	O
.	O

A	O
case	O
of	O
hypocholesterolemia	B-Disease
and	O
steatosis	B-Disease
in	O
a	O
carrier	O
of	O
a	O
PCSK9	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	B-Var
and	O
polymorphisms	O
predisposing	O
to	O
nonalcoholic	O
fatty	O
liver	O
disease	O
.	O

We	O
report	O
a	O
new	O
case	O
of	O
hypobetalipoproteinemia	O
in	O
a	O
44-year	O
-	O
old	O
man	O
of	O
Peruvian	O
origin	O
exhibiting	O
a	O
heterozygous	O
PCSK9	O
missense	O
mutation	O
(	B-Var
c.946	I-Var
G	I-Var
>	I-Var
T	I-Var
,	O
p.	O
Gly316Cys	O
)	O
.	O

In	O
vitro	O
functional	O
studies	O
demonstrated	O
that	O
this	O
mutation	O
leads	O
to	O
a	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
of	O
PCSK9	B-Gene
on	O
low	B-MPA
-	I-MPA
density	I-MPA
lipoprotein	I-MPA
receptor	I-MPA
degradation	I-MPA
.	O

This	O
patient	O
exhibited	O
liver	O
steatosis	O
;	O
he	O
was	O
neither	O
diabetic	O
,	O
nor	O
obese	O
or	O
alcoholic	O
,	O
but	O
is	O
a	O
carrier	O
of	O
2	O
polymorphisms	O
,	O
p	O
.	O
Ile148Met	O
(	O
rs738409	O
)	O
and	O
p	O
.	O
Glu167Lys	O
(	O
rs58542926	O
)	O
on	O
PNPLA3	O
and	O
TM6SF2	O
gene	O
,	O
respectively	O
,	O
previously	O
shown	O
to	O
be	O
associated	O
with	O
nonalcoholic	O
steatosis	O
and	O
fibrosis	O
evolution	O
.	O

These	O
data	O
suggested	O
that	O
if	O
a	O
resistance	O
to	O
hepatic	O
steatosis	O
mediated	O
by	O
the	O
PCSK9	O
deficiency	O
exists	O
,	O
as	O
demonstrated	O
in	O
mice	O
,	O
it	O
is	O
not	O
sufficient	O
to	O
prevent	O
hepatic	O
fatty	O
accumulation	O
in	O
the	O
case	O
of	O
genetic	O
factors	O
predisposing	O
to	O
nonalcoholic	O
fatty	O
liver	O
disease	O
.	O

Ovarian	B-Protein
aromatase	I-Protein
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutant	B-Var
medaka	O
undergo	B-Reg
ovary	B-CPA
degeneration	I-CPA
and	O
partial	B-CPA
female	I-CPA
-	I-CPA
to	I-CPA
-	I-CPA
male	I-CPA
sex	I-CPA
reversal	I-CPA
after	O
puberty	O
.	O

Although	O
estrogens	O
have	O
been	O
generally	O
considered	O
to	O
play	O
a	O
critical	O
role	O
in	O
ovarian	O
differentiation	O
in	O
non	O
-	O
mammalian	O
vertebrates	O
,	O
the	O
specific	O
functions	O
of	O
estrogens	O
during	O
ovarian	O
differentiation	O
remain	O
unclear	O
.	O

We	O
isolated	O
two	O
mutants	O
with	O
premature	O
stops	O
in	O
the	O
ovarian	O
aromatase	O
(	B-Gene
cyp19a1	I-Gene
)	I-Gene
gene	O
from	O
an	O
N	O
-	O
ethyl	O
-	O
N	O
-	O
nitrosourea	O
-	O
based	O
gene	O
-	O
driven	O
mutagenesis	O
library	O
of	O
the	O
medaka	O
,	O
Oryzias	O
latipes	O
.	O

In	O
XX	O
mutants	O
,	O
gonads	O
first	O
differentiated	O
into	O
normal	O
ovaries	O
containing	O
many	O
ovarian	O
follicles	O
that	O
failed	O
to	O
accumulate	O
yolk	O
.	O

Subsequently	O
,	O
ovarian	O
tissues	O
underwent	O
extensive	O
degeneration	O
,	O
followed	O
by	O
the	O
appearance	O
of	O
testicular	O
tissues	O
on	O
the	O
dorsal	O
side	O
of	O
ovaries	O
.	O

In	O
the	O
newly	O
formed	O
testicular	O
tissue	O
,	O
strong	O
expression	O
of	O
gsdf	O
was	O
detected	O
in	O
sox9a2-positive	O
somatic	O
cells	O
surrounding	O
germline	O
stem	O
cells	O
suggesting	O
that	O
gsdf	O
plays	O
an	O
important	O
role	O
in	O
testicular	O
differentiation	O
during	O
estrogen	O
-	O
depleted	O
female	O
-	O
to	O
-	O
male	O
sex	O
reversal	O
.	O

We	O
conclude	O
that	O
endogenous	O
estrogens	O
synthesized	O
after	O
fertilization	O
are	O
not	O
essential	O
for	O
early	O
ovarian	O
differentiation	O
but	O
are	O
critical	O
for	O
the	O
maintenance	O
of	O
adult	O
ovaries	O
.	O

Refining	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
Alström	O
syndrome	O
through	O
study	O
of	O
primary	O
human	O
fibroblasts	O
.	O

BACKGROUND	O
:	O
Alström	B-Disease
syndrome	I-Disease
(	O
AS	O
)	O
,	O
featuring	O
retinal	O
dystrophy	O
,	O
neuronal	O
deafness	O
,	O
cardiomyopathy	O
,	O
metabolic	O
syndrome	O
,	O
and	O
diffuse	O
fibrosis	O
,	O
is	O
caused	O
by	O
biallelic	O
mutations	O
in	O
the	O
centrosomal	O
protein	O
ALMS1	O
.	O

Genotype	O
-	O
phenotype	O
correlation	O
has	O
been	O
suggested	O
without	O
assessment	O
of	O
ALMS1	O
expression	O
.	O

METHODS	O
:	O
ALMS1	O
expression	O
(	O
real	O
-	O
time	O
PCR	O
and	O
immunocytochemistry	O
)	O
and	O
cilia	O
formation	O
(	O
immunocytochemistry	O
)	O
were	O
assessed	O
in	O
fibroblasts	O
from	O
deeply	O
phenotyped	O
volunteers	O
diagnosed	O
with	O
AS	O
recruited	O
from	O
a	O
dedicated	O
AS	O
Service	O
.	O

Exome	O
sequencing	O
was	O
used	O
in	O
two	O
participants	O
without	O
convincing	O
biallelic	O
ALMS1	O
mutations	O
,	O
and	O
BBS2	O
(	O
Bardet	O
-	O
Biedl	O
syndrome	O
2	O
)	O
protein	O
expression	O
was	O
assessed	O
in	O
one	O
patient	O
with	O
biallelic	O
BBS2	O
mutations	O
.	O

Hedgehog	O
-	O
induced	O
GLI1	O
expression	O
and	O
PDGFA	O
signaling	O
was	O
assessed	O
using	O
quantitative	O
real	O
-	O
time	O
PCR	O
,	O
immunoblotting	O
,	O
or	O
immunostaining	O
of	O
fixed	O
cells	O
after	O
stimulation	O
.	O

RESULTS	O
:	O
In	O
16	O
of	O
the	O
patient	O
cell	O
lines	O
examined	O
,	O
ALMS1	B-Gene
protein	B-Protein
was	O
undetectable	B-NegReg
(	O
14	O
with	O
biallelic	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LoF	O
)	O
mutations	B-Var
)	I-Var
,	O
and	O
in	O
two	O
,	O
ALMS1	O
staining	O
was	O
equivocal	O
(	O
one	O
with	O
biallelic	O
LoF	O
mutations	O
)	O
.	O

In	O
five	O
lines	O
,	O
ALMS1	O
expression	O
was	O
normal	O
using	O
at	O
least	O
one	O
fixation	O
method	O
(	O
one	O
with	O
biallelic	O
LoF	O
mutations	O
)	O
.	O

These	O
differences	O
were	O
not	O
accounted	O
for	O
by	O
major	O
differences	O
in	O
ALMS1	O
mRNA	O
expression	O
.	O

Exome	O
sequencing	O
of	O
two	O
participants	O
with	O
normal	O
ALMS1	O
expression	O
identified	O
biallelic	O
LoF	O
BBS2	O
mutations	O
in	O
one	O
.	O

No	O
second	O
,	O
known	O
ciliopathy	O
mutation	O
was	O
found	O
in	O
the	O
other	O
patient	O
,	O
who	O
had	O
one	O
LoF	O
ALMS1	O
mutation	O
.	O

Phenotypes	O
were	O
milder	O
or	O
atypical	O
in	O
participants	O
with	O
preserved	O
ALMS1	O
immunostaining	O
,	O
even	O
when	O
two	O
with	O
likely	O
alternative	O
genetic	O
diagnoses	O
were	O
excluded	O
.	O

All	O
cells	O
studied	O
developed	O
normal	O
cilia	O
,	O
ALMS1	O
and	O
BBS2	O
mutant	O
cells	O
showed	O
normal	O
Hedgehog	O
-	O
induced	O
upregulation	O
of	O
GLI1	O
expression	O
,	O
and	O
PDGFA	O
signaling	O
was	O
normal	O
in	O
ALMS1-deficient	O
cells	O
.	O

CONCLUSION	O
:	O
Milder	O
or	O
atypical	O
presentations	O
of	O
AS	O
should	O
prompt	O
genetic	O
evaluation	O
for	O
alternative	O
,	O
clinically	O
overlapping	O
ciliopathies	O
.	O

A	O
subgroup	O
of	O
patients	O
with	O
bona	O
fide	O
ALMS1	O
defects	O
have	O
milder	O
phenotypes	O
due	O
to	O
residual	O
ALMS1	O
expression	O
,	O
which	O
may	O
be	O
more	O
important	O
than	O
mutation	O
site	O
.	O

Small	O
chaperons	O
and	O
autophagy	O
protected	O
neurons	O
from	O
necrotic	O
cell	O
death	O
.	O

Neuronal	O
necrosis	O
occurs	O
during	O
early	O
phase	O
of	O
ischemic	O
insult	O
.	O

However	O
,	O
our	O
knowledge	O
of	O
neuronal	O
necrosis	O
is	O
still	O
inadequate	O
.	O

To	O
study	O
the	O
mechanism	O
of	O
neuronal	O
necrosis	O
,	O
we	O
previously	O
established	O
a	O
Drosophila	O
genetic	O
model	O
of	O
neuronal	O
necrosis	O
by	O
calcium	O
overloading	O
through	O
expression	O
of	O
a	O
constitutively	O
opened	O
cation	O
channel	O
mutant	O
.	O

Here	O
,	O
we	O
performed	O
further	O
genetic	O
screens	O
and	O
identified	O
a	O
suppressor	O
of	O
neuronal	O
necrosis	O
,	O
CG17259	O
,	O
which	O
encodes	O
a	O
seryl	O
-	O
tRNA	O
synthetase	O
.	O

We	O
found	O
that	O
loss	B-Var
-	I-Var
of	I-Var
-	I-Var
function	I-Var
(	O
LOF	O
)	O
CG17259	B-Gene
activated	B-PosReg
eIF2α	B-Protein
phosphorylation	B-CPA
and	O
subsequent	O
up	B-PosReg
-	I-PosReg
regulation	I-PosReg
of	O
chaperons	B-CPA
(	B-Protein
Hsp26	I-Protein
and	O
Hsp27	B-Protein
)	I-Protein
and	O
autophagy	B-CPA
.	O

Genetically	O
,	O
down	B-NegReg
-	I-NegReg
regulation	I-NegReg
of	O
eIF2α	B-Protein
phosphorylation	B-CPA
,	O
Hsp26	B-Protein
/	I-Protein
Hsp27	I-Protein
or	O
autophagy	B-CPA
reduced	B-NegReg
the	O
protective	B-CPA
effect	I-CPA
of	O
LOF	B-Var
CG17259	B-Gene
,	O
indicating	O
they	O
function	O
downstream	O
of	O
CG17259	O
.	O

The	O
protective	O
effect	O
of	O
these	O
protein	O
degradation	O
pathways	O
indicated	O
activation	O
of	O
a	O
toxic	O
protein	O
during	O
neuronal	O
necrosis	O
.	O

Our	O
data	O
indicated	O
that	O
p53	O
was	O
likely	O
one	O
such	O
protein	O
,	O
because	O
p53	O
was	O
accumulated	O
in	O
the	O
necrotic	O
neurons	O
and	O
down	O
-	O
regulation	O
of	O
p53	O
rescued	O
necrosis	O
.	O

In	O
the	O
SH	O
-	O
SY5Y	O
human	O
cells	O
,	O
tunicamycin	O
(	O
TM	O
)	O
,	O
a	O
PERK	O
activator	O
,	O
promoted	O
transcription	O
of	O
hsp27	O
;	O
and	O
necrosis	O
induced	O
by	O
glutamate	O
could	O
be	O
rescued	O
by	O
TM	O
,	O
associated	O
with	O
reduced	O
p53	O
accumulation	O
.	O

In	O
an	O
ischemic	O
stroke	O
model	O
in	O
rats	O
,	O
p53	O
protein	O
was	O
also	O
increased	O
,	O
and	O
TM	O
treatment	O
could	O
reduce	O
the	O
p53	O
accumulation	O
and	O
brain	O
damage	O
.	O

In	O
vivo	O
CRISPR	O
screening	O
identifies	O
Ptpn2	O
as	O
a	O
cancer	O
immunotherapy	O
target	O
.	O

Immunotherapy	O
with	O
PD-1	O
checkpoint	O
blockade	O
is	O
effective	O
in	O
only	O
a	O
minority	O
of	O
patients	O
with	O
cancer	O
,	O
suggesting	O
that	O
additional	O
treatment	O
strategies	O
are	O
needed	O
.	O

Here	O
we	O
use	O
a	O
pooled	O
in	O
vivo	O
genetic	O
screening	O
approach	O
using	O
CRISPR	O
-	O
Cas9	O
genome	O
editing	O
in	O
transplantable	O
tumours	O
in	O
mice	O
treated	O
with	O
immunotherapy	O
to	O
discover	O
previously	O
undescribed	O
immunotherapy	O
targets	O
.	O

We	O
tested	O
2,368	O
genes	O
expressed	O
by	O
melanoma	O
cells	O
to	O
identify	O
those	O
that	O
synergize	O
with	O
or	O
cause	O
resistance	O
to	O
checkpoint	O
blockade	O
.	O

We	O
recovered	O
the	O
known	O
immune	O
evasion	O
molecules	O
PD	O
-	O
L1	O
and	O
CD47	O
,	O
and	O
confirmed	O
that	O
defects	O
in	O
interferon	O
-	O
γ	O
signalling	O
caused	O
resistance	O
to	O
immunotherapy	O
.	O

Tumours	O
were	O
sensitized	O
to	O
immunotherapy	O
by	O
deletion	O
of	O
genes	O
involved	O
in	O
several	O
diverse	O
pathways	O
,	O
including	O
NF	O
-	O
κB	O
signalling	O
,	O
antigen	O
presentation	O
and	O
the	O
unfolded	O
protein	O
response	O
.	O

In	O
addition	O
,	O
deletion	B-Var
of	O
the	O
protein	O
tyrosine	O
phosphatase	O
PTPN2	B-Gene
in	O
tumour	O
cells	O
increased	B-PosReg
the	O
efficacy	B-CPA
of	I-CPA
immunotherapy	I-CPA
by	O
enhancing	B-PosReg
interferon	B-MPA
-	I-MPA
γ	I-MPA
-	I-MPA
mediated	I-MPA
effects	I-MPA
on	I-MPA
antigen	I-MPA
presentation	I-MPA
and	O
growth	B-CPA
suppression	I-CPA
.	O

In	O
vivo	O
genetic	O
screens	O
in	O
tumour	O
models	O
can	O
identify	O
new	O
immunotherapy	O
targets	O
in	O
unanticipated	O
pathways	O
.	O

A	O
patient	O
with	O
germ	O
-	O
line	O
gain	O
-	O
of	O
-	O
function	O
PDGFRB	O
p	O
.	O
N666H	O
mutation	O
and	O
marked	O
clinical	O
response	O
to	O
imatinib	O
.	O

PurposeHeterozygous	O
germ	O
-	O
line	O
activating	O
mutations	B-Var
in	O
PDGFRB	B-Gene
cause	B-Reg
Kosaki	B-Disease
and	I-Disease
Penttinen	I-Disease
syndromes	I-Disease
and	O
myofibromatosis	B-Disease
.	O

We	O
describe	O
a	O
10-year	O
-	O
old	O
child	O
with	O
a	O
germ	O
-	O
line	O
PDGFRB	B-Gene
p	B-Var
.	I-Var
N666H	I-Var
mutation	O
who	O
responded	B-MPA
to	I-MPA
the	I-MPA
tyrosine	I-MPA
kinase	I-MPA
inhibitor	I-MPA
imatinib	I-MPA
by	O
inhibition	B-NegReg
of	O
PDGFRB.MethodsThe	B-Gene
impact	O
of	O
p	O
.	O
N666H	O
on	O
PDGFRB	O
function	O
and	O
sensitivity	O
to	O
imatinib	O
was	O
studied	O
in	O
cell	O
culture	O
.	O

ResultsCells	O
expressing	O
the	O
p	O
.	O
N666H	O
mutation	O
showed	O
constitutive	O
PDGFRB	O
tyrosine	O
phosphorylation	O
.	O

PDGF	O
-	O
independent	O
proliferation	O
was	O
abolished	O
by	O
imatinib	O
at	O
1	O
μM	O
concentration	O
.	O

Patient	O
fibroblasts	O
showed	O
constitutive	O
receptor	O
tyrosine	O
phosphorylation	O
that	O
was	O
also	O
abrogated	O
by	O
imatinib	O
with	O
reduced	O
proliferation	O
of	O
treated	O
cells	O
.	O

This	O
led	O
to	O
patient	O
treatment	O
with	O
imatinib	O
at	O
400	O
mg	O
daily	O
(	O
340	O
mg	O
/	O
m(2	O
)	O
)	O
for	O
a	O
year	O
with	O
objective	O
improvement	O
of	O
debilitating	O
hand	O
and	O
foot	O
contractures	O
,	O
reduced	O
facial	O
coarseness	O
,	O
and	O
significant	O
improvement	O
in	O
quality	O
of	O
life	O
.	O

New	O
small	O
subcutaneous	O
nodules	O
developed	O
,	O
but	O
remained	O
stable	O
.	O

Transient	O
leukopenia	O
,	O
neutropenia	O
,	O
and	O
fatigue	O
resolved	O
without	O
intervention	O
;	O
however	O
,	O
mildly	O
decreased	O
growth	O
velocity	O
resulted	O
in	O
reducing	O
imatinib	O
dose	O
to	O
200	O
mg	O
daily	O
(	O
170	O
mg	O
/	O
m(2	O
)	O
)	O
.	O

The	O
patient	O
continues	O
treatment	O
with	O
ongoing	O
clinical	O
response	O
.	O

ConclusionTo	O
our	O
knowledge	O
,	O
this	O
is	O
one	O
of	O
the	O
first	O
personalized	O
treatments	O
of	O
a	O
congenital	O
disorder	O
caused	O
by	O
a	O
germ	O
-	O
line	O
PDGF	O
receptor	O
mutation	O
with	O
a	O
PDGFRB	O
inhibitor	O
.	O

GENETICS	O
in	O
MEDICINE	O
advance	O
online	O
publication	O
,	O
20	O
July	O
2017	O
;	O
doi:10.1038	O
/	O
gim.2017.104	O
.	O

Genetic	O
Diseases	O
of	O
PIEZO1	O
and	O
PIEZO2	O
Dysfunction	O
.	O

Mutations	O
in	O
the	O
genes	O
encoding	O
the	O
mechanosensitive	O
cation	O
channels	O
PIEZO1	O
and	O
PIEZO2	O
are	O
responsible	O
for	O
multiple	O
hereditary	O
human	O
diseases	O
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
the	O
human	O
PIEZO1	B-Gene
gene	O
cause	O
autosomal	B-Disease
recessive	I-Disease
congenital	I-Disease
lymphatic	I-Disease
dysplasia	I-Disease
.	O

Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutations	B-Var
in	O
the	O
human	O
PIEZO1	B-Gene
gene	O
cause	O
the	O
autosomal	B-Disease
dominant	I-Disease
hemolytic	I-Disease
anemia	I-Disease
,	O
hereditary	B-Disease
xerocytosis	I-Disease
(	O
also	O
known	O
as	O
dehydrated	B-Disease
stomatocytosis	I-Disease
)	I-Disease
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
the	O
human	O
PIEZO2	B-Gene
gene	O
cause	O
an	O
autosomal	B-Disease
recessive	I-Disease
syndrome	I-Disease
of	I-Disease
muscular	I-Disease
atrophy	I-Disease
with	O
perinatal	O
respiratory	O
distress	O
,	O
arthrogryposis	B-Disease
,	O
and	O
scoliosis	B-Disease
.	O

Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutations	B-Var
in	O
the	O
human	O
PIEZO2	B-Gene
gene	O
cause	O
three	O
clinical	O
types	O
of	O
autosomal	B-Disease
dominant	I-Disease
distal	I-Disease
arthrogryposis	I-Disease
.	O

This	O
chapter	O
will	O
review	O
the	O
hereditary	O
diseases	O
caused	O
by	O
mutations	O
in	O
the	O
PIEZO	O
genes	O
and	O
will	O
discuss	O
additional	O
physiological	O
systems	O
in	O
which	O
PIEZO	O
channel	O
dysfunction	O
may	O
contribute	O
to	O
human	O
disease	O
pathophysiology	O
.	O

Differential	O
calcium	O
sensitivity	O
in	O
NaV	O
1.5	O
mixed	O
syndrome	O
mutants	O
.	O

KEY	O
POINTS	O
:	O
SCN5a	B-Gene
mutations	B-Var
may	O
express	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	B-Disease
Long	I-Disease
QT	I-Disease
Syndrome-3	I-Disease
)	I-Disease
,	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	B-Disease
Brugada	I-Disease
Syndrome	I-Disease
1	I-Disease
)	I-Disease
or	O
both	O
(	O
mixed	O
syndromes	O
)	O
,	O
depending	O
on	O
the	O
mutation	O
and	O
environmental	O
triggers	O
.	O

One	O
such	O
trigger	O
may	O
be	O
an	O
increase	O
in	O
cytosolic	O
calcium	O
,	O
accompanying	O
exercise	O
.	O

Many	O
mixed	O
syndromes	O
mutants	O
,	O
including	O
∆KPQ	O
,	O
E1784	O
K	O
,	O
1795insD	O
and	O
Q1909R	O
,	O
are	O
found	O
in	O
calcium	O
-	O
sensitive	O
regions	O
.	O

Elevated	O
cytosolic	O
calcium	O
attenuates	O
gain	O
-	O
of	O
-	O
function	O
properties	O
in	O
∆KPQ	O
,	O
1795insD	O
and	O
Q1909R	O
,	O
but	O
not	O
in	O
E1784K.	O
By	O
contrast	O
,	O
elevated	O
cytosolic	O
calcium	O
further	O
exacerbates	O
gain	O
-	O
of	O
-	O
function	O
in	O
E1784	O
K	O
by	O
destabilizing	O
slow	O
inactivation	O
.	O

Action	O
potential	O
modelling	O
,	O
using	O
a	O
modified	O
O'Hara	O
Rudy	O
model	O
,	O
suggests	O
that	O
elevated	O
heart	O
rate	O
rescues	O
action	O
potential	O
duration	O
in	O
∆KPQ	O
,	O
1795insD	O
and	O
Q1909R	O
,	O
but	O
not	O
in	O
E1784K.	O
Action	O
potential	O
simulations	O
suggest	O
that	O
E1784	O
K	O
carriers	O
have	O
an	O
increased	O
intracellular	O
sodium	O
-	O
to	O
-	O
calcium	O
ratio	O
under	O
bradycardia	O
and	O
tachycardia	O
conditions	O
.	O

Elevated	O
cytosolic	O
calcium	O
,	O
which	O
is	O
common	O
during	O
high	O
heart	O
rates	O
,	O
ameliorates	O
or	O
exacerbates	O
the	O
mixed	O
syndrome	O
phenotype	O
depending	O
on	O
the	O
genetic	O
signature	O
.	O

ABSTRACT	O
:	O
Inherited	O
arrhythmias	O
may	O
arise	O
from	O
mutations	O
in	O
the	O
gene	O
for	O
SCN5a	O
,	O
which	O
encodes	O
the	O
cardiac	O
voltage	O
-	O
gated	O
sodium	O
channel	O
,	O
NaV	O
1.5	O
.	O

Mutants	O
in	O
NaV	O
1.5	O
result	O
in	O
Brugada	O
Syndrome	O
(	O
BrS1	O
)	O
,	O
Long	O
-	O
QT	O
Syndrome	O
(	O
LQT3	O
)	O
or	O
mixed	O
syndromes	O
(	O
an	O
overlap	O
of	O
BrS1	O
/	O
LQT3	O
)	O
.	O

Exercise	O
is	O
a	O
potential	O
arrhythmogenic	O
trigger	O
in	O
mixed	O
syndromes	O
.	O

We	O
aimed	O
to	O
determine	O
the	O
effects	O
of	O
elevated	O
cytosolic	O
calcium	O
,	O
which	O
is	O
common	O
during	O
exercise	O
,	O
in	O
mixed	O
syndrome	O
NaV	O
1.5	O
mutants	O
.	O

We	O
used	O
whole	O
-	O
cell	O
patch	O
clamp	O
to	O
assess	O
the	O
biophysical	O
properties	O
of	O
NaV	O
1.5	O
wild	O
-	O
type	O
(	O
WT	O
)	O
,	O
∆KPQ	O
,	O
E1784	O
K	O
,	O
1795insD	O
and	O
Q1909R	O
mutants	O
in	O
human	O
embryonic	O
kidney	O
293	O
cells	O
transiently	O
transfected	O
with	O
the	O
NaV	O
1.5	O
α	O
subunit	O
(	O
WT	O
or	O
mutants	O
)	O
,	O
β1	O
subunit	O
and	O
enhanced	O
green	O
fluorescent	O
protein	O
.	O

Voltage	O
-	O
dependence	O
and	O
kinetics	O
were	O
measured	O
at	O
cytosolic	O
calcium	O
levels	O
of	O
approximately	O
0	O
,	O
500	O
and	O
2500	O
nm	O
.	O

In	O
silico	O
,	O
action	O
potential	O
(	O
AP	O
)	O
model	O
simulations	O
were	O
performed	O
using	O
a	O
modified	O
O'Hara	O
Rudy	O
model	O
.	O

Elevated	O
cytosolic	O
calcium	O
attenuates	O
the	O
late	O
sodium	O
current	O
in	O
∆KPQ	O
,	O
1795insD	O
and	O
Q1909R	O
,	O
but	O
not	O
in	O
E1784K.	O
Elevated	O
cytosolic	O
calcium	O
restores	O
steady	O
-	O
state	O
slow	O
inactivation	O
(	O
SSSI	O
)	O
to	O
the	O
WT	O
-	O
form	O
in	O
Q1909R	O
,	O
but	O
depolarized	O
SSSI	O
in	O
E1784K.	O
Our	O
AP	O
simulations	O
showed	O
a	O
frequency	O
-	O
dependent	O
reduction	O
of	O
AP	O
duration	O
in	O
∆KPQ	O
,	O
1795insD	O
and	O
Q1909R	O
carriers	O
.	O

In	O
E1784	O
K	O
,	O
AP	O
duration	O
is	O
relatively	O
prolonged	O
at	O
both	O
low	O
and	O
high	O
heart	O
rates	O
,	O
resulting	O
in	O
a	O
sodium	O
overload	O
.	O

Cellular	O
perturbations	O
during	O
exercise	O
may	O
affect	O
BrS1	O
/	O
LQT3	O
patients	O
differently	O
depending	O
on	O
their	O
individual	O
genetic	O
signature	O
.	O

Thus	O
,	O
exercise	O
may	O
be	O
therapeutic	O
or	O
may	O
be	O
an	O
arrhythmogenic	O
trigger	O
in	O
some	O
SCN5a	O
patients	O
.	O

D242N	O
,	O
a	O
KV7.1	O
LQTS	O
mutation	O
uncovers	O
a	O
key	O
residue	O
for	O
IKs	O
voltage	O
dependence	O
.	O

KV7.1	O
and	O
KCNE1	O
co	O
-	O
assemble	O
to	O
give	O
rise	O
to	O
the	O
IKs	O
current	O
,	O
one	O
of	O
the	O
most	O
important	O
repolarizing	O
currents	O
of	O
the	O
cardiac	O
action	O
potential	O
.	O

Its	O
relevance	O
is	O
underscored	O
by	O
the	O
identification	O
of	O
>	O
500	O
mutations	B-Var
in	O
KV7.1	B-Gene
and	O
,	O
at	O
least	O
,	O
36	O
in	O
KCNE1	B-Gene
,	O
that	O
cause	B-Reg
Long	B-Disease
QT	I-Disease
Syndrome	I-Disease
(	O
LQTS	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
characterize	O
the	O
biophysical	O
and	O
cellular	O
consequences	O
of	O
the	O
D242N	B-Var
KV7.1	B-Gene
mutation	O
associated	B-Reg
with	O
the	O
LQTS	B-Disease
.	O

The	O
mutation	B-Var
is	O
located	O
in	O
the	O
S4	O
transmembrane	O
segment	O
,	O
within	O
the	O
voltage	O
sensor	O
of	O
the	O
KV7.1	O
channel	O
,	O
disrupting	B-NegReg
the	O
conserved	B-MPA
charge	I-MPA
balance	I-MPA
of	I-MPA
this	I-MPA
region	I-MPA
.	O

Perforated	O
patch	O
-	O
clamp	O
experiments	O
show	O
that	O
,	O
unexpectedly	O
,	O
the	O
mutation	B-Var
did	O
not	O
disrupt	O
the	O
voltage	O
-	O
dependent	O
activation	O
but	O
it	O
removed	B-NegReg
the	O
inactivation	B-MPA
and	O
slowed	B-NegReg
the	O
activation	B-MPA
kinetics	I-MPA
of	O
D242N	B-MPA
KV7.1	I-MPA
channels	I-MPA
.	O

Biotinylation	O
of	O
cell	O
-	O
surface	O
protein	O
and	O
co	O
-	O
immunoprecipitation	O
experiments	O
revealed	O
that	O
neither	O
plasma	O
membrane	O
targeting	O
nor	O
co	O
-	O
assembly	O
between	O
KV7.1	O
and	O
KCNE1	O
was	O
altered	O
by	O
the	O
mutation	O
.	O

However	O
,	O
the	O
association	O
of	O
D242N	O
KV7.1	O
with	O
KCNE1	O
strongly	O
shifted	O
the	O
voltage	O
dependence	O
of	O
activation	O
to	O
more	O
depolarized	O
potentials	O
(	O
+50mV	O
)	O
,	O
hindering	O
IKs	O
current	O
at	O
physiologically	O
relevant	O
membrane	O
potentials	O
.	O

Both	O
functional	O
and	O
computational	O
analysis	O
suggest	O
that	O
the	O
clinical	O
phenotype	O
of	O
the	O
LQTS	O
patients	O
carrying	O
the	O
D242N	B-Var
mutation	O
is	O
due	O
to	O
impaired	B-NegReg
action	B-MPA
potential	I-MPA
adaptation	I-MPA
to	I-MPA
exercise	I-MPA
and	O
,	O
in	O
particular	O
,	O
to	O
increase	B-PosReg
in	O
heart	B-MPA
rate	I-MPA
.	O

Moreover	O
,	O
our	O
data	O
identify	O
D242	O
aminoacidic	O
position	O
as	O
a	O
potential	O
residue	O
involved	O
in	O
the	O
KCNE1-mediated	O
regulation	O
of	O
the	O
voltage	O
dependence	O
of	O
activation	O
of	O
the	O
KV7.1	O
channel	O
.	O

A	O
Gene	O
Implicated	O
in	O
Activation	O
of	O
Retinoic	O
Acid	O
Receptor	O
Targets	O
is	O
a	O
Novel	O
Renal	O
Agenesis	O
Gene	O
in	O
Humans	O
.	O

Renal	B-Disease
agenesis	I-Disease
(	O
RA	O
)	O
is	O
one	O
of	O
the	O
more	O
extreme	O
examples	O
of	O
congenital	O
anomalies	O
of	O
the	O
kidney	O
and	O
urinary	O
tract	O
(	O
CAKUT	O
)	O
.	O

Bilateral	O
renal	O
agenesis	O
is	O
almost	O
invariably	O
fatal	O
at	O
birth	O
,	O
and	O
unilateral	O
renal	O
agenesis	O
can	O
lead	O
to	O
future	O
health	O
issues	O
including	O
end	O
stage	O
renal	O
disease	O
.	O

Genetic	O
investigations	O
have	O
identified	O
several	O
gene	O
variants	B-Var
which	O
cause	B-Reg
RA	B-Disease
,	O
including	O
EYA1	O
,	O
LHX1	O
,	O
and	O
WT1	O
However	O
,	O
whereas	O
compound	O
null	O
mutations	O
of	O
genes	O
encoding	O
α	O
and	O
γ	O
retinoic	O
acid	O
receptors	O
(	O
RARs	O
)	O
cause	O
RA	O
in	O
mice	O
,	O
to	O
date	O
there	O
have	O
been	O
no	O
reports	O
of	O
variants	O
in	O
RAR	O
genes	O
causing	O
RA	O
in	O
humans	O
.	O

In	O
this	O
study	O
,	O
we	O
carried	O
out	O
whole	O
exome	O
sequence	O
analysis	O
of	O
two	O
families	O
showing	O
inheritance	O
of	O
an	O
RA	O
phenotype	O
,	O
and	O
in	O
both	O
identified	O
a	O
single	O
candidate	O
gene	O
,	O
GREB1L	O
Analysis	O
of	O
a	O
zebrafish	O
greb1l	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutant	B-Var
revealed	O
defects	O
in	O
the	O
pronephric	B-MPA
kidney	I-MPA
just	I-MPA
prior	I-MPA
to	I-MPA
death	I-MPA
,	O
and	O
F0	O
CRISPR	O
/	O
Cas9	O
mutagenesis	B-Var
of	O
Greb1l	O
in	O
the	O
mouse	O
revealed	B-Reg
kidney	B-MPA
agenesis	I-MPA
phenotypes	I-MPA
,	O
implicating	O
Greb1l	O
in	O
this	O
disorder	O
.	O

GREB1L	O
resides	O
in	O
a	O
chromatin	O
complex	O
with	O
RAR	O
members	O
,	O
and	O
our	O
data	O
implicate	O
GREB1L	O
as	O
a	O
coactivator	O
for	O
RARs	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
associate	O
a	O
component	O
of	O
the	O
RAR	O
pathway	O
with	O
renal	O
agenesis	O
in	O
humans	O
.	O

Equivalent	O
missense	B-Var
variant	I-Var
in	O
the	O
FOXP2	B-Gene
and	O
FOXP1	B-Gene
transcription	O
factors	O
causes	B-Reg
distinct	O
neurodevelopmental	B-Disease
disorders	I-Disease
.	O

The	O
closely	O
related	O
paralogues	O
FOXP2	O
and	O
FOXP1	O
encode	O
transcription	O
factors	O
with	O
shared	O
functions	O
in	O
the	O
development	O
of	O
many	O
tissues	O
,	O
including	O
the	O
brain	O
.	O

However	O
,	O
while	O
mutations	B-Var
in	O
FOXP2	B-Gene
lead	B-Reg
to	I-Reg
a	O
speech	O
/	O
language	O
disorder	O
characterized	O
by	O
childhood	B-Disease
apraxia	I-Disease
of	I-Disease
speech	I-Disease
(	O
CAS	O
)	O
,	O
the	O
clinical	O
profile	O
of	O
FOXP1	B-Gene
variants	B-Var
includes	B-Reg
a	O
broader	O
neurodevelopmental	O
phenotype	O
with	O
global	B-Disease
developmental	I-Disease
delay	I-Disease
,	O
intellectual	B-Disease
disability	I-Disease
,	O
and	O
speech	B-Disease
/	I-Disease
language	I-Disease
impairment	I-Disease
.	O

Using	O
clinical	O
whole	O
-	O
exome	O
sequencing	O
,	O
we	O
report	O
an	O
identical	O
de	O
novo	O
missense	O
FOXP1	O
variant	O
identified	O
in	O
three	O
unrelated	O
patients	O
.	O

The	O
variant	O
,	O
p	O
.	O
R514H	O
,	O
is	O
located	O
in	O
the	O
forkhead	O
-	O
box	O
DNA	O
-	O
binding	O
domain	O
and	O
is	O
equivalent	O
to	O
the	O
well	O
-	O
studied	O
p	O
.	O
R553H	O
FOXP2	O
variant	O
that	O
cosegregates	O
with	O
CAS	O
in	O
a	O
large	O
UK	O
family	O
.	O

We	O
present	O
here	O
for	O
the	O
first	O
time	O
a	O
direct	O
comparison	O
of	O
the	O
molecular	O
and	O
clinical	O
consequences	O
of	O
the	O
same	O
mutation	O
affecting	O
the	O
equivalent	O
residue	O
in	O
FOXP1	O
and	O
FOXP2	O
.	O

Detailed	O
functional	O
characterization	O
of	O
the	O
two	O
variants	O
in	O
cell	O
model	O
systems	O
revealed	O
very	O
similar	O
molecular	O
consequences	O
,	O
including	O
aberrant	O
subcellular	O
localization	O
,	O
disruption	O
of	O
transcription	O
factor	O
activity	O
,	O
and	O
deleterious	O
effects	O
on	O
protein	O
interactions	O
.	O

Nonetheless	O
,	O
clinical	O
manifestations	O
were	O
broader	O
and	O
more	O
severe	O
in	O
the	O
three	O
cases	O
carrying	O
the	O
p	O
.	O
R514H	O
FOXP1	O
variant	O
than	O
in	O
individuals	O
with	O
the	O
p	O
.	O
R553H	O
variant	O
related	O
to	O
CAS	O
,	O
highlighting	O
divergent	O
roles	O
of	O
FOXP2	O
and	O
FOXP1	O
in	O
neurodevelopment	O
.	O

Novel	O
PRPS1	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
in	O
a	O
patient	O
with	O
congenital	O
hyperuricemia	O
and	O
facial	O
anomalies	O
.	O

Phosphoribosylpyrophosphate	O
synthetase	O
(	O
PRPPS	O
)	O
superactivity	O
(	O
OMIM	O
300661	O
)	O
is	O
a	O
rare	O
inborn	O
error	O
of	O
purine	O
metabolism	O
that	O
is	O
caused	O
by	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
X	O
-	O
chromosomal	O
gene	O
PRPS1	O
(	O
Xq22.3	O
)	O
.	O

Clinical	O
characteristics	O
include	O
congenital	O
hyperuricemia	O
and	O
hyperuricosuria	O
,	O
gouty	O
arthritis	O
,	O
urolithiasis	O
,	O
developmental	O
delay	O
,	O
hypotonia	O
,	O
recurrent	O
infections	O
,	O
short	O
stature	O
,	O
and	O
hearing	O
loss	O
.	O

Only	O
eight	O
families	O
with	O
PRPPS	O
superactivity	O
and	O
PRPS1	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
have	O
been	O
reported	O
to	O
date	O
.	O

We	O
report	O
on	O
a	O
7-year	O
-	O
old	O
boy	O
with	O
congenital	O
hyperuricemia	O
,	O
urolithiasis	O
,	O
developmental	O
delay	O
,	O
short	O
stature	O
,	O
hypospadias	O
,	O
and	O
facial	O
dysmorphisms	O
.	O

His	O
mother	O
also	O
suffered	O
from	O
hyperuricemia	O
that	O
was	O
diagnosed	O
at	O
age	O
13	O
years	O
.	O

A	O
novel	O
PRPS1	O
missense	O
mutation	O
(	O
c.573G	O
>	O
C	O
,	O
p.[Leu191Phe	O
]	O
)	O
was	O
detected	O
in	O
the	O
proband	O
and	O
his	O
mother	O
.	O

Enzyme	O
activity	O
analysis	O
confirmed	O
superactivity	O
of	O
PRPP	O
synthetase	O
.	O

Analysis	O
of	O
the	O
crystal	O
structure	O
of	O
human	O
PRPPS	O
suggests	O
that	O
the	O
Leu191Phe	B-Gene
mutation	B-Var
affects	B-Reg
the	O
architecture	B-MPA
of	O
both	O
allosteric	O
sites	O
,	O
thereby	O
preventing	B-NegReg
the	O
allosteric	B-MPA
inhibition	I-MPA
of	O
the	O
enzyme	B-Enzyme
.	O

The	O
family	O
reported	O
here	O
broadens	O
the	O
clinical	O
spectrum	O
of	O
PRPPS	O
superactivity	O
and	O
indicates	O
that	O
this	O
rare	O
metabolic	O
disorder	O
might	O
be	O
associated	O
with	O
a	O
recognizable	O
facial	O
gestalt	O
.	O

Naturally	O
-	O
Segregating	O
Variation	B-Var
at	O
Ugt86Dd	B-Gene
Contributes	B-Reg
to	O
Nicotine	B-MPA
Resistance	I-MPA
in	I-MPA
Drosophila	I-MPA
melanogaster	I-MPA
.	O

Identifying	O
the	O
sequence	O
polymorphisms	O
underlying	O
complex	O
trait	O
variation	O
is	O
a	O
key	O
goal	O
of	O
genetics	O
research	O
,	O
since	O
knowing	O
the	O
precise	O
causative	O
molecular	O
events	O
allows	O
insight	O
into	O
the	O
pathways	O
governing	O
trait	O
variation	O
.	O

Genetic	O
analysis	O
of	O
complex	O
traits	O
in	O
model	O
systems	O
regularly	O
starts	O
by	O
constructing	O
QTL	O
maps	O
,	O
but	O
generally	O
fails	O
to	O
identify	O
causative	O
sequence	O
polymorphisms	O
.	O

Previously	O
we	O
mapped	O
a	O
series	O
of	O
QTL	O
contributing	O
to	O
resistance	O
to	O
nicotine	O
in	O
a	O
Drosophila	O
melanogaster	O
multiparental	O
mapping	O
resource	O
,	O
and	O
here	O
use	O
a	O
battery	O
of	O
functional	O
tests	O
to	O
resolve	O
QTL	O
to	O
the	O
molecular	O
level	O
.	O

One	O
large	O
-	O
effect	O
QTL	O
resided	O
over	O
a	O
cluster	O
of	O
UDP	O
-	O
glucuronosyltransferases	O
,	O
and	O
quantitative	O
complementation	O
tests	O
using	O
deficiencies	O
eliminating	O
subsets	O
of	O
these	O
detoxification	O
genes	O
revealed	O
allelic	O
variation	O
impacting	O
resistance	O
.	O

RNAseq	O
showed	O
that	O
Ugt86Dd	O
had	O
significantly	O
higher	O
expression	O
in	O
genotypes	O
that	O
are	O
more	O
resistant	O
to	O
nicotine	O
,	O
and	O
anterior	O
midgut	O
-	O
specific	O
RNAi	O
of	O
this	O
gene	O
reduced	O
resistance	O
.	O

We	O
discovered	O
a	O
segregating	O
22-bp	O
frameshift	B-Var
deletion	I-Var
in	O
Ugt86Dd	B-Gene
,	O
and	O
accounting	O
for	O
the	O
InDel	O
during	O
mapping	O
largely	O
eliminates	B-NegReg
the	O
QTL	B-MPA
,	O
implying	O
the	O
event	O
explains	O
the	O
bulk	O
of	O
the	O
effect	O
of	O
the	O
mapped	O
locus	O
.	O

CRISPR	O
/	O
Cas9	O
editing	O
a	O
relatively	O
resistant	O
genotype	O
to	O
generate	O
lesions	B-Var
in	O
Ugt86Dd	B-Gene
that	O
recapitulate	O
the	O
naturally	O
-	O
occurring	O
putative	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
allele	O
leads	O
to	O
a	O
large	O
reduction	B-NegReg
in	O
resistance	B-MPA
.	O

Despite	O
this	O
major	O
effect	O
of	O
the	O
deletion	O
,	O
the	O
allele	O
appears	O
to	O
be	O
very	O
rare	O
in	O
wild	O
-	O
caught	O
populations	O
,	O
and	O
likely	O
explains	O
only	O
a	O
small	O
fraction	O
of	O
the	O
natural	O
variation	O
for	O
the	O
trait	O
.	O

Nonetheless	O
,	O
this	O
putatively	O
causative	O
coding	O
InDel	O
can	O
be	O
a	O
launchpad	O
for	O
future	O
mechanistic	O
exploration	O
of	O
xenobiotic	O
detoxification	O
.	O

Sequence	B-Var
exchange	I-Var
between	O
R	B-Gene
genes	O
converts	B-Reg
virus	O
resistance	O
into	O
nematode	B-MPA
resistance	I-MPA
,	O
and	O
vice	O
versa	O
.	O

Plants	O
have	O
evolved	O
a	O
limited	O
repertoire	O
of	O
NB	O
-	O
LRR	O
disease	O
resistance	O
(	O
R	O
)	O
genes	O
to	O
protect	O
themselves	O
against	O
a	O
myriad	O
of	O
pathogens	O
.	O

This	O
limitation	O
is	O
thought	O
to	O
be	O
counterbalanced	O
by	O
the	O
rapid	O
evolution	O
of	O
NB	O
-	O
LRR	O
proteins	O
,	O
as	O
only	O
few	O
sequence	O
changes	B-Var
have	O
been	O
shown	O
to	O
be	O
sufficient	O
to	O
alter	B-Reg
resistance	B-MPA
specificities	I-MPA
towards	I-MPA
novel	I-MPA
strains	I-MPA
of	I-MPA
a	I-MPA
pathogen	I-MPA
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
flexibility	O
of	O
NB	O
-	O
LRR	O
genes	O
to	O
switch	O
resistance	O
specificities	O
between	O
phylogenetically	O
unrelated	O
pathogens	O
.	O

To	O
investigate	O
this	O
,	O
we	O
created	O
domain	O
swaps	O
between	O
the	O
close	O
homologs	O
Gpa2	O
and	O
Rx1	O
,	O
which	O
confer	O
resistance	O
in	O
potato	O
to	O
the	O
cyst	O
nematode	O
Globodera	O
pallida	O
and	O
Potato	O
virus	O
X	O
(	O
PVX	O
)	O
,	O
respectively	O
.	O

The	O
genetic	O
fusion	O
of	O
the	O
CC	O
-	O
NB	O
-	O
ARC	O
of	O
Gpa2	O
with	O
the	O
LRR	O
of	O
Rx1	O
(	O
Gpa2CN	O
/	O
Rx1L	O
)	O
resulted	O
in	O
autoactivity	O
,	O
but	O
lowering	O
the	O
protein	O
levels	O
restored	O
its	O
specific	O
activation	O
response	O
including	O
extreme	O
resistance	O
to	O
PVX	O
in	O
potato	O
shoots	O
.	O

The	O
reciprocal	O
construct	O
(	O
Rx1CN	O
/	O
Gpa2L	O
)	O
showed	O
a	O
loss	O
-	O
of	O
-	O
function	O
phenotype	O
,	O
but	O
exchange	B-Var
of	O
the	O
first	O
3	O
LRR	O
repeats	O
of	O
Rx1	B-Gene
was	O
sufficient	O
to	O
regain	B-PosReg
a	O
wild	B-MPA
type	I-MPA
resistance	I-MPA
response	I-MPA
to	I-MPA
G.	I-MPA
pallida	I-MPA
in	I-MPA
the	I-MPA
roots	I-MPA
.	O

These	O
data	O
demonstrate	O
that	O
exchanging	B-Var
the	O
recognition	O
moiety	O
in	O
the	O
LRR	O
is	O
sufficient	O
to	O
convert	B-Reg
extreme	O
virus	O
resistance	O
in	O
the	O
leaves	O
into	O
mild	B-MPA
nematode	I-MPA
resistance	I-MPA
in	I-MPA
the	I-MPA
roots	I-MPA
,	O
and	O
vice	O
versa	O
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
the	O
CC	O
-	O
NB	O
-	O
ARC	O
can	O
operate	O
independently	O
of	O
the	O
recognition	O
specificities	O
defined	O
by	O
the	O
LRR	O
domain	O
,	O
either	O
above	O
or	O
belowground	O
.	O

These	O
data	O
show	O
the	O
versatility	O
of	O
NB	O
-	O
LRR	O
genes	O
to	O
generate	O
resistances	O
to	O
unrelated	O
pathogens	O
with	O
completely	O
different	O
lifestyles	O
and	O
routes	O
of	O
invasion	O
.	O

Lethal	O
digenic	O
mutations	B-Var
in	O
the	O
K(+	O
)	O
channels	O
Kir4.1	O
(	B-Gene
KCNJ10	I-Gene
)	I-Gene
and	O
SLACK	O
(	B-Gene
KCNT1	I-Gene
)	I-Gene
associated	B-Reg
with	O
severe	O
-	O
disabling	O
seizures	B-Disease
and	O
neurodevelopmental	B-Disease
delay	I-Disease
.	O

A	O
2-year	O
-	O
old	O
boy	O
presented	O
profound	O
developmental	O
delay	O
,	O
failure	O
to	O
thrive	O
,	O
ataxia	O
,	O
hypotonia	O
and	O
tonic	O
-	O
clonic	O
seizures	O
that	O
caused	O
the	O
death	O
of	O
the	O
patient	O
.	O

Targeted	O
and	O
whole	O
-	O
exome	O
sequencing	O
revealed	O
two	O
heterozygous	O
missense	O
variants	O
:	O
a	O
novel	O
mutation	O
in	O
KCNJ10	O
gene	O
that	O
encodes	O
for	O
the	O
inwardly	O
-	O
rectifying	O
K(+	O
)	O
channel	O
Kir4.1	O
and	O
another	O
previously	O
characterized	O
mutation	O
in	O
KCNT1	O
that	O
encodes	O
for	O
the	O
Na(+)-activated	O
K(+	O
)	O
channel	O
known	O
as	O
Slo2.2	O
or	O
SLACK	O
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
perform	O
the	O
clinical	O
and	O
genetic	O
characterization	O
of	O
the	O
proband	O
and	O
his	O
family	O
and	O
to	O
examine	O
the	O
functional	O
consequence	O
of	O
the	O
Kir4.1	O
mutation	O
.	O

The	O
mutant	O
and	O
wild	O
-	O
type	O
KCNJ10	O
constructs	O
were	O
generated	O
and	O
heterologously	O
expressed	O
in	O
Xenopus	O
laevis	O
oocytes	O
,	O
and	O
whole	O
-	O
cell	O
K(+	O
)	O
currents	O
were	O
measured	O
using	O
the	O
two	O
-	O
electrode	O
voltage	O
-	O
clamp	O
technique	O
.	O

The	O
KCNJ10	B-Gene
mutation	B-Var
c.652C	O
>	O
T	O
resulted	B-Reg
in	I-Reg
a	O
p	O
.	O
L218F	O
substitution	B-Var
at	O
a	O
highly	O
conserved	O
residue	O
site	O
.	O

Wild	O
-	O
type	O
KCNJ10	O
expression	O
yielded	O
robust	O
Kir	O
currents	O
,	O
while	O
currents	O
from	O
oocytes	O
expressing	O
the	O
mutation	O
were	O
reduced	O
.	O

Western	O
Blot	O
analysis	O
revealed	O
reduced	B-NegReg
protein	B-MPA
expression	I-MPA
by	O
the	O
mutation	B-Var
.	O

Kir5.1	O
subunits	O
display	O
selective	O
heteromultimerization	O
with	O
Kir4.1	O
constituting	O
channels	O
with	O
unique	O
kinetics	O
.	O

The	O
effect	O
of	O
the	O
mutation	O
on	O
Kir4.1/5.1	O
channel	O
activity	O
was	O
twofold	O
:	O
a	O
reduction	O
in	O
current	O
amplitudes	O
and	O
an	O
increase	O
in	O
the	O
pH	O
-	O
dependent	O
inhibition	O
.	O

We	O
thus	O
report	O
a	O
novel	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	B-Var
in	O
Kir4.1	O
found	O
in	O
a	O
patient	O
with	O
a	O
co	O
-	O
exiting	O
mutation	B-Var
in	O
SLACK	O
channels	O
that	O
results	B-Reg
in	I-Reg
a	O
fatal	B-Disease
disease	I-Disease
.	O

A	O
Novel	O
Missense	B-Var
Mutation	I-Var
in	O
Peripheral	B-Protein
Myelin	I-Protein
Protein-22	I-Protein
Causes	B-Reg
Charcot	B-Disease
-	I-Disease
Marie	I-Disease
-	I-Disease
Tooth	I-Disease
Disease	I-Disease
.	O

BACKGROUND	O
:	O
Charcot	O
-	O
Marie	O
-	O
Tooth	O
disease	O
(	O
CMT	O
)	O
is	O
the	O
most	O
common	O
inherited	O
peripheral	O
neuropathy	O
.	O

A	O
great	O
number	O
of	O
causative	O
genes	O
have	O
been	O
described	O
in	O
CMT	O
,	O
and	O
among	O
them	O
,	O
the	O
heterozygous	O
duplication	O
of	O
peripheral	O
myelin	O
protein-22	O
(	O
PMP22	O
)	O
is	O
the	O
major	O
cause	O
.	O

Although	O
the	O
missense	B-Var
mutation	I-Var
in	O
PMP22	B-Gene
is	O
rarely	O
reported	O
,	O
it	O
has	O
been	O
demonstrated	O
to	O
be	O
associated	B-Reg
with	O
CMT	B-Disease
.	O

This	O
study	O
described	O
a	O
novel	O
missense	B-Var
mutation	I-Var
of	O
PMP22	B-Gene
in	B-Reg
a	O
Chinese	O
family	O
with	O
CMT	B-Disease
phenotype	O
.	O

METHODS	O
:	O
Targeted	O
next	O
-	O
generation	O
sequencing	O
(	O
NGS	O
)	O
was	O
used	O
to	O
screen	O
the	O
causative	O
genes	O
in	O
a	O
family	O
featured	O
with	O
an	O
autosomal	O
dominant	O
demyelinating	O
form	O
of	O
CMT	O
.	O

The	O
potential	O
variants	O
identified	O
by	O
targeted	O
NGS	O
were	O
verified	O
by	O
Sanger	O
sequencing	O
and	O
classified	O
according	O
to	O
the	O
American	O
College	O
of	O
Medical	O
Genetics	O
and	O
Genomics	O
standards	O
and	O
guidelines	O
.	O

Further	O
cell	O
transfection	O
studies	O
were	O
performed	O
to	O
characterize	O
the	O
function	O
of	O
the	O
novel	O
variant	O
.	O

RESULTS	O
:	O
Using	O
targeted	O
NGS	O
,	O
a	O
novel	O
heterozygous	O
missense	O
variant	O
in	O
PMP22	O
(	O
c.320G	O
>	O
A	O
,	O
p	O
.	O
G107D	O
)	O
was	O
identified	O
.	O

In	O
vitro	O
cell	O
functional	O
studies	O
revealed	O
that	O
mutant	O
PMP22	B-Gene
protein	B-Protein
carrying	O
p	B-Var
.	I-Var
G107D	I-Var
mutation	O
lost	B-NegReg
the	O
ability	B-CPA
to	I-CPA
reach	I-CPA
the	I-CPA
plasma	I-CPA
membrane	I-CPA
,	O
was	O
mainly	O
retained	O
in	O
the	O
endoplasmic	O
reticulum	O
,	O
and	O
induced	B-Reg
cell	B-CPA
apoptosis	I-CPA
.	O

CONCLUSIONS	O
:	O
This	O
study	O
supported	O
the	O
notion	O
that	O
missense	B-Var
mutations	I-Var
in	O
PMP22	B-Gene
give	O
rise	O
to	O
a	O
CMT	B-Disease
phenotype	O
,	O
possibly	O
through	O
a	O
toxic	B-PosReg
gain	I-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mechanism	O
.	O

Allelic	O
Complexity	O
in	O
Long	O
QT	O
Syndrome	O
:	O
A	O
Family	O
-	O
Case	O
Study	O
.	O

Congenital	O
long	B-Disease
QT	I-Disease
syndrome	I-Disease
(	O
LQTS	O
)	O
is	O
associated	O
with	O
high	O
genetic	O
and	O
allelic	O
heterogeneity	O
.	O

In	O
some	O
cases	O
,	O
more	O
than	O
one	O
genetic	O
variant	O
is	O
identified	O
in	O
the	O
same	O
(	O
compound	O
heterozygosity	O
)	O
or	O
different	O
(	O
digenic	O
heterozygosity	O
)	O
genes	O
,	O
and	O
subjects	O
with	O
multiple	O
pathogenic	O
mutations	O
may	O
have	O
a	O
more	O
severe	O
disease	O
.	O

Standard	O
-	O
of	O
-	O
care	O
clinical	O
genetic	O
testing	O
for	O
this	O
and	O
other	O
arrhythmia	O
susceptibility	O
syndromes	O
improves	O
the	O
identification	O
of	O
complex	O
genotypes	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
distinguish	O
between	O
pathogenic	O
mutations	O
and	O
benign	O
rare	O
variants	O
.	O

We	O
identified	O
four	O
genetic	O
variants	O
(	O
KCNQ1-p	O
.	O

R583H	O
,	O
KCNH2-p	O
.	O

C108Y	O
,	O
KCNH2-p	O
.	O

K897	O
T	O
,	O
and	O
KCNE1-p	O
.	O

G38S	O
)	O
in	O
an	O
LQTS	O
family	O
.	O

On	O
the	O
basis	O
of	O
in	O
silico	O
analysis	O
,	O
clinical	O
data	O
from	O
our	O
family	O
,	O
and	O
the	O
evidence	O
from	O
previous	O
studies	O
,	O
we	O
analyzed	O
two	O
mutated	O
channels	O
,	O
KCNQ1-p	O
.	O

R583H	O
and	O
KCNH2-p	O
.	O

C108Y	O
,	O
using	O
the	O
whole	O
-	O
cell	O
patch	O
clamp	O
technique	O
.	O

We	O
found	O
that	O
KCNQ1-p	O
.	O

R583H	O
was	O
not	O
associated	O
with	O
a	O
severe	O
functional	O
impairment	O
,	O
whereas	O
KCNH2-p	B-Gene
.	I-Gene
C108Y	I-Gene
,	O
a	O
novel	O
variant	O
,	O
encoded	B-Reg
a	O
non	B-Pathway
-	I-Pathway
functional	I-Pathway
channel	I-Pathway
that	O
exerts	O
dominant	B-NegReg
-	I-NegReg
negative	I-NegReg
effects	B-MPA
on	O
the	O
wild	O
-	O
type	O
.	O

Notably	O
,	O
the	O
common	O
variants	O
KCNH2-p	O
.	O

K897	O
T	O
and	O
KCNE1-p	O
.	O

G38S	O
were	O
previously	O
reported	O
to	O
produce	O
more	O
severe	O
phenotypes	O
when	O
combined	O
with	O
disease	O
-	O
causing	O
alleles	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
novel	O
KCNH2-C108Y	B-Gene
variant	O
can	O
be	O
a	O
pathogenic	B-Reg
LQTS	B-Disease
mutation	O
,	O
whereas	O
KCNQ1-p	O
.	O

R583H	O
,	O
KCNH2-p	O
.	O

K897	O
T	O
,	O
and	O
KCNE1-p	O
.	O

G38S	O
could	O
be	O
LQTS	O
modifiers	O
.	O

POSITIVE	O
REGULATOR	O
OF	O
IRON	O
HOMEOSTASIS	O
1	O
(	O
OsPRI1	O
)	O
positively	O
regulates	O
iron	O
homeostasis	O
in	O
rice	O
.	O

OsHRZ1	O
is	O
a	O
potential	O
iron	O
-	O
binding	O
sensor	O
.	O

However	O
,	O
it	O
is	O
unclear	O
how	O
OsHRZ1	O
transmits	O
signals	O
.	O

In	O
this	O
study	O
,	O
we	O
reveal	O
that	O
OsPRI1	O
interacts	O
with	O
OsHRZ1	O
.	O

A	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	B-Var
to	O
OsPRI1	B-Gene
increased	B-PosReg
the	O
sensitivity	B-MPA
of	O
plants	O
to	O
Fe	O
-	O
deficient	O
conditions	O
and	O
downregulated	B-NegReg
the	O
expression	B-MPA
of	O
Fe	O
-	O
deficiency	O
-	O
responsive	O
genes	O
.	O

Yeast	O
one	O
-	O
hybrid	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
results	O
suggested	O
that	O
OsPRI1	O
binds	O
to	O
the	O
OsIRO2	O
and	O
OsIRO3	O
promoters	O
.	O

In	O
vitro	O
ubiquitination	O
experiments	O
indicated	O
that	O
OsPRI1	O
is	O
ubiquitinated	O
by	O
OsHRZ1	O
.	O

Cell	O
-	O
free	O
degradation	O
assays	O
revealed	O
that	O
the	O
stability	B-MPA
of	O
OsPRI1	O
decreased	O
in	O
wild	O
type	O
roots	O
,	O
but	O
increased	B-PosReg
in	O
the	O
hrz1	B-Gene
-	I-Gene
2	I-Gene
mutant	B-Var
,	O
suggesting	O
OsHRZ1	O
is	O
responsible	O
for	O
the	O
instability	O
of	O
OsPRI1	O
.	O

The	O
hrz1	O
-	O
2	O
seedlings	O
were	O
insensitive	O
to	O
Fe	O
-	O
deficient	O
conditions	O
.	O

When	O
the	O
pri1	B-Gene
-	I-Gene
1	I-Gene
mutation	B-Var
was	O
introduced	B-Interaction
into	O
hrz1	B-Gene
-	I-Gene
2	I-Gene
mutants	B-Var
,	O
the	O
pri1hrz1	O
double	O
mutant	O
was	O
more	B-PosReg
sensitive	B-MPA
to	I-MPA
Fe	I-MPA
deficiency	I-MPA
than	O
the	O
hrz1	O
-	O
2	O
mutant	O
.	O

Additionally	O
,	O
the	O
expression	O
levels	O
of	O
Fe	O
-	O
deficiency	O
-	O
responsive	O
genes	O
were	O
lower	O
in	O
the	O
hrz1pri1	O
double	O
mutant	O
than	O
in	O
the	O
hrz1	O
-	O
2	O
mutant	O
.	O

Collectively	O
,	O
these	O
results	O
imply	O
that	O
OsPRI1	O
,	O
which	O
is	O
ubiquitinated	O
by	O
OsHRZ1	O
,	O
mediates	O
rice	O
responses	O
to	O
Fe	O
-	O
deficiency	O
by	O
positively	O
regulating	O
OsIRO2	O
and	O
OsIRO3	O
expression	O
as	O
part	O
of	O
the	O
OsHRZ1-OsPRI1-OsIRO2/3	O
signal	O
transduction	O
cascade	O
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
but	O
not	O
dominant	O
-	O
negative	O
intragenic	O
IKZF1	B-Gene
deletions	B-Var
are	O
associated	O
with	O
an	O
adverse	O
prognosis	O
in	O
adult	O
BCR	O
-	O
ABL	O
-	O
negative	O
acute	B-Disease
lymphoblastic	I-Disease
leukemia	I-Disease
.	O

Genetic	O
alterations	O
of	O
the	O
transcription	O
factor	O
IKZF1	O
(	O
"	O
IKAROS	O
"	O
)	O
are	O
detected	O
in	O
around	O
15	O
-	O
30	O
%	O
of	O
cases	O
of	O
BCR	O
-	O
ABL	O
-	O
negative	O
B	O
-	O
cell	O
precursor	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
.	O

Different	O
types	O
of	O
intragenic	O
deletions	B-Var
have	O
been	O
observed	O
,	O
resulting	O
in	O
a	O
functionally	B-MPA
inactivated	I-MPA
allele	I-MPA
(	B-NegReg
"	I-NegReg
loss	I-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
"	I-NegReg
)	I-NegReg
or	O
in	O
"	B-NegReg
dominant	I-NegReg
-	I-NegReg
negative	I-NegReg
"	I-NegReg
isoforms	B-MPA
.	O

The	O
prognostic	O
impact	O
of	O
these	O
alterations	O
especially	O
in	O
adult	O
acute	O
lymphoblastic	O
leukemia	O
is	O
not	O
well	O
defined	O
.	O

We	O
analyzed	O
482	O
well	O
-	O
characterized	O
cases	O
of	O
adult	O
BCR	O
-	O
ABL	O
-	O
negative	O
B	O
-	O
precursor	O
acute	O
lymphoblastic	O
leukemia	O
uniformly	O
treated	O
in	O
the	O
framework	O
of	O
the	O
GMALL	O
studies	O
and	O
detected	O
IKZF1	O
alterations	O
in	O
128	O
cases	O
(	O
27	O
%	O
)	O
.	O

In	O
20	O
%	O
,	O
the	O
IKZF1	O
alteration	O
was	O
present	O
in	O
a	O
large	O
fraction	O
of	O
leukemic	O
cells	O
(	O
"	O
high	O
deletion	O
load	O
"	O
)	O
while	O
in	O
7	O
%	O
it	O
was	O
detected	O
only	O
in	O
small	O
subclones	O
(	O
"	O
low	O
deletion	O
load	O
"	O
)	O
.	O

Some	O
patients	O
showed	O
more	O
than	O
one	O
IKZF1	O
alteration	O
(	O
8	O
%	O
)	O
.	O

Patients	O
exhibiting	O
a	O
loss	O
-	O
of	O
-	O
function	O
isoform	O
with	O
high	B-Var
deletion	I-Var
load	I-Var
had	O
a	O
shorter	B-NegReg
overall	B-MPA
survival	I-MPA
(	O
OS	O
at	O
5	O
years	O
28	O
%	O
vs.	O
59	O
%	O
,	O
p<0.0001	O
)	O
,	O
also	O
significant	O
in	O
a	O
subgroup	O
analysis	O
of	O
standard	O
risk	O
patients	O
according	O
to	O
GMALL	O
classification	O
(	O
OS	O
at	O
5	O
years	O
37	O
%	O
vs.	O
68	O
%	O
,	O
p=0.0002	O
)	O
.	O

Low	O
deletion	O
load	O
or	O
dominant	O
-	O
negative	O
IKZF1	O
alterations	O
had	O
no	O
prognostic	O
impact	O
.	O

The	O
results	O
thus	O
suggest	O
that	O
there	O
is	O
a	O
clear	O
distinction	O
between	O
loss	O
-	O
of	O
-	O
function	O
and	O
dominant	O
-	O
negative	O
IKZF1	O
deletions	O
.	O

Affected	O
patients	O
should	O
thus	O
be	O
monitored	O
for	O
minimal	O
residual	O
disease	O
carefully	O
to	O
detect	O
incipient	O
relapses	O
at	O
an	O
early	O
stage	O
and	O
they	O
are	O
potential	O
candidates	O
for	O
alternative	O
or	O
intensified	O
treatment	O
regimes	O
.	O

Registered	O
at	O
http://www.clinicaltrials.gov	O
:	O
NCT00199056	O
,	O
NCT00198991	O
.	O

Stress	O
-	O
Induced	O
Sleep	O
After	O
Exposure	O
to	O
Ultraviolet	O
Light	O
Is	O
Promoted	O
by	O
p53	O
in	O
Caenorhabditis	O
elegans	O
.	O

Stress	O
-	O
induced	O
sleep	O
(	O
SIS	O
)	O
in	O
C.	O
elegans	O
is	O
important	O
for	O
restoration	O
of	O
cellular	O
homeostasis	O
and	O
is	O
a	O
useful	O
model	O
to	O
study	O
the	O
function	O
and	O
regulation	O
of	O
sleep	O
.	O

SIS	O
is	O
triggered	O
when	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
activates	O
the	O
ALA	O
neuron	O
,	O
which	O
then	O
releases	O
neuropeptides	O
to	O
promote	O
sleep	O
.	O

To	O
further	O
understand	O
this	O
behavior	O
,	O
we	O
established	O
a	O
new	O
model	O
of	O
stress	O
-	O
induced	O
sleep	O
using	O
irradiation	O
by	O
ultraviolet	O
C	O
(	O
UVC	O
)	O
light	O
.	O

While	O
UVC	O
irradiation	O
requires	O
ALA	O
signaling	O
and	O
leads	O
to	O
a	O
sleep	O
state	O
similar	O
to	O
that	O
induced	O
by	O
heat	O
and	O
other	O
stressors	O
,	O
it	O
does	O
not	O
induce	O
the	O
proteostatic	O
stress	O
seen	O
with	O
heat	O
exposure	O
.	O

Based	O
on	O
the	O
known	O
genotoxic	O
effects	O
of	O
UVC	O
irradiation	O
,	O
we	O
tested	O
two	O
genes	O
-	O
atl-1	O
and	O
cep-1-which	O
encode	O
proteins	O
that	O
act	O
in	O
the	O
DNA	O
damage	O
response	O
pathway	O
.	O

Loss	O
of	O
function	O
mutants	O
of	O
atl-1	O
had	O
no	O
defect	O
in	O
UVC	O
induced	O
SIS	O
but	O
a	O
partial	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
mutant	B-Var
of	O
cep-1	B-Gene
,	O
gk138	O
,	O
had	O
decreased	B-NegReg
movement	B-MPA
quiescence	I-MPA
following	O
UVC	O
irradiation	O
.	O

Germline	O
ablation	O
experiments	O
and	O
tissue	O
-	O
specific	O
RNA	O
interference	O
experiments	O
showed	O
that	O
cep-1	O
is	O
required	O
somatically	O
in	O
neurons	O
for	O
its	O
effect	O
on	O
SIS	O
.	O

The	O
cep-1(gk138	B-Gene
)	I-Gene
mutant	B-Var
suppressed	B-NegReg
body	B-MPA
movement	I-MPA
quiescence	I-MPA
controlled	I-MPA
by	I-MPA
EGF	I-MPA
,	O
indicating	O
that	O
CEP-1	O
acts	O
downstream	O
or	O
in	O
parallel	O
to	O
ALA	O
activation	O
to	O
promote	O
quiescence	O
in	O
response	O
to	O
ultraviolet	O
light	O
.	O

PCSK9	B-Gene
deficiency	B-Var
results	O
in	O
increased	B-PosReg
ectopic	B-MPA
fat	I-MPA
accumulation	I-MPA
in	O
experimental	O
models	O
and	O
in	O
humans	O
.	O

Background	O
Proprotein	O
convertase	O
subtilisin	O
kexin	O
type	O
9	O
(	O
PCSK9	O
)	O
regulates	O
low	O
-	O
density	O
lipoprotein	O
and	O
very	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
expression	O
in	O
several	O
tissues	O
.	O

Here	O
we	O
evaluated	O
whether	O
PCSK9	O
may	O
modulate	O
the	O
handling	O
of	O
triglycerides	O
in	O
the	O
liver	O
and	O
peripheral	O
tissues	O
.	O

Methods	O
Subjects	O
from	O
the	O
PLIC	O
cohort	O
were	O
genotyped	O
for	O
the	O
loss	O
-	O
of	O
-	O
function	O
PCSK9	O
R46L	O
variant	O
and	O
characterized	O
for	O
clinical	O
and	O
biochemical	O
parameters	O
,	O
total	O
and	O
android	O
fat	O
mass	O
,	O
hepatic	O
steatosis	O
and	O
epicardial	O
fat	O
thickness	O
.	O

Visceral	O
adipose	O
tissue	O
and	O
subcutaneous	O
adipose	O
tissue	O
in	O
PCSK9	O
KO	O
and	O
wild	O
type	O
mice	O
were	O
quantified	O
by	O
nuclear	O
magnetic	O
resonance	O
imaging	O
.	O

Results	O
Carriers	O
of	O
the	O
R46L	O
variant	O
(	O
n	O
=	O
13	O
)	O
had	O
lower	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	O
levels	O
,	O
higher	O
body	O
mass	O
index	O
and	O
increased	O
percentage	O
of	O
total	O
and	O
android	O
fat	O
masses	O
compared	O
with	O
non	O
-	O
carriers	O
(	O
n	O
=	O
521	O
)	O
.	O

R46L	B-Gene
variant	B-Var
associated	O
with	O
a	O
two	O
-	O
fold	O
increase	B-PosReg
prevalence	O
of	O
hepatic	B-MPA
steatosis	I-MPA
and	I-MPA
higher	I-MPA
epicardial	I-MPA
fat	I-MPA
thickness	I-MPA
.	O

These	O
observations	O
were	O
replicated	O
in	O
PCSK9	O
KO	O
mice	O
,	O
which	O
showed	O
increased	O
visceral	O
adipose	O
tissue	O
(	O
but	O
not	O
subcutaneous	O
adipose	O
tissue	O
)	O
when	O
fed	O
chow	O
or	O
high	O
-	O
fat	O
diet	O
for	O
20	O
weeks	O
,	O
compared	O
with	O
wild	O
type	O
mice	O
.	O

Conclusions	O
These	O
data	O
suggest	O
that	O
genetically	O
determined	O
PCSK9	B-Gene
deficiency	B-Var
might	O
be	O
associated	B-Reg
with	O
ectopic	B-MPA
fat	I-MPA
accumulation	I-MPA
.	O

[	O
Genetic	O
and	O
prenatal	O
diagnosis	O
for	O
a	O
haemophilia	B-Disease
A	I-Disease
family	O
with	B-Reg
two	O
novel	O
mutations	B-Var
of	O
F8	B-Gene
gene	O
]	O
.	O

OBJECTIVE	O
:	O
To	O
conduct	O
genetic	O
diagnosis	O
for	O
a	O
family	O
affected	O
with	O
hamophilia	O
A.	O
METHODS	O
:	O
Potential	O
mutations	O
of	O
the	O
F8	O
gene	O
were	O
analyzed	O
with	O
PCR	O
and	O
Sanger	O
sequencing	O
.	O

Carriers	O
of	O
the	O
mutation	O
were	O
identified	O
through	O
linkage	O
analysis	O
using	O
short	O
tandem	O
repeat	O
(	O
STR	O
)	O
markers	O
.	O

Suspected	O
mutations	O
were	O
verified	O
among	O
100	O
healthy	O
controls	O
to	O
rule	O
out	O
genetic	O
polymorphism	O
.	O

Prenatal	O
diagnosis	O
was	O
provided	O
based	O
on	O
the	O
above	O
results	O
.	O

RESULTS	O
:	O
Sequencing	O
analysis	O
has	O
identified	O
two	O
mutations	O
,	O
c.1	O
A	O
>	O
T	O
and	O
c.4	O
C	O
>	O
T	O
,	O
which	O
have	O
replaced	O
the	O
start	O
codon	O
(	O
ATG	O
)	O
with	O
leucine	O
(	O
TTG	O
)	O
and	O
glutamine	O
(	O
GAA	O
)	O
with	O
the	O
stop	O
codon	O
(	O
TAA	O
)	O
,	O
respectively	O
.	O

The	O
same	O
mutations	O
were	O
not	O
found	O
among	O
the	O
100	O
healthy	O
controls	O
.	O

The	O
patient	O
's	O
mother	O
and	O
sister	O
were	O
heterozygous	O
for	O
the	O
same	O
mutations	O
.	O

Upon	O
prenatal	O
diagnosis	O
,	O
the	O
fetus	O
was	O
determined	O
as	O
a	O
male	O
and	O
did	O
not	O
harbor	O
the	O
above	O
mutations	O
.	O

Linkage	O
analysis	O
also	O
confirmed	O
that	O
the	O
fetus	O
has	O
inherited	O
the	O
non	O
-	O
risk	O
X	O
chromosome	O
from	O
his	O
maternal	O
grandfather	O
.	O

CONCLUSION	O
:	O
Detection	O
of	O
pathogenic	O
mutations	O
can	O
enable	O
prenatal	O
diagnosis	O
for	O
the	O
disease	O
.	O

A	O
Braf	B-Gene
kinase	O
-	O
inactive	O
mutant	B-Var
induces	B-Reg
lung	B-Disease
adenocarcinoma	I-Disease
.	O

The	O
initiating	O
oncogenic	O
event	O
in	O
almost	O
half	O
of	O
human	O
lung	O
adenocarcinomas	O
is	O
still	O
unknown	O
,	O
a	O
fact	O
that	O
complicates	O
the	O
development	O
of	O
selective	O
targeted	O
therapies	O
.	O

Yet	O
these	O
tumours	O
harbour	O
a	O
number	O
of	O
alterations	O
without	O
obvious	O
oncogenic	O
function	O
including	O
BRAF	O
-	O
inactivating	O
mutations	O
.	O

Inactivating	O
BRAF	O
mutants	O
in	O
lung	O
predominate	O
over	O
the	O
activating	O
V600E	O
mutant	O
that	O
is	O
frequently	O
observed	O
in	O
other	O
tumour	O
types	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
expression	O
of	O
an	O
endogenous	O
Braf(D631A	O
)	O
kinase	O
-	O
inactive	O
isoform	O
in	O
mice	O
(	O
corresponding	O
to	O
the	O
human	O
BRAF(D594A	O
)	O
mutation	O
)	O
triggers	O
lung	O
adenocarcinoma	O
in	O
vivo	O
,	O
indicating	O
that	O
BRAF	O
-	O
inactivating	O
mutations	O
are	O
initiating	O
events	O
in	O
lung	O
oncogenesis	O
.	O

Moreover	O
,	O
inactivating	O
BRAF	O
mutations	O
have	O
also	O
been	O
identified	O
in	O
a	O
subset	O
of	O
KRAS	O
-	O
driven	O
human	O
lung	O
tumours	O
.	O

Co	O
-	O
expression	O
of	O
Kras(G12V	B-Gene
)	I-Gene
and	O
Braf(D631A	B-Gene
)	I-Gene
in	O
mouse	O
lung	O
cells	O
markedly	O
enhances	B-PosReg
tumour	B-MPA
initiation	I-MPA
,	O
a	O
phenomenon	O
mediated	O
by	O
Craf	O
kinase	O
activity	O
,	O
and	O
effectively	O
accelerates	O
tumour	O
progression	O
when	O
activated	O
in	O
advanced	O
lung	O
adenocarcinomas	O
.	O

We	O
also	O
report	O
a	O
key	O
role	O
for	O
the	O
wild	O
-	O
type	O
Braf	O
kinase	O
in	O
sustaining	O
Kras(G12V)/Braf(D631A)-driven	O
tumours	O
.	O

Ablation	O
of	O
the	O
wild	O
-	O
type	O
Braf	O
allele	O
prevents	O
the	O
development	O
of	O
lung	O
adenocarcinoma	O
by	O
inducing	O
a	O
further	O
increase	O
in	O
MAPK	O
signalling	O
that	O
results	O
in	O
oncogenic	O
toxicity	O
;	O
this	O
effect	O
can	O
be	O
abolished	O
by	O
pharmacological	O
inhibition	O
of	O
Mek	O
to	O
restore	O
tumour	O
growth	O
.	O

However	O
,	O
the	O
loss	B-Var
of	O
wild	O
-	O
type	O
Braf	B-Gene
also	O
induces	B-Reg
transdifferentiation	B-CPA
of	O
club	O
cells	O
,	O
which	O
leads	B-Reg
to	I-Reg
the	O
rapid	B-MPA
development	I-MPA
of	I-MPA
lethal	I-MPA
intrabronchiolar	I-MPA
lesions	I-MPA
.	O

These	O
observations	O
indicate	O
that	O
the	O
signal	O
intensity	O
of	O
the	O
MAPK	O
pathway	O
is	O
a	O
critical	O
determinant	O
not	O
only	O
in	O
tumour	O
development	O
,	O
but	O
also	O
in	O
dictating	O
the	O
nature	O
of	O
the	O
cancer	O
-	O
initiating	O
cell	O
and	O
ultimately	O
the	O
resulting	O
tumour	O
phenotype	O
.	O

Enpp1	O
is	O
an	O
anti	O
-	O
aging	O
factor	O
that	O
regulates	O
Klotho	O
under	O
phosphate	O
overload	O
conditions	O
.	O

Control	O
of	O
phosphate	O
metabolism	O
is	O
crucial	O
to	O
regulate	O
aging	O
in	O
mammals	O
.	O

Klotho	O
is	O
a	O
well	O
-	O
known	O
anti	O
-	O
aging	O
factor	O
that	O
regulates	O
phosphate	O
metabolism	O
:	O
mice	O
mutant	O
or	O
deficient	O
in	O
Klotho	O
exhibit	O
phenotypes	O
resembling	O
human	O
aging	O
.	O

Here	O
we	O
show	O
that	O
ectonucleotide	O
pyrophosphatase	O
/	O
phosphodiesterase	O
1	O
(	O
Enpp1	O
)	O
is	O
required	O
for	O
Klotho	O
expression	O
under	O
phosphate	O
overload	O
conditions	O
.	O

Loss	B-Var
-	I-Var
of	I-Var
-	I-Var
function	I-Var
Enpp1	B-Gene
(	O
ttw	O
/	O
ttw	O
)	O
mice	O
under	O
phosphate	O
overload	O
conditions	O
exhibited	B-Reg
phenotypes	O
resembling	O
human	O
aging	O
and	O
Klotho	O
mutants	O
,	O
such	O
as	O
short	O
life	O
span	O
,	O
arteriosclerosis	B-Disease
and	O
osteoporosis	B-Disease
,	O
with	O
elevated	B-PosReg
serum	B-MPA
1,25(OH)2D3	I-MPA
levels	I-MPA
.	O

Enpp1	O
(	O
ttw	O
/	O
ttw	O
)	O
mice	O
also	O
exhibited	O
significantly	O
reduced	O
renal	O
Klotho	O
expression	O
under	O
phosphate	O
overload	O
conditions	O
,	O
and	O
aging	O
phenotypes	O
in	O
these	O
mice	O
were	O
rescued	O
by	O
Klotho	O
overexpression	O
,	O
a	O
low	O
vitamin	O
D	O
diet	O
or	O
vitamin	O
D	O
receptor	O
knockout	O
.	O

These	O
findings	O
indicate	O
that	O
Enpp1	O
plays	O
a	O
crucial	O
role	O
in	O
regulating	O
aging	O
via	O
Klotho	O
expression	O
under	O
phosphate	O
overload	O
conditions	O
.	O

Characterization	O
of	O
the	O
autophagy	O
-	O
related	O
gene	O
BmATG8	O
in	O
Bipolaris	O
maydis	O
.	O

Autophagy	O
is	O
involved	O
in	O
cellular	O
development	O
and	O
the	O
maintenance	O
of	O
viability	O
under	O
nutrient	O
deprivation	O
in	O
a	O
wide	O
range	O
of	O
eukaryotes	O
.	O

A	O
filamentous	O
ascomycete	O
Bipolaris	O
maydis	O
,	O
responsible	O
for	O
southern	O
corn	O
leaf	O
blight	O
,	O
is	O
also	O
studied	O
as	O
a	O
model	O
fungus	O
for	O
sexual	O
reproduction	O
in	O
filamentous	O
ascomycetes	O
that	O
form	O
filiform	O
ascospores	O
.	O

In	O
order	O
to	O
clarify	O
the	O
roles	O
of	O
autophagy	O
in	O
various	O
stages	O
of	O
the	O
life	O
cycle	O
of	O
B.	O
maydis	O
,	O
we	O
constructed	O
null	O
mutants	O
of	O
BmATG8	O
,	O
an	O
orthologue	O
of	O
the	O
Saccharomyces	O
cerevisiae	O
autophagy	O
gene	O
ATG8	O
in	O
B.	O
maydis	O
.	O

Deletion	B-Var
of	O
BmATG8	B-Gene
impaired	B-NegReg
localization	B-MPA
of	O
cytosolic	O
components	O
to	O
the	O
vacuole	O
under	O
nitrogen	O
starvation	O
,	O
suggesting	O
that	O
autophagy	B-CPA
was	O
deficient	B-NegReg
in	O
the	O
null	O
mutants	O
.	O

Additionally	O
,	O
fluorescent	O
microscopic	O
observations	O
on	O
a	O
eGFP	O
-	O
fused	O
BmATG8	O
expressing	O
strain	O
showed	O
that	O
BmATG8	O
is	O
associated	O
with	O
autophagy	O
-	O
related	O
structures	O
.	O

In	O
vegetative	O
growth	O
,	O
ΔBmATG8	B-Var
strains	O
showed	O
a	O
reduction	B-NegReg
in	O
conidiation	B-CPA
and	I-CPA
aerial	I-CPA
mycelial	I-CPA
growth	I-CPA
.	O

Interestingly	O
,	O
the	O
mutant	O
conidia	O
indicated	O
loss	O
of	O
the	O
germination	O
rate	O
under	O
starvation	O
conditions	O
and	O
affected	O
longevity	O
.	O

However	O
,	O
germinated	O
mutant	O
conidia	O
were	O
still	O
capable	O
of	O
infecting	O
the	O
host	O
plant	O
via	O
appressoria	O
.	O

In	O
sexual	O
reproduction	O
,	O
ascospores	O
with	O
ΔBmATG8	O
genetic	O
background	O
were	O
aborted	O
.	O

Our	O
results	O
revealed	O
that	O
autophagy	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
function	O
of	O
conidia	O
,	O
not	O
in	O
host	O
infection	O
via	O
appressoria	O
in	O
B.	O
maydis	O
.	O

In	O
addition	O
,	O
conservation	O
of	O
the	O
importance	O
of	O
autophagy	O
in	O
ascospore	O
development	O
is	O
suggested	O
among	O
ascomycetes	O
including	O
species	O
that	O
form	O
bitunicate	O
ascus	O
.	O

Impairment	O
of	O
different	O
protein	O
domains	O
causes	O
variable	O
clinical	O
presentation	O
within	O
Pitt	O
-	O
Hopkins	O
syndrome	O
and	O
suggests	O
intragenic	O
molecular	O
syndromology	O
of	O
TCF4	O
.	O

Pitt	B-Disease
-	I-Disease
Hopkins	I-Disease
syndrome	I-Disease
is	O
a	O
neurodevelopmental	O
disorder	O
characterized	O
by	O
severe	O
intellectual	O
disability	O
and	O
a	O
distinctive	O
facial	O
gestalt	O
.	O

It	O
is	O
caused	B-Reg
by	I-Reg
haploinsufficiency	B-Var
of	O
the	O
TCF4	B-Gene
gene	O
.	O

The	O
TCF4	O
protein	O
has	O
different	O
functional	O
domains	O
,	O
with	O
the	O
NLS	O
(	O
nuclear	O
localization	O
signal	O
)	O
domain	O
coded	O
by	O
exons	O
7	O
-	O
8	O
and	O
the	O
bHLH	O
(	O
basic	O
Helix	O
-	O
Loop	O
-	O
Helix	O
)	O
domain	O
coded	O
by	O
exon	O
18	O
.	O

Several	O
alternatively	O
spliced	O
TCF4	O
variants	O
have	O
been	O
described	O
,	O
allowing	O
for	O
translation	O
of	O
variable	O
protein	O
isoforms	O
.	O

Typical	O
PTHS	O
patients	O
have	O
impairment	O
of	O
at	O
least	O
the	O
bHLH	O
domain	O
.	O

To	O
which	O
extent	O
impairment	O
of	O
the	O
remaining	O
domains	O
contributes	O
to	O
the	O
final	O
phenotype	O
is	O
not	O
clear	O
.	O

There	O
is	O
recent	O
evidence	O
that	O
certain	O
loss	O
-	O
of	O
-	O
function	O
variants	B-Var
disrupting	B-NegReg
TCF4	B-Gene
are	O
associated	O
with	O
mild	B-Disease
ID	I-Disease
,	O
but	O
not	O
with	O
typical	O
PTHS	O
.	O

We	O
describe	O
a	O
frameshift	B-Var
-	I-Var
causing	I-Var
partial	B-Var
gene	I-Var
deletion	I-Var
encompassing	O
exons	O
4	O
-	O
6	O
of	O
TCF4	B-Gene
in	O
an	O
adult	O
patient	O
with	B-Reg
mild	B-Disease
ID	I-Disease
and	O
nonspecific	O
facial	O
dysmorphisms	O
but	O
without	O
the	O
typical	O
features	O
of	O
PTHS	O
,	O
and	O
a	O
c.520C	B-Var
>	I-Var
T	I-Var
nonsense	O
variant	O
within	O
exon	O
8	O
in	O
a	O
child	O
presenting	O
with	B-Reg
a	O
severe	O
phenotype	O
largely	O
mimicking	O
PTHS	B-Disease
,	O
but	O
lacking	O
the	O
typical	O
facial	O
dysmorphism	O
.	O

Investigation	O
on	O
mRNA	O
,	O
along	O
with	O
literature	O
review	O
,	O
led	O
us	O
to	O
suggest	O
a	O
preliminary	O
phenotypic	O
map	O
of	O
loss	O
-	O
of	O
-	O
function	O
variants	O
affecting	O
TCF4	O
.	O

An	O
intragenic	O
phenotypic	O
map	O
of	O
loss	O
-	O
of	O
-	O
function	O
variants	O
in	O
TCF4	O
is	O
suggested	O
here	O
for	O
the	O
first	O
time	O
:	O
variants	O
within	O
exons	O
1	O
-	O
4	O
and	O
exons	O
4	O
-	O
6	O
give	O
rise	O
to	O
a	O
recurrent	O
phenotype	O
with	O
mild	O
ID	O
not	O
in	O
the	O
spectrum	O
of	O
Pitt	O
-	O
Hopkins	O
syndrome	O
(	O
biallelic	O
preservation	O
of	O
both	O
the	O
NLS	O
and	O
bHLH	O
domains	O
)	O
;	O
variants	O
within	O
exons	O
7	O
-	O
8	O
cause	O
a	O
severe	O
phenotype	O
resembling	O
PTHS	O
but	O
in	O
absence	O
of	O
the	O
typical	O
facial	O
dysmorphism	O
(	O
impairment	O
limited	O
to	O
the	O
NLS	O
domain	O
)	O
;	O
variants	O
within	O
exons	O
9	O
-	O
19	O
cause	O
typical	O
Pitt	O
-	O
Hopkins	O
syndrome	O
(	O
impairment	O
of	O
at	O
least	O
the	O
bHLH	O
domain	O
)	O
.	O

Understanding	O
the	O
TCF4	O
molecular	O
syndromology	O
can	O
allow	O
for	O
proper	O
nosology	O
in	O
the	O
current	O
era	O
of	O
whole	O
genomic	O
investigations	O
.	O

ARHGAP29	O
Mutation	O
Is	O
Associated	O
with	O
Abnormal	O
Oral	O
Epithelial	O
Adhesions	O
.	O

Nonsyndromic	B-Disease
cleft	I-Disease
lip	I-Disease
and/or	I-Disease
palate	I-Disease
(	O
NSCL	O
/	O
P	O
)	O
is	O
a	O
prevalent	O
birth	O
defect	O
of	O
complex	O
etiology	O
.	O

Previous	O
studies	O
identified	O
mutations	B-Var
in	O
ARHGAP29	B-Gene
associated	B-Reg
with	O
an	O
increased	O
risk	O
for	O
NSCL	B-Disease
/	I-Disease
P.	I-Disease
To	O
investigate	O
the	O
effects	O
of	O
ARHGAP29	O
in	O
vivo	O
,	O
we	O
generated	O
a	O
novel	O
murine	O
allele	O
by	O
inserting	O
a	O
point	O
mutation	O
identified	O
in	O
a	O
patient	O
with	O
NSCL	O
/	O
P.	O
This	O
single	B-Var
-	I-Var
nucleotide	I-Var
variation	I-Var
of	O
ARHGAP29	B-Gene
translates	O
to	O
an	O
early	O
nonsense	O
mutation	O
(	B-Var
K326X	I-Var
)	I-Var
,	O
presumably	O
resulting	O
in	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LoF	O
)	O
.	O

Embryos	O
from	O
Arhgap29(K326X/+	O
)	O
intercrosses	O
were	O
harvested	O
at	O
various	O
time	O
points	O
.	O

No	O
homozygous	O
Arhgap29(K326X	O
)	O
animals	O
were	O
found	O
in	O
the	O
45	O
analyzed	O
litters	O
,	O
assessed	O
as	O
early	O
as	O
embryonic	O
day	O
8.5	O
(	O
e8.5	O
)	O
.	O

Coronal	O
sectioning	O
of	O
e13.5	O
and	O
e14.5	O
heads	O
revealed	O
that	O
59	O
%	O
of	O
Arhgap29(K326X/+	O
)	O
mice	O
(	O
n	O
=	O
37	O
)	O
exhibited	O
improper	O
epithelial	O
contact	O
between	O
developing	O
oral	O
structures	O
,	O
while	O
none	O
were	O
observed	O
in	O
wild	O
types	O
(	O
n	O
=	O
10	O
)	O
.	O

In	O
addition	O
,	O
Arhgap29(K326X/+	O
)	O
embryos	O
exhibited	O
a	O
significantly	O
higher	O
percentage	O
of	O
maxillary	O
epithelium	O
in	O
contact	O
with	O
mandibular	O
epithelium	O
.	O

Immunofluorescent	O
analyses	O
of	O
the	O
periderm	O
and	O
oral	O
adhesions	O
revealed	O
the	O
presence	O
of	O
Arhgap29	O
in	O
periderm	O
cells	O
.	O

These	O
cells	O
were	O
p63	O
negative	O
,	O
keratin	O
17	O
positive	O
,	O
and	O
keratin	O
6	O
positive	O
and	O
present	O
at	O
sites	O
of	O
adhesion	O
,	O
although	O
occasionally	O
disorganized	O
.	O

Oral	O
adhesions	O
did	O
not	O
appear	O
to	O
impair	O
palatogenesis	O
,	O
as	O
all	O
analyzed	O
Arhgap29(K326X/+	O
)	O
embryos	O
showed	O
confluent	O
palatal	O
mesenchyme	O
and	O
epithelium	O
at	O
e18.5	O
(	O
n	O
=	O
16	O
)	O
,	O
and	O
no	O
mice	O
were	O
found	O
with	O
a	O
cleft	O
at	O
birth	O
.	O

Collectively	O
,	O
our	O
data	O
demonstrate	O
that	O
ARHGAP29	O
is	O
required	O
for	O
embryonic	O
survival	O
and	O
that	O
heterozygosity	O
for	O
LoF	B-NegReg
variants	B-Var
of	O
Arhgap29	B-Gene
increases	B-PosReg
the	O
incidence	B-CPA
and	I-CPA
length	I-CPA
of	I-CPA
oral	I-CPA
adhesions	I-CPA
at	I-CPA
a	I-CPA
critical	I-CPA
time	I-CPA
point	I-CPA
during	I-CPA
orofacial	I-CPA
development	I-CPA
.	O

In	O
conclusion	O
,	O
we	O
validate	O
the	O
LoF	B-NegReg
nature	O
of	O
the	O
human	O
K326X	B-Var
mutation	I-Var
in	O
vivo	O
and	O
reveal	O
a	O
previously	O
unknown	O
effect	O
of	O
Arhgap29	B-Gene
in	O
murine	O
craniofacial	B-CPA
development	I-CPA
.	O

Deciphering	O
the	O
molecular	O
basis	O
of	O
ferroportin	O
resistance	O
to	O
hepcidin	O
:	O
Structure	O
/	O
function	O
analysis	O
of	O
rare	O
SLC40A1	B-Gene
missense	B-Var
mutations	I-Var
found	B-Reg
in	O
suspected	O
hemochromatosis	B-Disease
type	I-Disease
4	I-Disease
patients	O
.	O

Genetic	O
medicine	O
applied	O
to	O
the	O
study	O
of	O
hemochromatosis	O
has	O
identified	O
the	O
systemic	O
loop	O
controlling	O
iron	O
homeostasis	O
,	O
centered	O
on	O
hepcidin	O
-	O
ferroportin	O
interaction	O
.	O

Current	O
challenges	O
are	O
to	O
dissect	O
the	O
molecular	O
pathways	O
underlying	O
liver	O
hepcidin	O
synthesis	O
in	O
response	O
to	O
circulatory	O
iron	O
,	O
HFE	O
,	O
TFR2	O
,	O
HJV	O
,	O
TMPRSS6	O
and	O
BMP6	O
functions	O
,	O
and	O
to	O
define	O
the	O
major	O
structural	O
elements	O
of	O
hepcidin	O
-	O
ferroportin	O
interaction	O
.	O

We	O
built	O
a	O
first	O
3D	O
model	O
of	O
human	O
ferroportin	O
structure	O
,	O
using	O
the	O
crystal	O
structure	O
of	O
EmrD	O
,	O
a	O
bacterial	O
drug	O
efflux	O
transporter	O
of	O
the	O
Major	O
Facilitator	O
Superfamily	O
,	O
as	O
template	O
.	O

The	O
model	O
enabled	O
study	O
of	O
disease	O
-	O
associated	O
mutations	O
,	O
and	O
guided	O
mutagenesis	O
experiments	O
to	O
determine	O
the	O
role	O
of	O
conserved	O
residues	O
in	O
protein	O
stability	O
and	O
iron	O
transport	O
.	O

Results	O
revealed	O
novel	O
amino	O
acids	O
that	O
are	O
critical	O
for	O
the	O
iron	O
export	O
function	O
and	O
the	O
hepcidin	O
-	O
mediated	O
inhibition	O
mechanism	O
:	O
for	O
example	O
,	O
tryptophan	O
42	O
,	O
localized	O
in	O
the	O
extracellular	O
end	O
of	O
the	O
ferroportin	O
pore	O
and	O
involved	O
in	O
both	O
biological	O
functions	O
.	O

Here	O
,	O
we	O
propose	O
a	O
strategy	O
that	O
is	O
not	O
limited	O
to	O
structure	O
analysis	O
,	O
but	O
integrates	O
information	O
from	O
different	O
sources	O
,	O
including	O
human	O
disease	O
-	O
associated	O
mutations	O
and	O
functional	O
in	O
vitro	O
assays	O
.	O

The	O
first	O
major	O
hypothesis	O
of	O
this	O
PhD	O
thesis	O
is	O
that	O
ferroportin	O
resistance	O
to	O
hepcidin	O
relies	O
on	O
different	O
molecular	O
mechanisms	O
that	O
are	O
critical	O
for	O
ferroportin	O
endocytosis	O
,	O
and	O
include	O
at	O
least	O
three	O
fundamental	O
steps	O
:	O
(	O
i	O
)	O
hepcidin	O
binding	O
to	O
ferroportin	O
,	O
(	O
ii	O
)	O
structural	O
reorganization	O
of	O
the	O
N-	O
and	O
C	O
-	O
ter	O
ferroportin	O
lobes	O
,	O
and	O
(	O
iii	O
)	O
ferroportin	O
ubiquitination	O
.	O

Loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
filaggrin	O
gene	O
and	O
malignant	O
melanoma	O
:	O
a	O
case	O
control	O
study	O
.	O

BACKGROUND	O
:	O
Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
filaggrin	O
gene	O
(	B-Gene
FLG	I-Gene
)	I-Gene
have	O
been	O
suggested	O
to	O
increase	O
the	O
susceptibility	O
of	O
skin	B-Disease
malignancies	I-Disease
due	O
to	O
reduced	B-NegReg
levels	B-MPA
of	I-MPA
epidermal	I-MPA
filaggrin	I-MPA
and	O
its	O
degradation	B-MPA
products	I-MPA
,	O
urocanic	B-MPA
acid	I-MPA
,	O
which	O
may	O
be	O
protective	O
against	O
ultraviolet	O
irradiation	O
.	O

OBJECTIVE	O
:	O
We	O
aimed	O
to	O
investigate	O
the	O
association	O
between	O
FLG	O
mutation	O
status	O
and	O
the	O
occurrence	O
of	O
malignant	O
melanoma	O
(	O
MM	O
)	O
in	O
Danish	O
adults	O
.	O

METHODS	O
:	O
The	O
prevalence	O
of	O
FLG	O
mutations	O
in	O
a	O
sample	O
of	O
MM	O
biopsies	O
was	O
compared	O
with	O
a	O
FLG	O
genotyped	O
cohort	O
from	O
two	O
general	O
population	O
studies	O
.	O

Pearson	O
's	O
chi	O
-	O
square	O
and	O
Fisher	O
's	O
exact	O
tests	O
were	O
used	O
to	O
compare	O
the	O
two	O
groups	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
867	O
MM	O
biopsies	O
and	O
9965	O
general	O
population	O
controls	O
were	O
genotyped	O
,	O
respectively	O
.	O

In	O
the	O
MM	O
sample	O
2	O
(	O
0.23	O
%	O
)	O
individuals	O
were	O
homozygous	O
and	O
80	O
(	O
9.4	O
%	O
)	O
heterozygous	O
mutation	O
carriers	O
.	O

In	O
the	O
general	O
population	O
controls	O
the	O
prevalence	O
of	O
FLG	O
mutations	O
was	O
18	O
(	O
0.18	O
%	O
)	O
and	O
835	O
(	O
8.4	O
%	O
)	O
for	O
homozygous	O
and	O
heterozygous	O
mutations	O
,	O
respectively	O
.	O

Fisher	O
's	O
exact	O
test	O
and	O
Pearson	O
's	O
chi	O
square	O
test	O
yielded	O
non	O
-	O
significant	O
p	O
-	O
values	O
when	O
the	O
groups	O
were	O
compared	O
.	O

CONCLUSION	O
:	O
FLG	O
mutation	O
was	O
not	O
associated	O
with	O
MM	O
in	O
the	O
studied	O
populations	O
.	O

This	O
finding	O
indicates	O
that	O
epidermal	O
deficiency	O
of	O
filaggrin	O
and	O
its	O
degradation	O
products	O
do	O
not	O
influence	O
the	O
risk	O
of	O
MM	O
significantly	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

A	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	B-Var
in	O
TNFRSF13B	B-Gene
is	O
a	O
candidate	O
for	O
predisposition	O
to	O
familial	B-Disease
or	I-Disease
sporadic	I-Disease
immune	I-Disease
thrombocytopenia	I-Disease
.	O

BACKGROUND	O
:	O
Most	O
immune	B-Disease
thrombocytopenia	I-Disease
(	O
ITP	O
)	O
is	O
sporadic	O
but	O
a	O
positive	O
family	O
history	O
of	O
ITP	O
in	O
some	O
patients	O
suggests	O
that	O
hereditary	O
forms	O
exist	O
.	O

Due	O
to	O
the	O
rarity	O
of	O
familial	O
ITP	O
families	O
available	O
for	O
study	O
and	O
the	O
heterogeneity	O
of	O
sporadic	O
ITP	O
,	O
family	O
linkage	O
analysis	O
or	O
genome	O
wide	O
association	O
studies	O
are	O
limited	O
.	O

OBJECTIVES	O
:	O
Based	O
on	O
one	O
ITP	O
pedigree	O
,	O
we	O
try	O
to	O
identify	O
the	O
predisposing	O
gene	O
in	O
familial	O
or	O
sporadic	O
ITP	O
and	O
reveal	O
the	O
way	O
in	O
which	O
it	O
causes	O
thrombocytopenia	O
.	O

METHODS	O
:	O
Gene	O
expression	O
profiling	O
analysis	O
and	O
whole	O
-	O
exome	O
sequencing	O
was	O
performed	O
on	O
samples	O
from	O
familial	O
ITP	O
members	O
,	O
sporadic	O
ITP	O
cases	O
and	O
healthy	O
individuals	O
.	O

We	O
also	O
evaluated	O
the	O
influence	O
of	O
potential	O
pathogenic	O
mutation	O
on	O
immune	O
function	O
and	O
megakaryocyte	O
apoptosis	O
.	O

RESULTS	O
:	O
Whole	O
-	O
exome	O
sequencing	O
identified	O
a	O
potential	O
pathologic	B-Reg
p	B-Var
.	I-Var
G76S	I-Var
heterozygous	O
mutation	O
on	O
the	O
TNFRSF13B	B-Gene
gene	O
in	O
familial	B-Disease
ITP	I-Disease
patients	O
.	O

ITP	O
patients	O
harboring	O
G76S	B-Var
mutation	O
displayed	O
upregulated	B-PosReg
"	B-MPA
cytokine	I-MPA
-	I-MPA
cytokine	I-MPA
receptor	I-MPA
interaction	I-MPA
"	I-MPA
signal	I-MPA
,	O
increased	B-PosReg
serum	B-MPA
TNFα	I-MPA
,	O
IL-17α	I-MPA
,	O
IFNγ	I-MPA
and	I-MPA
BAFF	I-MPA
levels	I-MPA
,	O
and	O
enhanced	B-PosReg
binding	B-Interaction
capacity	I-Interaction
of	I-Interaction
APRIL	I-Interaction
ligand	I-Interaction
to	I-Interaction
B	I-Interaction
cells	I-Interaction
.	O

Additionally	O
,	O
EBV	O
-	O
transformed	O
B	O
cells	O
with	O
the	O
G76S	B-Var
mutation	O
could	O
induce	B-PosReg
human	B-CPA
megakaryocyte	I-CPA
line	I-CPA
(	I-CPA
Meg-01	I-CPA
)	I-CPA
apoptosis	I-CPA
significantly	O
.	O

CONCLUSION	O
:	O
p	B-Var
.	I-Var
G76S	I-Var
mutation	O
on	O
TNFRSF13B	B-Gene
gene	O
is	O
responsible	B-Reg
for	O
ITP	B-Disease
,	O
and	O
is	O
a	O
genetic	O
predisposing	O
factor	O
for	O
familial	O
or	O
sporadic	O
ITP	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

A	O
single	O
active	O
site	O
mutation	O
in	O
the	O
pikromycin	O
thioesterase	O
generates	O
a	O
more	O
effective	O
macrocyclization	O
catalyst	O
.	O

Macrolactonization	O
of	O
natural	O
product	O
analogs	O
presents	O
a	O
significant	O
challenge	O
to	O
both	O
biosynthetic	O
assembly	O
and	O
synthetic	O
chemistry	O
.	O

In	O
the	O
preceding	O
paper	O
,	O
we	O
identified	O
a	O
thioesterase	O
(	O
TE	O
)	O
domain	O
catalytic	O
bottleneck	O
in	O
the	O
processing	O
of	O
un	O
-	O
natural	O
substrates	O
in	O
the	O
pikromycin	O
(	O
Pik	O
)	O
system	O
,	O
preventing	O
the	O
formation	O
of	O
epimerized	O
macrolactones	O
.	O

Here	O
,	O
we	O
perform	O
molecular	O
dynamics	O
(	O
MD	O
)	O
simulations	O
showing	O
the	O
epimerized	O
hexaketide	O
was	O
accommodated	O
within	O
the	O
Pik	O
TE	O
active	O
site	O
;	O
however	O
,	O
intrinsic	O
conformational	O
preferences	O
of	O
the	O
substrate	O
resulted	O
in	O
predominately	O
unproductive	O
conformations	O
,	O
in	O
agreement	O
with	O
the	O
observed	O
hydrolysis	O
.	O

Accordingly	O
,	O
we	O
engineered	O
the	O
stereospecific	O
Pik	O
TE	O
to	O
yield	O
a	O
variant	O
(	O
TES148C	O
)	O
with	O
improved	O
reaction	O
kinetics	O
and	O
gain	O
-	O
of	O
-	O
function	O
processing	O
of	O
an	O
unnatural	O
,	O
epimerized	O
hexaketide	O
.	O

Quantum	O
mechanical	O
(	O
QM	O
)	O
comparison	O
of	O
model	O
TES148C	O
and	O
TEWT	O
reaction	O
coordinate	O
diagrams	O
revealed	O
a	O
change	O
in	O
mechanism	O
from	O
a	O
stepwise	O
addition	O
-	O
elimination	O
(	O
TEWT	O
)	O
to	O
a	O
lower	O
energy	O
concerted	O
acyl	O
substitution	O
(	O
TES148C	O
)	O
,	O
accounting	O
for	O
the	O
gain	O
-	O
of	O
-	O
function	O
and	O
improved	O
reaction	O
kinetics	O
.	O

Finally	O
,	O
we	O
introduced	O
the	O
S148C	B-Var
mutation	O
into	O
a	O
polyketide	O
synthase	O
module	O
(	O
PikAIII	O
-	O
TE	O
)	O
to	O
impart	O
increased	B-PosReg
substrate	B-MPA
flexibility	I-MPA
,	O
enabling	B-PosReg
the	O
production	B-MPA
of	I-MPA
diastereomeric	I-MPA
macrolactones	I-MPA
.	O

A	O
comprehensive	O
functional	O
assessment	O
of	O
carboxylesterase	O
1	O
nonsynonymous	O
polymorphisms	O
.	O

Carboxylesterase	O
1	O
(	O
CES1	O
)	O
is	O
the	O
predominant	O
human	O
hepatic	O
hydrolase	O
responsible	O
for	O
the	O
metabolism	O
of	O
many	O
clinically	O
important	O
medications	O
.	O

CES1	O
expression	O
and	O
activity	O
vary	O
markedly	O
among	O
individuals	O
;	O
and	O
genetic	O
variation	O
is	O
a	O
major	O
contributing	O
factor	O
to	O
CES1	O
interindividual	O
variability	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
comprehensively	O
examined	O
the	O
functions	O
of	O
CES1	O
nonsynonymous	O
single	O
nucleotide	O
polymorphisms	O
(	O
nsSNPs	O
)	O
and	O
haplotypes	O
using	O
transfected	O
cell	O
lines	O
and	O
individual	O
human	O
liver	O
tissues	O
.	O

The	O
20	O
candidate	O
variants	O
include	O
CES1	O
nsSNPs	O
with	O
a	O
minor	O
allele	O
frequency	O
(	O
MAF	O
)	O
>	O
0.5	O
%	O
in	O
a	O
given	O
population	O
or	O
located	O
in	O
close	O
proximity	O
to	O
the	O
CES1	O
active	O
site	O
.	O

Five	O
nsSNPs	O
including	O
L40Ter	O
(	B-Var
rs151291296	I-Var
)	I-Var
,	O
G142E	O
(	B-Var
rs121912777	I-Var
)	I-Var
,	O
G147C	O
(	B-Var
rs146456965	I-Var
)	I-Var
,	O
Y170D	O
(	B-Var
rs148947808	I-Var
)	I-Var
,	O
and	O
R171C	O
(	B-Var
rs201065375	I-Var
)	I-Var
were	O
found	O
to	O
be	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
variants	O
for	O
metabolizing	B-MPA
the	O
CES1	B-Enzyme
substrates	O
clopidogrel	O
,	O
enalapril	O
,	O
and	O
sacubitril	O
.	O

Additionally	O
,	O
the	O
A158V	O
(	B-Var
rs202121317	I-Var
)	I-Var
,	O
R199H	O
(	B-Var
rs2307243	I-Var
)	I-Var
,	O
E220	O
G	O
(	B-Var
rs200707504	I-Var
)	I-Var
,	O
and	O
T290	O
M	O
(	B-Var
rs202001817	I-Var
)	I-Var
decreased	B-NegReg
CES1	B-Enzyme
activity	B-MPA
to	O
a	O
lesser	O
extent	O
in	O
a	O
substrate	O
-	O
dependent	O
manner	O
.	O

Several	O
nsSNPs	O
including	O
the	O
L40Ter	O
(	B-Var
rs151291296	I-Var
)	I-Var
,	O
G147C	O
(	B-Var
rs146456965	I-Var
)	I-Var
,	O
Y170D	O
(	B-Var
rs148947808	I-Var
)	I-Var
,	O
and	O
R171C	O
(	B-Var
rs201065375	I-Var
)	I-Var
significantly	O
reduced	B-NegReg
CES1	B-Protein
protein	I-Protein
and/or	O
mRNA	B-MPA
expressions	I-MPA
in	O
the	O
transfected	O
cells	O
.	O

Functions	O
of	O
the	O
common	O
nonsynonymous	O
haplotypes	O
D203E	O
-	O
A269S	O
and	O
S75N	O
-	O
D203E	O
-	O
A269S	O
were	O
evaluated	O
using	O
cells	O
stably	O
expressing	O
the	O
haplotypes	O
and	O
a	O
large	O
set	O
of	O
human	O
livers	O
.	O

Neither	O
CES1	O
expression	O
nor	O
activity	O
were	O
affected	O
by	O
the	O
two	O
haplotypes	O
.	O

In	O
sum	O
,	O
the	O
study	O
revealed	O
several	O
functional	O
nsSNPs	O
with	O
impaired	O
activity	O
on	O
the	O
metabolism	O
of	O
CES1	O
substrate	O
drugs	O
.	O

Clinical	O
investigations	O
are	O
warranted	O
to	O
determine	O
whether	O
these	O
nsSNPs	O
can	O
serve	O
as	O
biomarkers	O
for	O
the	O
prediction	O
of	O
therapeutic	O
outcomes	O
of	O
drugs	O
metabolized	O
by	O
CES1	O
.	O

Progranulin	B-Protein
haploinsufficiency	B-Var
reduces	B-NegReg
amyloid	B-MPA
beta	I-MPA
deposition	I-MPA
in	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
model	O
mice	O
.	O

Granulin	O
(	O
Grn	O
)	O
mutations	O
were	O
identified	O
in	O
familial	O
frontotemporal	B-Disease
lobar	I-Disease
degeneration	I-Disease
(	O
FTLD	O
)	O
patients	O
with	O
TAR	O
DNA	O
-	O
binding	O
protein	O
of	O
43	O
kd	O
(	O
TDP-43	O
)	O
pathology	O
.	O

Grn	B-Protein
transcript	O
haploinsufficiency	B-Var
is	O
proposed	O
as	O
a	O
disease	O
mechanism	O
that	O
leads	O
to	O
the	O
loss	B-NegReg
of	I-NegReg
functional	I-NegReg
progranulin	O
(	B-Protein
PGRN	I-Protein
)	I-Protein
protein	O
.	O

Thus	O
,	O
these	O
mutations	B-Var
are	O
strongly	O
involved	B-Reg
in	O
FTLD	B-Disease
pathogenesis	O
.	O

Moreover	O
,	O
recent	O
findings	O
indicate	O
that	O
Grn	B-Protein
mutations	B-Var
are	O
associated	B-Reg
with	O
other	O
neurodegenerative	O
disorders	O
with	O
tau	O
pathology	O
,	O
including	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
.	O

To	O
investigate	O
the	O
influence	O
of	O
PGRN	O
on	O
amyloid	O
beta	O
(	O
Aβ	O
)	O
accumulation	O
,	O
amyloid	O
precursor	O
protein	O
(	O
APP	O
)	O
transgenic	O
mice	O
were	O
interbred	O
with	O
Grn	O
-	O
deficient	O
mice	O
,	O
producing	O
APP	O
transgenic	O
mice	O
harboring	O
the	O
Grn	O
hemizygote	O
(	O
APP	O
/	O
Grn+/-	O
)	O
.	O

Brains	O
were	O
collected	O
from	O
16	O
-	O
18-month	O
-	O
old	O
APP	O
and	O
APP	O
/	O
Grn+/-	O
mice	O
and	O
sequential	O
extraction	O
of	O
proteins	O
,	O
immunoblotting	O
and	O
immunohistochemical	O
analysis	O
were	O
performed	O
.	O

Immunohistochemical	O
analysis	O
showed	O
that	O
the	O
number	O
and	O
area	O
of	O
Aβ	O
plaque	O
was	O
significantly	O
decreased	O
in	O
APP	O
/	O
Grn+/-	O
mice	O
as	O
compared	O
to	O
APP	O
mice	O
.	O

Immunoblotting	O
analysis	O
revealed	O
that	O
Aβ	O
was	O
reduced	O
in	O
the	O
sarkosyl	O
-	O
insoluble	O
fraction	O
of	O
16	O
-	O
18-month	O
-	O
old	O
APP	O
/	O
Grn+/-	O
mice	O
as	O
compared	O
with	O
that	O
of	O
APP	O
transgenic	O
mice	O
.	O

Our	O
data	O
suggest	O
that	O
PGRN	B-Protein
haploinsufficiency	B-Var
may	O
decrease	B-NegReg
accumulation	B-MPA
of	I-MPA
Aβ	I-MPA
.	O

Comprehensive	O
analysis	O
for	O
genetic	O
diagnosis	O
of	O
Dystrophinopathies	O
in	O
Japan	O
.	O

BACKGROUND	O
:	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	O
)	O
is	O
the	O
most	O
common	O
disease	O
in	O
children	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
DMD	B-Gene
gene	O
,	O
and	O
DMD	O
and	O
Becker	O
muscular	O
dystrophy	O
(	O
BMD	O
)	O
are	O
collectively	O
called	O
dystrophinopathies	O
.	O

Dystrophinopathies	O
show	O
a	O
complex	O
mutation	O
spectrum	O
.	O

The	O
importance	O
of	O
mutation	O
databases	O
,	O
with	O
clinical	O
phenotypes	O
and	O
protein	O
studies	O
of	O
patients	O
,	O
is	O
increasingly	O
recognized	O
as	O
a	O
reference	O
for	O
genetic	O
diagnosis	O
and	O
for	O
the	O
development	O
of	O
gene	O
therapy	O
.	O

METHODS	O
:	O
We	O
used	O
the	O
data	O
from	O
the	O
Japanese	O
Registry	O
of	O
Muscular	O
Dystrophy	O
(	O
Remudy	O
)	O
compiled	O
during	O
from	O
July	O
2009	O
to	O
March	O
2017	O
,	O
and	O
reviewed	O
1497	O
patients	O
with	O
dystrophinopathies	O
.	O

RESULTS	O
:	O
The	O
spectrum	O
of	O
identified	O
mutations	O
contained	O
exon	O
deletions	O
(	O
61	O
%	O
)	O
,	O
exon	O
duplications	O
(	O
13	O
%	O
)	O
,	O
nonsense	O
mutations	O
(	O
13	O
%	O
)	O
,	O
small	O
deletions	O
(	O
5	O
%	O
)	O
,	O
small	O
insertions	O
(	O
3	O
%	O
)	O
,	O
splice	O
-	O
site	O
mutations	O
(	O
4	O
%	O
)	O
,	O
and	O
missense	O
mutations	O
(	O
1	O
%	O
)	O
.	O

Exon	O
deletions	O
were	O
found	O
most	O
frequently	O
in	O
the	O
central	O
hot	O
spot	O
region	O
between	O
exons	O
45	O
-	O
52	O
(	O
42	O
%	O
)	O
,	O
and	O
most	O
duplications	O
were	O
detected	O
in	O
the	O
proximal	O
hot	O
spot	O
region	O
between	O
exons	O
3	O
-	O
25	O
(	O
47	O
%	O
)	O
.	O

In	O
the	O
371	O
patients	O
harboring	O
a	O
small	O
mutation	O
,	O
194	O
mutations	O
were	O
reported	O
and	O
187	O
mutations	O
were	O
unreported	O
.	O

CONCLUSIONS	O
:	O
We	O
report	O
the	O
largest	O
dystrophinopathies	O
mutation	O
dataset	O
in	O
Japan	O
from	O
a	O
national	O
patient	O
registry	O
,	O
"	O
Remudy	O
"	O
.	O

This	O
dataset	O
provides	O
a	O
useful	O
reference	O
to	O
support	O
the	O
genetic	O
diagnosis	O
and	O
treatment	O
of	O
dystrophinopathy	O
.	O

Identification	O
of	O
distinct	O
mutational	O
patterns	O
and	O
new	O
driver	O
genes	O
in	O
oesophageal	O
squamous	O
cell	O
carcinomas	O
and	O
adenocarcinomas	O
.	O

OBJECTIVES	O
:	O
Oesophageal	B-Disease
squamous	I-Disease
cell	I-Disease
carcinoma	I-Disease
(	O
OSCC	O
)	O
and	O
adenocarcinoma	O
(	O
OAC	O
)	O
are	O
distinct	O
cancers	O
in	O
terms	O
of	O
a	O
number	O
of	O
clinical	O
and	O
epidemiological	O
characteristics	O
,	O
complicating	O
the	O
design	O
of	O
clinical	O
trials	O
and	O
biomarker	O
developments	O
.	O

We	O
analysed	O
1048	O
oesophageal	O
tumour	O
-	O
germline	O
pairs	O
from	O
both	O
subtypes	O
,	O
to	O
characterise	O
their	O
genomic	O
features	O
,	O
and	O
biological	O
and	O
clinical	O
significance	O
.	O

DESIGN	O
:	O
Previously	O
exome	O
-	O
sequenced	O
samples	O
were	O
re	O
-	O
analysed	O
to	O
identify	O
significantly	O
mutated	O
genes	O
(	O
SMGs	O
)	O
and	O
mutational	O
signatures	O
.	O

The	O
biological	O
functions	O
of	O
novel	O
SMGs	O
were	O
investigated	O
using	O
cell	O
line	O
and	O
xenograft	O
models	O
.	O

We	O
further	O
performed	O
whole	O
-	O
genome	O
bisulfite	O
sequencing	O
and	O
chromatin	O
immunoprecipitation	O
(	O
ChIP)-seq	O
to	O
characterise	O
epigenetic	O
alterations	O
.	O

RESULTS	O
:	O
OSCC	O
and	O
OAC	O
displayed	O
nearly	O
mutually	O
exclusive	O
sets	O
of	O
driver	O
genes	O
,	O
indicating	O
that	O
they	O
follow	O
independent	O
developmental	O
paths	O
.	O

The	O
combined	O
sample	O
size	O
allowed	O
the	O
statistical	O
identification	O
of	O
a	O
number	O
of	O
novel	O
subtype	O
-	O
specific	O
SMGs	O
,	O
mutational	O
signatures	O
and	O
prognostic	O
biomarkers	O
.	O

Particularly	O
,	O
we	O
identified	O
a	O
novel	O
mutational	O
signature	O
similar	O
to	O
Catalogue	O
Of	O
Somatic	O
Mutations	O
In	O
Cancer	O
(	O
COSMIC)signature	O
16	O
,	O
which	O
has	O
prognostic	O
value	O
in	O
OSCC	O
.	O

Two	O
newly	O
discovered	O
SMGs	O
,	O
CUL3	O
and	O
ZFP36L2	O
,	O
were	O
validated	O
as	O
important	O
tumour	O
-	O
suppressors	O
specific	O
to	O
the	O
OSCC	O
subtype	O
.	O

We	O
further	O
identified	O
their	O
additional	O
loss	O
-	O
of	O
-	O
function	O
mechanisms	O
.	O

CUL3	B-Gene
was	O
homozygously	O
deleted	B-Var
specifically	O
in	B-Reg
OSCC	B-Disease
and	O
other	O
squamous	B-Disease
cell	I-Disease
cancers	I-Disease
(	O
SCCs	O
)	O
.	O

Notably	O
,	O
ZFP36L2	O
is	O
associated	O
with	O
super	O
-	O
enhancer	O
in	O
healthy	O
oesophageal	O
mucosa	O
;	O
DNA	O
hypermethylation	O
in	O
its	O
super	O
-	O
enhancer	O
reduced	O
active	O
histone	O
markers	O
in	O
squamous	O
cancer	O
cells	O
,	O
suggesting	O
an	O
epigenetic	O
inactivation	O
of	O
a	O
super	O
-	O
enhancer	O
-	O
associated	O
SCC	O
suppressor	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
comprehensively	O
contrast	O
differences	O
between	O
OSCC	O
and	O
OAC	O
at	O
both	O
genomic	O
and	O
epigenomic	O
levels	O
,	O
and	O
reveal	O
novel	O
molecular	O
features	O
for	O
further	O
delineating	O
the	O
pathophysiological	O
mechanisms	O
and	O
treatment	O
strategies	O
for	O
these	O
cancers	O
.	O

Gait	O
disturbance	O
and	O
lower	O
limb	O
pain	O
in	O
a	O
patient	O
with	O
PIK3CA	O
-	O
related	O
disorder	O
.	O

Post	O
-	O
zygotic	O
activating	O
mutations	O
in	O
PIK3CA	O
and	O
other	O
genes	O
encoding	O
members	O
of	O
PI3K	O
-	O
AKT	O
-	O
mTOR	O
pathway	O
have	O
been	O
found	O
in	O
various	O
overgrowth	O
syndromes	O
that	O
have	O
been	O
grouped	O
together	O
as	O
PIK3CA	O
-	O
related	O
overgrowth	O
spectrum	O
(	O
PROS	O
)	O
.	O

We	O
report	O
a	O
female	O
patient	O
with	O
gait	O
disturbance	O
,	O
leg	O
pain	O
,	O
isolated	O
macrodactyly	O
of	O
the	O
foot	O
,	O
and	O
mild	O
intellectual	O
disability	O
.	O

Imaging	O
of	O
the	O
lower	O
limb	O
showed	O
a	O
lipoblastoma	O
of	O
the	O
right	O
thigh	O
.	O

A	O
mosaic	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	O
in	O
the	O
catalytic	O
domain	O
of	O
PIK3CA	B-Gene
(	B-Var
c.3140	I-Var
A	I-Var
>	I-Var
G	I-Var
;	I-Var
p	B-Var
.	I-Var
His1047Arg	I-Var
)	I-Var
was	O
detected	O
in	O
the	O
adipose	O
tissue	O
and	O
in	O
skin	O
cultured	O
fibroblasts	O
from	O
the	O
macrodactyly	O
but	O
not	O
in	O
blood	O
.	O

The	O
leg	O
pain	O
and	O
the	O
severe	O
walking	O
disturbance	O
improved	O
slightly	O
over	O
time	O
and	O
serial	O
MRI	O
of	O
the	O
lower	O
limbs	O
suggested	O
that	O
the	O
size	O
of	O
the	O
lipoblastoma	O
relative	O
to	O
the	O
lower	O
limb	O
muscles	O
or	O
to	O
the	O
whole	O
lower	O
limb	O
was	O
unchanged	O
as	O
consequence	O
of	O
limb	O
growth	O
.	O

This	O
case	O
report	O
illustrates	O
that	O
pain	O
and	O
gait	O
disturbance	O
can	O
be	O
features	O
of	O
PROS	O
and	O
highlights	O
the	O
need	O
of	O
better	O
knowledge	O
about	O
the	O
natural	O
history	O
of	O
the	O
disease	O
.	O

A	O
Defective	O
mRNA	O
Cleavage	O
and	O
Polyadenylation	O
Complex	O
Facilitates	O
Expansions	O
of	O
Transcribed	O
(	O
GAA)n	O
Repeats	O
Associated	O
with	O
Friedreich	O
's	O
Ataxia	O
.	O

Expansions	O
of	O
microsatellite	O
repeats	O
are	O
responsible	O
for	O
numerous	O
hereditary	O
diseases	O
in	O
humans	O
,	O
including	O
myotonic	O
dystrophy	O
and	O
Friedreich	O
's	O
ataxia	O
.	O

Whereas	O
the	O
length	O
of	O
an	O
expandable	O
repeat	O
is	O
the	O
main	O
factor	O
determining	O
disease	O
inheritance	O
,	O
recent	O
data	O
point	O
to	O
genomic	O
trans	O
modifiers	O
that	O
can	O
impact	O
the	O
likelihood	O
of	O
expansions	O
and	O
disease	O
progression	O
.	O

Detection	O
of	O
these	O
modifiers	O
may	O
lead	O
to	O
understanding	O
and	O
treating	O
repeat	O
expansion	O
diseases	O
.	O

Here	O
,	O
we	O
describe	O
a	O
method	O
for	O
the	O
rapid	O
,	O
genome	O
-	O
wide	O
identification	O
of	O
trans	O
modifiers	O
for	O
repeat	O
expansion	O
in	O
a	O
yeast	O
experimental	O
system	O
.	O

Using	O
this	O
method	O
,	O
we	O
found	O
that	O
missense	B-Var
mutations	I-Var
in	O
the	O
endoribonuclease	O
subunit	O
(	B-Gene
Ysh1	I-Gene
)	I-Gene
of	O
the	O
mRNA	O
cleavage	O
and	O
polyadenylation	O
complex	O
dramatically	O
increase	B-PosReg
the	B-MPA
rate	I-MPA
of	I-MPA
(	I-MPA
GAA)n	I-MPA
repeat	I-MPA
expansions	I-MPA
but	O
only	O
when	O
they	O
are	O
actively	O
transcribed	O
.	O

These	O
expansions	O
correlate	O
with	O
slower	B-NegReg
transcription	B-MPA
elongation	I-MPA
caused	O
by	O
the	O
ysh1	B-Gene
mutation	B-Var
.	O

These	O
results	O
reveal	O
an	O
interplay	O
between	O
RNA	O
processing	O
and	O
repeat	O
-	O
mediated	O
genome	O
instability	O
,	O
confirming	O
the	O
validity	O
of	O
our	O
approach	O
.	O

Loss	O
-	O
of	O
-	O
Function	O
GRHL3	O
Variants	O
Detected	O
in	O
African	O
Patients	O
with	O
Isolated	O
Cleft	O
Palate	O
.	O

In	O
contrast	O
to	O
the	O
progress	O
that	O
has	O
been	O
made	O
toward	O
understanding	O
the	O
genetic	O
etiology	O
of	O
cleft	O
lip	O
with	O
or	O
without	O
cleft	O
palate	O
,	O
relatively	O
little	O
is	O
known	O
about	O
the	O
genetic	O
etiology	O
for	O
cleft	B-Disease
palate	I-Disease
only	I-Disease
(	O
CPO	O
)	O
.	O

A	O
common	O
coding	O
variant	O
of	O
grainyhead	O
like	O
transcription	O
factor	O
3	O
(	O
GRHL3	O
)	O
was	O
recently	O
shown	O
to	O
be	O
associated	O
with	O
risk	O
for	O
CPO	O
in	O
Europeans	O
.	O

Mutations	O
in	O
this	O
gene	O
were	O
also	O
reported	O
in	O
families	O
with	O
Van	O
der	O
Woude	O
syndrome	O
.	O

To	O
identify	O
rare	O
mutations	O
in	O
GRHL3	O
that	O
might	O
explain	O
the	O
missing	O
heritability	O
for	O
CPO	O
,	O
we	O
sequenced	O
GRHL3	O
in	O
cases	O
of	O
CPO	O
from	O
Africa	O
.	O

We	O
recruited	O
participants	O
from	O
Ghana	O
,	O
Ethiopia	O
,	O
and	O
Nigeria	O
.	O

This	O
cohort	O
included	O
case	O
-	O
parent	O
trios	O
,	O
cases	O
and	O
other	O
family	O
members	O
,	O
as	O
well	O
as	O
controls	O
.	O

We	O
sequenced	O
exons	O
of	O
this	O
gene	O
in	O
DNA	O
from	O
a	O
total	O
of	O
134	O
nonsyndromic	O
cases	O
.	O

When	O
possible	O
,	O
we	O
sequenced	O
them	O
in	O
parents	O
to	O
identify	O
de	O
novo	O
mutations	O
.	O

Five	O
novel	O
mutations	O
were	O
identified	O
:	O
2	O
missense	O
(	O
c.497C	O
>	O
A	O
;	O
p	O
.	O
Pro166His	O
and	O
c.1229A	O
>	O
G	O
;	O
p	O
.	O
Asp410Gly	O
)	O
,	O
1	O
splice	O
site	O
(	O
c.1282A	O
>	O
C	O
p	O
.	O
Ser428Arg	O
)	O
,	O
1	O
frameshift	O
(	O
c.470delC	O
;	O
p	O
.	O
Gly158Alafster55	O
)	O
,	O
and	O
1	O
nonsense	O
(	O
c.1677C	O
>	O
A	O
;	O
p	O
.	O
Tyr559Ter	O
)	O
.	O

These	O
mutations	O
were	O
absent	O
from	O
270	O
sequenced	O
controls	O
and	O
from	O
all	O
public	O
exome	O
and	O
whole	O
genome	O
databases	O
,	O
including	O
the	O
1000	O
Genomes	O
database	O
(	O
which	O
includes	O
data	O
from	O
Africa	O
)	O
.	O

However	O
,	O
4	O
of	O
the	O
5	O
mutations	O
were	O
present	O
in	O
unaffected	O
mothers	O
,	O
indicating	O
that	O
their	O
penetrance	O
is	O
incomplete	O
.	O

Interestingly	O
,	O
1	O
mutation	B-Var
damaged	B-NegReg
a	O
predicted	O
sumoylation	B-MPA
site	I-MPA
,	O
and	O
another	O
disrupted	B-NegReg
a	O
predicted	O
CK1	B-MPA
phosphorylation	I-MPA
site	O
.	O

Overexpression	O
assays	O
in	O
zebrafish	O
and	O
reporter	O
assays	O
in	O
vitro	O
indicated	O
that	O
4	O
variants	O
were	O
functionally	O
null	O
or	O
hypomorphic	O
,	O
while	O
1	O
was	O
dominant	O
negative	O
.	O

This	O
study	O
provides	O
evidence	O
that	O
,	O
as	O
in	O
Caucasian	O
populations	O
,	O
mutations	B-Var
in	O
GRHL3	B-Gene
contribute	O
to	O
the	O
risk	B-Reg
of	O
nonsyndromic	O
CPO	B-Disease
in	O
the	O
African	O
population	O
.	O

The	O
apolipoprotein	B-Protein
C	I-Protein
-	I-Protein
III	I-Protein
(	B-Var
Gln38Lys	I-Var
)	I-Var
variant	O
associated	O
with	O
human	B-Disease
hypertriglyceridemia	I-Disease
is	O
a	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	O
.	O

Recent	O
cell	O
culture	O
and	O
animal	O
studies	O
have	O
suggested	O
that	O
expression	O
of	O
human	O
apo	O
C	O
-	O
III	O
in	O
the	O
liver	O
has	O
a	O
profound	O
impact	O
on	O
the	O
triacylglycerol	O
(	O
TAG)-rich	O
VLDL1	O
production	O
under	O
lipid	O
-	O
rich	O
conditions	O
.	O

The	O
apoC	O
-	O
III	O
Gln38Lys	O
variant	O
was	O
identified	O
in	O
subjects	O
of	O
Mexican	O
origin	O
with	O
moderate	O
hypertriglyceridemia	O
.	O

We	O
postulated	O
that	O
Gln38Lys	O
(	O
C3QK	O
)	O
,	O
being	O
a	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
,	O
promotes	O
hepatic	O
VLDL1	O
assembly	O
/	O
secretion	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
expressed	O
C3QK	O
in	O
McA	O
-	O
RH7777	O
cells	O
and	O
apoc3-null	O
mice	O
to	O
contrast	O
its	O
effect	O
with	O
WT	O
apoC	O
-	O
III	O
(	O
C3WT	O
)	O
.	O

In	O
both	O
model	O
systems	O
,	O
C3QK	O
expression	O
increased	O
the	O
secretion	O
of	O
VLDL1-TAG	O
(	O
by	O
230	O
%	O
)	O
under	O
lipid	O
-	O
rich	O
conditions	O
.	O

Metabolic	O
labeling	O
experiments	O
with	O
C3QK	O
cells	O
showed	O
an	O
increase	O
in	O
de	B-MPA
novo	I-MPA
lipogenesis	I-MPA
(	O
DNL	O
)	O
.	O

Fasting	O
plasma	O
concentration	O
of	O
TAG	O
,	O
cholesterol	O
,	O
cholesteryl	O
ester	O
,	O
and	O
FA	O
were	O
increased	O
in	O
C3QK	O
mice	O
as	O
compared	O
with	O
C3WT	O
mice	O
.	O

Liver	O
of	O
C3QK	B-Var
mice	O
also	O
displayed	O
an	O
increase	B-PosReg
in	O
DNL	B-MPA
and	O
expression	B-MPA
of	O
lipogenic	B-Gene
genes	I-Gene
as	O
compared	O
with	O
that	O
in	O
C3WT	O
mice	O
.	O

These	O
results	O
suggest	O
that	O
C3QK	B-Var
variant	O
is	O
a	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
that	O
can	O
stimulate	B-PosReg
VLDL1	B-MPA
production	I-MPA
,	O
through	O
enhanced	B-PosReg
DNL	B-MPA
.	O

The	O
Impact	O
of	O
Heterozygous	O
KCNK3	O
Mutations	O
Associated	O
With	O
Pulmonary	O
Arterial	O
Hypertension	O
on	O
Channel	O
Function	O
and	O
Pharmacological	O
Recovery	O
.	O

BACKGROUND	O
:	O
Heterozygous	O
loss	O
of	O
function	O
mutations	B-Var
in	O
the	O
KCNK3	B-Gene
gene	O
cause	B-Reg
hereditary	O
pulmonary	B-Disease
arterial	I-Disease
hypertension	I-Disease
(	O
PAH	O
)	O
.	O

KCNK3	O
encodes	O
an	O
acid	O
-	O
sensitive	O
potassium	O
channel	O
,	O
which	O
contributes	O
to	O
the	O
resting	O
potential	O
of	O
human	O
pulmonary	O
artery	O
smooth	O
muscle	O
cells	O
.	O

KCNK3	O
is	O
widely	O
expressed	O
in	O
the	O
body	O
,	O
and	O
dimerizes	O
with	O
other	O
KCNK3	O
subunits	O
,	O
or	O
the	O
closely	O
related	O
,	O
acid	O
-	O
sensitive	O
KCNK9	O
channel	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
We	O
engineered	O
homomeric	O
and	O
heterodimeric	O
mutant	O
and	O
nonmutant	O
KCNK3	O
channels	O
associated	O
with	O
PAH	O
.	O

Using	O
whole	O
-	O
cell	O
patch	O
-	O
clamp	O
electrophysiology	O
in	O
human	O
pulmonary	O
artery	O
smooth	O
muscle	O
and	O
COS7	O
cell	O
lines	O
,	O
we	O
determined	O
that	O
homomeric	O
and	O
heterodimeric	O
mutant	O
channels	O
in	O
heterozygous	O
KCNK3	O
conditions	O
lead	O
to	O
mutation	O
-	O
specific	O
severity	O
of	O
channel	O
dysfunction	O
.	O

Both	O
wildtype	O
and	O
mutant	O
KCNK3	O
channels	O
were	O
activated	O
by	O
ONO	O
-	O
RS-082	O
(	O
10	O
μmol	O
/	O
L	O
)	O
,	O
causing	O
cell	O
hyperpolarization	O
.	O

We	O
observed	O
robust	O
gene	O
expression	O
of	O
KCNK3	O
in	O
healthy	O
and	O
familial	O
PAH	O
patient	O
lungs	O
,	O
but	O
no	O
quantifiable	O
expression	O
of	O
KCNK9	O
,	O
and	O
demonstrated	O
in	O
functional	O
studies	O
that	O
KCNK9	O
minimizes	O
the	O
impact	O
of	O
select	O
KCNK3	O
mutations	O
when	O
the	O
2	O
channel	O
subunits	O
co	O
-	O
assemble	O
.	O

CONCLUSIONS	O
:	O
Heterozygous	O
KCNK3	B-Gene
mutations	B-Var
in	O
PAH	O
lead	O
to	O
variable	O
loss	B-NegReg
of	O
channel	B-MPA
function	I-MPA
via	O
distinct	O
mechanisms	O
.	O

Homomeric	O
and	O
heterodimeric	O
mutant	O
KCNK3	O
channels	O
represent	O
novel	O
therapeutic	O
substrates	O
in	O
PAH	O
.	O

Pharmacological	O
and	O
pH	O
-	O
dependent	O
activation	O
of	O
wildtype	O
and	O
mutant	O
KCNK3	O
channels	O
in	O
pulmonary	O
artery	O
smooth	O
muscle	O
cells	O
leads	O
to	O
membrane	O
hyperpolarization	O
.	O

Co	O
-	O
assembly	O
of	O
KCNK3	O
with	O
KCNK9	O
subunits	O
may	O
provide	O
protection	O
against	O
KCNK3	O
loss	O
of	O
function	O
in	O
tissues	O
where	O
both	O
KCNK9	O
and	O
KCNK3	O
are	O
expressed	O
,	O
contributing	O
to	O
the	O
lung	O
-	O
specific	O
phenotype	O
observed	O
clinically	O
in	O
patients	O
with	O
PAH	O
because	O
of	O
KCNK3	O
mutations	O
.	O

Modifiers	O
of	O
GRN	O
-	O
Associated	O
Frontotemporal	O
Lobar	O
Degeneration	O
.	O

Heterozygous	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LOF	O
)	O
mutations	B-Var
in	O
the	O
human	O
progranulin	O
gene	O
(	B-Gene
GRN	I-Gene
)	I-Gene
cause	O
frontotemporal	B-Disease
lobar	I-Disease
degeneration	I-Disease
(	O
FTLD	O
)	O
by	O
a	O
mechanism	O
of	O
haploinsufficiency	O
.	O

Patients	O
present	O
most	O
frequently	O
with	O
frontotemporal	O
dementia	O
,	O
which	O
is	O
the	O
second	O
most	O
common	O
neurodegenerative	O
dementia	O
at	O
young	O
age	O
.	O

Currently	O
,	O
no	O
disease	O
-	O
modifying	O
therapies	O
are	O
available	O
for	O
these	O
patients	O
.	O

Stimulating	O
GRN	O
protein	O
expression	O
or	O
inhibiting	O
its	O
breakdown	O
is	O
an	O
obvious	O
therapeutic	O
strategy	O
,	O
and	O
is	O
indeed	O
the	O
focus	O
of	O
current	O
preclinical	O
research	O
and	O
clinical	O
trials	O
.	O

Multiple	O
studies	O
have	O
demonstrated	O
the	O
heterogeneity	O
in	O
clinical	O
presentation	O
and	O
wide	O
variability	O
in	O
age	O
of	O
onset	O
in	O
patients	O
carrying	O
a	O
GRN	O
LOF	O
mutation	O
.	O

Recently	O
,	O
this	O
heterogeneity	O
became	O
an	O
opportunity	O
to	O
identify	O
disease	O
modifiers	O
,	O
considering	O
that	O
these	O
might	O
constitute	O
suitable	O
targets	O
for	O
developing	O
disease	O
-	O
modifying	O
or	O
disease	O
-	O
delaying	O
therapies	O
.	O

De	O
novo	O
SETD5	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
variant	B-Var
as	O
a	O
cause	O
for	O
intellectual	B-Disease
disability	I-Disease
in	O
a	O
10-year	O
old	O
boy	O
with	O
an	O
aberrant	O
blind	O
ending	O
bronchus	O
.	O

Although	O
rare	O
,	O
3p	O
microdeletion	O
cases	O
have	O
been	O
well	O
described	O
in	O
the	O
clinical	O
literature	O
.	O

The	O
clinical	O
phenotype	O
includes	O
;	O
intellectual	O
disability	O
(	O
ID	O
)	O
,	O
growth	O
retardation	O
,	O
facial	O
dysmorphism	O
,	O
and	O
cardiac	O
malformations	O
.	O

Advances	O
in	O
chromosome	O
microarray	O
(	O
CMA	O
)	O
testing	O
narrowed	O
the	O
3p25	O
critical	O
region	O
to	O
a	O
124	O
kb	O
region	O
,	O
and	O
recent	O
Whole	O
Exome	O
Sequencing	O
(	O
WES	O
)	O
studies	O
have	O
suggested	O
that	O
the	O
SETD5	O
gene	O
contributes	O
significantly	O
to	O
the	O
3p25	O
phenotype	O
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
Function	I-NegReg
(	O
LoF	O
)	O
variants	B-Var
in	O
SETD5	B-Gene
are	O
now	O
considered	O
a	O
likely	O
cause	O
of	O
ID	B-Disease
.	O

We	O
report	O
here	O
a	O
patient	O
with	O
a	O
frameshift	O
LoF	O
variant	O
in	O
exon	O
12	O
of	O
SETD5	O
.	O

This	O
patient	O
has	O
features	O
overlapping	O
with	O
other	O
patients	O
described	O
with	O
LoF	O
SETD5	O
variants	O
to	O
include	O
;	O
similar	O
facial	O
morphology	O
,	O
feeding	O
difficulties	O
,	O
ID	O
,	O
behavioral	O
abnormalities	O
and	O
leg	O
length	O
discrepancy	O
.	O

In	O
addition	O
,	O
he	O
presents	O
with	O
an	O
aberrant	O
blind	O
ending	O
bronchus	O
.	O

This	O
report	O
adds	O
to	O
publications	O
describing	O
intragenic	O
mutations	O
in	O
SETD5	O
and	O
supports	O
the	O
assertion	O
that	O
de	O
novo	O
LoF	O
mutations	O
in	O
SETD5	O
present	O
with	O
an	O
overlapping	O
but	O
distinct	O
phenotype	O
in	O
comparison	O
with	O
3p25	O
microdeletion	O
syndromes	O
.	O

Signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
gain	O
-	O
of	O
-	O
function	O
primary	O
immunodeficiency	O
/	O
immunodysregulation	O
disorders	O
.	O

PURPOSE	O
OF	O
REVIEW	O
:	O
To	O
describe	O
primary	B-Disease
immunodeficiencies	I-Disease
caused	O
by	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
mutations	B-Var
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	B-Gene
STAT	I-Gene
)	I-Gene
genes	O
,	O
a	O
group	O
of	O
genetically	O
determined	O
disorders	O
characterized	O
by	O
susceptibility	O
to	O
infections	O
and	O
,	O
in	O
many	O
cases	O
,	O
autoimmune	O
manifestations	O
.	O

RECENT	O
FINDINGS	O
:	O
GOF	O
mutations	B-Var
affecting	O
STAT1	B-Gene
result	O
in	O
increased	B-PosReg
STAT	B-MPA
tyrosine	I-MPA
phosphorylation	I-MPA
and	O
secondarily	O
increased	B-PosReg
response	B-MPA
to	I-MPA
STAT1-signaling	I-MPA
cytokines	I-MPA
,	O
such	O
as	O
interferons	O
.	O

In	O
contrast	O
,	O
STAT3	O
hyperactivity	O
is	O
not	O
usually	O
related	O
to	O
hyperphosphorylation	O
but	O
rather	O
to	O
increased	O
STAT3-mediated	O
transcriptional	O
activity	O
.	O

In	O
both	O
cases	O
,	O
heterozygous	O
STAT1	O
and	O
STAT3	O
GOF	O
mutations	O
trigger	O
a	O
distinct	O
set	O
of	O
genes	O
in	O
target	O
cells	O
that	O
lead	O
to	O
abnormal	O
functioning	O
of	O
antimicrobial	O
response	O
and/or	O
autoimmunity	O
and	O
result	O
in	O
autosomal	O
dominant	O
diseases	O
.	O

SUMMARY	O
:	O
Clinical	O
manifestations	O
of	O
patients	O
with	O
STAT1	O
GOF	O
are	O
characterized	O
by	O
mucocutaneous	O
candidiasis	O
and	O
recurrent	O
lower	O
tract	O
respiratory	O
infections	O
.	O

In	O
addition	O
,	O
many	O
patients	O
have	O
thyroiditis	O
,	O
type	O
1	O
diabetes	O
mellitus	O
,	O
autoimmune	O
cytopenias	O
,	O
cancer	O
or	O
aneurysms	O
.	O

Patients	O
with	O
germline	O
STAT3	O
GOF	O
mutations	O
have	O
an	O
increased	O
frequency	O
of	O
early	O
-	O
onset	O
multiorgan	O
autoimmunity	O
(	O
i.e.	O
autoimmune	O
enteropathy	O
,	O
type	O
1	O
diabetes	O
mellitus	O
,	O
autoimmune	O
interstitial	O
lung	O
disease	O
and	O
autoimmune	O
cytopenias	O
)	O
,	O
lymphoproliferation	O
,	O
short	O
stature	O
and	O
,	O
less	O
frequently	O
,	O
severe	O
recurrent	O
infections	O
.	O

Treatment	O
options	O
range	O
from	O
antimicrobial	O
therapy	O
,	O
intravenous	O
or	O
subcutaneous	O
immunoglobulin	O
and	O
immunosuppressive	O
drugs	O
.	O

Some	O
patients	O
with	O
STAT1	O
GOF	O
disorder	O
have	O
undergone	O
hematopoietic	O
stem	O
cell	O
transplantation	O
,	O
although	O
these	O
have	O
been	O
difficult	O
because	O
of	O
the	O
underlying	O
proinflammatory	O
milieu	O
from	O
the	O
mutation	O
.	O

GNPTAB	O
missense	O
mutations	O
cause	O
loss	O
of	O
GlcNAc-1-phosphotransferase	O
activity	O
in	O
mucolipidosis	O
type	O
II	O
through	O
distinct	O
mechanisms	O
.	O

Mucolipidoses	O
(	O
ML	O
)	O
II	O
and	O
III	O
alpha	O
/	O
beta	O
are	O
lysosomal	O
storage	O
diseases	O
caused	O
by	O
pathogenic	O
mutations	O
in	O
GNPTAB	O
encoding	O
the	O
α⁄β	O
-	O
subunit	O
precursor	O
of	O
GlcNAc-1-phosphotransferase	O
.	O

To	O
determine	O
genotype	O
-	O
phenotype	O
correlation	O
and	O
functional	O
analysis	O
of	O
mutant	O
GlcNAc-1-phosphotransferase	O
,	O
13	O
Brazilian	O
patients	O
clinically	O
and	O
biochemical	O
diagnosed	O
for	O
MLII	O
or	O
III	O
alpha	O
/	O
beta	O
were	O
studied	O
.	O

By	O
sequencing	O
of	O
genomic	O
GNPTAB	B-Gene
of	O
the	O
MLII	O
and	O
MLIII	O
alpha	O
/	O
beta	O
patients	O
we	O
identified	O
six	O
novel	O
mutations	O
:	O
p	B-Var
.	I-Var
D76	I-Var
G	I-Var
,	O
p	B-Var
.	I-Var
S385L	I-Var
,	O
p	B-Var
.	I-Var
Q278Kfs*3	I-Var
,	O
p	B-Var
.	I-Var
H588Qfs*27	I-Var
,	O
p	B-Var
.	I-Var
N642Lfs*10	I-Var
and	O
p	B-Var
.	I-Var
Y1111	I-Var
*	I-Var
.	O

Expression	O
analysis	O
by	O
western	O
blotting	O
and	O
immunofluorescence	O
microscopy	O
revealed	O
that	O
the	O
mutant	O
α⁄β	O
-	O
subunit	O
precursor	O
p	B-Var
.	I-Var
D76	I-Var
G	I-Var
is	O
retained	O
in	O
the	O
endoplasmic	O
reticulum	O
whereas	O
the	O
mutant	O
p	B-Var
.	I-Var
S385L	I-Var
is	O
correctly	O
transported	O
to	O
the	O
cis	O
-	O
Golgi	O
apparatus	O
and	O
proteolytically	O
processed	O
.	O

Both	O
mutations	O
lead	O
to	O
complete	O
loss	B-NegReg
of	O
GlcNAc-1-phosphotransferase	B-Enzyme
activity	B-MPA
,	O
consistent	O
with	O
the	O
severe	O
clinical	O
MLII	O
phenotype	O
of	O
the	O
patients	O
.	O

Our	O
study	O
expands	O
the	O
genotypic	O
spectrum	O
of	O
MLII	O
and	O
provides	O
novel	O
insights	O
into	O
structural	O
requirements	O
to	O
ensure	O
GlcNAc-1-phosphotransferase	O
activity	O
.	O

Altered	O
Cav1.2	O
function	O
in	O
the	O
Timothy	O
syndrome	O
mouse	O
model	O
produces	O
ascending	O
serotonergic	O
abnormalities	O
.	O

Polymorphism	O
in	O
the	O
gene	O
CACNA1C	O
,	O
encoding	O
the	O
pore	O
-	O
forming	O
subunit	O
of	O
Cav1.2	O
L	O
-	O
type	O
calcium	O
channels	O
,	O
has	O
one	O
of	O
the	O
strongest	O
genetic	O
linkages	O
to	O
schizophrenia	O
,	O
bipolar	O
disorder	O
and	O
major	O
depressive	O
disorder	O
:	O
psychopathologies	O
in	O
which	O
serotonin	O
signaling	O
has	O
been	O
implicated	O
.	O

Additionally	O
,	O
a	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	B-Var
in	O
CACNA1C	B-Gene
is	O
responsible	O
for	O
the	O
neurodevelopmental	O
disorder	O
Timothy	B-Disease
syndrome	I-Disease
that	O
presents	O
with	O
prominent	O
behavioral	O
features	O
on	O
the	O
autism	O
spectrum	O
.	O

Given	O
an	O
emerging	O
role	O
for	O
serotonin	O
in	O
the	O
etiology	O
of	O
autism	O
spectrum	O
disorders	O
(	O
ASD	O
)	O
,	O
we	O
investigate	O
the	O
relationship	O
between	O
Cav1.2	O
and	O
the	O
ascending	O
serotonin	O
system	O
in	O
the	O
Timothy	O
syndrome	O
type	O
2	O
(	O
TS2-neo	O
)	O
mouse	O
,	O
which	O
displays	O
behavioral	O
features	O
consistent	O
with	O
the	O
core	O
triad	O
of	O
ASD	O
.	O

We	O
find	O
that	O
TS2-neo	O
mice	O
exhibit	O
enhanced	O
serotonin	O
tissue	O
content	O
and	O
axon	O
innervation	O
of	O
the	O
dorsal	O
striatum	O
,	O
as	O
well	O
as	O
decreased	O
serotonin	O
turnover	O
in	O
the	O
amygdala	O
.	O

These	O
regionally	O
specific	O
alterations	O
are	O
accompanied	O
by	O
an	O
enhanced	O
active	O
coping	O
response	O
during	O
acute	O
stress	O
(	O
forced	O
swim	O
)	O
,	O
serotonin	O
neuron	O
Fos	O
activity	O
in	O
the	O
caudal	O
dorsal	O
raphe	O
,	O
and	O
serotonin	O
type	O
1A	O
receptor	O
-	O
dependent	O
feedback	O
inhibition	O
of	O
the	O
rostral	O
dorsal	O
raphe	O
nuclei	O
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
the	O
global	O
gain	O
-	O
of	O
-	O
function	O
Cav1.2	O
mutation	O
associated	O
with	O
Timothy	O
syndrome	O
has	O
pleiotropic	O
effects	O
on	O
the	O
ascending	O
serotonin	O
system	O
including	O
neuroanatomical	O
changes	O
,	O
regional	O
differences	O
in	O
forebrain	O
serotonin	O
metabolism	O
and	O
feedback	O
regulatory	O
control	O
mechanisms	O
within	O
the	O
dorsal	O
raphe	O
.	O

Altered	O
activity	O
of	O
the	O
ascending	O
serotonin	O
system	O
continues	O
to	O
emerge	O
as	O
a	O
common	O
neural	O
signature	O
across	O
several	O
ASD	O
mouse	O
models	O
,	O
and	O
the	O
capacity	O
for	O
Cav1.2	O
L	O
-	O
type	O
calcium	O
channels	O
to	O
impact	O
both	O
serotonin	O
structure	O
and	O
function	O
has	O
important	O
implications	O
for	O
several	O
neuropsychiatric	O
conditions	O
.	O

Localization	O
of	O
Cdc7	O
Protein	O
Kinase	O
During	O
DNA	O
Replication	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

DDK	O
,	O
a	O
conserved	O
serine	O
-	O
threonine	O
protein	O
kinase	O
composed	O
of	O
a	O
regulatory	O
subunit	O
,	O
Dbf4	O
,	O
and	O
a	O
catalytic	O
subunit	O
,	O
Cdc7	O
,	O
is	O
essential	O
for	O
DNA	O
replication	O
initiation	O
during	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
through	O
MCM2	O
-	O
7	O
helicase	O
phosphorylation	O
.	O

The	O
biological	O
significance	O
of	O
DDK	O
is	O
well	O
characterized	O
,	O
but	O
the	O
full	O
mechanism	O
of	O
how	O
DDK	O
associates	O
with	O
substrates	O
remains	O
unclear	O
.	O

Cdc7	O
is	O
bound	O
to	O
chromatin	O
in	O
the	O
Saccharomyces	O
cerevisiae	O
genome	O
throughout	O
the	O
cell	O
cycle	O
,	O
but	O
there	O
is	O
little	O
empirical	O
evidence	O
as	O
to	O
specific	O
Cdc7	O
binding	O
locations	O
.	O

Using	O
biochemical	O
and	O
genetic	O
techniques	O
,	O
this	O
study	O
investigated	O
the	O
specific	O
localization	O
of	O
Cdc7	O
on	O
chromatin	O
.	O

The	O
Calling	O
Cards	O
method	O
,	O
using	O
Ty5	O
retrotransposons	O
as	O
a	O
marker	O
for	O
DNA	O
-	O
protein	O
binding	O
,	O
suggests	O
Cdc7	O
kinase	O
is	O
preferentially	O
bound	O
to	O
genomic	O
DNA	O
known	O
to	O
replicate	O
early	O
in	O
S	O
phase	O
,	O
including	O
centromeres	O
and	O
origins	O
of	O
replication	O
.	O

We	O
also	O
discovered	O
Cdc7	O
binding	O
throughout	O
the	O
genome	O
,	O
which	O
may	O
be	O
necessary	O
to	O
initiate	O
other	O
cellular	O
processes	O
,	O
including	O
meiotic	O
recombination	O
and	O
translesion	O
synthesis	O
.	O

A	O
kinase	O
dead	O
Cdc7	B-Gene
point	B-Var
mutation	I-Var
increases	B-PosReg
the	O
Ty5	B-MPA
retrotransposon	I-MPA
integration	I-MPA
efficiency	I-MPA
and	O
a	O
55-amino	B-MPA
acid	I-MPA
C	I-MPA
-	I-MPA
terminal	I-MPA
truncation	I-MPA
of	O
Cdc7	B-Gene
,	O
unable	B-NegReg
to	O
bind	B-Interaction
Dbf4	B-Gene
,	O
reduces	B-NegReg
Cdc7	B-Gene
binding	B-Interaction
suggesting	O
a	O
requirement	O
for	O
Dbf4	O
to	O
stabilize	O
Cdc7	O
on	O
chromatin	O
during	O
S	O
phase	O
.	O

Chromatin	O
immunoprecipitation	O
demonstrates	O
that	O
Cdc7	O
binding	O
near	O
specific	O
origins	O
changes	O
during	O
S	O
phase	O
.	O

Our	O
results	O
suggest	O
a	O
model	O
where	O
Cdc7	O
is	O
loosely	O
bound	O
to	O
chromatin	O
during	O
G1	O
At	O
the	O
G1	O
/	O
S	O
transition	O
,	O
Cdc7	O
binding	O
to	O
chromatin	O
is	O
increased	O
and	O
stabilized	O
,	O
preferentially	O
at	O
sites	O
that	O
may	O
become	O
origins	O
,	O
in	O
order	O
to	O
carry	O
out	O
a	O
variety	O
of	O
cellular	O
processes	O
.	O

Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	B-Var
in	O
PTPN11	B-Gene
in	O
histiocytic	B-Disease
sarcomas	I-Disease
of	O
Bernese	O
Mountain	O
Dogs	O
.	O

Histiocytic	O
sarcoma	O
(	O
HS	O
)	O
is	O
an	O
aggressive	O
malignant	O
neoplasm	O
of	O
dendritic	O
cell	O
origin	O
that	O
is	O
common	O
in	O
certain	O
breeds	O
of	O
dogs	O
.	O

High	O
prevalence	O
of	O
fatal	O
,	O
disseminated	O
HS	O
has	O
been	O
described	O
in	O
Bernese	O
Mountain	O
Dogs	O
(	O
BMDs	O
)	O
.	O

Support	O
for	O
genetic	O
predisposition	O
to	O
develop	O
HS	O
has	O
been	O
presented	O
in	O
several	O
studies	O
,	O
but	O
to	O
date	O
,	O
causative	O
genetic	O
events	O
have	O
not	O
been	O
reported	O
.	O

In	O
addition	O
,	O
no	O
driver	O
mutations	O
have	O
been	O
identified	O
in	O
tumours	O
.	O

Recently	O
,	O
E76	B-Var
K	I-Var
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	O
in	O
SHP2	O
encoded	O
by	O
the	O
PTPN11	B-Gene
gene	O
has	O
been	O
described	O
in	O
human	O
histiocytic	B-Disease
malignancies	I-Disease
.	O

In	O
our	O
study	O
,	O
we	O
identified	O
the	O
PTPN11E76	O
K	O
in	O
HS	O
of	O
BMDs	O
.	O

Amplification	O
of	O
exon	O
3	O
of	O
the	O
PTPN11	O
gene	O
followed	O
by	O
Sanger	O
sequencing	O
was	O
used	O
to	O
detect	O
the	O
mutation	O
and	O
estimate	O
the	O
prevalence	O
in	O
HS	O
from	O
30	O
BMDs	O
,	O
13	O
Golden	O
Retrievers	O
and	O
10	O
other	O
dog	O
breeds	O
.	O

The	O
overall	O
prevalence	O
of	O
PTPN11E76	O
K	O
in	O
HS	O
of	O
BMDs	O
was	O
36.67	O
%	O
compared	O
with	O
8.69	O
%	O
in	O
other	O
breeds	O
.	O

No	O
mutation	O
was	O
identified	O
in	O
normal	O
tissues	O
from	O
10	O
BMDs	O
with	O
HS	O
that	O
carried	O
the	O
mutation	O
and	O
12	O
control	O
dogs	O
with	O
no	O
neoplastic	O
disease	O
,	O
including	O
6	O
BMDs	O
.	O

Increased	O
immunoreactivity	O
for	O
AKT	O
,	O
phosphorylated	O
ERK1/2	O
and	O
phosphorylated	O
AKT	O
in	O
a	O
small	O
subset	O
of	O
BMDs	O
with	O
PTPN11E76	O
K	O
suggests	O
that	O
a	O
gain	O
-	O
of	O
-	O
function	O
might	O
be	O
mediated	O
by	O
the	O
ERK	O
and	O
AKT	O
pathways	O
.	O

These	O
data	O
suggest	O
PTPN11E76	O
K	O
as	O
an	O
important	O
driver	O
mutation	O
of	O
HS	O
in	O
BMDs	O
.	O

This	O
information	O
may	O
not	O
only	O
aid	O
in	O
unravelling	O
the	O
tumourigenic	O
events	O
associated	O
with	O
HS	O
in	O
BMDs	O
,	O
but	O
also	O
help	O
in	O
identifying	O
more	O
promising	O
therapeutic	O
strategies	O
.	O

Homozygous	O
KIDINS220	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
variants	B-Var
in	O
fetuses	O
with	O
cerebral	B-CPA
ventriculomegaly	I-CPA
and	O
limb	B-CPA
contractures	I-CPA
.	O

Heterozygous	B-Var
mutations	I-Var
in	O
KIDINS220	B-Gene
were	O
recently	O
suggested	O
a	O
cause	B-Reg
of	O
spastic	B-Disease
paraplegia	I-Disease
,	O
intellectual	B-Disease
disability	I-Disease
,	O
nystagmus	B-Disease
and	O
obesity	B-Disease
.	O

All	O
patients	O
carried	O
terminal	O
nonsense	O
de	O
novo	O
mutations	O
that	O
seemed	O
to	O
escape	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	O
.	O

The	O
mechanism	O
for	O
pathogenicity	O
is	O
yet	O
unexplained	O
,	O
as	O
it	O
seems	O
that	O
heterozygous	O
loss	O
-	O
of	O
-	O
function	O
variants	O
of	O
KIDINS220	O
are	O
generally	O
well	O
tolerated	O
.	O

We	O
present	O
a	O
consanguineous	O
couple	O
who	O
experienced	O
four	O
pregnancy	O
terminations	O
due	O
to	O
repeated	O
findings	O
in	O
the	O
fetuses	O
comprising	O
enlarged	O
cerebral	O
ventricles	O
and	O
limb	O
contractures	O
.	O

Exome	O
sequencing	O
in	O
two	O
of	O
the	O
aborted	O
fetuses	O
revealed	O
a	O
shared	O
homozygous	O
frameshift	O
variant	O
in	O
exon	O
24	O
in	O
KIDINS220	O
.	O

Sanger	O
sequencing	O
of	O
the	O
variant	O
in	O
available	O
family	O
members	O
showed	O
complete	O
segregation	O
with	O
the	O
affection	O
status	O
,	O
resulting	O
in	O
a	O
LOD	O
score	O
of	O
2.5	O
under	O
an	O
autozygous	O
inheritance	O
model	O
.	O

mRNA	O
studies	O
revealed	O
destruction	O
of	O
the	O
original	O
splice	O
site	O
,	O
resulting	O
in	O
an	O
out	O
-	O
of	O
-	O
frame	O
transcript	O
and	O
introduction	O
of	O
a	O
premature	O
termination	O
codon	O
in	O
exon	O
25	O
.	O

Premature	O
termination	O
codons	O
in	O
this	O
position	O
are	O
likely	O
to	O
cause	O
activation	O
of	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	O
and	O
result	O
in	O
complete	O
absence	O
of	O
KIDINS220	O
protein	O
in	O
individuals	O
homozygous	O
for	O
the	O
variant	O
.	O

The	O
phenotype	O
of	O
the	O
presented	O
fetuses	O
overlaps	O
with	O
findings	O
in	O
functional	O
studies	O
of	O
knockout	O
Kidins220	O
mice	O
embryos	O
that	O
are	O
non	O
-	O
viable	O
with	O
enlarged	O
cerebral	O
ventricles	O
.	O

The	O
human	O
fetuses	O
also	O
exhibit	O
several	O
similarities	O
to	O
the	O
milder	O
phenotype	O
described	O
in	O
patients	O
with	O
heterozygous	O
KIDINS220	O
mutations	O
.	O

We	O
hence	O
propose	O
that	O
the	O
identified	O
homozygous	O
loss	O
-	O
of	O
-	O
function	O
variant	O
in	O
KIDINS220	O
causes	O
the	O
phenotype	O
in	O
the	O
presented	O
fetuses	O
,	O
and	O
that	O
this	O
represents	O
a	O
hitherto	O
undescribed	O
severe	O
autosomal	O
recessive	O
neurodevelopmental	O
disorder	O
.	O

The	O
GNASR201C	O
mutation	O
associated	O
with	O
clonal	O
hematopoiesis	O
supports	O
transplantable	O
hematopoietic	O
stem	O
cell	O
activity	O
.	O

Genome	O
sequencing	O
efforts	O
have	O
identified	O
virtually	O
all	O
of	O
the	O
important	O
mutations	O
in	O
adult	O
myeloid	O
malignancies	O
.	O

More	O
recently	O
,	O
population	O
studies	O
have	O
identified	O
cancer	O
-	O
associated	O
variants	O
in	O
the	O
blood	O
of	O
otherwise	O
healthy	O
individuals	O
as	O
they	O
age	O
,	O
a	O
phenomenon	O
termed	O
clonal	O
hematopoiesis	O
of	O
indeterminate	O
potential	O
(	O
CHIP	O
)	O
.	O

This	O
suggests	O
that	O
these	O
mutations	O
may	O
occur	O
in	O
hematopoietic	O
stem	O
cells	O
(	O
HSCs	O
)	O
long	O
before	O
any	O
clinical	O
presentation	O
but	O
are	O
not	O
necessarily	O
harbingers	O
of	O
transformation	O
because	O
only	O
a	O
fraction	O
of	O
individuals	O
with	O
CHIP	O
develop	O
hematopoietic	O
pathologies	O
.	O

Delineation	O
between	O
CHIP	O
variants	O
that	O
predispose	O
for	O
disease	O
versus	O
those	O
that	O
are	O
more	O
benign	O
could	O
be	O
used	O
as	O
a	O
prognostic	O
factor	O
to	O
identify	O
individuals	O
at	O
greater	O
risk	O
for	O
transformation	O
.	O

To	O
achieve	O
this	O
,	O
the	O
biological	O
impact	O
of	O
CHIP	O
variants	O
on	O
HSC	O
function	O
must	O
be	O
validated	O
.	O

One	O
variant	O
that	O
has	O
been	O
identified	O
recurrently	O
in	O
CHIP	B-CPA
is	O
a	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
missense	B-Var
mutation	I-Var
in	O
the	O
imprinted	O
gene	O
GNAS	B-Gene
(	O
Guanine	O
Nucleotide	O
Binding	O
Protein	O
,	O
Alpha	O
Stimulating	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
effect	O
of	O
the	O
GNASR201C	O
variant	O
on	O
HSC	O
function	O
.	O

Ectopic	O
expression	O
of	O
GNASR201C	B-Gene
supported	B-PosReg
transplantable	B-CPA
HSC	I-CPA
activity	I-CPA
and	O
improved	B-PosReg
lymphoid	B-CPA
output	I-CPA
in	O
secondary	O
recipients	O
.	O

Because	O
declining	O
lymphoid	O
output	O
is	O
a	O
hallmark	O
of	O
aging	O
,	O
GNASR201C	O
mutations	O
may	O
sustain	O
lymphoid	O
-	O
biased	O
HSCs	O
over	O
time	O
and	O
maintain	O
them	O
in	O
a	O
developmental	O
state	O
favorable	O
for	O
transformation	O
.	O

N1366S	O
mutation	O
of	O
human	O
skeletal	O
muscle	O
sodium	O
channel	O
causes	O
paramyotonia	O
congenita	O
.	O

KEY	O
POINTS	O
:	O
Paramyotonia	B-Disease
congenita	I-Disease
is	O
a	O
hereditary	O
channelopathy	O
caused	B-Reg
by	O
missense	B-Var
mutations	I-Var
in	O
the	O
SCN4A	B-Gene
gene	O
,	O
which	O
encodes	O
the	O
α	O
subunit	O
of	O
the	O
human	O
skeletal	O
muscle	O
voltage	O
-	O
gated	O
sodium	O
channel	O
NaV1.4	O
.	O

Affected	O
individuals	O
suffered	O
from	O
myotonia	O
and	O
paralysis	O
of	O
muscles	O
,	O
which	O
were	O
aggravated	O
by	O
exposure	O
to	O
cold	O
.	O

We	O
report	O
a	O
three	O
-	O
generation	O
Chinese	O
family	O
with	O
patients	O
presenting	O
paramyotonia	O
congenita	O
and	O
identify	O
a	O
novel	O
N1366S	O
mutation	O
of	O
NaV1.4	O
.	O

Whole	O
-	O
cell	O
electrophysiological	O
recordings	O
of	O
the	O
N1366S	O
channel	O
reveal	O
a	O
gain	O
-	O
of	O
-	O
function	O
change	O
of	O
gating	O
in	O
response	O
to	O
cold	O
.	O

Modelling	O
and	O
molecular	O
dynamic	O
simulation	O
data	O
suggest	O
that	O
an	O
arginine	O
-	O
to	O
-	O
serine	O
substitution	O
at	O
position	O
1366	O
increases	O
the	O
distance	O
from	O
N1366	O
to	O
R1454	O
and	O
disrupts	O
the	O
hydrogen	O
bond	O
formed	O
between	O
them	O
at	O
low	O
temperature	O
.	O

We	O
demonstrate	O
that	O
N1366S	O
is	O
a	O
disease	O
-	O
causing	O
mutation	O
and	O
that	O
the	O
temperature	O
-	O
sensitive	O
alteration	O
of	O
N1366S	O
channel	O
activity	O
may	O
be	O
responsible	O
for	O
the	O
pronounced	O
paramyotonia	O
congenita	O
symptoms	O
of	O
these	O
patients	O
.	O

ABSTRACT	O
:	O
Paramyotonia	B-Disease
congenita	I-Disease
is	O
an	O
autosomal	O
dominant	O
skeletal	O
muscle	O
channelopathy	O
caused	B-Reg
by	O
missense	B-Var
mutations	I-Var
in	O
SCN4A	B-Gene
,	O
the	O
gene	O
encoding	O
the	O
α	O
subunit	O
of	O
the	O
human	O
skeletal	O
muscle	O
voltage	O
-	O
gated	O
sodium	O
channel	O
NaV1.4	O
.	O

We	O
report	O
a	O
three	O
-	O
generation	O
family	O
in	O
which	O
six	O
members	O
present	O
clinical	O
symptoms	O
of	O
paramyotonia	O
congenita	O
characterized	O
by	O
a	O
marked	O
worsening	O
of	O
myotonia	O
by	O
cold	O
and	O
by	O
the	O
presence	O
of	O
clear	O
episodes	O
of	O
paralysis	O
.	O

We	O
identified	O
a	O
novel	O
mutation	O
in	O
SCN4A	O
(	O
Asn1366Ser	O
,	O
N1366S	O
)	O
in	O
all	O
patients	O
in	O
the	O
family	O
but	O
not	O
in	O
healthy	O
relatives	O
or	O
in	O
500	O
normal	O
control	O
subjects	O
.	O

Functional	O
analysis	O
of	O
the	O
channel	O
protein	O
expressed	O
in	O
HEK293	O
cells	O
by	O
whole	O
-	O
cell	O
patch	O
clamp	O
recording	O
revealed	O
that	O
the	O
N1366S	O
mutation	O
led	O
to	O
significant	O
alterations	O
in	O
the	O
gating	O
process	O
of	O
the	O
NaV1.4	O
channel	O
.	O

The	O
N1366S	B-Var
mutant	O
displayed	O
a	O
cold	O
-	O
induced	O
hyperpolarizing	O
shift	O
in	O
the	O
voltage	O
dependence	O
of	O
activation	O
and	O
a	O
depolarizing	O
shift	O
in	O
fast	O
inactivation	O
,	O
as	O
well	O
as	O
a	O
reduced	B-NegReg
rate	B-MPA
of	O
fast	B-MPA
inactivation	I-MPA
and	O
accelerated	B-PosReg
recovery	B-MPA
from	O
fast	B-MPA
inactivation	I-MPA
.	O

In	O
addition	O
,	O
homology	O
modelling	O
and	O
molecular	O
dynamic	O
simulation	O
of	O
N1366S	O
and	O
wild	O
-	O
type	O
NaV1.4	O
channels	O
indicated	O
that	O
the	O
arginine	O
-	O
to	O
-	O
serine	O
substitution	O
disrupted	O
the	O
hydrogen	O
bond	O
formed	O
between	O
N1366	O
and	O
R1454	O
.	O

Together	O
,	O
our	O
results	O
suggest	O
that	O
N1366S	B-Var
is	O
a	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	O
of	O
NaV1.4	O
at	O
low	O
temperature	O
and	O
the	O
mutation	O
may	O
be	O
responsible	O
for	O
the	O
clinical	O
symptoms	O
of	O
paramyotonia	B-Disease
congenita	I-Disease
in	O
the	O
affected	O
family	O
and	O
constitute	O
a	O
basis	O
for	O
studies	O
into	O
its	O
pathogenesis	O
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
variants	B-Var
in	O
NFIA	B-Gene
provide	O
further	O
support	O
that	O
NFIA	O
is	O
a	O
critical	O
gene	O
in	O
1p32-p31	B-Disease
deletion	I-Disease
syndrome	I-Disease
:	I-Disease
A	O
four	O
patient	O
series	O
.	O

The	O
association	O
between	O
1p32-p31	O
contiguous	O
gene	O
deletions	O
and	O
a	O
distinct	O
phenotype	O
that	O
includes	O
anomalies	O
of	O
the	O
corpus	O
callosum	O
,	O
ventriculomegaly	O
,	O
developmental	O
delay	O
,	O
seizures	O
,	O
and	O
dysmorphic	O
features	O
has	O
been	O
long	O
recognized	O
and	O
described	O
.	O

Recently	O
,	O
the	O
observation	O
of	O
overlapping	O
phenotypes	O
in	O
patients	O
with	O
chromosome	O
translocations	O
that	O
disrupt	O
NFIA	O
(	O
Nuclear	O
factor	O
I	O
/	O
A	O
)	O
,	O
a	O
gene	O
within	O
this	O
deleted	O
region	O
,	O
and	O
NFIA	O
intragenic	O
deletions	O
has	O
led	O
to	O
the	O
hypothesis	O
that	O
NFIA	O
is	O
a	O
critical	O
gene	O
within	O
this	O
region	O
.	O

The	O
wide	O
application	O
and	O
increasing	O
accessibility	O
of	O
whole	O
exome	O
sequencing	O
(	O
WES	O
)	O
has	O
helped	O
identify	O
new	O
cases	O
to	O
support	O
this	O
hypothesis	O
.	O

Here	O
,	O
we	O
describe	O
four	O
patients	O
with	O
loss	O
-	O
of	O
-	O
function	O
variants	O
in	O
the	O
NFIA	O
gene	O
identified	O
through	O
WES	O
.	O

The	O
clinical	O
presentation	O
of	O
these	O
patients	O
significantly	O
overlaps	O
with	O
the	O
phenotype	O
described	O
in	O
previously	O
reported	O
cases	O
of	O
1p32-p31	O
deletion	O
syndrome	O
,	O
NFIA	O
gene	O
disruptions	O
and	O
intragenic	O
NFIA	O
deletions	O
.	O

Our	O
cohort	O
includes	O
a	O
mother	O
and	O
daughter	O
as	O
well	O
as	O
an	O
unrelated	O
individual	O
who	O
share	O
the	O
same	O
nonsense	O
variant	O
(	O
c.205C	O
>	O
T	O
,	O
p	O
.	O
Arg69Ter	O
;	O
NM_001145512.1	O
)	O
.	O

We	O
also	O
report	O
a	O
patient	O
with	O
a	O
frameshift	O
NFIA	O
variant	O
(	O
c.159_160dupCC	O
,	O
p	O
.	O
Gln54ProfsTer49	O
)	O
.	O

We	O
have	O
compared	O
published	O
cases	O
of	O
1p32-p31	O
microdeletion	O
syndrome	O
,	O
translocations	O
resulting	O
in	O
NFIA	O
gene	O
disruption	O
,	O
intragenic	O
deletions	O
,	O
and	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
(	O
including	O
our	O
four	O
patients	O
)	O
to	O
reveal	O
that	O
abnormalities	O
of	O
the	O
corpus	O
callosum	O
,	O
ventriculomegaly	O
/	O
hydrocephalus	O
,	O
macrocephaly	O
,	O
Chiari	O
I	O
malformation	O
,	O
dysmorphic	O
features	O
,	O
developmental	O
delay	O
,	O
hypotonia	O
,	O
and	O
urinary	O
tract	O
defects	O
are	O
common	O
findings	O
.	O

The	O
consistent	O
overlap	O
in	O
clinical	O
presentation	O
provides	O
further	O
evidence	O
of	O
the	O
critical	O
role	O
of	O
NFIA	O
haploinsufficiency	O
in	O
the	O
development	O
of	O
the	O
1p32-p31	O
microdeletion	O
syndrome	O
phenotype	O
.	O

Clcn7F318L/+	O
as	O
a	O
new	O
mouse	O
model	O
of	O
Albers	O
-	O
Schönberg	O
disease	O
.	O

Dominant	O
negative	B-NegReg
mutations	B-Var
in	O
CLCN7	B-Gene
,	O
which	O
encodes	O
a	O
homodimeric	O
chloride	O
channel	O
needed	O
for	O
matrix	O
acidification	O
by	O
osteoclasts	O
,	O
cause	O
Albers	B-Disease
-	I-Disease
Schönberg	I-Disease
disease	I-Disease
(	O
also	O
known	O
as	O
autosomal	O
dominant	O
osteopetrosis	O
type	O
2	O
)	O
.	O

More	O
than	O
25	O
different	O
CLCN7	O
mutations	O
have	O
been	O
identified	O
in	O
patients	O
affected	O
with	O
Albers	O
-	O
Schönberg	O
disease	O
,	O
but	O
only	O
one	O
mutation	O
(	O
Clcn7G213R	O
)	O
has	O
been	O
introduced	O
in	O
mice	O
to	O
create	O
an	O
animal	O
model	O
of	O
this	O
disease	O
.	O

Here	O
we	O
describe	O
a	O
mouse	O
with	O
a	O
different	O
osteopetrosis	O
-	O
causing	O
mutation	O
(	O
Clcn7F318L	O
)	O
.	O

Compared	O
to	O
Clcn7+/+	O
mice	O
,	O
12-week	O
-	O
old	O
Clcn7F318L/+	O
mice	O
have	O
significantly	O
increased	B-PosReg
trabecular	B-CPA
bone	I-CPA
volume	I-CPA
,	O
consistent	O
with	O
Clcn7F318L	B-Gene
acting	O
as	O
a	O
dominant	O
negative	B-NegReg
mutation	O
.	O

Clcn7F318L	O
/	O
F318L	O
and	O
Clcn7F318L	O
/	O
G213R	O
mice	O
die	O
by	O
1month	O
of	O
age	O
and	O
resemble	O
Clcn7	O
knockout	O
mice	O
,	O
which	O
indicate	O
that	O
p	B-Var
.	I-Var
F318L	I-Var
mutant	O
protein	B-Protein
is	O
non	B-NegReg
-	I-NegReg
functional	I-NegReg
and	O
p	O
.	O
F318L	O
and	O
p	O
.	O
G213R	O
mutant	O
proteins	O
do	O
not	O
complement	O
one	O
another	O
.	O

Since	O
it	O
has	O
been	O
reported	O
that	O
treatment	O
with	O
interferon	O
gamma	O
(	O
IFN	O
-	O
G	O
)	O
improves	O
bone	O
properties	O
in	O
Clcn7G213R/+	O
mice	O
,	O
we	O
treated	O
Clcn7F318L/+	O
mice	O
with	O
IFN	O
-	O
G	O
and	O
observed	O
a	O
decrease	O
in	O
osteoclast	O
number	O
and	O
mineral	O
apposition	O
rate	O
,	O
but	O
no	O
overall	O
improvement	O
in	O
bone	O
properties	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
benefits	O
of	O
IFN	O
-	O
G	O
therapy	O
in	O
patients	O
with	O
Albers	O
-	O
Schönberg	O
disease	O
may	O
be	O
mutation	O
-	O
specific	O
.	O

Highlighting	O
Interleukin-36	O
Signalling	O
in	O
Plaque	O
Psoriasis	O
and	O
Pustular	O
Psoriasis	O
.	O

Plaque	O
psoriasis	O
and	O
pustular	O
psoriasis	O
are	O
overlapping	O
,	O
but	O
distinct	O
,	O
disorders	O
.	O

The	O
therapeutic	O
response	O
to	O
biologics	O
supports	O
the	O
pivotal	O
role	O
of	O
the	O
tumour	O
necrosis	O
alpha	O
(	O
TNF-?)/	O
interleukin	O
(	O
IL)-23	O
/	O
IL-17	O
/	O
IL-22	O
axis	O
in	O
the	O
pathogenesis	O
of	O
these	O
disorders	O
.	O

Recently	O
,	O
functional	O
activation	O
of	O
the	O
IL-36	O
receptor	O
(	O
IL-36R	O
)	O
was	O
discovered	O
to	O
be	O
another	O
driving	O
force	O
in	O
the	O
pathogenesis	O
of	O
psoriasis	O
.	O

This	O
was	O
first	O
highlighted	O
by	O
the	O
discovery	O
that	O
a	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	B-Var
of	O
the	O
IL-36R	O
antagonist	O
(	B-Gene
IL-36Ra	I-Gene
)	I-Gene
causes	O
pustular	B-Disease
psoriasis	I-Disease
.	O

Although	O
the	O
TNF-?/IL-23	O
/	O
IL-17	O
/	O
IL-22	O
axis	O
and	O
the	O
functional	O
activation	O
of	O
IL-36R	O
are	O
fundamentally	O
involved	O
in	O
plaque	O
psoriasis	O
and	O
pustular	O
psoriasis	O
,	O
respectively	O
,	O
the	O
2	O
pathways	O
are	O
closely	O
related	O
and	O
mutually	O
reinforced	O
,	O
resulting	O
in	O
full	O
-	O
blown	O
clinical	O
manifestations	O
.	O

This	O
review	O
summarizes	O
current	O
topics	O
on	O
how	O
IL-36	O
agonists	O
(	O
IL-36	O
?	O
,	O
IL-36	O
?	O
,	O
IL-36	O
?	O
)	O
signal	O
IL-36R	O
,	O
the	O
pathological	O
expression	O
of	O
IL-36	O
agonists	O
and	O
IL-36Ra	O
in	O
plaque	O
and	O
pustular	O
psoriatic	O
lesions	O
,	O
and	O
the	O
cross	O
-	O
talk	O
between	O
the	O
TNF-?/IL-23	O
/	O
IL-17	O
/	O
IL-22	O
axis	O
and	O
the	O
functional	O
activation	O
of	O
IL-36R	O
in	O
the	O
epidermal	O
milieu	O
.	O

CCR5Δ32	O
(	O
rs333	O
)	O
polymorphism	O
is	O
associated	O
with	O
decreased	O
risk	O
of	O
chronic	O
and	O
aggressive	O
periodontitis	O
:	O
A	O
case	O
-	O
control	O
analysis	O
based	O
in	O
disease	O
resistance	O
and	O
susceptibility	O
phenotypes	O
.	O

Chronic	O
and	O
aggressive	O
periodontitis	O
are	O
infectious	O
diseases	O
characterized	O
by	O
the	O
irreversible	O
destruction	O
of	O
periodontal	O
tissues	O
,	O
which	O
is	O
mediated	O
by	O
the	O
host	O
inflammatory	O
immune	O
response	O
triggered	O
by	O
periodontal	O
infection	O
.	O

The	O
chemokine	O
receptor	O
CCR5	O
play	O
an	O
important	O
role	O
in	O
disease	O
pathogenesis	O
,	O
contributing	O
to	O
pro	O
-	O
inflammatory	O
response	O
and	O
osteoclastogenesis	O
.	O

CCR5Δ32	O
(	B-Var
rs333	I-Var
)	I-Var
is	O
a	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	O
in	O
the	O
CCR5	B-Gene
gene	O
,	O
which	O
can	O
potentially	O
modulate	B-Reg
the	O
host	B-CPA
response	I-CPA
and	O
,	O
consequently	O
periodontitis	O
outcome	O
.	O

Thus	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
the	O
CCR5Δ32	O
mutation	O
over	O
the	O
risk	O
to	O
suffer	O
periodontitis	O
in	O
a	O
cohort	O
of	O
Brazilian	O
patients	O
(	O
total	O
N=699	O
)	O
,	O
representative	O
of	O
disease	O
susceptibility	O
(	O
chronic	O
periodontitis	O
,	O
N=197	O
;	O
and	O
aggressive	O
periodontitis	O
,	O
N=91	O
)	O
or	O
resistance	O
(	O
chronic	O
gingivitis	O
,	O
N=193	O
)	O
phenotypes	O
,	O
and	O
healthy	O
subjects	O
(	O
N=218	O
)	O
.	O

Additionally	O
,	O
we	O
assayed	O
the	O
influence	O
of	O
CCR5Δ32	O
in	O
the	O
expression	O
of	O
the	O
biomarkers	O
TNFα	O
,	O
IL-1β	O
,	O
IL-10	O
,	O
IL-6	O
,	O
IFN	O
-	O
γ	O
and	O
T	O
-	O
bet	O
,	O
and	O
key	O
periodontal	O
pathogens	O
P.	O
gingivalis	O
,	O
T.	O
forsythia	O
,	O
and	O
T.	O
denticola	O
.	O

In	O
the	O
association	O
analysis	O
of	O
resistant	O
versus	O
susceptible	O
subjects	O
,	O
CCR5Δ32	O
mutant	O
allele	O
-	O
carriers	O
proved	O
significantly	O
protected	O
against	O
chronic	O
(	O
OR	O
0.49	O
;	O
95	O
%	O
CI	O
0.29	O
-	O
0.83	O
;	O
p	O
-	O
value	O
0.01	O
)	O
and	O
aggressive	O
(	O
OR	O
0.46	O
;	O
95	O
%	O
CI	O
0.22	O
-	O
0.94	O
;	O
p	O
-	O
value	O
0.03	O
)	O
periodontitis	O
.	O

Further	O
,	O
heterozygous	O
subjects	O
exhibited	O
significantly	O
decreased	B-NegReg
expression	B-MPA
of	O
TNFα	B-Protein
in	O
periodontal	O
tissues	O
,	O
pointing	O
to	O
a	O
functional	O
effect	O
of	O
the	O
mutation	B-Var
in	O
periodontal	O
tissues	O
during	O
the	O
progression	O
of	O
the	O
disease	O
.	O

Conversely	O
,	O
no	O
significant	O
changes	O
were	O
observed	O
in	O
the	O
presence	O
or	O
quantity	O
of	O
the	O
periodontal	O
pathogens	O
P.	O
gingivalis	O
,	O
T.	O
forsythia	O
,	O
and	O
T.	O
denticola	O
in	O
the	O
subgingival	O
biofilm	O
that	O
could	O
be	O
attributable	O
to	O
the	O
mutant	O
genotype	O
.	O

Diverse	O
phenotype	O
of	O
hypokalaemic	O
periodic	O
paralysis	O
within	O
a	O
family	O
.	O

Hypokalaemic	O
periodic	O
paralysis	O
typically	O
presents	O
with	O
intermittent	O
mild	O
-	O
to	O
-	O
moderate	O
weakness	O
lasting	O
hours	O
to	O
days	O
.	O

We	O
report	O
a	O
case	O
with	O
an	O
uncommon	O
phenotype	O
of	O
late	O
-	O
onset	O
myopathy	O
without	O
episodic	O
paralytic	O
attacks	O
.	O

Initial	O
work	O
-	O
up	O
including	O
muscle	O
biopsy	O
was	O
inconclusive	O
.	O

A	O
subsequent	O
review	O
of	O
the	O
right	O
deltoid	O
biopsy	O
,	O
long	O
exercise	O
testing	O
and	O
repeated	O
family	O
history	O
was	O
helpful	O
,	O
followed	O
by	O
appropriate	O
genetic	O
testing	O
.	O

We	O
identified	O
a	O
heterozygous	O
pathogenic	O
mutation	O
in	O
calcium	O
ion	O
channel	O
(	B-Gene
CACNA1S	I-Gene
:	I-Gene
c.1583G	I-Gene
>	I-Gene
A	I-Gene
p	I-Gene
.	I-Gene
Arg528His	I-Gene
)	I-Gene
causing	B-Reg
hypokalaemic	B-Disease
periodic	I-Disease
paralysis	I-Disease
.	O

Myopathy	O
can	O
present	O
without	O
episodic	O
paralysis	O
and	O
the	O
frequency	O
of	O
paralytic	O
episodes	O
does	O
not	O
correlate	O
well	O
with	O
the	O
development	O
and	O
progression	O
of	O
a	O
fixed	O
myopathy	O
.	O

Our	O
report	O
also	O
highlights	O
the	O
intrafamilial	O
phenotypic	O
variation	O
of	O
hypokalaemic	B-Disease
periodic	I-Disease
paralysis	I-Disease
secondary	O
to	B-Reg
a	O
CACNA1S	B-Gene
gene	O
mutation	B-Var
.	O

Tacrolimus	O
rescues	O
the	O
signaling	O
and	O
gene	O
expression	O
signature	O
of	O
endothelial	O
ALK1	O
loss	O
-	O
of	O
-	O
function	O
and	O
improves	O
HHT	O
vascular	O
pathology	O
.	O

Hereditary	B-Disease
hemorrhagic	I-Disease
telangiectasia	I-Disease
(	O
HHT	O
)	O
is	O
a	O
highly	O
debilitating	O
and	O
life	O
-	O
threatening	O
genetic	O
vascular	O
disorder	O
arising	O
from	O
endothelial	O
cell	O
(	O
EC	O
)	O
proliferation	O
and	O
hypervascularization	O
,	O
for	O
which	O
no	O
cure	O
exists	O
.	O

Because	O
HHT	B-Disease
is	O
caused	O
by	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
bone	O
morphogenetic	O
protein	O
9	O
(	B-MPA
BMP9)-ALK1-Smad1/5/8	I-MPA
signaling	I-MPA
,	O
interventions	O
aimed	O
at	O
activating	O
this	O
pathway	O
are	O
of	O
therapeutic	O
value	O
.	O

We	O
interrogated	O
the	O
whole	O
-	O
transcriptome	O
in	O
human	O
umbilical	O
vein	O
ECs	O
(	O
HUVECs	O
)	O
and	O
found	O
that	O
ALK1	O
signaling	O
inhibition	O
was	O
associated	O
with	O
a	O
specific	O
pro	O
-	O
angiogenic	O
gene	O
expression	O
signature	O
,	O
which	O
included	O
a	O
significant	O
elevation	O
of	O
DLL4	O
expression	O
.	O

By	O
screening	O
the	O
NIH	O
clinical	O
collections	O
of	O
FDA	O
-	O
approved	O
drugs	O
,	O
we	O
identified	O
tacrolimus	O
(	O
FK-506	O
)	O
as	O
the	O
most	O
potent	O
activator	O
of	O
ALK1	O
signaling	O
in	O
BMP9-challenged	O
C2C12	O
reporter	O
cells	O
.	O

In	O
HUVECs	O
,	O
tacrolimus	O
activated	O
Smad1/5/8	O
and	O
opposed	O
the	O
pro	O
-	O
angiogenic	O
gene	O
expression	O
signature	O
associated	O
with	O
ALK1	O
loss	O
-	O
of	O
-	O
function	O
,	O
by	O
notably	O
reducing	O
Dll4	O
expression	O
.	O

In	O
these	O
cells	O
,	O
tacrolimus	O
also	O
inhibited	O
Akt	O
and	O
p38	O
stimulation	O
by	O
vascular	O
endothelial	O
growth	O
factor	O
,	O
a	O
major	O
driver	O
of	O
angiogenesis	O
.	O

In	O
the	O
BMP9/10-immunodepleted	O
postnatal	O
retina	O
-	O
a	O
mouse	O
model	O
of	O
HHT	O
vascular	O
pathology	O
-	O
tacrolimus	O
activated	O
endothelial	O
Smad1/5/8	O
and	O
prevented	O
the	O
Dll4	O
overexpression	O
and	O
hypervascularization	O
associated	O
with	O
this	O
model	O
.	O

Finally	O
,	O
tacrolimus	O
stimulated	O
Smad1/5/8	O
signaling	O
in	O
C2C12	O
cells	O
expressing	O
BMP9-unresponsive	O
ALK1	O
HHT	O
mutants	O
and	O
in	O
HHT	O
patient	O
blood	O
outgrowth	O
ECs	O
.	O

Tacrolimus	O
repurposing	O
has	O
therefore	O
therapeutic	O
potential	O
in	O
HHT	O
.	O

Zebrafish	O
cdc6	O
hypomorphic	O
mutation	O
causes	O
Meier	O
-	O
Gorlin	O
syndrome	O
-	O
like	O
phenotype	O
.	O

Cell	O
Division	O
Cycle	O
6	O
(	O
Cdc6	O
)	O
is	O
a	O
component	O
of	O
pre	O
-	O
replicative	O
complex	O
(	O
preRC	O
)	O
forming	O
on	O
DNA	O
replication	O
origins	O
in	O
eukaryotes	O
.	O

Recessive	O
mutations	B-Var
in	O
ORC1	B-Gene
,	O
ORC4	B-Gene
,	O
ORC6	B-Gene
,	O
CDT1	B-Gene
or	O
CDC6	B-Gene
of	O
the	O
preRC	O
in	O
human	O
cause	B-Reg
Meier	B-Disease
-	I-Disease
Gorlin	I-Disease
syndrome	I-Disease
(	O
MGS	O
)	O
that	O
is	O
characterized	O
by	O
impaired	O
post	O
-	O
natal	O
growth	O
,	O
short	O
stature	O
and	O
microcephaly	O
.	O

However	O
,	O
vertebrate	O
models	O
of	O
MGS	O
have	O
not	O
been	O
reported	O
.	O

Through	O
N	O
-	O
ethyl	O
-	O
N	O
-	O
nitrosourea	O
mutagenesis	O
and	O
Cas9	O
knockout	O
,	O
we	O
generate	O
several	O
cdc6	O
mutant	O
lines	O
in	O
zebrafish	O
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
of	O
cdc6	B-Gene
,	O
as	O
manifested	O
by	O
cdc6tsu4305	O
and	O
cdc6tsu7cd	O
mutants	O
,	O
lead	O
to	O
embryonic	B-CPA
lethality	I-CPA
due	O
to	O
cell	B-CPA
cycle	I-CPA
arrest	I-CPA
at	I-CPA
the	I-CPA
S	I-CPA
phase	I-CPA
and	O
extensive	O
apoptosis	B-CPA
.	O

Embryos	O
homozygous	O
for	O
a	O
cdc6	O
hypomorphic	O
mutation	O
,	O
cdc6tsu21cd	O
,	O
develop	O
normally	O
during	O
embryogenesis	O
.	O

Later	O
on	O
,	O
compared	O
with	O
their	O
wild	O
-	O
type	O
(	O
WT	O
)	O
siblings	O
,	O
cdc6tsu21cd	B-Var
mutant	I-Var
fish	O
show	O
growth	O
retardation	O
,	O
and	O
their	O
body	B-CPA
weight	I-CPA
and	I-CPA
length	I-CPA
in	O
adulthood	O
are	O
greatly	O
reduced	B-NegReg
,	O
which	O
resemble	O
human	O
MGS	O
.	O

Surprisingly	O
,	O
cdc6tsu21cd	B-Var
mutant	I-Var
fish	O
become	O
males	O
with	O
a	O
short	O
life	O
and	O
fail	O
to	O
mate	O
with	O
WT	O
females	O
,	O
suggesting	O
defective	B-NegReg
reproduction	B-CPA
.	O

Overexpression	O
of	O
Cdc6	O
mutant	O
forms	O
,	O
which	O
mimic	O
human	O
CDC6(T323R	B-Gene
)	I-Gene
mutation	B-Var
found	O
in	O
a	O
MGS	O
patient	O
,	O
in	O
zebrafish	O
cdc6tsu4305	O
mutant	O
embryos	O
partially	O
represses	B-NegReg
cell	B-CPA
death	I-CPA
phenotype	I-CPA
,	O
suggesting	O
that	O
the	O
human	O
CDC6(T323R	O
)	O
mutation	O
is	O
a	O
hypomorph	O
.	O

cdc6tsu21cd	O
mutant	O
fish	O
will	O
be	O
useful	O
to	O
detect	O
more	O
tissue	O
defects	O
and	O
develop	O
medical	O
treatment	O
strategies	O
for	O
MGS	O
patients	O
.	O

Three	O
Cases	O
of	O
KCNT1	O
Mutations	O
:	O
Malignant	O
Migrating	O
Partial	O
Seizures	O
in	O
Infancy	O
with	O
Massive	O
Systemic	O
to	O
Pulmonary	O
Collateral	O
Arteries	O
.	O

KCNT1	B-Gene
mutations	B-Var
are	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutations	O
in	O
potassium	O
channels	O
resulting	O
in	O
severe	O
infantile	B-Disease
epilepsy	I-Disease
.	O

Herein	O
we	O
describe	O
3	O
infants	O
with	O
malignant	O
migrating	O
partial	O
seizures	O
with	O
KCNT1	O
mutations	O
accompanied	O
by	O
massive	O
systemic	O
to	O
pulmonary	O
collateral	O
arteries	O
with	O
life	O
-	O
threatening	O
hemoptysis	O
and	O
heart	O
failure	O
.	O

Homozygous	B-Var
indel	I-Var
mutation	I-Var
in	O
CDH11	B-Gene
as	O
the	O
probable	O
cause	B-Reg
of	O
Elsahy	B-Disease
-	I-Disease
Waters	I-Disease
syndrome	I-Disease
.	O

Two	O
sisters	O
from	O
a	O
consanguineous	O
couple	O
were	O
seen	O
in	O
genetics	O
department	O
for	O
facial	O
dysmorphic	O
features	O
and	O
glaucoma	O
.	O

They	O
both	O
had	O
broad	O
foreheads	O
,	O
hypertelorism	O
,	O
megalocorneas	O
,	O
thick	O
eyebrows	O
with	O
synophrys	O
,	O
flat	O
malar	O
regions	O
,	O
broad	O
and	O
bulbous	O
noses	O
,	O
and	O
mild	O
prognathism	O
.	O

Both	O
had	O
glaucoma	O
,	O
younger	O
one	O
also	O
had	O
cataracts	O
and	O
phthisis	O
bulbi	O
.	O

Other	O
findings	O
included	O
bilateral	O
partial	O
cutaneous	O
syndactyly	O
of	O
2nd	O
and	O
3rd	O
fingers	O
,	O
history	O
of	O
impacted	O
teeth	O
with	O
dentigerous	O
cyst	O
in	O
the	O
elder	O
one	O
,	O
and	O
intellectual	O
disability	O
(	O
mild	O
and	O
borderline	O
)	O
.	O

The	O
sisters	O
were	O
considered	O
to	O
have	O
Elsahy	O
-	O
Waters	O
syndrome	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
underlying	O
molecular	O
cause	O
,	O
sisters	O
and	O
their	O
healthy	O
parents	O
were	O
genotyped	O
by	O
SNP	O
arrays	O
,	O
followed	O
by	O
homozygosity	O
mapping	O
.	O

Homozygous	O
regions	O
were	O
further	O
analyzed	O
by	O
exome	O
sequencing	O
in	O
one	O
affected	O
individual	O
.	O

A	O
homozygous	O
indel	O
variant	O
segregating	O
with	O
the	O
condition	O
was	O
detected	O
in	O
CDH11	O
(	O
c.1116_1117delinsGATCATCAG	O
,	O
p.(Ile372MetfsTer9	O
)	O
)	O
,	O
which	O
was	O
then	O
validated	O
by	O
using	O
Sanger	O
sequencing	O
.	O

CDH11	O
encodes	O
cadherin	O
11	O
(	O
osteo	O
-	O
cadherin	O
)	O
that	O
regulates	O
cell	O
-	O
cell	O
adhesion	O
,	O
cell	O
polarization	O
and	O
migration	O
,	O
as	O
well	O
as	O
osteogenic	O
differentiation	O
.	O

Further	O
experiments	O
revealed	O
that	O
CDH11	O
expression	O
was	O
decreased	O
in	O
patient	O
-	O
derived	O
fibroblasts	O
as	O
compared	O
to	O
the	O
heterozygous	O
parent	O
and	O
another	O
healthy	O
donor	O
.	O

Immunostaining	O
showed	O
absence	O
of	O
the	O
protein	O
expression	O
in	O
patient	O
fibroblasts	O
.	O

In	O
addition	O
,	O
cell	B-CPA
proliferation	I-CPA
rate	I-CPA
was	O
slow	B-NegReg
and	O
osteogenic	B-CPA
differentiation	I-CPA
potential	I-CPA
was	O
delayed	B-NegReg
.	O

We	O
consider	O
that	O
this	O
study	O
reveals	O
loss	O
-	O
of	O
-	O
function	O
mutations	B-Var
in	O
CDH11	B-Gene
as	O
a	O
probable	O
cause	O
of	O
this	O
phenotype	O
.	O

Next	O
generation	O
sequencing	O
in	O
further	O
patients	O
would	O
both	O
prove	O
this	O
gene	O
as	O
causative	O
,	O
and	O
finely	O
delineate	O
this	O
clinical	O
spectrum	O
further	O
contributing	O
in	O
identification	O
of	O
other	O
possibly	O
involved	O
gene(s	O
)	O
.	O

Effect	B-Reg
of	O
Mutant	B-Var
p53	B-Gene
Proteins	B-Protein
on	O
Glycolysis	B-MPA
and	O
Mitochondrial	B-MPA
Metabolism	I-MPA
.	O

TP53	O
is	O
one	O
of	O
the	O
most	O
commonly	O
mutated	O
genes	O
in	O
human	O
cancers	O
.	O

Unlike	O
other	O
tumor	O
suppressors	O
that	O
are	O
frequently	O
deleted	O
or	O
acquire	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
,	O
the	O
majority	O
of	O
TP53	B-Gene
mutations	B-Var
in	O
tumors	O
are	O
missense	B-Var
substitutions	I-Var
,	O
which	O
lead	O
to	O
the	O
expression	B-MPA
of	O
full	O
-	O
length	O
mutant	B-Var
proteins	B-Protein
that	O
accumulate	B-PosReg
in	O
cancer	O
cells	O
and	O
may	O
confer	O
unique	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
activities	B-MPA
to	O
promote	B-PosReg
tumorigenic	B-CPA
events	I-CPA
.	O

Recently	O
,	O
mutant	B-Var
p53	B-Gene
proteins	B-Protein
have	O
been	O
shown	O
to	O
mediate	O
metabolic	B-CPA
changes	I-CPA
as	O
a	O
novel	O
GOF	B-PosReg
to	O
promote	B-PosReg
tumor	B-CPA
development	I-CPA
.	O

There	O
is	O
a	O
strong	O
rationale	O
that	O
the	O
GOF	O
activities	O
,	O
including	O
alterations	O
in	O
cellular	O
metabolism	O
,	O
might	O
vary	O
between	O
the	O
different	O
p53	O
mutants	O
.	O

Accordingly	O
,	O
the	O
effect	O
of	O
different	O
mutant	O
p53	O
proteins	O
on	O
cancer	O
cell	O
metabolism	O
is	O
largely	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
metabolically	O
profiled	O
several	O
individual	O
frequently	O
occurring	O
p53	O
mutants	O
in	O
cancers	O
,	O
focusing	O
on	O
glycolytic	O
and	O
mitochondrial	O
oxidative	O
phosphorylation	O
pathways	O
.	O

Our	O
investigation	O
highlights	O
the	O
diversity	O
of	O
different	O
p53	O
mutants	O
in	O
terms	O
of	O
their	O
effect	O
on	O
metabolism	O
,	O
which	O
might	O
provide	O
a	O
foundation	O
for	O
the	O
development	O
of	O
more	O
effective	O
targeted	O
pharmacological	O
approaches	O
toward	O
variants	O
of	O
mutant	O
p53	O
.	O

The	O
Roles	O
of	O
the	O
Sole	O
Activator	O
-	O
Type	O
Auxin	O
Response	O
Factor	O
in	O
Pattern	O
Formation	O
of	O
Marchantia	O
polymorpha	O
.	O

Cell	O
division	O
patterning	O
is	O
important	O
to	O
determine	O
body	O
shape	O
in	O
plants	O
.	O

Nuclear	O
auxin	O
signaling	O
mediated	O
by	O
AUXIN	O
RESPONSE	O
FACTOR	O
(	O
ARF	O
)	O
transcription	O
factors	O
affects	O
plant	O
growth	O
and	O
development	O
through	O
regulation	O
of	O
cell	O
division	O
,	O
elongation	O
and	O
differentiation	O
.	O

The	O
evolutionary	O
origin	O
of	O
the	O
ARF	O
-	O
mediated	O
pathway	O
dates	O
back	O
to	O
at	O
least	O
the	O
common	O
ancestor	O
of	O
bryophytes	O
and	O
other	O
land	O
plants	O
.	O

The	O
liverwort	O
Marchantia	O
polymorpha	O
has	O
three	O
phylogenetically	O
distinct	O
ARFs	O
:	O
MpARF1	O
,	O
the	O
sole	O
'	O
activator	O
'	O
ARF	O
;	O
and	O
MpARF2	O
and	O
MpARF3	O
,	O
two	O
'	O
repressor	O
'	O
ARFs	O
.	O

Genetic	O
screens	O
for	O
auxin	O
-	O
resistant	O
mutants	O
revealed	O
that	O
loss	O
of	O
MpARF1	O
function	O
conferred	O
auxin	O
insensitivity	O
.	O

Mparf1	B-Gene
mutants	B-Var
showed	O
reduced	B-NegReg
auxin	B-Gene
-	I-Gene
inducible	I-Gene
gene	I-Gene
expression	B-MPA
and	O
various	O
developmental	B-CPA
defects	I-CPA
,	O
including	O
thallus	O
twisting	O
and	O
gemma	O
malformation	O
.	O

We	O
further	O
investigated	O
the	O
role	O
of	O
MpARF1	O
in	O
gemma	O
development	O
,	O
which	O
is	O
traceable	O
at	O
the	O
cellular	O
level	O
.	O

In	O
wild	O
-	O
type	O
plants	O
,	O
a	O
gemma	O
initial	O
first	O
undergoes	O
several	O
transverse	O
divisions	O
to	O
generate	O
a	O
single	O
-	O
celled	O
stalk	O
and	O
a	O
gemma	O
proper	O
,	O
followed	O
by	O
rather	O
synchronous	O
longitudinal	O
divisions	O
in	O
the	O
latter	O
.	O

Mparf1	O
mutants	O
often	O
contained	O
multicelled	O
stalks	O
and	O
showed	O
defects	O
in	O
the	O
execution	O
and	O
timing	O
of	O
the	O
longitudinal	O
divisions	O
.	O

While	O
wild	O
-	O
type	O
gemmae	O
finally	O
generate	O
two	O
meristem	O
notches	O
,	O
Mparf1	O
gemmae	O
displayed	O
various	O
numbers	O
of	O
ectopic	O
meristems	O
.	O

These	O
results	O
suggest	O
that	O
MpARF1	O
regulates	O
formative	O
cell	O
divisions	O
and	O
axis	O
formation	O
through	O
auxin	O
responses	O
.	O

The	O
mechanism	O
for	O
activator	O
ARF	O
regulation	O
of	O
pattern	O
formation	O
may	O
be	O
shared	O
in	O
land	O
plants	O
and	O
therefore	O
important	O
for	O
the	O
general	O
acquisition	O
of	O
three	O
-	O
dimensional	O
body	O
plans	O
.	O

Loss	O
of	O
the	O
nutrient	O
sensor	O
TAS1R3	O
leads	O
to	O
reduced	O
bone	O
resorption	O
.	O

The	O
taste	O
receptor	O
type	O
1	O
(	O
TAS1R	O
)	O
family	O
of	O
heterotrimeric	O
G	O
protein	O
-	O
coupled	O
receptors	O
participates	O
in	O
monitoring	O
energy	O
and	O
nutrient	O
status	O
.	O

TAS1R	O
member	O
3	O
(	O
TAS1R3	O
)	O
is	O
a	O
bi	O
-	O
functional	O
protein	O
that	O
recognizes	O
amino	O
acids	O
such	O
as	O
L	O
-	O
glycine	O
and	O
L	O
-	O
glutamate	O
or	O
sweet	O
molecules	O
such	O
as	O
sucrose	O
and	O
fructose	O
when	O
dimerized	O
with	O
TAS1R	O
member	O
1	O
(	O
TAS1R1	O
)	O
or	O
TAS1R	O
member	O
2	O
(	O
TAS1R2	O
)	O
,	O
respectively	O
.	O

It	O
was	O
recently	O
reported	O
that	O
deletion	B-Var
of	O
TAS1R3	B-Gene
expression	O
in	O
Tas1R3	O
mutant	O
mice	O
leads	O
to	O
increased	B-PosReg
cortical	B-CPA
bone	I-CPA
mass	I-CPA
but	O
the	O
underlying	O
cellular	O
mechanism	O
leading	O
to	O
this	O
phenotype	O
remains	O
unclear	O
.	O

Here	O
,	O
we	O
independently	O
corroborate	O
the	O
increased	B-PosReg
thickness	B-CPA
of	I-CPA
cortical	I-CPA
bone	I-CPA
in	O
femurs	O
of	O
20-week	O
-	O
old	O
male	O
Tas1R3	B-Gene
mutant	B-Var
mice	O
and	O
confirm	O
that	O
Tas1R3	O
is	O
expressed	O
in	O
the	O
bone	O
environment	O
.	O

Tas1R3	O
is	O
expressed	O
in	O
undifferentiated	O
bone	O
marrow	O
stromal	O
cells	O
(	O
BMSCs	O
)	O
in	O
vitro	O
and	O
its	O
expression	O
is	O
maintained	O
during	O
BMP2-induced	O
osteogenic	O
differentiation	O
.	O

However	O
,	O
levels	O
of	O
the	O
bone	O
formation	O
marker	O
procollagen	O
type	O
I	O
N	O
-	O
terminal	O
propeptide	O
(	O
PINP	O
)	O
are	O
unchanged	O
in	O
the	O
serum	O
of	O
20-week	O
-	O
old	O
Tas1R3	O
mutant	O
mice	O
as	O
compared	O
to	O
controls	O
.	O

In	O
contrast	O
,	O
levels	B-MPA
of	I-MPA
the	I-MPA
bone	I-MPA
resorption	I-MPA
marker	I-MPA
collagen	I-MPA
type	I-MPA
I	I-MPA
C	I-MPA
-	I-MPA
telopeptide	I-MPA
are	O
reduced	B-NegReg
greater	O
than	O
60	O
%	O
in	O
Tas1R3	B-Gene
mutant	B-Var
mice	O
.	O

Consistent	O
with	O
this	O
,	O
Tas1R3	O
and	O
its	O
putative	O
signaling	O
partner	O
Tas1R2	O
are	O
expressed	O
in	O
primary	O
osteoclasts	O
and	O
their	O
expression	O
levels	O
positively	O
correlate	O
with	O
differentiation	O
status	O
.	O

Collectively	O
,	O
these	O
findings	O
suggest	O
that	O
high	B-PosReg
bone	B-CPA
mass	I-CPA
in	O
Tas1R3	B-Gene
mutant	B-Var
mice	O
is	O
due	O
to	O
uncoupled	O
bone	O
remodeling	O
with	O
reduced	B-NegReg
osteoclast	B-CPA
function	I-CPA
and	O
provide	O
rationale	O
for	O
future	O
experiments	O
examining	O
the	O
cell	O
-	O
type	O
-	O
dependent	O
role	O
for	O
TAS1R	O
family	O
members	O
in	O
nutrient	O
sensing	O
in	O
postnatal	O
bone	O
remodeling	O
.	O

Molecular	O
characterization	O
of	O
the	O
llama	O
FGF5	O
gene	O
and	O
identification	O
of	O
putative	O
loss	O
of	O
function	O
mutations	O
.	O

Llama	O
,	O
the	O
most	O
numerous	O
domestic	O
camelid	O
in	O
Argentina	O
,	O
has	O
good	O
fiber	O
-	O
production	O
ability	O
.	O

Although	O
a	O
few	O
genes	O
related	O
to	O
other	O
productive	O
traits	O
have	O
been	O
characterized	O
,	O
the	O
molecular	O
genetic	O
basis	O
of	O
fiber	O
growth	O
control	O
in	O
camelids	O
is	O
still	O
poorly	O
understood	O
.	O

Fibroblast	O
growth	O
factor	O
5	O
(	O
FGF5	O
)	O
is	O
a	O
secreted	O
signaling	O
protein	O
that	O
controls	O
hair	O
growth	O
in	O
humans	O
and	O
other	O
mammals	O
.	O

Mutations	O
in	O
the	O
FGF5	O
gene	O
have	O
been	O
associated	O
with	O
long	O
-	O
hair	O
phenotypes	O
in	O
several	O
species	O
.	O

Here	O
,	O
we	O
sequenced	O
the	O
llama	O
FGF5	O
gene	O
,	O
which	O
consists	O
of	O
three	O
exons	O
encoding	O
813	O
bp	O
.	O

cDNA	O
analysis	O
from	O
hair	O
follicles	O
revealed	O
the	O
expression	O
of	O
two	O
FGF5	O
alternative	O
spliced	O
transcripts	O
,	O
in	O
one	O
of	O
which	O
exon	O
2	O
is	O
absent	O
.	O

DNA	O
variation	O
analysis	O
showed	O
four	O
polymorphisms	O
in	O
the	O
coding	O
region	O
:	O
a	O
synonymous	O
SNP	O
(	O
c.210A	O
>	O
G	O
)	O
,	O
a	O
single	O
base	O
deletion	O
(	B-Var
c.348delA	I-Var
)	I-Var
,	O
a	O
12-bp	O
insertion	O
(	O
c.351_352insCATATAACATAG	O
)	O
and	O
a	O
non	O
-	O
sense	O
mutation	O
(	O
c.499C	O
>	O
T	O
)	O
.	O

The	O
deletion	O
was	O
always	O
found	O
together	O
with	O
the	O
insertion	O
forming	O
a	O
haplotype	O
and	O
producing	O
a	O
putative	O
truncated	O
protein	O
of	O
123	O
amino	O
acids	O
.	O

The	O
c.499C	B-Var
>	I-Var
T	I-Var
mutation	O
also	O
leads	O
to	O
a	O
premature	O
stop	O
codon	O
at	O
position	O
168	O
.	O

In	O
both	O
cases	O
,	O
critical	B-MPA
functional	I-MPA
domains	I-MPA
of	O
FGF5	B-Gene
,	O
including	O
one	O
heparin	B-MPA
binding	I-MPA
site	I-MPA
,	O
are	O
lost	B-NegReg
.	O

All	O
animals	O
analyzed	O
were	O
homozygous	O
for	O
one	O
of	O
the	O
deleterious	O
mutations	O
or	O
compound	O
heterozygous	O
for	O
both	O
(	O
i.e.	O
c.348delA	O
,	O
c.351_352insCATATAACATAG	O
/	O
c.499	O
T	O
)	O
.	O

Sequencing	O
of	O
guanaco	O
samples	O
showed	O
that	O
the	O
FGF5	O
gene	O
encodes	O
a	O
full	O
-	O
length	O
270-amino	O
acid	O
protein	O
.	O

These	O
results	O
suggest	O
that	O
FGF5	O
is	O
likely	O
functional	O
in	O
short	O
-	O
haired	O
wild	O
species	O
and	O
non	O
-	O
functional	O
in	O
the	O
domestic	O
fiber	O
-	O
producing	O
species	O
,	O
the	O
llama	O
.	O

Differential	O
regulation	O
of	O
two	O
FLNA	O
transcripts	O
explains	O
some	O
of	O
the	O
phenotypic	O
heterogeneity	O
in	O
the	O
loss	O
-	O
of	O
-	O
function	O
filaminopathies	O
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
the	O
X	O
-	O
linked	O
gene	O
FLNA	B-Gene
can	O
lead	O
to	O
abnormal	B-CPA
neuronal	I-CPA
migration	I-CPA
,	O
vascular	B-CPA
and	I-CPA
cardiac	I-CPA
defects	I-CPA
,	O
and	O
congenital	B-Disease
intestinal	I-Disease
pseudo	I-Disease
-	I-Disease
obstruction	I-Disease
(	O
CIPO	O
)	O
,	O
the	O
latter	O
characterized	O
by	O
anomalous	O
intestinal	O
smooth	O
muscle	O
layering	O
.	O

Survival	O
in	O
male	O
hemizygotes	O
for	O
such	O
mutations	O
is	O
dependent	O
on	O
retention	O
of	O
residual	O
FLNA	O
function	O
but	O
it	O
is	O
unclear	O
why	O
a	O
subgroup	O
of	O
males	O
with	O
mutations	O
in	O
the	O
5	O
'	O
end	O
of	O
the	O
gene	O
can	O
present	O
with	O
CIPO	O
alone	O
.	O

Here	O
,	O
we	O
demonstrate	O
evidence	O
for	O
the	O
presence	O
of	O
two	O
FLNA	O
isoforms	O
differing	O
by	O
28	O
residues	O
at	O
the	O
N	O
-	O
terminus	O
initiated	O
at	O
ATG+1	O
and	O
ATG+82	O
.	O

A	O
male	O
with	O
CIPO	O
(	O
c.18_19del	O
)	O
exclusively	O
expressed	O
FLNA	O
ATG+82	O
,	O
implicating	O
the	O
longer	O
protein	O
isoform	O
(	O
ATG+1	O
)	O
in	O
smooth	O
muscle	O
development	O
.	O

In	O
contrast	O
,	O
mutations	O
leading	O
to	O
reduction	O
of	O
both	O
isoforms	O
are	O
associated	O
with	O
compound	O
phenotypes	O
affecting	O
the	O
brain	O
,	O
heart	O
,	O
and	O
intestine	O
.	O

RNA	O
-	O
seq	O
data	O
revealed	O
three	O
distinct	O
transcription	O
start	O
sites	O
,	O
two	O
of	O
which	O
produce	O
a	O
protein	O
isoform	O
utilizing	O
ATG+1	O
while	O
the	O
third	O
utilizes	O
ATG+82	O
.	O

Transcripts	O
sponsoring	O
translational	O
initiation	O
at	O
ATG+1	O
predominate	O
in	O
intestinal	O
smooth	O
muscle	O
,	O
and	O
are	O
more	O
abundant	O
compared	O
with	O
the	O
level	O
measured	O
in	O
fibroblasts	O
.	O

Together	O
these	O
observations	O
describe	O
a	O
new	O
mechanism	O
of	O
tissue	O
-	O
specific	O
regulation	O
of	O
FLNA	O
that	O
could	O
reflect	O
the	O
differing	O
mechanical	O
requirements	O
of	O
these	O
cell	O
types	O
during	O
development	O
.	O

A	O
disulfide	O
bond	O
A	O
-	O
like	O
oxidoreductase	O
is	O
a	O
strong	O
candidate	O
gene	O
for	O
self	O
-	O
incompatibility	O
in	O
apricot	O
(	O
Prunus	O
armeniaca	O
)	O
pollen	O
.	O

S	O
-	O
RNase	O
based	O
gametophytic	O
self	O
-	O
incompatibility	O
(	O
SI	O
)	O
is	O
a	O
widespread	O
prezygotic	O
reproductive	O
barrier	O
in	O
flowering	O
plants	O
.	O

In	O
the	O
Solanaceae	O
,	O
Plantaginaceae	O
and	O
Rosaceae	O
gametophytic	O
SI	O
is	O
controlled	O
by	O
the	O
pistil	O
-	O
specific	O
S	O
-	O
RNases	O
and	O
the	O
pollen	O
S	O
-	O
locus	O
F	O
-	O
box	O
proteins	O
but	O
non	O
-	O
S	O
-	O
specific	O
factors	O
,	O
namely	O
modifiers	O
,	O
are	O
also	O
required	O
.	O

In	O
apricot	O
,	O
Prunus	O
armeniaca	O
(	O
Rosaceae	O
)	O
,	O
we	O
previously	O
mapped	O
two	O
pollen	O
-	O
part	O
mutations	B-Var
that	O
confer	B-Reg
self	B-MPA
-	I-MPA
compatibility	I-MPA
in	O
cultivars	O
Canino	O
and	O
Katy	O
at	O
the	O
distal	O
end	O
of	O
chromosome	O
3	O
(	O
M	O
-	O
locus	O
)	O
unlinked	O
to	O
the	O
S	O
-	O
locus	O
.	O

Here	O
,	O
we	O
used	O
high	O
-	O
resolution	O
mapping	O
to	O
identify	O
the	O
M	O
-	O
locus	O
with	O
an	O
~134	O
kb	O
segment	O
containing	O
ParM-1	O
-	O
16	O
genes	O
.	O

Gene	O
expression	O
analysis	O
identified	O
four	O
genes	O
preferentially	O
expressed	O
in	O
anthers	O
as	O
modifier	O
gene	O
candidates	O
,	O
ParM-6	O
,	O
-7	O
,	O
-9	O
and	O
-14	O
.	O

Variant	O
calling	O
of	O
WGS	O
Illumina	O
data	O
from	O
Canino	O
,	O
Katy	O
,	O
and	O
10	O
self	O
-	O
incompatible	O
cultivars	O
detected	O
a	O
358	O
bp	O
miniature	O
inverted	O
-	O
repeat	O
transposable	O
element	O
(	O
MITE	O
)	O
insertion	O
in	O
ParM-7	O
shared	O
only	O
by	O
self	O
-	O
compatible	O
apricots	O
,	O
supporting	O
ParM-7	O
as	O
strong	O
candidate	O
gene	O
required	O
for	O
SI	O
.	O

ParM-7	O
encodes	O
a	O
disulfide	O
bond	O
A	O
-	O
like	O
oxidoreductase	O
protein	O
,	O
which	O
we	O
named	O
ParMDO	O
.	O

The	O
MITE	B-Gene
insertion	B-Var
truncates	B-NegReg
the	O
ParMDO	B-MPA
ORF	I-MPA
and	O
produces	O
a	O
loss	B-NegReg
of	O
SI	B-MPA
function	I-MPA
,	O
suggesting	O
that	O
pollen	O
rejection	O
in	O
Prunus	O
is	O
dependent	O
on	O
redox	O
regulation	O
.	O

Based	O
on	O
phylogentic	O
analyses	O
we	O
also	O
suggest	O
that	O
ParMDO	O
may	O
have	O
originated	O
from	O
a	O
tandem	O
duplication	O
followed	O
by	O
subfunctionalization	O
and	O
pollen	O
-	O
specific	O
expression	O
.	O

The	O
Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
Function	I-PosReg
Integrin	O
β3	O
Pro33	O
Variant	B-Var
Alters	O
the	O
Serotonin	B-MPA
System	I-MPA
in	O
the	O
Mouse	O
Brain	O
.	O

Engagement	O
of	O
integrins	O
by	O
the	O
extracellular	O
matrix	O
initiates	O
signaling	O
cascades	O
that	O
drive	O
a	O
variety	O
of	O
cellular	O
functions	O
,	O
including	O
neuronal	O
migration	O
and	O
axonal	O
pathfinding	O
in	O
the	O
brain	O
.	O

Multiple	O
lines	O
of	O
evidence	O
link	O
the	O
ITGB3	O
gene	O
encoding	O
the	O
integrin	O
β3	O
subunit	O
with	O
the	O
serotonin	O
(	O
5-HT	O
)	O
system	O
,	O
likely	O
via	O
its	O
modulation	O
of	O
the	O
5-HT	O
transporter	O
(	O
SERT	O
)	O
.	O

The	O
ITGB3	B-Gene
coding	O
polymorphism	O
Leu33Pro	B-Var
(	O
rs5918	O
,	O
PlA2	O
)	O
produces	O
hyperactive	B-PosReg
αvβ3	B-Protein
receptors	I-Protein
that	O
influence	B-Reg
whole	B-MPA
-	I-MPA
blood	I-MPA
5-HT	I-MPA
levels	I-MPA
and	O
may	O
influence	B-Reg
the	O
risk	O
for	O
autism	B-Disease
spectrum	I-Disease
disorder	I-Disease
(	O
ASD	O
)	O
.	O

Using	O
a	O
phenome	O
-	O
wide	O
scan	O
of	O
psychiatric	O
diagnoses	O
,	O
we	O
found	O
significant	O
,	O
male	O
-	O
specific	O
associations	O
between	O
the	O
Pro33	O
allele	O
and	O
attention	O
-	O
deficit	O
hyperactivity	O
disorder	O
and	O
ASDs	O
.	O

Here	O
,	O
we	O
used	O
knock	O
-	O
in	O
(	O
KI	O
)	O
mice	O
expressing	O
an	O
Itgb3	B-Gene
variant	B-Var
that	O
phenocopies	O
the	O
human	O
Pro33	O
variant	O
to	O
elucidate	O
the	O
consequences	O
of	O
constitutively	O
enhanced	B-PosReg
αvβ3	B-MPA
signaling	I-MPA
to	I-MPA
the	I-MPA
5-HT	I-MPA
system	I-MPA
in	O
the	O
brain	O
.	O

KI	O
mice	O
displayed	O
deficits	O
in	O
multiple	O
behaviors	O
,	O
including	O
anxiety	O
,	O
repetitive	O
,	O
and	O
social	O
behaviors	O
.	O

Anatomical	O
studies	O
revealed	O
a	O
significant	O
decrease	O
in	O
5-HT	O
synapses	O
in	O
the	O
midbrain	O
,	O
accompanied	O
by	O
decreases	O
in	O
SERT	O
activity	O
and	O
reduced	O
localization	O
of	O
SERTs	O
to	O
integrin	O
adhesion	O
complexes	O
in	O
synapses	O
of	O
KI	O
mice	O
.	O

Inhibition	O
of	O
focal	O
adhesion	O
kinase	O
(	O
FAK	O
)	O
rescued	O
SERT	O
function	O
in	O
synapses	O
of	O
KI	O
mice	O
,	O
demonstrating	O
that	O
constitutive	O
active	O
FAK	O
signaling	O
downstream	O
of	O
the	O
Pro32Pro33	O
integrin	O
αvβ3	O
suppresses	O
SERT	O
activity	O
.	O

Our	O
studies	O
identify	O
a	O
complex	O
regulation	O
of	O
5-HT	O
homeostasis	O
and	O
behaviors	O
by	O
integrin	O
αvβ3	O
,	O
revealing	O
an	O
important	O
role	O
for	O
integrins	O
in	O
modulating	O
risk	O
for	O
neuropsychiatric	O
disorders	O
.	O

SIGNIFICANCE	O
STATEMENT	O
The	O
integrin	O
β3	O
Leu33Pro	O
coding	O
polymorphism	O
has	O
been	O
associated	O
with	O
autism	O
spectrum	O
disorders	O
(	O
ASDs	O
)	O
within	O
a	O
subgroup	O
of	O
patients	O
with	O
elevated	O
blood	O
5-HT	O
levels	O
,	O
linking	O
integrin	O
β3	O
,	O
5-HT	O
,	O
and	O
ASD	O
risk	O
.	O

We	O
capitalized	O
on	O
these	O
interactions	O
to	O
demonstrate	O
that	O
the	O
Pro33	O
coding	O
variation	O
in	O
the	O
murine	O
integrin	O
β3	O
recapitulates	O
the	O
sex	O
-	O
dependent	O
neurochemical	O
and	O
behavioral	O
attributes	O
of	O
ASD	O
.	O

Using	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
techniques	O
,	O
we	O
show	O
that	O
presynaptic	O
5-HT	O
function	O
is	O
altered	O
in	O
these	O
mice	O
,	O
and	O
that	O
the	O
localization	O
of	O
5-HT	O
transporters	O
to	O
specific	O
compartments	O
within	O
the	O
synapse	O
,	O
disrupted	O
by	O
the	O
integrin	O
β3	O
Pro33	O
mutation	O
,	O
is	O
critical	O
for	O
appropriate	O
reuptake	O
of	O
5-HT	O
.	O

Our	O
studies	O
provide	O
fundamental	O
insight	O
into	O
the	O
genetic	O
network	O
regulating	O
5-HT	O
neurotransmission	O
in	O
the	O
CNS	O
that	O
is	O
also	O
associated	O
with	O
ASD	O
risk	O
.	O

Parkin	B-Gene
absence	B-Var
accelerates	B-PosReg
microtubule	B-MPA
aging	I-MPA
in	I-MPA
dopaminergic	I-MPA
neurons	I-MPA
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
caused	O
by	O
mutations	B-Var
in	O
the	O
parkin	O
gene	O
(	B-Gene
PARK2	I-Gene
)	I-Gene
lead	O
to	O
early	B-Disease
-	I-Disease
onset	I-Disease
familial	I-Disease
Parkinson	I-Disease
's	I-Disease
disease	I-Disease
.	O

Recently	O
,	O
mechanistic	O
studies	O
proved	O
the	O
ability	O
of	O
parkin	O
in	O
regulating	O
mitochondria	O
homeostasis	O
and	O
microtubule	O
(	O
MT	O
)	O
stability	O
.	O

Looking	O
at	O
these	O
systems	O
during	O
aging	O
of	O
PARK2	O
knockout	O
mice	O
,	O
we	O
found	O
that	O
loss	B-Var
of	O
parkin	B-Gene
induced	O
an	O
accelerated	B-PosReg
(	B-MPA
over)acetylation	I-MPA
of	O
MT	O
system	O
both	O
in	O
dopaminergic	O
neuron	O
cell	O
bodies	O
and	O
fibers	O
,	O
localized	O
in	O
the	O
substantia	O
nigra	O
and	O
corpus	O
striatum	O
,	O
respectively	O
.	O

Interestingly	O
,	O
in	O
PARK2	O
knockout	O
mice	O
,	O
changes	O
of	O
MT	O
stability	O
preceded	O
the	O
alteration	O
of	O
mitochondria	O
transport	O
.	O

Moreover	O
,	O
in	O
-	O
cell	O
experiments	O
confirmed	O
that	O
loss	B-Var
of	O
parkin	B-Gene
affects	B-Reg
mitochondria	B-MPA
mobility	I-MPA
and	O
showed	O
that	O
this	O
defect	O
depends	O
on	O
MT	O
system	O
as	O
it	O
is	O
rescued	O
by	O
paclitaxel	O
,	O
a	O
well	O
-	O
known	O
MT	O
-	O
targeted	O
agent	O
.	O

Furthermore	O
,	O
both	O
in	O
PC12	O
neuronal	O
cells	O
and	O
in	O
patients	O
'	O
induced	O
pluripotent	O
stem	O
cell	O
-	O
derived	O
midbrain	O
neurons	O
,	O
we	O
observed	O
that	O
parkin	O
deficiencies	O
cause	O
the	O
fragmentation	O
of	O
stable	O
MTs	O
.	O

Therefore	O
,	O
we	O
suggest	O
that	O
parkin	O
acts	O
as	O
a	O
regulator	O
of	O
MT	O
system	O
during	O
neuronal	O
aging	O
,	O
and	O
we	O
endorse	O
the	O
hypothesis	O
that	O
MT	O
dysfunction	O
may	O
be	O
crucial	O
in	O
the	O
pathogenesis	O
of	O
Parkinson	O
's	O
disease	O
.	O

Parkinson	B-Disease
's	I-Disease
Disease	I-Disease
-	I-Disease
Associated	I-Disease
LRRK2	B-Gene
Hyperactive	O
Kinase	O
Mutant	B-Var
Disrupts	B-NegReg
Synaptic	B-MPA
Vesicle	I-MPA
Trafficking	I-MPA
in	I-MPA
Ventral	I-MPA
Midbrain	I-MPA
Neurons	I-MPA
.	O

Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
is	O
characterized	O
pathologically	O
by	O
the	O
selective	O
loss	O
of	O
substantia	O
nigra	O
(	O
SN	O
)	O
dopaminergic	O
(	O
DAergic	O
)	O
neurons	O
.	O

Recent	O
evidence	O
has	O
suggested	O
a	O
role	O
of	O
LRRK2	O
,	O
linked	O
to	O
the	O
most	O
frequent	O
familial	O
PD	O
,	O
in	O
regulating	O
synaptic	O
vesicle	O
(	O
SV	O
)	O
trafficking	O
.	O

However	O
,	O
the	O
mechanism	O
whereby	O
LRRK2	B-Gene
mutants	B-Var
contribute	B-Reg
to	O
nigral	B-MPA
vulnerability	I-MPA
remains	O
unclear	O
.	O

Here	O
we	O
show	O
that	O
the	O
most	O
common	O
PD	O
mutation	B-Var
LRRK2	B-Gene
G2019S	O
impairs	B-NegReg
SV	B-MPA
endocytosis	I-MPA
in	I-MPA
ventral	I-MPA
midbrain	I-MPA
(	I-MPA
MB	I-MPA
)	I-MPA
neurons	I-MPA
,	O
including	I-MPA
DA	I-MPA
neurons	I-MPA
,	O
and	O
the	O
slowed	O
endocytosis	O
can	O
be	O
rescued	O
by	O
inhibition	O
of	O
LRRK2	O
kinase	O
activity	O
.	O

A	O
similar	O
endocytic	O
defect	O
,	O
however	O
,	O
was	O
not	O
observed	O
in	O
LRRK2	O
mutant	O
neurons	O
from	O
the	O
neocortex	O
(	O
hereafter	O
,	O
cortical	O
neurons	O
)	O
or	O
the	O
hippocampus	O
,	O
suggesting	O
a	O
brain	O
region	O
-	O
specific	O
vulnerability	O
to	O
the	O
G2019S	O
mutation	O
.	O

Additionally	O
,	O
we	O
found	O
MB	O
-	O
specific	O
impairment	B-NegReg
of	O
SV	B-MPA
endocytosis	I-MPA
in	I-MPA
neurons	I-MPA
carrying	O
heterozygous	O
deletion	B-Var
of	O
SYNJ1	B-Gene
(	O
PARK20	O
)	O
,	O
a	O
gene	O
that	O
is	O
associated	O
with	O
recessive	O
Parkinsonism	O
.	O

Combining	O
SYNJ1+/-	B-Var
and	O
LRRK2	B-Var
G2019S	I-Var
does	O
not	O
exacerbate	O
SV	O
endocytosis	O
but	O
impairs	B-NegReg
sustained	B-MPA
exocytosis	I-MPA
in	I-MPA
MB	I-MPA
neurons	I-MPA
and	O
alters	B-Reg
specific	B-MPA
motor	I-MPA
functions	I-MPA
of	O
1-year	O
-	O
old	O
male	O
mice	O
.	O

Interestingly	O
,	O
we	O
show	O
that	O
LRRK2	B-Var
directly	O
phosphorylates	O
synaptojanin1	O
in	O
vitro	O
,	O
resulting	B-Reg
in	I-Reg
the	O
disruption	B-MPA
of	I-MPA
endophilin	I-MPA
-	I-MPA
synaptojanin1	I-MPA
interaction	I-MPA
required	I-MPA
for	I-MPA
SV	I-MPA
endocytosis	I-MPA
.	O

Our	O
work	O
suggests	O
a	O
merge	O
of	O
LRRK2	O
and	O
SYNJ1	O
pathogenic	O
pathways	O
in	O
deregulating	O
SV	O
trafficking	O
in	O
MB	O
neurons	O
as	O
an	O
underlying	O
molecular	O
mechanism	O
of	O
early	O
PD	O
pathogenesis	O
.	O

SIGNIFICANCE	O
STATEMENT	O
Understanding	O
midbrain	O
dopaminergic	O
(	O
DAergic	O
)	O
neuron	O
-	O
selective	O
vulnerability	O
in	O
PD	O
is	O
essential	O
for	O
the	O
development	O
of	O
targeted	O
therapeutics	O
.	O

We	O
report	O
,	O
for	O
the	O
first	O
time	O
,	O
a	O
nerve	O
terminal	O
impairment	O
in	O
SV	O
trafficking	O
selectively	O
in	O
MB	O
neurons	O
but	O
not	O
cortical	O
neurons	O
caused	O
by	O
two	O
PARK	O
genes	O
:	O
LRRK2	O
(	O
PARK8	O
)	O
and	O
SYNJ1	O
(	O
PARK20	O
)	O
.	O

We	O
demonstrate	O
that	O
the	O
enhanced	B-PosReg
kinase	B-MPA
activity	I-MPA
resulting	O
from	O
the	O
most	O
frequent	O
G2019S	B-Var
mutation	O
in	O
LRRK2	B-Gene
is	O
the	O
key	O
to	O
this	O
impairment	O
.	O

We	O
provide	O
evidence	O
suggesting	O
that	O
LRRK2	B-Gene
G2019S	B-Var
and	O
SYNJ1	B-Gene
loss	B-NegReg
of	I-NegReg
function	I-NegReg
share	O
a	O
similar	O
pathogenic	O
pathway	O
in	O
deregulating	B-MPA
DAergic	I-MPA
neuron	I-MPA
SV	I-MPA
endocytosis	I-MPA
and	O
that	O
they	O
play	B-Reg
additive	I-Reg
roles	I-Reg
in	O
facilitating	O
each	O
other	O
's	O
pathogenic	O
functions	O
in	O
PD	B-Disease
.	O

From	O
mutational	O
inactivation	O
to	O
aberrant	O
gain	O
-	O
of	O
-	O
function	O
:	O
Unraveling	O
the	O
structural	O
basis	O
of	O
mutant	O
p53	O
oncogenic	O
transition	O
.	O

Various	O
evidence	O
has	O
revealed	O
that	O
mutations	B-Var
in	O
p53	B-Gene
exert	O
activities	O
that	O
go	O
beyond	O
simply	O
inactivation	B-NegReg
of	O
wildtype	B-MPA
functions	I-MPA
but	O
rather	O
elicits	B-Reg
downstream	O
interactions	B-Interaction
that	O
promote	B-PosReg
malignancy	B-Disease
described	O
as	O
mutant	B-Var
p53	B-Gene
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
.	O

Here	O
we	O
report	O
the	O
first	O
account	O
of	O
the	O
dynamics	O
of	O
mutation	O
-	O
induced	O
structural	O
transition	O
of	O
native	O
p53	O
to	O
an	O
aberrant	O
gain	O
-	O
of	O
-	O
function	O
state	O
,	O
studying	O
the	O
wildtype	O
(	O
WT	O
)	O
and	O
high	O
incidence	O
contact	O
(	B-Var
R273C	I-Var
)	I-Var
and	O
structural	O
(	B-Var
R175H	I-Var
)	I-Var
mutant	O
p53	B-Gene
(	O
mutp53	O
)	O
through	O
molecular	O
dynamics	O
simulation	O
.	O

Result	O
analysis	O
revealed	O
that	O
both	O
mutants	O
exhibited	B-Reg
structural	B-Var
distortion	I-Var
and	O
reduced	B-NegReg
flexibility	B-MPA
,	O
indicative	O
of	O
rigidity	O
and	O
kinetic	O
stability	O
.	O

In	O
addition	O
,	O
surface	O
analysis	O
revealed	O
an	O
increase	O
in	O
the	O
accessible	O
surface	O
area	O
in	O
the	O
p53	O
mutants	O
.	O

This	O
suggests	O
that	O
the	O
GOF	O
transition	O
involves	O
protein	O
unfolding	O
and	O
exposure	O
of	O
buried	O
hydrophobic	O
surface	O
essential	O
for	O
interaction	O
with	O
HSF-1	O
oncogenic	O
partner	O
and	O
wildtype	O
p63	O
,	O
and	O
p73	O
homologs	O
.	O

Further	O
validation	O
revealed	O
binding	O
cavities	O
,	O
similar	O
in	O
the	O
mutants	O
but	O
dissimilar	O
to	O
the	O
WT	O
.	O

Taken	O
together	O
,	O
this	O
study	O
complements	O
experimental	O
findings	O
and	O
reveals	O
the	O
interplay	O
between	O
mutation	B-Var
-	I-Var
induced	I-Var
structural	B-Var
distortion	I-Var
,	O
loss	B-NegReg
of	O
flexibility	B-MPA
,	O
rigidity	B-MPA
,	O
enhanced	B-PosReg
stability	B-MPA
,	O
protein	O
unfolding	O
and	O
ultimately	O
,	O
exposure	O
of	O
binding	O
surfaces	O
as	O
conformational	O
attributes	O
that	O
characterize	O
mutP53	O
structure	O
-	O
GOF	O
activities	O
.	O

This	O
insight	O
is	O
,	O
therefore	O
,	O
of	O
great	O
importance	O
as	O
it	O
opens	O
up	O
a	O
novel	O
therapeutic	O
approach	O
toward	O
the	O
structure	O
based	O
targeting	O
of	O
mutP53	O
oncogenic	O
involvement	O
beyond	O
wildtype	O
inactivation	O
.	O

Furthermore	O
,	O
"	O
exposed	O
"	O
binding	O
site	O
information	O
obtained	O
from	O
this	O
study	O
can	O
be	O
explored	O
for	O
structure	O
-	O
based	O
design	O
of	O
substances	O
best	O
described	O
as	O
"	O
destabilizers	O
"	O
to	O
disrupt	O
the	O
GOF	O
interaction	O
of	O
mutp53	O
.	O

Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
HCN2	B-Gene
variants	B-Var
in	O
genetic	O
epilepsy	B-Disease
.	O

Genetic	O
generalized	O
epilepsy	O
(	O
GGE	O
)	O
is	O
a	O
common	O
epilepsy	O
syndrome	O
that	O
encompasses	O
seizure	O
disorders	O
characterized	O
by	O
spike	O
-	O
and	O
-	O
wave	O
discharges	O
(	O
SWDs	O
)	O
.	O

Pacemaker	O
hyperpolarization	O
-	O
activated	O
cyclic	O
nucleotide	O
-	O
gated	O
channels	O
(	O
HCN	O
)	O
are	O
considered	O
integral	O
to	O
SWD	O
genesis	O
,	O
making	O
them	O
an	O
ideal	O
gene	O
candidate	O
for	O
GGE	O
.	O

We	O
identified	O
HCN2	O
missense	O
variants	O
from	O
a	O
large	O
cohort	O
of	O
585	O
GGE	O
patients	O
,	O
recruited	O
by	O
the	O
Epilepsy	O
Phenome	O
-	O
Genome	O
Project	O
(	O
EPGP	O
)	O
,	O
and	O
performed	O
functional	O
analysis	O
using	O
two	O
-	O
electrode	O
voltage	O
clamp	O
recordings	O
from	O
Xenopus	O
oocytes	O
.	O

The	O
p	O
.	O
S632W	O
variant	O
was	O
identified	O
in	O
a	O
patient	O
with	O
idiopathic	O
photosensitive	O
occipital	O
epilepsy	O
and	O
segregated	O
in	O
the	O
family	O
.	O

This	O
variant	O
was	O
also	O
independently	O
identified	O
in	O
an	O
unrelated	O
patient	O
with	O
childhood	O
absence	O
seizures	O
from	O
a	O
European	O
cohort	O
of	O
238	O
familial	O
GGE	O
cases	O
.	O

The	O
p	O
.	O
V246	O
M	O
variant	O
was	O
identified	O
in	O
a	O
patient	O
with	O
photo	O
-	O
sensitive	O
GGE	O
and	O
his	O
father	O
diagnosed	O
with	O
juvenile	O
myoclonic	O
epilepsy	O
.	O

Functional	O
studies	O
revealed	O
that	O
both	O
p	B-Var
.	I-Var
S632W	I-Var
and	O
p	B-Var
.	I-Var
V246	I-Var
M	I-Var
had	O
an	O
identical	O
functional	O
impact	O
including	O
a	O
depolarizing	B-MPA
shift	I-MPA
in	I-MPA
the	I-MPA
voltage	I-MPA
dependence	I-MPA
of	O
activation	B-PosReg
that	O
is	O
consistent	O
with	O
a	O
gain	O
-	O
of	O
-	O
function	O
.	O

In	O
contrast	O
,	O
no	O
biophysical	O
changes	O
resulted	O
from	O
the	O
introduction	O
of	O
common	O
population	O
variants	O
,	O
p	O
.	O
E280	O
K	O
and	O
p	O
.	O
A705	O
T	O
,	O
and	O
the	O
p	O
.	O
R756C	O
variant	O
from	O
EPGP	O
that	O
did	O
not	O
segregate	O
with	O
disease	O
.	O

Our	O
data	O
suggest	O
that	O
HCN2	B-Gene
variants	B-Var
can	O
confer	O
susceptibility	B-MPA
to	O
GGE	O
via	O
a	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mechanism	O
.	O

Polymorphism	O
of	O
glutathione	O
S	O
-	O
transferase	O
M1	O
and	O
T1	O
genes	O
and	O
susceptibility	O
to	O
psoriasis	O
disease	O
:	O
A	O
study	O
from	O
North	O
India	O
.	O

BACKGROUND	O
:	O
Increased	O
oxidative	O
stress	O
and	O
resulting	O
inflammation	O
has	O
been	O
emphasized	O
as	O
a	O
factor	O
in	O
the	O
pathogenesis	O
of	O
many	O
diseases	O
including	O
psoriasis	O
.	O

Glutathione	O
S	O
-	O
transferases	O
(	O
GSTs	O
)	O
protect	O
against	O
oxidative	O
stress	O
,	O
inflammation	O
,	O
and	O
genotoxicity	O
.	O

Polymorphisms	B-Var
in	O
the	O
GST	B-Gene
genes	O
may	O
lead	B-Reg
to	I-Reg
an	O
imbalance	B-MPA
in	I-MPA
pro-	I-MPA
and	I-MPA
antioxidant	I-MPA
systems	I-MPA
resulting	O
in	O
the	O
increased	B-PosReg
production	B-MPA
of	I-MPA
reactive	I-MPA
oxygen	I-MPA
species	I-MPA
that	O
could	O
influence	B-Reg
the	O
pathogenesis	O
of	O
psoriasis	B-Disease
.	O

AIM	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
association	O
between	O
GSTs	O
(	O
GSTM1	O
and	O
GSTT1	O
)	O
gene	O
polymorphism	O
in	O
patients	O
with	O
chronic	O
plaque	O
psoriasis	O
as	O
a	O
factor	O
in	O
the	O
susceptibility	O
and	O
development	O
of	O
psoriasis	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
assessed	O
128	O
patients	O
with	O
psoriasis	O
and	O
250	O
age-	O
and	O
sex	O
-	O
matched	O
healthy	O
controls	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
by	O
the	O
phenol	O
chloroform	O
method	O
.	O

The	O
null	O
GSTT1	O
and	O
GSTM1	O
genotypes	O
were	O
identified	O
by	O
multiplex	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
method	O
.	O

RESULTS	O
:	O
The	O
null	O
genotype	O
of	O
GSTM1	O
and	O
GSTT1	O
was	O
seen	O
in	O
45.3	O
%	O
and	O
40.6	O
%	O
in	O
psoriasis	O
patients	O
whereas	O
in	O
the	O
controls	O
it	O
was	O
34.4	O
%	O
and	O
20.0	O
%	O
,	O
respectively	O
.	O

A	O
significant	O
association	O
was	O
seen	O
between	O
the	O
null	O
alleles	O
of	O
the	O
GSTT1	O
(	O
OR	O
=	O
2.74	O
)	O
and	O
GSTM1	O
(	O
OR	O
=	O
1.58	O
)	O
alone	O
or	O
in	O
combination	O
with	O
tobacco	O
use	O
(	O
P	O
<	O
0.001	O
)	O
and	O
psoriasis	O
risk	O
.	O

The	O
presence	B-Var
of	O
both	O
null	O
genotypes	O
of	O
GSTM1	B-Gene
and	O
GSTT1	B-Gene
further	O
increased	B-PosReg
the	O
risk	O
of	O
psoriasis	B-Disease
(	O
OR	O
=	O
3.52	O
)	O
when	O
compared	O
with	O
the	O
positive	O
genotypes	O
of	O
GSTM1	O
and	O
GSTT1	O
.	O

LIMITATIONS	O
:	O
A	O
major	O
limitation	O
of	O
this	O
study	O
was	O
the	O
small	O
sample	O
size	O
.	O

A	O
large	O
epidemiological	O
study	O
is	O
necessary	O
to	O
confirm	O
these	O
findings	O
.	O

CONCLUSIONS	O
:	O
The	O
null	O
genotype	O
of	O
GSTT1	O
is	O
a	O
strong	O
predisposing	O
factor	O
for	O
psoriasis	O
in	O
North	O
India	O
.	O

Loss	O
-	O
of	O
-	O
function	O
of	O
ASPARTIC	O
PEPTIDASE	O
NODULE	O
-	O
INDUCED	O
1	O
(	O
APN1	O
)	O
in	O
Lotus	O
japonicus	O
restricts	O
efficient	O
nitrogen	O
-	O
fixing	O
symbiosis	O
with	O
specific	O
Mesorhizobium	O
loti	O
strains	O
.	O

The	O
nitrogen	O
-	O
fixing	O
symbiosis	O
of	O
legumes	O
and	O
Rhizobium	O
bacteria	O
is	O
established	O
by	O
complex	O
interactions	O
between	O
the	O
two	O
symbiotic	O
partners	O
.	O

Legume	O
Fix-	O
mutants	O
form	O
apparently	O
normal	O
nodules	O
with	O
endosymbiotic	O
rhizobia	O
but	O
fail	O
to	O
induce	O
rhizobial	O
nitrogen	O
fixation	O
.	O

These	O
mutants	O
are	O
useful	O
for	O
identifying	O
the	O
legume	O
genes	O
involved	O
in	O
the	O
interactions	O
essential	O
for	O
symbiotic	O
nitrogen	O
fixation	O
.	O

We	O
describe	O
here	O
a	O
Fix-	O
mutant	O
of	O
Lotus	O
japonicus	O
,	O
apn1	O
,	O
which	O
showed	O
a	O
very	O
specific	O
symbiotic	O
phenotype	O
.	O

It	O
formed	O
ineffective	O
nodules	O
when	O
inoculated	O
with	O
the	O
Mesorhizobium	O
loti	O
strain	O
TONO	O
.	O

In	O
these	O
nodules	O
,	O
infected	O
cells	O
disintegrated	O
and	O
successively	O
became	O
necrotic	O
,	O
indicating	B-Reg
premature	B-MPA
senescence	I-MPA
typical	O
of	O
Fix-	B-Var
mutants	I-Var
.	O

However	O
,	O
it	O
formed	O
effective	O
nodules	O
when	O
inoculated	O
with	O
the	O
M.	O
loti	O
strain	O
MAFF303099	O
.	O

Among	O
nine	O
different	O
M.	O
loti	O
strains	O
tested	O
,	O
four	O
formed	O
ineffective	O
nodules	O
and	O
five	O
formed	O
effective	O
nodules	O
on	O
apn1	O
roots	O
.	O

The	O
identified	O
causal	O
gene	O
,	O
ASPARTIC	O
PEPTIDASE	O
NODULE	O
-	O
INDUCED	O
1	O
(	O
LjAPN1	O
)	O
,	O
encodes	O
a	O
nepenthesin	O
-	O
type	O
aspartic	O
peptidase	O
.	O

The	O
well	O
characterized	O
Arabidopsis	O
aspartic	O
peptidase	O
CDR1	O
could	O
complement	O
the	O
strain	O
-	O
specific	O
Fix-	O
phenotype	O
of	O
apn1	O
.	O

LjAPN1	O
is	O
a	O
typical	O
late	O
nodulin	O
;	O
its	O
gene	O
expression	O
was	O
exclusively	O
induced	O
during	O
nodule	O
development	O
.	O

LjAPN1	O
was	O
most	O
abundantly	O
expressed	O
in	O
the	O
infected	O
cells	O
in	O
the	O
nodules	O
.	O

Our	O
findings	O
indicate	O
that	O
LjAPN1	O
is	O
required	O
for	O
the	O
development	O
and	O
persistence	O
of	O
functional	O
(	O
nitrogen	O
-	O
fixing	O
)	O
symbiosis	O
in	O
a	O
rhizobial	O
strain	O
-	O
dependent	O
manner	O
,	O
and	O
thus	O
determines	O
compatibility	O
between	O
M.	O
loti	O
and	O
L.	O
japonicus	O
at	O
the	O
level	O
of	O
nitrogen	O
fixation	O
.	O

[	O
FILAGGRIN	O
GENE	O
NULL	O
-	O
MUTATIONS	O
AND	O
ATOPIC	O
DISEASES	O
]	O
.	O

Null	B-Var
-	I-Var
mutations	I-Var
which	O
cause	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
of	O
the	O
gene	O
encoding	O
filaggrin	O
(	B-Gene
FLG	I-Gene
)	I-Gene
have	O
been	O
strongly	O
linked	B-Reg
to	O
the	O
development	O
of	O
atopic	O
disorders	O
,	O
predominantly	O
atopic	B-Disease
eczema	I-Disease
/	I-Disease
dermatitis	I-Disease
syndrome	I-Disease
(	O
AEDS	O
)	O
.	O

Filaggrin	O
plays	O
a	O
key	O
role	O
in	O
epidermal	O
barrier	O
function	O
by	O
upholding	O
epidermal	O
structure	O
and	O
moisturization	O
.	O

Up	O
to	O
now	O
,	O
around	O
40	O
variants	O
of	O
FLG	O
null	O
-	O
mutations	O
have	O
been	O
genotyped	O
among	O
different	O
world	O
populations	O
.	O

FLG	O
null	O
-	O
mutations	O
are	O
present	O
in	O
up	O
to	O
10	O
%	O
of	O
the	O
Caucasian	O
population	O
in	O
Western	O
Europe	O
and	O
North	O
America	O
,	O
with	O
R05X	O
and	O
2282del4	O
as	O
the	O
most	O
common	O
null	O
-	O
mutations	O
.	O

Epidemiological	O
studies	O
conducted	O
in	O
Europe	O
indicate	O
a	O
latitude	O
dependent	O
distribution	O
of	O
common	O
FLG	O
null	O
-	O
mutations	O
with	O
a	O
decreasing	O
north	O
-	O
south	O
gradient	O
of	O
R501X	O
and	O
2282del4	O
mutation	O
frequencies	O
.	O

FLG	B-Gene
null	B-Var
-	I-Var
mutation	I-Var
carriers	O
are	O
prone	O
to	O
develop	B-PosReg
unspecific	B-Disease
skin	I-Disease
symptoms	I-Disease
related	O
to	O
atopic	O
and	O
non	O
-	O
atopic	O
skin	O
disorders	O
due	O
to	O
their	O
defect	O
of	O
epidermal	O
barrier	O
function	O
,	O
which	O
allows	O
greater	O
skin	O
penetration	O
of	O
various	O
hazards	O
.	O

Epidemiological	O
studies	O
indicate	O
an	O
association	B-Interaction
of	O
FLG	B-Gene
null	B-Var
-	I-Var
mutations	I-Var
with	O
AEDS	B-Disease
,	O
whereas	O
results	O
regarding	O
an	O
association	O
of	O
FLG	O
null	O
-	O
mutations	O
with	O
sensitization	O
to	O
common	O
inhalant	O
allergens	O
and	O
development	O
of	O
rhinitis	O
and	O
asthma	O
are	O
incoherent	O
.	O

A	O
study	O
conducted	O
in	O
Croatia	O
found	O
a	O
low	O
frequency	O
of	O
FLG	O
null	O
-	O
mutations	O
in	O
general	O
population	O
(	O
2.6	O
%	O
)	O
and	O
did	O
not	O
confirm	O
FLG	O
null	O
-	O
mutations	O
as	O
an	O
etiological	O
factor	O
for	O
atopy	O
and	O
atopic	O
disease	O
in	O
the	O
studied	O
population	O
.	O

Genetic	O
anticipation	O
in	O
Swedish	O
Lynch	O
syndrome	O
families	O
.	O

Among	O
hereditary	O
colorectal	O
cancer	O
predisposing	O
syndromes	O
,	O
Lynch	B-Disease
syndrome	I-Disease
(	O
LS	O
)	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
DNA	O
mismatch	O
repair	O
genes	O
MLH1	B-Gene
,	O
MSH2	B-Gene
,	O
MSH6	B-Gene
or	O
PMS2	B-Gene
is	O
the	O
most	O
common	O
.	O

Patients	O
with	O
LS	O
have	O
an	O
increased	O
risk	O
of	O
early	O
onset	O
colon	O
and	O
endometrial	O
cancer	O
,	O
but	O
also	O
other	O
tumors	O
that	O
generally	O
have	O
an	O
earlier	O
onset	O
compared	O
to	O
the	O
general	O
population	O
.	O

However	O
,	O
age	O
at	O
first	O
primary	O
cancer	O
varies	O
within	O
families	O
and	O
genetic	O
anticipation	O
,	O
i.e.	O
decreasing	O
age	O
at	O
onset	O
in	O
successive	O
generations	O
,	O
has	O
been	O
suggested	O
in	O
LS	O
.	O

Anticipation	O
is	O
a	O
well	O
-	O
known	O
phenomenon	O
in	O
e.g	O
neurodegenerative	O
diseases	O
and	O
several	O
reports	O
have	O
studied	O
anticipation	O
in	O
heritable	O
cancer	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
determine	O
whether	O
anticipation	O
can	O
be	O
shown	O
in	O
a	O
nationwide	O
cohort	O
of	O
Swedish	O
LS	O
families	O
referred	O
to	O
the	O
regional	O
departments	O
of	O
clinical	O
genetics	O
in	O
Lund	O
,	O
Stockholm	O
,	O
Linköping	O
,	O
Uppsala	O
and	O
Umeå	O
between	O
the	O
years	O
1990	O
-	O
2013	O
.	O

We	O
analyzed	O
a	O
homogenous	O
group	O
of	O
mutation	O
carriers	O
,	O
utilizing	O
information	O
from	O
both	O
affected	O
and	O
non	O
-	O
affected	O
family	O
members	O
.	O

In	O
total	O
,	O
239	O
families	O
with	O
a	O
mismatch	O
repair	O
gene	O
mutation	O
(	O
96	O
MLH1	O
families	O
,	O
90	O
MSH2	O
families	O
including	O
one	O
family	O
with	O
an	O
EPCAM	O
-	O
MSH2	O
deletion	O
,	O
39	O
MSH6	O
families	O
,	O
12	O
PMS2	O
families	O
,	O
and	O
2	O
MLH1+PMS2	O
families	O
)	O
comprising	O
1028	O
at	O
-	O
risk	O
carriers	O
were	O
identified	O
among	O
the	O
Swedish	O
LS	O
families	O
,	O
of	O
which	O
1003	O
mutation	O
carriers	O
had	O
available	O
follow	O
-	O
up	O
information	O
and	O
could	O
be	O
included	O
in	O
the	O
study	O
.	O

Using	O
a	O
normal	O
random	O
effects	O
model	O
(	O
NREM	O
)	O
we	O
estimate	O
a	O
2.1	O
year	O
decrease	O
in	O
age	O
of	O
diagnosis	O
per	O
generation	O
.	O

An	O
alternative	O
analysis	O
using	O
a	O
mixed	O
-	O
effects	O
Cox	O
proportional	O
hazards	O
model	O
(	O
COX	O
-	O
R	O
)	O
estimates	O
a	O
hazard	O
ratio	O
of	O
exp(0.171	O
)	O
,	O
or	O
about	O
1.19	O
,	O
for	O
age	O
of	O
diagnosis	O
between	O
consecutive	O
generations	O
.	O

LS	O
-	O
associated	O
gene	O
-	O
specific	O
anticipation	O
effects	O
are	O
evident	O
for	O
MSH2	O
(	O
2.6	O
years	O
/	O
generation	O
for	O
NREM	O
and	O
hazard	O
ratio	O
of	O
1.33	O
for	O
COX	O
-	O
R	O
)	O
and	O
PMS2	O
(	O
7.3	O
years	O
/	O
generation	O
and	O
hazard	O
ratio	O
of	O
1.86	O
)	O
.	O

The	O
estimated	O
anticipation	O
effects	O
for	O
MLH1	O
and	O
MSH6	O
are	O
smaller	O
.	O

FGF	O
-	O
FGFR	O
Mediates	O
the	O
Activity	O
-	O
Dependent	O
Dendritogenesis	O
of	O
Layer	O
IV	O
Neurons	O
during	O
Barrel	O
Formation	O
.	O

Fibroblast	O
growth	O
factors	O
(	O
FGFs	O
)	O
and	O
FGF	O
receptors	O
(	O
FGFRs	O
)	O
are	O
known	O
for	O
their	O
potent	O
effects	O
on	O
cell	O
proliferation	O
/	O
differentiation	O
and	O
cortical	O
patterning	O
in	O
the	O
developing	O
brain	O
.	O

However	O
,	O
little	O
is	O
known	O
regarding	O
the	O
roles	O
of	O
FGFs	O
/	O
FGFRs	O
in	O
cortical	O
circuit	O
formation	O
.	O

Here	O
we	O
show	O
that	O
Fgfr1/2/3	O
and	O
Fgf7/9/10/22	O
mRNAs	O
are	O
expressed	O
in	O
the	O
developing	O
primary	O
somatosensory	O
(	O
S1	O
)	O
barrel	O
cortex	O
.	O

Barrel	O
cortex	O
layer	O
IV	O
spiny	O
stellate	O
cells	O
(	O
bSCs	O
)	O
are	O
the	O
primary	O
recipients	O
of	O
ascending	O
sensory	O
information	O
via	O
thalamocortical	O
axons	O
(	O
TCAs	O
)	O
.	O

Detail	O
quantification	O
revealed	O
distinctive	O
phases	O
for	O
bSC	O
dendritogenesis	O
:	O
orienting	O
dendrites	O
toward	O
TCAs	O
,	O
adding	O
de	O
novo	O
dendritic	O
segments	O
,	O
and	O
elongating	O
dendritic	O
length	O
,	O
while	O
maintaining	O
dendritic	O
patterns	O
.	O

Deleting	O
Fgfr1/2/3	O
in	O
bSCs	O
had	O
minimal	O
impact	O
on	O
dendritic	O
polarity	O
but	O
transiently	O
increased	O
the	O
number	O
of	O
dendritic	O
segments	O
.	O

However	O
,	O
6	O
d	O
later	O
,	O
FGFR1/2/3	O
loss	O
of	O
function	O
reduced	O
dendritic	O
branch	O
numbers	O
.	O

These	O
data	O
suggest	O
that	O
FGFs	O
/	O
FGFRs	O
have	O
a	O
role	O
in	O
stabilizing	O
dendritic	O
patterning	O
.	O

Depolarization	O
of	O
cultured	O
mouse	O
cortical	O
neurons	O
upregulated	O
the	O
levels	O
of	O
several	O
Fgf	O
/	O
Fgfr	O
mRNAs	O
within	O
2	O
h.	O
In	O
vivo	O
,	O
within	O
6	O
h	O
of	O
systemic	O
kainic	O
acid	O
administration	O
at	O
postnatal	O
day	O
6	O
,	O
mRNA	O
levels	O
of	O
Fgf9	O
,	O
Fgf10	O
,	O
Fgfr2c	O
,	O
and	O
Fgfr3b	O
in	O
S1	O
cortices	O
were	O
enhanced	O
,	O
and	O
this	O
was	O
accompanied	O
by	O
exuberant	O
dendritogenesis	O
of	O
bSCs	O
by	O
24	O
h.	O
Deleting	O
Fgfr1/2/3	O
abolished	O
kainic	O
acid	O
-	O
induced	O
bSC	O
dendritic	O
overgrowth	O
.	O

Finally	O
,	O
FGF9/10	O
gain	O
of	O
function	O
also	O
resulted	O
in	O
extensive	O
dendritogenesis	O
.	O

Together	O
,	O
our	O
data	O
suggest	O
that	O
FGFs	O
/	O
FGFRs	O
can	O
be	O
regulated	O
by	O
glutamate	O
transmission	O
to	O
modulate	O
/	O
stabilize	O
bSC	O
dendritic	O
complexity	O
.	O

Both	O
male	O
and	O
female	O
mice	O
were	O
used	O
for	O
our	O
study	O
.	O

SIGNIFICANCE	O
STATEMENT	O
Glutamatergic	O
transmission	O
plays	O
critical	O
roles	O
in	O
cortical	O
circuit	O
formation	O
.	O

Its	O
dysregulation	O
has	O
been	O
proposed	O
as	O
a	O
core	O
factor	O
in	O
the	O
etiology	O
of	O
many	O
neurological	O
diseases	O
.	O

We	O
found	O
that	O
excessive	O
glutamate	O
transmission	O
upregulated	O
mRNA	O
expression	O
of	O
Fgfrs	O
and	O
their	O
ligands	O
Fgfs	O
Deleting	B-Var
Fgfr1/2/3	B-Gene
not	O
only	O
impaired	B-NegReg
bSC	B-MPA
dendritogenesis	I-MPA
but	O
also	O
abolished	B-NegReg
glutamate	B-MPA
transmission	I-MPA
-	I-MPA
induced	I-MPA
dendritic	I-MPA
overgrowth	I-MPA
.	O

Overexpressing	O
FGF9	O
or	O
FGF10	O
in	O
cortical	O
glutamatergic	O
neurons	O
results	O
in	O
excessive	O
dendritic	O
outgrowth	O
within	O
24	O
h	O
,	O
resembling	O
the	O
changes	O
induced	O
by	O
excessive	O
glutamate	O
transmission	O
.	O

Our	O
findings	O
provide	O
strong	O
evidence	O
for	O
the	O
physiological	O
role	O
of	O
fibroblast	O
growth	O
factors	O
(	O
FGFs	O
)	O
and	O
FGF	O
receptors	O
(	O
FGFRs	O
)	O
in	O
establishing	O
and	O
maintaining	O
cortical	O
circuits	O
.	O

Perturbing	O
the	O
expression	O
levels	O
of	O
FGFs	O
/	O
FGFRs	O
by	O
excessive	O
glutamatergic	O
neurotransmission	O
could	O
lead	O
to	O
abnormal	O
neuronal	O
circuits	O
,	O
which	O
may	O
contribute	O
to	O
neurological	O
and	O
psychiatric	O
disease	O
.	O

Why	O
are	O
there	O
hotspot	O
mutations	O
in	O
the	O
TP53	O
gene	O
in	O
human	O
cancers	O
?	O
The	O
p53	O
gene	O
contains	O
homozygous	O
mutations	O
in	O
~50	O
-	O
60	O
%	O
of	O
human	O
cancers	O
.	O

About	O
90	O
%	O
of	O
these	O
mutations	O
encode	O
missense	O
mutant	O
proteins	O
that	O
span	O
~190	O
different	O
codons	O
localized	O
in	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
the	O
gene	O
and	O
protein	O
.	O

These	O
mutations	B-Var
produce	O
a	O
protein	O
with	O
a	O
reduced	O
capacity	O
to	O
bind	O
to	O
a	O
specific	O
DNA	O
sequence	O
that	O
regulates	B-Reg
the	O
p53	B-Pathway
transcriptional	I-Pathway
pathway	I-Pathway
.	O

Eight	O
of	O
these	O
mutations	O
are	O
localized	O
in	O
codons	O
that	O
account	O
for	O
~28	O
%	O
of	O
the	O
total	O
p53	O
mutations	O
and	O
these	O
alleles	O
appear	O
to	O
be	O
selected	O
for	O
preferentially	O
in	O
human	O
cancers	O
of	O
many	O
tissue	O
types	O
.	O

This	O
article	O
explores	O
the	O
question	O
'	O
Why	O
are	O
there	O
hotspot	O
mutations	O
in	O
the	O
p53	O
gene	O
in	O
human	O
cancers	O
?	O
'	O
Four	O
possible	O
reasons	O
for	O
this	O
are	O
considered	O
;	O
(	O
1	O
)	O
the	O
hotspot	O
mutant	B-Var
alleles	O
produce	O
a	O
protein	O
that	O
has	O
a	O
highly	O
altered	B-Reg
structure	B-MPA
,	O
(	O
2	O
)	O
environmental	O
mutagens	O
produce	O
allele	O
-	O
specific	O
changes	O
in	O
the	O
p53	O
gene	O
,	O
(	O
3	O
)	O
these	O
mutations	O
arise	O
at	O
selected	O
sites	O
in	O
the	O
gene	O
due	O
to	O
a	O
specific	O
DNA	O
sequence	O
,	O
such	O
as	O
a	O
methylated	O
cytosine	O
residue	O
in	O
a	O
CpG	O
dinucleotide	O
,	O
which	O
has	O
a	O
higher	O
mutation	O
rate	O
changing	O
C	O
to	O
T	O
nucleotides	O
,	O
(	O
4	O
)	O
along	O
with	O
the	O
observed	O
change	O
in	O
mutant	O
p53	O
proteins	O
,	O
which	O
produce	O
a	O
loss	O
of	O
function	O
(	O
DNA	O
binding	O
and	O
transcription	O
)	O
,	O
some	O
mutant	B-Var
proteins	B-Protein
have	O
an	O
allele	O
-	O
specific	O
gain	B-PosReg
of	I-PosReg
function	I-PosReg
that	O
promotes	O
cancer	B-Disease
.	O

Evidence	O
is	O
presented	O
that	O
demonstrates	O
the	O
first	O
three	O
possibilities	O
all	O
contribute	O
some	O
property	O
to	O
this	O
list	O
of	O
hotspot	O
mutations	O
.	O

The	O
fourth	O
possibility	O
remains	O
to	O
be	O
tested	O
.	O

Mutant	O
p53	O
partners	O
in	O
crime	O
.	O

Mutant	B-Var
p53	B-Gene
proteins	B-Protein
impart	O
changes	B-Reg
in	O
cellular	B-MPA
behavior	I-MPA
and	O
function	B-MPA
through	O
interactions	B-Interaction
with	O
proteins	B-Protein
that	O
alter	O
gene	O
expression	O
.	O

The	O
milieu	O
of	O
intracellular	O
proteins	O
available	O
to	O
interact	O
with	O
mutant	O
p53	O
is	O
context	O
specific	O
and	O
changes	O
with	O
disease	O
,	O
cell	O
type	O
,	O
and	O
environmental	O
conditions	O
.	O

Varying	O
conformations	O
of	O
mutant	B-Var
p53	B-Gene
largely	O
dictate	B-Reg
protein	B-MPA
-	I-MPA
protein	I-MPA
interactions	I-MPA
as	O
different	O
point	O
mutations	O
within	O
protein	O
-	O
coding	O
regions	O
greatly	O
alter	O
the	O
extent	O
and	O
array	O
of	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
activities	O
.	O

Given	O
such	O
variables	O
,	O
how	O
can	O
knowledge	O
regarding	O
p53	O
missense	O
mutations	O
be	O
translated	O
into	O
predicting	O
or	O
altering	O
biologic	O
activity	O
for	O
therapy	O
?	O
How	O
may	O
knowledge	O
regarding	O
mutant	O
p53	O
functions	O
within	O
certain	O
disease	O
contexts	O
be	O
harnessed	O
to	O
blunt	O
or	O
ablate	O
mutant	O
p53	O
GOF	O
for	O
therapy	O
?	O
In	O
this	O
article	O
,	O
we	O
review	O
known	O
proteins	O
that	O
interact	O
with	O
mutant	B-Var
p53	B-Gene
and	O
result	O
in	O
the	O
activation	B-PosReg
of	O
genes	B-Gene
that	O
contribute	O
to	O
p53	O
GOF	O
with	O
particular	O
emphasis	O
on	O
context	O
dependency	O
and	O
an	O
evolving	O
appreciation	O
of	O
GOF	O
mechanisms	O
.	O

Exceptional	O
Response	O
to	O
Temsirolimus	O
in	O
a	O
Metastatic	O
Clear	O
Cell	O
Renal	O
Cell	O
Carcinoma	O
With	O
an	O
Early	O
Novel	O
MTOR	O
-	O
Activating	O
Mutation	O
.	O

mTOR	O
pathway	O
inhibitors	O
are	O
important	O
drugs	O
for	O
the	O
treatment	O
of	O
advanced	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
.	O

However	O
,	O
no	O
valid	O
predictive	O
markers	O
have	O
been	O
identified	O
to	O
guide	O
treatment	O
selection	O
and	O
identify	O
patients	O
who	O
are	O
sensitive	O
to	O
these	O
drugs	O
.	O

Mutations	O
activating	O
the	O
mTOR	O
pathway	O
have	O
been	O
suggested	O
to	O
predict	O
response	O
;	O
however	O
,	O
their	O
predictive	O
value	O
is	O
still	O
unclear	O
.	O

Here	O
,	O
we	O
present	O
the	O
genomic	O
and	O
functional	O
characterization	O
of	O
a	O
patient	O
with	O
metastatic	O
clear	O
cell	O
RCC	O
(	O
ccRCC	O
)	O
who	O
experienced	O
a	O
partial	O
response	O
to	O
temsirolimus	O
after	O
a	O
poor	O
response	O
to	O
2	O
previous	O
lines	O
of	O
treatment	O
.	O

At	O
the	O
time	O
of	O
publication	O
,	O
the	O
patient	O
was	O
disease	O
-	O
free	O
8	O
years	O
after	O
temsirolimus	O
treatment	O
.	O

Multiregion	O
whole	O
-	O
exome	O
sequencing	O
(	O
WES	O
)	O
on	O
3	O
regions	O
of	O
the	O
primary	O
tumor	O
,	O
1	O
metastasis	O
,	O
and	O
blood	O
revealed	O
tumor	O
mutations	O
in	O
driver	O
genes	O
in	O
ccRCC	O
:	O
a	O
missense	O
mutation	O
in	O
VHL	O
(	O
p	O
.	O
W88L	O
)	O
,	O
a	O
loss	O
-	O
of	O
-	O
function	O
mutation	O
in	O
BAP1	O
(	O
p	O
.	O
E454Rfs*15	O
)	O
,	O
and	O
a	O
novel	O
missense	O
mutation	O
in	O
MTOR	O
(	O
p	O
.	O
Y1974H	O
)	O
.	O

The	O
MTOR	O
mutation	O
was	O
present	O
in	O
all	O
tumor	O
regions	O
,	O
with	O
similar	O
allele	O
frequency	O
as	O
the	O
VHL	O
mutation	O
,	O
and	O
in	O
vitro	O
functional	O
assessment	O
of	O
the	O
MTOR	B-Gene
variant	B-Var
demonstrated	O
that	O
it	O
increased	B-PosReg
mTORC1	B-MPA
activity	I-MPA
.	O

Consistently	O
,	O
immunohistochemistry	O
in	O
the	O
tumor	O
samples	O
demonstrated	O
increased	O
levels	O
of	O
phospho	O
-	O
S6	O
.	O

In	O
conclusion	O
,	O
multiregion	O
WES	O
identified	O
a	O
novel	O
MTOR	B-Gene
mutation	B-Var
acquired	O
early	O
during	O
tumor	O
development	O
as	O
the	O
event	O
leading	B-Reg
to	I-Reg
a	O
high	B-MPA
sensitivity	I-MPA
to	I-MPA
temsirolimus	I-MPA
treatment	I-MPA
.	O

This	O
study	O
supports	O
tumor	O
multiregion	O
sequencing	O
to	O
detect	O
truncal	O
mutations	O
in	O
the	O
mTOR	O
pathway	O
to	O
identify	O
patients	O
sensitive	O
to	O
mTOR	O
inhibitors	O
.	O

Loss	O
of	O
function	O
JAK1	O
mutations	O
occur	O
at	O
high	O
frequency	O
in	O
cancers	O
with	O
microsatellite	O
instability	O
and	O
are	O
suggestive	O
of	O
immune	O
evasion	O
.	O

Immune	O
evasion	O
is	O
a	O
well	O
-	O
recognized	O
hallmark	O
of	O
cancer	O
and	O
recent	O
studies	O
with	O
immunotherapy	O
agents	O
have	O
suggested	O
that	O
tumors	O
with	O
increased	O
numbers	O
of	O
neoantigens	O
elicit	O
greater	O
immune	O
responses	O
.	O

We	O
hypothesized	O
that	O
the	O
immune	O
system	O
presents	O
a	O
common	O
selective	O
pressure	O
on	O
high	O
mutation	O
burden	O
tumors	O
and	O
therefore	O
immune	O
evasion	O
mutations	O
would	O
be	O
enriched	O
in	O
high	O
mutation	O
burden	O
tumors	O
.	O

The	O
JAK	O
family	O
of	O
kinases	O
is	O
required	O
for	O
the	O
signaling	O
of	O
a	O
host	O
of	O
immune	O
modulators	O
in	O
tumor	O
,	O
stromal	O
,	O
and	O
immune	O
cells	O
.	O

Therefore	O
,	O
we	O
analyzed	O
alterations	O
in	O
this	O
family	O
for	O
the	O
hypothesized	O
signature	O
of	O
an	O
immune	O
evasion	O
mutation	O
.	O

Here	O
,	O
we	O
searched	O
a	O
database	O
of	O
61,704	O
unique	O
solid	O
tumors	O
for	O
alterations	O
in	O
the	O
JAK	O
family	O
kinases	O
(	O
JAK1/2/3	O
,	O
TYK2	O
)	O
.	O

We	O
used	O
The	O
Cancer	O
Genome	O
Atlas	O
and	O
Cancer	O
Cell	O
Line	O
Encyclopedia	O
data	O
to	O
confirm	O
and	O
extend	O
our	O
findings	O
by	O
analyzing	O
gene	O
expression	O
patterns	O
.	O

Recurrent	O
frameshift	B-Var
mutations	I-Var
in	O
JAK1	B-Gene
were	O
associated	B-Reg
with	O
high	B-MPA
mutation	I-MPA
burden	I-MPA
and	O
microsatellite	B-MPA
instability	I-MPA
.	O

These	O
mutations	B-Var
occurred	B-Reg
in	O
multiple	O
tumor	O
types	O
including	O
endometrial	B-Disease
,	O
colorectal	B-Disease
,	O
stomach	B-Disease
,	O
and	O
prostate	B-Disease
carcinomas	B-Disease
.	O

Analyzing	O
gene	O
expression	O
signatures	O
in	O
endometrial	O
and	O
stomach	O
adenocarcinomas	O
revealed	O
that	O
tumors	O
with	O
a	O
JAK1	O
frameshift	O
exhibited	O
reduced	O
expression	O
of	O
interferon	O
response	O
signatures	O
and	O
multiple	O
anti	O
-	O
tumor	O
immune	O
signatures	O
.	O

Importantly	O
,	O
endometrial	O
cancer	O
cell	O
lines	O
exhibited	O
similar	O
gene	O
expression	O
changes	O
that	O
were	O
expected	O
to	O
be	O
tumor	O
cell	O
intrinsic	O
(	O
e.g.	O
interferon	O
response	O
)	O
but	O
not	O
those	O
expected	O
to	O
be	O
tumor	O
cell	O
extrinsic	O
(	O
e.g.	O
NK	O
cells	O
)	O
.	O

From	O
these	O
data	O
,	O
we	O
derive	O
two	O
primary	O
conclusions	O
:	O
1	O
)	O
JAK1	O
frameshifts	O
are	O
loss	O
of	O
function	O
alterations	O
that	O
represent	O
a	O
potential	O
pan	O
-	O
cancer	O
adaptation	O
to	O
immune	O
responses	O
against	O
tumors	O
with	O
microsatellite	O
instability	O
;	O
2	O
)	O
The	O
mechanism	O
by	O
which	O
JAK1	B-Var
loss	B-NegReg
of	I-NegReg
function	I-NegReg
contributes	O
to	O
tumor	B-MPA
immune	I-MPA
evasion	I-MPA
is	O
likely	O
associated	O
with	O
loss	O
of	O
the	O
JAK1-mediated	O
interferon	O
response	O
.	O

Gain	B-PosReg
of	I-PosReg
function	I-PosReg
of	O
TMEM16E	B-Gene
/	I-Gene
ANO5	I-Gene
scrambling	B-MPA
activity	I-MPA
caused	O
by	O
a	O
mutation	B-Var
associated	O
with	O
gnathodiaphyseal	B-Disease
dysplasia	I-Disease
.	O

Mutations	B-Var
in	O
the	O
human	O
TMEM16E	B-Gene
(	O
ANO5	O
)	O
gene	O
are	O
associated	B-Reg
both	O
with	O
the	O
bone	B-Disease
disease	I-Disease
gnathodiaphyseal	B-Disease
dysplasia	I-Disease
(	O
GDD	O
;	O
OMIM	O
:	O
166260	O
)	O
and	O
muscle	B-Disease
dystrophies	I-Disease
(	O
OMIM	O
:	O
611307	O
,	O
613319	O
)	O
.	O

However	O
,	O
the	O
physiological	O
function	O
of	O
TMEM16E	O
has	O
remained	O
unclear	O
.	O

We	O
show	O
here	O
that	O
human	O
TMEM16E	O
,	O
when	O
overexpressed	O
in	O
mammalian	O
cell	O
lines	O
,	O
displayed	O
partial	O
plasma	O
membrane	O
localization	O
and	O
gave	O
rise	O
to	O
phospholipid	O
scrambling	O
(	O
PLS	O
)	O
as	O
well	O
as	O
non	O
-	O
selective	O
ionic	O
currents	O
with	O
slow	O
time	O
-	O
dependent	O
activation	O
at	O
highly	O
depolarized	O
membrane	O
potentials	O
.	O

While	O
the	O
activity	O
of	O
wild	O
-	O
type	O
TMEM16E	O
depended	O
on	O
elevated	O
cytosolic	O
Ca2	O
+	O
levels	O
,	O
a	O
mutant	O
form	O
carrying	O
the	O
GDD	O
-	O
causing	O
T513I	O
substitution	O
showed	O
PLS	O
and	O
large	O
time	O
-	O
dependent	O
ion	O
currents	O
even	O
at	O
low	O
cytosolic	O
Ca2	O
+	O
concentrations	O
.	O

Contrarily	O
,	O
mutation	O
of	O
the	O
homologous	O
position	O
in	O
the	O
Ca2	O
+	O
-activated	O
Cl-	O
channel	O
TMEM16B	O
paralog	O
hardly	O
affected	O
its	O
function	O
.	O

In	O
summary	O
,	O
these	O
data	O
provide	O
the	O
first	O
direct	O
demonstration	O
of	O
Ca2	O
+	O
-dependent	O
PLS	O
activity	O
for	O
TMEM16E	O
and	O
suggest	O
a	O
gain	O
-	O
of	O
-	O
function	O
phenotype	O
related	O
to	O
a	O
GDD	O
mutation	O
.	O

Multiple	O
Legionella	O
pneumophila	O
effector	O
virulence	O
phenotypes	O
revealed	O
through	O
high	O
-	O
throughput	O
analysis	O
of	O
targeted	O
mutant	O
libraries	O
.	O

Legionella	O
pneumophila	O
is	O
the	O
causative	O
agent	O
of	O
a	O
severe	O
pneumonia	O
called	O
Legionnaires	O
'	O
disease	O
.	O

A	O
single	O
strain	O
of	O
L.	O
pneumophila	O
encodes	O
a	O
repertoire	O
of	O
over	O
300	O
different	O
effector	O
proteins	O
that	O
are	O
delivered	O
into	O
host	O
cells	O
by	O
the	O
Dot	O
/	O
Icm	O
type	O
IV	O
secretion	O
system	O
during	O
infection	O
.	O

The	O
large	O
number	O
of	O
L.	O
pneumophila	O
effectors	O
has	O
been	O
a	O
limiting	O
factor	O
in	O
assessing	O
the	O
importance	O
of	O
individual	O
effectors	O
for	O
virulence	O
.	O

Here	O
,	O
a	O
transposon	O
insertion	O
sequencing	O
technology	O
called	O
INSeq	O
was	O
used	O
to	O
analyze	O
replication	O
of	O
a	O
pool	O
of	O
effector	O
mutants	O
in	O
parallel	O
both	O
in	O
a	O
mouse	O
model	O
of	O
infection	O
and	O
in	O
cultured	O
host	O
cells	O
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
genes	O
encoding	O
effector	O
proteins	O
resulted	O
in	O
host	B-MPA
-	I-MPA
specific	I-MPA
or	O
broad	B-MPA
virulence	I-MPA
phenotypes	I-MPA
.	O

Screen	O
results	O
were	O
validated	O
for	O
several	O
effector	O
mutants	O
displaying	O
different	O
virulence	O
phenotypes	O
using	O
genetic	O
complementation	O
studies	O
and	O
infection	O
assays	O
.	O

Specifically	O
,	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
the	O
gene	O
encoding	O
LegC4	B-Gene
resulted	O
in	O
enhanced	B-PosReg
L.	B-CPA
pneumophila	I-CPA
in	O
the	O
lungs	O
of	O
infected	O
mice	O
but	O
not	O
within	O
cultured	O
host	O
cells	O
,	O
which	O
indicates	O
LegC4	B-Var
augments	B-PosReg
bacterial	B-CPA
clearance	I-CPA
by	O
the	O
host	O
immune	O
system	O
.	O

The	O
effector	O
proteins	O
RavY	O
and	O
Lpg2505	O
were	O
important	O
for	O
efficient	O
replication	O
within	O
both	O
mammalian	O
and	O
protozoan	O
hosts	O
.	O

Further	O
analysis	O
of	O
Lpg2505	O
revealed	O
that	O
this	O
protein	O
functions	O
as	O
a	O
metaeffector	O
that	O
counteracts	O
host	O
cytotoxicity	O
displayed	O
by	O
the	O
effector	O
protein	O
SidI.	O
Thus	O
,	O
this	O
study	O
identified	O
a	O
large	O
cohort	O
of	O
effectors	O
that	O
contribute	O
to	O
L.	O
pneumophila	O
virulence	O
positively	O
or	O
negatively	O
and	O
has	O
demonstrated	O
regulation	O
of	O
effector	O
protein	O
activities	O
by	O
cognate	O
metaeffectors	O
as	O
being	O
critical	O
for	O
host	O
pathogenesis	O
.	O

A	O
Partial	O
Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
Function	I-NegReg
Variant	B-Var
in	O
AKT2	B-Gene
Is	O
Associated	O
With	O
Reduced	B-NegReg
Insulin	B-CPA
-	I-CPA
Mediated	I-CPA
Glucose	I-CPA
Uptake	I-CPA
in	O
Multiple	O
Insulin	O
-	O
Sensitive	O
Tissues	O
:	O
A	O
Genotype	O
-	O
Based	O
Callback	O
Positron	O
Emission	O
Tomography	O
Study	O
.	O

Rare	O
fully	O
penetrant	O
mutations	O
in	O
AKT2	O
are	O
an	O
established	O
cause	O
of	O
monogenic	O
disorders	O
of	O
glucose	O
metabolism	O
.	O

Recently	O
,	O
a	O
novel	O
partial	O
loss	O
-	O
of	O
-	O
function	O
AKT2	O
coding	O
variant	O
(	O
p	O
.	O
Pro50Thr	O
)	O
was	O
identified	O
that	O
is	O
nearly	O
specific	O
to	O
Finns	O
(	O
frequency	O
1.1	O
%	O
)	O
,	O
with	O
the	O
low	O
-	O
frequency	O
allele	O
associated	O
with	O
an	O
increase	O
in	O
fasting	O
plasma	O
insulin	O
level	O
and	O
risk	O
of	O
type	O
2	O
diabetes	O
.	O

The	O
effects	O
of	O
the	O
p	O
.	O
Pro50Thr	O
AKT2	O
variant	O
(	O
p	O
.	O
P50T	O
/	O
AKT2	O
)	O
on	O
insulin	O
-	O
stimulated	O
glucose	O
uptake	O
(	O
GU	O
)	O
in	O
the	O
whole	O
body	O
and	O
in	O
different	O
tissues	O
have	O
not	O
previously	O
been	O
investigated	O
.	O

We	O
identified	O
carriers	O
(	O
N	O
=	O
20	O
)	O
and	O
matched	O
noncarriers	O
(	O
N	O
=	O
25	O
)	O
for	O
this	O
allele	O
in	O
the	O
population	O
-	O
based	O
Metabolic	O
Syndrome	O
in	O
Men	O
(	O
METSIM)study	O
and	O
invited	O
these	O
individuals	O
back	O
for	O
positron	O
emission	O
tomography	O
study	O
with	O
[	O
18F]-fluorodeoxyglucose	O
during	O
euglycemic	O
hyperinsulinemia	O
.	O

When	O
we	O
compared	O
p	O
.	O
P50T	O
/	O
AKT2	O
carriers	O
to	O
noncarriers	O
,	O
we	O
found	O
a	O
39.4	O
%	O
reduction	O
in	O
whole	O
-	O
body	O
GU	O
(	O
P	O
=	O
0.006	O
)	O
and	O
a	O
55.6	O
%	O
increase	O
in	O
the	O
rate	O
of	O
endogenous	O
glucose	O
production	O
(	O
P	O
=	O
0.038	O
)	O
.	O

We	O
found	O
significant	O
reductions	O
in	O
GU	O
in	O
multiple	O
tissues	O
-	O
skeletal	O
muscle	O
(	O
36.4	O
%	O
)	O
,	O
liver	O
(	O
16.1	O
%	O
)	O
,	O
brown	O
adipose	O
(	O
29.7	O
%	O
)	O
,	O
and	O
bone	O
marrow	O
(	O
32.9%)-and	O
increases	O
of	O
16.8	O
-	O
19.1	O
%	O
in	O
seven	O
tested	O
brain	O
regions	O
.	O

These	O
data	O
demonstrate	O
that	O
the	O
p	B-Var
.	I-Var
P50	I-Var
T	I-Var
substitution	O
of	O
AKT2	B-Gene
influences	B-Reg
insulin	B-MPA
-	I-MPA
mediated	I-MPA
GU	I-MPA
in	O
multiple	O
insulin	O
-	O
sensitive	O
tissues	O
and	O
may	O
explain	O
,	O
at	O
least	O
in	O
part	O
,	O
the	O
increased	O
risk	O
of	O
type	O
2	O
diabetes	O
in	O
p	O
.	O
P50T	O
/	O
AKT2	O
carriers	O
.	O

Common	O
and	O
rare	O
TBK1	B-Gene
variants	B-Var
in	B-Reg
early	B-Disease
-	I-Disease
onset	I-Disease
Alzheimer	I-Disease
disease	I-Disease
in	O
a	O
European	O
cohort	O
.	O

TANK	O
-	O
binding	O
kinase	O
1	O
(	B-Gene
TBK1	I-Gene
)	I-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LoF	O
)	O
mutations	B-Var
are	O
known	O
to	O
cause	O
frontotemporal	B-Disease
dementia	I-Disease
(	O
FTD	O
)	O
and	O
amyotrophic	B-Disease
lateral	I-Disease
sclerosis	I-Disease
(	O
ALS	O
)	O
,	O
often	O
combined	O
with	O
memory	O
deficits	O
early	O
in	O
the	O
disease	O
course	O
.	O

We	O
performed	O
targeted	O
resequencing	O
of	O
TBK1	O
in	O
1253	O
early	O
onset	O
Alzheimer	O
's	O
disease	O
(	O
EOAD	O
)	O
patients	O
from	O
8	O
European	O
countries	O
to	O
investigate	O
whether	O
pathogenic	O
TBK1	O
mutations	O
are	O
enriched	O
among	O
patients	O
with	O
clinical	O
diagnosis	O
of	O
EOAD	O
.	O

Variant	O
frequencies	O
were	O
compared	O
against	O
2117	O
origin	O
-	O
matched	O
controls	O
.	O

We	O
identified	O
only	O
1	O
LoF	O
mutation	O
(	O
p	O
.	O
Thr79del	O
)	O
in	O
a	O
patient	O
clinically	O
diagnosed	O
with	O
Alzheimer	O
's	O
disease	O
and	O
a	O
positive	O
family	O
history	O
of	O
ALS	O
.	O

We	O
did	O
not	O
observe	O
enrichment	O
of	O
rare	O
variants	O
in	O
EOAD	O
patients	O
compared	O
to	O
controls	O
,	O
nor	O
of	O
rare	O
variants	O
affecting	O
NFκB	O
induction	O
.	O

Of	O
3	O
common	O
coding	O
variants	O
,	O
rs7486100	O
showed	O
evidence	O
of	O
association	O
(	O
OR	O
1.46	O
[	O
95	O
%	O
CI	O
1.13	O
-	O
1.9	O
]	O
;	O
p	O
-	O
value	O
0.01	O
)	O
.	O

Homozygous	O
carriers	O
of	O
the	O
risk	O
allele	O
showed	O
reduced	O
expression	O
of	O
TBK1	O
(	O
p	O
-	O
value	O
0.03	O
)	O
.	O

Our	O
findings	O
are	O
not	O
indicative	O
of	O
a	O
significant	O
role	O
for	O
TBK1	O
mutations	O
in	O
EOAD	O
.	O

The	O
association	O
between	O
common	O
variants	O
in	O
TBK1	O
,	O
disease	O
risk	O
and	O
reduced	O
TBK1	O
expression	O
warrants	O
follow	O
-	O
up	O
in	O
FTD	O
/	O
ALS	O
cohorts	O
.	O

Polymorphisms	O
in	O
inflammasome	O
genes	O
and	O
risk	O
of	O
asthma	O
in	O
Brazilian	O
children	O
.	O

Considering	O
its	O
role	O
in	O
inflammation	O
and	O
recently	O
described	O
"	O
alternative	O
"	O
roles	O
in	O
epithelial	O
homeostasis	O
and	O
Th1	O
/	O
Th2	O
balance	O
,	O
we	O
hypothesize	O
that	O
inflammasome	O
genetics	O
could	O
contribute	O
to	O
the	O
development	O
of	O
asthma	O
.	O

Selected	O
functional	O
polymorphisms	O
in	O
inflammasome	O
genes	O
are	O
evaluated	O
in	O
a	O
cohort	O
of	O
asthmatic	O
children	O
and	O
their	O
families	O
.	O

Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
NLRP1	B-Gene
variants	B-Var
rs11651270	B-Var
,	O
rs12150220	B-Var
and	O
rs2670660	B-Var
resulted	O
significantly	O
associated	O
to	O
asthma	B-Disease
in	O
trios	O
(	O
TDT	O
)	O
analysis	O
;	O
and	O
rs11651270	B-Var
and	O
rs2670660	B-Var
also	O
with	B-Reg
asthma	B-Disease
severity	O
and	O
total	O
IgE	B-MPA
level	I-MPA
in	O
asthmatic	O
children	O
.	O

NLRP1	O
activators	O
in	O
humans	O
are	O
still	O
unknown	O
,	O
however	O
we	O
hypothesized	O
that	O
individuals	O
with	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
SNPs	B-Var
in	O
NLRP1	B-Gene
could	O
be	O
more	O
prone	B-PosReg
in	O
activating	B-MPA
inflammasome	I-MPA
in	O
the	O
presence	O
of	O
asthma	O
-	O
related	O
cell	O
stressors	O
(	O
i.e.	O
ER	O
stress	O
or	O
ROS	O
)	O
,	O
and	O
this	O
activation	O
contribute	O
to	O
exacerbate	B-PosReg
inflammatory	B-CPA
response	I-CPA
and	O
asthma	B-CPA
development	I-CPA
.	O

Gain	O
-	O
of	O
-	O
function	O
IL1A	B-Gene
rs17561	B-Var
resulted	O
significantly	O
associated	O
with	O
a	O
reduced	B-NegReg
pulmonary	B-CPA
capacity	I-CPA
in	O
asthmatic	O
children	O
.	O

IL18	B-Gene
rs5744256	B-Var
which	O
lead	O
to	O
lower	B-NegReg
serum	B-MPA
level	I-MPA
of	I-MPA
IL-18	I-MPA
appeared	O
to	O
be	O
associated	O
to	O
a	O
worse	O
response	O
to	O
bronchodilators	O
.	O

Concluding	O
,	O
this	O
work	O
provides	O
evidences	O
about	O
the	O
contribution	O
of	O
inflammasome	O
genetics	O
in	O
the	O
development	O
of	O
paediatric	O
asthma	O
,	O
both	O
considering	O
its	O
inflammatory	O
role	O
in	O
alveolar	O
macrophages	O
(	O
i.e.	O
:	O
NLRP1	O
)	O
or	O
its	O
homeostatic	O
role	O
in	O
lung	O
epithelial	O
cells	O
(	O
i.e.	O
:	O
IL1A	O
,	O
IL18	O
)	O
.	O

EYS	O
mutation	O
update	O
:	O
In	O
silico	O
assessment	O
of	O
271	O
reported	O
and	O
26	O
novel	O
variants	O
in	O
patients	O
with	O
retinitis	O
pigmentosa	O
.	O

Mutations	B-Var
in	O
Eyes	O
shut	O
homolog	O
(	B-Gene
EYS	I-Gene
)	I-Gene
are	O
one	O
of	O
the	O
most	O
common	O
causes	B-Reg
of	O
autosomal	B-Disease
recessive	I-Disease
(	I-Disease
ar	I-Disease
)	I-Disease
retinitis	I-Disease
pigmentosa	I-Disease
(	O
RP	O
)	O
,	O
a	O
progressive	O
blinding	O
disorder	O
.	O

The	O
exact	O
function	O
of	O
the	O
EYS	O
protein	O
and	O
the	O
pathogenic	O
mechanisms	O
underlying	O
EYS	O
-	O
associated	O
RP	O
are	O
still	O
poorly	O
understood	O
,	O
which	O
hampers	O
the	O
interpretation	O
of	O
the	O
causality	O
of	O
many	O
EYS	O
variants	O
discovered	O
to	O
date	O
.	O

We	O
collected	O
all	O
reported	O
EYS	O
variants	O
present	O
in	O
377	O
arRP	O
index	O
cases	O
published	O
before	O
June	O
2017	O
,	O
and	O
uploaded	O
them	O
in	O
the	O
Leiden	O
Open	O
Variation	O
Database	O
(	O
www.LOVD.nl/EYS	O
)	O
.	O

We	O
also	O
describe	O
36	O
additional	O
index	O
cases	O
,	O
carrying	O
26	O
novel	O
variants	O
.	O

Of	O
the	O
297	O
unique	O
EYS	O
variants	O
identified	O
,	O
almost	O
half	O
(	O
n	O
=	O
130	O
)	O
are	O
predicted	O
to	O
result	O
in	O
premature	O
truncation	O
of	O
the	O
EYS	O
protein	O
.	O

Classification	O
of	O
all	O
variants	O
using	O
the	O
American	O
College	O
of	O
Medical	O
Genetics	O
and	O
Genomics	O
guidelines	O
revealed	O
that	O
the	O
predicted	O
pathogenicity	O
of	O
these	O
variants	O
cover	O
the	O
complete	O
spectrum	O
ranging	O
from	O
likely	O
benign	O
to	O
pathogenic	O
,	O
although	O
especially	O
missense	O
variants	O
largely	O
fall	O
in	O
the	O
category	O
of	O
uncertain	O
significance	O
.	O

Besides	O
the	O
identification	O
of	O
likely	O
benign	O
alleles	O
previously	O
reported	O
as	O
being	O
probably	O
pathogenic	O
,	O
our	O
comprehensive	O
analysis	O
underscores	O
the	O
need	O
of	O
functional	O
assays	O
to	O
assess	O
the	O
causality	O
of	O
EYS	O
variants	O
,	O
in	O
order	O
to	O
improve	O
molecular	O
diagnostics	O
and	O
counseling	O
of	O
patients	O
with	O
EYS	O
-	O
associated	O
RP	O
.	O

MED13L	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
variants	B-Var
in	O
two	O
patients	O
with	O
syndromic	O
Pierre	B-Disease
Robin	I-Disease
sequence	I-Disease
.	O

We	O
report	O
two	O
unrelated	O
patients	O
with	O
Pierre	O
Robin	O
sequence	O
(	O
PRS	O
)	O
and	O
a	O
strikingly	O
similar	O
combination	O
of	O
associated	O
features	O
.	O

Whole	O
exome	O
sequencing	O
was	O
performed	O
for	O
both	O
patients	O
.	O

No	O
single	O
gene	O
containing	O
likely	O
pathogenic	O
point	O
mutations	O
in	O
both	O
patients	O
could	O
be	O
identified	O
,	O
but	O
the	O
finding	O
of	O
an	O
essential	O
splice	O
site	O
mutation	O
in	O
mediator	O
complex	O
subunit	O
13	O
like	O
(	O
MED13L	O
)	O
in	O
one	O
patient	O
prompted	O
the	O
investigation	O
of	O
copy	O
number	O
variants	O
in	O
MED13L	O
in	O
the	O
other	O
,	O
leading	O
to	O
the	O
identification	O
of	O
an	O
intragenic	O
deletion	O
.	O

Disruption	B-Var
of	O
MED13L	B-Gene
,	O
encoding	O
a	O
component	O
of	O
the	O
Mediator	O
complex	O
,	O
is	O
increasingly	O
recognized	O
as	O
the	O
cause	B-Reg
of	O
an	O
intellectual	B-Disease
disability	I-Disease
syndrome	I-Disease
with	O
associated	O
facial	B-Disease
dysmorphism	I-Disease
.	O

Our	O
findings	O
suggest	O
that	O
MED13L	O
-	O
related	O
disorders	O
are	O
a	O
possible	O
differential	O
diagnosis	O
for	O
syndromic	O
PRS	O
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
activity	I-NegReg
-	I-NegReg
mutation	I-NegReg
in	O
the	O
cardiac	B-MPA
chloride	I-MPA
-	I-MPA
bicarbonate	I-MPA
exchanger	I-MPA
AE3	I-MPA
causes	O
short	B-Disease
QT	I-Disease
syndrome	I-Disease
.	O

Patients	O
with	O
short	O
QT	O
syndrome	O
(	O
SQTS	O
)	O
may	O
present	O
with	O
syncope	O
,	O
ventricular	O
fibrillation	O
or	O
sudden	O
cardiac	O
death	O
.	O

Six	O
SQTS	O
susceptibility	O
genes	O
,	O
encoding	O
cation	O
channels	O
,	O
explain	O
<	O
25	O
%	O
of	O
SQTS	O
cases	O
.	O

Here	O
we	O
identify	O
a	O
missense	B-Var
mutation	I-Var
in	O
the	O
anion	O
exchanger	O
(	O
AE3)-encoding	O
SLC4A3	B-Gene
gene	O
in	O
two	O
unrelated	O
families	O
with	O
SQTS	O
.	O

The	O
mutation	O
causes	O
reduced	B-NegReg
surface	B-MPA
expression	I-MPA
of	I-MPA
AE3	I-MPA
and	O
reduced	B-NegReg
membrane	B-MPA
bicarbonate	I-MPA
transport	I-MPA
.	O

Slc4a3	O
knockdown	O
in	O
zebrafish	O
causes	O
increased	O
cardiac	O
pHi	O
,	O
short	O
QTc	O
,	O
and	O
reduced	O
systolic	O
duration	O
,	O
which	O
is	O
rescued	O
by	O
wildtype	O
but	O
not	O
mutated	O
SLC4A3	O
.	O

Mechanistic	O
analyses	O
suggest	O
that	O
an	O
increase	O
in	O
pHi	O
and	O
decrease	O
in	O
[	O
Cl-]i	O
shortened	O
the	O
action	O
potential	O
duration	O
.	O

However	O
,	O
other	O
mechanisms	O
may	O
also	O
play	O
a	O
role	O
.	O

Altered	O
anion	O
transport	O
represents	O
a	O
mechanism	O
for	O
development	O
of	O
arrhythmia	O
and	O
may	O
provide	O
new	O
therapeutic	O
possibilities	O
.	O

In	O
Silico	O
Approach	O
to	O
Investigate	O
the	O
Structural	O
and	O
Functional	O
Attributes	O
of	O
Familial	O
Hypercholesterolemia	O
Variants	O
Reported	O
in	O
the	O
Saudi	O
Population	O
.	O

Familial	B-Disease
hypercholesterolemia	I-Disease
(	O
FH	O
)	O
is	O
a	O
metabolic	O
disorder	O
that	O
leads	O
primarily	O
to	O
premature	O
cardiovascular	O
diseases	O
,	O
the	O
main	O
cause	O
of	O
mortality	O
in	O
Saudi	O
Arabia	O
(	O
SA	O
)	O
.	O

FH	O
is	O
underreported	O
and	O
underdiagnosed	O
in	O
SA	O
with	O
statistical	O
evidence	O
of	O
high	O
expected	O
prevalence	O
in	O
such	O
a	O
consanguineous	O
community	O
.	O

Lacking	O
knowledge	O
of	O
which	O
and	O
how	O
these	O
alterations	O
are	O
actually	O
impacting	O
lipid	O
metabolism	O
is	O
one	O
of	O
the	O
main	O
reasons	O
why	O
FH	O
is	O
insufficiently	O
diagnosed	O
in	O
the	O
region	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
develop	O
a	O
fast	O
prediction	O
approach	O
using	O
an	O
integrated	O
bioinformatics	O
method	O
for	O
future	O
screening	O
of	O
the	O
potential	O
causative	O
variants	O
from	O
national	O
registries	O
.	O

A	O
total	O
of	O
21	O
variants	O
were	O
detected	O
with	O
majority	O
rate	O
in	O
LDLR	O
(	O
81	O
%	O
)	O
.	O

Variants	O
were	O
classified	O
based	O
on	O
the	O
type	O
of	O
mutation	O
.	O

Missense	O
variants	O
resulting	O
in	O
amino	O
acid	O
changes	O
,	O
c.1429G	B-Var
>	I-Var
A	I-Var
(	O
p	O
.	O
D477N	O
)	O
,	O
c.1474G	B-Var
>	I-Var
A	I-Var
(	O
p	O
.	O
D492N	O
)	O
,	O
c.1731G	B-Var
>	I-Var
T	I-Var
(	O
p	O
.	O
W577C	O
)	O
,	O
and	O
c.1783C	B-Var
>	I-Var
T	I-Var
(	O
p	O
.	O
R595W	O
)	O
in	O
LDLR	B-Gene
gene	O
,	O
in	O
addition	O
to	O
c.9835A	B-Var
>	I-Var
G	I-Var
(	O
p	O
.	O
S3279	O
G	O
)	O
in	O
APOB	B-Gene
,	O
were	O
shown	O
to	O
be	O
deleterious	O
by	O
concordant	O
analysis	O
.	O

Furthermore	O
,	O
functional	B-Interaction
interaction	I-Interaction
deformities	B-Reg
showed	O
a	O
significant	O
loss	B-NegReg
and	O
gain	B-PosReg
of	O
energies	B-MPA
in	I-MPA
the	I-MPA
mutated	I-MPA
proteins	I-MPA
.	O

These	O
findings	O
will	O
help	O
in	O
distinguishing	O
the	O
most	O
harmful	O
mutations	O
needed	O
to	O
be	O
screened	O
for	O
clinically	O
diagnosed	O
FH	O
patients	O
in	O
SA	O
.	O

Such	O
computational	O
research	O
is	O
necessary	O
to	O
avoid	O
time	O
consumption	O
and	O
the	O
usage	O
of	O
expensive	O
biological	O
experiments	O
.	O

This	O
can	O
be	O
a	O
fast	O
track	O
to	O
facilitate	O
the	O
future	O
filtering	O
and	O
screening	O
of	O
causative	O
mutations	O
from	O
national	O
registries	O
.	O

Effects	O
of	O
null	O
mutation	O
of	O
the	O
heat	O
-	O
shock	O
gene	O
htpG	O
on	O
the	O
production	O
of	O
virulence	O
factors	O
by	O
Pseudomonas	O
aeruginosa	O
.	O

AIM	O
:	O
Pseudomonas	O
aeruginosa	O
is	O
one	O
of	O
the	O
most	O
clinically	O
important	O
opportunistic	O
pathogen	O
in	O
humans	O
.	O

The	O
aim	O
of	O
the	O
project	O
was	O
to	O
study	O
effects	O
of	O
HtpG	O
on	O
the	O
selected	O
virulence	O
factors	O
responsible	O
for	O
pathogenesis	O
and	O
biofilm	O
formation	O
of	O
P.	O
aeruginosa	O
.	O

METHODOLOGY	O
:	O
By	O
characterizing	O
a	O
htpG	O
null	O
mutant	O
of	O
P.	O
aeruginosa	O
,	O
we	O
have	O
identified	O
the	O
role	O
of	O
HtpG	O
in	O
the	O
production	O
of	O
selected	O
factors	O
.	O

RESULTS	O
:	O
We	O
showed	O
that	O
ΔhtpG	B-Gene
mutant	B-Var
affects	O
many	O
physiological	O
processes	O
containing	O
:	O
decreased	B-NegReg
activity	B-MPA
of	O
the	O
LasA	B-Enzyme
protease	I-Enzyme
,	O
reduction	B-NegReg
of	O
biofilm	B-MPA
formation	I-MPA
,	O
decreased	B-NegReg
motility	B-CPA
,	O
and	O
diminished	B-NegReg
amount	B-MPA
of	I-MPA
rhamnolipids	I-MPA
and	I-MPA
pyoverdine	I-MPA
/	I-MPA
pyocyanin	I-MPA
.	O

These	O
defects	O
were	O
most	O
evident	O
when	O
the	O
ΔhtpG	O
strain	O
was	O
cultured	O
at	O
42	O
°	O
C	O
.	O

CONCLUSION	O
:	O
Our	O
findings	O
demonstrate	O
the	O
unexplored	O
role	O
of	O
HtpG	O
in	O
the	O
pathogenicity	O
of	O
P.	O
aeruginosa	O
,	O
and	O
indicate	O
potential	O
targets	O
for	O
antibacterial	O
therapeutics	O
.	O

[	O
Formula	O
:	O
see	O
text	O
]	O
.	O

Molecular	O
and	O
cellular	O
issues	O
of	O
KMT2A	B-Gene
variants	B-Var
involved	B-Reg
in	I-Reg
Wiedemann	B-Disease
-	I-Disease
Steiner	I-Disease
syndrome	I-Disease
.	O

Variants	B-Var
in	O
KMT2A	B-Gene
,	O
encoding	O
the	O
histone	O
methyltransferase	O
KMT2A	O
,	O
are	O
a	O
growing	O
cause	B-Reg
of	O
intellectual	B-Disease
disability	I-Disease
(	O
ID	O
)	O
.	O

Up	O
to	O
now	O
,	O
the	O
majority	O
of	O
KMT2A	B-Gene
variants	B-Var
are	O
non	B-Var
-	I-Var
sense	I-Var
and	O
frameshift	B-Var
variants	O
causing	B-Reg
a	O
typical	O
form	O
of	O
Wiedemann	B-Disease
-	I-Disease
Steiner	I-Disease
syndrome	I-Disease
.	O

We	O
studied	O
KMT2A	O
gene	O
in	O
a	O
cohort	O
of	O
200	O
patients	O
with	O
unexplained	O
syndromic	O
and	O
non	O
-	O
syndromic	O
ID	O
and	O
identified	O
four	O
novel	O
variants	O
,	O
one	O
splice	O
and	O
three	O
missense	O
variants	O
,	O
possibly	O
deleterious	O
.	O

We	O
used	O
primary	O
cells	O
from	O
the	O
patients	O
and	O
molecular	O
approaches	O
to	O
determine	O
the	O
deleterious	O
effects	B-Reg
of	O
those	O
variants	B-Var
on	O
KMT2A	B-Gene
expression	B-MPA
and	O
function	B-MPA
.	O

For	O
the	O
putative	O
splice	O
variant	O
c.11322	B-Var
-	I-Var
1G	I-Var
>	I-Var
A	I-Var
,	O
we	O
showed	O
that	O
it	O
led	O
to	O
only	O
one	O
nucleotide	O
deletion	O
and	O
loss	B-NegReg
of	O
the	O
C	B-MPA
-	I-MPA
terminal	I-MPA
part	I-MPA
of	I-MPA
the	I-MPA
protein	I-MPA
.	O

For	O
two	O
studied	O
KMT2A	B-Gene
missense	O
variants	O
,	O
c.3460C	B-Var
>	I-Var
T	I-Var
(	O
p.(Arg1154Trp	O
)	O
)	O
and	O
c.8558T	B-Var
>	I-Var
G	I-Var
(	O
p.(Met2853Arg	O
)	O
)	O
,	O
located	O
at	O
the	O
cysteine	O
-	O
rich	O
CXXC	O
domain	O
and	O
the	O
transactivation	O
domain	O
of	O
the	O
protein	O
,	O
respectively	O
,	O
we	O
found	O
altered	B-Reg
KMT2A	O
target	O
genes	O
expression	B-MPA
in	O
patient	O
's	O
fibroblasts	O
compared	O
to	O
controls	O
.	O

Furthermore	O
,	O
we	O
found	O
a	O
disturbed	B-Reg
subcellular	B-MPA
distribution	I-MPA
of	O
KMT2A	B-Gene
for	O
the	O
c.3460C	B-Var
>	I-Var
T	I-Var
mutant	O
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrated	O
the	O
deleterious	O
impact	O
of	O
the	O
splice	O
variant	O
and	O
of	O
the	O
missense	O
variants	O
located	O
at	O
two	O
different	O
functional	O
domains	O
and	O
suggested	O
reduction	O
of	O
KMT2A	O
function	O
as	O
the	O
disease	O
-	O
causing	O
mechanism	O
.	O

First	O
Report	O
of	O
Prenatal	O
Ascertainment	O
of	O
a	O
Fetus	O
With	O
Homozygous	O
Loss	O
of	O
the	O
SOX10	O
Gene	O
and	O
Phenotypic	O
Correlation	O
by	O
Autopsy	O
Examination	O
.	O

The	O
SOX10	O
gene	O
plays	O
a	O
vital	O
role	O
in	O
neural	O
crest	O
cell	O
development	O
and	O
migration	O
.	O

Abnormalities	B-Var
in	O
SOX10	B-Gene
are	O
associated	B-Reg
with	O
Waardenburg	B-Disease
syndrome	I-Disease
Types	B-Disease
II	I-Disease
and	O
IV	B-Disease
,	O
and	O
these	O
patients	O
have	O
recognizable	O
clinical	O
features	O
.	O

This	O
case	O
report	O
highlights	O
the	O
first	O
ever	O
reported	O
homozygous	O
loss	O
of	O
function	O
of	O
the	O
SOX10	O
gene	O
in	O
a	O
human	O
.	O

This	O
deletion	O
is	O
correlated	O
using	O
family	O
history	O
,	O
prenatal	O
ultrasound	O
,	O
microarray	O
analysis	O
of	O
amniotic	O
fluid	O
,	O
and	O
ultimately	O
,	O
a	O
medical	O
autopsy	O
examination	O
to	O
further	O
elucidate	O
phenotypic	O
effects	O
of	O
this	O
genetic	O
variation	O
.	O

Incorporating	O
the	O
use	O
of	O
molecular	O
pathology	O
into	O
the	O
autopsy	O
examination	O
of	O
fetuses	O
with	O
suspected	O
congenital	O
anomalies	O
is	O
vital	O
for	O
appropriate	O
family	O
counseling	O
,	O
and	O
with	O
the	O
ability	O
to	O
use	O
formalin	O
-	O
fixed	O
and	O
paraffin	O
-	O
embedded	O
tissues	O
,	O
has	O
become	O
a	O
practical	O
approach	O
in	O
autopsy	O
pathology	O
.	O

Ciliopathy	O
-	O
associated	O
mutations	B-Var
of	O
IFT122	B-Gene
impair	B-NegReg
ciliary	B-Protein
protein	I-Protein
trafficking	B-MPA
but	O
not	O
ciliogenesis	O
.	O

The	O
intraflagellar	O
transport	O
(	O
IFT	O
)	O
machinery	O
containing	O
the	O
IFT	O
-	O
A	O
and	O
IFT	O
-	O
B	O
complexes	O
mediates	O
ciliary	O
protein	O
trafficking	O
.	O

Mutations	B-Var
in	O
the	O
genes	O
encoding	O
the	O
six	O
subunits	O
of	O
the	O
IFT	O
-	O
A	O
complex	O
(	B-Gene
IFT43	I-Gene
,	O
IFT121	B-Gene
,	O
IFT122	B-Gene
,	O
IFT139	B-Gene
,	O
IFT140	B-Gene
,	O
and	O
IFT144	B-Gene
)	I-Gene
are	O
known	O
to	O
cause	B-Reg
skeletal	O
ciliopathies	O
,	O
including	O
cranioectodermal	B-Disease
dysplasia	I-Disease
(	O
CED	O
)	O
.	O

As	O
the	O
IFT122	O
subunit	O
connects	O
the	O
core	O
and	O
peripheral	O
subcomplexes	O
of	O
the	O
IFT	O
-	O
A	O
complex	O
,	O
it	O
is	O
expected	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
complex	O
.	O

Indeed	O
,	O
we	O
here	O
showed	O
that	O
knockout	O
(	O
KO	O
)	O
of	O
the	O
IFT122	O
gene	O
in	O
hTERT	O
-	O
RPE1	O
cells	O
using	O
the	O
CRISPR	O
/	O
Cas9	O
system	O
led	O
to	O
a	O
severe	O
ciliogenesis	O
defect	O
,	O
whereas	O
KO	O
of	O
other	O
IFT	O
-	O
A	O
genes	O
had	O
minor	O
effects	O
on	O
ciliogenesis	O
but	O
impaired	O
ciliary	O
protein	O
trafficking	O
.	O

Exogenous	O
expression	O
of	O
not	O
only	O
wild	O
-	O
type	O
IFT122	O
but	O
also	O
its	O
CED	O
-	O
associated	O
missense	O
mutants	O
,	O
which	O
fail	O
to	O
interact	O
with	O
other	O
IFT	O
-	O
A	O
subunits	O
,	O
rescued	O
the	O
ciliogenesis	O
defect	O
of	O
IFT122-KO	O
cells	O
.	O

However	O
,	O
IFT122-KO	O
cells	O
expressing	O
CED	O
-	O
type	O
IFT122	B-Gene
mutants	B-Var
showed	O
defects	B-NegReg
in	O
ciliary	B-Protein
protein	I-Protein
trafficking	B-MPA
,	O
such	O
as	O
ciliary	O
entry	O
of	O
Smoothened	O
in	O
response	O
to	O
Hedgehog	O
signaling	O
activation	O
.	O

The	O
trafficking	O
defects	O
partially	O
resembled	O
those	O
observed	O
in	O
IFT144-KO	O
cells	O
,	O
which	O
demonstrate	O
failed	O
assembly	O
of	O
the	O
functional	O
IFT	O
-	O
A	O
complex	O
at	O
the	O
base	O
of	O
cilia	O
.	O

These	O
observations	O
make	O
it	O
likely	O
that	O
,	O
although	O
IFT122	O
is	O
essential	O
for	O
ciliogenesis	O
,	O
CED	O
-	O
type	O
missense	O
mutations	O
underlie	O
a	O
skeletal	O
ciliopathy	O
phenotype	O
by	O
perturbing	O
ciliary	O
protein	O
trafficking	O
with	O
minor	O
effects	O
on	O
ciliogenesis	O
per	O
se	O
.	O

A	O
novel	O
NR2F2	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	B-Var
predisposes	O
to	O
congenital	B-Disease
heart	I-Disease
defect	I-Disease
.	O

Congenital	O
heart	O
defect	O
(	O
CHD	O
)	O
is	O
the	O
most	O
common	O
type	O
of	O
birth	O
defect	O
in	O
humans	O
and	O
a	O
leading	O
cause	O
of	O
infant	O
morbidity	O
and	O
mortality	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
genetic	O
defects	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
pathogenesis	O
of	O
CHD	O
.	O

However	O
,	O
the	O
genetic	O
basis	O
of	O
CHD	O
remains	O
poorly	O
understood	O
due	O
to	O
substantial	O
genetic	O
heterogeneity	O
.	O

In	O
this	O
study	O
,	O
the	O
coding	O
exons	O
and	O
splicing	O
boundaries	O
of	O
the	O
NR2F2	O
gene	O
,	O
which	O
encodes	O
a	O
pleiotropic	O
transcription	O
factor	O
required	O
for	O
normal	O
cardiovascular	O
development	O
,	O
were	O
sequenced	O
in	O
168	O
unrelated	O
patients	O
with	O
CHD	O
,	O
and	O
a	O
novel	O
mutation	O
(	O
c.247	O
G	O
>	O
T	O
,	O
equivalent	O
to	O
p	O
.	O
G83X	O
)	O
was	O
detected	O
in	O
a	O
patient	O
with	O
double	O
outlet	O
right	O
ventricle	O
as	O
well	O
as	O
ventricular	O
septal	O
defect	O
.	O

Genetic	O
scanning	O
of	O
the	O
mutation	O
carrier	O
's	O
relatives	O
available	O
showed	O
that	O
the	O
mutation	O
was	O
present	O
in	O
all	O
affected	O
family	O
members	O
but	O
absent	O
in	O
unaffected	O
family	O
members	O
.	O

Analysis	O
of	O
the	O
index	O
patient	O
's	O
pedigree	O
displayed	O
that	O
the	O
mutation	O
co	O
-	O
segregated	O
with	O
CHD	O
,	O
which	O
was	O
transmitted	O
as	O
an	O
autosomal	O
dominant	O
trait	O
with	O
complete	O
penetrance	O
.	O

The	O
nonsense	O
mutation	O
was	O
absent	O
in	O
230	O
unrelated	O
,	O
ethnically	O
-	O
matched	O
healthy	O
individuals	O
used	O
as	O
controls	O
.	O

Functional	O
deciphers	O
by	O
using	O
a	O
dual	O
-	O
luciferase	O
reporter	O
assay	O
system	O
revealed	O
that	O
the	O
mutant	B-Var
NR2F2	B-Gene
protein	O
had	O
no	B-NegReg
transcriptional	B-MPA
activity	I-MPA
as	O
compared	O
with	O
its	O
wild	O
-	O
type	O
counterpart	O
.	O

Furthermore	O
,	O
the	O
mutation	B-Var
abrogated	B-NegReg
the	O
synergistic	B-MPA
transcriptional	I-MPA
activation	I-MPA
between	O
NR2F2	B-Gene
and	O
GATA4	B-Gene
,	O
another	O
core	O
cardiac	O
transcription	O
factor	O
associated	O
with	O
CHD	O
.	O

This	O
study	O
firstly	O
associates	O
NR2F2	O
loss	O
-	O
of	O
-	O
function	O
mutation	O
with	O
an	O
increased	O
susceptibility	O
to	O
double	O
outlet	O
right	O
ventricle	O
in	O
humans	O
,	O
which	O
provides	O
further	O
significant	O
insight	O
into	O
the	O
molecular	O
mechanisms	O
underpinning	O
CHD	O
,	O
suggesting	O
potential	O
implications	O
for	O
genetic	O
counseling	O
of	O
CHD	O
families	O
and	O
personalized	O
treatment	O
of	O
CHD	O
patients	O
.	O

Potential	O
pathogenic	O
mechanisms	O
underlying	O
Fragile	O
X	O
Tremor	O
Ataxia	O
Syndrome	O
:	O
RAN	O
translation	O
and/or	O
RNA	O
gain	O
-	O
of	O
-	O
function	O
?	O
Fragile	B-Disease
X	I-Disease
-	I-Disease
associated	I-Disease
tremor	I-Disease
/	I-Disease
ataxia	I-Disease
syndrome	I-Disease
(	O
FXTAS	O
)	O
is	O
an	O
inherited	O
neurodegenerative	O
disease	O
caused	B-Reg
by	I-Reg
an	O
expansion	B-Var
of	I-Var
55	I-Var
-	I-Var
200	I-Var
CGG	I-Var
repeats	I-Var
located	O
in	O
the	O
FMR1	B-Gene
gene	O
.	O

The	O
main	O
clinical	O
and	O
neuropathological	O
features	O
of	O
FXTAS	O
are	O
progressive	O
intention	O
tremor	O
and	O
gait	O
ataxia	O
associated	O
with	O
brain	O
atrophy	O
,	O
neuronal	O
cell	O
loss	O
and	O
presence	O
of	O
ubiquitin	O
-	O
positive	O
intranuclear	O
inclusions	O
in	O
both	O
neurons	O
and	O
astrocytes	O
.	O

At	O
the	O
molecular	O
level	O
,	O
FXTAS	O
is	O
characterized	O
by	O
increased	O
expression	O
of	O
FMR1	O
sense	O
and	O
antisense	O
RNA	O
containing	O
expanded	O
CGG	O
or	O
GGC	O
repeats	O
,	O
respectively	O
.	O

Here	O
,	O
we	O
discuss	O
the	O
putative	O
molecular	O
mechanisms	O
underlying	O
FXTAS	O
and	O
notably	O
recent	O
reports	O
that	O
expanded	O
CGG	O
and	O
GGC	O
repeats	O
may	O
be	O
pathogenic	O
through	O
RAN	O
translation	O
into	O
toxic	O
proteins	O
.	O

Deleterious	O
variants	B-Var
in	O
DCHS1	B-Gene
are	O
prevalent	B-Reg
in	O
sporadic	O
cases	O
of	O
mitral	B-Disease
valve	I-Disease
prolapse	I-Disease
.	O

BACKGROUND	O
:	O
A	O
recent	O
study	O
identified	O
DCHS1	O
as	O
a	O
causal	O
gene	O
for	O
mitral	O
valve	O
prolapse	O
.	O

The	O
goal	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
presence	O
and	O
frequency	O
of	O
known	O
and	O
novel	O
variants	O
in	O
this	O
gene	O
in	O
100	O
asymptomatic	O
patients	O
with	O
moderate	O
to	O
severe	O
organic	O
mitral	O
regurgitation	O
.	O

METHODS	O
:	O
DNA	O
sequencing	O
assays	O
were	O
developed	O
for	O
two	O
previously	O
identified	O
functional	O
missense	O
variants	O
,	O
namely	O
p	B-Var
.	I-Var
R2330C	I-Var
and	O
p	B-Var
.	I-Var
R2513H	I-Var
,	O
and	O
all	O
21	O
exons	O
of	O
DCHS1	B-Gene
.	O

Pathogenicity	O
of	O
variants	O
was	O
evaluated	O
in	O
silico	O
.	O

RESULTS	O
:	O
p	O
.	O
R2330C	O
and	O
p	O
.	O
R2513H	O
were	O
not	O
identified	O
in	O
this	O
cohort	O
.	O

Sequencing	O
all	O
coding	O
regions	O
revealed	O
eight	O
missense	O
variants	O
including	O
six	O
considered	O
deleterious	O
.	O

This	O
includes	O
one	O
novel	O
variant	O
(	O
p	O
.	O
A2464P	O
)	O
and	O
two	O
rare	O
variants	O
(	O
p	O
.	O
R2770Q	O
and	O
p	O
.	O
R2462Q	O
)	O
.	O

These	O
variants	O
are	O
predicted	O
to	O
be	O
deleterious	O
with	O
combined	O
annotation	O
-	O
dependent	O
depletion	O
(	O
CADD	O
)	O
scores	O
greater	O
than	O
25	O
,	O
which	O
are	O
in	O
the	O
same	O
range	O
as	O
p	O
.	O
R2330C	O
(	O
CADD	O
=	O
28.0	O
)	O
and	O
p	O
.	O
R2513H	O
(	O
CADD	O
=	O
24.3	O
)	O
.	O

More	O
globally	O
,	O
24	O
of	O
100	O
cases	O
were	O
carriers	O
of	O
at	O
least	O
one	O
in	O
silico	O
-	O
predicted	O
deleterious	O
missense	O
variant	O
in	O
DCHS1	O
,	O
suggesting	O
that	O
this	O
single	O
gene	O
may	O
account	O
for	O
a	O
substantial	O
portion	O
of	O
cases	O
.	O

CONCLUSION	O
:	O
This	O
study	O
reveals	O
an	O
important	O
contribution	O
of	O
germline	O
variants	O
in	O
DCHS1	O
in	O
unrelated	O
patients	O
with	O
mitral	O
valve	O
prolapse	O
and	O
supports	O
genetic	O
testing	O
of	O
this	O
gene	O
to	O
screen	O
individuals	O
at	O
risk	O
.	O

Primary	B-Disease
Ovarian	I-Disease
Insufficiency	I-Disease
and	O
Azoospermia	B-Disease
in	O
Carriers	B-Reg
of	O
a	O
Homozygous	O
PSMC3IP	B-Gene
Stop	O
Gain	O
Mutation	B-Var
.	O

Context	O
:	O
The	O
etiology	O
of	O
primary	O
ovarian	O
insufficiency	O
(	O
POI	O
)	O
remains	O
unknown	O
in	O
most	O
cases	O
.	O

Objective	O
:	O
We	O
sought	O
to	O
identify	O
the	O
genes	O
causing	O
POI	O
.	O

Design	O
:	O
The	O
study	O
was	O
a	O
familial	O
genetic	O
study	O
.	O

Setting	O
:	O
The	O
study	O
was	O
performed	O
at	O
two	O
academic	O
institutions	O
.	O

Patients	O
:	O
We	O
identified	O
a	O
consanguineous	O
Yemeni	O
family	O
in	O
which	O
four	O
daughters	O
had	O
POI	O
.	O

A	O
brother	O
had	O
azoospermia	O
.	O

Intervention	O
:	O
DNA	O
was	O
subjected	O
to	O
whole	O
genome	O
sequencing	O
.	O

Shared	O
regions	O
of	O
homozygosity	O
were	O
identified	O
using	O
Truploidy	O
and	O
prioritized	O
using	O
the	O
Variant	O
Annotation	O
,	O
Analysis	O
,	O
and	O
Search	O
Tool	O
with	O
control	O
data	O
from	O
387	O
healthy	O
subjects	O
.	O

Imaging	O
and	O
quantification	O
of	O
protein	O
localization	O
and	O
mitochondrial	O
function	O
were	O
examined	O
in	O
cell	O
lines	O
.	O

Main	O
Outcome	O
:	O
Homozygous	O
recessive	O
gene	O
variants	O
shared	O
by	O
the	O
four	O
sisters	O
.	O

Results	O
:	O
The	O
sisters	O
shared	O
a	O
homozygous	O
stop	O
gain	O
mutation	O
in	O
exon	O
6	O
of	O
PSMC3IP	O
(	O
c.489	O
C	O
>	O
G	O
,	O
p	O
.	O
Tyr163Ter	O
)	O
and	O
a	O
missense	O
variant	O
in	O
exon	O
1	O
of	O
CLPP	O
(	B-Var
c.100C	I-Var
>	I-Var
T	I-Var
,	O
p	O
.	O
Pro34Ser	O
)	O
.	O

The	O
affected	O
brother	O
also	O
carried	O
the	O
homozygous	O
PSMC3IP	O
mutation	O
.	O

Functional	O
studies	O
demonstrated	B-Reg
mitochondrial	B-CPA
fragmentation	I-CPA
in	O
cells	O
infected	O
with	O
the	O
CLPP	B-Gene
mutation	B-Var
.	O

However	O
,	O
no	O
abnormality	O
was	O
found	O
in	O
mitochondrial	O
targeting	O
or	O
respiration	O
.	O

Conclusions	O
:	O
The	O
PSMC3IP	O
mutation	O
provides	O
additional	O
evidence	O
that	O
mutations	O
in	O
meiotic	O
homologous	O
recombination	O
and	O
DNA	O
repair	O
genes	O
result	O
in	O
distinct	O
female	O
and	O
male	O
reproductive	O
phenotypes	O
,	O
including	O
delayed	O
puberty	O
and	O
primary	O
amenorrhea	O
caused	O
by	O
POI	O
(	O
XX	O
gonadal	O
dysgenesis	O
)	O
in	O
females	O
but	O
isolated	O
azoospermia	O
with	O
normal	O
pubertal	O
development	O
in	O
males	O
.	O

The	O
findings	O
also	O
suggest	O
that	O
the	O
N	O
-	O
terminal	O
missense	O
mutation	O
in	O
CLPP	O
does	O
not	O
cause	O
substantial	O
mitochondrial	O
dysfunction	O
or	O
contribute	O
to	O
ovarian	O
insufficiency	O
in	O
an	O
oligogenic	O
manner	O
.	O

HOP-1	O
Presenilin	O
Deficiency	O
Causes	O
a	O
Late	O
-	O
Onset	O
Notch	O
Signaling	O
Phenotype	O
That	O
Affects	O
Adult	O
Germline	O
Function	O
in	O
Caenorhabditis	O
elegans	O
.	O

Functionally	O
redundant	O
genes	O
present	O
a	O
puzzle	O
as	O
to	O
their	O
evolutionary	O
preservation	O
,	O
and	O
offer	O
an	O
interesting	O
opportunity	O
for	O
molecular	O
specialization	O
.	O

In	O
Caenorhabditis	O
elegans	O
,	O
either	O
one	O
of	O
two	O
presenilin	O
genes	O
(	O
sel-12	O
or	O
hop-1	O
)	O
facilitate	O
Notch	O
activation	O
,	O
providing	O
the	O
catalytic	O
subunit	O
for	O
the	O
γ	O
secretase	O
proteolytic	O
enzyme	O
complex	O
.	O

For	O
all	O
known	O
Notch	O
signaling	O
events	O
,	O
sel-12	O
can	O
mediate	O
Notch	O
activation	O
,	O
so	O
the	O
conservation	O
of	O
hop-1	O
remains	O
a	O
mystery	O
.	O

Here	O
,	O
we	O
uncover	O
a	O
novel	O
"	O
late	O
-	O
onset	O
"	O
germline	O
Notch	O
phenotype	O
in	O
which	O
HOP-1-deficient	O
worms	O
fail	O
to	O
maintain	O
proliferating	O
germline	O
stem	O
cells	O
during	O
adulthood	O
.	O

Either	O
SEL-12	O
or	O
HOP-1	O
presenilin	O
can	O
impart	O
sufficient	O
Notch	O
signaling	O
for	O
the	O
establishment	O
and	O
expansion	O
of	O
the	O
germline	O
,	O
but	O
maintenance	O
of	O
an	O
adult	O
stem	O
cell	O
pool	O
relies	O
exclusively	O
on	O
HOP-1-mediated	O
Notch	O
signaling	O
.	O

We	O
also	O
show	O
that	O
HOP-1	O
is	O
necessary	O
for	O
maximum	O
fecundity	O
and	O
reproductive	O
span	O
.	O

The	O
low	B-NegReg
-	I-NegReg
fecundity	I-NegReg
phenotype	O
of	O
hop-1	B-Gene
mutants	B-Var
can	O
be	O
phenocopied	O
by	O
switching	B-NegReg
off	I-NegReg
glp-1	B-MPA
/	I-MPA
Notch	I-MPA
function	I-MPA
during	O
the	O
last	O
stage	O
of	O
larval	O
development	O
.	O

We	O
propose	O
that	O
at	O
the	O
end	O
of	O
larval	O
development	O
,	O
dual	O
presenilin	O
usage	O
switches	O
exclusively	O
to	O
HOP-1	O
,	O
perhaps	O
offering	O
opportunities	O
for	O
differential	O
regulation	O
of	O
the	O
germline	O
during	O
adulthood	O
.	O

Additional	O
defects	B-NegReg
in	O
oocyte	B-CPA
size	I-CPA
and	O
production	B-CPA
rate	O
in	O
hop-1	B-Gene
and	O
glp-1	B-Gene
mutants	B-Var
indicate	O
that	O
the	O
process	O
of	O
oogenesis	O
is	O
compromised	O
when	O
germline	O
Notch	O
signaling	O
is	O
switched	O
off	O
.	O

We	O
calculate	O
that	O
in	O
wild	O
-	O
type	O
adults	O
,	O
as	O
much	O
as	O
86	O
%	O
of	O
cells	O
derived	O
from	O
the	O
stem	O
cell	O
pool	O
function	O
to	O
support	O
oogenesis	O
.	O

This	O
work	O
suggests	O
that	O
an	O
important	O
role	O
for	O
Notch	O
signaling	O
in	O
the	O
adult	O
germline	O
is	O
to	O
furnish	O
a	O
large	O
and	O
continuous	O
supply	O
of	O
nurse	O
cells	O
to	O
support	O
the	O
efficiency	O
of	O
oogenesis	O
.	O

Mild	O
Telomere	O
Dysfunction	O
as	O
a	O
Force	O
for	O
Altering	O
the	O
Adaptive	O
Potential	O
of	O
Subtelomeric	O
Genes	O
.	O

Subtelomeric	O
regions	O
have	O
several	O
unusual	O
characteristics	O
,	O
including	O
complex	O
repetitive	O
structures	O
,	O
increased	O
rates	O
of	O
evolution	O
,	O
and	O
enrichment	O
for	O
genes	O
involved	O
in	O
niche	O
adaptation	O
.	O

The	O
adaptive	O
telomere	O
failure	O
hypothesis	O
suggests	O
that	O
certain	O
environmental	O
stresses	O
can	O
induce	O
a	O
low	O
level	O
of	O
telomere	O
failure	O
,	O
potentially	O
leading	O
to	O
elevated	O
subtelomeric	O
recombination	O
that	O
could	O
result	O
in	O
adaptive	O
mutational	O
changes	O
within	O
subtelomeric	O
genes	O
.	O

Here	O
,	O
we	O
tested	O
a	O
key	O
prediction	O
of	O
the	O
adaptive	O
telomere	O
failure	O
hypothesis	O
-	O
that	O
telomere	O
dysfunction	O
mild	O
enough	O
to	O
have	O
little	O
or	O
no	O
overall	O
effect	O
on	O
cell	O
fitness	O
could	O
still	O
lead	O
to	O
substantial	O
increases	O
in	O
the	O
mutation	O
rates	O
of	O
subtelomeric	O
genes	O
.	O

Our	O
results	O
show	O
that	O
a	O
mutant	O
of	O
Kluyveromyces	O
lactis	O
with	O
stably	O
short	O
telomeres	O
produced	O
a	O
large	O
increase	O
in	O
the	O
frequency	O
of	O
mutations	O
affecting	O
the	O
native	O
subtelomeric	O
β	O
-	O
galactosidase	O
(	O
LAC4	O
)	O
gene	O
.	O

All	O
lac4	B-Gene
mutants	B-Var
examined	O
from	O
strains	O
with	O
severe	O
telomere	O
dysfunction	O
underwent	B-Reg
terminal	B-MPA
deletion	I-MPA
/	I-MPA
duplication	I-MPA
events	O
consistent	O
with	O
being	O
due	O
to	O
break	O
-	O
induced	O
replication	O
.	O

In	O
contrast	O
,	O
although	O
cells	O
with	O
mild	O
telomere	O
dysfunction	O
also	O
exhibited	O
similar	O
terminal	O
deletion	O
and	O
duplication	O
events	O
,	O
up	O
to	O
50	O
%	O
of	O
lac4	B-Gene
mutants	B-Var
from	O
this	O
background	O
unexpectedly	O
contained	B-Reg
base	B-MPA
changes	I-MPA
within	O
the	O
LAC4	O
coding	O
region	O
.	O

This	O
mutational	O
bias	O
for	O
producing	O
base	O
changes	O
demonstrates	O
that	O
mild	O
telomere	O
dysfunction	O
can	O
be	O
well	O
suited	O
as	O
a	O
force	O
for	O
altering	O
the	O
adaptive	O
potential	O
of	O
subtelomeric	O
genes	O
.	O

Association	O
of	O
the	O
AADAC	O
gene	O
and	O
Tourette	O
syndrome	O
in	O
a	O
Han	O
Chinese	O
cohort	O
.	O

Tourette	B-Disease
syndrome	I-Disease
(	O
TS	O
)	O
is	O
a	O
complex	O
neuropsychiatric	O
disorder	O
with	O
chronic	O
motor	O
and	O
vocal	O
tics	O
.	O

Though	O
the	O
etiology	O
is	O
elusive	O
,	O
strong	O
evidence	O
for	O
a	O
genetic	O
contribution	O
to	O
TS	O
has	O
been	O
established	O
.	O

To	O
date	O
,	O
various	O
chromosomal	O
or	O
genetic	O
alterations	O
have	O
been	O
implicated	O
in	O
its	O
pathogenesis	O
.	O

Recently	O
,	O
the	O
deletion	O
in	O
the	O
arylacetamide	O
deacetylase	O
gene	O
(	O
AADAC	O
)	O
was	O
reported	O
to	O
be	O
associated	O
with	O
TS	O
.	O

To	O
investigate	O
the	O
association	O
between	O
the	O
AADAC	O
gene	O
variants	O
and	O
TS	O
,	O
we	O
conducted	O
genetic	O
analysis	O
of	O
the	O
AADAC	O
gene	O
in	O
200	O
Han	O
Chinese	O
patients	O
and	O
300	O
ethnicity	O
-	O
matched	O
normal	O
controls	O
.	O

Two	O
variants	O
,	O
including	O
a	O
heterozygous	O
splice	O
-	O
site	O
variant	O
,	O
c.361	O
+	O
1	O
G	O
>	O
A	O
(	O
rs762169706	O
)	O
,	O
and	O
a	O
missense	O
variant	O
,	O
c.744A	O
>	O
T	O
(	O
p	O
.	O
R248S	O
,	O
rs186388618	O
)	O
,	O
were	O
identified	O
in	O
two	O
unrelated	O
patients	O
.	O

The	O
c.361	B-Var
+	I-Var
1	I-Var
G	I-Var
>	I-Var
A	I-Var
variant	O
,	O
absent	O
in	O
300	O
ethnicity	O
-	O
matched	O
controls	O
,	O
led	B-Reg
to	I-Reg
the	O
deletion	B-Var
of	O
exon	O
2	O
in	O
AADAC	O
mRNA	O
,	O
probably	O
associated	B-Reg
with	I-Reg
development	O
of	O
TS	B-Disease
.	O

The	O
c.744A	O
>	O
T	O
variant	O
,	O
predicted	O
to	O
be	O
damaging	O
,	O
was	O
identified	O
in	O
two	O
normal	O
controls	O
.	O

The	O
findings	O
indicate	O
that	O
the	O
AADAC	B-Gene
gene	O
c.361	B-Var
+	I-Var
1	I-Var
G	I-Var
>	I-Var
A	I-Var
variant	O
may	O
be	O
a	O
potential	O
candidate	B-Reg
factor	I-Reg
for	O
TS	B-Disease
development	O
,	O
though	O
further	O
investigations	O
are	O
warranted	O
.	O

Patients	O
with	O
a	O
Kabuki	O
syndrome	O
phenotype	O
demonstrate	O
DNA	O
methylation	O
abnormalities	O
.	O

Kabuki	B-Disease
syndrome	I-Disease
is	O
a	O
monogenic	O
disorder	O
caused	O
by	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
variants	B-Var
in	O
either	O
of	O
two	O
genes	O
encoding	O
histone	O
-	O
modifying	O
enzymes	O
.	O

We	O
performed	O
targeted	O
sequencing	O
in	O
a	O
cohort	O
of	O
27	O
probands	O
with	O
a	O
clinical	O
diagnosis	O
of	O
Kabuki	O
syndrome	O
.	O

Of	O
these	O
,	O
12	O
had	O
causative	O
variants	O
in	O
the	O
two	O
known	O
Kabuki	O
syndrome	O
genes	O
.	O

In	O
2	O
,	O
we	O
identified	O
presumptive	O
loss	O
of	O
function	O
de	O
novo	O
variants	B-Var
in	O
KMT2A	B-Gene
(	O
missense	O
and	O
splice	O
site	O
variants	O
)	O
,	O
a	O
gene	O
that	O
encodes	O
another	O
histone	O
modifying	O
enzyme	O
previously	O
exclusively	O
associated	B-Reg
with	O
Wiedermann	B-Disease
-	I-Disease
Steiner	I-Disease
syndrome	I-Disease
.	O

Although	O
Kabuki	O
syndrome	O
is	O
a	O
disorder	O
of	O
histone	O
modification	O
,	O
we	O
also	O
find	O
alterations	O
in	O
DNA	O
methylation	O
among	O
individuals	O
with	O
a	O
Kabuki	O
syndrome	O
diagnosis	O
relative	O
to	O
matched	O
normal	O
controls	O
,	O
regardless	O
of	O
whether	O
they	O
carry	O
a	O
variant	O
in	O
KMT2A	O
or	O
KMT2D	O
or	O
not	O
.	O

Furthermore	O
,	O
we	O
observed	O
characteristic	O
global	O
abnormalities	O
of	O
DNA	O
methylation	O
that	O
distinguished	O
patients	O
with	O
a	O
loss	O
of	O
function	O
variant	O
in	O
KMT2D	O
or	O
missense	O
or	O
splice	O
site	O
variants	O
in	O
either	O
KMT2D	O
or	O
KMT2A	O
from	O
normal	O
controls	O
.	O

Our	O
results	O
provide	O
new	O
insights	O
into	O
the	O
relationship	O
of	O
genotype	O
to	O
epigenotype	O
and	O
phenotype	O
and	O
indicate	O
cross	O
-	O
talk	O
between	O
histone	O
and	O
DNA	O
methylation	O
machineries	O
exposed	O
by	O
inborn	O
errors	O
of	O
the	O
epigenetic	O
apparatus	O
.	O

A	O
novel	O
homozygous	O
ARL13B	B-Gene
variant	B-Var
in	O
patients	O
with	O
Joubert	O
syndrome	O
impairs	B-NegReg
its	O
guanine	B-MPA
nucleotide	I-MPA
-	I-MPA
exchange	I-MPA
factor	I-MPA
activity	I-MPA
.	O

ARL13B	O
encodes	O
for	O
the	O
ADP	O
-	O
ribosylation	O
factor	O
-	O
like	O
13B	O
GTPase	O
,	O
which	O
is	O
required	O
for	O
normal	O
cilia	O
structure	O
and	O
Sonic	O
hedgehog	O
(	O
Shh	O
)	O
signaling	O
.	O

Disruptions	O
in	O
cilia	O
structure	O
or	O
function	O
lead	O
to	O
a	O
class	O
of	O
human	O
disorders	O
called	O
ciliopathies	O
.	O

Joubert	O
syndrome	O
is	O
characterized	O
by	O
a	O
wide	O
spectrum	O
of	O
symptoms	O
,	O
including	O
a	O
variable	O
degree	O
of	O
intellectual	O
disability	O
,	O
ataxia	O
,	O
and	O
ocular	O
abnormalities	O
.	O

Here	O
we	O
report	O
a	O
novel	O
homozygous	O
missense	O
variant	O
c.[223G	O
>	O
A	O
]	O
(	O
p.(Gly75Arg	O
)	O
in	O
the	O
ARL13B	O
gene	O
,	O
which	O
was	O
identified	O
by	O
whole	O
-	O
exome	O
sequencing	O
of	O
a	O
trio	O
from	O
a	O
consanguineous	O
family	O
with	O
multiple	O
-	O
affected	O
individuals	O
suffering	O
from	O
intellectual	O
disability	O
,	O
ataxia	O
,	O
ocular	O
defects	O
,	O
and	O
epilepsy	O
.	O

The	O
same	O
variant	O
was	O
also	O
identified	O
in	O
a	O
second	O
family	O
.	O

We	O
saw	O
a	O
striking	O
difference	O
in	O
the	O
severity	O
of	O
ataxia	O
between	O
affected	O
male	O
and	O
female	O
individuals	O
in	O
both	O
families	O
.	O

Both	O
ARL13B	O
and	O
ARL13B	O
-	O
c.[223G	O
>	O
A	O
]	O
(	O
p.(Gly75Arg	O
)	O
expression	O
rescued	O
the	O
cilia	O
length	O
and	O
Shh	O
defects	O
displayed	O
by	O
Arl13b	O
hennin	O
(	O
null	O
)	O
cells	O
,	O
indicating	O
that	O
the	O
variant	O
did	O
not	O
disrupt	O
either	O
ARL13B	O
function	O
.	O

In	O
contrast	O
,	O
ARL13B	B-Gene
-	I-Gene
c.[223G	I-Gene
>	I-Gene
A	I-Gene
]	I-Gene
(	O
p.(Gly75Arg	O
)	O
displayed	O
a	O
marked	O
loss	B-NegReg
of	O
ARL3	B-MPA
guanine	I-MPA
nucleotide	I-MPA
-	I-MPA
exchange	I-MPA
factor	I-MPA
activity	I-MPA
,	O
with	O
retention	O
of	O
its	O
GTPase	O
activities	O
,	O
highlighting	O
the	O
correlation	O
between	O
its	O
loss	O
of	O
function	O
as	O
an	O
ARL3	O
guanine	O
nucleotide	O
-	O
exchange	O
factor	O
and	O
Joubert	B-Disease
syndrome	I-Disease
.	O

Cantu	O
syndrome	O
-	O
associated	O
SUR2	O
(	B-Gene
ABCC9	I-Gene
)	I-Gene
mutations	B-Var
in	O
distinct	O
structural	O
domains	O
result	O
in	O
KATP	B-MPA
channel	I-MPA
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
by	O
differential	O
mechanisms	O
.	O

The	O
complex	O
disorder	O
Cantu	B-Disease
syndrome	I-Disease
(	O
CS	O
)	O
arises	O
from	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutations	B-Var
in	O
either	O
KCNJ8	B-Gene
or	O
ABCC9	B-Gene
,	O
the	O
genes	O
encoding	O
the	O
Kir6.1	O
and	O
SUR2	O
subunits	O
of	O
ATP	O
-	O
sensitive	O
potassium	O
(	O
KATP	O
)	O
channels	O
,	O
respectively	O
.	O

Recent	O
reports	O
indicate	O
that	O
such	O
mutations	B-Var
can	O
increase	B-PosReg
channel	B-MPA
activity	I-MPA
by	O
multiple	O
molecular	O
mechanisms	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
the	O
mechanism	O
by	O
which	O
KATP	B-MPA
function	I-MPA
is	O
altered	B-Reg
by	O
several	O
substitutions	O
in	O
distinct	O
structural	O
domains	O
of	O
SUR2	B-Gene
:	I-Gene
D207E	B-Var
in	O
the	O
intracellular	O
L0-linker	O
and	O
Y985S	B-Var
,	O
G989E	B-Var
,	O
M1060I	B-Var
,	O
and	O
R1154Q	B-Var
/	I-Var
R1154W	I-Var
in	O
TMD2	O
.	O

We	O
engineered	O
substitutions	O
at	O
their	O
equivalent	O
positions	O
in	O
rat	O
SUR2A	O
(	O
D207E	O
,	O
Y981S	O
,	O
G985E	O
,	O
M1056I	O
,	O
and	O
R1150Q	O
/	O
R1150W	O
)	O
and	O
investigated	O
functional	O
consequences	O
using	O
macroscopic	O
rubidium	O
(	O
86Rb+	O
)	O
efflux	O
assays	O
and	O
patch	O
-	O
clamp	O
electrophysiology	O
.	O

Our	O
results	O
indicate	O
that	O
D207E	B-Var
increases	B-PosReg
KATP	B-MPA
channel	I-MPA
activity	I-MPA
by	O
increasing	B-PosReg
intrinsic	B-MPA
stability	I-MPA
of	I-MPA
the	I-MPA
open	I-MPA
state	I-MPA
,	O
whereas	O
the	O
cluster	O
of	O
Y981S	B-Var
/	I-Var
G985E	I-Var
/	I-Var
M1056I	I-Var
substitutions	O
,	O
as	O
well	O
as	O
R1150Q	B-Var
/	I-Var
R1150W	I-Var
,	O
augmented	B-PosReg
Mg	B-MPA
-	I-MPA
nucleotide	I-MPA
activation	I-MPA
.	O

We	O
also	O
tested	O
the	O
responses	O
of	O
these	O
channel	O
variants	O
to	O
inhibition	O
by	O
the	O
sulfonylurea	O
drug	O
glibenclamide	O
,	O
a	O
potential	O
pharmacotherapy	O
for	O
CS	O
.	O

None	O
of	O
the	O
D207E	O
,	O
Y981S	O
,	O
G985E	O
,	O
or	O
M1056I	O
substitutions	O
had	O
a	O
significant	O
effect	O
on	O
glibenclamide	O
sensitivity	O
.	O

However	O
,	O
Gln	O
and	O
Trp	O
substitution	O
at	O
Arg-1150	O
significantly	O
decreased	O
glibenclamide	O
potency	O
.	O

In	O
summary	O
,	O
these	O
results	O
provide	O
additional	O
confirmation	O
that	O
mutations	O
in	O
CS	O
-	O
associated	O
SUR2	O
mutations	O
result	O
in	O
KATP	O
gain	O
-	O
of	O
-	O
function	O
.	O

They	O
help	O
link	O
CS	O
genotypes	O
to	O
phenotypes	O
and	O
shed	O
light	O
on	O
the	O
underlying	O
molecular	O
mechanisms	O
,	O
including	O
consequences	O
for	O
inhibitory	O
drug	O
sensitivity	O
,	O
insights	O
that	O
may	O
inform	O
the	O
development	O
of	O
therapeutic	O
approaches	O
to	O
manage	O
CS	O
.	O

Arabidopsis	O
Phospholipase	O
C3	O
is	O
Involved	O
in	O
Lateral	O
Root	O
Initiation	O
and	O
ABA	O
Responses	O
in	O
Seed	O
Germination	O
and	O
Stomatal	O
Closure	O
.	O

Phospholipase	O
C	O
(	O
PLC	O
)	O
is	O
well	O
known	O
for	O
its	O
role	O
in	O
animal	O
signaling	O
,	O
where	O
it	O
generates	O
the	O
second	O
messengers	O
,	O
inositol	O
1,4,5-trisphosphate	O
(	O
IP3	O
)	O
and	O
diacylglycerol	O
(	O
DAG	O
)	O
,	O
by	O
hydrolyzing	O
the	O
minor	O
phospholipid	O
,	O
phosphatidylinositol	O
4,5-bisphosphate	O
(	O
PIP2	O
)	O
,	O
upon	O
receptor	O
stimulation	O
.	O

In	O
plants	O
,	O
PLC	O
's	O
role	O
is	O
still	O
unclear	O
,	O
especially	O
because	O
the	O
primary	O
targets	O
of	O
both	O
second	O
messengers	O
are	O
lacking	O
,	O
i.e.	O
the	O
ligand	O
-	O
gated	O
Ca2	O
+	O
channel	O
and	O
protein	O
kinase	O
C	O
,	O
and	O
because	O
PIP2	O
levels	O
are	O
extremely	O
low	O
.	O

Nonetheless	O
,	O
the	O
Arabidopsis	O
genome	O
encodes	O
nine	O
PLCs	O
.	O

We	O
used	O
a	O
reversed	O
-	O
genetic	O
approach	O
to	O
explore	O
PLC	O
's	O
function	O
in	O
Arabidopsis	O
,	O
and	O
report	O
here	O
that	O
PLC3	B-Gene
is	O
required	O
for	O
proper	O
root	O
development	O
,	O
seed	O
germination	O
and	O
stomatal	O
opening	O
.	O

Two	O
independent	O
knock	B-Var
-	I-Var
down	I-Var
mutants	I-Var
,	O
plc3	O
-	O
2	O
and	O
plc3	O
-	O
3	O
,	O
were	O
found	O
to	O
exhibit	O
reduced	B-NegReg
lateral	B-CPA
root	I-CPA
densities	I-CPA
by	O
10	O
-	O
20	O
%	O
.	O

Mutant	B-Var
seeds	O
germinated	B-CPA
more	O
slowly	B-NegReg
but	O
were	O
less	O
sensitive	O
to	O
ABA	O
to	O
prevent	O
germination	O
.	O

Guard	O
cells	O
of	O
plc3	O
were	O
also	O
compromised	O
in	O
ABA	O
-	O
dependent	O
stomatal	O
closure	O
.	O

Promoter	O
-	O
β	O
-	O
glucuronidase	O
(	O
GUS	O
)	O
analyses	O
confirmed	O
PLC3	O
expression	O
in	O
guard	O
cells	O
and	O
germinating	O
seeds	O
,	O
and	O
revealed	O
that	O
the	O
majority	O
is	O
expressed	O
in	O
vascular	O
tissue	O
,	O
most	O
probably	O
phloem	O
companion	O
cells	O
,	O
in	O
roots	O
,	O
leaves	O
and	O
flowers	O
.	O

In	O
vivo	O
32Pi	O
labeling	O
revealed	O
that	O
ABA	O
stimulated	O
the	O
formation	B-MPA
of	I-MPA
PIP2	I-MPA
in	O
germinating	O
seeds	O
and	O
guard	O
cell	O
-	O
enriched	O
leaf	O
peels	O
,	O
which	O
was	O
significantly	O
reduced	B-NegReg
in	O
plc3	B-Gene
mutants	B-Var
.	O

Overexpression	O
of	O
PLC3	O
had	O
no	O
effect	O
on	O
root	O
system	O
architecture	O
or	O
seed	O
germination	O
,	O
but	O
increased	O
the	O
plant	O
's	O
tolerance	O
to	O
drought	O
.	O

Our	O
results	O
provide	O
genetic	O
evidence	O
for	O
PLC	O
's	O
involvement	O
in	O
plant	O
development	O
and	O
ABA	O
signaling	O
,	O
and	O
confirm	O
earlier	O
observations	O
that	O
overexpression	O
increases	O
drought	O
tolerance	O
.	O

Potential	O
molecular	O
mechanisms	O
for	O
the	O
above	O
observations	O
are	O
discussed	O
.	O

Rare	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
N	B-Protein
-	I-Protein
methyl	I-Protein
-	I-Protein
D	I-Protein
-	I-Protein
aspartate	I-Protein
glutamate	I-Protein
receptors	I-Protein
and	O
their	O
contributions	O
to	O
schizophrenia	B-Disease
susceptibility	O
.	O

In	O
schizophrenia	O
(	O
SCZ	O
)	O
and	O
autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
,	O
the	O
dysregulation	O
of	O
glutamate	O
transmission	O
through	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
receptors	O
(	O
NMDARs	O
)	O
has	O
been	O
implicated	O
as	O
a	O
potential	O
etiological	O
mechanism	O
.	O

Previous	O
studies	O
have	O
accumulated	O
evidence	O
supporting	O
NMDAR	O
-	O
encoding	O
genes	O
'	O
role	O
in	O
etiology	O
of	O
SCZ	O
and	O
ASD	O
.	O

We	O
performed	O
a	O
screening	O
study	O
for	O
exonic	O
regions	O
of	O
GRIN1	O
,	O
GRIN2A	O
,	O
GRIN2C	O
,	O
GRIN2D	O
,	O
GRIN3A	O
,	O
and	O
GRIN3B	O
,	O
which	O
encode	O
NMDAR	O
subunits	O
,	O
in	O
562	O
participates	O
(	O
370	O
SCZ	O
and	O
192	O
ASD	O
)	O
.	O

Forty	O
rare	O
variants	O
were	O
identified	O
including	O
38	O
missense	O
,	O
1	O
frameshift	O
mutation	O
in	O
GRIN2C	O
and	O
1	O
splice	O
site	O
mutation	O
in	O
GRIN2D.	O
We	O
conducted	O
in	O
silico	O
analysis	O
for	O
all	O
variants	O
and	O
detected	O
seven	O
missense	O
variants	O
with	O
deleterious	O
prediction	O
.	O

De	O
novo	O
analysis	O
was	O
conducted	O
if	O
pedigree	O
samples	O
were	O
available	O
.	O

The	O
splice	O
site	O
mutation	O
in	O
GRIN2D	O
is	O
predicted	O
to	O
result	O
in	O
intron	O
retention	O
by	O
minigene	O
assay	O
.	O

Furthermore	O
,	O
the	O
frameshift	O
mutation	O
in	O
GRIN2C	O
and	O
splice	O
site	O
mutation	O
in	O
GRIN2D	O
were	O
genotyped	O
in	O
an	O
independent	O
sample	O
set	O
comprising	O
1877	O
SCZ	O
cases	O
,	O
382	O
ASD	O
cases	O
,	O
and	O
2040	O
controls	O
.	O

Both	O
of	O
them	O
were	O
revealed	O
to	O
be	O
singleton	O
.	O

Our	O
study	O
gives	O
evidence	O
in	O
support	O
of	O
the	O
view	O
that	O
ultra	O
-	O
rare	O
variants	O
with	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
(	B-Var
frameshift	I-Var
,	O
nonsense	B-Var
or	I-Var
splice	I-Var
site	I-Var
)	I-Var
in	O
NMDARs	B-Gene
genes	O
may	O
contribute	O
to	O
possible	O
risk	O
of	O
SCZ	B-Disease
.	O

FRUCTOKINASE	O
-	O
LIKE	O
PROTEIN	O
1	O
interacts	O
with	O
TRXz	O
to	O
regulate	O
chloroplast	O
development	O
in	O
rice	O
.	O

Chloroplast	O
genes	O
are	O
transcribed	O
by	O
the	O
plastid	O
-	O
encoded	O
RNA	O
polymerase	O
(	O
PEP	O
)	O
or	O
nucleus	O
-	O
encoded	O
RNA	O
polymerase	O
.	O

FRUCTOKINASE	O
-	O
LIKE	O
PROTEINS	O
(	O
FLNs	O
)	O
are	O
phosphofructokinase	O
-	O
B	O
(	O
PfkB)-type	O
carbohydrate	O
kinases	O
that	O
act	O
as	O
part	O
of	O
the	O
PEP	O
complex	O
;	O
however	O
,	O
the	O
molecular	O
mechanisms	O
underlying	O
FLN	O
activity	O
in	O
rice	O
remain	O
elusive	O
.	O

Previously	O
,	O
we	O
identified	O
and	O
characterized	O
a	O
heat	O
-	O
stress	O
sensitive	O
albino	O
(	O
hsa1	O
)	O
mutant	O
in	O
rice	O
.	O

Map	O
-	O
based	O
cloning	O
revealed	O
that	O
HSA1	O
encodes	O
a	O
putative	O
OsFLN2	O
.	O

Here	O
,	O
we	O
further	O
demonstrated	O
that	O
knockdown	O
or	O
knockout	O
of	O
the	O
OsFLN1	O
,	O
a	O
close	O
homolog	O
of	O
HSA1	O
/	O
OsFLN2	O
,	O
considerably	O
inhibits	O
chloroplast	O
biogenesis	O
and	O
the	O
fln1	O
knockout	O
mutants	O
,	O
created	O
by	O
clustered	O
regularly	O
interspaced	O
short	O
palindromic	O
repeats	O
(	O
CRISPR	O
)	O
and	O
CRISPR	O
-	O
associate	O
protein	O
9	O
,	O
exhibit	O
severe	O
albino	O
phenotype	O
and	O
seedling	O
lethality	O
.	O

Moreover	O
,	O
OsFLN1	O
localizes	O
to	O
the	O
chloroplast	O
.	O

Yeast	O
two	O
-	O
hybrid	O
,	O
pull	O
-	O
down	O
and	O
bimolecular	O
fluorescence	O
complementation	O
experiments	O
revealed	O
that	O
OsFLN1	O
and	O
HSA1	O
/	O
OsFLN2	O
interact	O
with	O
THIOREDOXINZ	O
(	O
OsTRXz	O
)	O
to	O
regulate	O
chloroplast	O
development	O
.	O

In	O
agreement	O
with	O
this	O
,	O
knockout	O
of	O
OsTRXz	O
resulted	O
in	O
a	O
similar	O
albino	O
and	O
seedling	O
lethality	O
phenotype	O
to	O
that	O
of	O
the	O
fln1	O
mutants	O
.	O

Quantitative	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
and	O
immunoblot	O
analysis	O
revealed	O
that	O
the	O
transcription	B-MPA
and	O
translation	B-MPA
of	O
PEP	B-Gene
-	I-Gene
dependent	I-Gene
genes	I-Gene
were	O
strongly	O
inhibited	B-NegReg
in	O
fln1	B-Gene
and	O
trxz	O
mutants	B-Var
,	O
indicating	O
that	O
loss	O
of	O
OsFLN1	O
,	O
HSA1	O
/	O
OsFLN2	O
,	O
or	O
OsTRXz	O
function	O
perturbs	B-NegReg
the	O
stability	B-CPA
of	I-CPA
the	I-CPA
transcriptionally	I-CPA
active	I-CPA
chromosome	I-CPA
complex	I-CPA
and	O
PEP	B-Enzyme
activity	B-MPA
.	O

These	O
results	O
show	O
that	O
OsFLN1	O
and	O
HSA1	O
/	O
OsFLN2	O
contribute	O
to	O
chloroplast	O
biogenesis	O
and	O
plant	O
growth	O
.	O

The	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	O
E76	B-Var
K	I-Var
in	O
SHP2	B-Gene
promotes	B-PosReg
CAC	B-Disease
tumorigenesis	B-CPA
and	O
induces	B-PosReg
EMT	B-CPA
via	O
the	O
Wnt	B-Pathway
/	I-Pathway
β	I-Pathway
-	I-Pathway
catenin	I-Pathway
signaling	I-Pathway
pathway	I-Pathway
.	O

SHP2	O
is	O
encoded	O
by	O
the	O
protein	O
tyrosine	O
phosphatase	O
11	O
(	O
Ptpn11	O
)	O
gene	O
.	O

Several	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
mutations	O
in	O
Ptpn11	O
have	O
been	O
identified	O
in	O
human	O
hematopoietic	O
malignancies	O
and	O
solid	O
tumors	O
.	O

In	O
addition	O
,	O
the	O
mutation	B-Var
rate	O
for	O
SHP2	B-Gene
is	O
the	O
highest	B-Reg
for	O
colorectal	B-Disease
cancer	I-Disease
(	O
CRC	O
)	O
among	O
solid	O
tumors	O
.	O

The	O
E76	O
K	O
GOF	O
mutation	O
is	O
the	O
most	O
common	O
and	O
active	O
SHP2	O
mutation	O
;	O
however	O
,	O
the	O
pathogenic	O
effects	O
and	O
function	O
of	O
this	O
mutation	O
in	O
CRC	O
tumor	O
progression	O
have	O
not	O
been	O
well	O
characterized	O
.	O

The	O
Wnt	O
/	O
β	O
-	O
catenin	O
(	O
CTNNB1	O
)	O
signaling	O
pathway	O
is	O
crucial	O
for	O
CRC	O
,	O
and	O
excessive	O
activation	O
of	O
this	O
pathway	O
has	O
been	O
observed	O
in	O
several	O
tumors	O
.	O

We	O
used	O
Ptpn11E76	O
K	O
conditional	O
knock	O
-	O
in	O
mice	O
to	O
study	O
this	O
GOF	O
mutation	O
in	O
colitis	O
-	O
associated	O
CRC	O
(	O
CAC	O
)	O
and	O
used	O
the	O
CRC	O
cell	O
lines	O
HT29	O
and	O
HCT116	O
to	O
determine	O
the	O
relationship	O
between	O
SHP2	O
and	O
Wnt	O
/	O
β	O
-	O
catenin	O
signaling	O
.	O

Ptpn11E76	B-Gene
K	I-Gene
conditional	O
knock	O
-	O
in	O
mice	O
exhibited	O
aggravated	B-PosReg
inflammation	B-CPA
and	O
increased	B-PosReg
CAC	B-Disease
tumorigenesis	B-CPA
.	O

In	O
vitro	O
,	O
SHP2E76	B-Gene
K	I-Gene
and	O
SHP2WT	O
promoted	B-PosReg
malignant	B-CPA
biological	I-CPA
behaviors	I-CPA
of	I-CPA
CRC	I-CPA
cells	I-CPA
and	O
induced	B-PosReg
epithelial	B-CPA
-	I-CPA
mesenchymal	I-CPA
transition	I-CPA
(	O
EMT	O
)	O
via	O
the	O
Wnt	O
/	O
β	O
-	O
catenin	O
signaling	O
pathway	O
.	O

Together	O
,	O
our	O
results	O
showed	O
that	O
SHP2E76	B-Gene
K	I-Gene
acts	O
as	O
an	O
oncogene	O
that	O
promotes	B-PosReg
the	O
tumorigenesis	B-CPA
and	O
metastasis	B-CPA
of	O
CRC	B-Disease
.	O

Recessive	O
loss	O
of	O
function	O
PIGN	B-Gene
alleles	O
,	O
including	O
an	O
intragenic	O
deletion	B-Var
with	O
founder	O
effect	O
in	O
La	O
Réunion	O
Island	O
,	O
in	O
patients	O
with	O
Fryns	O
syndrome	O
.	O

Fryns	O
syndrome	O
(	O
FS	O
)	O
is	O
a	O
multiple	O
malformations	O
syndrome	O
with	O
major	O
features	O
of	O
congenital	O
diaphragmatic	O
hernia	O
,	O
pulmonary	O
hypoplasia	O
,	O
craniofacial	O
dysmorphic	O
features	O
,	O
distal	O
digit	O
hypoplasia	O
,	O
and	O
a	O
range	O
of	O
other	O
lower	O
frequency	O
malformations	O
.	O

FS	O
is	O
typically	O
lethal	O
in	O
the	O
fetal	O
or	O
neonatal	O
period	O
.	O

Inheritance	O
is	O
presumed	O
autosomal	O
recessive	O
.	O

Although	O
no	O
major	O
genetic	O
cause	O
has	O
been	O
identified	O
for	O
FS	O
,	O
biallelic	B-Var
truncating	I-Var
variants	I-Var
in	O
PIGN	B-Gene
,	O
encoding	O
a	O
component	O
of	O
the	O
glycosylphosphatidylinositol	O
(	O
GPI)-anchor	O
biosynthesis	O
pathway	O
,	O
have	O
been	O
identified	B-Reg
in	O
a	O
limited	O
number	O
of	O
cases	O
with	O
a	O
phenotype	O
compatible	O
with	O
FS	B-Disease
.	O

Biallelic	O
variants	O
in	O
PIGN	B-Gene
,	O
typically	O
missense	B-Var
or	O
compound	B-Var
missense	I-Var
with	O
truncating	B-MPA
,	O
also	O
cause	B-Reg
multiple	B-Disease
congenital	I-Disease
anomalies	I-Disease
-	I-Disease
hypotonia	I-Disease
-	I-Disease
seizures	I-Disease
syndrome	I-Disease
1	I-Disease
(	O
MCAHS1	O
)	O
.	O

Here	O
we	O
report	O
six	O
further	O
patients	O
with	O
FS	O
with	O
or	O
without	O
congenital	O
diaphragmatic	O
hernia	O
and	O
recessive	O
loss	O
of	O
function	O
PIGN	O
alleles	O
,	O
including	O
an	O
intragenic	O
deletion	O
with	O
a	O
likely	O
founder	O
effect	O
in	O
La	O
Réunion	O
and	O
other	O
Indian	O
Ocean	O
islands	O
.	O

Our	O
results	O
support	O
the	O
hypothesis	O
that	O
a	O
spectrum	O
of	O
phenotypic	O
severity	O
is	O
associated	O
with	O
recessive	O
PIGN	O
variants	O
,	O
ranging	O
from	O
FS	O
at	O
the	O
extreme	O
end	O
,	O
caused	O
by	O
complete	O
loss	O
of	O
function	O
,	O
to	O
MCAHS1	O
,	O
in	O
which	O
some	O
residual	O
PIGN	O
function	O
may	O
remain	O
.	O

Our	O
data	O
add	O
FS	O
resulting	O
from	O
PIGN	O
variants	O
to	O
the	O
catalog	O
of	O
inherited	O
GPI	O
deficiencies	O
caused	O
by	O
the	O
disruption	O
of	O
the	O
GPI	O
-	O
anchor	O
biosynthesis	O
pathway	O
.	O

New	O
insights	O
into	O
ANGPLT3	O
in	O
controlling	O
lipoprotein	O
metabolism	O
and	O
risk	O
of	O
cardiovascular	O
diseases	O
.	O

Dyslipidemia	O
,	O
characterized	O
by	O
elevation	O
of	O
plasma	O
low	O
density	O
lipoprotein	O
cholesterol	O
(	O
LDL	O
-	O
C	O
)	O
,	O
triglyceride	O
(	O
TG	O
)	O
and	O
reduction	O
of	O
plasma	O
high	O
density	O
lipoprotein	O
cholesterol	O
(	O
HDL	O
-	O
C	O
)	O
,	O
has	O
been	O
verified	O
as	O
a	O
causal	O
risk	O
factor	O
for	O
cardiovascular	O
diseases	O
(	O
CVD	O
)	O
,	O
leading	O
to	O
a	O
high	O
mortality	O
rate	O
in	O
general	O
population	O
.	O

It	O
is	O
important	O
to	O
understand	O
the	O
molecular	O
metabolism	O
underlying	O
dyslipidemia	O
in	O
order	O
to	O
reduce	O
the	O
risk	O
and	O
to	O
develop	O
effective	O
therapeutic	O
approaches	O
against	O
CVD	O
.	O

ANGPTL3	O
(	O
human	O
)	O
or	O
Angptl3	O
(	O
mouse	O
)	O
,	O
one	O
member	O
of	O
the	O
angiopoietin	O
-	O
like	O
protein	O
(	O
ANGPTL	O
)	O
family	O
,	O
has	O
been	O
identified	O
as	O
an	O
important	O
regulator	O
of	O
lipid	O
metabolism	O
by	O
inhibiting	O
LPL	O
and	O
EL	O
activity	O
.	O

Results	O
have	O
demonstrated	O
that	O
inactivation	O
of	O
Angptl3	O
in	O
mice	O
could	O
obviously	O
reduce	O
the	O
level	O
of	O
TG	O
,	O
LDL	O
-	O
C	O
and	O
the	O
atherosclerotic	O
lesion	O
size	O
,	O
leading	O
to	O
a	O
lower	O
risk	O
for	O
dyslipidemia	O
and	O
CVD	O
.	O

Additionally	O
,	O
in	O
humans	O
,	O
carriers	O
with	O
homozygous	O
LOF	B-NegReg
mutations	B-Var
in	O
ANGPTL3	B-Gene
have	O
lower	B-NegReg
plasma	B-MPA
LDL	I-MPA
-	I-MPA
C	I-MPA
,	O
TG	B-MPA
levels	I-MPA
and	O
lower	O
risk	O
of	O
atherosclerosis	O
compared	O
to	O
the	O
non	O
-	O
carriers	O
.	O

Here	O
,	O
we	O
collect	O
the	O
latest	O
data	O
and	O
results	O
,	O
giving	O
a	O
new	O
insight	O
into	O
the	O
important	O
role	O
of	O
ANGPTL3	O
in	O
controlling	O
lipoprotein	O
metabolism	O
.	O

Finally	O
,	O
we	O
introduce	O
two	O
update	O
reports	O
on	O
the	O
antisense	O
oligonucleotide	O
and	O
monoclonal	O
antibody	O
-	O
based	O
inactivation	O
of	O
ANGPTL3	O
in	O
human	O
clinical	O
trials	O
,	O
to	O
identify	O
that	O
ANGPTL3	O
could	O
be	O
a	O
novel	O
and	O
effective	O
target	O
for	O
the	O
treatment	O
of	O
dyslipidemia	O
and	O
CVD	O
.	O

Clonal	O
evolution	O
mechanisms	B-Reg
in	O
NT5C2	B-Gene
mutant	B-Var
-	I-Var
relapsed	I-Var
acute	I-Disease
lymphoblastic	I-Disease
leukaemia	I-Disease
.	O

Relapsed	B-Disease
acute	I-Disease
lymphoblastic	I-Disease
leukaemia	I-Disease
(	O
ALL	O
)	O
is	O
associated	O
with	O
resistance	O
to	O
chemotherapy	O
and	O
poor	O
prognosis	O
.	O

Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutations	B-Var
in	O
the	O
5'-nucleotidase	O
,	O
cytosolic	O
II	O
(	B-Gene
NT5C2	I-Gene
)	I-Gene
gene	O
induce	B-PosReg
resistance	B-MPA
to	I-MPA
6-mercaptopurine	I-MPA
and	O
are	O
selectively	O
present	O
in	O
relapsed	O
ALL	O
.	O

Yet	O
,	O
the	O
mechanisms	O
involved	O
in	O
NT5C2	O
mutation	O
-	O
driven	O
clonal	O
evolution	O
during	O
the	O
initiation	O
of	O
leukaemia	O
,	O
disease	O
progression	O
and	O
relapse	O
remain	O
unknown	O
.	O

Here	O
we	O
use	O
a	O
conditional	O
-	O
and	O
-	O
inducible	O
leukaemia	O
model	O
to	O
demonstrate	O
that	O
expression	O
of	O
NT5C2(R367Q	B-Var
)	I-Var
,	O
a	O
highly	O
prevalent	O
relapsed	B-Disease
-	I-Disease
ALL	I-Disease
NT5C2	B-Gene
mutation	O
,	O
induces	B-PosReg
resistance	B-MPA
to	I-MPA
chemotherapy	I-MPA
with	I-MPA
6-mercaptopurine	I-MPA
at	O
the	O
cost	O
of	O
impaired	O
leukaemia	O
cell	O
growth	O
and	O
leukaemia	O
-	O
initiating	O
cell	O
activity	O
.	O

The	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
fitness	I-NegReg
phenotype	B-CPA
of	O
NT5C2+/R367Q	B-Gene
mutant	O
cells	O
is	O
associated	O
with	O
excess	B-PosReg
export	B-MPA
of	I-MPA
purines	I-MPA
to	I-MPA
the	I-MPA
extracellular	I-MPA
space	I-MPA
and	O
depletion	B-MPA
of	I-MPA
the	I-MPA
intracellular	I-MPA
purine	I-MPA
-	I-MPA
nucleotide	I-MPA
pool	I-MPA
.	O

Consequently	O
,	O
blocking	O
guanosine	O
synthesis	O
by	O
inhibition	O
of	O
inosine-5'-monophosphate	O
dehydrogenase	O
(	O
IMPDH	O
)	O
induced	O
increased	O
cytotoxicity	O
against	O
NT5C2-mutant	O
leukaemia	O
lymphoblasts	O
.	O

These	O
results	O
identify	O
the	O
fitness	O
cost	O
of	O
NT5C2	O
mutation	O
and	O
resistance	O
to	O
chemotherapy	O
as	O
key	O
evolutionary	O
drivers	O
that	O
shape	O
clonal	O
evolution	O
in	O
relapsed	O
ALL	O
and	O
support	O
a	O
role	O
for	O
IMPDH	O
inhibition	O
in	O
the	O
treatment	O
of	O
ALL	O
.	O

The	O
protective	O
role	O
of	O
DOT1L	O
in	O
UV	O
-	O
induced	O
melanomagenesis	O
.	O

The	O
DOT1L	O
histone	O
H3	O
lysine	O
79	O
(	O
H3K79	O
)	O
methyltransferase	O
plays	O
an	O
oncogenic	O
role	O
in	O
MLL	O
-	O
rearranged	O
leukemogenesis	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
,	O
in	O
contrast	O
to	O
MLL	O
-	O
rearranged	O
leukemia	O
,	O
DOT1L	O
plays	O
a	O
protective	O
role	O
in	O
ultraviolet	O
radiation	O
(	O
UVR)-induced	O
melanoma	O
development	O
.	O

Specifically	O
,	O
the	O
DOT1L	B-Gene
gene	O
is	O
located	O
in	O
a	O
frequently	O
deleted	O
region	O
and	O
undergoes	O
somatic	O
mutation	O
in	O
human	O
melanoma	O
.	O

Specific	O
mutations	B-Var
functionally	O
compromise	B-NegReg
DOT1L	B-Gene
methyltransferase	B-Enzyme
enzyme	I-Enzyme
activity	B-MPA
leading	O
to	O
reduced	B-NegReg
H3K79	B-Protein
methylation	B-MPA
.	O

Importantly	O
,	O
in	O
the	O
absence	O
of	O
DOT1L	O
,	O
UVR	O
-	O
induced	O
DNA	O
damage	O
is	O
inefficiently	O
repaired	O
,	O
so	O
that	O
DOT1L	B-Gene
loss	B-NegReg
promotes	B-PosReg
melanoma	B-CPA
development	I-CPA
in	O
mice	O
after	O
exposure	O
to	O
UVR	O
.	O

Mechanistically	O
,	O
DOT1L	O
facilitates	O
DNA	O
damage	O
repair	O
,	O
with	O
DOT1L	O
-	O
methylated	O
H3K79	O
involvement	O
in	O
binding	O
and	O
recruiting	O
XPC	O
to	O
the	O
DNA	O
damage	O
site	O
for	O
nucleotide	O
excision	O
repair	O
(	O
NER	O
)	O
.	O

This	O
study	O
indicates	O
that	O
DOT1L	O
plays	O
a	O
protective	O
role	O
in	O
UVR	O
-	O
induced	O
melanomagenesis	O
.	O

Biallelic	B-Var
variants	I-Var
in	O
KIF14	B-Gene
cause	B-Reg
intellectual	B-Disease
disability	I-Disease
with	O
microcephaly	B-Disease
.	O

Kinesin	O
proteins	O
are	O
critical	O
for	O
various	O
cellular	O
functions	O
such	O
as	O
intracellular	O
transport	O
and	O
cell	O
division	O
,	O
and	O
many	O
members	O
of	O
the	O
family	O
have	O
been	O
linked	O
to	O
monogenic	O
disorders	O
and	O
cancer	O
.	O

We	O
report	O
eight	O
individuals	O
with	O
intellectual	O
disability	O
and	O
microcephaly	O
from	O
four	O
unrelated	O
families	O
with	O
parental	O
consanguinity	O
.	O

In	O
the	O
affected	O
individuals	O
of	O
each	O
family	O
,	O
homozygosity	O
for	O
likely	O
pathogenic	B-CPA
variants	O
in	O
KIF14	B-Gene
were	O
detected	O
;	O
two	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	B-Var
p	I-Var
.	I-Var
Asn83Ilefs*3	I-Var
and	O
p	B-Var
.	I-Var
Ser1478fs	I-Var
)	I-Var
,	O
and	O
two	O
missense	B-Reg
substitutions	I-Reg
(	B-Var
p	I-Var
.	I-Var
Ser841Phe	I-Var
and	O
p	B-Var
.	I-Var
Gly459Arg	I-Var
)	I-Var
.	O

KIF14	O
is	O
a	O
mitotic	O
motor	O
protein	O
that	O
is	O
required	O
for	O
spindle	O
localization	O
of	O
the	O
mitotic	O
citron	O
rho	O
-	O
interacting	O
kinase	O
,	O
CIT	B-Gene
,	O
also	O
mutated	B-Var
in	B-Reg
microcephaly	B-Disease
.	O

Our	O
results	O
demonstrate	O
the	O
involvement	O
of	O
KIF14	O
in	O
development	O
and	O
reveal	O
a	O
wide	O
phenotypic	O
variability	O
ranging	O
from	O
fetal	O
lethality	O
to	O
moderate	O
developmental	O
delay	O
and	O
microcephaly	O
.	O

APOC3	B-Gene
Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
Function	I-NegReg
Mutations	B-Var
,	O
Remnant	O
Cholesterol	O
,	O
Low	O
-	O
Density	O
Lipoprotein	O
Cholesterol	O
,	O
and	O
Cardiovascular	O
Risk	O
:	O
Mediation-	O
and	O
Meta	O
-	O
Analyses	O
of	O
137	O
895	O
Individuals	O
.	O

OBJECTIVE	O
:	O
Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
APOC3	B-Gene
associate	O
with	O
low	B-NegReg
remnant	B-MPA
cholesterol	I-MPA
levels	I-MPA
and	O
low	O
risk	O
of	O
ischemic	O
vascular	O
disease	O
(	O
IVD	O
)	O
.	O

Because	O
some	O
studies	O
show	O
an	O
additional	O
association	O
with	O
low	O
levels	O
of	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	O
(	O
LDL	O
-	O
C	O
)	O
,	O
low	O
LDL	O
-	O
C	O
may	O
explain	O
the	O
low	O
risk	O
of	O
IVD	O
in	O
APOC3	O
loss	O
-	O
of	O
-	O
function	O
heterozygotes	O
.	O

We	O
tested	O
to	O
what	O
extent	O
the	O
low	O
risk	O
of	O
IVD	O
in	O
APOC3	O
loss	O
-	O
of	O
-	O
function	O
heterozygotes	O
is	O
mediated	O
by	O
low	O
plasma	O
remnant	O
cholesterol	O
and	O
LDL	O
-	O
C.	O
APPROACH	O
AND	O
RESULTS	O
:	O
In	O
APOC3	O
loss	O
-	O
of	O
-	O
function	O
heterozygotes	O
versus	O
noncarriers	O
,	O
we	O
first	O
determined	O
remnant	O
cholesterol	O
and	O
LDL	O
-	O
C	O
levels	O
in	O
meta	O
-	O
analyses	O
of	O
137	O
895	O
individuals	O
.	O

Second	O
,	O
we	O
determined	O
whether	O
the	O
association	O
with	O
LDL	O
-	O
C	O
was	O
masked	O
by	O
lipid	O
-	O
lowering	O
therapy	O
.	O

Finally	O
,	O
using	O
mediation	O
analysis	O
,	O
we	O
determined	O
the	O
fraction	O
of	O
the	O
low	O
risk	O
of	O
IVD	O
and	O
ischemic	O
heart	O
disease	O
mediated	O
by	O
remnant	O
cholesterol	O
and	O
LDL	O
-	O
C.	O
In	O
meta	O
-	O
analyses	O
,	O
remnant	O
cholesterol	O
was	O
43	O
%	O
lower	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
40%-47	O
%	O
)	O
,	O
and	O
LDL	O
-	O
C	O
was	O
4	O
%	O
lower	O
(	O
1%-6	O
%	O
)	O
in	O
loss	O
-	O
of	O
-	O
function	O
heterozygotes	O
(	O
n=776	O
)	O
versus	O
noncarriers	O
.	O

In	O
the	O
general	O
population	O
,	O
LDL	O
-	O
C	O
was	O
3	O
%	O
lower	O
in	O
loss	O
-	O
of	O
-	O
function	O
heterozygotes	O
versus	O
noncarriers	O
,	O
4	O
%	O
lower	O
when	O
correcting	O
for	O
lipid	O
-	O
lowering	O
therapy	O
,	O
and	O
3	O
%	O
lower	O
in	O
untreated	O
individuals	O
(	O
P	O
values	O
,	O
0.06	O
-	O
0.008	O
)	O
.	O

Remnant	O
cholesterol	O
mediated	O
37	O
%	O
of	O
the	O
observed	O
41	O
%	O
lower	O
risk	O
of	O
IVD	O
and	O
54	O
%	O
of	O
the	O
observed	O
36	O
%	O
lower	O
risk	O
of	O
ischemic	O
heart	O
disease	O
;	O
corresponding	O
values	O
mediated	O
by	O
LDL	O
-	O
C	O
were	O
1	O
%	O
and	O
2	O
%	O
.	O

CONCLUSIONS	O
:	O
The	O
low	O
risk	O
of	O
IVD	O
observed	O
in	O
APOC3	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
heterozygotes	O
is	O
mainly	O
mediated	O
by	O
the	O
associated	O
low	B-NegReg
remnant	B-MPA
cholesterol	I-MPA
and	O
not	O
by	O
low	O
LDL	O
-	O
C.	O
Furthermore	O
,	O
the	O
contribution	O
of	O
LDL	O
-	O
C	O
to	O
IVD	O
risk	O
was	O
not	O
masked	O
by	O
lipid	O
-	O
lowering	O
therapy	O
.	O

This	O
suggests	O
APOC3	O
and	O
remnant	O
cholesterol	O
as	O
important	O
new	O
targets	O
for	O
reducing	O
cardiovascular	O
risk	O
.	O

Key	O
apoptotic	B-Gene
genes	I-Gene
APAF1	B-Gene
and	O
CASP9	B-Gene
implicated	O
in	O
recurrent	O
folate	O
-	O
resistant	O
neural	O
tube	O
defects	O
.	O

Neural	O
tube	O
defects	O
(	O
NTDs	O
)	O
remain	O
one	O
of	O
the	O
most	O
serious	O
birth	O
defects	O
,	O
and	O
although	O
genes	O
in	O
several	O
pathways	O
have	O
been	O
implicated	O
as	O
risk	O
factors	O
for	O
neural	O
tube	O
defects	O
via	O
knockout	O
mouse	O
models	O
,	O
very	O
few	O
molecular	O
causes	O
in	O
humans	O
have	O
been	O
identified	O
.	O

Whole	O
exome	O
sequencing	O
identified	O
deleterious	O
variants	O
in	O
key	O
apoptotic	O
genes	O
in	O
two	O
families	O
with	O
recurrent	O
neural	O
tube	O
defects	O
.	O

Functional	O
studies	O
in	O
fibroblasts	O
indicate	O
that	O
these	O
variants	B-Var
are	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
,	O
as	O
apoptosis	B-CPA
is	O
significantly	O
reduced	B-NegReg
.	O

This	O
is	O
the	O
first	O
report	O
of	O
variants	B-Var
in	O
apoptotic	B-Gene
genes	I-Gene
contributing	B-Reg
to	O
neural	B-Disease
tube	I-Disease
defect	I-Disease
risk	O
in	O
humans	O
.	O

Congenital	O
diaphragmatic	O
hernia	O
as	O
a	O
part	O
of	O
Nance	O
-	O
Horan	O
syndrome	O
?	O
Nance	O
-	O
Horan	O
syndrome	O
is	O
a	O
rare	O
X	O
-	O
linked	O
developmental	O
disorder	O
characterized	O
by	O
bilateral	O
congenital	O
cataract	O
,	O
dental	O
anomalies	O
,	O
facial	O
dysmorphism	O
,	O
and	O
intellectual	O
disability	O
.	O

Here	O
,	O
we	O
identify	O
a	O
patient	O
with	O
Nance	B-Disease
-	I-Disease
Horan	I-Disease
syndrome	I-Disease
caused	B-Reg
by	I-Reg
a	O
new	O
nonsense	B-Var
NHS	B-Gene
variant	O
.	O

In	O
addition	O
,	O
the	O
patient	O
presented	O
congenital	B-Disease
diaphragmatic	I-Disease
hernia	I-Disease
.	O

NHS	O
gene	O
expression	O
in	O
murine	O
fetal	O
diaphragm	O
was	O
demonstrated	O
,	O
suggesting	O
a	O
possible	O
involvement	O
of	O
NHS	O
in	O
diaphragm	O
development	O
.	O

Congenital	B-Disease
diaphragmatic	I-Disease
hernia	I-Disease
could	O
result	B-Reg
from	I-Reg
NHS	B-Gene
loss	B-NegReg
of	I-NegReg
function	I-NegReg
in	O
pleuroperitoneal	O
fold	O
or	O
in	O
somites	O
-	O
derived	O
muscle	O
progenitor	O
cells	O
leading	O
to	O
an	O
impairment	O
of	O
their	O
cells	B-CPA
migration	I-CPA
.	O

[	O
The	O
formation	O
of	O
skin	O
barrier	O
and	O
defective	O
barrier	O
-	O
associated	O
skin	O
diseases	O
]	O
.	O

Since	O
the	O
discovery	O
of	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
filaggrin	O
(	B-Gene
FLG	I-Gene
)	I-Gene
gene	O
in	O
atopic	B-Disease
dermatitis	I-Disease
(	O
AD	O
)	O
individuals	O
,	O
significant	O
attention	O
has	O
been	O
paid	O
against	O
the	O
skin	O
barrier	O
as	O
an	O
initial	O
starting	O
point	O
of	O
atopic	O
march	O
.	O

Although	O
FLG	O
is	O
a	O
significant	O
cornification	O
-	O
associated	O
gene	O
,	O
skin	O
barrier	O
formation	O
is	O
a	O
complex	O
process	O
mediated	O
by	O
an	O
array	O
of	O
genes	O
with	O
specific	O
functions	O
.	O

In	O
this	O
article	O
,	O
the	O
mechanism	O
of	O
physical	O
skin	O
barrier	O
formation	O
is	O
reviewed	O
in	O
detail	O
,	O
focusing	O
on	O
specific	O
gene	O
functions	O
and	O
inherited	O
disorders	O
caused	O
by	O
genetic	O
aberrations	O
.	O

Additionally	O
,	O
the	O
mechanism	O
of	O
percutaneous	O
sensitization	O
with	O
environmental	O
allergens	O
in	O
association	O
with	O
FLG	O
-	O
deficiency	O
is	O
reviewed	O
in	O
order	O
to	O
clarify	O
the	O
link	O
between	O
defective	O
skin	O
barrier	O
and	O
atopic	O
march	O
.	O

Finally	O
,	O
updated	O
knowledge	O
of	O
psoriasis	O
pathophysiology	O
in	O
connection	O
with	O
genetic	O
defect	O
in	O
skin	O
barrier	O
is	O
reviewed	O
.	O

This	O
article	O
would	O
provide	O
a	O
novel	O
opportunity	O
to	O
understand	O
the	O
allergic	O
/	O
autoimmune	O
disorders	O
from	O
the	O
viewpoint	O
of	O
non	O
-	O
classical	O
immune	O
cells	O
.	O

Tryptophan	O
hydroxylase	O
(	B-Gene
TRH	I-Gene
)	I-Gene
loss	B-NegReg
of	I-NegReg
function	I-NegReg
mutations	B-Var
induce	O
growth	B-CPA
and	I-CPA
behavioral	I-CPA
defects	I-CPA
in	O
Daphnia	O
magna	O
.	O

Tryptophan	O
hydroxylase	O
(	O
TRH	O
)	O
is	O
the	O
rate	O
limiting	O
enzyme	O
in	O
the	O
serotonin	O
synthesis	O
.	O

CRISPR	O
-	O
Cas9	O
technology	O
was	O
used	O
to	O
generate	O
seven	O
indel	O
TRH	O
mutants	O
in	O
Daphnia	O
magna	O
.	O

Mono	O
-	O
allelic	O
indel	O
TRH-/+	O
clones	O
showed	O
normal	O
levels	O
of	O
serotonin	O
,	O
measured	O
by	O
both	O
immunohistochemistry	O
and	O
mass	O
spectrometry	O
(	O
LC	O
-	O
MS	O
/	O
MS	O
)	O
,	O
whereas	O
bi	O
-	O
allelic	O
indel	O
TRH-/-	O
clones	O
showed	O
no	O
detectable	O
levels	O
of	O
serotonin	O
.	O

Life	O
history	O
and	O
behavioral	O
responses	O
of	O
TRH-/-	O
clones	O
showed	O
the	O
anti	O
-	O
phenotype	O
of	O
those	O
exposed	O
to	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SSRI	O
)	O
.	O

Mutants	B-Var
lacking	B-NegReg
serotonin	B-MPA
grew	B-CPA
less	B-NegReg
and	O
hence	O
reproduced	B-CPA
latter	O
,	O
produced	O
smaller	B-NegReg
clutches	B-CPA
of	O
smaller	B-NegReg
offspring	B-CPA
and	O
responded	O
to	O
a	O
greater	O
extent	O
to	O
light	O
than	O
wild	O
type	O
individuals	O
.	O

Mono	O
-	O
allelic	O
indel	O
TRH-/+	O
individuals	O
showed	O
the	O
intermediate	O
phenotype	O
.	O

The	O
SSRI	O
fluoxetine	O
enhanced	O
offspring	O
production	O
in	O
all	O
clones	O
and	O
decreased	O
the	O
response	O
to	O
light	O
only	O
in	O
those	O
clones	O
having	O
serotonin	O
,	O
thus	O
indication	O
that	O
behavioral	O
effects	O
of	O
this	O
drug	O
in	O
D.	O
magna	O
are	O
associated	O
to	O
serotonin	O
.	O

Results	O
obtained	O
with	O
the	O
TRH	O
mutants	O
are	O
in	O
line	O
with	O
reported	O
ones	O
in	O
TRH	O
knockouts	O
of	O
Caenorhabditis	O
elegans	O
,	O
Drosophila	O
and	O
mice	O
,	O
indicating	O
that	O
there	O
is	O
one	O
gene	O
encoding	O
TRH	O
,	O
which	O
is	O
the	O
serotonin	O
limiting	O
enzyme	O
in	O
both	O
the	O
central	O
and	O
the	O
periphery	O
nervous	O
system	O
in	O
Daphnia	O
and	O
that	O
deprivation	O
of	O
serotonin	O
increases	O
anxiety	O
-	O
like	O
behavior	O
.	O

Internal	B-Var
tandem	I-Var
duplication	I-Var
mutations	I-Var
in	O
the	O
tyrosine	O
kinase	O
domain	O
of	O
FLT3	B-Gene
display	O
a	O
higher	B-PosReg
oncogenic	B-CPA
potential	I-CPA
than	O
the	O
activation	O
loop	O
D835Y	O
mutation	O
.	O

Acute	B-Disease
myeloid	I-Disease
leukemia	I-Disease
(	O
AML	O
)	O
remains	O
the	O
most	O
common	O
form	O
of	O
acute	O
leukemia	O
among	O
adults	O
and	O
accounts	O
for	O
a	O
large	O
number	O
of	O
leukemia	O
-	O
related	O
deaths	O
.	O

Mutations	B-Var
in	O
FMS	O
-	O
like	O
tyrosine	O
kinase	O
3	O
(	B-Gene
FLT3	I-Gene
)	I-Gene
is	O
one	O
of	O
the	O
most	O
prevalent	B-Reg
findings	O
in	O
this	O
heterogeneous	O
disease	O
.	O

The	O
major	O
types	O
of	O
mutations	O
in	O
FLT3	O
can	O
be	O
categorized	O
as	O
internal	O
tandem	O
duplications	O
(	O
ITD	O
)	O
and	O
point	O
mutations	O
.	O

Recent	O
studies	O
suggest	O
that	O
ITDs	O
not	O
only	O
occur	O
in	O
the	O
juxtamembrane	O
region	O
as	O
originally	O
described	O
,	O
but	O
also	O
in	O
the	O
kinase	O
domain	O
.	O

Although	O
the	O
juxtamembrane	O
ITDs	O
have	O
been	O
well	O
characterized	O
,	O
the	O
tyrosine	O
kinase	O
domain	O
ITDs	O
have	O
not	O
yet	O
been	O
thoroughly	O
studied	O
due	O
to	O
their	O
recent	O
discovery	O
.	O

For	O
this	O
reason	O
,	O
we	O
compared	O
ITD	O
mutations	O
in	O
the	O
juxtamembrane	O
domain	O
with	O
those	O
in	O
the	O
tyrosine	O
kinase	O
domain	O
,	O
as	O
well	O
as	O
with	O
the	O
most	O
common	O
activating	O
point	O
mutation	O
in	O
the	O
tyrosine	O
kinase	O
domain	O
,	O
D835Y.	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
understand	O
whether	O
it	O
is	O
the	O
nature	O
of	O
the	O
mutation	O
or	O
the	O
location	O
of	O
the	O
mutation	O
that	O
plays	O
the	O
main	O
role	O
in	O
leukemogenesis	O
.	O

The	O
various	O
FLT3	O
mutants	O
were	O
expressed	O
in	O
the	O
murine	O
pro	O
-	O
B	O
cell	O
line	O
Ba	O
/	O
F3	O
and	O
examined	O
for	O
their	O
capacity	O
to	O
form	O
colonies	O
in	O
semisolid	O
medium	O
.	O

The	O
size	O
and	O
number	O
of	O
colonies	O
formed	O
by	O
Ba	O
/	O
F3	O
cells	O
expressing	O
either	O
the	O
internal	O
tandem	O
duplication	O
within	O
juxtamembrane	O
domain	O
of	O
the	O
receptor	O
(	O
JMD	O
-	O
ITD	O
)	O
or	O
the	O
tyrosine	O
kinase	O
domain	O
(	O
TKD)-ITD	O
were	O
indistinguishable	O
,	O
while	O
Ba	O
/	O
F3	O
cells	O
expressing	O
D835Y	O
/	O
FLT3	O
failed	O
to	O
form	O
colonies	O
.	O

Cell	B-CPA
proliferation	I-CPA
and	O
cell	B-CPA
survival	I-CPA
was	O
also	O
significantly	O
higher	B-PosReg
in	O
TKD	B-Var
-	I-Var
ITD	I-Var
expressing	O
cells	O
,	O
compared	O
to	O
cells	O
expressing	O
D835Y	O
/	O
FLT3	O
.	O

Furthermore	O
,	O
TKD	B-Var
-	I-Var
ITD	I-Var
is	O
capable	O
of	O
inducing	B-PosReg
phosphorylation	B-MPA
of	O
STAT5	B-Protein
,	O
while	O
D835Y	O
/	O
FLT3	O
fails	O
to	O
induce	O
tyrosine	O
phosphorylation	O
of	O
STAT5	O
.	O

Other	O
signal	O
transduction	O
pathways	O
such	O
as	O
the	O
RAS	O
/	O
ERK	O
and	O
the	O
PI3K	O
/	O
AKT	O
pathways	O
were	O
activated	O
to	O
the	O
same	O
level	O
in	O
TKD	O
-	O
ITD	O
cells	O
as	O
compared	O
to	O
D835Y	O
/	O
FLT3	O
expressing	O
cells	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
TKD	O
-	O
ITD	O
displays	O
similar	O
oncogenic	O
potential	O
to	O
the	O
JMD	O
-	O
ITD	O
but	O
a	O
higher	O
oncogenic	O
potential	O
than	O
the	O
D835Y	O
point	O
mutation	O
.	O

Reversal	O
of	O
end	O
-	O
stage	O
heart	O
failure	O
in	O
juvenile	O
hemochromatosis	O
with	O
iron	O
chelation	O
therapy	O
:	O
a	O
case	O
report	O
.	O

BACKGROUND	O
:	O
Juvenile	O
hemochromatosis	O
is	O
the	O
most	O
severe	O
form	O
of	O
iron	O
overloading	O
phenotype	O
.	O

Although	O
rare	O
,	O
it	O
should	O
be	O
suspected	O
in	O
patients	O
who	O
present	O
with	O
hypogonadotropic	O
hypogonadism	O
,	O
diabetes	O
mellitus	O
,	O
or	O
cardiomyopathy	O
without	O
a	O
clear	O
cause	O
.	O

CASE	O
PRESENTATION	O
:	O
A	O
young	O
Serbian	O
male	O
presenting	O
with	O
end	O
-	O
stage	O
heart	O
failure	O
was	O
referred	O
for	O
extracorporeal	O
membrane	O
oxygenation	O
.	O

An	O
endomyocardial	O
biopsy	O
revealed	O
cytoplasmic	O
iron	O
deposits	O
in	O
myocytes	O
.	O

His	O
condition	O
was	O
stabilized	O
with	O
biventricular	O
assist	O
devices	O
and	O
he	O
was	O
listed	O
for	O
heart	O
transplantation	O
.	O

Iron	O
chelation	O
therapy	O
was	O
commenced	O
and	O
resulted	O
in	O
rapid	O
removal	O
of	O
iron	O
burden	O
.	O

Serial	O
outpatient	O
echocardiograms	O
demonstrated	O
myocardial	O
recovery	O
such	O
that	O
a	O
successful	O
biventricular	O
assist	O
device	O
explant	O
occurred	O
131	O
days	O
after	O
initial	O
implant	O
.	O

Targeted	O
gene	O
sequencing	O
revealed	O
a	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	B-Var
within	O
the	O
HJV	B-Gene
gene	O
,	O
which	O
is	O
consistent	O
with	O
juvenile	B-Disease
hemochromatosis	I-Disease
.	O

CONCLUSIONS	O
:	O
This	O
rare	O
case	O
of	O
a	O
patient	O
with	O
juvenile	B-Disease
hemochromatosis	I-Disease
associated	B-Reg
with	O
a	O
HJV	B-Gene
mutation	B-Var
provides	O
histologic	O
evidence	O
documenting	O
the	O
reversal	O
of	O
associated	O
end	O
-	O
stage	O
heart	O
failure	O
,	O
requiring	O
emergent	O
mechanical	O
circulatory	O
support	O
,	O
with	O
iron	O
chelation	O
therapy	O
.	O

MeCP2	O
as	O
an	O
Activator	O
of	O
Gene	O
Expression	O
.	O

Rett	B-Disease
syndrome	I-Disease
is	O
a	O
neurodevelopmental	O
disorder	O
that	O
primarily	O
affects	O
females	O
and	O
is	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
methyl	O
-	O
CpG	O
-	O
binding	O
-	O
protein	O
2	O
(	B-Gene
MECP2	I-Gene
)	I-Gene
gene	O
.	O

Initially	O
,	O
MeCP2	O
had	O
been	O
shown	O
to	O
be	O
a	O
repressor	O
of	O
gene	O
transcription	O
.	O

In	O
their	O
2008	O
paper	O
,	O
Chahrour	O
and	O
colleagues	O
(	O
DOI	O
:	O
10.1126	O
/	O
science.1153252	O
)	O
reported	O
that	O
MeCP2	O
could	O
also	O
function	O
as	O
a	O
transcriptional	O
activator	O
.	O

TRPV1	B-Gene
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	B-Var
impairs	B-NegReg
pain	B-CPA
and	I-CPA
itch	I-CPA
sensations	I-CPA
in	O
mice	O
.	O

Transient	O
receptor	O
potential	O
vanilloid	O
1	O
(	O
TRPV1	O
)	O
is	O
a	O
non	O
-	O
selective	O
cation	O
channel	O
,	O
which	O
can	O
detect	O
various	O
noxious	O
stimuli	O
that	O
cause	O
pain	O
,	O
inflammation	O
,	O
hyperalgesia	O
,	O
and	O
itch	O
.	O

TRPV1	O
knock	O
-	O
out	O
mice	O
show	O
deficiency	O
in	O
nociception	O
,	O
but	O
the	O
in	O
vivo	O
effects	O
of	O
persistent	O
activation	O
of	O
TRPV1	O
are	O
not	O
completely	O
understood	O
.	O

Here	O
,	O
we	O
generated	O
TRPV1	O
knock	O
-	O
in	O
mice	O
with	O
a	O
G564S	O
mutation	O
.	O

In	O
the	O
heterologous	O
expression	O
system	O
,	O
an	O
electrophysiological	O
study	O
showed	O
that	O
the	O
G564S	B-Var
mutation	O
in	O
mouse	O
TRPV1	B-Gene
caused	O
increased	B-PosReg
basal	B-CPA
current	I-CPA
and	O
a	O
leftward	B-CPA
shift	I-CPA
of	I-CPA
voltage	I-CPA
dependence	I-CPA
.	O

Intriguingly	O
,	O
using	O
behavioral	O
analysis	O
,	O
we	O
found	O
that	O
knock	O
-	O
in	O
mice	O
showed	O
a	O
thermosensory	B-CPA
defect	B-NegReg
,	O
impaired	B-NegReg
inflammatory	B-MPA
thermal	I-MPA
pain	I-MPA
,	O
and	O
capsaicin	B-CPA
sensitivity	I-CPA
.	O

We	O
also	O
demonstrated	O
an	O
attenuated	O
behavioral	O
response	O
to	O
the	O
pruritic	O
agent	O
histamine	O
in	O
the	O
knock	O
-	O
in	O
mice	O
.	O

Indeed	O
,	O
calcium	O
imaging	O
together	O
with	O
electrophysiology	O
showed	O
that	O
the	O
overactive	O
mutant	O
had	O
decreased	O
capsaicin	O
sensitivity	O
.	O

Western	O
blot	O
analysis	O
revealed	O
that	O
the	O
G564S	B-Var
mutant	O
reduced	B-NegReg
TRPV1	B-Protein
phosphorylation	B-MPA
and	O
cell	B-CPA
membrane	I-CPA
trafficking	I-CPA
.	O

Together	O
,	O
we	O
have	O
generated	O
a	O
mouse	O
model	O
with	O
a	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	B-Var
in	O
Trpv1	B-Gene
gene	O
and	O
demonstrated	O
that	O
the	O
pain	B-CPA
and	I-CPA
histamine	I-CPA
-	I-CPA
dependent	I-CPA
itch	I-CPA
sensations	I-CPA
in	O
these	O
mice	O
are	O
impaired	B-NegReg
due	O
to	O
a	O
decreased	B-NegReg
phosphorylation	B-MPA
level	I-MPA
and	O
reduced	B-NegReg
membrane	B-MPA
localization	I-MPA
of	O
TRPV1	B-Protein
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
Function	I-NegReg
Mutations	B-Var
in	O
UNC45A	B-Gene
Cause	O
a	O
Syndrome	B-Disease
Associating	O
Cholestasis	B-Disease
,	O
Diarrhea	B-Disease
,	O
Impaired	B-Disease
Hearing	I-Disease
,	O
and	O
Bone	B-Disease
Fragility	I-Disease
.	O

Despite	O
the	O
rapid	O
discovery	O
of	O
genes	O
for	O
rare	O
genetic	O
disorders	O
,	O
we	O
continue	O
to	O
encounter	O
individuals	O
presenting	O
with	O
syndromic	O
manifestations	O
.	O

Here	O
,	O
we	O
have	O
studied	O
four	O
affected	O
people	O
in	O
three	O
families	O
presenting	O
with	O
cholestasis	B-Disease
,	O
congenital	B-Disease
diarrhea	I-Disease
,	O
impaired	B-Disease
hearing	I-Disease
,	O
and	O
bone	B-Disease
fragility	I-Disease
.	O

Whole	O
-	O
exome	O
sequencing	O
of	O
all	O
affected	O
individuals	O
and	O
their	O
parents	O
identified	O
biallelic	B-Var
mutations	I-Var
in	O
Unc-45	O
Myosin	O
Chaperone	O
A	O
(	B-Gene
UNC45A	I-Gene
)	I-Gene
as	O
a	O
likely	O
driver	O
for	O
this	O
disorder	O
.	O

Subsequent	O
in	O
vitro	O
and	O
in	O
vivo	O
functional	O
studies	O
of	O
the	O
candidate	O
gene	O
indicated	O
a	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
paradigm	O
,	O
wherein	O
mutations	O
attenuated	B-NegReg
or	O
abolished	B-NegReg
protein	B-Protein
activity	B-MPA
with	O
concomitant	O
defects	B-NegReg
in	O
gut	B-CPA
development	I-CPA
and	O
function	O
.	O

Loss	O
-	O
of	O
-	O
function	O
and	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
in	O
PPP3CA	O
cause	O
two	O
distinct	O
disorders	O
.	O

Calcineurin	O
is	O
a	O
calcium	O
(	O
Ca2+)/calmodulin	O
-	O
regulated	O
protein	O
phosphatase	O
that	O
mediates	O
Ca2	O
+	O
-dependent	O
signal	O
transduction	O
.	O

Here	O
,	O
we	O
report	O
six	O
heterozygous	O
mutations	O
in	O
a	O
gene	O
encoding	O
the	O
alpha	O
isoform	O
of	O
the	O
calcineurin	O
catalytic	O
subunit	O
(	O
PPP3CA	O
)	O
.	O

Notably	O
,	O
mutations	O
were	O
observed	O
in	O
different	O
functional	O
domains	O
:	O
in	O
addition	O
to	O
three	O
catalytic	O
domain	O
mutations	O
,	O
two	O
missense	O
mutations	O
were	O
found	O
in	O
the	O
auto	O
-	O
inhibitory	O
(	O
AI	O
)	O
domain	O
.	O

One	O
additional	O
frameshift	O
insertion	O
that	O
caused	O
premature	O
termination	O
was	O
also	O
identified	O
.	O

Detailed	O
clinical	O
evaluation	O
of	O
the	O
six	O
individuals	O
revealed	O
clinically	O
unexpected	O
consequences	O
of	O
the	O
PPP3CA	B-Gene
mutations	O
.	O

First	O
,	O
the	O
catalytic	B-Var
domain	I-Var
mutations	I-Var
and	O
frameshift	B-Var
mutation	I-Var
were	O
consistently	O
found	B-Reg
in	O
patients	O
with	O
nonsyndromic	B-Disease
early	I-Disease
onset	I-Disease
epileptic	I-Disease
encephalopathy	I-Disease
.	O

In	O
contrast	O
,	O
the	O
AI	B-Var
domain	I-Var
mutations	I-Var
were	O
associated	B-Reg
with	O
multiple	B-Disease
congenital	I-Disease
abnormalities	I-Disease
including	O
craniofacial	B-Disease
dysmorphism	I-Disease
,	O
arthrogryposis	B-Disease
and	O
short	B-Disease
stature	I-Disease
.	O

In	O
addition	O
,	O
one	O
individual	O
showed	O
severe	O
skeletal	O
developmental	O
defects	O
,	O
namely	O
,	O
severe	O
craniosynostosis	O
and	O
gracile	O
bones	O
(	O
severe	O
bone	O
slenderness	O
and	O
perinatal	O
fractures	O
)	O
.	O

Using	O
a	O
yeast	O
model	O
system	O
,	O
we	O
showed	O
that	O
the	O
catalytic	O
and	O
AI	B-Var
domain	I-Var
mutations	I-Var
visibly	O
result	O
in	O
decreased	O
and	O
increased	B-PosReg
calcineurin	B-MPA
signaling	I-MPA
,	O
respectively	O
.	O

These	O
findings	O
indicate	O
that	O
different	O
functional	O
effects	O
of	O
PPP3CA	B-Gene
mutations	O
are	O
associated	O
with	O
two	O
distinct	O
disorders	O
and	O
suggest	O
that	O
functional	O
approaches	O
using	O
a	O
simple	O
cellular	O
system	O
provide	O
a	O
tool	O
for	O
resolving	O
complex	O
genotype	O
-	O
phenotype	O
correlations	O
.	O

Genetic	O
Suppression	O
of	O
Basement	O
Membrane	O
Defects	O
in	O
Caenorhabditis	O
elegans	O
by	O
Gain	O
of	O
Function	O
in	O
Extracellular	O
Matrix	O
and	O
Cell	O
-	O
Matrix	O
Attachment	O
Genes	O
.	O

Basement	O
membranes	O
are	O
extracellular	O
matrices	O
essential	O
for	O
embryonic	O
development	O
in	O
animals	O
.	O

Peroxidasins	O
are	O
extracellular	O
peroxidases	O
implicated	O
in	O
the	O
unique	O
sulfilimine	O
cross	O
-	O
links	O
between	O
type	O
IV	O
basement	O
membrane	O
collagens	O
.	O

Loss	B-NegReg
of	I-NegReg
function	I-NegReg
in	O
the	O
Caenorhabditis	B-Enzyme
elegans	I-Enzyme
peroxidasin	I-Enzyme
PXN-2	I-Enzyme
results	O
in	O
fully	B-CPA
penetrant	I-CPA
embryonic	I-CPA
or	O
larval	B-CPA
lethality	I-CPA
.	O

Using	O
genetic	O
suppressor	O
screening	O
,	O
we	O
find	O
that	O
the	O
requirement	O
for	O
PXN-2	O
in	O
development	O
can	O
be	O
bypassed	O
by	O
gain	O
of	O
function	O
in	O
multiple	O
genes	O
encoding	O
other	O
basement	O
membrane	O
components	O
,	O
or	O
proteins	O
implicated	O
in	O
cell	O
-	O
matrix	O
attachment	O
.	O

We	O
identify	O
multiple	O
alleles	O
of	O
let-805	O
,	O
encoding	O
the	O
transmembrane	O
protein	O
myotactin	O
,	O
which	O
suppress	O
phenotypes	O
of	O
pxn-2	O
null	O
mutants	O
and	O
of	O
other	O
basement	O
membrane	O
mutants	O
such	O
as	O
F	O
-	O
spondin	O
/	O
spon-1	O
These	O
let-805	B-Gene
suppressor	O
alleles	O
cause	O
missense	B-Var
alterations	I-Var
in	O
two	O
pairs	O
of	O
FNIII	O
repeats	O
in	O
the	O
extracellular	O
domain	O
;	O
they	O
act	O
dominantly	O
and	O
have	O
no	O
detectable	O
phenotypes	O
alone	O
,	O
suggesting	O
they	O
cause	O
gain	B-PosReg
of	I-PosReg
function	I-PosReg
.	O

We	O
also	O
identify	O
suppressor	O
missense	O
mutations	O
affecting	O
basement	O
membrane	O
components	O
type	O
IV	O
collagen	O
(	O
emb-9	O
,	O
let-2	O
)	O
and	O
perlecan	O
(	O
unc-52	O
)	O
,	O
as	O
well	O
as	O
a	O
mutation	O
affecting	O
spectraplakin	O
(	O
vab-10	O
)	O
,	O
a	O
component	O
of	O
the	O
epidermal	O
cytoskeleton	O
.	O

These	O
suppressor	O
alleles	O
do	O
not	O
bypass	O
the	O
developmental	O
requirement	O
for	O
core	O
structural	O
proteins	O
of	O
the	O
basement	O
membrane	O
such	O
as	O
laminin	O
or	O
type	O
IV	O
collagen	O
.	O

In	O
conclusion	O
,	O
putative	O
gain	O
-	O
of	O
-	O
function	O
alterations	O
in	O
matrix	O
proteins	O
or	O
in	O
cell	O
-	O
matrix	O
receptors	O
can	O
overcome	O
the	O
requirement	O
for	O
certain	O
basement	O
membrane	O
proteins	O
in	O
embryonic	O
development	O
,	O
revealing	O
previously	O
unknown	O
plasticity	O
in	O
the	O
genetic	O
requirements	O
for	O
the	O
extracellular	O
matrix	O
.	O

Biallelic	B-Var
inactivating	I-Var
variants	I-Var
in	O
the	O
GTPBP2	B-Gene
gene	O
cause	B-Reg
a	O
neurodevelopmental	B-Disease
disorder	I-Disease
with	O
severe	O
intellectual	O
disability	O
.	O

Congenital	O
neurological	O
disorders	O
are	O
genetically	O
highly	O
heterogeneous	O
.	O

Rare	O
forms	O
of	O
hereditary	O
neurological	O
disorders	O
are	O
still	O
difficult	O
to	O
be	O
adequately	O
diagnosed	O
.	O

Pertinent	O
studies	O
,	O
especially	O
when	O
reporting	O
only	O
single	O
families	O
,	O
need	O
independent	O
confirmation	O
.	O

We	O
present	O
three	O
unrelated	O
families	O
in	O
which	O
whole	O
-	O
exome	O
sequencing	O
identified	O
the	O
homozygous	O
non	O
-	O
sense	O
variants	O
c.430[C	B-Var
>	I-Var
T];[C	I-Var
>	I-Var
T	I-Var
]	I-Var
p.(Arg144	I-Var
*	I-Var
)	I-Var
,	O
c.1219[C	B-Var
>	I-Var
T];[C	I-Var
>	I-Var
T	I-Var
]	I-Var
p.(Gln407	I-Var
*	I-Var
)	I-Var
and	O
c.1408[C	B-Var
>	I-Var
T];[C	I-Var
>	I-Var
T	I-Var
]	I-Var
p.(Arg470	I-Var
*	I-Var
)	I-Var
in	O
GTPBP2	B-Gene
.	O

Their	O
clinical	O
presentations	O
include	O
early	O
onset	O
and	O
apparently	O
non	B-CPA
-	I-CPA
progressive	I-CPA
motor	I-CPA
and	I-CPA
cognitive	I-CPA
impairment	I-CPA
,	O
and	O
thereby	O
overlap	O
with	O
findings	O
in	O
a	O
recently	O
described	O
family	O
harbouring	O
a	O
homozygous	O
GTPBP2	O
splice	O
site	O
variant	O
.	O

Notable	O
differences	O
include	O
structural	B-CPA
brain	I-CPA
abnormalities	I-CPA
(	O
e.g.	O
,	O
agenesis	B-CPA
of	I-CPA
the	I-CPA
corpus	I-CPA
callosum	I-CPA
,	O
exclusive	O
to	O
our	O
patients	O
)	O
,	O
and	O
evidence	O
for	O
brain	B-CPA
iron	I-CPA
accumulation	I-CPA
(	O
exclusive	O
to	O
the	O
previously	O
described	O
family	O
)	O
.	O

This	O
report	O
confirms	O
pathogenicity	O
of	O
biallelic	O
GTPBP2	O
inactivation	O
and	O
broadens	O
the	O
phenotypic	O
spectrum	O
.	O

It	O
also	O
underlines	O
that	O
a	O
potential	O
involvement	O
of	O
brain	O
iron	O
accumulation	O
needs	O
clarification	O
.	O

Further	O
patients	O
will	O
have	O
to	O
be	O
identified	O
and	O
characterised	O
in	O
order	O
to	O
fully	O
define	O
the	O
core	O
features	O
of	O
GTPBP2-associated	O
neurological	O
disorder	O
,	O
but	O
future	O
approaches	O
to	O
molecular	O
diagnosis	O
of	O
neurodevelopmental	O
disorders	O
should	O
implement	O
GTPBP2	O
.	O

Bi	B-Var
-	I-Var
allelic	I-Var
inactivating	I-Var
variants	I-Var
in	O
the	O
COCH	B-Gene
gene	O
cause	B-Reg
autosomal	B-Disease
recessive	I-Disease
prelingual	I-Disease
hearing	I-Disease
impairment	I-Disease
.	O

Pathogenic	O
variant	O
in	O
COCH	O
are	O
a	O
known	O
cause	O
of	O
DFNA9	O
autosomal	O
dominant	O
progressive	O
hearing	O
loss	O
and	O
vestibular	O
dysfunction	O
with	O
adult	O
onset	O
.	O

Hitherto	O
,	O
only	O
dominant	O
nonsynonymous	O
variants	O
and	O
in	O
-	O
frame	O
deletions	O
with	O
a	O
presumed	O
dominant	O
negative	O
or	O
gain	O
-	O
of	O
-	O
function	O
effect	O
have	O
been	O
described	O
.	O

Here	O
,	O
we	O
describe	O
two	O
brothers	O
with	O
congenital	O
prelingual	O
deafness	O
and	O
a	O
homozygous	O
nonsense	O
c.292C	B-Var
>	I-Var
T(p	I-Var
.	I-Var
Arg98	I-Var
*	I-Var
)	I-Var
COCH	B-Gene
variant	O
,	O
suggesting	O
a	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
effect	O
.	O

Vestibular	B-Disease
dysfunction	I-Disease
starting	O
in	O
the	O
first	O
decade	O
was	O
observed	O
in	O
the	O
older	O
patient	O
.	O

The	O
heterozygous	O
parents	O
and	O
sibling	O
have	O
normal	O
hearing	O
and	O
vestibular	O
function	O
,	O
except	O
for	O
the	O
mother	O
,	O
who	O
shows	O
vestibular	O
hyporeflexia	O
and	O
abnormal	O
smooth	O
pursuit	O
tests	O
,	O
most	O
likely	O
due	O
to	O
concomitant	O
disease	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
autosomal	O
recessive	O
inheritance	O
of	O
cochlea	O
-	O
vestibular	O
dysfunction	O
caused	O
by	O
a	O
pathogenic	O
variant	O
in	O
the	O
COCH	O
gene	O
.	O

An	O
earlier	O
onset	O
of	O
hearing	O
impairment	O
and	O
vestibular	O
dysfunction	O
compared	O
to	O
the	O
dominant	O
hearing	O
loss	O
causing	O
COCH	O
variants	O
is	O
observed	O
.	O

Serum	O
vitamin	O
C	O
levels	O
modulate	O
the	O
lifespan	O
and	O
endoplasmic	O
reticulum	O
stress	O
response	O
pathways	O
in	O
mice	O
synthesizing	O
a	O
nonfunctional	O
mutant	O
WRN	O
protein	O
.	O

Werner	B-Disease
syndrome	I-Disease
(	O
WS	O
)	O
is	O
a	O
premature	O
aging	O
disorder	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
a	O
RecQ	B-Protein
-	I-Protein
family	I-Protein
DNA	I-Protein
helicase	I-Protein
(	O
WRN	O
)	O
.	O

Mice	O
lacking	O
part	O
of	O
the	O
helicase	O
domain	O
of	O
the	O
WRN	O
ortholog	O
exhibit	O
several	O
phenotypic	O
features	O
of	O
WS	O
.	O

In	O
this	O
study	O
,	O
we	O
generated	O
a	O
Wrn	O
mutant	O
line	O
that	O
,	O
like	O
humans	O
,	O
relies	O
entirely	O
on	O
dietary	O
sources	O
of	O
vitamin	O
C	O
(	O
ascorbate	O
)	O
to	O
survive	O
,	O
by	O
crossing	O
them	O
to	O
mice	O
that	O
lack	O
the	O
gulonolactone	O
oxidase	O
enzyme	O
required	O
for	O
ascorbate	O
synthesis	O
.	O

In	O
the	O
presence	O
of	O
0.01	O
%	O
ascorbate	O
(	O
w	O
/	O
v	O
)	O
in	O
drinking	O
water	O
,	O
double	O
-	O
mutant	O
mice	O
exhibited	O
a	O
severe	O
reduction	O
in	O
lifespan	O
,	O
small	O
size	O
,	O
sterility	O
,	O
osteopenia	O
,	O
and	O
metabolic	O
profiles	O
different	O
from	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mice	O
.	O

Although	O
increasing	O
the	O
dose	O
of	O
ascorbate	O
to	O
0.4	O
%	O
improved	O
dramatically	O
the	O
phenotypes	O
of	O
double	O
-	O
mutant	O
mice	O
,	O
the	O
metabolic	O
and	O
cytokine	O
profiles	O
were	O
different	O
from	O
age	O
-	O
matched	O
WT	O
mice	O
.	O

Finally	O
,	O
double	O
-	O
mutant	O
mice	O
treated	O
with	O
0.01	O
%	O
ascorbate	O
revealed	O
a	O
permanent	O
activation	O
of	O
all	O
the	O
3	O
branches	O
of	O
the	O
ER	O
stress	O
response	O
pathways	O
due	O
to	O
a	O
severe	O
chronic	O
oxidative	O
stress	O
in	O
the	O
ER	O
compartment	O
.	O

In	O
addition	O
,	O
markers	O
associated	O
with	O
the	O
ubiquitin	O
-	O
proteasome	O
-	O
dependent	O
ER	O
-	O
associated	O
degradation	O
pathway	O
were	O
increased	O
.	O

Augmenting	O
the	O
dose	O
of	O
ascorbate	O
reversed	O
the	O
activation	O
of	O
this	O
pathway	O
to	O
WT	O
levels	O
rendering	O
this	O
pathway	O
a	O
potential	O
therapeutic	O
target	O
in	O
WS.-Aumailley	O
,	O
L.	O
,	O
Dubois	O
,	O
M.	O
J.	O
,	O
Brennan	O
,	O
T.	O
A.	O
,	O
Garand	O
,	O
C.	O
,	O
Paquet	O
,	O
E.	O
R.	O
,	O
Pignolo	O
,	O
R.	O
J.	O
,	O
Marette	O
,	O
A.	O
,	O
Lebel	O
,	O
M.	O
Serum	O
vitamin	O
C	O
levels	O
modulate	O
the	O
lifespan	O
and	O
endoplasmic	O
reticulum	O
stress	O
response	O
pathways	O
in	O
mice	O
synthesizing	O
a	O
nonfunctional	O
mutant	O
WRN	O
protein	O
.	O

CgPDR1	B-Gene
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutations	B-Var
lead	B-Reg
to	I-Reg
azole	B-MPA
-	I-MPA
resistance	I-MPA
and	O
increased	B-PosReg
adhesion	B-MPA
in	O
clinical	O
Candida	O
glabrata	O
strains	O
.	O

Recently	O
,	O
Candida	O
glabrata	O
has	O
emerged	O
as	O
a	O
health	O
-	O
threatening	O
pathogen	O
and	O
the	O
rising	O
resistance	O
to	O
antifungal	O
agent	O
in	O
C.	O
glabrata	O
often	O
leads	O
to	O
clinical	O
treatment	O
failure	O
.	O

To	O
investigate	O
the	O
evolution	O
of	O
drug	O
resistance	O
and	O
adherence	O
ability	O
in	O
four	O
paired	O
clinical	O
isolates	O
collected	O
before	O
and	O
after	O
antifungal	O
treatment	O
.	O

Sequence	O
analysis	O
,	O
gene	O
disruption	O
,	O
drug	O
-	O
susceptibility	O
,	O
adhesion	O
tests	O
and	O
real	O
-	O
time	O
quantitative	O
PCR	O
were	O
performed	O
.	O

The	O
azole	O
-	O
susceptible	O
strains	O
acquired	O
azole	O
resistance	O
after	O
antifungal	O
therapy	O
.	O

Four	O
gain	O
-	O
of	O
-	O
function	O
(	O
GOF	O
)	O
mutations	O
in	O
CgPDR1	O
were	O
revealed	O
by	O
sequence	O
analysis	O
,	O
namely	O
G1099D	O
,	O
G346D	O
,	O
L344S	O
and	O
P927S	O
,	O
the	O
last	O
being	O
reported	O
for	O
the	O
first	O
time	O
.	O

CDR1	B-MPA
,	O
CDR2	I-MPA
and	I-MPA
SNQ2	I-MPA
efflux	I-MPA
pump	I-MPA
gene	I-MPA
expression	I-MPA
levels	I-MPA
were	O
elevated	B-PosReg
in	O
strains	O
harbouring	O
GOF	B-PosReg
mutations	B-Var
in	O
CgPDR1	B-Gene
,	O
resulting	O
in	O
decreased	B-NegReg
azole	B-MPA
susceptibility	I-MPA
.	O

CgPDR1	O
alleles	O
with	O
distinct	O
GOF	O
mutations	O
displayed	O
different	O
expression	O
profiles	O
for	O
the	O
drug	O
-	O
related	O
genes	O
.	O

CgPDR1GOF	B-Gene
mutations	B-Var
led	O
to	O
increased	B-PosReg
efflux	B-MPA
pumps	I-MPA
expression	I-MPA
levels	I-MPA
in	O
a	O
strain	O
background	O
independent	O
way	O
.	O

Hyperactive	O
Pdr1G1099D	O
and	O
Pdr1P927S	O
displayed	O
strain	O
background	O
-	O
dependent	O
increased	O
adherence	O
to	O
host	O
cells	O
via	O
upregulation	O
of	O
EPA1	O
transcription	O
.	O

Interestingly	O
,	O
the	O
drug	O
transporter	O
gene	O
expression	O
levels	O
did	O
not	O
always	O
correspond	O
with	O
that	O
of	O
the	O
adhesin	O
EPA1	O
gene	O
.	O

GOF	B-PosReg
mutations	B-Var
in	O
CgPDR1	B-Gene
conferred	B-Reg
drug	B-MPA
resistance	I-MPA
and	O
increased	B-PosReg
adherence	B-MPA
in	O
the	O
clinical	O
strains	O
,	O
possibly	O
endowing	O
C.	O
glabrata	O
with	O
increased	O
viability	O
and	O
pathogenicity	O
.	O

Loss	O
of	O
Function	O
of	O
the	O
Nuclear	O
Receptor	O
NR2F2	O
,	O
Encoding	O
COUP	O
-	O
TF2	O
,	O
Causes	O
Testis	O
Development	O
and	O
Cardiac	O
Defects	O
in	O
46,XX	O
Children	O
.	O

Emerging	O
evidence	O
from	O
murine	O
studies	O
suggests	O
that	O
mammalian	O
sex	O
determination	O
is	O
the	O
outcome	O
of	O
an	O
imbalance	O
between	O
mutually	O
antagonistic	O
male	O
and	O
female	O
regulatory	O
networks	O
that	O
canalize	O
development	O
down	O
one	O
pathway	O
while	O
actively	O
repressing	O
the	O
other	O
.	O

However	O
,	O
in	O
contrast	O
to	O
testis	O
formation	O
,	O
the	O
gene	O
regulatory	O
pathways	O
governing	O
mammalian	O
ovary	O
development	O
have	O
remained	O
elusive	O
.	O

We	O
performed	O
exome	O
or	O
Sanger	O
sequencing	O
on	O
79	O
46,XX	O
SRY	O
-	O
negative	O
individuals	O
with	O
either	O
unexplained	O
virilization	O
or	O
with	O
testicular	O
/	O
ovotesticular	O
disorders	O
/	O
differences	O
of	O
sex	O
development	O
(	O
TDSD	O
/	O
OTDSD	O
)	O
.	O

We	O
identified	O
heterozygous	O
frameshift	O
mutations	O
in	O
NR2F2	B-Gene
,	O
encoding	O
COUP	O
-	O
TF2	O
,	O
in	O
three	O
children	O
.	O

One	O
carried	O
a	O
c.103_109delGGCGCCC	O
(	B-Var
p	I-Var
.	I-Var
Gly35Argfs∗75	I-Var
)	I-Var
mutation	O
,	O
while	O
two	O
others	O
carried	O
a	O
c.97_103delCCGCCCG	O
(	B-Var
p	I-Var
.	I-Var
Pro33Alafs∗77	I-Var
)	I-Var
mutation	O
.	O

In	O
two	O
of	O
three	O
children	O
the	O
mutation	O
was	O
de	O
novo	O
.	O

All	O
three	O
children	O
presented	B-Reg
with	I-Reg
congenital	B-Disease
heart	I-Disease
disease	I-Disease
(	O
CHD	O
)	O
,	O
one	O
child	O
with	O
congenital	O
diaphragmatic	O
hernia	O
(	O
CDH	O
)	O
,	O
and	O
two	O
children	O
with	O
blepharophimosis	O
-	O
ptosis	O
-	O
epicanthus	O
inversus	O
syndrome	O
(	O
BPES	O
)	O
.	O

The	O
three	O
children	O
had	O
androgen	O
production	O
,	O
virilization	O
of	O
external	O
genitalia	O
,	O
and	O
biochemical	O
or	O
histological	O
evidence	O
of	O
testicular	O
tissue	O
.	O

We	O
demonstrate	O
a	O
highly	O
significant	O
association	O
between	O
the	O
NR2F2	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
and	O
this	O
syndromic	B-Disease
form	I-Disease
of	I-Disease
DSD	I-Disease
(	O
p	O
=	O
2.44	O
×	O
10	O
-	O
8	O
)	O
.	O

We	O
show	O
that	O
COUP	O
-	O
TF2	O
is	O
highly	O
abundant	O
in	O
a	O
FOXL2-negative	O
stromal	O
cell	O
population	O
of	O
the	O
fetal	O
human	O
ovary	O
.	O

In	O
contrast	O
to	O
the	O
mouse	O
,	O
these	O
data	O
establish	O
COUP	O
-	O
TF2	O
as	O
a	O
human	O
"	O
pro	O
-	O
ovary	O
"	O
and	O
"	O
anti	O
-	O
testis	O
"	O
sex	O
-	O
determining	O
factor	O
in	O
female	O
gonads	O
.	O

Furthermore	O
,	O
the	O
data	O
presented	O
here	O
provide	O
additional	O
evidence	O
of	O
the	O
emerging	O
importance	O
of	O
nuclear	O
receptors	O
in	O
establishing	O
human	O
ovarian	O
identity	O
and	O
indicate	O
that	O
nuclear	O
receptors	O
may	O
have	O
divergent	O
functions	O
in	O
mouse	O
and	O
human	O
biology	O
.	O

Biallelic	B-Var
Mutations	I-Var
in	O
ATP5F1D	B-Gene
,	O
which	O
Encodes	O
a	O
Subunit	O
of	O
ATP	O
Synthase	O
,	O
Cause	B-Reg
a	O
Metabolic	B-MPA
Disorder	I-MPA
.	O

ATP	O
synthase	O
,	O
H+	O
transporting	O
,	O
mitochondrial	O
F1	O
complex	O
,	O
δ	O
subunit	O
(	O
ATP5F1D	O
;	O
formerly	O
ATP5D	O
)	O
is	O
a	O
subunit	O
of	O
mitochondrial	O
ATP	O
synthase	O
and	O
plays	O
an	O
important	O
role	O
in	O
coupling	O
proton	O
translocation	O
and	O
ATP	O
production	O
.	O

Here	O
,	O
we	O
describe	O
two	O
individuals	O
,	O
each	O
with	O
homozygous	O
missense	B-Var
variants	I-Var
in	O
ATP5F1D	B-Gene
,	O
who	O
presented	B-Reg
with	O
episodic	B-MPA
lethargy	I-MPA
,	O
metabolic	B-MPA
acidosis	I-MPA
,	O
3-methylglutaconic	B-MPA
aciduria	I-MPA
,	O
and	O
hyperammonemia	B-Disease
.	O

Subject	O
1	O
,	O
homozygous	O
for	O
c.245C	O
>	O
T	O
(	O
p	O
.	O
Pro82Leu	O
)	O
,	O
presented	O
with	O
recurrent	O
metabolic	O
decompensation	O
starting	O
in	O
the	O
neonatal	O
period	O
,	O
and	O
subject	O
2	O
,	O
homozygous	O
for	O
c.317T	O
>	O
G	O
(	O
p	O
.	O
Val106Gly	O
)	O
,	O
presented	O
with	O
acute	O
encephalopathy	O
in	O
childhood	O
.	O

Cultured	O
skin	O
fibroblasts	O
from	O
these	O
individuals	O
exhibited	O
impaired	O
assembly	O
of	O
F1FO	O
ATP	O
synthase	O
and	O
subsequent	O
reduced	O
complex	O
V	O
activity	O
.	O

Cells	O
from	O
subject	O
1	O
also	O
exhibited	O
a	O
significant	O
decrease	O
in	O
mitochondrial	O
cristae	O
.	O

Knockdown	O
of	O
Drosophila	O
ATPsynδ	O
,	O
the	O
ATP5F1D	O
homolog	O
,	O
in	O
developing	O
eyes	O
and	O
brains	O
caused	O
a	O
near	O
complete	O
loss	O
of	O
the	O
fly	O
head	O
,	O
a	O
phenotype	O
that	O
was	O
fully	O
rescued	O
by	O
wild	O
-	O
type	O
human	O
ATP5F1D.	O
In	O
contrast	O
,	O
expression	O
of	O
the	O
ATP5F1D	O
c.245C	O
>	O
T	O
and	O
c.317T	O
>	O
G	O
variants	B-Var
rescued	B-PosReg
the	O
head	B-MPA
-	I-MPA
size	I-MPA
phenotype	I-MPA
but	O
recapitulated	B-NegReg
the	O
eye	B-MPA
and	O
antennae	B-MPA
defects	I-MPA
seen	O
in	O
other	O
genetic	O
models	O
of	O
mitochondrial	O
oxidative	O
phosphorylation	O
deficiency	O
.	O

Our	O
data	O
establish	O
c.245C	O
>	O
T	O
(	O
p	O
.	O
Pro82Leu	O
)	O
and	O
c.317T	O
>	O
G	O
(	O
p	O
.	O
Val106Gly	O
)	O
in	O
ATP5F1D	O
as	O
pathogenic	O
variants	B-Var
leading	B-Reg
to	I-Reg
a	O
Mendelian	B-Disease
mitochondrial	I-Disease
disease	I-Disease
featuring	O
episodic	O
metabolic	O
decompensation	O
.	O

Multifocal	O
atrial	O
and	O
ventricular	O
premature	O
contractions	O
with	O
an	O
increased	O
risk	O
of	O
dilated	B-Disease
cardiomyopathy	I-Disease
caused	O
by	O
a	O
Nav1.5	B-Gene
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	O
(	B-Var
G213D	I-Var
)	I-Var
.	O

BACKGROUND	O
:	O
SCN5A	O
mutations	B-Var
can	O
lead	B-Reg
to	I-Reg
different	O
cardiac	B-Disease
diseases	I-Disease
.	O

Recently	O
,	O
SCN5A	O
mutations	O
have	O
been	O
linked	O
to	O
the	O
clinical	O
entity	O
multifocal	O
ectopic	O
Purkinje	O
-	O
related	O
premature	O
contractions	O
(	O
MEPPC	O
)	O
characterized	O
by	O
ventricular	O
ectopy	O
and	O
dilated	O
cardiomyopathy	O
.	O

METHODS	O
&	O
RESULTS	O
:	O
A	O
family	O
with	O
a	O
uniform	O
MEPPC	O
-	O
like	O
phenotype	O
,	O
associated	O
with	O
complex	O
atrial	O
and	O
ventricular	O
arrhythmias	O
and	O
dilated	O
cardiomyopathy	O
caused	O
by	O
a	O
high	O
frequency	O
of	O
ventricular	O
ectopy	O
was	O
clinically	O
assessed	O
.	O

Screening	O
of	O
the	O
SCN5A	B-Gene
gene	O
revealed	O
a	O
missense	B-Var
mutation	I-Var
in	O
the	O
linker	O
between	O
segments	O
3	O
and	O
4	O
in	O
domain	O
1	O
of	O
the	O
Nav1.5	O
protein	O
,	O
resulting	B-Reg
in	I-Reg
a	O
glycine	O
to	O
aspartate	O
substitution	O
at	O
position	O
213	O
(	B-Var
G213D	I-Var
)	I-Var
.	O

The	O
phenotype	O
co	O
-	O
segregated	O
with	O
the	O
missense	O
mutation	O
.	O

Electrophysiological	O
studies	O
of	O
wild	O
type	O
(	O
WT	O
)	O
hNav1.5	O
and	O
hNav1.5_G213D	O
expressed	O
in	O
CHO	O
-	O
K	O
cells	O
showed	O
that	O
the	O
voltage	O
of	O
half	O
-	O
maximal	O
activation	O
(	O
V½	O
)	O
was	O
significantly	O
more	O
negative	O
for	O
hNav1.5_G213D	O
compared	O
to	O
WT	O
(	O
V½=-38.7±0.5mV	O
for	O
WT	O
and	O
V½=-42.4±0.5mV	O
for	O
G213D	O
;	O
P<0.001	O
)	O
.	O

This	O
suggests	O
activation	O
of	O
Nav1.5_G231D	O
at	O
more	O
negative	O
potentials	O
.	O

The	O
V½	O
of	O
steady	O
-	O
state	O
inactivation	O
was	O
significantly	O
shifted	O
towards	O
more	O
positive	O
values	O
for	O
Nav1.5_G213D	O
(	O
V½=-86.7±0.2mV	O
for	O
WT	O
and	O
-82.2±0.3mV	O
for	O
G213D	O
;	O
P<0.001	O
)	O
,	O
also	O
contributing	O
to	O
a	O
gain	O
-	O
of	O
-	O
function	O
phenotype	O
.	O

Flecainide	O
and	O
amiodarone	O
markedly	O
reduced	O
premature	O
atrial	O
and	O
ventricular	O
contractions	O
in	O
four	O
patients	O
.	O

CONCLUSION	O
:	O
The	O
Nav1.5_G213D	B-Gene
mutation	O
is	O
associated	O
with	O
a	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
phenotype	O
,	O
multifocal	O
atrial	O
and	O
ventricular	O
ectopy	O
and	O
dilated	B-Disease
cardiomyopathy	I-Disease
.	O

Since	O
patients	O
with	O
a	O
MEPPC	O
-	O
like	O
phenotype	O
may	O
specifically	O
benefit	O
from	O
Class-1	O
antiarrhythmic	O
drugs	O
or	O
amiodarone	O
,	O
clinical	O
identification	O
of	O
this	O
disease	O
entity	O
is	O
important	O
.	O

The	O
Molecular	O
Chaperone	O
HSP90	O
Promotes	O
Notch	O
Signaling	O
in	O
the	O
Germline	O
of	O
Caenorhabditis	O
elegans	O
.	O

In	O
a	O
genetic	O
screen	O
to	O
identify	O
genes	O
that	O
promote	O
GLP-1	O
/	O
Notch	O
signaling	O
in	O
Caenorhabditis	O
elegans	O
germline	O
stem	O
cells	O
,	O
we	O
found	O
a	O
single	O
mutation	O
,	O
om40	O
,	O
defining	O
a	O
gene	O
called	O
ego-3	O
.	O

ego-3(om40	B-Gene
)	I-Gene
causes	B-Reg
several	O
defects	B-MPA
in	O
the	O
soma	O
and	O
the	O
germline	O
,	O
including	O
paralysis	B-Disease
during	O
larval	O
development	O
,	O
sterility	B-Disease
,	O
delayed	B-CPA
proliferation	I-CPA
of	O
germline	O
stem	O
cells	O
,	O
and	O
ectopic	B-CPA
germline	I-CPA
stem	I-CPA
cell	I-CPA
proliferation	I-CPA
.	O

Whole	O
genome	O
sequencing	O
identified	O
om40	O
as	O
an	O
allele	O
of	O
hsp-90	O
,	O
previously	O
known	O
as	O
daf-21	O
,	O
which	O
encodes	O
the	O
C.	O
elegans	O
ortholog	O
of	O
the	O
cytosolic	O
form	O
of	O
HSP90	O
.	O

This	O
protein	O
is	O
a	O
molecular	O
chaperone	O
with	O
a	O
central	O
position	O
in	O
the	O
protein	O
homeostasis	O
network	O
,	O
which	O
is	O
responsible	O
for	O
proper	O
folding	O
,	O
structural	O
maintenance	O
,	O
and	O
degradation	O
of	O
proteins	O
.	O

In	O
addition	O
to	O
its	O
essential	O
role	O
in	O
cellular	O
function	O
,	O
HSP90	O
plays	O
an	O
important	O
role	O
in	O
stem	O
cell	O
maintenance	O
and	O
renewal	O
.	O

Complementation	O
analysis	O
using	O
a	O
deletion	O
allele	O
of	O
hsp-90	O
confirmed	O
that	O
ego-3	O
is	O
the	O
same	O
gene	O
.	O

hsp-90(om40	O
)	O
is	O
an	O
I→N	O
conservative	O
missense	O
mutation	O
of	O
a	O
highly	O
conserved	O
residue	O
in	O
the	O
middle	O
domain	O
of	O
HSP-90	O
RNA	O
interference	O
-	O
mediated	O
knockdown	O
of	O
hsp-90	O
expression	O
partially	O
phenocopied	O
hsp-90(om40	O
)	O
,	O
confirming	O
the	O
loss	O
-	O
of	O
-	O
function	O
nature	O
of	O
hsp-90(om40	O
)	O
Furthermore	O
,	O
reduced	O
HSP-90	O
activity	O
enhanced	O
the	O
effect	O
of	O
reduced	O
function	O
of	O
both	O
the	O
GLP-1	O
receptor	O
and	O
the	O
downstream	O
LAG-1	O
transcription	O
factor	O
.	O

Taken	O
together	O
,	O
our	O
results	O
provide	O
the	O
first	O
experimental	O
evidence	O
of	O
an	O
essential	O
role	O
for	O
HSP90	O
in	O
Notch	O
signaling	O
in	O
development	O
.	O

Impact	O
of	O
CYP2C19	O
Polymorphisms	O
on	O
Clinical	O
Outcomes	O
and	O
Antiplatelet	O
Potency	O
of	O
Clopidogrel	O
in	O
Caucasian	O
Poststroke	O
Survivors	O
.	O

BACKGROUND	O
:	O
Variable	O
response	O
after	O
clopidogrel	O
is	O
well	O
documented	O
and	O
may	O
affect	O
major	O
adverse	O
clinical	O
events	O
after	O
stroke	O
.	O

Impact	O
of	O
CYP2C19	O
genetic	O
polymorphisms	O
is	O
an	O
established	O
marker	O
linked	O
to	O
variable	O
response	O
after	O
clopidogrel	O
.	O

However	O
,	O
the	O
association	O
of	O
certain	O
genetic	O
polymorphisms	O
with	O
prediction	O
of	O
major	O
adverse	O
clinical	O
events	O
following	O
stroke	O
still	O
remains	O
controversial	O
,	O
especially	O
in	O
Caucasians	O
.	O

STUDY	O
QUESTION	O
:	O
The	O
primary	O
aim	O
was	O
to	O
evaluate	O
the	O
impact	O
of	O
CYP2C19	O
allele	O
*	O
2	O
in	O
heterozygote	O
form	O
on	O
major	O
adverse	O
clinical	O
events	O
in	O
Caucasian	O
poststroke	O
survivors	O
treated	O
with	O
clopidogrel	O
.	O

The	O
secondary	O
aim	O
was	O
to	O
analyze	O
the	O
potential	O
link	O
between	O
CYP2C19	O
genetic	O
polymorphism	O
and	O
variable	O
response	O
after	O
clopidogrel	O
.	O

STUDY	O
DESIGN	O
:	O
One	O
hundred	O
thirty	O
patients	O
of	O
Caucasian	O
origin	O
following	O
documented	O
ischemic	O
stroke	O
were	O
included	O
.	O

Platelet	O
reactivity	O
was	O
assessed	O
by	O
light	O
transmittance	O
aggregometry	O
(	O
LTA	O
)	O
and	O
matched	O
with	O
various	O
CYP2C19	O
loss	O
-	O
of	O
-	O
function	O
genetic	O
polymorphisms	O
and	O
major	O
adverse	O
clinical	O
events	O
(	O
composite	O
of	O
vascular	O
deaths	O
,	O
stroke	O
/	O
transient	O
ischemic	O
attack	O
,	O
and	O
myocardial	O
infarction	O
)	O
.	O

RESULTS	O
:	O
Over	O
the	O
mean	O
follow	O
-	O
up	O
of	O
14.9	O
months	O
,	O
19	O
patients	O
experienced	O
major	O
adverse	O
clinical	O
events	O
.	O

The	O
risk	O
of	O
major	B-MPA
adverse	I-MPA
clinical	I-MPA
events	I-MPA
was	O
nearly	O
3-fold	O
in	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
allele	B-Var
carriers	O
(	O
hazard	O
ratio	O
=	O
2.904	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.083	O
-	O
7.786	O
;	O
P	O
=	O
0.013	O
)	O
,	O
whereas	O
the	O
risk	O
of	O
ischemic	B-MPA
stroke	I-MPA
or	O
transient	B-MPA
ischemic	I-MPA
attack	I-MPA
alone	I-MPA
was	O
also	O
higher	O
(	O
hazard	O
ratio	O
=	O
3.170	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.281	O
-	O
7.849	O
;	O
P	O
=	O
0.034	O
)	O
.	O

Platelet	B-MPA
activity	I-MPA
was	O
strongly	O
associated	B-Interaction
with	O
allele	B-Var
*	I-Var
2	I-Var
status	I-Var
(	O
rs	O
=	O
0.21	O
,	O
P	O
=	O
0.016	O
)	O
but	O
not	O
with	O
other	O
genetic	O
polymorphisms	O
.	O

Carriers	O
of	O
allele*2	O
exhibited	O
lower	O
platelet	O
response	O
to	O
adenosine	O
diphosphate	O
-	O
mean	O
LTA	O
(	O
30.1	O
%	O
vs.	O
42.0	O
%	O
;	O
P	O
=	O
0.017	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
LTA	O
results	O
with	O
other	O
agonists	O
.	O

Strong	O
association	O
of	O
increase	O
in	O
adenosine	O
diphosphate	O
-	O
induced	O
aggregation	O
with	O
diabetes	O
mellitus	O
(	O
rs	O
=	O
0.20	O
,	O
P	O
=	O
0.023	O
)	O
,	O
increasing	O
age	O
(	O
rs	O
=	O
0.23	O
,	O
P	O
=	O
0.008	O
)	O
,	O
and	O
conversely	O
diminishing	O
over	O
increased	O
weight	O
(	O
rs	O
=	O
0.23	O
,	O
P	O
=	O
0.009	O
)	O
was	O
also	O
detected	O
.	O

The	O
carriers	O
of	O
other	O
gene	O
allele	O
variants	O
lack	O
uniformed	O
impact	O
on	O
variable	O
response	O
after	O
clopidogrel	O
.	O

CONCLUSIONS	O
:	O
Even	O
heterozygous	O
CYP2C19	O
*	O
2	O
allele	O
carriers	O
among	O
Caucasian	O
patients	O
after	O
ischemic	O
stroke	O
had	O
a	O
higher	O
risk	O
of	O
major	O
adverse	O
clinical	O
events	O
.	O

The	O
LTA	O
,	O
however	O
,	O
did	O
not	O
predict	O
major	O
adverse	O
clinical	O
events	O
.	O

The	O
exact	O
clinical	O
utility	O
of	O
these	O
findings	O
is	O
still	O
uncertain	O
and	O
requires	O
large	O
outcome	O
-	O
driven	O
randomized	O
trial	O
in	O
Caucasians	O
for	O
proof	O
of	O
concept	O
.	O

The	O
Arabidopsis	O
thaliana	O
Mediator	O
subunit	O
MED8	O
regulates	O
plant	O
immunity	O
to	O
Botrytis	O
Cinerea	O
through	O
interacting	O
with	O
the	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
(	O
bHLH	O
)	O
transcription	O
factor	O
FAMA	O
.	O

The	O
Mediator	O
complex	O
is	O
at	O
the	O
core	O
of	O
transcriptional	O
regulation	O
and	O
plays	O
a	O
central	O
role	O
in	O
plant	O
immunity	O
.	O

The	O
MEDIATOR25	O
(	O
MED25	O
)	O
subunit	O
of	O
Arabidopsis	O
thaliana	O
regulates	O
jasmonate	O
-	O
dependent	O
resistance	O
to	O
Botrytis	O
cinerea	O
through	O
interacting	O
with	O
the	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
(	O
bHLH	O
)	O
transcription	O
factor	O
of	O
jasmonate	O
signaling	O
,	O
MYC2	O
.	O

Another	O
Mediator	O
subunit	O
,	O
MED8	O
,	O
acts	O
independently	O
or	O
together	O
with	O
MED25	O
in	O
plant	O
immunity	O
.	O

However	O
,	O
unlike	O
MED25	O
,	O
the	O
underlying	O
action	O
mechanisms	O
of	O
MED8	O
in	O
regulating	O
B.	O
cinerea	O
resistance	O
are	O
still	O
unknown	O
.	O

Here	O
,	O
we	O
demonstrated	O
that	O
MED8	O
regulated	O
plant	O
immunity	O
to	O
B.	O
cinerea	O
through	O
interacting	O
with	O
another	O
bHLH	O
transcription	O
factor	O
,	O
FAMA	O
,	O
which	O
was	O
previously	O
shown	O
to	O
control	O
the	O
final	O
proliferation	O
/	O
differentiation	O
switch	O
during	O
stomatal	O
development	O
.	O

Our	O
research	O
demonstrates	O
that	O
FAMA	O
is	O
also	O
an	O
essential	O
component	O
of	O
B.	O
cinerea	O
resistance	O
.	O

The	O
fama	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutants	B-Var
(	O
fama-1	O
and	O
fama-2	O
)	O
increased	B-PosReg
susceptibility	B-MPA
to	I-MPA
B.	I-MPA
cinerea	I-MPA
infection	I-MPA
and	O
reduced	B-NegReg
defense	B-MPA
-	I-MPA
gene	I-MPA
expression	I-MPA
.	O

On	O
the	O
contrary	O
,	O
transgenic	O
lines	O
constitutively	O
overexpressing	O
FAMA	O
showed	O
opposite	O
B.	O
cinerea	O
responses	O
compared	O
with	O
the	O
fama	O
loss	O
-	O
of	O
-	O
function	O
mutants	O
.	O

FAMA	O
-	O
overexpressed	O
plants	O
displayed	O
enhanced	O
resistance	O
to	O
B.	O
cinerea	O
infection	O
and	O
increased	O
expression	O
levels	O
of	O
defensin	O
genes	O
following	O
B.	O
cinerea	O
treatment	O
.	O

Genetic	O
analysis	O
of	O
MED8	O
and	O
FAMA	O
suggested	O
that	O
FAMA	O
-	O
regulated	O
pathogen	O
resistance	O
was	O
dependent	O
on	O
MED8	O
.	O

In	O
addition	O
,	O
MED8	O
and	O
FAMA	O
were	O
both	O
associated	O
with	O
the	O
G	O
-	O
box	O
region	O
in	O
the	O
promoter	O
of	O
ORA59	O
.	O

Our	O
findings	O
indicate	O
that	O
the	O
MED8	O
subunit	O
of	O
the	O
A.	O
thaliana	O
Mediator	O
regulates	O
plant	O
immunity	O
to	O
B.	O
cinerea	O
through	O
interacting	O
with	O
the	O
transcription	O
factor	O
FAMA	O
,	O
which	O
was	O
discovered	O
to	O
be	O
a	O
key	O
component	O
in	O
B.	O
cinerea	O
resistance	O
.	O

A	O
Gain	O
-	O
of	O
-	O
Function	O
Mutation	O
in	O
EPO	O
in	O
Familial	O
Erythrocytosis	O
.	O

Familial	B-Disease
erythrocytosis	I-Disease
with	O
elevated	O
erythropoietin	O
levels	O
is	O
frequently	O
caused	B-Reg
by	O
mutations	B-Var
in	O
genes	O
that	O
regulate	O
oxygen	O
-	O
dependent	O
transcription	O
of	O
the	O
gene	O
encoding	O
erythropoietin	O
(	O
EPO	B-Gene
)	I-Gene
.	O

We	O
identified	O
a	O
mutation	O
in	O
EPO	O
that	O
cosegregated	O
with	O
disease	O
with	O
a	O
logarithm	O
of	O
the	O
odds	O
(	O
LOD	O
)	O
score	O
of	O
3.3	O
in	O
a	O
family	O
with	O
autosomal	O
dominant	O
erythrocytosis	O
.	O

This	O
mutation	B-Var
,	O
a	O
single	O
-	O
nucleotide	O
deletion	O
(	O
c.32delG	O
)	O
,	O
introduces	O
a	O
frameshift	O
in	O
exon	O
2	O
that	O
interrupts	B-NegReg
translation	O
of	O
the	O
main	B-MPA
EPO	I-MPA
messenger	I-MPA
RNA	I-MPA
(	I-MPA
mRNA	I-MPA
)	I-MPA
transcript	I-MPA
but	O
initiates	O
excess	O
production	O
of	O
erythropoietin	O
from	O
what	O
is	O
normally	O
a	O
noncoding	O
EPO	O
mRNA	O
transcribed	O
from	O
an	O
alternative	O
promoter	O
located	O
in	O
intron	O
1	O
.	O

(	O
Funded	O
by	O
the	O
Gebert	O
Rüf	O
Foundation	O
and	O
others	O
.	O

)	O
.	O

Inactivation	B-Var
of	O
Fgfr2	B-Gene
gene	O
in	O
mouse	O
secondary	O
palate	O
mesenchymal	O
cells	O
leads	B-Reg
to	I-Reg
cleft	B-Disease
palate	I-Disease
.	O

Numerous	O
studies	O
have	O
been	O
conducted	O
to	O
understand	O
the	O
molecular	O
mechanisms	O
controlling	O
mammalian	O
secondary	O
palate	O
development	O
such	O
as	O
growth	O
,	O
reorientation	O
and	O
fusion	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
signaling	O
factors	O
regulating	O
palate	O
initiation	O
.	O

Mouse	O
fibroblast	O
growth	O
factor	O
(	O
FGF	O
)	O
receptor	O
2	O
gene	O
(	O
Fgfr2	O
)	O
is	O
expressed	O
on	O
E11.5	O
in	O
the	O
palate	O
outgrowth	O
within	O
the	O
maxillary	O
process	O
,	O
in	O
a	O
region	O
that	O
is	O
responsible	O
for	O
palate	O
cell	O
specification	O
and	O
shelf	O
initiation	O
.	O

Fgfr2	O
continues	O
to	O
express	O
in	O
palate	O
on	O
E12.5	O
and	O
E13.5	O
in	O
both	O
epithelial	O
and	O
mesenchymal	O
cells	O
,	O
and	O
inactivation	B-Var
of	O
Fgfr2	B-Gene
expression	O
in	O
mesenchymal	O
cells	O
using	O
floxed	O
Fgfr2	O
allele	O
and	O
Osr2-Cre	O
leads	B-Reg
to	I-Reg
cleft	B-Disease
palate	I-Disease
at	O
various	O
stages	O
including	O
reorientation	O
,	O
horizontal	O
growth	O
and	O
fusion	O
.	O

Notably	O
,	O
some	O
mutant	O
embryos	O
displayed	O
no	O
sign	O
of	O
palate	O
shelf	O
formation	O
suggesting	O
that	O
FGF	O
receptor	O
2	O
mediated	O
FGF	O
signaling	O
may	O
play	O
an	O
important	O
role	O
in	O
palate	O
initiation	O
.	O

MIB-1	O
Is	O
Required	O
for	O
Spermatogenesis	O
and	O
Facilitates	O
LIN-12	O
and	O
GLP-1	O
Activity	O
in	O
Caenorhabditis	O
elegans	O
.	O

Covalent	O
attachment	O
of	O
ubiquitin	O
to	O
substrate	O
proteins	O
changes	O
their	O
function	O
or	O
marks	O
them	O
for	O
proteolysis	O
,	O
and	O
the	O
specificity	O
of	O
ubiquitin	O
attachment	O
is	O
mediated	O
by	O
the	O
numerous	O
E3	O
ligases	O
encoded	O
by	O
animals	O
.	O

Mind	O
Bomb	O
is	O
an	O
essential	O
E3	O
ligase	O
during	O
Notch	O
pathway	O
signaling	O
in	O
insects	O
and	O
vertebrates	O
.	O

While	O
Caenorhabditis	O
elegans	O
encodes	O
a	O
Mind	O
Bomb	O
homolog	O
(	O
mib-1	O
)	O
,	O
it	O
has	O
never	O
been	O
recovered	O
in	O
the	O
extensive	O
Notch	O
suppressor	O
/	O
enhancer	O
screens	O
that	O
have	O
identified	O
numerous	O
pathway	O
components	O
.	O

Here	O
,	O
we	O
show	O
that	O
C.	O
elegans	O
mib-1	B-Gene
null	O
mutants	B-Var
have	O
a	O
spermatogenesis	B-Disease
-	I-Disease
defective	I-Disease
phenotype	I-Disease
that	O
results	B-Reg
in	I-Reg
a	O
heterogeneous	B-MPA
mixture	I-MPA
of	I-MPA
arrested	I-MPA
spermatocytes	I-MPA
,	O
defective	O
spermatids	O
,	O
and	O
motility	O
-	O
impaired	O
spermatozoa	O
.	O

mib-1	O
mutants	O
also	O
have	O
chromosome	O
segregation	O
defects	O
during	O
meiosis	O
,	O
molecular	O
null	O
mutants	O
are	O
intrinsically	O
temperature	O
-	O
sensitive	O
,	O
and	O
many	O
mib-1	O
spermatids	O
contain	O
large	O
amounts	O
of	O
tubulin	O
.	O

These	O
phenotypic	O
features	O
are	O
similar	O
to	O
the	O
endogenous	O
RNA	O
intereference	O
(	O
RNAi	O
)	O
mutants	O
,	O
but	O
mib-1	O
mutants	O
do	O
not	O
affect	O
RNAi	O
.	O

MIB-1	O
protein	O
is	O
expressed	O
throughout	O
the	O
germ	O
line	O
with	O
peak	O
expression	O
in	O
spermatocytes	O
followed	O
by	O
segregation	O
into	O
the	O
residual	O
body	O
during	O
spermatid	O
formation	O
.	O

C.	O
elegans	O
mib-1	O
expression	O
,	O
while	O
upregulated	O
during	O
spermatogenesis	O
,	O
also	O
occurs	O
somatically	O
,	O
including	O
in	O
vulva	O
precursor	O
cells	O
.	O

Here	O
,	O
we	O
show	O
that	O
mib-1	B-Gene
mutants	B-Var
suppress	B-NegReg
both	O
lin-12	B-Gene
and	O
glp-1	B-Gene
(	O
C.	O
elegans	O
Notch	O
)	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutants	B-Var
,	O
restoring	B-PosReg
anchor	B-MPA
cell	I-MPA
formation	I-MPA
and	O
a	O
functional	B-MPA
vulva	I-MPA
to	O
the	O
former	O
and	O
partly	O
restoring	O
oocyte	B-MPA
production	I-MPA
to	O
the	O
latter	O
.	O

However	O
,	O
suppressed	O
hermaphrodites	O
are	O
only	O
observed	O
when	O
grown	O
at	O
25	O
°	O
,	O
and	O
they	O
are	O
self	O
-	O
sterile	O
.	O

This	O
probably	O
explains	O
why	O
mib-1	O
was	O
not	O
previously	O
recovered	O
as	O
a	O
Notch	O
pathway	O
component	O
in	O
suppressor	O
/	O
enhancer	O
selection	O
experiments	O
.	O

The	O
curious	O
case	O
of	O
Gαs	O
gain	O
-	O
of	O
-	O
function	O
in	O
neoplasia	O
.	O

BACKGROUND	O
:	O
Mutations	B-Var
activating	B-PosReg
the	O
α	O
subunit	O
of	O
heterotrimeric	B-Protein
Gs	I-Protein
protein	I-Protein
are	O
associated	O
with	O
a	O
number	O
of	O
highly	O
specific	O
pathological	O
molecular	O
phenotypes	O
.	O

One	O
of	O
the	O
best	O
characterized	O
is	O
the	O
McCune	B-Disease
Albright	I-Disease
syndrome	I-Disease
.	O

The	O
disease	O
presents	O
with	O
an	O
increased	O
incidence	O
of	O
neoplasias	O
in	O
specific	O
tissues	O
.	O

MAIN	O
BODY	O
:	O
A	O
similar	O
repertoire	O
of	O
neoplasms	O
can	O
develop	O
whether	O
mutations	O
occur	O
spontaneously	O
in	O
somatic	O
tissues	O
during	O
fetal	O
development	O
or	O
after	O
birth	O
.	O

Glands	O
are	O
the	O
most	O
"	O
permissive	O
"	O
tissues	O
,	O
recently	O
found	O
to	O
include	O
the	O
entire	O
gastrointestinal	O
tract	O
.	O

High	O
frequency	O
of	O
activating	B-PosReg
Gαs	B-Gene
mutations	B-Var
is	O
associated	O
with	O
precise	O
diagnoses	O
(	O
e.g.	O
,	O
IPMN	B-Disease
,	O
Pyloric	B-Disease
gland	I-Disease
adenoma	I-Disease
,	O
pituitary	B-Disease
toxic	I-Disease
adenoma	I-Disease
)	I-Disease
.	O

Typically	O
,	O
most	O
neoplastic	O
lesions	O
,	O
from	O
thyroid	O
to	O
pancreas	O
,	O
remain	O
well	O
differentiated	O
but	O
may	O
be	O
a	O
precursor	O
to	O
aggressive	O
cancer	O
.	O

CONCLUSIONS	O
:	O
Here	O
we	O
propose	O
the	O
possibility	O
that	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutations	B-Var
of	O
Gαs	B-Gene
interfere	B-NegReg
with	O
signals	O
in	O
the	O
microenvironment	B-MPA
of	I-MPA
permissive	I-MPA
tissues	O
and	O
lead	B-Reg
to	I-Reg
a	O
transversal	B-MPA
neoplastic	I-MPA
phenotype	I-MPA
.	O

Dissecting	O
the	O
genetic	O
basis	O
of	O
heavy	O
panicle	O
hybrid	O
rice	O
uncovered	O
Gn1a	O
and	O
GS3	O
as	O
key	O
genes	O
.	O

KEY	O
MESSAGE	O
:	O
Shuhui498	O
(	O
R498	O
)	O
is	O
an	O
elite	O
parent	O
of	O
heavy	O
panicle	O
hybrid	O
rice	O
by	O
pyramiding	O
the	O
rare	O
gn1a	O
and	O
null	O
gs3	O
alleles	O
.	O

This	O
finding	O
reveals	O
the	O
genetic	O
basis	O
and	O
great	O
potential	O
application	O
in	O
future	O
breeding	O
of	O
R498	O
.	O

The	O
heavy	O
panicle	O
trait	O
,	O
defined	O
as	O
5	O
g	O
or	O
more	O
of	O
grain	O
weight	O
per	O
panicle	O
,	O
is	O
one	O
of	O
the	O
target	O
traits	O
in	O
super	O
-	O
high	O
-	O
yield	O
rice	O
breeding	O
programs	O
.	O

The	O
use	O
of	O
heavy	O
panicle	O
-	O
type	O
hybrid	O
rice	O
has	O
been	O
shown	O
to	O
be	O
a	O
successful	O
strategy	O
for	O
super	O
-	O
high	O
-	O
yield	O
breeding	O
programs	O
,	O
particularly	O
under	O
the	O
environmental	O
conditions	O
of	O
high	O
humidity	O
and	O
deficient	O
solar	O
radiation	O
in	O
southwestern	O
China	O
.	O

However	O
,	O
the	O
genetic	O
components	O
of	O
the	O
heavy	O
panicle	O
trait	O
in	O
hybrid	O
rice	O
remain	O
elusive	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
combination	O
of	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
Grain	O
number	O
1a	O
(	B-Gene
Gn1a	I-Gene
)	I-Gene
and	O
Grain	O
Size	O
3	O
(	B-Gene
GS3	I-Gene
)	I-Gene
is	O
responsible	B-Reg
for	O
the	O
heavy	B-MPA
panicle	I-MPA
phenotype	I-MPA
of	O
the	O
elite	O
hybrid	O
rice	O
restorer	O
line	O
Shuhui498	O
(	O
R498	O
)	O
.	O

The	O
null	O
gn1a	O
allele	O
is	O
the	O
determinant	O
factor	O
for	O
heavy	O
panicles	O
through	O
increased	O
grain	O
number	O
,	O
while	O
gs3	O
is	O
associated	O
with	O
grain	O
size	O
and	O
weight	O
.	O

R498	O
pyramided	O
the	O
two	O
major	O
null	O
alleles	O
,	O
resulting	O
in	O
heavy	O
panicles	O
with	O
a	O
high	O
grain	O
number	O
and	O
large	O
grains	O
.	O

Clustering	O
analysis	O
revealed	O
that	O
the	O
null	O
gn1aR498	O
allele	O
is	O
a	O
rare	O
haplotype	O
which	O
has	O
been	O
innovatively	O
utilized	O
in	O
R498	O
,	O
underscoring	O
the	O
great	O
potential	O
of	O
R498	O
for	O
breeding	O
purposes	O
.	O

Our	O
research	O
thus	O
sheds	O
light	O
on	O
the	O
distinct	O
genetic	O
compositions	O
of	O
heavy	O
panicle	O
-	O
type	O
rice	O
and	O
may	O
potentially	O
facilitate	O
super	O
-	O
high	O
-	O
yield	O
rice	O
breeding	O
.	O

A	O
Protein	O
-	O
Truncating	O
HSD17B13	O
Variant	O
and	O
Protection	O
from	O
Chronic	O
Liver	O
Disease	O
.	O

BACKGROUND	O
:	O
Elucidation	O
of	O
the	O
genetic	O
factors	O
underlying	O
chronic	O
liver	O
disease	O
may	O
reveal	O
new	O
therapeutic	O
targets	O
.	O

METHODS	O
:	O
We	O
used	O
exome	O
sequence	O
data	O
and	O
electronic	O
health	O
records	O
from	O
46,544	O
participants	O
in	O
the	O
DiscovEHR	O
human	O
genetics	O
study	O
to	O
identify	O
genetic	O
variants	O
associated	O
with	O
serum	O
levels	O
of	O
alanine	O
aminotransferase	O
(	O
ALT	O
)	O
and	O
aspartate	O
aminotransferase	O
(	O
AST	O
)	O
.	O

Variants	B-Var
that	O
were	O
replicated	O
in	O
three	O
additional	O
cohorts	O
(	O
12,527	O
persons	O
)	O
were	O
evaluated	O
for	O
association	B-Interaction
with	O
clinical	O
diagnoses	O
of	O
chronic	B-Disease
liver	I-Disease
disease	I-Disease
in	O
DiscovEHR	O
study	O
participants	O
and	O
two	O
independent	O
cohorts	O
(	O
total	O
of	O
37,173	O
persons	O
)	O
and	O
with	O
histopathological	O
severity	O
of	O
liver	O
disease	O
in	O
2391	O
human	O
liver	O
samples	O
.	O

RESULTS	O
:	O
A	O
splice	B-Var
variant	I-Var
(	O
rs72613567	O
:	O
TA	O
)	O
in	O
HSD17B13	B-Gene
,	O
encoding	O
the	O
hepatic	O
lipid	O
droplet	O
protein	O
hydroxysteroid	O
17-beta	O
dehydrogenase	O
13	O
,	O
was	O
associated	O
with	O
reduced	B-NegReg
levels	O
of	O
ALT	B-MPA
(	O
P=4.2×10	O
-	O
12	O
)	O
and	O
AST	B-MPA
(	O
P=6.2×10	O
-	O
10	O
)	O
.	O

Among	O
DiscovEHR	O
study	O
participants	O
,	O
this	O
variant	B-Var
was	O
associated	O
with	O
a	O
reduced	B-NegReg
risk	O
of	O
alcoholic	B-Disease
liver	I-Disease
disease	I-Disease
(	O
by	O
42	O
%	O
[	O
95	O
%	O
confidence	O
interval	O
{	O
CI	O
}	O
,	O
20	O
to	O
58	O
]	O
among	O
heterozygotes	O
and	O
by	O
53	O
%	O
[	O
95	O
%	O
CI	O
,	O
3	O
to	O
77	O
]	O
among	O
homozygotes	O
)	O
,	O
nonalcoholic	B-Disease
liver	I-Disease
disease	I-Disease
(	O
by	O
17	O
%	O
[	O
95	O
%	O
CI	O
,	O
8	O
to	O
25	O
]	O
among	O
heterozygotes	O
and	O
by	O
30	O
%	O
[	O
95	O
%	O
CI	O
,	O
13	O
to	O
43	O
]	O
among	O
homozygotes	O
)	O
,	O
alcoholic	B-Disease
cirrhosis	I-Disease
(	O
by	O
42	O
%	O
[	O
95	O
%	O
CI	O
,	O
14	O
to	O
61	O
]	O
among	O
heterozygotes	O
and	O
by	O
73	O
%	O
[	O
95	O
%	O
CI	O
,	O
15	O
to	O
91	O
]	O
among	O
homozygotes	O
)	O
,	O
and	O
nonalcoholic	B-Disease
cirrhosis	I-Disease
(	O
by	O
26	O
%	O
[	O
95	O
%	O
CI	O
,	O
7	O
to	O
40	O
]	O
among	O
heterozygotes	O
and	O
by	O
49	O
%	O
[	O
95	O
%	O
CI	O
,	O
15	O
to	O
69	O
]	O
among	O
homozygotes	O
)	O
.	O

Associations	O
were	O
confirmed	O
in	O
two	O
independent	O
cohorts	O
.	O

The	O
rs72613567	O
:	O
TA	O
variant	B-Var
was	O
associated	O
with	O
a	O
reduced	B-NegReg
risk	O
of	O
nonalcoholic	B-Disease
steatohepatitis	I-Disease
,	O
but	O
not	O
steatosis	O
,	O
in	O
human	O
liver	O
samples	O
.	O

The	O
rs72613567	O
:	O
TA	O
variant	B-Var
mitigated	B-NegReg
liver	B-Disease
injury	I-Disease
associated	O
with	O
the	O
risk	O
-	O
increasing	O
PNPLA3	O
p	O
.	O
I148	O
M	O
allele	O
and	O
resulted	O
in	O
an	O
unstable	O
and	O
truncated	O
protein	O
with	O
reduced	O
enzymatic	O
activity	O
.	O

CONCLUSIONS	O
:	O
A	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
variant	B-Var
in	O
HSD17B13	B-Gene
was	O
associated	O
with	O
a	O
reduced	B-NegReg
risk	O
of	O
chronic	B-Disease
liver	I-Disease
disease	I-Disease
and	O
of	O
progression	O
from	O
steatosis	O
to	O
steatohepatitis	O
.	O

(	O
Funded	O
by	O
Regeneron	O
Pharmaceuticals	O
and	O
others	O
.	O

)	O
.	O

Gain	O
-	O
of	O
-	O
function	O
mutations	O
in	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
receptor	O
(	O
CSF3R	O
)	O
reveal	O
distinct	O
mechanisms	O
of	O
CSF3R	O
activation	O
.	O

Granulocyte	O
colony	O
-	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
or	O
CSF3	O
)	O
and	O
its	O
receptor	O
CSF3R	O
regulate	O
granulopoiesis	O
,	O
neutrophil	O
function	O
,	O
and	O
hematopoietic	O
stem	O
cell	O
mobilization	O
.	O

Recent	O
studies	O
have	O
uncovered	O
an	O
oncogenic	O
role	O
of	O
mutations	B-Var
in	O
the	O
CSF3R	B-Gene
gene	O
in	O
many	O
hematologic	B-Disease
malignancies	I-Disease
.	O

To	O
find	O
additional	O
CSF3R	O
mutations	O
that	O
give	O
rise	O
to	O
cell	O
transformation	O
,	O
we	O
performed	O
a	O
cellular	O
transformation	O
assay	O
in	O
which	O
murine	O
interleukin	O
3	O
(	O
IL-3)-dependent	O
Ba	O
/	O
F3	O
cells	O
were	O
transduced	O
with	O
WT	O
CSF3R	O
plasmid	O
and	O
screened	O
for	O
spontaneous	O
growth	O
in	O
the	O
absence	O
of	O
IL-3	O
.	O

Any	O
outgrowth	O
clones	O
were	O
sequenced	O
to	O
identify	O
CSF3R	O
mutations	O
with	O
transformation	O
capacity	O
.	O

We	O
identified	O
several	O
novel	O
mutations	B-Var
and	O
determined	O
that	O
they	O
transform	B-Reg
cells	B-CPA
via	O
four	O
distinct	O
mechanisms	O
:	O
1	O
)	O
cysteine-	B-MPA
and	I-MPA
disulfide	I-MPA
bond	I-MPA
-	I-MPA
mediated	I-MPA
dimerization	I-MPA
(	O
S581C	O
)	O
;	O
2	O
)	O
polar	B-Var
,	O
noncharged	I-Var
amino	I-Var
acid	I-Var
substitution	I-Var
at	O
the	O
transmembrane	O
helix	O
dimer	O
interface	O
at	O
residue	O
Thr-640	O
;	O
3	O
)	O
increased	B-PosReg
internalization	B-MPA
by	O
a	O
Glu-524	O
substitution	O
that	O
mimics	O
a	O
low	O
G	O
-	O
CSF	O
dose	O
;	O
and	O
4	O
)	O
hydrophobic	B-Var
amino	I-Var
acid	I-Var
substitutions	I-Var
in	O
the	O
membrane	O
-	O
proximal	O
residues	O
Thr-612	O
,	O
Thr-615	O
,	O
and	O
Thr-618	O
.	O

Furthermore	O
,	O
the	O
change	O
in	O
signaling	O
activation	O
was	O
related	O
to	O
an	O
altered	O
CSF3R	O
localization	O
.	O

We	O
also	O
found	O
that	O
CSF3R	O
-	O
induced	O
STAT3	O
and	O
ERK	O
activations	O
require	O
CSF3R	O
internalization	O
,	O
whereas	O
STAT5	O
activation	O
occurred	O
at	O
the	O
cell	O
surface	O
.	O

Cumulatively	O
,	O
we	O
have	O
expanded	O
the	O
regions	O
of	O
the	O
CSF3R	O
extracellular	O
and	O
transmembrane	O
domains	O
in	O
which	O
missense	B-Var
mutations	I-Var
exhibit	B-PosReg
leukemogenic	B-Disease
capacity	O
and	O
have	O
further	O
elucidated	O
the	O
mechanistic	O
underpinnings	O
that	O
underlie	O
altered	O
CSF3R	O
expression	O
,	O
dimerization	O
,	O
and	O
signaling	O
activation	O
.	O

Biallelic	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
WNT5A	B-Gene
mutations	B-Var
in	O
an	O
infant	O
with	O
severe	O
and	O
atypical	O
manifestations	O
of	O
Robinow	B-Disease
syndrome	I-Disease
.	O

Robinow	O
syndrome	O
(	O
RS	O
)	O
is	O
a	O
well	O
-	O
recognized	O
Mendelian	O
disorder	O
known	O
to	O
demonstrate	O
both	O
autosomal	O
dominant	O
and	O
autosomal	O
recessive	O
inheritance	O
.	O

Typical	O
manifestations	O
include	O
short	O
stature	O
,	O
characteristic	O
facies	O
,	O
and	O
skeletal	O
anomalies	O
.	O

Recessive	O
inheritance	O
has	O
been	O
associated	O
with	O
mutations	O
in	O
ROR2	O
while	O
dominant	O
inheritance	O
has	O
been	O
observed	O
for	O
mutations	O
in	O
WNT5A	O
,	O
DVL1	O
,	O
and	O
DVL3	O
.	O

Through	O
trio	O
whole	O
genome	O
sequencing	O
,	O
we	O
identified	O
a	O
homozygous	B-Var
frameshifting	I-Var
single	I-Var
nucleotide	I-Var
deletion	I-Var
in	O
WNT5A	B-Gene
in	O
a	O
previously	O
reported	O
,	O
deceased	O
infant	O
with	O
a	O
unique	O
constellation	O
of	O
features	O
comprising	O
a	O
46,XY	O
disorder	O
of	O
sex	O
development	O
with	O
multiple	O
congenital	O
malformations	O
including	O
congenital	B-Disease
diaphragmatic	I-Disease
hernia	I-Disease
,	O
ambiguous	B-Disease
genitalia	I-Disease
,	O
dysmorphic	B-Disease
facies	I-Disease
,	O
shortened	B-Disease
long	I-Disease
bones	I-Disease
,	O
adactyly	B-Disease
,	O
and	O
ventricular	B-Disease
septal	I-Disease
defect	I-Disease
.	O

The	O
parents	O
,	O
who	O
are	O
both	O
heterozygous	O
for	O
the	O
deletion	O
,	O
appear	O
clinically	O
unaffected	O
.	O

In	O
conjunction	O
with	O
published	O
observations	O
of	O
Wnt5a	O
double	O
knockout	O
mice	O
,	O
we	O
provide	O
evidence	O
for	O
the	O
possibility	O
of	O
autosomal	O
recessive	O
inheritance	O
in	O
association	O
with	O
WNT5A	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
RS	O
.	O

Molecular	O
Analysis	O
-	O
Based	O
Genetic	O
Characterization	O
of	O
a	O
Cohort	O
of	O
Patients	O
with	O
Duchenne	O
and	O
Becker	O
Muscular	O
Dystrophy	O
in	O
Eastern	O
China	O
.	O

Background	O
:	O
Duchenne	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
DMD	O
)	O
and	O
Becker	B-Disease
muscular	I-Disease
dystrophy	I-Disease
(	O
BMD	O
)	O
are	O
common	O
X	O
-	O
linked	O
recessive	O
neuromuscular	O
disorders	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
dystrophin	B-Gene
gene	I-Gene
.	O

Multiplex	O
polymerase	O
chain	O
reaction	O
(	O
multiplex	O
PCR	O
)	O
and	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
(	O
MLPA	O
)	O
are	O
the	O
most	O
common	O
methods	O
for	O
detecting	O
dystrophin	O
gene	O
mutations	O
.	O

This	O
study	O
aimed	O
to	O
contrast	O
the	O
two	O
methods	O
and	O
discern	O
the	O
genetic	O
characterization	O
of	O
patients	O
with	O
DMD	O
/	O
BMD	O
in	O
Eastern	O
China	O
.	O

Methods	O
:	O
We	O
collected	O
121	O
probands	O
,	O
64	O
mothers	O
of	O
probands	O
,	O
and	O
15	O
fetuses	O
in	O
our	O
study	O
.	O

The	O
dystrophin	O
gene	O
was	O
detected	O
by	O
multiplex	O
PCR	O
primarily	O
in	O
28	O
probands	O
,	O
and	O
MLPA	O
was	O
used	O
in	O
multiplex	O
PCR	O
-	O
negative	O
cases	O
subsequently	O
.	O

The	O
dystrophin	O
gene	O
of	O
the	O
remaining	O
93	O
probands	O
and	O
62	O
female	O
potential	O
carriers	O
was	O
tested	O
by	O
MLPA	O
directly	O
.	O

In	O
fetuses	O
,	O
multiplex	O
PCR	O
and	O
MLPA	O
were	O
performed	O
on	O
4	O
fetuses	O
and	O
10	O
fetuses	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
sequencing	O
was	O
also	O
performed	O
in	O
4	O
probands	O
with	O
negative	O
MLPA	O
.	O

Results	O
:	O
We	O
found	O
that	O
61.98	O
%	O
of	O
the	O
subjects	O
had	O
genetic	O
mutations	O
including	O
deletions	O
(	O
50.41	O
%	O
)	O
and	O
duplications	O
(	O
11.57	O
%	O
)	O
.	O

There	O
were	O
43.75	O
%	O
of	O
mothers	O
as	O
carriers	O
of	O
the	O
mutation	O
.	O

In	O
15	O
fetuses	O
,	O
2	O
out	O
of	O
7	O
male	O
fetuses	O
were	O
found	O
to	O
be	O
unhealthy	O
and	O
2	O
out	O
of	O
8	O
female	O
fetuses	O
were	O
found	O
to	O
be	O
carriers	O
.	O

Exons	O
3	O
-	O
26	O
and	O
45	O
-	O
52	O
have	O
the	O
maximum	O
frequency	O
in	O
mutation	O
regions	O
.	O

In	O
the	O
frequency	O
of	O
exons	O
individually	O
,	O
exon	O
47	O
and	O
exon	O
50	O
were	O
the	O
most	O
common	O
in	O
deleted	O
regions	O
and	O
exons	O
5	O
,	O
6	O
,	O
and	O
7	O
were	O
found	O
most	O
frequently	O
in	O
duplicated	O
regions	O
.	O

Conclusions	O
:	O
MLPA	O
has	O
better	O
productivity	O
and	O
sensitivity	O
than	O
multiplex	O
PCR	O
.	O

Prenatal	O
diagnosis	O
should	O
be	O
applied	O
in	O
DMD	O
high	O
-	O
risk	O
fetuses	O
to	O
reduce	O
the	O
disease	O
incidence	O
.	O

Furthermore	O
,	O
it	O
is	O
the	O
responsibility	O
of	O
physicians	O
to	O
inform	O
female	O
carriers	O
the	O
importance	O
of	O
prenatal	O
diagnosis	O
.	O

Species	O
-	O
conserved	O
SYNGAP1	O
phenotypes	O
associated	O
with	O
neurodevelopmental	O
disorders	O
.	O

SYNGAP1	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
variants	B-Var
are	O
causally	O
associated	O
with	O
intellectual	B-Disease
disability	I-Disease
,	O
severe	B-Disease
epilepsy	I-Disease
,	O
autism	B-Disease
spectrum	I-Disease
disorder	I-Disease
and	O
schizophrenia	B-Disease
.	O

While	O
there	O
are	O
hundreds	O
of	O
genetic	O
risk	O
factors	O
for	O
neurodevelopmental	O
disorders	O
(	O
NDDs	O
)	O
,	O
this	O
gene	O
is	O
somewhat	O
unique	O
because	O
of	O
the	O
frequency	O
and	O
penetrance	O
of	O
loss	O
-	O
of	O
-	O
function	O
variants	O
found	O
in	O
patients	O
combined	O
with	O
the	O
range	O
of	O
brain	O
disorders	O
associated	O
with	O
SYNGAP1	O
pathogenicity	O
.	O

These	O
clinical	O
findings	O
indicate	O
that	O
SYNGAP1	O
regulates	O
fundamental	O
neurodevelopmental	O
processes	O
that	O
are	O
necessary	O
for	O
brain	O
development	O
.	O

Here	O
,	O
we	O
describe	O
four	O
phenotypic	O
domains	O
that	O
are	O
controlled	O
by	O
Syngap1	O
expression	O
across	O
vertebrate	O
species	O
.	O

Two	O
domains	O
,	O
the	O
maturation	O
of	O
cognitive	O
functions	O
and	O
maintenance	O
of	O
excitatory	O
-	O
inhibitory	O
balance	O
,	O
are	O
defined	O
exclusively	O
through	O
a	O
review	O
of	O
the	O
current	O
literature	O
.	O

Two	O
additional	O
domains	O
are	O
defined	O
by	O
integrating	O
the	O
current	O
literature	O
with	O
new	O
data	O
indicating	O
that	O
SYNGAP1	O
/	O
Syngap1	O
regulates	O
innate	O
survival	O
behaviors	O
and	O
brain	O
structure	O
.	O

These	O
four	O
phenotypic	O
domains	O
are	O
commonly	O
disrupted	O
in	O
NDDs	O
,	O
suggesting	O
that	O
a	O
deeper	O
understanding	O
of	O
developmental	O
Syngap1	O
functions	O
will	O
be	O
generalizable	O
to	O
other	O
NDDs	O
of	O
known	O
or	O
unknown	O
etiology	O
.	O

Therefore	O
,	O
we	O
discuss	O
the	O
known	O
molecular	O
and	O
cellular	O
functions	O
of	O
Syngap1	O
and	O
consider	O
how	O
these	O
functions	O
may	O
contribute	O
to	O
the	O
emergence	O
of	O
disease	O
-	O
relevant	O
phenotypes	O
.	O

Finally	O
,	O
we	O
identify	O
major	O
unexplored	O
areas	O
of	O
Syngap1	O
neurobiology	O
and	O
discuss	O
how	O
a	O
deeper	O
understanding	O
of	O
this	O
gene	O
may	O
uncover	O
general	O
principles	O
of	O
NDD	O
pathobiology	O
.	O

Loss	O
-	O
of	O
-	O
function	O
PCSK9	O
mutants	O
evade	O
the	O
unfolded	O
protein	O
response	O
sensor	O
GRP78	O
and	O
fail	O
to	O
induce	O
endoplasmic	O
reticulum	O
stress	O
when	O
retained	O
.	O

The	O
proprotein	O
convertase	O
subtilisin	O
/	O
kexin	O
type-9	O
(	B-Var
PCSK9	I-Var
)	I-Var
plays	O
a	O
central	O
role	O
in	O
cardiovascular	B-Disease
disease	I-Disease
(	O
CVD	O
)	O
by	O
degrading	B-NegReg
hepatic	B-MPA
low	I-MPA
-	I-MPA
density	I-MPA
lipoprotein	I-MPA
receptor	I-MPA
(	O
LDLR	O
)	O
.	O

As	O
such	O
,	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
(	O
LOF	O
)	O
PCSK9	B-Gene
variants	B-Var
that	O
fail	O
to	O
exit	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
increase	B-PosReg
hepatic	B-MPA
LDLR	I-MPA
levels	I-MPA
and	O
lower	B-NegReg
the	O
risk	B-MPA
of	I-MPA
developing	I-MPA
CVD	I-MPA
.	O

The	O
retention	O
of	O
misfolded	O
protein	O
in	O
the	O
ER	O
can	O
cause	O
ER	O
stress	O
and	O
activate	O
the	O
unfolded	O
protein	O
response	O
(	O
UPR	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
a	O
variety	O
of	O
LOF	O
PCSK9	O
variants	O
that	O
are	O
retained	O
in	O
the	O
ER	O
can	O
cause	O
ER	O
stress	O
and	O
hepatic	O
cytotoxicity	O
.	O

Although	O
overexpression	B-PosReg
of	O
these	O
PCSK9	B-Gene
variants	B-Var
caused	O
an	O
accumulation	B-PosReg
in	O
the	O
ER	B-MPA
of	I-MPA
hepatocytes	I-MPA
,	O
UPR	O
activation	O
or	O
apoptosis	O
was	O
not	O
observed	O
.	O

Furthermore	O
,	O
ER	O
retention	O
of	O
endogenous	O
PCSK9	O
via	O
splice	O
switching	O
also	O
failed	O
to	O
induce	O
the	O
UPR	O
.	O

Consistent	O
with	O
these	O
in	O
vitro	O
studies	O
,	O
overexpression	O
of	O
PCSK9	O
in	O
the	O
livers	O
of	O
mice	O
had	O
no	O
impact	O
on	O
UPR	O
activation	O
.	O

To	O
elucidate	O
the	O
cellular	O
mechanism	O
to	O
explain	O
these	O
surprising	O
findings	O
,	O
we	O
observed	O
that	O
the	O
94-kDa	O
glucose	O
-	O
regulated	O
protein	O
(	O
GRP94	O
)	O
sequesters	O
PCSK9	O
away	O
from	O
the	O
78-kDa	O
glucose	O
-	O
regulated	O
protein	O
(	O
GRP78	O
)	O
,	O
the	O
major	O
activator	O
of	O
the	O
UPR	O
.	O

As	O
a	O
result	O
,	O
GRP94	O
knockdown	O
increased	O
the	O
stability	O
of	O
GRP78-PCSK9	O
complex	O
and	O
resulted	O
in	O
UPR	O
activation	O
following	O
overexpression	O
of	O
ER	O
-	O
retained	O
PCSK9	O
variants	O
relative	O
to	O
WT	O
secreted	O
controls	O
.	O

Given	O
that	O
overexpression	O
of	O
these	O
LOF	O
PCSK9	O
variants	O
does	O
not	O
cause	O
UPR	O
activation	O
under	O
normal	O
homeostatic	O
conditions	O
,	O
therapeutic	O
strategies	O
aimed	O
at	O
blocking	O
the	O
autocatalytic	O
cleavage	O
of	O
PCSK9	O
in	O
the	O
ER	O
represent	O
a	O
viable	O
strategy	O
for	O
reducing	O
circulating	O
PCSK9	O
.	O

CBL	B-Gene
mutation	B-Var
and	O
MEFV	B-Gene
single	B-Var
-	I-Var
nucleotide	I-Var
variant	I-Var
are	O
important	O
genetic	O
predictors	O
of	O
tumor	B-Disease
reduction	B-NegReg
in	O
glucocorticoid	O
-	O
treated	O
patients	O
with	O
chronic	B-Disease
myelomonocytic	I-Disease
leukemia	I-Disease
.	O

Glucocorticoid	O
(	O
GC	O
)	O
therapy	O
occasionally	O
relieves	O
tumor	O
-	O
related	O
fever	O
and	O
promotes	O
tumor	O
reduction	O
in	O
patients	O
with	O
chronic	O
myelomonocytic	O
leukemia	O
(	O
CMML	O
)	O
.	O

A	O
mutation	O
analysis	O
of	O
24	O
patients	O
with	O
CMML	O
revealed	O
the	O
relationship	O
of	O
GC	O
effectiveness	O
,	O
defined	O
as	O
a	O
monocyte	O
reduction	O
of	O
>	O
50	O
%	O
within	O
3	O
days	O
of	O
methylprednisolone	O
administration	O
,	O
with	O
the	O
MEFV	O
single	O
-	O
nucleotide	O
variant	O
(	O
SNV	O
)	O
and	O
CBL	O
mutation	O
.	O

Lipopolysaccharide	O
-	O
stimulated	O
monocytes	O
harboring	O
MEFV	O
E148Q	O
produced	O
greater	O
amounts	O
of	O
IL-1β	O
and	O
TNF	O
-	O
α	O
than	O
did	O
wild	O
-	O
type	O
monocytes	O
;	O
this	O
was	O
effectively	O
suppressed	O
by	O
GC	O
.	O

Primary	O
CMML	O
cells	O
harboring	O
the	O
MEFV	O
SNV	O
and	O
CBL	O
mutation	O
,	O
and	O
the	O
myelomonocytic	O
leukemia	O
cell	O
line	O
GDM-1	O
,	O
harboring	O
the	O
CBL	O
mutation	O
,	O
were	O
both	O
more	O
significantly	O
suppressed	O
than	O
non	O
-	O
mutated	O
cells	O
following	O
GC	O
treatment	O
in	O
the	O
presence	O
of	O
GM	O
-	O
CSF	O
.	O

A	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
CBL	B-Gene
mutation	B-Var
prolonged	B-PosReg
STAT5	B-MPA
phosphorylation	I-MPA
after	O
GM	O
-	O
CSF	O
stimulation	O
,	O
which	O
was	O
rapidly	O
terminated	O
in	O
both	O
patient	O
samples	O
and	O
GDM-1	O
cells	O
.	O

In	O
conclusion	O
,	O
GC	O
therapy	O
effectively	O
treats	O
CMML	O
cells	O
harboring	O
the	O
MEFV	O
SNV	O
and	O
CBL	O
mutation	O
by	O
reducing	O
inflammatory	O
cytokine	O
production	O
and	O
terminating	O
prolonged	O
STAT5	O
phosphorylation	O
in	O
the	O
GM	O
-	O
CSF	O
signaling	O
pathway	O
.	O

Identification	O
of	O
a	O
unique	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	B-Var
in	O
IGF1R	B-Gene
and	O
a	O
crosstalk	B-Reg
between	O
IGF1R	B-Gene
and	O
Wnt	B-Pathway
/	I-Pathway
β	I-Pathway
-	I-Pathway
catenin	I-Pathway
signaling	I-Pathway
pathways	I-Pathway
.	O

IGF1R	O
is	O
a	O
ubiquitous	O
receptor	O
tyrosine	O
kinase	O
that	O
plays	O
critical	O
roles	O
in	O
cell	O
proliferation	O
,	O
growth	O
and	O
survival	O
.	O

Clinical	O
studies	O
have	O
demonstrated	O
upregulation	O
of	O
IGF1R	O
mediated	O
signaling	O
in	O
a	O
number	O
of	O
malignancies	O
including	O
colon	O
,	O
breast	O
,	O
and	O
lung	O
cancers	O
.	O

Overexpression	O
of	O
the	O
IGF1R	O
in	O
these	O
malignancies	O
is	O
associated	O
with	O
a	O
poor	O
prognosis	O
and	O
overall	O
survival	O
.	O

IGF1R	O
specific	O
kinase	O
inhibitors	O
have	O
failed	O
in	O
multiple	O
clinical	O
trials	O
partly	O
because	O
of	O
the	O
complex	O
nature	O
of	O
IGF1R	O
signaling	O
.	O

Thus	O
identifying	O
new	O
binding	O
partners	O
and	O
allosteric	O
sites	O
on	O
IGF1R	O
are	O
emerging	O
areas	O
of	O
research	O
.	O

More	O
recently	O
,	O
IGF1R	O
has	O
been	O
shown	O
to	O
translocate	O
into	O
the	O
nucleus	O
and	O
perform	O
many	O
functions	O
.	O

In	O
this	O
study	O
,	O
we	O
generated	O
a	O
library	O
of	O
IGF1R	O
deletion	O
and	O
point	O
mutants	O
to	O
examine	O
IGF1R	O
subcellular	O
localization	O
and	O
activation	O
of	O
downstream	O
signaling	O
pathways	O
.	O

We	O
show	O
that	O
the	O
nuclear	O
localization	O
of	O
IGF1R	O
is	O
primarily	O
defined	O
by	O
its	O
cytoplasmic	O
domain	O
.	O

We	O
identified	O
a	O
cross	O
-	O
talk	O
between	O
IGF1R	O
and	O
Wnt	O
/	O
β	O
-	O
catenin	O
signaling	O
pathways	O
and	O
showed	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
IGF1R	O
is	O
associated	O
with	O
upregulation	O
of	O
TCF	O
-	O
mediated	O
β	O
-	O
catenin	O
transcriptional	O
activity	O
.	O

Using	O
loss	O
-	O
of	O
-	O
function	O
mutants	O
,	O
deletion	O
analysis	O
and	O
IGF1R	O
specific	O
inhibitor(s	O
)	O
,	O
we	O
show	O
that	O
cytoplasmic	O
and	O
nuclear	O
activities	O
are	O
two	O
independent	O
functions	O
of	O
IGF1R.	O
Furthermore	O
,	O
we	O
identified	O
a	O
unique	O
loss	O
-	O
of	O
-	O
function	O
mutation	O
in	O
IGF1R.	O
This	O
unique	O
loss	O
-	O
of	O
-	O
function	O
mutant	O
retains	O
only	O
nuclear	O
functions	O
and	O
sits	O
in	O
a	O
pocket	O
,	O
outside	O
ATP	O
and	O
substrate	O
binding	O
region	O
,	O
that	O
is	O
suited	O
for	O
designing	O
allosteric	O
inhibitors	O
of	O
IGF1R.	O
Clinical	O
variability	O
and	O
onset	O
age	O
modifiers	O
in	O
an	O
extended	O
Belgian	O
GRN	O
founder	O
family	O
.	O

We	O
previously	O
reported	B-Reg
a	O
granulin	O
(	B-Gene
GRN	I-Gene
)	I-Gene
null	O
mutation	B-Var
,	O
originating	O
from	O
a	O
common	O
founder	O
,	O
in	O
multiple	O
Belgian	O
families	O
with	O
frontotemporal	B-Disease
dementia	I-Disease
.	O

Here	O
,	O
we	O
used	O
data	O
of	O
a	O
10-year	O
follow	O
-	O
up	O
study	O
to	O
describe	O
in	O
detail	O
the	O
clinical	O
heterogeneity	O
observed	O
in	O
this	O
extended	O
founder	O
pedigree	O
.	O

We	O
identified	O
85	O
patients	O
and	O
40	O
unaffected	O
mutation	O
carriers	O
,	O
belonging	O
to	O
29	O
branches	O
of	O
the	O
founder	O
pedigree	O
.	O

Most	O
patients	O
(	O
74.4	O
%	O
)	O
were	O
diagnosed	O
with	O
frontotemporal	O
dementia	O
,	O
while	O
others	O
had	O
a	O
clinical	O
diagnosis	O
of	O
unspecified	O
dementia	O
,	O
Alzheimer	O
's	O
dementia	O
or	O
Parkinson	O
's	O
disease	O
.	O

The	O
observed	O
clinical	O
heterogeneity	O
can	O
guide	O
clinical	O
diagnosis	O
,	O
genetic	O
testing	O
,	O
and	O
counseling	O
of	O
mutation	O
carriers	O
.	O

Onset	O
of	O
initial	O
symptomatology	O
is	O
highly	O
variable	O
,	O
ranging	O
from	O
age	O
45	O
to	O
80	O
years	O
.	O

Analysis	O
of	O
known	O
modifiers	O
,	O
suggested	O
effects	O
of	O
GRN	O
rs5848	O
,	O
microtubule	O
-	O
associated	O
protein	O
tau	O
H1	O
/	O
H2	O
,	O
and	O
chromosome	O
9	O
open	O
reading	O
frame	O
72	O
G4C2	O
repeat	O
length	O
on	O
onset	O
age	O
but	O
explained	O
only	O
a	O
minor	O
fraction	O
of	O
the	O
variability	O
.	O

Contrary	O
,	O
the	O
extended	O
GRN	O
founder	O
family	O
is	O
a	O
valuable	O
source	O
for	O
identifying	O
other	O
onset	O
age	O
modifiers	O
based	O
on	O
exome	O
or	O
genome	O
sequences	O
.	O

These	O
modifiers	O
might	O
be	O
interesting	O
targets	O
for	O
developing	O
disease	O
-	O
modifying	O
therapies	O
.	O

A	O
rare	O
variant	B-Var
in	O
MLKL	B-Gene
confers	O
susceptibility	B-Reg
to	O
ApoE	O
ɛ4-negative	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
in	O
Hong	O
Kong	O
Chinese	O
population	O
.	O

Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
is	O
the	O
most	O
common	O
neurodegenerative	O
disorders	O
in	O
the	O
elderly	O
.	O

To	O
identify	O
rare	O
genetic	O
factors	O
other	O
than	O
apolipoprotein	O
E	O
ɛ4	O
allele	O
(	O
ApoE	O
ɛ4	O
)	O
contributing	O
to	O
the	O
pathogenesis	O
of	O
late	O
-	O
onset	O
AD	O
(	O
LOAD	O
)	O
,	O
we	O
conducted	O
a	O
whole	O
-	O
exome	O
analysis	O
of	O
246	O
ApoE	O
ɛ4-negative	O
LOAD	O
cases	O
and	O
172	O
matched	O
controls	O
in	O
Hong	O
Kong	O
Chinese	O
population	O
.	O

LOAD	O
patients	O
showed	O
a	O
significantly	O
higher	O
burden	O
of	O
rare	O
loss	O
-	O
of	O
-	O
function	O
variants	O
in	O
genes	O
related	O
to	O
immune	O
function	O
than	O
healthy	O
controls	O
.	O

Among	O
the	O
genes	O
involved	O
in	O
immune	O
function	O
,	O
we	O
identified	O
a	O
rare	O
stop	O
-	O
gain	O
variant	O
(	O
p	O
.	O
Q48X	O
)	O
in	O
mixed	O
lineage	O
kinase	O
domain	O
like	O
pseudokinase	O
(	O
MLKL	O
)	O
gene	O
present	O
exclusively	O
in	O
6	O
LOAD	O
cases	O
.	O

MLKL	B-Gene
is	O
expressed	O
in	O
neurons	O
,	O
and	O
the	O
its	O
expression	B-MPA
levels	I-MPA
in	O
the	O
p	B-Var
.	I-Var
Q48X	I-Var
carriers	O
were	O
significantly	O
lower	B-NegReg
than	O
that	O
in	O
age	O
-	O
matched	O
wild	O
-	O
type	O
controls	O
.	O

The	O
ratio	O
of	O
Aβ42	O
to	O
Aβ40	O
significantly	O
increased	O
in	O
MLKL	O
knockdown	O
cells	O
compared	O
to	O
scramble	O
controls	O
.	O

MLKL	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	B-Var
might	O
contribute	O
to	O
late	O
-	O
onset	O
ApoE	O
ɛ4-negative	O
AD	B-Disease
in	O
the	O
Hong	O
Kong	O
Chinese	O
population	O
.	O

Investigation	O
of	O
TRPV1	O
loss	O
-	O
of	O
-	O
function	O
phenotypes	O
in	O
TRPV1	O
Leu206Stop	O
mice	O
generated	O
by	O
N	O
-	O
ethyl	O
-	O
N	O
-	O
nitrosourea	O
mutagenesis	O
.	O

N	O
-	O
ethyl	O
-	O
N	O
-	O
nitrosourea	O
(	O
ENU	O
)	O
random	O
mutagenesis	O
was	O
used	O
to	O
generate	O
a	O
mouse	O
model	O
for	O
the	O
analysis	O
of	O
the	O
transient	O
receptor	O
potential	O
vanilloid	O
1	O
(	B-Gene
TRPV1	I-Gene
)	I-Gene
cation	O
channel	O
.	O

A	O
transversion	O
from	O
T→A	O
in	O
exon	O
4	O
led	O
to	O
a	O
Leu206Stop	B-Var
mutation	O
generating	O
a	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutant	O
.	O

The	O
TRPV1	O
agonist	O
capsaicin	O
was	O
used	O
to	O
analyze	O
functional	O
and	O
nociceptive	O
parameters	O
in	O
vitro	O
and	O
in	O
vivo	O
in	O
TRPV1	O
Leu206Stop	O
mice	O
and	O
congenic	O
C3HeB	O
/	O
FeJ	O
controls	O
.	O

Capsaicin	B-MPA
-	I-MPA
induced	I-MPA
[	I-MPA
Ca2+]i	I-MPA
changes	O
in	O
small	O
diameter	O
DRG	B-CPA
neurons	I-CPA
were	O
significantly	O
diminished	B-NegReg
in	O
TRPV1	B-Gene
Leu206Stop	B-Var
mice	O
and	O
administration	O
of	O
capsaicin	O
induced	O
neither	O
hypothermia	O
nor	O
nocifensive	O
behaviour	O
in	O
vivo	O
.	O

TRPV1	O
Leu206Stop	O
mice	O
were	O
tested	O
in	O
the	O
spinal	O
nerve	O
ligation	O
of	O
mononeuropathic	O
pain	O
and	O
developed	O
mechanical	O
hypersensitivity	O
two	O
weeks	O
after	O
nerve	O
injury	O
.	O

In	O
the	O
open	O
field	O
test	O
,	O
a	O
significant	O
increase	B-PosReg
in	O
spontaneous	B-CPA
locomotion	I-CPA
was	O
detected	O
in	O
TRPV1	B-Gene
Leu206Stop	B-Var
mice	O
as	O
compared	O
to	O
wildtype	O
controls	O
.	O

TRPV1	O
knockout	O
mice	O
have	O
been	O
reported	O
to	O
carry	O
a	O
similar	O
phenotype	O
regarding	O
capsaicin	O
-	O
evoked	O
responses	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

However	O
,	O
in	O
contrast	O
to	O
TRPV1	O
Leu206Stop	O
mice	O
,	O
TRPV1	O
knockout	O
mice	O
did	O
not	O
differ	O
in	O
spontaneous	O
locomotion	O
as	O
compared	O
to	O
congenic	O
C57BL/6	O
mice	O
,	O
suggesting	O
subtle	O
ENU	O
-	O
dependent	O
or	O
independent	O
strain	O
differences	O
between	O
TRPV1	O
Leu206Stop	O
mice	O
and	O
their	O
wildtype	O
controls	O
.	O

In	O
summary	O
,	O
these	O
data	O
revealed	O
a	O
target	O
-	O
related	O
(	O
i.e.	O
capsaicin	O
-	O
evoked	O
)	O
phenotype	O
of	O
TRPV1	O
Leu206Stop	O
mice	O
closely	O
resembling	O
that	O
of	O
published	O
TRPV1	O
knockout	O
mice	O
.	O

However	O
,	O
since	O
ENU	O
-	O
mutant	O
mice	O
are	O
congenic	O
with	O
the	O
mouse	O
strain	O
initially	O
used	O
in	O
random	O
mutagenesis	O
,	O
direct	O
phenotypic	O
comparison	O
with	O
the	O
respective	O
wildtype	O
controls	O
is	O
possible	O
,	O
and	O
the	O
time	O
-	O
consuming	O
backcrossing	O
in	O
lines	O
with	O
targeted	O
mutations	O
is	O
avoided	O
.	O

Biallelic	O
TP53	B-Gene
gain	B-PosReg
of	I-PosReg
function	I-PosReg
mutations	B-Var
in	O
rapidly	B-Disease
progressing	I-Disease
solid	I-Disease
tumors	I-Disease
.	O

Recent	O
studies	O
are	O
discovering	O
TP53	B-Gene
mutations	B-Var
with	O
gain	B-PosReg
of	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
properties	O
that	O
promote	O
tumorigenesis	B-CPA
via	O
a	O
variety	O
of	O
mechanisms	O
.	O

To	O
our	O
knowledge	O
,	O
all	O
reported	O
compound	O
mutations	O
are	O
allelic	O
.	O

We	O
identified	O
two	O
patients	O
with	O
biallelic	O
GOF	O
TP53	O
mutations	O
in	O
their	O
tumors	O
and	O
a	O
third	O
with	O
allelic	O
compound	O
variants	O
.	O

The	O
correlation	O
with	O
p53	O
expression	O
was	O
also	O
examined	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissue	O
and	O
mutational	O
analysis	O
was	O
performed	O
using	O
Ion	O
AmpliSeq	O
™	O
Cancer	O
HotSpot	O
Panel	O
V2	O
.	O

Biallelic	O
GOF	B-PosReg
mutations	O
(	B-Var
p	I-Var
.	I-Var
R273H	I-Var
and	O
p	B-Var
.	I-Var
R273C	I-Var
)	I-Var
were	O
identified	O
in	O
a	O
19-year	O
-	O
old	O
male	O
with	O
glioblastoma	B-Disease
(	O
allele	O
frequencies	O
94	O
%	O
and	O
48	O
%	O
)	O
and	O
a	O
54-year	O
-	O
old	O
with	O
pT3	O
penile	O
squamous	O
cell	O
carcinoma	O
(	O
allele	O
frequencies	O
19	O
%	O
and	O
27	O
%	O
)	O
.	O

Immunohistochemistry	O
showed	O
nuclear	O
accumulation	O
of	O
p53	O
.	O

The	O
third	O
patient	O
,	O
a	O
62-year	O
-	O
old	O
female	O
with	O
metastatic	B-Disease
lung	I-Disease
adenocarcinoma	I-Disease
,	O
had	O
allelic	O
p	B-Var
.	I-Var
P278S	I-Var
(	B-PosReg
GOF	I-PosReg
)	I-PosReg
and	O
p	B-Var
.	I-Var
R283L	I-Var
(	B-Reg
non	I-Reg
-	I-Reg
GOF	I-Reg
)	I-Reg
variants	O
at	O
frequencies	O
of	O
61	O
%	O
but	O
with	O
null	O
staining	O
for	O
p53	O
.	O

Germline	O
testing	O
for	O
Patient	O
1	O
confirmed	O
wildtype	O
TP53	O
.	O

No	O
other	O
variants	O
were	O
discovered	O
among	O
the	O
genes	O
tested	O
in	O
these	O
cases	O
.	O

All	O
patients	O
succumbed	O
within	O
two	O
years	O
of	O
diagnosis	O
despite	O
aggressive	O
treatment	O
.	O

In	O
conclusion	O
,	O
implementation	O
of	O
TP53	O
mutation	O
analysis	O
in	O
clinical	O
practice	O
may	O
predict	O
patient	O
outcome	O
,	O
and	O
inhibition	O
of	O
GOF	O
p53	O
could	O
represent	O
an	O
attractive	O
target	O
for	O
therapy	O
.	O

Germline	O
pathogenic	O
variants	O
in	O
PALB2	O
and	O
other	O
cancer	O
-	O
predisposing	O
genes	O
in	O
families	O
with	O
hereditary	O
diffuse	O
gastric	O
cancer	O
without	O
CDH1	O
mutation	O
:	O
a	O
whole	O
-	O
exome	O
sequencing	O
study	O
.	O

BACKGROUND	O
:	O
Germline	O
pathogenic	O
variants	B-Var
in	O
the	O
E	O
-	O
cadherin	O
gene	O
(	B-Gene
CDH1	I-Gene
)	I-Gene
are	O
strongly	O
associated	B-Reg
with	I-Reg
the	O
development	O
of	O
hereditary	B-Disease
diffuse	I-Disease
gastric	I-Disease
cancer	I-Disease
.	O

There	O
is	O
a	O
paucity	O
of	O
data	O
to	O
guide	O
risk	O
assessment	O
and	O
management	O
of	O
families	O
with	O
hereditary	O
diffuse	O
gastric	O
cancer	O
that	O
do	O
not	O
carry	O
a	O
CDH1	O
pathogenic	O
variant	O
,	O
making	O
it	O
difficult	O
to	O
make	O
informed	O
decisions	O
about	O
surveillance	O
and	O
risk	O
-	O
reducing	O
surgery	O
.	O

We	O
aimed	O
to	O
identify	O
new	O
candidate	O
genes	O
associated	O
with	O
predisposition	O
to	O
hereditary	O
diffuse	O
gastric	O
cancer	O
in	O
affected	O
families	O
without	O
pathogenic	O
CDH1	O
variants	O
.	O

METHODS	O
:	O
We	O
did	O
whole	O
-	O
exome	O
sequencing	O
on	O
DNA	O
extracted	O
from	O
the	O
blood	O
of	O
39	O
individuals	O
(	O
28	O
individuals	O
diagnosed	O
with	O
hereditary	O
diffuse	O
gastric	O
cancer	O
and	O
11	O
unaffected	O
first	O
-	O
degree	O
relatives	O
)	O
in	O
22	O
families	O
without	O
pathogenic	O
CDH1	O
variants	O
.	O

Genes	O
with	O
loss	O
-	O
of	O
-	O
function	O
variants	O
were	O
prioritised	O
using	O
gene	O
-	O
interaction	O
analysis	O
to	O
identify	O
clusters	O
of	O
genes	O
that	O
could	O
be	O
involved	O
in	O
predisposition	O
to	O
hereditary	O
diffuse	O
gastric	O
cancer	O
.	O

FINDINGS	O
:	O
Protein	O
-	O
affecting	O
germline	O
variants	O
were	O
identified	O
in	O
probands	O
from	O
six	O
families	O
with	O
hereditary	O
diffuse	O
gastric	O
cancer	O
;	O
variants	O
were	O
found	O
in	O
genes	O
known	O
to	O
predispose	O
to	O
cancer	O
and	O
in	O
lesser	O
-	O
studied	O
DNA	O
repair	O
genes	O
.	O

A	O
frameshift	B-Var
deletion	I-Var
in	O
PALB2	B-Gene
was	O
found	B-Reg
in	O
one	O
member	O
of	O
a	O
family	O
with	O
a	O
history	O
of	O
gastric	B-Disease
and	O
breast	B-Disease
cancer	I-Disease
.	O

Two	O
different	O
MSH2	O
variants	O
were	O
identified	O
in	O
two	O
unrelated	O
affected	O
individuals	O
,	O
including	O
one	O
frameshift	O
insertion	O
and	O
one	O
previously	O
described	O
start	O
-	O
codon	O
loss	O
.	O

One	O
family	O
had	O
a	O
unique	O
combination	O
of	O
variants	O
in	O
the	O
DNA	O
repair	O
genes	O
ATR	O
and	O
NBN	O
.	O

Two	O
variants	O
in	O
the	O
DNA	O
repair	O
gene	O
RECQL5	O
were	O
identified	O
in	O
two	O
unrelated	O
families	O
:	O
one	O
missense	O
variant	O
and	O
a	O
splice	O
-	O
acceptor	O
variant	O
.	O

INTERPRETATION	O
:	O
The	O
results	O
of	O
this	O
study	O
suggest	O
a	O
role	O
for	O
the	O
known	O
cancer	O
predisposition	O
gene	O
PALB2	O
in	O
families	O
with	O
hereditary	O
diffuse	O
gastric	O
cancer	O
and	O
no	O
detected	O
pathogenic	O
CDH1	O
variants	O
.	O

We	O
also	O
identified	O
new	O
candidate	O
genes	O
associated	O
with	O
disease	O
risk	O
in	O
these	O
families	O
.	O

FUNDING	O
:	O
UK	O
Medical	O
Research	O
Council	O
(	O
Sackler	O
programme	O
)	O
,	O
European	O
Research	O
Council	O
under	O
the	O
European	O
Union	O
's	O
Seventh	O
Framework	O
Programme	O
(	O
2007	O
-	O
13	O
)	O
,	O
National	O
Institute	O
for	O
Health	O
Research	O
Cambridge	O
Biomedical	O
Research	O
Centre	O
,	O
Experimental	O
Cancer	O
Medicine	O
Centres	O
,	O
and	O
Cancer	O
Research	O
UK	O
.	O

Melanocortin	O
4	O
Receptor	O
Pathway	O
Dysfunction	O
in	O
Obesity	O
:	O
Patient	O
Stratification	O
Aimed	O
at	O
MC4R	O
Agonist	O
Treatment	O
.	O

Context	O
:	O
The	O
hypothalamic	O
melanocortin	O
4	O
receptor	O
(	O
MC4R	O
)	O
pathway	O
serves	O
a	O
critical	O
role	O
in	O
regulating	O
body	O
weight	O
.	O

Loss	B-NegReg
of	I-NegReg
function	I-NegReg
(	O
LoF	O
)	O
mutations	B-Var
in	O
the	O
MC4R	B-Pathway
pathway	I-Pathway
,	O
including	O
mutations	O
in	O
the	O
pro	O
-	O
opiomelanocortin	O
(	B-Gene
POMC	I-Gene
)	I-Gene
,	O
prohormone	O
convertase	O
1	O
(	B-Gene
PCSK1	I-Gene
)	I-Gene
,	O
leptin	O
receptor	O
(	B-Gene
LEPR	I-Gene
)	I-Gene
,	O
or	O
MC4R	B-Gene
genes	O
,	O
have	O
been	O
shown	O
to	O
cause	O
early	B-Disease
-	I-Disease
onset	I-Disease
severe	I-Disease
obesity	I-Disease
.	O

Methods	O
:	O
Through	O
a	O
comprehensive	O
epidemiological	O
analysis	O
of	O
known	O
and	O
predicted	O
LoF	O
variants	O
in	O
the	O
POMC	O
,	O
PCSK1	O
,	O
and	O
LEPR	O
genes	O
,	O
we	O
sought	O
to	O
estimate	O
the	O
number	O
of	O
US	O
individuals	O
with	O
biallelic	O
MC4R	O
pathway	O
LoF	O
variants	O
.	O

Results	O
:	O
We	O
predict	O
~650	O
α	O
-	O
melanocyte	O
-	O
stimulating	O
hormone	O
(	O
MSH)/POMC	O
,	O
8500	O
PCSK1	O
,	O
and	O
3600	O
LEPR	O
homozygous	O
and	O
compound	O
heterozygous	O
individuals	O
in	O
the	O
United	O
States	O
,	O
cumulatively	O
enumerating	O
>	O
12,800	O
MC4R	O
pathway	O
-	O
deficient	O
obese	O
patients	O
.	O

Few	O
of	O
these	O
variants	O
have	O
been	O
genetically	O
diagnosed	O
to	O
date	O
.	O

These	O
estimates	O
increase	O
when	O
we	O
include	O
a	O
small	O
subset	O
of	O
less	O
rare	O
variants	O
:	O
β	O
-	O
MSH	O
/	O
POMC	O
,	O
PCSK1	O
N221D	O
,	O
and	O
a	O
PCSK1	O
LoF	O
variant	O
(	O
T640A	O
)	O
.	O

To	O
further	O
define	O
the	O
MC4R	O
pathway	O
and	O
its	O
potential	O
impact	O
on	O
obesity	O
,	O
we	O
tested	O
associations	O
between	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
and	O
LoF	O
mutation	O
burden	O
in	O
the	O
POMC	O
,	O
PCSK1	O
,	O
and	O
LEPR	O
genes	O
in	O
various	O
populations	O
.	O

We	O
show	O
that	O
the	O
cumulative	O
allele	O
burden	O
in	O
individuals	O
with	O
two	O
or	O
more	O
LoF	O
alleles	O
in	O
one	O
or	O
more	O
genes	O
in	O
the	O
MC4R	O
pathway	O
are	O
predisposed	O
to	O
a	O
higher	O
BMI	O
than	O
noncarriers	O
or	O
heterozygous	O
LoF	O
carriers	O
with	O
a	O
defect	O
in	O
only	O
one	O
gene	O
.	O

Conclusions	O
:	O
Our	O
analysis	O
represents	O
a	O
genetically	O
rationalized	O
study	O
of	O
the	O
hypothalamic	O
MC4R	O
pathway	O
aimed	O
at	O
genetic	O
patient	O
stratification	O
to	O
determine	O
which	O
obese	O
subpopulations	O
should	O
be	O
studied	O
to	O
elucidate	O
MC4R	O
agonist	O
(	O
e.g.	O
,	O
setmelanotide	O
)	O
treatment	O
responsiveness	O
.	O

Mutations	B-Var
in	O
C11orf70	B-Gene
Cause	B-Reg
Primary	B-Disease
Ciliary	I-Disease
Dyskinesia	I-Disease
with	O
Randomization	O
of	O
Left	O
/	O
Right	O
Body	O
Asymmetry	O
Due	O
to	O
Defects	B-NegReg
of	O
Outer	B-Protein
and	I-Protein
Inner	I-Protein
Dynein	I-Protein
Arms	I-Protein
.	O

Primary	O
ciliary	O
dyskinesia	O
(	O
PCD	O
)	O
is	O
characterized	O
by	O
chronic	O
airway	O
disease	O
,	O
male	O
infertility	O
,	O
and	O
randomization	O
of	O
the	O
left	O
/	O
right	O
body	O
axis	O
as	O
a	O
result	O
of	O
defects	O
of	O
motile	O
cilia	O
and	O
sperm	O
flagella	O
.	O

We	O
identified	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
open	O
-	O
reading	O
frame	O
C11orf70	O
in	O
PCD	O
individuals	O
from	O
five	O
distinct	O
families	O
.	O

Transmission	O
electron	O
microscopy	O
analyses	O
and	O
high	O
-	O
resolution	O
immunofluorescence	O
microscopy	O
demonstrate	O
that	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
C11orf70	B-Gene
cause	O
immotility	B-CPA
of	O
respiratory	B-CPA
cilia	I-CPA
and	O
sperm	B-CPA
flagella	I-CPA
,	O
respectively	O
,	O
as	O
a	O
result	O
of	O
the	O
loss	B-NegReg
of	O
axonemal	B-Protein
outer	I-Protein
(	O
ODAs	O
)	O
and	O
inner	B-Protein
dynein	I-Protein
arms	I-Protein
(	O
IDAs	O
)	O
,	O
indicating	O
that	O
C11orf70	O
is	O
involved	O
in	O
cytoplasmic	O
assembly	O
of	O
dynein	O
arms	O
.	O

Expression	O
analyses	O
of	O
C11orf70	O
showed	O
that	O
C11orf70	O
is	O
expressed	O
in	O
ciliated	O
respiratory	O
cells	O
and	O
that	O
the	O
expression	O
of	O
C11orf70	O
is	O
upregulated	O
during	O
ciliogenesis	O
,	O
similar	O
to	O
other	O
previously	O
described	O
cytoplasmic	O
dynein	O
-	O
arm	O
assembly	O
factors	O
.	O

Furthermore	O
,	O
C11orf70	O
shows	O
an	O
interaction	O
with	O
cytoplasmic	O
ODA	O
/	O
IDA	O
assembly	O
factor	O
DNAAF2	O
,	O
supporting	O
our	O
hypothesis	O
that	O
C11orf70	O
is	O
a	O
preassembly	O
factor	O
involved	O
in	O
the	O
pathogenesis	O
of	O
PCD	O
.	O

The	O
identification	O
of	O
additional	O
genetic	O
defects	O
that	O
cause	O
PCD	O
and	O
male	O
infertility	O
is	O
of	O
great	O
importance	O
for	O
the	O
clinic	O
as	O
well	O
as	O
for	O
genetic	O
counselling	O
.	O

De	O
novo	O
and	O
inherited	O
private	O
variants	B-Var
in	O
MAP1B	B-Gene
in	O
periventricular	B-Disease
nodular	I-Disease
heterotopia	I-Disease
.	O

Periventricular	O
nodular	O
heterotopia	O
(	O
PVNH	O
)	O
is	O
a	O
malformation	O
of	O
cortical	O
development	O
commonly	O
associated	O
with	O
epilepsy	O
.	O

We	O
exome	O
sequenced	O
202	O
individuals	O
with	O
sporadic	O
PVNH	O
to	O
identify	O
novel	O
genetic	O
risk	O
loci	O
.	O

We	O
first	O
performed	O
a	O
trio	O
-	O
based	O
analysis	O
and	O
identified	O
219	O
de	O
novo	O
variants	O
.	O

Although	O
no	O
novel	O
genes	O
were	O
implicated	O
in	O
this	O
initial	O
analysis	O
,	O
PVNH	O
cases	O
were	O
found	O
overall	O
to	O
have	O
a	O
significant	O
excess	O
of	O
nonsynonymous	O
de	O
novo	O
variants	O
in	O
intolerant	O
genes	O
(	O
p	O
=	O
3.27x10	O
-	O
7	O
)	O
,	O
suggesting	O
a	O
role	O
for	O
rare	O
new	O
alleles	O
in	O
genes	O
yet	O
to	O
be	O
associated	O
with	O
the	O
condition	O
.	O

Using	O
a	O
gene	O
-	O
level	O
collapsing	O
analysis	O
comparing	O
cases	O
and	O
controls	O
,	O
we	O
identified	O
a	O
genome	O
-	O
wide	O
significant	O
signal	O
driven	O
by	O
four	O
ultra	O
-	O
rare	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
heterozygous	O
variants	B-Var
in	O
MAP1B	B-Gene
,	O
including	O
one	O
de	O
novo	O
variant	O
.	O

In	O
at	O
least	O
one	O
instance	O
,	O
the	O
MAP1B	B-Gene
variant	B-Var
was	O
inherited	B-Reg
from	I-Reg
a	O
parent	O
with	O
previously	O
undiagnosed	O
PVNH	B-Disease
.	O

The	O
PVNH	O
was	O
frontally	O
predominant	O
and	O
associated	O
with	O
perisylvian	O
polymicrogyria	O
.	O

These	O
results	O
implicate	O
MAP1B	O
in	O
PVNH	O
.	O

More	O
broadly	O
,	O
our	O
findings	O
suggest	O
that	O
detrimental	O
mutations	O
likely	O
arising	O
in	O
immediately	O
preceding	O
generations	O
with	O
incomplete	O
penetrance	O
may	O
also	O
be	O
responsible	O
for	O
some	O
apparently	O
sporadic	O
diseases	O
.	O

Protein	B-Enzyme
kinase	I-Enzyme
Cα	I-Enzyme
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
variant	B-Var
in	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
displays	O
enhanced	B-PosReg
catalysis	B-MPA
by	O
a	O
mechanism	O
that	O
evades	O
down	O
-	O
regulation	O
.	O

Conventional	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
family	O
members	O
are	O
reversibly	O
activated	O
by	O
binding	O
to	O
the	O
second	O
messengers	O
Ca2	O
+	O
and	O
diacylglycerol	O
,	O
events	O
that	O
break	O
autoinhibitory	O
constraints	O
to	O
allow	O
the	O
enzyme	O
to	O
adopt	O
an	O
active	O
,	O
but	O
degradation	O
-	O
sensitive	O
,	O
conformation	O
.	O

Perturbing	O
these	O
autoinhibitory	O
constraints	O
,	O
resulting	O
in	O
protein	O
destabilization	O
,	O
is	O
one	O
of	O
many	O
mechanisms	O
by	O
which	O
PKC	O
function	O
is	O
lost	O
in	O
cancer	O
.	O

Here	O
,	O
we	O
address	O
how	O
a	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
germline	B-Var
mutation	I-Var
in	O
PKCα	B-Enzyme
in	O
Alzheimer	B-Disease
's	I-Disease
disease	I-Disease
(	O
AD	O
)	O
enhances	B-PosReg
signaling	B-MPA
without	O
increasing	O
vulnerability	O
to	O
down	O
-	O
regulation	O
.	O

Biochemical	O
analyses	O
of	O
purified	O
protein	O
demonstrate	O
that	O
this	O
mutation	B-Var
results	O
in	O
an	O
∼30	O
%	O
increase	B-PosReg
in	O
the	O
catalytic	B-MPA
rate	O
of	O
the	O
activated	O
enzyme	O
,	O
with	O
no	O
changes	O
in	O
the	O
concentrations	O
of	O
Ca2	O
+	O
or	O
lipid	O
required	O
for	O
half	O
-	O
maximal	O
activation	O
.	O

Molecular	O
dynamics	O
simulations	O
reveal	O
that	O
this	O
mutation	B-Var
has	O
both	O
localized	O
and	O
allosteric	O
effects	O
,	O
most	O
notably	O
decreasing	B-NegReg
the	O
dynamics	B-MPA
of	I-MPA
the	I-MPA
C	I-MPA
-	I-MPA
helix	I-MPA
,	O
a	O
key	O
determinant	O
in	O
the	O
catalytic	O
turnover	O
of	O
kinases	O
.	O

Consistent	O
with	O
this	O
mutation	O
not	O
altering	O
autoinhibitory	O
constraints	O
,	O
live	O
-	O
cell	O
imaging	O
studies	O
reveal	O
that	O
the	O
basal	O
signaling	O
output	O
of	O
PKCα	O
-	O
M489V	O
is	O
unchanged	O
.	O

However	O
,	O
the	O
mutant	B-Var
enzyme	B-Enzyme
in	O
cells	O
displays	O
increased	B-PosReg
sensitivity	B-MPA
to	O
an	O
inhibitor	O
that	O
is	O
ineffective	O
toward	O
scaffolded	O
PKC	O
,	O
suggesting	O
the	O
altered	O
dynamics	O
of	O
the	O
kinase	O
domain	O
may	O
influence	B-Reg
protein	B-Protein
interactions	B-Interaction
.	O

Finally	O
,	O
we	O
show	O
that	O
phosphorylation	B-MPA
of	O
a	O
key	O
PKC	O
substrate	O
,	O
myristoylated	B-MPA
alanine	I-MPA
-	I-MPA
rich	I-MPA
C	I-MPA
-	I-MPA
kinase	I-MPA
substrate	I-MPA
,	O
is	O
increased	B-PosReg
in	O
brains	O
of	O
CRISPR	O
-	O
Cas9	O
genome	O
-	O
edited	O
mice	O
containing	O
the	O
PKCα	B-Enzyme
-	I-Enzyme
M489V	I-Enzyme
mutation	I-Var
.	O

Our	O
results	O
unveil	O
how	O
an	O
AD	B-Disease
-	I-Disease
associated	I-Disease
mutation	B-Var
in	O
PKCα	B-Enzyme
permits	O
enhanced	B-PosReg
agonist	B-MPA
-	I-MPA
dependent	I-MPA
signaling	I-MPA
via	O
a	O
mechanism	O
that	O
evades	B-NegReg
the	O
cell	O
's	O
homeostatic	B-MPA
down	I-MPA
-	I-MPA
regulation	I-MPA
of	O
constitutively	B-Enzyme
active	I-Enzyme
PKCα	I-Enzyme
.	O

Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
KCNJ6	B-Gene
Mutation	B-Var
in	O
a	O
Severe	B-Disease
Hyperkinetic	I-Disease
Movement	I-Disease
Disorder	I-Disease
Phenotype	O
.	O

Here	O
,	O
we	O
describe	O
a	O
fourth	O
case	O
of	O
a	O
human	O
with	O
a	O
de	O
novo	O
KCNJ6	B-Gene
(	O
GIRK2	O
)	O
mutation	B-Var
,	O
who	O
presented	B-Reg
with	O
clinical	O
findings	O
of	O
severe	B-Disease
hyperkinetic	I-Disease
movement	I-Disease
disorder	I-Disease
and	O
developmental	B-CPA
delay	I-CPA
,	O
similar	O
to	O
the	O
Keppen	O
-	O
Lubinsky	O
syndrome	O
but	O
without	O
lipodystrophy	O
.	O

Whole	O
-	O
exome	O
sequencing	O
of	O
the	O
patient	O
's	O
DNA	O
revealed	O
a	O
heterozygous	O
de	O
novo	O
variant	O
in	O
the	O
KCNJ6	B-Gene
(	B-Var
c.512T	I-Var
>	I-Var
G	I-Var
,	O
p	B-Var
.	I-Var
Leu171Arg	I-Var
)	I-Var
.	O

We	O
conducted	O
in	O
vitro	O
functional	O
studies	O
to	O
determine	O
if	O
this	O
Leu	O
-	O
to	O
-	O
Arg	O
mutation	O
alters	O
the	O
function	O
of	O
GIRK2	O
channels	O
.	O

Heterologous	O
expression	O
of	O
the	O
mutant	B-Var
GIRK2	B-Gene
channel	O
alone	O
produced	B-PosReg
an	O
aberrant	O
basal	B-MPA
inward	I-MPA
current	I-MPA
that	O
lacked	B-NegReg
G	B-Protein
protein	I-Protein
activation	B-MPA
,	O
lost	B-NegReg
K+	B-MPA
selectivity	I-MPA
and	O
gained	B-PosReg
Ca2	B-MPA
+	I-MPA
permeability	I-MPA
.	O

Notably	O
,	O
the	O
inward	O
current	O
was	O
inhibited	O
by	O
the	O
Na+	O
channel	O
blocker	O
QX-314	O
,	O
similar	O
to	O
the	O
previously	O
reported	O
weaver	O
mutation	O
in	O
murine	O
GIRK2	O
.	O

Expression	O
of	O
a	O
tandem	O
dimer	O
containing	O
GIRK1	O
and	O
GIRK2(p	O
.	O

Leu171Arg	O
)	O
did	O
not	O
lead	O
to	O
any	O
currents	O
,	O
suggesting	O
heterotetramers	O
are	O
not	O
functional	O
.	O

In	O
neurons	O
expressing	O
p	B-Var
.	I-Var
Leu171Arg	I-Var
GIRK2	B-Gene
channels	O
,	O
these	O
changes	O
in	O
channel	O
properties	O
would	O
be	O
expected	O
to	O
generate	O
a	O
sustained	O
depolarization	B-NegReg
,	O
instead	O
of	O
the	O
normal	O
G	B-MPA
protein	I-MPA
-	I-MPA
gated	I-MPA
inhibitory	I-MPA
response	I-MPA
,	O
which	O
could	O
be	O
mitigated	O
by	O
expression	O
of	O
other	O
GIRK	O
subunits	O
.	O

The	O
identification	O
of	O
the	O
p	O
.	O
Leu171Arg	O
GIRK2	O
mutation	O
potentially	O
expands	O
the	O
Keppen	O
-	O
Lubinsky	O
syndrome	O
phenotype	O
to	O
include	O
severe	O
dystonia	O
and	O
ballismus	O
.	O

Our	O
study	O
suggests	O
screening	O
for	O
dominant	O
KCNJ6	O
mutations	O
in	O
the	O
evaluation	O
of	O
patients	O
with	O
severe	O
movement	O
disorders	O
,	O
which	O
could	O
provide	O
evidence	O
to	O
support	O
a	O
causal	O
role	O
of	O
KCNJ6	O
in	O
neurological	O
channelopathies	O
.	O

De	O
Novo	O
and	O
Inherited	O
Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
Function	I-NegReg
Variants	B-Var
in	O
TLK2	B-Gene
:	I-Gene
Clinical	O
and	O
Genotype	O
-	O
Phenotype	O
Evaluation	O
of	O
a	O
Distinct	B-Disease
Neurodevelopmental	I-Disease
Disorder	I-Disease
.	O

Next	O
-	O
generation	O
sequencing	O
is	O
a	O
powerful	O
tool	O
for	O
the	O
discovery	O
of	O
genes	O
related	O
to	O
neurodevelopmental	O
disorders	O
(	O
NDDs	O
)	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
of	O
a	O
distinct	O
syndrome	O
due	O
to	O
de	O
novo	O
or	O
inherited	O
heterozygous	O
mutations	O
in	O
Tousled	O
-	O
like	O
kinase	O
2	O
(	O
TLK2	O
)	O
in	O
38	O
unrelated	O
individuals	O
and	O
two	O
affected	O
mothers	O
,	O
using	O
whole	O
-	O
exome	O
and	O
whole	O
-	O
genome	O
sequencing	O
technologies	O
,	O
matchmaker	O
databases	O
,	O
and	O
international	O
collaborations	O
.	O

Affected	O
individuals	O
had	O
a	O
consistent	O
phenotype	O
,	O
characterized	O
by	O
mild	O
-	O
borderline	O
neurodevelopmental	O
delay	O
(	O
86	O
%	O
)	O
,	O
behavioral	O
disorders	O
(	O
68	O
%	O
)	O
,	O
severe	O
gastro	O
-	O
intestinal	O
problems	O
(	O
63	O
%	O
)	O
,	O
and	O
facial	O
dysmorphism	O
including	O
blepharophimosis	O
(	O
82	O
%	O
)	O
,	O
telecanthus	O
(	O
74	O
%	O
)	O
,	O
prominent	O
nasal	O
bridge	O
(	O
68	O
%	O
)	O
,	O
broad	O
nasal	O
tip	O
(	O
66	O
%	O
)	O
,	O
thin	O
vermilion	O
of	O
the	O
upper	O
lip	O
(	O
62	O
%	O
)	O
,	O
and	O
upslanting	O
palpebral	O
fissures	O
(	O
55	O
%	O
)	O
.	O

Analysis	O
of	O
cell	O
lines	O
from	O
three	O
affected	O
individuals	O
showed	O
that	O
mutations	O
act	O
through	O
a	O
loss	O
-	O
of	O
-	O
function	O
mechanism	O
in	O
at	O
least	O
two	O
case	O
subjects	O
.	O

Genotype	O
-	O
phenotype	O
analysis	O
and	O
comparison	O
of	O
computationally	O
modeled	O
faces	O
showed	O
that	O
phenotypes	O
of	O
these	O
and	O
other	O
individuals	O
with	O
loss	O
-	O
of	O
-	O
function	O
variants	O
significantly	O
overlapped	O
with	O
phenotypes	O
of	O
individuals	O
with	O
other	O
variant	O
types	O
(	O
missense	O
and	O
C	O
-	O
terminal	O
truncating	O
)	O
.	O

This	O
suggests	O
that	O
haploinsufficiency	O
of	O
TLK2	O
is	O
the	O
most	O
likely	O
underlying	O
disease	O
mechanism	O
,	O
leading	O
to	O
a	O
consistent	O
neurodevelopmental	O
phenotype	O
.	O

This	O
work	O
illustrates	O
the	O
power	O
of	O
international	O
data	O
sharing	O
,	O
by	O
the	O
identification	O
of	O
40	O
individuals	O
from	O
26	O
different	O
centers	O
in	O
7	O
different	O
countries	O
,	O
allowing	O
the	O
identification	O
,	O
clinical	O
delineation	O
,	O
and	O
genotype	O
-	O
phenotype	O
evaluation	O
of	O
a	O
distinct	O
NDD	O
caused	O
by	O
mutations	O
in	O
TLK2	O
.	O

Progranulin	O
as	O
a	O
therapeutic	O
target	O
for	O
dementia	O
.	O

INTRODUCTION	O
:	O
Progranulin	O
(	O
PGRN	O
)	O
is	O
an	O
acrosomal	O
glycoprotein	O
that	O
is	O
synthesized	O
during	O
spermatogenesis	O
.	O

It	O
is	O
overexpressed	O
in	O
tumors	O
and	O
has	O
anti	O
-	O
inflammatory	O
properties	O
.	O

The	O
protein	O
may	O
be	O
cleaved	O
into	O
granulins	O
which	O
display	O
pro	O
-	O
inflammatory	O
properties	O
.	O

In	O
2006	O
,	O
mutations	B-Var
in	O
progranulin	O
gene	O
(	B-Gene
GRN	I-Gene
)	I-Gene
that	O
cause	O
haploinsufficiency	O
were	O
found	O
in	O
familial	O
cases	B-Reg
of	O
frontotemporal	B-Disease
dementia	I-Disease
(	O
FTD	O
)	O
.	O

Patients	O
with	O
null	O
mutations	O
in	O
GRN	O
display	O
very	O
low	O
-	O
plasma	O
PGRN	O
levels	O
;	O
this	O
analysis	O
is	O
useful	O
for	O
identifying	O
mutation	O
carriers	O
,	O
independent	O
of	O
the	O
clinical	O
presentation	O
,	O
and	O
in	O
those	O
before	O
the	O
appearance	O
of	O
symptoms	O
.	O

Areas	O
covered	O
:	O
Here	O
,	O
we	O
review	O
the	O
current	O
knowledge	O
of	O
PGRN	O
physiological	O
functions	O
and	O
GRN	O
mutations	O
associated	O
with	O
FTD	O
;	O
we	O
also	O
summarize	O
state	O
of	O
the	O
art	O
clinical	O
trials	O
and	O
those	O
compounds	O
able	O
to	O
replace	O
PGRN	O
loss	O
in	O
preclinical	O
models	O
.	O

Expert	O
opinion	O
:	O
PGRN	O
represents	O
a	O
promising	O
therapeutic	O
target	O
for	O
FTD	O
.	O

Cohorts	O
suitable	O
for	O
treatment	O
,	O
ideally	O
at	O
the	O
preclinical	O
stage	O
,	O
where	O
pathogenic	O
mechanisms	O
ongoing	O
in	O
the	O
brain	O
are	O
targeted	O
,	O
are	O
available	O
.	O

However	O
,	O
PGRN	O
may	O
have	O
side	O
effects	O
,	O
such	O
as	O
the	O
risk	O
of	O
tumorigenesis	O
,	O
and	O
the	O
risk	O
/	O
benefit	O
ratio	O
of	O
any	O
intervention	O
can	O
not	O
be	O
predicted	O
.	O

Furthermore	O
,	O
at	O
present	O
,	O
the	O
situation	O
is	O
complicated	O
by	O
the	O
absence	O
of	O
adequate	O
outcome	O
measures	O
.	O

A	O
novel	O
mutation	B-Var
in	O
RDH5	B-Gene
gene	O
causes	B-Reg
retinitis	B-Disease
pigmentosa	I-Disease
in	O
consanguineous	O
Pakistani	O
family	O
.	O

Retinitis	O
pigmentosa	O
(	O
RP	O
)	O
is	O
the	O
most	O
frequent	O
genetically	O
and	O
clinically	O
heterogeneous	O
inherited	O
retinal	O
degeneration	O
.	O

To	O
date	O
,	O
more	O
than	O
80	O
genes	O
have	O
been	O
identified	O
that	O
cause	O
autosomal	O
dominant	O
,	O
autosomal	O
recessive	O
and	O
X	O
linked	O
RP	O
.	O

However	O
,	O
locus	O
and	O
allelic	O
heterogeneity	O
of	O
RP	O
has	O
not	O
been	O
fully	O
captured	O
yet	O
.	O

This	O
heterogeneity	O
and	O
lack	O
of	O
an	O
accurate	O
genotype	O
phenotype	O
correlation	O
makes	O
molecular	O
dissection	O
of	O
the	O
disease	O
more	O
difficult	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
characterize	O
the	O
underlying	O
pathogenic	O
variants	O
of	O
RP	O
in	O
Pakistan	O
.	O

For	O
this	O
purpose	O
,	O
a	O
large	O
consanguineous	O
family	O
with	O
RP	O
phenotype	O
showing	O
autosomal	O
recessive	O
mode	O
of	O
inheritance	O
was	O
selected	O
after	O
a	O
complete	O
ophthalmological	O
examination	O
.	O

Next	O
generation	O
sequencing	O
was	O
used	O
for	O
the	O
identification	O
of	O
molecular	O
determinant	O
followed	O
by	O
Sanger	O
-	O
sequencing	O
for	O
confirmation	O
.	O

After	O
sequence	O
analysis	O
a	O
novel	O
homozygous	O
missense	O
mutation	O
,	O
(	B-Var
c.602	I-Var
C	I-Var
>	I-Var
T	I-Var
)	I-Var
in	O
exon	O
4	O
of	O
the	O
RDH5	B-Gene
gene	O
(	O
MIM	O
:	O
601617	O
)	O
was	O
identified	O
.	O

This	O
mutation	O
resulted	B-Reg
in	I-Reg
substitution	O
of	O
phenyl	O
alanine	O
for	O
serine	O
at	O
amino	O
acid	O
201	O
(	B-Var
p	I-Var
.	I-Var
Ser201Phe	I-Var
)	I-Var
of	O
the	O
RDH5	B-Gene
gene	O
.	O

The	O
same	O
mutation	O
was	O
not	O
detected	O
in	O
the	O
200	O
ethnically	O
-	O
matched	O
control	O
samples	O
by	O
Sanger	O
sequencing	O
.	O

The	O
identified	O
mutant	O
allele	O
segregated	O
in	O
homozygous	O
fashion	O
in	O
all	O
the	O
affected	O
individuals	O
of	O
pedigree	O
.	O

Identification	O
of	O
this	O
mutation	O
reveals	O
the	O
allelic	O
heterogeneity	O
of	O
RDH5	O
in	O
patients	O
with	O
RP	O
phenotype	O
.	O

The	O
findings	O
of	O
this	O
study	O
demonstrate	O
the	O
clinical	O
significance	O
of	O
next	O
generation	O
sequencing	O
to	O
understand	O
the	O
molecular	O
basis	O
of	O
diseases	O
and	O
would	O
help	O
to	O
reveal	O
new	O
proteins	O
and	O
their	O
function	O
in	O
visual	O
cycle	O
will	O
pave	O
the	O
way	O
for	O
early	O
diagnosis	O
,	O
genetic	O
counseling	O
and	O
better	O
therapeutic	O
inventions	O
.	O

Quantitative	O
phosphoproteomic	O
analysis	O
of	O
the	O
molecular	O
substrates	O
of	O
sleep	O
need	O
.	O

Sleep	O
and	O
wake	O
have	O
global	O
effects	O
on	O
brain	O
physiology	O
,	O
from	O
molecular	O
changes1	O
-	O
4	O
and	O
neuronal	O
activities	O
to	O
synaptic	O
plasticity3	O
-	O
7	O
.	O

Sleep	O
-	O
wake	O
homeostasis	O
is	O
maintained	O
by	O
the	O
generation	O
of	O
a	O
sleep	O
need	O
that	O
accumulates	O
during	O
waking	O
and	O
dissipates	O
during	O
sleep8	O
-	O
11	O
.	O

Here	O
we	O
investigate	O
the	O
molecular	O
basis	O
of	O
sleep	O
need	O
using	O
quantitative	O
phosphoproteomic	O
analysis	O
of	O
the	O
sleep	O
-	O
deprived	O
and	O
Sleepy	O
mouse	O
models	O
of	O
increased	O
sleep	O
need	O
.	O

Sleep	O
deprivation	O
induces	O
cumulative	O
phosphorylation	O
of	O
the	O
brain	O
proteome	O
,	O
which	O
dissipates	O
during	O
sleep	O
.	O

Sleepy	O
mice	O
,	O
owing	O
to	O
a	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	B-Var
in	O
the	O
Sik3	B-Gene
gene	O
12	O
,	O
have	O
a	O
constitutively	O
high	O
sleep	O
need	O
despite	O
increased	O
sleep	O
amount	O
.	O

The	O
brain	B-Protein
proteome	I-Protein
of	O
these	O
mice	O
exhibits	O
hyperphosphorylation	B-MPA
,	O
similar	O
to	O
that	O
seen	O
in	O
the	O
brain	O
of	O
sleep	O
-	O
deprived	O
mice	O
.	O

Comparison	O
of	O
the	O
two	O
models	O
identifies	O
80	O
mostly	O
synaptic	O
sleep	O
-	O
need	O
-	O
index	O
phosphoproteins	O
(	O
SNIPPs	O
)	O
,	O
in	O
which	O
phosphorylation	O
states	O
closely	O
parallel	O
changes	O
of	O
sleep	O
need	O
.	O

SLEEPY	O
,	O
the	O
mutant	B-Var
SIK3	B-Gene
protein	B-Protein
,	O
preferentially	B-PosReg
associates	B-Interaction
with	I-Interaction
and	O
phosphorylates	B-MPA
SNIPPs	B-Protein
.	O

Inhibition	O
of	O
SIK3	O
activity	O
reduces	O
phosphorylation	O
of	O
SNIPPs	O
and	O
slow	O
wave	O
activity	O
during	O
non	O
-	O
rapid	O
-	O
eye	O
-	O
movement	O
sleep	O
,	O
the	O
best	O
known	O
measurable	O
index	O
of	O
sleep	O
need	O
,	O
in	O
both	O
Sleepy	O
mice	O
and	O
sleep	O
-	O
deprived	O
wild	O
-	O
type	O
mice	O
.	O

Our	O
results	O
suggest	O
that	O
phosphorylation	O
of	O
SNIPPs	O
accumulates	O
and	O
dissipates	O
in	O
relation	O
to	O
sleep	O
need	O
,	O
and	O
therefore	O
SNIPP	O
phosphorylation	O
is	O
a	O
molecular	O
signature	O
of	O
sleep	O
need	O
.	O

Whereas	O
waking	O
encodes	O
memories	O
by	O
potentiating	O
synapses	O
,	O
sleep	O
consolidates	O
memories	O
and	O
restores	O
synaptic	O
homeostasis	O
by	O
globally	O
downscaling	O
excitatory	O
synapses4	O
-	O
6	O
.	O

Thus	O
,	O
the	O
phosphorylation	O
-	O
dephosphorylation	O
cycle	O
of	O
SNIPPs	O
may	O
represent	O
a	O
major	O
regulatory	O
mechanism	O
that	O
underlies	O
both	O
synaptic	O
homeostasis	O
and	O
sleep	O
-	O
wake	O
homeostasis	O
.	O

Germline	O
mutations	O
and	O
somatic	O
inactivation	O
of	O
TRIM28	O
in	O
Wilms	O
tumour	O
.	O

Wilms	O
tumour	O
is	O
a	O
childhood	O
tumour	O
that	O
arises	O
as	O
a	O
consequence	O
of	O
somatic	O
and	O
rare	O
germline	O
mutations	O
,	O
the	O
characterisation	O
of	O
which	O
has	O
refined	O
our	O
understanding	O
of	O
nephrogenesis	O
and	O
carcinogenesis	O
.	O

Here	O
we	O
report	O
that	O
germline	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
TRIM28	B-Gene
predispose	O
children	O
to	O
Wilms	B-Disease
tumour	I-Disease
.	O

Loss	O
of	O
function	O
of	O
this	O
transcriptional	O
co	O
-	O
repressor	O
,	O
which	O
has	O
a	O
role	O
in	O
nephrogenesis	O
,	O
has	O
not	O
previously	O
been	O
associated	O
with	O
cancer	O
.	O

Inactivation	B-NegReg
of	O
TRIM28	B-Gene
,	O
either	O
germline	O
or	O
somatic	O
,	O
occurred	O
through	O
inactivating	B-Var
mutations	I-Var
,	O
loss	B-Var
of	I-Var
heterozygosity	I-Var
or	O
epigenetic	B-Var
silencing	I-Var
.	O

TRIM28-mutated	O
tumours	O
had	O
a	O
monomorphic	O
epithelial	O
histology	O
that	O
is	O
uncommon	O
for	O
Wilms	O
tumour	O
.	O

Critically	O
,	O
these	O
tumours	O
were	O
negative	O
for	O
TRIM28	O
immunohistochemical	O
staining	O
whereas	O
the	O
epithelial	O
component	O
in	O
normal	O
tissue	O
and	O
other	O
Wilms	O
tumours	O
stained	O
positively	O
.	O

These	O
data	O
,	O
together	O
with	O
a	O
characteristic	O
gene	O
expression	O
profile	O
,	O
suggest	O
that	O
inactivation	O
of	O
TRIM28	O
provides	O
the	O
molecular	O
basis	O
for	O
defining	O
a	O
previously	O
described	O
subtype	O
of	O
Wilms	O
tumour	O
,	O
that	O
has	O
early	O
age	O
of	O
onset	O
and	O
excellent	O
prognosis	O
.	O

Mutational	O
and	O
functional	O
studies	O
on	O
NR5A1	B-Gene
gene	O
in	O
46,XY	B-Disease
disorders	I-Disease
of	I-Disease
sex	I-Disease
development	I-Disease
:	I-Disease
identification	O
of	O
six	O
novel	O
loss	B-NegReg
of	I-NegReg
function	I-NegReg
mutations	B-Var
.	O

OBJECTIVE	O
:	O
To	O
study	O
the	O
functional	O
properties	O
of	O
six	O
novel	O
missense	O
mutations	O
of	O
the	O
NR5A1	O
gene	O
encoding	O
the	O
steroidogenic	O
factor	O
1	O
(	O
SF-1	O
)	O
identified	O
in	O
six	O
patients	O
with	O
46,XY	O
disorders	O
of	O
sex	O
development	O
(	O
DSD	O
)	O
and	O
to	O
describe	O
their	O
relative	O
phenotype	O
-	O
genotype	O
relationship	O
.	O

DESIGN	O
:	O
Genetic	O
and	O
functional	O
studies	O
.	O

SETTING	O
:	O
University	O
department	O
.	O

PATIENT(S	O
)	O
:	O
Six	O
46,XY	O
DSD	O
patients	O
.	O

INTERVENTION(S	O
)	O
:	O
None	O
.	O

MAIN	O
OUTCOME	O
MEASURE(S	O
)	O
:	O
Sanger	O
sequencing	O
and	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
analysis	O
to	O
identify	O
the	O
mutations	O
or	O
deletions	O
/	O
duplications	O
of	O
the	O
NR5A1	O
gene	O
.	O

Functional	O
studies	O
by	O
transactivation	O
assays	O
to	O
predict	O
the	O
impact	O
of	O
mutations	O
on	O
molecular	O
function	O
.	O

RESULT(S	O
)	O
:	O
NR5A1	B-Gene
exons	O
sequencing	O
identified	B-Reg
in	I-Reg
six	O
46,XY	B-Disease
DSD	I-Disease
patients	O
six	O
novel	O
mutations	O
:	O
p	B-Var
.	I-Var
T40R	I-Var
,	O
p	B-Var
.	I-Var
T47C	I-Var
,	O
p	B-Var
.	I-Var
G328W	I-Var
,	O
p	B-Var
.	I-Var
A351E	I-Var
,	O
p	B-Var
.	I-Var
R427W	I-Var
,	O
and	O
p	B-Var
.	I-Var
Q460R.	I-Var
Five	O
missense	O
variants	O
were	O
heterozygous	O
,	O
and	O
one	O
was	O
homozygous	O
(	O
p	O
.	O
R427W	O
)	O
.	O

Functional	O
analysis	O
revealed	O
a	O
significant	O
loss	B-NegReg
of	O
DNA	B-Interaction
-	I-Interaction
binding	I-Interaction
and	O
transactivation	B-MPA
ability	O
for	O
all	O
variants	O
,	O
except	O
for	O
p	O
.	O
Q460R	O
,	O
which	O
showed	O
a	O
modest	O
reduced	O
activity	O
compared	O
with	O
that	O
of	O
the	O
wild	O
-	O
type	O
protein	O
.	O

Phenotypes	O
associated	O
with	O
these	O
mutations	O
varied	O
from	O
males	O
with	O
spontaneous	O
puberty	O
,	O
substantial	O
T	O
production	O
,	O
and	O
possible	O
fertility	O
,	O
to	O
females	O
with	O
and	O
without	O
müllerian	O
structures	O
and	O
primary	O
amenorrhea	O
.	O

CONCLUSION(S	O
)	O
:	O
We	O
describe	O
six	O
novel	O
mutations	B-Var
in	O
NR5A1	B-Gene
gene	O
and	O
showed	O
that	O
they	O
might	O
affect	B-Reg
protein	B-MPA
structure	I-MPA
,	O
therefore	O
compromising	B-NegReg
seriously	O
the	O
SF-1	B-MPA
role	O
in	O
regulating	O
gonadal	B-CPA
development	I-CPA
.	O

Clinically	O
,	O
we	O
suggest	O
that	O
NR5A1	O
analysis	O
should	O
be	O
performed	O
whenever	O
atypical	O
sex	O
organs	O
are	O
evidenced	O
or	O
there	O
is	O
an	O
abnormal	O
sexual	O
development	O
,	O
to	O
have	O
proper	O
diagnosis	O
and	O
better	O
management	O
of	O
patients	O
.	O

Multiple	O
regions	O
in	O
the	O
extracellular	O
domain	O
of	O
the	O
glycine	O
receptor	O
determine	O
receptor	O
activity	O
.	O

Glycine	O
receptors	O
(	O
GlyRs	O
)	O
are	O
Cys	O
-	O
loop	O
receptors	O
that	O
mediate	O
fast	O
synaptic	O
inhibition	O
in	O
the	O
brain	O
stem	O
and	O
spinal	O
cord	O
.	O

They	O
are	O
involved	O
in	O
the	O
generation	O
of	O
motor	O
rhythm	O
,	O
reflex	O
circuit	O
coordination	O
,	O
and	O
sensory	O
signal	O
processing	O
and	O
therefore	O
represent	O
targets	O
for	O
therapeutic	O
interventions	O
.	O

The	O
extracellular	O
domains	O
(	O
ECDs	O
)	O
of	O
Cys	O
-	O
loop	O
receptors	O
typically	O
contain	O
many	O
aromatic	O
amino	O
acids	O
,	O
but	O
only	O
those	O
in	O
the	O
receptor	O
binding	O
pocket	O
have	O
been	O
extensively	O
studied	O
.	O

Here	O
,	O
we	O
show	O
that	O
many	O
Phe	O
residues	O
in	O
the	O
ECD	O
that	O
are	O
not	O
located	O
in	O
the	O
binding	O
pocket	O
are	O
also	O
involved	O
in	O
GlyR	O
function	O
.	O

We	O
examined	O
these	O
Phe	O
residues	O
by	O
creating	O
several	O
GlyR	O
variants	O
,	O
characterizing	O
these	O
variants	O
with	O
the	O
two	O
-	O
electrode	O
voltage	O
clamp	O
technique	O
in	O
Xenopus	O
oocytes	O
,	O
and	O
interpreting	O
changes	O
in	O
receptor	O
parameters	O
by	O
using	O
currently	O
available	O
structural	O
information	O
on	O
the	O
open	O
and	O
closed	O
states	O
of	O
the	O
GlyR.	O
Substitution	B-Var
of	O
six	O
of	O
the	O
eight	O
Phe	O
residues	O
in	O
the	O
ECD	O
with	O
Ala	O
resulted	O
in	O
loss	B-NegReg
of	O
function	B-MPA
or	O
significantly	O
increased	B-PosReg
the	O
EC50	B-MPA
and	O
also	O
altered	B-Reg
the	O
maximal	B-MPA
response	I-MPA
to	I-MPA
the	I-MPA
partial	I-MPA
GlyR	I-MPA
agonist	I-MPA
taurine	I-MPA
compared	O
with	O
glycine	O
in	O
those	O
receptor	O
variants	O
that	O
were	O
functional	O
.	O

Substitutions	O
with	O
other	O
amino	O
acids	O
,	O
combined	O
with	O
examination	O
of	O
nearby	O
residues	O
that	O
could	O
potentially	O
interact	O
with	O
these	O
Phe	O
residues	O
,	O
suggested	O
interactions	O
that	O
could	O
be	O
important	O
for	O
GlyR	O
function	O
,	O
and	O
possibly	O
similar	O
interactions	O
could	O
contribute	O
to	O
the	O
function	O
of	O
other	O
members	O
of	O
the	O
Cys	O
-	O
loop	O
receptor	O
family	O
.	O

Overall	O
,	O
our	O
results	O
suggest	O
that	O
many	O
ECD	O
regions	O
are	O
important	O
for	O
GlyR	O
function	O
and	O
that	O
these	O
regions	O
could	O
inform	O
the	O
design	O
of	O
therapeutic	O
agents	O
targeting	O
GlyR	O
activity	O
.	O

Targeted	O
Next	O
Generation	O
Sequencing	O
Revealed	O
Novel	O
PRPF31	B-Gene
Mutations	B-Var
in	B-Reg
Autosomal	B-Disease
Dominant	I-Disease
Retinitis	I-Disease
Pigmentosa	I-Disease
.	O

BACKGROUND	O
:	O
Retinitis	O
pigmentosa	O
(	O
RP	O
)	O
is	O
a	O
rare	O
type	O
of	O
inherited	O
retinal	O
dystrophy	O
that	O
can	O
result	O
in	O
progressive	O
vision	O
loss	O
.	O

Molecular	O
diagnosis	O
of	O
RP	O
is	O
challenging	O
due	O
to	O
phenotypic	O
and	O
genotypic	O
heterogeneities	O
.	O

AIMS	O
:	O
This	O
study	O
aimed	O
to	O
identify	O
the	O
pathogenic	O
mutations	O
in	O
two	O
Chinese	O
families	O
with	O
autosomal	O
dominant	O
RP	O
(	O
adRP	O
)	O
and	O
in	O
a	O
patient	O
with	O
sporadic	O
RP	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Peripheral	O
blood	O
DNA	O
samples	O
were	O
obtained	O
from	O
the	O
participants	O
.	O

Targeted	O
next	O
generation	O
sequencing	O
(	O
NGS	O
)	O
was	O
applied	O
to	O
identify	O
mutations	O
in	O
these	O
patients	O
.	O

For	O
pathogenic	O
mutation	O
analyses	O
,	O
stringent	O
NGS	O
data	O
analyses	O
and	O
segregation	O
analyses	O
were	O
applied	O
.	O

Primers	O
were	O
designed	O
to	O
validate	O
the	O
identified	O
mutations	O
by	O
Sanger	O
sequencing	O
analyses	O
.	O

RESULTS	O
:	O
A	O
novel	O
heterozygous	O
insertion	O
frameshift	O
mutation	O
c.1226_1227insA	O
,	O
p	O
.	O
T410Dfs*65	O
,	O
and	O
a	O
novel	O
heterozygous	O
stopgain	O
mutation	O
c.1015C	O
>	O
T	O
,	O
p	O
.	O
Q339	O
*	O
were	O
identified	O
in	O
PRPF31	O
.	O

A	O
known	O
c.527	O
+	O
3A	O
>	O
G	O
splicing	O
mutation	O
was	O
identified	O
in	O
one	O
of	O
the	O
adRP-074	O
families	O
.	O

All	O
mutations	O
were	O
found	O
to	O
co	O
-	O
segregate	O
with	O
the	O
disease	O
,	O
and	O
none	O
of	O
these	O
mutations	O
were	O
detected	O
in	O
500	O
control	O
samples	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
identified	O
two	O
new	O
autosomal	O
dominant	O
mutations	O
in	O
PRPF31	O
,	O
expanding	O
the	O
mutational	O
spectrum	O
of	O
this	O
gene	O
.	O

RES	O
complex	O
is	O
associated	O
with	O
intron	O
definition	O
and	O
required	O
for	O
zebrafish	O
early	O
embryogenesis	O
.	O

Pre	O
-	O
mRNA	O
splicing	O
is	O
a	O
critical	O
step	O
of	O
gene	O
expression	O
in	O
eukaryotes	O
.	O

Transcriptome	O
-	O
wide	O
splicing	O
patterns	O
are	O
complex	O
and	O
primarily	O
regulated	O
by	O
a	O
diverse	O
set	O
of	O
recognition	O
elements	O
and	O
associated	O
RNA	O
-	O
binding	O
proteins	O
.	O

The	O
retention	O
and	O
splicing	O
(	O
RES	O
)	O
complex	O
is	O
formed	O
by	O
three	O
different	O
proteins	O
(	O
Bud13p	O
,	O
Pml1p	O
and	O
Snu17p	O
)	O
and	O
is	O
involved	O
in	O
splicing	O
in	O
yeast	O
.	O

However	O
,	O
the	O
importance	O
of	O
the	O
RES	O
complex	O
for	O
vertebrate	O
splicing	O
,	O
the	O
intronic	O
features	O
associated	O
with	O
its	O
activity	O
,	O
and	O
its	O
role	O
in	O
development	O
are	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
generated	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutants	B-Var
for	O
the	O
three	O
components	O
of	O
the	O
RES	O
complex	O
in	O
zebrafish	O
and	O
showed	O
that	O
they	O
are	O
required	O
during	O
early	O
development	O
.	O

The	O
mutants	O
showed	O
a	O
marked	O
neural	O
phenotype	O
with	O
increased	O
cell	O
death	O
in	O
the	O
brain	O
and	O
a	O
decrease	B-NegReg
in	O
differentiated	B-CPA
neurons	I-CPA
.	O

Transcriptomic	O
analysis	O
of	O
bud13	B-Gene
,	O
snip1	B-Gene
(	O
pml1	O
)	O
and	O
rbmx2	B-Gene
(	O
snu17	O
)	O
mutants	B-Var
revealed	O
a	O
global	O
defect	B-NegReg
in	O
intron	B-MPA
splicing	I-MPA
,	O
with	O
strong	O
mis	B-MPA
-	I-MPA
splicing	I-MPA
of	I-MPA
a	I-MPA
subset	I-MPA
of	I-MPA
introns	I-MPA
.	O

We	O
found	O
these	O
RES	O
-	O
dependent	O
introns	O
were	O
short	O
,	O
rich	O
in	O
GC	O
and	O
flanked	O
by	O
GC	O
depleted	O
exons	O
,	O
all	O
of	O
which	O
are	O
features	O
associated	O
with	O
intron	O
definition	O
.	O

Using	O
these	O
features	O
,	O
we	O
developed	O
and	O
validated	O
a	O
predictive	O
model	O
that	O
classifies	O
RES	O
dependent	O
introns	O
.	O

Altogether	O
,	O
our	O
study	O
uncovers	O
the	O
essential	O
role	O
of	O
the	O
RES	O
complex	O
during	O
vertebrate	O
development	O
and	O
provides	O
new	O
insights	O
into	O
its	O
function	O
during	O
splicing	O
.	O

Mutant	B-Var
p53	B-Gene
gain	B-PosReg
of	I-PosReg
function	I-PosReg
induces	B-Reg
HER2	B-Protein
over	B-MPA
-	I-MPA
expression	I-MPA
in	O
cancer	O
cells	O
.	O

BACKGROUND	O
:	O
HER2	O
over	O
-	O
expression	O
is	O
related	O
with	O
a	O
poor	O
prognosis	O
in	O
patients	O
with	O
invasive	O
breast	O
cancer	O
tumors	O
.	O

Clinical	O
associations	O
have	O
reported	O
that	O
somatic	O
mutations	O
of	O
p53	O
more	O
frequently	O
detected	O
in	O
cases	O
of	O
sporadic	O
breast	O
cancer	O
of	O
the	O
HER2	O
subtypes	O
,	O
besides	O
a	O
high	O
percentage	O
of	O
HER2-amplifying	O
tumors	O
carry	O
germline	O
mutations	O
of	O
p53	O
.	O

The	O
mechanisms	O
responsible	O
for	O
the	O
acquisition	O
of	O
oncogenic	O
functions	O
of	O
p53	O
mutant	O
proteins	O
(	O
mtp53	O
)	O
,	O
known	O
as	O
Gain	O
of	O
Function	O
(	O
GOF	O
)	O
,	O
over	O
HER2	O
expression	O
have	O
not	O
been	O
reported	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
a	O
possible	O
relationship	O
between	O
p53	O
mutants	O
and	O
HER2	O
regulation	O
.	O

METHODS	O
:	O
HER2	O
expression	O
(	O
transcription	O
and	O
protein	O
)	O
,	O
as	O
well	O
as	O
HER2	O
protein	O
stabilization	O
have	O
been	O
evaluated	O
after	O
inducing	O
or	O
silencing	O
of	O
p53	O
mutants	O
'	O
expression	O
in	O
cell	O
lines	O
.	O

Finally	O
,	O
we	O
evaluated	O
the	O
interaction	O
of	O
the	O
p53	O
mutants	O
over	O
the	O
HER2	O
receptor	O
promoter	O
.	O

RESULTS	O
:	O
Higher	B-PosReg
HER2	B-Protein
expression	B-MPA
in	O
cell	O
lines	O
harboring	O
endogenous	O
mtp53	B-Var
compared	O
with	O
wt	O
or	O
null	O
expression	O
of	O
p53	O
cell	O
lines	O
.	O

Transfection	O
of	O
p53	B-Gene
mutants	O
(	B-Var
R248Q	I-Var
and	O
R273C	B-Var
)	I-Var
in	O
cell	O
lines	O
increased	B-PosReg
the	O
expression	B-MPA
of	O
HER2	B-Protein
.	O

Silencing	O
of	O
p53	O
mutants	O
,	O
decrease	O
HER2	O
expression	O
.	O

The	O
p53	B-Gene
mutants	O
R248Q	B-Var
and	O
R273C	B-Var
significantly	O
increase	B-PosReg
the	O
luciferase	B-Enzyme
activity	B-MPA
on	O
the	O
HER2	O
promoter	O
,	O
and	O
both	O
mutants	O
also	O
promote	B-PosReg
acetylation	B-MPA
of	O
H3	B-Protein
and	O
H4	B-Protein
histones	I-Protein
binding	B-Interaction
in	O
it	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
show	O
for	O
the	O
first	O
time	O
that	O
p53	B-Gene
mutants	B-Var
induce	B-Reg
over	B-MPA
-	I-MPA
expression	I-MPA
of	O
HER2	B-Protein
at	O
transcriptional	O
level	O
of	O
the	O
HER2	O
protein	O
.	O

Our	O
results	O
could	O
have	O
clinical	O
implications	O
in	O
breast	O
cancer	O
and	O
other	O
types	O
of	O
cancer	O
where	O
HER2	O
is	O
over	O
-	O
expressed	O
and	O
used	O
as	O
a	O
therapy	O
target	O
.	O

Identification	O
of	O
deletion	B-Var
-	I-Var
duplication	I-Var
in	O
HEXA	B-Gene
gene	O
in	O
five	O
children	O
with	B-Reg
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
from	O
India	O
.	O

BACKGROUND	O
:	O
Tay	B-Disease
-	I-Disease
Sachs	I-Disease
disease	I-Disease
(	O
TSD	O
)	O
is	O
a	O
sphingolipid	O
storage	O
disorder	O
caused	B-Reg
by	I-Reg
mutations	B-Var
in	O
the	O
HEXA	B-Gene
gene	O
.	O

To	O
date	O
,	O
nearly	O
170	O
mutations	O
of	O
HEXA	O
have	O
been	O
described	O
,	O
including	O
only	O
one	O
7.6	O
kb	O
large	O
deletion	O
.	O

METHODS	O
:	O
Multiplex	O
Ligation	O
-	O
dependent	O
Probe	O
Amplification	O
(	O
MLPA	O
)	O
study	O
was	O
carried	O
out	O
in	O
5	O
unrelated	O
patients	O
for	O
copy	O
number	O
changes	O
where	O
heterozygous	O
and/or	O
homozygous	O
disease	O
causing	O
mutation	O
/	O
s	O
could	O
not	O
be	O
identified	O
in	O
the	O
coding	O
region	O
by	O
sequencing	O
of	O
HEXA	O
gene	O
.	O

RESULTS	O
:	O
The	O
study	O
has	O
identified	O
the	O
presence	O
of	O
a	O
homozygous	O
deletion	O
of	O
exon-2	O
and	O
exon-3	O
in	O
two	O
patients	O
,	O
two	O
patient	O
showed	O
compound	O
heterozygosity	O
with	O
exon	O
1	O
deletion	O
combined	O
with	O
missense	O
mutation	O
p	O
.	O
E462V	O
and	O
one	O
patient	O
was	O
identified	O
with	O
duplication	O
of	O
exon-1	O
with	O
novel	O
variants	O
c.1527	O
-	O
2A	O
>	O
T	O
as	O
a	O
second	O
allele	O
.	O

CONCLUSION	O
:	O
This	O
is	O
the	O
first	O
report	O
of	O
deletion	O
/	O
duplication	O
in	O
HEXA	O
gene	O
providing	O
a	O
new	O
insight	O
into	O
the	O
molecular	O
basis	O
of	O
TSD	O
and	O
use	O
of	O
MLPA	O
assay	O
for	O
detecting	O
large	O
copy	O
number	O
changes	O
in	O
the	O
HEXA	O
gene	O
.	O

Two	O
siblings	O
with	O
11qter	O
deletion	O
syndrome	O
that	O
had	O
been	O
rescued	O
in	O
their	O
mother	O
by	O
uniparental	O
disomy	O
.	O

Jacobsen	B-Disease
syndrome	I-Disease
refers	O
to	O
a	O
congenital	O
anomaly	O
caused	B-Reg
by	I-Reg
deletion	B-Var
at	O
11q23.3-qter	B-Gene
.	O

We	O
here	O
describe	O
two	O
siblings	O
with	O
the	O
same	O
11q23.3-qter	O
deletion	O
.	O

Both	O
parents	O
were	O
healthy	O
with	O
a	O
normal	O
karyotype	O
.	O

Cytogenetic	O
microarray	O
analysis	O
revealed	O
no	O
mosaicism	O
in	O
either	O
parent	O
but	O
the	O
mother	O
showed	O
uniparental	O
disomy	O
encompassing	O
the	O
deleted	O
region	O
found	O
in	O
the	O
two	O
siblings	O
.	O

The	O
pattern	O
of	O
X	O
chromosome	O
inactivation	O
was	O
almost	O
completely	O
skewed	O
in	O
the	O
mother	O
.	O

These	O
data	O
suggested	O
that	O
the	O
mother	O
was	O
a	O
carrier	O
of	O
the	O
11q23.3-qter	O
deletion	O
but	O
that	O
this	O
had	O
been	O
rescued	O
by	O
disomy	O
formation	O
during	O
early	O
embryogenesis	O
except	O
for	O
her	O
germinal	O
cells	O
.	O

Genotyping	O
of	O
five	O
Pakistani	O
patients	O
with	O
severe	O
inherited	O
factor	O
X	O
deficiency	O
:	O
identification	O
of	O
two	O
novel	O
mutations	O
.	O

:	O
Congenital	B-Disease
factor	I-Disease
X	I-Disease
deficiency	I-Disease
is	O
a	O
rare	O
coagulation	O
defect	O
characterized	O
by	O
variable	O
bleeding	O
tendency	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
give	O
a	O
first	O
insight	O
of	B-Reg
F10	B-Gene
gene	O
mutations	B-Var
in	O
Pakistani	O
probands	O
.	O

Direct	O
sequencing	O
and/or	O
next	O
-	O
generation	O
sequencing	O
was	O
performed	O
on	O
the	O
coding	O
regions	O
,	O
boundaries	O
and	O
5	O
'	O
and	O
3	O
'	O
untranslated	O
regions	O
of	O
the	O
F10	O
gene	O
in	O
five	O
severe	O
factor	O
X	O
-	O
deficient	O
patients	O
from	O
Pakistan	O
.	O

All	O
patients	O
were	O
born	O
from	O
consanguineous	O
marriages	O
and	O
displayed	O
FX	O
:	O
C	O
levels	O
below	O
2	O
%	O
.	O

Sequencing	O
revealed	O
five	O
different	O
substitutions	O
,	O
including	O
three	O
previously	O
reported	O
p	O
.	O
Ala15Asp	O
,	O
p	O
.	O
Gly406Ser	O
,	O
and	O
p	O
.	O
Gly420Arg	O
missense	O
variants	O
,	O
and	O
also	O
two	O
novel	O
variants	O
:	O
p	O
.	O
Cys57Arg	O
and	O
p	O
.	O
Gln175	O
*	O
.	O

Though	O
one	O
genotype	O
could	O
not	O
be	O
characterized	O
,	O
we	O
were	O
able	O
to	O
confirm	O
the	O
inherited	O
nature	O
of	O
the	O
defect	O
using	O
familial	O
studies	O
.	O

As	O
the	O
copy	O
number	O
variations	O
were	O
ruled	O
out	O
,	O
we	O
hypothesized	O
the	O
presence	O
of	O
deep	O
intronic	O
mutants	O
that	O
might	O
have	O
escaped	O
detection	O
from	O
sequencing	O
or	O
abnormalities	O
in	O
epigenetic	O
regulation	O
.	O

Three	O
patients	O
presented	O
with	O
severe	O
clinical	O
symptoms	O
,	O
in	O
the	O
early	O
days	O
of	O
life	O
,	O
whereas	O
two	O
presented	O
only	O
with	O
trauma	O
-	O
provoked	O
bleeds	O
and	O
bruises	O
later	O
in	O
life	O
.	O

Those	O
patients	O
with	O
milder	O
forms	O
bore	O
the	O
p	O
.	O
Gly406Ser	O
at	O
the	O
homozygous	O
state	O
and	O
F10	O
unknown	O
alleles	O
,	O
respectively	O
.	O

F10	O
mutation	O
spectrum	O
in	O
Pakistan	O
is	O
heterogeneous	O
as	O
seen	O
in	O
other	O
populations	O
.	O

Identification	O
of	O
the	O
F10	O
mutations	O
is	O
important	O
for	O
genetic	O
counseling	O
and	O
prenatal	O
diagnosis	O
in	O
subsequent	O
pregnancies	O
.	O

Mice	O
harboring	O
the	O
human	O
SLC30A8	B-Gene
R138X	B-Var
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	O
have	O
increased	B-PosReg
insulin	B-MPA
secretory	I-MPA
capacity	I-MPA
.	O

SLC30A8	O
encodes	O
a	O
zinc	O
transporter	O
that	O
is	O
primarily	O
expressed	O
in	O
the	O
pancreatic	O
islets	O
of	O
Langerhans	O
.	O

In	O
β	O
-	O
cells	O
it	O
transports	O
zinc	O
into	O
insulin	O
-	O
containing	O
secretory	O
granules	O
.	O

Loss	O
-	O
of	O
-	O
function	O
(	O
LOF	O
)	O
mutations	O
in	O
SLC30A8	O
protect	O
against	O
type	O
2	O
diabetes	O
in	O
humans	O
.	O

In	O
this	O
study	O
,	O
we	O
generated	O
a	O
knockin	O
mouse	O
model	O
carrying	O
one	O
of	O
the	O
most	O
common	O
human	O
LOF	O
mutations	O
for	O
SLC30A8	O
,	O
R138X.	O
The	O
R138X	O
mice	O
had	O
normal	O
body	O
weight	O
,	O
glucose	O
tolerance	O
,	O
and	O
pancreatic	O
β	O
-	O
cell	O
mass	O
.	O

Interestingly	O
,	O
in	O
hyperglycemic	O
conditions	O
induced	O
by	O
the	O
insulin	O
receptor	O
antagonist	O
S961	O
,	O
the	O
R138X	B-Var
mice	O
showed	O
a	O
50	O
%	O
increase	B-PosReg
in	O
insulin	B-MPA
secretion	I-MPA
.	O

This	O
effect	O
was	O
not	O
associated	O
with	O
enhanced	O
β	O
-	O
cell	O
proliferation	O
or	O
mass	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
SLC30A8	B-Gene
R138X	O
LOF	B-NegReg
mutation	B-Var
may	O
exert	O
beneficial	B-PosReg
effects	I-PosReg
on	O
glucose	B-MPA
metabolism	I-MPA
by	O
increasing	B-PosReg
the	O
capacity	O
of	O
β	O
-	O
cells	O
to	O
secrete	B-MPA
insulin	I-MPA
under	O
hyperglycemic	O
conditions	O
.	O

The	O
lateral	O
meningocele	O
syndrome	O
mutation	O
causes	O
marked	O
osteopenia	O
in	O
mice	O
.	O

Lateral	O
meningocele	O
syndrome	O
(	O
LMS	O
)	O
is	O
a	O
rare	O
genetic	O
disorder	O
characterized	O
by	O
neurological	O
complications	O
and	O
osteoporosis	O
.	O

LMS	B-Disease
is	O
associated	O
with	O
mutations	B-Var
in	I-Var
exon	I-Var
33	I-Var
of	O
NOTCH3	B-Gene
leading	O
to	O
a	O
truncated	B-MPA
protein	B-Protein
lacking	B-NegReg
sequences	B-MPA
for	I-MPA
NOTCH3	I-MPA
degradation	I-MPA
and	O
presumably	O
causing	O
NOTCH3	B-Gene
gain	B-PosReg
of	I-PosReg
function	I-PosReg
.	O

To	O
create	O
a	O
mouse	O
model	O
reproducing	O
human	O
LMS	O
-	O
associated	O
mutations	O
,	O
we	O
utilized	O
CRISPR	O
/	O
Cas9	O
to	O
introduce	O
a	O
tandem	O
termination	O
codon	O
at	O
bases	O
6691	O
-	O
6696	O
(	O
ACCAAG→TAATGA	O
)	O
and	O
verified	O
this	O
mutation	O
(	O
Notch3tm1.1Ecan	O
)	O
by	O
DNA	O
sequencing	O
of	O
F1	O
mice	O
.	O

One	O
-	O
month	O
-	O
old	O
male	O
and	O
female	O
heterozygous	O
Notch3tm1.1Ecan	B-Var
mice	O
had	O
cancellous	B-CPA
and	I-CPA
cortical	I-CPA
bone	I-CPA
osteopenia	B-NegReg
but	O
exhibited	O
no	O
obvious	O
neurological	O
alterations	O
,	O
and	O
histopathology	O
of	O
multiple	O
organs	O
revealed	O
no	O
abnormalities	O
.	O

Microcomputed	O
tomography	O
of	O
these	O
mutants	B-Var
revealed	O
a	O
35	O
-	O
60	O
%	O
decrease	B-NegReg
in	O
cancellous	B-CPA
bone	I-CPA
volume	I-CPA
associated	O
with	O
a	O
reduction	B-NegReg
in	O
trabecular	B-CPA
number	I-CPA
and	O
decreased	B-NegReg
connectivity	B-CPA
.	O

During	O
maturation	O
,	O
cancellous	O
and	O
cortical	O
bones	O
were	O
restored	O
in	O
female	O
but	O
not	O
in	O
male	O
mice	O
,	O
which	O
exhibited	O
cancellous	O
bone	O
osteopenia	O
at	O
4	O
months	O
.	O

Cancellous	O
bone	O
histomorphometry	O
revealed	O
increased	O
osteoblast	O
and	O
osteocyte	O
numbers	O
and	O
a	O
modest	O
increase	O
in	O
osteoclast	O
surface	O
and	O
bone	O
formation	O
rate	O
.	O

Notch3tm1.1Ecan	B-Var
calvarial	B-CPA
osteoblasts	I-CPA
had	O
increased	B-PosReg
proliferation	O
and	O
increased	B-PosReg
bone	B-Protein
γ	I-Protein
-	I-Protein
carboxyglutamate	I-Protein
protein	I-Protein
(	I-Protein
Bglap	I-Protein
)	I-Protein
and	O
TNF	B-Gene
superfamily	I-Gene
member	I-Gene
11	I-Gene
(	I-Gene
Tnfsf11	I-Gene
)	I-Gene
mRNA	B-MPA
levels	I-MPA
and	O
lower	B-NegReg
Tnfrsf11b	B-MPA
levels	I-MPA
.	O

Tnfsf11	O
mRNA	O
was	O
increased	O
in	O
osteocyte	O
-	O
rich	O
femora	O
from	O
Notch3tm1.1Ecan	O
mice	O
.	O

Cultures	O
of	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
from	O
Notch3tm1.1Ecan	O
mice	O
revealed	O
increased	O
osteoclast	O
formation	O
,	O
particularly	O
in	O
cocultures	O
with	O
osteoblasts	O
from	O
Notch3tm1.1Ecan	O
mice	O
.	O

In	O
conclusion	O
,	O
the	O
Notch3tm1.1Ecan	B-Var
mutation	I-Var
causes	O
osteopenia	B-Disease
despite	O
an	O
increase	B-PosReg
in	O
osteoblast	B-CPA
proliferation	I-CPA
and	O
function	B-CPA
and	O
is	O
associated	O
with	O
enhanced	B-PosReg
Tnfsf11	B-Gene
expression	B-MPA
in	O
osteoblasts	O
and	O
osteocytes	O
.	O

Heterogeneous	O
nature	O
of	O
diabetes	B-Disease
in	O
a	O
family	O
with	O
a	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
mutation	B-Var
in	O
the	O
ATP	O
-	O
binding	O
cassette	O
subfamily	O
C	O
member	O
8	O
(	B-Gene
ABCC8	I-Gene
)	I-Gene
gene	O
.	O

Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
ATP	O
-	O
binding	O
cassette	O
subfamily	O
C	O
member	O
8	O
(	B-Gene
ABCC8	I-Gene
)	I-Gene
mutations	B-Var
are	O
known	O
to	O
cause	B-Reg
neonatal	B-Disease
diabetes	I-Disease
mellitus	I-Disease
and	O
maturity	B-Disease
-	I-Disease
onset	I-Disease
diabetes	I-Disease
in	O
the	O
young	O
.	O

However	O
,	O
the	O
intrafamilial	O
heterogeneous	O
nature	O
of	O
diabetes	O
caused	O
by	O
the	O
ABCC8	O
mutation	O
is	O
not	O
fully	O
understood	O
to	O
date	O
.	O

To	O
clarify	O
the	O
intrafamilial	O
heterogeneous	O
nature	O
of	O
monogenetic	O
diabetes	O
,	O
we	O
conducted	O
a	O
case	O
study	O
on	O
a	O
family	O
with	O
ABCC8	O
mutations	O
.	O

We	O
investigated	O
eight	O
family	O
members	O
,	O
including	O
a	O
neonatal	O
diabetes	O
patient	O
,	O
based	O
on	O
metabolic	O
features	O
and	O
genetic	O
analysis	O
.	O

All	O
coding	O
exons	O
and	O
exon	O
-	O
intron	O
boundaries	O
of	O
the	O
KCNJ11	O
,	O
ABCC8	O
,	O
GCK	O
,	O
HNF1A	O
,	O
and	O
HNF4A	O
genes	O
were	O
amplified	O
from	O
genomic	O
DNA	O
and	O
directly	O
sequenced	O
.	O

Five	O
gene	O
mutation	O
carriers	O
with	O
ABCC8	O
(	O
c.1819G	O
>	O
A	O
/	O
p	O
.	O
V607	O
M	O
)	O
were	O
identified	O
in	O
this	O
family	O
,	O
and	O
the	O
onset	O
and	O
severity	O
of	O
diabetes	O
progressively	O
worsened	O
across	O
the	O
three	O
generations	O
.	O

Each	O
of	O
the	O
ABCC8	O
gene	O
mutation	O
carrier	O
family	O
members	O
were	O
diagnosed	O
with	O
diabetes	O
as	O
follows	O
:	O
the	O
grandfather	O
with	O
type	O
2	O
diabetes	O
at	O
35	O
years	O
of	O
age	O
,	O
the	O
aunt	O
with	O
slowly	O
-	O
progressive	O
insulin	O
-	O
dependent	O
diabetes	O
at	O
18	O
years	O
of	O
age	O
,	O
the	O
mother	O
with	O
ketosis	O
-	O
onset	O
insulin	O
-	O
dependent	O
diabetes	O
at	O
14	O
years	O
of	O
age	O
,	O
the	O
sister	O
with	O
impaired	O
glucose	O
tolerance	O
at	O
9	O
years	O
of	O
age	O
,	O
and	O
the	O
proband	O
with	O
transient	O
neonatal	O
diabetes	O
at	O
birth	O
.	O

The	O
present	O
study	O
shows	O
the	O
heterogeneous	O
nature	O
of	O
diabetes	O
in	O
a	O
family	O
with	O
a	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
in	O
the	O
ABCC8	O
gene	O
.	O

Spectrum	O
of	O
MECP2	B-Gene
mutations	B-Var
in	O
Vietnamese	O
patients	O
with	B-Reg
RETT	B-Disease
syndrome	I-Disease
.	O

BACKGROUND	O
:	O
Rett	O
syndrome	O
(	O
RTT	O
)	O
is	O
a	O
severe	O
neurodevelopmental	O
disorder	O
in	O
children	O
characterized	O
by	O
a	O
normal	O
neurodevelopmental	O
process	O
in	O
the	O
first	O
6	O
-	O
18	O
months	O
followed	O
by	O
a	O
period	O
of	O
motor	O
and	O
vocal	O
deterioration	O
with	O
stereotypic	O
hand	O
movements	O
.	O

Incidence	O
of	O
RTT	B-Disease
is	O
mostly	O
due	B-Reg
to	I-Reg
de	O
novo	O
mutation	B-Var
in	O
the	O
MECP2	B-Gene
gene	O
(	O
methyl	O
-	O
CpG	O
-	O
binding	O
protein	O
2	O
)	O
.	O

METHODS	O
:	O
The	O
study	O
assessed	O
27	O
female	O
patients	O
presented	O
with	O
classical	O
RTT	O
phenotype	O
age	O
range	O
from	O
18	O
months	O
to	O
48	O
months	O
.	O

Specialist	O
carried	O
out	O
the	O
clinical	O
evaluation	O
and	O
diagnosis	O
according	O
to	O
RTT	O
diagnosis	O
criteria	O
.	O

Blood	O
samples	O
from	O
patients	O
were	O
then	O
collected	O
for	O
genomic	O
DNA	O
extraction	O
.	O

We	O
next	O
performed	O
MECP2	O
gene	O
amplification	O
and	O
sequencing	O
of	O
the	O
whole	O
coding	O
region	O
to	O
screen	O
for	O
mutations	O
.	O

RESULT	O
:	O
MECP2	O
mutation	O
was	O
found	O
in	O
20	O
patients	O
(	O
74	O
%	O
)	O
including	O
:	O
2	O
missense	O
,	O
4	O
nonsense	O
,	O
6	O
frameshift	O
and	O
2	O
deletion	O
mutation	O
.	O

The	O
study	O
identified	O
14	O
pathogenic	O
mutations	O
which	O
we	O
found	O
4	O
mutation	O
,	O
to	O
our	O
knowledge	O
and	O
extensive	O
search	O
,	O
not	O
priory	O
reported	O
in	O
any	O
mutation	O
database	O
or	O
publication	O
:	O
c.1384	O
-	O
1385DelGT	O
,	O
c.1205insT	O
,	O
c.717delC	O
and	O
c.1132_1207del77	O
.	O

High	O
percentage	O
of	O
C	O
>	O
T	O
(	O
70	O
%	O
)	O
in	O
CpG	O
sites	O
mutation	O
was	O
found	O
.	O

CONCLUSION	O
:	O
Our	O
result	O
reveals	O
a	O
high	O
percentage	O
of	O
C	O
>	O
T	O
mutation	O
in	O
CpG	O
hot	O
spot	O
,	O
which	O
is	O
more	O
prone	O
to	O
modification	O
and	O
more	O
likely	O
to	O
be	O
detected	O
in	O
RTT	O
as	O
a	O
disorder	O
is	O
strictly	O
due	O
to	O
de	O
novo	O
mutations	O
.	O

The	O
study	O
is	O
the	O
first	O
to	O
identify	O
the	O
mutation	O
spectrum	O
of	O
MECP2	O
gene	O
in	O
Vietnamese	O
patients	O
and	O
also	O
an	O
important	O
step	O
toward	O
better	O
diagnosis	O
and	O
care	O
for	O
RTT	O
patients	O
in	O
Vietnam	O
.	O

Activating	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
(	O
HER2	O
)	O
gene	O
mutation	O
in	O
bone	O
metastases	O
from	O
breast	O
cancer	O
.	O

In	O
addition	O
to	O
amplification	O
,	O
point	B-Var
mutations	I-Var
of	O
the	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
2	O
(	O
HER2	O
)	O
gene	O
(	B-Gene
ERBB2	I-Gene
)	I-Gene
have	O
been	O
shown	O
to	O
activate	B-PosReg
the	O
corresponding	O
signaling	B-Pathway
pathway	I-Pathway
in	O
breast	B-Disease
cancer	I-Disease
.	O

The	O
prevalence	O
of	O
ERBB2	O
/	O
HER2	O
mutation	O
in	O
bone	O
metastasis	O
of	O
breast	O
cancer	O
and	O
the	O
associated	O
phenotype	O
are	O
not	O
known	O
.	O

In	O
this	O
study	O
,	O
bone	O
metastases	O
from	O
breast	O
cancer	O
patients	O
(	O
n	O
=	O
231	O
)	O
were	O
analyzed	O
for	O
ERBB2	O
/	O
HER2	O
mutation	O
.	O

In	O
7	O
patients	O
(	O
3	O
%	O
;	O
median	O
age	O
70	O
years	O
,	O
range	O
50	O
-	O
83	O
years	O
)	O
,	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
of	O
ERBB2	O
/	O
HER2	O
were	O
detected	O
.	O

The	O
most	O
frequent	O
mutation	O
was	O
p	O
.	O
L755S	O
(	O
71	O
%	O
)	O
.	O

In	O
29	O
%	O
of	O
mutated	O
cases	O
,	O
p	O
.	O
V777L	O
was	O
found	O
.	O

Lobular	O
breast	O
cancer	O
was	O
present	O
in	O
71	O
%	O
of	O
mutated	O
cases	O
(	O
n	O
=	O
5	O
)	O
and	O
in	O
49	O
%	O
of	O
all	O
samples	O
(	O
n	O
=	O
231	O
;	O
p	O
=	O
0.275	O
)	O
.	O

Mutation	O
frequency	O
was	O
4.4	O
%	O
in	O
the	O
lobular	O
subgroup	O
and	O
17.4	O
%	O
in	O
the	O
pleomorphic	O
subtype	O
of	O
lobular	O
cancer	O
(	O
n	O
=	O
23	O
)	O
,	O
respectively	O
.	O

All	O
but	O
one	O
mutated	O
lobular	O
cancers	O
were	O
of	O
the	O
pleomorphic	O
subtype	O
(	O
p	O
=	O
0.006	O
)	O
.	O

Mutated	O
cancers	O
belonged	O
either	O
to	O
the	O
luminal	O
(	O
n	O
=	O
4	O
)	O
or	O
to	O
the	O
triple	O
-	O
negative	O
types	O
(	O
n	O
=	O
3	O
)	O
.	O

With	O
regard	O
to	O
protein	O
expression	O
and	O
gene	O
amplification	O
,	O
HER2	O
was	O
negative	O
in	O
all	O
mutated	O
cases	O
.	O

Among	O
the	O
14	O
%	O
of	O
metastatic	O
luminal	O
cancers	O
with	O
estrogen	O
receptor	O
gene	O
(	O
ESR1	O
)	O
mutation	O
,	O
conveying	O
resistance	O
against	O
aromatase	O
inhibitors	O
,	O
no	O
concomitant	O
ERBB2	O
/	O
HER2	O
mutation	O
occurred	O
.	O

We	O
conclude	O
that	O
activating	B-PosReg
HER2	B-Gene
mutation	B-Var
is	O
present	O
in	O
about	O
3	O
%	O
of	O
bone	B-CPA
metastases	I-CPA
from	O
breast	B-Disease
cancers	I-Disease
,	O
with	O
significantly	O
higher	B-PosReg
rates	I-PosReg
in	O
the	O
pleomorphic	O
subtype	O
of	O
lobular	O
cancer	O
.	O

Since	O
mutated	O
cases	O
appear	O
to	O
be	O
HER2-negative	O
by	O
conventional	O
testing	O
,	O
the	O
opportunity	O
for	O
specific	O
anti	O
-	O
HER2	O
therapy	O
may	O
be	O
missed	O
.	O

Clinical	O
presentation	O
and	O
natural	O
history	O
of	O
infantile	O
-	O
onset	O
ascending	O
spastic	O
paralysis	O
from	O
three	O
families	O
with	O
an	O
ALS2	O
founder	O
variant	O
.	O

Biallelic	B-Var
mutations	I-Var
of	O
the	O
alsin	O
Rho	O
guanine	O
nucleotide	O
exchange	O
factor	O
(	B-Gene
ALS2	I-Gene
)	I-Gene
gene	O
cause	B-Reg
a	O
group	O
of	O
overlapping	O
autosomal	O
recessive	O
neurodegenerative	O
disorders	O
including	O
infantile	B-Disease
-	I-Disease
onset	I-Disease
ascending	I-Disease
hereditary	I-Disease
spastic	I-Disease
paralysis	I-Disease
(	O
IAHSP	O
)	O
,	O
juvenile	B-Disease
primary	I-Disease
lateral	I-Disease
sclerosis	I-Disease
(	O
JPLS	O
)	O
,	O
and	O
juvenile	B-Disease
amyotrophic	I-Disease
lateral	I-Disease
sclerosis	I-Disease
(	O
JALS	O
/	O
ALS2	O
)	O
,	O
caused	B-Reg
by	I-Reg
retrograde	B-CPA
degeneration	I-CPA
of	I-CPA
the	I-CPA
upper	I-CPA
motor	I-CPA
neurons	I-CPA
of	I-CPA
the	I-CPA
pyramidal	I-CPA
tracts	I-CPA
.	O

Here	O
,	O
we	O
describe	O
11	O
individuals	O
with	O
IAHSP	O
,	O
aged	O
2	O
-	O
48	O
years	O
,	O
with	O
IAHSP	B-Disease
from	O
three	O
unrelated	O
consanguineous	O
Iranian	O
families	O
carrying	B-Reg
the	O
homozygous	O
c.1640	B-Var
+	I-Var
1G	I-Var
>	I-Var
A	I-Var
founder	O
mutation	O
in	O
ALS2	B-Gene
.	O

Three	O
affected	O
siblings	O
from	O
one	O
family	O
exhibit	O
generalized	O
dystonia	O
which	O
has	O
not	O
been	O
previously	O
described	O
in	O
families	O
with	O
IAHSP	O
and	O
has	O
only	O
been	O
reported	O
in	O
three	O
unrelated	O
consanguineous	O
families	O
with	O
JALS	O
/	O
ALS2	O
.	O

We	O
report	O
the	O
oldest	O
individuals	O
with	O
IAHSP	O
to	O
date	O
and	O
provide	O
evidence	O
that	O
these	O
patients	O
survive	O
well	O
into	O
their	O
late	O
40s	O
with	O
preserved	O
cognition	O
and	O
normal	O
eye	O
movements	O
.	O

Our	O
study	O
delineates	O
the	O
phenotypic	O
spectrum	O
of	O
IAHSP	O
and	O
ALS2-related	O
disorders	O
and	O
provides	O
valuable	O
insights	O
into	O
the	O
natural	O
disease	O
course	O
.	O

A	O
novel	O
MFSD8	B-Gene
mutation	B-Var
in	O
a	O
Russian	O
patient	O
with	B-Reg
neuronal	B-Disease
ceroid	I-Disease
lipofuscinosis	I-Disease
type	O
7	O
:	O
a	O
case	O
report	O
.	O

BACKGROUND	O
:	O
Neuronal	O
ceroid	O
lipofuscinoses	O
(	O
NCLs	O
)	O
are	O
the	O
most	O
common	O
autosomal	O
recessive	O
neurodegenerative	O
disorders	O
in	O
children	O
.	O

Clinical	O
manifestations	O
include	O
progressive	O
cognitive	O
decline	O
,	O
motor	O
impairment	O
,	O
ataxia	O
,	O
visual	O
loss	O
,	O
seizures	O
and	O
early	O
death	O
.	O

To	O
date	O
more	O
than	O
440	O
NCL	O
-	O
causing	O
mutations	O
in	O
13	O
genes	O
are	O
known	O
.	O

CASE	O
PRESENTATION	O
:	O
We	O
report	O
clinical	O
and	O
genetic	O
characteristics	O
of	O
a	O
5-year	O
-	O
old	O
girl	O
affected	O
by	O
ceroid	O
lipofuscinosis	O
type	O
7	O
(	O
NCL7	O
)	O
.	O

She	O
had	O
progressive	O
motor	O
and	O
mental	O
deterioration	O
since	O
the	O
age	O
of	O
2,5	O
years	O
.	O

Later	O
she	O
developed	O
progressive	O
vision	O
loss	O
,	O
stereotypies	O
,	O
action	O
myoclonus	O
and	O
epilepsy	O
.	O

By	O
the	O
age	O
of	O
5	O
years	O
she	O
stopped	O
walking	O
.	O

Based	O
on	O
symptoms	O
,	O
diagnosis	O
of	O
Rett	O
syndrome	O
was	O
suggested	O
,	O
but	O
no	O
abnormalities	O
were	O
detected	O
in	O
MeCP2	O
.	O

We	O
identified	O
a	O
novel	O
homozygous	O
mutation	O
in	O
MFSD8	O
gene	O
(	O
c.525	O
T	O
>	O
A	O
,	O
p	O
.	O
Cys175Ter	O
)	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
MFSD8	O
gene	O
mutation	O
in	O
a	O
Russian	O
patient	O
with	O
variant	O
late	O
-	O
infantile	O
NCL	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
enlarge	O
mutational	O
spectrum	O
of	O
ceroid	O
lipofuscinosis	O
type	O
7	O
and	O
demonstrate	O
tremendous	O
diagnosis	O
value	O
of	O
exome	O
sequencing	O
for	O
pediatric	O
NCLs	O
.	O

Also	O
we	O
confirmed	O
that	O
NCL	O
should	O
be	O
suspected	O
in	O
patients	O
with	O
Rett	O
-	O
like	O
phenotype	O
at	O
onset	O
and	O
negative	O
MECP2	O
mutation	O
.	O

Altered	O
ER	O
-	O
mitochondria	O
contact	O
impacts	O
mitochondria	O
calcium	O
homeostasis	O
and	O
contributes	O
to	O
neurodegeneration	O
in	O
vivo	O
in	O
disease	O
models	O
.	O

Calcium	O
(	O
Ca2	O
+	O
)	O
homeostasis	O
is	O
essential	O
for	O
neuronal	O
function	O
and	O
survival	O
.	O

Altered	O
Ca2	O
+	O
homeostasis	O
has	O
been	O
consistently	O
observed	O
in	O
neurological	O
diseases	O
.	O

How	O
Ca2	O
+	O
homeostasis	O
is	O
achieved	O
in	O
various	O
cellular	O
compartments	O
of	O
disease	O
-	O
relevant	O
cell	O
types	O
is	O
not	O
well	O
understood	O
.	O

Here	O
we	O
show	O
in	O
Drosophila	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
models	O
that	O
Ca2	O
+	O
transport	O
from	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
to	O
mitochondria	O
through	O
the	O
ER	O
-	O
mitochondria	O
contact	O
site	O
(	O
ERMCS	O
)	O
critically	O
regulates	O
mitochondrial	O
Ca2	O
+	O
(	O
mito	O
-	O
Ca2	O
+	O
)	O
homeostasis	O
in	O
dopaminergic	O
(	O
DA	O
)	O
neurons	O
,	O
and	O
that	O
the	O
PD	O
-	O
associated	O
PINK1	O
protein	O
modulates	O
this	O
process	O
.	O

In	O
PINK1	B-Gene
mutant	B-Var
DA	O
neurons	O
,	O
the	O
ERMCS	B-MPA
is	O
strengthened	B-PosReg
and	O
mito	B-MPA
-	I-MPA
Ca2	I-MPA
+	I-MPA
level	I-MPA
is	O
elevated	B-PosReg
,	O
resulting	O
in	O
mitochondrial	B-MPA
enlargement	B-PosReg
and	O
neuronal	O
death	O
.	O

Miro	O
,	O
a	O
well	O
-	O
characterized	O
component	O
of	O
the	O
mitochondrial	O
trafficking	O
machinery	O
,	O
mediates	O
the	O
effects	O
of	O
PINK1	O
on	O
mito	O
-	O
Ca2	O
+	O
and	O
mitochondrial	O
morphology	O
,	O
apparently	O
in	O
a	O
transport	O
-	O
independent	O
manner	O
.	O

Miro	O
overexpression	O
mimics	O
PINK1	O
loss	O
-	O
of	O
-	O
function	O
effect	O
,	O
whereas	O
inhibition	O
of	O
Miro	O
or	O
components	O
of	O
the	O
ERMCS	O
,	O
or	O
pharmacological	O
modulation	O
of	O
ERMCS	O
function	O
,	O
rescued	O
PINK1	O
mutant	O
phenotypes	O
.	O

Mito	O
-	O
Ca2	O
+	O
homeostasis	O
is	O
also	O
altered	O
in	O
the	O
LRRK2-G2019S	O
model	O
of	O
PD	O
and	O
the	O
PAR-1	O
/	O
MARK	O
model	O
of	O
neurodegeneration	O
,	O
and	O
genetic	O
or	O
pharmacological	O
restoration	O
of	O
mito	O
-	O
Ca2	O
+	O
level	O
is	O
beneficial	O
in	O
these	O
models	O
.	O

Our	O
results	O
highlight	O
the	O
importance	O
of	O
mito	O
-	O
Ca2	O
+	O
homeostasis	O
maintained	O
by	O
Miro	O
and	O
the	O
ERMCS	O
to	O
mitochondrial	O
physiology	O
and	O
neuronal	O
integrity	O
.	O

Targeting	O
this	O
mito	O
-	O
Ca2	O
+	O
homeostasis	O
pathway	O
holds	O
promise	O
for	O
a	O
therapeutic	O
strategy	O
for	O
neurodegenerative	O
diseases	O
.	O

Bronchiectasis	B-Disease
and	O
Recurrent	B-Disease
Respiratory	I-Disease
Infections	I-Disease
with	O
a	O
De	O
Novo	O
STAT1	B-Gene
Gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
Function	I-PosReg
Variant	B-Var
:	I-Var
First	O
Case	O
in	O
Korea	O
.	O

Bronchiectasis	O
is	O
a	O
chronic	O
disease	O
characterized	O
by	O
airway	O
infection	O
and	O
inflammation	O
,	O
leading	O
to	O
permanent	O
dilation	O
of	O
the	O
bronchi	O
.	O

Evaluation	O
of	O
underlying	O
etiology	O
is	O
important	O
in	O
managing	O
young	O
bronchiectasis	O
patients	O
with	O
recurrent	O
infections	O
caused	O
by	O
unusual	O
pathogens	O
.	O

The	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
1	O
(	O
STAT1	O
)	O
protein	O
plays	O
a	O
key	O
role	O
in	O
STAT	O
signaling	O
and	O
immune	O
system	O
regulation	O
.	O

Heterozygotes	O
for	O
gain	B-PosReg
-	I-PosReg
of	I-PosReg
-	I-PosReg
function	I-PosReg
(	O
GOF	O
)	O
alleles	B-Var
of	O
the	O
STAT1	B-Gene
gene	O
usually	O
display	O
autosomal	B-Disease
dominant	I-Disease
chronic	I-Disease
mucocutaneous	I-Disease
candidiasis	I-Disease
(	O
CMC	O
)	O
and	O
a	O
wide	O
range	O
of	O
clinical	O
features	O
,	O
such	O
as	O
bronchiectasis	B-Disease
.	O

Here	O
,	O
we	O
report	O
on	O
a	O
patient	O
with	O
CMC	O
and	O
bronchiectasis	O
with	O
various	O
types	O
of	O
infections	O
who	O
carried	O
a	O
pathogenic	O
variant	O
of	O
the	O
STAT1	O
gene	O
.	O

The	O
24-year	O
-	O
old	O
female	O
presented	O
with	O
recurrent	O
respiratory	B-Disease
bacterial	I-Disease
and	I-Disease
nontuberculous	I-Disease
mycobacterial	I-Disease
infections	I-Disease
complicated	O
by	O
severe	O
bronchiectasis	B-Disease
and	O
CMC	B-Disease
.	O

Whole	O
-	O
exome	O
sequencing	O
revealed	B-Reg
a	O
c.800C	B-Var
>	I-Var
T	I-Var
(	O
p	O
.	O
Ala267Val	O
)	O
heterozygous	O
mutation	O
in	O
the	O
STAT1	B-Gene
gene	O
.	O

Further	O
analysis	O
by	O
Sanger	O
sequencing	O
of	O
STAT1	O
from	O
the	O
patient	O
and	O
her	O
parents	O
revealed	O
the	O
patient	O
had	O
a	O
de	O
novo	O
occurrence	O
of	O
the	O
variant	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
Korean	O
patient	O
with	O
a	O
GOF	O
pathogenic	O
variant	O
in	O
STAT1	O
.	O

Physicians	O
should	O
be	O
aware	O
of	O
the	O
existence	O
of	O
this	O
variant	O
as	O
a	O
genetic	O
factor	O
associated	O
with	O
CMC	O
and	O
bronchiectasis	O
complicated	O
by	O
recurrent	O
infection	O
.	O

Single	O
copy	O
/	O
knock	O
-	O
in	O
models	O
of	O
ALS	O
SOD1	O
in	O
C.	O
elegans	O
suggest	O
loss	O
and	O
gain	O
of	O
function	O
have	O
different	O
contributions	O
to	O
cholinergic	O
and	O
glutamatergic	O
neurodegeneration	O
.	O

Mutations	B-Var
in	O
Cu	O
/	O
Zn	O
superoxide	O
dismutase	O
1	O
(	B-Gene
SOD1	I-Gene
)	I-Gene
lead	B-Reg
to	I-Reg
Amyotrophic	B-Disease
Lateral	I-Disease
Sclerosis	I-Disease
(	O
ALS	O
)	O
,	O
a	O
neurodegenerative	O
disease	O
that	O
disproportionately	O
affects	O
glutamatergic	O
and	O
cholinergic	O
motor	O
neurons	O
.	O

Previous	O
work	O
with	O
SOD1	O
overexpression	O
models	O
supports	O
a	O
role	O
for	O
SOD1	O
toxic	O
gain	O
of	O
function	O
in	O
ALS	O
pathogenesis	O
.	O

However	O
,	O
the	O
impact	O
of	O
SOD1	O
loss	O
of	O
function	O
in	O
ALS	O
can	O
not	O
be	O
directly	O
examined	O
in	O
overexpression	O
models	O
.	O

In	O
addition	O
,	O
overexpression	O
may	O
obscure	O
the	O
contribution	O
of	O
SOD1	O
loss	O
of	O
function	O
in	O
the	O
degeneration	O
of	O
different	O
neuronal	O
populations	O
.	O

Here	O
,	O
we	O
report	O
the	O
first	O
single	O
-	O
copy	O
,	O
ALS	O
knock	O
-	O
in	O
models	O
in	O
C.	O
elegans	O
generated	O
by	O
transposon-	O
or	O
CRISPR	O
/	O
Cas9-	O
mediated	O
genome	O
editing	O
of	O
the	O
endogenous	O
sod-1	O
gene	O
.	O

Introduction	O
of	O
ALS	O
patient	O
amino	O
acid	O
changes	O
A4V	O
,	O
H71Y	O
,	O
L84V	O
,	O
G85R	O
or	O
G93A	O
into	O
the	O
C.	O
elegans	O
sod-1	O
gene	O
yielded	O
single	O
-	O
copy	O
/	O
knock	O
-	O
in	O
ALS	O
SOD1	O
models	O
.	O

These	O
differ	O
from	O
previously	O
reported	O
overexpression	O
models	O
in	O
multiple	O
assays	O
.	O

In	O
single	O
-	O
copy	O
/	O
knock	O
-	O
in	O
models	O
,	O
we	O
observed	O
differential	O
impact	O
of	O
sod-1	O
ALS	O
alleles	O
on	O
glutamatergic	O
and	O
cholinergic	O
neurodegeneration	O
.	O

A4V	O
,	O
H71Y	O
,	O
G85R	O
,	O
and	O
G93A	O
animals	O
showed	O
increased	O
SOD1	O
protein	O
accumulation	O
and	O
oxidative	O
stress	O
induced	O
degeneration	O
,	O
consistent	O
with	O
a	O
toxic	O
gain	O
of	O
function	O
in	O
cholinergic	O
motor	O
neurons	O
.	O

By	O
contrast	O
,	O
H71Y	O
,	O
L84V	O
,	O
and	O
G85R	O
lead	O
to	O
glutamatergic	O
neuron	O
degeneration	O
due	O
to	O
sod-1	O
loss	O
of	O
function	O
after	O
oxidative	O
stress	O
.	O

However	O
,	O
dopaminergic	O
and	O
serotonergic	O
neuronal	O
populations	O
were	O
spared	O
in	O
single	O
-	O
copy	O
ALS	O
models	O
,	O
suggesting	O
a	O
neuronal	O
-	O
subtype	O
specificity	O
previously	O
not	O
reported	O
in	O
invertebrate	O
ALS	O
SOD1	O
models	O
.	O

Combined	O
,	O
these	O
results	O
suggest	O
that	O
knock	O
-	O
in	O
models	O
may	O
reproduce	O
the	O
neurotransmitter	O
-	O
type	O
specificity	O
of	O
ALS	O
and	O
that	O
both	O
SOD1	O
loss	O
and	O
gain	O
of	O
toxic	O
function	O
differentially	O
contribute	O
to	O
ALS	O
pathogenesis	O
in	O
different	O
neuronal	O
populations	O
.	O

A	O
homozygous	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	B-Var
leading	O
to	O
CYBC1	B-Gene
deficiency	O
causes	O
chronic	B-Disease
granulomatous	I-Disease
disease	I-Disease
.	O

Mutations	B-Var
in	O
genes	O
encoding	O
subunits	O
of	O
the	O
phagocyte	O
NADPH	O
oxidase	O
complex	O
are	O
recognized	O
to	O
cause	B-Reg
chronic	B-Disease
granulomatous	I-Disease
disease	I-Disease
(	O
CGD	O
)	O
,	O
a	O
severe	O
primary	O
immunodeficiency	O
.	O

Here	O
we	O
describe	O
how	O
deficiency	O
of	O
CYBC1	O
,	O
a	O
previously	O
uncharacterized	O
protein	O
in	O
humans	O
(	O
C17orf62	O
)	O
,	O
leads	O
to	O
reduced	O
expression	O
of	O
NADPH	O
oxidase	O
's	O
main	O
subunit	O
(	O
gp91phox	O
)	O
and	O
results	O
in	O
CGD	O
.	O

Analyzing	O
two	O
brothers	O
diagnosed	O
with	O
CGD	O
we	O
identify	O
a	O
homozygous	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutation	O
,	O
p	B-Var
.	I-Var
Tyr2Ter	I-Var
,	O
in	O
CYBC1	B-Gene
.	O

Imputation	O
of	O
p	O
.	O
Tyr2Ter	O
into	O
155	O
K	O
chip	O
-	O
genotyped	O
Icelanders	O
reveals	O
six	O
additional	O
homozygotes	O
,	O
all	O
with	O
signs	O
of	O
CGD	O
,	O
manifesting	O
as	O
colitis	O
,	O
rare	O
infections	O
,	O
or	O
a	O
severely	O
impaired	O
PMA	O
-	O
induced	O
neutrophil	O
oxidative	O
burst	O
.	O

Homozygosity	O
for	O
p	B-Var
.	I-Var
Tyr2Ter	I-Var
consequently	O
associates	B-Reg
with	I-Reg
inflammatory	B-Disease
bowel	I-Disease
disease	I-Disease
(	O
IBD	O
)	O
in	O
Iceland	O
(	O
P	O
=	O
8.3	O
×	O
10	O
-	O
8	O
;	O
OR	O
=	O
67.6	O
)	O
,	O
as	O
well	O
as	O
reduced	O
height	O
(	O
P	O
=	O
3.3	O
×	O
10	O
-	O
4	O
;	O
-8.5	O
cm	O
)	O
.	O

Overall	O
,	O
we	O
find	O
that	O
CYBC1	O
deficiency	O
results	O
in	O
CGD	O
characterized	O
by	O
colitis	O
and	O
a	O
distinct	O
profile	O
of	O
infections	O
indicative	O
of	O
macrophage	O
dysfunction	O
.	O

Loss	O
of	O
Function	O
in	O
Zeaxanthin	O
Epoxidase	O
of	O
Dunaliella	O
tertiolecta	O
Caused	O
by	O
a	O
Single	O
Amino	O
Acid	O
Mutation	O
within	O
the	O
Substrate	O
-	O
Binding	O
Site	O
.	O

The	O
zea1	O
mutant	O
of	O
marine	O
microalga	O
Dunaliella	O
tertiolecta	O
accumulates	O
zeaxanthin	O
under	O
normal	O
growth	O
conditions	O
,	O
and	O
its	O
phenotype	O
has	O
been	O
speculated	O
to	O
be	O
related	O
to	O
zeaxanthin	O
epoxidase	O
(	O
ZEP	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
isolated	O
the	O
ZEP	O
gene	O
from	O
both	O
wild	O
-	O
type	O
D.	O
tertiolecta	O
and	O
the	O
mutant	O
.	O

We	O
found	O
that	O
the	O
zea1	O
mutant	O
has	O
a	O
point	B-Var
mutation	I-Var
of	O
the	O
1337th	O
nucleotide	O
of	O
the	O
ZEP	B-Gene
sequence	O
(	O
a	O
change	O
from	O
guanine	O
to	O
adenine	O
)	O
,	O
resulting	O
in	O
a	O
change	B-Reg
of	O
glycine	B-MPA
to	I-MPA
aspartate	I-MPA
in	I-MPA
a	I-MPA
highly	I-MPA
conserved	I-MPA
region	I-MPA
in	I-MPA
the	I-MPA
catalytic	I-MPA
domain	I-MPA
.	O

Similar	O
expression	O
levels	O
of	O
ZEP	O
mRNA	O
and	O
protein	O
in	O
both	O
wild	O
-	O
type	O
and	O
zea1	O
were	O
confirmed	O
by	O
using	O
qRT	O
-	O
PCR	O
and	O
western	O
blot	O
analysis	O
,	O
respectively	O
.	O

Additionally	O
,	O
the	O
enzyme	O
activity	O
analysis	O
of	O
ZEPs	O
in	O
the	O
presence	O
of	O
cofactors	O
showed	O
that	O
the	O
inactivation	O
of	O
ZEP	O
in	O
zea1	O
was	O
not	O
caused	O
by	O
deficiency	O
in	O
the	O
levels	O
of	O
cofactors	O
.	O

From	O
the	O
predicted	O
three	O
-	O
dimensional	O
ZEP	O
structure	O
of	O
zea1	O
,	O
we	O
observed	O
a	O
conformational	O
change	O
on	O
the	O
substrate	O
-	O
binding	O
site	O
in	O
the	O
ZEP	O
.	O

A	O
comparative	O
analysis	O
of	O
the	O
ZEP	B-Enzyme
structures	O
suggested	O
that	O
the	O
conformational	B-MPA
change	I-MPA
induced	O
by	O
a	O
single	B-Var
amino	I-Var
acid	I-Var
mutation	I-Var
might	O
impact	B-NegReg
the	O
interaction	B-Interaction
between	I-Interaction
the	I-Interaction
substrate	I-Interaction
and	I-Interaction
substrate	I-Interaction
-	I-Interaction
binding	I-Interaction
site	I-Interaction
,	O
resulting	O
in	O
loss	B-NegReg
of	O
zeaxanthin	B-Enzyme
epoxidase	I-Enzyme
function	B-MPA
.	O

LZTR1	O
is	O
a	O
regulator	O
of	O
RAS	O
ubiquitination	O
and	O
signaling	O
.	O

In	O
genetic	O
screens	O
aimed	O
at	O
understanding	O
drug	O
resistance	O
mechanisms	O
in	O
chronic	O
myeloid	O
leukemia	O
cells	O
,	O
inactivation	B-Var
of	O
the	O
cullin	O
3	O
adapter	O
protein	O
-	O
encoding	O
leucine	O
zipper	O
-	O
like	O
transcription	O
regulator	O
1	O
(	B-Gene
LZTR1	I-Gene
)	I-Gene
gene	O
led	O
to	O
enhanced	B-PosReg
mitogen	B-Pathway
-	I-Pathway
activated	I-Pathway
protein	I-Pathway
kinase	I-Pathway
(	I-Pathway
MAPK	I-Pathway
)	I-Pathway
pathway	I-Pathway
activity	B-MPA
and	O
reduced	B-NegReg
sensitivity	B-MPA
to	I-MPA
tyrosine	I-MPA
kinase	I-MPA
inhibitors	I-MPA
.	O

Knockdown	O
of	O
the	O
Drosophila	O
LZTR1	O
ortholog	O
CG3711	O
resulted	O
in	O
a	O
Ras	O
-	O
dependent	O
gain	O
-	O
of	O
-	O
function	O
phenotype	O
.	O

Endogenous	O
human	O
LZTR1	O
associates	O
with	O
the	O
main	O
RAS	O
isoforms	O
.	O

Inactivation	B-Var
of	O
LZTR1	B-Gene
led	O
to	O
decreased	B-NegReg
ubiquitination	B-MPA
and	O
enhanced	B-PosReg
plasma	B-MPA
membrane	I-MPA
localization	I-MPA
of	O
endogenous	O
KRAS	O
(	O
V	O
-	O
Ki	O
-	O
ras2	O
Kirsten	O
rat	O
sarcoma	O
viral	O
oncogene	O
homolog	O
)	O
.	O

We	O
propose	O
that	O
LZTR1	O
acts	O
as	O
a	O
conserved	O
regulator	O
of	O
RAS	O
ubiquitination	O
and	O
MAPK	O
pathway	O
activation	O
.	O

Because	O
LZTR1	O
disease	O
mutations	O
failed	O
to	O
revert	O
loss	O
-	O
of	O
-	O
function	O
phenotypes	O
,	O
our	O
findings	O
provide	O
a	O
molecular	O
rationale	O
for	O
LZTR1	O
involvement	O
in	O
a	O
variety	O
of	O
inherited	O
and	O
acquired	O
human	O
disorders	O
.	O

Molecular	O
genetics	O
of	O
the	O
POMT1-related	O
muscular	O
dystrophy	O
-	O
dystroglycanopathies	O
.	O

Protein	O
O	O
-	O
mannosyltransferase	O
1	O
(	O
POMT1	O
)	O
is	O
a	O
critical	O
enzyme	O
participating	O
in	O
the	O
first	O
step	O
of	O
protein	O
O	O
-	O
mannosylation	O
.	O

Mutations	B-Var
in	O
the	O
coding	O
gene	O
,	O
POMT1	B-Gene
,	O
have	O
been	O
described	O
to	O
be	O
related	O
to	O
a	O
series	O
of	O
autosomal	O
recessive	O
disorders	O
associated	O
with	O
defective	B-NegReg
alpha	B-MPA
-	I-MPA
dystroglycan	I-MPA
glycosylation	I-MPA
,	O
later	O
termed	O
muscular	B-Disease
dystrophy	I-Disease
-	I-Disease
dystroglycanopathies	I-Disease
(	O
MDDGs	O
)	O
.	O

MDDGs	O
are	O
characterized	O
by	O
a	O
broad	O
phenotypic	O
spectrum	O
of	O
congenital	O
muscular	O
dystrophy	O
or	O
later	O
-	O
onset	O
limb	O
-	O
girdle	O
muscular	O
dystrophy	O
,	O
accompanied	O
by	O
variable	O
degrees	O
of	O
intellectual	O
disability	O
,	O
brain	O
defects	O
,	O
and	O
ocular	O
abnormalities	O
.	O

To	O
date	O
,	O
at	O
least	O
76	O
disease	O
-	O
associated	O
mutations	O
in	O
the	O
POMT1	O
gene	O
,	O
including	O
missense	O
,	O
nonsense	O
,	O
splicing	O
,	O
deletion	O
,	O
insertion	O
/	O
duplication	O
,	O
and	O
insertion	O
-	O
deletion	O
mutations	O
,	O
have	O
been	O
reported	O
in	O
the	O
literature	O
.	O

In	O
this	O
review	O
,	O
we	O
highlight	O
the	O
present	O
knowledge	O
of	O
the	O
identified	O
disease	O
-	O
associated	O
POMT1	O
gene	O
mutations	O
and	O
genetic	O
animal	O
models	O
related	O
to	O
the	O
POMT1	O
gene	O
.	O

This	O
review	O
may	O
help	O
further	O
normative	O
classification	O
of	O
phenotypes	O
,	O
assist	O
in	O
definite	O
clinical	O
and	O
genetic	O
diagnoses	O
,	O
and	O
genetic	O
counseling	O
,	O
and	O
may	O
comprehensively	O
improve	O
our	O
understanding	O
of	O
the	O
basis	O
of	O
complex	O
phenotypes	O
and	O
possible	O
pathogenic	O
mechanisms	O
involved	O
.	O

Association	O
Between	O
Titin	O
Loss	O
-	O
of	O
-	O
Function	O
Variants	O
and	O
Early	O
-	O
Onset	O
Atrial	O
Fibrillation	O
.	O

Importance	O
:	O
Atrial	O
fibrillation	O
(	O
AF	O
)	O
is	O
the	O
most	O
common	O
arrhythmia	O
affecting	O
1	O
%	O
of	O
the	O
population	O
.	O

Young	O
individuals	O
with	O
AF	O
have	O
a	O
strong	O
genetic	O
association	O
with	O
the	O
disease	O
,	O
but	O
the	O
mechanisms	O
remain	O
incompletely	O
understood	O
.	O

Objective	O
:	O
To	O
perform	O
large	O
-	O
scale	O
whole	O
-	O
genome	O
sequencing	O
to	O
identify	O
genetic	O
variants	O
related	O
to	O
AF	O
.	O

Design	O
,	O
Setting	O
,	O
and	O
Participants	O
:	O
The	O
National	O
Heart	O
,	O
Lung	O
,	O
and	O
Blood	O
Institute	O
's	O
Trans	O
-	O
Omics	O
for	O
Precision	O
Medicine	O
Program	O
includes	O
longitudinal	O
and	O
cohort	O
studies	O
that	O
underwent	O
high	O
-	O
depth	O
whole	O
-	O
genome	O
sequencing	O
between	O
2014	O
and	O
2017	O
in	O
18	O
526	O
individuals	O
from	O
the	O
United	O
States	O
,	O
Mexico	O
,	O
Puerto	O
Rico	O
,	O
Costa	O
Rica	O
,	O
Barbados	O
,	O
and	O
Samoa	O
.	O

This	O
case	O
-	O
control	O
study	O
included	O
2781	O
patients	O
with	O
early	O
-	O
onset	O
AF	O
from	O
9	O
studies	O
and	O
identified	O
4959	O
controls	O
of	O
European	O
ancestry	O
from	O
the	O
remaining	O
participants	O
.	O

Results	O
were	O
replicated	O
in	O
the	O
UK	O
Biobank	O
(	O
346	O
546	O
participants	O
)	O
and	O
the	O
MyCode	O
Study	O
(	O
42	O
782	O
participants	O
)	O
.	O

Exposures	O
:	O
Loss	O
-	O
of	O
-	O
function	O
(	O
LOF	O
)	O
variants	O
in	O
genes	O
at	O
AF	O
loci	O
and	O
common	O
genetic	O
variation	O
across	O
the	O
whole	O
genome	O
.	O

Main	O
Outcomes	O
and	O
Measures	O
:	O
Early	O
-	O
onset	O
AF	O
(	O
defined	O
as	O
AF	O
onset	O
in	O
persons	O
<	O
66	O
years	O
of	O
age	O
)	O
.	O

Due	O
to	O
multiple	O
testing	O
,	O
the	O
significance	O
threshold	O
for	O
the	O
rare	O
variant	O
analysis	O
was	O
P	O
=	O
4.55	O
×	O
10	O
-	O
3	O
.	O

Results	O
:	O
Among	O
2781	O
participants	O
with	O
early	O
-	O
onset	O
AF	O
(	O
the	O
case	O
group	O
)	O
,	O
72.1	O
%	O
were	O
men	O
,	O
and	O
the	O
mean	O
(	O
SD	O
)	O
age	O
of	O
AF	O
onset	O
was	O
48.7	O
(	O
10.2	O
)	O
years	O
.	O

Participants	O
underwent	O
whole	O
-	O
genome	O
sequencing	O
at	O
a	O
mean	O
depth	O
of	O
37.8	O
fold	O
and	O
mean	O
genome	O
coverage	O
of	O
99.1	O
%	O
.	O

At	O
least	O
1	O
LOF	O
variant	O
in	O
TTN	O
,	O
the	O
gene	O
encoding	O
the	O
sarcomeric	O
protein	O
titin	O
,	O
was	O
present	O
in	O
2.1	O
%	O
of	O
case	O
participants	O
compared	O
with	O
1.1	O
%	O
in	O
control	O
participants	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
1.76	O
[	O
95	O
%	O
CI	O
,	O
1.04	O
-	O
2.97	O
]	O
)	O
.	O

The	O
proportion	O
of	O
individuals	O
with	O
early	B-Disease
-	I-Disease
onset	I-Disease
AF	I-Disease
who	O
carried	O
a	O
LOF	B-PosReg
variant	B-Var
in	O
TTN	B-Gene
increased	B-PosReg
with	O
an	O
earlier	O
age	O
of	O
AF	O
onset	O
(	O
P	O
value	O
for	O
trend	O
,	O
4.92	O
×	O
10	O
-	O
4	O
)	O
,	O
and	O
6.5	O
%	O
of	O
individuals	O
with	O
AF	O
onset	O
prior	O
to	O
age	O
30	O
carried	O
a	O
TTN	O
LOF	O
variant	O
(	O
OR	O
,	O
5.94	O
[	O
95	O
%	O
CI	O
,	O
2.64	O
-	O
13.35	O
]	O
;	O
P	O
=	O
1.65	O
×	O
10	O
-	O
5	O
)	O
.	O

The	O
association	O
between	O
TTN	O
LOF	O
variants	O
and	O
AF	O
was	O
replicated	O
in	O
an	O
independent	O
study	O
of	O
1582	O
patients	O
with	O
early	O
-	O
onset	O
AF	O
(	O
cases	O
)	O
and	O
41	O
200	O
control	O
participants	O
(	O
OR	O
,	O
2.16	O
[	O
95	O
%	O
CI	O
,	O
1.19	O
-	O
3.92	O
]	O
;	O
P	O
=	O
.01	O
)	O
.	O

Conclusions	O
and	O
Relevance	O
:	O
In	O
a	O
case	O
-	O
control	O
study	O
,	O
there	O
was	O
a	O
statistically	O
significant	B-Reg
association	I-Reg
between	O
an	O
LOF	B-NegReg
variant	B-Var
in	O
the	O
TTN	B-Gene
gene	O
and	O
early	B-Disease
-	I-Disease
onset	I-Disease
AF	I-Disease
,	O
with	O
the	O
variant	O
present	O
in	O
a	O
small	O
percentage	O
of	O
participants	O
with	O
early	O
-	O
onset	O
AF	O
(	O
the	O
case	O
group	O
)	O
.	O

Further	O
research	O
is	O
necessary	O
to	O
understand	O
whether	O
this	O
is	O
a	O
causal	O
relationship	O
.	O

HDX	O
-	O
MS	O
reveals	O
dysregulated	O
checkpoints	O
that	O
compromise	O
discrimination	O
against	O
self	O
RNA	O
during	O
RIG	O
-	O
I	O
mediated	O
autoimmunity	O
.	O

Retinoic	O
acid	O
inducible	O
gene	O
-	O
I	O
(	O
RIG	O
-	O
I	O
)	O
ensures	O
immune	O
surveillance	O
of	O
viral	O
RNAs	O
bearing	O
a	O
5'-triphosphate	O
(	O
5'ppp	O
)	O
moiety	O
.	O

Mutations	O
in	O
RIG	B-Gene
-	I-Gene
I	I-Gene
(	B-Var
C268F	I-Var
and	O
E373A	B-Var
)	I-Var
lead	O
to	O
impaired	B-NegReg
ATPase	B-Protein
activity	B-MPA
,	O
thereby	O
driving	O
hyperactive	B-PosReg
signaling	B-MPA
associated	O
with	O
autoimmune	O
diseases	O
.	O

Here	O
we	O
report	O
,	O
using	O
hydrogen	O
/	O
deuterium	O
exchange	O
,	O
mechanistic	O
models	O
for	O
dysregulated	O
RIG	O
-	O
I	O
proofreading	O
that	O
ultimately	O
result	O
in	O
the	O
improper	O
recognition	O
of	O
cellular	O
RNAs	O
bearing	O
7-methylguanosine	O
and	O
N1	O
-	O
2'-O	O
-	O
methylation	O
(	O
Cap1	O
)	O
on	O
the	O
5	O
'	O
end	O
.	O

Cap1-RNA	O
compromises	O
its	O
ability	O
to	O
stabilize	O
RIG	O
-	O
I	O
helicase	O
and	O
blunts	O
caspase	O
activation	O
and	O
recruitment	O
domains	O
(	O
CARD	O
)	O
partial	O
opening	O
by	O
threefold	O
.	O

RIG	B-Gene
-	I-Gene
I	I-Gene
H830A	B-Var
mutation	I-Var
restores	B-PosReg
Cap1-helicase	B-Protein
engagement	B-MPA
as	O
well	O
as	O
CARDs	B-MPA
partial	I-MPA
opening	I-MPA
event	I-MPA
to	O
a	O
level	O
comparable	O
to	O
that	O
of	O
5'ppp	O
.	O

However	O
,	O
E373A	B-Var
RIG	B-Gene
-	I-Gene
I	I-Gene
locks	O
the	O
receptor	O
in	O
an	O
ATP	O
-	O
bound	O
state	O
,	O
resulting	O
in	O
enhanced	B-PosReg
Cap1-helicase	B-Protein
engagement	B-MPA
and	O
a	O
sequential	B-MPA
CARDs	I-MPA
stimulation	I-MPA
.	O

C268F	B-Var
mutation	I-Var
renders	O
a	O
more	B-PosReg
tethered	B-MPA
ring	I-MPA
architecture	I-MPA
and	O
results	B-Reg
in	I-Reg
constitutive	B-MPA
CARDs	I-MPA
signaling	I-MPA
in	O
an	O
ATP	O
-	O
independent	O
manner	O
.	O

Variant	O
Prolactin	O
Receptor	O
in	O
Agalactia	O
and	O
Hyperprolactinemia	O
.	O

A	O
loss	O
-	O
of	O
-	O
function	O
variant	O
in	O
the	O
gene	O
encoding	O
the	O
prolactin	O
receptor	O
(	O
PRLR	O
)	O
was	O
reported	O
previously	O
in	O
a	O
woman	O
with	O
persistent	O
postpartum	O
galactorrhea	O
;	O
however	O
,	O
this	O
paradoxical	O
phenotype	O
is	O
not	O
completely	O
understood	O
.	O

Here	O
we	O
describe	O
a	O
35-year	O
-	O
old	O
woman	O
who	O
presented	O
with	O
idiopathic	O
hyperprolactinemia	B-Disease
that	O
was	O
associated	O
with	O
a	O
complete	O
lack	O
of	O
lactation	O
after	O
each	O
of	O
her	O
two	O
deliveries	O
.	O

She	O
is	O
a	O
compound	O
heterozygote	O
for	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
variants	B-Var
of	O
PRLR	B-Gene
.	O

Her	O
unaffected	O
parents	O
are	O
heterozygotes	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
previous	O
work	O
showing	O
that	O
mice	O
deficient	O
in	O
functional	O
Prlr	O
do	O
not	B-NegReg
lactate	B-CPA
.	O

WRKY12	O
represses	O
GSH1	O
expression	O
to	O
negatively	O
regulate	O
cadmium	O
tolerance	O
in	O
Arabidopsis	O
.	O

KEY	O
MESSAGE	O
:	O
The	O
WRKY	O
transcription	O
factor	O
WRKY12	O
negatively	O
regulates	O
Cd	O
tolerance	O
in	O
Arabidopsis	O
via	O
the	O
glutathione	O
-	O
dependent	O
phytochelatin	O
synthesis	O
pathway	O
by	O
directly	O
targeting	O
GSH1	O
and	O
indirectly	O
repressing	O
phytochelatin	O
synthesis	O
-	O
related	O
gene	O
expression	O
.	O

Cadmium	O
(	O
Cd	O
)	O
is	O
a	O
widespread	O
pollutant	O
toxic	O
to	O
plants	O
.	O

The	O
glutathione	O
(	O
GSH)-dependent	O
phytochelatin	O
(	O
PC	O
)	O
synthesis	O
pathway	O
plays	O
key	O
roles	O
in	O
Cd	O
detoxification	O
.	O

However	O
,	O
its	O
regulatory	O
mechanism	O
remains	O
largely	O
unknown	O
.	O

Here	O
,	O
we	O
showed	O
a	O
previously	O
unknown	O
function	O
of	O
the	O
WRKY	O
transcription	O
factor	O
WRKY12	O
in	O
the	O
regulation	O
of	O
Cd	O
tolerance	O
by	O
repressing	O
the	O
expression	O
of	O
PC	O
synthesis	O
-	O
related	O
genes	O
.	O

The	O
expression	O
of	O
WRKY12	O
was	O
inhibited	O
by	O
Cd	O
stress	O
.	O

Enhanced	B-PosReg
Cd	B-CPA
tolerance	I-CPA
was	O
observed	O
in	O
the	O
WRKY12	B-Gene
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutants	B-Var
,	O
whereas	O
increased	O
Cd	O
sensitivity	O
was	O
found	O
in	O
the	O
WRKY12-overexpressing	O
plants	O
.	O

Overexpression	O
and	O
loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
of	O
WRKY12	B-Gene
were	O
associated	O
respectively	O
with	O
increased	O
and	O
decreased	B-NegReg
Cd	B-CPA
accumulation	I-CPA
by	O
repressing	O
or	O
releasing	B-PosReg
the	O
expression	B-MPA
of	O
the	O
genes	O
involved	O
in	O
the	O
PC	O
synthesis	O
pathway	O
.	O

Transient	O
expression	O
assay	O
showed	O
that	O
WRKY12	O
repressed	O
the	O
expression	O
of	O
GSH1	B-Gene
,	O
GSH2	B-Gene
,	O
PCS1	B-Gene
,	O
and	O
PCS2	B-Gene
.	O

Further	O
analysis	O
indicated	O
that	O
WRKY12	O
could	O
directly	O
bind	O
to	O
the	O
W	O
-	O
box	O
of	O
the	O
promoter	O
in	O
GSH1	O
but	O
not	O
in	O
GSH2	O
,	O
PCS1	O
,	O
and	O
PCS2	O
in	O
vivo	O
.	O

Together	O
,	O
our	O
results	O
suggest	O
that	O
WRKY12	O
directly	O
targets	O
GSH1	O
and	O
indirectly	O
represses	O
PC	O
synthesis	O
-	O
related	O
gene	O
expression	O
to	O
negatively	O
regulate	O
Cd	O
accumulation	O
and	O
tolerance	O
in	O
Arabidopsis	O
.	O

Loss	B-NegReg
-	I-NegReg
of	I-NegReg
-	I-NegReg
function	I-NegReg
mutations	B-Var
in	O
QRICH2	B-Gene
cause	B-Reg
male	B-Disease
infertility	I-Disease
with	O
multiple	O
morphological	O
abnormalities	O
of	O
the	O
sperm	O
flagella	O
.	O

Aberrant	B-Var
sperm	B-CPA
flagella	I-CPA
impair	B-NegReg
sperm	B-CPA
motility	I-CPA
and	O
cause	B-Reg
male	B-Disease
infertility	I-Disease
,	O
yet	O
the	O
genes	O
which	O
have	O
been	O
identified	O
in	O
multiple	O
morphological	O
abnormalities	O
of	O
the	O
flagella	O
(	O
MMAF	O
)	O
can	O
only	O
explain	O
the	O
pathogenic	O
mechanisms	O
of	O
MMAF	O
in	O
a	O
small	O
number	O
of	O
cases	O
.	O

Here	O
,	O
we	O
identify	O
and	O
functionally	O
characterize	O
homozygous	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
of	O
QRICH2	O
in	O
two	O
infertile	O
males	O
with	O
MMAF	O
from	O
two	O
consanguineous	O
families	O
.	O

Remarkably	O
,	O
Qrich2	O
knock	O
-	O
out	O
(	O
KO	O
)	O
male	O
mice	O
constructed	O
by	O
CRISPR	O
-	O
Cas9	O
technology	O
present	O
MMAF	O
phenotypes	O
and	O
sterility	O
.	O

To	O
elucidate	O
the	O
mechanisms	O
of	O
Qrich2	O
functioning	O
in	O
sperm	O
flagellar	O
formation	O
,	O
we	O
perform	O
proteomic	O
analysis	O
on	O
the	O
testes	O
of	O
KO	O
and	O
wild	O
-	O
type	O
mice	O
.	O

Furthermore	O
,	O
in	O
vitro	O
experiments	O
indicate	O
that	O
QRICH2	O
is	O
involved	O
in	O
sperm	O
flagellar	O
development	O
through	O
stabilizing	O
and	O
enhancing	O
the	O
expression	O
of	O
proteins	O
related	O
to	O
flagellar	O
development	O
.	O

Our	O
findings	O
strongly	O
suggest	O
that	O
the	O
genetic	O
mutations	B-Var
of	O
human	O
QRICH2	B-Gene
can	O
lead	B-Reg
to	I-Reg
male	B-Disease
infertility	I-Disease
with	O
MMAF	B-CPA
and	O
that	O
QRICH2	O
is	O
essential	O
for	O
sperm	O
flagellar	O
formation	O
.	O

Segmental	O
uniparental	O
disomy	O
as	O
a	O
rare	O
cause	O
of	O
congenital	O
severe	O
factor	O
XIII	O
deficiency	O
in	O
a	O
girl	O
with	O
only	O
one	O
heterozygous	O
carrier	O
parent	O
.	O

Uniparental	B-Disease
disomy	I-Disease
(	O
UPD	O
)	O
refers	O
to	O
a	O
situation	O
when	O
a	O
person	O
inherits	O
both	O
homologs	O
of	O
a	O
region	O
or	O
complete	O
part	O
of	O
a	O
chromosome	O
from	O
only	O
one	O
parent	O
.	O

Here	O
,	O
we	O
present	O
an	O
unusual	O
case	O
of	O
UPD	O
in	O
congenital	O
severe	O
factor	O
(	O
F	O
)	O
XIII	O
deficiency	O
.	O

A	O
6-year	O
-	O
old	O
girl	O
experienced	O
cephalhematoma	O
and	O
umbilical	O
bleeding	O
after	O
birth	O
and	O
easy	O
bruising	O
,	O
and	O
postextraction	O
bleeding	O
since	O
early	O
infancy	O
.	O

FXIII	O
activity	O
was	O
0	O
%	O
[	O
mother	O
53.7	O
%	O
and	O
father	O
132.5	O
%	O
(	O
normal	O
70	O
-	O
140	O
%	O
)	O
]	O
and	O
the	O
FXIII	O
antigen	O
level	O
was	O
2.5	O
%	O
[	O
mother	O
38.9	O
%	O
and	O
father	O
151	O
%	O
(	O
normal	O
75	O
-	O
155	O
%	O
)	O
]	O
.	O

The	O
washed	O
platelet	O
FXIII	O
activity	O
was	O
0.1	O
%	O
in	O
the	O
patient	O
(	O
normal	O
64	O
-	O
144	O
%	O
)	O
,	O
suggesting	O
a	O
deficiency	O
of	O
FXIII	O
-	O
A	O
subunit	O
.	O

The	O
FXIII	O
-	O
A	O
subunit	O
genetic	O
analysis	O
detected	O
a	O
homozygous	O
p	O
.	O
Arg382Ser	O
mutation	O
.	O

A	O
similar	O
heterozygous	O
mutation	O
was	O
detected	O
in	O
the	O
mother	O
but	O
surprisingly	O
,	O
not	O
in	O
the	O
father	O
.	O

Kinship	O
was	O
confirmed	O
by	O
a	O
paternity	O
test	O
.	O

To	O
confirm	O
the	O
possibility	O
of	O
UPD	O
,	O
a	O
test	O
using	O
four	O
markers	O
in	O
the	O
vicinity	O
of	O
the	O
F13A1	B-Gene
gene	O
revealed	O
that	O
she	O
inherited	O
duplicate	B-Var
mutations	I-Var
from	O
a	O
heterozygous	O
mutation	O
in	O
her	O
mother	O
,	O
presenting	O
a	O
unique	O
case	B-Reg
of	I-Reg
unusual	O
maternal	O
segmental	O
UPD	B-Disease
in	O
otherwise	O
unexplained	O
congenital	O
(	O
homozygous	O
)	O
severe	O
FXIII	B-Disease
deficiency	I-Disease
.	O

UPD	O
as	O
a	O
rare	O
cause	O
of	O
autosomal	O
recessive	O
bleeding	O
disorder	O
when	O
only	O
one	O
parent	O
is	O
affected	O
is	O
critical	O
for	O
genetic	O
counseling	O
.	O
